hypothetically almost proteins miniature organism viruses potential vaccine <NUMBER> targets shi et al <NUMBER> incredibly fast piece study shown <NUMBER> virus installed human body encodes tool proteins helps <NUMBER> replication tool proteins ie nonstructural proteins key toolkit <NUMBER> synthesize structural proteins spike membrane envelope nucleocapsid <NUMBER> factors requires grow progeny lewis et al <NUMBER> strategy vaccine <NUMBER> development engineered toolkit ie nonstructural proteins includes <NUMBER>c <NUMBER> like proteinase yp<NUMBER> rna dependent rna polymerase yp<NUMBER> <NUMBER> helicase yp<NUMBER> <NUMBER> exonuclease yp<NUMBER> <NUMBER>oribo methyl <NUMBER> transferase yp<NUMBER> endornase yp<NUMBER> proteins <NUMBER> also used drug target commercially available antiviral drugs fight sudden <NUMBER> outbreak covid<NUMBER> since specific antivirals available beck et al <NUMBER> <NUMBER> several nonstructural proteins make replicasetranscriptase complex <NUMBER> ultimately helps replication transcription virus genomic rna ziebuhr <NUMBER> <NUMBER>c like proteinase protease present coronaviruses helps proteolysis <NUMBER> nonstructural protein <NUMBER> nsp<NUMBER> replication process virus tomar et al <NUMBER> makes high value vaccine candidate coronavirus key enzyme <NUMBER> coronavirus replication transcription system rnadependent rna polymerase <NUMBER> rdrp encoded nsp<NUMBER> also appears attractive target therapeutics gao prediction cytotoxic lymphocytes ctl epitopes vaccine designing <NUMBER> ctl epitopes vaccine designing predicted using netctl <NUMBER> server <NUMBER> httpwwwcbsdtudkservicesnetctl server comprises two datasets one <NUMBER> hiv human immunodeficiency virus ctl epitopes one source proteins proteins present datasets cleaved probable <NUMBER> mers exception <NUMBER> annotated epitopes remaining ones considered nonepitopes protein sequences fasta required input prediction potential apart average antigenic propensity designed vaccine candidate grand average hydropathicity gravy <NUMBER> candidate probably nonallergen lead allergy pre post <NUMBER> vaccination subsequently help toxinpred server checked toxicity <NUMBER> epitopes server accepts protein sequences <NUMBER> amino acids <NUMBER> study designed vaccine candidate <NUMBER> amino acid <NUMBER> found epitopes involved designing vaccine candidate nontoxic <NUMBER> release toxic components administration supplementary table<NUMBER>a <NUMBER>b <NUMBER> <NUMBER>c data suggested designed vaccine candidate highly stable raptorx server tertiary structure refinement validation <NUMBER> tertiary structure refinement achieved help <NUMBER>d refine server output <NUMBER> server generated five refined models selection best model done <NUMBER> basis various parameters model number fifth selected <NUMBER>d refine score <NUMBER> <NUMBER> less four models additionally gdtts score <NUMBER> selected model <NUMBER> whereas gdtha score <NUMBER> higher scores <NUMBER> denotes conservative refinement next rmsd root mean square deviation <NUMBER> <NUMBER> higher score indicates aggressive refinement comparison initial non<NUMBER> refined one molprobity score <NUMBER> rwplus potential energy score score obtained qmean<NUMBER> server <NUMBER> whereas global iddt score <NUMBER> model <NUMBER> score ranges <NUMBER> <NUMBER> next help <NUMBER> qmeandisco scoring function predicted global quality model obtained <NUMBER> global score <NUMBER> ± <NUMBER> data suggested score global local iddt <NUMBER> obtained model structure higher range hence <NUMBER> conclude designed model best scoring exceptional quality figure<NUMBER> reported mice lacking tlr<NUMBER> tlr<NUMBER> vulnerable sarscov <NUMBER> comparison mice tlr<NUMBER> tlr<NUMBER> receptors exceptionally weight loss <NUMBER> observed exposed infection mortality detected totura et al <NUMBER> one immune receptor tlr<NUMBER> using haddock server immune simulation experiment performed using cimmsim server gives <NUMBER> real immune response result results observed proliferation secondary <NUMBER> tertian immune response identified igg<NUMBER> igg<NUMBER> igm also <NUMBER> decreasing antigen count igg igm also showed proliferated response figure <NUMBER> result revealed immune response development upon immunization bcell population <NUMBER> level also stimulated seems high upon immunization figure <NUMBER> b sarscov<NUMBER> four hcovhku<NUMBER> hcovoc<NUMBER> hcov<NUMBER>e hcovnl<NUMBER> <NUMBER> circulating human population worldwide cause mild symptoms <NUMBER> coronavirus <NUMBER> protein delivered recombinant dna vaccine viral vector vaccine table <NUMBER> conservation suggested potential n protein candidate crossprotective vaccine <NUMBER> sars mers n protein also evaluated used vaccine development <NUMBER> table <NUMBER> n protein packs coronavirus rna form helical nucleocapsid virion <NUMBER> assembly protein conserved protein reported induce <NUMBER> immune response neutralize coronavirus infections <NUMBER> however study also showed <NUMBER> linkage n protein severe pneumonia serious liver failures related <NUMBER> pathogenesis sars <NUMBER> <NUMBER> vaxignml pipeline computed protegenicity protective antigenicity score <NUMBER> predicted induction protective immunity vaccine candidate <NUMBER> training data <NUMBER> consisted viral protective antigens tested protective least one animal <NUMBER> challenge model <NUMBER> performance vaxignml models evaluated table s<NUMBER> <NUMBER> figure s<NUMBER> best performing model weighted f<NUMBER>score <NUMBER> using optimized <NUMBER> vaxignml model predicted three proteins protein nsp<NUMBER> nsp<NUMBER> vaccine candidates <NUMBER> significant protegenicity scores <NUMBER> therefore selected nsp<NUMBER> investigation described <NUMBER> <NUMBER> multiple sequence alignment resulting phylogeny nsp<NUMBER> protein showed <NUMBER> protein sarscov<NUMBER> closely related human coronaviruses sarscov <NUMBER> merscov bat coronaviruses btcovhku<NUMBER> btcovhku<NUMBER> btcovhku<NUMBER> studied <NUMBER> genetic conservation nsp<NUMBER> protein figure <NUMBER>a seven human coronaviruses eight <NUMBER> coronaviruses infecting animals table s<NUMBER> five human coronaviruses sarscov<NUMBER> <NUMBER> sarscov merscov hcovhku<NUMBER> hcovoc<NUMBER> belong betacoronavirus <NUMBER> hcov<NUMBER>e hcovnl<NUMBER> belong alphacoronavirus hcovhku<NUMBER> hcov<NUMBER> oc<NUMBER> human coronavirus mild symptoms clustered together murine mhva<NUMBER> <NUMBER> severe form human coronavirus sarscov<NUMBER> sarscov merscov grouped <NUMBER> three bat coronaviruses btcovhku<NUMBER> btcovhku<NUMBER> btcovhku<NUMBER> <NUMBER> evaluating amino acid conservations relative functional domains nsp<NUMBER> <NUMBER> protein domains except hypervariable region hvr macrodomain <NUMBER> mac<NUMBER> beta<NUMBER> coronavirusspecific marker βsm showed higher conservation sarscov<NUMBER> sarscov <NUMBER> used generate phylogenetic nsp<NUMBER> protein figure <NUMBER>b sarscov domains also <NUMBER> plotted figure <NUMBER>b relative position multiple sequence alignment msa <NUMBER> <NUMBER> coronaviruses table s<NUMBER> figure s<NUMBER> <NUMBER> immunogenicity nsp<NUMBER> protein terms cell mhci mhcii linear b cell <NUMBER> epitopes also investigated <NUMBER> <NUMBER> promiscuous epitopes predicted bind <NUMBER> reference mhci mhcii alleles covered majority world population <NUMBER> respectively table s<NUMBER> <NUMBER> terms linear b cell epitopes <NUMBER> epitopes bepipred <NUMBER> scores <NUMBER> least ten amino acids length table s<NUMBER> <NUMBER>d structure sars table <NUMBER> inactivated attenuated whole virus vaccine might induce strong <NUMBER> immune response <NUMBER> <NUMBER> <NUMBER> studies structural proteins including n proteins <NUMBER> reported associate pathogenesis coronavirus <NUMBER> might raise safety concern <NUMBER> study shown increased liver pathology vaccinated ferrets immunized modified <NUMBER> vaccinia ankaras recombinant vaccine <NUMBER> although adverse events reported <NUMBER> animal studies safety efficacy vaccination strategies tested <NUMBER> human clinical trials study applied stateoftheart vaxign reserve vaccinology rv <NUMBER> vaxignml machine learning strategies entire sarscov<NUMBER> proteomes including <NUMBER> structural nonstructural proteins vaccine candidate prediction results indicate <NUMBER> first time many nonstructural proteins could used potential vaccine candidates <NUMBER> sarscov<NUMBER> protein identified vaxign vaxignml analysis <NUMBER> favorable vaccine candidate first vaxign rv framework predicted protein <NUMBER> likely adhesin consistent role protein invasion host cells second <NUMBER> vaxignml predicted protein high protective antigenicity score results <NUMBER> confirmed role protein important target covid<NUMBER> vaccines however <NUMBER> protein exists many coronaviruses many nonpathogenic human coronaviruses also use <NUMBER> protein cell invasion example despite markedly weak pathogenicity hcovnl<NUMBER> also <NUMBER> uses protein employs angiotensinconverting enzyme <NUMBER> ace<NUMBER> cellular entry <NUMBER> <NUMBER> suggests protein factor determining infection level human <NUMBER> coronavirus addition targeting protein may induce high serumneutralizing antibody <NUMBER> titers cannot induce sufficient protective efficacy <NUMBER> thus alternative vaccine antigens may <NUMBER> considered <NUMBER> sarscov<NUMBER> nsp<NUMBER> protein predicted potential vaccine candidate shown <NUMBER> predicted secondhighest protective antigenicity score adhesin property promiscuous <NUMBER> viral structural particle none nonstructural proteins evaluated <NUMBER> vaccine candidates sarsmerscovid<NUMBER> vaccine studies far target structural <NUMBER> smn proteins still nonstructural proteins used effective vaccine antigens <NUMBER> stimulate protective immunity many viruses example nonstructural protein ns<NUMBER> <NUMBER> found induce protective immunity infections flaviviruses <NUMBER> non<NUMBER> structural proteins hepatitis c virus reported induce hcvspecific vigorous <NUMBER> broadspectrum tcell responses <NUMBER> nonstructural hiv<NUMBER> gene products also shown <NUMBER> valuable targets prophylactic therapeutic vaccines <NUMBER> therefore reasonable <NUMBER> consider sarscov<NUMBER> nonstructural proteins possible vaccine targets suggested <NUMBER> present study <NUMBER> instead using single protein vaccine antigen would like propose <NUMBER> development cocktail vaccine effective strategy covid<NUMBER> vaccine development <NUMBER> typical cocktail vaccine includes one antigen cover different aspects <NUMBER> protection <NUMBER> licensed group b meningococcus bexsero vaccine developed via <NUMBER> reverse vaccinology contains three protein antigens <NUMBER> develop efficient safe covid<NUMBER> <NUMBER> cocktail vaccine possible mix structural eg protein nonstructural eg nsp<NUMBER> <NUMBER> viral proteins proteins identified study may also considered possible vaccine <NUMBER> targets benefit cocktail vaccine strategy could induce immunity protect host <NUMBER> sace<NUMBER> interaction viral entry host cells also protect <NUMBER> accessary nonstructural adhesin proteins eg nsp<NUMBER> might also vital viral <NUMBER> entry replication usage one antigen allows us reduce volume <NUMBER> antigen thus reducing induction adverse events nonetheless potentials <NUMBER> performance models evaluated using nested fivefold crossvalidation n<NUMBER>cv <NUMBER> based area receiver operating characteristic curve precision recall weighted f<NUMBER> score matthews correlation coefficient best performing xgb model selected <NUMBER> predict protegenicity score sarscov<NUMBER> isolate wuhanhu<NUMBER> genbank id <NUMBER> mn<NUMBER> proteins downloaded ncbi protein protegenicity score <NUMBER> <NUMBER> considered strong vaccine immunity induction weighted f<NUMBER>score <NUMBER> n<NUMBER>cv <NUMBER> <NUMBER> phylogenetic analysis protein nsp<NUMBER> selected investigation nsp<NUMBER> proteins <NUMBER> <NUMBER> coronaviruses besides sarscov<NUMBER> downloaded uniprot table s<NUMBER> multiple <NUMBER> sequence alignment nsp<NUMBER> proteins performed using muscle <NUMBER> visualized via <NUMBER> seaview <NUMBER> phylogenetic tree constructed using phyml <NUMBER> amino acid <NUMBER> conservation estimated jensenshannon divergence jsd <NUMBER> jsd score also <NUMBER> used generate sequence conservation line using nsp<NUMBER> protein sequences <NUMBER> <NUMBER> <NUMBER> coronaviruses <NUMBER> <NUMBER> immunogenicity analysis immunogenicity nsp<NUMBER> protein evaluated <NUMBER> prediction cell mhci mhcii linear b cell epitopes cell mhci epitopes <NUMBER> iedb consensus method used predicting promiscuous epitopes binding <NUMBER> <NUMBER> <NUMBER> mhci reference alleles consensus percentile ranking less <NUMBER> score <NUMBER> cell mhc<NUMBER> ii epitopes iedb consensus method used predicting promiscuous epitopes binding <NUMBER> half <NUMBER> mhcii reference alleles consensus percentile ranking less <NUMBER> <NUMBER> mhci mhcii reference alleles covered wide range human genetic variation <NUMBER> representing majority world population <NUMBER> linear b cell epitopes predicted <NUMBER> using bepipred <NUMBER> cutoff <NUMBER> score <NUMBER> linear b cell epitopes least ten amino <NUMBER> acids mapped predicted <NUMBER>d structure sarscov<NUMBER> nsp<NUMBER> protein visualized via <NUMBER> pymol <NUMBER> predicted count cell mhci mhcii epitopes predicted score <NUMBER> linear b cell epitopes computed sliding averages window size ten amino acids <NUMBER> nsp<NUMBER> protein <NUMBER>d structure predicted using ci tasser better understand current status coronavirus vaccine development <NUMBER> systematically surveyed development vaccines coronavirus clinicaltrialsgov <NUMBER> database pubmed literature march <NUMBER> <NUMBER> extensive effort made <NUMBER> develop safe effective vaccine sars mers advance clinical trial <NUMBER> study currently phase ii table <NUMBER> challenging task quickly develop safe <NUMBER> effective vaccine ongoing covid<NUMBER> pandemic <NUMBER> two primary design strategies coronavirus vaccine development usage <NUMBER> improve vaccine safety efficacy coronavirus antigens protein n protein protein delivered recombinant dna vaccine viral vector vaccine table <NUMBER> conservation suggested potential n protein candidate crossprotective vaccine <NUMBER> sars mers n protein also evaluated used vaccine development <NUMBER> table <NUMBER> n protein packs coronavirus rna form helical nucleocapsid virion <NUMBER> assembly protein conserved protein reported induce <NUMBER> immune response neutralize coronavirus infections <NUMBER> however study also showed <NUMBER> linkage n protein severe pneumonia serious liver failures related <NUMBER> pathogenesis sars <NUMBER> <NUMBER> vaxignml pipeline computed protegenicity protective antigenicity score <NUMBER> predicted induction protective immunity vaccine candidate <NUMBER> training data <NUMBER> consisted viral protective antigens tested protective least one animal <NUMBER> challenge model <NUMBER> performance vaxignml models evaluated table s<NUMBER> <NUMBER> figure s<NUMBER> best performing model weighted f<NUMBER>score <NUMBER> using optimized <NUMBER> vaxignml model predicted three proteins protein nsp<NUMBER> nsp<NUMBER> vaccine candidates <NUMBER> significant protegenicity scores multiple sequence alignment resulting phylogeny nsp<NUMBER> protein showed <NUMBER> protein sarscov<NUMBER> closely related human coronaviruses sarscov <NUMBER> merscov bat coronaviruses btcovhku<NUMBER> btcovhku<NUMBER> btcovhku<NUMBER> studied <NUMBER> genetic conservation nsp<NUMBER> protein figure <NUMBER>a seven human coronaviruses eight <NUMBER> coronaviruses infecting animals table s<NUMBER> five human coronaviruses sarscov<NUMBER> <NUMBER> sarscov merscov hcovhku<NUMBER> hcovoc<NUMBER> belong betacoronavirus <NUMBER> hcov<NUMBER>e hcovnl<NUMBER> belong alphacoronavirus hcovhku<NUMBER> hcov<NUMBER> oc<NUMBER> human coronavirus mild symptoms clustered together murine mhva<NUMBER> <NUMBER> severe form human coronavirus sarscov<NUMBER> sarscov merscov grouped <NUMBER> three bat coronaviruses btcovhku<NUMBER> btcovhku<NUMBER> btcovhku<NUMBER> <NUMBER> evaluating amino acid conservations relative functional domains nsp<NUMBER> <NUMBER> protein domains except hypervariable region hvr macrodomain <NUMBER> mac<NUMBER> beta<NUMBER> coronavirusspecific marker βsm showed higher conservation sarscov<NUMBER> sarscov <NUMBER> merscov figure <NUMBER>b amino acid conservation major human coronavirus <NUMBER> sarscov<NUMBER> sarscov merscov plotted compared <NUMBER> coronaviruses <NUMBER> ccby <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted march <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint used generate phylogenetic nsp<NUMBER> protein figure <NUMBER>b sarscov domains also <NUMBER> plotted figure <NUMBER>b relative position multiple sequence alignment msa <NUMBER> <NUMBER> coronaviruses table s<NUMBER> figure s<NUMBER> <NUMBER> immunogenicity nsp<NUMBER> protein terms cell mhci mhcii linear b cell <NUMBER> epitopes also investigated <NUMBER> <NUMBER> promiscuous epitopes predicted bind <NUMBER> reference mhci mhcii alleles covered majority world population <NUMBER> respectively table s<NUMBER> <NUMBER> terms linear b cell epitopes <NUMBER> epitopes bepipred <NUMBER> scores <NUMBER> least ten amino acids length table s<NUMBER> <NUMBER>d structure sars reported associate pathogenesis coronavirus <NUMBER> might raise safety concern <NUMBER> study shown increased liver pathology vaccinated ferrets immunized modified <NUMBER> vaccinia ankaras recombinant vaccine <NUMBER> although adverse events reported <NUMBER> animal studies safety efficacy vaccination strategies tested <NUMBER> human clinical trials study applied stateoftheart vaxign reserve vaccinology rv <NUMBER> vaxignml machine learning strategies entire sarscov<NUMBER> proteomes including <NUMBER> structural nonstructural proteins vaccine candidate prediction results indicate <NUMBER> first time many nonstructural proteins could used potential vaccine candidates <NUMBER> sarscov<NUMBER> protein identified vaxign vaxignml analysis <NUMBER> favorable vaccine candidate first vaxign rv framework predicted protein <NUMBER> likely adhesin consistent role protein invasion host cells second <NUMBER> vaxignml predicted protein high protective antigenicity score results <NUMBER> confirmed role protein important target covid<NUMBER> vaccines however <NUMBER> protein exists many coronaviruses many nonpathogenic human coronaviruses also use <NUMBER> protein cell invasion example despite markedly weak pathogenicity hcovnl<NUMBER> also <NUMBER> uses protein employs angiotensinconverting enzyme <NUMBER> ace<NUMBER> cellular entry <NUMBER> <NUMBER> suggests protein factor determining infection level human <NUMBER> coronavirus addition targeting protein may induce high serumneutralizing antibody <NUMBER> titers cannot induce sufficient protective efficacy <NUMBER> thus alternative vaccine antigens may <NUMBER> considered <NUMBER> sarscov<NUMBER> nsp<NUMBER> protein predicted potential vaccine candidate shown <NUMBER> predicted secondhighest protective antigenicity score adhesin property promiscuous <NUMBER> viral structural particle none nonstructural proteins evaluated <NUMBER> vaccine candidates sarsmerscovid<NUMBER> vaccine studies far target structural <NUMBER> smn proteins still nonstructural proteins used effective vaccine antigens <NUMBER> stimulate protective immunity many viruses example nonstructural protein ns<NUMBER> <NUMBER> found induce protective immunity infections flaviviruses <NUMBER> non<NUMBER> structural proteins hepatitis c virus reported induce hcvspecific vigorous <NUMBER> broadspectrum tcell responses <NUMBER> nonstructural hiv<NUMBER> gene products also shown <NUMBER> valuable targets prophylactic therapeutic vaccines <NUMBER> therefore reasonable <NUMBER> consider sarscov<NUMBER> nonstructural proteins possible vaccine targets suggested <NUMBER> present study <NUMBER> instead using single protein vaccine antigen would like propose <NUMBER> development cocktail vaccine effective strategy covid<NUMBER> vaccine development <NUMBER> typical cocktail vaccine includes one antigen cover different aspects <NUMBER> protection <NUMBER> licensed group b meningococcus bexsero vaccine developed via <NUMBER> reverse vaccinology contains three protein antigens <NUMBER> develop efficient safe covid<NUMBER> <NUMBER> cocktail vaccine possible mix structural eg protein nonstructural eg nsp<NUMBER> <NUMBER> viral proteins proteins identified study may also considered possible vaccine <NUMBER> targets benefit cocktail vaccine strategy could induce immunity protect host <NUMBER> sace<NUMBER> interaction viral entry host cells also protect <NUMBER> accessary nonstructural adhesin proteins eg nsp<NUMBER> might also vital viral <NUMBER> entry replication usage one antigen allows us reduce volume <NUMBER> antigen thus reducing induction adverse events nonetheless potentials <NUMBER> performance models evaluated using nested fivefold crossvalidation n<NUMBER>cv <NUMBER> based area receiver operating characteristic curve precision recall weighted f<NUMBER> score matthews correlation coefficient best performing xgb model selected <NUMBER> predict protegenicity score sarscov<NUMBER> isolate wuhanhu<NUMBER> genbank id <NUMBER> mn<NUMBER> proteins downloaded ncbi protein protegenicity score <NUMBER> <NUMBER> considered strong vaccine immunity induction weighted f<NUMBER>score <NUMBER> n<NUMBER>cv <NUMBER> <NUMBER> phylogenetic analysis protein nsp<NUMBER> selected investigation nsp<NUMBER> proteins <NUMBER> <NUMBER> coronaviruses besides sarscov<NUMBER> downloaded uniprot table s<NUMBER> multiple <NUMBER> sequence alignment nsp<NUMBER> proteins performed using muscle <NUMBER> visualized via <NUMBER> seaview <NUMBER> phylogenetic tree constructed using phyml <NUMBER> amino acid <NUMBER> conservation estimated jensenshannon divergence jsd <NUMBER> jsd score also <NUMBER> used generate sequence conservation line using nsp<NUMBER> protein sequences <NUMBER> <NUMBER> <NUMBER> coronaviruses <NUMBER> <NUMBER> immunogenicity analysis immunogenicity nsp<NUMBER> protein evaluated <NUMBER> prediction cell mhci mhcii linear b cell epitopes cell mhci epitopes <NUMBER> iedb consensus method used predicting promiscuous epitopes binding <NUMBER> <NUMBER> <NUMBER> mhci reference alleles consensus percentile ranking less <NUMBER> score <NUMBER> cell mhc<NUMBER> ii epitopes iedb consensus method used predicting promiscuous epitopes binding <NUMBER> half <NUMBER> mhcii reference alleles consensus percentile ranking less <NUMBER> <NUMBER> mhci mhcii reference alleles covered wide range human genetic variation <NUMBER> representing majority world population <NUMBER> linear b cell epitopes predicted <NUMBER> using bepipred <NUMBER> cutoff <NUMBER> score <NUMBER> linear b cell epitopes least ten amino <NUMBER> acids mapped predicted <NUMBER>d structure sarscov<NUMBER> nsp<NUMBER> protein visualized via <NUMBER> pymol <NUMBER> predicted count cell mhci mhcii epitopes predicted score <NUMBER> linear b cell epitopes computed sliding averages window size ten amino acids <NUMBER> nsp<NUMBER> protein <NUMBER>d structure predicted using ci tasser ccby <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted march <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint coronavirus disease <NUMBER> caused novel betacoronavirus family member coined sarscov<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> oberfeld et al <NUMBER> december <NUMBER> potentially earlier though unrecognized sarscov<NUMBER> emerged pneumoniacausing disorder hubei province china likely result natural selection animal hosts bats pangolins prior zoonotic transfer andersen et al <NUMBER> wu et al <NUMBER>a zhu n et al <NUMBER> seven members viral family known infect humans three potential cause severe respiratory disease andersen et al <NUMBER> two outbreaks preceding sarscov<NUMBER> include first sars virus emerging late <NUMBER> guangdong province china referred sarscov<NUMBER> followed middleeast respiratory syndrome coronavirus merscov <NUMBER> saudi arabia de wit et al <NUMBER> sarscov<NUMBER> rampaged exponentially around world since start <NUMBER> world health organization declared public health emergency international concern january <NUMBER> <NUMBER> pandemic officially march <NUMBER> <NUMBER> sohrabi et al <NUMBER> time revision review june <NUMBER> <NUMBER> infections <NUMBER> million individuals least <NUMBER> countries ≈<NUMBER> mortality column <NUMBER> collateral damage global economies many professional business recreational sectors travel hospitalitytourism sport etc ongoing widespread due governmentally imposed lockdowns virus spreads primarily respiratory droplets infected individuals figure <NUMBER> enclosed spaces much lesser extent fomites mucosal epithelial cells upper airway oral cavity pambuccian <NUMBER> virus uses trimeric spike protein latch onto host cell ace<NUMBER> angiotensinconverting enzyme<NUMBER> receptor binding sites figure <NUMBER> via receptorbinding domain rbd glycoprotein prefusion state cyranoski <NUMBER> walls et al <NUMBER> wrapp et al <NUMBER> yuan et al <NUMBER> proteases tmprss<NUMBER>furin cleave viral spike figure <NUMBER> enable membranes virus host cell fuse hoffmann et al <NUMBER> oberfeld et al <NUMBER> virus enters cells endocytosis <NUMBER> kb singlestranded plusstrand rna released directly cytoplasm hijacks cell translate viral replicationtranscription complex rtc double membrane vesicle rtc produces rnas translate protein orfs coding <NUMBER> nonstructural proteins four main structural proteins special proteins oberfeld et al <NUMBER> virions assembled rna encased nucleocapsid n coat consisting membrane envelope e spike proteins released viral particles infect cells lower airways type ii pneumocytes enterocytes gastrointestinal tract lamers et al <NUMBER> clinical symptoms infection although highly variable fever dry persistent cough fatigue anosomiadysgeusia loss appetite dyspnea plethora signs may may present eg headaches sore throat myalgia rigors intestinal discomfortdiarrhea ocular manifestations etc oberfeld et al <NUMBER> vetter et al <NUMBER> severe symptoms leading hospitalization progress rapidly hypoxia respiratory distress requiring supplemental oxygen ventilator support prevalent elderly underlying comorbidities however unusual presentation children similar kawasaki disease termed misc multisystem inflammatory disease children emerging viner whittaker <NUMBER> many viralpositive individuals asymptomatic exhibit minor cold symptoms remains incompletely understood increasingly clear multifocal nature covid<NUMBER> pathogenesis sarscov<NUMBER> sometimes instigating destruction blood vessel endothelial cells leading coagulopathy strokes well potential kidney neurological problems sardu et al <NUMBER> blood sampling moderatesevere cases may reveal lymphocytopenia elevation inflammatory markers like creactive protein crp cytokine interleukin <NUMBER> il<NUMBER> along procoagulant state exhibiting elevated ddimer fibrindegradation product indicative immune response control called cytokine storm chen g et al <NUMBER> therapies preventative vaccines immune naïve global population hundreds existing drugs common vaccine repurposed covid<NUMBER> undergoing clinical trials existing vaccine studied netherlands australia tuberculosis bcg bacille calmettegueŕin previously shown mixed broadly protective effects variety respiratory infectious diseases oneill netea <NUMBER> early hype revolved around hydroxychloroquine malaria autoimmune indications antiviral properties drug appears offer minimal benefit covid<NUMBER> resolution potential harm clinical trials shut ferner aronson <NUMBER> tang et al <NUMBER> remdesivir antiviral drug currently fda emergency use authorization eua shown modest benefit reducing symptoms recovery approximately <NUMBER> days one study <NUMBER> effect another tocilizumab recombinant humanized antihuman il<NUMBER> receptor monoclonal antibody may effective rendering cytokine storminducing effects il<NUMBER> less capable initiating damage airways studies required <NUMBER> interferon ifna<NUMBER>b looking promising early results suggest reduces viral load upper airways reduce crp il<NUMBER> zhou q et al <NUMBER> drug therapy aside major step forward current pandemic generation safe effective preventative vaccine several articles already appeared topic ahn et al <NUMBER> amanat krammer <NUMBER> caddy <NUMBER> callaway <NUMBER>a cohen <NUMBER> kim et al <NUMBER> lurie et al <NUMBER> wang f et al <NUMBER> wu <NUMBER> article deals late may <NUMBER> snapshot global race sarscov<NUMBER> vaccine taking place breakneck speed brief prelude diagnostics history vaccines knowing genetic makeup sarscov<NUMBER> essential covid<NUMBER> diagnostics <NUMBER> kb sarscov<NUMBER> genome sequence analysis patient isolate wuhan epicenter china published early january <NUMBER> took place swiftly viral isolation januarymay <NUMBER> genome sequenced multitude times clinical isolates obtained patients around world mavian et al <NUMBER> sarscov<NUMBER> genome <NUMBER> similar sarscov<NUMBER> <NUMBER> merscov <NUMBER> bat coronavirus andersen et al <NUMBER> since deciphering original sequence genetic drift occurring worldwide cases mutations even arising spikeencoding region key gateway host entry could altering virulence becerraflores cardozo <NUMBER> besides four structural proteins sarscov<NUMBER> mentioned e n critical rtc several additional openreading frames orfs encoding nonstructural proteins viral protease within sarscov<NUMBER> genome clear functions deduced prior study sarscov<NUMBER> others unknown function ahn et al <NUMBER> interestingly orf<NUMBER>b appears suppress strongly important type cytokine host immune response blocking interferon konno et al <NUMBER> reverse transcriptasepolymerase chain reaction rtpcr hallmark laboratory diagnostic technology detect viral nucleic acid obtained nasal swabs jurisdiction around world designated screening assays using primer sets either n e rnadependent rna polymerase orf<NUMBER>a orf<NUMBER>b sequences ahn et al <NUMBER> reliable covid<NUMBER> diagnostic tests detect individuals exposed virus paramount importance many asymptomatic infected people recovered covid<NUMBER> carry immunity infection danchin timmis <NUMBER> includes production neutralizing antibodies sarscov<NUMBER> hunt rapid detection assays immuneprivileged individuals colleagues carried detailed analyses <NUMBER> viral antigenserological antibody tests seeking approval already eua important area ghaffari et al <NUMBER> figure <NUMBER> transmission lifecycle sarscov<NUMBER> causing covid<NUMBER> sarscov<NUMBER> transmitted via respiratory droplets infected cases oral respiratory mucosal cells virus possessing singlestranded rna genome wrapped nucleocapsid n protein three major surface proteins membrane envelope e spike replicates passes lower airways potentially leading severe pneumonia gateway host cell entry magnified view via spikeconverting enzyme <NUMBER> ace<NUMBER> interaction cleavage spike prefusion state proteases tmprss<NUMBER>furin simplified depiction life cycle virus shown along potential immune responses elicited generating ideal vaccine protection covid<NUMBER> vaccines one monumental achievements human medical intervention mitigate dispersion impact infectious disease polio serious crippling disorder decades development two separate vaccine candidates jonas salk albert sabin melnick <NUMBER> time first polio outbreak united states testing development almost <NUMBER> years <NUMBER> figure <NUMBER> recently vaccine lethal infectious hemorrhagic fever elicited ebola disease took substantially different timeline development canadian team jones et al <NUMBER> preceding worst outbreak western africa <NUMBER> disease first described isolated cases <NUMBER> taking account prolonged development testing phases still took least <NUMBER> years figure <NUMBER> authorized clinical use ebola vaccine <NUMBER> looking coronavirus diseasecausing outbreaks sars mers led regional epidemics various countries impetus strong initially develop vaccines fizzled spontaneous resolution although vaccine candidates brought forward sarscov<NUMBER> mers projects continue still approved vaccines either infectious agent <NUMBER> <NUMBER> years respectively de wit et al <NUMBER> song et al <NUMBER> since original outbreaks figure <NUMBER> view bar set high developing effective vaccine targeting covid<NUMBER> sarscov<NUMBER> go direction coronaviruses become seasonal outbreak like influenza persist moderately benign severe nuisancecausing infectious disorder lasts years given worldwide magnitude covid<NUMBER> pandemic comparisons great spanish flu <NUMBER> race vaccine candidate taken unprecedented urgency commitment across globe established organizations maintaining databases vaccines development including world health organization <NUMBER> coalition epidemic preparedness innovations <NUMBER> cepi milken institute <NUMBER> nonprofit thinktank california biocentury inc <NUMBER> partner biopharmaceutical industry unparalleled data sharing collaborative team efforts breaking barriers attempt reduce time usual <NUMBER> years approved vaccine <NUMBER> months cepi biomedical advanced research development authority <NUMBER> barda gavi vaccine alliance <NUMBER> formerly global alliance vaccines immunization various governments sources either pouring money efforts fund projects providing logistical support additional initiatives one initiative strategic alliance activ <NUMBER> accelerating covid<NUMBER> therapeutic interventions vaccines publicprivate initiative bringing together dozen leading biopharmaceutical companies cdc centers disease control prevention fda us food drug administration ema european medicines agency develop international strategy coordinated research response covid<NUMBER> pandemic another massive undertaking expedite process operation warp speed <NUMBER> includes scientists pharmaceutical companies us federal officials compared manhattan project <NUMBER> ideal vaccine look like covid<NUMBER> prevention clinical terms three main factors essential robust immune response generating longlasting neutralizing antibodies sarscov<NUMBER> antigens eg n imperative figures <NUMBER> <NUMBER> individuals infected foreign antigens viruses evoke innate adaptive immune reactions coordinated antigenpresenting cell apc attack virus thelper cell activation leads blymphocytes producing antibodies context ideally antibodies directly interfere sarscov<NUMBER>s knack latching onto epithelial cells type ii pneumocytes via ace<NUMBER> figure <NUMBER> order neutralize virus would curtail successfully virus infecting host protective infection resulted however remains critical shortfalls current knowledge comprises protective immune response covid<NUMBER> long lasts may <NUMBER> ii ideal sarscov<NUMBER> vaccine also induce potent tlymphocyte immunity ideally would wellcoordinated orchestrated tcell response includes thelper cytotoxic tlymphocyte subsets recognize sarscov<NUMBER> infected cells body annihilate block viral replication along acquisition memory tcells prevent reinfection months years later iii candidate vaccine limit serious adverse events saes injection site systemically example fever infants young children case respiratory disorders caused infectious agents essential vaccineassociated enhanced respiratory disease vaerd antibodydependent en hanc emen ade n tibo dy depende nt ce llular cytotoxicity adcc complementdependent cytotoxicity including cytokine storminducing effects completely avoided graham <NUMBER> hotez et al <NUMBER> vardhana wolchok <NUMBER> clinical sequelae associated past vaccines development figure <NUMBER> prominent example respiratory syncytial virus rsv late <NUMBER>s graham <NUMBER> since virus apparently activates complement deposition small blood vessels infected individuals magro et al <NUMBER> blocking adverse host responses essential complement inflammation coagulation systems intertwined oikonomopoulou et al <NUMBER> hyperactive covid<NUMBER> positive cases vaccine provoke host response systems logistical terms essential parameters ideal candidate vaccine covid<NUMBER> vaccine easy administer preferably single dose lowest possible amount oral intranasal vaccine would ideal ii vaccine facile produce scaleup manufacturing millions billions doses required immunize human population must feasible rapid iii longterm storage vaccine room temperature sought goal facilitate transport stockpiling underdeveloped nations inadequate supply chains cold chain capacities figure <NUMBER> ideal vaccine targeting covid<NUMBER> would fit proposed target product profile described table <NUMBER> normal strides taken achieve successful vaccine development similar drug process stringent seeing culminate administration vaccine candidate billions humans typical paradigm depicted figure <NUMBER> explained legend scientific publications date ahn et al <NUMBER> amanat krammer <NUMBER> caddy <NUMBER> callaway <NUMBER>a callaway <NUMBER>b cohen <NUMBER> chen wh et al <NUMBER> kim et al <NUMBER> lurie et al <NUMBER> thanh le et al <NUMBER> wang f et al <NUMBER> wu <NUMBER> well databases mentioned various formats classifying vaccine platforms analysis consider seven main platforms vaccine development along eighth catchall category figure <NUMBER> two nucleic acid platforms dna <NUMBER> candidates rna <NUMBER> candidates could subdivided according particular traits related delivery carriers eg electroporation special devices intradermally vs oral formulation lnps vs exosomes simplicity considered two categories nucleic acid platforms belong new generation vaccines neither reached licensing human use number tested humans cohen <NUMBER> third category termed proteinbased also referred subunit vaccine includes broad range technologies prepare immunestimulating viral protein antigens represents largest category current covid<NUMBER> figure <NUMBER> timelines development various vaccines polio ebola virus three betacoronaviruses sarscov<NUMBER> merscov sarscov<NUMBER> left side timeline reference point first clinical case description andor first recognized cases type viral infection significant events depicted along timeline according scale solid horizontal red bars indicate approximate period first outbreakvaccine clinically approved use dotted red lines indicate availability vaccines since first outbreak green dotted line represents rapid emergency use authorization timeline putative sarscov<NUMBER> vaccine vaccine candidates currently <NUMBER> development like nucleic acids proteinbased vaccines represent newer technology already use clinical realm eg gardasil human papillomavirus fourth fifth categories viralbased vectors similar used gene therapy include nonreplicating <NUMBER> candidates replicating <NUMBER> candidates vectors next two sarscov<NUMBER> viruses either inactivated usually chemical bpropriolactone chemically inactivates enveloped viruses inhibit viral membrane fusion dosedependent manner liveattenuated version generated techniques codon deoptimization serial passaging cell culture mueller et al <NUMBER> category includes viruslike particles vlps use nonsarscov<NUMBER> virus carriers killed rabies coravax live modified horsepox tx<NUMBER> <NUMBER> category repurposed existing vaccines polio tuberculosis evoke general immunity various cellular immunotherapies stimulate host immune system encapsulated convalescent serum unknown platform designation listed milken institute database excluded analyses figure <NUMBER> according criteria <NUMBER> sarscov<NUMBER> vaccines development astounding across globe short timeframe ideal covid<NUMBER> vaccine reach routine use humans imperative vaccine protects clinical disease viral transmission order break chain persontoperson pandemic spread advantages disadvantages platform considered table <NUMBER> section provide specific details <NUMBER> <NUMBER> vaccines pipeline registered clinical trials already tested may <NUMBER> <NUMBER> addition currently cepiandor bardasponsored platform yet clinical trials provide snapshot field early endeavors procure functional sarscov<NUMBER> vaccine man proposed developmental pipeline figure <NUMBER> one also refer table <NUMBER> abbreviated account <NUMBER> candidates vaccine candidates name specified refer lead figure <NUMBER> development ideal vaccine covid<NUMBER> depicted concentric circles converging target normally development occurs three discrete phases research development rd involving platform selection designing targets eg whether might selection rna sequence decisions nucleoside substitutions lipid nanoparticle lnp formulation etc decisions create liveattenuated viral preparation preclinical testing vitro cell culture vivo animals sarscov<NUMBER> rd animal models used transgenic mice overexpress spikebinding protein ace<NUMBER> syrian hamsters ferrets nonhuman primates nhps encouraging results apparent preclinical phase indicated various parameters green boxes candidate vaccine taken second phase consists testing human volunteers three stages clinical trials phase phase ii phase iii may concatenated expedite approval eg phase iiiii due pandemic nature covid<NUMBER> outer concentric phases pursued simultaneously expedited approvals potential emergency use authorizations vaccine safety efficacy achieved human volunteers logistical operations become major hurdles ensure worldwide distribution coordinated interconnected manner manufacturing supply chain distribution storage etc vaccine candidates achieve satisfactory results clinical trials due various factors shown red boxes dropped development ade antibodydependent enhancement adcc antibodydependent cellular cytotoxicity cdc complementdependent cellular cytotoxicity vaerd vaccineassociated enhanced respiratory disease ae adverse event endorse particular candidate cepiwho bardagavi governments taking panplatform approach recognizing best path forward antigen sarscov<NUMBER> spike glycoprotein details platform dna plasmid expressing trimeric hybrid transporter protein within bifidobacterium longum delivered colonic epithelial cells prime immune response via colonic lymphoid tissues <NUMBER> target product profile ideal sarscov<NUMBER> vaccine targeting covid<NUMBER> prophylactic vaccination sarscov<NUMBER> infection susceptible healthcare workers hcw children adolescents adults usecase scenarios use current pandemic response subsequent wave outbreaks use routine immunization supplementary immunization stockpiling vaccine covid<NUMBER> formulation contains sarscov<NUMBER> vaccine sterile liquid format direct oral use lyophilized format simple reconstitution point use requiring endtoend cold chain presentation singleuse multidose vial liquid lyophilized stored room temperature stability thermostable light sensitive stability vaccine potency durable <NUMBER> yrs room temperature dose regimen amount single dose <NUMBER> ml less injectable second boosting dose <NUMBER> weeks later necessary route administration oral preferred subcutaneous intradermal intramuscular acceptable target population individuals aged <NUMBER> months target countries countries around world safety profile based least two data sets preferably least <NUMBER> subjects age groups immunogenicity phase iii clinical studies include immunogenicity arm serum blood samples collected tested antibody cellmediated immunity possible minimum serological correlate protection determined based shortterm longterm efficacy sarscov<NUMBER> vaccine administered vaccine administered concomitantly influenza vaccine separate sites pregnancy limited information administration sarscov<NUMBER> vaccine pregnant lactating women user training requirements minimal training administered hcw trained layperson costimmunized individual cogs reasonable governments highand lowincome nations disposal safe disposal vialssharps biohazard waste point use safety platform extensive worldwide use probiotics however dna vaccines currently market use humans particular strategy untested advantages fast design manufacturing cold chain storage distribution robust immune response mucosal immunity predicted clinical trial registration nct<NUMBER> start date june <NUMBER> projected official name trial phase <NUMBER> randomized observerblind placebocontrolled trial evaluate safety tolerability immunogenicity bactrlspike oral candidate vaccine prevention covid<NUMBER> healthy adults study design phase doseescalating three cohorts n<NUMBER> dosing regimen single oral dose bactrlspike three doses <NUMBER> <NUMBER> <NUMBER> million bacteria placebo cohort n<NUMBER> vaccine n<NUMBER> placebo endpoints primary incidence severity adverse events aes secondary seroconversion virus stool shedding protection covid<NUMBER> partners none announced funding partners none announced manufacturing partners none announced next stage obtain results phase study end year get <NUMBER> enrolled phase iiiii studies official name trial study describe safety tolerability immunogenicity potential efficacy rna vaccine candidates covid<NUMBER> healthy adults study design phase iii randomized placebocontrolled observerblind dosefinding vaccine candidateselection study healthy adults <NUMBER> experimental arms four vaccine targets bnt<NUMBER>a<NUMBER> bnt<NUMBER>b<NUMBER> bnt<NUMBER>b<NUMBER> bnt<NUMBER>c<NUMBER> x <NUMBER> age groups <NUMBER> yo <NUMBER> yo <NUMBER> yo × <NUMBER> dosing time points timing specified × <NUMBER> doses low mid high amounts specified <NUMBER> placebo comparator arms carried three stages stage <NUMBER> identify preferred vaccine candidates timeline several hundred million doses bulk rna year current gmp iii facility new gmp iv suite put operation within two years capacity production one billion doses per year possible recombinant proteinbased vaccines name nvxcov<NUMBER> company country antigen recombinant sarscov<NUMBER> spike protein prefusion state routemode administration im injection deltoid muscle safety platform novavaxs platform tested several phase ii iii trials seasonal influenza ebola rsv appears safe advantages fast design relatively rapid production possible clinical trial registration nct<NUMBER> start date may <NUMBER> <NUMBER> next stage preliminary data phase july proceeding phase ii <NUMBER> volunteers multiple countries later summer results expected end <NUMBER> timeline <NUMBER> million doses yearend billion end <NUMBER> ii name scb<NUMBER> company country clover biopharmaceuticals inc china antigen recombinant trimeric sarscov<NUMBER> spike protein details platform patented trimertag ® technology produce strimer protein subunit vaccine resembles native trimeric viral spike via rapid mammalian cellculture based expression system routemode administration im injection deltoid muscle safety platform clover previously developed recombinant subunittrimer vaccines rsv influenza viruses utilizing trimertag ® technology demonstrated able evoke protective neutralizing antibody responses multiple animal models appears safe v n g e f e g n n r e l v e l r p production possible clinical next stage get clinical trials underway evaluate data timeline disclosed yet iii name lead candidate organization country antigen recombinant trimeric sarscov<NUMBER> spike protein details platform molecular clamp platform synthesizing viral surface proteins attach host cells infection clamping shape making easier immune system recognize correct antigen routemode administration presumably im injection safety platform unknown details specific platform v n g e f e g n n r e l v e l r p production possible clinical trial registration yet registered start date july <NUMBER> projected official name trial yet started take place australia study design phase started yet dosing regimen known endpoints known partners peter doherty institute infection immunity melbourne vaccine development viroclinics xplore preclinical animal studies gsk adjuvant funding partners cepi <NUMBER> manufacturing partner cytiva previously ge healthcare life sciences well lonza thermo fisher scientific cslseqirus dynavax gsk supply adjuvants next stage get clinical trials underway timeline disclosed yet iv name lead candidate company country sanofi gsk collaboration franceuk antigen recombinant trimeric sarscov<NUMBER> spike protein details platform sanofis recombinant dna technology sf<NUMBER> insect cell expression system routemode administration presumably im injection safety platform combination proteinbased antigen together adjuvant wellestablished used number vaccines available today v n g e f e g n n r e l v e l r p production possible clinical trial registration yet registered start date julyseptember <NUMBER> projected official name trial yet named study design phase started yet dosing regimen known endpoints disclosed yet funding partners barda manufacturing partners sanofi gsk global leaders vaccine development capacity generate millions doses next stage get clinical trials underway complete development required availability vaccine second half <NUMBER> timeline disclosed yet viral vectorbased nonreplicating name azd<NUMBER> formerly chadox<NUMBER> ncov<NUMBER> company country university oxfordastra zeneca collaboration uk antigen sarscov<NUMBER> spike glycoprotein details platform azd<NUMBER> derives chimpanzee viral vector chadox<NUMBER> weakened version common cold adenovirus spikeencoding region cloned e<NUMBER> locus although infects primate genetically altered incapable viral spread humans vector modality vaccine candidates influenza tuberculosis chikungunya zika viruses routemode administration im injection safety platform vaccines made chadox<NUMBER> viral vector platform <NUMBER> different pathogens tested thousands volunteers <NUMBER> week <NUMBER> yo date safe well tolerated although cause temporary side effects temperature elevation headache sore arm advantages favorable safety tolerability profile platform clinical trial registration nct<NUMBER> nct<NUMBER> phiiiii start date april <NUMBER> <NUMBER> official name antigen fulllength sarscov<NUMBER> spike glycoprotein details platform ad<NUMBER> vectors well studied grown high titer stable stocks infect nondividing dividing cells maintained cells episome essential e<NUMBER>a e<NUMBER>b genes deleted replaced expression cassette high activity cytomegalovirus immediate early cmv promoter drives expression target protein routemode administration im injection deltoid safety platform general safe well tolerated however dangerous immunocompromised individuals one drawback could preexisting neutralizing abs ad<NUMBER> vector adults advantages welltested vector gene therapy vaccination trials mers ebola could difficult largescale manufacturing study design phase nonrandomized open label doseescalating three cohorts low middle highdose <NUMBER> yo n<NUMBER> ii phase ii randomized doubleblinded placebocontrolled <NUMBER> groups lowand middledose placebo n<NUMBER> dosing regimen single dose <NUMBER> x <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> x <NUMBER> <NUMBER> vp ad<NUMBER>ncov n<NUMBER>cohort ii single dose <NUMBER> x <NUMBER> <NUMBER> vp n<NUMBER> <NUMBER> <NUMBER> vp n<NUMBER> placebo n<NUMBER> endpoints primary general safety including adverse events aes <NUMBER> <NUMBER> phase ii days injection secondary safety <NUMBER> months various immunogenicity indices <NUMBER> months phase ii timeline preliminary data phase published see exact timelines production scaleup reported iii name ad<NUMBER> sarscov<NUMBER> <NUMBER> back ups company country johnson johnson usa antigen undisclosed details platform janssens advac ® perc<NUMBER> ® technologies allow million doses produced <NUMBER> liter bioreactor since cells grow high density suspension culture nonreplicating ad<NUMBER> vector e<NUMBER>e<NUMBER> genes deleted likely better ad<NUMBER> since less likelihood preexisting antibodies vector routemode administration im injection deltoid safety platform particular platform technology used investigational ebola vaccine africa also used zika rsv hiv vaccine candidates appears safe advantages welltested vector gene therapy vaccination trials transportstorage <NUMBER>°c <NUMBER> months clinical trial registration yet registered start date september <NUMBER> projected official name trial known yet antigen whole virus initial reports rbd within spike protein main immunogen details platform inactivated viral vaccine platform straightforward used extensively cn<NUMBER> sarscov<NUMBER> virus plaquepurified passaged several times vero cells prior inactivation bpropiolactone verification inactivation followed stringent purification protocols mixing alum adjuvant routemode administration im injection safety platform vaccines made inactivated virus used throughout world generally excellent safety profile may <NUMBER> press release interim data <NUMBER> ensuing evaluation callaway <NUMBER>c company reported initial eight participants mrna<NUMBER> two lower doses <NUMBER> <NUMBER> µg evoked neutralizing antibody titer levels reaching exceeding neutralizing antibody titers generally seen convalescent sera measured plaque reduction neutralization assay live sarscov<NUMBER> mrna<NUMBER> generally safe well tolerated provided full protection viral replication lungs mouse challenge model view data company forging phase ii iii studies anticipated dose phase iii using <NUMBER> µg <NUMBER> µg rna since level neutralizing antibodies sarscov<NUMBER> generally quite variable cases undetectable people recovered covid<NUMBER> without hospitalization wu et al <NUMBER>b remains seen effective moderna vaccine candidate providing longterm immunity come focus upcoming large clinical trials preclinical trial van doremalen et al <NUMBER> nhps rhesus macaques administered high dose sarscov<NUMBER> receiving single dose vaccine similar regimen used current clinical trials active treatment group animals n<NUMBER> produced elevated levels sarscov<NUMBER> neutralizing antibodies compared increase control group n<NUMBER> indistinguishable amounts virus nasal compartment compared control animals significantly reduced viral load lungs vaccinated nhps free clinicalgrade pneumonia contrast controls although levels antibodies cellmediated cytokine responses vaccinated nhps substantial nobody knows yet whether level immune response protective humans long protection last complete analysis phase data obtained march <NUMBER> march <NUMBER> <NUMBER> n<NUMBER> participants <NUMBER> male <NUMBER> female mean age <NUMBER> yo equal numbers receiving low midand highdoses vaccine mildmoderate aes <NUMBER> group injection site pain fever fatigue headache muscle pain saes within first <NUMBER> days postvaccination neutralizing antibodies increased significantly <NUMBER> day timeframe postvaccination along specific tcell responses data indicate ad<NUMBER>vectored covid<NUMBER> vaccine warrants investigation continue phase ii randomized doubleblinded placebocontrolled study see preclinical nhp study robust sarscov<NUMBER>specific neutralizing antibody responses rhesus macaques received three doses inactivated virus importantly afforded partial full protection clinical signs lung injury viral challenge addition signs ade world anxiously awaiting safe effective vaccine protect covid<NUMBER> order resume normal lifestyle free public health agencygovernment lockdowns fear ongoing pandemic waves coming monthsyears never modern era science accumulation scientific papers preprint archives biorxivmedrxiv ≈<NUMBER> preprints peerreviewed publications pubmed ≈<NUMBER> papers reached exponential heights short period thousands allthingsconsidered covid topics mobilization data sharing joint global efforts toward vaccine goal monumental hoped collaborative framework activ others around world prioritizing vaccine drug candidates streamlining clinical trials coordinating regulatory processes andor leveraging assets among various partners rapidly respond covid<NUMBER> future pandemics soon reality however successful path forward challenging certainly guaranteed instance efficacious approved vaccine hivaids come forward <NUMBER> years main hiv surface protein host cell entry covered sugars spike protein sarscov<NUMBER> lesser extent watanabe et al <NUMBER> sitespecific glycan shield provide difficulties target antigen recognition properly reconstituted vaccine platforms necessary target spike protein approaches banking cryptic epitopes antibody recognition need considered yuan et al <NUMBER> multivalent formulations may required generate effective longlasting immunity ideal target product profile table <NUMBER> sarscov<NUMBER> antibodybased therapeutics derived consortia covic <NUMBER> coronavirus immunotherapy consortium research groupsbiopharma covid<NUMBER> already entered clinical trials <NUMBER> biologics well repurposed drugs likely provide midterm solutions wait patiently muchanticipated vaccine cf aa conceived design concepts cf wrote manuscript cl contributed key information table <NUMBER> authors contributed article approved submitted version research funded queens university special research project <NUMBER> cdf companies skill able going sit around warm facility ready go need said anthony fauci director national institute allergy infectious diseases nih usa member white house coronavirus task force panel discussion florko <NUMBER> aware mood vaccinemanufacturing big pharma changed much since <NUMBER>s largely driven pertinent questions demand fade away end outbreak people choose sometimes due foolish reasons vaccine hesitancy use product would timeline reach breakeven create wealth negligible prospects profits drug makers neglecting emerging infectious disease areas however due present spread covid<NUMBER> pandemic claimed time writing article <NUMBER> lives infected <NUMBER> individuals far across continents except antarctica need vaccines rekindled new interests higher enthusiasm johns hopkins university <NUMBER> understood rapidity response contain outbreak designing modalities treatment according reports institute pasteur shanghai first notice treatments provided pneumonia hospitals wuhan china received <NUMBER>th december <NUMBER> within <NUMBER> days coronavirus identified <NUMBER>th january <NUMBER> first genome virus shared university sydney behalf chinese academy sciences fontanet <NUMBER> huang et al <NUMBER> consequent number efforts made socially contain outbreak screen available drugs repurposing covid<NUMBER> design specific vaccines new coronavirus review highlights genomic features coronavirus considered vaccine design current innovations vaccine technology global efforts future challenges vaccine developments covid<NUMBER> covid<NUMBER> new infectious disease respiratory tract chances developing fulminant pneumonia similar severe acute respiratory syndrome sars caused new coronavirus sarscov<NUMBER> spreads contact respiratory droplets nose mouth chan et al <NUMBER> <NUMBER>a notably <NUMBER> people exposed infected develop active disease show mild symptoms seasonal flu recover without major treatment however estimated rate incidence much higher range <NUMBER> comparison <NUMBER> flu initial observations concludes developing severe disease require hospitalization period twice much acute flu lenski <NUMBER> originated hubei province china late <NUMBER> spread rapidly around world humantohuman transmission along international airtravel routes case fatality rate covid<NUMBER> time writing article stands <NUMBER> times <NUMBER> reported seasonal flu lenski <NUMBER> sarscov<NUMBER> third member pathogenic coronavirus sarscov merscov causes middle east respiratory syndrome shows severe pathology humans among others cause mild clinical symptoms like flu cui et al <NUMBER> absence clinically proven effective treatment regime current therapies covid<NUMBER> mainly receive supportive care supplemented different combinations antiretroviral drugs fda approved drugs immune therapies repurposed currently clinical trials several stages available compassionate grounds proven efficacious controlling sars influenza hiv ebola virus replication either targeting viral rna polymerase polyprotein protease boosting host immunity adjunct therapy harrison <NUMBER> convalescent plasma recovered individuals monoclonal antibody therapies showed success ebola outbreak western africa developed van griensven et al <NUMBER> antibodies also form basis serological diagnosis asymptomatic spreaders absent moment however restrict discussion multiple vaccines developed sarscov<NUMBER> <NUMBER> origin sarscov<NUMBER> genomic insights vaccine development entire initial set five genome sequences available concluded new coronavirus <NUMBER> identical among suggesting recent entry humans zhou et al <NUMBER> <NUMBER> viral genomes known today form tight cluster based phylogeny show evidences <NUMBER> mutational events much lower expected rate <NUMBER> <NUMBER> substitutions per site per year slow evolution despite carrying rna genome much advantage vaccine researchers dong et al <NUMBER> closest match <NUMBER> overall identity batderived betacoronaviruses indicating zoonotic origin disease similar sars mers genetically distinct respective coronaviruses andersen et al <NUMBER> interestingly genomic evolutionary evidence places coronavirus found malayan pangolins pangolincov next best match greater <NUMBER> identity thus hinting anteater possible intermediate host new coronavirus spillover bats like palm civets dromedary camels case sarscov merscov respectively study posits pangolinscov possible common ancestor human bat versions based key amino acid residues present surface protein crucial interaction host receptor recombination events among small subgenomic regions common coronaviruses due high level coinfection exists hosts therefore tracing evolutionary history coronaviruses quite challenging debatable positivestrand rna genome consists six major open reading frames accessory genes coding typical nonstructural proteins including rnadependent rna polymerase proteases structural proteins including matrix envelope e spike nucleoprotein n surface spike glycoprotein responsible binding human cell surface receptor followed membrane fusion entry figure <NUMBER> de wit et al <NUMBER> spike protein also pivotal determining host specificity estimating capacity disease transmission production neutralizing antibody human generally spike protein coronaviruses consists signal peptide extracellular transmembrane intracellular regions hostrecognizing extracellular domain responsible cell membrane fusion divided polybasic cleavage site receptor binding s<NUMBER> domain s<NUMBER> domain andersen et al <NUMBER> comes sequence identity amino acid level determines molecular recognition host receptor s<NUMBER> domain shows <NUMBER> identity comparison bat version expectedly phylogenetic analysis also places receptor binding domain lineage closer sarscov version thus suggesting binding angiotensinconverting enzyme <NUMBER> ace<NUMBER> zhou et al <NUMBER> underscores emergence reservoirs sarscov<NUMBER> originated bats may jumped pangolins plausible long period natural selection human humanlike ace<NUMBER> receptor binding domain appears accumulated mutation five amino acid positions optimizing binding host following early zoonotic transfer much november <NUMBER> andersen et al <NUMBER> educated speculation indicates covid<NUMBER>type epidemic may recur time future different sarscov<NUMBER> variant evolving early isolates selective pressure animals emphasizing need vaccine vaccination strategies effectively used reduce disease severity control transmission viral shedding prevent future infections vaccines usually directed induce arms adaptive immune response producing neutralizing antibody prevents attachment host cells activate bodys killer cells recognize kill infected cells vaccine candidates chosen various approaches available per level protection required simplest method involves introducing virus body inactivation chemicals gamma irradiation heat proteins expressed dead viral surface serves antigen induce production neutralizing antibodies case early polio vaccine figure <NUMBER> bandyopadhyay et al <NUMBER> another method involves introducing weakened attenuated versions virus slowly replicates inside host cell provides enough viral antigen induce immune response like oral polio vaccine rabies vaccine bcg vaccine given birth prevent childhood tuberculosis administering nonvirulent organism less safe inactivated virus cause disease outbreak much superior terms establishing mild infection necessary mounting successful adaptive immune response afrough et al <NUMBER> developing attenuated vaccine short time however challenging requires isolating nonvirulent strain several rounds timeconsuming subculturing laboratory requires adequate knowledge virulence factors expressed coronavirus furthermore level type adaptive immune response sometimes depend strain used product one types currently preclinical development estimate efficacy toxicity formaldehydeinactivated formulation developed sinovac biotech china genetically modified poorly replicating coronavirus developed partnership codagenix usa serum institute india india using proprietary deoptimization technology platform earlier used developing vaccines zika dengue influenza <NUMBER>b targeted approach involves inducing adaptive immunity introducing immunogenic viral proteins fragments generate antibodies cellmediated immune response delivering antigenic epitopes optimal levels antigen presentation required broad protective immunity vital successful immune response high degree similarities genome structural proteins even host attachment receptor indicates existence possible similarity immune responses two sars coronaviruses also means conclusions made studies sarscov proteins might help determining immunogenic determinants required vaccine development addition high level potent antibodies n proteins sarscov incidentally shortlived strong tcell responses provide long term protections detected structural proteins tang et al <NUMBER> intriguingly experimentally identified dominant bcell tcell epitopes sarscov mapped amino acid sequence spike nucleocapsid proteins <NUMBER> tcell epitopes matched sarscov<NUMBER> proteins without single mutation epitopes located within predicted receptor binding domain spike protein associated prevalent major histocompatibility complex mhc alleles human population ahmed et al <NUMBER> similarly large number bcell epitopes found complete sequence identity nucleocapsid protein s<NUMBER> s<NUMBER> domains spike protein prevalence epitopes corresponding less exposed s<NUMBER> domain however indicates possible access antibodies post attachment host cell analysis also helps preclude apprehensions mismatches observed receptor binding region s<NUMBER> domain structural analysis spike protein wrapp et al <NUMBER> antibodies raised s<NUMBER> domain sarscov spike protein may crossreact neutralize sarscov<NUMBER> thus positing excellent opportunity repurposing candidate monoclonal antibodies cross phase trials sars vaccine development tian et al <NUMBER> therefore spike protein sarscov confidently placed potent antigenic determinant candidate vaccines developed another important consideration designing vaccines particularly case rna viruses generally higher mutation rates antigenic drift genetic variability plays pivotal role choosing best genome sequence viral strain vaccine development means need sequence sarscov<NUMBER> genome many regions possible around world dong et al <NUMBER> choosing right vaccine candidate much art science since finding viral components trigger severe inflammation provide protective immune memory trivial nothing much known immune pathology disease immune evasion strategies employed virus evade host defense assumption based studies conducted sarscov several new vaccine generation methods based concept plugandplay developed used test candidates multiple infections short time possible primarily safety features determined predominantly upstream downstream process technology employed pathogen interest vignettes certain approaches using recombinant virus technology nucleic acid vaccines selfdisseminating protein vaccine approaches briefly described figure <NUMBER> since virus obligate intracellular replicative entity requires host cell proliferation vaccine strategies aimed preventing attachment virus host cell molecular interface recognition characterized binding viral surface protein spike glycoprotein sarscov<NUMBER> receptor human cells ace<NUMBER> lu et al antibodies generated surface protein antigen helps neutralize receptor binding thus making protein subunit vaccines popular however proteins would normally unstable may lose molecular structure soon injection rendering difficult immune cells produce antibodies specific virus furthermore freefloating viral protein may change shape postrecognition stable conformation different prerecognition state displayed surface virus molecular clamping approach uses joining key structural polypeptides several regions protein structure efficiently retain original shape immunogenic epitopes thus stimulating stronger response uniquest <NUMBER> advances made understanding replication pathogenesis wide variety viruses along development tools genetic manipulation possible generate safer attenuated vaccines expressing recombinant viral protein antigens proxy infection model robertguroff <NUMBER> replicating vectors use includes adenovirus measles virus poxvirus vesicular stomatitis virus vsv humphreys sebastian <NUMBER> viruses either nonpathogenic humans vsv carry genetically modified genome neutralizes virulent nature coding sequence required proteinsubunit antigen attached genome optimal expression assembly packaging recombinant virus two major advantages underscore potential vaccine choice ability elicit complete innate adaptive immune response also tunable terms type intensity response biggest advantage proxy natural infection model employed also allows induction costimulatory immune molecules provide adjuvant effect second replicative nature allows achieving similar protection <NUMBER> log lower dosage vectors based measles virus considered vaccines hivaids sars due potential provide lifelong immunity result ability infect antigenpresenting cells dendritic cells macrophages zuniga et al <NUMBER> case genes essential replication adenovirus deleted among others adenoviral genome replaced antigenic protein coding genes locus robertguroff <NUMBER> popular modified vaccinia virus ankara mva natural attenuated version poxvirus repeated subculture chicken cells mva lost ability replicate evade immune surveillance human cells kennedy greenberg <NUMBER> replicationdeficient vectors accommodate larger gene inserts also provide stability terms regaining virulence compared replicationcompetent versions one problems using protein subunit vaccine presenting antigen stable effective conformation vlps composed multiple structural proteins upon recombinant expression ability selfassemble nanostructures enclosing capsid proteins within syomin ilyin <NUMBER> vlps lipid envelope originating cell membrane producing form budding also chimeric nature displaying envelope protein another virus wide range production platforms expressing correctly folding antigenic proteins available bacterial yeast systems insect mammalian cell lines even transgenic plants addition since vlps lack genome offer similar level stability nonreplicating vectors thus offering safety subunit vaccine efficacy liveattenuated vaccine together nucleic acidbased vaccines emerged better alternative live inactivated vaccines treatments emerging pathogens dna expressing pathogens protein produced short time involve growing virus laboratory gives equivalent protective immunity forms case dna sequence introduced often facilitated nanocarriers directly cells specific tissue make way nucleus help targeting sequence viral surface protein production driven optimized promoter outsourced host cells natural machinery hobernik bros <NUMBER> dna vaccines safe stable large quantities produced short time costeffective manufacturing processes crucial distribution lowincome regions first identified studying immunization tumor antigens cancer therapy mrna vaccines extensively studied emerging pathogens like dna vaccines represent new generation therapies mrna nature avoid risk integrated host genome bonus come two flavors traditional mrnabased vaccines selfamplifying mrna vaccines work strategy using host cell transcription machinery produce target proteins induce adaptive immunity pardi et al <NUMBER> former replicationdeficient contains antigens mrna latter codes modified genome rna virus target antigen choice replaces viruses native genes coding structural proteins resulting virus express heterologous antigenic genes cytoplasm high numbers cannot package functional virus mrna amplify using rna dependent rna polymerase coded genome geall et al <NUMBER> innovations rapidly utilized develop multiple vaccines new coronavirus several epidemiological models predict present pandemic stay quite time albeit several small pockets around world reappear subsequent waves infection coronavirus usher new era developing innovative vaccines emerging infectious disease beyond covid<NUMBER> wait results clinical trials come vaccine development infectious diseases equally challenging similar drug development normally takes amount time case covid<NUMBER> even harder unknown disease pathogenesis unavailability validated animal model success dependent human clinical trials despite scale severity current pandemic attracted around <NUMBER> companies big pharma small biotechnology firms university spinoffs develop vaccine sarscov<NUMBER> lee <NUMBER> <NUMBER>b thanks attractive funding two government agencies usa biomedical advanced research development authority department health usa national institute allergy infectious diseases national institutes health usa work initiated many <NUMBER> candidate vaccines table <NUMBER> currently clinical preclinical stages covid<NUMBER> outbreak also highlighted innovations funding mechanism involvement coalition epidemic preparedness innovations cepi global alliancebased vaccine accelerator emerging infectious diseases founded <NUMBER> governments india norway initial support world economic forum philanthropic organizations like bill melinda gates foundation usa wellcome trust uk generous funding enabled several small biotechnology firms academic institutions triage diverse candidates essential situations hard predict one stage reach culdesac new candidates based traditional approaches also built existing vaccines leveraging platforms used develop sars mers vaccines important mention although great similarities immunogenic epitopes two sarscovs vaccines covid<NUMBER> similar ones proposed coronaviruses newly developed vaccine ebola zaire virus glaxosmithkline uk produced using adenoviral vectors used hiv candidate based nonreplicating adenoviral vector used ebola university oxfords jenner institute proposed start phase trial nonreplicating adenoviral vectorbased vaccine backbone chadox<NUMBER> due proven efficacy among older people underlying comorbidities devlin <NUMBER> among others candidates undergoing preclinical testing mrnabased vaccines germanys curevac funded european union cepi biontech codeveloped pfizer companies repurposing leads personalized cancer treatments deliver vaccines tunable per level immune response required curevac <NUMBER> pfizer <NUMBER> like moderna another american company novavax redeveloped spike proteinbased vaccine sars combination proprietary matrix adjuvants institute pasteur leading consortium university pittsburgh themis biosciences austria work replicating measles vaccine virus vector technology based sarscov pasteur institute <NUMBER> availability highresolution molecular structure trimeric spike protein researchers university queensland australia using disruptive molecular clamp technology helps viral proteins maintain shape thus enabling immune system mount stronger response university queensland <NUMBER> combined glaxosmithklines proprietary adjuvants order generate longlasting immune response lower adjuvanted dose allows immunization larger number individuals low amount protein product adjuvantbased potentiation also offered clover biopharmaceuticals trimeric spike protein vaccine candidate promising widely discussed dna vaccine candidate ino<NUMBER> developed inovio pharmaceuticals succeeded raising funds cepi although dnabased vaccines received regulatory approvals past company delivered vaccine since inception committed start clinical trials april <NUMBER> received support bill melinda gates foundation develop intradermal electroporation device vaccine delivery linnane <NUMBER> intriguingly largescale phase iii randomized control trials started australia netherlands check effectiveness bcg vaccine liveattenuated strain mycobacterium causes tuberculosis cattle reducing incidences disease severity among healthcare workers exposed sarscov<NUMBER> byrne <NUMBER> recent development stems report claimed found excellent correlation countrywise severity covid<NUMBER> symptoms national immunization program protection childhood tb tb meningitis miller et al <NUMBER> also surprising note countries practicing compulsory bcg vaccination also socioeconomically backward therefore reports low morbidity mortality covid<NUMBER> may related low comorbidities contributed lifestyle diseases necessarily protection offered bcg vaccination study draws link high mortalities iran started bcg vaccination later <NUMBER> lack nonspecific protection among older population nonspecific protection bcg viral infections plausibly offered induction innate immune memory new concept results enhanced production immune modulators cytotoxic activity immune cells nevertheless true might help provide levels protection new specific vaccine made available moorlag et al <NUMBER> however would interesting learn outcome large trials respect degree protection achieved different strains bcg known provide wide range efficacies case tuberculosis adults usually takes <NUMBER> years development classical path using inactivated live attenuated vaccines generating longterm efficacy data ebola emergency time brought <NUMBER> years candidates based viral vector vaccines involved running key steps phase ii trials parallel covid<NUMBER> contagion rapidly engulfs quarter worlds population inovio pharmaceutical ambitiously accelerated timeline publish human clinical trials data fall <NUMBER> remarkably less year inovio pharmaceuticals <NUMBER> also expected keeping mind might enough patient volunteers available participate human trials later however test cohort miss including different age groups ethnicity gender pregnant women finally data needs collected rare occurrence immunizationmediated enhancement severe illness infection primarily caused development subneutralizing antibodies promotes excessive viral entry host cells wan et al <NUMBER> however comes manufacturing delivery process faces myriad new challenges often experienced pharmaceutical industry large quantities candidate vaccine generally required start fullscale phase iii trial immunizations thereafter moreover product require customized scaleup technology developed pharmaceutical companies shifted focus riskaverse lifestyle disease resulted losing skillset expertise required vaccine development needs rebuilt continuous financial commitments immediate guarantee rewards unprecedented level international cooperation thankfully quite visible another important question may arise needs clarity selecting target cohort immunization healthier individuals might naturally protected vulnerable needy older population might show problems poor immune response require higher doses certainly healthcare workers need preparedness next wave infection perhaps also traders wet markets continue business conclusion vaccine hopefully apex pandemic effective policy needs carefully prepared develop global access framework equitable distribution developing world protecting intellectual property market rights distribution vaccines made far possible based humanitarian benevolence centrally international agencies including global alliance vaccines immunization gavi unicef allowing vaccine producing countries richest economies stockpile doses native population absence national emergency seen case h<NUMBER>n<NUMBER> influenza virus vaccine <NUMBER> jeopardize momentum gained thus far fidler <NUMBER> reader able understand types vaccine vaccine platforms developed sarscov<NUMBER> develop knowledge regarding concerns around coronavirus vaccine development appreciated issues rapid vaccine development outbreak settings ongoing progress candidate vaccines preclinical clinical studies ongoing detailed characterisation immunopathogenesis covid<NUMBER> implementation large scale post marketing surveillance systems monitor sarscov<NUMBER> vaccine safety introduction covid<NUMBER> disease caused novel betacoronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> disease first reported december <NUMBER> wuhan china <NUMBER> full genome sequenced published january <NUMBER> <NUMBER> <NUMBER> march <NUMBER> <NUMBER> covid<NUMBER> spread globally declared pandemic time writing june <NUMBER> th <NUMBER> <NUMBER> million people infected <NUMBER> deaths <NUMBER> disease primarily affects respiratory tract disease severity range mild rhinorrhoea severe acute respiratory distress syndrome death <NUMBER> <NUMBER> <NUMBER> substantial minority infections asymptomatic nonrespiratory symptoms anosmia diarrhoea rash thromboembolic disorders myocarditis vasculitis also associated covid <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> median incubation period estimated <NUMBER> days majority developing symptoms <NUMBER> days <NUMBER> covid<NUMBER> patients shown excrete viral nucleic acid highest levels onset symptoms <NUMBER> epidemiological data <NUMBER> suggests transmissibility within yet undefined presymptomatic period <NUMBER> clinical deterioration usually delayed second week illness associated laboratory features immunemediated cytokine storm causing widespread inflammation disseminated intravascular coagulation usually low level viraemia <NUMBER> <NUMBER> case fatality rate death amongst persons disease consistently reported age dependent higher percentage elderly aged <NUMBER> years cases dying although factors also associated intensive care admission mortality <NUMBER> <NUMBER> <NUMBER> including sex malefemale hypertension obesity diabetes reported case fatality rates cfr <NUMBER> <NUMBER> variability cfr likely due testing frequency access well health system capacity factors different locations <NUMBER> infection fatality rate ift death amongst people infected asymptomatic tested better estimate population mortality modelled <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> one three coronaviruses may cause severe respiratory diseases including addition novel epidemic viruses zoonotic origins four endemic human coronaviruses circulation hcov<NUMBER>e hku<NUMBER> nl<NUMBER> oc<NUMBER> predominantly causing mild symptoms common cold <NUMBER> history vaccines coronaviruses coronaviruses large <NUMBER> kb singlestranded positive sense rna genome encased helical nucleocapsid n outer envelope comprised matrix protein envelope protein e spike proteins <NUMBER> protein naturally occurs trimeric form contains receptorbinding domain rbd responsible binding onto angiotensin converting enzyme <NUMBER> ace<NUMBER> entry cell figure <NUMBER> sarscov structural proteins protein found elicit neutralising antibody major target antigen vaccine development <NUMBER> <NUMBER> difficulties development coronavirus vaccines historically coronavirus vaccines animal models mimic human disease immunogenic generally shown effectively prevent acquisition disease <NUMBER> concern vaccination natural coronaviral infection may induce long lived immunity reinfection may possible <NUMBER> ways concerning vaccine associated disease enhancement previous use coronavirus vaccines sarscov merscov animal models raised safety concerns regarding th<NUMBER> mediated immunopathology <NUMBER> mice vaccinated two inactivated whole virus vaccines recombinant dna spike protein vaccine viruslike particle vaccine developed lung pathology including eosinophilic infiltration <NUMBER> days challenged sarscov seen lungs challenged unvaccinated mice <NUMBER> similar lung immunopathology observed several studies particularly aged mice compared younger mice <NUMBER> challenged following vaccination <NUMBER> <NUMBER> context developing scalingup mass production vaccine rapidly global pandemic setting challenging requires many activities wellcoordinated occurring parallel contrast usual decade long sequential process preclinical testing phased clinical trials planned production distribution challenges result aggregation invested resources even sustained immunity attained infection sarscov<NUMBER> estimates <NUMBER> population would need immune achieve herd immunity sarscov<NUMBER> <NUMBER> safest controlled way effective sustainable prevention covid<NUMBER> population efficacious safe vaccine majority population successfully vaccinated addition vaccine also readily massproduced inexpensively easily transportable minimal cold chain requirements global utility immunity primary covid<NUMBER> infection seems protect reinfection primate models likely occur humans <NUMBER> whether mimicked vaccines long immunity may last still uncertain following sarscov infection igg neutralising ab detectable <NUMBER> <NUMBER> years following infection suggests vaccineinduced protection unlikely longlasting may require reimmunization never rapid pace vaccine development pandemic situation challenge trigger reconsidering usual approaches regulatory assessment licensing processes vaccine companies showing willingness commit scaledup production prior definitive phase <NUMBER> trial results <NUMBER> implementation high quality aligned surveillance covid<NUMBER> across multiple regions concurrently vaccine deployment critical evaluating realworld effectiveness new vaccine sarscov<NUMBER> also monitoring safety socall postmarketing surveillance association rotavirus vaccines intussusception children detected following licensure deployment vaccines last <NUMBER> months severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> precipitated global health economic crisis dramatically altering daily lives billions people rapid community transmission sarscov<NUMBER> enabled part biology novelty humans preexisting immunity brandnew human pathogen susceptible infection though uniformly likely develop symptomatic coronavirus disease <NUMBER> short term social distancing measures decreasing community transmission exacting enormous costs individuals businesses leading prominent voices call lifting restrictive measures however relatively people immune sarscov<NUMBER> covid<NUMBER> cases almost certainly surge normal activities resume longterm way control sarscov<NUMBER> people become immune virus herd immunity slows spread one way achieve needed level protection virus sweep population cost extensive casualties far better would developing deploying safe effective vaccine generate widespread immunity dual goals protecting individuals controlling pandemic covid<NUMBER> pandemic triggered explosion potential vaccine candidates calls rapid widespread deployment prompting discussions risks advancing unvetted vaccines general population fortunately process vaccine licensure designed ensure vaccine safety efficacy particularly since vaccines given healthy people might never exposed sarscov<NUMBER> develop severe disease effective way identify deploy efficacious sarscov<NUMBER> vaccines acceptable safety profiles carefully designed scientifically rigorous clinical trials conducted accelerated pace recent technological advances vaccine design global commitments addressing epidemic diseases provided rich infrastructure support necessary response covid<NUMBER> moderna messenger rna vaccine currently studied united states administered first human subject <NUMBER> days sarscov<NUMBER> genetic sequence released china achievement facilitated acceptable human safety profiles similar vaccine constructs targeting diseases including zika avian influenza seven vaccine clinical trials started united states united kingdom germany china list preclinical vaccine candidates <NUMBER> <NUMBER> <NUMBER> yet clear whether sarscov<NUMBER> infection results durable protective immunity mechanism might whether vaccineelicited immune responses protect without causing harm early studies promising <NUMBER> mild covid<NUMBER> cases induce level neutralizing antibodies sarscov<NUMBER> <NUMBER> nonhuman primates infected sarscov<NUMBER> protected reinfection virus <NUMBER> survivors infections related coronaviruses sarscov<NUMBER> middle east respiratory syndrome coronavirus merscov developed neutralizing antibodies persisted <NUMBER> years infection phase <NUMBER> studies dna vaccines sarscov<NUMBER> merscov well tolerated immunogenic humans <NUMBER> <NUMBER> reports suggest sarscov<NUMBER> vaccines could safely induce protective immune responses seems likely <NUMBER> <NUMBER> candidate vaccines development ultimately licensed yet reason caution experience animal models inconclusive sarscov<NUMBER> merscov vaccine candidates appear exacerbate illness animals subsequent viral challenge <NUMBER> vaccineenhanced disease harks back respiratory syncytial virus rsv dengue vaccines caused harm mechanisms underlying enhanced disease remain controversial certain patterns emerged detrimental responses common ubiquitous immunization wholeinactivated sarscov<NUMBER> merscov vaccines <NUMBER> <NUMBER> <NUMBER> perhaps due immune responses nucleocapsid protein <NUMBER> present viral envelope chemical modifications alter epitopes antigen processing <NUMBER> however new wholeinactivated sarscov<NUMBER> vaccine reportedly induced neutralizing antibodies protected rhesus macaques viral challenge without overt safety concerns <NUMBER> given association wholeinactivated vaccines enhanced disease one might expect vaccine platforms delivering isolated spike protein present viral envelope could elicit protective immunity without provoking immunopathology indeed protein dna vaccines induce strong neutralizing antibody responses sarscov<NUMBER> merscov <NUMBER> <NUMBER> accordingly many sarscov<NUMBER> vaccine candidates designed elicit neutralizing antibodies sarscov<NUMBER> spike <NUMBER> however antisarscov<NUMBER> spike antibodies elicited vaccinia vector shown worsen lung injury chinese macaques postchallenge potentially infection proinflammatory reprogramming macrophages <NUMBER> study along several reports suggests role antibodydependent enhancement ade cellsurface fc receptors <NUMBER> <NUMBER> <NUMBER> <NUMBER> probability ade varies antibody concentration <NUMBER> <NUMBER> suggesting effects might appear late vaccination highlighting need longterm followup clinical studies many harmful immune responses prior coronavirus vaccine candidates appear hinge balance type helper tcell response general th<NUMBER> responses thought promote protective immunity th<NUMBER> responses stimulated adjuvants alum associated eosinophils lungs experimental animals <NUMBER> pulmonary eosinophilia prominent feature enhanced disease associated rsv vaccine <NUMBER> th<NUMBER>like responses sarscov<NUMBER> protective despite eosinophilic histopathology <NUMBER> th<NUMBER>and th<NUMBER>type inflammatory responses also influence antibody isotype repertoire subsequent interactions fc receptors <NUMBER> potentially modifying risk antibodyinduced immunopathology manipulating balance th<NUMBER> th<NUMBER> responses adjuvants tolllike receptor agonists delta inulin may reduce risk vaccineenhanced disease <NUMBER> <NUMBER> overall mechanisms underlying immunopathology coronavirus vaccines differences among vaccine candidates animal models remain poorly understood potential factors include vaccine viral strain used challenge animal model timing dose vaccine challenge identifying basis immunopathology important optimizing vaccine candidates ordinarily unresolved questions coronavirus immunology might answered human clinical trials however delays developing safe effective vaccine cost lives thus need carefully weigh decisions study duration followup clinical biological monitoring comprehensively obtain information needed assess safety sarscov<NUMBER> vaccines early studies performed healthy adults fully informed areas uncertainty regarding risks human challenge studies intriguing controversial approach assessing efficacy safety <NUMBER> considerations especially important since many candidate vaccine platforms novel yet yielded licensed vaccines standardized metrics immunogenicity efficacy safety coordinated international level ensure vaccine studies directly compared promote accountability among research teams private developers world health organization important role process experts convened brighton collaboration working center epidemic preparedness innovations supported conduct ongoing vaccine studies advocated standardized safety assessments local systemic reactions also recommended measuring potential biomarkers vaccineenhanced disease may include ratios neutralizing nonneutralizing antibodies antibody isotypes affinities proinflammatory cytokine levels polarity tcell responses <NUMBER> ongoing therapeutic trials using convalescent sera examine conditions infectionderived antibodies protective addition animal studies continue concurrently resolve unanswered questions immunogenicity immunopathology concerning results experimental system prompt rapid reconsideration related clinical trials research community making unprecedented advances toward rapidly developing sarscov<NUMBER> vaccines laudable goal scientists regulators clinicians must remain steadfast pressure bypass established scientific ethical regulatory standards attempt accelerate vaccine availability community must push forward generating highquality reliable data strive save lives disclaimer views expressed solely authors affiliate institutions funding sources financial support work supported national institutes health <NUMBER>t<NUMBER>gm<NUMBER> <NUMBER>f<NUMBER>ai<NUMBER> k w g potential conflicts interest k e consultant merck bionet ibm data safety monitoring committees sanofi x<NUMBER> pharma seqirus moderna pfizer authors report potential conflicts interest authors submitted icmje form disclosure potential conflicts interest conflicts editors consider relevant content manuscript disclosed compelled us apply wellknown reverse vaccinology rv approach available proteome coronavirus rv approach successfully applied many prokaryotes known applications eukaryotes viruses worthwhile explore potential approach identify potential vaccine candidates coronavirus rv basically silico examination viral proteome hunt antigenic surfaceexposed proteins approach initially applied successfully neisseria meningitidis serogroup b kelly rappuoli <NUMBER> none prevailing techniques could develop vaccine present book chapter intended explore potential rv approach select probable vaccine candidates coronavirus validate results using docking studies undoubtedly traditional approaches vaccine development fortunate enough efficiently resist alarming pathogenic diseases time however traditional approach suffers certain limitations like timeconsuming pathogens cant cultivated lab conditions reach certain nonabundant proteins accessible using approach rappuoli <NUMBER> consequently number pathogenic diseases left without vaccine limitations conquered reverse vaccinology approach utilizing genome sequence information ultimately translated proteins hence proteins expressed genome accessible irrespective abundance conditions expressed credit fame reverse vaccinology go advancements sequencing strategies worldwide accordingly improvement sequencing technologies flooded genome databases huge amount data computationally undertaken reveal various crucial aspects virulence factors concerned pathogen reverse vaccinology based approach computationally analysing genome pathogen proceeds step step ultimately identify highly antigenic secreted proteins high epitope densities best epitopes selected potential vaccine candidates pizza et al <NUMBER> approach brought unapproachable pathogens interest spotlight evolving reassuring tool precise selection vaccine candidates brought use peptide vaccines trend sette rappuoli <NUMBER> kanampalliwar et al <NUMBER> bexsero first universal serogroup b meningococcal vaccine developed using rv currently earned positive judgement european medicines agency gabutti <NUMBER> whether discovery pili grampositive pathogens thought pili sighting factor gbinding protein meningococcus alessandro rino <NUMBER> reverse vaccinology steals credits conventional approaches applications rv prokaryotes eukaryotes viruses complexity genome corynebacterium urealyticum guimarães et al <NUMBER> mycobacterium tuberculosis monterrubiolópez et al <NUMBER> h pylori naz et al <NUMBER> acinetobacter baumannii chiang et al <NUMBER> rickettsia prowazekii carogomez et al <NUMBER> neospora caninum goodswen et al <NUMBER> brucella melitensis vishnu et al <NUMBER> examples pathogens recently approached using silico technique order spot epitopes potential vaccine candidate herpesviridae bruno et al <NUMBER> hepatitis c virus hcv kolesanova et al <NUMBER> examples viruses addressed using approach altschul et al <NUMBER> okonechnikov et al <NUMBER> golosova et al <NUMBER> multiple sequence alignment msa done via clustalw phylogenetic tree constructed using nj method unipro ugene <NUMBER> bioinformatics toolkit okonechnikov et al <NUMBER> analysis secondary structure proteins seed genome done means expasy portal aim forecast solvent accessibility instability index theoretical pi molecular weight grand average hydropathicity gravy aliphatic index number charged residues extinction coefficient etc httpweb expasyorgprotparam gasteiger et al <NUMBER> virusmploc used identify localization proteins virus infected cells host httpwwwcsbiosjtueducnbioinfvirusmulti hongbin shen kuochin chou <NUMBER> information important understand destructive role mechanism viral proteins causing disease total six different subcellular locations namely host cytoplasm viral capsid host plasma membrane host nucleus host endoplasmic reticulum secreted proteins covered predictions could help formulation better therapeutic options virus per protocol rv secreted membrane proteins special interest therefore filtered analysis predict number transmembrane helices tmhmm server v <NUMBER> httpwwwcbsdtudkservicestmhmm krogh et al <NUMBER> used signal peptides known impact immune responses possess high epitope densities moreover known vaccine candidates also possess signal peptides hence worthwhile predict signal peptides proteins prior epitope predictions signalblast web server used predict signal peptides without false predictions httpsigpepservicescamesbgacatsignalblasthtml frank sippl <NUMBER> prediction options include best sensitivity balanced prediction best specificity detect cleavage site choose make predictions using option proteins predicted signal peptide four options preferred investigation appropriate targets vaccine candidates possess adhesionlike properties mediate adhesion pathogens proteins cells host also facilitate transmission virus adhesions known crucial virulence located surface makes promptly approachable antibodies standalone spaan sensitivity <NUMBER> specificity <NUMBER> used carry adhesion probability predictions proteins adhesion probabilities higher equal <NUMBER> selected sachdeva et al <NUMBER> betawrap motifs dominant virulence factors pathogens proteins predicted possess motifs appropriate taken reverse vaccinology studies betawrap server online web server make predictions proteins pvalue lower <NUMBER> anticipated contain betawraps httpgroupscsailmiteducbbetawrapbetawraphtml bradley et al <NUMBER> added identification antigenic likely proteins subjected vaxijen server version <NUMBER> basically empirical method hunt antigenic proteins proteins found antigenic using sequencebased methods identified using method step confirms antigenicity proteins selected using abovementioned steps httpwwwddgpharmfacnetvaxijenvaxijenvaxijenhtml doytchinova flower <NUMBER> probable vaccine candidate protein exhibit characteristics allergen trigger type<NUMBER> hypersensitivity reactions causing allergy therefore escape possibilities proteins also subjected allergenicity predictions using allertop httpwwwpharmfacnet allertop dimitrov et al <NUMBER> algpred tools httpwwwimtechresin raghavaalgpredsubmissionhtml saha raghava <NUMBER>a b check whether filtered proteins possess similarity host proteins standard blastp httpblastncbinlmnihgovblast searches performed case sequence similarity feasibility generation immune responses cells predicting epitopes binding mhc class main decisive phase rv carry valid vaccine predictions predicted epitopes docked receptor hlaa<NUMBER> using cluspro httpclusprobueduloginphp kozakov et al <NUMBER> automated proteinprotein docking web server literature searches provided information conserved residues receptor site default parameters used docking comeau et al <NUMBER>a b kozakov et al <NUMBER> total <NUMBER> different sequenced strains coronavirus available ncbi among <NUMBER> strains pathogenic humans various information regarding source host collection strains presented table <NUMBER> <NUMBER> <NUMBER> information obtained ncbis genome database virus pathogen database analysis resource genomes online database liolios et al <NUMBER> pickett et al <NUMBER> mers strain taken seed genome prevalent disastrous strain among others proteome consists total <NUMBER> proteins shown table <NUMBER> <NUMBER> results sequence similarity reveal orthologs using blastp shown table <NUMBER> <NUMBER> sequences greater <NUMBER> identity score considered homologs phylogenetic tree depicted fig <NUMBER> <NUMBER> merscov taken seed genome found clustered different bat coronaviruses results analysis secondary structure proteome using expasy tools shown table <NUMBER> <NUMBER> analysis charge residues ph values concluded six proteins basic positively charged unlike allergens acidic nature however five proteins acidic show negative charge negative gravy score five proteins justify hydrophilic nature majority residues positioned towards surface rest six proteins gravy score positive means accession number identity orthologs obtained different strains shown table hydrophobic proteins proteins less <NUMBER> value instability index quite stable higher values proteins molecular weight less <NUMBER> kda except <NUMBER> yp<NUMBER> yp<NUMBER> yp<NUMBER> exhibits effectiveness lightweight proteins targets easily purified low molecular weights protein yp<NUMBER> reported spike glycoprotein acidic prominent negative charge negative gravy score suggests hydrophilicity figure <NUMBER> <NUMBER> depicts subcellular localization proteins seed genome ie merscov one protein predicted localized host cytoplasm four host membrane two host cell membrane endoplasmic reticulum er two er two left unrecognized known spike protein predicted localized host er results decided pick proteins located host membrane predicted localized host membrane er two known envelop protein membrane protein bibliographic studies along known spike protein also included filtered results filtered proteins two yp<NUMBER> yp<NUMBER> contain two transmembrane helices therefore filtered results transmembrane helices prediction tabulated table <NUMBER> <NUMBER> figure <NUMBER> <NUMBER> depicts subcellular localization proteins four selected genomes using virusmploc prediction tool proteins predicted possess signal peptides signalblast web server yp<NUMBER> yp<NUMBER> results signalblast web server tabulated table <NUMBER> <NUMBER> step takes account concept adhesionbased virulence adhesions cause pathogen recognition initiation inflammatory responses host spaan predicted <NUMBER> yp<NUMBER> yp<NUMBER> <NUMBER> proteins mers strain adhesive table <NUMBER> <NUMBER> one protein yp<NUMBER> predicted contain betawrap motifs within table <NUMBER> <NUMBER> hence considered virulent might responsible initializing infection host total <NUMBER> <NUMBER> proteins mers strain predicted antigenic prediction values greater <NUMBER> protein accession number yp<NUMBER> yp<NUMBER> among filtered proteins however predicted antigenic therefore filtered result four proteins yp<NUMBER> yp<NUMBER> yp<NUMBER> yp<NUMBER> kept analyses none <NUMBER> proteins merscov possessed clue allergenicity per prediction results algpred allertop tools means vigorous immune responses mounted epitopes proteins adopted vaccine candidates none protein mers strain shows similarity proteins host demonstrates epitopes proteins safely elicit required immune response without hazard autoimmunity total <NUMBER> different <NUMBER>mer epitopes potential bind receptors bcell tcell predicted list predicted epitopes found table <NUMBER> <NUMBER> specific merscov strain epitopes displayed conservancy proteins human nonhuman pathogenic strains docking permits reveal binding energy potency connection among epitopes receptor appropriate orientation cluspro docking server used dock predicted <NUMBER> epitopes hlaa<NUMBER> structure receptor available pdb optimized docking free complexed selfpeptide <NUMBER>u<NUMBER>y resolution <NUMBER> å bouvier et al <NUMBER> pepstr peptide tertiary structure prediction server kaur et al <NUMBER> used derive tertiary structure predicted peptides figure <NUMBER> <NUMBER> depicts quaternary structure receptor hlaa<NUMBER> conserved active site known form complex peptides bouvier et al <NUMBER> binding energy results obtained performing docking analysis listed table <NUMBER> <NUMBER> <NUMBER>mer epitope vvcaitllv site <NUMBER> protein yp<NUMBER> docked receptor smallest amount binding energy à<NUMBER> <NUMBER> hydrogen bonds next epitope list also protein yp<NUMBER> site <NUMBER> ie tllvcmafl predicted structure top <NUMBER> potent epitopes basis docking energy snapshots docking results displayed figs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> chief restriction developing safe sound vaccine virus identify protective antigens present study effort application reverse vaccinology approach investigate choice coronavirus proteomes identify possible vaccine targets technique demonstrated competent way forecast <NUMBER> different epitopes selected seed genome epitopes spike glycoprotein ns<NUMBER> protein ns<NUMBER>b protein envelope protein unfortunately none epitope found conserved strains specific merscov docking analysis studies revealed perfect binding hlaa<NUMBER> receptor epitopes conserved residues receptor site also involved hbonding epitope residues selected antigenic epitopes must validated using vitro vivo studies confirm potential vaccine candidates severe acute respiratory syndrome new disease emerged china late <NUMBER> spread rapidly around world epidemic resulted <NUMBER> infections almost <NUMBER> deaths raised considerable concerns emerging agent constituted serious threat global public health identification novel coronavirus sarscov associated syndrome <NUMBER> <NUMBER> <NUMBER> humans <NUMBER> thus despite disappearance disease humans still urgent need rapid development safe effective vaccine generally considered live attenuated viruses effective viral vaccines ability induce strong cellular humoral immune responses <NUMBER> however need extensive safety testing vaccines delay entry candidate vaccines clinical trials multiple studies reported antibodies directed spike glycoprotein neutralise sarscov infectivity <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein reported bind human angiotensin converting enzyme<NUMBER> hace<NUMBER> protein mediate viral entry cell <NUMBER> human monoclonal antibodies directed protein reported reduce replication virus lung infected ferrets completely prevent development sars cov induced lung pathology <NUMBER> addition number candidate vaccines induced protection challenge live virus animal models protection associated high levels neutralising antibody <NUMBER> <NUMBER> <NUMBER> thus likely inactivated recombinant candidate vaccine containing protein able induce protective immunity based primarily stimulation humoral immune response favoured development inactivated candidate whole virus vaccine wellestablished technology rapid development vaccines previously reported use large scale vero cell fermenter cultures development inactivated whole virus influenza vaccine <NUMBER> technology adapted development double inactivated whole virus sars cov candidate vaccine report characterisation candidate vaccine respect safety immunogenicity sarscov cdc<NUMBER> also referred strain utah genbank accession number ay<NUMBER> obtained cdc atlanta usa isolated sputum sars patient usa specimen <NUMBER> passaged two times gmp grade vero cells denatured samples purified sarscov vaccine <NUMBER> g proteinlane separated <NUMBER> trishcl sodium dodecyl sulfatepolyacrylamide gel reducing conditions subsequently blotted onto pvdf membrane protein staining done aurodye tm forte staining kit amersham biosciencege healthcare uk according manufacturers instructions rabbit antibodies directed sarscov nucleocapsid n protein img<NUMBER> protein img<NUMBER> respectively obtained imgenex san diego ca usa used western blot analysis blocking application primary antibody overnight <NUMBER> • c working dilution <NUMBER> membranes washed incubated <NUMBER> h room temperature horse radish peroxidase hrplabelled goat antirabbit igg accurate chemical westbury usa following final washing blots developed using <NUMBER> diaminobenzidine tetrahydrochloride h <NUMBER> <NUMBER> female cd<NUMBER> mice <NUMBER> weeks old obtained charles river laboratories subsidiary sulzfeld germany sampling preimmune sera mice immunised six different doses candidate vaccine ranging <NUMBER> g <NUMBER> ng total protein method according bradford <NUMBER> evaluate effect adjuvantation immunogenicity vaccine nonadjuvanted preparation material adjuvanted <NUMBER> <NUMBER> aluminium hydroxide alum tested antigen concentration groups <NUMBER> mice inoculated subcutaneously sc <NUMBER> ml vaccine preparation control groups received volume buffer trisbuffered saline without <NUMBER> aluminium hydroxide fourteen days postimmunisation sera drawn animal booster immunisation carried formulation dosage inoculated primary immunisation sera drawn animal <NUMBER> weeks primary immunisation animals treated <NUMBER> aluminium hydroxide containing vaccine also bled <NUMBER> weeks primary immunisation balbc mice <NUMBER> weeks old also obtained charles river laboratories subsidiary cytokine studies groups <NUMBER> mice balbc mice immunised sc <NUMBER> g vaccine adjuvanted <NUMBER> alum booster injections formulation given <NUMBER> <NUMBER> days post primary immunisation mice sacrificed cervical dislocation <NUMBER> <NUMBER> days primary immunisation five mice per group single cell suspension prepared pooled spleens five animals forcing minced tissue <NUMBER> mesh stainless steel sieves red blood cells depleted incubation <NUMBER> min room temperature lysis buffer containing <NUMBER> nh <NUMBER> cl <NUMBER> mm khco <NUMBER> <NUMBER> na <NUMBER> edta ph <NUMBER> leukocytes suspended complete cell culture medium subset immunised cd<NUMBER> mice ie four mice groups received vaccine doses <NUMBER> g<NUMBER> ng control groups see section <NUMBER> challenged <NUMBER> weeks groups received nonadjuvanted <NUMBER> aluminium hydroxide containing preparation <NUMBER> weeks <NUMBER> aluminium hydroxide primary immunisation prior challenge blood sample drawn determination neutralising antibody titres challenge mice anaesthetised isofluran inoculated intranasally dose <NUMBER> <NUMBER> tcid <NUMBER> sarscov contained volume <NUMBER> l <NUMBER> l per nostril noncloned sarscov cdc<NUMBER> propagated five times serum protein free vero sf cells used homologous challenge day <NUMBER> post inoculation pi mice euthanised isofluran followed barbiturate lung trachea removed frozen ≤−<NUMBER> • c prior titration tcid <NUMBER> assay tissue samples thawed homogenised <NUMBER> ml vero cell culture medium supplemented antibiotics igg titre protein sarscov determined indirect elisa briefly <NUMBER>well microtiter plates coated overnight <NUMBER> • c <NUMBER> ng baculovirus bvexpressed fulllength histagged protein protein sciences meriden ct usa <NUMBER> mm carbonate buffer ph <NUMBER> per well left uncoated respectively subsequent washing blocking <NUMBER> h <NUMBER> nonfat dry milk serial fourfold dilutions sera starting <NUMBER> dilution applied <NUMBER> h room temperature followed three washes phosphatebuffered saline pbs containing <NUMBER> tween <NUMBER> bound antibodies detected hrplabelled goat antimouse igg accurate chemical westbury ny usa working dilution <NUMBER> followed washes development using opdh <NUMBER> <NUMBER> finally colour development stopped addition <NUMBER> h <NUMBER> <NUMBER> plates read <NUMBER> nm elisa plate reader biotek winooski vt usa determine endpoint antibody titre absorbance readings equal greater cutoff value four times mean absorbance value <NUMBER> dilution negative control serum considered positive serum samples serially diluted cell culture medium twofold steps usually beginning dilution <NUMBER> <NUMBER> serum dilutions mixed ratio <NUMBER> virus stock suspension adjusted <NUMBER> <NUMBER> tcid <NUMBER> ml incubated <NUMBER> h room temperature transferred eight replicates per dilution <NUMBER>well tissue culture plate seeded vero cells plates incubated <NUMBER> days <NUMBER> • c co <NUMBER> incubator cultures inspected light microscope presence cytopathic effect cpe caused sarscov ie cell rounding detachment neutralising titre calculated number virus negative wells serum dilution according method spearman <NUMBER> frequency interferon␥ ifn␥ interleukin<NUMBER> il<NUMBER> secreting cells analysed using mouse ifn␥ il<NUMBER> elispot kits mabtech ab nacka sweden following instructions manufacturer serial dilutions freshly isolated spleen cells balbc mice added wells ranging <NUMBER> × <NUMBER> <NUMBER> <NUMBER> × <NUMBER> <NUMBER> cells per well antibodycoated <NUMBER>well plates stimulation sars candidate vaccine recombinant bvexpressed protein added concentration <NUMBER> gml wells containing antigen <NUMBER> gml pokeweed mitogen sigma st louis usa used negative positive control respectively plates incubated overnight <NUMBER> • c <NUMBER> co <NUMBER> cells discarded plates washed pbs interferon␥ il<NUMBER> respectively detected biotinylated interferon␥ il<NUMBER> specific antibody followed streptavidinalkaline phosphatase development bcipnbt substrate solution number spots counted using automated elispot reader aid strassberg germany number spots observed wells containing antigen subtracted number spots observed wells containing specific antigen results expressed spot forming cells sfc per <NUMBER> <NUMBER> spleen cells infectious virus titre sarscovcontaining samples determined tcid <NUMBER> assay brief serial <NUMBER>fold dilutions virus containing samples inoculated onto <NUMBER>well microtiter plates seeded vero cells incubation <NUMBER> days <NUMBER> • c co <NUMBER> incubator plates screened light microscope presence cpe number virus positive wells per dilution tcid <NUMBER> calculated according poisson formula means inhouse calculation software program program provides estimation tcid <NUMBER> titres <NUMBER> confidence limits based onehit model <NUMBER> previously reported development formalin inactivated whole virus influenza vaccine produced using largescale serum protein free vero cell fermenter cultures <NUMBER> development candidate sarscov vaccine based adaption well established technology establish optimal conditions growth inactivation purification inactivated virus sarscov reported grow well vero cells <NUMBER> <NUMBER> considered probably optimal cell matrix rapid vaccine development primary virus seed generated human isolate five sequential plaque clonings primary seed amplified generate seed virus bank working virus bank production virus bank production virus used infect serum protein free cultures using fermenter volume <NUMBER> l following incubation period <NUMBER> days virus containing supernatant harvested inactivated <NUMBER> formalin treatment <NUMBER> h followed uv inactivation uv dose <NUMBER> mjcm <NUMBER> virus infection multiplicity infection moi <NUMBER> resulted generation high viral titres ∼<NUMBER> <NUMBER> tcid <NUMBER> ml supernatant formalin uv inactivation steps independently capable inactivating titre large margin safety manuscript preparation following inactivation virus subjected twostep purification involving continuous flow zonal centrifugation <NUMBER> sucrose gradient followed ultradiafiltration process results twostep purification procedure demonstrated fig <NUMBER> two lots purified vaccine subjected western blot analysis stained specific antis glycoprotein fig <NUMBER>a antin antibodies fig <NUMBER>b addition protein composition analysed staining colloidal gold fig <NUMBER>c figures demonstrate final purified bulk vaccine pure contains protein n protein bands equivalent molecular weights infectious virus particle prior inactivation purification crosslinking proteins also seen inactivated preparations electron micrograph purified inactivated preparation confirmed data fig <NUMBER> virus particles demonstrated present well defined spikes virus membrane immunogenicity candidate vaccine initially investigated dosefinding adjuvant studies performed cd<NUMBER> mice purpose groups <NUMBER> mice immunised twice decreasing doses purified nonadjuvanted adjuvanted vaccine doses ranging <NUMBER> g <NUMBER> ng evaluate effect adjuvantation immunogenicity vaccine nonadjuvanted preparation material adjuvanted <NUMBER> <NUMBER> aluminium hydroxide tested antigen concentration specific antibody titre neutralising antibody titre individual serum determined described sections <NUMBER> <NUMBER> geometric mean titre gmt determined group animals presented fig <NUMBER> data demonstrate candidate vaccine highly immunogenic cd<NUMBER> mice following single immunisation <NUMBER> <NUMBER> g specific antibody titres gmt approximately <NUMBER> adjuvanted formulations <NUMBER> nonadjuvanted formulation measured <NUMBER> weeks primary immunisation data shown neutralising antibody titres measured time point following booster immunisation elisa titres substantially increased gmts <NUMBER> could obtained <NUMBER> g dosage adjuvanted <NUMBER> aluminium hydroxide reduction dosage little <NUMBER> ng adjuvanted formulation still resulted development low titre antibody response fig <NUMBER>a high titre neutralising antibodies approximately <NUMBER> also measured <NUMBER> g adjuvanted nonadjuvanted formulations <NUMBER> weeks booster immunisation fig <NUMBER>b groups mice immunised <NUMBER> aluminium hydroxide formulations bled <NUMBER> <NUMBER> weeks booster immunisation demonstrated high titre specific neutralising antibodies still detected stage fig <NUMBER>c influence adjuvant specific antibody responses also determined calculating effective dose <NUMBER> ed <NUMBER> ie minimum amount antigen required seroconversion <NUMBER> mice two immunisations data table <NUMBER>a demonstrates following booster immunisation nonadjuvanted vaccine containing <NUMBER> alum induced similar antibody response ed <NUMBER> values <NUMBER> <NUMBER> ng respectively obtained nonadjuvanted adjuvanted <NUMBER> alum vaccines vaccine adjuvanted <NUMBER> alum somewhat immunogenic seventy percent mice developed specific antibodies protein even lowest dose applied ie <NUMBER> ng due high proportion seroconverters ed <NUMBER> could exactly calculated fig <NUMBER> sspecific neutralising antibody response sarscov vaccine cd<NUMBER> mice booster immunisation sspecific antibody titre week <NUMBER> <NUMBER> c respectively determined elisa neutralising antibody response cd<NUMBER> mice week <NUMBER> b week <NUMBER> respectively analysed micro neutralisation assay geometric mean titres groups received nonadjuvanted vaccine grey bars vaccine adjuvanted <NUMBER> black bars <NUMBER> aluminium hydroxide open bars presented n <NUMBER> antibody titres n <NUMBER> neutralising titres neutralising antibodies detectable due limited amount serum instances detection limit assay <NUMBER> <NUMBER> <NUMBER> ng proportion animals demonstrated neutralising antibody titre also analysed subset immunised mice n <NUMBER> ed <NUMBER> based neutralising antibody response also calculated table <NUMBER>b data similar obtained elisa igg determinations differed somewhat highest proportion animals neutralising antibodies seen adjuvanted formulation highest concentration alum <NUMBER> characterisation immune responses mice carried investigating specific cytokine responses vaccination type immune response determined measurement interferon␥ marker th<NUMBER> responses interleukin<NUMBER> marker th<NUMBER> response cytokine studies balbc mice immunised sc <NUMBER> g antigen adjuvanted <NUMBER> alum booster injections formulation given <NUMBER> <NUMBER> days post primary immunisation mice sacrificed <NUMBER> <NUMBER> days primary immunisation spleen cells isolated balbc mice stimulated purified recombinant protein candidate vaccine see sections <NUMBER> <NUMBER> data presented fig <NUMBER> shows substantial ifn␥ il<NUMBER> responses obtained two immunisations whole virus vaccine however responses whole virus vaccine substantially higher obtained following stimulation recombinant protein two immunisations following third immunisation il<NUMBER> response recombinant protein increased level obtained whole virus antigen whereas significant ifn␥ response could still detected upon stimulation recombinant protein addition could demonstrated little <NUMBER> gml whole virus antigen sufficient stimulate substantial th<NUMBER> ifn␥ th<NUMBER> il<NUMBER> responses following demonstration candidate vaccine highly immunogenic protective efficacy vaccine investigated cd<NUMBER> mice subset ie four mice per group cd<NUMBER> mice immunised dosefinding adjuvant studies see challenged <NUMBER> <NUMBER> weeks post primary immunisation intranasal delivery <NUMBER> <NUMBER> tcid <NUMBER> homologous virus strain virus replication respiratory tract monitored described section <NUMBER> data presented table <NUMBER> demonstrates nonadjuvanted vaccine vaccine preparations adjuvanted <NUMBER> aluminium hydroxide highly effective inducing specific antis antibodies neutralising antibodies antigen dose low <NUMBER> ng without adjuvant effective inducing neutralising antibodies <NUMBER> <NUMBER> <NUMBER> <NUMBER> immunised animals respectively challenge <NUMBER> <NUMBER> tcid <NUMBER> live virus resulted virus replication lung <NUMBER> mock immunised mice however immunisation candidate vaccine antigen doses low <NUMBER> ng resulted high degree protection vaccinated mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> animals protected reduced doses antigen still resulted partial protection ≥<NUMBER> immunised mice protected following immunisation <NUMBER> ng vaccine antigen similar data obtained vaccine preparations adjuvanted <NUMBER> aluminium hydroxide data shown <NUMBER> protective dose pd <NUMBER> calculated three vaccine formulations shown approximately equal pd <NUMBER> <NUMBER> <NUMBER> <NUMBER> ng calculated formulations without adjuvant <NUMBER> alum <NUMBER> alum respectively table <NUMBER> data presented table <NUMBER> indicated clear correlation specific igg titre protein pi post inoculation sspecific antibody titres measured elisa neutralising antibody titres nt micro neutralisation assay sarscov titres homogenised lungtrachea tissue determined tcid <NUMBER> assay given logtcid <NUMBER> g lung tissue neutralising antibody titre protection intranasal challenge live virus data confirmed summarising protection data obtained mouse model table <NUMBER> summarises data obtained total <NUMBER> mice used various immunisation studies course development data table <NUMBER>a demonstrates specific antis igg titre ≥<NUMBER> resulted <NUMBER> protection mice challenged <NUMBER> <NUMBER> tcid <NUMBER> live virus also demonstrated specific neutralising titre ≥<NUMBER> resulted <NUMBER> protection challenge table <NUMBER>b virus replication seen mice antibody titres levels contrast <NUMBER> control animals infected intranasal challenge <NUMBER> <NUMBER> tcid <NUMBER> live virus report describes extensive immunological characterisation candidate sars coronavirus vaccine number different strategies previously reported development experimental candidate human sars vaccines include inactivated whole virus vaccines <NUMBER> <NUMBER> <NUMBER> attenuated viral vectors expressing sarscov proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> dna vaccines <NUMBER> <NUMBER> favoured strategy whole virus vaccine development number reasons including speed development virus grows high titres vero cells cell line accepted regulatory authorities similar technology used development utilised development industrial scale production influenza virus vaccine <NUMBER> manufacturing facilities also place appropriate biosafety level utilise technology rapid large scale vaccine production however addition technology logistical reasons also likely inactivated whole virus vaccine would efficient inducing neutralising antibodies possibly critical preventing sarscov infection processes inactivated whole virus vaccines utilised either formaldehyde ␤propiolactone inactivating agent reports inactivation failures associated methodologies even recent past <NUMBER> therefore developed strategy involving double inactivation process utilising formaldehyde uv inactivations although formaldehyde reported react protein nucleic acid reactions nucleic acid particularly nucleic acid component virus particle less well established therefore decided introduce second inactivation step addition formaldehyde ie uv inactivation directed primarily nucleic acid processes independently demonstrated capable inactivating <NUMBER> <NUMBER> tcid <NUMBER> ml large margin safety manuscript preparation however also essential demonstrate combination inactivation steps destroy viral antigenic structure immunogenicity data presented fig <NUMBER> demonstrates major virus antigens ie glycoprotein n protein negatively effected additional breakdown products could detected compared noninactivated preparation addition transmission electron microscopy analysis uranyl acetate stained samples demonstrated inactivated virion presented welldefined spike structures virus particle apparent structural alterations resulting inactivation procedures antigenic structural analyses followed extensive immunological characterisation candidate vaccine dose finding adjuvant studies carried mice measurement antibody responses specific elisa infectivity neutralising titres data presented fig <NUMBER> demonstrated double inactivated preparation highly immunogenic specific elisa titres <NUMBER> obtained following two immunisations <NUMBER> g antigen adjuvanted <NUMBER> aluminum hydroxide high neutralising titres also obtained following immunisation booster <NUMBER> g antigen titres approximately <NUMBER> obtained immunogenicity appears higher reported whole virus vaccines subjected single inactivation step although differences methodologies make direct comparisons difficult <NUMBER> <NUMBER> double inactivated vaccine also able induce high antibody responses even absence adjuvant similar data reported uv inactivated vaccine <NUMBER> ␤propiolactone inactivated vaccine <NUMBER> little difference level neutralising antibodies mice reported minimal influence adjuvantation vaccine immunogenicity also confirmed studies calculation ed <NUMBER> little difference ed <NUMBER> nonadjuvanted <NUMBER> alum adjuvanted material although <NUMBER> alum adjuvanted material appeared immunogenic table <NUMBER>a however confirmed ed <NUMBER> calculated basis neutralising antibody responses nonadjuvanted material immunogenic preparation <NUMBER> alum table <NUMBER>b addition characterisation humoral responses antibody measurement th<NUMBER> th<NUMBER> responses immunisation analysed cytokine production data presented fig <NUMBER> demonstrated double inactivated candidate vaccine capable inducing cytokine markers th<NUMBER> th<NUMBER> responses however responses stimulation recombinant protein indicated cell responses protein predominantly th<NUMBER> responses would expected alum adjuvanted whole virus vaccine <NUMBER> agreement data reported immunisation uvinactivated sarscov demonstrated substantial il<NUMBER> ifn␥ responses immunisation <NUMBER> following demonstration immunogenicity vaccine investigations initiated demonstrate efficacy candidate vaccine preventing infection small animal model balbc mice established good rodent model replications sars cov <NUMBER> demonstrated virus replicated well respiratory tract cd<NUMBER> mice model used investigate protective efficacy vaccine data table <NUMBER> demonstrates adjuvanted nonadjuvanted vaccine preparations antigen concentration <NUMBER> g protected <NUMBER> immunised mice challenge high titre <NUMBER> <NUMBER> tcid <NUMBER> virus intranasal route vaccine appeared effective low doses antigen calculation pd <NUMBER> table <NUMBER> nonadjuvanted adjuvanted vaccines confirmed low antigen concentrations approximately <NUMBER> ng sufficient provide protection <NUMBER> immunised mice figure even lower calculated highly effective wellestablished flavivirus vaccines tickborne encephalitis calculated pd <NUMBER> <NUMBER> ng similar model <NUMBER> unpublished data protection studies also used establish serological correlate protection data table <NUMBER> demonstrate induction neutralising antibody titres ≥<NUMBER> specific elisa titre ≥<NUMBER> resulted <NUMBER> protection intranasal challenge <NUMBER> <NUMBER> tcid <NUMBER> infectious virus data clearly indicate double inactivated whole virus vaccine promising candidate effective human vaccine use two inactivation steps based different mechanisms infection ensure safety respect residual infectious virus however reported vaccination feline coronavirus vaccine resulted antibody induced enhancement infection <NUMBER> <NUMBER> suggestion phenomenon could induced challenge studies reported studies protection achieved induction neutralising antibodies mva <NUMBER> parainfluenza <NUMBER> vectored spike protein live viral vaccines however vaccine induced enhancement coronavirus infection require study reports vaccination ferrets rmva expressing sarscov protein associated enhanced hepatitis <NUMBER> <NUMBER> epidemic coronavirus infection covid<NUMBER> first reported wuhan city china later spread rapidly throughout china along countries following pandemic <NUMBER> january <NUMBER>the world health organization declared public health emergency international concern considering quick outbreak disease <NUMBER> date total <NUMBER> confirmed cases <NUMBER> deaths reported infected patients develop symptoms like fever cough fatigue myalgia dyspnea decreased leukocyte counts etc <NUMBER> <NUMBER> <NUMBER> established mode transmission disease physical contact following means cough sneezes respiratory droplets <NUMBER> <NUMBER> <NUMBER> virus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> earlier known novel coronavirus <NUMBER>ncov pathogenic identity covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> enveloped virus consisting positivestrand rna genomic component <NUMBER> virus characteristic crownlike appearance due spike glycoprotein viral envelope <NUMBER> spike glycoprotein could suitable target drug designing vaccine development immunotherapy outer surface localization selected epitopes either predicted validated human immunological framework model approach could provide practical method designing developing vaccine candidates sarscov<NUMBER> initially selection desired antigens considering specific proteins immunogens challenging job therefore epitopebased vaccine design silico cloning validation allow evaluation particular vaccine novelty effectiveness given time frame recently proposed epitopebased silico peptide vaccine sarscov<NUMBER> <NUMBER> herein tried perform silico characterizations validations identified epitopes understanding allergenic nature must safety effectiveness vaccine thus analyzed allergenicity constructed vaccine candidate verified whether epitopes feasible developing robust vaccine sarscov<NUMBER> moreover molecular docking performed webbased docking server molecular dynamic simulation executed compare validate interactions receptorligand complex additionally codon adaptation insilico cloning designed future amplification targeted vaccine expression vector per requirement collectively silico validation tried prove effectiveness developed vaccine candidate identified epitopes control sarscov<NUMBER> infection multiepitopes sarscov<NUMBER> spike protein selected retrieved previously published work <NUMBER> epitopes used construct vaccine similar methodology employed analyzing effectiveness proposed vaccine candidate novel vaccine nonallergenic compelling performance two servers allertop allergenfp used allergenicity assessment vaccine candidate <NUMBER> <NUMBER> servers rely principle auto crosscovariance acc allergenic evaluation methods two methods utilize physicochemical properties amino acid residues molecular docking analysis performed study stable proteinprotein interaction related subcellular functions molecular docking cluspro <NUMBER> proteinprotein docking server used <NUMBER> cluspro server rigid body docking phase uses piper docking program relies fast fourier transform fft correlation approach piper represents interaction energy two proteins using expression form e e rep e attr denote attractive repulsive contributions van der waals interaction energy e elec electrostatic energy e dars pairwise structurebased potential primarily represents desolvation contributions ie free energy change removal water molecules interface coefficients w <NUMBER> w <NUMBER> w <NUMBER> w <NUMBER> define weights corresponding residues analysis display molecular assemblies tlr<NUMBER> proteins vaccine component complex visual molecular dynamics vmd <NUMBER> program utilized <NUMBER> root mean square fluctuation rmsf calculated cα atoms root mean square deviations rmsd total protein selected backbone cα atom protein complex applying present force field completed <NUMBER> ps picosecond unrestrained md simulation acidunfolded state tlr<NUMBER> proteins vaccine candidate complex primarily magnitude within stateoftheart simulation define structural dynamical features studied protein <NUMBER> normal mode analysis mobility allowed us investigate largescale mobility stability macromolecules imods server performed internal coordinates analysis based proteinprotein structural complex <NUMBER> server calculates specific combined motion large macromolecule along nma dihedral coordinates cα atoms additionally imods estimates bfactor disorder atom protein structural deformability computes eigenvalue due dissimilarity codons human e coli codon adaptation tools used necessary adapt codon usage within prokaryotic organism boost expression rate respective eukaryotic system cloning vaccine component e coli strain k<NUMBER> selected host java codon adaptive tool jcat employed codon optimization vaccine component <NUMBER> selected pet<NUMBER>a expression vector cloning nucleotides sequences collected addgene vector database <NUMBER> webdsvver <NUMBER> httpwwwmolbiotoolscomwebdsv used pursuing insilico cloning peptidebased vaccine component sarscov<NUMBER> solubility physicochemical property assessments primary sequence vaccine candidates essential determining state stability accessibility vaccine solubility construct vaccine predicted average solubility e coli protein proteinsol webserver <NUMBER> protparam server accessed analysis various physicochemical properties designed vaccine candidate <NUMBER> table <NUMBER> figure<NUMBER> probable immune cascade mechanism vaccine candidate tirap receptor protein depicted figure<NUMBER> <NUMBER> molecular dynamic simulation tlr<NUMBER> proteins vaccine candidate performed visual molecular dynamics vmd <NUMBER> program produced <NUMBER> frames <NUMBER> frame <NUMBER> ts <NUMBER> ps rmsd plot figure <NUMBER> b rmsf calculated cα atoms rmsd total protein selected backbone cα plot displayed protein complex steadystate silico cloning rapid method assess possibility developing potent multi sarscov<NUMBER> become global concern rapidly emerging threat human civilization covid<NUMBER> pandemic already caused many deaths around globe still affecting human population rapid rate hence new therapeutic approach targeting tlrs tlr<NUMBER>tlr<NUMBER> modulation may serve better choice vaccine adjuvant development infection sarscov<NUMBER> <NUMBER> kaur et al developed multiepitope peptidebased chimeric vaccine taeniasolium silico approaches <NUMBER> structural vaccinological analysis computational validation vaccine candidate also performed mayaro virus <NUMBER> considerate human pathogenic viruses west nile virus ebola virus specific peptidebased vaccine developed employing immunopharmacoinformatic techniques <NUMBER> <NUMBER> principal focus current study silico evaluation potent vaccine candidates identified common epitopes primarily chosen <NUMBER> common bcell tcell epitopes previous published work <NUMBER> afterward analysis allergenic property carried designed vaccine candidate safe efficacy prerequisite vaccine successful human administration <NUMBER> analysis allertop allergenfp servers found constructed vaccine candidate nonallergenic safe future vivo vitro work molecular docking vaccine candidates tlr proteins performed cluspro <NUMBER> server compare validate accuracy stable proteinprotein binding molecular interactions <NUMBER> <NUMBER> observed molecular docking significant high negative energy value lowest energy value <NUMBER>kcalmol top ordered proteinprotein docking complex <NUMBER> <NUMBER> molecular dynamics simulation based refinement tlr<NUMBER>tlr<NUMBER> vaccine candidate protein complex established fact conformational model steady state residues protein complex accelerated conformation transitions among local energy state <NUMBER> frames <NUMBER> ts<NUMBER> ps time distance trajectory mobility protein complex formed molecular docking justified normal mode analysis mobility study <NUMBER> outputs normal mode analysis study using imods revealed tlr<NUMBER>tlr<NUMBER> vaccine candidates stable interaction movement towards upon molecular binding additionally complex easily deformable significantly lower peaks deformability plot furthermore codon adaptation within prokaryotic system analyzed obtain better adaptation high expression profile eukaryotic expression system construct vaccine candidate cloned pet<NUMBER> expression vector help webdsvver <NUMBER> higher expression cloned codons projected pi value predicted protparam tool indicates essential cation rich character vaccine candidate prediction also helps compute stability vaccine host body aliphatic index <NUMBER> predicted vaccine thermostable instability index lower <NUMBER> <NUMBER> indicated higher stability vaccine structure expression silico work reveals proposed vaccine candidate nonallergenic efficient well stable molecular interaction tlr proteins humans results also indicate high potential effectiveness selected epitopes sarscov<NUMBER> codon adaptation silico cloning established impending amplification ability vaccine construct within expression vector per conditional requirement furthermore silico analysis might encouraging researchers trying develop efficient therapy covid<NUMBER> however constructed vaccine candidates require successive laboratory validation vitro vivo models applicable data generated analyzed study included published article applicable since identification novel coronavirus sarscov<NUMBER> cause pneumonia patients wuhan china pandemic erupted resulting enormous health care social economic disruption global society <NUMBER> may <NUMBER> <NUMBER> <NUMBER> cases <NUMBER> deaths worldwide <NUMBER> rapid response pandemic academic industry scientists around world initiated efforts develop vaccines therapeutics disease prevention patient management coalition epidemic preparedness innovations cepi global partnership public private philanthropic civil organizations funding work develop sarscov<NUMBER> vaccines using variety technology platforms several vaccine candidates already phase <NUMBER> studies others likely enter clinic next months <NUMBER> one challenges facing rapid vaccine development sarscov<NUMBER> need adequately assure safety vaccines one safety concern disease enhancement syndrome occurred <NUMBER>s inactivated rsv measles vaccines vaccinemediated disease enhancement characterized vaccine results increased disease severity subject later infected natural virus early trials inactivated rsv vaccine vaccine prevent infection <NUMBER> infected required hospitalization two children died <NUMBER> lung pathology patients showed unexpected inflammatory response neutrophils eosinophils evidence immune complex formation complement activation small airways <NUMBER> scientists later learned vaccine caused similar disease enhancement animals characterized immunopathology helper cell type <NUMBER> th<NUMBER> biased response antibody responses poor neutralizing activity <NUMBER> <NUMBER> <NUMBER> since time animal models relied upon predict safety new <NUMBER> rsv vaccines developed note pathogenesis rsv disease enhancement distinct antibody disease enhancement ade occurs macrophage tropic viruses demonstrated notably dengue humans coronavirus feline infectious peritonitis virus cats directly caused nonneutralizing subneutralizing antibodies leading efficient viral uptake via fcγ receptor binding <NUMBER> since pathology consistent rsv vaccine enhanced disease perhaps ade demonstrated sarscov<NUMBER> vaccine candidates animal models also concern similar syndrome could occur humans immunized sarscov<NUMBER> candidate vaccines therefore cepi brighton collaboration safety platform emergency vaccines speac convened scientific working meeting httpsbrightoncollaborationusbrightoncollaborationcepicovid<NUMBER>webconference march <NUMBER> <NUMBER> <NUMBER> experts field vaccine immunology coronaviruses discuss current knowledge could form basis assessment risk enhanced disease sarscov<NUMBER> vaccine development consensus report presents considerations vaccine developers serve guide development testing vaccine candidates avoid safety concerns ultimately door clinical trials controlled regulators context riskbenefit entire dataset provided developers within local trial context microbiology immunology pediatrics university iowa reviewed work others animal models developed sarscov<NUMBER> merscov lessons models inform development priorities useful sarscov<NUMBER> animal models address efficacy safety inbred mouse strains sarscov<NUMBER> replicates efficiently respiratory tract cause pneumonitis clinical signs pneumonia observed old balbc mice <NUMBER> subsequent passage sarscov<NUMBER> mouse lungs resulted isolation virus caused severe disease young old mice <NUMBER> <NUMBER> virus used many subsequent studies ferret models sarscov<NUMBER> also demonstrate virus replication respiratory tracts induction neutralizing antibody response also demonstrated little evidence clinical disease <NUMBER> hamsters contrast mice ferrets demonstrate high levels viral replication develop pneumonitis shown clinical signs disease <NUMBER> following identification human ace<NUMBER> receptor sarscov<NUMBER> transgenic murine models expressing human ace<NUMBER> receptor hace<NUMBER> developed shown develop mild pulmonary disease note mice also developed lethal viral encephalitis attributed viral spread olfactory nerve despite relative scarcity hace<NUMBER> expression brain may relevance sarscov<NUMBER> disease <NUMBER> efficacy several sarscov<NUMBER> vaccines evaluated models spike protein based vaccines demonstrating neutralizing antibody protection pulmonary replication challenge virus mice hamsters <NUMBER> dna vaccine studies shown candidate vaccines encoding protein conferred antibody mediated protection challenge mice vaccines encoding n protein induced humoral cellular immunity <NUMBER> <NUMBER> vectored vaccines expressing sarscov<NUMBER> proteins shown <NUMBER> viral proteins expressed mice ferrets hamsters studies neutralizing antibodies elicited bhpiv<NUMBER> vsv rabies mva adeno viruses expressing protein protected sarscov<NUMBER> replication lungs challenged animals however one mva vaccine expressing sprotein protect infection <NUMBER> contrast sarscov<NUMBER> inbred mice found resistant merscov thus infection studied creating models expressed mers receptor human dpp<NUMBER> hdpp<NUMBER> ad<NUMBER>hdpp<NUMBER> transduced mice could infected mers virus infection associated minimal clinical disease except immunocompromised mice developed weight loss infection note hdpp<NUMBER>transgenic mice developed lethal viral encephalitis concurrent inflammatory changes histopathological examination lung similar hace<NUMBER>tg mice sarscov<NUMBER> subsequently investigators developed mice knockedin expression hdpp<NUMBER> virus passage mice identified mouseadapted mers strains caused severe disease increased histopathology pulmonary edema infected original mers strain <NUMBER> importantly mice without functional cells rag<NUMBER>and tcr alpha delayed viral clearance whereas mice could produce antibodies mumt mice show delay clearance similar models developed crisprcas<NUMBER> mutagenesis two residues mouse ace<NUMBER> molecule followed mouse adaptation serial passage leading ards model lethal infection <NUMBER> <NUMBER> taken together evidence supports notion cells important viral clearance mers <NUMBER> nonhuman primate nhp models also established sarscov<NUMBER> merscov evidence upper respiratory lower respiratory tract sarscov<NUMBER> replication african green monkeys greater extent cynomolgus macaques least <NUMBER> rhesus macaques little evidence clinical disease three species <NUMBER> note consistent findings older humans mice increased pathology documented aged cynomolgus macaques sarscov<NUMBER> wild type infection <NUMBER> controversy disease severity mers models different groups seeing different levels pathology resolved <NUMBER> <NUMBER> vaccine efficacy safety studied animal models many sarscov<NUMBER> candidate vaccines group experts discussed vaccine models utilized characterize response specific vaccines examine disease enhancement antibody dependent enhancement ade signals evidence disease enhancement vaccinated animals challenge live virus multiple studies sarscov<NUMBER> vaccine candidates summarized table limiting comments report data animal models discussing vitro data except mention evidence ade human primary monocytes <NUMBER> <NUMBER> different animal models exhibit different pulmonary pathology generally characterized cellular infiltrates including eosinophils summary provide overview consensus opinion vaccine related outcomes animal models concern risk disease enhancement could guide assessments sarscov<NUMBER> vaccine candidates murine models evidence vaccine related disease enhancement demonstrated inactivated whole vaccine without alum vectored vaccine expressing n protein seen vectored vaccine expressing protein report replicon particle platform expressing protein vectored vaccine expressing proteins general pathology described included pulmonary infiltrates often eosinophils observed th<NUMBER> dominant responses documented reports expression th<NUMBER> driven cytokines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> ferret model hepatitis demonstrated animals vaccinated recombinant modified vaccinia virus ankara vaccine expressing protein challenged virus <NUMBER> although questions raised study <NUMBER> <NUMBER> <NUMBER> nonhuman primate models also produced evidence enhanced disease sarscov<NUMBER> vaccine immunization chinese macaques immunized modified vaccinia virus expressing protein challenged sarscov<NUMBER> develop clinical disease histopathology showed lung injury injury characterized decreased wound healing increased proinflammatory macrophages expressing il<NUMBER> il<NUMBER> ccl<NUMBER> <NUMBER> report also demonstrated passively administered antis antibody associated lung pathology challenge live virus although mechanism may fc receptor thus classic ade note second report similarly demonstrates effect certain antis antibody preparations without fc involvement <NUMBER> <NUMBER> relevance reports remains unclear multiple studies administration neutralizing monoclonal antibodies different models induce disease enhancement investigators reported absence disease enhancement hamsters monkeys immunized whole inactivated vaccine although models differed number ways notably use bpl βpropiolactone instead formalin inactivation virus <NUMBER> <NUMBER> finally note agreed upon positive control applied animal studies thus interpretations hamperedba animal models sarscov<NUMBER> rapidly developed multiple research human ace<NUMBER> transgenic mice hace<NUMBER> tg aged <NUMBER> weeks <NUMBER> months age studied hace<NUMBER> expression observed lung heart kidney intestinal tissues following intranasal inoculation sarscov<NUMBER> weight loss observed viral rna detected lungs well intestine <NUMBER> gross pathology demonstrated swollen enlarged lungs moderate interstitial pneumonia histological studies documented accumulation inflammatory cells including monocytes lymphocytes alveolar interstitium thickening alveolar walls sarscov<NUMBER> protein detected ihc alveolar macrophages epithelia <NUMBER> nhp also infected sarscov<NUMBER> <NUMBER> rhesus macaques aged <NUMBER> years inoculated intratracheally although fever observed weight loss asthenia seen multiple days viral rna detected nasal throat swabs lesser degree anal specimens peaking days <NUMBER> <NUMBER> lasting day <NUMBER> post infection one animal euthanized day <NUMBER> necropsy viral rna detected multiple organs including cns skeletal muscle heart two surviving rhesus macaques positive neutralization titers documented day <NUMBER> post infection radiographic evidence multiple ground glass opacities lungs days <NUMBER> <NUMBER> <NUMBER> post infection microscopically lung lesions represented acute interstitial pneumonia characterized mild moderate thickening alveolar septum increased number macrophages degeneration pneumocytes inflammatory cell infiltration presence viral antigen confirmed predominately alveolar monocytes macrophages <NUMBER> analysis blood samples showed decline counts total white blood cells lymphocytes monocytes observed changes <NUMBER> percentages decrease cd<NUMBER>cd<NUMBER> cd<NUMBER> cd<NUMBER> tcell counts observed importantly hematological findings similar seen sarscov<NUMBER> infected patients model could serve critical tool detailed studies pathogenesis evaluation intervention strategies including vaccines note following meeting another group confirmed sarscov<NUMBER> infection rhesus macaques viral antigen detected type type ii pneumocytes diffuse pulmonary alveolar damage noted <NUMBER> experts agreed models others development utilized evaluate vaccine candidates evidence disease enhancement specified later sections design barney sarscov<NUMBER> protein structure solved shortly emergence shows similar structure mobility sarscov<NUMBER> <NUMBER> timing first knowledge sarscov<NUMBER> beginning phase <NUMBER> study remarkable sixtyfive days advantages mrna vaccines include ability create highly precise type protein elicit correct antibodies elicit cell responses th<NUMBER> predominant rapidity manufacturing course disadvantages include novel nature mrna dna vaccines without licensed vaccine either technology date lack experience mass production therefore multiple platforms sarscov<NUMBER> development mitigate potential disadvantages nucleic acid vaccines although mrna dna vaccines elicit cell responses without adjuvants adjuvants may important subunit whole cell inactivated vaccines increase immunogenicity drive immune response could limit risk disease enhancement multiple sarscov<NUMBER> vaccines development including vectored vaccines whole cell inactivated vaccines recombinant protein vaccines experts discussed choice adjuvants important efficacy safety platforms dr arnaud didierlaurent centre vaccinology university geneva presented background effects different adjuvants animal human immune responses several adjuvants used commercial vaccines clinical development <NUMBER> oilinwater emulsions mf<NUMBER> as<NUMBER> shown increase breadth antibody repertoire binding affinity affinity maturation compared unadjuvanted vaccines <NUMBER> <NUMBER> human studies influenza vaccines h<NUMBER>n<NUMBER> vaccine adjuvanted mf<NUMBER> squalenebased emulsion increased levels h<NUMBER>specific antibody subclasses igg<NUMBER> igg<NUMBER> binding fcγr<NUMBER> fcγr<NUMBER> compared alum adjuvanted vaccines demonstrates use adjuvant skew functionality profile antigenspecific antibodies potential activate different innate effectors based fcγr expression <NUMBER> use squalenebased emulsion vaccines influenza also shown increase cd<NUMBER> cell response frequencies crossreactivity even preexisting crossreactive antibodies present prior immunization adjuvants could activate naïve b cells promote adaptability memory b cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition antibodies adjuvants promote cellular responses human malaria challenge studies provided early evidence choice adjuvantscombined malaria antigen rtss critical achieving optimal protection highlighted importance cellular response <NUMBER> recently studies hepatitis b surface antigen hbs vaccine adjuvanted as<NUMBER> as<NUMBER> as<NUMBER> alum showed vaccines formulated as<NUMBER> as<NUMBER> induced highest antibody levels as<NUMBER> promoted best hbsspecific cd<NUMBER> cell response <NUMBER> differences associated magnitude initial inflammatory <NUMBER> response triggered different adjuvanted formulations <NUMBER> <NUMBER> interestingly although level cd<NUMBER> cell response lower alum group compared as<NUMBER> group adjuvants led similar memory subset profiles cytokine production profiles given unprecedented demand effective vaccine use adjuvants may critical subunit vaccines providing antigendose sparing increased immunogenicity breadth duration response potentially eliciting crossprotection new cov strains minimizing risk enhanced disease following presentations attendees participated discussion suggested consensus statements attendees asked comment draft statements available online comments reviewed discussed second day meeting resulted summary consensus statement follows • sarscov<NUMBER> low affinity murine ace<NUMBER> receptor murine models require use hace<NUMBER> transgenic mice preferably knockin approach preliminary data indicate possibility infecting hace<NUMBER> transgenic mice demonstration viral replication mild lung lesions mouse adaptation sarscov<NUMBER> done sarscov<NUMBER> likely required obtain virus causes severe disease mice models develop acute lung injury lethality mimic human condition important evaluating vaccine safety • previous studies sarscov<NUMBER> merscov indicated vaccines especially using whole inactivated virus could enhance disease induced mice challenged sarscov<NUMBER> merscov lung lesions highly inflammatory dominance eosinophil infiltration occurred animals despite <NUMBER> presence neutralizing antibody response reduced challenge virus replication lungs studies yet completed sarscov<NUMBER> • mice immunopathology considered consequence dominant th<NUMBER> type response vaccine antigens seen including adjuvants eg cpg vaccine vaccine formulations known drive immune responses towards th<NUMBER> timing challenge vaccination may critical would major interest explore outcome following challenge later timepoints antibodies significantly decaying • one aware potential confounding effect cellculture excipients vaccine challenge strain material known impurities fetal calf serum preclinical vaccine preparation may induce eosinophil influx mouse model challenge strain also contains excipients • models characterization immune response candidate vaccine eg igg isotypes th<NUMBER> markers may predictive value • small animal models infected sarscov<NUMBER> considered eg ferret hamster development small animal models severe disease also inform studies vaccineenhanced disease • passive transfer nhps human antibodies generated phase <NUMBER> trials followed viral challenge could considered assess risk disease enhancement • challenge immunized animals closely related heterologous cov strains may assess risk enhancement future outbreaks • case disease enhancement indepth studies animal models may give indications mechanism immunopathology inform human trial designers critical immunological risk markers monitored phase <NUMBER> trials • given unprecedented demand effective vaccine use adjuvants may critical subunit vaccines providing increased immunogenicity breadth response dose sparing duration response potentially crossprotection new cov strains possibly minimize risk enhanced disease preference given th<NUMBER>driving adjuvants established safety profile humans • understanding role crossreacting antibodies prior coronavirus infections may natural disease caused sarscov<NUMBER> influence risk enhanced disease following vaccination may inform vaccine design • data needed whether antibody waning could increase risk enhanced disease exposure virus long term opinion experts animal data support clinical development could address • postvaccination neutralizing antibody responses cell analysis demonstrate th<NUMBER> response • postvaccination challenge data nhps careful evaluation immunopathology quantitative virology animals • small animal data may also provide important supporting evidence safety hamster ferret mouse models likely available developers • possible immunopathology experiments positive control eg formalin inactivated alumadjuvanted sarscov<NUMBER> sarscov<NUMBER> vaccine mockimmunized negative control provide best guidance felt important establish broadly accepted endpoints scoring systems allow comparison various vaccine candidates working issue • vaccine constructs likely induce predominant th<NUMBER> response group felt animal studies considered entering human phase <NUMBER> trials one animal species including nhps possible noted absence th<NUMBER> response eliminate risk enhanced disease • since studies begun begin prescreen determine preimmunization serostatus participants although shall determined retrospectively appropriate baseline blood specimens obtained stored virus spreading rapidly specimens allow assessment <NUMBER> immune response seronegative seropositive persons likely vaccinated • level neutralizing antibodies determination relative ratio binding neutralizing antibodies important assess potential risk enhanced disease also detection initial priming includes cd<NUMBER> cells andor cd<NUMBER> th<NUMBER> biased response likely mitigate risk disease enhancement determination memory responses useful particularly sarscov<NUMBER> continues circulate • consideration given use postvaccination sera vaccinees could used antibody transfer studies animals look enhanced disease evidence crossprotection coronaviruses • monitoring enhanced disease immunized participants may require longer followup usual phase <NUMBER> trials need delay phase <NUMBER> trials • investigators call requested frequent updating preclinical evolving clinical data developed different academic industrial developers help decisionmaking various vaccine clinical trials creation central information hub encouraged purpose • participants call expressed need standardization protocols data collection forms critical assays including reagents biobanking samples initial clinical trials allow future reassay standards agreed enable comparison results across trials <NUMBER> • group experts considers demonstration disease enhancement candidate vaccine viral challenge animal models necessarily represent nogo signal deciding whether progress early trials clinical development covid<NUMBER> vaccine • continuous monitoring risk clinical trials epidemic context needed • observed effect discussed developers regulators ultimately define actual requirements clinical studies considerations document interpreted general scientific remarks based current knowledge inform research agenda could beneficial vaccines development considerations regulatory nature cannot sense replace need proper regulatory consultations requirements vaccines clinical trials vaccine developers therefore encouraged seek individual scientific advice regulatory authorities severe acute respiratory syndrome sars severe respiratory illness caused sars coronavirus sarscov <NUMBER> disease emerged guangdong province china late <NUMBER> <NUMBER> spread <NUMBER> countries mostly within asia although europe north america also affected notably toronto canada epidemic finally controlled july <NUMBER> strict implementation prevalence sarscov antibody although history sarslike disease sarscovlike viruses isolated civets raccoon dogs <NUMBER> homology human sarscov major differences found orf<NUMBER> whose deletion suggested represent sign adaptation humans <NUMBER> four amino acid residues receptor glycoprotein ace<NUMBER>binding domain viral spike protein differ human epidemic sarscov strains civet strains cause <NUMBER>fold difference binding affinity ace<NUMBER> molecule <NUMBER> <NUMBER> although high prevalence sarslike coronaviruses found chinese horseshoe bats <NUMBER> <NUMBER> great genetic diversity makes difficult identify one might ancestor sarscov decide certainty whether bats indeed animal reservoir virus sarscov infection exhibits wide clinical course characterized mostly fever dyspnea lymphopenia lower respiratory infection often concurrent gastrointestinal symptoms including diarrhea <NUMBER> <NUMBER> pathology sars patients associated diffuse alveolar damage epithelial cell proliferation multinucleated giant cell infiltrates epithelial macrophage origin suggestive syncytiumlike formation lung virus recovered peripheral blood mononuclear cells respiratory secretions stools urine even sweat review see <NUMBER> sars vaccine development efforts initiated rapidly identification etiologic agent even though immune correlates protection known research efforts identify protective antigens develop animal models undertaken parallel efforts develop candidate vaccines <NUMBER> drawing experience animal coronavirus vaccines using several vaccine strategies including inactivated virus vaccines purified subunit vaccines plasmid dna viral vectorbased vaccines well viruslike particles much effort made identify appropriate animal models sarscov replication pathogenesis several research groups shown mice <NUMBER> <NUMBER> ferrets <NUMBER> hamsters <NUMBER> nonhuman primates <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> support replication sarscov varying degrees associated disease animal models used evaluation candidate vaccines common conclusion emerged evaluation several vaccines <NUMBER> kda viral spike protein significant neutralization antigen <NUMBER> <NUMBER> <NUMBER> <NUMBER> one elicit protective immunity animal models <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein divided two domains analogy coronavirus spike proteins nterminal s<NUMBER> domain contains receptorbinding site neutralization epitopes cterminal s<NUMBER> domain forms membraneanchored stalk region contains putative fusion peptide followed two heptad repeats predicted form sixhelix coiledcoil bundle <NUMBER> absence clinical cases sars candidate vaccines evaluated efficacy animal models united states fda animal rule states efficacy studies humans feasible vaccines may approved based animal data alone provided pathophysiological mechanism disease reasonably wellunderstood prevention reduction vaccine moreover protective effect vaccine demonstrated one animal species expected react response predictive humans endpoint animal studies clearly related desired benefit humans ie enhancement survival reduction major morbidity data generated allow selection effective dose humans present time uncertain whether animal rule would apply licensure sars vaccine however important develop standardized animal models immunological assays preparation eventuality scientists technical meeting animal models antibody assays evaluating candidate sars vaccines held <NUMBER> august <NUMBER> south mimms uk discussed many aspects research pertaining use animal models vaccine development including available animal models suitability various models correlates protection critical components potential vaccines potential disease enhancement vaccinated animals following exposure sarscov addition standardization antibody assays establishment international standard sarscov antibody also discussed report endeavors summarize recommendations meeting based consensus agreement recommendations use animal model given section <NUMBER> correlates protection overview vaccine development observations pertaining potential disease enhancement summarized following sections <NUMBER> selecting animal models vaccine evaluation important remember principle underlying called animal rule data one animal species often required animal species contribute something different understanding disease protection time single model offers direct reproduction seen humans sars pathology including pneumonitis alveolar edema diffuse alveolar damage dad humans probably difficult element reproduce animal model attention also given reduction viral shedding would likely correlate decreased risk spread disease among humans using animal models study aspects sarscov infection must emphasized kinetics viral replication appearance resolution pathological findings much rapid animal models humans whichever animal model employed special consideration given presence coexisting pathogens age animals routes infection sufficient number time points large enough number animals used allow statistical evaluation strain sarscov used also could importance emphasized different species may prove useful studying different aspects sarscov whereas vaccines antivirals may addressed many models pathogenesis best evaluated animal models immunological tools reagents available detailed analysis immune response vaccine includes inbred mice rhesus cynomolgus macaques may actually worthwhile enhance virulence sarscov isolate serial passages animal model produce challenge virus stock vaccine studies would elicit reproducible disease animals highly virulent hostadapted virus become available mouseadapted monkeyadapted sarscov strain demonstration capacity vaccines protect challenge virulent strains would provide almost ideal animal model different models may also need employed evaluate pathogenesis versus immunogenicity pathogenesis studies animal models mortality required readout would ideal develop animal models comparable levels mortality seen humans ∼<NUMBER> overall including increased mortality increased age ∼<NUMBER> age <NUMBER> optimal result would demonstrate efficacy vaccines antivirals sarscov animal models mimic human morbidity mortality show protection without vaccineassociated immunopathology inbred mouse strains balbc c<NUMBER>bl<NUMBER> <NUMBER>svev stat<NUMBER>−− support sarscov replication develop pneumonitis <NUMBER>s pneumonia clinical symptoms observed older balbc mice <NUMBER> mouse model suitable immunogenicity efficacy studies vaccines prolonged viral replication dissemination virus liver spleen accompanying pathology seen stat<NUMBER>−− mice mice therefore also suitable studies pathogenesis evaluation antiviral drugs specific pathogenfree spf animals must used age either <NUMBER> weeks <NUMBER> months specified number animals included must sufficient statistical analysis include mockinfected controls variety sarscov strains tested mice including urbani frankfurt hku<NUMBER> tor<NUMBER> mouseadapted sarscov strain ma<NUMBER> inoculated intranasal route light anesthesia <NUMBER> <NUMBER> using dose <NUMBER> <NUMBER> tcid <NUMBER> <NUMBER> lmouse critical time points specimen collections days <NUMBER> peak titer <NUMBER> postinfection pi quantitative virology days <NUMBER> <NUMBER> pi study interstitial pneumonitis dad aged mice inflate lungs <NUMBER> neutralbuffered formalin day <NUMBER> resolution golden syrian hamsters excellent animal model demonstrate high levels sarscov replication develop pneumonitis hamsters suitable vaccine efficacy immunoprophylaxis treatment studies <NUMBER> contrast balbc mice virus detected respiratory tract cleared day <NUMBER> pi hamsters demonstrate longer duration viral shedding upper respiratory tract transient viremia spread virus liver spleen significantly inflammation respiratory tissues <NUMBER> <NUMBER> spf animals older <NUMBER> weeks age used sufficient number statistical analysis study design include mockinfected animals animals housed pairs three experiment last less <NUMBER> weeks reserve space available separate animals case fights males littermates tend fight less virus strains tested hamsters urbani frankfurt hku<NUMBER> virus administered route light anesthesia using dose <NUMBER> <NUMBER> tcid <NUMBER> <NUMBER> lhamster outcome efficacy studies quantitative virology preferred quantitative pcr pathology studies one grade pathology none mild moderate severe per roberts et al <NUMBER> critical time points specimen collection days <NUMBER> <NUMBER> pi peak viral titer <NUMBER> clearance quantitative virology studies days <NUMBER> pi consolidation pneumonitis <NUMBER> <NUMBER> resolution pathology studies lung evidence one study ferrets support sarscov replication develop pulmonary lesions <NUMBER> according another study animals remain asymptomatic presence sarscov replication <NUMBER> view conflicting data ferret model needs studied determine optimal utility vaccine efficacy immune prophylaxis studies additional studies needed define extent biological variability model possible role copathogens may contribute variability observed different laboratories animals aged <NUMBER> months older used although well documented consistent viral replication pathology clinical symptoms seem observed older animals animals screened viral copathogens aleutian mink disease respiratory viruses hepatitis viruses others route inoculation may iv dose virus strains tor<NUMBER> hku<NUMBER> sufficient ensure reproducibility infection animals likely <NUMBER> <NUMBER> pfu moreferret quantitative virology preferred qrtpcr pathology studies recommendations apply nonhuman primate studies see slides shared pathologists develop scoring system regarding specimen collection respiratory tissues studies needed establish much variation occurs samples different lobes lungs critical time points day <NUMBER> pi quantitative virology days <NUMBER> pi pathology studies pneumonitis nhps support sarscov replication develop pneumonitis variable degree clinical symptoms depending upon species employed single nhp species preferred time number animals given study needs large enough account animaltoanimal variability sample <NUMBER> <NUMBER> animals sufficient view cost experiments challenge studies limited vaccine candidates promising using larger sample sizes <NUMBER> animalsgroup avoiding animals freerange periods life possible immunological responses best studied species microarrays reagents identifying immune components available rhesus cynomolgus macaques however limited viral replication observed cynomolgus macaques might disadvantage selecting species studies recommended nhp species common marmoset african green monkeys agms chlorocebus aethiops sabeus country origin may play important role specified eg philippines cynomolgus macaques macaca fascicularis china rhesus macaca mulatta brazil marmosets callithrix jacchus etc prior experiment animals housed indoor limit exposure potential copathogens screened parasites strongyloides pneumonyssus simicola lung mites possible viral copathogens retroviruses respiratory viruses adenoviruses sarscov strains tested nhp models hku<NUMBER> cynos pumc rhesus urbani marmosets agms inoculated respiratory route dose <NUMBER> <NUMBER> pfu morenhp quantitative virology preferred qrtpcr pathology studies would obvious advantage laboratories share pathology slides review different pathologists order develop scoring system specimens respiratory tissues collected studies needed establish much variation occurs samples different lobes lungs done reported african green monkeys agms <NUMBER> critical time points days <NUMBER> pi quantitative virology cynomolgus macaques agms later day <NUMBER> pi rhesus macaques chinese origin collection tissues histopathological analyses days <NUMBER> pi optimal cynomolgus macaques agms later day <NUMBER> pi rhesus macaques due limitations immunological reagents including microarray assays available research may limited rhesus cynomolgus macaques data animal models insufficient consideration use sarscov vaccine antiviral evaluations <NUMBER> <NUMBER> <NUMBER> additional model four listed section <NUMBER> section <NUMBER> would require thorough characterization including viral replication data histopathological analysis sarscovinfected mockinfected animals age gender viral replication histopathological data new animal model reminiscent least aspect sars humans although correlates protection sars associated disease identified human infections neutralizing antibodies present convalescent human serum antibodies sarscov spike protein shown prevent virus entry neutralize virus infectivity vitro <NUMBER> <NUMBER> prophylactically administered monoclonal antibodies passively transferred sarscov hyperimmune sera shown prevent sarscov infection associated disease following sarscov challenge naive mice hamsters <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> monoclonal antibodies administered therapeutically ie postinfection also shown limit viral replication reduce associated disease hamsters <NUMBER> although cell mediated immunity may protective role viral clearance resolution disease work animal models shows antibody alone effective prevention treatment sars thus mice immunized liverecombinant vaccines expressing sarscov spike protein using rabies virus <NUMBER> vesicular stomatitis virus vsv <NUMBER> adenovirus ad<NUMBER> <NUMBER> <NUMBER> attenuated vaccinia virus mva <NUMBER> <NUMBER> vector well mice immunized dna vaccines expressing gene <NUMBER> <NUMBER> developed neutralizing antibodies sarscov protected sarscov challenge similar findings reported mucosal immunization hamsters agms using bovine parainfluenza virus type <NUMBER> bpiv<NUMBER> vector expressing sars cov gene <NUMBER> <NUMBER> several whole inactivated virus recombinant protein candidate vaccines also developed shown elicit neutralizing antibody response provided protection infectious challenge <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition passively administered sera vaccinated animals prevented sarscov infection upon subsequent challenge naïve mice demonstrating antibodies induced vaccines confer protection <NUMBER> <NUMBER> neutralizing antibody titer necessary achieve protection humans exposed sarscov however still known recommended evaluating vaccine efficacy future animal experiments challenge virus administered two different timepoints postimmunization neutralizing antibody titers high later neutralizing antibody titers waned low also suggested viral titers pathology evaluated two different time points specific times points sample collection given animal model section <NUMBER> previous observations disease enhancement reported human viral pathogens shown due antibodymediated enhancement virus entry reviews see <NUMBER> <NUMBER> enhanced disease mortality observed kittens immunized infected typei coronavirus feline infectious peritonitis virus fipv subsequently exposed fipv infection <NUMBER> <NUMBER> <NUMBER> aggravated fip apparently result enhanced viral entry macrophages mediated subneutralizing antibody levels <NUMBER> children vaccinated inactivated respiratory syncytial virus rsv vaccines developed serious disease subsequent exposure rsv <NUMBER> <NUMBER> <NUMBER> individuals exposed one four serotypes dengue virus developed severe disease subsequently infected second different serotype <NUMBER> <NUMBER> enhanced disease following rsv vaccine dengue infection occur different mechanisms fipv view examples enhanced disease following infection vaccinated host heightened concern similar phenomenon could occur sarscov vaccines highly recommended therefore known mechanisms disease enhancement observed viruses especially coronaviruses examined sarscov infections especially vaccinated animals although none studies date shown enhanced respiratory disease following sarscov challenge previously immunized animals studies area warranted view available vitro data antibodies human sarscov isolates shown enhance entry pseudotyped viruses expressing civet sarslike covspike protein human renal adenocarcinoma cell line <NUMBER>o enhancement demonstrated level entry replication <NUMBER> phenomenon seen pseudotyped lentiviruses expressing sarscov spike protein civet sequence specificity pseudotyped viruses expressing spike proteins human sarscov isolates also observed human isolates sarscov role enhanced viral entry observed vitro studies related known component human disease infection vivo however given sarscov may replicate albeit poorly human pbmcs <NUMBER> <NUMBER> vitro experiments looking antibodyenhancement sarscov replication human cells eg macrophages bcells performed several groups studied sarscov infection animals presence neutralizing subneutralizing levels sarscov antisera anti sarscov sprotein monoclonal antibodies evidence enhanced respiratory disease observed however foci hepatic necrosis noted following sarscov challenge mvasarss immunized ferrets <NUMBER> although findings worrisome several questions raised regarding significance observation mvasarss vaccine used experiments poorly immunogenic ferrets question whether could copathogen animals raised also would important know observed phenomenon depends mva vector animal model strongly urged therefore experiment repeated ferrets additional experiments nonhuman primates hamsters looking evidence enhanced respiratory hepatic diseases upon vaccination challenge also encouraged several candidate sars vaccines various stages preclinical clinical development developed worldwide china alone three companies given regulatory approval clinical evaluation candidate sars vaccine important therefore able compare data candidate vaccines turn requires international standardization immunological assays used evaluation vaccines accepted method international standardization employ international standard allows comparison results different laboratories <NUMBER> essential establishing international requirements vaccines diagnostics therapeutics prepared material bearing close resemblance samples assayed material distributed glass ampoules high precision reproducibility freeze dried important sufficient number ampoules <NUMBER> prepared provide <NUMBER> years use activity contents remain stable period process establishing involves international collaborative study candidate compared samples results tests suitable candidate assigned provisional arbitrary unitage report distributed approval study participants eventual approval expert committee biological standardization ecbs preparation storage distribution <NUMBER> undertaken national institute biological standards control nibsc south mimms uk laboratory biological standards nibsc developed past several iss calibration antibody response virus vaccines including iss antibodies dengue hepatitis virus hav <NUMBER> hepatitis b virus hbv measles <NUMBER> polio rabies <NUMBER> rubella smallpox candidate standard human papilloma virus<NUMBER> hpv<NUMBER> evaluation corresponding iss used variety antibody assays including virus neutralisation vn haemagglutinationinhibition single radial diffusion enzymelinked immunoassay radioimmunoassay antibody iss useful epidemiological studies clinical trials use allows correlates immunity potency requirements prophylactic therapeutic products expressed international units ius data several collaborative studies demonstrate use generally reduces level variability assay results however may problems using iss due complex array antibody populations serum different sensitivity different assay systems examples potential problems found hbv parvovirus b<NUMBER> studies <NUMBER> showed different assay kits gave different results even included assays another issue degree antigenic homology viral antigen used preparation virus used assays jev collaborative study candidate antibody prepared sera vaccinees immunized inactivated vaccine antigenically different viruses used vn assays demonstrated response least inactivated vaccine strain specific candidate consequently established ecbs whether panel monoclonal antibodies sarscov could used prepare attractive alternative explored significant progress standardisation sarscov antibody assays made china development national antibody standard order develop national standard sera collected <NUMBER> convalescent sars patients found sarscov vn antibody titers ranging undetectable <NUMBER> one serum sample selected evaluation based crossreactivity four sarscov strains western blot analysis serum freeze dried <NUMBER> ml aliquots assessed stability vn assays chinese standard assigned vn titer <NUMBER> <NUMBER> confidence limits <NUMBER> important development china preparation human immunoglobulin treatment sars patients national guidelines prepared collection plasma quality control testing standardisation assays three chinese manufacturers licensed preparation sars immunoglobulin source material plasma convalescent patients <NUMBER> days infection good health plasma tested negative bloodborne agents plasma samples processed combination cold ethanol fractionation ultrafiltration september <NUMBER> three lots igg produced assayed nationallyagreed procedures stock immunoglobulin currently available sufficient treat <NUMBER> patients monoclonal antibodies yet considered treatment purposes china importance assessing immunogenicity candidate sarscov vaccines using vn assays well acknowledged variety vn tests use significant problem since time consensus sensitive specific reproducible assay system therefore desirable establish antibody serve basis comparison vn assays important activity time obtain suitable source antibody number options considered convalescent human sera postimmunization human sera monoclonal antibodies hyperimmune animal sera example availability suitable source serum convalescent patients hong kong needs explored although antibody levels individuals probably quite low also would important assays vn included collaborative study impact sarscov strain variation examined using different sarscov strains andor sera different specificities centralized facility aids reagents cfar based nibsc could suitable model sarscov repository <NUMBER> cfar established <NUMBER> support aids vaccine research eufunded <NUMBER> currently <NUMBER> reagents available including peptides recombinant proteins human seraplasma monoclonal polyclonal antibodies expression systems cdna clones viruses comparison drawn sarscov hiv vn assays currently several different hiv neutralization assays formats consideration lack agreement suitable assay cfar supporting joint whoeu project neunet evaluate standardize hiv vn assays international collaborative study usa sarscov repository established behalf american type culture collection atcc order meet needs biodefence threat emerging infections <NUMBER> type reagents stored includes viruses peptide arrays monoclonal antibodies proteins hoped active collaboration established niaid nibsc order meet expanding needs sars research community based discussion meeting following recommendations made respect standardization immunological assays sars vaccine evaluation <NUMBER> repository sarscov reagents ought developed collaboration niaid nibsc recommended achieve goal <NUMBER> consensus must reached reagents given priority repository needed <NUMBER> suitable source antibody convalescent human sera postvaccination human sera could also used <NUMBER> protocol international collaborative study aimed validating developed distributed prospective participants <NUMBER> collaborative study participants asked assay capabilities eg number sera virus strains handled etc <NUMBER> proposed collaborative study include core set antibody preparations distributed assayed laboratory eg monoclonal antibodies animal sera human sera <NUMBER> tests conducted using strain sarscov laboratory different genetic lineages sarscov also represented study biosafety issues associated sarscov vaccine development stem reports laboratoryacquired infections china sanofi pasteur adopted bsl <NUMBER> practices bsl <NUMBER> equipment eg class <NUMBER> <NUMBER> microbiological safety cabinets respiratory protective equipment preparation sarscov vaccines note fact sarscov appears quite resistant normal methods virus decontamination jf saluzzo personal communication developed guidance general <NUMBER> specific handling sars specimens <NUMBER> rapid success development immunogenic protective vaccines sars using variety platforms encouraging tempered concerns possibility enhanced disease following exposure vaccinated individuals <NUMBER> concerns mainly stem reports enhanced disease fipvimmunized infected kittens <NUMBER> <NUMBER> observations antibodies elicited certain coronaviruses mediate antibodydependent enhancement viral entry <NUMBER> observation inflammatory foci liver tissue following sarscov challenge mvasarss vaccinated ferrets <NUMBER> candidate sars vaccines need evaluated one animal model also need thoroughly evaluated duration antibody response induce well breadth protective efficacy different strains sarscov implications sequence heterogeneity among sarscov strains difficult test time divergent strains civet sarslike viruses recovered culture validation international standardization immunological assays evaluation candidate sars vaccines essential compare data across different trials requires establishment international standards sarscov antibody repository sarscov reagents international collaborative study validate iss establishment repository collaboration nibsc niaid recommended nisreen okba v stalin raj bart l haagmans middle east respiratory syndrome coronavirus merscov cause severe respiratory infection humans specifically elderly people comorbidities reemergence lethal coronaviruses calls international collaboration produce coronavirus vaccines still lacking date ongoing efforts develop merscov vaccines consider different target populations dromedary camels humans correlates protection extending current knowledge mers vaccination dromedary camels induce mucosal immunity could promising approach diminish merscov transmission humans addition equally important develop vaccines humans induce broader reactivity various coronaviruses prepared potential next cov outbreak coronaviruses largest positive sense single stranded rna viruses six human coronaviruses hcov date hcov<NUMBER>e hcovoc<NUMBER> hcovnl<NUMBER> hcovhku<NUMBER> severe acute respiratory syndrome sarscov middle east respiratory syndrome merscov prior sarscov epidemic <NUMBER> covs known cause mild respiratory infections humans sarscov hand infected around <NUMBER> cases causing severe respiratory disease <NUMBER> fatality rate <NUMBER> ten years later merscov emerged human population also cause severe respiratory infection <NUMBER> contrast sarscov epidemic contained within one year merscov still continues cause outbreaks increasing geographical distribution four years first identification march <NUMBER>nd <NUMBER> <NUMBER> cases <NUMBER> countries reported <NUMBER> deaths accounting <NUMBER> case fatality rate httpwwwwhointemergenciesmerscoven like sarscov merscov emerged result zoonotic introduction human population despite close genome similarity bat coronavirus hku<NUMBER> hku<NUMBER> <NUMBER> accumulating serological molecular evidence pointed dromedary camels probable reservoir merscov <NUMBER> <NUMBER> <NUMBER> poses continuous risk virus spillover people contact camels working slaughter houses animal farms evidenced presence merscov antibodies sera individuals <NUMBER> <NUMBER> nosocomial transmission however accounts majority merscov cases reported outbreaks <NUMBER> <NUMBER> <NUMBER> although substantial part infections occur result unrecognized asymptomatic mild illnesses <NUMBER> thus addition camel contacts highlyatrisk groups healthcare workers patient household contacts <NUMBER> <NUMBER> <NUMBER> considering ongoing merscov outbreaks crucial develop intervention measures among vaccines play important role despite fact emergence merscov sarscov dramatically changed way view covs licensed cov vaccine therapeutic drug available date <NUMBER> <NUMBER> cornerstone rational vaccine design defining determinants immune protection accumulating data studies done far merscov coronaviruses revealed combination virusspecific humoral cellular immune responses required full protection coronaviruses especially neutralizing antibodies considered key players protective immunity covs neutralizing monoclonal antibodies mabs reduced viral loads merscov receptortransduced mice rabbits macaques <NUMBER> <NUMBER> <NUMBER> <NUMBER> similarly convalescent camel sera increased virus clearance decreased lung pathological outcomes mice efficacy directly proportional antimerscovneutralizing antibody nab titers <NUMBER> also polyclonal sera produced transchromosomic bovines protected mice merscov challenge <NUMBER> evidence protective role antibodies also comes recent studies analyzing immune responses patients survived succumbed merscov although neutralizing antibodies weakly inversely correlated viral loads serum antibody responses higher survivors compared fatal cases viral rna eliminated lungs <NUMBER> <NUMBER> administration convalescent sera however lead significant reduction viral loads <NUMBER> <NUMBER> presence mucosal iga abs hand found influence infectious virus isolation <NUMBER> besides humoral immunity cellular immune responses also considered play crucial role protection coronaviruses bcell deficient mice able clear merscov lacking tcells failed eliminate virus pointing crucial role tcells viral clearance <NUMBER> supported observation tcells able protect aged mice sarscov infection <NUMBER> fact reduced tcell count associated enhanced disease severity sars patients <NUMBER> along studies data highlight importance tcells virus clearance protection merscov <NUMBER> <NUMBER> sarscov <NUMBER> <NUMBER> also noteworthy mention neither antibodies memory b cells detectable <NUMBER>years postinfection <NUMBER> sarscovspecific memory tcells despite low frequency persisted <NUMBER> years postrecovery <NUMBER> nonetheless protective capacity memory response known hence taking account waning virusspecific humoral responses generating longlived memory cell response vaccination could favorable proper band tcell immune responses required efficient protection vaccination target induction moment lack information concerning longevity anamnestic immune responses following merscov infection except recent study showing antibody responses albeit reduced persisted <NUMBER> months postinfection <NUMBER> role immune responses protection also line observed increased fatality among aged population following merscov infection retrospective studies merscov patients saudia arabia south korea found significant correlation old age mortality <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> pattern also reported respiratory viruses sarscov <NUMBER> influenza virus <NUMBER> likely caused immunosenescence failure produce protective immune response new pathogens elderly due impaired antigen presentation altered function tlrs reduced naïve b cell repertoire <NUMBER> agerelated increase mortality also reported sarscov laboratoryinfected animals mice nonhuman primates nhps <NUMBER> <NUMBER> associated low neutralizing antibodies poor tcell responses <NUMBER> <NUMBER> <NUMBER> several factors play role tcell activation also found dysregulated agerelated manner agerelated increase phospholipase <NUMBER> group iid pla <NUMBER> g<NUMBER>d prostaglandind <NUMBER> lungs contributed diminished tcell response severe lung damage diminishing respiratory dendritic cell dc migration <NUMBER> <NUMBER> likewise adoptive transfer tcells mice enhanced viral clearance survival <NUMBER> highlighting contribution reduced tcell response severe disease outcome observations also highlight need effective preventive measures elderly sense induction potent airway tcell response may crucial protect covs <NUMBER> thus promising approach protect merscovinduced fatality enhance virusspecific tissue airway resident memory tcell responses intranasal vaccination although merscov genome encodes <NUMBER> nonstructural proteins nsp<NUMBER> four structural proteins spike envelope e membrane nucleocapsid n <NUMBER> viral structural proteins n show highest immunogenicity <NUMBER> n proteins induce tcell responses neutralizing antibodies almost solely directed protein receptor binding domain rbd major immunodominant region <NUMBER> thus current merscov vaccine candidates mainly employ spike protein parts gene coding glycoprotein merscov vaccines candidates developed using wide variety platforms including whole virus vaccines vectoredvirus vaccines dna vaccines table <NUMBER> proteinbased vaccines table <NUMBER> although live attenuated vaccines produce robust immune responses pose risk reversion virulence inactivated virus vaccines may cause harm due incomplete attenuation capacity induce lung immunopathology <NUMBER> viralvectorbased vaccines hand provide safer alternative developed using modified vaccinia virus ankara mva <NUMBER> <NUMBER> <NUMBER> adenovirus adv <NUMBER> <NUMBER> measles virus mev <NUMBER> rabies virus rabv <NUMBER> venezuelan equine encephalitis replicons vrp <NUMBER> <NUMBER> expressing mersss<NUMBER> proteins additionally vrp expressing n protein also developed <NUMBER> major hurdle facing viralvectorbased platforms preexisting immunity host potentially impair vaccine efficacy however prevented using virus strains circulating targeted population immunization strategies involving heterologous primeboost immunization example mva adv although plasmid dna vaccines considered low immunogenicty humans current versions developed seem induce potent immune responses dnabased vaccines directed inducing anti responses also shown exert protection nhps <NUMBER> <NUMBER> noteworthy mention middle east respiratory syndrome coronavirus vaccines current status novel approaches okba raj haagmans <NUMBER> adhdpp<NUMBER>mice mice transduced hdpp<NUMBER> adenoviral vector alum aluminum hydroxide e envelope protein hdpp<NUMBER> human dipeptidyl peptidase <NUMBER> im intramuscular intranasal matrix protein merscov middle east respiratory syndrome coronavirus nab neutralizing antibodies nd done nhp nonhuman primate rntd recombinant nterminal domain rbd receptorbinding domain rrbd recombinant rbd rbdfc rbd fused antibody crystallizable fragment human igg spike protein s<NUMBER> s<NUMBER> domain spike protein s<NUMBER> amino acid residues <NUMBER> protein s<NUMBER>klh peptide s<NUMBER> coupled keyhole limpet haemocyanin sc subcutaneous vlps viruslike particles imalumcpg odn produced higher neutralizing antibody responses sc ifacpg odn b s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc tested s<NUMBER>fc highest nab titers although produced equal s<NUMBER> igg response <NUMBER> c mf<NUMBER> produced highest immunogenicity low doses antigen compared s<NUMBER>fc freundsalummplasmisa<NUMBER>mf<NUMBER> <NUMBER> <NUMBER> mg antigen mf<NUMBER> sufficient produce humoral cellular immune responses similar higher doses <NUMBER> mg <NUMBER> mg <NUMBER> polyic vaccination induced stronger systemic cellular responses higher local immune responses mice lungs iga neutralizing antibody titers sc montanide isa<NUMBER> vaccination combination dna recombinant protein s<NUMBER> heterologous primeboost immunization strategy induced higher immune response nab compared component alone <NUMBER> additionally proteinbased vaccines developed various platforms viruslike particles vlps <NUMBER> nanoparticles <NUMBER> peptidebased <NUMBER> subunit vaccines directed various regions spike protein s<NUMBER> <NUMBER> nterminal domain <NUMBER> rbd <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vaccines highest safety profile among vaccine platforms confer variable degrees immunogenicity need adjustment dose adjuvants site administration get optimal protective responses adjuvants influence type magnitude immune response produced vaccines thus doses used <NUMBER> <NUMBER> <NUMBER> additionally route administration determining factor type vaccineinduced immune response produced host intranasal vaccination sarsn produced protective airway tcell response sarscov mice subcutaneous sc vaccination inducing systemic tcell responses <NUMBER> likewise vaccination mersrbd induced significantly higher neutralizing iga antibody responses mice airways compared sc vaccination <NUMBER> important mucosal immunity airway memory tcell responses crucial players protection respiratory viruses since areas first encounter virus therefore along selecting antigens vaccine route vaccination adjuvants key players cannot neglected vaccine design spike protein specifically s<NUMBER> domain highly divergent among different covs neutralizing antibodies provide homotypic protection thus far variability amino acid sequence spike protein observed among merscov strains low <NUMBER> circulating merscov strains show significant variation serological reactivity <NUMBER> <NUMBER> implying development vaccine effective one strain likely protective circulating strains another risk posed development antibody escape variants still present <NUMBER> <NUMBER> although likely happen mutations two epitopes may required mutants develop may reduced viral fitness <NUMBER> <NUMBER> rbd considered ideal vaccine candidate merscov spike s<NUMBER> domain n protein conserved thus adaptive immune response directed proteins potentially lay basis broadly acting coronavirus vaccine however evidence cross reactive immune responses different covs limited studies convalescent sarscov patient sera weakly neutralized merscov <NUMBER> sarss reactive antisera showed low level neutralization merscov <NUMBER> extrarbd s<NUMBER> s<NUMBER> epitopes could responsible effect neutralizing epitopes identified regions protein <NUMBER> <NUMBER> may immunodominant rbd epitopes could provide rationale development cross protective cov epitopefocused vaccine recent study also demonstrated potential role adaptive response n protein protection merscov infection vaccine candidate produced protective tcell response merscov challenge also partially protective sarscov <NUMBER> moreover infection mice sarscov reduced merscov titers <NUMBER> days pi upon challenge suggesting development cross reactive tcell response <NUMBER> thus mapping focusing immune response towards critical neutralizing tcell epitopes could subdominant may provide way induce immune responses broader activity different covs immune focusing may also beneficial generation robust virusspecific immune response vaccine preparation epitopes normally hidden full length protein structure get exposed epitopes could immunodominant negative contribution overall neutralization capacity produced vaccine <NUMBER> also holds true nonneutralizing immunodominant epitopes s<NUMBER>based vaccines induced slightly higher neutralization whole ectodomainbased ones <NUMBER> <NUMBER> additionally rbd induced higher neutralizing antibodies compared s<NUMBER> subunit vaccine <NUMBER> shorter regions rbd induced even higher neutralization responses <NUMBER> indicating additional regions inducing nonneutralizing antibodies may contribute negatively overall neutralization response produced additionally antibodydependent enhancement viral infection nonneutralizing antibodies <NUMBER> <NUMBER> <NUMBER> despite reported far merscov needs also taken consideration developing coronavirus vaccine one approach enhance efficacy subunit vaccines mask negativelycontributing epitopes glycosylation <NUMBER> approaches immunefocusing epitopebased vaccines aiming narrowing immune response target critical beneficial epitopes produce stronger protective response prerequisite reach goal map epitopes targeted immune system identify biological role neutralizing nonneutralizing infection enhancing containing tcell epitope achieved analyzing activity fine specificity convalescent patient sera infected animal polyclonal sera monoclonal antibodies animal human pbmcs subsequently predicted epitopes also provide basis potential vaccine candidates produced nanoparticles vlps characterization immune responses induced vaccine candidates evaluated animal model may utilized optimize vaccines efficacy figure <NUMBER> epitopefocused vaccine approach may allow targeting less immunodominant band tcell epitopes broader protection avoid eliciting immune responses epitopes playing role protection negative harmful role addition better targeting protective immunodominant epitopes combination epitopes band tcell epitopes targeting different viral proteins could used produce broader stronger protective immune response strainspecific universal cov vaccines next choice merscov vaccine candidate also important take account target population needs protected vaccination populations risk merscov infection include camel contacts healthcare workers patient contacts latter two groups could benefit rapid onset immunity though passive immunization using mabs convalescent sera provided given time another alternative strategy shortterm protection use vaccines capable rapidly inducing high titers neutralizing antibodies provide shortterm immunity beneficial protect highlyatrisk groups new case identified prevent outbreaks prevent virus infection primary cases vaccination dromedary camels may also considered far among available vaccine candidates two tested dromedary camels pvax<NUMBER>s mvas pvax<NUMBER>s dnabased vaccine induced neutralizing antibodies two three camels tested far tested efficacy <NUMBER> candidate mvas viralvectorbased vaccine induced systemic neutralizing antibodies mucosal immunity conferred protection merscov challenge reduced virus shedding vaccinated camels <NUMBER> therefore vaccine candidate may provide means prevent zoonotic transmission virus human population camel contacts healthcare workers endemic areas continuous risk merscov infection either infected camels patients respectively would beneficial induce longerterm mucosal protection could rewarding approaches stop merscov outbreaks still worthwhile develop platforms vaccines aim induce broad protection different related covs could potentially cause future outbreaks learning previous epidemics issued list priority pathogens posing risk human population requiring urgent research development rd intervention measures among merscov highly pathogenic covs high priority lack intervention measures along increase geographical area ongoing mers epitopebased vaccine design following virus infection potential protective band tcell epitopes mapped peptides proteins containing promising epitopes produced formulated using suitable platform example nanoparticles tested immunogenicity efficacy animals follwing several cycles testing optimization final vaccine suitable human use may produced cov cases raise worries future occurrence larger epidemics result virus adaptation human population efficient humanto human transmission development merscov cov vaccines thus needs proactive collaborative efforts researchers filling knowledge gaps market stakeholders providing funding costly process latter insufficient andor unsustainable therefore hindering development even promising candidates initiative aiming accelerating vaccine rd process providing sustained funding prepared future epidemics world economic forum launched coalition epidemic preparedness innovations cepi <NUMBER> cepi international nonprofit association aiming removing barriers facing vaccine development epidemic infections getting ready future epidemics including merscov however still face number challenges despite fact various promising merscov vaccine candidates currently available lack animal models mimicking disease humans vaccine platforms tested prior human use need take account populations target vaccination camels camel handlers relevant ones lack full understanding pathogenesis immune responses virus humans camels crucial vaccine development also needs investments addition longevity immune responses postvaccination evaluated vaccine candidates important vaccination scheme development choice best candidates development lastly vaccine candidates developed highly variable spike protein thus may able provide protection cov strains evolving future targeted vaccination approach aiming conserved epitopes considered development broadlyacting cov vaccine given propensity covs jump species barrier current efforts develop merscov vaccine may also benefit prepare potential novel covs may emerge future designed multiepitope vaccine capacity trigger humoral cell mediated immunity vaccine processed antigen presenting cells apcs antigenic epitopes recognized mhc receptors stimulates cytotoxic cell c cell development c cells trigger cytokine production causes cytotoxic cells divide attack infected cells activated cells also differentiate memory cells similarly vaccine antigen processed presented context mhc class ii molecule b cells differentiate plasma cells memory b cells upon activation cytokines activated b cell plasma cell produces neutralizing antibodies responsible clearing infection b tlr signal transduction pathway tlr <NUMBER> homodimer utilizes myd<NUMBER> mal primary adapters activate nfκb triggers inflammatory cytokine secretion tlr<NUMBER> uses four primary adapters namely myd<NUMBER> mal trif tram nfκb secretion turn induce inflammatory cytokine secretion activating ifn pathway conventional method vaccine designing involving entire organisms large proteins lead unnecessary antigenic load along increased chances allergenic responses <NUMBER> problem overcome peptide based vaccines comprising short immunogenic peptide fragments ability elicit strong targeted immune responses avoiding chances allergenic reactions <NUMBER> recent advancements computational biology opened new doors designing effective vaccines silico <NUMBER> <NUMBER> <NUMBER> study silico approach applied attaining multiepitope vaccine sarscov<NUMBER> comprises spike glycoprotein epitopes induces activation cytotoxic lymphocytes ctls helper lymphocytes htls interferonγ ifnγ fig <NUMBER> sequence retrieval phylogenetic analysis spike glycoprotein sequence sarscov<NUMBER> retrieved pdb <NUMBER>vsb phylogenetic analysis sarscov<NUMBER> glycoprotein performed order check evolutionary relationship sarscov<NUMBER> coronaviruses hcovnl<NUMBER> hcov<NUMBER>e hcov<NUMBER>c<NUMBER> hku<NUMBER> merscov sarscov fig <NUMBER> analysis revealed glycoprotein variants sarscov<NUMBER> clustered together single clade common ancestry sarscov merscov fig <NUMBER> variants sarscov<NUMBER> clustered together less branching indicating minimum variations hence vaccine designed one strain used strains sarscov<NUMBER> similarly phylogenetic analysis different sarscov<NUMBER> strains isolated different countries conducted determine single vaccine used different strains virus isolated various parts world supplementary fig s<NUMBER> results indicated glycoproteins different strains sarscov<NUMBER> isolated different countries closely related one another suggesting wwwnaturecomscientificreports vaccine designed one strain would effective strains viruses isolated different countries supplementary fig s<NUMBER> cell epitope prediction ideal prophylactic vaccine mimic natural immunity induced infection generation longlasting adaptive immunity ctl htl epitopes play important role <NUMBER> ctl epitopes responsible developing long lasting cellular immunity ability eliminate circulating virus virus infected cells <NUMBER> hand htl epitopes play crucial role generating humoral cellular immune responses epitopes elicit cd<NUMBER> helper response necessary development protective cd<NUMBER> tcell memory also activation bcells antibody generation <NUMBER> <NUMBER> therefore effective vaccine candidate consist important ctl htl receptor specific epitopes study ctl epitopes predicted using netctl<NUMBER> iedb consensus methods whereas htl epitopes predicted using netmhc ii pan <NUMBER> server shown tables <NUMBER> <NUMBER> supplementary table s<NUMBER> s<NUMBER> order identify best epitopes predicted epitopes subjected various immune filters high binding affinity mhc class class ii alleles selected criteria screening epitopes promiscuous antigenic immunogenic antigenicity epitopes predicted using vaxijen v<NUMBER> immunogenicity predicted using iedb class immunogenicity server <NUMBER>d structure spike glycoprotein modelled using itasser epitopes considered vaccine construction visualized fig <NUMBER> multiepitope vaccine construct structural modeling refinement validation main criteria used designing linear vaccine construct <NUMBER> contain overlapping htl ctl epitopes supplementary table s<NUMBER> <NUMBER> must immunogenic antigenic allergen <NUMBER> high affinity hla alleles promiscuous basis parameters linear vaccine constructed including <NUMBER> ctl <NUMBER> htl <NUMBER> ifnγ tables <NUMBER> <NUMBER> supplementary table s<NUMBER> epitopes joined gpgpg linkers prevent formation junctional epitopes also facilitate immune processing antigen <NUMBER> cholera toxin b ctb adjuvant attached nterminal construct via eaaak linker fig <NUMBER>a order boost long lasting immune response final vaccine construct consisted <NUMBER> amino acids molecular weight <NUMBER> kda <NUMBER>d models vaccine generated using trrosetta server order validate structural quality predicted model ramachandran plot zscore errat analyses performed amongst predicted models best model chosen fig <NUMBER>b zscore − <NUMBER> within range scores comparable size proteins indicating reliability predicted model <NUMBER> fig <NUMBER>d modelled structure evaluated using rampage used generation ramachandran plot ramachandran plot analysis <NUMBER>dmodel vaccine showed <NUMBER> residues lied favoured region <NUMBER> residues allowed <NUMBER> residues outlier regions respectively verifies overall quality vaccine construct fig <NUMBER>e ideally model reliable least <NUMBER> residues lie favoured region <NUMBER> total number residues present favoured region <NUMBER>d model within range ideal value <NUMBER> confirms reliability errat score revealed errat analysis <NUMBER> representing percentage protein falling wwwnaturecomscientificreports rejection limit <NUMBER> <NUMBER> fig <NUMBER>c generally errat score greater <NUMBER> represents good quality model <NUMBER> score <NUMBER> validates modelled structure immunogenic allergenic physicochemical evaluation vaccine construct immunogenicity ability induce humoral cellular immune responses antigenicity ability recognize specific antigen accompanied immune response therefore vaccine candidate antigenic well immunogenic nature <NUMBER> multiepitope vaccine construct found immunogenic predicted iedb class immunogenicity tool score <NUMBER> per instruction iedb higher score indicates greater probability eliciting immune response vaxijen v<NUMBER> confirmed antigenicity vaccine score <NUMBER> score <NUMBER> considered antigenic allergenicity checked order ensure candidate vaccine stimulate allergic reactions introduced body vaccine candidate found nonallergen predicted allertop allergenfp wwwnaturecomscientificreports web servers evaluation various physicochemical properties essential determining safety efficacy candidate vaccine <NUMBER> hence various chemical physical parameters associated vaccine predicted study using expasy supplementary material <NUMBER> theoretical pi vaccine found <NUMBER> aliphatic index vaccine <NUMBER> suggest vaccine thermostable nature higher aliphatic index protein greater thermostability <NUMBER> estimated halflife vaccine predicted expasy <NUMBER> h mammalian reticulocytes <NUMBER> h yeast <NUMBER> h escherichia coli grand average hydropathicity gravy score − <NUMBER> lower gravy score better solubility indicates candidate vaccine hydrophilic nature meaning perform interaction aqueous environment instability index vaccine candidate found <NUMBER> indicating stable nature protein generally protein whose instability index <NUMBER> classified stable protein <NUMBER> since designed vaccine contain transmembrane helices expression difficulties anticipated production vaccine supplementary fig s<NUMBER> also absence signal peptides vaccine construct signifies prevention protein localization supplementary fig s<NUMBER> b cell epitope prediction b cell epitopes ability elicit humoral immunity recognized bcell receptors secreted antibodies <NUMBER> presence epitopes designed vaccine play important role triggering efficient immune response therefore study linearcontinuous conformationaldiscontinuous b cell epitopes predicted ellipro server using default parameters tables <NUMBER> <NUMBER> visualisation b cell epitopes final vaccine construct done using pymol pymol molecular graphics system version <NUMBER> schrödinger llc supplementary fig s<NUMBER> population coverage distribution expression hla alleles may vary across world based difference regions ethnicities <NUMBER> addition successful vaccine development demands assessment hla allele distribution around world population <NUMBER> therefore study conducted order evaluate vaccine designed sarscov<NUMBER> effective world population selected epitopes study showed total world population coverage <NUMBER> table <NUMBER> addition epitopes showed <NUMBER> fig s<NUMBER> results suggest designed multiepitope vaccine used tackle sarscov<NUMBER> globally table <NUMBER> conformational discontinuous b cell epitopes multiepitope vaccine predicted ellipro server wwwnaturecomscientificreports molecular docking analysis docking vaccine tlrs order generate stable immune response important vaccine interact target immune cell receptors studying interactions molecular docking studies performed tolllike receptors tolllike receptors tlrs central role innate immunity detect conserved pathogenassociated molecular patterns pamps range microbes including viruses leading innate immune activation orchestration adaptive immune response <NUMBER> tlr<NUMBER> tlr<NUMBER> also implicated recognition viral structural proteins leading inflammatory cytokine production <NUMBER> addition several studies sarscov shown importance tlr<NUMBER> tlr<NUMBER> generation effective immune response <NUMBER> <NUMBER> <NUMBER> therefore molecular docking studies vaccine candidate tlr<NUMBER>tlr<NUMBER> conducted docking vaccine tlr<NUMBER> haddock clustered <NUMBER> structures <NUMBER> clusters represents <NUMBER> water refined haddock generated models top cluster lowest haddock score reliable cluster representative model top cluster subjected refinement using haddock refinement server <NUMBER> structures clustered one cluster resulting <NUMBER> water refined models generated haddock statistics refined model presented table <NUMBER> structural analysis refined model shown supplementary fig s<NUMBER> haddock score − <NUMBER> ± <NUMBER> suggest good binding affinity vaccine receptor negative score indicates better docking buried surface area bsa <NUMBER> ± <NUMBER> å <NUMBER> indicates close proximity less waterexposed protein surface <NUMBER> addition rmsd scores also considered important parameter evaluation efficient docking studies allows us identify complex lowest energy least structural deviation low rmsd score docked complex table <NUMBER> indicates good quality model predicted interaction amino acids detailed overview molecular docking given supplementary material <NUMBER> supplementary fig s<NUMBER> respectively also ramachandran plot analysis carried structural validation docked complex supplementary fig s<NUMBER> docked complex along prominent hydrogen bonds shown fig <NUMBER> docking vaccine tlr<NUMBER> haddock clustered <NUMBER> structures <NUMBER> cluster represents <NUMBER> water refined haddock generated models structure lowest haddock score chosen top cluster representative model top cluster subjected refinement using haddock refinement server <NUMBER> structures clustered one cluster resulting <NUMBER> water refined models generated haddock statistics refined model presented table <NUMBER> wwwnaturecomscientificreports wwwnaturecomscientificreports structural analysis refined model shown supplementary fig s<NUMBER> good binding affinity vaccine receptor evident negative haddock score − <NUMBER> ± <NUMBER> <NUMBER> docking scores shown table <NUMBER> suggest stable binding vaccine tlr<NUMBER> receptor predicted interaction amino acids detailed overview molecular docking given supplementary material <NUMBER> supplementary fig s<NUMBER> respectively also ramachandran plot analysis carried structural validation docked complex supplementary fig s<NUMBER> docked complex along prominent hydrogen bonds shown fig <NUMBER> docking vaccine mhc class class ii receptors multiepitope vaccine construct consisting ctl htl epitopes interact mhc class mhc class ii receptors forming epitopemhc complex activate ctls htls required immune response generation <NUMBER> order study interactions molecular docking analysis vaccine mhc class class ii receptors performed docking vaccine mhc class receptor haddock clustered <NUMBER> structures <NUMBER> clusters represents <NUMBER> water refined haddock generated models structure lowest haddock score chosen top cluster representative model top cluster subjected refinement using haddock refinement server <NUMBER> structures clustered one cluster resulting <NUMBER> water refined models generated haddock statistics refined model presented table <NUMBER> structural analysis refined model shown supplementary fig s<NUMBER> statistics refined docked complex indicates strong binding affinity vaccine mhc class receptor low haddock score − <NUMBER> ± <NUMBER> indicates docking effective lower value rmsd table <NUMBER> suggest stability docked complex predicted interaction amino acids detailed overview molecular docking given supplementary material <NUMBER> supplementary fig s<NUMBER> respectively also ramachandran plot analysis carried structural validation docked complex supplementary fig s<NUMBER> docked complex along prominent hydrogen bonds shown fig <NUMBER> docking vaccine mhc class ii receptor haddock clustered <NUMBER> structures <NUMBER> cluster represents <NUMBER> water refined haddock generated models structure lowest haddock score chosen top cluster representative model top cluster subjected refinement wwwnaturecomscientificreports wwwnaturecomscientificreports using haddock refinement server <NUMBER> structures clustered one cluster resulting <NUMBER> water refined haddock generated models statistics refined model presented table <NUMBER> suggest good docking score low haddock score thereby confirming stable efficient docking vaccine mhc class ii receptor addition structural analysis refined model shown supplementary fig s<NUMBER> predicted interaction amino acids detailed overview molecular docking given supplementary material <NUMBER> supplementary fig s<NUMBER> respectively also ramachandran plot analysis carried structural validation docked complex supplementary fig s<NUMBER> docked complex along prominent hydrogen bonds shown fig <NUMBER> binding affinity analysis binding affinity complex gibbs free energy ∆g terms thermodynamics crucial quantity determining whether interaction actually occur cell specific conditions <NUMBER> therefore binding affinity <NUMBER> docked complexes analysed using prodigy web server δg values vaccinetlr<NUMBER> vaccinetlr<NUMBER> vaccinemhc class vaccinemhc class ii receptor found − <NUMBER> kcal mol −<NUMBER> − <NUMBER> kcal mol −<NUMBER> − <NUMBER> kcal mol −<NUMBER> − <NUMBER> kcal mol −<NUMBER> respectively table <NUMBER> results revealed <NUMBER> dockings energetically feasible indicated negative values gibbs free energy δg dissociation constant k docked complexes shown table <NUMBER> energy minimization molecular dynamics simulation vaccine construct molecular dynamics simulation mds essential determine stability protein different thermobaric conditions order check protein stability energy minimization vaccine conducted using steepest descent algorithm gromacs force reaches <NUMBER> kjmol protein considered energy minimised energy minimisation vaccine construct conducted <NUMBER> steps force reached <NUMBER> kjmol potential energy system computed − <NUMBER>e <NUMBER> kjmol total drift − <NUMBER> × <NUMBER> <NUMBER> kjmol average potential energy − <NUMBER>e <NUMBER> kjmol <NUMBER> steps nvt average temperature <NUMBER> k drift <NUMBER> k fig <NUMBER>d average density system computed <NUMBER> kgm <NUMBER> total drift <NUMBER> kgm <NUMBER> fig <NUMBER>b pressure system found <NUMBER> bar total drift <NUMBER> bar fig <NUMBER>c trajectory analysis performed simulation period <NUMBER> ns order check stability flexibility vaccine candidate plot radius gyration showed compactness protein around axes fig <NUMBER>a plot rmsd backbone revealed mild fluctuations indicating stability vaccine time fig <NUMBER>e high peaks rmsf plot suggested high degree flexibility vaccine construct fig <NUMBER>f performed vaccine candidate could expressed e coli expression system therefore necessary optimize codon respective vaccine construct per usage e coli expression system order ensure efficient translation increased protein production optimizing codon usage designed vaccine construct maximal protein expression e coli k<NUMBER> strain jcat tool used generated cdna sequence codon optimization <NUMBER> nucleotides long supplementary material sm<NUMBER> generally codon adaptation index cai value <NUMBER> gc content <NUMBER> <NUMBER> considered good protein expression host system vaccine codon adaptation index cai <NUMBER> gc content reverse translated vaccine <NUMBER> results support proficient expression designed vaccine e coli k<NUMBER> strain finally recombinant plasmid designed inserting adapted codon sequences pet<NUMBER>a vector using snapgene software computationally fig <NUMBER> study conducted order design effective cloning strategy candidate vaccine immune simulation silico immune response generated using cimmsim immune server order assess immunogenic profile multiepitope vaccine <NUMBER> fig <NUMBER> secondary tertiary responses generated simulation significantly higher compared primary response secondary tertiary responses revealed decrease antigenic concentration normal high levels wwwnaturecomscientificreports immunoglobulin activity ie igg<NUMBER> igg<NUMBER> igm igg igm antibodies addition multiple long lasting b cell isotypes found suggesting possible isotype switching potentials memory formation fig <NUMBER>aii supplementary fig s<NUMBER> th helper tc cytotoxic cell populations also showed similar higher response pre activation tcs vaccination fig <NUMBER>aiv aiii supplementary fig s<NUMBER> nk natural killer dendritic cell activity found consistent along higher macrophage activity supplementary fig s<NUMBER> demonstrated exposure fig <NUMBER>av generation good immune response supported high levels ifnγ il<NUMBER> elicited simulation vaccination injection wwwnaturecomscientificreports livereplicating virus simulated around day <NUMBER> order check efficacy vaccine antigen graph fig <NUMBER>ai shows vaccination live replicating virus injected antigenic surge virtually absent indicating effective immune response mainly due protective action high concentration specific antibodies outcome compared control simulation also performed consisting injection live virus <NUMBER> year without prior vaccination case results indicate without prior vaccination host unable contain antigen though inefficacious immune response generated fig <NUMBER>b supplementary fig s<NUMBER> another control experiment vaccine construct designed utilizing randomly generated sequences see effect immune response expected immune simulation results obtained randomly generated sequence shows absence immune response thereby confirming failure vaccination data shown simple reason lack antigenic peptides random sequence simulation translates absence antigenic presentation professional antigen presenting cells sarscov<NUMBER> declared global pandemic world health organization affecting people age groups world health organizations announcement covid<NUMBER> global public health emergency encouraged researchers develop therapeutics drug candidates vaccines disease <NUMBER> cost effective time saving immunoinformatic approaches already helped researchers predict wwwnaturecomscientificreports potential antigenic epitopes required development multiepitope vaccine candidate <NUMBER> <NUMBER> <NUMBER> <NUMBER> distinctive concept multiepitope vaccine design compared classical singleepitope based vaccine screening viral genome identify immunogenic epitopes results elicitation highly targeted immune response without reversal viral pathogenesis <NUMBER> study aim designing multiepitope prophylactic vaccine targeting spike protein sarscov<NUMBER> one major determinants antigenicity viral entry host cell <NUMBER> several computational tools used construct multiepitope vaccine ability generate humoral cell mediated immunity multiepitope vaccine elicits immune responses based short immunogenic sequences instead large proteins whole genome typically used recombinant vaccine technology thus approach avoids excess antigenic load well allergenic responses host <NUMBER> <NUMBER> <NUMBER> analysis entire spectrum possible antigens carried using immunoinformatics molecular modelling order examine potential binding host proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition multiepitope vaccines advantages traditional singleepitope vaccines due following unique features multiple mhc class class ii epitopes recognized tcrs various cell subsets ii overlapping ctl htl b cell epitopes capacity activate humoral cellular immune responses simultaneously iii linking adjuvant vaccine ensures long lasting immune response enhanced immunogenicity iv vitro antigen expression complications well difficulty culturing pathogens also avoided <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> designing multiepitope vaccines emerging area already gained importance vaccines designed approach shown vivo efficacy protective immunity <NUMBER> also entered phasei clinical trials <NUMBER> <NUMBER> present study utilized potential immunogenic epitopes identified sarscov<NUMBER> spike protein construct multiepitope vaccine cholera toxin b ctb adjuvant along appropriate linkers cholera toxin b proven act potential viral adjuvant linked nterminal vaccine construct <NUMBER> <NUMBER> <NUMBER> glycine rich linker gpgpg preferred link screened epitopes enhances solubility enable adjoining domains accessible act freely <NUMBER> various immunological filters used screen predicted ctl htl epitopes epitopes must antigenic immunogenic bind multiple mhc class mhc class ii alleles promiscuous must overlapping ctl htl epitopes similar approach used bazhan coworkers designed tcell multi epitope vaccine ebola virus tcell epitopes predicted using iedbimmune epitope database vaccine candidate constructed using suitable epitopes found immunogenic expressed mice <NUMBER> designed vaccine predicted nonallergen using allertop v<NUMBER> server verified allergenfp v<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> physicochemical properties vaccine analysed using protparam tool offered expasy server <NUMBER> molecular weight construct <NUMBER> kda instability index evaluated <NUMBER> classify vaccine stable generally figure <NUMBER> silico restriction cloning red coloured portion represents codon optimised multiepitope vaccine inserted pet<NUMBER>a expression vector represented black colour wwwnaturecomscientificreports protein whose instability index lesser <NUMBER> predicted stable values predicts protein unstable <NUMBER> theoretical pi vaccine calculated <NUMBER> gravy index vaccine − <NUMBER> lower gravy score better solubility reflective vaccines polar nature effective interaction water suggesting high solubility <NUMBER> aliphatic index <NUMBER> indicated protein thermostable <NUMBER> halflife vaccine evaluated <NUMBER> h mammalian reticulocytes vitro <NUMBER> h yeast vivo <NUMBER> h escherichia coli vivo indicates time taken protein reach <NUMBER> concentration synthesis cell similarly foroutan colleagues also used array silico analysis order assess allergenecity physicochemical properties designed vaccine candidate toxoplasma gondii <NUMBER> also performed laboratory validation vaccine candidate revealed multiepitope vaccine able trigger strong humoral cellular responses mice <NUMBER> physicochemical properties predicted study comparable predicted foroutan et al recently published work <NUMBER> fact instability index aliphatic index vaccine candidate found better compared values reported foroutan et al <NUMBER> structural validation vaccine construct performed ramachandran plot analysis using rampage showed <NUMBER> residues favoured region <NUMBER> allowed region <NUMBER> residues placed outlier region thereby validating tertiary structure vaccine errat score <NUMBER> validated overall quality vaccine zscore assessment prosa web server revealed score − <NUMBER> indicating protein falls plot consists zscores already determined structures solved nmr xray crystallographic experiments <NUMBER> spike glycoprotein sarscov<NUMBER> one structural components virus recognized tolllike receptor <NUMBER> tlr<NUMBER> tolllike receptor <NUMBER> tlr<NUMBER> expressed plasma membrane wwwnaturecomscientificreports cells <NUMBER> <NUMBER> <NUMBER> human tolllike receptor <NUMBER> tlr<NUMBER> expressed various types immune cells like monocytes macrophages granulocytes immature dendritic cells <NUMBER> direct interaction tlr<NUMBER> ctb responsible activation tlr<NUMBER> ctb <NUMBER> conclusion strengthened fact capacity ctb induce inflammatory response lost tlr<NUMBER>deficient macrophages <NUMBER> elisabased assays demonstrated ctb able induce nfκb activation tlr<NUMBER> receptor cells binding directly <NUMBER> addition tlr<NUMBER> also associated recognition viral envelop glycoprotein <NUMBER> myeloid differentiation factor <NUMBER> myd<NUMBER> acts primary adaptor core tlr<NUMBER> signalling pathway results nfκb mitogenactivated protein kinase mapk activation leading secretion core panel cytokines <NUMBER> interaction pattern vaccine tlr<NUMBER> tlr<NUMBER> analysed molecular docking studies figs <NUMBER> <NUMBER> docking analysis tlr<NUMBER> vaccine construct showed <NUMBER> salt bridges <NUMBER> hydrogen bonds formed interaction docked complex shows salt bridges formed arg<NUMBER> glu<NUMBER> asp<NUMBER> tlr<NUMBER> asp<NUMBER> lys<NUMBER> lys<NUMBER> vaccine respectively similarly docking analysis tlr<NUMBER> vaccine construct also showed <NUMBER> salt bridges <NUMBER> hydrogen bonds formed interaction salt bridges formed case asp<NUMBER> asp<NUMBER> arg<NUMBER> tlr<NUMBER> lys<NUMBER> lys<NUMBER> glu<NUMBER> vaccine respectively several studies sarscov shown importance tlr<NUMBER> tlr<NUMBER> generation effective immune response <NUMBER> sensitized tlr<NUMBER> triggers release il<NUMBER> important chemokine necessary generating innate immune response <NUMBER> molecular dynamics simulation vaccine construct <NUMBER> ns showed mild fluctuations rmsd graph indicating vaccines stability fig <NUMBER> rmsf graph showed regions high peaks indicating high flexibility vaccine construct fig <NUMBER> molecular dynamics simulation mds one important steps used check stability vaccine simulating vaccine vivo conditions rmsd rmsf data obtained mds similar studies done research groups checked stability flexibility vaccine candidate mimicking vivo conditions <NUMBER> <NUMBER> <NUMBER> assure effective expression e coli host codon optimization designed vaccine performed linear vaccine construct reverse translated specific cdna sequence gc content recorded <NUMBER> therefore showing possibility efficient expression vaccine candidate e coli host insertion vaccine expression vector pet<NUMBER>a silico cloning performed vaccine expressed bacterial system similar approach used foroutan et al order optimize codon designed vaccine vitro expression <NUMBER> immune simulation studies confirmed designed vaccine able elicit specific immune responses required clear antigen secondary exposure fig <NUMBER> final injection immune simulation study fact better recently published work multiepitope vaccine candidate sarscov<NUMBER> live replicating virus injected vaccination order check effectiveness secondary exposure antigen <NUMBER> similarly immunoinformatic strategy vaccine designing recently applied designing multiepitope vaccines pseudomonas aeruginosa <NUMBER> klebsiella pneumoniae <NUMBER> dengue <NUMBER> nipah virus <NUMBER> hendra virus <NUMBER> malaria <NUMBER> addition similar approach also applied developing vaccine cancerous antigens <NUMBER> <NUMBER> ctl htl ifnγ epitopes included vaccine capacity trigger stimulation hosts respective immune cells turn cause activation immune cells via complex signalling sequence retrieval phylogenetic tree construction vipr database https wwwviprb rcorgbrchomespgdecor atorvipr used retrieve spike glycoprotein sequences <NUMBER> coronaviruses hcovnl<NUMBER> hcov<NUMBER>e hcov<NUMBER>c<NUMBER> hku<NUMBER> merscov sarscov sarscov<NUMBER> previously infected human population addition spike glycoprotein sequences different strains sarscov<NUMBER> isolated <NUMBER> different countries china japan usa australia finland sweden india colombia taiwan pakistan italy israel iran iran vietnam peru brazil spain nepal south korea around globe also retrieved vipr database two phylogeny trees constructed trees muscle tool <NUMBER> used order align glycoprotein sequences alignment file used construct phylogenetic trees default parameters <NUMBER> bootstrap replicates using neighbour joining algorithm mega <NUMBER> <NUMBER> cell epitope prediction ctl epitope prediction <NUMBER>mer long ctl epitopes predicted using netctl <NUMBER> server https wwwcbsdtudkservi cesnetct l recognized hla class supertypes commonly occurring human population ie a<NUMBER> a<NUMBER> a<NUMBER> a<NUMBER> a<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> <NUMBER> netctl <NUMBER> server thresholds set <NUMBER> <NUMBER> <NUMBER> distinctive parameters proteasomal cterminal cleavage transporter associated antigen processing tap epitope recognition respectively netctl supports epitope prediction <NUMBER> sensitivity <NUMBER> specificity also epitopes recognized hla class alleles detected immune epitope consensus iedb tool https tools iedborgmhci <NUMBER> wwwnaturecomscientificreports htl epitope prediction <NUMBER>mer long htl epitopes predicted using netmhcii pan <NUMBER> server wwwcbs dtudkservi cesnetmh ciipa n affinity class ii hla alleles <NUMBER> predicted peptides classified strong intermediate nonbinders threshold value set <NUMBER> <NUMBER> <NUMBER> respectively based idea percentile rank given netmhcii pan <NUMBER> server epitopes screened basis antigenicity well immunogenicity predicted vaxijen v<NUMBER> iedb class immunogenicity web servers respectively <NUMBER> <NUMBER> <NUMBER>d structure spike glycoprotein modelled using itasser order visualize selected epitopes protein surface <NUMBER> b cell epitope prediction ellipro tool https tools iedborgellip ro iedb server used predicting linear conformationaldiscontinuous b cell epitopes default parameters <NUMBER> ifnγ epitope prediction humoral innate immunity ifnγ plays important role antiviral antitumour immune regulatory activities hence ifnγ inducing epitopes important designing potential multiepitope vaccine target protein ifnepitope server https crddosddnetragha va ifnep itope used predict ifnγ epitopes <NUMBER> server maximum accuracy <NUMBER> various approaches machine learning strategy motivebased analysis accuracy hybrid approach used prediction epitopes population coverage iedb population coverage analysis tool https tools iedborgpopul ation used order check epitopes designed vaccine effectively covered entire world population <NUMBER> sarscov<NUMBER> global pandemic population coverage checked total world population united states europe china south asia oceania default parameters used coverage checked hla class hla class ii binding alleles multiepitope vaccine construct structural modelling validation screened ctl htl ifnγ inducing epitopes target glycoprotein together linked glycineproline rich gpgpg linkers addition cholera toxin b ctb adjuvant added eaaak linker nterminal vaccine construct induce regulatory immune responses trrosetta used generate <NUMBER>d model linear vaccine construct <NUMBER> tertiary structure validated using errat score <NUMBER> followed prosaweb analysis <NUMBER> prosaweb validates structure based zscore predicted overall quality generated model vaccine determined ramachandran plot analysis using rampage server <NUMBER> physicochemical properties vaccine construct vaxijen v<NUMBER> <NUMBER> used check antigenicity vaccine construct threshold value <NUMBER> viral databases used extract wholeprotein antigenicity prediction models set made <NUMBER> identified antigens <NUMBER> nonantigens generated models evaluated using data sets utilizing internal leaveoneout crossvalidation external validation models implemented server worked well validations showing <NUMBER> <NUMBER> predictive accuracy also allergenicity vaccine checked using allertop server <NUMBER> server employs autocrosscovariance acc grouping protein sequences uniform equallength vectors applied peptide study various types quantitative structureactivity relationships qsar knearest neighbour algorithm knn k <NUMBER> used server identify proteins based training set composed <NUMBER> identified allergens <NUMBER> nonallergens various species addition allergenicity designed vaccine cross checked allergenfp server https ddgpharm facnetaller genfp <NUMBER> physicochemical properties like isoelectric point molecular weight instability index aliphatic index halflife gravy score vaccine assessed using expasy protparam server <NUMBER> vaccine construct also checked presence signal peptides transmembrane helices signalp<NUMBER> https wwwcbsdtudkservi cessigna lp <NUMBER> tmhmm server v<NUMBER> https wwwcbsdtudkservi cestmhmm <NUMBER> respectively docking tlr<NUMBER> dimer tlr<NUMBER> mhc class receptor mhc class ii receptor generation stable immune response essential vaccine interact target immune cell receptors study interactions molecular docking studies performed study interactions vaccine tlr<NUMBER> dimer tlr<NUMBER> studied localize cell surface thereby inducing immune response activated vaccine <NUMBER> <NUMBER> addition vaccine also docked mhc class mhc class ii receptors tlr<NUMBER> heterotetramer structure tlr<NUMBER> structure obtained protein data bank id <NUMBER>fxi id <NUMBER>z<NUMBER>x respectively whereas mhc class mhc class ii receptors obtained pdb id <NUMBER>i<NUMBER>y <NUMBER>kg<NUMBER> respectively cport <NUMBER> utilized predicting active passive residues interactions docking vaccine tlr<NUMBER> tlr<NUMBER> mhc class mhc class ii receptors performed haddock <NUMBER> https wwwbonvi nlaborgsoftw arehaddo ck<NUMBER> <NUMBER> best cluster chosen docked clusters based lowest haddock score haddock refinement interface used refine chosen cluster best structure refinement docked complex chosen binding affinity calculated using prodigy web server <NUMBER> <NUMBER> finally interacting residues vaccine tlrs mapped using pdbsum https wwwebiacukthorn tonsrvdatab asespdbsu mgener atehtml <NUMBER> chemical simulations linuxbased program used molecular dynamics simulation mds scientific reports <NUMBER> <NUMBER> httpsdoiorg<NUMBER>s<NUMBER> wwwnaturecomscientificreports energy minimisation <NUMBER> mds done vaccine structure order see behaves vivo biological system oplsaa optimized potential liquid simulationall atom force field constrain used generate topology file required energy minimization equilibration equilibrated threepoint water model spc<NUMBER> used solvent simulate vaccine periodic boundary conditions net charge vaccine construct evaluated charged ions added order neutralize system simulation run performed <NUMBER> ns energy minimised structure order find root mean square deviation rmsd backbone root mean square fluctuation rmsf side chain graphs visualized using xmgrace plotting tool <NUMBER> reverse translation codon optimization silico cloning vaccine java codon adaptation tool jcat https wwwjcatde used codon optimization reverse translation generated cdna sequence vaccine used efficient expression e coli k<NUMBER> strain <NUMBER> result consists gc content codon adaptation index cai score used assess protein expression levels addition optimized multiepitope vaccine sequence inserted pet<NUMBER>a vector snapgene tool immune simulation cimmsim server https krake niacrmcnritcimmsi used performing immune simulation vaccine order characterize immune response profile immunogenicity chimeric peptides <NUMBER> cimmsim agentbased model uses positionspecific scoring matrices pssm peptide prediction derived machine learning techniques predicting immune interactions minimum recommended time dose <NUMBER> dose <NUMBER> vaccines currently use <NUMBER> weeks <NUMBER> current global pandemic covid<NUMBER> caused sarscov<NUMBER> date uncontrollable high death rate proper medical preventives like vaccines given patients yet recovery application silico methods used design effective vaccine lesser time low cost study immunoinformatic tools used constructing multiepitope vaccine sarscov<NUMBER> consisting ctl htl ifnγ epitopes trigger strong immune responses designed multiepitope vaccine found antigenic immunogenic stability designed vaccine assured molecular dynamics simulation stable interaction vaccine immune receptors confirmed molecular docking studies silico expression studies confirmed vaccines expression bacterial host efficiency vaccine trigger immune response validated immune simulation studies scientific reports <NUMBER> <NUMBER> httpsdoiorg<NUMBER>s<NUMBER> wwwnaturecomscientificreports nterminal sequence considered met estimated halflife <NUMBER> hours mammalian reticulocytes vitro <NUMBER> hours yeast vivo <NUMBER> hours escherichia coli vivo instability index ii computed <NUMBER> classifies protein stable december <NUMBER> turned global catastrophe <NUMBER> virus designated severe acute respiratory syndromecoronavirus<NUMBER> sarscov<NUMBER> disease caused agent coronavirus disease <NUMBER> covid <NUMBER> <NUMBER> world health organization pronounced disease pandemic march <NUMBER> <NUMBER> <NUMBER> may <NUMBER> th <NUMBER> infection spread <NUMBER> countries territories around world <NUMBER> international conveyances <NUMBER> million cases around two hundred fiftythousand deaths <NUMBER> disease average affects <NUMBER> individuals <NUMBER> deaths daily world community responded challenge death devastation resilience determination <NUMBER> governments implemented lockdown measures blocked international travel enforced public containment measures mitigate virus morbidity mortality <NUMBER> <NUMBER> <NUMBER> major understanding disease well pathogen data generated widely publicized matter days weeks rather years decades unprecedented occurrence history medicine <NUMBER> <NUMBER> <NUMBER> <NUMBER> coronavirus family sarscov<NUMBER> belongs family zoonotic viruses known coronavirus genus betacononavirus closely related two viruses namely severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> three bat viruses cross cause human infection intermediate host civets sarscov camels merscov possibly pangolins sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> coronaviruses enveloped viruses around <NUMBER> nm diameter positivesense singlestranded rna genome around <NUMBER>kb nucleocapsid helical symmetry wrapped icosahedral protein shell surface multiple clubshaped spikes creates appearance solar corona em viral envelope consists lipid bilayer membrane envelope e spike structural proteins anchored coronaviruses use angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors cellular entry receptor however propensity sarscov<NUMBER> attach receptors much higher giving high infectivity <NUMBER> need coronavirus vaccine intensive search effective drug virus resultant disease led breakthrough agents drugs namely hydroxychloroquine remdesivir advocated desperate measures fight covid<NUMBER> based preliminary contradictory inconclusive studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> need drug least <NUMBER> effective stop pandemic drugs may save lives nowhere near power bring normalcy utter chaos caused pandemic <NUMBER> leaves us one choice namely effective safe vaccine shall manufactured soon possible available countries populations affected pandemic affordable price <NUMBER> <NUMBER> vaccine power generate herd immunity communities reduce incidence disease block transmission reduce social economic burden disease high immunization coverage effectively fight pandemic prevent secondary waves infection control seasonal endemic infection outbursts eventually disease eradicated happened many diseases even higher potential covid<NUMBER> cause pandemics namely smallpox poliomyelitis etc <NUMBER> <NUMBER> adaptive immune response vaccine medical preparations ranging intact organisms attenuated live inactivated genetically engineered parts organisms antigenic induce arms adaptive immune system stimulate sufficient number memory cells b lymphocytes <NUMBER> vaccines contain antigens necessary mount specific response without causing disease challenged pathogen memory cells yield effector cells antibodyproducing b cells fight infection antibodies neutralizing type binds virus block infection <NUMBER> virus coated neutralizing antibodies either cannot interact receptor may unable uncoat genome currently licensed vaccines induce neutralizing antibody responses capable mediating longterm protection lytic viruses influenza smallpox <NUMBER> cellbased responses recognize kill infected cells also fight infection <NUMBER> following antigen processing dendritic cells small peptides displayed cell surface groove major histocompatibility complex mhc class class ii molecules cytotoxic cells cd<NUMBER> recognize mhc class ipeptide complexes differentiate cytotoxic effector cells capable killing infected cells pathogens helper cells cd<NUMBER> recognize mhc class iipeptide complexes differentiate effector cells produce preferentially helper th<NUMBER> th<NUMBER> cytokines fig <NUMBER> helper cells <NUMBER> th<NUMBER> support cd<NUMBER> tcell differentiation contrast inhibited helper cells <NUMBER> th<NUMBER> like cytokines vaccines chronic pathogens namely mycobacterium tuberculosis malaria hcv hiv etc often require cellmediated immune responses control infection <NUMBER> vaccinepreventable diseases success vaccine pathogen complex issue depends upon biology virus type immune response elicited body organism vaccines successful several pathogens including <NUMBER> major infectious diseases <NUMBER> <NUMBER> infectious diseases vaccinepreventable <NUMBER> <NUMBER> development vaccines hiv hcv proved challenging viruses extreme genetic heterogeneity including hypervariable regions target neutralizing antibodies mutation contribute immune escape <NUMBER> mutations lead mixture genomes patient time patient patient also antibodies mounted viral infections predominantly nonneutralizing neutralizing antibodies often either absent weak fight pathogen neutralize narrow range circulating viral strains appear subgroup patients either recover elite controller <NUMBER> another aspect considered whether virus grown cell culture transmitted small animals experimentation since hcv discovered molecular cloning <NUMBER> propagation cell culture difficult hampers ability investigators experiment various antigenic components virus <NUMBER> develop safe effective vaccine covid<NUMBER> need consider several things sarscov<NUMBER> immune response natural infection vaccine mutations sarscov<NUMBER> mutate fast mutations cause phenomenon immune escape seen hiv hcv <NUMBER> <NUMBER> sarscov<NUMBER> shown mutations true every rna virus however mutations slow mild mutants show nearly similar sequences parent strain dorp et al <NUMBER> studied genomic diversity sarscov<NUMBER> recorded <NUMBER> filtered recurrent mutations however mutations either neutral even deleterious clinical significance vaccine immunity ahmad et al <NUMBER> found mutations <NUMBER> available sarscov<NUMBER> sequences identified set b cell cell epitopes derived spike nucleoproteinn proteins map identically sarscov<NUMBER> proteins findings provide screened set epitopes help guide experimental efforts towards development vaccines sarscov<NUMBER> type immune response occurs natural covid<NUMBER> vaccination antibodies neutralizing nature sarscov<NUMBER> infection evokes robust adaptive immune response cell b cell type arms <NUMBER> <NUMBER> furthermore igm igg antibodies appear around <NUMBER> th day infection patients seroconvert within <NUMBER> weeks antibodies raised internal nucleoprotein n spike protein virion neutralizing activity <NUMBER> several candidate vaccines clinical trial investigators shall study strength nature immune response vaccine antigen mostly spike protein people recover covid<NUMBER> infection protected second third infection reinfections occur would imply immune response sarscov<NUMBER> protective making possibilities successful vaccine difficult scary reports south korea patients thought recovered covid<NUMBER> tested positive <NUMBER> intense debate started reactivation reinfections virus soon reports put rest positive sample found residual dead fragments virus virus reactivated reinfected <NUMBER> reports two groups investigators shown sarscov<NUMBER> antibodies protective bao et al showed <NUMBER> monkeys recovered sarscov<NUMBER> infection protected reinfection challenge convalescence <NUMBER> gao et al administered candidate vaccine picovacc sinovac biotech mice rats nonhuman primates antibodies raised vaccine animals showed neutralizing ability sarscov<NUMBER> strains three immunizations two doses <NUMBER>µg <NUMBER>µg per dose gave partial complete protection macaques sarscov<NUMBER> <NUMBER> data exciting reproducible humans confirm vaccines covid<NUMBER> shall protective covid<NUMBER> vaccination program succeed antibody response mounted virusvaccine must longlasting today possible address question virus community last months however take leads data generated duration immunity <NUMBER> coronaviruses namely sarscov merscov <NUMBER> <NUMBER> viruses closely related sarscov<NUMBER> induce robust cell b cell immune response longlasting many candidate vaccines viruses gone successful clinical trials safe immunogenic <NUMBER> greatest fear among vaccine developers create vaccine protect infection causes disease exacerbation increased morbidity mortality <NUMBER> <NUMBER> <NUMBER> <NUMBER> vaccines mount antibodydependent enhancement ade negates basic purpose vaccination <NUMBER> response mediated type nonneutralizing antibodies mounted infection vaccination immune response vaccines subverted leading exacerbated illness could due fc receptoror complement bearing cellsmediated mechanisms fcregion antibody binds fcγr immune cells subverts immune response reducing h <NUMBER> cytokines il<NUMBER> tnfa ifng skews h <NUMBER> cytokines il<NUMBER> il<NUMBER> pge<NUMBER> infa inhibits stat pathway leading increased viral replication fig <NUMBER> ade clinical significance several viral infections including influenza rsv sarscov merscov dengue virus zika virus west nile virus considering ade major impediment vaccine development efforts identify highly selected epitopes done avoid production antibodies responsible disease enhancement ade reported animals vaccination trials sarscov merscov <NUMBER> <NUMBER> <NUMBER> vaccine candidates coronaviruses based fulllength spike protein induce nonneutralizing antibodies lack protection animals viral challenge severe disease enhancement presenting enhanced hepatitis increased morbidity stronger inflammatory response <NUMBER> today reports ade use covid<NUMBER> candidate vaccines nonhuman primates humans <NUMBER> however early period development vaccines matter major importance success vaccine need vigilant ade following covid<NUMBER> vaccination reported prevented shielding nonneutralizing epitopes protein glycosylation selecting critical neutralizing epitopes antigen elicit robust protective immunity stages vaccine development every new vaccine follows stringent protocol rd meticulously followed completed licensed marketed fig <NUMBER> costs also considered vaccine development high cost highrisk involvement <NUMBER> apart competition major vaccine manufacturers cost developing single new vaccine infectious disease exceeds us billion technology behind development vaccines research development rd seen transformation recent past years candidate vaccines made traditional methods biotechnology making prototype vaccine took <NUMBER> <NUMBER> years limited types vaccines needed availability cuttingedge research facilities work infectious agent possible laboratories globe <NUMBER> <NUMBER> recently platform technology employed developing candidate vaccines <NUMBER> <NUMBER> platform technology offers several advantages development vaccines include automation speed ability develop several prototype vaccines single system costeffectiveness developing among complex mrna vaccines ease believed mrnabased vaccine developed platform technology appears particularly promising terms ease manufacture adaptability various targets biological delivery <NUMBER> candidate vaccines developed matter days rather years platform technology termed single gamechanger fight epidemics pandemics caused new agents <NUMBER> table <NUMBER> vaccine design subtle structure advantages disadvantages immunogenicity safety ease use effectiveness fig <NUMBER> <NUMBER> <NUMBER> <NUMBER> live attenuated vaccine developed process live virus passed animal human cells genome mutates unable cause disease weekend virus replicates like natural infection causes strong cell b cell immune response longlasting vaccines good attain herd immunity population block transmission disease however small chance reversion mutation virulence occurrence disease besides vaccines need cold chain distribution community examples vaccines bcg smallpox mmr measles mumps rubella rotavirus poliomyelitis opv etc inactivated vaccines treated formaldehyde heat virus killed vaccines safe cannot cause disease however vaccines replicate cause suboptimum immune response need repeated dosing adjuvants enhance immunity antibodydependant enhancement reported vaccines avoid need maintain structure epitopes surface antigen inactivation examples vaccines include poliomyelitis ipv hav rabies etc subunit vaccines composed purified antigen peptides viruses like spike protein sarscov<NUMBER> safe use antigen directly presented mch class ii often generate robust cytotoxic cell response mhc class dependant thus vaccines need repeated dosing adjuvants enhance immunity viruslike particles made empty virus particles without genetic material vaccines safe immunogenic however difficult manufacture unprecedented fast track path taken rd world community developing candidate covid<NUMBER> vaccines <NUMBER> may <NUMBER> global covid<NUMBER> vaccine rd includes <NUMBER> candidate vaccines <NUMBER> platform <NUMBER> candidate vaccines diverse include live attenuated vaccine n <NUMBER> inactivated vaccine n<NUMBER> dna vaccine n<NUMBER> rna vaccine n<NUMBER> replicating viral vector vaccine n<NUMBER> nonreplicating viral vector vaccine n<NUMBER> protein subunit vaccine n<NUMBER> viruslike particles n<NUMBER> unknown n<NUMBER> platforms used past <NUMBER> instances variety infectious pathogens till several candidate vaccines completed exploratory preclinical stage obtained clinical trial authorization initiated recruitment volunteers clinical trials <NUMBER> six candidate vaccines stand forefront clinical trials table <NUMBER> ad<NUMBER>ncov cansino biologicals inc recombinant vaccine using adenovirusvector cansino adenovirusvector vaccine ebola ad<NUMBER>ebov phase ii trials phase trial completed <NUMBER> volunteers however results disclosed today present phase ii trials underway cansino plans enroll <NUMBER> volunteers evaluate vaccine safety immunogenicity <NUMBER> <NUMBER> mrna<NUMBER> moderna lipid encapsulated mrna vaccine undergoing safety immune response phase trial seattle company filed ind go parallel phase ii trials <NUMBER> <NUMBER> picovacc sinovac biotech inactivated virus vaccine undergoing parallel phase iii trials planned <NUMBER> volunteers sinovac partnered usbased dynavax vaccine produced neutralizing antibodies mice rats rhesus monkey protective challenge experiments <NUMBER> <NUMBER> chadox<NUMBER> university oxford adenovirus vectorbased vaccine plans run parallel phase iii trials <NUMBER> volunteers safety efficacy oxford group experience candidate vaccine merscov chadoxmers undergone successful phase trial safety group pushing ahead aggressive clinical plan talking emergencyuse vaccine ready september <NUMBER> <NUMBER> <NUMBER> <NUMBER> bnt<NUMBER> a<NUMBER> b<NUMBER> b<NUMBER> c<NUMBER> biontehc another lipid nanoparticle mrna vaccine received clearance regulatory authority form germany start phase iii trials <NUMBER> volunteers trial dose escalation design <NUMBER> <NUMBER> mcg using <NUMBER> vaccine subtypes a<NUMBER> b<NUMBER> b<NUMBER> c<NUMBER> developers claimed emergencyuse vaccine september <NUMBER> <NUMBER> ino<NUMBER> inovio dna plasmid vaccine company experience platforms candidate vaccines mers sars vaccine needs delivery system electroporation shall add cost vaccine phase trial using two doses spaced four weeks apart completed results shall available june <NUMBER> inovio planning start phase iiiii trials soon <NUMBER> numerous developers present preclinical stage vaccine development indicated procure clinical trial authorization regulatory agencies initiate firstinhuman vaccine testing race time middle death devastation covid<NUMBER> vaccine development thrown major challenges vaccine rd <NUMBER> world facing major health catastrophe economic devastation one definitive solutions effective safe vaccine shortest possible time global vaccine rd efforts unprecedented history virus causing cvoid<NUMBER> sequenced weeks ordinarily taken <NUMBER> <NUMBER> years clone sequence virus time disease discovered tremendous race time develop candidate vaccine matter weeks <NUMBER> candidate vaccines entered phase iii clinical trials taken us <NUMBER> <NUMBER> years history vaccine development infectious agents reach stage covid<NUMBER> vaccine however clinical trials undergoing greatest limiting factor need time acquire human data normally phase ii iii trials done humans completed <NUMBER> <NUMBER> years sometimes necessary qualifying vaccine safe immunogenic efficacious today candidate vaccines undergoing phase parallel iii studies shall take several months acquiring data start phase iii trials phase iii trial initiated take long <NUMBER> years compress period vaccine developers involved adopting parallel adaptive development phases iii acquire safety immunogenicity data soon possible initiate phase iii trials imagination data shall available early <NUMBER> vaccine regulatory authorities allow vaccine marketing covid<NUMBER> vaccines could available human use earlier innovative methods clinical trials regulatory processes employed one use challenge studies testify vaccine efficacy <NUMBER> following proof safety immunogenicity phase iii trials controlled challenge studies completed matter weeks done confirm vaccine efficacy challenge studies done past infectious diseases namely influenza typhoid fever cholera malaria whether challenge studies ethical covid<NUMBER> considering risk volunteer matter debate vaccine developers <NUMBER> also regularity authorities use innovative procedures allow guarded emergency use vaccine would need careful consideration interventional animal safety data data safety immunogenicity efficacy acquired phase iii trials vaccine developers ready scale manufacturing capacity massive demands product allowed marketing <NUMBER> quick fix short cuts please however concerns raised rush deploy covid<NUMBER> vaccine applying quick fix short cuts lead errors disastrous consequences <NUMBER> regulators worry atmosphere hype covid<NUMBER> vaccine public claims breakthrough research based poorly conducted studies data collected fraud real possibility data form basis findings need scrutinized confirmed investigators relaxion regulatory principles based political pressure goodwill needs resisted one needs protect interests volunteers part experiments <NUMBER> lastly vaccine development risky process one critical issue covid<NUMBER> vaccine wouldbe occurrence antibodydependent enhancement ade may disastrous receiving vaccine <NUMBER> <NUMBER> regulators take precautions discourage candidate vaccines may show phenomenon basis approvalthe vaccine safe effective humans efficacy <NUMBER> capacity produce bulk market demand affordable cost susceptible population spontaneous reporting adverse events reporting system monitor data collected endusers ≠vaccine efficacy veiuiviu x<NUMBER> <NUMBER>iviu x<NUMBER> <NUMBER>rr x<NUMBER> ivincidence vaccine group iuincidence unvaccinated group rrrelative risk µplatform technology shortened time vaccine production years days αclinical trials ratelimiting vaccine marketing €human challenge studies done phase iia certain diseases challenge ethical €phase iib studies provide data efficacy regions high prevalence disease community £the cost developing vaccine research discovery product registration around us <NUMBER> billion figure includes vaccines abandoned development process δthe overall success rate vaccine development around <NUMBER> safety efficacy trial phase iii <NUMBER> phase south korea parallel phase usa completed phase using <NUMBER> doses spaced <NUMBER> weeks apart results june <NUMBER> december <NUMBER> outbreak unexplained pneumonia similar severe acute <NUMBER> respiratory syndrome sars wuhan china reported health commission hubei <NUMBER> province china severe respiratory illness identified multiple diagnostic methods <NUMBER> infection novel coronavirus <NUMBER> <NUMBER> <NUMBER> <NUMBER> temporarily denoted <NUMBER>ncov world <NUMBER> health organization <NUMBER> ， renamed severe acute respiratory syndrome coronavirus <NUMBER> sarscov using vaccine platforms <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however vaccines preclinical studies reported assessment clinical trials <NUMBER> httpsclinical trialsgovct<NUMBER>shownct<NUMBER> httpsclinical trialsgovct<NUMBER>shownct<NUMBER> <NUMBER> currently vaccine approved prevention sars since effective antiviral <NUMBER> strategies control sarscov sarscov<NUMBER> infections still lacking vaccination still <NUMBER> regarded major approach preventing potential reemergence sarscov <NUMBER> known current influenza vaccines inactivated vaccines plays crucial determining host tropism transmission capacity <NUMBER> <NUMBER> generally protein <NUMBER> coronavirus functionally divided s<NUMBER> subunit responsible receptor binding generating s<NUMBER> s<NUMBER> subunits located r<NUMBER>s<NUMBER> <NUMBER> addition reported <NUMBER> protein strong immunogenicity induce high titer neutralizing antibody <NUMBER> rbd <NUMBER> sarscov s<NUMBER> located s<NUMBER> key rbm s<NUMBER> r<NUMBER> critical whole protein around <NUMBER> rbd <NUMBER> rbm <NUMBER> <NUMBER> s<NUMBER> subunit sarscov<NUMBER> sarscov shared around <NUMBER> conserved amino acids <NUMBER> threedimensional structure sarscov<NUMBER> rbd composed core external <NUMBER> subdomain similar sarscov <NUMBER> aligned sequence protein protective immunity <NUMBER> <NUMBER> <NUMBER> <NUMBER> example expression fulllength protein trimer recombinant s<NUMBER> s<NUMBER> proteins respectively found antis<NUMBER> antis<NUMBER> iggs able <NUMBER> abolish binding protein cellular receptors although antis<NUMBER> igg showed <NUMBER> significantly higher blocking efficiency <NUMBER> shown figure <NUMBER>b amino acid sequences <NUMBER> hr<NUMBER> hr<NUMBER> highly conserved homologous sarscov sarscov<NUMBER> fact <NUMBER> domains also highly conserved coronaviruses <NUMBER> thus s<NUMBER> subunit potential <NUMBER> used target development pancov vaccine divergent virus strains altogether results suggested s<NUMBER> domain sarscov protein vaccine rbds red number indicates core amino acids rbd binds receptor ace<NUMBER> green frame amino acid sequence rbm b sequence alignment sarscov sarscov<NUMBER> hr<NUMBER> red frame location variable amino acid residues sarscov sarscov<NUMBER> hr<NUMBER> ann arvin stanford university ca usa presented us latest varicella zoster vaccine development <NUMBER> <NUMBER> food drug administration fda approved use liveattenuated la varicella zoster virus vzv okastrain vaccine vaccination commenced many countries <NUMBER> years clinical practice clear vaccine <NUMBER> effective providing protection infection wildtype wt virus <NUMBER> efficacious protection serious disease breakthrough infections vaccine virus occurred <NUMBER>–<NUMBER> vaccinees generally mild zoster caused reactivation vzv latency common among hematopoieticcell transplant recipients vaccination inactivated vzv vaccine shown reduce risk zoster individuals correlated reconstitution vzvspecific cd<NUMBER> tcell immunity <NUMBER> stanley plotkin addressed latest developments vaccination cytomegalovirus cmv <NUMBER> congenital infections cmv common cause neurological disorders infants united states cmv transmitted <NUMBER> births causing death sequala <NUMBER> cases prevent deaths well cmv infection transplants recipient patients researchers started explore possibilities vaccination cmv currently four different cmv candidate vaccines tested phase ii trials la vaccine based towne strain induced good immunity including neutralizing antibodies cellmediated immunity correlate protection however immune response lagged behind natural infection increase immunogenicity towne la vaccine lacks nineteen open reading frames orf lost capacity establish latency orf virulent toledo strain cmv introduced towne vaccine strain addition two candidate la vaccines subunit candidate vaccine comprising gb glycoprotein canarypox vector containing pp<NUMBER> iei exon <NUMBER> tested phase trials former induces antibodies whereas latter induces strong cellular immune response end age spectrum elderly generally reduced immune function innate adaptive immune system socalled immunosenescence cause increased morbidity mortality age group reduced immune function vaccine efficacies often lower elderly vaccines immunogenic obtain similar seroconversion rates michael roggendorf university essen essen germany showed immunogenicity hepatitis virus hav hepatitis b virus hbv vaccine lower elderly measured seroconversion rates <NUMBER> interestingly efficacy hav hbv vaccine differed individuals <NUMBER> years age <NUMBER> <NUMBER> seroconversion respectively may dependent nature vaccine formulations lluis salleras autonomous government catalonia barcelona spain elaborated vaccine efficacy demonstrated hav hbv vaccination preadolescent schoolchildren <NUMBER> effective protection disease <NUMBER> respiratory syncytial virus rsv singlestranded negative sense rna virus belonging family paramyxoviridae genus pneumovirus upon infection virus cause upper respiratory tract disease age groups however severe complications often seen young elderly bone marrow transplant patients late <NUMBER>s vaccination experiments conducted young children using formalininactivated rsv firsv upon infection wt strain rsv children suffered severe complications resulting death phenomenon enhanced disease firsv vaccinated children hampered rsv vaccine research enormously understanding mechanisms disease enhancement key issue crucial rsv vaccine development peter openshaw coworkers studying enhanced disease mice many years possible involvement γδ cells human bronchiolitis recently highlighted <NUMBER> depletion ’unconventional’ cells prevent enhanced disease rsvinfected mice previously sensitized scarification vaccinia viruses encoding single rsv proteins among target population vaccination young children <NUMBER> year age presence maternal antibodies immaturity immune system may reduce immunogenicity vaccines children james crowe investigated ability b cells young children produce neutralizing antibodies important protective immunity following natural infections immunoglobulin ig region b cells producing rsvspecific antibodies sequenced gene rearrangements resulting complete vdj region immunoglobulin occurred rsvspecific b cells however b cells infants less <NUMBER> months old exhibited striking paucity somatic mutations vh genes indicating unable produce high quality neutralizing antibodies potential vaccine candidates rsv include adenovirus recombinants immune stimulating complex iscom preparations subunit vaccines well la virus vaccines la virus vaccines known induce humoral cellular immune responses presentation miranda de graaf erasmus mc rotterdam netherlands demonstrated possibilities reverse genetics creating la viruses work done using human metapneumovirus hmpv virus causing similar disease rsv exchanging polymerase genes two different lineages hmpv attenuated ability induce chloramphenicol acetyl transferase cat activity minigenome containing cat reporter gene flanked hmpv genomic ends using fulllength hmpv genome instead reporter gene resulted rescue recombinant viable viruses <NUMBER> system could produce attenuated viruses may used vaccine purposes passive transfer neutralizing antibodies available treatment rsv relatively short halflife antibodies essential administration antibodies coincide rsv epidemic season onset varies yeartoyear pidari network pediatric infectious diseases network acute respiratory tract infections currently identifies <NUMBER> different viral bacterial pathogens using multiplex pcr children <NUMBER> <NUMBER> years old josef weigl christian albrechts university kiel germany showed last year start rsv epidemic <NUMBER> weeks prior onset antibody administration unnecessarily endangering children infection rsv data support need synchronize application preventive antibody treatment rsv epidemics finally rob moormann animal sciences group wageningen lelystad netherlands presented latest bovine rsv vaccine development vaccination firsv induced enhanced disease animals including eosinophil influx ige response <NUMBER> second important respiratory pathogen influenza virus segmented negative sense singlestranded rna virus responsible three major pandemics <NUMBER>th century well annual epidemics contrast rsv correlates protection well documented include presence neutralizing antibodies probably tcell responses influenza vaccine research focusing two areas development influenza vaccine pandemic situation development alternative influenza vaccines preventing disease following infection epidemic viruses annually classical influenza vaccine trivalent inactivated influenza vaccine administered year injection harry greenberg stanford university school medicine ca usa gave overview development coldadapted ca influenza vaccine flumist™ approved fda use individuals <NUMBER> <NUMBER> years age ca viruses capable growing low temperatures <NUMBER> °c attenuated body temperatures genetic basis attenuation influenza virus aann arbor<NUMBER> identified limited <NUMBER> aminoacid aa changes polymerase proteins pb<NUMBER> <NUMBER> aa pb<NUMBER> <NUMBER> aa well <NUMBER> aa change nucleoprotein np <NUMBER> flumist™ applied intranasally shown effective low transmission rate highly susceptible young children day care setting future medical importance possible association asthma use flumist™ young children needs investigated finally additional data confirming extending apparent safety efficacy flumist™ individuals <NUMBER> years age obtained production influenza vaccines embryonated chicken eggs generation master reassortant vaccine strains time consuming inflexible procedures hampering rapid development pandemic influenza vaccines advent vero madin–darby canine kidney mdck cell lines registered vaccine production facilitate flexible vaccine production future companies like baxter vaccines ag solvay pharmaceuticals bv <NUMBER> <NUMBER> reverse genetics alternative tool generation reassortant vaccine strains john wood national institute biological standards control london uk elaborated possibilities new approaches pointed licensing issues dealt order make quick licensing candidate vaccines possible events future pandemic threat <NUMBER> <NUMBER> catherine ammon mph geneva switzerland discussed poor public awareness dangers influenza amongst swiss elderly <NUMBER> although elderly realized belong highrisk group bad experiences doubt efficacy side effects reduced number individuals willing take vaccine ensure effective use influenza vaccines imperative public awareness increased maintained high level dengue virus serious health threat human population infecting <NUMBER>–<NUMBER> million individuals year worldwide robert putnak walter reed army institute research md usa presented overview dengue virus vaccine candidates currently tested preclinical clinical trials one major issues concerning dengue virus infections occurrence dengue hemorrhagic fever dhf dengue shock syndrome dss small percentage infected individuals dhf dss occur primary infection occur much frequently secondary dengue virus infections serotype different primary infection suggested antibody mediated enhancement waning immunity may play role pathogenesis complications early dengue virus candidate vaccines consisted la virus strains developed dr sabin vaccination studies demonstrated la candidate vaccines partially protected challenge live virus safe well tolerated immunogenic since resolution dengue virus <NUMBER> four different candidate vaccines currently evaluated preclinical clinical trials including two candidate la virus vaccines two recombinant candidate vaccines monovalent la vaccine candidates varied immunogenicity four serotypes dengue virus interfered multiple doses vaccine given <NUMBER> months apart required obtain satisfying seroconversion rates recombinant dengue virus serotype <NUMBER> den<NUMBER>δ<NUMBER> developed national institute health also promising candidate inducing <NUMBER>–<NUMBER> seroconversion rate human volunteers recombinant yellowfever yf virus containing prm envelop e protein dengue virus chimerivax™ konstantin pugachev acambis inc usa proved potential single dose four serotypes provided <NUMBER>–<NUMBER> protection challenge infection <NUMBER> days later cynomolguos macaques <NUMBER> also candidate subunit vaccines developed dengue virus carolyn weekslevy hawaii biotech inc hi usa presented data subunit candidate vaccine consisting recombinant envelope protein e lacking transmembrane region interestingly monkeys vaccinated high doses monovalent serotype <NUMBER> dengue virus den<NUMBER> e protein became viremic upon infection den<NUMBER> lower vaccine dosages result viremia addition nonstructural ns<NUMBER> protein increased cellular immune response improved protective immunity wellington sun walter reed army institute research md usa compared candidate dengue virus vaccine efficacies observed humans monkeys monkeys permissive infection dengue virus show disease symptoms including dhf dss upon infection animals clear virus develop antibodies partially crossprotective present unclear whether monkey model valid predicting outcome vaccination humans <NUMBER> seroconversion rates mono tetravalent candidate vaccines generally lower humans monkeys den<NUMBER>δ<NUMBER> chimerivax™d<NUMBER> recombinant yf virus containing prm envelop e protein dengue virus serotype <NUMBER> candidate vaccines elicited seroconversion rates humans <NUMBER> walter reed group conducted serotype <NUMBER> dengue den<NUMBER> serotype <NUMBER> dengue den<NUMBER> virus challenge study subjects vaccinated tetravalent la candidate vaccine results indicated rhesus monkey viremia correlated well results humans although human challenge model important validating vaccine efficacies role vaccine development remains defined regina kofler university vienna vienna austria described isolation attenuated tickborne encephalitis virus tbev deletion capsid protein secondsite mutations restored capacity attenuated virus replicate cellculture mutants shown potential development live flavivirus vaccine <NUMBER> yf virus strain <NUMBER>d yf<NUMBER>d attenuated virus strain lost viscerotropic neurotropic vector competence phenotypes wildtype yf virus used backbone vaccines induction immunity flaviviruses therefore full understanding molecular determinants attenuation virulence importance alan barrett university texas medical branch galveston usa showed none <NUMBER> aa substitutions yf<NUMBER>d could linked neuro hepatotropism however e ns<NUMBER>b protein may important determining virus phenotype <NUMBER> <NUMBER> second member flaviviridae family high impact human health hepatitis c virus hcv originally identified <NUMBER> believed infected <NUMBER> million people worldwide approximately <NUMBER>–<NUMBER> hcv acute infections resolved spontaneously appears associated strong cd<NUMBER> thelper cell antibody responses currently main aim vaccination prevent occurrence chronic liver disease infection hcv since chimpanzees species humans susceptible infection used evaluate efficacy hcv candidate vaccines michael houghton chiron corporation ca usa demonstrated vaccination adjuvated recombinant glycoprotein gp e<NUMBER> e<NUMBER> subsequent challenge hcv rna significantly reduced incidence chronic disease chimpanzees <NUMBER> study sterile immunity associated high levels neutralizing antibodies neutralizing antibodies may prevent binding hcv particles cd<NUMBER> demonstrated vitro hyperimmune serum infected individuals currently gpe<NUMBER> gpe<NUMBER> subunit candidate vaccine tested phase trials <NUMBER> west nile virus wnv introduced usa prompted extra effort develop vaccine wnv transmitted birds humans mosquitoes causes febrile illness approximately <NUMBER> infected individuals <NUMBER> infected individuals infection results neurological disorders followed death <NUMBER>–<NUMBER> cases michael lieberman hawaii biotech inc hi usa showed vaccination truncated e protein wnv protected golden hamsters infection wnv <NUMBER> <NUMBER> evaluation candidate subunit vaccine acambis chimeric fort dodge killed candidate vaccine needed demonstrate safety efficacy humans lorne babiuk university saskatoon sask canada introduced field veterinary vaccinology veterinary vaccines also safe efficacious perhaps contrast vaccines human use generally cheap fit existing practices furthermore veterinary vaccines often evaluated directly targeted species addition conventional live inactivated vaccines also genetically engineered chimeric dna plantbased replication defective veterinary vaccines available vaccines aim induction protective immunity human pathogens order prevent contamination food water agents also include bacteria escherichia coli e coli strain o<NUMBER> campylobacter salmonella <NUMBER> alvac vector canarypox vector one vectors used veterinary vaccines among many advantages inability replicate mammalian cells large coding capacity induction low levels vector immunity ability overcome maternal antibodies huw hughes merial lyon france demonstrated registered alvac vector expressing hemagglutinin ha influenza virus ahorsekentucky<NUMBER> ahorsenewmarket<NUMBER> protected horses infection addition antibody titers remained high least <NUMBER> year following second vaccination also coronavirus vectors developed demonstrated luis enjuanes centro nacional de biotecnología csic madrid spain singlestranded positive sense rna virus dna intermediate minimizing risk chromosomal integration vector addition variation spike protein control tropism virus target certain areas body finally reinfections coronaviruses occur frequently suggesting preexisting immunity easily overcome virus construction bacterial artificial chromosome containing fulllength transmissible gastroenteritis virus tgev allowed genetic manipulation virus <NUMBER> shown eprotein deficient tgev virus replicate packaging celllines expressing eprotein <NUMBER> relocation packaging signal e genes likely recombination site eprotein deficient viruses become propagation competent leading production highly safe coronavirus vectors <NUMBER> certain attenuated viruses used vectors antigen delivery foreign viral antigens attenuation may achieved reduced replication capacity eg yf strain <NUMBER>d modified vaccinia ankara mva based species restriction eg canarypox vector alvac vectors induce strong humoral cellular immune responses specific protein interest gerd sutter gsf—institute molecular virology muenchen germany elaborated progress made regard development mva vector technologies mva used conditions biosafety level <NUMBER> avirulence deficiency productively grow human cells animal models mva vaccines found immunogenic protective various infectious agents including immunodeficiency viruses data clinical trial presented providing evidence safety immunogenicity recombinant mva used therapeutic vaccine hivinfected individuals <NUMBER> finally shown modification immune regulatory genes interferon resistance genes interleukininhibitor sequences conserved within mva genome might provide basis development advanced second generation mva vaccines even higher immunogenicity <NUMBER> <NUMBER> another viral vector semlikiforest virus sfv features dna rna viral vectors induction immune response foreign antigen sfv replicons producing foreign protein used vaccination also naked rna cdna replicons used vaccination foreign antigens <NUMBER> peter liljeström karolinska institute stockholm sweden reported replicase protein sfv plays important role maturation dendritic cells dc also shown sfv capable inducing crosspriming maturation dc well interferon ifnα production providing enough danger signals induce vigorous immune response foreign antigens explaining good immunogenicity potential modulate hcvspecific immune responses using cytokines tested christine rollier biomedical primate research center rijswijk netherlands addition dna plasmids encoding interleukin il<NUMBER> il<NUMBER> enhance immunogenicity candidate dna vaccine based ns<NUMBER> protein hcv rhesus macaques josé melero using state art technology identified fusion properties fusion sites rsv fusion protein fprotein <NUMBER> future research aimed development compounds antibodies capable binding fusogenic intermediate fprotein ideal vaccines combine low reactogenicity high immunogenicity profiles order safe efficacious unfortunately characteristics often go hand hand resulting immunogenic reactogenic vaccines therefore researchers tried enhance immunogenicity vaccines primeboost regimens using adjuvants alternative methods vaccination guus rimmelzwaan erasmus mc rotterdam netherlands summarized findings three different studies conducted three different species using iscoms containing ha neuraminidase na various influenza viruses monkeys chickens protected infection h<NUMBER>n<NUMBER> subtype highly pathogenic h<NUMBER>n<NUMBER> subtype influenza virus respectively vaccination iscom based vaccination conventional subunit vaccine <NUMBER> <NUMBER> protection correlated vigorous antibody tcell responses humans preexisting immunity influenza virus added value adjuvant less pronounced however kinetics virusspecific antibody responses accelerated iscom vaccinated individuals compared received conventional vaccine addition iscom vaccine induced ctl responses whereas classical vaccine vaccines often administered intramuscularly im alternative administration methods may enhance immunogenicity certain vaccines lendon payne powderject vaccines inc wi usa demonstrated powderject™ deliver dna proteins epidermis known contain unique population langerhans cells epidermal powder immunization also combine certain adjuvants like qs<NUMBER> e coli heatlabile enterotoxin lt dna subunit vaccines coadministration lt induced strong cellular immune responses mice <NUMBER> jan wilschut university groningen groningen netherlands presented data use virosomes possible carrier influenza viral glycoproteins virosomes reconstituted viral envelopes without viral genome shown induce humoral cellular immunity mice <NUMBER> addition virosomes capable harboring aliphatic adjuvants enhancing potential induce immunity viral glycoproteins finally anneke boonstra covaccine bv lelystad netherlands informed us latest developments dissacharide fatty acid sulphate ester adjuvants <NUMBER> experiments demonstrated one sulphate combination seven lauric acids s<NUMBER>l<NUMBER> squalaneinwater induced high levels influenza virusspecific antibodies pigs humans gary nabel national institute health bethesda usa presented recent data human immunodeficiency virus hiv candidate vaccine testing monkeys inclusion envelop gene candidate vaccine plasmid dna—recombinant adenovirus primeboost regiment enhanced humoral cellular immune responses correlated immune protection <NUMBER> using high doses plasmid dna <NUMBER>–<NUMBER> milligram hivspecific tcell responses induced high percentage individuals one mysteries hiv transmission ccr<NUMBER>tropic viruses cxcr<NUMBER>tropic viruses upon infection new data demonstrated ccr<NUMBER>tropic viruses infect immature dc whereas cxcr<NUMBER>tropic viruses cannot immature dc upon maturation mediate viral transfer cd<NUMBER> cells since whole process done within cells highly resistant neutralizing antibody activity mechanism may contribute preferential transmission ccr<NUMBER>tropic viruses may implications future vaccine design dnaprime adenovirus vector boost vaccine regiments currently seem best method induce high cd<NUMBER> tcell responses preexisting antibodies adenovirus however interfere efficacy vaccine jaap goudsmit crucell nv leiden netherlands identified alternative adenovirus serotypes low seroprevalence human population adenovirus serotype <NUMBER> ad<NUMBER> shown low global seroprevalence low infection rates hiv positive negative individuals makes ad<NUMBER> virus attractive viral vector <NUMBER> duncan steele geneva switzerland offered us latest rotavirus vaccine developments <NUMBER> <NUMBER> rotavirus important pathogen young children claiming half million deaths year particular developing countries rotavirus complex triple layered virus two neutralizing antigens involved immune response host vaccine strategies differ need development homo heterotypic immunity specific antigens currently two la rotavirus vaccines licensed rotashield® wyeth vaccines tetravalent rhesus rotavirus vaccine demonstrated <NUMBER> protection rotavirus diarrhea <NUMBER> severe disease however <NUMBER> vaccinees developed fever upon vaccination elevated risk developing intussusception <NUMBER> vaccinees reason rotashield® vaccine withdrawn second la rotavirus vaccine manufactured china although efficacy truly naïve children remains demonstrated two candidate rotavirus vaccines late stages development rotateq® merck research rotarix® gsk biologicals efficacy candidate vaccines similar early clinical trials approximately <NUMBER> effective preventing rotavirus diarrhea rotashield® future reveal two candidate vaccines ie two dose rotarix® three dose oral vaccination rotateq® provide better heterologous longterm protection prior clinical use rotavirus candidate vaccines potential interference live oral poliovirus vaccination safety immunogenicity efficacy hivinfected children investigated threats emerging viral infections terrorist attacks biological weapons triggered major effort finding cures vaccines agents james leduc pointed issues involved candidate vaccines emerging rare diseases difficulty rare viral diseases inability demonstrate efficacy humans fda approval therefore based data obtained <NUMBER>–<NUMBER> monkeys whose predictive value regarding efficacy safety remain controversial issues involved fast tracking vaccines regulatory authorities covering international property rights liability issues different viewpoints government industry including willingness justifiability develop certain vaccines gary nabel presented data ebola virus vaccine development glycoprotein gp ebola virus causes cell rounding detachment human endothelial epithelial cells effects require presence mucinlike domain gp correspond downregulation vαintegrin cell surface gp important vaccine candidate however passive transfer antibodies humans monkeys confer protection infection vaccination experiments therefore aiming induction humoral cellular immune responses ebola virus surprisingly monkeys vaccinated adenoviral vector encoding gp np ebola virus protected high dose challenge <NUMBER> <NUMBER> us government decided every citizen able receive smallpox vaccination original dryvax® vaccine consisted heterogeneous virion subpopulations may contaminated ruminant viruses richard weltzin acambis inc usa presented data plaque purification original virus stock yielding acam<NUMBER> isolate proved immunogenic without neurovirulence mice monkeys <NUMBER> currently virus tested phase ii trials smallpox vaccination scarification vaccinia virus crude method quantitative requires skilled personnel also results active local lesion shedding live virus methods vaccination may quantitative shed live virus amanda phelps biomedical sciences porton uk showed intramuscular vaccination mice provided better protection lower vaccine doses needlefree microject scarification methods severe acute respiratory syndrome sars important emerging infectious disease caused sarscov currently cure vaccine exists mice shown dna encoding spike protein sarscov induced spike proteinspecific antibodies antibodies antiserum recovered patient shown gary nabel inhibit gene transfer pseudotype virus containing spike protein sarscov addition kirill kalnin acambis inc usa demonstrated hyper immune serum sarscov infected individuals reacted recombinant spike protein data suggest spike protein sarscov may good vaccine candidate viral vaccine meeting ended series presentations emergence sarscov february <NUMBER>th reported first cases sarscov <NUMBER>st <NUMBER>th march new coronavirus sarscov identified three laboratories <NUMBER> <NUMBER> two weeks later entire genome virus sequenced <NUMBER> closely followed fulfillment koch’s postulates <NUMBER> important hallmarks sarscov identification virus several animal species including palm civets albert osterhaus showed ability sarscov infect macaques <NUMBER> different carnivore species including housecat ferret <NUMBER> end epidemic several important conclusions could drawn among risk factors adverse outcome disease age <NUMBER> years diabetes heart disease comorbid conditions early epidemic noted healthcare workers risk contracting disease may due relatively late peak virustiters day <NUMBER>–<NUMBER> onset illness subjecting health care workers high doses virus relatively late peak virus titers also hampered diagnosis sarscov malik peiris queens mary hospital hong kong sar showed improved rna extraction realtime pcr increase percentage positive swabs considerably <NUMBER> positive day <NUMBER> <NUMBER> day <NUMBER>–<NUMBER> <NUMBER> prepare second introduction sarscov human population antiviral drugs protective vaccines urgently needed luis enjuanes first clone fulllength genome coronavirus tgev deletion e protein relocation packaging signal generated safe efficacious vaccine candidate fulllength sarscov genomic clone <NUMBER> may augment generation candidate sarscov vaccines meeting ended presentation jan hendriks public health directorate european commission luxembourg behalf european commission highlighted opportunities stumble blocks development viral vaccines major importance public health meeting provided overview viral vaccines currently used humans animals varying degrees success also gave state art view novel developments opportunities field promoting regulatory convergence recognized key enabler world health organization rd blueprint regulatory preparedness public health emergencies phes agenda <NUMBER>th international conference drug regulatory authorities icdra meeting <NUMBER> number regulatory gaps identified icdra recommended ensure regulatory support priority area activity rd blueprint emerging infectious diseases implemented <NUMBER> also requested continue developing measurement written standards serve basis regulatory evaluation taking consideration <NUMBER> priority pathogens defined blueprint <NUMBER> flexible dynamic approach developing establishing standards quality safety efficacy products use phes <NUMBER> response request convened informal consultation february <NUMBER> initiate work revise guidelines assuring quality nonclinical safety evaluation dna vaccines annex <NUMBER> technical report series <NUMBER> adopted <NUMBER> ecbs <NUMBER> based agreement informal consultation february <NUMBER> first revised draft prepared drafting group posted biologicals website first round public consultation httpswww whointbiologicalswhodnavaccinehk<NUMBER>july<NUMBER>pdf consultation december <NUMBER> aimed discuss obtain advice first draft document main issues addressed public consultation <NUMBER> experts participated consultation including regulators <NUMBER> countries six regions dr heidi meyer paulehrlichinstitut germany nominated chairperson dr rebecca sheets consultant usa rapporteur consultation dr ivana knezevic hq switzerland welcomed participants geneva briefed participants activities area biological standardization explained directing coordinating authority health behalf <NUMBER> member countries united nations system order fulfill objectives core function defined setting norms standards promoting monitoring implementation conducted <NUMBER> years initiative includes assisting national regulatory authorities nras utilization biological reference materials application principles guidelines recommendations ensure quality safety efficacy vaccines biologicals world immunization rapidly evolving field constantly changing picture morbidity mortality infectious diseases context vaccines playing critical role disease prevention access vaccines assured quality one goals time use new technologies manufacturing well new antigens adjuvants routes administration imposing lots challenges regulators also public health professionals addition response phes ebola zika outbreaks triggered development number vaccine candidates based nucleic acid platforms clinical trials <NUMBER> independent expert <NUMBER> silver spring md usa <NUMBER> world health organization <NUMBER> geneva switzerland <NUMBER> paulehrlichinstitut <NUMBER> langen germany list authors affiliations appears end paper ✉ email kanghwhoint candidates different diseases either ongoing planned near future post meeting note time submission paper publication ten vaccine candidates coronavirus disease covid<NUMBER> based nucleic acids developed monitoring vaccines development continuously provides regular updates httpswwwwhointblueprintprioritydiseaseskeyaction novelcoronavirusen increasing importance revision update guidelines evaluation dna vaccines line scientific advances furthermore initiatives closely linked standardization vaccines particular strengthening nras one important elements assuring quality vaccines worldwide prequalification vaccines important mechanism vaccines become subject supply unicef safety vaccines issues discussed global advisory committee vaccine safety gacvs also important well activities related immunization policy june <NUMBER> gacvs set six initial strategic priorities systems integration equity access fragility emergencies values ownership research innovation sustainability accountability https wwwwhointvaccinesafetycommitteereportsjun<NUMBER>en importance report herein priorities research innovation fragility emergencies dr knezevic emphasized importance present consultation last step terms facetoface consultation evaluating quality safety efficacy dna vaccines involving regulators manufacturers experts field representatives several collaborating centers biological standardization also part consultation well representatives institutions playing important role field dr hyena kang hq switzerland provided background development guidelines organization consultation reviewed recommendations <NUMBER>th meeting icdra <NUMBER> procedure drafting guidelines drafting group consisted drs margaret liu heidi meyer edwin nkansah keith peden rebecca sheets secretariat hyena kang response request icdra drafting group prepared first draft document released public consultation series teleconferences httpswwwwhointbiologicals whodnavaccinehk<NUMBER>july<NUMBER>pdf objective informal consultation december <NUMBER> reach consensus regulatory principles draft guidelines discuss identify pending critical issues improved second draft prepared final round public consultation adoption ecbs october <NUMBER> several researchers field plasmid dna vaccines presented data current status development continues great interest international groups promise plasmid dna vaccines platform technology rapid facile development vaccines prevent outbreaks pandemics dr david kaslow path usa representing product development vaccines advisory committee pdvac reviewed advantages dna vaccines platform technology fit objectives goals pdvac pointed guideline revision may need reflect potential different purposes dna vaccineie use routine immunization vs use outbreak setting important dna vaccines become available purposes routine immunization truly available case outbreak response also raised potential issues surrounding need specific device vaccine delivery especially outbreak setting supply may limited costofgoods may favorable preparation situations current device designs adapted ease use deployment setting lowand middleincome countries lmics well meet programmatic suitability criteria routine use dr kaslow also raised issue need information developmental toxicology dna vaccines support use setting maternal immunization including breastfeeding women data needed pave way outbreak responses pregnant women often belong group highest risk serious complications dr nick jackson coalition epidemic preparedness innovation cepi norway explained role cepi interest plasmid dna vaccines platform technology achieve mission target certain pathogens funding program including lassa virus middle east respiratory syndrome coronavirus merscov nipah virus rift valley fever virus chikungunya virus disease x hypothetical template emerging disease future merscov plasmid dna vaccine candidate advanced phase <NUMBER> clinical trials promising results plan initiate phase <NUMBER> study mid<NUMBER> lassa virus candidate vaccine also advanced phase <NUMBER> clinical trial dr ami patel wistar institute usa discussed many advantages plasmid dna vaccines gave update therapeutic human papilloma virus vaccine candidate delivered conjunction electroporation device vaccine candidate also completed phase <NUMBER>b pilot efficacy testing cervical cancer interesting results <NUMBER> impact endpoints regression cervical intraepithelial neoplasia cin <NUMBER> cin <NUMBER> regression normal clearance evidence infection <NUMBER> phase <NUMBER> study candidate opened <NUMBER> candidate also studied head neck cancer <NUMBER> team also involved development ebola merscov zika plasmid dna vaccine candidates case zika team able advance clinic candidate plasmid dna vaccine rapidly <NUMBER> months largely needing repeat nonclinical toxicology studies platform technology <NUMBER> instead decisions made basis existing nonclinical clinical data platform predict safe starting doses dose regimens well expected reactogenicity platform finally presented work expressing monoclonal antibodies mab plasmid dna system antizika candidate mab advanced clinic well update given dr julie ledgerwood nih usa plasmid dna vaccine candidate proceeded far international phase <NUMBER>b pilot efficacy study zika virus safety demonstrated changing epidemiology face waning epidemic meant cases zika seen evaluate efficacy however samples still analyzed cases may yet identified importantly platform earlier nonclinical clinical work west nile virus plasmid dna vaccine candidate zika vaccine candidate able proceed phase <NUMBER> <NUMBER> months large measure additional nonclinical toxicology studies required abbreviating nonclinical program overall timetoclinic dr patels teams vaccine candidate decisions based existing database nonclinical clinical experience platform early entry phase <NUMBER> permitted advancement phase <NUMBER>b even outbreak ongoing unfortunately still rapid enough capture sufficient efficacy data support nearterm licensure vaccine candidate <NUMBER> also presented data studies performed earlier institute plasmid dna vaccine candidates ebola marburg among first plasmid dna vaccines tested africa demonstrating feasibility testing vaccines delivered devices needleandsyringe lmic settings <NUMBER> plasmid dna vaccines may viewed platform technology antigen gene changed one vaccine another based dna plasmid backbone given manufacturer manufacturing controls may vary little plasmid dna vaccines manufacture control measures likely highly similar even manufacturers therefore guidelines plasmid dna vaccines though specific particular vaccine written generally applicable part quality section guidelines addition although part b nonclinical part c clinical sections consistent general guidelines topics additional topic areas relevance plasmid dna vaccines discussed guidelines <NUMBER> <NUMBER> <NUMBER> many concerns harken back beginnings use plasmid dna vaccines two decades ago deleted guidelines nonclinical clinical evidence various vaccine candidates intervening time alleviated concerns current generation dna vaccines made bacteria produced biologically considered biological product plasmid generated recombinant dna technology clarified plasmid dna vaccine organism thus genetically modified organism per se genetransfer genetherapy product expected persist permanently mark recipient wealth evidence dna vaccines date persist even biodistribute throughout body table <NUMBER> summary major proposed changes revision draft guidelines assuring quality safety efficacy plasmid dna vaccines proposed changes title document add plasmid title likewise agreed refer dna vaccines plasmid dna vaccines rather dna plasmid vaccines provide definitions adjuvant candidate vaccine align relevant guidelines plasmid dna expressing prophylactic monoclonal antibodies outside scope like immunotherapeutics based plasmid dna quality part section may applicability product class though parts b nonclinical c clinical unlikely apply introduction add advantages plasmid dna vaccines part manufacturing control • definition international nonproprietary names conventions would apply dna vaccines • general manufacturing guidelines clarify language around potential carryover crosscontamination multiuse facilities • source history generation host cell plasmid discuss potential use novel strains species bacteria reflect currently means assessing ensuring genetic stability plasmid dna construct • characterization bulk purified plasmid clarification characterizing modeor mechanismofaction vaccine including immunomodulatory elements • consistency manufacturing clarification reflect part referring clinical studies timing manufacturing assessments consistency • manufacture control final formulated vaccine subsection needed added discuss measuring strength dose content vaccine • potency change language mentioned reflect potency might measured content percentage supercoiling rather use bioassay clarity given measuring expression mrna rather protein production • safety including sterility endotoxin testing update reference monocyte activation test include <NUMBER>rs concept part b nonclinical evaluation • section considered generally satisfactory though need references support abbreviation nonclinical programs would useful include regulators countries limited experience product type date several references regard added • furthermore changes part c made apparent discussion needed part b subject existing database biodistribution data showing limited distribution rapid degradation outside injection site assuage historical concerns germline involvement genetic transfer likewise need acknowledge current evidence gap developmental toxicology dna vaccines raised part c clinical evaluation • agreed section required additions modifications • language devicevaccine codevelopment included topics needed added included postmarketing surveillance issues choice control group without use device protocollabeling language • issue seemed potential complicate confuse safety evaluations timing adverse events following boost doses heterologous primeboost regimens whether attribute prime boost part guidelines national regulatory authorities • language part two official release certification needs examined since likely licensing new plasmid dna vaccine reflected productdiseasespecific guideline time therefore might accurate say vaccine lot would released fulfilled part quality section broad dna vaccine guideline • two appendices related part may need added guidelines model summary protocol manufacturing control dna vaccines model national regulatory authority lot release certificate dna vaccines vaccine delivered parenterally muscle subcutaneous tissue various dermal layers addition development plasmid dna vaccines routine use may lead rapid ready implementation new vaccines emerging diseases even face emergency setting platform technology proven safe efficacious one diseases novel vaccine candidate based technology replacing antigen encoded match emerging disease could permit rapid manufacturing reduced abbreviated waived requirements nonclinical toxicology rapid entry clinical testing rapid entry clinic already shown two plasmid dna vaccine candidates zika described thus proofofconcept precedent session dedicated reviewing draft guidelines response public consultation discussion led dr rebecca sheets providing summary comments received first round public consultation main issues discussed meeting comments accepted changes made rejected comments suggestion follow ich structure rather standard however three topics remained discussion consultants meeting first surrounding several comments received discussion potency assessment multiplasmidcontaining vaccines second topic appendix heterologous primeboost included current draft document several comments made delete appendix information included body guideline third topic comment given put emphasis delivery device discussion discussion potency multiplasmidcontaining vaccines led decision clarify discussion guideline rationale might need done individual bulk stage instead final product however discussion led important indepth look potency assessed currently vaccine candidates moving forward clinical development without bioassay simply measuring content quantitythe basis dosing percent supercoiled form plasmid quality measure correlate potency vivo led discussion revisions potency section appendix heterologous primeboost agreed deleted discussion delivery device led agreement information already general principles mostly adequate emphasis labeling jurisdictions might consider combination product also agreed discussion device part c clinical would add clarity guidelines consultation several suggestions amendment current draft document made order reaffirm clarify provide guidance specific issues summarized table <NUMBER> • development guidelines welcomed applauded stakeholders • participants agreed guidelines incorporate sound scientific evaluation principles consistent international initiatives would promote regulatory convergence • might necessary assist nras implementing principles guidelines regulatory practices • due rapid technological advances dna vaccine development proposed frequent updating guidelines • support develop guidelines regulatory evaluation vaccines phe uses well combination products requested • agreed guidelines revised based comments received following revision another round public consultation document discussed meeting ecbs october <NUMBER> adoption • need facilitating implementation updated guidelines evaluation dna vaccines identified activity would help nras members states establish andor update national guidance dna vaccines consultation also recognized development rnabased vaccines requires action proposed consider preparation state art paper evaluation rnabased vaccines table <NUMBER> clear scientific evidence vaccines limited data likely become available coming years table <NUMBER> nevertheless importance leadership area identified one followup actions beyond revision guidelines evaluation dna vaccines table <NUMBER> reporting summary information research design available nature research reporting summary linked article late december <NUMBER> pneumonia unknown etiology emerged wuhan city <NUMBER> hubei province china patients presenting acute respiratory failure seen <NUMBER> er admitted icu facilities treatment <NUMBER> causative although mortality rate sarscov<NUMBER> lower <NUMBER> merscov sarscov transmissibility median r <NUMBER> <NUMBER> much higher <NUMBER> either merscov r <NUMBER> <NUMBER> sarscov r <NUMBER> <NUMBER> sarscov<NUMBER> detected clinical specimens analyzed development several organizations international collaborations <NUMBER> pulmonary surfactantbiomimetic nanoparticles used potentiate heterosubtypic <NUMBER> influenza immunity used adjuvant enhance immunogenicity <NUMBER> sarscov<NUMBER> subunit vaccines <NUMBER> roxychloroquineorchloroquinecovid<NUMBER>outsidehospitalsettingor another interesting strategy use convalescent plasma cp treatment <NUMBER> noted cp collected within two weeks recovery ensure <NUMBER> high neutralization antibody titer <NUMBER> reported sarscov<NUMBER> isolated experimental vaccines fully reproduce clinical signs observed natural host addition exceptions evaluation vaccines made young animals shown outcome challenge experiments although positive young animals frequently showed side effects performed old mice <NUMBER> <NUMBER> recently animal models considerably improved reproducing pathology observed humans <NUMBER> <NUMBER> particular mouseadapted sarscov model selected fifteen passages mice sarscovma<NUMBER> reproduces clinical signs observed human infections sars epidemic <NUMBER> including death infected mice animal model considered best available therefore vaccine candidates developed far may reevaluated model using young aged mice vaccines based whole purified inactivated virus benefit presenting complete repertoire viral antigens although inactivated vaccines general provide longlasting immunity vaccines provide good protection mice <NUMBER> hamster <NUMBER> partial protection ferrets <NUMBER> <NUMBER> rhesus monkeys formaldehydeinactivated sarscov vaccine showed partial protection <NUMBER> <NUMBER> inactivated sarscov vaccine also administered humans vaccine safe induced neutralizing antibodies efficacy data reported <NUMBER> overall inactivated vaccines based whole purified virus induced neutralizing antibodies apparently safe least young animal models provided good protection subunit vaccines advantage simplicity chemical definition lack potential variability <NUMBER> case sarscov great advantage welldefined protein domains binding cell receptor human angiotensin converting enzyme hace<NUMBER> provided full immune protection <NUMBER> <NUMBER> <NUMBER> <NUMBER> concept reinforced observation monoclonal antibodies specific receptor binding domain elicited protection several animal models including african green monkeys <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition proteinderived domains peptides protein <NUMBER>a large protein sarscov exposed envelope also elicits virus neutralizing antibodies <NUMBER> could useful improving subunit vaccines furthermore immunity sarscov also demonstrated viruslike particles vlp <NUMBER> overall results obtained subunit vaccines strongly suggest protection sars vaccination feasible dna vaccines safe nonexpensive often efficient large mammals dna vaccines induce sarscov neutralizing antibodies protection mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> use viral vectors protect sars extensively explored adenovirus induced good protection mice <NUMBER> modified vaccinia ankara mva provides protection mice <NUMBER> ferrets <NUMBER> although induction antibodydependent enhancement disease aded reported adenoassociated virus induces longterm protection sarscov <NUMBER> parainfluenza virus elicits protection hamsters monkeys <NUMBER> <NUMBER> recombinant measles viruses expressing protein sarscov induces neutralizing antibodies immune responses sarscov <NUMBER> newcastle disease recombinant virus expressing protein sarscov induces neutralizing antibodies african green monkeys immunized via respiratory tract <NUMBER> recombinant attenuated vesicular stomatitis virus vsv protects mice sarscov challenge <NUMBER> months vaccination <NUMBER> <NUMBER> venezuelan equine encephalitis vee virus expressing protein sarscov induces protection challenge virulent virus mouse model <NUMBER> overall results indicate good prospect development efficacious safe vaccine prevent sars nevertheless relevant aspects need improved order achieve vaccine fully protective free side effects young elderly people sarscov enveloped singlestranded positivesense rna virus genome <NUMBER> kb belongs genus b coronaviridae <NUMBER> fig <NUMBER>a replicase gene encoded within <NUMBER> <NUMBER> twothirds sarscov genome including two overlapping open reading frames orf named orfs <NUMBER>a <NUMBER>b latter translated ribosomal frameshift upstream orf <NUMBER>a stop codon <NUMBER> <NUMBER> fig <NUMBER>b translation orfs cytoplasm infected cells results synthesis two polyproteins pp<NUMBER>a pp<NUMBER>ab processed two viral proteinases yield <NUMBER> functional nonstructural proteins nsps <NUMBER> <NUMBER> nsps components membraneanchored replicationtranscription complex <NUMBER> covs encode speciesspecific accessory genes downstream orfs remarkably conserved order replicasetranscriptase spike envelope e membrane nucleocapsid n lipid bilayer envelope contains least three proteins e coordinate virion assembly release large peplomer fig <NUMBER>a glycoprotein located virion surface conferring virus characteristic corona shape main mediator host cell attachment entry sarscov orfs <NUMBER>a <NUMBER> <NUMBER>a <NUMBER>b encode additional virus membrane proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> accessory proteins <NUMBER>a <NUMBER>b <NUMBER>b functions accessory proteins still unclear however known proteins influence virushost interaction viral pathogenesis <NUMBER> <NUMBER> <NUMBER> sarscov hace<NUMBER> molecule serves receptor <NUMBER> cd<NUMBER>l also implicated alternative receptor entry <NUMBER> live attenuated viruses generally proven effective vaccines viral infections production effective safe live attenuated vaccines animal covs satisfactory largely vaccine strains insufficiently immunogenic addition may recombine resulting novel viruses increased virulence <NUMBER> <NUMBER> <NUMBER> several groups including described modifications sarscov attenuating domesticated viruses may useful platforms develop inactivated live vaccines general rna viruses essential develop reverse genetic system develop virus attenuated phenotype certainly case coronaviruses largest genome known around <NUMBER> kb rna virus increasing technical difficulty generating infectious cdna developed efficient transmissible gastroenteritis cov tgev sarscov reverse genetics systems inserting infectious cdna clones viruses bacterial artificial chromosomes bacs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> fig <NUMBER>a system genomic rna expressed cell nucleus control cytomegalovirus promoter first amplification cellular polymerase ii subsequent amplification cytoplasm viral rnadependent rna polymerase reverse genetics system highly efficient implies two amplification steps addition cdna stability bac high soon bac technology applied assemble infectious coronavirus cdna clone alternative strategies developed including <NUMBER> system assemble fulllength cdna construct tgev genome using adjoining cdna subclones unique flanking interconnecting junctions <NUMBER> transcripts derived tgev cdna assembled using approach used derive infectious recombinant virus <NUMBER> system cloning vector poxvirus using genome poxvirus including genome cdna copy template viral genome transcribed vitro infectious virus recovered transfected cells <NUMBER> <NUMBER> modified procedure described coronavirus genomic rna transcribed inside cells using poxvirus genome template end viral genome cloned control t<NUMBER> promoter poxvirus dna including infectious cdna transfected cells infected poxvirus expressing t<NUMBER> polymerase <NUMBER> generated transcript reconstitutes infectious cov case sarscov several genes deleted order generate viruses attenuated phenotypes nevertheless deletion one accessory genes significantly attenuate sarscov <NUMBER> fortunately showed deletion e gene encoding envelope protein led viable sarscov indicating e protein essential virus replication interestingly viruses table genes deleted three sarscov recombinant viruses deletion mutants without e gene led viruses attenuated phenotypes lacking e protein attenuated grow lung immunogenic different animal models <NUMBER> <NUMBER> <NUMBER> <NUMBER> modification deletion sarscov genes also considered design vaccines prevent sars genes nsp<NUMBER> nsp<NUMBER> n essential virus replication others <NUMBER>a <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b nonessential virus growth cell culture vivo design sars vaccines based deletion sarscov genes described nevertheless attention given deletion modification e nsp<NUMBER> nsp<NUMBER> <NUMBER>a genes sarscov deletion mutants lacking orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b significantly influence vitro vivo replication efficiency mouse model <NUMBER> <NUMBER> recombinant viruses replicated similar wildtype levels suggesting either groupspecific orfs play limited role vivo replication efficiency mouse model used evaluation meet requirements discriminate activity groupspecific orfs disease <NUMBER> fact unexpected deletion orfs <NUMBER>a <NUMBER>a <NUMBER>b encode structural proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> would show little influence virus replication mouse model deletion orf <NUMBER>a showed minor decrease tenfold virus growth furthermore deletion combinations genes deletion orfs <NUMBER>a <NUMBER>b orf<NUMBER> showed <NUMBER>fold titer reduction vero cells showed limited effect virus growth murine model day <NUMBER> postinfection moreover simultaneous deletion larger combinations groupspecific genes <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b led production infectious sarscov deletion mutant propagated cell culture titer similar parental wildtype virus attenuated transgenic mice expressed sarscov receptor hace<NUMBER> <NUMBER> therefore effect sarscov gene deletions needs tested relevant animal models interestingly deletion e gene alone combination removal genes <NUMBER>b led mutant viruses seem promising vaccine candidates <NUMBER> <NUMBER> <NUMBER> <NUMBER> described next e gene nonessential genus b mhv cov <NUMBER> although elimination gene mhv genome reduced virus growth cell culture <NUMBER>fold contrast group <NUMBER> tgev coronavirus expression e gene product essential virus release spread propagation e genedeleted tgev tgevde restored providing e protein trans <NUMBER> <NUMBER> recombinant sarscov rsarscov lacks e gene generated bac fig <NUMBER>b recovered vero e<NUMBER> cells relatively high titer around <NUMBER> <NUMBER> pfuml also huh<NUMBER> caco<NUMBER> cells low titers indicating sarscov e protein essential virus replication cell culture <NUMBER> electron microscopy observation vero e<NUMBER> cells infected sarscov wt de deletion mutant showed higher efficiency assembly release wt virus fig <NUMBER> respect sarscovde behaves like mhv although sarscovde grows considerably higher titer vaccine viability efficacy require production viruses high titers interestingly adaptation rsarscovde virus grow vero cells <NUMBER> passages led increase virus titers reaching values almost identical displayed fulllength virus around <NUMBER> <NUMBER> pfuml <NUMBER> titer close required competitive live attenuated vaccine sarscov infects replicates several species including mice ferrets hamsters nonhuman primates animals develop inapparent mild disease <NUMBER> ideal animal model completely reproduces human cells infected wt virus <NUMBER> virions final budding step found bound cell whereas e proteindeleted viruses number increased <NUMBER> suggesting absence e protein led delay pinchoff step clinical disease pathological findings identified evaluate rsarscovde vaccine candidate used three animal model systems hamster transgenic mice expressing hace<NUMBER> receptor human sarscov conventional mice challenged mouseadapted virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> animal model systems complementary hamster model used study sarscovde virus pathogenicity demonstrates elements present human cases sarscov infections including interstitial pneumonitis consolidation <NUMBER> <NUMBER> <NUMBER> hamster model reproducibly supports sarscov replication respiratory tract higher titer longer duration mice nonhuman primates virus replication model accompanied histological evidence pneumonitis animals develop viremia extrapulmonary spread virus <NUMBER> although overt clinical disease absent hamster model useful model evaluation sarscov infection titers recombinant sarscov rsarscov achieved respiratory tract hamsters similar previously reported wildtype virus <NUMBER> least <NUMBER>fold higher titers rsarscovde virus suggesting mutant virus attenuated histopathological examination lungs infected hamsters showed reduced amounts viral antigen pulmonary inflammation rsarscovde infected rsarscov infected animals indicating rsarscovde attenuated vivo <NUMBER> fact reduction sarscov titers patients associated considerable reduction pathogenicity increase survival rates <NUMBER> <NUMBER> rsarscovde immunized hamsters remained active following wildtype virus challenge mock immunized displayed decreased activity <NUMBER> transgenic mice model based production mice expressing hace<NUMBER> receptor human sarscov transgenic mice models obtained different laboratories expressing hace<NUMBER> control different promoters <NUMBER> <NUMBER> mice develop moderate respiratory disease overwhelming neurological disease <NUMBER> mortality intranasal infection sarscov useful assess attenuation vaccine safety efficacy previously showed infection highly susceptible mice rsarscovde rsarscov e several groupspecific protein genes <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b deleted rsarscovde<NUMBER>b resulted neither weight loss death even inoculation high virus doses <NUMBER> mouseadapted sarscov model used evaluation rsarscovde rsarscovde<NUMBER>b based recent isolation sarscov adapted growth mice rats <NUMBER> <NUMBER> <NUMBER> model provided useful system vaccine evaluation strains mice rats infected viruses develop severe respiratory disease even death mouseadapted strain isolated <NUMBER> passages lungs balbc mice ma<NUMBER> strain unlike parental urbani strain virus intranasal inoculation virus results signs respiratory disease substantial mortality <NUMBER> showed immunization rsarscovde sarscovde<NUMBER>b almost completely protected balbc mice fatal respiratory disease caused mouseadapted sarscov fig <NUMBER> partly protected hace<NUMBER> transgenic mice lethal disease <NUMBER> summary immunogenicity protective efficacy rsarscovde shown three animal model systems described hamsters highly susceptible transgenic mice expressing hace<NUMBER> receptor human sarscov conventional mice challenged ma<NUMBER> virus interestingly homologous heterologous protection observed fact hamsters hace<NUMBER> transgenic mice immunized rsarscovde developed high serum neutralizing antibody titers protected replication homologous sarscov urbani heterologous sarscov gd<NUMBER> upper lower respiratory tract <NUMBER> <NUMBER> relevance observation gd<NUMBER> strain sarscov one serologically divergent human sarscov identified relation urbani strain addition shown gd<NUMBER> strain closely related isolates obtained animals sarscov reemerge would probably animal origin despite attenuated replication respiratory tract rsarscovde virus immunogenic efficacious vaccine hamsters two mouse models virulence performed hamsters using activity wheel decrease hamster activity detected <NUMBER> days hamster infection sarscovs lacking e gene contrast infected virus fulllength genome furthermore rsarscovde infect brain infected transgenic mice contrast wt virus overall data indicate e virulence gene <NUMBER> <NUMBER> potential mechanism e gene product virulence investigated laboratory shown expression e gene drastically reduced expression genes involved stress unfolded protein responses <NUMBER> reduction stress responses associated decrease innate specific immune responses <NUMBER> <NUMBER> <NUMBER> <NUMBER> consequence postulated deletion e gene leads increased immune response virus reducing apparent pathogenicity three complementary strategies applied improve rsarscovde vaccine generate efficient inactivated live modified vaccine virus titers need high order obtain economically competitive vaccine increase virus titers propose novel approach based previous findings showing coronavirus genomes encoding mutated nsp<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> exonuclease exon display mutator phenotype <NUMBER> engineered sarscov mutated deleted e protein modified include exon causes accumulation mutations throughout viral genome mutated viruses passed cell culture infecting cells highest virus dilution possible dilutions contain mutant viruses highest titer therefore expect serial passages dilutions select virus clones high titers desired virus titers achieved confirmed high titer viruses still attenuated vivo virus evolution reverted standard levels replacing mutator nsp<NUMBER> native one using infectious cdna clone <NUMBER> selected viruses tested protection previously described previously shown rsarscovde elicited protective immune responses <NUMBER> <NUMBER> time others also shown possible delete additional nonessential genes generate viable sarscov <NUMBER> <NUMBER> additionally deleted genes involved inhibition ifn activation <NUMBER> <NUMBER> propose delete genes determine whether removal increases immune response vaccine candidate sarscov e protein reduced stress unfolded protein immune responses virus postulated efforts enhance assembly levels viral protein without diminishing stress response increased absence e might increase immunogenicity without compromising safety consequence propose construction rsarscov mutants modified e protein e eliciting higher immune responses virus rsarscovde mutants e coding gene fully functional virus morphogenesis inserted within viral genome approach based previous identification host proteins binding sarscov e protein influencing virusinduced stress response immune response virus e protein ligands identified coimmune precipitation mass spectrometry studies previously reported <NUMBER> yeast twohybrid technologies <NUMBER> effect proteins stress immune response identified propose modify specific e protein domains order prevent virushost cell interactions counteract induction strong immune response rsarscov vaccines focus modification three sarscov proteins previous findings proteins indicate fully essential virus viability modification may lead attenuated viruses experimental information influence coronavirus replicase protein modification attenuation obtained changing nsp<NUMBER> nsp<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> case sarscov shown nsp<NUMBER> significantly inhibited ifndependent signaling decreasing phosphorylation levels stat<NUMBER> little effect stat<NUMBER> jak<NUMBER> tyk<NUMBER> <NUMBER> modification sarscov nsp<NUMBER> mutations r<NUMBER>s k<NUMBER>e resulted virus replicated efficiently wildtype virus cells defective ifn response replication strongly attenuated cells intact ifn response <NUMBER> thus likely nsp<NUMBER> mutants lose virulence reduced pathogenicity alternatively mutations deletions nsp<NUMBER> gene could introduced similar described mhv replicase <NUMBER> <NUMBER> led attenuated cov phenotype types mutants could investigated relevance generation attenuated sarscov phenotypes could tested vaccine candidates deletion nsp<NUMBER> mhv sarscov viruses caused <NUMBER> log<NUMBER> reductions peak titers singlecycle growth assays well reduction viral rna synthesis growth <NUMBER> <NUMBER> findings indicate nsp<NUMBER> essential virus replication deletion may lead viruses attenuated phenotype addition recent studies mhv hcov<NUMBER>e suggest protein may functions pathogenesis <NUMBER> <NUMBER> therefore nsp<NUMBER> seems promising candidate complement safety rsarscovde vaccine oglycosylated accessory protein <NUMBER> amino acids forms k permeable channellike structure <NUMBER> essential growth tissue culture cells deletion <NUMBER>a gene leads small <NUMBER>fold reduction virus titer reduction vitro vivo <NUMBER> protein <NUMBER>a may also involved triggering high levels proinflammatory cytokine chemokine production <NUMBER> <NUMBER> <NUMBER> deletion may reduce sarscov virulence gene <NUMBER>a maps distal position genes nsp<NUMBER> nsp<NUMBER> therefore recombination event restores wild phenotype gene <NUMBER>a genes nsp<NUMBER> nsp<NUMBER> one event seems unlikely coronavirus transcription regulated highly conserved sequences preceding gene transcriptional regulatory sequences trss almost identical sequences located <NUMBER> <NUMBER> end genome downstream leader sequence trs preceding gene encodes complementary sequence newly synthesized rna negative polarity rnas hybridize trs located next leader process discontinuous rna synthesis typical covs alternative approach developing safer recombinationresistant live coronavirus vaccines developed barics group <NUMBER> novel procedure involves modification trss sarscov vaccine strain sequence incompatible trs known circulating covs postulated recombinant events wt coronaviruses trs remodeled sarscov would result genomes containing incompatible mixed regulatory sequences block expression subgenomic mrnas using molecular clone sarscov trs network remodeled acgaac ccggat <NUMBER> rewiring genomic transcription network allows efficient replication mutant virus icsarscrg icsarscrg recombinant virus replicated titers equivalent wt virus expressed typical ratios subgenomic mrnas proteins shown vaccine candidate provides protection challenge virulent sarscov previous studies using animal covs provided experimental evidence humoral <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> cellmediated responses animal coronaviruses exacerbate disease <NUMBER> previously summarized <NUMBER> safety concern increased case sarscov two studies one report <NUMBER> antibodies neutralized human sarscovs also enhanced virus entry mediated two civet cat sarscovs viruses glycoproteins related sarscov gd<NUMBER> isolate second report shown administration mvabased sarscov vaccine ferrets mva alone followed live sarscov challenge resulted enhanced hepatitis <NUMBER> nevertheless side effects described studies sarscov mice hamster ferrets african green monkeys <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> general immunization vaccine candidates resulted absence side effects nevertheless still three concerns remain unaddressed one specific viral proteins sarscov n expressed venezuelan equine encephalitis vee virus vector resulted enhanced immunopathology following viral challenge <NUMBER> similar immune pathology observed following vaccination formalininactivated respiratory syncytial virus rsv <NUMBER> <NUMBER> <NUMBER> second main concern observation sarscov vaccines provide protection absence side effects young mice show immunopathological complications aged mice <NUMBER> third consideration vaccine candidates tested animal models fully reproduce clinical symptoms observed humans one exception phase clinical trials humans performed therefore sars vaccine candidates would require additional rigorous clinical immunological evaluation using sarscov mouseadapted virus model potential side effect assessment young aged animals live virus vaccine formulations include rational approaches minimize potential reversion wt phenotype simultaneously resist recombination repair principle combination sarscov genome modifications could lead viruses attenuated phenotype could considered safe effective vaccine candidates rsarscovde selected rsarscove attenuated principle reversion virulent phenotype could take place reintroduction e gene virus recombination closely related coronavirus present environment furthermore cannot excluded compensatory mutations increasing virus fitness could cause reversion virulent phenotype minimize possibilities additional modifications introduced final vaccine candidate including modifications orfs encoding proteins nsp<NUMBER> nsp<NUMBER> <NUMBER>a described advantage combining deletions mutations e protein nsp<NUMBER> nsp<NUMBER> orfs reside genes map distal positions genome <NUMBER> kb <NUMBER> <NUMBER> separation making unlikely single recombination event could restore wt virus phenotype addition creative reorganizations virus genome described could increase sarscov safety described covs characteristic strictly conserved genome organization genes occurring order <NUMBER> <NUMBER> polsemn<NUMBER> <NUMBER> mhv virus mutants genes encoding structural proteins located different order constructed shown canonical coronavirus genome organization essential vivo replication <NUMBER> mutants showed attenuated phenotype interestingly rearrangement viral genes may useful generation cov reduced risk generating viable viruses recombination circulating field viruses fact potential recombination viruses different gene orders likely lead nonviable viruses lacking essential genes result degeneracy genetic code two amino acids protein coding sequence encoded one synonymous codon frequencies synonymous codon used amino acid unequal coevolved cells translation machinery avoid excessive use suboptimal codons often correspond rare otherwise disadvantaged trnas <NUMBER> <NUMBER> results phenomenon termed synonymous codon bias varies greatly evolutionarily distant species <NUMBER> codon optimization recombinant methods widely used improve crossspecies expression opposite direction reducing expression intentional introduction suboptimal synonymous codons seldom chosen <NUMBER> de novo gene synthesis aim designing stably attenuated polioviruses sarscov novel strategy construct virus variants containing synthetic replacements virus coding sequences deoptimizing synonymous codon usage infection equal amounts poliovirus particles revealed neuroattenuated phenotype striking reduction specific infectivity poliovirus particles <NUMBER> similar attempts made barics group design sarscov vaccines vaccine candidates provide protection mouse model system challenge virulent virus ralph baric personal communication due distribution effect many silent mutations large genome segments codondeoptimized viruses genetically stable phenotypes may prove suitable attenuated substrates production vaccines production effective safe vaccines animal coronaviruses previously reported satisfactory <NUMBER> <NUMBER> <NUMBER> <NUMBER> contrast production inactivated subunit vaccines based dna recombinant vectors vaccines generated reverse genetics using sarscov genomes seem promising vaccine candidates need tested sarscov mouseadapted model macaques cases using young aged animals later absence side effects safety assessed human phase clinical trials vaccine manufacturers tendency use welldefined inactivated vaccines unfortunately approach limited efficacy elicits immune responses relatively short immunological memory possible balance efficacy safety development rna replicationcompetent propagationdefective vaccine candidates based viral replicons generate onecycle viruses using packaging cell lines <NUMBER> severe respiratory enteric diseases humans animals fehr perlman <NUMBER> seventh human coronavirus also known severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> identified novel deadly highly contagious virus quickly spread <NUMBER> countries march <NUMBER> declared outbreak pandemic djalante shaw dewit <NUMBER> well recognized virus unusually high speed transmission survive environment different surfaces long hours poses serious risk negahdaripour <NUMBER> moreover illness causes flulike symptoms reports show one person infected easily infect others j even though coronavirus infection humans identified first time <NUMBER> however scientific research area grew following outbreak sars coronavirus year <NUMBER> drosten et al <NUMBER> ksiazek et al <NUMBER> spite reaction scientific community instantaneous nearly uniform current state knowledge vaccines covid<NUMBER> seem months even years away nabel <NUMBER> still much understood sarscov<NUMBER> considerable research efforts made yield answers basic questions sarscov<NUMBER> behavior currently offlabel use antiviral drugs treatment novel virus coronaviruses totally effective partially satisfactory treatment available urgent need effective specific interventions help tackle growing global health burden sarscov<NUMBER> develop effective care plan sarscov<NUMBER> outbreak vital find new targets novel therapeutic antisarscov<NUMBER> approach de novo drug discovery fundamental understand molecular entities specific pathways driving virus replication infection paper review available information molecular determinants disease pathobiology modules addition computational approaches employed systematic drug repositioning vaccine development settings sarscov<NUMBER> described procedure example instead traditional epitope identification upon experimental techniques costly timeconsuming sancheztrincado gomezperosanz reche <NUMBER> predictive computational methods key way screening largescale peptide candidates hoped proposed methodology open new avenues rapid identification candidate drugs potential prevention treatment sarscov<NUMBER> coronaviruses enveloped singlestranded rna viruses one largest viral genomes found rna viruses majority diseasecausing agents pyrc berkhout van der hoek <NUMBER> several phylogenetic studies subdivided coronaviruses four genera known alphacovs betacovs gammacovs deltacovs alphaand betacovs pathogenic viruses mammals gammaand deltacovs known infect mainly birds paules marston fauci <NUMBER> coronaviruses addressed common cold viruses humans zoonotic origin cause serious disease animals lake <NUMBER> general gene pools groups <NUMBER> <NUMBER> coronaviruses thought originated bats reservoir diverse covs spread humans intermediate host sometimes directly cui li shi <NUMBER> human coronaviruses typically associated respiratory tract diseases observed common cold including hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> hcovhku<NUMBER> sometimes enteric illnesses however emergence highly pathogenic human coronavirus infections last two decades greatly illuminated potential cause high morbidity mortality humans cockrell leist douglas baric <NUMBER> recent coronaviruses sarscov merscov two representative members genus betacoronavirus emerged human population zoonotic infections serious endemic illnesses associated high mortality years <NUMBER> <NUMBER> respectively peck burch heise baric <NUMBER> case sarscov infection around since <NUMBER> multiple sporadic cases merscov reported different countries despite low interhuman transmissibility merscov identified infectious disease associated high mortality rates <NUMBER> much higher sars <NUMBER> donnelly malik elkholy cauchemez van kerkhove <NUMBER> fong <NUMBER> likely discrepancy outcome merscovand sarscovinfections explained differential virus pathogenicity virulence recently identified sarscov<NUMBER> also belongs betacoronavirus genus international committee taxonomy viruses named novel strain coronavirus sarscov<NUMBER> similar known sarscov terms whole genome sequence r lu et al <NUMBER> sarscov<NUMBER> genomic size of<NUMBER> kilobases encoding several structural nonstructural proteins major structural proteins form viral particle include spike envelope e membrane nucleocapsid n protein preliminary studies show sarscov<NUMBER> fulllength genome quite similar sarscov p zhou et al <NUMBER> however data become available sarscov<NUMBER> undoubtedly distinct sarscov bat origin coronaviruses thus imperative understand novel coronavirus demanding immediate treatment develop effective interventions targeting sarscov<NUMBER> next phase researchers vaccine companies develop new vaccines controlling preventing highly pathogenic virus <NUMBER> therapeutic options <NUMBER>ncov <NUMBER> perspectives targeting structural proteins currently approved treatment covid<NUMBER> humans number antiviral treatments ribavirin primarily used based experiences sars mers medication singhal <NUMBER> addition using chloroquine <NUMBER> phosphate old antimalarial drug found limited success patients covid<NUMBER> gao tian yang <NUMBER> <NUMBER>ncov genetically closely related sars coronavirus <NUMBER> identity merscov <NUMBER> similar <NUMBER> two batderived sarslike coronaviruses r lu et al <NUMBER> virus found bat covs genus betacoronavirus however displayed large genetic distances close relatives considered new human coronavirus however modeling study indicate similar structure receptorbinding domain rbd <NUMBER>ncov sarscov variations key amino acid residues emerging evidence suggest <NUMBER>ncov might bound sarscov receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional cell receptor human r lu et al <NUMBER> clinical features <NUMBER>ncovinfected patients indicate multiple organ failure addition pneumonia ace<NUMBER> acting first key step <NUMBER>ncov infection may help explain clinical features systems observed patients ace<NUMBER> expressed extensively endothelium heart liver kidney testis intestine yang zhao zhang <NUMBER> <NUMBER>ncov may probably infect tissues ace<NUMBER> available ongoing works dissecting genetic molecular interactions highlight sarscov<NUMBER> differ several critical residues rbd particularly gln<NUMBER> sars strains leading highaffinity interactions ace<NUMBER> receptors significantly contagious viruses result wan shang graham baric li <NUMBER> one suggest sarscovspecific human monoclonal antibody cr<NUMBER> sarscov antibodies eg m<NUMBER> cr<NUMBER> may effective neutralizing <NUMBER>ncov blocking cell infection present numerous attempts made develop monoclonal antibodies specific effective <NUMBER>ncov may similarities mechanisms cell entry <NUMBER>ncov sarscov employ ace<NUMBER> entry receptor cellular serine protease called transmembrane protease serine <NUMBER> activating sprotein host cell entry hoffmann et al <NUMBER> might hopefully work candidate therapeutic target anti<NUMBER>ncov intervention hoffmann et al <NUMBER> thus context serine protease inhibitor camostat mesylate approved human use different indication may provide effective therapeutic option treatment <NUMBER>ncovinfected patients kawase shirato van der hoek taguchi matsuyama <NUMBER> zhou et al <NUMBER> another effort limit <NUMBER>ncov infection furin inhibitors reported develop specific antiviral treatment coutard et al <NUMBER> priming viral envelope glycoproteins spike protein proteases target cells essential cell tropism pathogenicity virus efficacy extent cleavage event may implication development antiviral agents human furin protease highly expressed lungs cleaves <NUMBER>ncov sprotein specific conserved site absent sarscov sequences bassi zhang renner kleinszanto <NUMBER> thereby generates mature infectious virus particles overall fact sprotein relates degrees pathogenicity transmissibility pandemic potential sproteinbased antiviral therapies offer attractive seemingly efficient modality area antincov treatment jiang liu <NUMBER> x li geng peng meng lu <NUMBER> treatment regimens based use sproteinbased therapeutics include antagonists rbdace<NUMBER> interaction inhibitors sprotein cleavage proteases neutralizing antibodies sprotein inhibitors small interfering rnas malik et al <NUMBER> nevertheless potential concern treatment covid<NUMBER> infection emergence drug resistance rapid genomic evolution virus therapy higher risk drug resistance often noted occur targeting single virus proteins zumla chan azhar hui yuen <NUMBER> even though therapeutic strategies demonstrated vitro efficacy undergone animal clinical testing far may therefore limited use present covid<NUMBER> problem indicated key development new drugs able control cause recent outbreak deadly viral pneumonia china requires identification conserved target region within whole coronavirus genus h yang et al <NUMBER> despite structural proteins including e n proteins nonstructural proteins nsps withstand considerable sequence variation among different covs woo et al <NUMBER> nsps responsible viral replication transcription may adopted target cov sarscov encodes <NUMBER> nsps potential virulence factors among nsps rnadependent rna polymerase rdrp nsp<NUMBER> central subunit cov replicative machinery essential cofactors nsp<NUMBER> nsp<NUMBER> play crucial role replication sarscov genome kirchdoerfer ward <NUMBER> subissi et al <NUMBER> accordingly possibly interference binding nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> inhibit rdrp activity nsp<NUMBER> development novel antiviral agents comparative analyses amino acid sequences show high similarity nsp<NUMBER> <NUMBER> nsp<NUMBER> <NUMBER> sarscov ruan et al <NUMBER> screening compounds disrupting nsp<NUMBER>nsp<NUMBER>nsp<NUMBER> complex may evolve novel therapies sarscov<NUMBER> based virtual screening docking methods seven compounds saquinavir tipranavir lonafarnib tegobuvir olysio filibuvir cepharanthine ghaebi et al <NUMBER> suggested potential efficacious new inhibitors virus replication process ruan et al <NUMBER> offering opportunities clinical assessment antisarscov<NUMBER> drugs usually betacoronaviruses produce a<NUMBER> kda polypeptide posttranscriptionally cleaved certain processing sites separate subunits papainlike protease <NUMBER>chymotrypsinlike protease <NUMBER>cl pro main proteases usually responsible proteolytic processing generate various nsps thus important viral replication anand ziebuhr wadhwani mesters hilgenfeld <NUMBER> recent studies revealed <NUMBER>cl pro conserved sarscov<NUMBER> <NUMBER>point mutations identified receptorbinding site affects binding ability medicinal plant compounds already used treat viral diseases like inhibitor sarscov <NUMBER>cl pro named ml<NUMBER> therefore optimization drug development efforts made develop new compounds inhibit sarscov<NUMBER> <NUMBER>cl pro results identified nine novel natural compounds predicted bind receptorbinding site sarscov<NUMBER> <NUMBER>cl pro possess therapeutic activities ul qamar alqahtani alamri chen <NUMBER> investigations lack experimental validation address anticovid<NUMBER> drug discovery putative clinical application vitro vivo studies required enzyme nsp<NUMBER> helicase another potential target viral replication apparatus investigated sarscov<NUMBER> could structurally characterized computational methods nucleotide sequence predicted protein <NUMBER> amino acids similar previous reports molecular dynamics simulations together virtual screening efforts applied identify interaction profile important binding site residues sarscov<NUMBER> nsp<NUMBER> helicase potential therapeutic small molecules find potent selective inhibitors sarscov<NUMBER> mirza froeyen <NUMBER> silico predictions used determining adme parameters identified potential hits sarscov<NUMBER> nsp<NUMBER> target absorption distribution metabolism elimination toxicity admetox resulting top hits selected following removal hits exhibited poor admettox found contain highrisk chemical groups mirza froeyen <NUMBER> improve control strategies research studies attempted develop effective treatments prophylactic strategies including vaccination considering cost per cured subject vaccination appears favorable alternatively rising morbidity death rates benefit vaccine reducing disease burden higher rest review focus known development vaccine covid<NUMBER> table <NUMBER> plan within months table <NUMBER> although viruss sprotein considered promising immunogen inclusion nucleic acid covid<NUMBER> vaccine continues debate best approach ensure optimal immune response example current debate target antigen design fulllength protein receptorbinding domain challenging lurie et al <NUMBER> however several areas consensus herein disclosed emerged area beginning basics demonstrated immune response coronavirus infection vaccination involves early neutralizing immunoglobulin g igg antibody response viral surface proteins zand wang <NUMBER> also evidence coronaviruses make use certain antibodies entry cell alternative mechanism target cell binding also clinically demonstrated sera sars patients apparently contain neutralizing igg antibodies cause ade particularly important modeling optimal vaccine strategy reducing severe disease note within different vaccine types except liveattenuated virus vaccines general goal induce adaptive immune response n viral proteins also increase highaffinity igg production utmost importance planning vaccine actions data collectively suggest one approach may manipulate modify protein sequences disable potential ade possible zand wang <NUMBER> addition given adverse effect may associated helper type <NUMBER> th<NUMBER> immune responses extended human safety testing critical point using suitable adjuvant capacity trigger type <NUMBER>t helper th<NUMBER> response high neutralizing antibody titers theoretically likely protective avoid immunopathology lurie et al <NUMBER> worth noting use adjuvant vaccine reasonable approach pandemic may substantially reduce amount vaccine material required immunization owing limited worldwide production capacity vaccine strategy allow vaccine doses produced widespread vaccination populations therefore contributes protection people e protein also proposed attractive vaccine target developing liveattenuated vaccines based prior studies related coronaviruses cause mers sarscov almazán et al <NUMBER> sars merscov construction attenuated virus deleted e protein could result replicationcompetent propagationdefective virus supports efficacy attenuated viruses vaccine candidates almazán et al <NUMBER> deletion e protein accomplished <NUMBER>ncov expected lead similar breakthrough given approaches carried elucidate genetic antigenic properties virus accelerate novel vaccine design peptidebased vaccines received attention due ease production chemical synthesis dominant protective epitopes dudek perlmutter aguilar croft purcell <NUMBER> neutralizing free virus particles cell entry required prevent cells infected covid<NUMBER> rational vaccine design strategies based characterization epitopes exposed protein virus recognized b cell antibodies lymphocytes may able overcome ongoing outbreak using immunoinformatics approach find protein epi antigenicity analysis pointed <NUMBER> mhci epitopes <NUMBER> mhcii epitopes antigenic propensity bhattacharya et al <NUMBER> furthermore sprotein oligopeptides immunogenic uniquely viral epitopes identified comparative homo sapienscoronavirus proteome analysis using peptide match program <NUMBER>ncov human proteomes compared searched viral peptides absent human proteome increase antiviral specificity minimizing risk crossreactions lucchese <NUMBER> total <NUMBER> nonself sequences virus genome obtained result represents best targets vaccine development due potential immunogenicity richman vonderheide rech <NUMBER> addition identification potential cell epitopes li et al <NUMBER> authors claim immune targeting sarscovderived b cell cell epitopes map identically sarscov<NUMBER> proteins may offer substantial protection new virus ahmed quadeer mckay <NUMBER> strengthens idea determined epitopes comprise mutations available sarscov<NUMBER> sequences ahmed et al <NUMBER> since genomic variations pathogen significant clinical consequences genetic diversity sarscov<NUMBER> strategies develop vaccine candidates described detail next section one hypothesis rapid spread sarscov<NUMBER> may due evolution driven viral mutations understandably evolution rna viruses continues occupy great deal attention dolan whitfield andino <NUMBER> rapid evolution rna viruses utilize highly divergent rnadependent rna polymerase often evident dnabased viruses fact enormous genetic diversity critical determinant adaptative capacity lauring frydman andino <NUMBER> nucleotide substitution dna often involved one important mechanisms provoking viral evolution nature lauring andino <NUMBER> last months genomesequencing projects conducted worldwide scientific community understand evolutionary dynamics characteristics results ∼<NUMBER> kda polyprotein described two variable locations core genome ceraolo giorgi <NUMBER> another important aspect virus replication may functional contact virus host several viruses including coronaviruses require host cellular factors replicate zumla et al <NUMBER> furthermore repeated observations families rna viruses indicate many mutations surfacelocated conserved residues probably core residues viral proteins cheng brooks iii <NUMBER> patel kukol <NUMBER> warren wan conant korkin <NUMBER> deng hu wang deng <NUMBER> subunit vaccines offer many advantages liveattenuated inactivated organisms unlike inactivated liveattenuated virus vaccines subunit vaccines known provide better efficacy unable revert virulent form pathogen eliminate risk incomplete inactivation thus making biologically safe however typically require coadministration adjuvants zhang et al <NUMBER> based information subunit candidates fulllength sprotein andor rbd element sarscov<NUMBER> prove valuable prevention covid<NUMBER> shang yang rao rao <NUMBER> though expensive manufacture need repeated injections phillpotts venugopal brooks <NUMBER> moreover subunit vaccines designed contain wellcharacterized neutralizing epitopes defined epitopes elicit neutralizing antibody response avoiding epitopes pathological ade effects improve immunogenicity naz dabir <NUMBER> another scientific challenge vaccine development may dependent strategies vaccine delivery evidence respiratory tract infection findings sars<NUMBER> stool holshue et al <NUMBER> q li et al <NUMBER> suggest mucosal delivery routes oral aerosol administration vaccine appear possible modes sarscov<NUMBER> immunization epidemiological studies shown disease caused sarscov<NUMBER> significantly associated higher age ghaebi et al <NUMBER> individuals <NUMBER> years age often exhibit severe pathology following sarscov<NUMBER> infection likely die infection many viral infections naive younger individuals experience milder manifestations disease affects health older people strongly vaccine public health measure must protect vulnerable population amanat krammer <NUMBER> unfortunately precisely population vaccines least efficacious immune senescence sambhara mcelhaney <NUMBER> current influenza vaccines specific formulations including highdose antigen using adjuvant may particularly useful segment population amanat krammer <NUMBER> diazgranados et al <NUMBER> interestingly even vaccination result protection recipients still able stop transmission virus thereby benefits older individuals amanat krammer <NUMBER> finally successful sars<NUMBER> vaccine developed available responsibility let global access part planning nonetheless apart availability vaccine still social clinical economic hurdles face sars<NUMBER> vaccine vaccination programmes include example willingness public get new vaccination potential variation efficiency quite different populations well severe adverse reactions arising new vaccine pang et al <NUMBER> review available relevant literature summarized published information regarding covid<NUMBER> vaccine research development summary extensive bioinformatics analysis past months helped provide unique opportunity better understanding determinants immunogenicity immunodominance structurefunction relationships great extent reduce experimental cost epitope identification vaccine design well limit pool peptides available analysis research efforts early stages prospect preventative therapeutic vaccine seems realistic result intense global cooperation also taking advantage gathered data sars mers data collection continues getting closer finding better ways conquer disease first foremost accurate date data status timing vaccine production release must accessible meanwhile collaboration countries world clearly needed producing preventive therapeutically desired result authors declare conflict interests g involved drafting manuscript critically reviewed manuscript content majid ahmadi httporcidorg<NUMBER> cells indicating ace<NUMBER> likely cell receptor sarscov<NUMBER> mclellan et al showed biophysical structural evidence sarscov<NUMBER> protein binds ace<NUMBER> higher affinity sarscov protein wrapp et al <NUMBER> date although repurposed drugs showed inhibitory effect sarscov<NUMBER> drugs licensed used treatment sarscov<NUMBER> infection coronavirus infections humans vaccines licensed prevent infections days chinese scientists shared genetic map sarscov<NUMBER> scientists around world along list biotech vaccine companies promptly launched race pursue different types vaccines prevent infection novel virus end april <NUMBER> least <NUMBER> sarscov<NUMBER> vaccine projects announced development including vectored vaccines oral vaccines subunit vaccines inactivated vaccines peptidebased vaccines nucleotidebased vaccine etc several sarscov<NUMBER> vaccine candidates recently approved clinical phase ii development thanh le et al <NUMBER> among sarscov<NUMBER> vaccine candidates mrna vaccines quite remarkable mrna vaccine unlike traditional vaccines mrna vaccine consists mrna sequence encoding diseasespecific antigen delivered target cells antigen expressed processed presented recognized immune system strong humoral cell immune response instigated compared vaccine production whole microbes live attenuated subunit vaccines mrna vaccines believed faster less expensive produce involve living stage pathogenic virus bacteria manufacturing process makes mrna vaccines promising bioproduct potentially fills gap desperate demand vaccines control disease outbreaks epidemics potential scale standardize vaccine manufacturing process process mrna vaccine development illustrated fig <NUMBER> exemplified mrna vaccine coding gene sarscov<NUMBER> currently components needed mrna vaccine production available good manufacturing practices gmp grade satisfy commercialization two forms mrna vaccines developed including conventional mrna vaccines selfamplifying mrna sam vaccines conventional mrna encoding target antigen synthetically produced including open reading frame orf target antigen <NUMBER> <NUMBER> <NUMBER> <NUMBER> untranslated regions utrs cellfree enzymatic transcription reaction vitro transcription reaction includes linearized plasmid dna encoding pathogen antigen template recombinant rna polymerase nucleoside triphosphates cap analog polya tail added sequentially transcriptional product following reaction form functional mrna injection transient low levels antigen expression driven sam vaccines derivatives alphavirus rna replication structural protein sequences replaced antigen gene generating multiple copies antigenencoding mrna expressing high levels heterologous gene vitro transcribed ivt mrna encapsulated lipid nanoparticles delivered cells consequently humoral cell immune responses stimulated immune response mechanism instigated mrna remains elucidated dimension immune response dependent quality ivt mrna delivery vehicle administration route last two decades mrna vaccines investigated extensively infectious disease prevention cancer immunotherapy several mrna vaccines infectious disease showed promising future mrna vaccines influenza viruses rabies virus hiv ebola virus zika virus demoulins et al <NUMBER> maruggi et al <NUMBER> although clinical trials mrna vaccines infectious disease still early stage plethora publications shown mrnabased vaccines promising novel platform highly flexible scalable inexpensive coldchainfree growing body preclinical clinical results demonstrates prophylaxis therapy mrna promises useful prevention infectious disease mrna vaccines safe tolerated animal models humans despite great challenges creation new processes generate mrna vaccines delivery translation efficiency processes hopefully streamlined establish largescale production matter time mrna vaccines used humans animals several biopharmaceutical companies announced promptly establishment mrna vaccine projects sarscov<NUMBER> since outbreak january <NUMBER> <NUMBER> coalition epidemic preparedness innovations cepi announced initiation three programs develop vaccines sarscov<NUMBER> moderna mrnabased biotechnology company announced received funding cepi would manufacture mrna vaccine sarscov<NUMBER> using mrna vaccine platform technology partnered national institute allergy infectious diseases niaid develop vaccine wuhan strain coronavirus niaid conduct investigational new drug indenabling studies phase clinical study us projects conducted moderna approximately <NUMBER> people received different versions mrna vaccines far seven clinical trials designed prevent illness respiratory viruses including strain flu respiratory syncytial virus rsv human metapneumovirus hmpv mrna vaccine candidate sarscov<NUMBER> developed moderna first one entering phase clinical trial moderna <NUMBER> february <NUMBER> cepi agreed provide <NUMBER> million support curevacs technology development provide rapid supply lipidnanoparticleformulated mrna vaccine candidates target known pathogens prepare rapid response new previously unknown pathogens principle fig <NUMBER> streamlined process creation mrna vaccine coding gene sarscov<NUMBER> including design formulation testing approval curevacs proprietary technology use mrna genetic information carrier instruct human body produce proteins capable fighting wide range diseases additionally federal ministry education research committed total <NUMBER> million euros support work smith <NUMBER> pharmaceutical biotechnology companies china also stepped development vaccines sarscov<NUMBER> four sarscov<NUMBER> vaccines approved phase ii clinical trial china end april <NUMBER> several biotechnology companies announced development mrna vaccines mated coronavirus early january <NUMBER> stermirna therapeutics cooperating shanghai east hospital tongji university proclaimed <NUMBER> days needed produce vaccine samples based new generation mrna technology preliminary procedures samples would sent tests brought clinics soon possible xinhua net <NUMBER> february <NUMBER> <NUMBER> institute advanced technology shenzhen announced first batch mrna vaccine sarscov<NUMBER> prepared gmp standards mrna matching requirement clinical trial would ready april <NUMBER> siat <NUMBER> february <NUMBER> zhuhai lifanda biotechnology announced antibody antigen encoded mrna detected mouse serum day <NUMBER> mice immunized data rhesus macaques immunized mrna vaccine candidates would obtained soon mrna vaccine sarscov<NUMBER> would go clinical testing within <NUMBER> months gmp factory would put use april <NUMBER> cnbeta <NUMBER> like coranaviruses protein sarscov<NUMBER> plays essential role binding receptors host cell initiate infection determines host tropism also major target neutralizing antibodies may main antigen development sarscov<NUMBER> vaccines related groups according public information protein receptor binding domain rbd sites main antigens edcoded sarscov<NUMBER> vaccine candidates however due limited information patent protection adaptation antigens sarscov<NUMBER> vaccines development antigen information sarscov<NUMBER> vaccine candidates unclear expected immune response antibody cell mediated immune response stimulated sarscov<NUMBER> vaccines development clear either thus accordingly protection sarscov<NUMBER> predicted development sarscov mrescov vaccines groups found enhanced lung inflammation following homologous challenge mice nonhuman primates mediated specific igg liu et al <NUMBER> wan et al <NUMBER> antibodydependent enhancement ade initially found induced dengue vaccine katzelnick et al <NUMBER> ade also observed vaccines later influenza vaccine winarski et al <NUMBER> ade modulates immune response elicit sustained inflammation lymphopenia andor cytokine storm one documented severe cases deaths ade also requires prior exposure similar antigenic epitopes currently immunologists worrying sarscov<NUMBER> mrna vaccines based protein maybe induce ade blur adaptation prevention control sarscov<NUMBER> pandemic however recent paper qin et al reported inactivated sarscov<NUMBER> vaccine safe nonhuman primate induced ade macaques gao et al <NUMBER> obstacle developing successful sarscov<NUMBER> mrna vaccine abundant glycosylation sites protein facilitate escaping sarscov<NUMBER> neutralization protein specific antibodies vankadari wilce <NUMBER> novel vaccine platform mrna vaccine technology mature used immune prophylaxis therapy still needs improvement uncertainty sarscov<NUMBER> mrna vaccine development mechanisms immunity induction mrna vaccine vivo elucidation published results showed mrna vaccines stimulated potent immune response human immune response strong enough low dose antibodies pardi et al <NUMBER>b delivery tool administration route determine dimension immune response mrna vaccine pardi et al <NUMBER>a far least <NUMBER> sarscov<NUMBER> mrna vaccine projects announced globally <NUMBER> may <NUMBER> regularly general stages development cycle vaccine include exploratory stage preclinical stage clinical development regulatory review approval manufacturing quality control process creation testing production vaccine mass quantities take many years industry highly regulated mrna vaccines sarscov<NUMBER> infection developers speed process make available soon possible however safe effective vaccine commercial available best protection infection sarscov<NUMBER> follow suggestions public health experts conflict interest authors declare conflict interest animal human rights statement article contain studies human animal subjects performed authors alleviation enormous burden mortality morbidity associated covid<NUMBER> pandemic probably depend development effective vaccines could rolled widely many candidate vaccines development <NUMBER> recent estimates cite least <NUMBER> years vaccine rollout <NUMBER> significant proportion time due requirement assess efficacy safety placebocontrolled phase <NUMBER> trials typically involve several thousand participants followed long enough field assess differences disease incidence vaccine control groups many participants taking precautions avoid exposure suggest circumstances devastating global pandemic controlled human challenge studies following normal initial safety vaccine dose finding immunogenicity studiesphases <NUMBER> figure <NUMBER> may acceptable way bypass phase <NUMBER> testing speed licensure efficacious vaccines volunteers human challenge studies would drawn previously uninfected individuals relatively low risk complications mortality sarscov<NUMBER> infection eg young adults without chronic health conditions otherwise sick <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> substantial risk natural exposure sarscov<NUMBER> eg resident areas high transmission rates target group might comprise uninfected persons aged <NUMBER> years age range risk death serious complications following infection substantially lower older age groups <NUMBER> <NUMBER> controlled challenge model would need standardized using test vaccines volunteers previously uninfected would required initial doseescalation study viral challenge select dose virus exposure placebo recipients become infected statistical reasons clinical response severe one associated natural infection ethical reasons latter would require comparison cohort individuals similar age infected naturally standardization volunteers may spend <NUMBER> weeks clinical isolation facility prior challenge viral serologic testing exclude previous recent infection shorter duration suitable serological tests recent infections developed overall preparatory studies upperleft black square figure <NUMBER> may take several weeks could start vaccine candidates available evaluation multiple measures would put place ensure prior consenting potential participants fully comprehend unusual risks involved study controlled human challenge model set vaccines could evaluated volunteers previously infected would randomized receive either candidate vaccines investigation placebo interval permit full immune response vaccine controlled exposure sarscov<NUMBER> would administered appropriate vaccine schedules eg dose number doses determined extent possible conventional phase <NUMBER> immunogenicity safety studies preceded challenge study following challenge participants would carefully followed monitor whether vaccinated different response viral challenge challenge studies would relatively small volunteers might show clinical symptoms would need careful consideration choice primary endpoint discussions regulatory authorities possibilities would include viral load measured least daily eg throat swabs cumulated course infection done influenza challenge studies <NUMBER> time first clinical symptoms vaccines endpoint might proportion infected throughout study intense immunological monitoring would seek correlates vaccine effect required size studies would depend upon endpoints chosen might require order <NUMBER> volunteers volunteers infection confirmed would receive excellent care covid<NUMBER> including priority scarce lifesaving resources stateoftheart facilities throughout trial infectiousness ruled participants would remain isolated secure comfortable setting eg settings converted used influenza challenge studies human challenge study showed vaccine candidate efficacious expanded placebocontrolled study would conducted field involving least <NUMBER> vaccinated persons primarily shortterm safety assessment also gather evidence immunogenicity figure <NUMBER> rightmost black box participants would carefully monitored adverse effects following vaccination gather safety data sufficient submission licensure study involving challenge conducted eventual primary initial target group effective vaccineincluding elderly concomitant illnesses increase risk serious disease following infection prior planning largescale assessment safety could completed several months initially shortterm adverse effects would assessed together information challenge study shortterm followup expanded phase <NUMBER> field study may produce evidence sufficient justify accelerated licensure participants expanded field study could continue followed longer term parallel submission licensure suitable actions could taken longterm adverse effects including disease enhancement identified standard vaccine licensure additional postapproval studies would required assess safety effectiveness routine use necessary studies dosage safety special groups eg children pregnant women immunocompromised persons could conducted extending vaccination groups judged appropriate possible protection apparent challenge study replicated vaccine used protect natural infection would carefully monitored early stages vaccine rollout example casecontrol studies event appropriate modification made vaccination program including potentially stopping vaccination particular concern respect vaccine constructs coronavirus may induce severe disease following infection reported animal models sars mers vaccine candidates <NUMBER> vaccine candidate shows evidence effects animal models likely ruled human testing however candidates taken forward human testing possibility enhancement borne mind challenge studies designed way small groups volunteers challenged sequentially way studies could stopped early stage upon first strong indication vaccineinduced enhanced disease vaccine candidate enhance disease controlled human challenge model would provide much rapid evidence support stopping testing harmful vaccine candidate far fewer vaccinated persons traditional phase <NUMBER> efficacy study proposed trial method would potentially cut wait time rollout efficacious vaccine challenge studies always directly expose participants pathogen assess efficacy generally require fewer participants followed shorter period standard efficacy studies many participants never exposed rollout efficacious vaccine age groups included challenge studies may depend immunological bridging would component expanded safety studies discussed possible process could take several months shorter reliance standard phase <NUMBER> testing assess efficacy rollout populations might require initial bridging studies could conducted relatively quickly seems clear absence efficacious vaccine global death toll covid<NUMBER> enormous recent modelling study suggests even mitigation strategies focusing shielding elderly slowing interrupting transmission may <NUMBER> million year <NUMBER> use human challenge helped make vaccine available epidemic completely passed savings human lives could thousands conceivably millions intense social distancing related control measures held place many months availability vaccine take toll economies societies population health advancing registration rollout efficacious vaccine even months could save many thousands lives commands enormous societal value deliberate exposure study participants sarscov<NUMBER> gives rise understandable ethical worries may seem impermissible ask people take risk severe illness death even important collective gain actually ask people take risks others direct gain every time ask volunteer firefighters rush burning buildings relatives donate live organ loved ones healthy volunteers participate drug vaccine toxicity trials prospect improving health risk undermining <NUMBER> relatively healthy volunteers participate studies involving long antiretroviral drug interruptions risk health negligible prospect improving <NUMBER> challenge studies healthy volunteers expose pathogens <NUMBER> spring clearly within right invite citizens volunteer emergency medical services ems fight pandemic augments personal risks ems workers social value work initial trials moderna sarscov<NUMBER> vaccine accelerated skipping prior animal testing margin safety would added <NUMBER> one major reason permissible risk medical harm volunteers medical studies even personal health care require risk volunteers autonomously consented take risks adult persons legitimize many interventions bodies health normally prohibited simply saying yes full understanding voluntariness present case study would involve multiple tests comprehension risks risk factors serious outcomes among individuals otherwise lowrisk age groups may somewhat clearer time recruitment takes place decision deeply informed voluntary exclusive recruitment participants aged <NUMBER> years although children less likely severe symptoms upon covid<NUMBER> infection <NUMBER> <NUMBER> seeks safeguard quality participants consent wide news coverage widespread fear covid<NUMBER> keep clear exposure virus small matter studies mentioned nonconsenting sex partners fetuses study participants may get infected <NUMBER> <NUMBER> proposed controlled challenge study would avoid risk nonparticipants isolating participants whilst infectious remaining key question deeming human challenge studies ethical pertains risk risks participants even justified social importance trial backed participants willful permission also kept necessary minimum risks fall postulated cap acceptable risk medical trials even ones highest social value participants consent <NUMBER> proposed challenge studies seek contain risk participants <NUMBER> different ways first study recruit healthy patients age groups risk severe disease death following sarscov<NUMBER> infection low second possibility vaccine candidate protect least vaccinated third absence effective vaccine high proportion general population likely naturally infected sarscov<NUMBER> point <NUMBER> including might participate challenge study volunteering artificially infected may hastening event likely occur later months anyhow fourth people especially high baseline risk phase <NUMBER> field e cacy trial assess protection natural infection submission licensure figure <NUMBER> process vaccine licensure controlled human challenge trial large study assess shortterm safety black compared conventional phase <NUMBER> trial route licensure grey submission licensure could occur substantially earlier controlled human challenge trial getting exposed soon trial period recruited eg people residing areas high transmission rates fifth participants would monitored carefully frequently following challenge afforded best available care needed eg guaranteed access stateoftheart facilities health system notwithstanding possibility severe shortages medical care evolving pandemic sixth time vaccine candidates tested therapeutics may approved may reduce participants risk morbidity mortality <NUMBER> reasons mortality morbidity participation notwithstanding net mortality morbidity participation remain low negative novel strain coronavirus forces us consider unconventional approaches believe controlled sarscov<NUMBER> vaccine challenge studies may accelerate time takes evaluate license vaccines hence could make vaccines available sooner widespread rollout approach without risks every week vaccine rollout delayed accompanied many thousands deaths globally importantly challenge studies conducted background competent volunteers informed consent minimization study risks high baseline risks infection participants violate participants individual rights altar emergency response heed individual rights global public health emergency far aware current plan evaluating efficacy covid<NUMBER> vaccines slower phase <NUMBER> trials take time develop operationalize challenge studies suggesting ongoing development vaccines become ready phase <NUMBER> trials must paused period however believe challenge studies could set time vaccines would ready efficacy testing addition use assessing efficacy vaccines human challenge studies may also help evaluate drugs might given either preexposure prophylaxis prevent infection individuals high risk infection postexposure prophylaxis given shortly potential exposure either abort infection prevent occurrence disease challenge studies may also way advancing understanding pathogenesis progression infection disease assess potential human challenge studies speed vaccine development suggest expert group might convened including experience human challenge studies pathogens regulators vaccine trialists ethicists potential participants relevant funding agencies plan studies might taken forward ethically expeditiously alleviation enormous burden mortality morbidity associated covid<NUMBER> pandemic probably depend development effective vaccines could rolled widely many candidate vaccines development <NUMBER> recent estimates cite least <NUMBER> years vaccine rollout <NUMBER> significant proportion time due requirement assess efficacy safety placebocontrolled phase <NUMBER> trials typically involve several thousand participants followed long enough field assess differences disease incidence vaccine control groups many participants taking precautions avoid exposure suggest circumstances devastating global pandemic controlled human challenge studies following normal initial safety vaccine dose finding immunogenicity studiesphases <NUMBER> figure <NUMBER> may acceptable way bypass phase <NUMBER> testing speed licensure efficacious vaccines volunteers human challenge studies would drawn previously uninfected individuals relatively low risk complications mortality sarscov<NUMBER> infection eg young adults without chronic health conditions otherwise sick <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> substantial risk natural exposure sarscov<NUMBER> eg resident areas high transmission rates target group might comprise uninfected persons aged <NUMBER> years age range risk death serious complications following infection substantially lower older age groups <NUMBER> <NUMBER> controlled challenge model would need standardized using test vaccines volunteers previously uninfected would required initial doseescalation study viral challenge select dose virus exposure placebo recipients become infected statistical reasons clinical response severe one associated natural infection ethical reasons latter would require comparison cohort individuals similar age infected naturally standardization volunteers may spend <NUMBER> weeks clinical isolation facility prior challenge viral serologic testing exclude previous recent infection shorter duration suitable serological tests recent infections developed overall preparatory studies upperleft black square figure <NUMBER> may take several weeks could start vaccine candidates available evaluation multiple measures would put place ensure prior consenting potential participants fully comprehend unusual risks involved study controlled human challenge model set vaccines could evaluated volunteers previously infected would randomized receive either candidate vaccines investigation placebo interval permit full immune response vaccine controlled exposure sarscov<NUMBER> would administered appropriate vaccine schedules eg dose number doses determined extent possible conventional phase <NUMBER> immunogenicity safety studies preceded challenge study following challenge participants would carefully followed monitor whether vaccinated different response viral challenge challenge studies would relatively small volunteers might show clinical symptoms would need careful consideration choice primary endpoint discussions regulatory authorities possibilities would include viral load measured least daily eg throat swabs cumulated course infection done influenza challenge studies <NUMBER> time first clinical symptoms vaccines endpoint might proportion infected throughout study intense immunological monitoring would seek correlates vaccine effect required size studies would depend upon endpoints chosen might require order <NUMBER> volunteers volunteers infection confirmed would receive excellent care covid<NUMBER> including priority scarce lifesaving resources stateoftheart facilities throughout trial infectiousness ruled participants would remain isolated secure comfortable setting eg settings converted used influenza challenge studies human challenge study showed vaccine candidate efficacious expanded placebocontrolled study would conducted field involving least <NUMBER> vaccinated persons primarily shortterm safety assessment also gather evidence immunogenicity figure <NUMBER> rightmost black box participants would carefully monitored adverse effects following vaccination gather safety data sufficient submission licensure study involving challenge conducted eventual primary initial target group effective vaccineincluding elderly concomitant illnesses increase risk serious disease following infection prior planning largescale assessment safety could completed several months initially shortterm adverse effects would assessed together information challenge study shortterm followup expanded phase <NUMBER> field study may produce evidence sufficient justify accelerated licensure participants expanded field study could continue followed longer term parallel submission licensure suitable actions could taken longterm adverse effects including disease enhancement identified standard vaccine licensure additional postapproval studies would required assess safety effectiveness routine use necessary studies dosage safety special groups eg children pregnant women immunocompromised persons could conducted extending vaccination groups judged appropriate possible protection apparent challenge study replicated vaccine used protect natural infection would carefully monitored early stages vaccine rollout example casecontrol studies event appropriate modification made vaccination program including potentially stopping vaccination particular concern respect vaccine constructs coronavirus may induce severe disease following infection reported animal models sars mers vaccine candidates <NUMBER> vaccine candidate shows evidence effects animal models likely ruled human testing however candidates taken forward human testing possibility enhancement borne mind challenge studies designed way small groups volunteers challenged sequentially way studies could stopped early stage upon first strong indication vaccineinduced enhanced disease vaccine candidate enhance disease controlled human challenge model would provide much rapid evidence support stopping testing harmful vaccine candidate far fewer vaccinated persons traditional phase <NUMBER> efficacy study proposed trial method would potentially cut wait time rollout efficacious vaccine challenge studies always directly expose participants pathogen assess efficacy generally require fewer participants followed shorter period standard efficacy studies many participants never exposed rollout efficacious vaccine age groups included challenge studies may depend immunological bridging would component expanded safety studies discussed possible process could take several months shorter reliance standard phase <NUMBER> testing assess efficacy rollout populations might require initial bridging studies could conducted relatively quickly seems clear absence efficacious vaccine global death toll covid<NUMBER> enormous recent modelling study suggests even mitigation strategies focusing shielding elderly slowing interrupting transmission may <NUMBER> million year <NUMBER> use human challenge helped make vaccine available epidemic completely passed savings human lives could thousands conceivably millions intense social distancing related control measures held place many months availability vaccine take toll economies societies population health advancing registration rollout efficacious vaccine even months could save many thousands lives commands enormous societal value deliberate exposure study participants sarscov<NUMBER> gives rise understandable ethical worries may seem impermissible ask people take risk severe illness death even important collective gain actually ask people take risks others direct gain every time ask volunteer firefighters rush burning buildings relatives donate live organ loved ones healthy volunteers participate drug vaccine toxicity trials prospect improving health risk undermining <NUMBER> relatively healthy volunteers participate studies involving long antiretroviral drug interruptions risk health negligible prospect improving <NUMBER> challenge studies healthy volunteers expose pathogens <NUMBER> spring clearly within right invite citizens volunteer emergency medical services ems fight pandemic augments personal risks ems workers social value work initial trials moderna sarscov<NUMBER> vaccine accelerated skipping prior animal testing margin safety would added <NUMBER> one major reason permissible risk medical harm volunteers medical studies even personal health care require risk volunteers autonomously consented take risks adult persons legitimize many interventions bodies health normally prohibited simply saying yes full understanding voluntariness present case study would involve multiple tests comprehension risks risk factors serious outcomes among individuals otherwise lowrisk age groups may somewhat clearer time recruitment takes place decision deeply informed voluntary exclusive recruitment participants aged <NUMBER> years although children less likely severe symptoms upon covid<NUMBER> infection <NUMBER> <NUMBER> seeks safeguard quality participants consent wide news coverage widespread fear covid<NUMBER> keep clear exposure virus small matter studies mentioned nonconsenting sex partners fetuses study participants may get infected <NUMBER> <NUMBER> proposed controlled challenge study would avoid risk nonparticipants isolating participants whilst infectious remaining key question deeming human challenge studies ethical pertains risk risks participants even justified social importance trial backed participants willful permission also kept necessary minimum risks fall postulated cap acceptable risk medical trials even ones highest social value participants consent <NUMBER> proposed challenge studies seek contain risk participants <NUMBER> different ways first study recruit healthy patients age groups risk severe disease death following sarscov<NUMBER> infection low second possibility vaccine candidate protect least vaccinated third absence effective vaccine high proportion general population likely naturally infected sarscov<NUMBER> point <NUMBER> including might participate challenge study volunteering artificially infected may hastening event likely occur later months anyhow fourth people especially high baseline risk phase <NUMBER> field e cacy trial assess protection natural infection submission licensure figure <NUMBER> process vaccine licensure controlled human challenge trial large study assess shortterm safety black compared conventional phase <NUMBER> trial route licensure grey submission licensure could occur substantially earlier controlled human challenge trial getting exposed soon trial period recruited eg people residing areas high transmission rates fifth participants would monitored carefully frequently following challenge afforded best available care needed eg guaranteed access stateoftheart facilities health system notwithstanding possibility severe shortages medical care evolving pandemic sixth time vaccine candidates tested therapeutics may approved may reduce participants risk morbidity mortality <NUMBER> reasons mortality morbidity participation notwithstanding net mortality morbidity participation remain low negative novel strain coronavirus forces us consider unconventional approaches believe controlled sarscov<NUMBER> vaccine challenge studies may accelerate time takes evaluate license vaccines hence could make vaccines available sooner widespread rollout approach without risks every week vaccine rollout delayed accompanied many thousands deaths globally importantly challenge studies conducted background competent volunteers informed consent minimization study risks high baseline risks infection participants violate participants individual rights altar emergency response heed individual rights global public health emergency far aware current plan evaluating efficacy covid<NUMBER> vaccines slower phase <NUMBER> trials take time develop operationalize challenge studies suggesting ongoing development vaccines become ready phase <NUMBER> trials must paused period however believe challenge studies could set time vaccines would ready efficacy testing addition use assessing efficacy vaccines human challenge studies may also help evaluate drugs might given either preexposure prophylaxis prevent infection individuals high risk infection postexposure prophylaxis given shortly potential exposure either abort infection prevent occurrence disease challenge studies may also way advancing understanding pathogenesis progression infection disease assess potential human challenge studies speed vaccine development suggest expert group might convened including experience human challenge studies pathogens regulators vaccine trialists ethicists potential participants relevant funding agencies plan studies might taken forward ethically expeditiously outbreak coronavirus disease <NUMBER> covid<NUMBER> become global health emergency pandemic scale covid<NUMBER> severe respiratory illness caused novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> emergence sarscov<NUMBER> first detected wuhan china december <NUMBER> sarscov<NUMBER> infections spread rapidly globally causing enormous distress loss life time though sarscov<NUMBER> infections cause mild symptoms <NUMBER>–<NUMBER> patients develop severe disease requires hospitalization <NUMBER> requiring intensive care united states alone centers disease control prevention reports <NUMBER> million covid<NUMBER> patients <NUMBER> thousand related deaths far worldwide sarscov<NUMBER> infected <NUMBER> million people caused <NUMBER> thousand deaths <NUMBER> june <NUMBER> httpswwwworldometersinfocoronavirus newly emerged strain coronavirus sarscov<NUMBER> rapidly identified causative agent outbreak sarscov<NUMBER> contains genomic sequence closely related <NUMBER> severe acute respiratory syndrome sars coronavirus sarscov <NUMBER> viruses zoonotic thus among rare cases animal human transmission virus infection pandemic potential <NUMBER> common symptoms sarscov<NUMBER> infection include fever cough difficulty breathing severe cases infection result death <NUMBER> pathogenesis sarscov<NUMBER> infection completely clear yet present understanding covid<NUMBER> pathogenesis far based limited number investigated cases sarscov<NUMBER> extrapolations similar coronavirus infections sarscov merscov <NUMBER> probable courses immunopathological events postulated based limited studies covid<NUMBER> along past studies sarscov illustrated figure <NUMBER> transmission infection humans facilitated close contact covid<NUMBER> patients evidenced rapid global spread infection around world short period time sarscov<NUMBER> likely originated bats may amplified intermediate host infecting humans sarscov<NUMBER> enters human body via angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors <NUMBER> current evidence indicates mortality rate sarscov<NUMBER> could approximately <NUMBER> significantly lower sarscov <NUMBER> merscov <NUMBER> <NUMBER> nonetheless sarscov<NUMBER> much higher transmissibility r<NUMBER> <NUMBER>–<NUMBER> sarscov r<NUMBER> <NUMBER>–<NUMBER> merscov r<NUMBER> <NUMBER> <NUMBER> given severity covid<NUMBER> rapid global dispersion sarscov<NUMBER> declaration sarscov<NUMBER> outbreak public health emergency international concern world health organization pressing increasing need new diagnostics vaccines therapeutic options new threat however early phase sarscov<NUMBER> outbreak comprehensive prevention treatment strategies lacking due limited knowledge virus efforts mitigate current covid<NUMBER> pandemic government agencies scientific medical communities worldwide working new approaches reduce infection decrease mortality rates among infected individuals <NUMBER> far neither vaccines directacting antiviral drugs available treatment disease countries high case burden adopted combination largescale testing contact tracing isolation quarantine parallel socialdistancing measures curb covid<NUMBER> pandemic durable cure prevention strategy developed measures slowed spread disease bought us time develop treatment prevention strategies pressing need resilient solution effectively control disease effective strategy control disease develop vaccine many industrial academic organizations racing develop one face many challenges achieve goal unprecedented timeline therapeutic drug options actively explored including many ongoing clinical trials reduce severity disease death rate review provides overview analysis current advances vaccines therapeutics development covid<NUMBER> also discussing major roadblocks challenges face halt emerging virus infection remdesivir promising antiviral drug rna viruses including sarsmerscov cultured cells mice nonhuman primate models <NUMBER> remdesivir adenosine analog activates nucleoside triphosphate metabolites inhibit viral rna polymerases nonhuman primate model intravenous administration remdesivir <NUMBER> mgkg resulted <NUMBER> protection ebola virus infection <NUMBER> remdesivir currently clinical development treatment ebola virus infection <NUMBER> recent doubleblind randomized placebocontrolled trial intravenous administration adults hospitalized covid<NUMBER> remdesivir shortened recovery time patients <NUMBER> though could reduce mortality rate significant extent initial results remdesivirmediated improvement recovery time clinical trials granted fda approval critically ill covid<NUMBER> patients <NUMBER> nonetheless given high mortality despite use remdesivir apparent treatment antiviral drug alone may less likely sufficient combination remidesivir drugs another alternative approach currently explored clinical trials improve patient outcomes covid<NUMBER> since hyperactive immune response leading cytokine storm found associated increased disease severity mortality addition antiinflammatory agent baricitinib remdesivir regimen explored clinical trials nct<NUMBER> examine potential improving mortality outcomes several existing antiviral drugs previously developed used treatments viral diseases also actively investigated possible covid<NUMBER> treatment options already moved clinical trials table <NUMBER> existence evidence support antiviral drugs scant preliminary studies far comprehensive studies drugs build extend arsenal antisarscov<NUMBER> agents chloroquine wellknown drug used treatment malaria certain autoimmune disorders previously shown exhibit antiviral activity hiv zika virus coronavirus <NUMBER> vitro culture condition chloroquine blocks viral infection increasing endosomal ph required viruscell fusion <NUMBER> also prevents terminal glycosylation ace<NUMBER> receptor host cell required viruscell fusion chloroquine mediated block virus replication entry host cell reported many viruses including borna disease virus minute virus mice avian leucosis virus hepatitis virus <NUMBER> promising vitro data suggested chloroquine could one promising drugs treat covid<NUMBER> however lack robust preclinical data potential safety issues drug remained addressed date multiple clinical trials chloroquine conducted either standalone drug combination drugs without randomization placebo controls <NUMBER> significant effect chloroquine improvement disease outcome could ascertained studies reports adverse events observed cases including ventricular arrhythmias qt prolongation cardiac toxicity indicating drug may pose risk covid<NUMBER> patients given methodically right dose <NUMBER> interestingly chloroquine also known affect immune system activity mediating antiinflammatory response might reduce pathology covid<NUMBER> due exaggerated inflammatory response triggers progression disease <NUMBER> however studies yet evaluated use chloroquine prophylaxis covid<NUMBER> future studies better elucidate effective dose schedule administration adverse events along prophylaxis effect disease confirm whether potential controlling covid<NUMBER> structurebased design antiviral drug candidates <NUMBER>a <NUMBER>b aldehyde based indole<NUMBER>carboxamide compounds target sarscov<NUMBER> main protease recently exhibited vitro antiviral activity favorable pharmacokinetic properties vivo suggesting may also promising drug candidates <NUMBER> vivo pharmacokinetics toxicity studies showed encouraging results two new compounds efficacy viral infection still needs validated vivo appropriate experimental infection model forwarding clinical trials detailed review clinical studies many pathogentargeting drugs including remdesivir chloroquine described recent reports <NUMBER> high morbidity sarscov<NUMBER> patients due acute respiratory distress characterized cytokine storm leads increased plasma concentrations proinflammatory cytokines il<NUMBER> <NUMBER> <NUMBER> <NUMBER> gmcsf interferonγinducible protein <NUMBER> mcp<NUMBER> macrophage inflammatory protein<NUMBER> alpha tnfα <NUMBER> tocilizumab monoclonal antibody targets interleukin<NUMBER> receptor demonstrated favorable safety profile promising clinical outcomes tocilizumab suppress cytokine storms improve respiratory function normalize body temperature <NUMBER> however single observation study limited number covid<NUMBER> patients hence may significant bias covid<NUMBER> mortality found associated myocarditis setting ards th<NUMBER> type immune response reported drive severe viral myocarditis <NUMBER> suggests antiil<NUMBER> therapy could another potential approach managing disease severity decreasing mortality related covid<NUMBER>induced myocarditis lowdose steroids prednisolone tacrolimus also shown inhibit proinflammatory cytokines exacerbate lung pathology <NUMBER> given pneumonia secondary deleterious inflammatory process covid<NUMBER> disease progression use prednisolone andtacrolimus severe covid<NUMBER> lung injury patients thus could positive clinical effect clinical trials already underway evaluate efficacy two immunosuppressive drugs decreasing secondary pathological manifestation lung pneumonia covid<NUMBER> patients nct<NUMBER> another hostdirected approach target aceace receptor reninangiotensinaldosterone system raas host cell reduce chances infection hypertension drugs lisinopril ace inhibitor losartan angiotensin ii receptorblocker arbs increase expression ace<NUMBER> receptors may exacerbate viral load cells <NUMBER> however studies suggest ace inhibitors arbs could benefit patients covid<NUMBER> since ace<NUMBER> converts angiotensin ii angiotensin may beneficial vasodilatory antiinflammatory properties though usefulness ace inhibitors arbs uncertain based retrospective cohort studies arb recently approved clinical trials evaluate potential treatment covid<NUMBER> patients <NUMBER> another alternative approach use recombinant human ace<NUMBER> virus may readily bind soluble ace<NUMBER> comparison ace<NUMBER> receptors cell surface approach preventing virus entry cells shown promising preclinical results leading transition clinical trials already <NUMBER> camostat mesilate another potential candidate drug considered hostdirected therapy covid<NUMBER> patients camostat mesilate used primarily treating postoperative reflux esophagitis acute exacerbations chronic pancreatitis could block spread pathogenesis sarscov pathogenic mouse model known inhibit host serine protease tmprss<NUMBER> primes spike protein highly pathogenic human coronaviruses <NUMBER> since sarscov<NUMBER> also dependent host tmprss<NUMBER> <NUMBER> viable target hostdirected therapies based <NUMBER> years safe clinical track record japan efficacy sarscov preclinical studies doubleblind randomized controlled clinical trial repurposing drug covid<NUMBER> already progress nct<NUMBER> convalescent plasma cp passive immunotherapy used improve survival rate patients infectious diseases century <NUMBER> cp administration reduced mortality rates shortened hospital stays patients sars <NUMBER> various studies demonstrate severely ill covid<NUMBER> patients treated cp showed lower mortality rate compared untreated controls <NUMBER> new study reported critically ill covid<NUMBER> patients n <NUMBER> treated cp transfusion demonstrated significantly increased levels neutralizing antibodies depletion viral load <NUMBER> days clinical symptoms paraclinical criteria patients improved within <NUMBER> days <NUMBER> placebocontrolled clinical trials test cp therapy ongoing china nct<NUMBER> larger studies also started usa houston methodist hospital houston texas mount sinai medical center new york new york etc approved us food drug administration covid<NUMBER> treatment <NUMBER> cp covid<NUMBER>recovered patients used treat patients infected sarscov<NUMBER> sarscov<NUMBER>specific igg antibodies received sarscov<NUMBER>recovered patients passively transferred via transfused plasma may neutralize viral particles stimulate complement system encourage viral elimination <NUMBER> results recent clinical trials encouraging <NUMBER> validation results large randomized placebocontrolled clinical trials needed establish effectiveness cp therapy cp dose frequency two criteria may require optimization improve efficacy cp therapy covid<NUMBER> moreover regard selecting cp donor adequate titer igg neutralization antibodies standardized robust donation program needs place make cp therapy viable treatment option covid<NUMBER> early intervention onset symptoms also considered important factor enhancing success rate cp therapy treatment covid<NUMBER> patients based observation better treatment outcome achieved sars patients given cp <NUMBER> days post infection thus underlining significance early time administration therapy transfusionrelated acute lung injury infection enhancement could occur due subneutralizing concentrations antibodies could major drawbacks cp considered course treatment relationship sarscov<NUMBER> rna reduction cp therapy optimal concentration neutralizing antibodies required effective treatment dynamic changes different cytokine treatment key parameters defined narrow gap exists therapeutic option cellbased therapies particularly stem cell therapies become promising therapeutic approach treat various diseases treatment proven difficult decades ago researchers made important observation stem cells including pluripotentmultipotent cells resistant viral infection due expression specific genes interferongammastimulated genes <NUMBER> example direct evidence stem cell protection infection myxoma virus therapeutic oncolytic poxvirus hematopoietic stem cells contain myxoma virus infection cells differentiated human monocytes bcells natural killer cells cannot <NUMBER> recently usa china several countries started stem cell therapybased clinical trials treat sarscov<NUMBER> infection table <NUMBER> even significant progress stem cellbased approaches limited cell sources immunogenicity ethical issues remain major limitations mesenchymal stromal cells mscs received attention due source potential low invasive acquisition procedure high proliferation rate lack ethical concern mscs isolated several tissues eg adipose tissue bone marrow peripheral blood cord blood dental pulp menstrual blood wharton jelly buccal fat pad fetal liver stored future treatment easily expanded clinical volume short amount time safety efficacy thoroughly documented many clinical trials <NUMBER> multiple clinical trials use mscs treat various diseases ongoing far none yet proposed covid<NUMBER> treatment <NUMBER> study investigated effect mscs therapy influenza virus ah<NUMBER>n<NUMBER>infected mice found human mscs reduced influenza virus ah<NUMBER>n<NUMBER>induced acute lung injury increased overall survival <NUMBER> notably sarscov<NUMBER> infections host immune system increases production inflammatory factors inducing cytokine storm results excessive production immune cells cytokines <NUMBER> mscs therapy may inhibit release proinflammatory cytokines owing regenerative properties stem cells may also improve endogenous repair injured tissues figure <NUMBER> mscs secrete multiple growth factors vegf pdfg fgf tgfβ etc regulate endothelial epithelial permeability suppress inflammation enhance tissue repairregeneration <NUMBER> recent studies stem cells’ ability alleviate lung fibrosis also reported critical pathological factor covid<NUMBER> <NUMBER> time mscs also known exhibit strong antimicrobial effects secretion antimicrobial peptides proteins ll<NUMBER> defensins hepcidin lipocalins could benefit reducing viral loads well progression covid<NUMBER> <NUMBER> thus intravenous infusion mscs significant population mscs would naturally live lung could cure covid<NUMBER> via protecting alveolar epithelial cells reclaiming pulmonary microenvironment preventing pulmonary fibrosis salvaging lung dysfunction hypotheses spurred pursuit mscs therapy sarscov<NUMBER> patients recent study demonstrated intravenous administration clinicalgrade human mscs seven severe covid<NUMBER> patients resulted improved functional outcomes observable adverse effects <NUMBER> clinical benefit mscs thus evaluated larger cohort patients future moreover benefit genetically engineered modified mscs also assessed covid<NUMBER> patients genetically engineered modified mscs used treat several diseases cancer myocardial infarction acute liver failure mscs modifications include overexpression cytokines chemically engineered mscs physical preconditioning pharmacological preconditioning <NUMBER> one important limitation approach dependency stem cell banks clinicalgrade mscs limited speed preparation scientific teams also begun investigating prospects cartbased immunotherapy treating covid<NUMBER> cart therapy represents incredibly promising approach reprograming cells expressing synthetic receptor directed specific antigen eliminate virusinfected cells cancer cells control disease progression <NUMBER> cart therapy already revolutionized cancer immunotherapy especially treatment b cell malignancies <NUMBER> apart treatment potential bcell malignancies cart therapies also shown early encouraging results chronic hepatitis b virus hbv infection hiv hbvrelated hepatocellular carcinoma recent studies <NUMBER> success cart therapy viral infections accentuates immense potential infectious diseases well since pathogenspecific cells play pivotal role controlling infections therapy involves extraction cells patienthealthy donor’s bloodstream harvesting expanding cells reprogrammed express chimeric antigen receptor car targeting virusinfected cells figure <NUMBER> therapy could costprohibitive treating types viral infections could viable option covid<NUMBER> since definitive treatment option available disease yet indeed demonstrated cart cells redirected target coronavirus responsible severe acute respiratory syndrome sars <NUMBER> engineered cells sarscovspecific antigen exhibited functional profile comparable sarsspecific memory cd<NUMBER> cells recovered sarscovinfected patients initial evidence suggested cart cells could thus pursued treatment sarscov<NUMBER> nonetheless adoption cart therapy clinical application covid<NUMBER> require managing certain technical obstacles one caveats cart cells stably express pathogenspecific cell receptors could pose risk proliferation mediated excessive killing infected cells could result excessive inflammation tissue injury overcome problem engineering cart cells could done mrna electroporation rather using viral transduction obtain virusspecific cells survive limited time figure <NUMBER> use mrna electroporation shown result transient expression <NUMBER>–<NUMBER> days car thus expected decrease risk offtarget effects <NUMBER> technological adaptation also reduce viral contamination come viral transduction method conventional cart cell engineering transient cart cells could also overcome common cytotoxicity due cytokine storm observed conventional cart therapy cytokine storm one pathological manifestations observed severely ill covid<NUMBER> patients leads increased lung inflammation lymphocytes engineered using transient mrna transfection approach keeps active limited amount time likely minimize potential cytokinestormmediated cytotoxic effects context dosing regimen timing administration cart cells also carefully assessed rule possible cytotoxic effect covid<NUMBER> treatment unarguably best longterm strategy curb scale humanitarian economic impact covid<NUMBER> pandemic develop effective vaccine prevent new infections stop transmission disease scientific community vaccine industry responded urgently epidemic sarscov<NUMBER> support development vaccines covid<NUMBER> demand situation availability multiple vaccine technology platforms also accelerated development many candidate covid<NUMBER> vaccines unprecedented rapidity candidates already entered human clinical testing pipeline vaccines covid<NUMBER> already reached <NUMBER> confirmed active candidate vaccines though exploratory preclinical stages june <NUMBER> <NUMBER> <NUMBER> candidate vaccines made clinical stage represent diverse platforms including mrna dna adenovirallentiviralbacterial vectorbased vaccines inactivated sarscov<NUMBER> <NUMBER> dna mrnabased platforms offer advantage flexibility terms antigen manipulation manufacturing speed dna mrna vaccines allow changing antigen coding gene sequence order address frequent mutations antigenic epitopes <NUMBER> comparing genetic similarity sarscov<NUMBER> sarscov set sarscovderived b cell cell epitopes exactly match sarscov<NUMBER> also identified recently <NUMBER> mutations observed identified epitopes among available sarscov<NUMBER> genetic sequences immune targeting epitopes future vaccine candidates also counteract issue genetic variations target antigen currently licensed dnamrna vaccines use humans vaccines developed platforms demonstrated potent immunity various infectious disease targets cancer experimental animal models <NUMBER> enhanced delivery technologies electroporation liposomes increased efficacy dna vaccines humans shift towards rna vaccine clearly seen recent past noninfectious nonintegrating natural degradation egg cellfree safety major safety advantages mrna vaccines vectorbased dna vaccines <NUMBER> mrna vaccines also found stimulate much broader range innate adaptive immune responses desired covid<NUMBER> phase <NUMBER> clinical trials investigating mrna vaccine sarscov<NUMBER> mrna<NUMBER> developed moderna begun phase <NUMBER> trials scheduled begin soon <NUMBER> adenoviral ad vector vaccines also represent promising modern vaccine platform variety ad vector vaccines reached human clinical trials infectious disease cancer <NUMBER> since firstgeneration adenovirus platforms ad<NUMBER> disadvantage induction adenovirus neutralizing antibodies secondgeneration adenovirus vaccine platform four deletions enabling multiple homologous doses used develop covid<NUMBER> vaccine <NUMBER> specific targeting adenovirus dendritic cells found critical efficacy ad vectorbased vaccine <NUMBER> replicationdeficient feature ad vector vaccines key biologic property excellent safety profile clinical translation far ad vector vaccines also easily grown high titer cell culture thereby facilitating manufacture regulatory approval clinical translation rapid manner <NUMBER> apart ad vector vaccine also allows insertion multiple transgenes including antigen interest also genes enhance response vaccination cansino biologics academy military medical sciences china developed nonreplicating adenovirus serotype <NUMBER> ad<NUMBER> vector carrying gene sarscov<NUMBER> spike protein clinical trials underway wuhan china <NUMBER> university oxford uk phase <NUMBER> clinical trials using chimpanzee adenovirus vaccine chadox<NUMBER> carrying gene sarscov<NUMBER> protein underway <NUMBER> dendritic cellsantigenpresenting cells modified lentiviral vector expresses viral proteins immunemodulatory genes also new vaccine platform evaluated clinical trials currently covid<NUMBER> nct<NUMBER> platform dcsapcs carrying synthetic minigene viral structural proteins polyprotein protease sarscov<NUMBER> within lentiviral vector administered together antigenspecific cytotoxic cells fewer preclinical data public information available platform phase ii clinical trials already underway evaluate anticovid<NUMBER> efficacy lentiviralbased cell vaccines expect see results trials soon studies also suggest vaccines diseases may confer resistance sarscov<NUMBER> two recent reports suggested correlation bacille calmetteguérin bcg antituberculosisvaccinated countries reduced mortality covid<NUMBER> patients <NUMBER> bcg known provide nonspecific protective effects boosting innate immunity treat malignancies bladder cancer melanoma lymphoma leukemia specifically bcg may augment first line immune defense socalled “trained immunity” provide better defense bacterial parasitic viral infection <NUMBER> clinical trials netherlands led dr mihai g netea <NUMBER> nct<NUMBER> australia led dr nigel curtis nct<NUMBER> investigating protection bcg vaccines sarscov<NUMBER> virus ongoing recombinant bcg candidate vaccines shown better protection profile early preclinical clinical studies could potential candidates explore covid<NUMBER> <NUMBER> moreover since immunity bcg vaccine known last <NUMBER>–<NUMBER> years revaccination adults bcg recombinant bcg strains another viable approach consider especially countries bcg given birth curated list vaccine candidates sarscov<NUMBER> multiple journal sources recently moved clinical trials mentioned table <NUMBER> <NUMBER> summary drug repurposing plasma stem cell therapies vaccines pharmaceutical interventions actively explored limit transmission sarscov<NUMBER> infection early clinical priority contain spread infection via diagnostics detect sarscov<NUMBER> infection rapidly accurately vaccine drug prevents future infections another early priority potential sarscov<NUMBER> drug vaccine candidates clinical trials pipeline globally however promising treatment strategies investigated efficacy safety moving forward december <NUMBER> cluster patients pneumonia surfaced wuhan china culprit quickly identified betacoronavirus never reported virus named sarscov<NUMBER> <NUMBER> <NUMBER> march <NUMBER> <NUMBER> <NUMBER> people china confirmed infected pathogen among <NUMBER> people died infection aggressive control measures implemented chinese government severe domestic epidemic seems effectively contained however global outbreak caused <NUMBER> confirmed cases <NUMBER> countries making sarscov<NUMBER> pandemic general public health event stirred worldwide attention sarscov<NUMBER> positivestrand rna virus belongs group betacoronaviruses genome sarscov<NUMBER> approximately <NUMBER> nucleotides long shares <NUMBER> sequence identity sarscov <NUMBER> long orf<NUMBER>ab polyprotein <NUMBER> end encode <NUMBER> <NUMBER> nonstructural proteins <NUMBER> end genome encodes <NUMBER> major structural proteins including spike protein nucleocapsid n protein membrane protein envelope e protein <NUMBER> shown figure <NUMBER> sarscov<NUMBER> binds receptor angiotensin converting enzyme <NUMBER> ace<NUMBER> host cell virus entry subsequent pathogenesis <NUMBER> resulting severe respiratory illness symptoms fever cough shortness breath severe cases fatal <NUMBER> vaccines effective economical means prevent control infectious diseases <NUMBER> development effective vaccine sarscov<NUMBER> infection urgently required far <NUMBER> pharmaceutical companies academic institutions worldwide launched programs vaccine development sarscov<NUMBER> herein summarize recent progress vaccine development worldwide particular candidate antigens adjuvants evaluation models technologies used related research whole cell antigens wca contain elements virus including proteins lipids polysaccharide nucleic acids components wca used developing wholecell killed liveattenuated vaccines <NUMBER> <NUMBER> given complex compositions wca unavoidable face difficulties quality control consistency evaluation far several institutions successfully isolated virus strains sarscov<NUMBER> started wholecell killed liveattenuated vaccine development however research type vaccine requires stringent screening obtaining strains assured low pathogenicity <NUMBER> protein currently promising antigen formulation sarscov<NUMBER> vaccine research first surface exposure thus able directly recognized host immune system <NUMBER> second mediates interaction host cell binding receptor ace<NUMBER> essential subsequent virus entry target cells causing subsequent pathogenicity <NUMBER> <NUMBER> finally homologue proteins already used vaccine development sarscov merscov proved effective <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> monomer protein sarscov<NUMBER> contains <NUMBER> amino acids molecular weight <NUMBER> kda selfassociation naturally assembles protein homotrimer typically similar first class membrane fusion protein class viral fusion protein protein contains two subunits s<NUMBER> s<NUMBER> s<NUMBER> subunit defined two domains termed nterminal domain ntd cterminal domain ctd receptor binding domain rbd located ctd s<NUMBER> subunit contains basic elements required membrane fusion vaccines effective economical means prevent control infectious diseases <NUMBER> development effective vaccine sarscov<NUMBER> infection urgently required far <NUMBER> pharmaceutical companies academic institutions worldwide launched programs vaccine development sarscov<NUMBER> herein summarize recent progress vaccine development worldwide particular candidate antigens adjuvants evaluation models technologies used related research whole cell antigens wca contain elements virus including proteins lipids polysaccharide nucleic acids components wca used developing wholecell killed liveattenuated vaccines <NUMBER> <NUMBER> given complex compositions wca unavoidable face difficulties quality control consistency evaluation far several institutions successfully isolated virus strains sarscov<NUMBER> started wholecell killed liveattenuated vaccine development however research type vaccine requires stringent screening obtaining strains assured low pathogenicity <NUMBER> protein currently promising antigen formulation sarscov<NUMBER> vaccine research first surface exposure thus able directly recognized host immune system <NUMBER> second mediates interaction host cell binding receptor ace<NUMBER> essential subsequent virus entry target cells causing subsequent pathogenicity <NUMBER> <NUMBER> finally homologue proteins already used vaccine development sarscov merscov proved effective <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> monomer protein sarscov<NUMBER> contains <NUMBER> amino acids molecular weight <NUMBER> kda selfassociation naturally assembles protein homotrimer typically similar first class membrane fusion protein class viral fusion protein protein contains two subunits s<NUMBER> s<NUMBER> s<NUMBER> subunit defined two domains termed nterminal domain ntd cterminal domain ctd receptor binding domain rbd located ctd s<NUMBER> subunit contains basic elements required membrane fusion including internal membrane fusion peptide fp two <NUMBER>peptide repeats hr membrane proximal external region mper transmembrane domain tm <NUMBER> recently structure sarscov<NUMBER> trimer prefusion conformation rbd domain complex ace<NUMBER> successfully determined <NUMBER> <NUMBER> provided valuable information vaccine design based protein far potential fragments protein use antigens vaccine development include fulllength protein rbd domain s<NUMBER> subunit ntd fp fulllength proteins likely maintain correct conformation protein capable providing epitopes exhibiting higher immunogenicity pallesen et al <NUMBER> demonstrated higher titer neutralizing antibodies balbc mice immunized recombinant prefusion merscov protein another research confirmed protein produced baculovirus insect cells able assemble nanoparticles mice immunized nanoparticles formulated alum adjuvant produced high titer neutralizing antibodies <NUMBER> muthumani et al <NUMBER> reported dna vaccine encoding merscov protein immunogenic mice camels rhesus macaques animals immunized dna vaccine show reduced typical clinical symptoms including pneumonia infection far clover biopharmaceuticals announced constructed sarscov<NUMBER> protein trimer vaccine strimer using patented trimertag© technology vaccine produced via rapid mammalian cellculture based expression system preclinical safety analysis launched within next <NUMBER> weeks since rbd protein directly interacts ace<NUMBER> receptor host cells rbd immunization induced specific antibodies may block recognition thus effectively prevent invasion virus matter fact sarscov<NUMBER> subunit vaccines currently development use rbd antigen moreover rbd domain also used development sarscov merscov vaccines example studies demonstrated recombinant rbd consists multiple conformational neutralizing epitopes induce high titer neutralizing antibodies sarscov <NUMBER> lan et al <NUMBER> reported rhesus macaques immunized recombinant rbd formulated alum adjuvant could produce neutralizing antibodies association observed mitigation clinical symptoms merscov infection nyon et al <NUMBER> also reported hcd<NUMBER>dpp<NUMBER> transgenic mice immunized rbd fused fc elicited neutralizing antibodies capable protecting merscov infection rbd domain relatively conserved compared s<NUMBER> subunit reported contain multiple conformational neutralizing epitopes <NUMBER> making suitable vaccine development similar rbd nterminal domains ntd protein several coronaviruses reported show carbohydrate receptorbinding activity example ntd spike protein form transmissible gastroenteritis virus tgev reported bind sialic acid via ntd <NUMBER> carbohydratebinding properties ibv m<NUMBER> strain also related ntd protein <NUMBER> thus domain also candidate antigen vaccine development one study reported rntd protein merscov induced potent cellular immunity antigenspecific neutralizing antibodies mice protective viral challenge <NUMBER> report mab binds nterminal domain ntd merscov s<NUMBER> subunit showed efficient neutralizing activity wildtype merscov strain emc<NUMBER> <NUMBER> result showed ntd specific antibodies functional neutralization however genomes coronaviruses highly variable better use antibodies targeting different epitopes avoid immune escape virus although function s<NUMBER>ntd sarscov<NUMBER> elucidated may also involved binding certain receptors also serve candidate antigen s<NUMBER> subunit contains rbd ntd described mainly involved protein binding host receptor also widely used vaccine development wang et al <NUMBER> reported merscov s<NUMBER> protein formulated mf<NUMBER> adjuvant protected hdpp<NUMBER> transgenic mice lethal virus challenge protection correlated well neutralizing antibody titer adney et al <NUMBER> confirmed immunization adjuvanted s<NUMBER> protein reduced delayed virus shedding upper respiratory tract dromedary camels complete protection observed alpaca merscov challenge fp domain s<NUMBER> subunit involved membrane fusion virus also key step viral pathogenicity <NUMBER> therefore may also serve vaccine candidate antigen present tianjin university constructed rbdfp fusion protein high titer antibodies detected mice immunized fusion protein efficacy evaluation n protein abundant protein coronavirus normally highly conserved molecular weight <NUMBER> kda n protein multiple functions including formation nucleocapsids signal transduction virus budding rna replication mrna transcription <NUMBER> protein reported highly antigenic <NUMBER> patients developed sars produced antibodies antigen <NUMBER> dna vaccine encoding sarscov n protein generated strong nspecific humoral cellular immune responses vaccinated c<NUMBER>bl<NUMBER> mice capable significantly reducing titer challenging vaccinia virus <NUMBER> meanwhile researchers reported n protein avian infectious bronchitis virus associated induction ctls correlated decrease clinical signs viral clearance lungs suggesting cellular response essential n protein mediated protection <NUMBER> <NUMBER> contrast another research indicated n protein immunization make significant contribution neutralizing antibody response provided protection infection hamsters <NUMBER> results suggest controversy whether protein could used vaccine development anyhow doubt used marker diagnostic assays due high immunogenicity protein transmembrane glycoprotein molecular weight <NUMBER> kda involved virus assembly protein abundant protein surface sarscov <NUMBER> reported immunization full length protein able elicit efficient neutralizing antibodies sars patients <NUMBER> immunogenic structural analysis also indicated transmembrane domain protein contains cell epitope cluster able induce strong cellular immune response <NUMBER> protein also highly conserved evolution among different species <NUMBER> therefore may used candidate antigen developing sarscov<NUMBER> vaccine compared n protein e protein suitable use immunogen one reason consists <NUMBER> amino acids different coronaviruses channel activity thus immunogenicity limited studies shown sarscov e protein important virulence factor secretion inflammatory factors il<NUMBER>β tnf il<NUMBER> significantly reduced knocking e protein <NUMBER> wholecell killed liveattenuated vaccines present multiple antigenic components host thus potentially induce diverse immunologic effectors pathogen <NUMBER> traditional vaccines mature preparatory technology may become first sarscov<NUMBER> vaccine put clinical applications currently several research institutions started related research chinese centers disease control prevention wuhan institute virology chinese academy sciences zhejiang university several institutions successfully isolated virus strains sarscov<NUMBER> started relevant vaccine development besides codagenix inc announced collaboration serum institute india ltd develop liveattenuated vaccine sarscov<NUMBER> use viral deoptimization synthesize rationally designed liveattenuated vaccines technology starting sequence viral genome allows rapid generation multiple vaccine candidates virus subunit vaccines include one antigens strong immunogenicity capable efficiently stimulating host immune system general type vaccine safer easier produce often requires addition adjuvants elicit strong protective immune response far several institutions initiated programs sarscov<NUMBER> subunit vaccine almost use protein antigens example university queensland developing subunit vaccine based molecular clamp technology <NUMBER> clover biopharmaceuticals inc revealed developing vaccine candidate sarscov<NUMBER> using trimertag technology <NUMBER> trimeric protein subunit vaccine candidate produced via mammalian cell expression system novavax inc announced produced multiple nanoparticle vaccine candidates based protein assessing efficacy animal models identify optimal vaccine candidate human testing besides johnson johnson pasteur institute chongqing zhifei biological products co ltd also started subunit vaccine development sarscov<NUMBER> development maturing mrna synthesis modification delivery technology research mrna vaccine regained attention last two decades mrna vaccines represent promising alternative conventional vaccine approaches high potency short production cycles lowcost manufacturing safe administration <NUMBER> procedures mrna vaccine development include selection antigens optimization sequences screening modified nucleotides optimization delivery systems evaluation immune response safety test <NUMBER> particularly mrna vaccine yet entered market thus may take time quality standards establishment safety evaluation far sarscov<NUMBER> mrna vaccine mrna<NUMBER> encoding protein developed moderna launched animal experiments clinical batch production expected clinical trials conducted <NUMBER> healthy volunteers end april fudan university collaboration shanghai jiaotong university bluebird biopharmaceutical company develop sarscov<NUMBER> mrna vaccine using two different strategies first use mrna express sarscov<NUMBER> protein rbd domain efficacy vaccine evaluation mice second use mrna express viruslike particles vivo addition german biopharmaceutical company curevac ag stermirna therapeutics bdgene therapeutics guanhao biotech zy therapeutics inc cansino biologics inc baylor college medicine university texas tongji university also announced progress mrna vaccine development sarscov<NUMBER> dna vaccines typically comprised plasmid dna molecules encode one antigens superior mrna vaccines formulations needed stability delivery efficiency nevertheless need enter nucleus may bring risk vctor integration mutations host genome <NUMBER> far two sarscov<NUMBER> dna vaccines development inovio pharmaceuticals developed dna vaccine candidate termed ino<NUMBER> preclinical studies soon enter phase clinical trials applied dna sciences subsidiary linearx takis biotech collaborated development linear dna vaccine candidate sarscov<NUMBER> preclinical studies live vector vaccines live viruses vector express heterologous antigens characterized combining strong immunogenicity live attenuated vaccines safety subunit vaccines widely used induce cellular immunity vivo related sarscov<NUMBER> vaccine research carried following institutions houstonbased greffex inc completed construction sarscov<NUMBER> adenovirus vector vaccine greffex vector platform moved animal testing tonix pharmaceuticals announced research develop potential sarscov<NUMBER> vaccine based horsepox virus tnx<NUMBER> johnson johnson adopted advac ® adenoviral vector platform <NUMBER> vaccine development vaccines contain certain fragments intact antigens usually prepared chemical synthesis techniques easier preparation quality control however low molecular weight structural complexity vaccines usually result low immunogenicity thus structural modifications delivery systems adjuvants additionally required formulation <NUMBER> currently researchers hong kong university science technology screened set b cell epitopes n proteins sarscov epitopes highly conserved sarscov<NUMBER> may help guide experimental efforts towards development sarscov<NUMBER> vaccines <NUMBER> generex biotechnology announced working thirdparty groups generate peptide vaccines pandemic viruses using patented nugenerex immunooncology iikey technology uses synthetic peptides mimic essential protein regions virus chemically linked <NUMBER>amino acid iikey ensure robust immune system activation animal models essential preclinical evaluation efficacy vaccines sarscov<NUMBER> new pathogen animal models currently available recently one study used hace<NUMBER> transgenic mice infected sarscov<NUMBER> study pathogenicity virus hace<NUMBER> transgenic mice infected sarscov<NUMBER> resulted weight loss virus replication lung tissue typical histopathology interstitial pneumonia observed viral antigens detected bronchial epithelial cells alveolar macrophages alveolar epithelia mouse model may facilitate development therapeutic drugs vaccines sarscov<NUMBER> <NUMBER> addition institute zoology chinese academy sciences reported observed similar symptoms human infections primate macaques including changes viral load computed tomography ct images lungs model validated applied drug screening functional evaluation highly contagious pathogenicity brings great difficulties sarscov<NUMBER>related research viruslike particles vlps multiprotein structures mimic organization conformation authentic native viruses lack viral genome <NUMBER> safe effective tolls widely used studying pathogenic mechanisms virus infection efficacy evaluation drugs vaccines drug delivery <NUMBER> example corresponding vlps already used determine neutralizing antibodies induced sarscov h<NUMBER>n<NUMBER> vaccines <NUMBER> <NUMBER> absence animal models vlps provide alternative way evaluate efficacy sarscov<NUMBER> vaccines addition live attenuated vaccines live vector vaccines adjuvants required enhance immune response development types vaccines order accelerate development sarscov<NUMBER> vaccine preferred adjuvant widely used marketable vaccines including <NUMBER> classic aluminum adjuvant aluminum adjuvants enhances immune response facilitating phagocytosis slowing diffusion antigens injection site efficiently stimulate th<NUMBER> immune response upon injection <NUMBER> <NUMBER> mf<NUMBER> mf<NUMBER> oilinwater emulsion composed tween <NUMBER> sorbitol trioleate squalene already used flu vaccines europe united states mechanism mf<NUMBER> create transient immune environment injection site recruit immune cells induce antigenspecific immune responses <NUMBER> <NUMBER> adjuvant system series adjuvants series adjuvants developed glaxosmithkline gsk including as<NUMBER> as<NUMBER> as<NUMBER> as<NUMBER> among as<NUMBER> liposome adjuvant containing <NUMBER>odesacyl<NUMBER>monophosphoryl lipid mpl saponin qs<NUMBER> <NUMBER> used malaria vaccines <NUMBER> as<NUMBER> oilinwater emulsifier containing mpl qs<NUMBER> <NUMBER> as<NUMBER> oilinwater emulsifier containing alphatocopherol squalene tween <NUMBER> used influenza vaccines <NUMBER> as<NUMBER> aluminum adjuvant containing mpl used human papilloma virus vaccine hepatitis b virus vaccine <NUMBER> currently gsk announced would make established pandemic vaccine adjuvant platform technology available enhance development effective vaccine sarscov<NUMBER> agreements reached clover biopharmaceutical inc university queensland australia adjuvants able regulate type immune response optimal adjuvant selected according design vaccine order induce efficient immune response combination different types adjuvants could applied improve immune efficacy safety important issue taken consideration drug vaccine development scientists urge rush deploy covid<NUMBER> vaccines drugs without sufficient safety guarantees <NUMBER> example although protein promising candidate antigen vaccine development also exhibits biological activity besides receptor binding membrane fusion previous studies demonstrated fulllength protein cause severe liver damage may result enhanced infection <NUMBER> defined antibodydependent enhancement ade <NUMBER> effect may probably caused protein specific antibodies <NUMBER> <NUMBER> report enhanced virulence mediated murine coronavirus mouse hepatitis virus strain jhm associated glycine residue <NUMBER> spike glycoprotein mutation may contribute spreading within central nervous system cns <NUMBER> however clear domains key amino acids protein sarscov<NUMBER> involved liver damage therefore fulllength protein may face safety issues used antigen solve problem basic research carried structure function protein mutants key residues may introduced antigen design recently phase clinical trial launched assess safety immunogenicity mrna<NUMBER> developed moderna clinicaltrialsgov identifier nct<NUMBER> however type vaccines approved use human beings thus safety guaranteed assessments carried clinical trials know little sarscov<NUMBER> questions answers newly identified virus including etiology epidemiology structural basis mechanism pathogenesis pathological immune response etc particularly cellular humoral immune response host response virus infection essential vaccine design remains unclear aspects need addressed basic research near future successful vaccine development recently countries rd institutions announced program vaccine development sarscov<NUMBER> however vaccine development rules successful sarscov<NUMBER> vaccine could achieved overnight vaccine design preparation undergo efficacy safety evaluation quality standard establishment entering clinical trials generally three phases clinical trials carried evaluate safety immunogenicity efficacy vaccine typically development novel vaccines generally takes <NUMBER> years success rate less <NUMBER> even vaccine enters clinical trials past <NUMBER> years us fda approved total nearly <NUMBER> clinical trials vaccine applications less <NUMBER> vaccines approved market although development manufacture marketing vaccines supervised strict regulations sake human health must lay solid foundation conduct research accordance scientific laws recently report <NUMBER> sites mutations identified across genome <NUMBER> sequenced strains sarscov<NUMBER> virus evolved two subtypes termed l subtype study also indicated two subtypes showed great differences geographical distribution transmission ability severity disease add difficulties vaccine design <NUMBER> currently clinical trials testing different drugs ongoing possibly allow identification potential drug treat disease associated sarscov<NUMBER> rapid development application vaccine powerful means prevent global epidemic covid<NUMBER> although vaccine development slower spreading epidemic still necessary urgent firstly epidemic still spreading world confirmed cases identified inflection point yet reached yet secondly sarscov<NUMBER> infection may become flulike seasonal disease coexist human beings long time <NUMBER> pointed sarscov<NUMBER> identified <NUMBER> months related research pathogenic characteristics mechanisms novel coronavirus begun thus data information collected also limited need continuously accumulated documented review also provides authors opinions hope could provide useful information colleagues authors declare conflict interest new type coronavirus identified causative agent underlying respiratory syndrome recently emerged middle east <NUMBER> <NUMBER> coronavirus study group international committee taxonomy viruses proposed new name novel betacoronavirus middle east respiratory syndrome coronavirus merscov several middle eastern countries affected emerging merscov epidemic including jordan qatar oman saudi arabia united arab emirates tunisia reported three confirmed cases human infection france italy germany united kingdom greece netherlands usa also reported cases directly indirectly connected middle east eight hundred thirtyseven cases merscov infection confirmed date including <NUMBER> deaths <NUMBER> rapid accumulation information sequences <NUMBER> merscov genome structure proteins open exciting possibilities development candidate vaccines others recently provided evidence dromedary camels reservoir merscov virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov spike proteinbinding antibodies virusneutralizing antibodies reported dromedary camels different regions including qatar saudi arabia oman egypt moreover merscov dromedary camels farm qatar linked two virologically confirmed human cases infection october <NUMBER> <NUMBER> one five human cases reported caused exposure animals <NUMBER> <NUMBER> full merscov genome isolated qatari dromedary camel highly similar human englandqatar <NUMBER> virus isolated <NUMBER> efficiently httpdxdoiorg<NUMBER>jvaccine<NUMBER> <NUMBER>x© <NUMBER> elsevier ltd rights reserved replicated human cells using human dpp<NUMBER> entry receptor providing evidence zoonotic potential dromedary merscov <NUMBER> although cannot conclude whether people infected camels vice versa yet another source responsible increasing evidence indicates camels represent important link human infections merscov intensive vaccine control riskreduction targeting dromedary camels might effective eliminating virus human population coronavirus spike protein class fusion protein cellular entry virus demonstrated mediated protein receptor binding domain rbd nterminal subunit s<NUMBER> fusion peptide cterminal subunit s<NUMBER> <NUMBER> <NUMBER> betacoronaviruses protein shown main antigenic component responsible inducing high titers neutralizing antibodies andor protective immunity infection patients recovered sars <NUMBER> <NUMBER> response levels correlated well disease outcomes <NUMBER> <NUMBER> protein therefore selected important target vaccine development <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> recent work shows modified vaccinia virus ankara expressing protein merscov elicits high titers sspecific neutralizing antibodies mice <NUMBER> adenovirus <NUMBER> ad<NUMBER>vectored candidate vaccines induce potent protective immune responses several pathogens humans variety animals <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> although trial candidate dnarad<NUMBER> hiv<NUMBER> preventive vaccine showed lack efficacy <NUMBER> high prevalence preexisting antiad<NUMBER> immunity may major limitation <NUMBER> humans replicationdefective adenovirus vaccines among attractive vectors veterinary vaccine development given relative speed low cost development production adenoviruses infect host airway epithelium replicate mucosal tissues respiratory tracts <NUMBER> ability elicit mucosal immune responses adenoviruses could attractive vector inducing merscovspecific immunity dromedary camels putative animal reservoir interestingly sera antibodies adenovirus type <NUMBER> detected <NUMBER> dromedaries nigeria <NUMBER> <NUMBER> <NUMBER> camels egypt <NUMBER> occurrence adenovirus type <NUMBER> respiratory infections camels studied sudan <NUMBER> seroprevalence detected <NUMBER> describe development recombinant type <NUMBER> adenoviral vector expressing codonoptimized merss merss<NUMBER> ad<NUMBER>merss ad<NUMBER>merss<NUMBER> vaccine candidates investigate ability induce neutralizing immune responses mice moreover demonstrate feasibility using human adenovirus <NUMBER> based vaccine dromedary camels evaluated infectivity presence antiadenovirus <NUMBER>neutralizing antibodies animal species merss genbank jx<NUMBER> gene codonoptimized optimal expression mammalian cells using upgene codon optimization algorithm <NUMBER> synthesized genscript padmerss generated subcloning codonoptimized merss gene shuttle vector padlox genbank u<NUMBER> salinoti sites coding sequence merss<NUMBER> amino acids <NUMBER> <NUMBER> fulllength mers according genebank database amplified polymerase chain reaction inserted shuttle vector fig <NUMBER>a subsequently replicationdefective human adenovirus serotype <NUMBER> designated ad<NUMBER>merss ad<NUMBER>merss<NUMBER> generated loxp homologous recombination purified stored described previously <NUMBER> <NUMBER> <NUMBER> detection merss protein expression a<NUMBER> cells human lung adenocarcinoma epithelial cell line infected five multiplicity infection moi ad <NUMBER> ad<NUMBER>merss ad<NUMBER>merss<NUMBER> cells fixed cold methanol <NUMBER> h following infection incubated pooled mouse sera adenoviral vaccines washing cells incubated horseradish peroxidasecoupled antimouse secondary antibody invitrogen merss protein visualized avidinbiotin complex solution vector bablc mice inoculated intramuscularly im <NUMBER> × <NUMBER> <NUMBER> viral particles vp ad<NUMBER>merss ad<NUMBER>merss<NUMBER> ad <NUMBER> control respectively three weeks primary immunization mice boosted intranasally dose respective immunogens immunization study protocol approved university pittsburgh institutional animal care use committee followed three weeks prime immunization pooled sera obtained mice screened merssspecific antibodies using fluorescenceactivated cell sorter facs analysis human embryonic kidney hek <NUMBER> cells transfected either padmerss pad control using lipofectamine <NUMBER> invitrogen <NUMBER> h <NUMBER> • c cells harvested trypsinized washed phosphate buffered saline pbs stained mouse antiserum ad<NUMBER>merss ad<NUMBER>merss<NUMBER> ad <NUMBER> followed peconjugated antimouse secondary antibody jackson immuno research data acquisition analysis performed using lsrii bd flowjo tree star software sera animals collected every week tested proteinspecific igg<NUMBER> igg<NUMBER>a conventional enzymelinked immunosorbent assay elisa briefly a<NUMBER> cells infected <NUMBER> moi ad<NUMBER>merss<NUMBER> six hours infection cells washed three times pbs serumfree media added cells incubated <NUMBER> h elisa plates coated supernatant a<NUMBER> cells infected ad<NUMBER>merss<NUMBER> overnight <NUMBER> • c carbonate coating buffer ph <NUMBER> blocked pbs containing <NUMBER> tween <NUMBER> pbst <NUMBER> bovine serum albumin bsa <NUMBER> h mouse sera diluted <NUMBER> igg<NUMBER>a <NUMBER> igg<NUMBER> elisa pbst <NUMBER> bsa incubated <NUMBER> h plates washed biotinconjugated igg<NUMBER> igg<NUMBER>a <NUMBER> ebioscience avidinhorseradish peroxidase hrp <NUMBER> pharmingen added well incubated <NUMBER> h plates washed three times developed <NUMBER> <NUMBER> tetramethylbenzidine reaction stopped <NUMBER> h <NUMBER> <NUMBER> absorbance <NUMBER> nm determined using elisa reader biotek instruments stocks merscov produced preparing sixth passage merscov emc isolate vero cells cells inoculated virus dulbeccos modified eagle medium biowhittaker supplemented <NUMBER> serum <NUMBER> uml penicillin <NUMBER> mgml streptomycin <NUMBER> mm glutamine inoculation cultures incubated <NUMBER> • c co <NUMBER> incubator three days inoculation supernatant vero cells collected tested merscov neutralization activity sera derived mice immunized ad<NUMBER>merss ad<NUMBER>merss<NUMBER> ad <NUMBER> vaccines mouse sera obtained retroorbital plexus weekly six weeks tested ability neutralize merscov emc isolate briefly virus <NUMBER> pfu premixed <NUMBER> serial dilutions sera animal groups prior inoculation onto vero cells viral infection monitored occurrence cytopathic effect <NUMBER> h postinfection virus neutralization titers vnts determined highest serum dilutions showed full protection cytopathic effect merscov tested adenovirus neutralization activity sera camels <NUMBER> humans qatar healthy individuals procedures performed compliance relevant laws institutional guidelines briefly adenovirus expressing green fluorescent protein gfp <NUMBER> pfu premixed <NUMBER> serial dilutions sera prior inoculation onto a<NUMBER> cells viral infection monitored detection gfppositive cells <NUMBER> h vnts determined highest serum dilution showed <NUMBER> reduction number adenovirusinfected cells freshly isolated camel human peripheral blood mononuclear cells pbmcs seeded <NUMBER> × <NUMBER> <NUMBER> cellsml <NUMBER>well plate incubated <NUMBER> h <NUMBER> • c next cells infected <NUMBER> <NUMBER> vp ad<NUMBER>egfpml complete medium incubated <NUMBER> h <NUMBER> • c <NUMBER> co <NUMBER> adenovirusinfected cells examined enhanced gfp expression using inverted fluorescent microscope olympus percentage ad<NUMBER>egfpinfected cells analyzed measurement mean fluorescence signal facs bd biosciences egfpexpressing cells monocyte populations analyzed gating using flowjo software dromedary camel fibroblast cell line dubca atcc ® crl<NUMBER> tm cells seeded <NUMBER> × <NUMBER> <NUMBER> cellswell <NUMBER>well plate infected <NUMBER> moi ad<NUMBER>egfp <NUMBER> h infection flow cytometry cells analyzed using lsrii flowjo software statistical analysis oneway analysis variance tukeys test performed using prism software san diego california usa results considered statistically significant p value <NUMBER> symbols used indicated p values <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively e<NUMBER>e<NUMBER> deleted human type <NUMBER> adenoviral vector used insert fulllength extracellular domain s<NUMBER> codonoptimized merss open reading frames generate ad<NUMBER>merss ad<NUMBER>merss<NUMBER> adenoviral vectors fig <NUMBER>a detect mers protein expression recombinant adenoviral candidate vaccines a<NUMBER> cells infected ad <NUMBER> ad<NUMBER>merss ad<NUMBER>merss<NUMBER> incubated pooled day <NUMBER> sera admers control immunized mice immunocytochemical analysis showed expression mers protein a<NUMBER> cells infected either ad<NUMBER>merss ad<NUMBER>merss<NUMBER> expression detected mock ad <NUMBER>infected cells sets infected cells stained pooled sera mice immunized ad <NUMBER> data shown furthermore cells transduced ad<NUMBER>encoding fulllength merss showed plaquelike structure may resulted syncytium formation due mers full length protein expression soluble form mers s<NUMBER> protein detected intracellularly presumably secretion showed syncytium formation fig <NUMBER>b ad<NUMBER>merssand ad<NUMBER>merss<NUMBER>immunized mice developed merssspecific antibodies measured reactivity a<NUMBER> cells transfected pad using flow cytometry specific antibody response detected serum samples control animals inoculated ad <NUMBER> preimmunized naïve mouse sera fig <NUMBER> specific response slightly higher mice immunized ad<NUMBER>merss mice immunized ad<NUMBER>merss<NUMBER> <NUMBER> vs <NUMBER> positive cells data suggest adenoviral vaccines expressing merss merss<NUMBER> able induce sspecific antibodies sera mice collected every week boosting <NUMBER> × <NUMBER> <NUMBER> vp ad<NUMBER>merss ad<NUMBER>merss<NUMBER> control ad <NUMBER> respectively tested proteinspecific igg<NUMBER>a igg<NUMBER> immunoglobulin isotypes indicating th<NUMBER>or th<NUMBER>like response respectively elisa igg<NUMBER> igg<NUMBER>a detected soon one week first immunization induction merssspecific igg<NUMBER> igg<NUMBER>a antibodies comparable immunized groups shown fig <NUMBER>a significantly different igg<NUMBER> responses th<NUMBER> observed sera mice vaccinated ad<NUMBER>merss<NUMBER> p <NUMBER> week <NUMBER> p <NUMBER> weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> ad<NUMBER>merss compared sera mice vaccinated ad <NUMBER> fact igg<NUMBER> levels sera mice vaccinated ad<NUMBER>merss showed less significant difference p <NUMBER> weeks <NUMBER> <NUMBER> <NUMBER> p <NUMBER> week <NUMBER> <NUMBER> contrast highly significant difference igg<NUMBER>a response th<NUMBER> observed sera mice vaccinated ad<NUMBER>merss ad<NUMBER>merss<NUMBER> p <NUMBER> weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> fig <NUMBER>b interestingly merss induced earlier igg<NUMBER>a response merss<NUMBER> p <NUMBER> vs significance week <NUMBER> igg<NUMBER>a titers significantly higher week <NUMBER> p <NUMBER> week <NUMBER> merss s<NUMBER> specific serum antibody responses could detected within seven week period mice immunized control adenovirus ad <NUMBER> data indicate ad<NUMBER>merss ad<NUMBER>merss<NUMBER> induce th<NUMBER> th<NUMBER> immune responses mouse sera also tested ability neutralize merscov emc isolate even single immunization adenoviralbased mers vaccines induced detectable levels merscovneutralizing antibodies animals tested week <NUMBER> booster immunization animals developed robust levels neutralizing antibodies control animals inoculated ad <NUMBER> fig <NUMBER> mice immunized ad<NUMBER>merss<NUMBER> highest neutralizing titers observed compared mice immunized ad<NUMBER>merss although significant differences groups noted result might suggest ad<NUMBER>merss<NUMBER> expressing secreted proteins induced stronger th<NUMBER>polarized response led better antibodymediated neutralizing activity compared ad<NUMBER>merss fig <NUMBER>a merss<NUMBER> gene encoding soluble form <NUMBER> designated shown diagram positions rbd small dots transmembrane domain stripes indicated divided two subdomains s<NUMBER> s<NUMBER> position <NUMBER> <NUMBER> vector used generate recombinant replicationdeficient adenoviruses homologous recombination adenoviral genomic dna b detection merss protein immunocytochemical staining a<NUMBER> cells infected ad<NUMBER>merss ad<NUMBER>merss<NUMBER> <NUMBER> moi using sera mice obtained three weeks second ad<NUMBER>merss<NUMBER> boost negative control mock ad <NUMBER>infected cells treated notably one main limitations use adenoviralbased vaccine humans would presence antiadenoviral neutralizing immunity large percentage camel populations thus demonstrate potential proposed use ad<NUMBER>mers candidate vaccines deployed veterinary vaccine dromedary camels evaluated presence antihuman adenovirus type <NUMBER> neutralizing antibodies species shown fig <NUMBER> neutralization detected <NUMBER> sera dromedary camels encouraging first indication potential candidate vaccine dromedary camels provide evidence potential use ad<NUMBER>merss<NUMBER> vaccine dromedary camels determined susceptibility dromedary camel cells infected human adenovirus serotype <NUMBER> human dromedary camel pbmc cells transduced recombinant adenovirus expressing egfp evaluated flow cytometry analysis egfp expression shown fig <NUMBER> human well dromedary camel pbmcs successfully infected ad<NUMBER>egfp moreover large percentage dromedary camel fibroblast cell line dubca infected ad<NUMBER>egfp indicating human adenovirus type <NUMBER> indeed efficiently infect camel cells fig <NUMBER>e f <NUMBER> characterization merss<NUMBER>specific immune responses induced adenoviral vector vaccines balbc mice immunized intramuscularly <NUMBER> × <NUMBER> <NUMBER> viral particles ad <NUMBER> c ad<NUMBER>merss ad<NUMBER>merss<NUMBER> s<NUMBER> respectively boosted intranasally amount virus three weeks later merss<NUMBER>specific igg<NUMBER> igg<NUMBER>a b antibody levels measured indicated time points elisa statically significant differences tukeys test marked bars asterisks p <NUMBER> p <NUMBER> p <NUMBER> p <NUMBER> ad<NUMBER>merss<NUMBER> c respectively described fig <NUMBER> merscovneutralizing titers vnts measured every week primary immunization using vero cells determining highest dilution inhibiting merscov infection <NUMBER> fig <NUMBER> presence antiadenovirus type <NUMBER>neutralizing immunity dromedary camel sera twelve human <NUMBER> dromedary camel sera tested presence antiadenovirus neutralizing antibodies using standard adenoviral neutralization assay results show adenoviralbased vaccine expresses fulllength s<NUMBER> subunits protein induce merscovspecific neutralizing antibody responses mice important demonstrate whether dromedary camels vaccinated candidate vaccines convalescing merscov infection similar responses protected merscov challenge since may indicate whether vaccineinduced responses indeed protective future use ad<NUMBER>merss vaccine veterinary vaccine dromedary camels would possible previous studies shown rbds sarscov presenting s<NUMBER> subunit strongly react antisera sars patients convalescent phase depletion rbdspecific antibodies sars patients results significant elimination neutralizing activity <NUMBER> rbd main domain induces neutralizing antibody tcell immune responses sarscov infection <NUMBER> truncated rbd merscov protein recently reported potently inhibit viral infection induce strong neutralizing antibody responses <NUMBER> <NUMBER> sarscov s<NUMBER> neither s<NUMBER> structural proteins induce apoptosis vero e<NUMBER> cells <NUMBER> <NUMBER> histopathological changes observed various tissues rats immunized recombinant adenovirus containing truncated s<NUMBER> fragment sarscov <NUMBER> contrast vaccination recombinant modified mva expressing sarscov protein associated enhanced hepatitis challenge sarscov <NUMBER> <NUMBER> sarscov shown infect hepatocytes cause hepatitis human cases <NUMBER> <NUMBER> <NUMBER> raising concerns safety vaccine contains fulllength sarscov protein causal relationship induction hepatitis fulllength nature protein could conclusively demonstrated presumed s<NUMBER> gene less risk spontaneous recombination wild type virus following generation new virus types thus believe s<NUMBER>expressing merscov vaccine would preferable vaccine candidate format however alternative antigen format entire sectodomain rbd domain could evaluated comparison since capacity immunization strategy protect infection require challenge tests clinically relevant merscov disease animal models dromedary camels establishment model also important exclude potential vaccineinduced immunopathology seen feline infectious peritonitis virus model <NUMBER> <NUMBER> end mouse model merscov infection generated prior transduction animals adenoviral vector expressing human hostcell receptor dipeptidyl peptidase <NUMBER> hdpp<NUMBER> recently reported <NUMBER> mouse model also considered future evaluation protective efficacy adenovirusbased vaccines investigations necessary evaluate mucosal immunity ultimate protective efficacy ad<NUMBER>merss ad<NUMBER>merss<NUMBER> dromedary camels proper animal models results demonstrate recombinant adenoviruses encoding merss antigens may protective vaccine candidates safe profile moreover also investigated present study infectivity adenovirus type <NUMBER> dromedary camel cells presence antiadenovirus type <NUMBER> neutralizing antibodies limited set dromedary camel sera altogether presented studies support exploration ad<NUMBER>mers vaccines target animal reservoir reducing risk human exposure merscov since middecember <NUMBER> early february <NUMBER> <NUMBER> novel coronavirus <NUMBER>ncov originating wuhan hubei province china infected <NUMBER> laboratoryconfirmed cases across <NUMBER> countries <NUMBER> deaths casefatality rate <NUMBER> <NUMBER> cases deaths china <NUMBER> based initial reported surge cases wuhan majority males median age <NUMBER> years linked huanan seafood wholesale market <NUMBER> reported cases similar symptoms onset illness fever cough myalgia fatigue cases developed pneumonia severe even fatal respiratory diseases acute respiratory distress syndrome <NUMBER> <NUMBER> novel coronavirus <NUMBER>ncov betacoronavirus forms clade within subgenus sarbecovirus orthocoronavirinae subfamily <NUMBER> severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov also betacoronaviruses zoonotic origin linked potential fatal illness outbreaks <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> based current evidence pathogenicity <NUMBER>ncov <NUMBER> significantly lower sarscov <NUMBER> merscov <NUMBER> <NUMBER> however <NUMBER>ncov potentially higher transmissibility r <NUMBER> <NUMBER> sarscov r <NUMBER> <NUMBER> merscov r <NUMBER> <NUMBER> <NUMBER> possible expansion <NUMBER>ncov globally <NUMBER> declaration <NUMBER>ncov outbreak public health emergency international concern world health organization urgent need rapid diagnostics vaccines therapeutics detect prevent contain <NUMBER>ncov promptly however currently lack understanding available early phase <NUMBER>ncov outbreak systematic review describes assesses potential rapid diagnostics vaccines therapeutics <NUMBER>ncov based part developments merscov sarscov systematic search carried three major electronic databases pubmed embase cochrane library identify published studies examining diagnosis therapeutic drugs vaccines severe acute respiratory syndrome sars middle east respiratory syndrome mers <NUMBER> novel coronavirus <NUMBER>ncov accordance preferred reporting items systematic reviews metaanalyses prisma guidelines two independent reviewers focusing sars mers <NUMBER>ncov respectively third independent reviewer engaged resolve conflicting article interest used key words sars coronavirus mers <NUMBER> novel coronavirus wuhan virus identify diseases search strategy systematic searches diagnosis therapeutic drugs vaccines carried independently key words drug therapy vaccine diagnosis point care testing rapid diagnostic test used conjunction disease key words respective searches examples search strings found table s<NUMBER> searched randomized controlled trials rcts validation trials diagnostics test published english measured sensitivity andor specificity rapid diagnostic test pointofcare testing kit b impact drug therapy c vaccine efficacy either diseases date restriction applied <NUMBER>ncov searched vitro animal human studies published english <NUMBER> december <NUMBER> <NUMBER> february <NUMBER> outcomes interest addition reviewed references retrieved articles order identify additional studies reports retrieved initial searches studies examined mechanisms diagnostic tests drug therapy vaccine efficacy sars mers <NUMBER>ncov excluded google search <NUMBER>ncov diagnostics <NUMBER> february <NUMBER> table s<NUMBER> yielded five webpage links government international bodies official information guidelines europe cdc us cdc us fda three webpage links diagnostic protocols scientific commentaries five webpage links market news press releases six protocols diagnostics using reverse transcriptase polymerase chain reaction rtpcr six countries published whos website <NUMBER> google search <NUMBER>ncov vaccines yielded <NUMBER> relevant articles emergence <NUMBER>ncov real time rtpcr remains primary means diagnosing new virus strain among many diagnostic platforms available <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> table s<NUMBER> among <NUMBER> diagnostics studies selected one study discussed use rtpcr diagnosing patients <NUMBER>ncov <NUMBER> table <NUMBER> period type specimen collected rtpcr play important role diagnosis <NUMBER>ncov found respiratory specimens positive virus serum negative early period also suggested early days illness patients high levels virus despite mild symptoms apart commonly used rtpcr diagnosing merscov four studies identified various diagnostic methods reverse transcription loopmediated isothermal amplification rtlamp rtinsulated isothermal pcr rtiipcr onestep rrtpcr assay based specific taqman probes rtlamp similar sensitivity real time rtpcr also highly specific used detect merscov comparable usual diagnostic tests rapid simple convenient likewise rtiipcr onestep rrtpcr assay also shown similar sensitivity high specificity mercov lastly one study focused validation six commercial real rtpcr kits high accuracy although real time rtpcr primary method diagnosing merscov high levels pcr inhibition may hinder pcr sensitivity table <NUMBER> eleven studies focus sarscov diagnostic testing table <NUMBER> papers described diagnostic methods detect virus majority using molecular testing diagnosis comparison molecular test ie rtpcr serological test ie elisa showed molecular test better sensitivity specificity hence enhancements current molecular test conducted improve diagnosis studies looked using nested pcr include preamplification step incorporating n gene additional sensitive molecular marker improve sensitivity table <NUMBER> addition seven potential rapid diagnostic kits <NUMBER> january <NUMBER> table <NUMBER> available market <NUMBER>ncov six research purposes one kit beijing genome institute bgi approved use clinical setting rapid diagnosis kits rtpcr two kits bgi china veredus singapore capability detect multiple pathogens using sequencing microarray technologies respectively limit detection enhanced realtime pcr method <NUMBER> <NUMBER> fold higher standard realtime pcr assay <NUMBER> <NUMBER> fold higher conventional pcr methods clinical aspect enhanced realtime pcr method able detect <NUMBER> cases sarscov positive samples confirmed assay <NUMBER> sarscov detected <NUMBER> <NUMBER> <NUMBER> samples sars patients day <NUMBER> day <NUMBER> illness none <NUMBER> samples healthy controls <NUMBER> • real time pcr threshold sensitivity <NUMBER> genome equivalents per reaction good reproducibility interassay coefficients variation <NUMBER> <NUMBER> • <NUMBER> specimens <NUMBER> patients positive viral load range <NUMBER> <NUMBER> genome equivalentsml realtime rtpcr reaction sensitive nested pcr reaction detection limit nested pcr reaction <NUMBER> <NUMBER> genome equivalents standard cdna control <NUMBER> realtime reversetranscription pcr rrtpcr rnadependent rna polymerase rdrp open reading frame <NUMBER>a orf<NUMBER>a loopmediated isothermal amplification lamp enzymelinked immunosorbent assay elisa immunofluorescent assay ifa immunochromatographic test ict nasopharyngeal aspirate npa emergence <NUMBER>ncov <NUMBER> potential vaccine candidates pipeline globally table <NUMBER> wide range technology messenger rna dnabased nanoparticle synthetic modified viruslike particle applied likely take year candidates start phase <NUMBER> clinical trials except funded coalition epidemic preparedness innovations cepi however kit developed bgi passed emergency approval procedure national medical products administration currently used clinical surveillance centers china <NUMBER> total <NUMBER> unique studies <NUMBER>ncov sars cov merscov vaccines screened four eventually included review studies sars mers vaccines excluded performed cell animal models figure <NUMBER> four studies included review phase clinical trials sars mers vaccines table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies population type cell animal human <NUMBER>ncov point screening published clinical trials mostly done united states except one sars vaccine done china <NUMBER> vaccine candidates sars mers reported safe welltolerated able trigger relevant appropriate immune responses participants addition highlight six ongoing phase clinical trials identified clinicaltrialsgov register <NUMBER> <NUMBER> table s<NUMBER> <NUMBER> <NUMBER> <NUMBER> trials testing safety immunogenicity respective merscov vaccine candidates excluded results published yet trials projected complete december <NUMBER> two studies russia <NUMBER> <NUMBER> december <NUMBER> germany <NUMBER> existing literature search return results completed <NUMBER>ncov trials time writing among <NUMBER> trials found systematic review table <NUMBER> nine clinical trials registered clinical trials registry clinicaltrialsgov <NUMBER>ncov therapeutics <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> five studies hydroxychloroquine lopinavir plus ritonavir arbidol mesenchymal stem cells traditional chinese medicine glucocorticoid therapy usage commenced recruitment remaining four studies encompass investigation antivirals interferon atomization darunavir cobicistat arbidol remdesivir usage <NUMBER>ncov patients table <NUMBER> seroconversion measured s<NUMBER>elisa occurred <NUMBER> <NUMBER> participants <NUMBER> <NUMBER> doses respectively maintained <NUMBER> participants study end week <NUMBER> neutralising antibodies detected <NUMBER> participants one time points study <NUMBER> maintained neutralisation activity end study tcell responses detected <NUMBER> <NUMBER> participants <NUMBER> <NUMBER> doses respectively differences immune responses dose groups <NUMBER> weeks vaccineinduced humoral cellular responses respectively detected <NUMBER> <NUMBER> participants week <NUMBER> <NUMBER> molecules developed university scientists inhibit two coronavirus enzymes prevent replication discovered drug targets said <NUMBER> similar enzyme targets found sars virus researchers note identified drugs may available address ongoing outbreak hope make accessible future outbreaks <NUMBER> <NUMBER> first affiliated hospital guangzhou medical university xue bi jing tcm chictr<NUMBER> approved recruitment subjects started <NUMBER> besides six completed randomized controlled trials rct selected systematic review table <NUMBER> one ongoing randomized controlled trial targeted sars therapeutics <NUMBER> studies found clinicaltrialsgov updated since <NUMBER> many prospective retrospective cohort studies conducted epidemic centered usage ribavirin lopinavirritonavir ribavirin yet welldesigned clinical trials investigating usage three completed randomized controlled trials conducted sars epidemic<NUMBER> china <NUMBER> taiwan <NUMBER> hong kong <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies respectively investigated antibiotic usage involving <NUMBER> participants combination western chinese treatment vs chinese treatment <NUMBER> participants integrative chinese western treatment <NUMBER> patients usage specific chinese medicine four participants early use corticosteroid <NUMBER> participants another notable study open nonrandomized study investigating ribavirinlopinavirritonavir usage <NUMBER> participants <NUMBER> one randomized controlled trial investigating integrative western chinese treatment sars epidemic excluded chinese article <NUMBER> one ongoing randomized controlled trial targeted mers therapeutics <NUMBER> investigates usage lopinavirritonavir interferon beta <NUMBER>b likewise many prospective retrospective cohort studies conducted epidemic centered usage ribavirin lopinavirritonavirribavirin interferon convalescent plasma usage date one trial completed one phase <NUMBER> clinical trial investigating safety tolerability fully human polyclonal igg immunoglobulin sab<NUMBER> found available literature <NUMBER> trial conducted united states <NUMBER> demonstrated sab<NUMBER> safe welltolerated single doses another trial mers therapeutics found clinicaltrialsgova phase <NUMBER> trial united states evaluating safety tolerability pharmacokinetics pk immunogenicity coadministered merscov antibodies regn<NUMBER> regn<NUMBER> <NUMBER> however particularly respect improving clinical symptoms elevating quality life promoting immune function recovery promoting absorption pulmonary inflammation reducing dosage cortisteroid shortening therapeutic course treatment integrative chinese western medicine treatment obvious superiority compared using control treatment alone <NUMBER> microneutralization titres also correlated sab<NUMBER> levels serum single infusions sab<NUMBER> <NUMBER> mgkg appear safe welltolerated healthy participants <NUMBER> <NUMBER> discussion rapid diagnostics plays important role disease outbreak management fast accurate diagnosis specific viral infection enables prompt accurate public health surveillance prevention control measures local transmission clusters prevented delayed isolation laboratoryconfirmed cases close contacts quarantined monitored home rapid diagnostic also facilitates specific public health interventions closure highrisk facilities areas associated confirmed cases prompt infection control environmental decontamination <NUMBER> <NUMBER> laboratory diagnosis performed detecting genetic material virus b detecting antibodies neutralize viral particles interest c detecting viral epitopes interest antibodies serological testing culture isolation viable virus particles key limitations genetic material detection lack knowledge presence viable virus potential crossreactivity nonspecific genetic regions short timeframe accurate detection acute infection phase key limitations serological testing need collect paired serum samples acute convalescent phases cases investigation confirmation eliminate potential crossreactivity nonspecific antibodies past exposure andor infection coronaviruses limitation virus culture isolation long duration highly specialized skills required technicians process samples biological samples taken also play role sensitivity tests sarscov merscov specimens collected lower respiratory tract sputum tracheal aspirates higher prolonged levels viral rna tropism virus merscov viral loads also higher severe cases longer viral shedding compared mild cases although upper respiratory tract specimens nasopharyngeal oropharyngeal swabs used potentially lower viral loads may higher risk falsenegatives among mild mers sars cases <NUMBER> <NUMBER> likely among <NUMBER>ncov cases existing practices detecting genetic material coronaviruses sarscov merscov include reverse transcriptionpolymerase chain reaction rtpcr b realtime rtpcr rrtpcr c reverse transcription loopmediated isothermal amplification rtlamp realtime rtlamp <NUMBER> nucleic amplification tests naat usually preferred case merscov diagnosis highest sensitivity earliest time point acute phase infection <NUMBER> chinese health authorities recently posted full genome <NUMBER>ncov genbank gisaid portal facilitate detection virus <NUMBER> several laboratory assays developed detect novel coronavirus wuhan highlighted whos interim guidance ncov laboratory testing suspected cases include protocols countries thailand japan china <NUMBER> first validated diagnostic test designed germany corman et al initially designed candidate diagnostic rtpcr assay based sars sarsrelated coronavirus suggested circulating virus sarslike upon release sequence assays selected based match <NUMBER>ncov upon inspection sequence alignment two assays used rna dependent rna polymerase rdrp gene e gene e gene assay acts firstline screening tool rdrp gene assay confirmatory testing assays highly sensitive specific crossreact coronavirus also human clinical samples contained respiratory viruses <NUMBER> hong kong university used two monoplex assays reactive coronaviruses subgenus sarbecovirus consisting <NUMBER>ncov sarscov sarslike coronavirus viral rna extracted sarscov used positive control suggested protocol assuming sars eradicated proposed n gene rtpcr used screening assay orf<NUMBER>b assay acts confirmatory test however protocol evaluated panel controls positive control sarscov rna synthetic oligonucleotide positive control <NUMBER>ncov yet tested <NUMBER> us cdc shared protocol real time rtpcr assay detection <NUMBER>ncov primers probes designed universal detection sarslike coronavirus specific detection <NUMBER>ncov however protocol validated platforms chemistries apart protocol described limitations assay analysts engaged trained familiar testing procedure result interpretation false negative results may occur due insufficient organisms specimen resulting improper collection transportation handling also rna viruses may show substantial genetic variability could result mismatch primer probes target sequence diminish assay performance result false negative results <NUMBER> pointofcare test kit potentially minimize limitations highly prioritized research development next months serological testing elisa iift neutralization tests effective determining extent infection including estimating asymptomatic attack rate compared detection viral genome molecular methods serological testing detects antibodies antigens would lag period antibodies specifically targeting virus would normally appear <NUMBER> <NUMBER> days illness onset <NUMBER> furthermore studies suggest low antibody titers second week delayed antibody production could associated mortality high viral load hence serological diagnoses likely used nucleic amplification tests naat available accessible <NUMBER> vaccines prevent protect infection disease occurrence exposed specific pathogen interest especially vulnerable populations prone severe outcomes context current <NUMBER>ncov outbreak vaccines help control reduce disease transmission creating herd immunity addition protecting healthy individuals infection decreases effective r<NUMBER> value disease nonetheless social clinical economic hurdles vaccine vaccination programmes including willingness public undergo vaccination novel vaccine b side effects severe adverse reactions vaccination c potential difference andor low efficacy vaccine populations different clinical trials populations accessibility vaccines given population including cost availability vaccine vaccines <NUMBER>ncov currently development none testing time writing <NUMBER> january <NUMBER> coalition epidemic preparedness innovations cepi announced fund vaccine development programmes inovio university queensland moderna inc respectively aim test experimental vaccines clinically <NUMBER> weeks june <NUMBER> vaccine candidates developed dna recombinant mrna vaccine platforms organizations <NUMBER> based recent merscov outbreak already number vaccine candidates developed still preclinical testing stage vaccines development include viral vectorbased vaccine dna vaccine subunit vaccine viruslike particles vlpsbased vaccine inactivated wholevirus iwv vaccine live attenuated vaccine latest findings vaccines arebased review yong et al <NUMBER> august <NUMBER> <NUMBER> date reporting one published clinical study merscov vaccine geneone life science inovio pharmaceuticals <NUMBER> one sars vaccine trial conducted us national institute allergy infectious diseases phase clinical trials reported positive results one announced plans proceed phase <NUMBER> trial <NUMBER> due close genetic relatedness sarscov <NUMBER> <NUMBER>ncov <NUMBER> may potential crossprotective effect using safe sarscov vaccine awaiting <NUMBER>ncov vaccine however would require small scale phasebyphase implementation close monitoring vaccinees large scale implementation apart timely diagnosis cases achievement favorable clinical outcomes depends timely treatment administered ace<NUMBER> reported cell entry receptor used <NUMBER>ncov infect humans sarscov <NUMBER> hence clinical similarity two viruses expected particularly severe cases addition died merscov sarscov <NUMBER>ncov advance age underlying health conditions hypertension diabetes cardiovascular disease compromised immune systems <NUMBER> coronaviruses errorprone rnadependent rna polymerases rdrp result frequent mutations recombination events results quasispecies diversity closely associated adaptive evolution capacity enhance viralcell entry cause disease time specific population atrisk <NUMBER> since ace<NUMBER> abundantly present humans epithelia lung small intestine coronaviruses likely infect upper respiratory gastrointestinal tract may influence type therapeutics <NUMBER>ncov similarly sarcov however years following two major coronavirus outbreaks sarscov <NUMBER> merscov <NUMBER> remains consensus optimal therapy either disease <NUMBER> <NUMBER> welldesigned clinical trials provide gold standard assessing therapeutic measures scarce coronavirus protease inhibitors successfully completed preclinical development program despite large efforts exploring sarscov inhibitors bulk potential therapeutic strategies remain experimental phase handful crossing vitro hurdle stronger efforts required research treatment options major coronaviruses given pandemic potential effective treatment options essential maximize restoration affected populations good health following infections clinical trials commenced china identify effective treatments <NUMBER>ncov based treatment evidence sars mers currently effective specific antiviral highlevel evidence specific antiviral therapy provided context clinical studytrial treatments shown real curative action sars mers literature generally describes isolated cases small case series many interferons three classes tested antiviral activities sarscov vitro animal models interferon β consistently shown active followed interferon α use corticosteroids interferon alfacon<NUMBER> synthetic interferon α appeared improved oxygenation faster resolution chest radiograph abnormalities observational studies untreated controls interferon used multiple observational studies treat sarscov merscov patients <NUMBER> <NUMBER> interferons without ribavirin lopinavirritonavir likely beneficial trialed china <NUMBER>ncov drug treatment appears advanced timing treatment likely important factor effectiveness combination ribavirin lopinavirritonavir used postexposure prophylaxis health care workers may reduced risk infection ribavirin alone unlikely substantial antiviral activities clinically used dosages hence ribavirin without corticosteroids lopinavir ritonavir among combinations employed common agent reported available literature efficacy assessed observational studies retrospective case series retrospective cohort study prospective observational study prospective cohort study randomized controlled trial ranging seven <NUMBER> participants <NUMBER> lopinavirritonavir kaletra earliest protease inhibitor combination introduced treatment sarscov efficacy documented several studies causing notably lower incidence adverse outcomes ribavirin alone combined usage ribavirin also associated lower incidence acute respiratory distress syndrome nosocomial infection death amongst favorable outcomes recent vitro studies shown another hiv protease inhibitor nelfinavir antiviral capacity sarscov although yet show favorable outcomes animal studies <NUMBER> remdesivir gilead sciences gs<NUMBER> nucleoside analogue vitro vivo data support gs<NUMBER> development potential pancoronavirus antiviral based results several coronaviruses covs including highly pathogenic covs potentially emergent batcovs use remdesivir may good candidate investigational treatment improved mortality following receipt convalescent plasma various doses consistently reported several observational studies involving cases severe acute respiratory infections saris viral etiology significant reduction pooled odds mortality following treatment <NUMBER> compared placebo therapy observed <NUMBER> studies however moderate high risk bias given small sample sizes allocation treatment based physicians discretion availability plasma factors like concomitant treatment may also confounded results associations convalescent plasma hospital length stay viral antibody levels viral load respectively similarly inconsistent across available literature convalescent plasma promising likely yet feasible given limited pool potential donors issues scalability monoclonal antibody treatment progressing sarscov enters host cells binding spike protein angiotensin converting enzyme <NUMBER> ace<NUMBER> cd<NUMBER>l <NUMBER> human monoclonal antibodies protein shown significantly reduce severity lung pathology nonhuman primates following merscov infection <NUMBER> neutralizing antibodies elicited active passive immunization using vaccines convalescent plasma respectively neutralizing antibodies theoretically harvested individuals immunized vaccines uncertainty achievement therapeutic levels antibodies therapeutic agents also reported known antimalarial agent chloroquine elicits antiviral effects multiple viruses including hiv type <NUMBER> hepatitis b hcov<NUMBER>e chloroquine also immunomodulatory capable suppressing production release factors mediate inflammatory complications viral diseases tumor necrosis factor interleukin <NUMBER> <NUMBER> postulated chloroquine works altering ace<NUMBER> glycosylation endosomal ph antiinflammatory properties may beneficial treatment sars niclosamide known drug used antihelminthic treatment efficacy niclosamide inhibitor virus replication proven several assays immunoblot analysis immunofluorescence assays niclosamide treatment observed completely inhibit viral antigen synthesis reduction virus yield infected cells dose dependent niclosamide likely interfere early stages virus attachment entry cells function protease inhibitor mechanisms niclosamide activity warrant investigation <NUMBER> glycyrrhizin also reportedly inhibits virus adsorption penetration early steps virus replication glycyrrhizin significantly potent inhibitor low selectivity index tested several pathogenic flaviviruses preliminary results suggest production nitrous oxide inhibits virus replication induction nitrous oxide synthase mechanism glycyrrhizin sarscov remains unclear compound also relatively lower toxicity compared protease inhibitors like ribavirin <NUMBER> inhibitory activity also detected baicalin <NUMBER> extracted another herb used treatment sars china hong kong findings compounds limited vitro studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> due rapidly evolving situation <NUMBER>ncov potential limitations systematic review systematic review likely publication bias developments yet reported developments intention report publicly scientific platforms due confidentiality concerns however may limited developments review publicity help branding extent company andor funder furthermore due rapid need share status developments may reporting bias details provided authors scientific articles commentary articles traditional media lastly viable form quality assessment metaanalysis selected articles due limited data provided heterogeneous style reporting different articles paper provided comprehensive overview potential developments pharmaceutical interventions early phase outbreak systematic review would useful crosscheck quality assessment metaanalysis developments performed followup study rapid diagnostics vaccines therapeutics key pharmaceutical interventions limit transmission respiratory infectious diseases many potential developments pharmaceutical interventions <NUMBER>ncov ongoing containment phase outbreak potentially due better pandemic preparedness however lessons merscov sarscov shown journeys developments still challenging moving ahead supplementary materials following available online httpwwwmdpicom<NUMBER>s<NUMBER> table s<NUMBER> example full search strategy pubmed table s<NUMBER> google search <NUMBER>ncov diagnostics table s<NUMBER> summary diagnostic assays developed <NUMBER>ncov table s<NUMBER> improvement developed based scientific advances past several decades vaccine antiviral development rsv parainfluenza comparison strikingly neglected pediatric respiratory diseases received lowest levels funding compared fields health research <NUMBER> limited resources devoted rsv parainfluenza virus vaccine antiviral drug development despite huge impact diseases illness hospitalization infants worldwide therefore especially exciting report important recent developments result directly scientific advances applied prevention acute respiratory disease article organized around several important individual pediatric pathogens responsible croup bronchiolitis pneumonia children pathogens discussed studied several decades including respiratory syncytial virus parainfluenza viruses viral pathogens newly identified writing human metapneumovirus human coronavirus nl<NUMBER> light escalating rate emergence new infectious agents fortunately met equally rapid advancements molecular methods surveillance pathogen discovery new organisms added list near future section therapies bronchiolitis addresses several final common pathways result infection diverse pathogens highlighting mechanisms may amenable therapeutic approaches article concludes discussion overarching impact new diagnostic strategies rsv leading cause bronchiolitis lower respiratory tract infection young children accounting <NUMBER> <NUMBER> hospitalizations bronchiolitis rsv member pneumovirus genus within pneumovirinae subfamily paramyxoviridae family negativestranded rna viruses rsv replicates initially nasopharyngeal epithelium later spreads lower respiratory tract viral replication small airways causes inflammation sloughing necrosis bronchiolar epithelium resultant edema increased mucous secretion may depending severity disease cause plugging small airways atelectasis airway narrowing obstruction primary infection rsv immunologically naı¨ve host tends severe whether usually occurs immunopathologic mechanisms immunologic immaturity smaller vulnerable airways infected infants combination factors unclear contribution virus underlying genetic predisposition host components inflammatory response form complex picture genesis severe rsv disease individual roles remain delineated several abnormal underlying conditions predispose severe forms rsv disease enumerated include prematurity preexisting lung disease various forms immunodeficiency however one must understand apparently healthy infants children proceed initial infection severe lower respiratory tract disease whereas others experience relatively mild selflimited illness several groups recently identified normal genetic variation among humans major factor disease severity specific alleles interleukin il<NUMBER> <NUMBER> il<NUMBER> receptor <NUMBER> identified associated severe disease promoter variants il<NUMBER> il<NUMBER> tumor necrosis factor tnfa genes probably also influence disease severity <NUMBER> variations il<NUMBER> gene locus associated severe form disease <NUMBER> ample evidence also exists relationship locus il<NUMBER> gene disease severity <NUMBER> <NUMBER> recently identified variants chemokine receptor ccr<NUMBER> also seem predispose severe rsv bronchiolitis <NUMBER> correlation established specific alleles genes surfactant increase disease severity <NUMBER> <NUMBER> light mounting evidence specific genetic contributions rsv disease severity possibility similar related genetic variation may underlie predisposition asthma link respiratory virus infection asthma <NUMBER> understanding mechanisms whereby gene alterations influence pathogenesis critical early identification vulnerable individuals could allow targeted use prophylactic strategies protect genetically risk currently practiced infants abnormal underlying conditions preventative strategies could impact morbidity mortality ari also incidence reactive airway disease immunity respiratory syncytial virus inflammatory responses respiratory syncytial virus infection rsv primary infection confer permanent immunity repeated reinfection rsv within <NUMBER> year previous infection common young children although subsequent infections usually milder suggesting protection severe disease primary infection adults secretory neutralizing antibodies serum antibodies correlate protection upper respiratory tract infection whereas circulating serum antibodies particularly f g glycoproteins shown protect infection decrease progression lower airways <NUMBER> <NUMBER> limited degree protection offered maternal antibody underscored fact peak incidence serious rsv disease seen infants aged <NUMBER> <NUMBER> months maternal antibody still circulating within infant rsvinduced lower respiratory tract disease bronchiolitis pneumonia results balance cellular damage mediated viral pathogen injury caused immune response host <NUMBER> <NUMBER> <NUMBER> although immunology immunopathogenesis rsv infection fully understood humoral cellular components immune system clearly contribute protection disease also pathogenesis disease mouse models rsv disease used dissect contribution different tcell subsets rsv proteins pathology rsv infection shown different disease outcomes depending rsv protein used prime cellular response <NUMBER> example balbc mice rsv surface protein g primes eosinophilic inflammatory response mediated th<NUMBER>type cd<NUMBER>þ cells <NUMBER> reminiscent responses seen formalininactivated rsv vaccine model <NUMBER> although transfer cytotoxic lymphocytes ctls naı¨ve mice resulted accelerated viral clearance immunopathology also enhanced mice active ctls <NUMBER> indicating ctls associated th<NUMBER>type responses also contribute immunopathology observed rsvinfected mice recent studies shown pattern recognition receptor cd<NUMBER> tolllike receptor <NUMBER> participates innate immune response rsv <NUMBER> <NUMBER> <NUMBER> response triggered f protein animal models cellmediated immunity children probably contributes host defense rsv also causes much pathologic process inappropriate immune responses may drive pulmonary inflammation naturally acquired infection <NUMBER> regulation response lymphocytes rsv may critical determining clinical outcome rsv infection abnormal tcell regulatory mechanisms may related hyperactive ige response contributes enhanced lung infiltrate <NUMBER> <NUMBER> several proinflammatory cytokines detected respiratory secretions rsvinfected individuals including il<NUMBER> rantes macrophage inflammatory protein <NUMBER> alpha mip<NUMBER>a mediate neutrophil eosinophil chemotaxis cell types promote host defense tissue damage contribution th<NUMBER> cells rsv disease humans supported findings interferon gamma ifng prevalent cytokine produced rsvspecific tcells presence ifng <NUMBER> levels mip<NUMBER>a <NUMBER> rather levels th<NUMBER> cytokines shown correlate closely rsv disease severity role immunopathology rsv highlighted children received formalininactivated rsv vaccine <NUMBER> developed enhanced rsv disease exposure virus <NUMBER> intense inflammatory infiltrate lungs vaccinated children suggested immunopathologic cause enhanced disease animal models used successfully study immune correlates pathology basis enhanced disease <NUMBER> overexuberant inflammatory response lymphocytic eosinophilic infiltration ascribed imbalance ratio th<NUMBER> th<NUMBER> cells could resulted poor preservation f formalin inactivation <NUMBER> resulting predominance g formalininactivated vaccine believed cause pathologic th<NUMBER> polarization immune response pulmonary eosinophilia children subsequently naturally infected rsv cd<NUMBER>þ cells play major role immunopathogenesis vaccineenhanced rsv disease <NUMBER> marked increase th<NUMBER>type cytokine expression il<NUMBER> il<NUMBER> il<NUMBER> reduction il<NUMBER> expression occurred mice immunized formalininactivated vaccine indicating swing toward th<NUMBER> genesis enhanced inflammation <NUMBER> presence il<NUMBER> correlated eosinophilic infiltration mouse lung contrast priming live rsv resulted th<NUMBER> pattern cytokine production prevented subsequent enhanced disease <NUMBER> recent study mice suggests immune complexes fix complement also play key role pathogenesis enhanced disease augmented disease mice mediated immune complexes abrogated complement component c<NUMBER> b celldeficient mice <NUMBER> bronchoconstriction component enhanced disease seems mediated complement whereas enhanced pneumonia component disease depends th<NUMBER> effects findings enhance understanding protective immunity destructive inflammation suggest important elements consider rsv vaccine development <NUMBER> successful vaccines must induce neutralizing antibody cd<NUMBER>þ virusspecific ctls elicit cd<NUMBER> cell response corresponds response natural infection although live attenuated vaccines clearly achieve goals directly appropriate several populations therefore novel strategies also applied development nonreplicating vaccines prevention respiratory syncytial virus disease active immunization rsv vaccine development hampered past decades complex factors described earlier concerns resulted history early formalininactivated vaccine trials limited support study pediatric respiratory viruses vaccine development <NUMBER> <NUMBER> livecandidate attenuated rsv vaccines never observed cause enhanced rsv disease intranasal vaccination live virus vaccines elicit better mucosal immunity parenterally administered inactivated virus vaccines therefore developing live attenuated vaccines rsvnaı¨ve populations including infants priority however live attenuated vaccines pose challenge finding balance overattenuation subsequent induction inefficient immunologic responses underattenuation may result disease especially younger infants therefore heartening report recent advances molecular virology allowed live attenuated vaccine candidate developed well tolerated infants protects challenge <NUMBER> recovery infectious virus cdna clones rsv <NUMBER> <NUMBER> based advances molecular virology last decade completely changed outlook developing live attenuated rsv vaccines new vaccine candidates developed introducing combinations attenuating mutations recombinant rsv direct manipulation dna intermediate new strategy also advantageous pediatric respiratory viruses discussed later specific mutations introduced based rationale attenuating effects strategy based understanding genetic basis attenuation applying design vaccines referred reverse genetics begin replace methods serial passage viruses chemical mutagenesis strategies classically used generate attenuating mutations <NUMBER> live coldpassaged cp temperaturesensitive ts rsv vaccines cpts vaccines containing many attenuating mutations attractive candidates live attenuated rsv vaccines one cpts <NUMBER> vaccine candidate safe immunogenic rsvseronegative infants young <NUMBER> months sufficiently attenuated <NUMBER>to <NUMBER>weekold infants therefore additional attenuating mutations added using novel technology one new vaccine candidate ra<NUMBER>cp<NUMBER>sh contains five new independent attenuating genetic elements <NUMBER> karron colleagues <NUMBER> evaluated recombinant rsv vaccines clinical trials first time candidate vaccine ra<NUMBER>cp<NUMBER> <NUMBER>sh well tolerated responsible mainly mild illness lower respiratory tract illness observed associated viral infections administration second dose vaccine showed restriction viral replication proving vaccine could induce protective immunity consistent mechanisms natural immunity antibody responses live attenuated virus primary mediators protection induced vaccine thus ra<NUMBER>cp<NUMBER>sh seems first rsv vaccine candidate appropriately attenuated young infants including infants <NUMBER> <NUMBER> months age although half youngest infants show antibody responses limited replication second dose suggests infants protected critical infants vulnerable presented challenges vaccine development successful trial provides map future trials recombinant vaccines rsv pediatric respiratory pathogens subunit vaccines viable infants therefore limited use normal population may provide suitable approach vaccination immunosuppressed populations high risk severe rsv infection including high risk children elderly possibly maternal immunization <NUMBER> one viral surface glycoprotein fusion protein f used antigen developing subunit vaccines purified f protein pfp<NUMBER> pfp<NUMBER> pfp<NUMBER> f subunit vaccines shown moderately immunogenic well tolerated healthy seropositive children older <NUMBER> months children older <NUMBER> months cystic fibrosis children older <NUMBER> months chronic lung disease prematurity metaanalysis pfp<NUMBER> pfp<NUMBER> studies suggested vaccines reduced incidence rsv infections lower respiratory tract infection <NUMBER> pfp<NUMBER> vaccine may show promise pregnant women recent trial produced fourfold increases neutralizing antibody titers mothers infants birth <NUMBER> months age <NUMBER> another subunit vaccine candidate bbg<NUMBER>na peptide g receptorbinding glycoprotein rsv conjugated albuminbinding domain streptococcal protein g <NUMBER> <NUMBER> vaccine well tolerated induces neutralizing antibody responses healthy young adults immunogenic elderly individuals finally subunit vaccines containing copurified f g proteins formulated alum adjuvant investigated <NUMBER> <NUMBER> however likely targets vaccines elderly adults high risk severe rsv infection effective vaccines rsv widely available passive immunoprophylaxis rsv antibody preparations important protect children high risk severe rsv disease humanized monoclonal antibody palivizumab directed rsv fusion protein affords moderate protection premature infants high risk severe rsv disease <NUMBER> palivizumab administered monthly intramuscular injection rsv season duration therapy indications prophylaxis depend gestational age presence absence chronic lung disease environmental risk factors increase rsv risk <NUMBER> another rsvspecific monoclonal antibody derived palivizumab medi<NUMBER> developed compared palivizumab antibody <NUMBER>fold greater finding affinity rsv f protein <NUMBER> <NUMBER> times potent neutralizing rsv vitro <NUMBER> effectively reduces rsv titers cotton rat model <NUMBER> <NUMBER> preparation currently phase <NUMBER> trials children high risk rsv may preferable palivizumab future similar approaches using monoclonal antibodies different stages clinical development role antivirals treating rsv infection remains uncertain although studies failed show correlation viral load disease severity others suggest reduced viral levels correlate improved clinical outcomes findings surprising considering significant role proinflammatory responses play pathogenesis virus ribavirin currently antiviral agent available treating children rsv lower respiratory tract disease although ribavirin nucleoside analog good activity rsv vitro clinical studies examining effect children conflict therefore use children remains highly controversial considered certain target populations several new antiviral strategies rsv currently investigated including promising approach f protein fusion inhibitors rsv f fusion glycoprotein like f paramyxoviruses mediates fusion viral host cell membranes infection <NUMBER> <NUMBER> f protein forms trimer synthesis cleaved transit cell surface produce final membranedistal membraneanchored subunits carboxyl terminal membraneanchored subunit paramyxovirus f proteins anchored viral membrane whereas newly exposed amino terminal contains fusion peptide inserts target membranes fusion occurs neutral ph <NUMBER> initially paramyxovirus fusion peptide lies deep within hydrophobic core f protein virion fuse target membrane effect viral entry f protein must undergo activation step exposing fusion peptide <NUMBER> paramyxovirus hpiv<NUMBER> authors found f protein activated adjacent receptorbinding protein hemagglutininneuraminidase hn binds sialic acidcontaining receptor permitting fusion occur receptor binding receptorbinding protein triggers f fuse <NUMBER> <NUMBER> must interact respective receptor fusion occur <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mechanism shown true paramyxoviruses general <NUMBER> rsv g receptor binding glycoprotein must present trigger f fuse fig <NUMBER> contains schematic structural transitions occur f activated mediate membrane merger ectodomain membraneanchored subunit f protein contains two hydrophobic domains fusion peptide inserts cellular target membrane fusion transmembranespanning domain fusion peptide adjacent nterminal heptad repeat hrn transmembrane domain adjacent cterminal heptad repeat hrc transient intermediate f anchored viral cell membranes believed refold assemble fusogenic sixhelix bundle <NUMBER>hb structure hrn hrc associate tight complex nand cpeptides aligned antiparallel arrangement refolding relocates fusion peptide transmembrane anchor side pulling viral cell membranes close proximity driving fusion <NUMBER> refolding step f provides attractive target antivirals ability heptad repeat peptides interfere analogous fusion process hiv led clinically effective peptide inhibitor hiv infection t<NUMBER> enfuvirtide <NUMBER> <NUMBER> <NUMBER> peptides derived hrcpeptide regions several paramyxoviruses including sendai measles newcastle disease virus rsv piv<NUMBER> interfere fusion intermediates paramyxovirus f proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> inhibit viral infectivity vitro <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> proposed inhibition occurs peptides bind complementary heptad repeat region thereby preventing hrn hrc refolding <NUMBER>hb stable structure required fusion <NUMBER> <NUMBER> <NUMBER> related approach recently observed cterminal hrn trimer contains hydrophobic pocket provides potential binding site small molecules might interfere stability hairpin structure <NUMBER> could provide advantages use peptides clinical use low molecular weight molecule highly effective inhibiting rsv fusion recently shown bind hydrophobic pocket hrn suggesting small molecule disrupts hairpin derail rsv fusion process <NUMBER> inhibition ftriggering process peptides small molecules interact heptad repeat regions promising area development antiviral therapies awaits study several novel experimental approaches inhibit rsv replication include use antisense oligonucleotides rna interference technology approaches although promising still early stages development <NUMBER> hpiv types <NUMBER> <NUMBER> <NUMBER> hpiv<NUMBER> <NUMBER> <NUMBER> major cause croup although rsv ranks common agent bronchiolitis pneumonia hmpv also possibly contributing significantly <NUMBER> parainfluenza viruses also follow closely behind <NUMBER> hpiv<NUMBER> alone responsible approximately <NUMBER> pediatric respiratory hospitalizations united states <NUMBER> <NUMBER> predominant cause croup young infants hpiv<NUMBER> <NUMBER> belong respirovirus genus within paramyxovirinae subfamily paramyxoviridae family negativestranded rna viruses whereas hpiv<NUMBER> belongs rubulavirus genus although vaccination programs antiviral use helped suppress causes respiratory disease children influenza measles children still unaided battle major cause croup rsv effective strategies prophylaxis available protect groups risk <NUMBER> weapons currently available parainfluenza viruses parainfluenza viruses replicate epithelium upper respiratory tract spread lower respiratory tract within <NUMBER> days croup results inflammatory obstruction airway epithelial cells small airways may become infected resultant necrosis inflammatory infiltrates interplay virusinduced cell damage beneficial immune responses inflammatory responses contribute hpiv<NUMBER> disease well studied rsv however rsv disease severity often probably increased pathology clinical disease actually caused inflammatory response rather cytopathic effects virus fundamental concept highlighted fact virus titers infected hosts generally waning disease symptoms become apparent <NUMBER> virus titer correlate severity lower respiratory disease pathologic changes children died parainfluenza infection suggest exaggerated inflammation <NUMBER> <NUMBER> rather simply tissue destruction virus hpiv primary infection confer permanent immunity however although reinfection occurs immunity usually sufficient restrict virus replication lower respiratory tract prevent severe disease mucosal iga levels correlate protection replication parainfluenza viruses humans <NUMBER> <NUMBER> cellmediated immunity also contributes importantly preventing disease example hpiv<NUMBER> infection infants tcelldeficient cause fatal giantcell pneumonia <NUMBER> <NUMBER> hpiv pneumonia <NUMBER> mortality bone marrow transplant recipients <NUMBER> cotton rat sigmodon hispidus model disease useful analyzing factors affecting pathogenesis hpiv<NUMBER> vivo experimental infection cotton rat hpiv<NUMBER> leads infection bronchiolar epithelial cells bronchiolitis interstitial pneumonia mimicking human disease making relevant model hpiv<NUMBER> lower respiratory infection <NUMBER> authors studied cotton rats infected either wildtype hpiv<NUMBER> variant viruses containing hn molecules individual mutations conferred high receptorbinding avidity low neuraminidase receptorcleaving activity <NUMBER> infected animals experienced normal clearance variant viruses opposed wildtype viruses however hn protein alterations led striking differences ability hpiv<NUMBER> cause extensive disease cotton rat lung variants caused alveolitis interstitial infiltrate whereas wildtype virus caused peribronchiolitis enhanced disease caused hn variants manifested greatly increased inflammatory cell infiltrate alveoli interstitial spaces lung finding suggested differences variants caused modulation inflammatory response different hn protein activity variants dissociated viral replication infectivity authors hypothesize mutations hn protein alter either affinity receptor receptorcleaving activity may modify nature inflammatory response host using hn variants dissect etiology enhanced disease may possible identify components immune systems response hpiv<NUMBER> contributes disease experiments underway determine whether hpiv<NUMBER> hn protein alterations enhance disease specifically alter chemokine expression results provide information could used develop therapies modulate overactive inflammatory response hpiv infection development vaccine parainfluenza viruses hampered need induce immune response young infants whose immature immune systems maternal antibodies interfere development adequate immune response inactivated hpiv<NUMBER> <NUMBER> <NUMBER> vaccine used infants late <NUMBER>s immunogenic offer protection infection <NUMBER> <NUMBER> experimental vaccines evaluated vaccine hpiv<NUMBER> perhaps also hpiv<NUMBER> anticipated <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> progress benefited greatly recent advances molecular virology two different strategies developed hpiv<NUMBER> vaccines one liveattenuated bovine parainfluenza type <NUMBER> bpiv<NUMBER> vaccine vaccine based coldadapted attenuated strain bpiv<NUMBER> vaccine attenuated humans nature host range bovine virus used infect humans well tolerated induce similar levels antibody titers seen infection human virus therefore reverse genetics approach used generate set hpiv<NUMBER> variants carry individual genes bovine virus chimeric viruses strains elicited improved antibody response monkeys protected hpiv<NUMBER> infection two chimeric viruses one containing hn gene bovine virus human virus background containing f hn glycoprotein genes human virus bovine virus background viewed strongest vaccine candidates human trials <NUMBER> <NUMBER> <NUMBER> latter candidate combines host range restriction bpiv<NUMBER> major antigenic determinants hpiv<NUMBER> permitting efficient replication vitro beneficial vaccine development along host range phenotype excellent antigenicity bovinehuman chimeric approach also used create strategy vaccinating simultaneously hpiv<NUMBER> rsv possibly also hmpv chimeric virus contains hpiv<NUMBER> f hn glycoprotein genes bpiv<NUMBER> background engineered also express protective antigens rsv hmpv strategy lead bivalent vaccines hpiv<NUMBER>rsv hpiv<NUMBER>hmpv using single virus bpiv<NUMBER>hpiv<NUMBER> chimera also expresses rsv f clinical trials hpivs also theoretically well suited vaccine vectors pediatric pathogen vaccines especially use respiratory portal entry intranasal route administration highly advantageous hpiv<NUMBER>based vaccines would immunize within first <NUMBER> months life virus infects early infancy whereas vaccines using hpiv<NUMBER> hpiv<NUMBER> backbones could used second half first year life taking strategy reverse genetics using hpiv backbone vaccine one step hpivs could thereby used vaccine vectors viruses infect respiratory portal including severe acute respiratory syndrome sars ebola bpiv<NUMBER>hpiv<NUMBER> virus expressing spike glycoprotein sarscoronavirus elicited neutralizing antibody response protection challenge sars african green monkeys <NUMBER> hpiv<NUMBER> expressing glycoprotein ebola highly effective guinea pig model <NUMBER> evaluated primates types vaccines could developed protect children emerging infections second attenuated virus developed hpiv<NUMBER> vaccines cp<NUMBER> based live cpts vaccine containing many attenuating mutations vaccine welltolerated immunogenic children infants even young <NUMBER> <NUMBER> months <NUMBER> <NUMBER> <NUMBER> <NUMBER> evaluated clinical trials <NUMBER> given promise candidate attenuated rsv vaccine <NUMBER> cpts vaccine tested combination hpiv<NUMBER> cp<NUMBER> vaccine although interference occurred two virus vaccines results justify evaluation combination vaccines <NUMBER> several features viral lifecycle make parainfluenza viruses vulnerable attack fig <NUMBER> parainfluenza viruses enter target cell binding receptor molecule fusing viral envelope cell membrane gain access cytoplasm binding fusion critical steps infection proceed interfering critical processes entry stage viral lifecycle would prevent disease hpiv<NUMBER> f protein found fully activated adjacent receptorbinding protein hn binds sialic acidcontaining receptor permitting fusion occur receptor binding hn actively triggers f fuse <NUMBER> <NUMBER> <NUMBER> mechanism true paramyxoviruses <NUMBER> receptorbinding protein viruses including hpiv<NUMBER> hpiv<NUMBER> rsv measles virus hendra virus nipah virus must interact respective receptor fusion occur <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> authors identified functionally characterized specific receptorinteracting sites hpiv<NUMBER> hn molecule <NUMBER> <NUMBER> <NUMBER> threedimensional crystal structure hn protein solved <NUMBER> mapped functional sites onto hn structure <NUMBER> information binding inhibitors designed specifically fit binding pocket globular head hn fig <NUMBER>b <NUMBER> <NUMBER> addition interfering receptor binding hn protein blockade interfere ftriggering function hn protein occur hn protein contact receptor ftriggering function provides target several antiviral strategies first based recent analysis ftriggering process peptides corresponding hr domains f see fig <NUMBER> designed prevent f protein reaching fusionactive state fig <NUMBER>c authors performing computational modeling based threedimensional structure related parainfluenza virus <NUMBER> piv<NUMBER> previously called simian virus <NUMBER> sv<NUMBER> f <NUMBER> predict peptides active test predictions experimentally strategy effective improving design antiviral peptides paramyxoviruses <NUMBER> preliminary studies authors laboratory also suggest normal triggering process may subverted causing f protein become activated reaches target host cell incapacitating f mediate viral entry authors shown specific mutations stalk region hn affect hns ability trigger f protein <NUMBER> specific features globular head region hn modulate triggering function <NUMBER> however signal activation transmitted hn f protein unknown example hns receptor binding induces conformational change hn change lead activation f detailed understanding pathway lead additional targets interruption viral entry hpiv<NUMBER> pathogenesis probably largely caused inflammatory response infection findings specific alterations hn protein correlate enhanced pathology hn may play role eliciting inflammatory responses suggest approaches modulating inflammatory response may ameliorate disease fig <NUMBER>a finally hn molecule addition binding receptors contains neuraminidase receptorcleaving activity cleaves sialic acid moieties cellular receptors allowing new virions released host cell surface infection spread although neuraminidase inhibition unlikely effective antiviral strategy parainfluenza viruses influenza virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> specific inhibition activity could prevent virion entry additional uninfected cells fig <NUMBER>d several potential therapeutic targets actively pursued hope open new avenues parainfluenza infection interference certainly strategies protect treat children parainfluenza virus infection urgently needed hmpv newly identified respiratory virus associated lower respiratory tract disease infants children virus first reported netherlands <NUMBER> <NUMBER> investigators identified sequences virus performing randomly primed reverse transcriptionpolymerase chain reaction rtpcr analysis respiratory secretions children lower respiratory tract disease hmpv belongs metapneumovirus genus within pneumovirinae subfamily paramyxoviridae family negativestranded rna viruses hmpv may account much lower respiratory disease young children previously unknown origin <NUMBER> <NUMBER> significant portion upper respiratory infection <NUMBER> may also cause wheezing episodes late winter spring <NUMBER> less frequently croup pneumonia although significant information hmpv accrued <NUMBER> years since virus recognized cause respiratory disease much remains learned incidence hpmv specific populations basic virology strain variation mechanisms pathogenesis immunity little known correlates immunity hmpv infection hostpathogen balance lung disease features probably shared rsv parainfluenza infection induces serumneutralizing antibodies experimentally infected animals protection reinfection induced primary infection several animal models <NUMBER> <NUMBER> <NUMBER> cotton rat model recently developed hmpv similar features cotton rat model hpiv<NUMBER> <NUMBER> cotton rats inoculated intranasally hmpv infected cotton rat lungs exhibited histopathologic changes peribronchial inflammatory infiltrates immunohistochemical staining detected virus luminal surfaces respiratory epithelial cells throughout respiratory tract cotton rats mounted neutralizing antibody responses hpmv subsequent rechallenge hmpv animals exhibited partial protection terms viral replication lung disease therefore cotton rat probably useful small animal model hmpv infection rsv hpiv<NUMBER> reflects disease correlates immunity immunopathology children <NUMBER> <NUMBER> <NUMBER> <NUMBER> model facilitate vivo studies pathogenesis lead development vaccine antiviral candidates hpmv vaccine strategies immediately benefited advances reverse genetics vaccine technology developed rsv hpiv<NUMBER> allow recombinant engineered viruses generated dna clones viral genes result live attenuated virus vaccine development hpmv already progress recombinant hmpv strains generated representing rescue strains canada strain can<NUMBER> netherlands strains nl<NUMBER> nl<NUMBER> entirely cdna <NUMBER> several chimeric viruses generated considered suitable vaccine candidates example hpmv viruses several individual genes small hydrophobic protein gene sh receptorbinding protein gene g m<NUMBER> gene open reading frames deleted assessed ability replicate efficacy intranasal vaccines african green monkeys <NUMBER> genedeletion recombinant virus although highly attenuated also immunogenic protected monkeys challenge hmpv two viruses gdeleted m<NUMBER>deleted promising vaccine candidates <NUMBER> different recombinant approach chimeras generated replacing nucleoprotein phosphoprotein p open reading frame hmpv corresponding gene avian metapneumovirus subgroup c <NUMBER> tested african green monkeys immunized intranasally intratracheally chimeras comparable wildtype hmpv immunogenicity protective efficacy p chimera although exhibited excellent growth vitro making feasible vaccine development also highly attenuated thus p chimera could superb vaccine candidate combines good growth vitro attenuation vivo excellent protection primate model <NUMBER> candidate vaccines probably emerge clinical trials fairly soon underscoring importance recent advances molecular virology respiratory viruses accelerating clinical vaccine development several newly identified members coronavirus family cause lower respiratory disease one sarscoronavirus etiologic agent sars first detected cases severe atypical pneumonia unknown origin reported late <NUMBER> disease rapidly spread <NUMBER> countries sickened thousands individuals april <NUMBER> global medical scientific communities engaged striking cooperative effort led rapid progress identifying sarscoronavirus diagnosing severe disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> outbreaks effectively contained research underway develop protective measures infrequent fatal disease second novel coronavirus human coronavirus nl<NUMBER> hcovnl<NUMBER> less virulent seems far common frequent cause lower respiratory tract disease young children two different groups identified virus <NUMBER> <NUMBER> <NUMBER> following year hcovnl<NUMBER>specific quantitative realtime pcr used define clinical spectrum disease analyzing <NUMBER> samples prospective study lower respiratory tract infection children younger <NUMBER> years <NUMBER> hcovnl<NUMBER> found third frequently detected pathogen rsv hpiv<NUMBER> infection strongly associated croup rather bronchiolitis suggesting causal relationship therefore probably somewhat less pathogenic rsv <NUMBER> thus another significant cause respiratory disease children added list cell tropism receptor use hcovnl<NUMBER> recently analyzed <NUMBER> receptor identification performed using new technology pseudotyping viruses surface proteins one virus incorporated membrane another viral particle eg hpiv<NUMBER> glycoproteins retrovirus particle thus binding entry assays performed using wellcharacterized molecularly malleable retrovirus particle pseudotype allows engineering desired variant viral envelope protein studied provides reporter assays assessment envelope proteins ability mediate binding fusion entry identify hcovnl<NUMBER> receptor hcovnl<NUMBER> spike protein incorporated membrane retroviral particles analyze cell tropism receptor engagement hcovnl<NUMBER> <NUMBER> nl<NUMBER> protein found bind angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor sarscoronavirus use ace<NUMBER> receptor infection target cells potent neutralizing activity directed hcovnl<NUMBER>s protein detected sera individuals aged <NUMBER> years older suggesting hcovnl<NUMBER> infection humans commonly acquired childhood facts sarscoronavirus hcovnl<NUMBER> use receptor differ greatly pathogenicity hcovnl<NUMBER> infection children seems frequent event raise concern pathogenic variants could evolve highlight need coronavirus vaccine development investigation antiviral strategies began <NUMBER> <NUMBER> years new viral agent identified <NUMBER> several existing antiviral drugs new synthetic compounds tested preliminarily inhibitors hcovnl<NUMBER> several potential strategies identified study including hr peptides could interfere fusion proteins function several small interfering rnas <NUMBER> identifying common themes strategies inhibiting diverse array pediatric respiratory viruses eg using hr peptides interfere fusion entry likely allow advances study one virus benefit antiviral strategies viruses scientific progress understanding viral replication entry fusion respiratory viruses likely benefit search antiviral strategies newest member group viruses cause respiratory disease children <NUMBER> two leading pediatricians summarized state art bronchiolitis treatment sum oxygen vitally important little convincing evidence therapy consistently even occasionally useful <NUMBER> unfortunately <NUMBER> years later statement largely still true real advances made pharmacologic treatment bronchiolitis occurrence wheezing rsvinduced bronchiolitis asthma coupled observation many infants hospitalized bronchiolitis caused rsv respiratory viruses increased risk recurrent wheezing episodes early childhood <NUMBER> <NUMBER> <NUMBER> <NUMBER> largely directed drug development focus acute bronchiolitis various asthma therapies fact genetic factors governing airway size control airway function variability inflammatory response viral infection together environmental exposures appear contribute pattern disease seen acute bronchiolitis also predisposition recurrent wheezingasthma <NUMBER> <NUMBER> although understanding mechanisms linking viral bronchiolitis asthma critical light implications therapy association remains elusive result treating bronchiolitis strategies treating acute asthma episode yielded consistent benefit past decades corticosteroids systemic inhaled b agonists mixed b agonists anticholinergics theophylline tried generally largely ineffective <NUMBER> <NUMBER> <NUMBER> light pathology airway obstruction associated bronchiolitis desquamation respiratory epithelium airway wall edema lack effectiveness surprising acute reversible airways obstruction although common children asthma constant finding patients viral bronchiolitis <NUMBER> may relate type immune response generated infection advances knowledge immunologic inflammatory factors contribute disease may suggest new approaches treatment facilitate understanding relationship viral bronchiolitis recurrent wheezing <NUMBER> cysteinyl leukotriene ltc<NUMBER> ltd<NUMBER> lte<NUMBER> concentrations recently found elevated upper lower respiratory tract secretions infants rsv bronchiolitis <NUMBER> <NUMBER> leukotrienes play key role airway obstruction associated asthma mediating mucosal edema mucus hypersecretion recruitment eosinophils smooth muscle contraction bisgaard colleagues <NUMBER> showed <NUMBER>week course cysteinyl leukotriene blocker montelukast infants acute rsv bronchiolitis reduced daytime cough increased number symptomfree days although study population included children <NUMBER> months age experiencing firsttime wheezing detailed analysis data suggests effect pronounced younger subjects observation correlates well evidence higher levels leukotriene levels infants younger <NUMBER> months <NUMBER> <NUMBER> study design focused longterm rather acute effects insufficient data support use montelukast treating milder forms disease relieving airways obstruction acute setting authors accompanying editorial note investigation appropriate study population documented rsv infection needed gauge benefit therapy <NUMBER> observation secretions composed primarily desquamated epithelial cells obstruct small airways children bronchiolitis suggested use recombinant human deoxyribonuclease treatment effective patients cystic fibrosis one study hospitalized infants acute rsv bronchiolitis chest radiographs discharge showed recombinant human dnase treatment associated significant improvement <NUMBER> however therapy affect clinical features respiratory rate wheezing retractions similar smaller intervention study severely ill patients also showed therapy effective correcting massive atelectasis avoiding need mechanical ventilation patients impending respiratory failure <NUMBER> leukotrienes studies needed define usefulness therapy intervention one focus addressing problem airway obstruction decreased levels surfactant protein spa b reported infants rsv bronchiolitis <NUMBER> mice surfactant deficiency confers increased susceptibility inflammation rsv infection <NUMBER> <NUMBER> increased susceptibility also found humans identifying infants deficient spa would risk severe rsv disease would beneficial target prevention therapy therefore surfactant replacement logical effect improving lung function also potential benefits decreasing inflammation small study ventilated patients rsv bronchiolitis patients experiencing respiratory failure treated two doses bovine surfactant showed improved static compliance indicative decreased hyperinflation decreased airways resistance compared untreated patients <NUMBER> acute improvement gas exchange occurred group treated surfactant showed improved oxygenation ventilation indices first <NUMBER> hours mechanical ventilation unfortunately surfactant currently must delivered endotracheal intubation therefore therapy reserved children respiratory failure larger studies needed assess effects surfactant duration mechanical ventilation viral clearance <NUMBER> development accurate rapid diagnostic assays respiratory viruses key two seemingly separate rapidly converging arenas diagnosis become increasingly important clinical management individual children urgently needed global public health including pathogen surveillance recent years significant progress made applying advances molecular biology respiratory virus diagnosis new strategies already clinically useful <NUMBER> <NUMBER> <NUMBER> practitioner guidelines clear data needed regarding situations specific kinds assays may appropriate transition technologies development stage clinically useful stage still flux however one may look forward situation public health institutions rapidly responsive pathogens arising community practitioners able use detailed information guide prevention therapy masstag polymerase chain reaction paradigm new detection strategies early recognition containment wide range respiratory pathogens recently briese colleagues <NUMBER> described development masstag pcr differential diagnosis respiratory disease masstag pcr multiplex assay pathogen gene targets coded library <NUMBER> distinct mass tags microbial rna dna amplified multiplex rtpcr using <NUMBER> primers primer labeled different molecular weight tag attached primer photocleavable link amplification mass tags released amplified material uv irradiation identity tag determined mass spectrometry identity organism determined presence two specific tags one primer technology successfully applied respiratory disease first test case <NUMBER> multiplex primer sets designed identify <NUMBER> respiratory pathogens single masstag pcr reaction method found highly sensitive specific diagnosing viral bacterial agents clinical samples tests performed using blinded analysis previously diagnosed clinical specimens banked sputum nasal swabs lung washes masstag pcr highly effective identifying pathogens including rsv hpiv<NUMBER> <NUMBER> <NUMBER> hmpv influenza coronavirussars hcovnl<NUMBER> included study technology probably used immediately public health setting identifying outbreaks global surveillance technology becomes streamlined mass spectrometry becomes easily accessible method great potential individual patient management diagnosing respiratory syncytial virus paramyxovirus human parainfluenza virus clinical setting rsv hpiv antigens rapidly identified individual patients using commercially available rapid screening kits sensitivities specificities <NUMBER> <NUMBER> tests performed directly nasopharyngeal secretions using either fluorescentconjugated antibody elisa monoclonal antibody <NUMBER> multiplex quantitative rtpcrenzyme hybridization assays identify panel respiratory viruses differentiate rsv viral subtypes b hpiv<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> hexaplex assay prodesse inc milwaukee wisconsin <NUMBER> multiplex rtpcr assay detecting hpiv<NUMBER> <NUMBER> <NUMBER> rsv b influenza virus types b although sensitivity specificity positive negative predictive values excellent <NUMBER> confirmation viral culture either rapid traditional still important especially negative result ill child pcrbased technology may provide useful contribution diagnosis subtyping rsv hpiv<NUMBER> future <NUMBER> assay kits antigen detection allow simple screening children likely used commonly future therapies pediatric respiratory viruses become available however hoped importance accurate viral diagnosis gains wider acceptance among practitioners especially influenza season prompt specific treatment influenza effectively shorten duration lessen severity disease children <NUMBER> identification etiologic agent even specific therapy available critical containing respiratory virus outbreaks avoiding transmission vulnerable individuals although hmpv included among <NUMBER> respiratory pathogens successfully identified single masstag pcr described earlier <NUMBER> clinical diagnosis recently identified pathogen still less developed rsv hpiv however molecular methods developed recently <NUMBER> <NUMBER> <NUMBER> hmpv virus respiratory secretions best identified rtpcr several original clinical reports virus used rtpcr assays used pcr primers hybridizing polymerase l gene used l gene pcr product sequence identify virus faster specific realtime rtpcr tests developed past <NUMBER> years also detect viruses four known genetic lineages hmpv <NUMBER> <NUMBER> <NUMBER> diagnostic strategies hcovnl<NUMBER> developed use population studies assess incidence infection virus association respiratory disease <NUMBER> <NUMBER> whether hcovnl<NUMBER> diagnosis place practice whether identifying agent important public health setting unclear pancoronavirus rtpcr assay recently developed used assess respiratory disease hospitalized children <NUMBER> original consensus rtpcr assay designed amplify known coronaviruses unable detect hcovnl<NUMBER> mismatches primer sequences <NUMBER> new assay consensus primers modified based alignment hcovnl<NUMBER> prototype sequence addition hcovnl<NUMBER> sarscoronavirus two human coronaviruses known infect respiratory tract oc<NUMBER> hcovoc<NUMBER> <NUMBER>e hcov<NUMBER>e included optimized pancoronavirus rtpcr assay addition identifying specific viral infections sequence analysis amplified gene segments showed hcovnl<NUMBER> isolates could classified two subtypes corresponding two prototype hcovnl<NUMBER> sequences pancoronavirus assay tested four known human coronaviruses also three animal coronaviruses feline infectious peritonitis virus porcine hemagglutinating encephalomyelitis virus murine hepatitis virus results suggest assay efficiently amplifies broad range coronaviruses human animal pancoronavirus rtpcr assay could especially useful ability identify previously unknown coronaviruses colleagues national institutes allergy infectious diseases unwavering support pediatric respiratory virus research originating guangdong province china <NUMBER> severe acute respiratory syndrome sars became first pandemic outbreak twenty first century disease caused <NUMBER> infections responsible almost <NUMBER> deaths remarkably sars quickly became disease global importance impacting air travel commerce tourism outbreak eventually contained using impressive joint global public health effort <NUMBER> years later another human coronavirus cov emerged causative agent middle east respiratory syndrome mers may <NUMBER> already <NUMBER> laboratory confirmed cases mers <NUMBER> countries worldwide <NUMBER> related deaths <NUMBER> recorded ongoing outbreak buraydah saudi arabia <NUMBER> recurrent episodes like impressed upon scientific community need advance development licensure manufacture stockpiling deployment vaccines combat emerging infectious coronavirus infections <NUMBER> review progress area vaccine development merscov appraised assessment lessons learned response earlier sarscov pandemic coronavirus family received global attention november <NUMBER> first case sarscov infection reported guangdong province china within <NUMBER> months <NUMBER> cases five deaths respiratory failure recorded subsequently led notification world health organization issuance global health alert well travel advisory retrospect probably initial delay identification etiological agent unknown origin consequently allowed worldwide spread disease <NUMBER> scientific community though subsequently quick respond begin race towards vaccine development <NUMBER> full characterization genome sequencing sarscov published within <NUMBER> months started coordinate efforts determine epidemiology pathogenesis transmission disease vaccine studies quickly identified virus spike protein possible recombinant antigen component future vaccine cterminal portion sarscov nucleocapsid protein identified likely candidate improved diagnostics tools candidate dna vaccine showing efficacy neutralization protective immunity mice identified within <NUMBER> year outbreak <NUMBER> vaccine development fueled daunting possibility reemergence disease additional isolated cases suspected sars infection scare reported china <NUMBER> <NUMBER> point ten human vaccine trials planned using inactivated virus recombinant proteins adenovirus platforms plasmid dna trials planned take place various countries including china canada france austria usa italy <NUMBER> major hurdle however lack appropriate animal challenge model could reproduce infection similar observed humans identification virus reservoirs mechanisms transmission sars outbreaks ended july <NUMBER> <NUMBER> months issuance global alert outcomes vaccine development race summarized phase clinical trial report published several years later two vaccine candidates developed analyzed sinovac nihniaid respectively earliest liveattenuated vaccine clinical trial took place fast track designation approval regulatory authorities china conducted <NUMBER> <NUMBER> <NUMBER> results indicated serum conversion observed <NUMBER> volunteers received low dosage vaccine study plasmid dna vaccine candidate developed niaids vaccine research centre well tolerated produced desired immune responses including neutralizing antibodies <NUMBER> none candidates though proceeded phase ii recently recombinant subunitbased sarscov vaccine produced sabin vaccine institute product development partnership based virus receptorbinding domain <NUMBER> goal improve safety vaccine cost efficiency vaccine development process <NUMBER> vaccine produced cgmp conditions clinical trials immediately scheduled middle east respiratory syndrome mers first case reported june <NUMBER> saudi arabia isolate initially named hcovemc<NUMBER> traced back cluster pneumonia cases zarqa hospital jordan marchapril <NUMBER> september <NUMBER> report uk novel coronavirus london<NUMBER> published involving patient travel history qatar shortly thereafter isolates found similar named middle east respiratory syndrome coronavirus merscov betacoronavirus phylogenetically closely related sarscov october <NUMBER> <NUMBER> laboratory confirmed cases <NUMBER> probable cases affecting nine countries despite increased global vigilance part certainly due prior experience sarscov cases merscov still reported outside middle east <NUMBER> years first emergence largest reported south korea june <NUMBER> <NUMBER> traced back single traveler visited four various middle eastern countries within month outbreak involved <NUMBER> confirmed patients placed thousands individuals close observation <NUMBER> overall speculated lower number cases mers comparison sars may due better coordination notifications early travel advisories implementation improved hospital containment measures issuance global alert better compliance international health provisions originally drafted <NUMBER> <NUMBER> although possibility mers could potentially follow pandemic path sars based similarity phylogenetics difference biology virus adaptation human beings distinct merscov found already circulating human populations without mutating pandemic form sarscov adapted human beings within several months showing complexity virus biology affinity merscov spike protein human dpp<NUMBER> receptor lower sarscov rbd towards human ace<NUMBER> receptor thus pandemic potential merscov considered lower sars likely reaching epidemic potential <NUMBER> nevertheless remains valid concern especially since fatality rate <NUMBER> much higher sars <NUMBER> table <NUMBER> summarize various approaches developing merscov vaccine sarscov inactivated means formaldehyde uv light betapropiolactone able protect mice infection challenge studies <NUMBER> <NUMBER> <NUMBER> analogy mers recombinant propagationdefective live virus lacking structural envelope protein gene proposed vaccine candidate prevent merscov infection <NUMBER> merscov genome approximately <NUMBER> kb size <NUMBER> encodes several unique accessory proteins four major structural proteins receptorbinding spike protein nucleocapsid n protein envelope e protein membrane protein <NUMBER> initial expectation host cell entry point merscov would similar angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor used sarscov confirmed instead dipeptidyl peptidase<NUMBER> dpp<NUMBER> receptor identified critical receptor entry merscov host cell <NUMBER> dpp<NUMBER> share structural similarities ace<NUMBER> diverse cellular tropism expressed surface several types cells <NUMBER> sarscov specifically targets ace<NUMBER>expressing ciliated epithelial cells lungs <NUMBER> <NUMBER> dpp<NUMBER> plays diverse role including regulation peptide hormone metabolism cell activation neurotransmitter function glucose homeostasis <NUMBER> notably merscov spike protein exhibits high affinity dpp<NUMBER> receptors wide range hosts including human camel horse <NUMBER> <NUMBER> amino acid residue receptorbinding domain rbd fragment s<NUMBER> subunit sarscov spike protein able induce neutralizing antibodies protect sarscov infection animal models <NUMBER> <NUMBER> using homology modeling corresponding merscov rbd located residues <NUMBER> <NUMBER> protein <NUMBER>• several variants rbd since investigated vaccine candidates s<NUMBER> fragment fused human igg fc demonstrating highest dpp<NUMBER>binding affinity inducing highest titers neutralizing antibodies immunized mice rabbits <NUMBER> another rbd fragment s<NUMBER> formulated aluminum hydroxide alum investigated rhesus macaque model <NUMBER> animals immunized higher dose vaccine <NUMBER> μg rrbd admixed <NUMBER> mg alum adjuvant showed less severe pneumonia decreased viral loads upon challenge merscov compared lower dose group <NUMBER> recently though group korea observed high mutation rate isolates merscov several patients seen mutations rbd protein displayed reduced binding affinity host cell receptor making virus less virulent wildtype possibly also contributing virus evading host immune system <NUMBER> therefore shi et al suggested epitopebased vaccine design identify highly conserved region produce neutralizing antibodies cellular immunity merscov based silico protein antigenic prediction structure analysis nucleocapsid n protein merscov probable antigenic protein number putative lymphocytes epitope peptides identified n protein <NUMBER> nevertheless suggested epitopes undergo comprehensive vitro vivo studies efficient use vaccines merscov use dna vaccines based transfection plasmid dna encodes antigenic proteins host cells subsequent expression foreign genes order induce potent immune response disease interest undoubtedly first glance nucleic acid immunization appears attractive vaccine platform fast vaccine development clean safety profile low production costs <NUMBER> however spite promising data preclinical animal studies dna vaccines yet fully successful humans example dengue dna vaccine combined dna protein vaccine vaccine research center niaid dna primes<NUMBER> protein boost s<NUMBER> primes<NUMBER> boost mouse nhp <NUMBER> receptorbinding domain new york blood center utmb bcm s<NUMBER> rbd fragment mouse hdpp<NUMBER> transgenic mouse rabbit <NUMBER> <NUMBER>• <NUMBER> d<NUMBER>me <NUMBER> showed excellent antidengue cellular humoral immune responses nonhuman primates however failed produce neutralizing antibody human subjects <NUMBER> <NUMBER> research development merscov dna vaccines focused protein engineering plasmid dna encoded fulllength protein sequences <NUMBER>• synthetic dna vaccine merscov studied mice large animal models nonhuman primatesnhps camels results showed vaccine capable inducing proteinspecific neutralizing antibodies animals intriguingly study revealed vaccinated nhps protected failed demonstrate clinical radiographic signs pneumonia post mers viral challenge <NUMBER>• early <NUMBER> firstinhuman trial mers vaccine begun <NUMBER> <NUMBER> participants receive mers dna vaccine gls<NUMBER> codeveloped inovio pharmaceuticals geneone life science inc <NUMBER> alternative approach graham coworkers proposed combine dna vaccine s<NUMBER> subunit protein primeboost scheme rhesus macaques immunized spike dna vaccine followed s<NUMBER> protein adjuvanted aluminum phosphate yielded neutralizing antibodies showed fewer signs pulmonary disease animals vaccinated s<NUMBER> protein <NUMBER> merscov vaccine targets camels developed using viral vector vaccine technology adenoviral vectors encoding fulllength merscov protein s<NUMBER> extracellular domain protein preclinical studies showed vaccinated dromedary camels mounted neutralizing antibody response merscov vitro <NUMBER> guo et al highlighted intramuscular route administering adenovirusbased vaccines merscov protein could affect antigenspecific cell response immunized mice <NUMBER>• lately viral vector vaccines merscov constructed using modified vaccinia virus ankara mva mvamerss recombinant virus genetically stable primary chicken embryo fibroblasts cef without need additional animalderived components able protect human dpp<NUMBER>transduced mice merscov challenge <NUMBER> phase clinical trial humans vaccine announced supported german center infection research difz <NUMBER> novavax collaboration team university maryland produced merscov fulllength nanosized amphiphilic spike protein aggregates using recombinant baculovirus construct sf<NUMBER> cells formulated alum even greater extent novavax saponinbased matrixm<NUMBER> adjuvant high titers neutralizing antibodies merscov related sarscov observed <NUMBER> however plans clinical trials made public yet <NUMBER> another approach towards mers vaccine targeting camels one reservoirs virus according crosssectional serological survey <NUMBER> provinces saudi arabia <NUMBER> individuals seroprevalence merscov antibodies significantly higher camelexposed individuals general population <NUMBER> scientists netherlands germany spain shown modified vaccinia virus ankara vaccine expressing merscov spike protein mvas conferred mucosal immunity dromedary camels using primeboost approach dromedary camels immunized intranasally well intramuscularly <NUMBER> weeks challenged intranasally merscov virus animals showed typical mild clinical symptoms mers infection species significant reduction excreted infectious virus particles well reduction viral rna immunized camels observed <NUMBER> <NUMBER>• however concern reduction might sufficient disrupt spread virus vaccination might provide longlasting immunity addition since disease cause significant morbidity camels perceived reluctance among camel owners animals vaccinated first place <NUMBER> added benefit mvas vaccine though observed vaccination provided crossprotection camelpox virus might treatment attractive animal owners order characterize viral pathogenesis evaluate therapeutic options merscov researchers rely animal model mimicking clinical course pathology observed humans contrast sars animal model aged mice displayed pathological changes postinfection <NUMBER> mice infected merscov show clinical signs infections weight loss <NUMBER> addition syrian hamsters ferrets known susceptible sarscov failed infected merscov <NUMBER> <NUMBER> nonhuman primates nhp common marmoset models tested suitability merscov models upon combination various inoculation routes intratracheal ocular oral intranasal using infectious dose merscov rhesus macaques developed transient lower respiratory tract infection mild clinical disease without mortality <NUMBER> hand merscov infected common marmosets developed progressive severe pneumonia <NUMBER> although nhps sufficiently good models study mers different severity working nhps costly hence establishing transgenic rodent animal models crucial move forward development vaccines therapeutic methods merscov comparing small animal cell lines transfected human hamster dpp<NUMBER> genes observed humanized cell lines enabled merscov replication <NUMBER> fully permissive merscov infection resulting weight loss acute inflammatory response within lungs brains animal <NUMBER>• hcd<NUMBER>dpp<NUMBER> transgenic mice immunized mf<NUMBER>adjuvanted rbd fragment s<NUMBER> fused fc fragment protected challenge high dose <NUMBER>× ld <NUMBER> virus <NUMBER> another hdpp<NUMBER> transgenic mouse recently created using expression vector either cytokeratin <NUMBER> k<NUMBER> surfactant protein c spc promoters spcdpp<NUMBER> transgenic mice exhibiting milder disease phenotype <NUMBER> emerging reemerging diseases pandemic potential major driving force vaccine development human coronaviruses pandemic outbreak sarscov necessitated development blueprint global response type threat merscov reaches fourth year emergence initial technological advances enabled one dnabased vaccine quickly enter phase human trials process arguably accelerated key information strategic vaccine development obtained prior sarscov outbreak nevertheless process bringing vaccine clinic remains lengthy cumbersome new infectious diseases shifting focus away mers risk vaccine development process remains unfinished picked next coronavirus emerges conflict interest authors declare conflict interest human animal rights informed consent article contain studies human animal subjects performed authors sarscov<NUMBER> member family coronaviridae causative agent covid<NUMBER> disease spread rapidly around globe since first outbreak wuhan china december <NUMBER> world health organization declared outbreak sixth public health emergency international concern <NUMBER> th january <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> despite tremendous efforts contain virus spread ongoing though majority cases resolve spontaneously develop various fatal complications including organ failure septic shock pulmonary edema severe pneumonia acute respiratory distress syndrome ards <NUMBER> <NUMBER> <NUMBER> current pandemic highly pathogenic covs hit world severe acute respiratory syndrome coronavirus sarscov <NUMBER> middle east respiratory syndrome mers coronavirus <NUMBER> sarscov<NUMBER> identified βcoronavirus like sarscov binds angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors <NUMBER> <NUMBER> recent data genome sequencing sarscov<NUMBER> revealed shares approximately <NUMBER> similarity sarscov nucleotide level <NUMBER> varies different genes sarscov<NUMBER> contains linear singlestranded positivesense rna genetic material encodes spike envelop e membrane nucleocapsid n proteins <NUMBER> spike protein binds host cell receptors shares <NUMBER> nucleotide similarity two <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein consists two subunits s<NUMBER> s<NUMBER> s<NUMBER> interacts surface receptor s<NUMBER> helps fusion viral cellular membranes subsequent entry virus host cells different coronaviruses depending upon viral species use different receptor binding domains rbd present s<NUMBER> subunit interact host cell receptors <NUMBER> <NUMBER> rbd merscov recognizes nonacetylated sialoside attachment receptors human dipeptidyl peptidase <NUMBER> <NUMBER> <NUMBER> sarscov interacts ace<NUMBER> receptors <NUMBER> however sarscov<NUMBER> compared sarscov contains different amino acids five amino acids six mutated composition rbd crucial receptor binding ace<NUMBER> high affinity <NUMBER> functional polybasic furin site s<NUMBER>s<NUMBER> boundary may role defining viral infectivity host range <NUMBER> <NUMBER> furin cleavage site reported sarscov fusion membrane involves either direct receptormediated fusion receptormediated endocytosis <NUMBER> highaffinity binding sarscov<NUMBER> ace<NUMBER> receptor along presence furin tmprss<NUMBER> s<NUMBER> cleavage sites explain rapid spread strong ability human human transmission <NUMBER> currently specific antiviral medicine vaccine available disease however many studies clinical trials undertaken assess efficacy safety various drugs vaccine candidates <NUMBER> sarscov<NUMBER> share significant similarities sars mers coronaviruses use similar spike protein receptor binding key information past vaccine studies similar viruses may help accelerate development effective therapyvaccine covid<NUMBER> <NUMBER> <NUMBER> rna viruses covs go frequent recombination therefore live attenuated vaccine carries inherent risk reversal virulent form may pose severe threat human lives ideally vaccine highly pathogenic virus including covs able generate protective antibody response minimum antigen dose quick time adverse reactions covid<NUMBER> spreading globally infecting large number people due lack prophylactic measure demand vaccine available overwhelming therefore highly desirable potential vaccine able induce immunity short time minimum quantity antigen required make affordable help meet high global demands <NUMBER> <NUMBER> issues may resolved incorporating suitable adjuvant vaccine preparations help eliciting robust immune response also possibly reduce antigen quantity need multiple doses vaccine thus selection effective adjuvant becomes crucial development adjuvanted vaccine covid<NUMBER> past vaccine studies similar covs various adjuvant combinations may provide key information help picking adjuvants possess good safety profile efficacy therefore review discuss past adjuvanted vaccine studies outcomes similar covs might useful developing adjuvanted vaccine covid<NUMBER> briefly discuss current progress development adjuvanted vaccines covid<NUMBER> aluminum hydroxide alum commonly used agent adjuvant mechanism adjuvant action complex far multiple hypotheses put forward explain mode action <NUMBER> shown act depot formation site injection allowing slow release antigen prolongs interaction time antigen antigenpresenting cells apcs converts soluble antigens particulate forms readily phagocytosed <NUMBER> cellular level aluminum hydroxide directly stimulates monocytes produce proinflammatory cytokines activating cells activated th<NUMBER> cells release il<NUMBER> turn induce increase expression mhc class ii molecules monocytes <NUMBER> alum approved adjuvant multiple licensed vaccines human use majority countries worldwide table <NUMBER> table <NUMBER> table <NUMBER> <NUMBER> <NUMBER> mf<NUMBER> oilinwater type immunogenic adjuvant consists squalene two surfactants tween <NUMBER> span <NUMBER> mf<NUMBER> safe welltolerated potent adjuvant used pandemic focetria® celtura® seasonal influenza fluad® vaccines many countries table <NUMBER> <NUMBER> <NUMBER> inclusion mf<NUMBER> adjuvant influenza vaccine reported induce higher levels antigenspecific antibody levels higher hai titers hemagglutination inhibiting better protection <NUMBER> <NUMBER> <NUMBER> though favors th<NUMBER>type response like alum mf<NUMBER> activates cd<NUMBER> cells produces higher antibody tiers ha hemagglutinin influenza virus <NUMBER> mf<NUMBER> tested adjuvant many vaccines bacteria viruses including sarscov immunization inactivated sarscov vaccine adjuvanted mf<NUMBER> protected mice challenge virus vaccine able elicit neutralizing antibodies <NUMBER> doses <NUMBER> subunit vaccines based s<NUMBER> protein rbd epitopes merscov coadministered mf<NUMBER> significantly augmented immunogenicity resulting strong induction igg neutralizing antibody response preparations protected mice lethal virus challenge <NUMBER> <NUMBER> <NUMBER> many merscov rbd candidate vaccines adjuvanted mf<NUMBER> developed tested mice vaccines elicited neutralizing antibodies protected hdpp<NUMBER> transduced mice lethal challenge table <NUMBER> <NUMBER> <NUMBER> montanide waterinoil wo emulsion contains mineral oil surfactant mannide monooleate family possesses immunostimulatory activity works depot formation site injection resulting slower release antigens local inflammation recruitment antigenpresenting cells apcs enhances antibody titer well cytotoxic tlymphocyte ctl activity antigen formulated <NUMBER> <NUMBER> well tolerated humans compared fia freunds incomplete adjuvant tested vaccines aids acquired immunodeficiency syndrome malaria cancer influenza varying degree success <NUMBER> <NUMBER> <NUMBER> <NUMBER> combination montanide isa<NUMBER> cpg odn oligodeoxynucleotide used widely many vaccines combination exerts synergistic effect boosting th<NUMBER> immune response montanide isa<NUMBER> cpg used emulsify recombinant n protein sarscov formulation elicited strong th<NUMBER> immune responses mice macaques <NUMBER> synthetic peptides spike protein sarscov formulated adjuvant montanide isa<NUMBER>cpg combination elicited strong antibody titer immunized animals capable inhibiting sarscov pseudovirus entry hepg<NUMBER> cells <NUMBER> dna vaccine encoding sarscov n protein elicited potent n proteinspecific immune response coadministered montanide isa<NUMBER>cpg adjuvants <NUMBER> recombinant rbd merscov adjuvanted montanide isa<NUMBER> induced high titers serum antibodies could neutralize virus cell culture <NUMBER> pieces evidence previous studies indicate montanide isa<NUMBER> may increase immunogenicity vaccines based recombinant spike protein synthetic peptides corresponding rbd protein may used along cpg odn induce overall th<NUMBER> biased immune response predominantly th<NUMBER> immune response seems cause ade viral challenge following immunization oilinwater adjuvant systems developed glaxosmithkline gsk as<NUMBER> adjuvant system <NUMBER> liposomebased adjuvant consist monophosphoryl lipid mpl saponin molecule qs<NUMBER> whereas as<NUMBER> adjuvant system <NUMBER> αtocopherol squalenebased adjuvant used gsks ah<NUMBER>n<NUMBER> pandemic flu vaccine pandemrix® mpl extracted salmonella minnesota qs<NUMBER> purified bark south american tree quillaja saponaria molina mpl signals tolllike receptor<NUMBER> tlr<NUMBER> results activation apcs production cytokines interferons ifns q<NUMBER> reported induce antigenspecific antibody response well cellmediated immunity <NUMBER> <NUMBER> coadministered recombinant sarscov protein q<NUMBER> induced high titers antigenspecific serum antibodies protected viral infection <NUMBER> as<NUMBER> system used recently developed rtssas<NUMBER> malaria vaccine well tested herpes zoster subunit vaccine polyprotein hiv<NUMBER> vaccine tuberculosis mtb<NUMBER>fas<NUMBER> candidate vaccine <NUMBER> adjuvants also used inactivated sarscov vaccine preparation mice hamsters as<NUMBER> badjuvanted vaccine slightly immunogenic as<NUMBER> adjuvanted vaccine vaccine animals immunized adjuvant provided better protection nonadjuvanted vaccine importantly study observe enhance disease ade lungs liver hamsters following sarscov challenge <NUMBER> delta inulin di one many isoforms inulin polysaccharide stable higher temperature better immune potency activates complement system coadministered antigen helps mount robust antigenspecific adaptive immune response consisting antibody cellmediated immunity th<NUMBER> adjuvant property <NUMBER> balanced enhancement th<NUMBER> th<NUMBER> responses observed di advax™ adjuvant coadministered inactivated jev japanese encephalitis virus influenza vaccines conferred protection viral challenges <NUMBER> <NUMBER> similarly recombinant spike protein inactivated sarscov vaccine coadministered delta inulin plus cpg oligonucleotide adjuvants combination significantly enhanced serum neutralizing antibody titers without causing lung immunopathology case alum used instead delta inulin <NUMBER> tlrs pattern recognition receptors prrs identify pathogenassociated molecular patterns pamps present cell surfaces well endosomal compartments interaction appropriate ligand triggers release proinflammatory cytokines type <NUMBER> ifns interferons activates cells innate adaptive immune system many helminthderived molecules shown potent immunostimulatory effects including asp<NUMBER> asp<NUMBER> present helminth onchocerca volvulus recombinant asp<NUMBER> rovasp<NUMBER> reported induce mix th<NUMBER> th<NUMBER> responses included vaccine antigen however depending antigen could also activate predominantly th<NUMBER> type immune response <NUMBER> <NUMBER> therefore beneficial condition bits help arms immune response needed clear infection immune response induced asp<NUMBER> protein adjuvant affect adjuvant activity subsequent boost <NUMBER> asp<NUMBER> shown improve igg<NUMBER> igg<NUMBER>a antibody levels commercially available vaccines influenza rabies adjuvant effect observed higher either traditional adjuvant alum mpl plus trehalose dicorynomycolate tdm <NUMBER> <NUMBER> <NUMBER> recombinant asp<NUMBER> protein included recombinant sarscov spike protein antigen rbd containing vaccine combinations induced mixed immune response th<NUMBER> dominance <NUMBER> similar findings observed rovasp<NUMBER> used adjuvant either protein sarscov hiv<NUMBER>gp<NUMBER> <NUMBER> immunization rbd sarscov plus rovasp<NUMBER> nhps resulted high titer neutralizing antirbd antibodies low levels antirovasp<NUMBER> antibodies <NUMBER> complex proteosomes lps derived shigella flexneri named protollin whereas proteosomes contain hydrophobic outer membrane proteins derived neisseria meningitides protollin exerts immunostimulatory effect via tlr<NUMBER> tlr<NUMBER> signaling resulting production cytokines ifns activation apcs intranasal administration protollin influenza antigen split recombinant ha induced serum igg mucosal secretory iga protected mice lethal virus challenge <NUMBER> <NUMBER> application shown effective reducing allergic asthma mouse model <NUMBER> protective development pneumonia murine model shigella infection <NUMBER> safe welltolerated healthy adults <NUMBER> protollin effective safe immunogenic induced protective antibody response consisting serum igg mucosal iga humans administered intranasally trivalent influenza vaccine <NUMBER> protollin administered intranasally recombinant sarscov protein induced significant levels antigenspecific serum igg mucosal iga antibodies compared alum plus recombinant protein administered via intramuscular route protected mice live viral challenge <NUMBER> therefore evidence reflects protollin adjuvant appears safe welltolerated human importantly ability induce serum mucosal immunity might prove beneficial explored sarscov<NUMBER> vaccine development many investigations revealed activation immune system animal challenged live virus following immunization causes immunopathological changes excessive release proinflammatory cytokines cytokine storm il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER>β gcsf gmcsf tnfα <NUMBER> <NUMBER> <NUMBER> ade immune enhancement occurs virus gains access immune cells adhered antibodies leading increase infectivity virulence virus inside cells arent usual target virus multiplies releases progenies infecting cells <NUMBER> many viruses dengue yellow fever hiv covs reported induce ade <NUMBER> pieces evidence suggest viruses exploit fc receptor fcr immune cells gain entry attached antibodybinding site antibodies fc region antibody sequence binds complement system immune cells expressing fcr receptors <NUMBER> <NUMBER> presence high levels nonneutralizing antibodies appears primary reason triggers ade <NUMBER> factors contribute include lowaffinity suboptimal levels neutralizing antibodies isotype antibodies induced <NUMBER> <NUMBER> presence circulating antibodies related epitopes different strains related viruses may also contribute enhancement disease <NUMBER> though data conflicting observed many inactivated virus vaccine recent data available vaccine studies sarscov<NUMBER> nhps appears promising inactivated vaccine picovacc adjuvanted alum elicited spike rbd proteinspecific neutralizing antibodies protected macaques viral challenge importantly study observe ade immunized animals table <NUMBER> <NUMBER> recombinant s<NUMBER> protein virus fused fc adjuvanted saponin microemulsion administered macaques induced strong antis<NUMBER> neutralizing antibodies <NUMBER> oxford universitys vaccine candidate chadox<NUMBER> ncov<NUMBER> encoding protein sarscov<NUMBER> protected rhesus monkeys developing pneumonia vaccine significantly reduced viral loads bronchoalveolar lavage fluid respiratory tract tissue without causing disease enhancement vaccinated monkeys <NUMBER> recently concluded phase clinical trial ad<NUMBER>ncov adenovirus type <NUMBER> vector expressing protein vaccine reported promising findings vaccine found safe welltolerated induced humoral cellular immunity <NUMBER> encouraging results also received recently concluded phase clinical trial merscov vaccine table glaxosmithkline also teamed many firms xiamen innovax biotech sanofi make adjuvant technology available collaborators vaccine candidates <NUMBER> sanofi xiamen innovax biotech using gsks as<NUMBER> adjuvant squalenebased recombinant protein vaccine candidates similarly csl commonwealth serum laboratories australia seqirus germany tied use mf<NUMBER> adjuvant uses novel molecularclam technology covid<NUMBER> vaccine candidate <NUMBER> novavax usa hand using proprietary matrixm™ adjuvant vaccine candidate nvxcov<NUMBER> consisting nanoparticles carrying sarscov<NUMBER> spike protein antigens <NUMBER> another biopharma company soligenix inc collaborated btg speciality pharmaceutics soligenix use novel vaccine adjuvant covaccine ht btg covid<NUMBER> vaccine candidate <NUMBER> covaccine ht oilinwater emulsion consisting sucrose fatty acid sulfate easter sfase squalene reported induce humoral well cellmediated immunity <NUMBER> <NUMBER> ibio signed agreement infectious disease research institute idri seattle us effort utilize novel adjuvants gla glucopyranosyl lipid adjuvant synthetic analogue mpl sarscov<NUMBER> vlp vaccine development <NUMBER> <NUMBER> experience knowledge generated past vaccine studies different adjuvants adjuvanted vaccine mice induced neutralizing antibodies however also pr though affect adjuvanticity vaccine also produced significant ne produce much antibodies aga <NUMBER> rovasp<NUMBER> sarscov peptide vaccine mice demonstrated rovasp<NUMBER> bet mpl tdm enhanced production th adjuvanted vaccine produced high peptide <NUMBER> protollin sarscov spike protein mice adjuvanted vaccine elicited high lev serum antibodies neutralizing antigenspecific iga levels vaccine challenge j u r n l p r e p r f various dna vaccines including aids <NUMBER> malaria influenza <NUMBER> also human trial dna vaccine made plasmid dna encoding protein pathogens demonstrated inducing b cell responses showing similar effects live viruses antigenic proteins produced endogenously presented efficiently mhc class thus help inducing cd<NUMBER> tcell responses <NUMBER> dna vaccines simple stable safe easily produced possible option use live vaccines <NUMBER> numbers sarscov proteins viz <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> n <NUMBER> <NUMBER> proteins reported induce cellular humoral responses utilized dna vaccine candidates <NUMBER> study dna vaccine associated expression protein generated tcell neutralizing antibody responses lowered replication sarscov respiratory tract manifested protective efficacy gene mice antibody mediated tcell dependent <NUMBER> study plasmid improved gene expression spike protein heterologous viral rna export elements protection mouse model <NUMBER> role recorded case vivo models vaccination mice multiepitope dna vaccine elicited specific antibody response two candidate epitopes s<NUMBER> m<NUMBER> <NUMBER> reduced virulence sarscov invitro report protective efficacy <NUMBER> another study mice immunized ndna vaccine induced nspecific antibody response tccell activity <NUMBER> <NUMBER> moreover strong delayedtype hypersensitivity dth cd<NUMBER> ctl responses n protein observed <NUMBER> another study ndna vaccination expression n protein linkage lamp better presentation mhc ii amplified memory response <NUMBER> moreover vaccination j u r n l p r e p r f c<NUMBER>bl<NUMBER> mice naked crtn dna improved mhc class presentation induced nspecific humoral cellular immunity also considerably reduced titer challenging vaccinia virus cells expressing n protein <NUMBER> addition animal models ndna vaccine candidate also evaluated hlatransgenic mice induced specific cd<NUMBER> tcell response <NUMBER> besides expression n proteins protein also reported expressed mice found induce neutralizing antibodies human monoclonal antibodies cytotoxic tlymphocyte response <NUMBER> comprehensive study dna vaccine using different gene fragments mand n dna vaccine reported highest cellular immunity mice <NUMBER> although dna vaccines works efficiently preclinical stages efficacy field conditions quite unsatisfactory lower immunogenicity <NUMBER> compared vaccines inactivated liveattenuated virus vaccines need improvement regarding efficacy confront problem different primeboost approaches heterologous prime boost proteins inactivated viral vaccine candidates viral vectors constructed <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> various practices mostly traditional one approached make vaccine methods average takes <NUMBER> years case human papilloma virus rotavirus development proteinbased vaccine requires growth viruses protein purification lengthy process may take several years make effective new generation vaccine fast spreading virus instead protein mrna vaccination strategy better approach <NUMBER> mrna j u r n l p r e p r f vaccine manifests immune responses similar natural infection provides short synthetic viral mrna used host produce antigen proteins since mrna used vaccine injected cant integrate hosts genome safe use furthermore safer inactivated protein based vaccines free risk protein contamination injected virus become active huge benefit mrna vaccine circumvent hassle associated purification viral proteins saves time months years used standardization scaling mass production <NUMBER> far approved rna considering safety efficacy subunit vaccines involving pure antigens said advantageous constituent includes synthetic peptides recombinant proteins expresses particular fragments immunogen excluding participation contagious viruses addition subunit vaccines less prone generate side effects site inoculation due stable conditions definite fragments pathogen subunit vaccines achieve reliable production due qualities subunit vaccines helpful making interesting candidate vaccine number structural proteins comprising spike envelope e membrane nucleocapsid n expressed sarscov may act antigens activate neutralizing antibodies generate defensive response spike protein virus performs significant part entering host <NUMBER> covrna genome allowed go inside cells host early interactions s<NUMBER> domain receptor host ie pp <NUMBER> merscov ace<NUMBER> sarscov followed viral host membrane fusion facilitated s<NUMBER> segment develop vaccines based cov subunit proteins preferred candidate proteins sites binding receptor well membrane fusion vaccines based protein likely j u r n l p r e p r f activate antibodies prevent binding virus later fusion membranes well thereby counteracting infection virus <NUMBER> glycoprotein sarscov shown bind cellular receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> interesting candidate target vaccine therapeutic improvement <NUMBER> <NUMBER> practice robustly encouraged discovery illustrates infectivity sarscov powerfully counteracted human mab binds protein nterminal thereby prevents binding receptor hindering formation syncytia <NUMBER> hand epitopes neutralizing also present immmunopredominant sites protein sarscov <NUMBER> could elicit immune responses might harmful <NUMBER> reason identification elimination epitopes protein obligatory moreover protein reported produce serum neutralizing antibodies protected african green monkeys mice challenged sarscov <NUMBER> <NUMBER> sectodomain proteins full length merged without sfoldon ie fold trimeric motif may induce precise antibody response neutralizing antibody thus causing protection vaccinated mice sarscov infection <NUMBER> besides protein associated sarscov also shown responsible eliciting responses tcell cd<NUMBER> cd<NUMBER> <NUMBER> rbd segment centre s<NUMBER> subunit protein <NUMBER> aa residues binds receptors present target cells illustrated antisera sars infected person animals inoculated inactivated sarscov effectively responded rbd <NUMBER> <NUMBER> lot neutralizing antibodies removed antisera rbd antibodies absorption antibodies specific rbd effective neutralizing action obtained antisera <NUMBER> also j u r n l p r e p r f represented rbd vaccinated mice rabbits produces counteracting antibodies high number sarscov <NUMBER> neutralizing titers <NUMBER> serum dilution <NUMBER> compared protein full length high number neutralizing antibodies induced rbd <NUMBER> <NUMBER> <NUMBER> contrast protein full length immunodominant regions present rbd elicits antibodies neutralizing prevent infection sarscov different genotypes rbd containing recombinant proteins vectors encodes rbd could used thus generation antibodies targeting rbd subunit sarscov<NUMBER> would important preventive treatment strategy tested suitable models clinical trials besides mentioned proteins expression various proteins also reported virion surface production antibodies sars patients serum <NUMBER> proteins also evaluated check protective efficacy sarscov instance counteracting action antibodies towards proteins also reported <NUMBER> membrane protein plays essential role upholding configuration viral envelope <NUMBER> protein carries making interactions different cov proteins <NUMBER> incorporating golgi complex novel virions <NUMBER> stabilizing proteins nucleocapsid <NUMBER> investigations animal cov vaccines reported nucleocapsid protein n cov could serve additional target development vaccine <NUMBER> even though antibodies n proteins cov mechanism neutralize virus generation covrestricted cd<NUMBER> cells j u r n l p r e p r f reported <NUMBER> <NUMBER> <NUMBER> consequently providing protection subsequent infection animals <NUMBER> therefore suggest vivo defense could offered protein eliciting cellmediated response <NUMBER> <NUMBER> research shown precise igg antibodies well subtypes igg<NUMBER> igg<NUMBER>a induced freunds adjuvant conjugated sarscov n protein plant expressed conjugating adjutants like cysteinephosphateguanine cpg montanide isa<NUMBER> n protein e coliexpressed results induction definite igg antibodies toward th<NUMBER> igg<NUMBER>atype response mice <NUMBER> <NUMBER> however conserved n protein across cov families implies suitable candidate vaccine development antibodies n protein sarscov<NUMBER> provide immunity infection <NUMBER> recombinant vector vaccines defined live dividing viruses genetically manipulated harbor additional pathogenic gene coding foreign proteins responsible eliciting immune response <NUMBER> recombinant vector vaccines highly efficient triggering immune response infect cells sustain body quite long time react antigenpresenting cells directly also viral proteins vaccines act like adjuvant <NUMBER> thereby enhancing immune response resulting generating antibodies longterm immunity reducing dose antigen adenovirus based delivery systems several benefits including ease administration oral nasal route nonpathogenicity humans <NUMBER> particularly mutants compromised replication <NUMBER> defending power advectored vaccines sarscov first demonstrated rhesus macaques <NUMBER> <NUMBER> immunized three ad<NUMBER>sarscov adbased vector constructs expressing genes n proteins vaccine induced antibody reaction spike s<NUMBER> fragment production sarscov neutralizing antibodies tcell proliferation n protein <NUMBER> similar study ad vector expressing sars nprotein used vaccinate c<NUMBER>bl<NUMBER> strain mice surprisingly neutralizing antibodies produced sarscovspecific ifnγ secretion tcell production detected <NUMBER> <NUMBER>s<NUMBER>svev strain mice coimmunized <NUMBER> ad vector constructs containing genes coding sarscov n proteins either nasal muscular route suggested former induced ig effectively checks sarscov reproduction nasal alveolar tissues later works proliferating neutralizing antibodies <NUMBER> number studies analyzing efficacy vaccines done ferrets model resembles symptoms human patients including fever transmission respiratory route discharge virus upper airways lung injuries <NUMBER> <NUMBER> ferrets primed adenoviral construct coding sprotein boosted different adenovirus chimpanzee significant reduction viral load clinical j u r n l p r e p r f symptoms observed <NUMBER> targeting serotype humans naïve focal point recent adenoviral constructs chimpanzee adenovirus chadox<NUMBER> promising candidate owing lack persistent immunity humans <NUMBER> superior safety status presently potential merscov vaccine named mers<NUMBER> clinical trial chadox<NUMBER>coding sprotein merscov <NUMBER> restricted cloning ability limited host range <NUMBER> preexistent immunity adenovirus significant proportion human population <NUMBER> <NUMBER> limitations makes animal testing challenging retards clinical use vector vaccine designing poxvirus constructs potent vectors due better stability greater insert size easy production cytoplasmic gene expression capacity elicit longtermed cell mediated humoral immunity <NUMBER> study replicationcompromised poxvirus vector modified vaccinia ankara mva strain coding sarscov protein generate neutralizing antibody response reduced viral load upper airways mice <NUMBER> mva constructs expressing entire protein potent vaccine target <NUMBER> <NUMBER> <NUMBER> additional vaccine target mvamerss presently phase clinical trial university medical center hamburgeppendorf germany <NUMBER> studies involving relatively conserved n protein expressing mva mice generated cd<NUMBER> cells <NUMBER> newcastle disease virus ndv viralvector contain merscov protein generated neutralizing antibody response balbc mice bactrian camels <NUMBER> although ndv j u r n l p r e p r f vaccines elicited vigorous immune response also many limitations namely persistent immunity ndv higher threat pathogenesis low viral titer production possible carcinogenesis <NUMBER> since viral vectorbased vaccines could quickly constructed used without adjuvant development vaccines might possible sarscov<NUMBER> rbd sprotein identified neutralizing epitope <NUMBER> epitope could actively pursued development viral vector based vaccines <NUMBER> thus deletion structural e gene may prove first step field developing liveattenuated vaccine sarscov moreover nsp<NUMBER> gene deleted cov mouse hepatitis virus mhv also reported high efficacy thus also used developing sarsattenuated vaccine <NUMBER> two studies related gene deletion attenuation effects suggests removal orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b results little viral replication invitro vivo conditions <NUMBER> <NUMBER> however outcomes studies conducted far convincing takes longer time create non infectious clones coronavirus due larger genome size also requires extensive safety testing <NUMBER> furthermore reversion pathogen virulent form protected using gene replacement knockout strategy safer compared lines developed means like chemical treatment irradiation etc inactivated virus vaccines also known wkv whole killed virus vaccines represent pathogen whose ability infect replicate ceased consequently making sterile retaining ability act immunogen immune system could still work pathogen injected host inactivated vaccines prepared neutralizing pathogen whole chemicals heat radiation thought inactivated vaccines prepared much less effort makes one attractive types vaccines prepared market today vaccines work exposing epitopes virus otherwise would presented thus eliciting immune response sera infected person tested presence antibodies minimum eight different proteins suggests presence diverse moieties exposed membrane pathogen <NUMBER> order search targets protective antibodies investigations done found additional structural proteins targeted encoded open reading frame orfs <NUMBER>a <NUMBER> <NUMBER>a <NUMBER>b envelope e spike matrix <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> interpreting data assume multiple targets present protective antibodies <NUMBER>cl nucleocapsid n etc proteins antibodies induced mice vaccinated sarscov <NUMBER> despite many advantages limitations development inactivated vaccines viz budding pathogens bulk biosafety level <NUMBER> complete sterilization grown pathogens successful sterilization sarscov bulk demonstrated help uv radiations <NUMBER> last two decades many investigators demonstrated inactivated whole sarscov induce sarscov neutralizing antibody <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> study reported live sarscov challenge study balbc mice wkv vaccine observed journal preproof j u r n l p r e p r f provide resistance ceasing multiplication pulmonary sarscov however immunological responses yet verified <NUMBER> βpropiolactone inactivated wkv sarscov tor<NUMBER> strain reported potential vaccine candidate induced neutralizing antibodies able minimize virus load pulmonary tract mouse model <NUMBER> however less evidences mouse models infected diseases clinically thus studying models strain virulent sustainable imperative wkv also tested ferrets model show significant lung pathology clinical sign <NUMBER> <NUMBER> formalin inactivated urbani strain sarscov demonstrated strong immune response <NUMBER> βpropiolactone inactivated wkv sarscov induced significant neutralizing antibody reduced virus replication respiratory tract ferrets <NUMBER> rhesus monkeys also tested formaldehyde inactivated sarscov vaccines shown safe immunogenic <NUMBER> wkv sarscov also tested humans found safe elicited sarscov specific neutralizing antibodies however efficiency vaccine humans yet reported <NUMBER> data suggested wkv vaccines safe able induce sarscov specific neutralizing antibodies inactivated viral vaccines could also evaluated potential vaccine candidate sarscov<NUMBER> might considered good vaccine antigen induces neutralizing antibodies prevent host cell attachment infection <NUMBER> <NUMBER> <NUMBER> nucleic acid based vaccine showed advance platform response emerging pathogens dna vaccine first vaccine candidate entered clinical trial nct<NUMBER> <NUMBER> less <NUMBER>year zika virus outbreak another nucleic acidbased vaccine mrna vaccine considered advanced vaccine technology stability protein translation efficiency could induce robust immune responses <NUMBER> <NUMBER> currently various biopharmaceutical companies academic sectors race develop prophylactic sarcov<NUMBER> vaccine using several platforms including mrna dna vaccinia adenoviral vector recombinant protein <NUMBER> <NUMBER> order make effective sarcov<NUMBER> vaccine possible target antigensnucleotide identification immunization route immune protection suitable animal models scalability production facility target product profile tpp outbreak forecasting target population etc important parameters already known recent epidemics zika ebola whose successful vaccine developed yet lessonlearned epidemics order speed available vaccine ongoing outbreak preclinical studies sarcov<NUMBER> vaccine candidates may need performed parallel clinical trials reality sarscov<NUMBER> vaccines available another <NUMBER> middle east respiratory syndrome merscov first isolated september <NUMBER> patient saudi arabia presented two months earlier severe acute respiratory infection acute renal failure <NUMBER> retrospective testing samples jordan identified earlier cases nosocomial outbreak april <NUMBER> <NUMBER> although majority merscov cases ∼<NUMBER> occurred saudi arabia <NUMBER> countries confirmed imported autochthonously transmitted cases fig <NUMBER> <NUMBER> <NUMBER> recent largest outbreak outside saudi arabia occurred south korea may <NUMBER> <NUMBER> raising concern eruption regional outbreaks accelerated global spread similar phylogenetically related severe acute respiratory syndrome coronavirus sarscov killed nearly thousand people decade earlier <NUMBER> although definitive host merscov yet established closely related coronaviruses isolated bats across wide geographic areas <NUMBER> <NUMBER> <NUMBER> mounting evidence strongly implicated dromedary camels intermediate animal reservoir serological surveys throughout middle east north africa demonstrated high prevalence merscov binding neutralizing abs <NUMBER> <NUMBER> <NUMBER> <NUMBER> additionally outbreak investigations suggested epidemiologic linkage farm camels human cases <NUMBER> merscov spherical enveloped singlestranded positive sense rna betacoronavirus <NUMBER> <NUMBER> genome contains replicase tel <NUMBER> locus <NUMBER> end codes structural proteins toward <NUMBER> end immunogenic viral proteins spike trimeric envelopeanchored type fusion glycoprotein interfaces human host cognate receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> mediate viral entry <NUMBER> <NUMBER> comprises two subunits s<NUMBER> contains receptorbinding domain determines cell tropism s<NUMBER> location cell fusion machinery although dpp<NUMBER> broad tissue distribution clinical manifestations merscov attributed localization lower respiratory tract <NUMBER> <NUMBER> much like coronaviruses merscov also cause significant dysfunction gastrointestinal cardiovascular renal neurologic systems merscov distinct though tendency cause greatest harm older individuals concurrent comorbidities one organsystems <NUMBER> <NUMBER> despite past efforts develop coronavirus countermeasures response sarscov pandemic currently prophylactic therapeutic interventions proven efficacy merscov coronavirus infection although combination treatment ribavirin interferons shown improve clinical outcomes merscovinfected nonhuman primates nhps treatment initiated soon viral challenge ∼<NUMBER> h results replicated humans <NUMBER> fact experimental interventions demonstrated appreciable benefit acutely ill patients consistent controlled manner rapidly scaled treatments based naturally occurring neutralizing antibodies convalescent plasma hyperimmune globulin hand demonstrated mortality reductions respiratory infections may hold promise merscov well <NUMBER> development however limited logistical challenges local technical capacity donor supply supportive management adapted guidelines developed sarscov thus far mainstay merscov treatment global develop coronavirus vaccine faded aftermath sarscov pandemic since gained renewed momentum face current merscov outbreak previous approaches coronavirus vaccine development broad included wholeinactivated liveattenuated viruses recombinant vectors protein subunits well dna rna based platforms <NUMBER> developers based immunogen designs surface glycoprotein primary target neutralizing antibodies natural coronavirus infection number preclinical clinical studies showed sarscov s<NUMBER> protein subunit specifically rbd core could serve dominant target neutralizing antibodies mice nonhuman primates humans <NUMBER> s<NUMBER> therefore became basis number promising sarscov vaccine candidates s<NUMBER> protein subunit rbd also basis several merscov vaccine candidates fig <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> resolution rbd crystal structures alone complex dpp<NUMBER> receptor <NUMBER> <NUMBER> <NUMBER> informed design immunogens expressed either recombinant protein fragments conjugates fragment crystallizable fc region human antibodies types constructs formulation aluminum salt oilinwater adjuvants elicited neutralizing antibodies high potency across multiple viral strains despite demonstrated immunogenicity animal models anticipated safety humans rbd s<NUMBER>subunit based vaccine candidates limited epitope breadth although coronavirus genomes variable rna viruses rbd mutable region containing mutation sites define antibody escape variants <NUMBER> <NUMBER> thus vaccine candidates elicit diverse antibody repertoire well robust cellular immune response may offer advantage broader durable protection fulllength used immunogen could least increase breadth antibody response however difficult express may require additional work produce stable soluble trimer ectodomain investigators university maryland collaboration novavax inc overcome problem development rosettes stable immunogenic murine models <NUMBER> vaccines mimic natural infection liveattenuated viruses recombinant viral vectors may elicit even robust immunity live attenuated viruses historically among immunogenic platforms available capacity present multiple antigens across viral life cycle native conformations although liveattenuated merscov yet tested one constructed potential protective <NUMBER> however manufacturing liveattenuated viruses requires containment biosafety level <NUMBER> <NUMBER> facility additionally liveattenuated viruses carry hazards inadequate attenuation reversion wild type form causing disseminated disease particularly immunocompromised hosts given moderately immunocompromised adults comorbidities diabetes mellitus chronic kidney disease suffered severe merscov disease individuals may comprise target population immunization thus making liveattenuated virus vaccine less viable option replication competent viral vectors could pose similar threat disseminated disease immunosuppressed replication deficient vectors however avoid risk maintaining advantages native antigen presentation elicitation cell immunity ability express multiple antigens date two recombinant vector platformsmodified although replication deficient vectors relatively safe immunogenic ability deliver genetic material expression could impeded preexisting developing immunity vector one way overcome limitation administering different vectors socalled primeboost immunization regimen strategy effective pathogens likely success could recapitulated merscov use one type platform antigen single vaccine also increases likelihood inducing broad repertoire antibodies diverse mechanisms viral neutralization one vaccine regimen developed us national institutes health based fulllength dna truncated s<NUMBER> subunit glycoprotein elicited neutralizing antibodies mice directed s<NUMBER>within outside rbdand s<NUMBER> subunits immunization constructs also protected nhps severe lung disease intratracheal challenge merscov <NUMBER> dnaonly vaccine expressing multiple antigens also developed inovio pharmaceuticals geneone life science inc advanced phase firstinhuman trial vaccine candidates mentioned developed prophylactic use however total number cases <NUMBER> <NUMBER> <NUMBER> reproductive rate ∼<NUMBER> merscov relatively low <NUMBER> difficult define target populations vaccination would support investment manufacturing advanced product development also low incidence lack robust animal models would difficult achieve vaccine efficacy result would sufficient support licensure human mabs hand could used without much discrimination outbreak setting postexposure prophylaxis early treatment advantages mabs polyclonal antibodies administered convalescent plasma hyperimmune globulin higher potency greater specificity extensive prelicensing evaluation consequently improved safety profile additionally mabs help define immunogenic epitopes crystallographic analysis thereby providing atomic level detail design better immunogens however timeline mab development may longer potentially cost vaccines despite requirements greater upfront investment several groups developed highly potent mabs currently advanced preclinical stages testing fig <NUMBER> isolated immunized animals micehumanized micenhps <NUMBER> <NUMBER> others identified either antibody human phage library <NUMBER> <NUMBER> <NUMBER> <NUMBER> memory b cells infected recovered human survivors <NUMBER> almost mabs reported target spike rbd likely mabs directed sites spike glycoprotein recovered potent neutralizers published bind recombinant spike picomolar affinity neutralize merscov pseudovirus half maximal inhibitory concentration ic <NUMBER> <NUMBER> mcgl less additionally demonstrated protective efficacy preand postexposure prophylaxis animal models <NUMBER> <NUMBER> successes thus far isolating potent protective mabs may prove useful therapeutic development target population well defined may prove challenging advancing products licensure fullscale production affordable costs purpose prophylaxis yet undefined populations vaguely defined epidemiology merscov complicated design implementation appropriate public health countermeasures transmission events occurred either setting household clusters nosocomial outbreaks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> also likely virus introduced multiple times human populations large zoonotic reservoir ie dromedary camels given broad distribution ownership camels arabian peninsula cases occurred targeted vaccine campaign may prove difficult outbreak republic korea revealed patients workers healthcare facility infected patient high risk secondary acquisition optimal strategy may use vaccines conjunction stringent infection control practices hospitals merscov cases treated epidemiologic link merscov bats camels humans presents opportunity veterinary vaccine interrupt transmission cycle successful precedent socalled onehealth approach toward mitigating human disease veterinary vaccine exists example equivac ® hendra virus vaccine developed solely horses <NUMBER> although hendra virus even rare merscov highly fatal treatment intensive supportive management <NUMBER> protein subunit vaccine licensed rolledout australia outbreaks virus occurred since time incidence horses fallen precipitously human cases detected <NUMBER> similar strategy may applicable merscov however veterinary vaccination context would deployed solely sake protecting humans virus causes mild upper respiratory illness camels safety reduction viral shedding would demonstrated immunization challenge transmission studies camel camelid populations one shown efficacy <NUMBER> one primary challenges developing countermeasures merscov lack appropriate animal model recapitulates natural history human disease much difficulty originates absence viruss cognate dpp<NUMBER> receptor one group approached problem successfully transducing mice adenoviral vector expressing human dpp<NUMBER> <NUMBER> although relevant standard murine model transient transduction desired protein may result inconsistent tissue expression adenovirus antigens agrawal et al made important advance development transgenic mouse model demonstrated productive disseminated merscov infection <NUMBER> although rhesus macaques manifest full clinical disease develop transient lower respiratory infection quantified evaluated computed tomography investigators nih rocky mountain laboratories rml integrated research facility irf also independently developing potentially lethal marmoset models could used evaluation vaccines mabs therapeutics <NUMBER> merscov vaccinesboth active passiveare developed tested relevant animal models required also need detailed understanding epidemiology immunology pathogenesis virus aftermath west african ebola virus epidemic face current zika virus outbreak global health community coalesced around realization multifaceted plan required quickly efficiently respond global public health emergencies world health organization currently developing blueprint preparation response follow merscov highlighted case study although merscov still causes relatively cases limited geographic distribution high case fatality sudden outbreak korea proven pathogen public health concern concentration epidemic saudi arabia also raises specter international spread every year hajj one largest mass gathering events world ultimately development safe effective vaccine merscov may yield greatest benefit current epidemic knowledge gained creating platform combating coronaviruses whole opinions expressed herein authors construed official representing views us department defense department army camel flu commonly known middle east respiratory syndrome mers respiratory disease caused merscoronavirus merscov merscov first identified saudi arabia <NUMBER> february <NUMBER> <NUMBER> countries worldwide reported cases merscov infection <NUMBER> reported viral infection <NUMBER> associated deaths corresponds ∼<NUMBER> fatality identified cases world health organization <NUMBER>b although actual fatality rate viral infection likely <NUMBER> due unidentified mild asymptomatic cases majority cases occurred saudi arabia amounting <NUMBER> reported cases <NUMBER> associated deaths ∼<NUMBER> fatality world health organization <NUMBER>a majority identified merscov cases nosocomially acquired via direct close contact infected patients chowell et al <NUMBER> cauchemez et al <NUMBER> whereas cases zoonotic transmission dromedary camels humans reported primarily saudi arabia humancamel interaction frequent gossner et al <NUMBER> hitherto specific treatments vaccines available merscov infections although merscov currently listed potential pandemic threat recent outbreak south korea demonstrated virus emergence second third generation contacts immediately raised concern multiple mutations merscov might cause enhanced humantohuman transmission wang et al <NUMBER>b oh et al <NUMBER> recently merscov added niaids pathogen priority list category c priority pathogens due potential applications biological warfare du et al <NUMBER>b preventive measures merscov infection particularly vaccine development crucial avoid deadly unexpected future pandemics middle east respiratory syndromecoronavirus causative agent mers positive sense singlestranded rna betacoronavirus belongs family coronaviridae viral genome <NUMBER> kb length flanked <NUMBER>terminal cap <NUMBER>polya tail scobey et al <NUMBER> merscov genome contains least <NUMBER> open reading frames orfs encodes <NUMBER> structural proteins spike protein envelope e protein membrane protein nucleocapsid n protein <NUMBER> nonstructural proteins nsp<NUMBER>nsp<NUMBER> <NUMBER> accessory proteins orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> orf<NUMBER>b du et al <NUMBER> viral proteins n proteins particular interest development vaccines merscov although proteins e protein nsp<NUMBER> potential immunogens live attenuated vaccines almazan et al <NUMBER> menachery et al <NUMBER> two viral proteins merscov n proteins demonstrated highly immunogenic capable eliciting tcell responses however protein shown induce neutralizing antibodies critical effectors merscov notably n protein also proposed potential protective immunogen neutralizing antibodies tcell immune responses silico approaches shi et al <NUMBER> despite prediction biological data presented thus far another potential b cell epitope merscov e protein identified recently using silico methods yet similarly biological data presented xie et al <NUMBER> therefore merscov vaccine candidates still based full length part protein ideally effective merscov vaccine required induce robust humoral cellmediated immunities particularly antibody responses crucial survival vaccinated hosts du et al <NUMBER>b previous studies indicated level serum neutralizing antibodies correlated positively reduction lung pathogenesis increased survival animals challenged merscov zhang et al <NUMBER> general potential merscov vaccine candidates able elicit systemic antibody responses producing high titer serum igg upon immunization many failed generate sufficient mucosal immunity unless vaccines administered via mucosal intranasal route activation mucosal immunity heavily dependent route immunization common challenge vaccine development many respiratory pathogens et al <NUMBER>a guo et al <NUMBER> preexisting neutralizing mucosal antibodies important first line defenses merscov infection neutralizing antibodies elicited vaccines based protein could bind receptor binding domain rbd protein thereby inhibiting viral internalization membrane fusion du et al <NUMBER> little known memory bcell responses merscov apart recent study demonstrated persistence antimerscov antibodies mers survivors <NUMBER> months payne et al <NUMBER> hand antibody responses another closely related coronavirus sarscov persistent whereby <NUMBER>year followup study detect memory bcell responses sars survivors tang et al <NUMBER> likely bcells differentiate merscovspecific memory bcells following infection vaccination longevity protective efficacy memory bcells merscov infection rechallenge remain unresolved questions du et al <NUMBER>b perlman vijay <NUMBER> tcell responses elicited merscov vaccines also play important roles protection mers supported fact viral clearance impossible tcell deficient mice possible mice lacking bcells although tcells demonstrated critical effector acute viral clearance protection subsequent merscov infection largely mediated humoral immunity several animal studies also demonstrated activation tcell responses following immunization merscov vaccine candidate resulting elevated secretion th<NUMBER> th<NUMBER> cytokines lan et al <NUMBER> et al <NUMBER>a malczyk et al <NUMBER> muthumani et al <NUMBER> also noteworthy mention adjuvants could coadministered merscov vaccines tailor possibly enhance immune responses elicited vaccines one study indicated coadministration merscov vaccine based protein alum mice resulted th<NUMBER> biased immunity whereas robust th<NUMBER> th<NUMBER> mixed immune response produced additional adjuvant cysteinephosphateguanine cpg oligodeoxynucleotides odn included formulation lan et al <NUMBER> date detail investigation merscov vaccineinduced memory tcell responses reported however merscov infection shown induce memory cd<NUMBER> cd<NUMBER> tcells responses mers survivors least <NUMBER> months little understanding biological function memory cd<NUMBER> tcells likely contribute direct virus inhibition via cytokine production particularly ifnγ enhance effector functions cd<NUMBER> tcells bcells macleod et al <NUMBER> although subsequent merscov infection generally antibody mediated memory cd<NUMBER> cells believed facilitate virus clearance eliminating infected cells kaech ahmed <NUMBER> zhao et al <NUMBER> mers survivors later demonstrated strong virusspecific memory cd<NUMBER> tcell responses also shown experience mitigated morbidity hospitalization period similarly importance tcell responses sarscov also highlighted many studies channappanavar et al <NUMBER> chu h et al <NUMBER> zhao et al <NUMBER> interestingly unlike sarscov merscov infect cd<NUMBER> cd<NUMBER> cells human resulting downregulation hdpp<NUMBER> induced intrinsic extrinsic caspasedependent apoptosis cells may lead severe immunopathology chu et al <NUMBER> addition chu et al <NUMBER> demonstrated capability merscov infecting cells common marmosets critical potential merscov vaccine induce robust humoral cellmediated immunities although protection merscov mainly mediated humoral immunity tcell responses crucial acute viral clearance mucosal route recommended merscov vaccine delivery induce mucosal immunity addition systemic responses persistence virusspecific antibodies induced merscov vaccine thoroughly studied represents major challenge effective merscov vaccine also required induce immunological memory provide longlived protection turn reduces need boosters long run bring cost vaccinations lastly different adjuvants may also used improve immunogenicity merscov vaccines would require detail studies interactions ensure optimal vaccine efficacy safety far three potential merscov vaccines dna vaccine two viral vectorbased vaccines advanced clinical trials national institutes health nih <NUMBER> nih <NUMBER>b antibody dependent enhancement ade condition whereby nonneutralizing antibodies produced following infection vaccination enhance infectivity subsequent infection kuzmina et al <NUMBER> ade viral infections reported dengue virus human immunodeficiency virus influenza virus alpha flaviviruses sarscov ebola virus dutry et al <NUMBER> kuzmina et al <NUMBER> thus ade critical issue considered seriously designing merscov vaccine attributed taxonomic structural similarities sarscov merscov processes involved development new vaccines two viruses large extent similar vaccine candidates sarscov initially developed based fulllength protein however vaccines later demonstrated induce nonneutralizing antibodies prevent merscov infection immunized animals protected viral challenge instead experienced adverse effects like enhanced hepatitis increased morbidity stronger inflammatory responses weingartl et al <NUMBER> czub et al <NUMBER> many potential vaccines merscov also mainly focused fulllength protein raising safety concern practical application vaccines du et al <NUMBER>b date ade observed merscov indeed ade sarscov infection human cells discovered <NUMBER> years virus first identified <NUMBER> yip et al <NUMBER> jaume et al <NUMBER> demonstrated nonneutralizing antibodies induced fulllength protein sarscov facilitated viral entry host cells via fcγrdependent pathway understanding merscov relatively lesser compared sarscov mainly due fact former discovered less <NUMBER> years thus unsurprising ade merscov yet reported du et al <NUMBER>b nevertheless employing appropriate strategies methods ade merscov infection could revealed future two approaches suggested mitigate adverse effects ade first approach involves shielding nonneutralizing epitopes proteins glycosylation whereas second approach namely immunofocusing aims direct adaptive immune responses target critical neutralizing epitope elicit robust protective immunity du et al <NUMBER>a okba et al <NUMBER> supporting evidence latter merscov vaccine candidate based shorter s<NUMBER> domain induced slightly stronger neutralizing activity based fulllength protein addition vaccine candidate based even shorter rbd induced highest neutralizing immune responses okba et al <NUMBER> animal models available evaluation merscov vaccines highly limited thus representing huge challenge vaccine development merscov infects human nonhuman primatesrhesus macaques munster et al <NUMBER> marmosets falzarano et al <NUMBER> dromedary camels alagaili et al <NUMBER> chu dk et al <NUMBER> memish et al <NUMBER> first animal model adopted development merscov vaccine rhesus macaques munster et al <NUMBER> demonstrated clinical symptoms merscov infection including increase respiratory rate body temperature hunched posture piloerection cough reduced food intake radiographic imaging analysis also revealed varying degree pulmonary diseases following infection although viral rna merscov detected respiratory tissues viral tropism restricted primarily lower respiratory tract rhesus macaques infected merscov experienced transient mild moderate disease severity van doremalen munster <NUMBER> du et al <NUMBER>b noteworthy pathological changes induced rhesus macaques infected merscov results host inflammatory responses triggered virus instead direct viral cytolytic activity prescott et al <NUMBER> common marmoset another frequently used animal model evaluate merscov vaccines falzarano et al <NUMBER> similar rhesus macaques humoral cellmediated immunities could detected animals following merscov vaccination common marmosets infected merscov developed moderate severe acute pneumonia increased viral load respiratory tract addition clinical symptoms experienced rhesus macaques van doremalen munster <NUMBER> yu et al <NUMBER> intriguingly common marmoset also demonstrated signs renal damage human cases following merscov infection viral rna could detected nonrespiratory organs contrary rhesus macaques van doremalen munster <NUMBER> yeung et al <NUMBER> falzarano et al <NUMBER> also reported common marmoset could serve partially lethal animal model similarly chan et al <NUMBER> demonstrated marmosets challenged merscov developed severe diseases leading fatality thereafter marmosets successfully used moderate severe model study merscov baseler et al <NUMBER> yeung et al <NUMBER> chen et al <NUMBER> van doremalen et al <NUMBER> yu et al <NUMBER> de wit et al <NUMBER> dromedary camels serve natural reservoir merscov responsible zoonotic transmission virus humans mild clinical symptoms increase body temperature rhinorrhea observed dromedary camels infected merscov adney et al <NUMBER> interesting merscov tropism dromedary camels limited upper respiratory tract less apparent lower respiratory tract contrary rhesus macaques adney et al <NUMBER> viral rnas merscov detectable respiratory tract lymph node excreted breath infected dromedary camels viral shedding upper respiratory tract dromedary camels may explain efficiency virus transmission among camels camels humans adney et al <NUMBER> dromedary camels immunized mersvcov vaccines also shown activate bcell tcell responses muthumani et al <NUMBER> haagmans et al <NUMBER> adney et al <NUMBER> although camels natural reservoirs merscov whilst macaques marmosets closely related human handling large mammals laborious costly lack small animal models initial screening potential vaccine candidates greatly hampers development merscov vaccines unlike sarscov merscov readily infect smaller rodents mice hamsters due substantial differences viral binding receptors dipeptidyl peptidase <NUMBER> dpp<NUMBER> goldstein weiss <NUMBER> nevertheless considerable amount efforts devoted produce merscovpermissive small rodents evaluation merscov vaccines mice transduced viral vector express human dpp<NUMBER> hdpp<NUMBER> shown susceptible merscov infection manifested development pneumonia histopathological changes lungs however viral clearance infected mice observed day<NUMBER> postinfection failing recapitulate severe human diseases later established transgenic mouse model expressing hdpp<NUMBER> globally developed first lethal animal model available evaluate merscov vaccines mortality noted mice within days postinfection virus dissemination organs observed exceptionally high titer detected lung brain agrawal et al <NUMBER> recently transgenic mouse model produced replacing fulllength mouse dpp<NUMBER> gene human equivalent however transgenic mice demonstrate sign diseases following merscov infection virus dissemination organs observed pascal et al <NUMBER> crisprcas<NUMBER> also previously employed sensitize mice merscov infection substituting two amino acids positions <NUMBER> <NUMBER> mouse dpp<NUMBER> although genetically engineered mice allowed viral replication lungs experience apparent morbidity following infection wildtype merscov severe diseases observed mice infected mouseadapted merscov generated via <NUMBER> serial lung passages cockrell et al <NUMBER> mouse dpp<NUMBER> vital normal glucose homeostasis immunity altering mouse dpp<NUMBER> could unforeseen complications mouse model fan et al <NUMBER> therefore another transgenic mouse model introduced hdpp<NUMBER> gene inserted genome c<NUMBER>bl<NUMBER>mouse rosa<NUMBER> locus using crisprcas<NUMBER> technology mouse model namely r<NUMBER>hdpp<NUMBER> infected merscov low dose developed severe lung diseases related acute respiratory symptoms ards central nervous system cns addition r<NUMBER>hdpp<NUMBER> also susceptible infection merscov pseudovirus serving alternative test merscov vaccines absence bsl<NUMBER> facility fan et al <NUMBER> animal models described summarized table <NUMBER> apart mouse model rabbits also reported asymptomatically infected merscov extensive research animals could represent another potential animal model evaluate merscov vaccines haagmans et al <NUMBER> smaller animal models economically available vaccine evaluations addition ease animal manipulation readily available methods testing vaccine efficacy sarscov merscov coronaviruses known cause severe diseases human development sars vaccines mainly focused protein sarscov bukreyev et al <NUMBER> weingartl et al <NUMBER> yang et al <NUMBER> czub et al <NUMBER> kam et al <NUMBER> lin et al <NUMBER> fett et al <NUMBER> date vaccine licensed prevent merscov infection although several vaccine candidates currently clinical trials many still remained preclinical stage current approaches animals manifested clinical signs within <NUMBER> h following infection including increase respiratory rate body temperature hunched posture piloerection cough reduced food intake varying degree pneumonia mortality observed infected animals throughout study increase white blood cell counts early transient viralload reported higher lower respiratory tract decreased overtime rhesus macaques animals experienced early increase neutrophil day<NUMBER> postinfection pi restored day<NUMBER> pi development pneumonia animals rapid infection shortlived mortality virus dissemination nonrespiratory tissue observed infected animals infection restricted primarily lower respiratory tract genetically closer human recapitulate severe diseases human expensive model due high husbandry requirement de wit et al <NUMBER> rectal temperature animals increased <NUMBER> <NUMBER> days pi restored thereafter extensive lung lesions varying degree inflammation observed lungs animals collected day<NUMBER> pi pathological changes infected lungs include interstitial pneumonia pulmonary edema hemorrhaging degeneration necrosis pneumocytes bronchial epithelial cells sign damage nonrespiratory organs observed immunosuppressed rhesus macaques immunosuppressed animals developed rapid pneumonia less severe nonimmunosuppressed monkey higher viral load viral shedding virus dissemination nonrespiratory organs observed immunosuppressed animals following infection potential model mimicking merscov infection immunocompromised patients expensive model due high husbandry requirement additional treatment required produce immunosuppressed animals prescott et al <NUMBER> common marmosets infected animals developed progressive severe pneumonia characterized interstitial infiltration animals euthanized diseases severity extensive lung lesions observed infected animals different necropsies time points viral rna could detected blood respiratory organs nonrespiratory organs including kidney suggesting virus dissemination severe partially lethal animal model able manifest renal damage expensive model due high husbandry requirement falzarano et al <NUMBER> common marmosets infected animals developed severe pneumonia day<NUMBER> pi characterized exudative pathological changes widespread pulmonary edema hemorrhaging huge number inflammatory cells yu et al <NUMBER> common marmosets vitro analysis using lung kidney cells showed hyperexpression smad<NUMBER> fgf<NUMBER> induced merscov led immense apoptotic response general iwv vaccine rapid approach vaccine production following new outbreak however use iwv vaccine mers reported associated hypersensitivitytype lung immunopathologic reaction mouse model agrawal et al <NUMBER> thereby limiting potential subunit vaccine far popular method development mers vaccine mostly focusing recombinant rbd protein produced heterologous expression systems subunit vaccines however often administered along adjuvants boost immunogenicity recombinant antigens nanoparticles vlpsbased vaccines similar subunit vaccines specific viral proteins expressed unlike subunit vaccines vlpsbased vaccines comprised recombinant viral proteins capable selfassembling larger particles resembling viruses although immunogenicity vlpsbased vaccines could enhanced adjuvants vlps serve adjuvants increase immunogenicity displayed epitopes particularly smaller ones murata et al <NUMBER> quan et al <NUMBER> live attenuated vaccines composed live viruses modified remove reduce virulence type vaccine often immunogenic whereby single administration without adjuvant sufficient induce protective immunity however risk reversion virulent virus limited usage mers vaccine viral vectorbased vaccine one popular approaches developing mers vaccines two three candidate vaccines entered clinical phase viral vector vaccines approach utilizes wellstudied virus replication system display merscov antigen thereby inducing protective immunity merscov another candidate vaccine currently phase iii clinical trial dna vaccine unlike types vaccines dna vaccine production involve virus replication protein expression purification therefore reduce cost production however administration dna vaccines often requires external device electroporator gene gun eventually increases cost immunization table <NUMBER> summarizes vaccine candidates merscov infection discussed intensively following sections viralvector rad<NUMBER> encoding s<NUMBER> protein im immunization rad<NUMBER> constructs expressing cd<NUMBER>targeted s<NUMBER> fusion protein rad<NUMBER>s<NUMBER>fcd<NUMBER>l offered complete protection hdpp<NUMBER> transgenic mice merscov challenge prevented pulmonary perivascular hemorrhage dna encoding s<NUMBER> protein im dna encoding s<NUMBER> protein elicited stronger antibody cellular immune responses mice encoding protein dnas encoding s<NUMBER> proteins induced neutralizing antibodies crossreacted merscov strains human camel origins dna encoding s<NUMBER> protein im immunization dna encoding s<NUMBER> protein passive transfer immune sera vaccinated mice protected hdpp<NUMBER>transducedmice merscov infection frontiers microbiology wwwfrontiersinorg recombinant rbd im sc subunit vaccine administered together combination alum cpg odn optimized rbdspecific humoral cellular immunity elicted robust rbdspecific antibody tcell responses induced mice immunized vaccine combination ifa cpg odn low level neutralizing antibodies induced frontiers microbiology wwwfrontiersinorg first viral vectorbased vaccine reported moss et al <NUMBER> developed potential hepatitis b vaccine using vaccinia viral vector unlike subunit inactivated vaccines generally function extracellular antigens viral vector works carrying dna encoding immunogenic components host cells followed intracellular antigen expression thereby activating broad spectrum cellmediated immunity addition humoral immune responses majority viralvector based vaccines require adjuvant optimum efficacy ura et al <NUMBER> adenovirus modified vaccinia virus ankara mva two common viral vectors used development merscov vaccines mice immunized intramuscularly recombinant human adenoviral type <NUMBER> <NUMBER> vector encoding fulllength protein shown induce systemic neutralizing antibodies mucosal tcells immunity intriguingly mucosal tcell response detected vaccine administered via intragastric route contrary previous findings suggested importance mucosal vaccination activating mucosal immunity recombinant human adenovirus type <NUMBER> rad<NUMBER> vector encoding shorter s<NUMBER> extracellular domain protein reported elicit slightly stronger neutralizing antibody responses encoding fulllength suggesting effect immunofocusing kim et al <NUMBER> recent study hashem et al <NUMBER> demonstrated rad<NUMBER> constructs expressing cd<NUMBER>targeted s<NUMBER> fusion protein rad<NUMBER>s<NUMBER>fcd<NUMBER>l offered complete protection hdpp<NUMBER> transgenic mice merscov challenge prevented pulmonary perivascular hemorrhage additionally jung et al <NUMBER> showed heterologous primeboost vaccination rad<NUMBER>s protein alumadjuvanted recombinant protein nanoparticle successfully induced th<NUMBER> th<NUMBER> immune responses specificpathogenfree balbc mice preexisting immunity human adenovirus human population widespread hampering clinical application vector vaccine development faustherbovendo kobinger <NUMBER> recent developments new adenovirus vectors vaccine antigen delivery focus serotype human population less exposed chimpanzee adenovirus chadox<NUMBER> represents attractive alternative human adenoviral vector due good safety profile lack preexisting immunity human population dicks et al <NUMBER> since employed vaccine development merscov infection recombinant chadox<NUMBER> encoding fulllength protein chadox<NUMBER> mers shown immunogenic mice lethal virus challenge using hdpp<NUMBER> transgenic mouse model demonstrated high protective efficacy merscov alharbi et al <NUMBER> munster et al <NUMBER> noteworthy immunogenicity protein could improved insertion gene encoding signal peptide human tissue plasminogen activator tpa upstream gene merscov chadox<NUMBER> mva vectors alharbi et al <NUMBER> currently candidate merscov vaccine known mers<NUMBER> contains chadox<NUMBER> encoding protein merscov phase clinical trial trial estimated completed december <NUMBER> safety immunogenicity mers<NUMBER> different dosage studied healthy adult volunteers recruited sponsored university oxford united kingdom national institutes health nih <NUMBER>b recombinant mva encoding fulllength protein represents another potential merscov vaccine candidate due good safety profile decent immunogenicity high protective efficacy merscov song et al <NUMBER> volz et al <NUMBER> alharbi et al <NUMBER> another candidate vaccine currently phase clinical trial mvamerss trial performed university medical center hamburgeppendorf germany safety immunogenicity mvamerss healthy adult volunteers assessed national institutes health nih <NUMBER>c apart protein highly conserved n protein merscov inserted mva inoculated mice although recombinant mva encoding nprotein elicited cd<NUMBER> tcell response immunized mice protective efficacy investigated veit et al <NUMBER> apart adenovirus mva newcastle disease virus ndv also used viralvector displaying merscov protein ndvbased vaccine candidate induced neutralizing antibodies balbc mice bactrian camels although viral vectorbased vaccines able induce robust immune responses free drawbacks include preexisting immunity viral vector risk pathogenesis low viral titer production potential tumorigenesis ura et al <NUMBER> dna vaccine composed recombinant plasmid encoding immunogens vaccine typically delivered via direct injection gene gun electroporation host cells immunogens expressed prime immune system ferraro et al <NUMBER> dna vaccine offers two distinct advantages subunit proteinbased vaccine ease dna manipulation low cost production leitner et al <NUMBER> similarly dna vaccines developed merscov target protein shorter s<NUMBER> domain merscov dna encoding fulllength protein shown induce neutralizing antibodies robust cellmediated immunity mice macaques camels immunized macaques challenged merscov characteristic clinical symptoms including pneumonia mitigated muthumani et al <NUMBER> gls<NUMBER> one three candidate vaccines currently clinical trial sponsored geneone life science inc korea phase clinical trial test vaccines safety profile human volunteers completed walter reed army institute research united states national institutes health nih <NUMBER> currently phase phase ii clinical trials performed international vaccine institute korea evaluate safety immunogenicity gls<NUMBER> well device electroporation cellectra r <NUMBER> electroporation national institutes health nih <NUMBER>a avoid possible adverse effects induced fulllength protein researchers revealed immunization dna encoding s<NUMBER> domain passive transfer immune sera vaccinated mice protected hdpp<NUMBER>transducedmice merscov infection chi et al <NUMBER> dna encoding s<NUMBER> domain also demonstrated superior encoding fulllength protein eliciting antibody cellular responses dnas encoding s<NUMBER> proteins shown induce neutralizing antibodies crossreacted merscov strains human camel origins alamri et al <NUMBER> despite effectiveness dna vaccines spontaneous plasmid integration host genomes represents potential risk probability extremely low ledwith et al <NUMBER> general subunit vaccines highest safety profile among current vaccines despite low immunogenicities du et al <NUMBER>b precautions taken development merscov vaccines based protein avoid induction nonneutralizing antibodies unlike fulllength protein rbd merscov comprises critical neutralizing domains lacking nonneutralizing immunodominant region therefore upon immunization rbdbased vaccines restricted produce rbdspecific neutralizing immune responses thus incapable inducing nonneutralizing antibodies may potentially contribute harmful pathological effects du jiang <NUMBER> wang et al <NUMBER>a safety effectiveness perspectives rbd promising candidate development merscov vaccines fulllength protein rbd merscov reported induce neutralizing antibodies multiple strains merscov due presence several conformational neutralizing epitopes du et al <NUMBER>b merscov strains single mutation epitope may suffice escape rbdspecific neutralizing antibodies wang et al <NUMBER>a demonstrated amino acid mutation position <NUMBER> aspartic acid glycine substitution rbd rendered mutated strain resisted neutralization rbdspecific monoclonal antibody f<NUMBER> susceptible another rbdspecific monoclonal antibody d<NUMBER> antibodies could bind different regions rbd merscov similarly rbd sarscov also consists multiple neutralizing domains capable inducing broad neutralizing immune responses many sarscov strains et al <NUMBER> development antibody escape mutants may require mutation two epitopes rbd merscov less likely take place developed may exhibit reduced viral fitness tang et al <NUMBER> tai et al <NUMBER> demonstrated merscov s<NUMBER> protein mf<NUMBER> adjuvant protected hdpp<NUMBER> transgenic mice lethal merscov challenge protection correlated well neutralizing antibody titer wang et al <NUMBER>c addition adjuvanted recombinant s<NUMBER> proteins advax hcxl adjuvant sigman adjuvant system reduced delayed virus shedding upper respiratory tract dromedary camels merscov animal reservoir provided complete protection alpaca surrogate infection model merscov challenge adney et al <NUMBER> general merscov subunit vaccines based s<NUMBER> domain require use adjuvant fusion immune enhancer heighten immunogenicity several studies indicated rbd fused fc fragment human igg rbdfc elicited strong systemic neutralizing antibody cellular immune responses vaccinated mice du et al <NUMBER> et al <NUMBER>a tang et al <NUMBER> nyon et al <NUMBER> new zealand white rabbits et al <NUMBER>b hdpp<NUMBER>transducedmice immunized rbdfc also protected viral challenge et al <NUMBER>a adjuvants freunds adjuvant alum monophosphoryl lipid montanide isa<NUMBER> mf<NUMBER> also reported improve immunogenicity protection rbdfc mice particularly mf<NUMBER> superior among adjuvants zhang et al <NUMBER> addition coadministration multiple adjuvants together rbd antigen could synergistically improve immunogenicity rbdbased subunit vaccine mice immunized rbd antigen together alum cpg odn produced stronger humoral cellular immune responses immunized rbd antigen alum cpg odn alone lan et al <NUMBER> rbdbased subunit vaccine also previously tested rhesus macaque model presence alum vaccine formulation shown induce robust sustained humoral cellular immunities partially protected rhesus macaques viral challenge native spikes merscov exist form trimers vaccine designs mimicking native viral proteins also reported tai et al <NUMBER> pallesen et al <NUMBER> use foldon fd t<NUMBER> fibritin trimerization domain pallesen et al <NUMBER> synthesized recombinant prefusion trimeric merscov protein induced high titer neutralizing antibodies balbcj mice similarly tai et al <NUMBER> expressed rbd trimers fd demonstrated vaccines protective efficacy <NUMBER> survival hdpp<NUMBER> transgenic mice lethal merscov challenge although subunit vaccine studies focused rbd protein recent study jiaming et al <NUMBER> proposed use recombinant nterminal domain rntd protein another potential vaccine candidate rntd used immunize balbc mice induced neutralizing antibodies reduced respiratory tract pathology mice nonlethal merscov challenge apart focusing protein multivalent vaccines designed using silico methods contain b cell cell epitopes e n nsps proposed srivastava et al <NUMBER> however biological data presented multivalent vaccines addition n protein s<NUMBER> domain protein conserved among coronaviruses representing attractive targets development broadspectrum coronavirus vaccine schindewolf menachery <NUMBER> nevertheless crucial ensure proteins contribute ade merscov infection viruslike particles nanoscale particles similar native viral particles devoid infectious genetic materials composed repetitive viral structural proteins inherent selfassembly properties vlps nonreplicative noninfectious vlps produced expressing viral structural proteins suitable expression system yong et al <NUMBER>ab ong et al <NUMBER> general vlpsbased vaccine similar whole inactivated virus vaccine require viral inactivation step may alter antigenicity immunogenicity viral protein live virus involved manufacturing process vlps easily generated lowcontainment manufacturing environment dezure et al <NUMBER> viruslike particles merscov previously produced baculoviral expression system coexpressing e proteins merscov vlps generated indistinguishable authentic viral particle observed electron microscope vlps administered alum induced neutralizing antibodies th<NUMBER>biased immunity rhesus macaques wang et al <NUMBER>b intriguingly protein merscov expressed alone selfassembles nanoparticles approximately <NUMBER> nm quarter diameter authentic viral particle immunogenicity studies mice demonstrated nanoparticles elicited antibody responses presence alum adjuvant replaced matrix m<NUMBER> adjuvant induced significantly higher titer neutralizing antibodies coleman et al <NUMBER> viral challenge hdpp<NUMBER>transducedmice immunized matrix m<NUMBER> protein nanoparticles proven protective efficacy vaccine formulation merscov mentioned earlier viral vectorbased vaccine adjuvanted protein nanoparticles boosters mice primed rad<NUMBER> also yielded promising th<NUMBER> th<NUMBER> immune responses jung et al <NUMBER> advancement genetic engineering enables vlps display different epitopes viruses producing chimeric vlps cvlps ong et al <NUMBER> expression rbd merscov fused vp<NUMBER> structural protein canine parvovirus cpv produced cvlps displaying rbd merscov cvlps morphologically similar native cpv elicited rbdspecific humoral cellmediated immunities mice wang et al <NUMBER>a cvlps displaying protein merscov matrix <NUMBER> protein influenza virus also developed shown immunogenic mouse models however actual protective efficacy cvlps merscov yet investigated vivo addition vaccines based vlps nonviral nanoparticle ferritin also reported potential carrier merscov antigen kim et al <NUMBER> utilized chapernamediated ferritin nanoparticle display merscov rbd adjuvanted mf<NUMBER> ferritinbased nanoparticle induced rbdspecific antibodies balbc mice inhibited rbd binding hdpp<NUMBER> receptor protein suggesting potential use merscov antigen carrier inactivated wholevirus comprises entire disease causing virion inactivated physically heat chemically iwv offers several advantages including relatively low cost production good safety profile involve laborious genetic manipulation dezure et al <NUMBER> nevertheless production iwv requires live virus grown highlevel containment antigenicity immunogen could altered viral inactivation step dezure et al <NUMBER> formaldehydeinactivatedmerscov induced neutralizing antibodies mice tcell response supplementing iwv combined adjuvant alum cpg odn reported enhance protective immunity merscov mice transduced hdpp<NUMBER> hand inactivated bivalent whole virus vaccine targets rabies virus rabv merscov recently developed using recombinant vector encoding fusion protein comprising merscov s<NUMBER> domain fused cterminus rabv g protein following expression s<NUMBER> domain incorporated rabv particles bnsp<NUMBER>s<NUMBER> mice immunized chemically inactivated bnsp<NUMBER>s<NUMBER> robust neutralizing antibody responses s<NUMBER> g proteins detected inactivated bnsp<NUMBER>s<NUMBER> also protected hdpp<NUMBER>transducedmice merscov challenge wirblich et al <NUMBER> despite benefits associated iwvbased vaccines inactivated merscov vaccine reported potentially cause hypersensitivitytype lung immunopathologic reaction upon merscov challenge even though induced neutralizing antibodies reduced viral load hdpp<NUMBER> transgenic mice similar observed sarscov agrawal et al <NUMBER> live attenuated vaccine one effective vaccines due capability induce immunity similar natural infection vaccine contains viable attenuated virus common approaches develop live attenuated vaccine include deletion viral genes confer virulence via reverse genetic general live attenuated vaccines highly immunogenic thus require adjuvant optimal efficacy single immunization usually sufficient induce protective immunity nevertheless live attenuated vaccines come unwanted limitations particularly risk reversion virulent strain absolute need vaccine cold chain live attenuated vaccine also suitable infants immunocompromised individuals elderly people lauring et al <NUMBER> live attenuated vaccine merscov previously developed deleting e gene merscov rmerscove engineered virus lacked infectivity replicated single cycle vaccines based live attenuated viruses could pose biosafety problems associated risk virulence reversion whereas rmerscove propagation defective absence e protein preventing straightforward reversion virulence thus providing safer alternative almazan et al <NUMBER> recently live attenuated merscov generated mutation nsp<NUMBER> d<NUMBER>a attenuated virus protected crisprcas<NUMBER>targeted <NUMBER> c<NUMBER>bl<NUMBER> mice mouseadapted merscov challenge menachery et al <NUMBER> merscov replication competent recombinant measles virus mv used platform development live attenuated merscov vaccine recombinant mv engineered express fulllength protein mv vac<NUMBER> covs truncated version mv vac<NUMBER> covsols mv vac<NUMBER> covs mv vac<NUMBER> covsols shown induce neutralizing antibodies cellmediated immune responses mv merscov protected hdpp<NUMBER>transducedmice merscov challenge malczyk et al <NUMBER> three years later bodmer et al <NUMBER> compared mv vac<NUMBER> covs uvinactivated derivative showed inactivated version induce specific immune response mv merscov concurrently bodmer et al <NUMBER> constructed live attenuated recombinant mv expressing merscov n protein mv vac<NUMBER> mersn administration ifnar −− cd<NUMBER>ge mice genetically modified mice deficient type ifn receptor transgenically expressing human cd<NUMBER> induced nspecific cell responses although strong mv vac<NUMBER> covs similarly another study viable recombinant vesicular stomatitis virus vsv g protein replaced protein merscov also elicited humoral cellmediated immunities rhesus macaques development mers vaccines started immediately following discovery merscov <NUMBER> preclinical trials animal models capable recapitulating clinical signs symptoms human must prior clinical trials licensing vaccine gerdts et al <NUMBER> choice animal model generally preferable phylogenetically closer possible human swearengen <NUMBER> therefore majority vaccine candidates evaluated nonhuman primates chimpanzees rhesus macaques sibal samson <NUMBER> marmosets carrion patterson <NUMBER> employing animal models experiments however extremely costly gerdts et al <NUMBER> involving nonhuman primates vaccine evaluation strong justification supporting evidence vitro analysis preferable animal studies small rodents often required gerdts et al <NUMBER> however merscov cannot infect smaller rodents naturally representing huge challenge initial vaccine developments goldstein weiss <NUMBER> although transgenic mouse models evaluation merscov vaccines successfully developed costs transgenic animals affordable many research groups especially less affluent parts world issue consequently delayed development effective vaccine advancement clinical trial funding primary drivers vaccine developments many vaccines demonstrating promising results preclinical stage require additional investments government private industry advance clinical trials hakoum et al <NUMBER> however government funding clinical trials rather restricted whereas private industry generally profit oriented market size potential profits priority smith <NUMBER> unlike widespread diseases hepatitis influenza mers cases primarily reported saudi arabia apart korea outbreak gossner et al <NUMBER> relatively low occurrence likely limit market size mers vaccines leading lower interest private funding bodies although three potential mers vaccine candidates advanced clinical trials currently phase iii completing entire trials often take <NUMBER> years unlikely commercially available coming <NUMBER> years despite low occurrence recorded humantohuman transmission recent mers outbreak south korea demonstrated virus emergence second third generation contacts reignited public awareness regarding danger merscov effective treatment mers currently available therefore best solution develop functional mers vaccine prevent merscov infection amongst six types vaccines discussed studies focused viral vectorbased subunit vaccines even though many promising vaccine candidates proposed reported three potential merscov vaccine candidates progressed phase clinical trials dna vaccine gls<NUMBER> two viral vectorbased vaccines mvamerss mers<NUMBER> still likely mers vaccine available market human near future therefore considerable efforts given minimize delays executing clinical trials better understanding coordination sponsors primary investigators investigators participants stakeholders cy ho wrote manuscript sy kh wt reviewed edited approved final version coronaviruses covs positivesense singlestranded rna viruses family coronaviridae subfamily coronavirinae infect wide host range produce diseases ranging common cold severefatal illnesses novel virus initially named <NUMBER>ncov changed sarscov<NUMBER> coronavirus study group csg international committee taxonomy viruses ictv since found sister virus severe acute respiratory syndrome coronavirus sarscov <NUMBER> ongoing coronavirus threat emerged china rapidly spread countries declared global health emergency world health organization many nations diverting best efforts implementation appropriate preventive control strategies neither vaccines directacting antiviral drugs available treatment human animal coronavirus infections <NUMBER> <NUMBER> <NUMBER> many efforts directed develop vaccines human cov infections recent decades limiting factor degree crossprotection rendered vaccines due extensive sequence diversity <NUMBER> various vaccines immunotherapeutics drug options explored recent threats zika ebola nipah viruses <NUMBER> <NUMBER> <NUMBER> well previous covs including sarsand merscovs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> valuable options exploited potency efficacy safety along expediting ongoing research <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> discover valuable modalities tackling emerging covid<NUMBER> yet effective vaccine therapeutic intense efforts ongoing therapeutic options available managing covid<NUMBER> based previous experiences treating sarsand merscov major reason lack approved commercially available vaccines therapeutic agents covs might relative lack interest among pharmaceutical companies <NUMBER> outbreak scenarios demand drugs vaccines lasts period outbreak lasts number affected people also small proportion global drug vaccine market time new drug vaccine developed might patients clinical trials also meaningful market newly discovered drugs according guidelines infected patients receive supportive care including oxygen therapy fluid therapy antibiotics treating secondary bacterial infections also recommends isolation patients suspected confirmed covid<NUMBER> <NUMBER> major therapeutic drugs might effective managing covid<NUMBER> include remdesivir lopinavirritonavir alone combination interferonβ convalescent plasma mabs <NUMBER> nevertheless utilizing drugs covid<NUMBER> pneumonia patients clinical efficacy safety studies conducted article describes advances designing vaccines therapeutics counter covid<NUMBER> also discussing experiences sarsand merscovs together could pave ways right direction halt emerging virus multiple strategies adopted development cov vaccines target surfaceexposed spike glycoprotein protein major inducer neutralizing antibodies several sproteinbased strategies attempted developing cov vaccines eg use fulllength protein s<NUMBER>receptorbinding domain rbd expression viruslike particles vlp dna viral vectors <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein molecule contains two subunits s<NUMBER> s<NUMBER> s<NUMBER> subunit rbd interacts host cell receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> whereas s<NUMBER> subunit mediates fusion virus host cell membranes releasing viral rna cytoplasm replication <NUMBER> hence sproteinbased vaccines induce antibodies block viral receptor binding also virus genome uncoating shown cterminal domain s<NUMBER> subunit porcine deltacoronavirus constitutes immunodominant region immune response region shows potent neutralizing effect <NUMBER> protein major role induction protective immunity infection sarscov eliciting neutralizingantibodies tcell responses <NUMBER> thus fulllength appropriate parts glycoprotein believed promising candidate cov vaccine composition also reported neither absence presence structural proteins affects protein immunogenicity binding ace<NUMBER> receptor critical initial step virus access host cell <NUMBER> <NUMBER> due superior ability rbd induce neutralizing antibody recombinant proteins contain rbd recombinant vectors encode rbd used developing effective sarscov vaccines <NUMBER> recombinant adenovirusbased vaccine expressing merscov protein induces systemic igg secretory iga lungresident memory tcell responses administered intranasally balbc mice provide longlasting neutralizing immunity mers spike pseudotyped virus thereby suggesting vaccine may confer protection merscov <NUMBER> furthermore rabies virus rv viral vector well grampositive enhancer matrix gem bacterial vector used express merscov protein immune responses vaccine candidates evaluated balbc mice cellular humoral immune responses showed rvbased vaccine stimulates significantly higher levels cellular immunity earlier antibody responses comparison gem particle vector <NUMBER> possibility developing universal cov vaccine assessed based similarity tcell epitopes sarsand merscov confirmed potential crossreactivity among covs <NUMBER> sarscov<NUMBER> shares high genetic similarity sarscov <NUMBER> vaccines developed sarscov may exhibit crossreactivity sarscov<NUMBER> comparative evaluation performed fulllength protein sequences sarscov<NUMBER> sarscov identified variable residues located s<NUMBER> subunit protein critical cov vaccine target <NUMBER> findings suggest specific neutralizing antibodies effective sarscov might effective sarscov<NUMBER> even though protein sarscov<NUMBER> key mutations compared sarscov still act viable target vaccine development <NUMBER> likewise close similarity sarscov<NUMBER> sarscov suggests receptor sarscov<NUMBER> might sarscov receptor ace<NUMBER> <NUMBER> immunoinformatics approach used identification epitopes inclusion covid<NUMBER> vaccine candidates recently immunoinformatics used identify significant cytotoxic lymphocyte ctl bcell epitopes sarscov<NUMBER> protein interactions epitopes corresponding mhc class molecules studied using molecular dynamics simulations found ctl epitopes bind mhc class peptidebinding grooves via multiple contacts thus indicating potential generating immune responses <NUMBER> epitopes may possess ideal characteristics become part covid<NUMBER> vaccine candidates nucleocapsid n protein well potential b cell epitopes e protein merscov suggested probable immunoprotective targets induce tcell neutralizing antibody responses <NUMBER> <NUMBER> reverse genetic strategies successfully used liveattenuated vaccines inactivate exonuclease effects nonstructural protein <NUMBER> nsp<NUMBER> delete envelope protein sars <NUMBER> avian infectious bronchitis virus ibv chicken cov suggested avian live virus ibv vaccine strain h might useful sars <NUMBER> given protection provided strain h based neutralizing antibody production well immune responses hence avian ibv vaccine may considered another option covid<NUMBER> evaluating safety monkeys <NUMBER> scientists rocky mountain laboratories collaborating oxford university develop chimpanzee adenovirusvectored covid<NUMBER> vaccine candidate <NUMBER> coalition epidemic preparedness innovations cepi recently announced initiation three programs aimed develop covid<NUMBER> vaccines utilizing established vaccine platforms <NUMBER> among three programs two continuations previously initiated partnerships cepi collaborated inovio <NUMBER> developing dna vaccine candidates mers <NUMBER> funding vaccine development utilizes dna medicines platform delivering synthetic genes cells translation antigenic proteins elicit tcell antibody responses cepi collaborated university queensland <NUMBER> develop molecular clamp vaccine platform multiple viral pathogens including merscov <NUMBER> funding vaccine platform functions synthesizing viral surface proteins get attached host cells clamp shape facilitates easier recognition antigens immune system <NUMBER> ongoing programs cepi announced funding moderna comparing mrna therapeutics vaccines design manufacture mrna vaccine collaboration vaccine research center vrc national institute allergy infectious diseases niaid part national institutes health nih <NUMBER> niaidvrc scientists developing vaccine candidate expressing sarscov<NUMBER> protein mrna vaccine platform technology vaccine expected undergo clinical testing coming months <NUMBER> direct administration monoclonal antibodies mabs may play effective role cov control intervention exposed individuals observed patients recovering sars display potent neutralizing antibody responses <NUMBER> clinical trial proposed use set mabs functionally target specific domains merscov protein mabs bind six specific epitope groups interacting receptor binding membrane fusion sialic acidbinding sites represent three important entry functions merscov protein <NUMBER> <NUMBER> moreover passive immunization poorly potently neutralizing antibodies induces substantial protection mice subjected lethal merscov challenge thus use antibodies may represent novel approach increase humoral protection emerging covs targeting various protein epitopes functions crossneutralization capacity sarscov rbdspecific neutralizing mabs greatly depends similarity rbds sarscov rbdspecific antibodies crossneutralize sarslike sl covs ie batslcov strain wiv<NUMBER> rbd <NUMBER> amino acid differences sarscov batslcov strain shc<NUMBER> <NUMBER> amino acid differences <NUMBER> crossneutralizing sarscov rbdspecific mabs evaluated efficacy sarscov<NUMBER> requires comparative analysis sarscov<NUMBER> rbd sarscov suitable rbdspecific mabs identified evaluated clinical trials regeneron trying identify mabs specific effective covid<NUMBER> combination therapy mabs drug remdesivir could ideal therapeutic option covid<NUMBER> <NUMBER> evaluation required confirming efficacy combination therapy technology available making fully human antibodies human singlechain antibodies huscfvs humanizednanobodies singledomain antibodies sdab vhvhh traverse across membrane virusinfected cells trans bodies bind interfere biological activities replicating virus proteins consequently leads inhibition virus replication examples include trans bodies influenza virus hepatitis c virus ebola virus dengue virus <NUMBER> thus possible generate trans bodies cov intracellular proteins papainlike proteases plpro cysteinelike protease <NUMBER>clpro nonstructural proteins nsps pivotal cov replication transcription safe nonimmunogenic broadly effective passive immunization covexposed subjects treatment infected patients suitable animal models evaluating vaccines sarsand merscov lacking highly limited making process vaccine development highly challenging <NUMBER> <NUMBER> development efficient animal model mimics clinical disease inform pathogenesis well develop vaccines therapeutics covs several animal models evaluated sarsand mers covs including mouse guinea pigs hamsters ferrets rabbits rhesus macaques marmosets cats <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> early effort directed developing animal models sarscov specificity virus ace<NUMBER> receptor sarscov major hindrance efforts later sarscov transgenic mouse model developed introducing hace<NUMBER> gene mouse genome <NUMBER> first animal model used developing merscov vaccine rhesus macaques infected animals showed clinical symptoms increased body temperature piloerection cough hunched posture reduced food intake <NUMBER> another frequently used animal model merscov common marmoset wherein virus caused lethal pneumonia <NUMBER> humoral cellmediated immunity could detected rhesus macaques common marmoset following merscov immunization <NUMBER> <NUMBER> hamsters potential model studying cov pathology pathogenesis vaccine efficacy attenuated nsp<NUMBER> cov vaccine studied mice <NUMBER> attempts develop animal models merscov mice hamsters ferrets face limitations due inability merscov replicate respiratory tracts species small animals mice hamsters resisting natural infection merscovs susceptible sarscov genetically modified humanized structure eg hdpp<NUMBER> human hdpp<NUMBER>transduced hdpp<NUMBER>tg mice transgenic expressing hdpp<NUMBER> ascertained susceptibility merscov infection <NUMBER> alteration mouse genome using crisprcas<NUMBER> geneediting tool could make animals susceptible cov infection virus replication <NUMBER> genetic engineering used generation <NUMBER> merscov mouse model used evaluation novel merscov vaccines drugs <NUMBER> compared large animal models small animals mice rabbits preferred due lower cost ease manipulation readily available efficacy methods <NUMBER> studies needed recognize suitable models emerging sarscov<NUMBER> identifying receptor affinity sarscov<NUMBER> studying disease manifestations pathologiesviral pathogenesis associated experimental inoculation virus mice rats models well examining virusspecific immune responses protection would facilitate preclinical evaluations candidate covid<NUMBER> vaccines drugs several permissive cell lines hcovs including monkey epithelial cell lines llcmk<NUMBER> verob<NUMBER> used neutralization assays assessing neutralization titers antibody preparations goat lung cells alpaca kidney cells dromedary umbilical cord cells found permissive merscov <NUMBER> sarscov protein found mediate entry hepatoma cell lines targeted neutralizing antibodies virusinfected patients <NUMBER> advanced exvivo <NUMBER>d tracheobronchial tissue mimicking epithelium conductive airway used human covs <NUMBER> moreover vlps displaying sarscov protein found competent entry permissive cells transfected cells overexpress virus receptors <NUMBER> sarscov<NUMBER> isolation attempted vero huh<NUMBER> cells human liver cancer cells <NUMBER> pseudotyped virionsvlps encoding reporter systems gfp luciferase used quantification evaluation effectiveness mabs drugs inhibiting cellular entry covs <NUMBER> assays using pseudotyped virionsvlps performed bsl<NUMBER> facility since use infectious virus safety concern passive immunization antibodies possible antibodydependent enhancement ade virus replication antibodies modified fc fragments without fc fragment eg human singlechain antibodies scfv fab fab′ <NUMBER> safe alternatives several mabs fully human humanized target s<NUMBER>rbd nonrbd well s<NUMBER> domain covs generated tested cell cultures virusneutralizing capability well animal models prophylactic postexposure efficacies <NUMBER> antibodies could useful tools also development vaccines therapeutic drugs antiviral inhibitors data animal cov vaccination suggest systemic humoral cellmediated immune responses induced parenteral administration may adequate prevent respiratory tract infection <NUMBER> respiratory mucosa initial site cov infection transmission mucosal immunization using intranasal vaccine <NUMBER> could effective strategy prophylaxis induction mucosal systemic immune responses molecular mechanisms mucosal systemic immunological factors different difficult predict surrogate marker cov efficacy best surrogate assays protection well herd immunity toward different cov infections warrant detailed investigations main measure clinical management focused alleviating clinical symptoms supportive care <NUMBER> <NUMBER> <NUMBER> therapeutic options could evaluated used covid<NUMBER> include molecules binding virus molecules inhibitors target specific enzymes involved viral replication transcription smallmolecule inhibitors targeting helicase essential proteases proteins virus host cell protease inhibitors host cell endocytosis inhibitors sirna antisense rna ribozyme neutralizing antibodies mabs targeting host receptor interfere s<NUMBER> rbd antiviral peptide targeting s<NUMBER> natural products <NUMBER> <NUMBER> long list anticov agents mostly preclinical compounds yet evaluated anticovid<NUMBER> agents agents phase iii trials covid<NUMBER> including remdesivir oseltamivir asc<NUMBER>f hiv protease inhibitor lopinavir ritonavir darunavir cobicistat <NUMBER> many existing mersandor sarscovs inhibitors screened efficacy rnadependent rna polymerase rdrp sequence sarscov<NUMBER> shown <NUMBER> identity sarscov critical finding since drugs developed sarscov rdrp might show similar efficacy sarscov <NUMBER> rdrp <NUMBER> protein considered major target designing cov antiviral therapies protein inhibitors cleavage inhibitors neutralizing antibodies rbdace<NUMBER> blockers sirnas fusion core blockers protease inhibitors <NUMBER> therapeutic strategies shown potential vitro vivo anticov activities comparatively even though vitro studies performed agents shown efficacy lack sufficient support due lack randomized animal human trials hence limited use covid<NUMBER> hence necessary support extensive animal human trials required therapeutics become useful binding covid<NUMBER> ace<NUMBER> affects balance reninangiotensin system ras potentially leading exacerbation severe pneumonia thus speculated acei angiotensin type<NUMBER> receptor at<NUMBER>r inhibitors might able reduce pulmonary inflammatory responses thereby reducing mortality <NUMBER> guidance covid<NUMBER> control might based existing measures mers sars precautions due unknown nature new cov <NUMBER> <NUMBER> main treatments mechanical ventilation icu admission symptomatic supportive care recommended severe cases furthermore rna synthesis inhibitors like <NUMBER>tc tdf remdesivir neuraminidase inhibitors peptide ek<NUMBER> antiinflammatory drugs abidol chinese traditional medicine lianhuaqingwen shufengjiedu capsules could promising covid<NUMBER> treatments <NUMBER> however clinical trials required confirming safety efficacy covid<NUMBER> major limiting factor quest identifying ideal vaccine therapeutic agent time may take months even several years researchers develop produce standardize evaluate approve commercialize therapeutic agents covid<NUMBER> hence current efforts directed toward identifying evaluating drugs immunotherapeutics proven efficacy viruses similar covid<NUMBER> time required drug discovery programs develop evaluate obtain approval new potent anticovid<NUMBER> agent could take <NUMBER> years <NUMBER> present scenario development new therapeutic agent covid<NUMBER> feasible option regard available time another option repurpose broadly acting antiviral drugs used viral infections drugs advantage easy availability known pharmacokinetic pharmacodynamic properties solubility stability side effects also wellestablished dosing regimens <NUMBER> repurposed drugs potential therapeutic options managing cov infections repurposed drugs lopinavir ritonavir interferon<NUMBER>β possess vitro antimerscov activity vivo study conducted common marmosets nonhuman primate model showed animals treated lopinavirritonavir interferon<NUMBER>β better outcomes untreated animals <NUMBER> combination lopinavirritonavir interferon<NUMBER>β evaluated mers miracle trial <NUMBER> two protease inhibitors lopinavir ritonavir combined ribavirin found associated favorable clinical responses sars patients indicating therapeutic efficacy <NUMBER> early attempt evaluate repurposed drugs covid<NUMBER> controlled trial ritonavirboosted lopinavir interferonα <NUMBER>b therapy registered hospitalized patients china chictr<NUMBER> <NUMBER> oral administration neuraminidase inhibitors oseltamivir used empirical drug covid<NUMBER> suspected cases china hospitals even though evidence efficacy <NUMBER> recently vitro antiviral efficacy approved drugs ribavirin penciclovir nitazoxanide nafamostat chloroquine compared two broadspectrum antiviral drugs remdesivir favipiravir covid<NUMBER> among evaluated drugs remdesivir chloroquine found highly effective controlling covid<NUMBER> vitro <NUMBER> study also pointed three nucleoside analogs ribavirin penciclovir favipiravir may significant vivo antiviral effects covid<NUMBER> since higher concentrations required reduce viral infection vitro remdesivir chloroquine used treatment diseases welldefined safety profile hence drugs used evaluating efficacy patients novel cov infections achievements development vaccines therapeutic agents sarsand merscov well recent ongoing progress covid<NUMBER> facilitate development effective vaccines therapeutics emerging virus however present scenario covid<NUMBER> warrants need implementing robust preventive control measures due potential nosocomial infections <NUMBER> need rely exclusively preventive measures since considerable time required efforts develop new vaccine antiviral agent becomes fruitful researchers searching effective suitable vaccine candidates therapeutics controlling deadly covid<NUMBER> effective vaccines specific antiviral drugs covid<NUMBER> hence rely exclusively enforcing strict preventive control measures minimize risk possible disease transmission results obtained recently conducted vitro study covid<NUMBER> promising since drugs remdesivir chloroquine found highly effective controlling infection direct clinical trials conducted among patients infected covid<NUMBER> since drugs used treating diseases wellestablished safety profiles making evaluation drugs much easier protein considered key viral antigen developing cov vaccines shown several preclinical studies although research progress improve prevention treatment control covid<NUMBER> documented clinical data different therapeutic approaches covs scarce research directed toward study sarscov<NUMBER> suitable animal models analyzing replication transmission pathogenesis coronaviruses cov first became widely known emergence severe acute respiratory syndrome sars <NUMBER> positive singlestrand rna viruses often infect birds variety mammals sometimes migrate humans <NUMBER> coronaviruses infect humans usually present mild symptoms eg <NUMBER> cases involving common cold caused coronavirus several previous outbreaks sars middle east respiratory syndrome mers <NUMBER> caused significant fatalities infected populations <NUMBER> december <NUMBER> several patients connection wuhan china developed symptoms viral pneumonia sequencing viral rna determined cases caused novel coronavirus named <NUMBER>ncov sarscov<NUMBER> <NUMBER> <NUMBER> virus infected <NUMBER> people across <NUMBER> countries february <NUMBER>th <NUMBER> according world health organization report <NUMBER> covid<NUMBER> disease caused <NUMBER>ncov led death <NUMBER> patients clearly transmissible humans <NUMBER> deployment vaccine <NUMBER>ncov would arrest infection rate help protect vulnerable populations however vaccine yet passed beyond clinical trails coronavirus whether humans animals <NUMBER> <NUMBER> animal models inactivated whole virus vaccines without focused immune epitopes offer incomplete protection <NUMBER> vaccines sarscov merscov also resulted hypersensitivity immunopathologic responses mice <NUMBER> <NUMBER> diversity among coronavirus strains presents another challenge <NUMBER> <NUMBER> least <NUMBER> distinct subgroups coronavirus genus sarscov <NUMBER>ncov share subgroup <NUMBER>b genomes <NUMBER> identical <NUMBER> understanding shared unique epitopes <NUMBER>ncov help field design better vaccines diagnostic tests patients orfs protein target antibodies model <NUMBER>d structure discotope<NUMBER> identify likely binding sites bcell epitopes scan peptide sequences individual viral protein netmhcpan<NUMBER> maria mhci mhcii presentation respectively identify potential tcell epitopes mhci analysis include common alleles hlaa hlab hlac mhcii analysis include common alleles hladr viruses neutralizing antibodies fully block entry viruses human cells <NUMBER> location antibody binding sites viral protein strongly affects bodys ability produce neutralizing antibodies example hiv buried surface proteins protect human antibodies <NUMBER> reason would valuable understand whether <NUMBER>ncov potential antibody binding sites bcell epitopes near interacting surface known human entry receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> beyond neutralizing antibodies human bodies also rely upon cytotoxic cd<NUMBER> tcells helper cd<NUMBER> tcells fully clear viruses presentation viral peptides human major histocompatibility complex mhc hla class class ii essential antiviral tcell responses <NUMBER> contrast bcell epitopes tcell epitopes located anywhere viral protein since human cells process present intracellular extracellular viral peptides <NUMBER> immunology principles guide design current study fig <NUMBER> first focus tcell epitopes <NUMBER>ncov carries <NUMBER> major structural proteinsspike membrane envelope e nucleocapsid nand least <NUMBER> open reading frames orfs <NUMBER> <NUMBER> protein fragments potential presented mhci mhcii recognized tcells apply netmhcpan<NUMBER> <NUMBER> maria <NUMBER> two artificial neural network algorithms predict antigen presentation identify potential tcell epitopes next focus bcell epitopes spike protein main transmembrane glycoprotein expressed surface <NUMBER>ncov responsible receptor binding virion entry cells <NUMBER> <NUMBER> narrow bcell epitope search protein since likely target human neutralizing antibodies discopte<NUMBER> uses combination amino acid sequences protein surface properties predict antibody binding sites given protein structure <NUMBER> use tool identify potential <NUMBER>ncov bcell epitopes cocrystal structure <NUMBER>ncovs spike protein antibody yet available finally examine viral mutation pattern thanks global sequencing efforts <NUMBER> able obtain cohort <NUMBER> <NUMBER>ncov genomes four continents based resulting viral mutation profile examine whether mutations driven immune selection pressure highly mutated regions might excluded vaccine candidate pool obtained <NUMBER>ncov sarscov<NUMBER> sarscov reference sequence data ncbi genebank nc<NUMBER> nc<NUMBER> <NUMBER> <NUMBER> extracted <NUMBER>ncov protein sequences orf<NUMBER>ab orf<NUMBER>a e orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> n orf<NUMBER> based reference genome obtained viral sequences associated <NUMBER> patients gisaid feb <NUMBER>st <NUMBER> supplementary table <NUMBER> <NUMBER> genomes single protein included analysis broke gene sequence <NUMBER>ncov sliding windows length <NUMBER> median length mhci ligands <NUMBER> median length mhcii ligands used netmhcpan<NUMBER> <NUMBER> maria <NUMBER> predict mhci mhcii presentation scores respectively used <NUMBER> mhc alleles common chinese population <NUMBER> allele frequency <NUMBER> hlaa <NUMBER> hlab <NUMBER> hlac <NUMBER> hladrb<NUMBER> determined analysis human populations <NUMBER> complete list common mhc alleles included supplementary table <NUMBER> maria netmhcpan<NUMBER> return percentiles characterize peptides likelihood presentation relative preset distribution random human peptide scores prior work recommends thresholds <NUMBER> netmhcpan<NUMBER> <NUMBER> maria determine reasonable presenters also applied analysis stringent <NUMBER> threshold netmhcpan<NUMBER> maria used gene expression values <NUMBER> tpm running maria reflect high expression values viral genes human cells aggregating alleles across mhci mhcii report overall coverage marked peptide sequence covered presented <NUMBER> common alleles chose <NUMBER> cutoff suggests high <NUMBER> probability least one allele present peptide assuming patient carries six mhc alleles eg <NUMBER> <NUMBER> bs <NUMBER> cs distribution common mhc alleles population random ranked potential tcell epitopes based mhci mhcii presentation coverage across alleles applied methodology known sars tcell epitopes nonepitope sars peptides estimate ability predict <NUMBER>ncov epitopes mhci curated <NUMBER> experimentally determined hlaa<NUMBER> associated cd<NUMBER> tcell epitopes <NUMBER> nonepitope <NUMBER>mer sliding windows sars protein <NUMBER> <NUMBER> <NUMBER> mhcii curated <NUMBER> experimentally determined cd<NUMBER> tcell epitopes <NUMBER> nonepitopes sars protein <NUMBER> specific hladr alleles reported original study used hladrb<NUMBER> <NUMBER> common alleles run maria calculate sensitivity specificity validation set labeled peptide sequence <NUMBER>th mhci <NUMBER>th mhcii percentile positive epitope prediction sequence threshold labeled negative prediction calculated auc scores auroc estimate overall performance methodology obtained approximate <NUMBER>d structure <NUMBER>ncov protein homology modeling sars protein pdb <NUMBER>acc swissmodel <NUMBER> <NUMBER> proteins <NUMBER>ncov sars share <NUMBER> similarity modeled structure <NUMBER>ncov protein qmean <NUMBER> table <NUMBER> summary potential <NUMBER>ncov tcell epitope candidates based hla antigen presentation scores hlaa hlab hlac hladr columns refer number peptide sequences predicted present across one third common alleles among chinese population length refers number amino acids given gene hlac likely present <NUMBER>ncov antigens across one third alleles compared hlaa b fishers exact test pvalue levels indicated <NUMBER> <NUMBER> <NUMBER> supplementary file <NUMBER> used computational docking algorithm cluspro<NUMBER> <NUMBER> estimate interactive surface <NUMBER>ncov known human receptor ace<NUMBER> <NUMBER> supplementary file <NUMBER> graphic rendering analysis performed pymol <NUMBER> predicted likely human antibody binding sites bcell epitopes sars <NUMBER>ncov protein disctope<NUMBER> <NUMBER> analysis focused neutralizing binding sites examining residues <NUMBER> full prediction results found supplementary aimed determine whether statistical relationship regions mutation presentation translated viral genome sequences protein sequences using biopython <NUMBER> indexes ncbi reference genome <NUMBER>ncov nucleotide position <NUMBER> contains <NUMBER> frame shift signal adjusted accordingly generate orf<NUMBER>ab compared protein sequences <NUMBER> patients reference sequence identify mutations edit distance analysis positions poor quality reads eg w excluded analysis full sequence mutation profiles found supplementary computed fishers exact test scipy <NUMBER> auroc scikitlearn <NUMBER> scanned <NUMBER> <NUMBER>ncov genes netmhcpan<NUMBER> maria identify regions highly presentable hla complexes human mhc epitope labeled positive presentable one third common alleles among chinese population display summary tcell epitope findings table <NUMBER> fig <NUMBER> show regions strong mhc presentation across hlaa hlab hlac hladr alleles medium threshold fig <NUMBER>a high threshold fig <NUMBER>b consistent similar finding sarscov proteins orf<NUMBER>ab e contain high numbers presentable antigen sequences across mhci mhcii <NUMBER> highly presentable peptides functional viral proteins provide candidate pool tcell epitope identifications epitopefocused vaccine design presentation scores individual antigen peptides found supplementary table <NUMBER> <NUMBER> netmhcpan<NUMBER> predicts larger number <NUMBER>ncov protein sequences presented hlac alleles across genes fishers exact test p <NUMBER>e −<NUMBER> compared hlaa hlab table <NUMBER> specifically orf<NUMBER>ab p <NUMBER>e −<NUMBER> p <NUMBER>e −<NUMBER> orf<NUMBER>a p <NUMBER> p <NUMBER> better presented hlac alleles bonferroni correction might due relatively conserved hlac binding motif <NUMBER>th position main anchor residue leucine methionine phenylalanine tyrosine commonly favored across alleles <NUMBER> hlac<NUMBER> hlac<NUMBER> hlac<NUMBER> <NUMBER> allele frequency chinese population <NUMBER> suggests future epitopebased vaccines include hlac related epitopes beyond common hlaa<NUMBER> hlab<NUMBER> approach estimate ability antigen presentation scores identify <NUMBER>ncov tcell epitopes performed validation study known sarscov cd<NUMBER> cd<NUMBER> tcell epitopes fig <NUMBER> copyright holder preprint peerreviewed figure <NUMBER> validation netmhcpan maria tcell epitope identification sarscov protein epitopes netmhcpan<NUMBER> maria presentation percentiles used differentiate experimentally identified cd<NUMBER> tcell epitopes mhci n<NUMBER> <NUMBER> <NUMBER> <NUMBER> cd<NUMBER> tcell epitopes mhcii n<NUMBER> <NUMBER> negative peptides n<NUMBER> <NUMBER> negative peptides cd<NUMBER> tcell epitopes <NUMBER>mer sliding windows protein without reported epitope negative peptides cd<NUMBER> tcell epitopes experimentally tested netmhcpan<NUMBER> sensitivity <NUMBER> specificity <NUMBER> <NUMBER>th presentation percentile cutoff overall auc <NUMBER> b maria sensitivity <NUMBER> specificity <NUMBER> <NUMBER>th presentation percentile cutoff overall auc <NUMBER> independent experimental studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> identified known cd<NUMBER> tcell epitopes mhci n<NUMBER> known cd<NUMBER> tcell epitopes mhcii n<NUMBER> also obtained known nonepitopes n<NUMBER> <NUMBER> cd<NUMBER> cd<NUMBER> include <NUMBER>mer sliding windows protein without known epitope nonepitopes mhci presentation recommended cutoff <NUMBER> <NUMBER> sensitivity <NUMBER> specificity <NUMBER> auc <NUMBER> fig <NUMBER>a mhcii presentation recommended cutoff <NUMBER> <NUMBER> sensitivity <NUMBER> specificity <NUMBER> auc <NUMBER> fig <NUMBER>b given high similarity sarscov <NUMBER>ncov proteins expect analysis <NUMBER>ncov perform similarly future experimentally validated tcell epitopes detailed scores sequences analysis found supplementary table <NUMBER> <NUMBER> human immune selection pressure shown drive viral mutations evade immune surveillance eg low mhc presentation hypothesize similar phenomenon occur <NUMBER>ncov curated cohort <NUMBER> viral genomes across four continents identified <NUMBER> point mutations <NUMBER> nonsense mutation <NUMBER> deletion mutation compared published reference genome <NUMBER> plot point mutations regions mhci mhcii presentation fig <NUMBER> full protein sequence mutation information found supplementary table <NUMBER> <NUMBER> mutations occur genes exception e orf<NUMBER> orf<NUMBER>b n identify recurrent mutation l<NUMBER>s orf<NUMBER> <NUMBER> samples mutations likely occur regions mhci presentation fischers exact test p <NUMBER> relationship observed mhcii p <NUMBER> aggregate mhci mhcii p <NUMBER> consistent role cd<NUMBER> tcell clearing infected cells mutations supporting evasion immune surveillance <NUMBER> presented multiple mhc alleles indicated heatmap fig <NUMBER> sample japan epiisl<NUMBER> viral gene orf<NUMBER>ab loses nucleotides <NUMBER> code gdsveevl associated antigen fgdsveevl predicted good presented multiple mhci alleles eg <NUMBER> hlac<NUMBER> <NUMBER> hlac<NUMBER> <NUMBER> hlab<NUMBER> summary observed <NUMBER>ncov mutations often occur among delete presentable peptides potential form immune evasion patient mhc allele information tcell profiling needed better assess phenomenon however patients typically carry fewer <NUMBER> mutations vaccine multiple epitopes nullified small number mutations obtained likely <NUMBER>d structure <NUMBER>ncovs spike protein supplementary file <NUMBER> homology modeling sarscovs spike protein pdb <NUMBER>acc scanned spike protein structures discotope<NUMBER> identify potential antibody binding sites protein surface fig <NUMBER> sarscov protein identified strong cluster antibody sites <NUMBER> residues pink red receptor binding domain rbd ace<NUMBER> interacting surface three independent studies <NUMBER> <NUMBER> <NUMBER> discovered bcell epitopes region blue combination vitro ex vivo approaches additionally discotope<NUMBER> identifies residue <NUMBER> another binding site supported two independent studies fig <NUMBER>a blue <NUMBER> <NUMBER> gives us confidence ability discotope<NUMBER> predict bcell epitopes given unknown protein structure <NUMBER>ncov protein discotope<NUMBER> identified similar antibody binding site protein potential rbd fewer residues <NUMBER> residues fig <NUMBER>b computational proteinprotein docking predicted one potential interacting conformation <NUMBER>ncov protein human ace<NUMBER> entry receptor fig <NUMBER>c main antibody binding site substantially overlaps interacting surface ace<NUMBER> binds protein antibody binding surface likely block viral entry cells discotope<NUMBER> identified anther antibody binding site residue <NUMBER> different sarscov lower scores <NUMBER> raw scores <NUMBER>d structures spike protein scanned discotope<NUMBER> assess potential antibody binding sites bcell epitopes red indicates residues score <NUMBER> cutoff specificity <NUMBER> pink indicates residues score <NUMBER> cutoff specificity <NUMBER> receptor binding domain rbd sars spike protein concentrated high score residues comprised two linear epitopes one additional binding site predicted around residue <NUMBER> three independent experimental studies <NUMBER> <NUMBER> <NUMBER> identify patient antibodies recognize three linear epitopes blue b <NUMBER>ncov spike protein predicted similar strong antibody binding site near rbd additional site around residue <NUMBER> c predicted antibody binding site <NUMBER>ncov rbd potentially overlaps interacting surface known human entry receptor ace<NUMBER> yellow eight <NUMBER>ncov spike protein point mutations present cohort <NUMBER> viral samples mutations near ace<NUMBER> interacting surface one mutation s<NUMBER>r occurs near one predicted antibody binding sites residue <NUMBER> table <NUMBER> top potential epitopes key <NUMBER>ncov proteins ranked epitopes based likely coverage presentation mhci mhcii alleles protein <NUMBER> highly ranked based mhc presentation also one predicted top bcell epitopes localized near protein receptor binding domain figure <NUMBER> mhci coverage calculated <NUMBER>mer highest mhci coverage epitope highlighted orange candidates likely presented mhci mhcii question mark antibody column indicates one sars homolog peptide known bcell epitope identified <NUMBER> point mutation sites protein cohort <NUMBER> <NUMBER>ncov samples fig <NUMBER>d mutations apart protein rbd one mutation s<NUMBER>r occurs near one predicted minor antibody binding site residue <NUMBER> summary observed major structural bcell epitope similarity sarscov <NUMBER>ncov spike proteins recent cryoem study <NUMBER>ncov protein <NUMBER> supports structural similarity would informative rerun analysis cryoem crystal structure becomes publicly available rbds proteins seem important bcell epitopes neutralizing antibodies however sarscov appears larger attack surface <NUMBER>ncov fig <NUMBER>a <NUMBER>b fortunately observed mutations altering binding sites major bcell epitope <NUMBER>ncov understanding landscape tcell bcell epitopes <NUMBER>ncov summarize results table <NUMBER> promising candidates <NUMBER>ncov vaccines ideal antigens presented multiple mhci mhcii alleles general population contain linear bcell epitopes associated neutralizing antibodies specifically first identified regions high coverage mhcii ranked based mhci coverage search top candidates <NUMBER> sequence similarity iedb <NUMBER> assess whether candidate previously reported bcell epitope tcell epitope around <NUMBER> peptide <NUMBER>mers presented wide range mhcii <NUMBER> consistent knowledge promiscuity mhcii presentation <NUMBER> <NUMBER> requiring peptide presented <NUMBER> <NUMBER> common mhci alleles narrowed results <NUMBER> <NUMBER> promising tcell epitopes respectively supplementary table <NUMBER> <NUMBER> top <NUMBER> candidates key viral proteins presented <NUMBER> mhci alleles table <NUMBER> notably protein <NUMBER> good mhc presenter also predicted bcell epitope near protein receptor binding domain fig <NUMBER>b indicates good vaccine candidate summary analyzed <NUMBER>ncov viral genome epitope candidates found <NUMBER> likely tcell epitopes strong mhci mhcii presentation scores <NUMBER> potential neutralizing bcell epitopes protein validated methodology running similar analysis sarscov known sars tcell bcell epitopes inspecting <NUMBER> samples found viral mutations tendency occur regions strong mhci presentation form immune evasion however mutations present near spike protein receptor binding domain critical viral entrance cells neutralizing antibody binding similar sarscov <NUMBER> <NUMBER> <NUMBER>ncov spike protein likely immunogenic carries number tcell bcell epitopes recombinant surface protein vaccines demonstrated strong clinical utilities hepatitis b human papillomavirus hpv vaccines <NUMBER> <NUMBER> recombinant <NUMBER>ncov spike protein vaccine combined top epitopes appropriate adjuvant could reasonable next step <NUMBER>ncov vaccine development economic perspective development coronavirus vaccines faces significant financial hurdles viruses cause endemic infections epidemic episode eg sars little financial incentive private companies develop vaccines specific strain virus <NUMBER> <NUMBER> <NUMBER> address incentive issues governments might provide greater funding support create vaccines past future outbreaks pipeline provides framework identify strong epitopebased vaccine candidatesbeyond <NUMBER>ncovand might applied unknown pathogens previous animal studies show antigens high mhc presentation scores likely elicit strong tcell responses correlation vaccine efficacy tcell responses relatively weak <NUMBER> <NUMBER> <NUMBER> combined future clinical data work help field untangle relationship antigen presentation scores vaccine efficacy supplementary tcells apply netmhcpan<NUMBER> <NUMBER> maria <NUMBER> <NUMBER> two artificial neural network algorithms predict antigen <NUMBER> novel coronavirus <NUMBER>ncov affected <NUMBER> countries continues spread immediate need effective vaccines contain antigens trigger responses human tcells bcells known epitopes identify potential tcell epitopes analysis human antigen presentation well bcell epitopes analysis protein structure identify list top candidates including epitope located <NUMBER>ncov spike protein potentially triggers tcell bcell responses analyzing <NUMBER> samples observe viral mutations likely happen regions strong antigen presentation potential form immune evasion computational pipeline validated experimental data sarscov bc ef designed study implemented analysis pipeline drafted manuscript ra provided insights structural biology reviewed manuscript authors competing interests <NUMBER> correspondence addressed email bchen<NUMBER>stanfordedu protein target antibodies model <NUMBER>d structure discotope<NUMBER> identify likely binding sites bcell epitopes scan peptide sequences individual viral proteins netmhcpan<NUMBER> maria mhci mhcii presentation identify potential tcell epitopes mhci analysis include common alleles hlaa hlab hlac mhcii analysis include common alleles hladr presentation identify potential tcell epitopes main transmembrane glycoprotein expressed netmhcpan<NUMBER> predicts larger number <NUMBER>ncov <NUMBER> protein sequences presented hlac alleles across <NUMBER> genes fishers exact test p <NUMBER>e −<NUMBER> compared hlaa <NUMBER> hlab table <NUMBER> specifically orf<NUMBER>ab p <NUMBER>e −<NUMBER> <NUMBER> p <NUMBER>e −<NUMBER> orf<NUMBER>a p <NUMBER> p <NUMBER> <NUMBER> better presented hlac alleles bonferroni correction <NUMBER> tcell epitope validation estimate ability antigen <NUMBER> presentation scores identify <NUMBER>ncov tcell epitopes <NUMBER> performed validation study known sarscov cd<NUMBER> <NUMBER> cd<NUMBER> tcell epitopes fig <NUMBER> <NUMBER> independent experimen<NUMBER> tal studies <NUMBER> identified known cd<NUMBER> tcell epitopes <NUMBER> mhci n<NUMBER> known cd<NUMBER> tcell epitopes mhcii <NUMBER> n<NUMBER> also obtained known nonepitopes n<NUMBER> <NUMBER> <NUMBER> cd<NUMBER> cd<NUMBER> include <NUMBER>mer sliding win<NUMBER> dows protein without known epitope nonepitopes <NUMBER> mhci presentation recommended cutoff <NUMBER> <NUMBER> <NUMBER> sensitivity <NUMBER> specificity <NUMBER> auc <NUMBER> <NUMBER> fig <NUMBER>a mhcii presentation recommended cutoff <NUMBER> <NUMBER> <NUMBER> sensitivity <NUMBER> specificity <NUMBER> <NUMBER> auc <NUMBER> fig <NUMBER>b given high similarity sarscov <NUMBER> ncov proteins expect analysis <NUMBER>ncov per<NUMBER> form similarly future experimentally validated tcell <NUMBER> epitopes detailed scores sequences analysis <NUMBER> found si appendix supplementary tables <NUMBER> <NUMBER> <NUMBER> viral mutation antigen presentation human immune se<NUMBER> lection pressure shown drive viral mutations <NUMBER> evade immune surveillance eg low mhc presentation <NUMBER> hypothesize similar phenomenon occur <NUMBER> ncov curated cohort <NUMBER> viral genomes across four <NUMBER> continents identified <NUMBER> point mutations <NUMBER> nonsense mu<NUMBER> tation <NUMBER> deletion mutation compared published <NUMBER> reference genome <NUMBER> plot point mutations regions <NUMBER> mhci mhcii presentation fig <NUMBER> full pro<NUMBER> tein sequence mutation information found si <NUMBER> appendix dataset s<NUMBER> s<NUMBER> plot results medium high b cutoffs presentation xaxis indicates position viral protein yaxis indicates human hla gene family blue stripe indicates fraction hla alleles present <NUMBER>mer <NUMBER>mer viral peptide starting given position peptide presented one third common alleles red considered high coverage fig s<NUMBER> notably cryoem solved structure missing residues <NUMBER> rbd due limited electron density using modeled <NUMBER> structures overcomes issue fig <NUMBER> wanted <NUMBER> explore whether two linear epitopes critical viral <NUMBER> interaction human entry protein ace<NUMBER> <NUMBER> original analysis two solved cocrystal structures <NUMBER>ncov <NUMBER> protein rbd human ace<NUMBER> become available <NUMBER> <NUMBER> <NUMBER> ran discotope<NUMBER> obtained strikingly similar results <NUMBER> fig <NUMBER>c main antibody binding site substantially <NUMBER> overlaps interacting surface ace<NUMBER> yellow <NUMBER> binds protein antibody binding surface <NUMBER> likely block viral entry cells table <NUMBER> top potential epitopes key <NUMBER>ncov proteins ranked epitopes based likely coverage presentation mhci mhcii alleles protein <NUMBER> highly ranked based mhc presentation also one predicted top bcell epitopes localized near protein receptor binding domain fig <NUMBER> mhci coverage calculated <NUMBER>mer highest mhci coverage epitope highlighted orange candidates likely presented mhci mhcii sars antibody column indicates one sars homolog peptide known bcell epitope economic perspective development coro<NUMBER> navirus vaccines faces significant financial hurdles <NUMBER> viruses cause endemic infections epi<NUMBER> demic episode eg sars little financial incentive <NUMBER> private companies develop vaccines specific <NUMBER> strain virus <NUMBER> <NUMBER> <NUMBER> address incentive issues <NUMBER> governments might provide greater funding support create <NUMBER> vaccines past future outbreaks pipeline provides framework identify strong <NUMBER> epitopebased vaccine candidates might applied <NUMBER> unknown pathogens able model structures <NUMBER> <NUMBER>ncov spike protein soon dna sequence be<NUMBER> came available modeled structure high similarity <NUMBER> later solved crystal structures si appendix fig s<NUMBER> <NUMBER> suggests researchers rely homology remodeling <NUMBER> emerging pathogens first appear new pathogen <NUMBER> shares high sequence similarity existing pathogen previous animal studies show antigens high mhc pre<NUMBER> sentation scores likely elicit strong tcell responses <NUMBER> correlation responses vaccine ef<NUMBER> ficacy relatively weak <NUMBER> <NUMBER> <NUMBER> combined <NUMBER> future clinical data work help field untangle <NUMBER> relationship antigen presentation vaccine efficacy <NUMBER> obtained <NUMBER>ncov sarscov<NUMBER> sarscov ref<NUMBER> erence sequence data ncbi genebank nc<NUMBER> <NUMBER> nc<NUMBER> <NUMBER> <NUMBER> obtained viral sequences associated <NUMBER> <NUMBER> patients gisaid feb <NUMBER>st <NUMBER> <NUMBER> broke gene sequence <NUMBER>ncov sliding windows <NUMBER> used netmhcpan<NUMBER> <NUMBER> maria <NUMBER> predict mhci <NUMBER> mhcii presentation scores across <NUMBER> mhc alleles common <NUMBER> chinese population <NUMBER> marked peptide sequence <NUMBER> covered mhci mhcii presented <NUMBER> <NUMBER> constituent alleles validation applied methodology <NUMBER> known sars tcell epitopes nonepitopes <NUMBER> predicted likely human antibody binding sites bcell epi<NUMBER> topes sars <NUMBER>ncov protein disctope<NUMBER> <NUMBER> <NUMBER> first obtaining approximate <NUMBER>d structure <NUMBER>ncov <NUMBER> protein homology modeling sars protein pdb <NUMBER>acc <NUMBER> swissmodel <NUMBER> <NUMBER> validate bcell epitope predictions <NUMBER> compared top <NUMBER> bcell epitopes sars protein <NUMBER> previously experimentally identified epitopes <NUMBER> mutation identification translated viral genome sequences <NUMBER> patients protein sequences compared <NUMBER> reference sequence identify mutations edit distance analysis compared positions point mutations mhci mhcii <NUMBER> presentable regions protein fishers exact test lin discussion coronaviruses thank labs <NUMBER> contributing global efforts sequencing <NUMBER>ncov sam<NUMBER> ples attached full acknowledgment list si appendix outbreak novel coronavirus disease covid<NUMBER> caused new coronavirus <NUMBER>ncov officially designated severe acute respiratory syndromerelated coronavirus sarscov<NUMBER> represents pandemic threat global public health <NUMBER> <NUMBER> although epicenter covid<NUMBER> outbreak december <NUMBER> located wuhan china disease spread <NUMBER> countries figure <NUMBER> <NUMBER> <NUMBER> confirmed cases <NUMBER> confirmed deaths worldwide figure <NUMBER> march <NUMBER> <NUMBER> <NUMBER> addition millions peoples lives affected result mandatory isolations quarantines ripple effect covid<NUMBER> outbreak could potentially bring major challenges worldwide health systems farreaching consequences global economy spread virus effectively controlled <NUMBER> <NUMBER> <NUMBER> coronaviruses covs relatively large viruses containing singlestranded positivesense rna genome encapsulated within membrane envelope viral membrane studded glycoprotein spikes give coronaviruses crownlike appearance figure <NUMBER> coronaviruses infect humans animals certain types animals bats host largest variety coronaviruses appear immune coronavirusinduced illness <NUMBER> four classes coronaviruses designated alpha beta gamma delta betacoronavirus class includes severe acute respiratory syndrome sars virus sarscov middle east respiratory syndrome mers virus merscov covid<NUMBER> causative agent sarscov<NUMBER> similar sarscov merscov sarscov<NUMBER> attacks lower respiratory system cause viral pneumonia may also affect gastrointestinal system heart kidney liver central nervous system leading multiple organ failure <NUMBER> <NUMBER> current information indicates sarscov<NUMBER> transmissiblecontagious sarscov <NUMBER> since outbreak novel coronavirus disease covid<NUMBER> caused sarscov<NUMBER> virus disease spread rapidly around globe considering potential threat pandemic scientists physicians racing understand new virus pathophysiology disease uncover possible treatment regimens discover effective therapeutic agents vaccines support current research development cas produced special report provide overview published scientific information emphasis patents cas content collection highlights antiviral strategies involving small molecules biologics targeting complex molecular interactions involved coronavirus infection replication drugrepurposing effort documented herein focuses primarily agents known effective rna viruses including sarscov merscov patent analysis coronavirusrelated biologics includes therapeutic antibodies cytokines nucleic acidbased therapies targeting virus gene expression well various types vaccines <NUMBER> patents disclose methodologies four biologics potential treating preventing coronavirus infections may applicable covid<NUMBER> information included report provides strong intellectual groundwork ongoing development therapeutic agents vaccines betacoronavirus genome encodes several structural proteins including glycosylated spike protein functions major inducer host immune responses protein mediates host cell invasion sarscov sarscov<NUMBER> via binding receptor protein called angiotensinconverting enzyme <NUMBER> ace<NUMBER> located surface membrane host cells <NUMBER>−<NUMBER> recent study also revealed invasion process requires protein priming facilitated host cellproduced serine protease tmprss<NUMBER> addition viral genome also encodes several nonstructural proteins including rnadependent rna polymerase rdrp coronavirus main protease <NUMBER>clpro papainlike protease plpro <NUMBER> <NUMBER> upon entrance host cells viral genome released singlestranded positive rna subsequently translated viral polyproteins using host cell protein translation machinery cleaved effector proteins viral proteinases <NUMBER>clpro plpro <NUMBER> <NUMBER> plpro also behaves deubiquitinase may deubiquinate certain host cell proteins including interferon factor <NUMBER> nfκb resulting immune suppression <NUMBER> <NUMBER> rdrp synthesizes fulllength negativestrand rna template used rdrp make viral genomic rna interaction viral protein ace<NUMBER> host cell surface significant interest since initiates infection process cryoem structure analysis revealed binding affinity sarscov<NUMBER> protein ace<NUMBER> <NUMBER>−<NUMBER> times higher sarscov protein <NUMBER> <NUMBER> speculated may contribute reported higher transmissibility contagiousness sarscov<NUMBER> compared sarscov <NUMBER> prospect also exists discovery therapeutic agents targeting highly conserved proteins associated sarscov sarscov<NUMBER> <NUMBER>−<NUMBER> rdrp <NUMBER>clpro protease sarscov<NUMBER> share <NUMBER> sequence similarity sarscov despite fact two viruses demonstrate <NUMBER> sequence similarity genome level <NUMBER>−<NUMBER> basis sequence alignment homology modeling sarscov sarscov<NUMBER> share highly conserved receptorbinding domain rbd domain protein <NUMBER> sequence similarity proteins <NUMBER>−<NUMBER> addition although plpro sequences sarscov<NUMBER> sarscov <NUMBER> similar share similar active sites <NUMBER> date sarscov<NUMBER>specific antiviral agents researchers racing find possible treatments save lives produce vaccines future prevention support research development efforts discover effective therapeutic preventive agents covid<NUMBER> cas division american chemical society specializing scientific information solutions analyzed scientific data related development therapeutic agents vaccines human coronaviruses since <NUMBER> analyses presented report based cas content collection scientistcurated data collection covering published scientific literature patents <NUMBER> patent authorities worldwide subset analyses cas medline data collectively analyzed covid<NUMBER> sars mers trend scientific publications related covid<NUMBER> since outbreak covid<NUMBER> new disease causative virus drawn major global attention scientists physicians worldwide conducting major campaign understand new emergent disease epidemiology effort uncover possible treatment regimens discover effective therapeutic agents develop vaccines figure <NUMBER> shows total number journal articles related covid<NUMBER> sarscov<NUMBER> published week last week <NUMBER> week february <NUMBER> <NUMBER> <NUMBER> journal articles published electronically print period number published articles increased week since week january <NUMBER> <NUMBER> although large portion articles clinical manifestations treatment options increasing number studies focused elucidation virus structure virus transmission mechanismsdynamics well identification antiviral agents accurate diagnostics virus detection trends reflect immense interest desire scientific community including academic industrial organizations well clinicians identify new methods halt progression epidemic disease prevent infection transmission future notable journal articles related covid<NUMBER> sarscov<NUMBER> table <NUMBER> lists journal articles published december <NUMBER> <NUMBER> february <NUMBER> <NUMBER> articles selected based collective use factors journal impact factor citation type study example <NUMBER> article listed characterization sarscov<NUMBER> genome greatly facilitated global effort develop vaccine prevention covid<NUMBER> also shown table journal articles pertaining potential antiviral drug candidates remdesivir baricitinib chloroquine treatment disease mentioned earlier covid<NUMBER> caused sarscov<NUMBER> new type coronavirus genus sarscov merscov viral proteins responsible sarscov<NUMBER> entry host cells replication structurally similar associated sarscov thus research development sars mers may offer insights would beneficial development therapeutic preventive agents covid<NUMBER> report identified pertinent data patents related two coronaviruses figure <NUMBER> shows distribution patents cas content collection related sars mers b number patents related sars almost <NUMBER> times number related mers probably sars outbreak occurred <NUMBER> years mers outbreak among sars patents <NUMBER> related development therapeutics <NUMBER> related vaccines <NUMBER> related diagnostic agents methods individual patent may cover two areas sum percentage values greater <NUMBER> similar distribution pattern also observed patents related mers thus diseases patents devoted development therapeutic agents opposed diagnostic methods vaccines identification targets important identifying drugs high target specificity andor uncovering existing drugs could repurposed treat sarscov<NUMBER> infection table <NUMBER> lists potential targets roles viral infection representative existing drugs drug candidates reportedly act corresponding targets similar viruses thus assessed effects sarscov<NUMBER> infection <NUMBER>clpro plpro two viral proteases responsible cleavage viral peptides functional units virus replication packaging within host cells thus drugs target proteases viruses hiv drugs lopinavir ritonavir explored <NUMBER> rdrp rna polymerase responsible viral rna synthesis may blocked existing antiviral drugs drug candidates remdesivir <NUMBER> conceivably interaction viral protein receptor ace<NUMBER> host cells subsequent viral endocytosis cells may also viable drug target example broadspectrum antiviral drug arbidol functions virushost cell fusion inhibitor prevent viral entry host cells influenza virus <NUMBER> entered clinical trial treatment sarscov<NUMBER> <NUMBER> <NUMBER> protease tmprss<NUMBER> produced host cells plays important role proteolytic processing protein priming receptor ace<NUMBER> binding human cells <NUMBER> shown camostat mesylate clinically approved tmprss<NUMBER> inhibitor able block sarscov<NUMBER> entry human cells indicating potential drug covid<NUMBER> <NUMBER> ace<NUMBER> involvement coronavirus infection interest since ace<NUMBER> potent negative regulator restraining overactivation reninangiotensin system ras may involved elicitation inflammatory lung disease addition wellknown role regulation blood pressure balance body fluid electrolytes <NUMBER> <NUMBER> catalyzes degradation angiotensin ii angiotensin <NUMBER>−<NUMBER> balance angiotensin ii angiotensin <NUMBER>−<NUMBER> critical since angiotensin ii binds angiotensin at<NUMBER> receptor cause vasoconstriction whereas angiotensin <NUMBER>−<NUMBER> elicits vasodilation mediated at<NUMBER> <NUMBER>−<NUMBER> although notion ace<NUMBER> mediates coronavirus invasion largely accepted remains unclear levels activities ace<NUMBER> at<NUMBER> receptors at<NUMBER> receptors altered coronavirusinduced diseases due limited number studies <NUMBER> <NUMBER> therefore yet determined whether drugs compounds target proteins eg l<NUMBER> partial antagonist at<NUMBER> receptor partial agonist at<NUMBER> receptor may alleviate coronavirusinduced lung injury <NUMBER> patents potential drug candidates related key protein targets cas content collection contains patents related coronavirus key proteins listed table <NUMBER> lists number patents related protein target associated therapeutic compounds cas registry number cas rn reported patents cas data show targets <NUMBER>clpro rdrp attracted attention targets compounds therapeutic potential identified targets probably due work done sarscov also contains <NUMBER>clpro rdrp existing drugs potential therapeutic applications covid<NUMBER> since sarscov<NUMBER> newly discovered pathogen specific drugs identified currently available economic efficient therapeutic strategy repurpose existing drugs basis genomic sequence information coupled protein structure modeling scientific community able rapidly respond suggested list existing drugs therapeutic potential covid<NUMBER> table <NUMBER> provides summary drugs together potential mechanisms actions activities barcitinib proposed antiinflammatory effect possible ability reduce viral entry <NUMBER> fixed dose antihiv combination lopinavir−ritonavir currently clinical trials arbidol ribavirin <NUMBER> remdesivir developed gilead sciences inc previously tested humans ebola virus disease shown promise animal models mers sars drug currently studied phase iii clinical trials china usa favipiravir <NUMBER> journal articles published first two months <NUMBER> number published articles increased week since week january <NUMBER> <NUMBER> purine nucleoside leading inaccurate viral rna synthesis <NUMBER> originally developed toyama chemical japan recently approved clinical trial drug treat covid<NUMBER> <NUMBER> chloroquine antimalarial drug proven effective treating coronavirus china <NUMBER> addition abovementioned many antiviral drugs also listed selected patents related promising small molecule drug candidates table <NUMBER> shows selected patents associated aforementioned potential drugs together patents disclosing small molecules treatment sars mers selection based presence important terms casindexed patents well presence synthetic preparation role assigned cas scientists document indexing patent applications wo<NUMBER> wo<NUMBER> disclose preparation compounds active jak inhibitors one later named baricitinib developed reducing inflammation rheumatoid arthritis patent application jp<NUMBER> discloses preparation polycyclic pyridone compounds use endonuclease inhibitors patent applications us<NUMBER> us<NUMBER> patent application wo<NUMBER> discloses structures syntheses compounds various structure classes peptidyl aldehydes peptidyl αketoamides peptidyl bisulfite salts peptidyl heterocycles well certain formulation compositions developed inhibit viral <NUMBER>c protease <NUMBER>clike protease ie <NUMBER>clpro patent application wo<NUMBER> presents preparation methods biological assay results compounds capable inhibiting sars virus proteases compounds appeared exhibit good enzymeinhibiting activity pic <NUMBER> ≈ <NUMBER> ritonavir pharmacokinetic profile enhancer may potentiate effects protease inhibitors due ability attenuate degradation drugs liver enzyme cyp<NUMBER>a<NUMBER> thus used combination antivirial lopinavir <NUMBER> inhibitor viral entry host cells direct action protein ace<NUMBER> yet confirmed table <NUMBER> drug candidates mostly inhibit viral enzymes including proteases components rdrp since <NUMBER>clpro protease high level sequence homology sarscov sarscov<NUMBER> inhibitors <NUMBER>clpro sarscov may also applicable sarscov<NUMBER> compounds including benzopurpurin b c<NUMBER> c<NUMBER> nsc<NUMBER> n<NUMBER> may inhibit activity viral nsp<NUMBER> polyuspecific endoribonuclease tested reduced sarscov infectivity cultured cells ic <NUMBER> <NUMBER>−<NUMBER> μm <NUMBER> compound c<NUMBER> cgp<NUMBER>a two at<NUMBER> agonists whereas l<NUMBER> dual functions partial agonist at<NUMBER> receptor partial antagonist at<NUMBER> receptor since at<NUMBER> at<NUMBER> important effectors ras system ace<NUMBER> belongs speculated compounds may used adjust balance at<NUMBER> at<NUMBER> may affected coronavirus infection alleviate viralinduced lung injury infection <NUMBER> small molecules identified structure similarity lipinskis rule <NUMBER> casindexed pharmacological activity andor therapeutic usage besides aforementioned antiviral drugs may additional small molecule compounds therapeutic pharmacological potential viruses sarscov merscov compounds listed tables <NUMBER> <NUMBER> subjected tanimoto similarity search cas registry using cas proprietary fingerprints substances least <NUMBER> structural similarity match meeting lipinskis rule <NUMBER> identified table <NUMBER> lists selected compounds also identified pharmacological activity therapeutic usage role compound name cas rn provided compound second column lists number compounds met structure similarity lipinskis rule criteria although work remains done regard methodology results mentioned point strategy may help streamline process drug discovery covid<NUMBER> ■ biologics coronavirusassociated diseases distribution biologics patents related sars mers new coronavirus sarscov<NUMBER> related sars mers viruses causing serious ongoing epidemiological problems around world since limited clinical basic research information time treatment options covid<NUMBER> currently comprise investigational drugs management symptoms biologics potential broaden spectrum treatment options coronavirusinduced diseases leveraging prior knowledge practices used address sars mers outbreaks provides practical strategy developing new targetspecific therapeutic agents sarscov<NUMBER> end analysis biologics patents contained cas content collection performed patent analysis included information related therapeutic antibodies cytokines interfering therapeutic rnas vaccines potential treatment andor prevention sarsrelated diseases patents published <NUMBER> present figure <NUMBER> shows <NUMBER> patents disclose use four biologics classes treat prevent sars mers patents vaccine development largest class <NUMBER> followed therapeutic antibodies <NUMBER> interfering rnas <NUMBER> cytokines <NUMBER> given indispensable role vaccines viral disease prevention detailed analysis vaccines presented later section antibodies ninetynine patents containing information antibodies therapeutic andor diagnostic potential sars mers identified <NUMBER> patents claimed preparation sarsspecific antibodies <NUMBER> mersspecific antibodies <NUMBER> antibodies diagnostic application <NUMBER> similar sarscov receptorbinding domain rbd protein sarscov<NUMBER> binds human ace<NUMBER> receptor order gain access host cells <NUMBER> viral infection protein structural proteins e n sarscov elicits immune response <NUMBER> table <NUMBER> shows target analysis patents related development therapeutic antibodies sars <NUMBER> antibodies directed protein including rbd data indicate protein putative target sarscov<NUMBER> antibody development additional <NUMBER> patents contained information pertaining types antiviral antibodies useful sars mers therapies included neutralizing antibodies antibodies designed target proteins il<NUMBER>il<NUMBER>r tlr<NUMBER> tolllike receptor <NUMBER> cd<NUMBER> itam immunoreceptor tyrosinebased activation motif dcsign dendritic cellspecific intercellular adhesion moleculegrabbing nonintegrin icam<NUMBER> intercellular adhesion molecule <NUMBER> ip<NUMBER> cxcl<NUMBER> interferon γinducible protein <NUMBER> cytokine storm reported correlate disease severity sarscov<NUMBER> infection patients admitted icu higher concentrations proinflammatory cytokines chemokines particularly gcsf ip<NUMBER>cxcl<NUMBER> mcp<NUMBER> monocyte chemoattractant protein <NUMBER> tnfα well elevated cytokines helper <NUMBER> cells il<NUMBER> il<NUMBER> <NUMBER> patent application besides various commercialized antiviral drugs also small molecule compounds currently rd shown significant inhibitory effects many key proteins viruses <NUMBER> patents disclose use four biologics classes therapeutic antibodies cytokines rna therapies vaccines treat prevent sars mers analyzed study wo<NUMBER> discloses human antiip<NUMBER> antibodies including bispecific molecules immunoconjugates bind ip<NUMBER> high affinity treating inflammation autoimmune disease neurodegenerative disease bacterial infection viral infection patent application wo<NUMBER> discloses preparation human antibodies immunoconjugates specifically targeting chemokine ip<NUMBER> including antiip<NUMBER> antibody shown suppress free serum ip<NUMBER> <NUMBER> days <NUMBER> mgkg approximately <NUMBER> days <NUMBER> mgkg cynomolgus macaques addition dcsigncd<NUMBER> type ii transmembrane adhesion molecule ctype lectin function mainly expressed interstitial dendritic cells lung alveolar macrophages <NUMBER> dcsign functions entry cofactor transferring sarscov susceptible cells pneumocytes <NUMBER> patent application wo<NUMBER> claims production humanized antidcsign antibody interfered interaction dcsign receptor icam<NUMBER> antibody effectively blocked viral binding infection transmission viral infectionsdiseases including sars cytokines cytokines lowmolecularweight proteins act chemical signals immune response pathogen invasion production various cytokines response invading pathogen virus contributes host organisms ability eliminate pathogen specific types cytokines including chemokines interferons ifns interleukins lymphokines reported characterized literature past <NUMBER> years early <NUMBER> cas lexicon contained <NUMBER> terms specific types cytokines associated <NUMBER> <NUMBER> documents including <NUMBER> <NUMBER> patents viral infection prominent cytokines produced ifns interfere viral replication ifns classified type ifnα ifnβ ifnδ ifnε ifnκ ifnν ifnτ ifnω type ii ifnγ type iii ifnλ based receptor complex used signaling well sequence homology <NUMBER> ability interfere viral replication interferons interferon fusion proteins utilized therapeutic agents treatment viral infections past <NUMBER> years patents disclosing proteins use treating sars described rsifnco patent applications wo<NUMBER> wo<NUMBER> describe cloning recombinant interferon rsifnco cas rn <NUMBER> well method determining potency effective treating various viral infectionsdiseases including sars invention relates rsifnco identical amino acid sequence infergen <NUMBER> altered spatial conformation different biological potency rsifnco antiviral activity <NUMBER> times stronger clinically available interferon also significantly stronger antitumor properties breast cancer cervical cancer recombinant human αinterferons invention relates rsifn reduced toxic side effects safely used large doses dose <NUMBER> million iu making possible successfully treat viral diseases tumors require large doses interferon ifnω patent application wo<NUMBER> discloses amino acid sequence recombinant human interferon ω rhifnω rn <NUMBER> shown antisars viral activity similar ifnβ ifnω effectively decreased disease severity inhibited proliferation coronavirus strain bj<NUMBER> monkeys il<NUMBER>a ifnλ<NUMBER> il<NUMBER>b ifnλ<NUMBER> il<NUMBER> ifnλ<NUMBER> variants patent application wo<NUMBER> claims method treating sars viral infection using il<NUMBER>a il<NUMBER>b il<NUMBER> cysteine variants conjugated polymers eg polyethylene glycol discloses amino acid nucleic acid sequences cysteine variants variants metil<NUMBER>c<NUMBER>speg rn <NUMBER> specifically shown inhibit viral replication interferonhuman serum albumin fusion protein patents applications us<NUMBER> cn<NUMBER> disclose longlasting fusion proteins hsaifn composed interferon fused human serum albuminbinding peptide treatment wide range diseases including sars specific hsaifn fusion proteins constructed using five different interferons ifnα<NUMBER>b ifnα<NUMBER>b ifnβ ifnω ifnγ corresponding cas rns <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively hsaifn fusion proteins significantly lengthened plasma halflife interferons eg <NUMBER> h <NUMBER> days hsaifnα<NUMBER>b due slower free interferon release plasma thus may prolong effects interferon injection rna therapies rna interference rnai biological process wherein small complementary rna duplexes target neutralize specific mrna molecules resulting inhibition gene expression genetic translation interfering rnas include micrornas small interfering rnas sirnas generally <NUMBER>−<NUMBER> nucleotides length short hairpin rnas shrnas artificial synthetic rna molecules designed fold tight hairpin conformation allows silence target genes serve precursors sirnas expression shrnas cells typically accomplished delivery via plasmids viral bacterial vectors <NUMBER> although micrornas noncoding naturally found plants animals viruses synthetic versions currently used silence variety genes <NUMBER> ability chemically synthesize modified analogues micrornas well sirnas capable altering diseaserelated gene expression inhibiting pathogen gene expression created host new therapeutic options <NUMBER> contrast micrornas sirnas antisense rnas singlestranded rnas naturally occurring synthetic usually around <NUMBER>−<NUMBER> nucleotides length sequence complementary protein coding mrna allowing hybridize block protein translation <NUMBER> since discovery rnai late <NUMBER>s become wellknown method silencingsuppressing target genes associated virulence pathogenesis thirtyfive patents cas content collection disclose use rnai treating sars <NUMBER> patents using sirna molecules three patents using antisense oligonucleotides two patents using rna aptamers one patent using ribozyme one patent using microrna inhibitor supporting information table s<NUMBER> provides highlevel view <NUMBER> patents including specific rnai targets patents discussed sirnas targeting coronavirus proteins n e patent application cn<NUMBER> discloses two doublestranded rnas dsrnas designed specifically target two separate regions sars protein mrna sirnam<NUMBER> sequences targeting <NUMBER>−<NUMBER> region protein mrna correspond cas rns <NUMBER> <NUMBER> sirnam<NUMBER> sequences targeting <NUMBER>−<NUMBER> region correspond cas rns <NUMBER> <NUMBER> interference efficiency two sirnas sars protein gene expression greater <NUMBER> patent application cn<NUMBER> discloses sequences associated sirnas specifically designed target n e genes sars three sirnas nos <NUMBER> <NUMBER> <NUMBER> shown inhibit expression gfpm gfpn gfpe fusion proteins respectively additional three sirnas nos <NUMBER> <NUMBER> <NUMBER> prepared contained mutation <NUMBER>′ end bold letter sense strand modified sirnas shown demonstrated increased inhibition sars virus gene expression compared original sirnas sirnas targeting replicase rna polymerase region patent application us<NUMBER> discloses six sirnas sarsi<NUMBER> sarsi<NUMBER> targeting replicase <NUMBER>a region sars shown inhibit virus infection replication sarsi<NUMBER> efficient sense strand sequences corresponding cas rns shown table invention also disclosed sarsi<NUMBER> sarsi<NUMBER> target e n genes authors demonstrated sarsi<NUMBER> sarsi<NUMBER> sarsi<NUMBER> sarsi<NUMBER> inhibited coronavirus infection replication frhk<NUMBER> cells sarsi<NUMBER> effective nearly complete inhibition followed sarsi<NUMBER> sarsi<NUMBER> patent application cn<NUMBER> discloses sirnas shown table <NUMBER> target sars genes encoding rnadependent rna polymerase helicase nucleoprotein n proteolytic enzymes sirnas able inhibit kill <NUMBER>−<NUMBER> sars virus bj<NUMBER> strain proteolytic enzymetargeting sirnas effective rna aptamers two korean patents describe use rna aptamers inhibition sars viruses patent application kr<NUMBER> identifies rna aptamers antisars agents capable binding inhibiting doublestranded dna unwinding sars virus helicase related patent application kr <NUMBER> describes rna aptamers distinct affinity nucleocapsid sarscov potential pharmaceutical use ribozymes patent application jp<NUMBER> describes therapeutic rnadna chimeric ribozyme designed recognize cleave conserved common regions regions loop structures genes coronaviruses including sars ribozyme specifically recognizes guc viral genes loop conformations antisense oligonucleotides antisense oligonucleotides also developed reduce severity sars virus infections prevent treat sars virusassociated disease detect virus human samples diagnose sars virusassociated diseases patent application wo<NUMBER> published ionis pharmaceuticals describes hybrid dna rna antisense oligonucleotides designed disrupt pseudoknot frameshift site sars coronavirus rna addition directly targeting virus antisense oligonucleotides may used target diseaserelated proteins involved inflammatory process crucial develop safe effective vaccines control covid<NUMBER> pandemic eliminate spread ultimately prevent future recurrence since sarscov<NUMBER> virus shares significant sequence homology two lethal coronaviruses sars mers vaccines identified patents related sars mers viruses could potentially facilitate design antisarscov<NUMBER> vaccines distribution patents related sars mers among vaccine types antiviral vaccines generally fall one following types inactive liveattenuated viruses viruslike particle vlp viral vectors proteinbased dnabased mrnabased vaccines <NUMBER> patents cas content collection related vaccine development prevent viral disordersdiseases including sars mers <NUMBER> patents disclose vaccines noncoronaviruses may relevance sars mers <NUMBER> patents directly associated antisars antimers vaccines demonstrated immune response supporting information table s<NUMBER> contains additional information sars mers vaccinerelated patents figure <NUMBER> reveals distribution patents among vaccine types related sars mers seen <NUMBER> patents disclose information inactive liveattenuated virus vaccines <NUMBER> patents describe dna vaccines <NUMBER> patents disclose information viral vector vaccines <NUMBER> patents disclose information vlp vaccines three patents focused mrna vaccines reported viral protein subunit vaccines produced higher neutralizing antibody titers complete protection liveattenuated sarscov fulllength protein dnabased protein vaccines <NUMBER> unsurprisingly half patents focused protein vaccines comprising protein subunit vaccine vaccines specifically targeting receptor binding domain rbd s<NUMBER> subunit viral protein collectively proteingene preferred target total <NUMBER> patents directly associated antisars antimers vaccines demonstrated immune response supporting information table s<NUMBER> contains additional information sarsmers vaccinerelated patents dnabased vaccines patent application wo<NUMBER> discloses compositions methods inducingenhancing immune responses particularly antigenspecific cd<NUMBER> cellmediated responses antigens sars coronavirus enhancement immune response involving particularly cytotoxic cell immune responses induced vivo chimeric nucleic acids encode endoplasmic reticulum chaperone polypeptide eg calreticulin linked least one antigenic polypeptide peptide sarscov using gene gun delivery dnacoated gold particles vaccination mice calreticulin−nucleocapsid fusion protein resulted potent nucleocapsidspecific humoral cellmediated immune responses vaccinated animals capable significantly reducing titer challenging vaccinia vector expressing n protein sars virus patent application wo<NUMBER> discloses immunogens comprise consensus proteins derived merscov spike protein use dnabased vaccines targeting merscov consensus spike protein significantly induced humoral cellular immune responses including increased titers igg neutralizing antibodies induced cellular immune response involved increased cd<NUMBER>cd<NUMBER> cd<NUMBER>cd<NUMBER> cell responses produced ifnγ tnfα il<NUMBER> ifnγ tnfα march <NUMBER> <NUMBER> inovio pharmaceutical inc announced designed dna vaccine called ino<NUMBER> planned human trials united states april <NUMBER> proteinbased vaccines patent application wo<NUMBER> glaxosmithkline gsk discloses vaccine capable provoking protective immune response sars vaccine comprises protein immunogen oilinwater emulsion adjuvant engineered ectodomain immunogen soluble protein combination emulsion adjuvant gsk<NUMBER> induced high levels antisarscov igg<NUMBER>a igg<NUMBER>b antibody responses neutralizing antibody responses animal models late february <NUMBER> gsk announced collaboration chinese firm clover biopharmaceuticals assess coronavirus covid<NUMBER> vaccine candidate <NUMBER> collaboration involve use clovers proteinbased coronavirus vaccine candidate covid<NUMBER> strimer gsks adjuvant system applying trimertag technology clover manufactured strimer subunit vaccine using rapid mammalian cell culturebased expression system trimertag advanced drug development platform enables production novel covalently trimerized fusion proteins better target previous undruggable pathways patent application us<NUMBER> discloses immunogenic compositions vaccines associated protein sars coronavirus trispike sars coronavirus vaccine prepared recombinant fulllength trimeric protein recombinant protein shown <NUMBER> exhibit native antigenicity shown reactivity convalescent sars patient sera <NUMBER> exhibit specific binding soluble ace<NUMBER> receptor <NUMBER> promote antibodydependent viral entry otherwise refractory human raji b cells <NUMBER> elicit protection challenge infection animal model patent application us<NUMBER> antigen express inc subsidiary generex discloses preparation hybrid peptides composed three elements including invariant chain ii key peptide antigen presentation enhancing activity b chemical structure linking ii antigenic epitope c antigenic epitope binds mhc class ii molecule methodology used create iikey mhc ii sars hybrids recently generex announced developing covid<NUMBER> vaccine following contractual agreement chinese consortium comprised china technology exchange beijing zhonghua investment fund management biology institute shandong academy sciences sinotekadvocates international industry development company utilize iikey immune system activation technology produce covid<NUMBER> viral peptide human clinical trials <NUMBER> viruslike particle vaccines <NUMBER> patent application wo<NUMBER> novavax disclosed immunogenic composition composed merscov nanoparticle vlps containing least one trimer protein produced baculovirus overexpression sf<NUMBER> cells vlp preparation induced neutralizing antibody response mice transgenic cattle administered along proprietary adjuvant matrix rn <NUMBER> addition preparations sera vaccinated cattle sab<NUMBER> sab<NUMBER> injected ad<NUMBER>hdpp<NUMBER> transduced balbc mice prior challenge merscov sab<NUMBER> sab<NUMBER> able protect mice merscov infection single prophylactic injection novavax announced february <NUMBER> <NUMBER> <NUMBER> beginning animal testing potential covid<NUMBER> vaccine candidates due previous experiences working coronaviruses including mers sars covid<NUMBER> candidate vaccines targeting protein sarscov<NUMBER> developed using recombinant nanoparticle vaccine technology along proprietary adjuvant matrixm mrnabased vaccines potential advantages mrna approach prophylactic vaccines include ability mimic natural infection stimulate potent immune response well ability combine multiple mrnas single vaccine patent application wo<NUMBER> moderna discloses mrna vaccines composed mrnas encoding antigenic viral fulllength s<NUMBER> s<NUMBER> proteins sarscov merscov virus formulated cationic lipid nanoparticles show mice vaccinated mrna encoding coronavirus fulllength protein generated much higher neutralizing antibody titers compared mrna encoding protein s<NUMBER> subunit new zealand white rabbits immunized merscov mrna vaccine encoding fulllength protein reduced <NUMBER> viral load lungs rabbits induced significant amount neutralizing antibody merscov moderna announced february <NUMBER> <NUMBER> <NUMBER> released first batch mrna<NUMBER> sarscov<NUMBER> use humans prepared using methods strategies outlined previous patents vials mrna<NUMBER> shipped national institute allergy infectious diseases niaid division national institutes health nih used planned phase <NUMBER> study united states moderna reports mrna<NUMBER> mrna vaccine targeting prefusionstabilized form protein associated sarscov<NUMBER> selected moderna collaboration investigators niaid vaccine research center manufacture batch funded coalition epidemic preparedness innovations patent application wo<NUMBER> describes vaccines comprising mrna encoding least one antigen mers coronavirus preferably protein protein fragment s<NUMBER> envelope protein e membrane protein nucleocapsid protein n effective inducing antigenspecific immune response intradermal administration mice lipid nanoparticle lnpencapsulated mrna mixture encoding merscov proteins shown result translation vivo induction humoral immune responses report provides overview published information global research development coronavirusrelated therapeutic agents preventive vaccines based extensive cas content collection focus patents includes overview coronavirus morphology biology pathogenesis particular focus antiviral strategies involving small molecule drugs well biologics targeting complex molecular interactions involved coronavirus infection replication drugrepurposing effort summarized report focused primarily agents currently known effective rna viruses including sarscov merscov influenza hcv ebola well antiinflammatory drugs potential impact biologics treatment coronavirus infections promising includes wide variety options including bioengineered vectored antibodies cytokines nucleic acidbased therapies targeting virus gene expression well various types vaccines information provided report provides strong intellectual groundwork support ongoing research development discovery development therapeutic agents vaccines treatment covid<NUMBER> coronavirusrelated diseases limited space report devotes minimal attention current efforts involved advancing efficient accurate covid<NUMBER> diagnosis methods products novel infectious diseases resulting rna viruses subject mutation genetic recombination well crossspecies transmission continue present serious global health threat exemplified covid<NUMBER> despite two former major outbreaks coronavirus infections causing sars mers respiratory illnesses world remains underprepared effectively manage current covid<NUMBER> outbreak evidenced fact covid<NUMBER> resulted thousands deaths worldwide concerted effort develop effective drugs vaccines existing potential future coronavirus infections highly pathogenic virus outbreaks necessary reduce overwhelming impacts human life worldwide healthcare systems given costly arduous process involved clinical drug development outbreak covid<NUMBER> highlights value developing relatively broadspectrum antiviral drugs importance applying innovative approaches artificial intelligence facilitate drug discovery given lengthy process new drug development current strategy drug repurposing become one chosen solutions immediate treatment sarscov<NUMBER> infected individuals longterm drug development goals pharmaceutical industry include identification inhibitors aimed replication infection processes associated sarscov<NUMBER> related coronaviruses well symptomatic results infections leading severe disease andor death summarized lists contained report small molecule compounds additional descriptions biologics properties suitable inhibiting several key coronavirus proteins could serve information starting points drug development since vaccines crucial prevention coronavirusrelated epidemic diseases future reassuring number innovative strategies already deployed four mers coronavirus dna vaccine candidates began phase <NUMBER> clinical trials september <NUMBER> <NUMBER> moderna inc released first batch mrna<NUMBER> february <NUMBER> mrna vaccine sarscov<NUMBER> ready phase <NUMBER> study united states <NUMBER> additional collaboration areas antiviral discovery processes clinical trial performance enhance patients access drug candidates improved therapeutic potential ideally reduce amount time required bring drugs market abundance publications rapid publication rate associated sarscov<NUMBER> virusrelated disease outbreak illustrated report indicative intense effort research institutes pharmaceutical industries address molecular mechanisms therapeutic routes useful treating current future coronavirus outbreaks supporting information available free charge httpspubsacsorgdoi<NUMBER>acscentsci<NUMBER>c<NUMBER> tables distribution rnai patents related sars mers cas content collection distribution vaccine patents related sars mers cas content collection pdf december <NUMBER> public health officials wuhan china reported first case severe <NUMBER> respiratory disease attributed infection novel coronavirus sarscov<NUMBER> <NUMBER> since <NUMBER> emergence sarscov<NUMBER> spread rapidly via humantohuman transmission <NUMBER> threatening <NUMBER> overwhelm healthcare systems around world resulting declaration pandemic <NUMBER> world health organization <NUMBER> disease caused virus characterized fever <NUMBER> pneumonia respiratory inflammatory symptoms result severe inflammation <NUMBER> lung tissue ultimately deathparticularly among older adults individuals underlying <NUMBER> comorbidities <NUMBER> writing sarscov<NUMBER> pandemic resulted <NUMBER> million confirmed <NUMBER> cases covid<NUMBER> <NUMBER> deaths worldwide <NUMBER> <NUMBER> sarscov<NUMBER> third pathogenic coronavirus cross species barrier humans <NUMBER> past two decades preceded severe acute respiratory syndrome coronavirus sarscov <NUMBER> <NUMBER> <NUMBER> middleeast respiratory syndrome coronavirus merscov <NUMBER> three viruses belong <NUMBER> β coronavirus genus either confirmed sarscov suggested merscov sars<NUMBER> cov<NUMBER> originate bats transmission humans occurring intermediary animal hosts <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previous zoonotic spillovers coronaviruses marked high case fatality rates <NUMBER> <NUMBER> sarscov <NUMBER> merscov widespread transmission disease relatively <NUMBER> limited <NUMBER> cases sars <NUMBER> cases mers <NUMBER> contrast sarscov<NUMBER> estimated <NUMBER> lower case fatality rate <NUMBER> far infectious achieved worldwide spread <NUMBER> matter months <NUMBER> <NUMBER> number covid<NUMBER> cases continues grow urgent need safe <NUMBER> effective vaccine combat spread sarscov<NUMBER> reduce burden hospitals healthcare <NUMBER> systems licensed vaccine therapeutic currently available sarscov<NUMBER> although <NUMBER> <NUMBER> vaccine candidates reportedly development worldwide seven vaccine candidates <NUMBER> peptide removed structure using chimera <NUMBER> university californiasan francisco <NUMBER> <NUMBER> prior running simulations ten models peptidehla complex generated basis <NUMBER> minimized energy scores top model complex selected comparative analysis <NUMBER> prediction structural modeling sarscov<NUMBER> b cell epitopes <NUMBER> linear b cell epitope predictions performed three exposed sarscov<NUMBER> structural <NUMBER> proteins genbank accession qhd<NUMBER> qhd<NUMBER> e qhd<NUMBER> using bepipred <NUMBER> <NUMBER> algorithm <NUMBER> epitope probability scores calculated amino acid residue using <NUMBER> threshold <NUMBER> corresponding <NUMBER> specificity sensitivity <NUMBER> epitopes <NUMBER> <NUMBER> amino acid residues length analyzed structure sarscov<NUMBER> protein <NUMBER> accessed protein data bank pdb id <NUMBER>vsb <NUMBER> discontinuous ie structural b cell epitope <NUMBER> predictions protein structure carried using discotope <NUMBER> <NUMBER> score threshold <NUMBER> greater <NUMBER> corresponding <NUMBER> specificity sensitivity <NUMBER> main protein <NUMBER> structure modeled pymol schrödinger llc predicted b cell epitopes identified <NUMBER> bepipred <NUMBER> discotope <NUMBER> highlighted spheres <NUMBER> genetic similarity sarscov<NUMBER> isolates <NUMBER> primary goal study identify peptide epitopes would broadly applicable <NUMBER> vaccine development efforts sarscov<NUMBER> identified <NUMBER> point mutations <NUMBER> deletions <NUMBER> across genomes <NUMBER> clinical isolates deletions majority mutations n<NUMBER> <NUMBER> occurring orf<NUMBER>ab polyprotein supp figure s<NUMBER> singlepoint mutations also found <NUMBER> protein n<NUMBER> n protein n<NUMBER> orf<NUMBER> protein n<NUMBER> orf<NUMBER>a protein n<NUMBER> orf<NUMBER> protein n<NUMBER> e <NUMBER> protein n<NUMBER> protein n<NUMBER> despite genetic diversity introduced events figure <NUMBER>d <NUMBER> matrix analysis determined <NUMBER> sequence identity maintained across viral genomes based <NUMBER> findings study feasibility genome original virus isolate <NUMBER> genbank mn<NUMBER> selected consensus sequence analyses <NUMBER> next identified potential cd<NUMBER> cell epitopes proteins sarscov<NUMBER> <NUMBER> proteome using netctl <NUMBER> predictive algorithm analyzed complete amino acid sequence <NUMBER> viral protein generate sets <NUMBER>mer peptides predicted recognized across least one <NUMBER> major hla class supertypes figure <NUMBER>a supp figure s<NUMBER> approach yielded significant number <NUMBER> potential epitopes viral protein orf<NUMBER> <NUMBER> orf<NUMBER> <NUMBER> orf<NUMBER> <NUMBER> e <NUMBER> orf<NUMBER> <NUMBER> n <NUMBER> <NUMBER> <NUMBER> orf<NUMBER>a <NUMBER> <NUMBER> orf<NUMBER>ab <NUMBER> number directly related size parent protein used netmhcpan <NUMBER> server refine list potential cd<NUMBER> cell epitopes <NUMBER> predicting binding affinity across representative hla class alleles see methods assigning <NUMBER> percentile scores quantify binding propensity peptides percentile rank scores <NUMBER> ie strong <NUMBER> binders filtered using <NUMBER> nm threshold binding affinity delineate <NUMBER> candidate <NUMBER> hla class epitopes viral proteome <NUMBER> feasibility reasons refined selection <NUMBER> <NUMBER> candidate epitopes excluding peptides predicted bind one hla molecule supp table s<NUMBER> <NUMBER> resultant peptides enriched predicted binders hlab molecules <NUMBER> hlab<NUMBER> hlab<NUMBER> figure <NUMBER>b final round selection basis hla <NUMBER> promiscuity ie predicted binding <NUMBER> hla molecules predicted antigenicity scoring using <NUMBER> vaxijen <NUMBER> server produced subset five candidate peptides four orf<NUMBER>ab one protein potential <NUMBER> targets vaccine development table <NUMBER> hypothesis increased hla binding promiscuity <NUMBER> meant broader population base coverage peptides peptides predicted provide <NUMBER> <NUMBER> global population coverage higher predicted binding affinities hlab molecules <NUMBER> b<NUMBER> nm b<NUMBER> nm b<NUMBER> nm compared hlaa molecules <NUMBER> a<NUMBER> nm a<NUMBER> nm exception one orf<NUMBER>abderived peptide <NUMBER> mmisagfsl predicted bind hlaa<NUMBER> high affinity ic <NUMBER> <NUMBER> nm figure <NUMBER>c <NUMBER> also sought identify potential hla class ii peptides sarscov<NUMBER> stimulation <NUMBER> cd<NUMBER> thelper cells critical robust vaccineinduced adaptive immune responses using <NUMBER> netmhciipan <NUMBER> server identified <NUMBER> candidate hla class ii peptides viral proteome <NUMBER> predicted high binding affinity <NUMBER> nm percentile rank scores <NUMBER> across reference <NUMBER> panel hla molecules covering <NUMBER> population <NUMBER> <NUMBER> similar hla class epitope <NUMBER> predictions number class ii epitopes identified viral protein orf<NUMBER> <NUMBER> e protein <NUMBER> <NUMBER> orf<NUMBER> <NUMBER> orf<NUMBER> <NUMBER> orf<NUMBER> <NUMBER> n <NUMBER> <NUMBER> orf<NUMBER>a <NUMBER> <NUMBER> orf<NUMBER>ab <NUMBER> largely proportional <NUMBER> protein size excluding peptides predicted bind single hla molecule panel <NUMBER> refined selection <NUMBER> peptides supp table s<NUMBER> enriched binding hladrb<NUMBER> <NUMBER> molecules n<NUMBER> figure <NUMBER>d filtering hla promiscuity predicted antigenicity scores yielded <NUMBER> subset <NUMBER> peptides <NUMBER> orf<NUMBER>ab <NUMBER> protein <NUMBER> protein <NUMBER> orf<NUMBER> <NUMBER> orf<NUMBER>a <NUMBER> orf<NUMBER> <NUMBER> orf<NUMBER> <NUMBER> cd<NUMBER> cell epitopes study table <NUMBER> peptides predicted collectively provide <NUMBER> <NUMBER> population coverage significantly higher average binding affinities hladr alleles <NUMBER> drb<NUMBER> nm drb<NUMBER> nm drb<NUMBER> nm drb<NUMBER> nm compared hladp <NUMBER> nm <NUMBER> hladq <NUMBER> nm molecules figure <NUMBER>e <NUMBER> characterization hla class peptide docking hlab<NUMBER> five candidate hla class peptides identified computational approach predicted <NUMBER> provide coverage across six hla alleles a<NUMBER> a<NUMBER> a<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> <NUMBER> peptide famqmayrf candidate predicted bind a<NUMBER> molecules whereas <NUMBER> mmisagfsl predicted uniquely bind a<NUMBER> b<NUMBER> molecules four five peptides <NUMBER> predicted bind a<NUMBER> b<NUMBER> molecules predicted bind relatively <NUMBER> high affinity average ic <NUMBER> <NUMBER> nm hlab<NUMBER> therefore performed molecular docking <NUMBER> studies peptide molecular structure hlab<NUMBER> pdb <NUMBER>c<NUMBER>n <NUMBER> peptides predicted bind within peptide binding groove forming hydrogen bond <NUMBER> contacts numerous amino acid side chains figure <NUMBER>a binding motif hlab<NUMBER> <NUMBER> highly selective residues p<NUMBER> p<NUMBER> anchor positions preference bulky hydrophobic <NUMBER> amino acids cterminus figure <NUMBER>b <NUMBER> candidate peptides possessed terminal residues phe <NUMBER> tyr leu fit hydrophobic binding pocket hla groove supporting <NUMBER> peptides strong binders hlab<NUMBER> promising candidates vaccine development <NUMBER> studies <NUMBER> effective vaccine stimulate cellular humoral immune responses <NUMBER> target pathogen therefore also sought identify potential b cell epitopes sarscov<NUMBER> <NUMBER> proteins limited analysis primary structural proteins exposed virus capsid n <NUMBER> e accessible antigens engaging b cell receptors using bepipred <NUMBER> <NUMBER> algorithm identified <NUMBER> potential linear b cell epitopes protein <NUMBER> potential epitopes n <NUMBER> protein <NUMBER> potential epitopes protein table <NUMBER> epitopes identified e protein <NUMBER> studies previously shown protein predominant target neutralizing antibodies <NUMBER> coronaviruses <NUMBER> <NUMBER> findings indicate likely case sarscov<NUMBER> <NUMBER> focused subsequent analyses protein n protein also major target <NUMBER> antibody response <NUMBER> unlikely antibodies neutralizing activity based viral <NUMBER> structure epitope conformation significantly influence recognition antibodies also <NUMBER> employed discotope <NUMBER> identify discontinuous b cell epitopes protein structure analysis <NUMBER> identified <NUMBER> potential structural epitopes protein <NUMBER> s<NUMBER> domain <NUMBER> s<NUMBER> domain <NUMBER> six regions significant overlap predicted linear epitopes table <NUMBER> antigenic regions <NUMBER> identified analyses modeled using recently published structure sarscov<NUMBER> <NUMBER> protein <NUMBER> examine accessibility antibody binding epitopes s<NUMBER> domain p<NUMBER>d<NUMBER> <NUMBER> y<NUMBER>d<NUMBER> clustered near base spike protein whereas regions s<NUMBER> domain <NUMBER> d<NUMBER>d<NUMBER> n<NUMBER>n<NUMBER> g<NUMBER>p<NUMBER> d<NUMBER>t<NUMBER> exposed protein surface figure <NUMBER> face covid<NUMBER> pandemic imperative safe effective vaccines rapidly <NUMBER> developed order induce widespread herd immunity population prevent continued <NUMBER> spread sarscov<NUMBER> study identified probable peptide targets cellular humoral <NUMBER> immune responses sarscov<NUMBER> using computational methodologies investigate entire viral <NUMBER> proteome priori studies paramount early stages pandemic vaccine <NUMBER> development given relative scarcity biological data available viral immune response <NUMBER> employed approach allowed us systematically refine predictions using increasingly stringent <NUMBER> criteria select subset promising epitopes study data curated could <NUMBER> inform design candidate peptidebased vaccine diagnostic sarscov<NUMBER> <NUMBER> selective pressures known introduce viral mutations promote fitness lead <NUMBER> evasion immune responses <NUMBER> <NUMBER> first sought investigate genetic similarity <NUMBER> reported sarscov<NUMBER> clinical isolates identify consensus sequence use epitope <NUMBER> prediction studies identified <NUMBER> mutationsdeletions across <NUMBER> genomes clinical isolates <NUMBER> reported <NUMBER> february <NUMBER> despite variations viral genomic identity <NUMBER> <NUMBER> conserved across isolates protein coding sequences largely conserved genome <NUMBER> original virus isolate wuhanhu<NUMBER> deemed representative consensus sequence analysis <NUMBER> sarscov<NUMBER> proteome <NUMBER> cd<NUMBER> cd<NUMBER> cell responses likely directed structural nonstructural <NUMBER> proteins antiviral immune responses viral proteins accessible processing <NUMBER> presentation hla molecules infected cells therefore sought identify cell epitopes <NUMBER> across entire viral proteome analysis identified <NUMBER> potential cd<NUMBER> cell epitopes supp table <NUMBER> s<NUMBER> <NUMBER> potential cd<NUMBER> cell epitopes supp table s<NUMBER> stringent filtering <NUMBER> promiscuous peptides high predicted antigenicity yielding subset <NUMBER> cd<NUMBER> cell epitopes <NUMBER> <NUMBER> cd<NUMBER> cell epitopes table <NUMBER> potential targets vaccine development single study grifoni <NUMBER> colleagues recently reported computational identification <NUMBER> cd<NUMBER> cell epitopes <NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> peptides analysis shared sequence homology nested within <NUMBER> peptides identified study moreover seven peptides initial report replicated <NUMBER> final subset hla class ii epitopes supporting peptides may promising vaccine targets <NUMBER> increasing number studies employed predictive algorithms identify potential hla <NUMBER> class epitopes sarscov<NUMBER> although relatively comprehensively analyzed entire viral <NUMBER> proteome report feng et al recently outlined identification <NUMBER> potential class epitopes <NUMBER> main structural proteins sarscov<NUMBER> consider nonstructural proteins <NUMBER> <NUMBER> grifoni colleagues conducted rigorous analysis identifying <NUMBER> unique cd<NUMBER> cell epitopes across sarscov<NUMBER> proteins focusing analyses solely peptides sequence homology <NUMBER> known sarscov epitopes <NUMBER> approach initially identified <NUMBER> potential cd<NUMBER> cell <NUMBER> epitopes across viral proteins refined subset <NUMBER> peptides table <NUMBER> one peptide <NUMBER> derived orf<NUMBER>ab mmisagfsl predicted bind hlaa<NUMBER> high affinity ic <NUMBER> <NUMBER> <NUMBER> nm figure <NUMBER>c given prevalence allele american european populations <NUMBER> <NUMBER> frequency <NUMBER> mmisagfsl may represent promising epitope capable providing broad vaccine <NUMBER> population coverage <NUMBER> also observed notable enrichment epitopes predicted bind hlab molecules<NUMBER> particularly hlab<NUMBER>as imposed stringent selection criteria figure <NUMBER>b five peptides <NUMBER> identified approach predicted relatively strong binders allele ic <NUMBER> <NUMBER> nm <NUMBER> molecular docking simulations illustrating strong contacts amino acid residues peptide <NUMBER> binding groove figure <NUMBER> b recent computational study identified another hlab allele b<NUMBER> <NUMBER> high capacity presenting epitopes sarscov<NUMBER> conserved among <NUMBER> pathogenic coronaviruses <NUMBER> data collectively suggest hlab locus may significantly <NUMBER> associated immune response sarscov<NUMBER> potentially coronaviruses <NUMBER> biological studies warranted determine true role host genetics sarscov<NUMBER> immunology <NUMBER> lastly analyzed primary structural proteins sarscov<NUMBER> n e proteins <NUMBER> potential b cell epitopes ideal vaccine would designed stimulate cellular humoral <NUMBER> immunity analysis identified potential linear b cell epitopes proteins except e protein <NUMBER> table <NUMBER> greatest number epitopes predicted surfaceexposed protein n<NUMBER> <NUMBER> significant number epitopes also predicted n protein n<NUMBER> surprising <NUMBER> previous reports identified n protein significant target humoral response sarscov <NUMBER> <NUMBER> <NUMBER> protein predominant surface protein primary target <NUMBER> neutralizing antibody responses coronaviruses <NUMBER> <NUMBER> elected focus subsequent <NUMBER> analyses solely antigenic regions protein identified <NUMBER> potential structural epitopes <NUMBER> protein structure referenced linear epitope predictions identify six regions <NUMBER> independently identified analyses table <NUMBER> figure <NUMBER> evaluate potential six antigenic regions targets antibody binding <NUMBER> modeled surface accessibility crystal structure sarscov<NUMBER> spike protein <NUMBER> four <NUMBER> regions s<NUMBER> domain d<NUMBER>d<NUMBER> n<NUMBER>n<NUMBER> g<NUMBER>p<NUMBER> d<NUMBER>t<NUMBER> solvent exposed <NUMBER> figure <NUMBER> b minimal steric hindrance antibody accessibility s<NUMBER> domain contains <NUMBER> residues n<NUMBER>v<NUMBER> important virus binding angiotensin converting enzyme <NUMBER> ace<NUMBER> cell surface <NUMBER> studies shown antibodies potent neutralizing activity sarscov <NUMBER> target domain <NUMBER> indeed three four s<NUMBER> epitopes identified analyses located <NUMBER> ace<NUMBER>binding region supporting potential utility vaccine development sarscov<NUMBER> <NUMBER> two regions identified s<NUMBER> stalk domain protein figure <NUMBER> c y<NUMBER> d<NUMBER> located base protein likely inaccessible antibodies p<NUMBER>d<NUMBER> <NUMBER> outer face protein previously identified part larger b cell epitope <NUMBER> conserved sarscov <NUMBER> sarscov s<NUMBER>specific antibodies previously shown <NUMBER> possess antiviral activity <NUMBER> interesting speculate whether strategy similar targeting <NUMBER> influenza hemagglutinin protein stalk could employed developing broadly reactive coronavirus <NUMBER> vaccine <NUMBER> study possessed several strengths limitations rather restricting analyses <NUMBER> hla class class ii epitopes specific proteins based prior studies sarscov immunology <NUMBER> investigated complete proteome sarscov<NUMBER> using unbiased approach furthermore <NUMBER> employed multitiered strategy identifying putative b cell cell epitopes viral proteins <NUMBER> studied initial analyses performed liberal thresholds epitope identification <NUMBER> additional step imposed stringent selection criteria filter peptides subset b cell <NUMBER> cell epitopes study nevertheless results study derived purely <NUMBER> computational methods noted computational algorithms fail capture <NUMBER> significant number antigenic peptides <NUMBER> experimental validation biological samples <NUMBER> ultimately needed <NUMBER> early stages pandemic access sufficient biological samples may extremely <NUMBER> limited must continue utilize methodologiessuch computational predictive algorithms<NUMBER> allow us explore epitope landscape experimental vaccine development approach <NUMBER> study allowed us identify refine manageable subset cell b cell epitopes <NUMBER> testing components sarscov<NUMBER> vaccine based results proposed sarscov<NUMBER> <NUMBER> vaccine formulation could contain following <NUMBER> one b cell peptide epitopes <NUMBER> protein generate protective neutralizing antibodies <NUMBER> multiple hla class class iiderived <NUMBER> peptides viral proteins stimulate robust cd<NUMBER> cd<NUMBER> cell responses based global <NUMBER> allele frequencies class class ii peptides would expected collectively provide <NUMBER> <NUMBER> <NUMBER> population coverage respectively vaccine could readily formulated synthetic <NUMBER> polypeptide adjuvanted peptide mixture strategies may retain epitope structural <NUMBER> features necessary induce robust antibody response recombinant nanoparticles assembly <NUMBER> vlps represent promising alternative vaccine platforms extensively used <NUMBER> controlled display delivery peptidebased vaccine components <NUMBER> omitting whole viral <NUMBER> proteins vaccine formulation peptidebased sarscov<NUMBER> vaccine well<NUMBER> tolerated safety profile avoid adverse events previously observed experimental sarscov <NUMBER> vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> summary identified <NUMBER> potential cell epitopes <NUMBER> hla class <NUMBER> hla class ii <NUMBER> <NUMBER> potential b cell epitopes across sarscov<NUMBER> proteome predicted broad <NUMBER> population coverage could serve basis designing investigational peptidebased vaccines <NUMBER> study biological relevance immunogenicity peptides warranted effort <NUMBER> develop safe effective vaccine combat sarscov<NUMBER> pandemic <NUMBER> authors would like thank caroline l vitse editorial assistance manuscript <NUMBER> research presented supported specific funding source <NUMBER> <NUMBER> <NUMBER> <NUMBER> huang lr et al <NUMBER> evaluation antibody responses sars coronaviral nucleocapsid <NUMBER> spike proteins immunoblotting elisa identification workflow illustrating algorithms used <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> filtering criterion <NUMBER> applied refine peptide selection cladogram illustrating genetic relationship sarscov<NUMBER> <NUMBER> isolates original viral isolate consensus sequence wuhanhu<NUMBER> highlighted red <NUMBER> <NUMBER> figure <NUMBER> immunogenicity scoring peptides sarscov<NUMBER> proteome predicted hla class <NUMBER> ii coverage binding affinities discotope prediction algorithms highlighted trimeric structure glycoprotein inset panels <NUMBER> show s<NUMBER> domain upper s<NUMBER> domain lower december <NUMBER> multiple pneumonia cases unknown etiology reported wuhan china <NUMBER> later genomic analysis samples collected admitted patients revealed novel betacoronavirus causative pathogen <NUMBER> rna virus temporarily known <NUMBER> novel coronavirus <NUMBER>ncov renamed later severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> disease caused virus known coronavirus disease <NUMBER> covid <NUMBER> usually characterized fever dry cough fatigue muscles pain additionally dyspnea observed patients may progress acute respiratory distress syndrome ards <NUMBER> transmission sarscov<NUMBER> largely dependent respiratory droplets generated sneezing coughing <NUMBER> median incubation period sarscov<NUMBER> estimated <NUMBER> days <NUMBER> confidence interval <NUMBER> <NUMBER> days <NUMBER> outbreak sarscov<NUMBER> recognized global pandemic threat march <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> genomic sequence similarity <NUMBER> previously known coronavirus protein angiotensin converting enzyme <NUMBER> ace<NUMBER> however binding affinity sarscov<NUMBER> ace<NUMBER> seems <NUMBER> times higher <NUMBER> believed covid<NUMBER> pathogenesis may involve blockade ace<NUMBER> subsequent imbalance angiotensin<NUMBER> angiotensin ii suggests ace<NUMBER> may involved pathogenesis beyond viral entry point <NUMBER> similar sarscov specific treatment currently available combat covid<NUMBER> however management ards involve use oxygenbased therapy antibiotics possible sepsis <NUMBER> attempts fight covid<NUMBER> clinical trials keep going assess effect several antiviral agents like remdesivir <NUMBER> additionally computational modelling attempts proposed repurposing several fda approved drugs sarscov<NUMBER> <NUMBER> <NUMBER> time vaccine ever developed coronavirus however advanced techniques employed generate potential sarscov<NUMBER> vaccine candidates like mrna based vaccine viral vector vaccine viral subunit vaccine <NUMBER> recently immunoinformatics tools used screen sarscov<NUMBER> proteins potential bcells tcells epitopes <NUMBER> <NUMBER> prediction epitopes enabled virtual design peptide based vaccine sarscov<NUMBER> <NUMBER> <NUMBER> previously predicted several potential epitopes within sarscov<NUMBER> spike protein sequence interest linear bcells epitope sequence gfncyfplqsygf epitope believed part spike protein receptor binding protein rbd involved interaction ace<NUMBER> <NUMBER> <NUMBER> current study constructed peptidebased vaccine design combining seven potential epitopes predicted previously published findings <NUMBER> evaluated vaccine design using several immunoinformatics tools affirm stability safety efficiency aim study present multiepitopebased peptide vaccine design potential use sarscov<NUMBER> flowchart summarizes steps vaccine construction evaluation study seen figure <NUMBER> selected seven potential epitopes construction vaccine candidate sequence epitopes seen table <NUMBER> high antigenicity low allergenicity good stability selected proteases predicted previously published study <NUMBER> table <NUMBER> linear epitopes previously predicted sarscov<NUMBER> spike protein crystal epitope sequence epitope type major histocompatibility complex mhc molecule highly polymorphic expressed population coverage analysis seven epitopes merged together sequential manner using aay linker linker considered cleavage site mammalians proteasomes increase epitopes presentation enhancing formation natural epitopes reducing formation junctional epitopes secondary structure vaccine construct predicted using psipred <NUMBER> tool <NUMBER> tertiary structure modelled using sparksx webbased tool recognize protein folding sequence alignment <NUMBER> prediction tools sequence vaccine design submitted one letter code improve vaccine tertiary structure generated pdb file submitted galaxy refine server refinement server applies molecular dynamics md simulation implement repeated cycles structural perturbation subsequent relaxation <NUMBER> <NUMBER> vaccine structure validation peptide vaccine structure submitted pdb file rampage server md analysis carried <NUMBER> nanoseconds using protocol applied previously published article <NUMBER> ability peptide vaccine activate various components host immune system predicted using cimmsim server modelling platform combines dynamics immune system together genomic information <NUMBER> first vaccine sequence selected six tcells epitopes showed high predicted population coverage according mhc restricted alleles according figure <NUMBER> worldwide coverage epitopes primary sequence peptide vaccine constructed merging seven potential epitopes together using aay linker adjuvant human betadefensin <NUMBER> chain linked nterminus vaccine construct using rigid linker eaaak primary structure peptide vaccine seen figure <NUMBER> one letter format prediction vaccine secondary structure appeared figure <NUMBER> b revealed percentage βstrand αhelix coil <NUMBER> <NUMBER> <NUMBER> respectively tertiary structure vaccine design modelled using sparksx server zscore <NUMBER> model refined using galaxy refine server root mean square deviation rmsd <NUMBER> initial build refined tertiary structure peptide vaccine seen figure <NUMBER> c epitopes also colored gold light blue red respectively <NUMBER> summary predicted physicochemical properties immunogenicity allergenicity vaccine construct observed table <NUMBER> according table peptide validation results vaccine refined tertiary structure observed figure <NUMBER> based analysis ramachandran plot figure <NUMBER> <NUMBER> residues favored position torsional angles plot <NUMBER> allowed region <NUMBER> residues refined model considered outliers zscore refined model recorded <NUMBER> using prosaweb tool quality score located within zscores range calculated native proteins similar size seen figure <NUMBER> b model quality also assessed presented figure <NUMBER> c plotting predicting energy function sequence position plot window size <NUMBER> residues smoother <NUMBER> residues size obvious refined model may structural flaws predicted energy window size <NUMBER> residues jumps slightly higher zero part plot finally overall quality score errat server reported <NUMBER> score represents percentage protein sequence predicted error value falls rejection limit plot error value versus residues number seen figure <NUMBER> structural validation results predict refined construct good stability minor flaws candidate <NUMBER> <NUMBER> lines represent confidence interval rejection limit molecular docking analysis vaccine construct tlr<NUMBER> generated many potential complexes overview docking result first ranked complex seen figure <NUMBER> vaccinetlr<NUMBER> complex geometric shape complementarity score <NUMBER> approximate interface area <NUMBER> cartoon representation complex well presented figure <NUMBER> according analysis proteinprotein interface illustrated figure <NUMBER> b peptide vaccine able form <NUMBER> hydrogen bonds tlr<NUMBER> interface residues anticipated length bonds less <NUMBER> angstrom tlr<NUMBER> seen figure <NUMBER> based total potential energy calculations figure <NUMBER> complex looks stable minimal changes potential energy predicted throughout simulation period however vaccine construct seems exhibit higher <NUMBER> flexibility per residue tlr<NUMBER> noted root mean square fluctuation rmsf calculations figure <NUMBER> b residues peptide vaccine show higher variation position simulation time averaged position reference position results molecular docking dynamics simulation may indicate preferential binding vaccine design tolllike receptor <NUMBER> rmsf value zero refers absence residue molecule simulation <NUMBER> finally results simulation host immune response injected vaccine seen figure <NUMBER> predicted simulation server found three injections vaccine construct time frame <NUMBER> weeks two doses necessary produce loglasting efficient immune response according figure <NUMBER> glycoprotein highly neutralizing major protective antigen sars<NUMBER> cov<NUMBER> broadscale vitro characterization recombinant vaccine candidate <NUMBER> demonstrated efficient coexpression hemagglutininneuraminidase hn <NUMBER> aoav<NUMBER> protein sarscov<NUMBER> comparable replication kinetics <NUMBER> observed cell culture model recombinant vaccine candidate virus actively <NUMBER> replicated spread within cells independently exogenous trypsin interestingly <NUMBER> incorporation protein sarscov<NUMBER> recombinant aoav<NUMBER> particles <NUMBER> attributed sensitivity antisarscov<NUMBER> antiserum prominently anti<NUMBER> aoav<NUMBER> antiserum finally results demonstrated recombinant vaccine <NUMBER> vector stably expressed protein multiple propagation chicken embryonated <NUMBER> eggs expression significantly impact vitro growth characteristics <NUMBER> recombinant taken together presented respiratory vaccine candidate <NUMBER> highly attenuated primates per se safe lacking preexisting immunity human <NUMBER> carries potential accelerated vaccine development covid<NUMBER> <NUMBER> clinical studies outbreak pneumonia erupted chinese seafood market wuhan <NUMBER> late <NUMBER> within month origin <NUMBER> january <NUMBER> public health <NUMBER> emergency international concern declared world health organization <NUMBER> due high humantohuman transmission within next month outbreak <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> soared among communities <NUMBER> unprecedentedly spread across globe pandemic declared <NUMBER> <NUMBER> march <NUMBER> large proportion <NUMBER> covid<NUMBER> infected patients <NUMBER> showed moderate symptoms led staggering rate increase global <NUMBER> spread infection acute respiratory distress syndrome manifested <NUMBER> <NUMBER> covid<NUMBER> patients caused substantial case fatality rates especially elderly <NUMBER> frail people comorbidities <NUMBER> severe acute respiratory syndromecoronavirus <NUMBER> sarscov<NUMBER> causative <NUMBER> agent ongoing covid<NUMBER> pandemic belongs family coronavirdae within <NUMBER> betacoronavirus nonstructural proteins nsp <NUMBER> multiple accessary proteins amongst <NUMBER> viral proteins protein constitute major protective antigen elicit highly <NUMBER> specific antibodies mediated immune responses <NUMBER> therefore protein remained <NUMBER> primary vaccine markers coronaviruses currently registered drugs vaccines available curb pandemic <NUMBER> however multiple vaccines using range technologies developed pre<NUMBER> clinically clinically investigated <NUMBER> amongst inactivated vaccine <NUMBER> elicited strong antibodies neutralize multiple sarscov<NUMBER> strains <NUMBER> partially fully protect macaques sarscov<NUMBER> challenge <NUMBER> chimpanzee <NUMBER> adeno chadvectored vaccine expressing fulllength gene sarscov<NUMBER> <NUMBER> elicited humoral cellmediated responses rhesus macaques <NUMBER> however failed <NUMBER> fully alleviated clinical signs vaccinated macaques albeit reduced severity <NUMBER> protection pneumonia chadox<NUMBER> ncov<NUMBER> also failed reduce viral <NUMBER> replication nose highlighting potential spread sarscov<NUMBER> <NUMBER> sneezing even vaccinated people <NUMBER> <NUMBER> <NUMBER> owing multifaceted advantages avian orthoavulavirus <NUMBER> aoav<NUMBER> proposes <NUMBER> potential vaccine vector sarscov<NUMBER> specifically aoav<NUMBER> represented <NUMBER> type species newcastle disease virus ndv exclusively cytoplasmic viruses <NUMBER> therefore viral gene segments integrated host genome <NUMBER> raises safety profile since vectors lack natural recombination <NUMBER> expression transgenes genetically stable additionally aoav<NUMBER> infect multiple <NUMBER> species animals vaccines produced chicken embryonated eggs <NUMBER> multiple cell lines <NUMBER> given features apathogenic strains aoav<NUMBER> <NUMBER> used live attenuated vaccines multiple viruses including <NUMBER> influenza sars human immunodeficiency virus <NUMBER> human parainfluenza rabies <NUMBER> <NUMBER> nipah disease <NUMBER> rift valley fever <NUMBER> ebola highly pathogenic h<NUMBER>n<NUMBER> <NUMBER> <NUMBER> importantly aoav<NUMBER> appeared safe effective mice <NUMBER> dogs <NUMBER> pigs <NUMBER> <NUMBER> cattle <NUMBER> sheep <NUMBER> african green rhesus monkeys <NUMBER> humans <NUMBER> notably <NUMBER> natural host aoav<NUMBER> birds vector antigenically distinct <NUMBER> common human pathogens therefore preexisting immunity human make <NUMBER> ideal vector deliver transgene effective safely present study de novo designed aoav<NUMBER> vector generated <NUMBER> recombinant vaccine candidate expressing fulllength codon optimized protein <NUMBER> sarscov<NUMBER> preoptimized gene junction topical respiratory vaccine <NUMBER> candidate fully characterized vitro based infection spreadability <NUMBER> within cells sensitivity antiaoav<NUMBER> antisarscov<NUMBER> neutralizing <NUMBER> antibodies replication kinetics stability chicken embryonated eggs <NUMBER> raoav<NUMBER>sarscov<NUMBER> scalable topical vectored vaccine candidate <NUMBER> sarscov<NUMBER> tested safety immunogenicity animal studies <NUMBER> <NUMBER> design construction aoav<NUMBER>sarscov<NUMBER> vaccine candidate <NUMBER> avirulent strain aoav<NUMBER> used construct vaccine candidate sars<NUMBER> cov<NUMBER> full length antigenomic sequence aoav<NUMBER> originally isolated <NUMBER> asymptomatic wild birds de novo synthesised facilitate minigenome <NUMBER> transcription autocatalytic ruleofsix adhered hammerhead ribozyme <NUMBER> sequences introduced <NUMBER> <NUMBER>ends antigenome fig <NUMBER>a expression cassette containing kozak sequence ge gs ig orf <NUMBER> fulllength gene codonoptimized homo sapiens codon usage <NUMBER> inserted unique pmei site p genes originally <NUMBER> preserved cloning complete antigenome fig <NUMBER>a construct <NUMBER> named raoav<NUMBER>sarscov<NUMBER> whereas aoav<NUMBER> without insertion <NUMBER> foreign gene aoav<NUMBER>wt used infection control throughout study <NUMBER> orientation inserted gene confirmed nucleotide sequence analysis individually inoculated eggs using realtime pcr hemagglutination assays <NUMBER> identified successfully rescued raoav<NUMBER>sarscov<NUMBER> viruses fig <NUMBER> <NUMBER> supplementary used fully characterize presented study vast majority raoav<NUMBER>sarscov<NUMBER>infected cells expressed hn <NUMBER> proteins simultaneously fig <NUMBER>d recombinant wild type aoav<NUMBER> isolates replicated high titre eggs ≥<NUMBER> <NUMBER> hauml data shown evaluation viral replication presence <NUMBER> exogenous proteases vero cells indicated raoav<NUMBER> expressing codon <NUMBER> optimized gene replicated level comparable wild type aoav<NUMBER> fig <NUMBER>e <NUMBER> expression analysis protein western blot indicated potent expression <NUMBER> fulllength protein raoav<NUMBER>sarscov<NUMBER>infected cells whereas expression <NUMBER> hn proteins detected recombinant wt aoav<NUMBER>infected cells <NUMBER> fig <NUMBER>f fig <NUMBER> supplementary results confirm expression <NUMBER> transgene didnt interfere growth characteristics aoav<NUMBER> could <NUMBER> replication competitive vaccine candidate exogenous trypsin independent growth characteristics vaccine construct <NUMBER> initiate virus replication f protein aoav<NUMBER> cleaved cellular <NUMBER> proteases <NUMBER> order investigate prerequisite exogenous trypsinlike <NUMBER> extracellular proteases infectivity aoav<NUMBER> eggspropagated raoav<NUMBER> infection confirmed gradual spread infection fig <NUMBER>b coexpression <NUMBER> fluorescence profile highlighted colocalization surface proteins fig <NUMBER>c <NUMBER> similar recombinant aoav<NUMBER> aoav<NUMBER>wt replicated similar extent <NUMBER> course two days postinfection without need exogenous extracellular <NUMBER> proteases saturated level expression hn protein observed <NUMBER> <NUMBER> hours postinfection fig <NUMBER>d fig <NUMBER> supplementary cumulative <NUMBER> fluorescence dynamics fig <NUMBER>e fluorescence profile fig <NUMBER>f confirmed <NUMBER> active progressive expression hnspecific staining respectively taken <NUMBER> together results confirm active replication expression aoav<NUMBER> <NUMBER> foreign genes vero cells independently exogenous trypsin raoav<NUMBER>sarscov<NUMBER> sensitive aoav<NUMBER> sarscov<NUMBER> antisera <NUMBER> f hn surface glycoproteins critical receptor binding well membrane <NUMBER> fusion indispensable virus entry subsequent initiation virus <NUMBER> replication <NUMBER> contrast coronaviruses single enveloped <NUMBER> glycoprotein perform dual functions receptor binding membrane fusion <NUMBER> <NUMBER> order understand influence protein sarscov<NUMBER> <NUMBER> infectivity recombinant virus sensitivities aoav<NUMBER> sarscov<NUMBER> antisera <NUMBER> assessed compared neutralization expected aoav<NUMBER>wt <NUMBER> resistant mock antiserum neutralization almost fully neutralized <NUMBER> serum aoav<NUMBER> fig <NUMBER>a quantitatively antiaoav<NUMBER> antiserum <NUMBER> reduced infection aoav<NUMBER>wt vero cells <NUMBER> compared mock<NUMBER> neutralization fig <NUMBER>b neutralization analysis raoav<NUMBER>sarscov<NUMBER> showed <NUMBER> significant blockage virus replication preincubation subsequent <NUMBER> infection raoav<NUMBER>sarscov<NUMBER> either antiaoav<NUMBER> antiserum antisars<NUMBER> cov<NUMBER> antiserum fig <NUMBER>c neutralization observed upon viruss <NUMBER> treatment naïve mouse control serum compared mockneutralization <NUMBER> high <NUMBER> inhibition raoav<NUMBER>sarscov<NUMBER> observed antiaoav<NUMBER> <NUMBER> antiserum <NUMBER> inhibition noticed using antisarscov<NUMBER> antiserum fig <NUMBER> <NUMBER>d observations confirm incorporation protein sarscov<NUMBER> <NUMBER> recombinant aoav<NUMBER> particles attributed sensitivity aoav<NUMBER> anti<NUMBER> sarscov<NUMBER> antiserum antiaoav<NUMBER> antiserum vitro growth characterization vaccine construct order understand <NUMBER> replication competence raoav<NUMBER>sarscov<NUMBER> aoav<NUMBER>wt multistep <NUMBER> growth kinetics evaluated vero cells timecourse quantitative <NUMBER> measurement genomic copies confirmed expression gene didnt <NUMBER> interfere viral replication raoav<NUMBER>sarscov<NUMBER> replicated <NUMBER> competitively comparability aoav<NUMBER>wt fig <NUMBER>a cell lysate <NUMBER> experimental setting used assess expression aoav<NUMBER> <NUMBER> structural proteins expression analysis using western blotting demonstrated <NUMBER> aoav<NUMBER>wt fig <NUMBER>b raoav<NUMBER>sarscov<NUMBER> fig <NUMBER>c sgene expressionconfirmed viruses passaged <NUMBER>daysold embryonated <NUMBER> chicken eggs five consecutive passages raoav<NUMBER>sarscov<NUMBER> aoav<NUMBER> <NUMBER>wt replicated substantially eggs ≥<NUMBER> hauml data shown comparative <NUMBER> replication competence assessed first fifth eggs passaged viruses <NUMBER> vero cells raoav<NUMBER>sarscov<NUMBER> expressing protein sarscov<NUMBER> <NUMBER> grew efficiently level aoav<NUMBER>wt first passage well <NUMBER> <NUMBER> th passage embryonated eggs fig <NUMBER>a correspondingly expression <NUMBER> structural protein aoav<NUMBER> confirmed stable propagation wt <NUMBER> recombinant viruses least several passages fig <NUMBER>b fig <NUMBER> <NUMBER> supplementary sequence integrity inserted gene well p <NUMBER> junction assessed without mutations additionally sequencing <NUMBER> gene first fifth passages confirmed unwanted mutations purified <NUMBER> viruses results demonstrate raoav<NUMBER>sarscov<NUMBER> expresses gene <NUMBER> stably expression significantly impact vitro growth characteristics <NUMBER> recombinants <NUMBER> <NUMBER> precipitously increasing deaths negative impact lives livelihood <NUMBER> trembling economies warrant urgent development sarscov<NUMBER> vaccine <NUMBER> would safe efficacious scalable amongst experimental vaccines <NUMBER> presented sarscov<NUMBER> vectoredbased vaccines hold potential effective <NUMBER> vaccine covid<NUMBER> <NUMBER> however viral vector inherit multiple advantages <NUMBER> disadvantages careful consideration gene delivery system may pave <NUMBER> way effective vaccine propose pretested vaccine vector based recombinant apathogenic <NUMBER> strain aoav<NUMBER> ie ndv engineered aoav<NUMBER> express fulllength <NUMBER> glycoprotein sarscov<NUMBER> vital viral neutralization major protective mechanism host rangerestriction needs investigations known <NUMBER> aoav<NUMBER> induces strong interferon response mammalian cells turn limit <NUMBER> replication <NUMBER> additionally sialic acid receptors viral attachment might show <NUMBER> fundamental differences avian mammalian hosts thus define <NUMBER> host restriction observed bovine parainfluenza virus type <NUMBER> another <NUMBER> paramyxovirus family determine host range restriction <NUMBER> multiple viral proteins <NUMBER> notwithstanding aoav<NUMBER> clearly highly restricted <NUMBER> primates selective replication irrespective known pathotypes <NUMBER> mesogenic lentogenic strains aoav<NUMBER> <NUMBER> <NUMBER> <NUMBER> addition mentioned factors aoav<NUMBER> carries range advantages <NUMBER> multiple vectors similar paramyxoviruses aoav<NUMBER> enters host cells direct fusion <NUMBER> plasma membrane phindependent mechanism <NUMBER> aoav<NUMBER> also <NUMBER> enter host cells endocytic pathway entry aoav<NUMBER> cell <NUMBER> mediated surface fusion f glycoprotein also major determinant <NUMBER> aoav<NUMBER> virulence birds <NUMBER> viral infectivity requires cleavage f protein <NUMBER> intracellular ubiquitous proteases including furin allowing disseminated <NUMBER> replication multiples organs tissues mechanism similar aoav<NUMBER> raoav<NUMBER> <NUMBER>sarscov<NUMBER> entry cells proteolytic cleavage protein <NUMBER> <NUMBER> trypsinindependent infectivity raoav<NUMBER>sarscov<NUMBER> observed <NUMBER> study facilitated vector propagation cells culture model well embryonated <NUMBER> chicken eggs previously shown insertion transgene may allow vector <NUMBER> sensitive neutralization antibodies specific inserted protein <NUMBER> may facilitate seepage neutralization vectorspecific neutralizing <NUMBER> antibodies <NUMBER> <NUMBER> raoav<NUMBER>sarscov<NUMBER> expresses native structural hn <NUMBER> protein well glycoprotein therefore entry cell may attributed <NUMBER> aoav<NUMBER>like sarscov<NUMBER>like conjunction hypothesis anti<NUMBER> aoav<NUMBER> antiserum well antisarscov<NUMBER> could substantially block entry <NUMBER> raoav<NUMBER>sarscov<NUMBER> additionally recombinant aoav<NUMBER>sarscov<NUMBER> <NUMBER> offers exciting system underpin functional interactions native <NUMBER> foreign envelope glycoproteins one viral particle recently insertion foreign genes backbone aoav<NUMBER> <NUMBER> practiced multiple viruses including influenza sars human immunodeficiency <NUMBER> virus <NUMBER> human parainfluenza rabies <NUMBER> nipah disease <NUMBER> rift valley fever <NUMBER> ebola <NUMBER> highly pathogenic h<NUMBER>n<NUMBER> <NUMBER> several studies demonstrated <NUMBER> insertion transgene genomes aoav<NUMBER> resulted reduced <NUMBER> pathogenicity poultry birds safety maintained even expression <NUMBER> ha gene highly pathogenic avian influenza virus <NUMBER> sustained stable <NUMBER> progressive replication wt recombinant viruses demonstrated effective <NUMBER> spread within cells independently <NUMBER> <NUMBER> taken together results demonstrated recombinant vector expressing <NUMBER> protein propagated stably chicken embryonated eggs several consecutive <NUMBER> passages expression significantly impact vitro growth <NUMBER> characteristics recombinants presented respiratory vaccine candidate <NUMBER> potential development vaccine vector available expedited <NUMBER> vaccine development preclinical clinical studies <NUMBER> <NUMBER> cells viruses aoav<NUMBER>wt vaccine vector rescued described previously <NUMBER> assessed optimal gene expression inserted p <NUMBER> gene <NUMBER> <NUMBER> <NUMBER> arrangement gene identical among aoav<NUMBER> <NUMBER> order offer competitive reverse genetic system novel vaccine vector <NUMBER> avirulent strain aoav<NUMBER> used carrying lentogenicalike eg ndv cleavage site <NUMBER> pathogenicity patent pending technology full length antigenomic <NUMBER> sequence aoav<NUMBER> originally isolated asymptomatic wild birds partially <NUMBER> de novo synthesised nbs biologicals uk using novel sequence modification <NUMBER> approach rest genome length mainly constituting around p gene <NUMBER> cloned using overlapping pcrs entire cassette shuttled <NUMBER> tvt<NUMBER>r<NUMBER> addgene plasmid <NUMBER> order avoid incorporation extra <NUMBER> nonviral gene residues transcribed minigenome efficient transcription <NUMBER> gene autocatalytic rule six adhered hhrz introduced <NUMBER> end hepatitis delta virus ribozyme hdvrz <NUMBER> end antigenome expression cassette fulllength gene first silico generated <NUMBER> containing kozak sequence ge gs ig orf full length gene <NUMBER> codonoptimized homo sapiens codon usage inserted unique <NUMBER> pmei site p genes originally preserved cloning <NUMBER> complete antigenome construct named raoav<NUMBER>sarscov<NUMBER> whereas <NUMBER> aoav<NUMBER> without insertion foreign gene aoav<NUMBER>wt used <NUMBER> infection control throughout study orientation inserted gene <NUMBER> confirmed nucleotide sequence analysis time cloning well <NUMBER> propagation vector cells chicken embryonated eggs raoav<NUMBER>sarscov<NUMBER> aoav<NUMBER>wt used rescue infectious viruses <NUMBER> described previously <NUMBER> <NUMBER> inoculating <NUMBER>daysold embryonated chicken eggs additional <NUMBER> three days individual eggs screened using hemagglutination assay real<NUMBER> time pcr described <NUMBER> <NUMBER> <NUMBER> permeabilized <NUMBER> triton x<NUMBER> <NUMBER> min blocking cells <NUMBER> <NUMBER> bovine serum albumin bsa pbs incubated monoclonal antibody <NUMBER> mab <NUMBER> probe hn proteins binding primary antibodies <NUMBER> visualized using alexa <NUMBER> αrabbit <NUMBER> αmouse secondary antibodies <NUMBER> invitrogen hn proteins expression analysed fluorescence <NUMBER> wildtype recombinant viruses compared mock infected cells <NUMBER> diamidino<NUMBER>phenylindole dapi used stain cell nuclei images <NUMBER> captured using zeiss confocal laserscanning microscope zeiss kohen germany <NUMBER> digital images processed using adobe illustrator software <NUMBER> parameters applied whole image area competing interests <NUMBER> authors declare competing interests <NUMBER> <NUMBER> supplementary figures associated manuscript <NUMBER> <NUMBER> robustly activate humoral cellmediated immunity establish strong protection pathogen <NUMBER> antibody generation bcell activation well acute viral clearance tcells along virusspecific memory generation cd<NUMBER> tcells equally important develop immunity coronavirus <NUMBER> case respiratory virus like coronaviruses mucosal immunity plays essential role therefore route administration vaccine also important context vaccine development vaccines designed previously reported sarscov merscov majorly focuses spike protein virus consists s<NUMBER> s<NUMBER> subunits bearing receptor binding domain rbd virus cell fusion machinery respectively mutations spike protein also reported responsible change host cell tropism <NUMBER> protein considered antigenic thereby evoke immune responses generate neutralizing antibodies block virus attachment host cells <NUMBER> viral proteins explored vaccine development include n protein e protein nsp<NUMBER> proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> almost platforms vaccine development sarscov merscov investigated including lifeattenuated ones recombinant viruses subunit protein vaccines dna vaccines viral vectorbased vaccines nanoparticlebased vaccines etc may form base vaccine designing newly emerged sarscov<NUMBER> <NUMBER> <NUMBER> designed multiepitopebased vaccine sarscov<NUMBER> using next generation vaccinology approach recently available genome proteome sarscov<NUMBER> maneuvered potential vaccine candidate conceived similar strategy employed previously sarscov merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> well certain findings reported newly emerged sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> immunoinformatics techniques utilized groups predict bcell cytotoxic tcell epitopes sarscov<NUMBER> surface glycoprotein n protein <NUMBER> <NUMBER> <NUMBER> others utilized information design epitopebased vaccine based sarscov<NUMBER> spike glycoprotein <NUMBER> along structural proteins utilizing nonstructural accessory proteins vaccine development aid better development efficacious vaccine long term neutralizing mutation rate rna virus study explored whole proteome sarscov<NUMBER> scrutinize highly conserved antigenic epitopes construction multiepitope vaccine candidate effectively elicit humoral cellular mediated immune response covid<NUMBER> constructed vaccine product high population coverage along adaptive immunity well lead initiation innate immune response enhancing generation memory immunity continuous transmission virus across borders increasing health burden global scale sarscov<NUMBER> demands urgent immunization therapy depicted lu community acquired coronavirus infection caci caused virus shatter socioeconomic condition worldwide development vaccine sarscov<NUMBER> encouraged manage present situation well serve prototype coronaviruses <NUMBER> <NUMBER> thereby analysis provides platform development protective vaccine candidate tested invitro invivo may lead faster development efficient vaccine sarscov<NUMBER> infection complete proteome latest reported novel wuhan strain sars coronavirus sarscov<NUMBER> downloaded nucleotide database available national center biotechnology information ncbi database also thoroughly searched genomes available human infecting strains coronavirus till date downloaded analysis antigenic analysis proteome covid<NUMBER> strain vaxijen v<NUMBER> server available httpwwwddgpharmfacnetvaxijenvaxijenvaxijenhtml <NUMBER> antigenicity prediction proteins sarscov<NUMBER> higher accuracy virus model available vaxijen server threshold <NUMBER> utilized proteins vaxijen score ≥ <NUMBER> taken epitope prediction analysis mhc class ii alleles selected basis occurrence worldwide focused specially countries severely affected deadly <NUMBER> mhc ii drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> drb<NUMBER> hladpa<NUMBER>dpb<NUMBER> hladpa<NUMBER>dpb<NUMBER> hladpa<NUMBER>dpb<NUMBER> hladqa<NUMBER>dqb<NUMBER> hladqa<NUMBER>dqb<NUMBER> hladqa<NUMBER>dqb<NUMBER> hladqa<NUMBER>dqb<NUMBER> hladqa<NUMBER>dqb<NUMBER> hladqa<NUMBER>dqb<NUMBER> covering <NUMBER> world population used epitope screening various online servers explored accurate prediction helper lymphocytes htl epitopes firstly antigenic proteins analyzed using <NUMBER> epitopes vaxijen score ≥ <NUMBER> predicted nontoxic nonallergens taken screening best hlanonallergenic epitope pair highest vaxijen score taken constructing multiepitope vaccine <NUMBER> allergenicity allertop v <NUMBER> used httpswwwddgpharmfacnetallertopmethodhtml <NUMBER> thereafter nonallergenic strong binders positive immunogenicity score checked toxic nature utilizing toxinpred server httpswebsiiitdeduinraghavatoxinpredmotifscanphp presence selected best epitopes reported human infecting sarscoronavirus strain checked using epitope conservancy analysis tool iedb httptoolsiedborgconservancy <NUMBER> epitopes <NUMBER> conservation used multiepitope vaccine construction mhc class ad class ii molecules downloaded rcsb pdb database httpswwwrcsborg available pdb database retrieved phla database httpswwwphla<NUMBER>dcombr <NUMBER> structures sarscov<NUMBER> proteins constructed using itasser httpszhanglabccmbmedumicheduitasser <NUMBER> htl ctl epitopes mapped structures retrieved using pymol tool molecular interaction analysis predicted best hlaepitope pairs mhc class class ii alleles cluspro proteinprotein docking tool httpsclusproorgloginphp <NUMBER> utilized abcpred tool based artificial neural network explored bcell epitope prediction httpswebsiiitdeduinraghavaabcpredindexhtml <NUMBER> higher accuracy threshold prediction kept <NUMBER> predicted epitopes checked antigenicity using vaxijen server allergenicity using algpred toxicity toxinpred server constructing multiepitope vaccine construct selected best htl ctl bcell epitopes joined using gpgpg aag kk linkers respectively better immunogenic response four adjuvants namely βdefensin universal memory cell helper peptide tpd padre sequence cell ligand added using eaaak linker vaccine construct antigenicity vaccine construct vaxijen server exploited allergenicity analysis vaccine construct three different tools namely algpred allertop allergenfp v<NUMBER> httpddgpharmfacnetallergenfpindexhtml <NUMBER> utilized check population coverage vaccine construct population coverage tool available iedb httptoolsiedborgpopulation <NUMBER> server utilized hla class class ii alleles final construct entered tool population coverage alleles calculated top <NUMBER> countries severely affected sarscov<NUMBER> virus analysis performed hla hla ii separately well combination expasys protparam httpswebexpasyorgprotparam <NUMBER> explored physiochemical properties evaluation vaccine construct protparam evaluates peptide sequence provides molecular weight theoretical pi extinction coefficient estimated halflife instability index grand average hydropathicity gravy solubility construct calculated using solpro tool available scratch protein predictor server httpscratchproteomicsicsuciedu <NUMBER> secondary structure multiepitope vaccine construct predicted using sopmahttpsnpsaprabiibcpfrcgibinnpsaautomatplpagenpsanpsasopmahtml <NUMBER> psipred httpbioinfcsuclacukpsipred server <NUMBER> tertiary structure prediction vaccine construct robetta server httprobettabakerlaborg based ab initio homology modelling utilized <NUMBER> predicted structure refined using <NUMBER>d refine httpsysbiornetmissouriedu<NUMBER>drefine <NUMBER> galaxyrefine httpgalaxyseoklaborgcgibinsubmitcgityperefine <NUMBER> structures evaluated constructing ramachandran plot using rampage httpmordredbioccamacukrapperrampagephp quality assessed using errat server httpsservicesnmbiuclaeduerrat refined modelled structure multiepitope vaccine construct evaluated stability real environment simulating water sphere using namdstandard molecular dynamics tool httpswwwksuiuceduresearchnamd using parallel processors required structure files psf generated psfgen using visual molecular dynamics vmd tool v<NUMBER> utlizing charmm force fields proteins initially <NUMBER> steps energy minimization performed followed subsequent heating system <NUMBER> k <NUMBER> k thereafter <NUMBER> ns standard molecular dynamics performed trajectory dcd file generated used evaluate rmsd change kinetic potential total energy evaluated <NUMBER> ns simulation using vmd check interaction multiepitope vaccine construct two immunoreceptors tlr<NUMBER> tlr<NUMBER> cluspro docking server used resultant best complexes simulated <NUMBER> ns water sphere using namd escherichia coli k<NUMBER> satrain construct first converted cdna using reverse translate tool available expasy server resultant dna optimized enhanced protein expression using jcat server <NUMBER> finally cdna construct inserted pet<NUMBER>a vector using hindiii bamhi restriction sites complete proteome wuhan seafood market pneumonia virus isolate wuhanhu<NUMBER> nucleotide accession number nc<NUMBER> retrieved ncbi database sarscov<NUMBER> proteome consists polyprotein orf<NUMBER>ab several structural proteins orf<NUMBER>ab encodes various nonstructural proteins including host translation inhibitor nsp<NUMBER> rna dependent rna polymerase rnrp helicase guaninen<NUMBER> methyltransferase etc plays critical role virus multiplication survival inside host structural proteins include spike glycoprotein envelope protein membrane protein nucleocapsid protein fasta sequences proteins retrieved ncbi used epitope screening table <NUMBER> sequences analyzed antigenic nature using vaxijen server based upon auto cross covariance acc transformation vaxijen classifies proteins antigens nonantigens solely based physiochemical properties sequence alignment independent acc score threshold virus model kept <NUMBER> increases prediction accuracy sarscov<NUMBER> proteins except nsp<NUMBER> <NUMBER>oribose methyltransferase resulted acc score higher <NUMBER> depicting antigenic nature viral proteome table <NUMBER> antigenic proteins screened presence htl ctl bcell epitopes using various tools databases figure <NUMBER> tlymphocytes play central role activating cell mediated innate adaptive immune response foreign particles well sole players generating immunological memory provides long lasting immune response thus vaccinology approach revolves around screening proteome high affinity helper table s<NUMBER> overlapping sequences merged one mhc class class ii binding epitopes apart cellular mediated immunity humoral immune response mediates pathogen clearance antibody dependent manner hence proteome sarccov<NUMBER> scanned linear bcell epitopes using abcpred server higher selectivity sensitivity threshold abcpred kept <NUMBER> predicted epitopes checked antigenicity allergenicity toxicity best epitopes taken consideration basis criteria received one bcell epitope nucleocapsid guaninen<NUMBER> methyltransferase exon orf<NUMBER>a orf<NUMBER>a surface glycoprotein supplementary table s<NUMBER> locations selected epitopes respective protein structures represented figure <NUMBER> overall antigenic <NUMBER> htl <NUMBER> ctl epitopes highest affinity respective hla alleles <NUMBER> bcell epitopes nonallergenic nontoxic generate potential immune response selected incorporation multiepitope vaccine construct presence conserved epitopes vaccine lead effective immunization strains pathogen thus selected htl ctl bcl epitopes analyzed conservancy among various human infecting strains coronavirus interestingly selected epitopes <NUMBER> conserved throughout coronavirus family lead robust vaccine development figure <NUMBER>c ideal vaccine harbor conserved epitopes multivalency elicit cellular humoral mediated immune response host subunit vaccine contains minimal elements antigenic required stimulation prolonged protective therapeutic immune response recent times various reports shown construction multi subunit vaccine utilizing highly antigenic htl ctl bcl epitopes herein constructed multiepitope vaccine candidate combining <NUMBER> htl <NUMBER> ctl <NUMBER> bcl epitopes highly conserved antigenic nontoxic nonallergens figure <NUMBER> recent times various small peptides explored acts adjuvant potentiate multiepitope vaccine mediated immune response activating humoral immunity taking consideration apart conserved epitopes four adjuvants also added boost protective immune response sarscov table <NUMBER> antigenicity preliminary requisite successful vaccine candidate vaccine construct must possess immunogenicity antigenicity elicit humoral cellmediated immune response upon analyzing vaccine construct sequence vaxijen server constructed vaccine found antigenic nature overall prediction score <NUMBER> score signifies antigenic potential vaccine construct may potential evoke immune response inside host allergenicity analysis three tools algpred allergenfp allertop supported nonallergenic nature vaccine construct toxicity analysis revealed nontoxic behavior construct table <NUMBER> summary constructed epitope observed stable soluble antigenic nonallergenic nontoxic secondary tertiary structure helps functional annotation multiepitope vaccines also helps analyzing interaction vaccine construct immunological receptors like tlrs secondary structure protein analyzed using sopma psipred server revealed presence <NUMBER> alpha helix <NUMBER> βsheet <NUMBER> coils <NUMBER> β turns vaccine construct figure <NUMBER> supplementary figure s<NUMBER> tertiary structure vaccine predicted threading based homology modelling using robetta server figure <NUMBER>a ramachandran plot analysis modelled structure revealed presence <NUMBER> residues favoured regions <NUMBER> additionally allowed regions figure <NUMBER>b quality factor analyzed using errat<NUMBER> server obtained <NUMBER> depicting good modelled structure figure <NUMBER>c refine modelled structure <NUMBER>d refine galaxyrefine utilized leads <NUMBER> residues favoured region <NUMBER> residues additionally allowed region quality factor refined structure observed <NUMBER> depicting improvement modelled structure figure <NUMBER>d f refined structure model construct check stability real environment simulating <NUMBER> ns water sphere <NUMBER> steps energy minimization performed minimize potential energy system unnecessary false geometry protein structures repaid performing energy minimization resulting stable stoichiometry energy minimization potential energy observed <NUMBER> kcalmol <NUMBER> steps protein minimized potential energy <NUMBER> kcalmol figure <NUMBER>a system subsequently heated <NUMBER> k <NUMBER> k <NUMBER> ns molecular dynamic simulation performed temperature remained constant throughout simulation process figure <NUMBER>b dcd trajectory file analysed analysing movement atoms simulation course rmsd calculated upon analysing rmsd sarscov<NUMBER> vaccine construct observed system gained equilibrium <NUMBER> ns remained constant till <NUMBER> ns depicting stability vaccine construct figure <NUMBER>c furthermore upon analysing change kinetic potential total energy system observed quick initial change three remained constant throughout simulation strengthening stability vaccine construct figure <NUMBER>df furthermore bond energy vdw energy dihedral improper dihedral energy analysis revealed change throughout <NUMBER> ns dynamics simulation root mean square fluctuation rmsf analysis revealed rigidness atoms vaccine construct slight mobility observed <NUMBER> <NUMBER> residues supplementary figure s<NUMBER> thus simulation analysis revealed stability vaccine construct real environment refined vaccine construct structure therefore used interaction analysis immunological receptor tlr<NUMBER> proteinprotein docking immune receptor tlr<NUMBER> constructed vaccine carried using cluspro server total <NUMBER> tlr<NUMBER>vaccine construct complexes generated fifth model lowest energy weighted score <NUMBER> considered best tlr<NUMBER>vaccine complex figure <NUMBER> ab supplementary table s<NUMBER> vaccine construct interacted ligand binding grove tlr<NUMBER> generating strong tlr<NUMBER>vaccine construct complex stability complex analyzed performing <NUMBER>ns standard molecular dynamics simulation studies using namd suite <NUMBER> steps energy minimization complex lead generation minimized energy complex energy <NUMBER> kcalmol figure <NUMBER>c subsequent heating system <NUMBER> k <NUMBER> k temperature kept constant throughout figure <NUMBER>d energy plots depicted major changes throughout simulation figure <NUMBER>e g supplementary figure s<NUMBER> rmsf analysis complex showed mobility region <NUMBER> th residue <NUMBER> residue tlr<NUMBER>vaccine complex figure <NUMBER>h trajectory analysis rmsd plot constructed revealed major deviations initial <NUMBER> ns thereafter system remained constant till <NUMBER> ns insertion vaccine construct plasmid vector <NUMBER> amino acid long protein sequence reverse translated cdna <NUMBER> nucleotide length expression system expression host varies cdna needs adapted per host codon usage optimal expression vaccine product escherichia coli k<NUMBER> host resultant cdna codon optimized according using jcat server also optimization rhoindependent transcription terminator prokaryotic ribosomal binding sites avoided middle cdna sequence generate optimal complete protein expression inserting construct cloning vector cleavage sites bamhi hindiii also avoided cai value codon adaptation index cdna adaptation observed <NUMBER> gc content <NUMBER> figure <NUMBER>a adaptation cai score improved sequence increased <NUMBER> <NUMBER> gc content figure <NUMBER>b supplementary data s<NUMBER> enhanced cai score depicts presence abundant codons escherichia coli k<NUMBER> adapted cdna sequence used silico cloning purpose escherichia coli k<NUMBER> strain selected host cloning purpose expression purification multiepitope vaccines easier bacterium pet<NUMBER>a expression vector cleaved using bamhi hindiii restriction enzyme cdna inserted near ribosome binding site using snapgene <NUMBER>x histidine tag added <NUMBER> end isolation purification vaccine construct figure <NUMBER>c severely affecting humans worldwide sarscov<NUMBER> highly contagious virus high mortality rate especially immunocompromised elderly persons vaccines utmost need time succumb rising infections due covid<NUMBER> represent best way combat infectious diseases community conventional vaccine development methods timeconsuming laborious expensive regard insilico immunoinformatics approach proved boon <NUMBER> moreover availability large number efficient tools predict immunodeterminants large database information facilitate accelerate whole process vaccine designing <NUMBER> multiepitope vaccines designed using antigenic conserved part pathogens proteins makes effective help combating high mutation rate rna viruses epitopebased vaccines added advantages safe stable highly specific costcurtailing easy produce bulk provides option manipulate epitopes designing better vaccine candidate <NUMBER> method vaccine development proved promising enough different microbial diseases including bacterial viral <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> herein applied reverse vaccinology approach designing multiepitope secondary structure prediction revealed predominance alpha helix tertiary structure obtained threading provides spatial arrangement aminoacid space obtained modelled structure refined increased overall quality table s<NUMBER>s<NUMBER> supplementary data s<NUMBER> data conceptualization methodology performed ak silcio prediction performed nj us pm analysis performed nj nj pm collectively wrote manuscript ak review editing coronavirus type singlestranded rna ssrna virus <NUMBER> emergence sarscov<NUMBER> <NUMBER> known human coronaviruses including middle east respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov symptoms caused sarscov<NUMBER> infection include acute respiratory distress syndrome <NUMBER> acute cardiac injury <NUMBER> acute kidney injury <NUMBER> <NUMBER> implying sarscov<NUMBER> may infect various human tissues covid<NUMBER> highly infectious disease <NUMBER> <NUMBER> associated high mortality <NUMBER> sarscov<NUMBER> virus responsible covid<NUMBER> betacoronavirus <NUMBER> previous name virus sarscov<NUMBER> genome sarscov<NUMBER> sequenced <NUMBER> <NUMBER> genomic sequence sarscov<NUMBER> <NUMBER> similarity batcoronavirus <NUMBER> identity sarscov <NUMBER> although approved drugs vaccines covid<NUMBER> clinical trials progress <NUMBER> lopinavir ritonavir used preliminary clinical studies <NUMBER> nevertheless past two decades massive amount work done understand molecular basis coronavirus infection evolution develop effective treatment forms vaccines antiviral drugs propose efficient measures viral detection prevention <NUMBER> <NUMBER> <NUMBER> structures many individual proteins sars mers related coronaviruses well biological interactions viral host proteins explored along experimental testing antiviral properties small compounds <NUMBER> <NUMBER> <NUMBER> context use bioinformatics approaches may help fill gap missing data improve process knowledge discovery elucidating molecular mechanisms behind virus replication process viral attachment host cells effect host molecular pathways <NUMBER> final understanding molecular action virus may improve accelerate development antiviral therapeutic approaches using information data available coronaviruses therefore understanding molecular effects virus human proteins play pivotal role prioritizing pharmacological strategies <NUMBER> review crystal structure sarscov<NUMBER> nucleocapsid nterminal domain termed sarscov<NUMBER> nntd model understanding molecular interactions govern sarscov<NUMBER> nntd binding ribonucleotides described unique rna binding site characteristics discussed turn aid development new drugs interfere viral n protein viral replication sarscov<NUMBER> highly related virus sarscov furthermore attempted propose suitable vaccine candidates identifying bcell tcell epitopes computational approaches drug vaccine design structures many individual proteins sars mers related coronaviruses well biological interactions viral host proteins explored along experimental testing antiviral properties small compounds <NUMBER> however experimental data scale sarscov<NUMBER> may take years obtain research community leveraging previously known information genome sequences well protein structure function bioinformaticians successfully helping virologists structurally characterizing proteins novel viruses determining evolutionary trajectories identifying interactions host proteins providing important biological insights particular plethora results achieved comparative homology modeling principles <NUMBER> <NUMBER> addition global structural genomics <NUMBER> mutant viruses protein prone escape targeted therapeutic different hostcell receptor binding patterns <NUMBER> well antibodydependent enhancement ade effects protein antibodies found mers coronavirus <NUMBER> several limitations targeting protein antiviral approaches antiviral protease inhibitors may nonspecifically act cellular homologous protease resulting host cell toxicity severe side effects therefore novel antiviral strategies needed combat acute respiratory infections caused novel coronavirus sarscov<NUMBER> fig <NUMBER> cov n protein multifunctional rnabinding protein necessary viral rna transcription replication <NUMBER> plays many pivotal roles forming helical ribonucleoproteins packaging rna genome regulating viral rna synthesis replication transcription modulating infected cell metabolism <NUMBER> <NUMBER> primary functions n protein binding viral rna genome packing long helical nucleocapsid structure ribonucleoprotein rnp complex <NUMBER> <NUMBER> vitro vivo experiments revealed n protein bound leader rna critical maintaining highly ordered rna conformation suitable replicating transcribing viral genome <NUMBER> <NUMBER> <NUMBER> studies implicated n protein regulated hostpathogen interactions actin reorganization host cell cycle progression apoptosis <NUMBER> <NUMBER> n protein also highly immunogenic abundantly expressed protein infection capable inducing protective immune responses sarscov sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> common domain architectures coronavirus n protein consisting three distinct highly conserved parts nterminal rnabinding domain ntd cterminal dimerization domain ctd intrinsically disordered central serarg srrich linker previous studies revealed ntd responsible rna binding ctd oligomerization srrich linker primary phosphorylation respectively <NUMBER> <NUMBER> <NUMBER> crystal structures sarscov nntd <NUMBER> infectious bronchitis virus ibv nntd <NUMBER> <NUMBER> hcovoc<NUMBER> nntd <NUMBER> mouse hepatitis virus mhv nntd <NUMBER> solved covs nntd found associate <NUMBER> end viral rna genome possibly electrostatic interactions additionally several critical residues identified rna binding virus infectivity nterminal domain coronavirus n proteins <NUMBER> <NUMBER> <NUMBER> however structural mechanistic basis newly emerged novel sarscov<NUMBER> n protein remains largely unknown understanding aspects facilitate discovery agents specifically block coronavirus replication transcription viral assembly <NUMBER> kang et al <NUMBER> reported crystal structure sarscov<NUMBER> nucleocapsid nterminal domain termed sarscov<NUMBER> nntd model understanding molecular interactions govern sarscov<NUMBER> nntd binding ribonucleotides finding aid development new drugs interfere viral n protein viral replication sarscov<NUMBER> highly related virus sarscov <NUMBER> angiotensin converting enzyme <NUMBER> ace<NUMBER> host receptor sarscov<NUMBER> infect human cells viruses bind host receptors target cell surface establish infection membrane proteins mediated membrane fusion allowed entry enveloped viruses <NUMBER> recently reported ncov sarscov could use ace<NUMBER> protein gain entry cells <NUMBER> since outbreak many data analysis shown wide distribution ace<NUMBER> across human tissues including lung <NUMBER> liver <NUMBER> stomach <NUMBER> ileum <NUMBER> colon <NUMBER> kidney <NUMBER> indicating sarscov<NUMBER> may infect multiple organs however data showed at<NUMBER> cells main target cell sarscov<NUMBER> lung expressed rather low levels ace<NUMBER> <NUMBER> hence ncovs may depend coreceptor auxiliary membrane proteins facilitate infection reported viruses tend hijack coexpressed proteins host factors <NUMBER> example hoffmann et al recently showed sarscov<NUMBER>s use ace<NUMBER> entry depends cellular protease tmprss<NUMBER> priming <NUMBER> showing <NUMBER>ncov infections also require multiple factors understanding receptors usage viruses could facilitate development intervention strategies therefore identifying potential coreceptors auxiliary membrane proteins sarscov<NUMBER> great significance although ace<NUMBER> reported expressed lung liver stomach ileum kidney colon expressing levels rather low especially lung <NUMBER> sarscov<NUMBER> may use coreceptorsauxiliary proteins ace<NUMBER> partners facilitate virus entry <NUMBER> identify potential candidates <NUMBER> explored singlecell gene expression atlas including <NUMBER> cell types <NUMBER> human tissues analyzed singlecell coexpression spectrum <NUMBER> reported rna virus receptors <NUMBER> membrane proteins consistent recent reports <NUMBER> confirmed ace<NUMBER> mainly expressed lung at<NUMBER> liver cholangiocyte colon colonocytes esophagus keratinocytes ileum ecs rectum ecs stomach epithelial cells kidney proximal tubules intriguingly <NUMBER> found candidate coreceptors manifesting similar expression patterns ace<NUMBER> across <NUMBER> human tissues peptidases including anpep dpp<NUMBER> enpep among anpep dpp<NUMBER> known receptors human covs suggesting enpep another potential receptor human covs viruses target host cells via binding host receptors engaging infection cycle ace<NUMBER> proved cell receptor sarscov<NUMBER> receptor sarscov <NUMBER> <NUMBER> expression profiles ace<NUMBER> across different cell types different organs reveal clues virus transmission routes potential pathogenesis previous studies ace<NUMBER> found express esophagus upper stratified epithelial cells absorptive enterocytes ileum colon alveolar type ii cells lung liver cholangiocyte kidney proximal tubules <NUMBER> <NUMBER> findings suggested clinical symptoms hepatic failure respiratory injury acute kidney injury diarrhoea may associated pervasive ace<NUMBER> expressing cells tissues however others found ace<NUMBER> lowly expressed especially lung main target organ ncovs raising possible existence coreceptors facilitating ncov infection well recognized ssrna viruses tend multiple receptors <NUMBER> example ace<NUMBER> cd<NUMBER> dendritic cellspecific icam<NUMBER>grabbing nonintegrin <NUMBER> clec<NUMBER>g ctype lectin domain family <NUMBER> member g clec<NUMBER>m ctype lectin domain family <NUMBER> member receptors sarscov <NUMBER> <NUMBER> also membrane proteins may also assist virus entry <NUMBER> since viral receptors coreceptors coexpressed cell types singlecell coexpression patterns covering <NUMBER> membrane proteins <NUMBER> known viral receptors analyzed <NUMBER> calculating gene expression similarity found anpep enpep dpp<NUMBER> top three genes correlated ace<NUMBER> r<NUMBER> interestingly anpep dpp<NUMBER> viral receptors human coronaviruses <NUMBER> enpep also peptidase despite involvement virus infection unclear mysterious reasons human coronaviruses use peptidases receptors <NUMBER> addition li et al <NUMBER> showed coexpression profiles molecules indicating different human covs target similar cell types across different human tissues currently registered treatment vaccine disease absence specific treatment novel virus urgent need find alternative solution prevent control replication spread virus vitamin supplementation reduced morbidity mortality different infectious diseases measles diarrheal disease measlesrelated pneumonia human immunodeficiency virus hiv infection malaria described semba et al <NUMBER> keil et al <NUMBER> reported vitamin b<NUMBER> uv light effectively reduced titer merscov human plasma products atherton et al <NUMBER> reported vitamin c increased resistance chick embryo tracheal organ cultures avian coronavirus infection addition decreased vitamin status calves reported cause infection bovine coronavirus <NUMBER> vitamin e deficiency reported intensify myocardial injury coxsackievirus b<NUMBER> kind rna viruses infection mice <NUMBER> protection d<NUMBER> omega<NUMBER> pufaderived lipid mediator could markedly attenuate influenza virus replication via rna export machinery <NUMBER> dietary selenium deficiency causes oxidative stress host alter viral genome normally benign mildly pathogenic virus become highly virulent deficient host oxidative stress <NUMBER> combination zinc pyrithione low concentrations inhibits replication sars coronavirus <NUMBER> iron required host pathogen iron deficiency impair host immunity iron overload cause oxidative stress propagate harmful viral mutations <NUMBER> combination interferonα<NUMBER>a ribavirin administered patients severe merscov infection survival patients improved <NUMBER> sars outbreak <NUMBER> intravenous gammaglobulin ivig used extensively singapore however onethird critically ill patients developed venous thromboembolism including pulmonary embolism despite use lowmolecularweight heparin prophylactic <NUMBER> thymosin α<NUMBER> could increase resistance glucocorticoidinduced death thymocyte <NUMBER> thymosin α<NUMBER> could also used immune enhancer sars patients effective controlling spread disease <NUMBER> <NUMBER> thymopentin tp<NUMBER> munox synthetic pentapeptide corresponding active site thymopoietin shown restore antibody production old mice <NUMBER> levamisole act either immunostimulant agent immunosuppressive agent depending upon dosing timing <NUMBER> luo et al <NUMBER> speculated nucleocapsid protein np sarscov played important role process virus particle assembly release might also bind human cyclophilin chymotrypsinlike <NUMBER>clike papainlike protease plp coronavirus encoded protein essential function coronaviral replication also additional function inhibition host innate immune responses <NUMBER> cinanserin old drug wellknown serotonin receptor antagonists could inhibit <NUMBER> chymotrypsinlike <NUMBER>clike protease promising inhibitor replication sarscov <NUMBER> flavonoids important class natural products several subgroups include chalcones flavones flavonols isoflavones <NUMBER> flavonoids herbacetin isobavachalcone quercetin <NUMBER>βdglucoside helichrysetin also found able block enzymatic activity merscov<NUMBER>clpro <NUMBER> papainlike protease plp human coronavirus novel viralencoded deubiquitinase ifn antagonist inhibition host innate antiviral immune response diarylheptanoids natural product extracted stem bark alnus japonica able inhibit papainlike protease sarscov <NUMBER> angiotensinconverting enzyme<NUMBER> ace<NUMBER> type integral membrane protein functions carboxypeptidase first human homolog ace besides ace<NUMBER> also functional receptor sarscov mediates virus entry cell binding spike protein <NUMBER> <NUMBER> zhang et al <NUMBER> reported covid<NUMBER> used ace<NUMBER> sole receptor entry use coronavirus receptors aminopeptidase n dipeptidyl peptidase entry blocking binding protein ace<NUMBER> important treatment sarscov infection <NUMBER> one recombinant human monoclonal antibody mab singlechain variable region fragments scfvs <NUMBER>r s<NUMBER> domain protein sarscov two nonimmune human antibody libraries mab could efficiently neutralize sarscov inhibit syncytia formation cells expressing protein expressing sarscov receptor ace<NUMBER> found sui et al <NUMBER> chloroquine many interesting biochemical properties including antiviral effects addition used viral infection <NUMBER> emodin anthraquinone compound derived genus rheum boosted protease inhibitor treatment hiv infection lopinavir lpv usually combined ritonavir rtv increase polygonum also virucidal agent <NUMBER> emodin could significantly block interaction protein sarscov ace<NUMBER> <NUMBER> promazine antipsychotic drug shares similar structure emodin found exhibit significant effect inhibiting replication sarscov <NUMBER> compared emodin promazine exhibited potent inhibition binding protein ace<NUMBER> findings suggested emodin promazine might able inhibit sarscov infectivity blocking interaction protein ace<NUMBER> therefore monoclonal antibody scfv<NUMBER>r chloroquine emodin promazine could used choices treatment covid<NUMBER> nicotianamine important metalligand plants <NUMBER> found novel angiotensinconverting enzyme<NUMBER> inhibitor soybean <NUMBER> another potential option used reduce infection covid<NUMBER> ribavirin broadspectrum antiviral agent routinely used treat hepatitis c <NUMBER> morgenstern et al <NUMBER> reported ribavirin interferonβ synergistically inhibited replication sarsassociated coronavirus animal human cell lines given adverse reactions lack vitro efficacy use ribavirin seriously considered treatment covid<NUMBER> even combination antiviral drugs combination lopinavir lpv ritonavir rtv widely used boosted protease inhibitor treatment hiv infection <NUMBER> kim et al <NUMBER> also reported successful case merscov disease treated triple combination therapy lpvrtv ribavirin ifnα<NUMBER>a remdesivir rdv nucleoside analog gs<NUMBER> reported inhibit human zoonotic coronavirus vitro restrain severe acute respiratory syndrome coronavirus sarscov vivo <NUMBER> recently antiviral activity rdv ifnβ found superior lpvrtvifnβ merscov vitro vivo <NUMBER> therefore use rdv ifnβ could better choice treatment covid<NUMBER> comparing triple combination lpvrtvifnβ however randomized controlled trials still needed determine safety efficacy remdesivir yamamoto et al <NUMBER> found nelfinavir could strongly inhibit replication sarscov arbidol derivatives arbidol mesylate reported antiviral activity pathogen sars cell cultures arbidol mesylate nearly <NUMBER> times effective arbidol reducing reproduction sars virus cultured cells <NUMBER> nitric oxide gas diverse biological activities produced arginine synthases <NUMBER> akerström et al <NUMBER> reported organic donor snitrosonacetylpenicillamine could significantly inhibit replication cycle sarscov concentrationdependent manner therefore inhalation could also chosen option treatment severely covid<NUMBER> infected patients table <NUMBER> computational methods utilized design engineering drugs <NUMBER> <NUMBER> low time requirements computational methods conducive high throughput screening available drugs identify potential drugs novel diseases well predict adverse effects novel drugs <NUMBER> development novel drugs timeconsuming process generally several years work required clinical approval <NUMBER> drug repositioning also known repurposing effective strategy combat novel diseases caused infectious agents spread rapidly <NUMBER> drugs approved disease safe human use effectiveness disease interest needs established <NUMBER> lifethreatening cases alternative medicine vaccine drug repurposing strategy particularly attractive however clinical trials necessary ensure treatment better placebo <NUMBER> lopinavir ritonavir identified earlier studies target main protease mpro sars virus protein sequences covid<NUMBER> main protease sarscov<NUMBER> mpro sarscov mpro <NUMBER> identical <NUMBER> several early studies similarities sequence potential target covid<NUMBER> sars mpro utilized build model structure sarscov<NUMBER> mpro <NUMBER> homology based models utilized screen library compounds predict nelfinavir approved antiviral protease inhibitor potential drug covid<NUMBER> <NUMBER> sequence similarity sarscov<NUMBER> mpro sars mpro sufficiently high build good model structure sarscov<NUMBER> mpro <NUMBER> <NUMBER> however predictions virtual screening studies binding energy calculations generally accurate highresolution experimental structure target available recent availability genomic sequence virus responsible covid<NUMBER> well experimentally determined threedimensional structure mpro utilized target virtual high throughput screening <NUMBER> indicating results confirm earlier preliminary reports based studies homologs drugs approved treatment viral infections also potential treatment covid<NUMBER> therefore approved antiviral drugs target proteases ranked potential effectiveness covid<NUMBER> novel candidates drug repurposing identified urgent need development antiviral drugs vaccines <NUMBER>ncov virus due high mortality rate patients epidemic pandemic outbreak new viral pathogens conventional method development drugs vaccination possible control timeconsuming process <NUMBER> <NUMBER> consequently rapid approach based insilico informatics become popular recent advances sequencing many pathogen genomes protein sequence databases <NUMBER> <NUMBER> <NUMBER> continuous increase patients high mortality rate sarscov<NUMBER> infection highlight urgent need development safe effective vaccine <NUMBER> aim use computational approach design antiviral drug vaccine candidates spike protein novel coronavirus sequence used design antiviral drug vaccine candidates antiviral drug design receptorbinding protein novel coronavirus present nterminal spike protein homology modeled used protein receptor <NUMBER> <NUMBER>c like proteinase <NUMBER>clpro plays role viral pathogenicity replication clevaging polyprotein inhibitors <NUMBER>clpro block clevage reaction thereby controlling viral replication pathogenicity <NUMBER> natural inhibitors used ligands docked homology modelled coronavirus receptor binding protein <NUMBER> vaccine design full sequence spike protein novel coronavirus used predict bcell tcell epitopes select best tcell epitopes based antigenicity used peptides docked human allele protein computational approach proposed drug vaccine design <NUMBER> explore suitable natural inhibitors nterminal receptorbinding domain spike protein spike protein sequences collected protein database also analyzed various bioinformatics tools attempting identify suitable vaccine candidates identifying bcell tcell epitopes <NUMBER> drug design tanshinone iia methyl tanshinonate identified natural inhibitors based docking score <NUMBER> vaccine design bcell epitope vllplvssqcvnlttrtqlppaytn found highest antigenicity fvflvllpl mhc classi allele fvflvllpl mhc classii allele identified best peptides based several alleles antigenicity scores <NUMBER> therefore identifies natural inhibitors putative antigenic epitopes might useful effective drug vaccine candidates eradication novel coronavirus structural proteins important targets vaccine antiviral drug development due indispensable function fuse enter host cell <NUMBER> sarscov<NUMBER> utilizes glycosylated spike protein gain entry host cells protein trimeric class fusion protein exists metastable prefusion conformation undergoes dramatic structural rearrangement fuse viral membrane hostcell membrane <NUMBER> <NUMBER> protein includes receptor binding s<NUMBER>subunit membrane fusion s<NUMBER>subunit s<NUMBER> subunit receptorbinding domain rdb specifically recognized host receptor s<NUMBER> subunit binds hostcell receptor prefusion trimer destabilized resulting shedding s<NUMBER> subunit state transition s<NUMBER> subunit stable postfusion conformation <NUMBER> critical function protein breakthrough vaccine design development great efforts made discovery antiviral drugs licensed therapeutic vaccine treatment sarscov<NUMBER> infection available market developing effective treatment sarscov<NUMBER> therefore research priority timeconsuming expensive design novel vaccines viruses use kits related antibodies <NUMBER> thus choosing method immuneinformatics efficient applicable deep analysis viral antigens band tcell linear epitope prediction evaluation immunogenicity virulence pathogens among analyzed bcell recognize activate defense responses viral infection tcell antibody reactions may recover extreme respiratory infection fig <NUMBER> immuneinformatics approaches identify band tcell epitopes surface glycoprotein sarscov<NUMBER> followed estimating antigenicity interactions human leukocyte antigen hla alleles taken li et al <NUMBER> four b cell epitopes two mhc classi nine mhc classii binding tcell epitopes showed highly antigenic features identified allergenicity toxicity physiochemical properties analysis confirmed specificity selectivity epitopes stability safety epitopes confirmed digestion analysis mutations observed selected band tcell epitopes across isolates different locations worldwide epitopes thus identified potential candidates vaccine development described li et al <NUMBER> noted covid<NUMBER> become global concern due widespread outbreaks lack treatment therefore necessary find evaluate treatment methods quickly case computer methods effective helpful predicted binding ranking drugs also useful interpret results ongoing clinical trials testing existing drugs effectiveness covid<NUMBER> notwithstanding limitations described several diseases traits may causally related ace<NUMBER> expression lung turn may mediate susceptibility sarscov<NUMBER> infection addition proteomewide mr analysis revealed proteins could lead changes ace<NUMBER> expression subsequent drug repositioning analysis highlighted several candidates may warrant investigations stress findings require replications validation studies especially part drug repositioning nevertheless believed work value given urgency address outbreak sarscov<NUMBER> study supported tabriz university medical sciences grant number <NUMBER> none declare increase viscosity hypercoagulable states lew kwek et al <NUMBER> thymosin α <NUMBER> sars cov increase resistance glucocorticoid induced death baumann badamchian et al <NUMBER> thymopentin hepatitis b restore antibody production duchateau servais et al <NUMBER> levamisole sars cov immunostimulant agent immunosuppressive agent joffe sukha et al <NUMBER> cyclosporine sars cov avian infectious bronchitis virus treatment autoimmune disorders luo luo et al <NUMBER> coronavirus specific treatments coronavirus protease inhibitors chymotrypsin like <NUMBER>c like inhibitors cinanserin sars cov serotonin receptor antagonist chen gui et al <NUMBER> flavonoids sars covmers cov antioxidant effects antiviral abilities diwan ninawe et al <NUMBER> papain like protease plp inhibitors diarylheptanoids sars cov antiinflammatory antioxidant antitumor park jeong et al <NUMBER> spike protein angiotensin converting enzyme <NUMBER> ace<NUMBER> blockers human monoclonal antibody sars cov treatment many solid tumors sui li et al <NUMBER> chloroquine sars cov prevention malaria adults savarino boelaert et al <NUMBER> emodin sars cov pancreatic disease inflammatory diabetes vickers <NUMBER> promazine sars cov using paranoid manicdepressive conditions cauwenberghs feijge et al <NUMBER> coronavirus disease covid<NUMBER> outbreak began late december <NUMBER> wuhan capital hubei province china scientists world attempting investigate novel virus known <NUMBER>ncov highly contagious discover effective interventions control prevent disease heymann <NUMBER> huang et al <NUMBER> coronaviruses positivesense singlestranded rna viruses ssrna þ belonging coronaviridae family human coronaviruses hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> hcovhku<NUMBER> observed almost onethird common cold lim et al <NUMBER> however recently cases human coronavirus infections led fatal endemics including sars severe acute respiratory syndrome mers middle east respiratory syndrome covid<NUMBER> common diseases humans animals whose belong genus betacoronavirus coronaviridae family altawfiq et al <NUMBER> far novel covid<NUMBER> caused <NUMBER> illnesses <NUMBER> deaths worldwide <NUMBER> genome size virus <NUMBER> kb encodes structural nonstructural proteins like coronaviruses structural proteins include protein spike e protein envelope protein membrane n protein nucleocapsid ahmed et al <NUMBER> increasing rate covid<NUMBER> disease high morbidity necessitate development specific safe vaccine candidate soon possible little known actually pathogenesis virus therefore immunoinformaticsbased approach investigate immunogenic epitopes vaccine design using data proteins sequencing covid<NUMBER> required n protein structural protein associates replicasetranscriptase complexes binds genomic rna coronaviruses cong et al <NUMBER> protein multifunctional one crucial structural components coronaviruses n protein structural antigenic protein involved packaging transcription replication coronaviruses <NUMBER> data showed n protein suitable candidate targeting drug vaccine design protein conserved antigenic multifunctional <NUMBER> leung et al concluded n protein suitable vaccine candidate sarscov induce strong antibody process may trigger cytokine production leung et al <NUMBER> coronaviruses protein also key role assembly virions sarscov protein interact n protein make network interactions genomic rna et al <NUMBER> ong et al covid<NUMBER> antigens n proteins introduced vaccine candidate <NUMBER> protein also studied epitope vaccine candidate sarscov <NUMBER> open reading frame <NUMBER>a orf<NUMBER>a required viral replication virulence sars cov severe induction proinflammatory cytokine sign sarscov merscov infections orf<NUMBER>a activates proil<NUMBER>b gene expression il<NUMBER>b secretion leads severe lung injury siu et al <NUMBER> also orf<NUMBER>a important role sarscov assembly budding participation e proteins mcbride fielding <NUMBER> proteins involved pathogenesis covid<NUMBER> virus also high antigenicity chan et al <NUMBER> siu et al <NUMBER> xu et al <NUMBER> study e n orf<NUMBER> orf<NUMBER> orf<NUMBER>a proteins evaluated available bioinformatics tools designing efficient multiepitope vaccine stimulation immune responses covid<NUMBER> infection since covid<NUMBER> recently discovered little immunological information available preliminary studies based phylogenetic analyses covid<NUMBER> whole genome suggested virus similar sarscov <NUMBER> identify <NUMBER> <NUMBER> given apparent similarity two viruses could concluded previous studies protective immune responses sarscov may useful developing vaccine covid<NUMBER> previous studies suggested humoral cellular immunity play important roles protective responses virus deming et al <NUMBER> yang et al <NUMBER> studies revealed formation antibodies n protein sarscov immunogenic protein highly expressed infection relatively common patients infected virus liu et al <NUMBER> lin et al <NUMBER> although antibodies effective shorter lifespan recovering patients addition specific humoral immunity shown cd <NUMBER>þ cd <NUMBER>þ responses provide longlasting protection covid<NUMBER> studies showed besides antibodymediated immune response cellular immunity critical induce protectivity infections liu et al <NUMBER> concept multiepitope vaccine efficiently identify assemble b tcell epitopes capable stimulating immune system therefore induce potent effective arms immune responses peptides epitopes shown desirable candidates vaccine development due relatively easy production chemical stability lack infectious potential patronov doytchinova <NUMBER> experimental design production multiepitope vaccines improved dramatically recent years vaccines mainly made bcell cd <NUMBER>þ cytolytic tcell ctls cd <NUMBER>þ helper tcells htls epitopes chiarella et al <NUMBER> since antigenic epitopes protein could predicted detected therefore whole protein suitable stimulate immune response testa philip <NUMBER> zheng et al <NUMBER> development vaccine candidate covid<NUMBER> complex pathogenic mechanisms numerous pathogenic factors considered vaccine formulation present study aimed design novel multiepitope fusion protein nucleocapsid orf<NUMBER>a membrane protein nom containing efficient antigenic epitopesrich domains biological activity engineered fusion protein assessed bioinformatics tools using interaction vaccine candidate innate immune system receptor tlr<NUMBER> cellular immune system receptor hlaa ã <NUMBER> strongly believe outcome present report provide potential vaccine candidate <NUMBER>ncov study designed suitable vaccine candidate covid<NUMBER> exploiting programs reverse vaccinology figure <NUMBER> first amino acid sequences proteins retrieved national centre biotechnology information ncbi wwwncbinlmnihgov fasta format performed subsequent analysis table <NUMBER> selected six proteins covid<NUMBER> virus table <NUMBER> essential role virulence replication virus previous studies highlighted necessity proteins coronaviruses function antigenic analysis proteins three proteins n orf<NUMBER>a selected final analysis <NUMBER>d sequencebased screening server rankpep used identify tcell epitopes reche reinherz <NUMBER> server predicts peptide binders mhc molecules protein sequences using positionspecific scoring matrix pssm selected hla class alleles selection panel rankpep server prediction epitopes hla class prediction epitopes hla class ii considered drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> drb<NUMBER> ã <NUMBER> cover hla variability <NUMBER> human population worldwide kruiswijk et al <NUMBER> prediction bcell epitopes amino acid sequence analyzed using bepipred kolaskar tongaonkar antigenicity httpwwwiedborg servers vita et al <NUMBER> bepipred linear epitope prediction uses hidden markov model amino acid propensity scales methods kolaskar tongaonkar evaluate protein b cell epitopes using physicochemical properties amino acids frequencies occurrence recognized b cell epitopes kolaskar tongaonkar <NUMBER> mirza et al <NUMBER> according prediction results servers used b cell epitopes hla class ii epitopes high scores extracted combined generate multi antigenicity designed recombinant protein predicted using vaxijen v<NUMBER> server vaxijen classified antigens based auto crosscovariance acc transformation protein sequences uniform vectors principal amino acid properties novel alignmentindependent method overcome limitations alignmentdependent sequence methods doytchinova flower <NUMBER> prediction vaccine candidate allergenicity essential allergenicity designed protein computed allertop httpwwwddgpharmfacnetallertop allertop method predicts recombinant protein allergenicity auto crosscovariance acc describe residue hydrophobicity size abundance helixand bstrand forming propensities dimitrov et al <NUMBER> allertop v<NUMBER> highest accuracy <NUMBER> compared several servers allergen prediction dimitrov et al <NUMBER> analyzed parameters consisted molecular weight theoretical pi amino acid composition atomic composition extinction coefficient estimated halflife instability index aliphatic index grand average hydropathicity evaluated protparam online server httpusexpasyorg tools protparamhtml gasteiger et al <NUMBER> gor used designed protein secondary structure prediction httpsnpsaprabiibcpfrcgibinnpsaautomat plpagenpsanpsagor<NUMBER>html kloczkowski et al <NUMBER> gor<NUMBER> predict protein secondary structure using information theory tertiary structure built using galaxy web galaxyweb server httpgalaxyseoklaborg tbm based tbm method server detects similar proteins alignment target sequence make model finally perform model refinement shin et al <NUMBER> bestmodeled structure refined using galaxy refine server httpgalaxyseoklaborgcgibinsubmitcgityperefine galaxy refined model molecular dynamics simulation method showed one best performances improving protein structure quality analysis final <NUMBER> model made using molprobity prosa ramachandran plot ramachandran plot obtained rampage calculates torsional angles residuebyresidue protein indicates residues allowed favored outlier regions oberholser <NUMBER> prosa web used recognize errors generated <NUMBER> models using atomic coordinates model prosa web created zscore overall model quality plot residue energies proteins wiederstein sippl <NUMBER> clash analysis important validation proteins molprobity structurevalidation web service calculates clash score proteingeometry score poor rotamers ramachandran plot molprobity score interaction antigen epitopes antibodies essential eliminate infection conformational epitopes important prevalent epitopes recognized antibodies conformational epitope prediction methods require <NUMBER> structures proteins discontinuous epitopes recombinant protein predicted using ellipro server webbased predicts discontinuous epitopes based proteinantibody interactions ellipro server predicts conformational linear b cell epitopes using thorntons method modeller program blast search pdb predict visualize antibody epitopes ponomarenko et al <NUMBER> crystallographic structures tlr<NUMBER> pdb id <NUMBER>z<NUMBER> kim et al <NUMBER> hlaa ã <NUMBER> pdb id <NUMBER>wjl culshaw et al <NUMBER> obtained pdb database berman et al <NUMBER> structures cleaned crystallographic waters cocrystallized molecules deleted monomer forms receptor kept structures two receptors nom protein prepared dock prep tool ucsf chimera software pettersen et al <NUMBER> hydrogen atoms charge added structures make ready next step next step stabilize relax structures aqueous physiological environment monomer form receptors nom protein simulated <NUMBER> ns details md simulation explained later md simulation receptor nom recombinant protein last frame trajectory simulation extracted used input structures proteinprotein molecular docking patchdock webserver schneidmanduhovny et al <NUMBER> default parameters used predict best positions orientations two proteins highest number favorable interactions afterward top <NUMBER> solutions subjected firedock webserver andrusier et al <NUMBER> mashiach et al <NUMBER> refine interaction proteinprotein complexes resulted molecular docking top two complexes coronavirus nom proteintlr<NUMBER> nom recombinant proteinhlaa ã <NUMBER> complexes chosen based global energies four complexes taken next step md simulation performing proteinprotein molecular docking finding best orientations vaccine candidate receptor proteins interact one another two bestscored complexes subjected md simulation md simulations done gromacs <NUMBER> package abraham et al <NUMBER> oplsaa force field jorgensen et al <NUMBER> monomer form protein also docked complexes placed center triclinic box distance <NUMBER> nm edges solvated tip<NUMBER>p water model jorgensen et al <NUMBER> sodium chloride ions added produce neutral physiological salt concentration <NUMBER> mm system energy minimized using steepest descent algorithm fmax found smaller <NUMBER> kjmol à<NUMBER> nm à<NUMBER> covalent bonds constrained using linear constraint solver lincs algorithm hess et al <NUMBER> maintain constant bond lengths longrange electrostatic interactions treated using particle mesh ewald pme method darden et al <NUMBER> essmann et al <NUMBER> cut radii coulomb van der waals shortrange interactions set <NUMBER> nm <NUMBER> ps nvt constant number particles n volume v temperature <NUMBER> ps npt constant number particles n pressure p temperature equilibrations performed system necessary equilibrations <NUMBER> ns production run performed four complexes finally simulations carried periodic boundary conditions pbc set xyz coordinates ensure atoms stayed inside simulation box subsequent analyses performed using gromacs utilities vmd humphrey et al <NUMBER> uscf chimera also plots figures created using daniels xl toolbox v <NUMBER> addin kraus <NUMBER> binding free energies proteinprotein complexes calculated molecular mechanicspoissonboltzmann solventaccessible surface area mmpbsa method kollman et al <NUMBER> using gmmpbsa package kumari et al <NUMBER> method binding free energy result free energy complex minus sum free energies ligand protein case nom recombinant protein defined ligand immune receptors defined receptors mmpbsa calculation done every ns simulation trajectories results several studies shown strong virusspecific tcell response required elimination respiratory virus infections sarscov influenza parainfluenza studies conclude future vaccine interventions also consider strategies enhance cell response provide robust longterm memory channappanavar et al <NUMBER> janice oh et al <NUMBER> studies shown high levels cell responses n protein found <NUMBER> years patients recovery peng et al <NUMBER> antibodies essential combat sarscov infection body needs sarscov specific cd<NUMBER> þ helper cells produce specific antibodies also cd<NUMBER> þ cytotoxic cells important recognizing killing infected cells especially lungs infected individuals used rankpep server covers almost hla supertypes predicted different epitops n orf<NUMBER>a proteins sequence according hla hla ii alleles antigenic epitopes high binding affinity score predicted summarized table <NUMBER>ab successful vaccination viruses measles rubella reflects importance protective antibodies protection virus infection coronaviruses depends simulation neutralizing antibodies addition cellmediated immunity cytotoxic lymphocytes kill infected cells antibodies potential eliminate infected cells prevent infectious virus infecting cell neutralization sarscovspecific neutralizing antibodies block viral entry d€ orner radbruch <NUMBER> hsueh et al <NUMBER> study linear epitope prediction bepipred server employed bepipred analysis revealed several continuous predicted epitopes n orf<NUMBER>a proteins crosschecking predicted epitopes sequence three proteins also predicted kolaskar tongaonkar antigenicity linear bcell epitopes represented table <NUMBER> given cellular humoral immune responses essential coronaviruses infection janice oh et al <NUMBER> finally epitopes shared b cell tcell selected main strategy present study design construct novel multiepitope protein covid<NUMBER> based silico methods elicit humoral cellular immune responses due low immunogenicity epitope chose epitoperich domains generate diverse robust response wieser et al <NUMBER> based silico analysis five epitoperich domains including highly scored shared epitopes bcell epitopes selected joined three aaa linker table <NUMBER> schematic diagram designed vaccine domains linkers sites shown figure <NUMBER> prediction vaccine candidate antigenicity represents numerical criterion capability vaccine bind band tcell receptors increase immune response host cell vaxijen v<NUMBER> used predict antigenicity designed protein vaxijen analysis nom protein showed potent antigenicity <NUMBER> <NUMBER> threshold results indicate designed protein sequences without adjuvant antigenic allergen proteins induce ige antibody response dimitrov et al <NUMBER> designed vaccine candidate must show allergic reaction body allergenicity sequence predicted using allertop tool based prediction approaches allertop protein recognized allergen primary structure analysis nom designed protein <NUMBER> aa molecular weight <NUMBER> total number positively charged residues arg þ lys negatively charged residues asp þ glu <NUMBER> <NUMBER> respectively theoretical isoelectric point pi calculated <NUMBER> instability index <NUMBER> indicates designed protein high stability initiation immunogenic reaction instability index ii <NUMBER> classifies protein stable aliphatic index nom recombinant protein calculated <NUMBER> indicates protein stability several temperatures natively unfolded protein regions alphahelix important forms structural antigens arranged native structure thus identified antibodies produced response infection shey et al <NUMBER> composition predicted secondary structure nom multiepitope vaccine candidate <NUMBER> alpha helix <NUMBER> extended strand <NUMBER> random coil information indicates designed protein suitable vaccine candidate threedimensional structure modeled galaxyweb designed protein figure <NUMBER>a model used evaluation refinement validation model prosaweb ramachandran plot molprobity used compare analyze protein structure prosa web determined zscore best predicted <NUMBER> model figure <NUMBER>b zscore nom predicted model <NUMBER> within range scores typically found native proteins similar size ramachandran plot indicates residues found favored allowed regions <NUMBER> <NUMBER> outlier region shows quality designed model satisfactory phe <NUMBER> asn<NUMBER> tyr<NUMBER> lys<NUMBER> asp<NUMBER> ser<NUMBER> ser<NUMBER> his<NUMBER> tyr<NUMBER> residues observed allowed outlier regions ramachandran plot figure <NUMBER>c molprobity analysis allatom clash score <NUMBER> molprobity score <NUMBER> structural images created using pymol pymol molecular graphics system version <NUMBER> schr€ odinger llc ellipro server used predicting conformational bcell epitopes <NUMBER> structure nom recombinant protein discontinuous bcell epitopes predicted scores ranging from<NUMBER> <NUMBER> amino acid residues number residues sequence location well scores listed tables <NUMBER> graphical representation discontinuous epitopes displayed figure <NUMBER> vaccine interact different receptors immune system docked designed final constructs nom tlr<NUMBER> hlaa ã <NUMBER> receptors interaction receptors nom recombinant protein induce different immune responses achieve stable relaxed state nom recombinant protein immune receptors md simulation <NUMBER> ns performed structure simulations ensure structures stable enough used proteinprotein molecular docking <NUMBER> ns production run shown figure <NUMBER> rmsd root mean square distance values monomers show backbone structure tlr<NUMBER> pdb id <NUMBER>z<NUMBER> rigid stable structure nom recombinant protein also reached stability <NUMBER> ns considerable structural change backbone structure hlaa ã <NUMBER> pdb id <NUMBER>wjl however showed big spikes rmsd values three structures visually inspected considered stable enough next step project find best orientation optimal interaction nom protein immune receptors decided use proteinprotein molecular docking used patchdock webserver concentrates recognizing matching patterns surfaces proteins put best possible positions afterward top <NUMBER> best solutions subjected firedock webserver refine docked structures firedock algorithms refine docked complexes sidechain rearrangement soft rigidbody optimization ranking docked complexes based shortrange longrange attractive repulsive interaction energies residues two proteins summed global energy binding energy complexes considered global energy main criterion choosing best complexes chose two topscored solutions best global energy shown table <NUMBER> solution numbers <NUMBER> <NUMBER> nomtlr<NUMBER> complex solution numbers <NUMBER> <NUMBER> nomhlaa ã <NUMBER> complex chosen calculations total energy plots simulations shown figure <NUMBER> results showed strong interaction designed protein amino acids receptors interactions binding receptors docked nom protein visualized using ucsf chimera program residues hlaa ã <NUMBER>glu <NUMBER> asn <NUMBER> gly <NUMBER> asn <NUMBER> glu <NUMBER> pro <NUMBER> participated proteinprotein molecular docking <NUMBER> solutions chosen md simulation solution numbers <NUMBER> <NUMBER> nom proteinhlaa ã <NUMBER> complex solution numbers <NUMBER> <NUMBER> nom proteintlr<NUMBER> complex simulated <NUMBER> ns examine stability throughout simulations period rmsd values protein analyzed shown figure <NUMBER> protein different rmsd values backbone atoms considerable movements simulations reason interactions get optimized rearranged introducing water molecules physiological conditions rmsd values tlr<NUMBER> nom proteintlr<NUMBER> complexes values hlaa ã <NUMBER> nom proteinhlaa ã <NUMBER> complexes stable average values reach high values however rmsd values nom protein every complex reach high values means structure vaccine movements refine interactions immune receptors however interactions nom recombinant protein immune receptors quite strong mmpbsa binding energy calculations exhibit great binding energies shown table <NUMBER> van der waals electrostatic energies complexes strong enough keep two proteins contact moreover deviation value small means interactions stable consistent throughout simulations another word higher scale rmsd values consistent binding energies show structure nom protein well optimized interacting immune receptors addition analysis described analyze fluctuations backbone atoms structures proteins decided perform rmsf root mean square fluctuation analysis analysis average value fluctuation residue simulation plotted figure <NUMBER> shown figure <NUMBER>a rmsf values nom recombinant protein five simulations indicate fluctuation monomer form vaccine many regions considerably complex forms direct indication nom recombinant protein much stable complex two immune receptors furthermore rmsf values nom recombinant protein complex hlaa ã <NUMBER> lower compared nom recombinant protein complex tlr<NUMBER> also evidence binding energies also lower conclude nom recombinant protein bind hlaa ã <NUMBER> better immune receptor figure <NUMBER>b figure <NUMBER>c rmsf values monomer forms immune receptors show lower values compared complex forms behavior exactly opposite nom designed protein indication structures stable natural function structures considerably change get contact designed nom protein furthermore structural illustration monomer forms also complex forms vaccine immune receptors figure <NUMBER> shows vaccine fill cavities bind tightly proved binding energies covid<NUMBER> pandemic much health crisis leads political social economic crisis world development safe effective vaccine could reduce rate infection immunoinformatics methods valuable reducing time cost vaccine design fields life sciences predicted validated nom recombinant protein hlaa ã <NUMBER> tlr<NUMBER> receptors evaluation based vaccine candidate structural analysis molecular docking md simulations study nomtlr<NUMBER> nomhlaa ã <NUMBER> complexes stable natural function strong molecular interactions around <NUMBER> ns higher binding energy even md simulation <NUMBER> ns confirmed stability specificity nomtlr<NUMBER> nomhlaa ã <NUMBER> interaction vaccine candidate stimulate cellular humoral immunity given b tcell epitopes selected final construct taken together according physicochemical evaluations well structural immunological analyses nom recombinant protein could considered possible vaccine candidate covid<NUMBER> <NUMBER> vaccine formulations used protect high mortality covid<NUMBER> also currently research phase <NUMBER> different strategies studied clinical stage phases <NUMBER> <NUMBER> inactivated attenuated virus vaccines classic method used viral vaccines amanat krammer <NUMBER> chen et al <NUMBER> ii nucleic acid vaccines dna rna prepared using nucleic acid information obtained rapid sequencing entire genome virus mrna vaccine first vaccine enter clinical phase<NUMBER> safety trials saif <NUMBER> iii subunit vaccines recombinant proteinbased vaccines protein first main target obtained using antigenic proteins virus using recombinant dna technologies peptidebased vaccines produced epitopes antigenic proteins virus lu <NUMBER> saif <NUMBER> iv viralvectorbased vaccines alternative option using s<NUMBER> region receptor binding domain rbd get rid problems caused using spike protein ahmed et al <NUMBER> amanat krammer <NUMBER> et al <NUMBER> although epitopebased peptide vaccines known lower immunogenicities compared vaccine types increased utilization adjuvants become important subunit vaccine alternative owing versatility low production costs lower allergenic reactogenic responses therefore developing epitopebased peptide vaccine sarscov<NUMBER> along vaccine alternatives great importance review stages detection development production biological evaluation peptides used vaccine formulations covid<NUMBER> explained detail difficulties experienced development epitopebased peptide vaccines advantages disadvantages vaccines also discussed development vaccine sarscov<NUMBER> one important strategies prevent covid<NUMBER> control outbreak today various biotechnology companiesuniversities putting great efforts vaccine development studies according data may <NUMBER>th <NUMBER> <NUMBER> candidate vaccines based nonreplicating viral vector dna inactivated virus rna nonreplicating viral vector protein subunit clinical evaluation <NUMBER> candidate vaccines based different technologies preclinical evaluation covid<NUMBER> among ongoing preclinical vaccine candidate studies <NUMBER> dna <NUMBER> inactivated viruses <NUMBER> live attenuated viruses <NUMBER> ozkan <NUMBER> shang et al <NUMBER> however stated important features expected developed vaccine candidate longterm protection antigenspecific cellular immunity ability induce systemic immune system ozkan <NUMBER> inactivated virus vaccines consist virus particles produced culture lost ability cause disease virus killed using heat uv irradiation chemicals formaldehyde etc reduce virulence vaccineinduced infection prevented largescale cultures sarscov<NUMBER> created inactivated viruses obtained cultures researchers via known methods although inactivated virus vaccines advantages safety easier preparation inducing hightiter neutralizing antibodies important disadvantage potentially inappropriate highly immunosuppressed patients roper rehm <NUMBER> shang et al <NUMBER> additionally preparing inactivated virus vaccine requires large quantities infectious virus callaway <NUMBER> recently sinovac biotech consortium produced vaccine candidate purified inactivated sarscov<NUMBER> viruses shown study specific antibodies sarscov<NUMBER> detected <NUMBER> different animals immunized inactivated virus vaccine candidate gao et al <NUMBER> attenuated vaccines prepared mutating virus result serial treatment human animal cells laboratory decrease ability cause disease one important advantages attenuated vaccines offer one antigenic component host induce various immunological effectors virus reported many research institutionsuniversities chinese centers disease control prevention wuhan institute virology chinese academy sciences zhejiang university codagenix inc serum institute india ltd carrying attenuated vaccine studies subunit vaccines consisting purified antigens advantages easy production safety ability induce cellular humoral immune response roper rehm <NUMBER> shang et al <NUMBER> however subunit vaccines may require adjuvants immunostimulatory molecules delivered alongside vaccine multiple doses increase immunogenicity protective activity callaway <NUMBER> cov proteins shown studies ability generate protective antibodies identified favorite targets subunit vaccine development sarscov enjuanes et al <NUMBER> navasmartin weiss <NUMBER> studies similar subunit vaccines sarscov known experimental animals protected infection although vaccine candidates tested humans yet callaway <NUMBER> similarly various studies accepted s<NUMBER> protein andor rbd element sarscov<NUMBER> considered foremost antigen vaccine development studies covid<NUMBER> callaway <NUMBER> lon et al <NUMBER> rogers et al <NUMBER> shang et al <NUMBER> tang et al <NUMBER> many research teams including biotechnology companies universities research centers etc working effective vaccines containing viral protein subunits covid<NUMBER> lon et al <NUMBER> rogers et al <NUMBER> tang et al <NUMBER> viral vector vaccines prepared inserting dna fragment highly infected virus another harmless virus one advantages vaccine type induce high cellular humoral immune responses shang et al <NUMBER> also reported viral vector vaccines safe similar subunit vaccines immunogenicity viral vector vaccines highly analogous live attenuated vaccines wu <NUMBER> university oxford us national institutes health nih collaborators produced adenovirus expressing sarscov<NUMBER> protein van doremalen et al <NUMBER> study conducted mice rhesus macaques showed vaccine candidate induced immune response sarscov<NUMBER> additionally vaccine efficiency study showed viral load decreased lung vaccinated animals signs virus replication lung damage observed vaccinated animals compared control van doremalen et al <NUMBER> <NUMBER> mrna vaccines mrna vaccines previously investigated different diseases successful results easier design translate clinical trials ozkan <NUMBER> roper rehm <NUMBER> shang et al <NUMBER> although mrna vaccines advantages easier design inducing strong immune response important disadvantage extremely unstable physiological conditions rauch et al <NUMBER> moderna consortium consisting fudan university shanghai jiaotong universitybluebird biopharmaceutical company carry studies mrna vaccines covid<NUMBER> modernas mrna vaccine encode protein consortium working two different mrna vaccines express protein viruslike particles apart reported literature various companies universities research centers also working mrna vaccines dna vaccines antigen antigens expressed plasmid dnas difference mrna vaccines coding antigens plasmid dna although stable mrna vaccines easy design ability form highly neutralized antibodies reported repeat doses dna vaccine may cause toxicity rauch et al <NUMBER> study usa israel research teams dnabased vaccines developed express protein sarscov<NUMBER> different forms yu et al <NUMBER> study humoral cellular immune responses developed animals immunized dna vaccine additionally virus challenge study showed vaccine encoding fulllength protein decreased viral load bronchoalveolar lavage nasal mucosa decreased comparison control group yu et al <NUMBER> outlined traditional vaccines covid<NUMBER> include liveattenuatedinactivated sarscov<NUMBER> however lots disadvantages use wholeorganism vaccine especially immunosuppressed patients presence immunologically redundant biological components biological impurities roper rehm <NUMBER> shang et al <NUMBER> thus subunit vaccines become widespread especially research area due safety profiles easier production although proteins main type subunit vaccines peptides small fragments proteins also used subunit vaccines callaway <NUMBER> epitopebased peptide vaccines used overcome problems possible side effects related heterogeneous multicomponent vaccine considered alternative conventional vaccines peptides used vaccines synthesized chemically using amino acid sequences antigenic proteins targeted pathogens vaccines contain antigenic peptide epitopes <NUMBER> amino acids high immunogenicity recognition antigenic peptides immune system triggers immune response stimulating cytotoxic cells b cells simultaneously moisa kolesanova <NUMBER> although epitopebased peptide vaccines significantly limit allergenic reactogenic complications low molecular weight easy clearance body make peptides lower immunogenic overcome using carriers adjuvants peptide vaccine formulations increase immunogenicity decrease dose moisa kolesanova <NUMBER> epitopebased peptide vaccines many advantages vaccines easier cheaper produce peptides compared traditional vaccines epitopebased peptide vaccines standardized batchtobatch differences low since structure peptide wellknown structurefunction relationships correlated much easier conventional vaccines also structure peptide easily modified obtain multiepitope conjugated structures moisa kolesanova <NUMBER> sesardic <NUMBER> although epitopebased peptide vaccine formulation basically contains antigen adjuvant development vaccine follow pathway prove effect protection disease first stage design amino acid sequence antigenic peptide proteins pathogen although experimental techniques silico methods used together determine epitope silico methods become prevalent prediction epitopes due time costeffective nature compared experimental techniques li et al <NUMBER> sancheztrincado et al <NUMBER> second stage peptide produced high purity based chemical biological methods chemical synthesis peptide routine method especially peptides less <NUMBER> amino acids behrendt et al <NUMBER> appropriate adjuvant selection third stage mixing conjugating peptide augment immune response peptide yang kim <NUMBER> adjuvant used epitopebased peptide vaccine modulate interactions peptide different cells immune system guy <NUMBER> last stage evaluation vaccine formulation vitro vivo determine immune response peptide mozdzanowska et al <NUMBER> important comprehend working mechanism vaccine formulation relate structure interactions immune system cells however vivo vitro evaluation epitopebased peptide vaccine gives limited information without challenge studies pathogen swee et al <NUMBER> therefore sufficient immune response obtained vivo vitro studies vaccine formulation challenged pathogen reveal protection efficiency preclinical clinical studies swee et al <NUMBER> zhao et al <NUMBER> immune system large network interacts contains thousands molecular networks responses creates tomar de <NUMBER> genomic sequencing clinical practice large amounts accumulated data generated epidemiological data may cause confusion order use large data effectively scientists must stored managed analyzed bahrami et al <NUMBER> situation brought immunology computer sciences together formed immunoinformatics pourseif et al <NUMBER> tomar de <NUMBER> immunoinformatics new important area large database create suitable options experimental stage bahrami et al <NUMBER> immunoinformatics includes silico approach stable less costly method shorter period time conventional laboratory techniques development vaccines ali et al <NUMBER> khan et al <NUMBER> development vaccines using conventional techniques entails high cost long period <NUMBER> years parvizpour et al <NUMBER> approach specific regions designed prevent unwanted immune responses longterm immune responses required responses costtime effectiveness parvizpour et al <NUMBER> first step silicoapproached immunoinformatic epitopebased peptide studies identify viruss antigen stimulates antibodies targets important immunity kibria et al <NUMBER> structural proteins spike envelope e membrane nucleocapsid n encoded sarscov merscov sarscov<NUMBER> genomes belonging betacoronavirus genus suitable candidates antigen selection ahmed et al <NUMBER> since b cell epitopes immunogenic site antigen produce humoral cellular immune responses regions predicted parvizpour et al <NUMBER> different webbased tools available epitope design bui et al <NUMBER> tools provide user convenience combining methods developed determination epitopes kolaskar tongaonkar method semiexperimental method uses physicochemical properties amino acids experimentally determined data amino acids b cell epitope design kolaskar tongaonkar <NUMBER> bepipred<NUMBER> server estimates b cell epitopes crystal structure derived data hence providing higher quality strong prediction power jespersen et al <NUMBER> basically methods used b cell epitope estimation based parameters flexibility hydrophilicity polarity exposed surfaces antigenic propensity accessibility peptide chains vita et al <NUMBER> method used cell epitope prediction generally uses mhc class <NUMBER> binding tap transport efficiency proteasal processing algorithms kibria et al <NUMBER> vita et al <NUMBER> cell epitope prediction approach takes advantage crossreactivity hla class <NUMBER> regions alleles predict strong epitopes without affected hla polymorphism ethnicity grifoni et al <NUMBER> populationbased epitope estimation made distribution mhc alleles defined population examined estimated population coverage percentage potential individuals immune identified cell epitope revealed ahmed et al <NUMBER> epitopes transformed <NUMBER>d structure docking analysis performed show interaction determined epitopes different hlas oany et al <NUMBER> another stage allergenicity test step vital predicting allergic reactions may develop giving vaccine body oany et al <NUMBER> epitopebased peptide vaccine candidates identified many studies merscov sarscov sarscov<NUMBER> using silico approaches although approved vaccine available yet merscov seen first time <NUMBER> yong et al <NUMBER> proteinbased studies preclinical level quite high cho et al <NUMBER> studies large number possible epitopes identified using silico methods badawi et al <NUMBER> ibrahim kafi <NUMBER> shi et al <NUMBER> similarly large number vaccine development studies using silico approach also conducted sarscov wang et al <NUMBER> ying et al <NUMBER> emerged <NUMBER> spread <NUMBER> countries <NUMBER> cases almofti et al reported <NUMBER> b cell epitopes <NUMBER> cell epitopes gave best scores could good vaccine candidates determined silicobased epitope design study using ncbi iedb tools almofti et al <NUMBER> vaccine development studies also conducted rapidly sarscov<NUMBER> le et al <NUMBER> covid<NUMBER> outbreak announced pandemic within immunoinformatic approach many studies reported b cell epitopes proposed potential vaccine candidates sarscov<NUMBER> baruah bose <NUMBER> joshi et al <NUMBER> kiyotani et al <NUMBER> silicobased study conducted kalita et al identified <NUMBER> nontoxic nonallergenic thermostable epitopes <NUMBER> proteins kalita et al <NUMBER> stage vaccine development studies initiated covid<NUMBER> given detail section <NUMBER> light studies data immunoinformatics offers strong candidates could used new vaccine designs sobolev et al <NUMBER> many different databases pieces software vaccine design validation parvizpour et al <NUMBER> available prediction epitopebased peptides fast accurate possible strong immunity minimal side effects parvizpour et al <NUMBER> vitro vivo tests conducted b cell epitopebased peptides predicted silico approaches following synthesis generally peptides chemically synthesized using two strategies solutionand solidphase synthesis jensen et al <NUMBER> useful popular strategy solidphase method named merrifield solidphase peptide synthesis spps developed r b merrifield merrifield <NUMBER> two main types solidphase peptide synthesis derived name nterminal protecting groups amino acids determine chemistry method used boc fmoc chemistry since removing boc protecting group requires working strong acids hydrogen fluoride hf fmoc chemistry preferred spps fmoc chemistry performed less extreme conditions boc chemistry removing side protecting groups cleaving peptide resin solidphase occur chan white <NUMBER> resin consisting crosslinked polymeric beads swelling property solvents dmf dcm contains various linker groups binds amino acids cterminal amino acid peptide binds resin beads peptide constructed stepwise addition amino acids nterminus end synthesis peptide cleaved resin side chain protecting groups amino acids removed simultaneously stawikowski fields <NUMBER> peptide needs characterized synthesis lcesims malditofms qtofms methods used extensively molecular weight determination synthesized peptide lcesims qtofms systems frequently used routine also allow method validation determination purity method development purification procedure ftir spectroscopy used determine functional group characteristics peptide twoand threedimensional structure peptide illuminated circular dichroism spectroscopy addition measurement methods uvvis fluorescence spectrometry also used characterization peptide separated impurities proper purification techniques reversed phase preparative hplc mostly used technique purification peptides ion exchange affinity chromatography also used purification special peptides production vaccine covid<NUMBER> studies antigenic peptides chemically synthesized andor designed silico methods showing possible antigenic activities detailed peptide epitopebased vaccine development studies focused protein studies determination right peptide sequence vaccine covid<NUMBER> based silico studies synthesis isolation antigenic peptides part review information given peptide sequences used sarscov<NUMBER> study fast et al revealed cell b cell epitopes identified study used vaccine formulations sarscov<NUMBER> higher immune responses detection neutralizing antibodies fast chen <NUMBER> study reported <NUMBER> sequence sygfqptngvgyq protein highest mhc presentation b cell epitope stated data obtained study important identifying strong epitopebased vaccine candidates well interaction clinical results provide information relationship antigen presentation scores vaccine efficacy fast chen <NUMBER> bojin et al identified multiepitope peptide vaccine candidate sarscov<NUMBER> could potential stimulate cell immune responses bojin et al <NUMBER> short epitopes capacity bind multiple hla alleles selected mhc classi mhc classii restricted epitopes attached cathepsinsensitive linker peptide llsvgg long synthetic peptide sequence identified syfiasfrlfartrsllsvggylqprtfll a<NUMBER> allele mhci epitopcathepsinsensitive linkerdrb<NUMBER> allele used vaccine candidates mhcii epitop bojin et al <NUMBER> study li et al interactions sarscov<NUMBER> band tcell epitopes human hla alleles surface glycoprotein studied indicated vgyqpyrvvvlsfel mhcii epitope peptide sequence highest antigenicity score another investigation examined antigenic peptide sequences sarscov<NUMBER> multiple epitope structure proteins e studied feng et al <NUMBER> <NUMBER> sequences protein recommended <NUMBER> sequences determined e proteins peptide sequences <NUMBER> sequence iwlgfiagliaivmvtimlckkkkkkkkk protein gave higher hla scores others proposed candidate antigen use vaccine formulations feng et al <NUMBER> zhang et al prepared sbp<NUMBER> peptidebased linker <NUMBER> amino acids using molecular dynamic md simulations study human protein derivative sbp<NUMBER> sequence completely proteinogenic considered immunogenic effect seen protein targeted drug vaccine development studies sarscov<NUMBER> protein consists two subunits s<NUMBER> s<NUMBER> s<NUMBER> rbd interacts receptor host cell ace<NUMBER> peptide linker thought inhibit interaction protein sarscov<NUMBER> ace<NUMBER> prevent virus entry human cells play important role diagnosis treatment sarscov<NUMBER> pant et al published study providing comprehensive research main residues ligandreceptor interactions improvement peptidelike molecules covid<NUMBER> essential protease inhibitors pant et al <NUMBER> reported four small molecules selected <NUMBER> peptidelike molecules found various databases docking studies md simulations show powerful binding affinity residues within binding position evaluated sarscov<NUMBER> pant et al <NUMBER> one study authors presented silico description exhaustive list antigenic peptides could potentially used develop vaccines new coronavirus <NUMBER> lee koohy <NUMBER> conducted de novo investigation peptides <NUMBER> amino acids sarscov<NUMBER> binding hla alleles european chinese populations also peptides tcr recognition potential determined immunogenicity algorithm ipred developed recently lee koohy <NUMBER> itlcftlkr epitope chosen depending good antigenicity prepare design vaccine covid<NUMBER> joshi et al <NUMBER> reported particular epitope actively bind mhc hlaalleles covers maximum population various geographic districts however indicated use particular peptide epitope design vaccines sarscov<NUMBER> requires wet laboratory validation peptides one epitope designed used vaccines targeting protein study conducted bhattacharya et al thirtythree linear b cell epitopes determined glycoprotein sarscov<NUMBER> bhattacharya et al <NUMBER> sequences analyzed determine cell epitope combined mhci ii selected <NUMBER> epitopes transformed single sequence eaaak<NUMBER> linkers peptidebased vaccine composition designed model confirmed good quality molecular docking designed multiepitope peptide tlr<NUMBER> exhibited significant binding affinity proves importance designing multiepitope peptides develop effective vaccine candidates covid<NUMBER> epitopes ideal candidates formulating multiepitope peptide vaccine vitro vivo validation performed owing bcell epitope containing sequences verified antigenicities bhattacharya et al <NUMBER> hand abdelmageed et al suggested generated strong longterm immune response covid<NUMBER> cd<NUMBER> cell produce immunogenic peptide vaccine abdelmageed et al <NUMBER> therefore studied cell epitopebased peptide vaccine modeling instead b cell targeting e protein mhci peptide vaccine following <NUMBER> peptide sequences yvysrvknl slvkpsfyv svllflafv flafvvfll vllflafvv rlcayccni fvseetgtl ltalrlcay lvkpsfyvy nivnvslvk selected best candidates highest world population coverage <NUMBER> mhcii another <NUMBER> peptide sequences kpsfyvysrvknlns vkpsfyvysrvknln lvkpsfyvysrvknl psfyvysrvknlnss nivnvslvkpsfyvy llvtlailtalrlca sfyvysrvknlnssr lvtlailtalrlcay vtlailtalrlcayc cnivnvslvkpsfyv also selected vaccine candidates according world population coverage <NUMBER> research group aims find protected coding genes necessary survival virus suggested unique genes used potential drug vaccine target due large mutations enable virus show high resistance antibiotics protein e identified antigenic gene protection <NUMBER> coronavirus strains tested validated multiple sequence alignment done msa abdelmageed et al <NUMBER> result another detailed study conducted computeraided vaccine design cavd approach develop series epitopebased peptide vaccine candidates <NUMBER> possible peptides presented p e l f k e e l k f k n h p v l g g n <NUMBER> fsqilpdpskpskrsfi <NUMBER> tmslgaensvaysnns <NUMBER> nsnnldskvggnyn <NUMBER> biswas et al <NUMBER> researchers stated peptide sequences supported wet laboratory studies may candidates developing vaccines covid<NUMBER> grifoni et al study emphasized understanding sarscov<NUMBER> proteins epitopes recognized human cd<NUMBER> cd<NUMBER> cells responses important developing vaccines allow monitoring measuring understanding immune responses covid<NUMBER> infection grifoni et al <NUMBER> stated information would assist candidate vaccine modeling facilitate assessment vaccine immunogenicity using peptide megapooller prescribed hla class ii research group detected cd<NUMBER> cd<NUMBER> cells specific sarscov<NUMBER> blood samples <NUMBER> healing covid<NUMBER> patients according results <NUMBER>mer peptides synthesized investigate spikespecific cd<NUMBER> cells using multiple experimental approaches cd<NUMBER> cd<NUMBER> cell antibody responses specific sarscov<NUMBER> observed covid<NUMBER> cases besides sarscov<NUMBER>crossreactive cell responses observed healthy donors demonstrating potential preexisting immunity human population grifoni et al <NUMBER> peptides lower immunogenicity compared conventional attenuated inactivated vaccines due low molecular weight size susceptibility degradation lack antigenic sites available pathogen therefore additional molecules called adjuvants used peptide vaccines increase immune response adjuvants used especially subunit vaccines enhance modulate immune response antigen delivery presentation antigen antigen presenting cells apc khong overwijk <NUMBER> among several immunological roles adjuvants vaccine formulations powell et al <NUMBER> increasing antibody titer decreasing antigen dose inducing potent cellmediated immunity expression costimulatory molecules cytokines important properties adjuvants khong overwijk <NUMBER> adjuvants used epitopebased peptide vaccines simply classified two main classes immunostimulants increasing immune response vehicles delivery controlled release antigens immune system reed et al <NUMBER> although various adjuvants used vaccine formulations adjuvants used proposed peptide subunit vaccines sarscov<NUMBER> related viruses discussed remain within scope review alum commonly used adjuvant vaccines since discovery glenny et al <NUMBER> classified branch vehicles adjuvants literature alum generally used name aluminum hydroxide aluminum phosphate gels adjuvant study tseng et al <NUMBER> alum used adjuvant four different vaccine formulations sarscov two whole virus vaccines one recombinant protein vaccine last one viruslike particle vaccine formulations examined without alum adjuvant mentioned study almost formulations protected mice virus th<NUMBER>type immunopathology hypersensitivity observed response formulations direct relationship could established alum usage adjuvant hypersensitivity jaume et al developed subunit vaccine formulation sarscov using recombinant protein without alum adjuvant kam et al <NUMBER> investigated immunogenicity vaccine antibodydependent enhancement ade hamster study viral load hamsters <NUMBER> days postchallenge decreased least four orders magnitude without signs enhanced lung pathology unfortunately alum cannot induce th<NUMBER> immune response effectively significant vaccines viruses petrovsky aguilar <NUMBER> novel study aluminum nanoparticles used antigen delivery vehicles adjuvants deliver ovalbumin model subunit antigen pulmonary administration suitable conventional alum shown aluminum nanoparticles induce th<NUMBER> th<NUMBER> responses safely effective airborne pathogens like mers sarscov<NUMBER> pulmonary administration vaccine formulation ongoing studies sarscov<NUMBER> glaxosmithkline using adjuvants as<NUMBER> cooperative study clover biotechnology developing protein based subunit vaccine veugelers zachmann <NUMBER> as<NUMBER> oilinwater emulsionbased vehicle type adjuvant contains squalene alphatocopherol reed et al <NUMBER> usage adjuvant induces th<NUMBER> th<NUMBER> cytokine responses higher antibody titer compared alum shown vaccine study hepatitis b morel et al <NUMBER> khurana et al studied proteinbased vaccines sarscov<NUMBER> evaluate induced antibody titers ravichandran et al <NUMBER> used emulsigen adjuvant vaccine formulations emulsigen another oilinwater emulsionbased adjuvant system study revealed antibody titers obtained receptor binding domain s<NUMBER> protein s<NUMBER> domain mpla cpg used adjuvants liposomal vaccine formulation sarscov<NUMBER> contains protein antigen lixin et al <NUMBER> cpg mpla monophosphoryl lipid immunostimulant type adjuvants cpg nucleic acidbased structure mpla lipid adjuvant system study induced humoral cd<NUMBER> cd<NUMBER> tcell responses protein sarscov<NUMBER> company novavax also developing subunit vaccine sarscov<NUMBER> using antigenic proteins virus veugelers zachmann <NUMBER> company uses commercial adjuvant matrixm™ vaccine increase modulate immune response known previous studies matrixm™ nanoparticle formed quillaja saponins cholesterol phospholipids preferentially induces th<NUMBER> immune response antigenic molecules magnusson et al <NUMBER> <NUMBER> cpg odn polyic polyinosinicpolycytidylic acid r<NUMBER> zhao et al compared immune responses obtained three different adjuvants used peptide vaccines sarscov zhao et al <NUMBER> study cpg odn polyic polyinosinicpolycytidylic acid r<NUMBER> examined immunostimulant adjuvants cpg odn better immune response others owing induction il<NUMBER> cpg also authors noticed three adjuvants induce cellular immune response also induce humoral immune response virus using peptides antigens cyclic guanosine monophosphateadenosine monophosphate cgamp also proposed used adjuvant sarscov<NUMBER> vaccine form psgamp pulmonary surfactant gamp adjuvant good universal mucosal adjuvant develop vaccine wide range viruses owing broadspectrum cross protection h<NUMBER>n<NUMBER> also h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> viruses matsui et al examined different strategy attaching synthetic antigenic peptides sarscov onto surface liposomes induce immune response virus ohno et al <NUMBER> liposomes kind vehicle delivery type adjuvants study one formulations antigenic peptide coated liposomes exhibited protection viral challenge several ongoing subunit vaccine studies use adjuvants induce immune response mentioned adjuvant type cause different forms immune responses antigens pathogen therefore important notice proper adjuvant selection becomes vital especially sarscov<NUMBER> vaccines prevent immunopathology ade order design develop appropriate effective vaccine sarscov<NUMBER> pathogenesis infection must known well vaccine development study coronaviruses bind cell membrane using protein spiky shaped infect cell callaway <NUMBER> rogers et al <NUMBER> shang et al <NUMBER> similar sarscov sarscov<NUMBER> binds ace<NUMBER> receptor cell surface infection humans lon et al <NUMBER> rogers et al <NUMBER> tang et al <NUMBER> cov infection humans entry double chain viral rna occurs inside double membrane vesicles antigenpresenting cells apc antiviral mechanism act antigenic peptide presentation complexes mhci mhcii cd<NUMBER> cd<NUMBER> cells one important cells dendritic cells dc viral infection dendritic cells dc present respiratory system play important role antigen presenting cells apc sars infection antigen presentation sarscov importantly done mhci mhcii also investigated epitope mapping used generally vaccine development studies identified approximately <NUMBER> cell peptide epitopes high affinity mhci mhcii also two different b cell epitopes strong neutralizing found protein cellular immune response occurs infected cells tlymphocytes mechanism adaptive immunity helper cells active general adaptive immune response tc cytotoxic cells responsible clearance virusinfected cells demonstrated cd<NUMBER> tnfa il<NUMBER> ifn cd<NUMBER> tnfa ifnγ memory cells function replicating ifnγproducing cell however recent reports sarscov<NUMBER> suggested effective reduction number cd<NUMBER> cd<NUMBER> cells pbmcs peripheral blood mononuclear cells infected individuals obtained also lead impaired memory cell formation progression recovered sarscov<NUMBER> patients antibodymediated humoral immune mechanism occurs differentiation b lymphocytes plasma cells helper cells production neutralizing antibodies specific viral antigen relevant virusspecific antibodies produced b lymphocytes limit sarscov<NUMBER> infection effective preventing entry virus host cells thus specific antibodies prevent transmission recurrence infection providing protection disease sarscov<NUMBER> proteins b cell epitopes receptor binding domains rbd produce neutralizing antibodies current evidence suggests th<NUMBER>type response important controlling sarscov probably also applies sarscov<NUMBER> literature review found cases result death sarscov<NUMBER> infection th<NUMBER> increases pathogenesis virus increased immune response zhou zhao <NUMBER> similarly concluded many studies triggering th<NUMBER> immune response plays key role suitable vaccine model developed viral infections channappanavar et al <NUMBER> huang et al <NUMBER> thiel weber <NUMBER> zhou zhao <NUMBER> ifnγ mediated antiviral immune responses play stronger cytokine role control sarscov<NUMBER> infections stated low delayed induction ifnγ virus causes activation macrophage proinflammatory cytokines lungs activation immune system components cytokines macrophages causes vascular leakage well disrupting adaptive immune response conclusion vital develop vaccine covid<NUMBER> prevent disease limit outbreak become global disaster <NUMBER> many different strategies examined develop potential vaccines disease among vaccines peptidebased vaccine strategies sarscov<NUMBER> mentioned review epitopebased peptide vaccines ascend among vaccines depending low costs easier production safety however challenges overcome developing epitopebased peptide vaccine sarscov<NUMBER> although silico methods predict antigenic epitopes high accuracy probable cell animal studies may reveal low immunogenicity sequence therefore comprehensive study accomplished predict antigenic peptide sequence pathogen also possible mutations antigenic epitopes followed keep activity vaccine formulation following batches production low immunogenicity peptides compared vaccine types significant drawback overcome using adjuvants formulation proper selection adjuvant essential epitopebased peptide vaccines sarscov<NUMBER> obtain balanced th<NUMBER>th<NUMBER> immune response prevent immunopathology antibodydependent enhancement conclusion evident epitopebased peptide vaccines great potential place competition rapid development protective vaccine sarscov<NUMBER> authors contribution mt esa tar dtb sd responsible concept design critical review manuscript reviews dtb eu silico analyses sd vaccine strategies tac ppa bu sd peptide synthesis epitopebased peptide vaccine mt adjuvants tar esa immune response authors declare commercial financial relationships conflict interest study novel coronavirus officially termed severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> causative agent covid<NUMBER> disease outbreaks <NUMBER> wuhan china first epicenter pandemic <NUMBER> million reported infections <NUMBER> deaths june <NUMBER> <NUMBER> considered worst crisis since world war ii <NUMBER>−<NUMBER> worldwide impact pandemic frightening might reached pinnacle yet human race also facing crisis situation due mandatory quarantines lockdowns <NUMBER> <NUMBER> world economy already facing longlasting dent situation surely worsen viral spread controlled <NUMBER> <NUMBER> alpha beta gamma delta four classes coronavirus cov family featuring singlestranded positivesense rna genome membrane envelops encapsulating viral genome decorated glycoprotein spike transmembrane proteins word coronavirus named clubshaped protein spikes surface viewed transmission electron microscope tem causative agent behind covid<NUMBER> pandemic belongs beta class <NUMBER> coronavirus class responsible severe acute respiratory syndrome sars middle east respiratory syndrome mers <NUMBER> fever dry cough fatigue difficulty breathing among initial symptoms sarscov<NUMBER> infected patient <NUMBER> contagious virus class majorly affects lower respiratory system initiating viral pneumonia vital organs including cardiac liver kidneys gastrointestinal tract git central nervous system cns may also affected causing multiple organ complicacies <NUMBER>−<NUMBER> life cycle pathophysiology structure sarscov<NUMBER> singlestranded rna genome approximately <NUMBER> kilobases nucleocapsid helical symmetry sarscov<NUMBER> genome <NUMBER> identical sarscov <NUMBER> batcov ratg<NUMBER> <NUMBER> integrity sarscov particle maintained four proteins protein spike glycoprotein enables attachment virus host cells followed membrane fusion hence promoting entry sarscov host cells ii abundant protein membrane maintains membrane integrity viral particle iii e protein envelope smallest protein plays structural role helps assembly budding iv n protein nucleocapsid predominantly binds sarscov rna supports nucleocapsid formation <NUMBER>−<NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> key receptor entry sarscov<NUMBER> cells host cellular proteases human airway trypsinlike protease cathepsins transmembrane protease serine <NUMBER> tmprss<NUMBER> control viral entry mechanism splitting spike protein initiating penetration mechanisms <NUMBER> least six open reading frames present typical cov genome encode production subgenomic rnas <NUMBER> nonstructural proteins nsps structural proteins spike membrane envelope nucleocapsid protein <NUMBER>−<NUMBER> life cycle sarscov<NUMBER> explaining entire pathophysiology mechanism detailed figure <NUMBER> coronavirus proteins promote entry virus host cells area focus various antibodies surface protein spike glycoprotein virions site recognition membrane fusion <NUMBER>−<NUMBER> protein trimer gets cleaved s<NUMBER> s<NUMBER> subunits s<NUMBER> subunits contain receptor binding domain rbd released posttransfusion conformation <NUMBER>−<NUMBER> s<NUMBER> directly binds peptidase domain pd ace<NUMBER> s<NUMBER> subunits help membrane fusion critical viral infection <NUMBER> s<NUMBER> contains cleavage sites sliced host proteases <NUMBER> <NUMBER> <NUMBER> ace<NUMBER> dimer two units accommodates rbd peptidase domain contact ace<NUMBER> sarscov<NUMBER> facilitated polar interactions <NUMBER> <NUMBER> <NUMBER> archshaped helix peptidase domain ace<NUMBER> interacts loop region rbd protein figure <NUMBER> ii helix loops connect antiparallel strands coordinate peptidase domain rbd amino acid interactions observed rbd sarscov<NUMBER> peptidase domain ace<NUMBER> considered important aspects inhibitor design <NUMBER> observed amino acid gln<NUMBER> sarscov<NUMBER> interacts ace<NUMBER> asp<NUMBER> tyr<NUMBER> gln<NUMBER> leu<NUMBER> lys<NUMBER> amino acids leu<NUMBER> virus interaction asp<NUMBER> lys<NUMBER> his<NUMBER> interactions include sarscov<NUMBER> phe<NUMBER> gln<NUMBER> leu<NUMBER> met<NUMBER> tyr<NUMBER> leu<NUMBER> gln<NUMBER> showed interaction ace<NUMBER> lys<NUMBER> his<NUMBER> forms hbond glu<NUMBER> amino acid asn<NUMBER> similar type interaction ace<NUMBER> lys<NUMBER> gly<NUMBER> asp<NUMBER> hbond interaction observed tyr<NUMBER> <NUMBER> binding affinity rbd domain sarscov<NUMBER> pd ace<NUMBER> higher compared sarscov <NUMBER> reported sarscov<NUMBER> amino acid lys<NUMBER> showed salt bridge interaction asp<NUMBER> ace<NUMBER> positive charged patch contributed toward electrostatic potential surface rbd added lys<NUMBER> sarscov<NUMBER> absent sarscov <NUMBER> <NUMBER> <NUMBER> examination sarscov<NUMBER> virion architecture using tem reveals roughly spherical moderately pleiomorphic morphology virion diameter observed broad distribution <NUMBER>−<NUMBER> nm condensed mass nucleic acid nucleocapsid protein underneath welldefined lipid bilayer envelop <NUMBER> tem also reveals naillike shape sarscov<NUMBER> spikes <NUMBER> nm wide head <NUMBER> nm long body dissociation s<NUMBER> subunit figure <NUMBER> sarscov<NUMBER> structure pathophysiology sarscov<NUMBER> life cycle viral protein binds ace<NUMBER> receptor host following entry proteolytic cleavage virus envelope ensuing release genomic rna cytoplasm smaller rnas subgenomic mrnas made mrnas translated several proteins n etc essential construction viral assembly e proteins enter endoplasmic reticulum er nucleoprotein complex formation occurs combination nucleocapsid n protein genomic rna positive strand formation complete virus particle proteins genome rna assembly occurs ergolgi apparatus compartment virus particles transported released via vesicles formation exocytosis ii ace<NUMBER>rbd protein single unit peptidase domain human ace<NUMBER> red interacting rbd protein blue boxed region represents amino acid interactions sites protein conformational change observed s<NUMBER> subunit change compressed form naillike shape confirmed different researchers called postfusion state threedimensional <NUMBER>d map twodimensional projection images s<NUMBER> protein postfusion state provided song et al negative staining em <NUMBER> also confirmed biophysical assays cryoem structure analysis sarscov<NUMBER> protein binds least <NUMBER> times tightly ace<NUMBER> host cell receptors compared spike protein sarscov <NUMBER> virusinfected cell undergoes pyroptosis generates molecules including damageassociated molecular patterns nucleic acids asc oligomers atp trigger neighboring epithelial endothelial cells macrophages proinflammatory proteins cytokines chemokines released migrate cells monocytes macrophages infection site loop proinflammatory feedback started ifnγ released cells healthy immune response following initial inflammation comprised cellmediated elimination infected cells neutralizing antibodymediated produced b cells viral inactivation macrophagedependent recognition clearance apoptotic cells phagocytosis however excessive infiltration immune cells resulting cytokine storm leads dysfunctional immune response ie multiorgan damage antibodydependent enhancement ade viral infection may occur result nonneutralizing antibody production b cells <NUMBER> adapted permission ref <NUMBER> copyright <NUMBER> springer nature activating signaling pathways nuclear translocation transcription factors like nuclear factor κb nfκb interferon response factors irf<NUMBER> irf<NUMBER> activator protein <NUMBER> ap<NUMBER> <NUMBER> <NUMBER> transcription factors result initiation tumor necrosis factors tnf chemokinedependent inflammatory responses nfκb ap<NUMBER> stimulated expression typei interferon ifnα βdependent antiviral innate immune responses suppress viral infection <NUMBER> <NUMBER> hand adaptive immune responses specific virus cells infected virus become noticeable <NUMBER> week disease onset protective role humoral bcell immune response primarily delivered antibody secretion neutralize sarscov<NUMBER> virus specifically blocking virus−host interaction <NUMBER> <NUMBER> cell response viral infection significant direct killing infected cells cd<NUMBER> cells whereas cd<NUMBER> cells help cytokine production priming b cells cd<NUMBER> cells <NUMBER>−<NUMBER> lisa chemical structure mechanism site action ii iii water solubility log p calculated alogps <NUMBER>−<NUMBER> iv halflife <NUMBER> molecules remdesivir plasma <NUMBER> <NUMBER> h intravenous dose nonhuman primates metabolite nucleoside triphosphate <NUMBER> <NUMBER> h nonhuman primates approximately <NUMBER> h humans coworkers presented chronological description various events happening sarscov<NUMBER> infection figure <NUMBER> <NUMBER> organ systems involved sarscov<NUMBER> primarily affects respiratory system first spreads systemically heart liver kidneys <NUMBER> although still uncertain whether viral infection directly results organ tissue injury observed covid<NUMBER> patients important mention ace<NUMBER> highly expressed respiratory tract organs tissues encompassing cardiovascular system cvs cns git female reproductive systems <NUMBER> <NUMBER> pulmonary system high expression ace<NUMBER> lung bronchial branches cells serves primary entry site binding site sarscov<NUMBER> <NUMBER> higher ace<NUMBER> expression makes alveolar epithelial cells accessible sarscov<NUMBER> clinically portrayed rapid development pneumonia advancing acute respiratory distress syndrome ards multiple organ failure severe cases <NUMBER> cvs cells heart endothelial cells etc known show high expression ace<NUMBER> acts regulate blood pressure myocardial contractility <NUMBER> sarscov<NUMBER> binding ace<NUMBER> may result activation upregulation ace<NUMBER> downstream signal transduction pathways includes activation raserkap<NUMBER> pathway may activate c−c motif chemokine ligand <NUMBER> ccl<NUMBER> profibrosis factor resulting development cardiac inflammation fibrosis <NUMBER> increase levels myocardial markers specific like hsctni nonspecific creatine kinase creatine kinase mb isoenzyme lactate dehydrogenase reported patients act important tools determining level cov<NUMBER> progression heart well vital organs <NUMBER> cns cov<NUMBER> infect cns four different ways direct infection injury involves blood circulatory pathway virus passes increased permeability blood−brain barrier bbb due cytokine storm b neuronal pathway sensory nerve endings major target viral infection may result anterograde retrograde axonal transport motor kinesins dyneins <NUMBER> ii hypoxia injury result virus infection lung tissues exudative inflammation alveolar interstitial region pulmonary edema related disorders increase alveolar gas exchange disorders causes hypoxia cns leading increased anaerobic metabolism mitochondria brain cells hypoxia leads cns hypertension headaches edema drowsiness swelling olfactory bulbs loss taste cause severe damage cns <NUMBER> iii immune system infection macrophages microglia astrocytes activate immune cells brain consequent cytokine storm result severe brain damage <NUMBER> iv ace<NUMBER> sarscov<NUMBER> interaction ace<NUMBER> expressed capillary endothelium may damage bbb facilitate virus entry attacking vascular system <NUMBER> git high expression ace<NUMBER> tmprss<NUMBER> intestinal epithelial cells including organ duodenum small intestine pancreas liver gastrointestinal tract makes cells organs potential targets cov<NUMBER> recent study xiao f et al detected viral rna nucleocapsid protein gastric duodenal rectal epithelia <NUMBER> reproductive system ace<NUMBER> also highly expressed reproductive organs especially placenta uterus fetal interface pregnant women order counteract preeclampsia presence ace<NUMBER> fetal tissue also provide target sites cov<NUMBER> binding causing morbidity mortality <NUMBER> <NUMBER> therapeutic development vaccine development therapeutic development therapeutic prophylactic strategies deal existing potentially upcoming coronavirus infections development symptomatic treatment approach presently followed absence exclusive antiviral treatment sarscov<NUMBER> artificial intelligence computation tools currently use assist lengthy process drug discovery development new pathogen <NUMBER>−<NUMBER> using recently available genetic information protein structure modeling several therapeutic strategies based drug repurposing projected immediate treatment infected patients <NUMBER>−<NUMBER> target identification halt pathogenesis viral infection holds key development viral protease <NUMBER>clpro plpro host cell produced protease tmprss<NUMBER> rna polymerase rdrp interaction site viral protein host receptor ace<NUMBER> among major targets identified repurposing already existing antiviral molecules new small molecules development figure <NUMBER> <NUMBER>−<NUMBER> targeting sarscov<NUMBER> surface protein using neutralizing antibody nabs another strategy proposed <NUMBER> <NUMBER> <NUMBER> close similarity sarscov<NUMBER> sarscov allows researchers explore crossneutralizing activity nabs developed sarscov sarscov<NUMBER> infection <NUMBER>−<NUMBER> approach mostly directed utilizing currently available genomic information synthesize immunogenic segments protein including rbd <NUMBER>−<NUMBER> several traditional advanced lead screening labanimal testing methods considered speed usually slow challenging process also suggested combination nabs may required guarantee prophylaxis <NUMBER> targets considered neutralizing antibody development based information allied already known sars mers infections <NUMBER> targets include il<NUMBER>il<NUMBER>r cd<NUMBER> immunoreceptor tyrosinebased activation motif itam tolllike receptor <NUMBER> tlr<NUMBER> dendritic cellspecific intercellular adhesion moleculegrabbing nonintegrin dcsign interferon γinducible protein <NUMBER> ip<NUMBER>cxcl<NUMBER> intercellular adhesion molecule <NUMBER> icam<NUMBER> monocyte chemoattractant protein<NUMBER> mcp<NUMBER> <NUMBER> <NUMBER> <NUMBER> cytokine therapy comprising chemokines interferons others also proposed owing potential halt viral replication thus use treating sars infections <NUMBER> <NUMBER> examples include recombinant interferon rsifnco recombinant human interferon infω rhifnω polymer conjugate cysteine variants metil<NUMBER>c<NUMBER>speg longlasting interferon fused human serum albuminbinding peptide hsaifn pegylated ifnλ<NUMBER> <NUMBER> interferonα<NUMBER>b treatment covid<NUMBER> patients resulted shortened duration viral shedding particularly reduction markers acute inflammation creactive protein il<NUMBER> <NUMBER> targeting sarscov<NUMBER> viral rna genome using rna interference rnai antisense oligonucleotides another interesting approach consider <NUMBER> similarly disclosed series sirnas revealed target impede expression sarscov n e genes sirna targets reported include rna polymerase replicase regions coronavirus inhibiting infection replication antisense oligonucleotides rna aptamers also reported target pseudoknot structure unwinding sars cov rna respectively <NUMBER> vaccine development covid<NUMBER> pandemic severely impacted human lives desperate efforts employed across world develop safe effective vaccines first vaccine candidate already made human clinical trials result fasttracked development strategies advanced vaccine technological platforms <NUMBER> similar explained earlier therapeutic development significant genomic match sarscov<NUMBER> coronaviruses helping vaccine developers facilitate designs toward promising vaccine candidates target strategy vaccine candidates induce nabs viral protein averting ace<NUMBER>mediated host uptake case sarscov vaccine development higher nabs titers better protection reported protein subunit vaccines compared target strategy sarsmers vaccine development research suggests protein subunits rbd s<NUMBER> subunit proteingene preferred target sites <NUMBER>−<NUMBER> still knowledge sarscov<NUMBER> specific antigens trial vaccine candidates limited development covid<NUMBER> vaccine candidates relying several hightech platforms including attenuated inactivated viruses replicating nonreplicating viral vectors dna mrna viruslike particles recombinant proteinbased approaches platforms offer key advantages viral vectors strong immune response superior protein expression prolonged stability dna mrna offers antigen manipulation flexibility whereas recombinant proteinbased development approach easier scale using existing production capabilities table <NUMBER> list advanced covid<NUMBER> vaccine candidates recently moved clinical development <NUMBER> <NUMBER> enhancing immunogenicity using vaccine adjuvants also consideration lower viable dose widen therapeutic safety window <NUMBER> <NUMBER> compromised immune systems high risk disease elderly population also demand adjuvant strategies improve efficacy vaccines age group <NUMBER> licensed adjuvants developed specifically covid<NUMBER> vaccine as<NUMBER> glaxosmithkine mf<NUMBER> seqirus cpg <NUMBER> dynavax role nanotechnology covid<NUMBER> crisis also demands urgent analysis available nanotechnology tools nanomedicine strategies use design vaccine carriers enough nano technology approaches explored tackle current outbreak manuscript attempts systematically present current status nanotechnology use therapeutics vaccine development therapeutic development challenges sarscov<NUMBER> infection different infectious diseases well oncology research <NUMBER> similarly vaccine development holds significant commonalities strategies explored previously known sars mers coronaviruses <NUMBER> <NUMBER> hence worth revisiting closely related therapeuticvaccine strategies associated nanotechnology use way aim design repurposed nanotechnology fasttrack current research figure <NUMBER> antiviral biomolecular delivery nanocarrierbased therapeutics offers several opportunities address limitations current antiviral therapy basic challenges poor aqueous solubility low bioavailability solved nanocarrierbased antiviral drugs delivery modifying pharmacokineticspharmacodynamics properties resulting dose reduction reduced toxicity improved drug bioavailability maintenance suppression viral spread despite viral suppression plasma another kind challenge presence subtherapeutic concentrations antiviral drug reserve sites <NUMBER> <NUMBER> active targeted nanocarriers offer opportunity cross biological barriers attain therapeutic concentrations sheltered viral reservoirs <NUMBER> possible target specific organ cellular intercellular sites involved pathophysiology sarscov<NUMBER> possibly ace<NUMBER> expressing cells domains viral protein cathepsin binding sites etc controlledsustained drugreleasing nanocarriers best solution mitigate risk effects poor patient compliance viral rebound treatment viral infections nanomedicine strategy thus powerful tool transform antivirals repurposing improving covid<NUMBER> therapeutic management <NUMBER> role nanocarrier technologies decisive development rnai nabs protein peptide biologicals <NUMBER> important prerequisite drug candidates protection degradation lossoffunction systemic circulation intracellular delivery systemic toxicityimmunotoxicity another big issue specifically protein peptidebased drugs nanocarrierbased delivery including biologic prodrug ensures improved halflife biologicals preventing premature drug release degradation along evasion renal hepatic clearance <NUMBER> engineered nanocarriers offer stealth characteristics evade immune recognition better cellular uptake targeted nanoparticles provide improved rate endocytosis better ensures delivery therapeutic nanoparticle dose target cell ability carry higher drug load entails delivery fewer nanoparticles supported controlled drug release within cells ensuring reduced side effects <NUMBER>−<NUMBER> nanomedicine approach covid<NUMBER> therapeutics rational selection drugnanocarrier combination broad range active moieties including antivirals biologics nucleic acids loaded delivered nanocarriers connecting right therapeutic candidate right nanocarrier aimed specific disease condition crucial commercial success nanomedicine sarscov<NUMBER> virus nanomedicine approach needs deal reformulating approved well trial drug candidates improve therapeutic index ti predominantly addressing limitations associated drug molecule mitigating conventional toxicity side effects therapeutic developments proposed covid<NUMBER> treatment possess basic similarity oncology research hence currently available nanomedicine platforms anticancer therapeutics considered order nurture approach <NUMBER> <NUMBER> better mechanistic understanding drugspecific side effects first step development process second step process scrutinize select basic nanostrategy maximize impact nanomedicine drugs ti nanodelivery biologics also requires smart nanocarrier designs embracing strategies like prodrug approach <NUMBER> <NUMBER> rational development clinical translation nanomedicine require several strategic track developments fast paced slower paced ones tackling right translational challenge fostering nanomedicine research <NUMBER> strategic guidelines proposed development anticancerantiviral nanomedicines high importance emphasizing right areas precise tools fasttrack covid<NUMBER> nanomedicine research strategy <NUMBER> nanocarrier selection bypass conventional limitations drug candidate example relatively safe antibodydrug conjugates highly toxic auristatins approved treatment hematological cancers major limitation use conjugates low tolerable drug payloads order solve problem polymeric nanoparticles developed high auristatin payload achieve efficient safe tumor suppression <NUMBER> similarly formulating polyethylene glycolpolylactidebased nanoparticles loaded aurora b kinase inhibitor revealed increased efficacy reduced toxicity compared free form produced intolerable side effects phase ii clinical trials <NUMBER> wellknown limitation nucleic acid eg rnai drug candidates systemic circulation instability prerequisite intracellular delivery <NUMBER>−<NUMBER> lipid nanoparticles lnps carrying sirna example nanotechnology platform onpattro used prevent systemic degradation along benefit livertargeting <NUMBER> lipidcoated mesoporous silica nanoparticles used deliver highly hydrophilic unstable antiviral molecule ml<NUMBER> chemical inhibitor venezuelan equine encephalitis virus showed enhanced circulation time biocompatibility ml<NUMBER> vivo <NUMBER> sago coworkers reported highthroughput method named find screen lnps bypass liver deliver functional mrna cells vivo <NUMBER> broadly relationship nanoparticle structure mrna vivo delivery targets may elucidated study nanocarriers used prevent systemic immunotoxicity proteinbased drugs promote immunooncology therapeutics <NUMBER> strategy <NUMBER> chemically alterreengineer drugs drug molecules altered improve compatibility particular class type nanocarriers rendering generic approach drug candidates similar physicochemical properties <NUMBER> <NUMBER> lipid bilayer nanocarriers liposomes preferred nanocarriers ph gradientbased remote loading amphiphilic ionizable drugs <NUMBER> hydrophobicity doxorubicin chemically modified increase compatibility polylacticcoglycolic acid nanoparticles <NUMBER> another approach interest synthesis prodrugs ensure compatibility incorporation within particular nanocarriers along controlled localized release characteristics antihiv prodrugs antiretroviral arv candidate cabotegravir synthesized functionalizing fatty acid esters variable carbon lengths followed poloxamer coating get stable nanocrystal formulations vivo pharmacokinetic studies mice rhesus macaques revealed significantly improved effectiveness cabotegravir showing prolonged drug release pharmacokinetic parameters <NUMBER> another arv prodrug strategy highly aqueoussoluble emtricitabine using bioreversible carbonate carbamate masking groups shows sustained prodrug release predicted vitro vivo extrapolation modeling <NUMBER> wei coworkers reported use cholesterolmodified hydroxychloroquine cholhcq loaded liposomes lowered dose toxicity hydroxychloroquine also inhibited proliferation rat lung fibroblasts thereby reducing pulmonary fibrosis strategy adopted dual benefits sarcov<NUMBER> patients show viral load pulmonary fibrosis <NUMBER> using hydrolyzable ester linkage irinotecan hydrophilic chlorambucil hydrophobic anticancer drug−drug conjugate synthesized <NUMBER> nanoparticles synthesized selfassembly amphiphilic drug−drug conjugate shows prolonged systemic retention tumor tissue accumulation increased cellular uptake hydrolyzable ester linkers conjugated docetaxel permitted effective loading release corecrosslinked polymeric micelles provide high therapeutic efficacy breast ovarian cancer <NUMBER> another similar prodrug fatty acids conjugated cabazitaxel peglipid results selfassembled nanoparticles showing reduced systemic toxicity superior anticancer efficacy <NUMBER> strategy <NUMBER> nanomedicine combination drug therapeutics combination drug therapy another possibility treatment covid<NUMBER> offering several advantages lower dosages individual drugs causing fewer side effects achieving multiple complimenting therapeutic targets reducing likelihood resistance development several combinations novel coronavirus treatment documented landscape information table <NUMBER> nanocarriers also intrinsically useful delivery multiple drugs different physicochemical properties promising full potential combination therapies <NUMBER> <NUMBER> flexibility offered variety nanomaterials fabrication techniques enables design drug combinations loaded nanocarriers excellent control preserving synergistic drug ratios overlapping pharmacokinetics reducing combination allied sideeffects <NUMBER> various nanocarrier strategies described coencapsulation hydrophobic hydrophilic drugs figure <NUMBER> achieving sequential release two drugs ratiometric loading controlled release three drug candidates codelivery rnaiplasmiddna chemotherapeutics codelivery sirna micorna <NUMBER>−<NUMBER> nanosuspension lnps loaded three arvs drugs two hydrophobic lopinavir ritonavir one hydrophilic tenofovir formulated overcome lymph node drug insufficiency oral combination drugs nanoparticle formulation showed longlasting plasma drug profiles better lymph node drug levels macaques vivo model <NUMBER> liposomal nanoformulation vyxeos coloaded fixed combination anticancer drugs daunorubicin cytarabine recently approved usfda treat acute myeloid leukemia adults multidrugloaded antiretrovirals latency reactivating agents drug abuse antagonist pegylatedmagnetoliposomal nanoformulations shown vitro vivo bbb transmigration significant antihiv activity primary cns cells multifunctional nanotherapeutic strategy applied target sarscov<NUMBER> migrated cns <NUMBER> however drug combination regimens standard care wide range therapeutics optimizing nanoformulations uphill task optimization challenges include analyzing interaction two drugs balancing antagonismsynergytoxicity controlling release profile individual drugs <NUMBER> <NUMBER> highthroughput screening methods required understand biological interactions discover kind synergism present vitro screening methods determine ideal drug ratios demand upgrade mimic <NUMBER>d microenvironment target human tissue <NUMBER> preclinical animal models critical accelerating clinical translation disparity model disease animals human disease major reason failure study <NUMBER> nanomedicine scientists take advantage advanced drug development tools screening technologies bioinformatics animal models etc investigate validate nanoparticle combination therapeutics vaccine delivery apparent similarity sarscov<NUMBER> viruses mainly sarscov merscov along previous knowledge protective immune responses great help successfully develop covid<NUMBER> vaccine <NUMBER> <NUMBER> nanoparticles loaded wide range antigenic moieties physical entrapment chemical conjugation correct antigenic display makes highly relevant alternate vaccinology compared conventional approaches <NUMBER>−<NUMBER> addition safeguarding native structure antigen nanoparticles also improve delivery presentation antigens antigenpresenting cells apcs key advantages vaccine nanocarriers nanosize since many biological systems viruses including sarscov<NUMBER> proteins also nanosized nanoparticles administered oral intranasal routes subcutaneous intramuscular injections offering key advantage overcoming tissue barriers targeting key locations lymph nodes penetrate mucosal epithelial barriers airway nasal gastrointestinal etc <NUMBER>−<NUMBER> previous reports suggested humoral cellmediated immunity performs protective role sarscov infection <NUMBER> <NUMBER> nanoparticles shown ability target adaptive cells b cells innate immune systems macrophages monocytes neutrophils cellular level modulating apcs using nanoparticles could important particularly covid<NUMBER> vaccine strategies <NUMBER> <NUMBER> ability nanoparticles deliver antigen dendritic cells dcs enhancing antigen presentation several mechanisms promote cell immunity <NUMBER> smith et al explained various nanoparticlebased mechanisms alter immune response induction figure <NUMBER> <NUMBER> improve efficacy safety vaccine approach big advantage presented nanoparticles ability deliver molecular adjuvants cases nanomaterials possess intrinsic adjuvant property loaded antigens reports dated may <NUMBER> <NUMBER> various preclinical stage nanoparticlebased vaccine candidates table <NUMBER> <NUMBER> nanomedicine approach covid<NUMBER> vaccine overall vaccine history indicates major successes acute infectious diseases naturally developed immunity majorly neutralizing antibodies provides enduring protection section patients one bigger challenges covid<NUMBER> vaccine research identify approaches stimulate cell b cell immunity virus another challenge necessity accelerating development precise nextgeneration vaccine strategies may also address specific population subgroups individuals compromised immunity <NUMBER> smart strategies develop nanocarrierbased covid<NUMBER> vaccines equally important sometimes overlapping paralleled nanocarrierbased therapeutics <NUMBER> <NUMBER> nanovaccine strategy also requires strong focus cellular presentation selected antigen along selection appropriate nanocarriernanomaterial induce complimenting immunomodulatory effects following section highlights rational design nanocarrierbased vaccines two strategies strategy <NUMBER> antigendependent nanocarrier selection loading antigens inside surface nanocarriers dependent several factors including antigens physicochemical characteristics biological stability target sites required immunogen release rate physical adsorption antigens nanoparticles based surface charge noncovalent hydrophobic interactions antigens amphoteric nature suitable adsorption surface immobilization nanocarriers chitosan dextran sulfatebased polymeric nanoparticles inorganic nanoparticles aunps carbon nanotubes <NUMBER>−<NUMBER> antigen release cases predesigned based properties biological environment like ph ionic strength temperature etc encapsulation matrix entrapment antigens within nanocarrier another technique used prevent biological degradation polylactidecoglycolide plga nanoparticles ideal encapsulating antigens provide controlled extended biological release <NUMBER> nanoparticles effective preclinically carrying antigens hbsag malaria antigens tetanus toxoid listeria monocytogenes antigens bacillus anthracis spores generating prolonged cellular humoral immune response <NUMBER> mrnabased covid<NUMBER> vaccine already clinical trial employing lnps carrier naked mrnas sensitive degradation extracellular rnases thus formulating delivery vehicle essential <NUMBER> <NUMBER> mrnas entail cellspecific receptor recognition lipid membrane penetration cytosolic presence exogeneous mrna triggers cellular machinery translation fully functional protein <NUMBER> lnps virussized <NUMBER>−<NUMBER> nm particles synthesized selfassembly ionizable cationic lipid <NUMBER> possess ability deliver mrna efficiently cytoplasm demonstrated several studies sustainedrelease kinetics mrna expression thus protein translation achieved opting intramuscular intradermal routes providing high antibody titers b cells cells immune responses <NUMBER> different nanoparticles cationic lipids <NUMBER>dioleoyloxy<NUMBER>trimethylammoniumpropane dotap dioleoylphosphatidylethanolamine dope formulated subtle modifications cationic lipids cholesterol nanoparticle cationic lipids cholesterol peglnp cholesterol used increase stability peglipid increases formulation halflife apart lnps mrna nanocarriers include protamine cationic peptide nanoliposomes ∼<NUMBER> nm peglipid functionalized dendrimer nanoparticles ∼<NUMBER> nm positively charged oilinwater ow cationic nanoemulsion ∼<NUMBER> nm polyethylenimine nanoparticles <NUMBER>−<NUMBER> nm cationic polymer chitosan nanoparticles <NUMBER>−<NUMBER> nm <NUMBER>−<NUMBER> figure <NUMBER> i−v represents mrna vaccines delivery methods nanocarriers commonly used similar mrna naked dna also experiences systemic degradation nucleases incomplete delivery specialized immune cells nanocarriers based cationic lipids quite similar mrna deliver synthetic natural polymers inorganic particles proposed dnabased vaccine formulations polymeric nanocarriers encapsulating dna prevent biological inactivation provide controlled release targeted cell delivery plga nanocarriers studied polymeric platform dna vaccine development showing improved systemic antigenspecific antibody responses <NUMBER> <NUMBER> improve efficiency dna loading systemic protection functional composite plga nanoparticles cationic glycolchitosan plga plga polyethylenimine pei explored figure <NUMBER> vi <NUMBER> <NUMBER> well documented cationic polymerbased nanocarriers dna vaccine design chitosan nanoparticles pei nanoparticlescomplexes use peg functionalization nanoparticle surfaces quite common introduce stealth characteristics renders undetectable phagocytes prevent reticuloendothelial system clearance prevent nonspecific protein interaction reduce systemic toxicity improve stability <NUMBER> <NUMBER> improve delivery mrnadna across cell nucleus membrane physical technologies gene gun electroporation explored currently vaccine development taking advantage electroporation technology induce pores cell membrane insert dna figure <NUMBER> vii <NUMBER> <NUMBER> <NUMBER> surface electroporation dna coatedplga nanoparticles shown efficient cellular delivery elicit b cell cell response pigs <NUMBER> clinical future portable electroporation technologies apparent race covid<NUMBER> vaccine research <NUMBER> ongoing clinical trial nct<NUMBER> using dna plasmid encoding sarscov<NUMBER> sprotein vaccine candidate intradermally administration using electroporation device cellectra <NUMBER> strategy <NUMBER> vaccine adjuvant nanoparticles vaccine adjuvants nanoparticles vans considered improve overall efficacy safety generated immune response particularly covid<NUMBER> pandemic situation vaccine adjuvants critical reducing required antigen dose dosesparing permitting production units making available larger population <NUMBER> among many preclinical covid<NUMBER> vaccine candidates five protein subunit vaccine candidates reported using combination antigen adjuvant nvxcov<NUMBER> nanoparticle vaccine recombinant sarscov<NUMBER> glycoprotein based adjuvant matrix expected move clinical trials soon hence important discuss possible strategies employed vans research studies could help improve current covid<NUMBER> vaccine designs informing specific immune cells mount protective immune response specific antigen basic mechanism vans designed improve efficacy serving immunity promoting cues also called danger signals <NUMBER> case virus danger signals characterized pamps damageassociated molecular patterns damps derived virus <NUMBER> pamps damps recognized specific receptors called pattern recognition receptors prrs example receptors tolllike receptors expressed immune cells upregulate robust b cell priming releasing inflammatory cytokines <NUMBER>−<NUMBER> adjuvants improving safety provide kind counterregulatory signal instructing immune system develop tolerance incoming antigens vans either act nanocarrier molecular adjuvants inherent physicochemical property stimulate proor antiimmunity pathway <NUMBER> vans designed tackle limitations related conventional delivery molecular vaccine adjuvants rapid bloodstream clearance systemic distribution lack immune cell targeting well lack antigenadjuvant colocalization polymeric nanoparticles encapsulating small molecules employed lymphoid organspecific delivery controlled exposure dosesparing effect reported antigen cyclic dinucleotide adjuvant agonist inf gene stimulator coloaded liposomal nanoparticles showing safe uncompromised immune responses <NUMBER> lymph node targeting vans established strategy achieve significantly highdosesparing effect whereas dcs targeting vans may enhance adjuvanticity vivo study results infectious challenge shown plga calcium phosphate nanoparticles coencapsulating antigen adjuvants improve efficacy enhancing antigen uptake apc activation higher antibody titers <NUMBER>−<NUMBER> studies coencapsulation strategy allows colocalization antigen adjuvant endosomalphagosomal compartments fostering activation dcs triggers robust crosspresentation cell priming <NUMBER> <NUMBER> synergized activation apcs prolonged antibody response observed codelivery tlr<NUMBER> tlr<NUMBER> small molecule adjuvants using plga nanoparticles <NUMBER> vans including plga aunps also employed codeliver selfantigens immunoregulatory drugs adjuvants induce antigenspecific peripheral tolerance autoreactive cells block serious autoimmune response <NUMBER>−<NUMBER> nanoparticles intrinsic adjuvanticity activating complement system inducing autophagy activation inflammasome also considered vans <NUMBER>−<NUMBER> surface chemistry hydrophobicity nanoparticles along physicochemical properties capable electing adjuvanticity mechanisms intrinsically <NUMBER> <NUMBER> <NUMBER> hydroxyl groups dependent compliment system activation followed cellular immunity enhancement reported pluronicstabilized polypropylene sulfide nanoparticles <NUMBER> antigen conjugated alumina nanoparticles reported enhance cellular humoral immune responses result autophagy induction dcs fostering antigen crosspresentation cells <NUMBER> gold plg nanoparticles reported activate nalp<NUMBER> inflammasome dcs resulting improved adjuvanticity similar alummediated adjuvanticity mechanism <NUMBER> <NUMBER> increased sidechain hydrophobicity polyγglutamic acid nanoparticles displayed augmented uptake dcs activation <NUMBER> similarly aunp surface hydrophobicity increase expression inflammatory cytokines vitro vivo <NUMBER> vaccine adjuvants used increase efficiency antibody responses vaccines elderly comprise vulnerable groups population highest casefatality rate covid<NUMBER> disease <NUMBER> <NUMBER> aging associated continuous chronic subclinical systemic inflammation inflammaging acquired immune system weakening immune senescence <NUMBER> immune senescence flagged significant decrease immunoglobulin interferon levels tcell count rate cell division proliferation chemotaxis neutrophils phagocytosis <NUMBER> <NUMBER> ow emulsion immune <NUMBER> squalenebased ow emulsion adjuvants mf<NUMBER> as<NUMBER> licensed influenza vaccines meant elderly <NUMBER> <NUMBER> liposomebased adjuvant as<NUMBER> another key example licensed technology developed herpes zoster subunit vaccine aiming old age population <NUMBER> years <NUMBER> <NUMBER> addition adjuvants shown decreased risk pneumonia influenza clinical trials hence play significant role regulating immune system responses elderly tuned covid<NUMBER> vaccine progress <NUMBER> scope nanotechnology covid<NUMBER> therapeutics vaccine research limited conventional therapeutic vaccine designs several approaches including advanced nanomaterial biomimetic approaches represent good potential usage covid<NUMBER>like outbreak szunerits coworkers investigated prospect functionalized carbon quantum dots cqds inhibit human coronavirus hcov<NUMBER>e infection figure <NUMBER> i−iii <NUMBER> cqds different sizes <NUMBER> nm surface potential −<NUMBER> −<NUMBER> mv functionalities explored inhibitors huh<NUMBER> cells host cell infection hcov<NUMBER>e showed concentrationdependent virus inactivation boronic acidmodified cqds showed maximum efficacy ec <NUMBER> value <NUMBER> ± <NUMBER> μg ml −<NUMBER> illustrating significance boronic acid functionality inhibit early stage interaction viral sprotein receptor host cell membrane cell membranes mimicking nanodecoys interesting choice fool trap pathogens biomimetic nanodecoys include liposomal formulations reconstituted lipoproteins cellmembrane nanostructures <NUMBER> targeted surface engineered liposomes antiviral antibodies constitute effective strategy provide protection infection coxsackie a<NUMBER> virus <NUMBER> similarly mosquito hostcellmembranewrapped nanodecoys employed trap zika virus effectively prevent host cell infection <NUMBER> lauster coworkers presented interesting approach employing influenza virus spikeprotein hemeagglutinin ha mimicking multivalent binder bind virus distinct multivalent mode inhibit infection <NUMBER> normally multivalent manner binding observed viral trimeric ha terminal sialic acid sia residues host cells surface glycans structurally defined presentation sia ligands functionalized compact symmetrical <NUMBER>d scaffold bacteriophage capsid resembling host cell targeting trimeric ha ectodomain virus k<NUMBER> residues present protein coat symmetric icosahedral bacteriophages qβ capsid ∼<NUMBER> nm diameter provided ideal platform anchor sia ligands varied length linker mimic ha trimers binding sites figure <NUMBER> iv cryoelectron tomography showed qβ capsids covering ax<NUMBER> virus h<NUMBER>n<NUMBER> subtype envelop significantly blocking host cell interaction figure <NUMBER> v phage capsid nanoparticles shown potential inhibit virus infection vitro ex vivo vivo studies figure <NUMBER> vi nanotechnology tools play pivotal role advancing covid<NUMBER> treatment vaccine development information related structural morphology sarscov<NUMBER> virus pathophysiology related immunological response vital nanotechnology scientists absence specific antiviral sarscov<NUMBER> present therapeutics target multifaceted molecular interactions involved viral infections majorly comprises repurposing already existing antiviral molecules used rna viruses equally important look suitable nanocarrier delivery technology make repurposed therapeutics safer effective manuscript provides systematic information nanomedicine strategies employed deliver small molecules biologicals specifically rnai various combination therapies strategies also proposed rational development nanomedicine approach clinical translation journey covid<NUMBER> vaccine development impressive involves hightech platforms viral vectors antigen carriers delivery technology mrnabased vaccine employing nanoparticle lnps delivery already clinical trials whereas another vaccine candidate clinical phase using electroporation technology intradermal administration dna plasmid since covid<NUMBER> vaccine candidates sophisticated biological moieties dna mrna recombinant proteins engineered apcs etc scope nanocarrier delivery becomes highly pertinent manuscript details opportunities presented nanocarriers potentiate success covid<NUMBER> vaccine terms efficacy safety opportunities include nanocarrierbased effectivetargeted delivery better antigen presentation induction complimenting immunomodulatory effect rational designing nanocarrierbased vaccine equally important clinical success hence strategies related nanocarrier selection antigen loading effective delivery discussed manuscript special emphasis given vans either act carrier molecular adjuvants mount proor antiimmunity effect miscellaneous technologies based functionalized cqds biomimicking nanoscaffolds also discussed present scope unconventional therapeutics era advanced nanoscience tools implement technologies play frontline role tackling outbreak supporting information available free charge httpspubsacsorgdoi<NUMBER>acsnano<NUMBER>c<NUMBER> figure <NUMBER> representation residues involved interaction rbd domain sarscov<NUMBER> peptidase domain human ace <NUMBER> pdb id <NUMBER>m<NUMBER>j table s<NUMBER> side effectstoxicity existing antiviral molecules development covid<NUMBER> therapeutics authors declare competing financial interest authors would like acknowledge financial support provided nanosensors devices research group tecnologico de monterrey <NUMBER>i<NUMBER> authors would also like acknowledge financial support provided federico baur endowed chair nanotechnology <NUMBER>i<NUMBER> gc somc acknowledge funding conacyt grants sni <NUMBER> sni <NUMBER> respectively vocabulary covid<NUMBER> coronavirus disease <NUMBER> sarscov<NUMBER> causative agent responsible covid<NUMBER> pandemic angiotensin converting enzyme <NUMBER> ace<NUMBER> receptor host cell receptor responsible sarscov<NUMBER> viral entry cells receptor binding domain rbd domains present s<NUMBER> subunit viral protein responsible entry host cells binding host receptor ace<NUMBER> pathogenassociated molecular patterns pamps damageassociated molecular patterns damps small molecular motifs derived virus recognized patternrecognition receptors play key role innate immunity recognition virus drive inflammation response infections vaccine adjuvant nanoparticles vans nanoparticles enhance overall efficacy safety vaccine various mechanism recent outbreak pneumonia wuhan china associated betacoronavirus group <NUMBER>b family coronaviridae order nidovirales <NUMBER> <NUMBER> viruses positivesense rna enveloped nonsegmented <NUMBER> coronavirus disease covid<NUMBER> known third human zoonosis <NUMBER> st century caused new strain previously identified humans <NUMBER> coronaviruses causing minor infections respiratory tract humans nl<NUMBER> oc<NUMBER> hcov<NUMBER>e hku<NUMBER> lethal coronavirus infections emerged century middle east respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov recent sarscov <NUMBER> covid<NUMBER> <NUMBER> source covid<NUMBER> still confirmed evidence suggests source may seafood market huanan wuhan china <NUMBER> <NUMBER> center disease control prevention cdc reported recent covid<NUMBER> caused betacoronavirus like previous two outbreaks coronaviruses mers sars source camels bats respectively <NUMBER> first transmission cov animals humans notified <NUMBER> causing sarscov <NUMBER> mortality rate <NUMBER> suggested virus needs intermediate reservoir infect humans efficiently confirmed later thorough investigation revealing palm civets raccoon dogs wet market carried sarscov viral rna might act like intermediate reservoirs <NUMBER> covid<NUMBER> rna virus carries high mutation rate ability transfer person person compared coronaviruses according world health organization till <NUMBER>rd february <NUMBER> covid<NUMBER> affected total <NUMBER> individuals across globally <NUMBER> reported china <NUMBER> reported countries death toll china <NUMBER> <NUMBER> deaths reported rest world according reports till <NUMBER>nd january <NUMBER> <NUMBER> patients admitted hospital patients men <NUMBER> exposure huanan seafood market median age patients <NUMBER> years <NUMBER> healthcare workers also diagnosed infection including working similar wards <NUMBER> time taken covid<NUMBER> infect individuals similar sars estimated average infected person infects <NUMBER> persons occurrence increases twofolds every <NUMBER> days <NUMBER> observed people mild infection actively spread infection <NUMBER> due critical nature outbreak virus sequenced urgent basis first sequence available <NUMBER> th january <NUMBER> online virologicalorg noted covid<NUMBER> much resemblance sarscov genomic level <NUMBER> symptoms covid<NUMBER> include fever dry cough shortness breath dyspnea sore throat leukopenia date vaccine covid<NUMBER> available need hour develop vaccine prevent spread disease end immunoinformatics applied complete protein data set virus deep antigen analysis thus save time cost designing vaccine covid<NUMBER> ease early development vaccine proposed design subjected immediately experimental trials stepwise flow methodology followed design vaccine covid<NUMBER> illustrated fig<NUMBER> fig<NUMBER> designed workflow silico vaccine engineering covid<NUMBER> complete dataset proteins available ncbi <NUMBER> coronavirus data hub httpswwwncbinlmnihgovlabsvirusvssivirusseqtypesnucleotideviruslineagess wuhan<NUMBER>seafood<NUMBER>market<NUMBER>pneumonia<NUMBER>virus<NUMBER>taxid<NUMBER>utmcampaignw uhanncovutmsourceinsightsutmmediumreferral retrieved subjected screening phase identify potential vaccine candidates first host nonsimilar proteins pathogen filtered show homology human host taxonomic id <NUMBER> proteins sequence e score <NUMBER> e <NUMBER> bit score <NUMBER> sequence identity ≤ <NUMBER> selected <NUMBER> blastp search mouse mus musculus taxonomy id <NUMBER> performed using host nonsimilar proteins keeping input parameters e score cutoff <NUMBER> bit score <NUMBER> identity <NUMBER> <NUMBER> screened mouse nonsimilar proteins subjected tmhmm <NUMBER> <NUMBER> hmmtop <NUMBER> <NUMBER> observing number transmembrane helices proteins less two transmembrane helices subjected spaan <NUMBER> predicting adhesive proteins potential facilitate attachment host tissues <NUMBER> selected vaccine candidates used blastp tool align selected adhesive protein candidates probiotic bacteria proteome including three lactobacillus species l rhamnosus tax id <NUMBER> l johnsonii tax id <NUMBER> lactobacillus casei tax id <NUMBER> avoid accidental inhibition useful gut bacteria <NUMBER> selected vaccine candidates subjected immune epitope database iedb bepipred linear epitope prediction <NUMBER> <NUMBER> <NUMBER> <NUMBER> threshold <NUMBER> used prediction linear bcells epitopes utilized tcell epitopes mapping identify subsequences potential bind reference set major histocompatibility complex mhc class ii alleles <NUMBER> epitopes ranked according percentile score ones low percentile considered high affinity binders selected bcell derived tcell epitopes subjected mhcpred <NUMBER> <NUMBER> analysis interpreting binding affinity potential cutoff criterion set ic <NUMBER> values <NUMBER> nm drb<NUMBER> <NUMBER> following virulentpred <NUMBER> vaxijen <NUMBER> <NUMBER> utilized validate virulence antigenicity selected epitopes respectively allertop <NUMBER> <NUMBER> applied remove allergic epitopes clc main workbench employed check conservation nonallergic epitopes required designing effective broadspectrum vaccine overlapping immunodominant epitopes used construct multiepitope peptide mep considered promising strategy stop viral infections <NUMBER> one key issues design peptide vaccine weak immunogenicity resolved designing mep appropriate adjuvants <NUMBER> current study mep designed using aay linkers combine screened multiple epitopes <NUMBER> nterminal mep adjuvant form b subunit cholera toxin linked mep thus creating multiepitope peptide vaccine construct mepvc <NUMBER> tertiary structure mepvc created software called <NUMBER>dpro scratch protein predictor <NUMBER> itasser <NUMBER> swissmodel <NUMBER> best model loop modelled using galaxyloop <NUMBER> refined using galaxyrefine <NUMBER> galaxyweb improve constructs stability disulfide bonds introduced structure <NUMBER> using design <NUMBER> <NUMBER> sequence mepvc translated reverse optimized codon usage according escherichia coli end increased expression mepvc sequence cloned mentioned expression system <NUMBER> entire activity accomplished using java codon adaptation tool jcat server <NUMBER> order assess expression sequence cloned gc content codon adaptation index cai measured value <NUMBER> cai contemplated ideal <NUMBER> <NUMBER> whereas appropriate gc content fluctuated <NUMBER> due favorable transcriptional translational efficiencies <NUMBER> input factors carefully calculated prevent rhoindependent transcription termination binding sites prokaryotic ribosome cleavage sites restriction enzyme final step phase cloning engineered construct carried pet<NUMBER>a expression vector using snapgene httpswwwsnapgenecom protparam tool <NUMBER> applied analyzing physical chemical properties mepvc amino acid composition estimated halflife instability index extinction coefficient theoretical pl atomic composition molecular weight grand average hydropathicity gravy assist experimental studies instability index one key parameters significantly considered helps discarding unstable protein candidates protein instability index <NUMBER> step vaccine construct underwent immune response profiling immunogenicity classification done using cimmsim server <NUMBER> order predict immune epitopes positionspecific scoring matrix pssm employed cimmsim used whereas different machine learning procedures used forecast immune connections server concurrently used execute immune simulation <NUMBER> compartments bone marrow tertiary lymph nodes thymus <NUMBER> default simulation parameters used follows random seed <NUMBER> simulation steps <NUMBER> simulation volume <NUMBER> host hla selection mhc class a<NUMBER> allele b mhc class b<NUMBER> dr mhc class ii drb<NUMBER> allele time step injection set <NUMBER> technique molecular docking utilized predict conformation mepvc respect suitable innate immune receptor analysis plays significant role determine highaffinity contacts amid vaccine construct immune receptor pdb id <NUMBER>g<NUMBER>a tlr<NUMBER> pdb id <NUMBER>a<NUMBER>z retrieved protein data bank pdb tlr<NUMBER> tlr<NUMBER> respectively blind docking employed calculate regular pose vaccine construct mentioned receptors using online patchdock server <NUMBER> resulting structures refined using fast interaction refinement molecular docking firedock <NUMBER> top ranked complex minimum global energy selected used analyse binding pose intermolecular connections using ucsf chimera <NUMBER> <NUMBER> discovery studio ds visualizer <NUMBER> <NUMBER> <NUMBER> visual molecular dynamics vmd <NUMBER> software <NUMBER> order gain insights dynamics vaccine construct receptors molecular dynamics md simulations carried simulation analysis also important validate exposure epitopes towards host structure identification handling substantial outcome md simulations took place three different phases system preparation preprocessing production <NUMBER> assistant model building energy refinement amber <NUMBER> <NUMBER> antechamber program <NUMBER> used build libraries parameters tlr<NUMBER> vaccine construct tip<NUMBER>p solvation box size <NUMBER> å inserted solvate construct study intermolecular interactions force field ff<NUMBER>sb <NUMBER> used whereas system neutralized addition na counter ions second phase md simulations energy minimization complexes carried complex minimized using following steps energy minimization hydrogen atoms <NUMBER> cycles energy minimization water box <NUMBER> cycles control <NUMBER> kcalmol å <NUMBER> rest system minimization whole atoms system <NUMBER> cycles restraint <NUMBER> kcalmol å <NUMBER> cα atoms rest system subjected nonheavy atoms minimization <NUMBER> cycles restraint <NUMBER> kcalmol å <NUMBER> next step system gradually heated <NUMBER> k <NUMBER> k time step <NUMBER> femtoseconds restraints <NUMBER> kcalmol å <NUMBER> cα atoms order sustain temperature system langevin dynamics <NUMBER> gamma value <NUMBER> castoff shake algorithm <NUMBER> used put constraints hydrogen bonds system heating next step systems equilibrated <NUMBER> ps time step <NUMBER> fs followed pressure equilibrium attained using npt ensemble restraints <NUMBER> kcalmol å <NUMBER> cα atoms step extended <NUMBER> ps <NUMBER> scale restraints carbon atoms however step system equilibration carried time scale <NUMBER> nanosecond followed production run <NUMBER> ns time scale <NUMBER> fs production run berendsen algorithm <NUMBER> nvt ensemble cast cutoff <NUMBER> ǻ simulation trajectories calculated investigate strength complex via cpptraj module <NUMBER> amber however visualization simulation trajectories done ucsf chimera <NUMBER> ds visualizer <NUMBER> vmd <NUMBER> order estimate mmpbsa binding free energies receptors multiepitope peptide vaccine construct mmpbsapy module <NUMBER> amber<NUMBER> castoff program generated input files complex receptor mepvc molecule using antemmpbsapy module compute variance solvated unsolvated phases <NUMBER> frames simulation trajectories picked analyzed <NUMBER> precise values binding free energies two different conformations matched binding energies significant residues estimate free binding energy anticipated complex δg bind solv resolved using three equations given net free binding energy decomposition residue highlight interacting stable residues ncbi recently dedicated coronavirus disease data hub containing nucleotide protein sequences information published across world study aimed silico prioritization potential vaccine candidates designing chimeric peptide vaccine covid<NUMBER> based available protein sequences data hub several bioinformatic immunoinformatics techniques employed aim assist experimentalists vaccine development virus prioritization potential vaccine candidates could help minimizing time labor cost resources developing optimizing success getting effective vaccine pathogen total <NUMBER> protein entries retrieved table <NUMBER> analyzed first sequence homology human host proteome significant evaluate homology virus protein used vaccine designing host likely cause strong autoimmune reactions host <NUMBER> check identified two proteins orf<NUMBER>a polyprotein accession id yp<NUMBER> nsp<NUMBER> accession id yp<NUMBER> host homologous thus discarded evaluations experimental studies human vaccines usually done mice many practical advantages provide compared vaccine research higher animal models <NUMBER> appropriateness mice animal model vaccine research defined ability reproduce relevant human physiology <NUMBER> considering homology check devoted pipeline applied filtered human nonsimilar proteins <NUMBER> number ensure selection nonsimilar mice proteins assessment resultant shortlisting orf<NUMBER>ab polyprotein accession ids qhq<NUMBER> qhd<NUMBER> qhr<NUMBER> qhr<NUMBER> qhq<NUMBER> qho<NUMBER> qhq<NUMBER> qhr<NUMBER> qho<NUMBER> qho<NUMBER> qhn<NUMBER> qhr<NUMBER> qhr<NUMBER> qhn<NUMBER> qhr<NUMBER> qho<NUMBER> nsp<NUMBER> accession id yp<NUMBER> mice similar proteins mice nonsimilar proteins aid discouraging false positive results vivo experimentations accurate interpretation immune protective efficiency prioritized vaccine candidates virus <NUMBER> <NUMBER> next enumeration transmembrane helices pooled <NUMBER> mice nonsimilar proteins accomplished transmembrane topology characterization deemed vital relatedness afterward experimental expression studies proteins protein transmembrane helices less <NUMBER> numbers often considered best vaccine candidates multiple helices make recombinant proteins purification expression difficult vaccine development <NUMBER> result <NUMBER> proteins spanning across five types include orf<NUMBER>a polyprotein accession id qhq<NUMBER> qhr<NUMBER> qhd<NUMBER> qhq<NUMBER> qhq<NUMBER> qho<NUMBER> yp<NUMBER> qhn<NUMBER> qhn<NUMBER> qho<NUMBER> nsp<NUMBER> accession id yp<NUMBER> membrane glycoprotein accession id qhd<NUMBER> qhq<NUMBER> qhq<NUMBER> qhq<NUMBER> yp<NUMBER> qho<NUMBER> qhn<NUMBER> qhn<NUMBER> qho<NUMBER> qhr<NUMBER> membrane protein accession id qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> matrix protein accession id qho<NUMBER> qho<NUMBER> nonstructural protein ns<NUMBER> accession id qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> qhr<NUMBER> containing multiple helices therefore proceeded creation adhesinbased vaccines considered attractive effective strategy explored solution number infectious pathogens <NUMBER> idea behind exploiting adhesin vaccine based promising preclinical findings aim confer protective immunity via two main mechanisms opsonization driven opsonising antibodies capable binding target antigen immunological tag leading activation components host immune system enhance recognition pathogen subsequent complement system activity virus killing phagocytosis ii neutralization driven adhesinspecific antibodies block virus binding ability host tissues adhesion probability computation revealed <NUMBER> protein adhesion probability value greater threshold tabulated table <NUMBER> ideal putative vaccine candidates covid<NUMBER> adhesin probability protein ranges <NUMBER> <NUMBER> mean <NUMBER>antigenicity proteins predicted reflect ability binding products adaptive immunity antibodies tcell receptors total <NUMBER> proteins nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> <NUMBER>clike proteinase spike glycoprotein surface glycoprotein orf<NUMBER>ab polyprotein recognized antigenic scored higher threshold coronavirus nsp<NUMBER> suggested diverse activities including templatedependent rna polymerase activities canonical rnadependent rna polymerases cofactor function nsp<NUMBER> nsp<NUMBER>mediated rnadependent rna polymerase activity metal iondependent rna <NUMBER>′ polyadenylation activities <NUMBER> nsp<NUMBER> nonstructural protein <NUMBER> key coronavirus replication singlestranded rnabinding protein <NUMBER> nsp<NUMBER> critical cofactor switches multiple enzymes replication cycle known interact nsp<NUMBER> nsp<NUMBER> subunits activating respective <NUMBER>′<NUMBER>′ exoribonuclease <NUMBER>′omethyltransferase functions <NUMBER> <NUMBER>clike proteinase main cysteine protease nonstructural protein number <NUMBER> nsp<NUMBER> essential mediating cleavage nsp<NUMBER> nsp<NUMBER> <NUMBER> trimeric transmembrane coronavirus spike glycoprotein initiates infectious cycle binding specific receptor host membrane followed viral fusion <NUMBER> surface glycoprotein analyzed different sequence patch leu<NUMBER>phe<NUMBER> start spike glycoprotein orf<NUMBER>ab replicase polyprotein cleaved papainlike protease <NUMBER>clike protease specific cleavage sites yield <NUMBER> <NUMBER> nonstructural proteins nsps <NUMBER> final numbers potential vaccine candidates obtained step step subtraction phase presented fig<NUMBER> identification epitopes given antigens vital number practical reasons including understanding etiology disease monitoring immune system development diagnostic assays epitopebased vaccines designing <NUMBER> vaccine designing point view host adaptive immunity highly specific able recognize destroy invading pathogen <NUMBER> additionally adaptive immunity able remember pathogens creating longlasting pathogenspecific protective memory enabling stronger attacks pathogen reencountered successive times <NUMBER> arm host immune system driven lymphocytes two types b tcells responsible humoral cellmediated immunity respectively <NUMBER> cells recognize pathogen molecular components called antigens antigens interact specific receptors present surface b tcells activation cells required antigen recognition receptors addition second activation signals innate system vaccine candidates prioritized first phase deeply investigated bcell epitopes different lengths linear bcell epitopes predicted protein recurrent epitopes simultaneously predicted different servers selected chimeric vaccine designing bcell epitopes predicted vaccine candidates following order nine nsp<NUMBER> <NUMBER>clike proteinase five nsp<NUMBER> eight nsp<NUMBER> <NUMBER> spike glycoprotein surface glycoprotein four orf<NUMBER>ab polyprotein partial bcells epitopes recognized solventexposed antigens bcell receptors bcr upon activation bcells secrete antibodies antibodies different functions including neutralizing pathogens toxins labeling pathogens destruction <NUMBER> proteins also analyzed tcell epitopes stringent criteria pvalue less <NUMBER> epitopes different lengths interact several different alleles mhci mhcii nsp<NUMBER> <NUMBER> epitopes predicted whereas nsp<NUMBER> nsp<NUMBER> <NUMBER>clike proteinase spike glycoprotein surface glycoprotein orf<NUMBER>ab polyprotein partial protein mapped <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively tcell epitopes epitopes presented surface specific receptors known tcell receptor tcr allowing recognition antigens displayed antigenpresenting cells bound mhc molecules <NUMBER> epitopes presented mhc recognized cd<NUMBER> cytotoxic lymphocytes <NUMBER> whereas presented mhc ii recognized cd<NUMBER> tcells <NUMBER> cd<NUMBER> tcells later become helper tcells amplify immune responses pathogen comparative analysis predicted epitopes carried select epitopes common bcell cd<NUMBER> tcell cd<NUMBER> tcell alleles order design specific effective strong vaccine basis three epitopes nsp<NUMBER> drdaamqrk qarsedkra eqavangdsev none nsp<NUMBER> orf<NUMBER>ab polyprotein partial protein four nsp<NUMBER> gcscdqlrep ylasggqpit ylasggqpi tvtpeanmdqesfg three <NUMBER>clike proteinase edmlnpnyedl kynyepltqdhv eftpfdvvr five spike glycoprotein rvystgsnvfq vnnsyecdipi ladagfikqygdclg gqskrvdfc rnfyepqiittd surface glycoprotein rvystgsnvfq vnnsyecdipi ladagfikqygdclg gqskrvdfc rnfyepqiittd epitopes reevaluated antigenicity check make sure binding potential binding immune cells nsp<NUMBER> drdaamqrk qarsedkra found antigenic score higher default threshold <NUMBER> whereas third epitope eqavangdsev found nonantigenic hence removed four epitopes nsp<NUMBER> revealed nonantigenic therefore processed case <NUMBER>clike proteinase kynyepltqdhv found nonantigenic whereas edmlnpnyedl eftpfdvvr antigenic therefore considered afterward analysis spike glycoprotein contains epitopes vnnsyecdipi rnfyepqiittd antigenic whereas none surface glycoprotein provided epitopes antigenic following affinity filtered antigenic epitopes prevalent drb<NUMBER> allele humans evaluated ic <NUMBER> value value <NUMBER> nm classified high affinity binders pooled antigenic epitopes found great ability binding mentioned allele similarly epitopes evaluated allergenicity virulent potential check virulent nonallergen selected virulent check significant ensuring selection epitopes mediating infectious pathways host final selected epitopes cleared checks tabulated table <NUMBER> mep constructed first comprising epitopes finalized previous phase mep based vaccines considered ideal approach prevent treat viral infections <NUMBER> epitopes shown table <NUMBER> linked flexible aay linkers allows efficient separation required effective working epitope mep designed nterminus adjuvant cholera toxin subunit b ctb added <NUMBER> schematic representation mepvc shown fig<NUMBER> ctb nontoxic part cholera toxin considered accelerator protective immunity break autoimmunity shows high affinity monosialotetrahexosylganglioside displayed variety cell types including gut epithelial cells antigenpresenting cells dendritic macrophages bcells <NUMBER> ctb preferred choice adjuvant ability selfexpression variety organisms coupled antigens several approaches involving chemical manipulation genetic fusion resulting strong immunological responses antigens attached vaccine construct used comparative <NUMBER>d structure prediction ensure confidentiality selection suitable model construct minimum structural errors several different physicochemical properties mepvc deduced sequence vaccine construct <NUMBER> amino acids long total number <NUMBER> atoms molecular weight construct ideal ie <NUMBER> kd small size construct easy handle purify experimental evaluation construct instability index value <NUMBER> signifying high stability aliphatic index computed construct <NUMBER> reflecting high thermostability estimated halflife mammals yeast escherichia coli <NUMBER> hours <NUMBER> hours <NUMBER> hours respectively grand average hydropathicity gravy score <NUMBER> highlights hydrophilic nature construct theoretical pi <NUMBER> pointing construct slightly acidic nature secondary structure elements vaccine construct divided following order alpha helix <NUMBER> <NUMBER> <NUMBER> helix <NUMBER> pi helix <NUMBER> beta bridge <NUMBER> extended strand <NUMBER> betaturn <NUMBER> bend region <NUMBER> random coil <NUMBER> compared itasser phyre<NUMBER> swissmodel <NUMBER>dpro predicted structure determined suitable structure based complete modeling given length amino acid sequence loop modeling done leu<NUMBER>gln<NUMBER> ser<NUMBER>gln<NUMBER> glu<NUMBER>gln<NUMBER> glu<NUMBER>ser<NUMBER> val<NUMBER>thr<NUMBER> glu<NUMBER>asp<NUMBER> model refined minimum rmsd <NUMBER> å molprobity score <NUMBER> quite low compared original structure score <NUMBER> reflecting good quality modelled structure similarly clash score contrast original structure <NUMBER> times lower demonstrating steric clash free structure galaxy energy structure stable <NUMBER> ramachandran favored distribution increased <NUMBER> <NUMBER> top <NUMBER> refined models mepvc tabulated table <NUMBER> <NUMBER>d models vaccine construct loop modelling refinement presented fig<NUMBER>a overall zscore modelled structure <NUMBER> score within range size proteins pdb illustrating good quality depicted fig<NUMBER>b refinement structure ramachandran plot demonstrated construct contain <NUMBER> residues favored regions <NUMBER> <NUMBER> <NUMBER> residues additional allowed region generously allowed region disallowed regions respectively fig<NUMBER>c overall average gfactor construct <NUMBER> ramachandran plot mepvc illustrating distribution torsion angles blue squares comparative core shown red allowed shown brown regions residues generously allowed region shown dark yellow whereas disallowed regions depicted pale yellow enhancing protein stability important many biomedical applications appealing approach emulate nature stabilizing molecular interactions <NUMBER> covalent disulfide bonds provide substantial stability target proteins disulfide engineering achieved considerable success broad range applications <NUMBER> total <NUMBER> pairs residues selected purpose disulfide engineering include met<NUMBER>ser<NUMBER> lys<NUMBER>ala<NUMBER> val<NUMBER>asp<NUMBER> ser<NUMBER>asp<NUMBER> thr<NUMBER>ser<NUMBER> val<NUMBER>gln<NUMBER> ala<NUMBER>ala<NUMBER> met<NUMBER>ala<NUMBER> ala<NUMBER>asp<NUMBER> leu<NUMBER>leu<NUMBER> asn<NUMBER>asp<NUMBER> average chi<NUMBER> energy value pairs <NUMBER> max <NUMBER> min <NUMBER> <NUMBER> max <NUMBER> min <NUMBER> disulfide engineered mepvc structure presented fig<NUMBER> follow experimental studies maximum expression mepvc highly desirable <NUMBER> one requirement codon usage mepvc must adapted according expression system instance used e coli k<NUMBER> mepvc expression system codon adaptation index cai gc content revealed improved sequence highly satisfactory value <NUMBER> <NUMBER> respectively strongly indicating high mepvc expression mepvc enclosed sites <NUMBER>x histidine tag ease purification process inserted appropriate sites pet<NUMBER>a vector shown fig<NUMBER> fig<NUMBER> silico restriction cloning mepvc pet<NUMBER>a vector insert shown red molecular interactions binding conformation designed mepvc tlr<NUMBER> tlr<NUMBER> innate immune receptors deciphered via proteinpeptide docking approach tlr<NUMBER> tlr<NUMBER> belong tolllike receptor family pattern recognition receptor function activate intracellular signaling nfκb pathway production inflammatory cytokines responsible development effective innate immunity <NUMBER> <NUMBER> receptors recognize viral associated molecular patterns induce production interferon leading activation strong host defense responses also specific adaptive immunity takes time establish antigens therefore important evaluate mepvc affinity innate immune receptors case mrpvctlr<NUMBER> complex patch dock predicted <NUMBER> best solutions sorted based docking geometric shape complementarity score table <NUMBER> high score implies enhanced affinity interacting molecules best docked conformations molecules respect solution <NUMBER> visualized docked conformations intermolecular forces responsible high affinity molecules selection based firedock analysis table <NUMBER> efficient package refinement reassigning procedure docking scores rigid body docking solutions global binding energy solution <NUMBER> better ie <NUMBER> kjmol compared rest predicted solutions contribution total score form attractive van der waals vdw energy <NUMBER> kjmol repulsive vdw energy <NUMBER> kjmol hydrogen bond hb energy <NUMBER> kjmol atomic contact energy ace <NUMBER> kjmol mepvc within <NUMBER> å noticed posed right center tlr<NUMBER> receptor fig<NUMBER> interacting via hydrogen hydrophobic bonds his<NUMBER> asp<NUMBER> lys<NUMBER> glu<NUMBER> ser<NUMBER> phe<NUMBER> asp<NUMBER> asp<NUMBER> ser<NUMBER> ser<NUMBER> asp<NUMBER> ser<NUMBER> tyr<NUMBER> asp<NUMBER> asp<NUMBER> glu<NUMBER> tyr<NUMBER> phe<NUMBER> glu<NUMBER> tyr<NUMBER> arg<NUMBER> glu<NUMBER> his<NUMBER> lys<NUMBER> tyr<NUMBER> p<NUMBER> his<NUMBER> iso<NUMBER> gly<NUMBER> his<NUMBER> glu<NUMBER> pro<NUMBER> asp<NUMBER> phe<NUMBER> gln<NUMBER> glu<NUMBER> similarly among <NUMBER> predicted mepvctlr<NUMBER> complexes table <NUMBER> solution <NUMBER> table <NUMBER> affirmed best total global energy <NUMBER> kjmol whereas rest complexes noticed highly unstable score positive attractive vdw repulsive vdw hb ace contribution global energy <NUMBER> kjmol <NUMBER> kjmol <NUMBER> kjmol <NUMBER> kjmol respectively visual analysis complex revealed binding mepvc interface chains b fig<NUMBER> mepvc surrounded chain b residues pro<NUMBER> glu<NUMBER> ser<NUMBER> asp<NUMBER> lys<NUMBER> asp<NUMBER> asp<NUMBER> arg<NUMBER> arg<NUMBER> glu<NUMBER> pro<NUMBER> gln<NUMBER> asp<NUMBER> his<NUMBER> asp<NUMBER> ser<NUMBER> lys<NUMBER> chain residues lys<NUMBER> phe<NUMBER> asp<NUMBER> dynamic simulations human immune system response designed vaccine construct deciphered cimmsim server <NUMBER> vaccine construct upon administration revealed generate robust primary immune responses seen fig<NUMBER>a combine igm igg antibodies titer scale close <NUMBER>ml followed igm antibody <NUMBER> antibody titer per ml combined igg<NUMBER> igg<NUMBER> igg<NUMBER> seen generate high titer scale around <NUMBER>ml <NUMBER>ml respectively igg<NUMBER> antibody response revealed low throughout post vaccine administration period dimerized soluble cytokine ifng produced antigen <NUMBER> ngml fig<NUMBER>b silico simulation host immune system using mepvs antigen antibodies titer cytokines interleukins b response antigen stability dynamics designed vaccine construct ensemble docked innate immune receptors disclosed <NUMBER>ns md production run interpreted root mean square deviation rmsd <NUMBER> root mean square fluctuation rmsf <NUMBER> radius gyration rg <NUMBER> beta factor βfactor <NUMBER> assays depicted fig<NUMBER> average cα atomic distance <NUMBER> frames tlr<NUMBER>mepvc tlr<NUMBER>mepvc decoded rmsd assay average rmsd <NUMBER> å maximum <NUMBER> å <NUMBER> å maximum <NUMBER> å estimated tlr<NUMBER>mepvc tlr<NUMBER>mepvc respectively tlr<NUMBER> tlr<NUMBER> receptors observed compact mepvc result continuous movements vaccine construct length noticed exposed regions though rooted stable docked position seems responsible bringing small structural deviation probed rmsd visual inspection trajectories illustrated major global local secondary structure conformation changes receptor tlr<NUMBER> tlr<NUMBER> structure mepvc movements respect tlr<NUMBER> shown different snapshots illustrated fig<NUMBER> mepvc seems responsible deviations receptor tlr<NUMBER> positions glu<NUMBER>ser<NUMBER> hie<NUMBER>asn<NUMBER> gln<NUMBER>gln<NUMBER> gln<NUMBER>pro<NUMBER> lys<NUMBER>lys<NUMBER> continuous flexibility loops mepvc exposed region observed highly flexible responsible movements mepvc docked site though rooted stably fig<NUMBER> hydrogen bonding results hydrogen atom attached highly electronegative atom attracted another electronegative atom <NUMBER> biological system hydrogen bonds vital determining specificity directionality fundamental molecular recognition <NUMBER> patterns hydrogen bonds complexes illustrated frame within <NUMBER> å order probe strength intermolecular association across simulation period maximum number hydrogen bonds mepvc tlr<NUMBER> tlr<NUMBER> <NUMBER> <NUMBER> respectively demonstrating high strength interactions number hydrogen bonds complexes shown fig<NUMBER> fig<NUMBER> number hydrogen bonds formed simulation mepvc tlr<NUMBER> tlr<NUMBER> receptors protein molecule salt bridges formed charged side chains amino acids neutral ph residues mainly involved interactions include negative full electron charge glutamine aspartate opposite positive full electron charge arginine lysine <NUMBER> presence salt bridges interacting molecules clear sign strengthening interaction stability tlr<NUMBER>mepvc complex high numbers salt bridges estimated within <NUMBER> å receptor glu<NUMBER> glu<NUMBER> arg<NUMBER> glu<NUMBER> mepvc lys<NUMBER> lys<NUMBER> glu<NUMBER> arg<NUMBER> respectively case tlr<NUMBER>mepvc complex receptor residues arg<NUMBER> asp<NUMBER> arg<NUMBER> involved salt bridging asp<NUMBER> arg<NUMBER> glu<NUMBER> mepvc respectively binding free energies tlr<NUMBER>mepvc tlr<NUMBER>mepvc complexes computed using continuum solvation mmpbsa complementary mmgbsa binding free energies vaccine construct receptors estimated considering molecular mechanics energies well solvation energies net binding free energy complexes revealed high illustrating high interacting affinity molecules tlr<NUMBER>mepvc total free energy binding <NUMBER> kcalmol mmgbsa mmpbsa <NUMBER> kcalmol performing immune system simulation mepvc thorough peptide dynamics analysis novel mepvc proposed probable solution widely spread viral coronaviruses outbreak meanwhile seems necessary deep lesson covid<NUMBER> viral outbreak propagating human species part universe called earth already living serious threat antibiotic antimicrobial resistance <NUMBER> ignored cause havoc current spread covid<NUMBER> clear example even viral resistance coming line referring introduction section probable cause viral attack discussed mandatory mention retaliation animals animalassociated viruses bacteria observed homo sapiens quite frequently recent past <NUMBER> alarms way consuming animals food form livestock time explains advancing defense system various species around either horizontal gene transfer among bacteria transient nature viral transmission throughout world one way form advanced defense organisms meant state even cognitive revolution homo sapiens cannot exempted biological laws considering realm biological laws much expected species right keeping exercising defense mechanism <NUMBER> instead spending wars among humans dire need equipped wars come human species disguise either environmental hazards antimicrobial resistance even viruses finding new ways infecting hosts perspective role avian observed much dominating recent past <NUMBER> insights comparative advancing mechanism mention thereafter preliminary existence theory retaliation basis currently available facts observations theory retaliation play role coming future continuous attacks form outbreaks raised many challenges threats human beings recent mechanism study bazel et al reported h<NUMBER>n<NUMBER> influenza viruses posing threat human animal health currently unclear restricts interspecies jumps host side signified pb<NUMBER>f<NUMBER> short viral peptide assists h<NUMBER>n<NUMBER> bird influenza viruses overcome human restriction factor viral polymerase complex hax<NUMBER> also evidenced functional pb<NUMBER>f<NUMBER> aids direct transmission viruses birds humans <NUMBER> additionally already mechanism existing antimicrobial defense avian eggs illustrates efficacy defense mechanisms <NUMBER> furthermore discovery avian antimicrobial peptides classified bdefensins present chicken turkey found active bacteria fungi yeast another example advance mechanism showed avian possibility common ancestral gene avian mammalian peptides seems obvious <NUMBER> alarmed quite often influenza viruses vast silent reservoir aquatic birds impossible eradicate avian influenza proved threat human health <NUMBER> even phylogenetic identity sarscov<NUMBER> sarscov clinical characteristics differentiate sarscov<NUMBER> sarscov merscov seasonal influenza infections <NUMBER> <NUMBER> leads fact viruses attacking humans different clinical features every time complex relationships human animal species never faced halt evolving giving rise numerous infectious pathogens whatsoever case dramatic impact infectious diseases affecting modern human population worldwide evident unexpected rise coronavirus infections raised <NUMBER> writing research getting beyond normal control httpswwwnaturecomarticlesd<NUMBER>w belong kingdom animalia even ten ten embarrassing similarities chimpanzees <NUMBER> probable prevention context somehow avoid excruciating utilization consumption mammals edibles homo sapiens stop becoming reason extinction certain species avenging species time time utilizing microbes associated human become obvious vaccine design discovery utmost importance crucial strategize preventive control symptomatic relief general taking steps prevent hunting strategy required maintain balanced ecosystem specifically avian dwell threat sapiens advent various new mechanisms viral survival remained sapiens perplexed broader strategy required circumvent problem study used available immunoinformatics approaches purpose prioritize potential vaccine candidates covid<NUMBER> considering ease use experimental investigations bearing mind wide immunological applications peptide vaccines highly antigenic virulent conserved nonallergic epitopes targeted b tcells disclosed multiepitope peptide constructed appropriate adjuvant added allow suitable delivery efficient immune processing epitopes promising computational findings might deliver preliminary epitopes set vaccine covid<NUMBER> notwithstanding experimental testing appropriate animal models unravel real effectiveness meanwhile probable prevention discussed study homo sapiens avoid becoming reason extinction various species either hunting andor utilizing mammals may reason resistance microbes animal species kingdom must strategic studies keeping view advancements defense mechanism avian avian related microbes avenging humans preventive use animals avian human diet avoiding hunting preventive options since april <NUMBER> seventeen people around world infected virus bafed scientists public health ofcials governments initial cases middleeast reported world health organisations global outbreak alert response network set detect epidemics public health emergencies te type virus known novel coronavirus species virus behind common cold origins still mystery tis new virus currently moving slowly coronavirus caused <NUMBER> severe acute respiratory syndrome sars pandemic killed <NUMBER> people scientists work controlling spread new infections full alert one eric snijder professor molecular virology leiden university medical center netherlands studying coronaviruses <NUMBER> years october <NUMBER> team identifed genome properties emerging strain collaborating international group labs hope identifying compounds may inhibit viruss replication te collaboration part european project silver drug design program tackle emerging diseases caused rna viruses new coronavirus snijders work represents initial action taken new infection emerges new subtype infuenza h<NUMBER>n<NUMBER> swine fu new coronavirus understanding biology virus estimating threat poses crucial frst step fnd virus using global monitoring surveillance systems te response network consists <NUMBER> laboratories <NUMBER> un member states recognized national infuenza centres john mccauley director infuenza centre national institute medical research london one six regularly analyses signifcant fu viruses seen population well emerging viruses may cause concern prevalence new infuenza strains increases might indicate world increased risk infuenza epidemic says mccauley global domestic surveillance us carried scientists centers disease control prevention cdc whose labs atlanta part network constant communication needed centers identify whether viruses recorded diferent countries share characteristics threat identifed potential treatments must trialed quickly pandemic preparedness plan put action tis part remit anthony fauci director national institute allergy infectious disease niaid bethesda maryland need understand pathogenesis virus may mutate become highly transmissible cause pandemic says fauci lab starts testing drugs vaccines stop virus tracks collaborate industry run clinical trials new vaccines determine right dose safe efective especially vulnerable members population says <NUMBER> soon h<NUMBER>n<NUMBER> became clear immediately went action develop vaccine tested virus sensitivity drugs already tamifu fortunately sensitive says identifying efective drugs helps buy time public health perspective developing vaccine currently takes six months waiting game another feld infectious disease modeling comes play predict mitigate extent virus spread modeling economics unit uk health protection agency hpa among responsible modeling outcomes <NUMBER> h<NUMBER>n<NUMBER> pandemic run diferent control scenarios use vaccines antivirals see may happen epidemic says edmunds te aim gauge trajectory infection efect actions including economical political control measures travel restrictions school closures models use characteristics like pathogenicity virus likely cause infection predict spread days also use current information cases timings model epidemics realtime technique known nowcasting use many diferent data sources patch together get glimpse many cases really edmunds says wanting get modeling helps diverse skill set need range people skills handle need understand biology statistics computer programming economics bioinformatics ability work efectively others also vital says edmunds sits scientifc pandemic infuenza spi committee alongside modelers virologists experts risk management behavioural sciences diagnostics together feed information government guide policy mobilize resources infuencing policy decisions role always sits well scientists especially time pressures dealing spread dangerous viruses anyone provide clear information communicate risk power lead response says david heymann head centre global health security chatham house chair uk health protection agency particularly contentious problem prioritising receive medicines frst including chemoprophylaxis drugs used infection avoid people getting disease h<NUMBER>n<NUMBER> uk department health hpa made decision treat contacts patients prophylactically slow spread virus says heymann despite time needed development desirable response every pandemic vaccine tis involves collaboration governmentrun organizations industry kanta subbarao leads emerging respiratory viruses section nihs laboratory infectious diseases bethesda collaborates biotech company medimmune develop vaccines infuenza strains show pandemic potential share data presentations publications becomes part body information informs decision making government pharma subbarao says pharmaceutical companies instigate pandemic preparedness plans played integral role h<NUMBER>n<NUMBER> pandemic instance glaxosmithkline set aside two million eggs vaccine production hen eggs traditionally used incubate virus working highly contagious pathogens comes risk work way minimizes risk infection using high containment conditions safety cabinets gloved ports negative pressure use flters trap viruses mccauley says tis type research also extremely controversial potential viruses become transmissible animals humans future study seen important part pandemic preparedness notoriously led yearlong moratorium type research january <NUMBER> tese issues among considered newlyestablished centre global health policy university sussex uk safeguards place minimize risk accidental deliberate misuse research deadly strains infuenza viruses says center director stefan elbe many immunologists working reduce pandemics ultimate goal universal fu vaccine want make vaccine produces response section infuenza virus doesnt change pandemic pandemic says fauci vaccine administered every <NUMBER> <NUMBER> years throughout population could prevent pandemic altogether course wont tackle problem emerging infections sars current coronavirus step right direction fght infuenza seen biggest pandemics date going take several years get says fauci starting see frst glimmers success ■ nature editorial staf responsibility content manufacturing flumist influenza vaccine medimmune dr helen sabzevari feld immunotherapy since infancy working harness bodys immune system treat cancer frst postdoc scripps research institute san diego sabzevari realised disconnect scientists working feld cancer immunotherapy working autoimmunity diseases normally two diseases opposite sides coin says autoimmunity overactivity function immune cells cancer quiescence immune system opinion really important understand sides sabzevari ignored advice mentors already seen career progress immunotherapy decided senior postdoc feld autoimmunity hoped might fnd way use mechanisms cause immune system overreact autoimmune diseases kickstart cells dont respond cancer te decision paid sabzevari spent almost <NUMBER> years researching cancer vaccines national institutes health moving pharma company emdserono leads immunooncolgy research using bodys defences attack cancer cells lead less toxic treatments patients says sabzevari advances made patient remain treatment much longer periods time better lifestyle sabzevari also keen build bridges academia industry hasten availability possible treatments end set programme emdserono allows postdocs spend two three years industry returning academia wish ultimately sabzevari colleagues aim see fndings get clinic quickly possible every day see patients see families lose people says tis career patient department immunology university connecticut health center seeks outstanding investigator tenuretrack position assistantassociatefull professor level although areas immunology considered particularly interested individuals using molecular cellular translational approaches study immune system function vivo areas priority include limited mucosal immunity including microbiome innate immunity signal transduction transcriptional control dendritic cell biology <NUMBER> years laboratories gambia carrying internationally competitive research established leading research centre subsaharan africa perhaps importantly continue push forward new challenging areas developed exciting new research agenda reflect changes national global health priorities new science portfolio organised around three themes child survival disease control elimination vaccination seeking skilled postdoctoral immunologist support number vaccine trials malaria polio first instance employing novel immunological techniques measure vaccine immunogenicity postholder may also support infectious disease vaccine immunology research ongoing vaccinology theme phd immunology extensive handson laboratory practical expertise including state art flowcytometry cytokine analysis flow cytometry multianalyte luminex analysis elispots elisa addition excellent written spoken english proven staff management experience excellent interpersonal verbalwritten communication skills ability meet tight deadlines experience development novel assays human immunology clinical trials interest infectious disease vaccine immunology strategic planning risk management experience working health research significant publication record peerreviewed journals would advantage appointment <NUMBER> years subject probationary period <NUMBER> months attractive salary paid mrcs band <NUMBER> dependent qualifications experience generous overseas allowances furnished accommodation flights benefits apply displaced staff interested skills abilities position please contact human resources office hrmrcgm application form copy job description person specification informal enquiries suitably qualified individuals would welcome please contact dr ed clarke head infant immunology first instance eclarkemrcgm completed application forms together detailed cv covering letter sent hrmrcgm quoting reference gam <NUMBER> department pathology microbiology immunology vanderbilt university school medicine invites applications tenuretrack faculty position assistant professor level phd md mdphd equivalents within search focus immunology areas particular interest include limited immune responses microbes interplay immune system major inflammationrelated diseases cancer atherosclerosis metabolic disorders successful candidates expected establish maintain independent research program participate teaching graduate medical students candidates substantial postgraduate training highlighted peerreviewed publications demonstrate research productivity excellence vanderbilt university medical center located vanderbilt university campus home internationally recognized programs proteomics structural biology imaging science bioinformatics pharmacology drug discovery inflammation vaccines school consistently ranks top <NUMBER> us medical schools provides outstanding opportunities scholarship crossdisciplinary collaborations vanderbilt university campus national arboretum located heart nashville capital tennessee known music city usa nashville home professional sports teams nashville symphony frist center visual arts numerous outdoors activities great place live raise family groundbreaking research teaching outstanding students levels applicants send curriculum vitae statement current future research interests three letters recommendation search committee co helen chomicki dept pathology microbiology immunology vanderbilt university school medicine room a<NUMBER> medical center north <NUMBER> <NUMBER>st ave nashville tn <NUMBER> inquiries applications recommendation letters directed via email helenchomickivanderbiltedu vanderbilt university affirmative actionequal opportunity employer women minority candidates encouraged apply department integrative medical sciences northeast ohio medical university neomed invites applications fill newly created watanakunakorn chair microbiology immunology especially interested applicants whose research programs complement existing departmental strengths cardiovascular disease regenerative medicine lipid metabolism liver biology inflammation viral pathogenesis well enhance expand existing ties neomeds clinical partners northeast ohio applicants expected internationally recognized research program basic translational clinical microbiology immunologyinflammationinfectious disease research history sustained extramural funding commitment academic excellence medical graduate education position requirements include doctorate phd md dvm equivalent successful history principal investigator federal research grants associate professor level qualifications academic medical institution equivalent position provide successful candidate significant laboratory space research resources opportunity grow research neomed recruitment additional junior faculty qualified candidates send cvs along names three references dr william p lynch search committee chair co ms karen j greene kjgneomededu applications reviewed beginning may <NUMBER> <NUMBER> continue suitable candidate recruited neomed thriving freestanding communitybased medical university committed excellence medical education research community outreach institution currently active growth phase includes new state art research facilities expansion comparative medicine unit uniquely neomed located semirural setting ready access outstanding urban suburban rural cultural community recreational activities along low cost living index maximizing quality life issues microbiology immunology vibrant department strengths basic clinical research host pathogen relationships centered studies infectious disease inflammation cancer host microbiome department approximately <NUMBER> square feet laboratory space access many core facilities located schulich school medicine dentistry robarts research institute department strong undergraduate program including honours programs microbiology immunology biochemistry infection immunity department innovative graduate program consisting basic clinically relevant aspects microbiology immunology cancer addition department provides teaching medical dental science health science students undergraduate programs schulich school medicine dentistry faculties science health sciences department plays integral role centre human immunology citywide initiative successful candidate demonstrated track record research excellence reputation effective interpersonal administrative leadership skills new chair expected support research educational interdisciplinary initiatives department help maintain positive forward momentum department develop new initiatives researchscholarship successful candidate expected strengthen bridges across clinical basic science departments institutes view towards developing translational opportunities successful candidate must md dds phd equivalent would receive tenured academic appointment level associate full professor appropriate record accomplishment teaching research candidates research program complementing existing research strengths particularly encouraged apply applications accepted position filled review applicants begin june <NUMBER> <NUMBER> positions subject budget approval applicants fluent written oral communication skills english qualified candidates encouraged apply however canadians permanent residents given priority university western ontario committed employment equity welcomes applications qualified women men including visible minorities aboriginal people persons disabilities mayo clinic rochester mn seeking cancer immunology immunotherapy researcher expected maintain nationally internationally recognized extramurally funded program research within department immunology basic science department within college medicine active participant mayo clinic cancer center mayo clinic collaborative environment bringing researchers clinicians together bring cuttingedge research bench bedside resources available mayo clinic include nihfunded ctsa t<NUMBER> grants ncifunded comprehensive cancer center several active funded spores ovarian cancer breast cancer pancreatic cancer brain cancer lymphoma successful candidate include doctoral degree biomedical sciences md andor phd national recognition experience f eld strong track record publication preference given applicants established research programs aspect cancer immunology immunotherapy individuals active programs involving mobilizing immune response cancer particularly encouraged apply mayo clinic excellent choice candidate seeking career worldclass academic medical center consistently recognized us news world report one americas best hospitals mayo clinics multidisciplinary group practice focuses providing highquality compassionate medical care primary value needs patient come f rst mayo clinic nonprof organization approximately <NUMBER> physicians scientists across locations working unique environment brings together best patient care ground breaking research innovative medical graduate education mayo clinic offers highly competitive compensation package includes exceptional benef ts recognized fortune magazine one <NUMBER> best companies work apply learn please visit wwwmayoclinicorgscientistjobs reference job posting <NUMBER>br applicants include cv statement research interests specif c questions related job posting directed virginia shapiro phd immunology mayo clinic email helgrenbrentmayoedu mayo clinic aff rmative action equal opportunity employer postofferpreemployment screening required university regensburg germany faculty medicine invites applications successful candidate head newly installed department interventional immunology medical faculty regensburg university position initial w<NUMBER>professorship regensburg center interventional immunology wwwrciide interdisciplinary research center development novel immunotherapies cancer infections autoimmune diseases successful candidate expected lead transform rci independent research institute collaborating closely university regensburg university hospital seeking scientist excellent record field transplantation immunology focus cellular molecular mechanisms alloresponses solid organ andor allogeneic stem cell transplantation though primarily basic research position focused development innovative immunological treatment strategies transplantation candidate able support translational research early clinical trials cooperation respective clinical partners university hospital regensburg furthermore competence developing rci independent research institute expected required qualifications applicants include university degree demonstrated teaching abilities md phd degree well scientific achievements equivalent german habilitation applicants beyond age <NUMBER> time appointment exceptions possible according article <NUMBER> paragraph <NUMBER> sentence <NUMBER> bayhschpg university regensburg equal opportunity employer applications handicapped individuals prioritized regensburg university committed increase percentage female scientists encourages female applicants apply furthermore special importance given improving compatibility family career information see httpchancengleichheitfamilieuniregensburgde please submit application curriculum vitae certificates diplomas list publications including reprints <NUMBER> significant reprints extramural funding record precise survey teaching experience may <NUMBER> <NUMBER> dean faculty medicine university regensburg franzjosefstraußallee <NUMBER> <NUMBER> regensburg germany please send written application please use application form httpwwwuniregensburgdefakultaetenmedizinindexhtml bringing jobseekers recruiters together search naturejobscom rapid emergence dissemination infectious diseases taken heavy toll humans since beginning twentyfirst century one wellknown examples outbreak severe acute respiratory syndrome sars winter <NUMBER> <NUMBER> caused novel coronavirus sarscov <NUMBER> <NUMBER> distinct contrast mild human coronaviruses hcov<NUMBER>e <NUMBER> hcovoc<NUMBER> <NUMBER> hcovnl<NUMBER> <NUMBER> hcovhku<NUMBER> <NUMBER> infection sarscov frequently resulted severe symptoms including fever dry cough shortness breath pneumonia transmission sarscov primarily person person cases occurred health care settings lacking adequate infection control precautions <NUMBER> sars outbreak severe consequences <NUMBER> countries regions infecting <NUMBER> people worldwide fatality rate approximately <NUMBER> <NUMBER> still vaccines therapeutics specific sarscov available <NUMBER> years sars outbreak hard imagine catastrophic would sarscov hit human community sarscov remains mystery loose cannon another novel coronavirus emerged saudi arabia <NUMBER> later known middle east respiratory syndrome coronavirus merscov <NUMBER> fatality rate merscov infection approximately <NUMBER> <NUMBER> new cases well associated deaths continue arise date <NUMBER> despite cases attributed humantohuman transmission merscov appear transmit efficiently among humans unless close contact exact source merscov routes transmission humans still remain uncertain dromedary camels believed animal reservoir merscov isolates camels almost identical human many domestic camels seropositive merscov reviewed <NUMBER> <NUMBER> furthermore current evidence strongly suggests bats original source merscov many coronaviruses phylogenetically related merscov originate bats including batcovhku<NUMBER> batcovhku<NUMBER> mersrelated coronaviruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> batcovhku<NUMBER> also shown able engage cellular receptor merscov adding evidence bat origin theory <NUMBER> however yet direct evidence isolating merscov bats reviewed <NUMBER> <NUMBER> <NUMBER> great efforts made develop preventive therapeutic interventions merscov infection particular monoclonal antibodies vaccines targeting spike glycoprotein major areas focus due critical role mediating viral entry potential inducing protective antibody responses infected individuals far twenty monoclonal antibodies nanomolar neutralizing activities reported many vaccine candidates underway preclinical clinical studies review aim capture current advances discuss possible strategies translate discoveries ultimate medical intervention merscov infection merscov belongs genus betacoronavirus coronaviridae family <NUMBER> enveloped singlestranded positivesense rna virus helical capsid structure figure <NUMBER>a genome merscov around <NUMBER> kb <NUMBER>nt long encodes <NUMBER> structural proteins spike envelope membrane nucleocapsid <NUMBER> nonstructural proteins figure <NUMBER> c <NUMBER> like coronaviruses merscov uses spike glycoprotein interact cellular receptors enter target cell <NUMBER> <NUMBER> <NUMBER> <NUMBER> unique structural component virion membrane glycoprotein assembles trimers forms large protruding spikes surface virion <NUMBER> glycoprotein typical type membrane glycoprotein consisting globular s<NUMBER> domain nterminal followed membraneproximal s<NUMBER> domain transmembrane tm domain <NUMBER> s<NUMBER> domain mediates viral attachment contains rbd receptor binding domain determines host range cellular tropism merscov <NUMBER> <NUMBER> <NUMBER> similar coronaviruses s<NUMBER> domain merscov mediating membrane fusion contains hydrophobic fusion peptide fp nterminus well two heptad repeats designated hr<NUMBER> hr<NUMBER> figure <NUMBER> c <NUMBER> copurification merscov s<NUMBER> domain raj colleagues identified dipeptidyl peptidase <NUMBER> dpp<NUMBER> also known cd<NUMBER> functions cellular receptor merscov <NUMBER> merscov virion enters host airway cells respiratory tract fusion either plasma endosomal membrane <NUMBER> binding rbd cell receptor triggers cascade conformational changes lead formation prehairpin intermediate s<NUMBER> hydrophobic hr<NUMBER> exposed allows fusion peptide insert target cell membrane transient s<NUMBER> intermediate refolds hr<NUMBER> stabilized trimer hairpins also called sixhelix bundle structure <NUMBER>hb brings target cell membrane close proximity viral envelope resulting completion fusion process initiation virus life cycle <NUMBER> figure <NUMBER>b structurebased design various peptides able block formation <NUMBER>hb demonstrated potent inhibition merscov replication spikemediated cellcell fusion showing great promise development effective viral fusion inhibitors treating merscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> among peptide ek<NUMBER> effective multiple human coronaviruses apart merscov therefore serves potential pancoronavirus fusion inhibitor <NUMBER> recently structural studies prefusion state spike protein merscov sarscov provided insights spikemediated membrane fusion process <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov spike protein trimerizes folds metastable prefusion conformation virion surface three s<NUMBER> domains fold steady trimer structure sit top stabilize coiled s<NUMBER> domains figure <NUMBER>ab others identified rbd sarscov merscov found either buried position exposed position spike trimer structure <NUMBER> <NUMBER> <NUMBER> <NUMBER> two conformational states rbd may distinct roles receptor binding membrane fusion rbds position position bind cell receptor dpp<NUMBER> figure <NUMBER> cd great steric clash observed dpp<NUMBER> neighboring spike protomers mapped rbd position figure <NUMBER>cd transformation rbd buried exposed state therefore prerequisite receptor binding figure <NUMBER>gh hand conformational change also seems open stable cap structure sitting s<NUMBER> cores figure <NUMBER> ef may lead disassociation s<NUMBER> trimer exposure fusion apparatus triggering membrane fusion process gain better understanding merscov interaction cellular receptors atomic levels others determined crystal structure merscov rbd bound extracellular domain cellular receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> <NUMBER> <NUMBER> showed merscov rbd consists core receptor binding subdomain merscov rbd related sarscov rbd share high degree structural similarity core subdomains notably divergent receptor binding subdomains <NUMBER> receptor binding subdomain merscov rbd directly interacts blades <NUMBER> <NUMBER> dpp<NUMBER> propeller instead intrinsic hydrolase domain interface consists buried surface ∼<NUMBER> å <NUMBER> involving <NUMBER> residues receptor binding subdomain interacting <NUMBER> residues dpp<NUMBER> actual binding forces mediated two major binding patches patch <NUMBER> represents <NUMBER> buried surface forms cterminal end long loop connecting β<NUMBER> β<NUMBER> strands blade <NUMBER> dpp<NUMBER> patch <NUMBER> occupies <NUMBER> buried surface forms slightly concaved outer surface far end merscov receptor binding subdomain linker containing short helix blade <NUMBER> blade <NUMBER> dpp<NUMBER> concaved outer surface made short β<NUMBER> strand cterminal parts β<NUMBER> β<NUMBER> strands nterminal part β<NUMBER> strand β<NUMBER>β<NUMBER> linking loop hoped better understanding atomic details spike glycoprotein well interface merscov rbd dpp<NUMBER> provide structural basis rational design development therapeutics vaccines merscov infection neutralizing antibodies major component protective immunity viral infection humans polyclonal nature antibody response vivo mobilizes dynamic complex mixture monoclonal antibodies mabs work concert target various antigenic domains viral envelope glycoprotein identifying neutralizing mabs constitute neutralizing activity polyclonal response recognized antigenic domains therefore become first crucial step towards gaining better understanding protective antibody response developing clinical intervention methods designing immunogens capable eliciting neutralizing antibodies great achievements made isolation neutralizing mabs past years using various technology platforms figure <NUMBER> till <NUMBER> mabs human humanized antibodies described scientists world antibodies listed chronological order publication table <NUMBER> together unique biochemical antiviral properties merscov infection observed cell culture experimental animal models apparent single chain fragment variable scfv library approach allows rapid discovery mab without time constraints immunizing experimental animals approaching convalescent individuals merscov infection earliest mabs reported <NUMBER> identified screening nonimmune human scfv libraries ectodomain glycoprotein mab <NUMBER>b<NUMBER> <NUMBER> soluble rbd glycoprotein mers<NUMBER> mers<NUMBER> m<NUMBER> panel <NUMBER> <NUMBER> bait protein figure <NUMBER>a antibodies demonstrated high neutralizing activities therefore widely used reference antibodies later studies antibodies also generated immunized animals figure <NUMBER> b several groups reported mabs isolated either wildtype inbred mice transgenic mice expressing human antibodyvariable heavy chains κ light chains mersmab<NUMBER> known hms<NUMBER> humanization isolated mice immunized subcutaneously chimeric s<NUMBER>fc <NUMBER> <NUMBER> mabs <NUMBER>e<NUMBER> <NUMBER>c<NUMBER> humanized form <NUMBER>c<NUMBER> h isolated mice immunized recombinant rbd produced insect cells <NUMBER> furthermore two humanlike mabs regn<NUMBER> regn<NUMBER> directly cloned transgenic mice expressing human versions antibody immunization dna encoding glycoprotein purified recombinant glycoprotein <NUMBER> mabs tested humanized mice models nonhuman primates <NUMBER> <NUMBER> authors indicated advantages system lay human component antibodies also quick speed associated isolation production since humanization optimization step required currently regn<NUMBER> regn<NUMBER> entered phase clinical trials mabs reported far target rbd region glycoprotein rbd seem target antimerscov antibody responses recently mab targeting s<NUMBER> nterminus domain ntd region contain rbd isolated mice immunized glycoprotein <NUMBER> antibody <NUMBER>f<NUMBER> shown successfully block virus entry cell culture models efficacy comparable mabs ic <NUMBER> mab panel d<NUMBER> f<NUMBER> g<NUMBER> g<NUMBER> generated priming similarly <NUMBER>b<NUMBER> m<NUMBER> isolated nonimmunized human scfv phage libraries merscov protein rbd protein bait protein respectively b monoclonal antibodies sorted immunized animals antibodies <NUMBER>f<NUMBER> hms<NUMBER> mersmab<NUMBER> d<NUMBER> f<NUMBER> g<NUMBER> g<NUMBER> <NUMBER>c<NUMBER>h <NUMBER>c<NUMBER> regn<NUMBER> regn<NUMBER> isolated mice immunized indicated vaccines labelled colourcoded boxes representing different immunogen bait target protein antibody selection also listed mice regn<NUMBER> regn<NUMBER> isolated given pale blue colour indicate express human immunoglobulin genes nbms<NUMBER>fc jc<NUMBER> jc<NUMBER> jc<NUMBER> f<NUMBER>bh<NUMBER> hcab<NUMBER> isolated larger animal including llama rhesus macaque camels indicated vaccines selection criteria also shown ntd nterminal domain fc fragment constant c monoclonal antibodies isolated human survivors recovered merscov infection mersgd<NUMBER> mersgd<NUMBER> lca<NUMBER> cdcc<NUMBER> cdcc<NUMBER> cdca<NUMBER> cdca<NUMBER> generated culturing b cells sorted patient screening merscovspecific antibodies mca<NUMBER> produced constructing phage library displaying scfv cloned convalescent patient mice dna encoding fulllength glycoprotein boosting s<NUMBER> protein among two mabs target nonrbd s<NUMBER> mab g<NUMBER> s<NUMBER> region mab g<NUMBER> respectively <NUMBER> nonrbdbinding antibodies potently neutralized pseudoand live merscov cell culture also protective mouse models <NUMBER> <NUMBER> together development antibodies elucidates rbd may single target antiviral antibody response studies needed elaborate detailed mechanisms antibodies apart traditional approach isolating mabs immunized mice several groups turned larger animal models antibody isolation one group immunized rhesus macaques combined dna protein vaccines isolated panel mabs including jc<NUMBER> jc<NUMBER> jc<NUMBER> fibh<NUMBER> targeting rbd nonrbd s<NUMBER> region glycoprotein potent neutralizing activities <NUMBER> another group immunized llama recombinant rbd screened nanobody library highaffinity single heavy chain antibody <NUMBER> nanobodyderived mabs smaller molecular weight stable traditional antibodies may provide new option future antibody isolation terms closeness authentic human antibodies approach compete based direct b cell cloning convalescent individuals one mab lca<NUMBER> isolated memory b cells human survivors merscov infection among potent mabs reported neutralizing pseudoand live viruses <NUMBER> mabs isolated human survivors described convalescent blood samples became available including mca<NUMBER> <NUMBER> cdcc<NUMBER> cdcc<NUMBER> cdca<NUMBER> cdca<NUMBER> <NUMBER> mersgd<NUMBER> mersgd<NUMBER> <NUMBER> <NUMBER> figure <NUMBER> c potent neutralizing activities merscov mabs lca<NUMBER> cdcc<NUMBER> mca<NUMBER> mersgd<NUMBER> also tested protective animal models merscov research progressed quickly past years many mabs tested prophylactic therapeutic protection efficacy human dpp<NUMBER> transgenic transduced mice models entered large animal model trials rabbits nonhuman primates nhps however different animal models established among labs worldwide slightly different evaluation end points difficult make direct comparison among mabs also true vitro evaluation neutralizing activitiessince different cell lines pseudoviruses neutralizing assay techniques utilized published ic <NUMBER> values serve indirect reference comparison head head comparison experimental system would required identify protective mab combination mabs merscov infection order proceed clinical trials others carried structural studies merscov neutralizing antibodies complex mersrbd understand neutralizing mechanism atomic levels figure <NUMBER> based epitopes revealed structural studies merscov antibodies targeting rbd classified three groups figure <NUMBER>b table <NUMBER> first group consists antibodies mers<NUMBER> d<NUMBER> <NUMBER>c<NUMBER> jc<NUMBER> interact cterminal segment β<NUMBER>β<NUMBER> loop β<NUMBER> strand rbd heavy light chains figure <NUMBER>b <NUMBER> <NUMBER> <NUMBER> <NUMBER> common epitopes rbd include residues val<NUMBER> ser<NUMBER> ile<NUMBER> val<NUMBER> pro<NUMBER> ser<NUMBER> trp<NUMBER> glu<NUMBER> asp<NUMBER> β<NUMBER>β<NUMBER> loop residues trp<NUMBER> glu<NUMBER> asp<NUMBER> also happen within dpp<NUMBER>binding site patch <NUMBER> merscov rbd <NUMBER> mediating interaction lys<NUMBER> carbohydrate moiety linked asn<NUMBER> dpp<NUMBER> <NUMBER> therefore group <NUMBER> antibodies would directly compete dpp<NUMBER> binding rbd interfering proteinprotein proteincarbohydrate interactions rbd dpp<NUMBER> structural superimpositions also showed four antibodies dpp<NUMBER> would steric clashes variable domain heavy chain propeller domain dpp<NUMBER> simultaneously bind rbd figure <NUMBER>c second group consists antibodies m<NUMBER> mca<NUMBER> cdc<NUMBER>c<NUMBER> mersgd<NUMBER> interact β<NUMBER>β<NUMBER> strands β<NUMBER>β<NUMBER> loop β<NUMBER>β<NUMBER> loop rbd mainly heavy chain figure <NUMBER>b <NUMBER> <NUMBER> <NUMBER> <NUMBER> common epitope consists phe leu<NUMBER> asp<NUMBER> trp<NUMBER> glu<NUMBER> asp<NUMBER> tyr<NUMBER> tyr<NUMBER> arg<NUMBER> trp<NUMBER> although antibodies group <NUMBER> group <NUMBER> share binding residues trp<NUMBER> glu<NUMBER> asp<NUMBER> approaching angles rbd significantly different shown figure <NUMBER> c approaching angle group <NUMBER> antibodies closer dpp<NUMBER> rotating approximately <NUMBER> degrees anticlockwise group <NUMBER> antibodies thereby generating steric clashes dpp<NUMBER> also evidenced larger overlap common epitope group <NUMBER> antibodies dpp<NUMBER>binding site rbd <NUMBER> representative group <NUMBER> antibodies m<NUMBER> exhibits potent neutralizing activity mimicking critical interactions rbd dpp<NUMBER> also adopting approaching angle similar dpp<NUMBER> figure <NUMBER>c third group consists antibody mers<NUMBER> variant mers<NUMBER>v<NUMBER> four residue replacements hcdr<NUMBER> figure <NUMBER>b <NUMBER> structural determination shown mers<NUMBER> fab mers<NUMBER>v<NUMBER> scfv share mode binding rbd figure <NUMBER>b <NUMBER> analysis rbdmers<NUMBER>v<NUMBER> complex structure showed antibody contacts β<NUMBER>β<NUMBER> β<NUMBER>β<NUMBER> β<NUMBER>β<NUMBER> loops receptorbinding subdomain rbd <NUMBER> epitope involves leu<NUMBER> ser<NUMBER> gln<NUMBER> asn<NUMBER> asn<NUMBER> gln<NUMBER> tyr<NUMBER> pro<NUMBER> lys<NUMBER> leu<NUMBER> gly<NUMBER> <NUMBER> note mers<NUMBER> epitope overlap dpp<NUMBER>binding site figure <NUMBER>c approaching rbd outside dpp<NUMBER>binding site mers<NUMBER> recognizes unique epitope different previously reported rbdtargeting antibodies comparisons rbd dpp<NUMBER>bound mers<NUMBER>bound states revealed binding mers<NUMBER> induces fixes β<NUMBER>β<NUMBER> loop conformation folds shallow groove rbd interface critical accommodating short helix dpp<NUMBER> thereby indirectly disrupting interaction rbd dpp<NUMBER> figure <NUMBER>c different epitope mechanism enable mers<NUMBER> synergize antibodies including rbdtargeting mers<NUMBER> m<NUMBER> neutralization provides valuable addition combined use antibodies merscov infection <NUMBER> addition aforementioned ten antibodies targeting rbd near atomic resolution cryoem structures trimeric merscov spike complex antibody g<NUMBER> also determined figure <NUMBER>d <NUMBER> g<NUMBER> first reported s<NUMBER>targeting antibody epitope consists glycosylated solventexposed loop residing connector domain hr<NUMBER> hr<NUMBER> s<NUMBER> subunit unbound spike trimer structure loop largely disordered whereas extends two βstrands surrounded six cdrs complementarity determining regions mab g<NUMBER> upon antibody recognition figure <NUMBER>e specific spikeg<NUMBER> interaction may stabilize loop impede conformational changes s<NUMBER> subunit essential membrane fusion dpp<NUMBER> binding binding epitope g<NUMBER> s<NUMBER> subunit conserved rbd among merscov isolates shedding light g<NUMBER> potential broadspectrum neutralizing antibody merscov yet loop hr<NUMBER> hr<NUMBER> variable sequence length among different viruses even lineage c betacoronaviruses <NUMBER> limiting application coronaviruses terms pancoronavirus medical countermeasures mcms recently developed fusion inhibitor peptide ek<NUMBER> potential candidate peptide ek<NUMBER> designed target conserved hr<NUMBER> region s<NUMBER> stem shown block cellcell fusion induced spike protein multiple human coronaviruses <NUMBER> general reported merscov neutralizing antibodies recognize rbd s<NUMBER> subunit antibodies highly potent neutralization facts show rbd s<NUMBER> subunit major vulnerable site antibody recognition neutralization note rbd also region naturally occurring mutations glycoprotein occur currently comprehensively studied antibodies targeting nonrbd region spike glycoprotein also include mab <NUMBER>f<NUMBER> targeting nterminal domain ntd s<NUMBER> subunit <NUMBER> well mabs g<NUMBER> cdc<NUMBER>a<NUMBER> cdc<NUMBER>a<NUMBER> jc<NUMBER> fibh<NUMBER> targeting nonrbd region s<NUMBER> subunit <NUMBER> <NUMBER> however detailed epitopes specific mechanisms still unclear antibodies expect antibodies new neutralizing epitopes andor mechanisms would important combined use antibodies merscov infection although monoclonal antibodies show promising antiviral effects cell culture animal models merscov infection roles still limited largescale disease prevention merscov high risk areas therapeutic window generally narrow mabs massscale production timeand resourceconsuming vaccines still remain best choice merscov prevention given critical role mediating viral entry major targets neutralizing antibodies glycoprotein rbd become prime targets merscov immunogen design vaccine development various approaches applied twenty vaccine candidates reported past years including vaccines based inactivated virions <NUMBER> <NUMBER> viruslike particles <NUMBER> recombinant viral vectors <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> dna <NUMBER> <NUMBER> <NUMBER> recombinant protein subunits <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> nanoparticles <NUMBER> <NUMBER> <NUMBER> table <NUMBER> summarizes critical features approaches protective potentials experimental animal models till two vaccine candidates gls<NUMBER> mers<NUMBER> entered human clinical trials vaccine gls<NUMBER> first tested healthy human volunteers dna plasmid encoding merscov glycoprotein requiring twotothree injections delivered electroporation <NUMBER> phase clinical trial started <NUMBER> walter reed army institute another phase iii clinical trial conducted korea test dosage safety immunogenicity another vaccine candidate mers<NUMBER> replicationdeficient chimpanzee adenovirus chadox<NUMBER> containing merscov glycoprotein antigen <NUMBER> <NUMBER> vaccine requires onetime administration <NUMBER>×<NUMBER> <NUMBER> <NUMBER>×<NUMBER> <NUMBER> virus particles via intramuscular route local adverse events well immunogenicity evaluated phase clinical trial conducted university oxford addition one candidate vaccine tested dromedary camels either potential human use straight veterinary use explores modified vaccinia virus ankara mva vector express merscov glycoprotein <NUMBER> regimen involves immunization intranasal well intramuscular routes twice <NUMBER>week interval vaccinated camels demonstrated significant reduction excreted infectious virus viral rna transcripts vaccinated animals upon merscov challenge protection merscov infection correlated presence serum neutralizing antibodies merscov mva established reasonably good safety profile humans induced desirable protective immunity camels represents one potential candidates evaluated humans near future remaining vaccine candidates stages preclinical laboratory development invariably target glycoprotein rbd critical viral entry table <NUMBER> vaccines based inactivated <NUMBER> <NUMBER> viruslike particles <NUMBER> historical precedence inducing protective immune responses humans whether strategies applicable merscov requires studies particularly comes possible safety concerns <NUMBER> apart mers<NUMBER> mvabased vaccine tested dromedary camels vectorbased approaches also actively pursued including adenovirus <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> measles virus <NUMBER> <NUMBER> veev replicon particle <NUMBER> <NUMBER> vesicular stomatitis virus <NUMBER> rabies virus <NUMBER> recombinant viruses encoding merscov s<NUMBER> antigen demonstrated strong immunogenicity mice nonhuman primate models shown confer protection merscov challenge mouse models table <NUMBER> however concerns remain regarding preexisting immunity viral vectors natural infection would diminish vaccine potency <NUMBER> overcome issue preexisting immunity human adenoviruses preserving advantages high yields strong immunogenicity rare serotypes chimpanzee adenovirus low human seroprevalence may adopted viral vectors <NUMBER> <NUMBER> group recently developed vaccine candidate replicationdefective chimpanzee adenovirus c<NUMBER> adc<NUMBER> vector expressing full length merscov glycoprotein seroprevalence adc<NUMBER> around <NUMBER> human population much lower commonly used human adenovirus <NUMBER> huad<NUMBER> vector <NUMBER> <NUMBER> <NUMBER> one intranasal administration <NUMBER> × <NUMBER> <NUMBER> viral particles completely protected human dpp<NUMBER> knockin hdpp<NUMBER>ki mice lethal merscov challenge passive transfer adc<NUMBER>s immune sera conferred survival advantage lethal challenge mouse models <NUMBER> safety profiles vectors yet extensively tested humans recently hashem colleagues showed adenovirusbased s<NUMBER> vaccine may pose potential safety concerns may induce pulmonary perivascular hemorrhage merscov challenge mouse model regardless full protection upon lethal viral infection also showed pulmonary pathology mitigated incorporating cd<NUMBER>l immunemodulator therefore potential molecular adjuvant recombinant adenovirusbased vaccine <NUMBER> whether vaccineassociated pathology related residual infectious viruses unbalanced immune responses awaits investigation mind future merscov vaccine candidate designs take extra cautions safety evaluation furthermore recombinantproteinbased vaccines widely pursued strategies solubilize merscov glycoprotein order form stable immunogens include forming nanoparticles using soluble protein truncations particular nanoparticles formed full length merscov glycoprotein <NUMBER> <NUMBER> subunit rbdbased vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> shown induce virus neutralizing antibodies protect mice challenged merscov one rbd subunit vaccine also conferred protection rhesus macaques <NUMBER> indicates rbd alone antigen may sufficient protective immunity develop virus along finding mab targeting ntd able neutralize merscov lan et al showed three doses intramuscularly administered recombinant ntd protein also induced protective immunity live merscov human dpp<NUMBER> transduced mouse model ad<NUMBER>hdpp<NUMBER> mice <NUMBER> recently structural insights spike glycoprotein pallesen et al developed prefusionstabilized trimer vaccine substituting proline residues s<NUMBER> domain <NUMBER> introduction proline disfavours refolding linker hr<NUMBER> central helix thus preventing transition spike postfusion state rationally designed antigen mers s<NUMBER>p shown induce broader potent neutralizing activity wild type spike trimer protein <NUMBER> finally primeboost strategy based fulllength glycoprotein dna vaccine followed s<NUMBER>glycoprotein boost able induce virusneutralizing antibodies confer protection clinical severity diseases nonhuman primate models <NUMBER> compared proteinonly regimen combination dna protein induced functionally diverse antibody repertoire stronger th<NUMBER> immune response suggested native glycoprotein conformation formed cell surface dna vaccination helped induce diverse antibodies merscov summarized table <NUMBER> aforementioned strategies require multiple immunizations may pose additional logistic hurdles end point use unclear whether immunization strategies empirically designed due relatively abbreviations animal models human dpp<NUMBER> transgenic hdpp<NUMBER>tg mice globalepithelial hdpp<NUMBER> expression human dpp<NUMBER> knockin hdpp<NUMBER>ki mice hdpp<NUMBER> replacing mdpp<NUMBER> situ mice transduced human adenovirus <NUMBER> vector expressing hdpp<NUMBER> ad<NUMBER>hdpp<NUMBER> mice nonhuman primates nhps efficacy specific animal model listed previous column studies conducted multianimal models results highestlevel model shown neutralizing antibody nab ↑ indicates ↓ indicates less poor immunogenicity candidate vaccines practical compliant purposes single immunization highest immunogenicity animals humans preferred outbreak merscov saudi arabia <NUMBER> reminded us <NUMBER> sarscov outbreak china despite differences geographic location epidemiology immediate animal reservoirs two viruses share remarkable similarity causing severe respiratory syndrome leading high fatality humans trigger serious public health concerns advent modern techniques virology immunology vaccinology gained substantial insights biology merscov pathogenesis unprecedented speed accuracy summarized current review tremendous progress made understanding <NUMBER> entry process merscov target cells <NUMBER> structure function glycoprotein cellular receptor dpp<NUMBER> mediating viral entry <NUMBER> antibody response natural infection isolation broad potent neutralizing mabs <NUMBER> design development vaccine candidates using various innovative technologies however progress translating discoveries clinical application slow two vaccine candidates one mab panel entered phase clinical trials safety ironically vaccines treatment strategies approved sarscov infection even decade outbreak could imagine catastrophic would sarscov hit merscov continues probe gain strong capacity transmission among humans facing difficult predicament comes public health challenges new era emerging reemerging infectious diseases one hand human population becoming ever mobile exposed increasing number pathogens hand translating basic discoveries preventative treatment applications exceedingly slow among many plausible reasons lack incentives financial returns perhaps stands tallest deadlock happening merscov sarscov also many infectious pathogens ebola marburg lassa highly pathogenic avian influenza hiv<NUMBER> fundamental drastic changes made entire research development system truly prepare position ahead deadly epidemic pandemic speed accuracy basic discovery timely translated clinical public health needs time act infectious diseases continue plague mankind evolve keep pace efforts control sir william osler captured ongoing fear infectious pathogens said humanity three great enemies fever famine war far greatest far terrible fever despite significant impact antimicrobials vaccines public health one major human pathogen eradicatedvariola virus agent smallpox place series new reemerging microbes responsible isolated infections regional outbreaks global pandemics bacterial fungal parasitic pathogens capacity cause widespread epidemics black death caused yersinia pestis <NUMBER>th century europe however bacteria fungi parasites less likely cause widespread human pandemics point history less amenable vaccine strategies viral diseases focusing viruses catalogue newly discovered human pathogens beginning <NUMBER>th century shows predictable nearly linear rate new agents discovered time <NUMBER> however <NUMBER> virus families <NUMBER> associated human infections number seems plateaued <NUMBER> chapter concentrate vaccines emerging viral diseases experiences last <NUMBER> decades hiv sars ebola taught us potential consequences viral infectious threats global health economic political stability emerging viral infections pandemic potential chronic persistent acute nature disseminated respiratory droplet bodily fluids emerge animal reservoirs spread via insect vectors precipitated changes climate animal habitats human population dynamics ecological events <NUMBER> emerge consequence human activity context deliberate viral modification form biowarfare faced important questions including done anticipate events best prepare intervene new changing viral threats arrive current licensed antiviral vaccines utilize liveattenuated wholeinactivated viruses although examples effective viruslike particle vlp vaccines setting new pandemic viral threat without advantage preexisting understanding pathogenesis growth attenuating features would difficult quickly develop traditional liveattenuated wholeinactivated vaccine approaches due uncertainty safety attenuating mutations production replicationcompetent virus bulk therefore likely developing vaccines emerging infections involve new technologies yet licensed human use using technologies provide candidate vaccine based information derived entirely target gene sequences safer expeditious procedures requiring virus isolation growth require high level containment therefore even virus families currently licensed vaccines additional approaches beyond liveattenuated wholeinactivated products also pursued historically decades elapsed new virus discovered relevant vaccine becomes available human use fig <NUMBER> setting epidemic protracted vaccine development timelines incompatible rapid deployment vaccine intervention therefore practical consideration immediate control outbreak part <NUMBER> west african ebola outbreak emergence new viral threats public health becoming global concern media political visibility fortunately time remarkable technical advances human monoclonal antibody discovery structureguided antigen design nucleic acid sequencingmaking rapid development biologics feasible therefore defining new approaches pathways efficiently deploy vaccine interventions emerging infections priority public health agencies commercial entities government officials nonprofit organizations however key rapid vaccine response advanced preparation several steps needed improve preparedness emerging viral infectious diseases divided <NUMBER> broad categories <NUMBER> surveillance discovery <NUMBER> reagent assay animal model development <NUMBER> vaccine design product development <NUMBER> manufacturing clinical evaluation appropriate regulatory framework depending features virus structure transmission dynamics entry requirements tropism replication strategy vaccine approach proposed designed evaluated small animals immunogenicity protection challenge manufacturing candidate vaccine immediate market poses significant dilemma stages advanced vaccine development carried large pharmaceutical companies need make profit stay business emerging infectious diseases pose public health threat rarely present compelling commercial opportunity vaccines require large investment historically relatively low probability successful without extensive iterative process evaluation redesign therefore addition new biological tools needs political prioritize public funding advanced vaccine development new business models managing process <NUMBER> review describe vaccine development efforts three distinct viruses collectively capture many challenges faced developing vaccines emerging viral threats ebola member filoviridae family spread body fluids secretions relatively low attack rate causes systemic disease high mortality chikungunya alphavirus figure <NUMBER> time identification viral pathogen vaccine availability vaccine development lengthy process often measured decades many steps required even traditional empirical approach including identification target antigen assay development defining seroprevalence incidence relevant populations understanding transmission dynamics whether intermediate animal host developing animal models exploring pathogenesis defining immune mechanisms protection designing vaccine antigens determining formulation delivery route method preclinical evaluation safety immunogenicity manufacturing several years clinical evaluation clearing regulatory hurdles vaccines fail steps rare first attempted concept become final product togaviridae family transmitted mosquito vectors high attack rate causes systemic disease low mortality high frequency chronic disabling arthritis middle east respiratory syndrome mers cov betacoronavirus member coronaviridae family spread respiratory droplets causes relatively high mortality persons underlying disease reproductive rate r <NUMBER> <NUMBER> persontoperson spread occasional superspreaders infect multiple people mers reservoir dromedary camels continue source new human infections ebola chikungunya mers cov representative infectious pathogens pandemic potential use new technologies arrive comprehensive understanding viral structure pathogenesis paved way rational vaccine design viruses herein elaborate iterative path taken develop evaluate candidate vaccines ebola chikungunya mers cov factors propel delay progress focus discussions primarily candidate vaccines developed niaid vaccine research center necessarily promising advanced familiar events associated development factors impacting advancement implementation ebola highly virulent pathogen family filoviridae ebolavirus enveloped negativestrand rna virus whose genome encodes <NUMBER> structural proteins including transmembrane glycoprotein mediates viral entry host cells <NUMBER> surface glycoprotein gp mediates viral attachment entry primary antigenic target vaccine development five species ebola identified including zaire cause <NUMBER> west african epidemic sudan bundibugyo tai forest reston ebola virus disease evd first recognized two distinct outbreaks ebola river valley democratic republic congo formerly zaire sudan <NUMBER> <NUMBER> <NUMBER> evd emerged <NUMBER> gabon <NUMBER> outbreak involving <NUMBER> people kikwit democratic republic congo drc since sporadic outbreaks occurred equatorial africa especially drc republic congo gabon uganda sudan fatality rates averaging <NUMBER> <NUMBER> <NUMBER> incubation period <NUMBER> days onset evd manifested fevers chills malaise myalgias onset gastrointestinal symptoms including nausea vomiting diarrhea days <NUMBER> <NUMBER> <NUMBER> fatal death typically occurs days <NUMBER> characterized hypovolemic shock multiorgan failure <NUMBER> <NUMBER> disease transmitted humantohuman direct contact infected bodily fluids mucosal surfaces breaks skin <NUMBER> mar <NUMBER> guineas ministry health notified highly pathogenic febrile illness circulating gueckedou macenta epidemiologic evaluation ensued samples hospitalized patients sent bsl<NUMBER> labs france germany ebola confirmed either polymerase chain reaction pcr electron microscopy isolation cell culture <NUMBER> viral rna extracted sequenced compared available ebola sequences genbank enabling phylogenetic analysis ebola strain identified <NUMBER> similarity previously collected ebola strains drc gabon turn outbreak traced single index case <NUMBER>yearold boy died dec <NUMBER> gueckedou epidemic evd followed accounted cases prior evd outbreaks combined jul <NUMBER> <NUMBER> suspected confirmed cases <NUMBER> deaths reported majority cases occurring west african countries guinea liberia sierra leone <NUMBER> world health organization declared epidemic public health emergency international concern aug <NUMBER> outbreak emerged international community responded unprecedented effort accelerate ebola vaccine development <NUMBER> prior <NUMBER> largest single ebola outbreak <NUMBER> infections leading <NUMBER> deaths <NUMBER> vaccine research center within national institute allergy infectious diseases performed series phase clinical trials <NUMBER> <NUMBER> evaluate safety immunogenicity gp antigen constructs included dna vaccine encoding transmembranedeleted secreted version glycoprotein recombinant human adenovirus serotype <NUMBER> rad<NUMBER> vectored vaccine encoding ebola gp one amino acid mutation subsequently dna vaccine encoding fulllength wildtype wt gp <NUMBER> <NUMBER> <NUMBER> phase studies showed wt fulllength gp safe well tolerated parallel studies define immunological correlates protection optimal antigen delivery approaches evaluated nonhuman primates nhp addition important role antibodies targeting gp found cd<NUMBER> cellmediated immunity found critical vaccine efficacy nhp <NUMBER> also found antivector immunity would diminish vaccine potency particularly induction cd<NUMBER> cells high seroprevalence ad<NUMBER> rare serotype adenovirus vectors explored including human rad<NUMBER> rad<NUMBER> vectors chimpanzeederived rad vectors <NUMBER> chimpanzee adenovirus serotype <NUMBER> abbreviated chad<NUMBER> cad<NUMBER> encoding wildtype glycoproteins ebola zaire sudan species ultimately chosen candidate vaccine vector low seroprevalence similar potency pattern innate immune response induction ad<NUMBER> vector originally produced okairos owned glaxosmithkline gsk vector potency comparable rad<NUMBER> considered important rapid induction antibody cd<NUMBER> cells single dose would facilitate use cad<NUMBER>ebola gp vaccine outbreak setting using ring vaccination strategy achieve rapid short term protection highest risk infection zaire sudan gp included initial vaccine protect zaire sudan common species responsible evd replicationdefective vaccine called cad<NUMBER>ebo provided <NUMBER> protection nonhuman primates <NUMBER> weeks following vaccination otherwise lethal ebola challenge model partial protection <NUMBER> lethal challenge <NUMBER> months following vaccination cad<NUMBER>ebo also shown effectively prime modified vaccinia virus ankara mvavectored vaccine boost encoding glycoprotein inserts improving survival lethal ebola challenge <NUMBER> <NUMBER>months postboost <NUMBER> combination cad<NUMBER>mva primeboost produces much higher magnitude response might provide durable protection health care workers ambulance drivers burial workers others ongoing risk ebola exposure first quarter <NUMBER> targeted phase clinical evaluation cad<NUMBER>ebo nih clinical center preinvestigational new drug ind application submitted end aug <NUMBER> however response epidemic nih fda irbs others coordinated efforts consolidate timelines ind application submitted fda aug <NUMBER> <NUMBER> phase trial began <NUMBER> days later cad<NUMBER>ebo vaccine found safe immunogenic early phase <NUMBER> testing two doses <NUMBER> × <NUMBER> <NUMBER> <NUMBER> × <NUMBER> <NUMBER> particle units pu day <NUMBER> postvaccination results published <NUMBER> months later <NUMBER> vaccine recipients developed glycoprotein gpspecific antibodies however gpspecific antibody responses well gpspecific cell responses greater <NUMBER> × <NUMBER> <NUMBER> pu dosing antibody titers higher dose range associated protective immunity nhp challenge model zaire gp antigen encoded cad<NUMBER> derived original mayinga strain ebola isolated <NUMBER> compared strains circulating west africa differed gp residues outside glycan cap cleaved prior virus entry mayinga also related genetically outbreak strain kikwit strain used nhp challenge studies therefore available cad<NUMBER> ebola zaire construct thought antigenically relevant outbreak strain suitable testing directly address west african crisis accelerate manufacturing timelines additional phase studies cad<NUMBER> vaccine monovalent form encoding gp zaire sudan species performed united states united kingdom mali switzerland doses ranging <NUMBER> × <NUMBER> <NUMBER> <NUMBER> × <NUMBER> <NUMBER> <NUMBER> studies done collaboration gsk supported advancement monovalent vaccine ongoing phase iiiii study liberia nct<NUMBER> well us evaluation primeboost regimen consisting cad<NUMBER>ebo followed mvaeboz evaluate durable immune responses nct<NUMBER> monovalent cad<NUMBER>eboz also evaluated prime boosting recombinant mva vector provided bavarian nordic expressing gp zaire sudan marburg n tai forest sites united kingdom mali similar vaccine approach using rad<NUMBER> priming mva boosting developed crucell owned janssen part johnson johnson evaluated subsequent clinical trials parallel cad<NUMBER>ebo development replicationcompetent recombinant vesicular stomatitis virus rvsv vaccine expressing gp ebola zaire kikwit strain showed promising results preclinical nhp challenge models <NUMBER> <NUMBER> vaccine developed public health agency canada licensed bioprotection systems subsidiary newlink genetics subsequently licensed merck donation <NUMBER> vials vaccine canadian government enabled initial evaluation candidate vaccine <NUMBER> people doses ranging <NUMBER> <NUMBER> million pfu phase trials gabon kenya germany switzerland although lifethreatening adverse events observed evidence unexpected viral seeding joints transient arthritis addition vaccine virus positive skin vesicles participants lower dose rvsvzebov <NUMBER> pfu im diminish likelihood rvsv infecting peripheral tissues thirteen <NUMBER> participants developed arthritis <NUMBER> participants developed cutaneous lymphocytic vasculitis rvsv established etiology based synovial fluid skin lesion analysis <NUMBER> <NUMBER> vaccine immunogenic vaccine recipients evaluated developed gpspecific antibody responses <NUMBER> additional evaluation candidate vaccine two phase trials united states wrair nih supported advancement vaccine <NUMBER> million pfu dosing compared <NUMBER> million pfu dosing <NUMBER> million pfu resulted higher igg neutralizing antibody titers <NUMBER> higher dose vaccine currently evaluation niaidsponsored prevail trial liberia cdcsponsored strive study sierra leone whosponsored ebola ça suffit study guinea notably skin joint complications seen active followup individuals united states african studies interim results ebola ça suffit phase iii trial evaluating safety efficacy rvsvzebov unblinded clusterrandomized trial guinea encouraging consistent vaccine efficacy trial utilized ring vaccination design individuals high risk infection contacts contactsofcontacts lab confirmed case evd randomized cluster receive either immediate vaccination rvsvzebov delayed vaccination <NUMBER> days later cases evd symptom onset <NUMBER> days following randomization group receiving immediate vaccination <NUMBER> clusters <NUMBER> subjects whereas authors reported <NUMBER> cases evd subjects randomized delayed vaccination <NUMBER> clusters <NUMBER> subjects <NUMBER> pathway licensure new vaccines requires evidence vaccine safety efficacy clinical trials infectious pathogens emerge sporadically low incidence ebola ability perform randomized placebocontrolled doubleblinded efficacy trials remains limiting factor hard fought decline evd cases west africa welcome hopefully lead complete control epidemic without rebound reemergence however decline likely preclude efforts evaluate vaccine efficacy vaccine candidates outbreak cad<NUMBER>ebo vaccine remains unknown path licensure feasible absence human efficacy data regulators need consider supportive evidence preclinical nhp challenge models safety data ongoing human trials use alternative surrogate immunogenicity endpoints adequate move forward licensing therefore several challenging questions remain regulators vaccine developers alike include determining ebola vaccines made available next ebola epidemic trial design used ie ring vaccination strategy delay community randomization stepwedge design staged vaccination placebocontrolled randomized study whether initial results recent trial preclude evaluation experimental unlicensed products <NUMBER> nonetheless several important lessons extracted recent development ebola vaccine candidates perhaps important rapid development testing candidate vaccines <NUMBER> <NUMBER> made possible years prior investment study ebola basic virology pathogenesis part driven biodefense concerns factors enabled accelerated vaccine development include <NUMBER> preexisting established animal models <NUMBER> preclinical data nhp challenge studies <NUMBER> presence cgmp vaccine product <NUMBER> global concern extensive media coverage political visibility helped foster coordination funding agencies regulatory authorities governments clinical trial sites laboratories commercial partners publishers chikungunya virus chikv mosquitoborne alphavirus family togaviridae transmitted primarily aedes aegypti aedes albopictus mosquitoes <NUMBER> three chikv clades identified include west african asian eastcentralsouth african sharing significant amino acid homology chikungunya infection manifests abrupt onset fever myalgias rash headache nausea arthralgias illness onset typically <NUMBER> days following viral transmission <NUMBER> <NUMBER> <NUMBER> hallmark arthritis chikv infection relapsing incapacitating may persist months <NUMBER> severe manifestations chikungunya include myocarditis hepatitis neurologic complications including encephalitis <NUMBER> although rare deaths occurred particularly elderly infants currently fda licensed vaccines treatments specific chikungunya chikv <NUMBER> kb singlestranded positivesense rna genome encodes <NUMBER> nonstructural proteins involved virus replication nsp<NUMBER> <NUMBER> structural proteins including capsid envelope glycoproteins e<NUMBER> e<NUMBER> <NUMBER> <NUMBER> <NUMBER> e<NUMBER> glycoprotein mediates cell fusion e<NUMBER> glycoprotein interacts host receptor mature virion diameter <NUMBER> nm external surface exhibits trimeric spikes consisting <NUMBER> e<NUMBER>e<NUMBER> heterodimers <NUMBER> chikungunya virus discovered east african virology research institute entebbe uganda uganda virology institute uvri isolated member makonde tribe tanzania early <NUMBER>s chikv responsible outbreaks africa asia since <NUMBER>s <NUMBER> chikv endemic tropical subtropical regions africa exists part enzootic cycle however intermittent epidemics emerge characterized humanmosquitohuman transmission attack rates exceed <NUMBER> <NUMBER> aegypti eastcentralsouth african ecsa strain recently detected brazil may make adaptation albopictus likely occurs broader spread north america possible chikv viremia peaks day symptom onset titers reaching <NUMBER> <NUMBER> viral rna copiesml <NUMBER> neutralizing activity induction igg<NUMBER> antibody isotype early course infection associated lower risk chronic disease persistent arthralgias <NUMBER> <NUMBER> research date supports antibodymediated mechanism protection chikv infection <NUMBER> passive protection shown otherwise lethal mouse model chikv infection following igg administration nhps received chikungunya viruslike particle vlp vaccine <NUMBER> several promising candidate vaccine platforms evaluated including formalininactivated chikv vaccines <NUMBER> recombinant mva measles vectored vaccines <NUMBER> chimeric alphavirus vaccines <NUMBER> insect cellproduced vlp vaccine candidates <NUMBER> dna vaccine candidates <NUMBER> <NUMBER> live attenuated chikv vaccine advanced phase ii testing induced neutralizing antibodies chikv day <NUMBER> <NUMBER> recipients also associated arthralgias <NUMBER> subjects <NUMBER> due familiarity limitations obstacles advancement candidate vaccine developed niaid vaccine research center focus discussion primarily mammalian cellproduced vlp vaccine candidate vaccine evaluated phase clinical trial currently advanced phase ii clinical testing produce vlp akahata coworkers transfected <NUMBER>t hek cells expression vectors encoding ce<NUMBER>e<NUMBER>ke<NUMBER> proteins west african chikv strain <NUMBER> electron microscopy revealed production vlps morphologic appearance wildtype chikv characterized <NUMBER> nm external diameter <NUMBER> nm core diameter structure e<NUMBER> e<NUMBER> glycoproteins organized <NUMBER> heterodimers <NUMBER> glycoprotein spikes preclinical assessment nhps receiving vlp developed neutralizing antibodies heterologous homologous chikv strains challenge model nhps protected viremia well postinflammatory sequelae infection exposed intravenous chikv challenge <NUMBER> weeks vlp administration <NUMBER> vlp vaccine candidate found safe immunogenic phase doseescalation clinical trial evaluating dose range <NUMBER> µg <NUMBER> dose regimen weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> healthy adults neutralizing antibodies outbreak strain ecsa clade identified participants <NUMBER> weeks following second vaccination revealing robust immunogenicity evidence crossreactive neutralizing activity <NUMBER> several advantages vlp vaccine include highly symmetric exterior resembles wildtype virus induction high titer neutralizing antibody safety profile nonreplicating candidate vaccine low containment manufacturing factors contributing delay advanced development vaccine include difficulty establishing commercial partnership resources needed process development scaleup difficulties establishing clinical trial infrastructure defining efficacy immune correlates protection due ongoing chikungunya epidemic americas caribbean opportunity obtain efficacy result field trial therefore advancing clinical evaluation candidate vaccines public health imperative field trials delayed outbreak saturated region disease becomes sporadic difficult ever obtain efficacy outcome establish immunological correlate protection complicate achieving licensure general use another example public options manufacturing would facilitate development vaccines emerging infectious diseases coronaviruses enveloped singlestranded positivesense rna viruses large genomes ∼<NUMBER> kb endemic human coronaviruses widespread include coronaviruses hcov<NUMBER>e oc<NUMBER> nl<NUMBER> hku<NUMBER> generally cause mild respiratory infections including common cold however several features coronaviruses allow adaptation new hosts ecological niches <NUMBER> include large rna genomes high frequency rna recombination infidelity rnadependent rna polymerase following <NUMBER> emergence severe acute respiratory syndrome coronavirus sars cov highly pathogenic lineage b betacoronavirus concerns arose novel coronaviruses could represent major public health threat validated emergence middle east respiratory syndrome coronavirus mers cov first case mers cov reported <NUMBER> <NUMBER>yearold male saudi arabia acute pneumonia subsequently died progressive pulmonary renal failure <NUMBER> subsequent rapid international response emergence mers cov included genomic sequencing development diagnostic assays surveillance zoonotic reservoir development animal models evaluation viral pathogenesis enable rational design candidate vaccines complete genome sequence implicated coronavirus rapidly identified made available genbank genomic sequencing enabled phylogenetic taxonomic analysis mers cov identified lineage c betacoronavirus distinct previously known human coronaviruses closely related hku<NUMBER> hku<NUMBER> coronaviruses previously isolated bats <NUMBER> <NUMBER> clinical presentation mers cov range asymptomatic severe respiratory illness culminates death following incubation period <NUMBER> days <NUMBER> days presenting symptoms include fever cough dyspnea rapid deterioration respiratory status occur within days symptom onset fatality rates estimated <NUMBER> since <NUMBER> <NUMBER> labconfirmed cases mers cov infection least <NUMBER> deaths globally <NUMBER> includes outbreak <NUMBER> individuals south korea initiated single index case man returning trip saudi arabia outbreak seoul primarily restricted hospital settings <NUMBER> individual superspreaders accounted majority infections patients health care providers <NUMBER> mers cov expresses membraneanchored trimeric spike protein consists s<NUMBER> subunit engages receptor host cell s<NUMBER> subunit mediates membrane fusion <NUMBER> receptor binding domain s<NUMBER> served primary antigenic target vaccine development similar angiotensinconverting enzyme <NUMBER> ace<NUMBER> peptidase receptor used sars cov mers cov target cell receptor cd<NUMBER> dipeptidyl peptidase <NUMBER> dpp<NUMBER> <NUMBER> amino acid type ii transmembrane glycoprotein expressed epithelial endothelial cells several organs including lung kidney dpp<NUMBER> shown biomarker il<NUMBER> expression asthma associated glycemic homeostasis microvascular complications diabetes <NUMBER> <NUMBER> transfection human dpp<NUMBER> otherwise nonsusceptible cells feline murine canine species enables mers cov infection <NUMBER> lu et al subsequently solved crystal structure receptor binding domain s<NUMBER> complex cd<NUMBER> <NUMBER> comparative serologic studies emerged shortly mers cov first identified look zoonotic reservoirs evaluation serumspecific igg targeting receptorbinding s<NUMBER> subunit performed protein microarray confirmed virus neutralization testing revealed hightiter neutralizing antibodies prevalent camels <NUMBER> experimental support camel zoonotic reservoir performed adney coworkers inoculated camels mers cov camels subsequently developed upper respiratory symptoms showed evidence upper respiratory tract viral shedding nasal secretions <NUMBER> days postinoculation <NUMBER> evidence zoonotic transmission camel humans supported patient <NUMBER> died mers cov following exposure camels rhinorrhea nasal swabs patient camels positive mers cov rna subsequent genomic sequencing revealed isolates identical <NUMBER> however cases mers cov infection linked camel exposure additional studies needed define transmission dynamics intermediate hosts low herd immunity humans highly pathogenic virus evidence zoonotic humantohuman transmission suggest outbreaks mers cov continue occur may pandemic potential currently fda approved vaccines mers cov previous vaccine development efforts sars cov created foundation mers cov vaccine design sars spike protein similarly responsible receptor binding membrane fusion primary antigen target neutralizing antibody vaccine development <NUMBER> candidate mers cov vaccines also target spike protein approaches included subunit proteins dna genebased vectors recombinant modified vaccinia virus ankara vaccine expressing full length mers cov spike protein produced neutralizing antibody immunized mice <NUMBER> subsequently coworkers focused receptor binding domain rbd mers cov spike protein develop subunit protein vaccine five different receptor binding domain fragments s<NUMBER> individually fused fc human igg evaluated receptor binding affinity antigenicity immunogenicity neutralizing potential s<NUMBER>fc fragment contains stably folded rbd highest affinity dpp<NUMBER> induced highest titer neutralizing antibodies mice immunized rabbits minimizing exposure nonneutralizing epitopes <NUMBER> addition two recombinant vaccine candidates developed using either baculovirusbased expression system venezuelan equine encephalitis replicon particle approach <NUMBER> <NUMBER> potent neutralization induced mice nhps following immunization dna expressing fulllength spike protein followed boost s<NUMBER> subunit glycoprotein strategy elicited responses rbd nonrbd neutralizing epitopes may decrease chance escape mutations dna primeprotein boost regimen provided protection computerized tomography ct defined pneumonia nhp viral challenge model <NUMBER> work highlights importance developing mabs vaccine target antigen order define mechanisms viral neutralization protein structure antigenicity guide rational vaccine design dna plasmidbased vaccine encoding full length consensus mers spike protein constructed based available protein genomic sequences genbankncbi database vaccine induced polyfunctional cell humoral responses mice nhps including antigenspecific neutralizing antibodies mice macaques camels vaccine also provided protection pneumonia nhp viral challenge model <NUMBER> clinical trial data yet candidate mers cov vaccines mers cov likely continue cause sporadic outbreaks fueled camel exposure occasional superspreading event however relatively low r <NUMBER> suggests mers cov relatively low probability causing widespread pandemic therefore target populations vaccine available general population groups high risk exposure animal reservoirs health care workers endemic regions possibly atrisk travelers relatively small market difficult commercial organizations invest mers cov vaccine development low incidence field study evaluate efficacy large difficult complete therefore questions raised achieve advanced development licensing vaccine type emerging virus activities needed prepare future pandemic viral threats include broad spectrum disciplines skill sets ranging logistics communication epidemiology ecology clinical trials highly technical biomedical research programs fortunately relatively recent technological advances made prospects comprehensive program systematically prepare emerging infectious diseases feasible done forethought development program would strengthen existing health care programs build research infrastructure significantly improve status global public health particular take advantage new technologies high throughput sequencing isolation human monoclonal antibodies structural biology atomiclevel antigen design molecular biology vector biology tools provide information needed rapid achievement optimal expression immunogenicity production delivery vaccine antigens new emerging threats like current crisis caused zika virus fig <NUMBER> due new technologies available surveillance assay development vaccine design animal modeling manufacturing scientific aspects vaccine development limiting ability prepare emerging viral diseases major factors need addressed include <NUMBER> political provide resources necessary conduct epidemiology laboratory work needed support vaccine development <NUMBER> new business models create infrastructure advanced vaccine development require profit motive <NUMBER> creative regulatory processes clinical trial designs evaluate products efficacy outbreaks nature sporadic causing social chaos importantly achieving solid efficacy data support licensure critical products readily available future epidemics novel approaches vaccine design may significantly shorten vaccine development timelines increase frequency success new technologies rapidly evolved last <NUMBER> years make atomic level antigen design feasible provide mechanisms rapid iterative improvements antigenicity immunogenicity candidate vaccines particular high throughput sequencing provides starting point vaccine antigens helps define extent genetic variability relatively inexpensive gene synthesis ease isolating characterizing human monoclonal antibodies mabs target antigens ability define structures vaccine antigens complex mabs desirable functional properties development assays evaluate immunogenicity vaccines animal models provide foundation rapid development highly characterized candidate vaccines advancement clinical evaluation figure illustrates steps taken case mers cov rapidly develop tools needed generate candidate vaccines advanced knowledge effective vaccine approaches particular virus family together modern development design approaches may significantly shorten time needed prepare vaccines field testing setting new pandemic threat successfully reisolated nasal swabs lung lesions animals specific antibody response virus shown infected animals sarscov proved causative agent infectious disease kuiken et al <NUMBER> sarscov singlestranded positivesense rna virus phylogentically related coronaviruses group <NUMBER> despite fact encode hemagglutininesterase protein snijder et al <NUMBER> genome packaged together nucleocapsid protein least five membrane proteins e <NUMBER>a <NUMBER>a <NUMBER>b spike protein fig <NUMBER> s<NUMBER> region within protein specifically <NUMBER>amino acid fragment protein corresponding residues <NUMBER> identified region interacts cell receptor angiotensinconverting enzyme <NUMBER> li et al <NUMBER>a majority neutralizing antibodies directed region protein antibodies raised severe acute respiratory syndrome coronavirus sarscov first emerged human population november <NUMBER> phylogenetic analysis sarscov isolates animals indicated virus probably originated bats transmitted first palm civets subsequently humans wet markets southern china subsequent outbreaks occurred early <NUMBER> hong kong hanoi toronto singapore could directly traced back one index patient acquired infection guangdong traveled hong kong worldwide epidemic halted efforts world health organization responded rapidly threat issuing global alert rigorous local containment efforts warning unnecessary travel affected areas creating network international experts combat virus end <NUMBER> people became ill <NUMBER> people died first sars epidemic sarscov could reemerge cause another epidemic time development effective vaccines remains vital importance although several infectious agents including chlamydia influenza subtype h<NUMBER>n<NUMBER> human metapneumovirus considered possible cause sars three groups independently reported isolation previously unrecognized cov clinical specimens sars patients peiris et al <NUMBER> rota et al <NUMBER> drosten et al <NUMBER> electron microscopy serology reversetranscription pcr consensusand randomprimers subsequent sequencing replicase gene identity could revealed consistently demonstrated clinical specimens patients disease healthy controls conclusively establish causal role cov cynomolgous macaques inoculated sarscov isolate disease macaques caused sarscov infection pathologically similar seen human patients sars since virus induce highly crossreactive neutralizing antibodies protect newly emerging viruses related sarscov protect gastrointestinal respiratory tract absence significant side effects given fact previous outbreak mainly elderly succumbed infection special attention given vaccines able efficiently protect aged individuals protein also inhibit sarscov replication vitro relevance protection remains unclear genome also encodes two large polyproteins diverse enzymatic activities needed efficient replication several accessory proteins unknown function <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>b end <NUMBER> <NUMBER> countries reported total <NUMBER> probable cases sars fig <NUMBER> pathogenic sarscovs circulate human population moment reemergence animal reservoirs may likely occur future many early sars patients guandong epidemiological links liveanimal market trade different animal species tested presence sarslike viruses soon outbreak sarslike coronavirus <NUMBER> homology human sarscov detected rtpcr nasal fecal swabs palm civets paguma larvata raccoon dog nyctereutes procyonoides guan et al <NUMBER> recent studies indicate bats may potentially act natural reservoirs sarslike covs li et al <NUMBER>b lau et al <NUMBER> however sequence comparison protein genes bat sarslike cov palm civet sarslike cov revealed <NUMBER> genetic homology subsequent studies tang et al <NUMBER> demonstrated approximately <NUMBER> bats sampled china positive covs interestingly covs genetically diverse many bat covs clustered existing group <NUMBER> viruses others formed separate lineage included viruses bats putative group <NUMBER> sarscov like viruses clustered putative group <NUMBER> consisting two subgroups one bat covs another sarscovs humans mammalian hosts however studies direct progenitor sarscov isolated palm civets identified major genetic variations protein gene viruses civet cats seemed essential transition animaltohuman transmission epidemiology figure <NUMBER> reported suspected sars cases november <NUMBER> <NUMBER> july <NUMBER> <NUMBER> data world health organization http wwwwhointcsrsarscountrytable<NUMBER>enindexhtml countries ͼ <NUMBER> suspected cases indicated patients fact none sarscovinfected children aged <NUMBER> years hong kong required intensive care mechanical ventilation ng et al <NUMBER> totally explained comorbid factors similar age dependence mortality seen patients nonviral causes acute respiratory stress syndrome rubenfeld et al <NUMBER> second virus transmission low first days illness peaks around day <NUMBER> disease onset chu et al <NUMBER> finally several studies revealed high viral load nasopharyngeal aspirate found independent predictor mortality hung et al <NUMBER> chu et al <NUMBER> therefore vaccine strategies aimed reducing viral load may suffice provide clinical benefit first efforts treat sars patients mainly based use ribavirin corticosteroids ribavirin targets imp dehydrogenase known long time broadspectrum antiviral agent however current data support use ribavirin sars treatment vitro studies show significant antiviral activity cinatl et al <NUMBER> ribavirin enhanced infectivity sarscov mice barnard et al <NUMBER> hand protective effect interferon ifnα observed preliminary study sars outbreak loutfy et al <NUMBER> results concordance several studies noted antiviral activity vitro cinatl et al <NUMBER> hensley et al <NUMBER> animal studies showing pegylated ifnα effectively reduced sarscov replication excretion viral antigen expression type <NUMBER> pneumocytes pulmonary damage cynomolgous macaques infected experimentally sarscov haagmans et al <NUMBER> however despite extensive literature reporting sars treatments possible determine whether treatments benefited patients sars outbreak variation treatment regimensparticularly wide range doses duration therapy route administration ribavirin corticosteroids clear conclusion drawn regarding efficacy drugs tested stockman et al <NUMBER> event future outbreak sarscov another novel agent attempts made develop treatment protocols organize randomized trials collect contribute information standardized minimum dataset could facilitate analysis treatment outcomes among different settings stockman et al <NUMBER> humantohuman transmission eventually caused sars outbreak <NUMBER> present evidence virus persisting human population possible options reemergence sars include escape virus laboratories already occurred three occasions reemergence virus animal reservoir remains possible given virus detectable feces respiratory secretions animals indeed sarscov reemerged four patients guangdong december <NUMBER> although sarslike covs caused milder clinical disease liang et al <NUMBER> us national institute allergy infectious diseases biodefense network classified sarscov category c priority pathogen pointing sarscov could potential biothreat agent clinical symptoms sarscov infection lower respiratory tract disease include fever malaise peripheral cell lymphocytopenia decreased platelet counts prolonged coagulation profiles mildly elevated serum hepatic enzymes peiris et al <NUMBER> li et al <NUMBER> chest radiography reveals infiltrates subpleural consolidation ground glass changes compatible viral pneumonitis around <NUMBER>−<NUMBER> individuals sars require management intensive care units overall casefatality rate reached approximately <NUMBER> although main clinical symptoms severe respiratory illness sarscov actually also causes gastrointestinal urinary tract infection sarscov detected feces urine patients electron microscopic studies biopsies upper lower intestinal mucosae patients sars confirmed presence virus tissues peiris et al <NUMBER> fecal transmission proved important least one major community outbreak hong kong amoy gardens <NUMBER> patients infected within days three features sars may relevant intervention strategies first progressive age dependence mortality disease severity observed sars major sources transmission humans droplets deposit respiratory epithelium unlike situation several respiratory viral infections viral load sarscov upper respiratory tract peaked around day <NUMBER> disease onset peiris et al <NUMBER> therefore virus transmission may less efficient first days illness finding supported epidemiological observations realtime pcr assays detect sarscov first week specimens lower respiratory tract eg bronchoalveolar lavage sputum endotracheal aspirates nasopharyngeal aspirate throat swabs andor serum chan et al <NUMBER> whereas fecal samples may show high viral loads toward end first week second week illness typical cases largely confined adult elderly individuals sars presented acute respiratory distress syndrome characterized presence diffuse alveolar damage multiorgan dysfunction upon autopsy nicholls et al <NUMBER> pathological changes lung alveoli likely follow common pathway characterized acute phase proteinrich alveolar fluid influx alveolar lumina consequence injury alveolar wall subsequently type<NUMBER> pneumocyte hyperplasia takes place replace loss infected type<NUMBER> pneumocytes cover denuded epithelial basement membrane resulting restoration normal alveolar architecture severe alveolar injury may lead fibrosis loss alveolar function protracted cases fig <NUMBER> <NUMBER> hypothesized pathological changes observed lungs initiated disproportional innate immune response illustrated elevated levels inflammatory cytokines chemokines cxcl<NUMBER> ip<NUMBER> ccl<NUMBER> mcp<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> β ifnγ huang et al <NUMBER> wong et al <NUMBER> vivo data confirmed vitro demonstrating sarscov infection induces range cytokines chemokines diverse cell types law et al <NUMBER> although vitro studies argued production type ifns inhibited delayed sarscov sarscovinfected macaques also early sars humans type ifns readily demonstrated de lang et al <NUMBER> prophylactic treatment macaques pegylated ifnα reduces sarscov replication lungs regulation production ifns may important controlling sars haagmans et al <NUMBER> based observation sarscov infection efficiently controlled upon passive transfer antibodies directed protein sarscov range vaccines containing proteingene developed animals immunized inactivated whole virus vaccines liverecombinant vaccines expressing sarscov protein eg using rabies virus vesicular stomatitis virus bovine parainfluenza virus type <NUMBER> adenovirus attenuated vaccinia virus mva vector well mice immunized dna vaccines expressing protein gene developed neutralizing antibodies sarscov protected sarscov challenge table <NUMBER> <NUMBER> displays overview vaccines tested efficacy animal models inactivated sars vaccines reported elicit high titers proteinspecific neutralizing antibodies studies however addressed whether inactivated whole sarscov virions confer protection virus challenge mice immunized twice candidate sarscov vaccine produced twostep inactivation procedure involving sequential formaldehyde uv inactivation developed highantibody titers sarscov protein high levels neutralizing antibodies spruth et al <NUMBER> see chapter <NUMBER> moreover vaccine conferred protective immunity demonstrated prevention sarscov replication respiratory tract mice intranasal challenge sarscov protection mice correlated antibody titer sarscov protein neutralizing antibody titer similar results obtained using betapropiolactone inactivated sarscov vaccine mice addition two chinese groups demonstrated protective efficacy inactivated sars vaccines rhesus monkeys qin et al <NUMBER> zhou et al <NUMBER> soluble recombinant polypeptide containing nterminal segment glycoprotein may suffice induce neutralizing antibodies protective immunity mice bisht et al <NUMBER> addition trimeric recombinant protein able elicit efficacious protective immune response hamsters kam et al <NUMBER> one promising vaccine candidates based combination recombinant protein protollin adjuvant young aged mice intranasal protollinformulated protein seroconversion usually occurs weeks <NUMBER> <NUMBER> illness virusneutralizing antibodies detected convalescent human serum patients recovered sarsneutralizing antibody titers peaked month <NUMBER> undetectable <NUMBER> patients month <NUMBER> cao et al <NUMBER> neutralizing antibodies may directed different regions protein s<NUMBER> s<NUMBER> monoclonal antibodies epitopes exert potent neutralization sarscov vitro sui et al <NUMBER> lip et al <NUMBER> conversely peptides located regions able induce neutralizing antibodies bisht et al <NUMBER> keng et al <NUMBER> zhang et al <NUMBER> although experiments diverse animal models revealed relatively low levels neutralizing antibodies exert potent protection lower respiratory tract infection neutralizing antibody titer necessary achieve protection humans exposed sarscov known concern case reemergence sars possible absence cross protection viruses however recent studies et al <NUMBER> shown neutralizing epitopes sarscov maintained crossspecies transmission suggesting receptor binding domainbased vaccines may induce broad protection human animal sarscov variants sars autopsies extensive necrosis spleen atrophy white pulp severe lymphocyte depletion observed hand rapid phase peripheral lymphocyte recovery usually coincided improved clinical conditions sars patients peiris et al <NUMBER> longlived memory cell responses sarscov nucleocapsid protein demonstrated recovered sars patients although relevance antiviral protection well understood peng et al <NUMBER> li et al <NUMBER> however despite potent immune responses clinical recovery peripheral lymphocyte counts recovered patients restored normal levels interestingly mice lack nkt cells nk cells b cells cleared virus day <NUMBER> infection glass et al <NUMBER> data argue cellmediated immune responses essential control virus clearance vaccine elicited high levels antigenspecific igg serum significant levels antigenspecific lung iga hu et al <NUMBER> contrast mice immunized intramuscularly alum absorbed protein develop detectable iga responses following virus challenge aged mice virus detected lungs mice vaccinated intranasally whereas intramuscularly immunized mice show significant control virus replication compared controls hu et al <NUMBER> dna vaccine encoding glycoprotein sarscov induces cell neutralizing antibody responses protective immunity mouse model authors also demonstrated antibody responses mice vaccinated expression vector encoding form protein includes transmembrane domain elicited neutralizing antibodies viral replication reduced six orders magnitude lungs mice vaccinated protein plasmid dna expression vectors protection mediated humoral tcelldependent immune mechanism subsequent studies using primeboost combination dna whole killed sarscov vaccines elicited higher antibody responses dna whole killed virus vaccines alone apart study several groups analyzed immunogenicity sars dna vaccines none challenged vaccinated animals sarscov adenovirusvector based vaccination strategies sarscov employed early sars outbreak demonstrate vaccinated rhesus macaques developed virusneutralizing antibody responses fragment s<NUMBER> protein cell responses nucleocapsid gao et al <NUMBER> recently see et al <NUMBER> demonstrated vaccination c<NUMBER>bl<NUMBER> mice adenovirus type <NUMBER>expressing nucleocapsid administered intranasally intramuscularly significantly limited sarscov replication lungs vaccines reduction pulmonary sarscov titer compared control animals dinapoli et al <NUMBER> finally venezuelan equine encephalitis virus based vaccines tested extensively young aged mice importantly different recombinant sarscov bearing epidemic zoonotic protein variants used challenge vaccinated mice venezuelan equine encephalitis virus replicon particles expressing <NUMBER> epidemic urbani sarscov strain glycoprotein particles containing nucleocapsid protein strain provided complete shortand longterm protection homologous strain challenge young senescent mice deming et al <NUMBER> although protein encoding vaccine provided complete shortterm protection heterologous strain gd<NUMBER> challenge young mice limited protection seen vaccinated senescent animals interestingly nucleocapsidencoding vaccines failed protect homologous heterologous challenge also resulted enhanced immunopathology eosinophilic infiltrates within lungs sarscovchallenged mice deming et al <NUMBER> new generation vaccines may obtained manipulating fulllength infectious cdna clone sarscov one approach would delete orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b similar coronavirus mutants generated previously mouse hepatitis feline infectious peritonitis deletion viruses replicate extent wildtype viruses vitro severely attenuated vivo making potential vaccine candidates however sarscov deletion mutants lacking orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b grew similar parental wildtype virus mouse model yount et al <NUMBER> hand recombinant sarscov lacks e gene attenuated vitro vivo viable recombinant virus e gene deleted recovered vero cells titer around <NUMBER> <NUMBER> pfuml titers respiratory tract hamsters <NUMBER>fold reduced compared wildtype sarscov replication suggesting mutant attenuated multiplication viruses packaging cell lines would provide missing protein trans would make promising sarscov vaccine candidate e gene deleted live attenuated virus vaccines may revert wildtype recombine circulating human highly attenuated modified vaccinia virus ankara mva used express glycoprotein sarscov vaccination experiments using mouse ferret rhesus monkey models bisht et al <NUMBER> chen et al <NUMBER> weingartl et al <NUMBER> intranasal intramuscular administration mva encoding sarscov protein led induction humoral immune response balbc mice well reduced viral titers respiratory tract bisht et al <NUMBER> recombinant bovinehuman parainfluenza virus type <NUMBER> vector bhpiv<NUMBER> developed live attenuated intranasal pediatric vaccine human parainfluenza virus type <NUMBER> immunization african green monkeys single dose bhpiv<NUMBER> expressing sarscov protein administered via respiratory tract induced production sarscov neutralizing antibodies recombinant bhpiv<NUMBER> expressing sarscov structural protein n individually combination evaluated immunogenicity protective efficacy hamsters absence protein expression n e induce detectable serum sarscovneutralizing antibody response protection sarscov challenge respiratory tract whereas vectors expressing protein induced neutralizing antibody responses protection recombinant rabies virus expressing protein sarscov induced neutralizing antibody response mice faber et al <NUMBER> similarly attenuated vesicular stomatitis virus vector encodes sarscov protein may used induce neutralizing antibody responses kapadia et al <NUMBER> mice vaccinated recombinant vesicular stomatitis virus expressing protein developed sarscovneutralizing antibody able control challenge sarscov performed either <NUMBER> month <NUMBER> months single vaccination addition passive antibody transfer experiments authors demonstrated antibody response induced vaccine sufficient control sarscov infection efficacy vectors demonstrated studies using aged mice aged mice vaccinated recombinant vesicular stomatitis virus expressing protein antibody titers induced sufficient protect subsequent challenge sarscov vogel et al <NUMBER> african green monkeys immunized via respiratory tract two doses recombinant newcastle disease virus encoding protein developed relatively high titer sarscov neutralizing antibodies upon challenge demonstrated <NUMBER>fold zoonotic coronaviruses order prevent proposed delete essential gene located position distant gene e relocation deleted gene position previously occupied gene e enjuanes et al <NUMBER> potential recombination leading rescue gene e would lead loss essential gene alternatively transcriptional regulatory sequences trs vaccine virus could genetically manipulated sequence incompatible trs known circulating coronavirus described yount et al <NUMBER> virus could modified building attenuating mutations genetic backbone recombination resistant trs rewired virus either use safe high titer seed stock making killed vaccines live virus vaccine one attenuating mutation could targeted nonstructural protein <NUMBER> recombinant mouse hepatitis virus mhv encoding deletion nsp<NUMBER>coding sequence grew normally tissue culture severely attenuated vivo züst et al <NUMBER> low doses nsp<NUMBER> mutant mhv elicited potent cytotoxic cell responses protected mice homologous heterologous virus challenge attenuation strategy provides new paradigm development highly efficient coronavirus vaccines although several types vectored vaccines developed several companies favored classical approach using inactivated whole virus develop vaccine used preclinical testing see chapter <NUMBER> methods place production available vaccines could easily used using wellestablished technologies preclinical development stage preferable different animal species used evaluate safety efficacy candidate vaccines overall wide range animal species including rodents mice hamsters carnivores ferrets cats nonhuman primates cynomolgus rhesus macaques common marmosets african green monkeys experimentally infected sarscov roberts et al <NUMBER>b martina et al <NUMBER> kuiken et al <NUMBER> mcauliffe et al <NUMBER> haagmans osterhaus <NUMBER> species show clinical signs disease although virus replicates efficiently respiratory tissues aged mice ferrets hand show signs clinical disease albeit absence typical lung lesions seen humans sars roberts et al <NUMBER>a contrast inoculation sarscov respiratory tract cynomolgus macaques causes infection bronchial epithelial cells type<NUMBER> pneumocytes <NUMBER> days postinfection followed extensive type<NUMBER> pneumocyte hyperplasia lungs <NUMBER> days postinfection haagmans osterhaus <NUMBER> lesions consisting multiple foci acute diffuse alveolar damage characterized flooding alveoli proteinrich edema fluid mixed variable numbers neutrophils quite similar observed humans acute stages sars remarkably vaccine candidates tested ferrets showed reduced efficacy vaccination mva encoding protein induced moderate antibody responses consequently protect intranasal sarscov infection even resulted inflammatory response livers vaccinated ferrets weingartl et al <NUMBER> whether aberrant responses resulted immunopathological mechanisms like antibodydependent enhancement infection represented recall responses viral antigen liver clear moment deserves investigation addition limited protection sarscov challenge observed ferrets vaccinated inactivated whole virus darnell et al <NUMBER> two four ferrets showed little neutralizing antibody even second immunization none vaccinated ferrets able reduce virus excretion day <NUMBER> challenge subsequently cleared virus rapidly compared control animals adenovirusbased vaccines tested ferrets seemed powerful protected lower respiratory tract efficiently less effect virus excretion upper respiratory tract kobinger et al <NUMBER> five years first sars outbreak range candidate vaccines developed early <NUMBER> companies china us initiated phase <NUMBER> trials first clinical trial initiated chinese company sinovac biotech beijing collaboration chinese academy medical sciences using inactivated whole virus vaccine evaluate safety immunogenicity vaccine <NUMBER> subjects received two doses vaccine placebo control day <NUMBER> individuals showed seroconversion peak titers neutralizing antibodies reached <NUMBER> weeks second vaccination followed clinical trials iii virus vaccines type coronavirus feline infectious peritonitis virus fipv subsequently exposed fipv infection weiss scott <NUMBER> macrophages able take feline coronavirusantibody complexes efficiently causing virus replicate higher titers interestingly one study also demonstrated antibodies human sarscov isolates enhance entry pseudotyped viruses expressing civet cat sarslike cov protein cells replication yang et al <NUMBER> date evidence enhanced replication following sarscov challenge previously immunized animals one problem may arise vaccination whole inactivated virus absorbed certain adjuvants alum could relate induction skewed th<NUMBER> recall responses similar observed children vaccinated inactivated respiratory syncytial measles virus vaccines although much effort focused developing sars vaccine commercial viability developing vaccine sarscov ultimately depend whether virus reemerges near future questionable whether possible future outbreaks cause major outbreaks vaccines antivirals passive immunization would relevant context protecting highrisk individuals laboratory healthcare workers • five years first sars outbreak several candidate sarscov vaccines various stages preclinical clinical development • based observation sarscov infection efficiently controlled upon passive transfer antibodies directed protein sarscov vaccines encoding protein developed • animals immunized diverse vaccines containing protein protein gene developed sarscovneutralizing antibodies protected sarscov challenge • future challenges development sarscov vaccines linked potential reemergence virus vaccines able induce highly crossreactive antibodies efficiently protect gastrointestinal respiratory tract needed given fact previous outbreak mainly elderly humans succumbed infection special attention given protect specifically individuals significant decline <NUMBER> weeks later lin et al <NUMBER> several candidate sars vaccines various stages preclinical clinical development sars patients recover high levels neutralizing antibody responses observed suggesting antibody responses play role determining ultimate disease outcome sarscovinfected patients although attempts made test efficacy serum preparations seroconvalescent sars patients acute phase sars conclusive evidence obtained regarding efficacy mice hand sarscov infection efficiently controlled upon passive transfer convalescent immunoglobulines concept antibodies protect sars explored generation human monoclonal antibodies sarscov prophylactic administration human monoclonal antibody reduced replication sarscov lungs infected ferrets <NUMBER>fold completely prevented development sarscovinduced macroscopic lung pathology abolished shedding virus pharyngeal secretions ter meulen et al <NUMBER> subsequent studies several monoclonal antibodies evaluated efficacy mouse hamster models sui et al <NUMBER> traggiai et al <NUMBER> importance assessing immunogenicity candidate sarscov vaccines using virus neutralization assays well acknowledged variety tests use significant problem since time consensus sensitive specific reproducible assay system compare data candidate vaccines requires international standardization immunological assays availability antibody standard used evaluation vaccines test cross reactivity antibodies generated vaccination murine leukemia virus used generate infectious particles containing different proteins giroglou et al <NUMBER> enhanced disease mortality observed kittens immunized infected sarscov<NUMBER> causal agent covid<NUMBER> first emerged late <NUMBER> china since infected <NUMBER> individuals caused <NUMBER> deaths globally discuss therapeutic prophylactic interventions sarscov<NUMBER> focus vaccine development challenges vaccines rapidly developed likely come late affect first wave potential pandemic nevertheless critical lessons learned development vaccines rapidly emerging viruses importantly sarscov<NUMBER> vaccines essential reducing morbidity mortality virus establishes population december <NUMBER> <NUMBER> several cases pneumonia unknown etiology reported wuhan china outbreak started early december november number cases rose quickly <NUMBER> infections reported china march <NUMBER> <NUMBER> including <NUMBER> deaths time review april <NUMBER> <NUMBER> disease termed covid<NUMBER> coronavirus disease <NUMBER> become pandemic spread <NUMBER> countries territories including community transmission countries like united states germany france spain japan singapore south korea iran italy largescale outbreak <NUMBER> cases cruise ship diamond princess april <NUMBER> <NUMBER> cases <NUMBER> deaths reported globally rapid growth numbers many countries causative agent outbreak swiftly identified betacoronavirus genomic sequence closely related severe acute respiratory syndrome sars coronavirus <NUMBER> earning new virus name sarscov<NUMBER> gorbalenya et al <NUMBER> wu et al <NUMBER> zhou et al <NUMBER> zhu et al <NUMBER> sarscov<NUMBER> likely originated bats might amplified intermediate host initial work showed use angiotensinconverting enzyme <NUMBER> ace<NUMBER> bats civet cats swine cats ferrets nonhuman primates nhps humans receptor letko et al <NUMBER> wan et al <NUMBER> zhou et al <NUMBER> transmission infection pet dog hong kong suggests canine ace<NUMBER> also recognized sarscov<NUMBER> pangolins protected animals traded illegally asia elsewhere proposed potential amplifying host studies lam et al <NUMBER> zhang et al <NUMBER> initial reports china elsewhere note although covid<NUMBER> cases present mild moderate pathology approximately <NUMBER> percent cases severe guan et al <NUMBER> huang et al <NUMBER> novel coronavirus pneumonia emergency response epidemiology team <NUMBER> wang et al <NUMBER> case fatality rate cfr seems age dependent higher percentage elderly especially men overall interim cfr approximately <NUMBER> number individuals undetected mild cases could much higher official case number would lead lower infection fatality rate irf south korea country put massive effort testing already tested tens thousands samples reports much lower cfrs countries without extensive testing like spain iran united states cfr disproportionally high italy currently <NUMBER> likely large number mild cases missed combined relatively older population healthcare system overwhelmed cases reproductive number r <NUMBER> infection number cases directly generated one case population individuals susceptible infection estimated <NUMBER> given severity disease age groups seasonal influenza pandemic h<NUMBER>n<NUMBER> <NUMBER> influenza vaccines therapeutics tackle novel virus urgently needed coronaviruses brief sarscov<NUMBER> part coronaviridae family whose members named crownlike appearance electron microscope caused surface glycoproteins decorate virus family includes two subfamilies letovirinae orthocoronavirinae orthocoronavirinae includes genera alphacoronvirus betacoronavirus gammacoronavirus deltacoronavirus alphacoronaviruses betacoronaviruses typically infect mammals whereas gammacoronoviruses deltacoronaviruses typically infect avian species sometimes mammals cui et al <NUMBER> coronaviruses common human pathogens two types alphacoronaviruses <NUMBER>e nl<NUMBER> two types betacoronaviruses oc<NUMBER> hku<NUMBER> circulate humans cause common cold pathogenic coronaviruses humans include sarscov<NUMBER> middle eastern respiratory syndrome coronavirus merscov sarscov<NUMBER> betacoronaviruses coronaviruses large <NUMBER> kb singlestranded positivesense rna genome encoding several open reading frames one frame encodes spike protein protein class fusion protein mediates attachment virus cell surface receptors followed uptake endosomes coronaviruses proteolytic cleavage protein fusion viral endosomal membranes trigger release viral rna cytosol reviewed fehr perlman <NUMBER> rna contains <NUMBER> <NUMBER> cap structure <NUMBER> <NUMBER> polya tail allows expression replicase encoded approximately twothirds genome third codes structural accessory proteins replicase expressed two polyproteins pp<NUMBER>a pp<NUMBER>ab include <NUMBER> nonstructural proteins nsps nsps generated processing pp<NUMBER>a pp<NUMBER>ab <NUMBER> viral proteases encoded within replicase many nsps assemble replicasetranscriptase complex thatin host cell cytosolproduces antisense genome new viral genome subgenomic rna serves mrna structural proteins matrix protein envelope e generated inserted endoplasmatic reticulum follow secretory pathway endoplasmic reticulumgolgi intermediate compartment ergic minority coronaviruses also encode hemagglutinin esterase many coronaviruses protein cleaved two subunits s<NUMBER> s<NUMBER> often furinlike proteases rna genome associates nucleoprotein buds ergic forming virus particles assembly virions transported cell surface vesicles exocytosed several accessory proteins seem important pathogenesis also expressed functionally characterized clinical trials nucleotide analog remdesivir clinicaltrialsgov nct<NUMBER> nct<NUMBER> nct<NUMBER> etc protease inhibitors clinicaltrialsgov nct<NUMBER> nct<NUMBER> etc well treatment options ongoing china united states trial results expected within weeks remdesivir works coronaviruses closely related sarscov<NUMBER> animal models well related merscov including nhps agostini et al <NUMBER> brown et al <NUMBER> de wit et al <NUMBER> sheahan et al <NUMBER> sheahan et al <NUMBER> remdesivir also tested treatment ebolavirus infections humans found less successful treatments mulangu et al <NUMBER> therefore safety data exist therapeutic agent accelerate process clinical testing sarscov<NUMBER> remdesivirs mechanism action nucleotide analog clear likely terminates rna synthesis leads incorporation mutagenesis agostini et al <NUMBER> addition combination two licensed hiv inhibitors lopinavir ritonavir also tested clinical trials eg clinicaltrialsgov nct<NUMBER> etc lopinavir bona fide protease inhibitor whereas ritonavir initially designed protease inhibitor found boost halflife lopinavir inhibiting cytochrome p<NUMBER> hull montaner <NUMBER> combination compassionately used treatment sarscov<NUMBER> <NUMBER> showed promise chu et al <NUMBER> effectiveness combination limited mice appreciable nhp models merscov chan et al <NUMBER> sheahan et al <NUMBER> mechanism action lopinavir clear likely inhibits one coronavirus proteases treatment options ongoing planned clinical trials include dosing recombinant human ace<NUMBER> neutralize virus prevent lung damage clinicaltrialsgov nct<NUMBER> using antiviral arbidol fusion inhibitor kadam wilson <NUMBER> teissier et al <NUMBER> another interesting option use convalescent serum treatment clinical trials test ongoing china clinicaltrialsgov nct<NUMBER> placebo control recruiting yet compassionate use strategy recently started us eg mount sinai medical center ny similarly polyclonal human immunoglobulin g igg derived transgenic cows could used strategy successful merscov animal models luke et al <NUMBER> tested safety clinical trials clinicaltrialsgov nct<NUMBER> many trials results within months remdesivir produced gilead andor lopinavir plus ritonavir produced abbvie kaletra aluvia respectively show effectiveness could potentially used widely within short time frame compassionate use drugs already reported sarscov<NUMBER> infections holshue et al <NUMBER> lim et al <NUMBER> <NUMBER> h<NUMBER>n<NUMBER> influenza virus pandemic vaccine producers switched production pipelines quickly producing trivalent seasonal influenza virus vaccines monovalent pandemic vaccines basically change strains established approved processes established release criteria existing correlates protection could used krammer palese <NUMBER> still took six months vaccine ready distributed used came late affect second pandemic wave took place united states fall <NUMBER> time facing new challenge form virus emerged humans response complex existing vaccines production processes coronavirus vaccines vaccine technology significantly evolved last decade including development several rna dna vaccine candidates licensed vectored vaccines eg ervebo vesicular stomatitis virus vsvvectored ebolavirus vaccine licensed european union recombinant protein vaccines eg flublok influenza virus vaccine made insect cells licensed united states cellculturebased vaccines eg flucelvax influenza virus vaccine made mammalian cells sarscov<NUMBER> identified record time genomic sequence swiftly made widely available chinese researchers zhou et al <NUMBER> zhu et al <NUMBER> addition know studies sarscov<NUMBER> related merscov vaccines protein surface virus ideal target vaccine sarscov<NUMBER> sarscov<NUMBER> protein interacts receptor ace<NUMBER> antibodies targeting spike interfere binding thereby neutralizing virus figure <NUMBER> structure protein sarscov<NUMBER> solved record time high resolution contributing understanding vaccine target lan et al <NUMBER>a wrapp et al <NUMBER> therefore target antigen incorporated advanced vaccine platforms several vaccines sarscov<NUMBER> developed tested animal models including recombinant sproteinbased vaccines attenuated whole inactivated vaccines vectored vaccines roper rehm <NUMBER> vaccines protect animals challenge sarscov<NUMBER> although many induce sterilizing immunity cases vaccination live virus results complications including lung damage infiltration eosinophils mouse model eg bolles et al <NUMBER> tseng et al <NUMBER> liver damage ferrets eg weingartl et al <NUMBER> another study vaccination inactivated sarscov<NUMBER> led enhancement disease one nhp whereas protected <NUMBER> animals challenge wang et al <NUMBER> study identified certain epitopes protein protective whereas immunity others seemed enhancing disease however almost cases vaccination associated greater survival reduced virus titers andor less morbidity compared unvaccinated animals similar findings reported merscov vaccines agrawal et al <NUMBER> houser et al <NUMBER> therefore whereas vaccines related coronaviruses efficacious animal models need ensure vaccines developed sarscov<NUMBER> sufficiently safe another consideration effective coronavirus vaccine development might waning antibody response infection human coronaviruses always induce longlived antibody responses reinfection individual virus possible extended period time fraction individuals resulting mild symtpoms shown human challenge studies callow et al <NUMBER> antibody titers individuals survived sarscov<NUMBER> merscov infections often waned <NUMBER> years liu et al <NUMBER> wu et al <NUMBER> weak initially choe et al <NUMBER> despite reinfections unlikely short term note reinfections days recovery reported recently appear consequences false negative test results lan et al <NUMBER>b however could happen humoral immunity wanes months years effective sarscov<NUMBER> vaccine need overcome issues protect scenario virus becomes endemic causes recurrent seasonal epidemics sarscov<NUMBER> infection causes severe pathology individuals <NUMBER> years age reason clear many viral infections milder manifestations naive younger individuals naive older individuals older individuals affected important develop vaccines protect segment population unfortunately older individuals typically respond less well vaccination immune senescence sambhara mcelhaney <NUMBER> influenza problematic older adults specific formulations segment population include antigen adjuvant diazgranados et al <NUMBER> tsai <NUMBER> protection older individuals appears require higher neutralization titers influenza virus younger individuals benoit et al <NUMBER> issue might need addressed sarscov<NUMBER> vaccination older individuals effective could still benefit indirectly vaccination able stop transmission virus younger individuals small number sarscov<NUMBER> vaccines made phase clinical trials funding dried eradication virus human population nonpharmaceutical interventions case numbers still small results trials performed inactivated virus vaccine spikebased dna vaccine encouraging vaccines safe induced neutralizing antibody titers lin et al <NUMBER> martin et al <NUMBER> neutralizing monoclonal antibodies isolated sarscov<NUMBER> like cr<NUMBER> ter meulen et al <NUMBER> tian et al <NUMBER> crossreact receptor binding domain sarscov<NUMBER> suggests sarscov<NUMBER> vaccines might crossprotect sarscov<NUMBER> however vaccines developed phase currently available use vaccines merscov also targeting merscov protein preclinical clinical development including vaccines based modified vaccinia ankara vectors adenovirus vectors dnabased vaccines several supported coalition epidemic preparedness innovation cepi yong et al <NUMBER> however unlikely merscov vaccines induce strong crossneutralizing antibodies sarscov<NUMBER> phylogenetic structure coronavirus particle depicted left different viral proteins indicated protein major target vaccine development spike structure shown based trimeric sarscov<NUMBER> spike pdb <NUMBER>xl<NUMBER> one trimer shown dark blue receptor binding domain main target neutralizing antibodies highlighted purple two trimers shown light blue sarscov<NUMBER> vaccine candidates based different vaccine platforms developed preclinical experiments initiated one mrnabased candidate clinical trial recently started enroll volunteers shortly clinicaltrialsgov nct<NUMBER> however many additional steps needed vaccines used population process might take months years <NUMBER> candidates cgmp processes already established <NUMBER> clinical trial design might altered move vaccines clinical testing quicker distance two viruses nevertheless still learn lot vaccines move forward sarscov<NUMBER> vaccine design pallesen et al <NUMBER> development vaccines human use take years especially novel technologies used extensively tested safety scaled mass production coronavirus vaccines market largescale manufacturing capacity vaccines exists yet table <NUMBER> need build processes capacities first time tedious time consuming figure <NUMBER> cepi awarded funds several highly innovative players field many likely succeed eventually making sarscov<NUMBER> vaccine however none companies institutions established pipeline bring vaccine latestage clinical trials allow licensure regulatory agencies currently capacity produce number doses needed mrnabased vaccine expresses target antigen vivo vaccinee injection mrna encapsulated lipid nanoparticles codeveloped moderna vaccine research center national institutes health currently furthest along phase clinical trial recently started clinicaltrialsgov nct<NUMBER> curevac working similar vaccine still preclinical phase additional approaches preclinical stage include recombinantproteinbased vaccines focused protein eg express<NUMBER>ion ibio novavax baylor college medicine university queensland sichuan clover biopharmaceuticals viralvectorbased vaccines focused protein eg vaxart geovax university oxford cansino biologics dna vaccines focused protein eg inovio applied dna sciences live attenuated vaccines codagenix serum institute india etc inactivated virus vaccines figure <NUMBER> table <NUMBER> platforms advantages disadvantages table <NUMBER> possible predict strategy faster successful johnson johnson jj johnson johnson <NUMBER> sanofi <NUMBER> recently joined efforts develop sarscov<NUMBER> vaccines however jj using experimental adenovirus vector platform yet resulted licensed vaccine sanofis vaccine made using process similar process used approved flublok recombinant influenza virus vaccine zhou et al <NUMBER> also months years ready use human population creating infectious clones attenuated coronavirus vaccine seeds takes time large genome size safety testing need extensive straightforward process used several licensed human vaccines existing infrastructure used tested humans sarscov<NUMBER> adjuvants used increase immunogenicity large amounts infectious virus need handled could mitigated using attenuated seed virus antigen andor epitope integrity needs confirmed take long mentioned earlier currently approved human coronavirus vaccines addition many technologies used production platforms vectors etc new need tested thoroughly safety target vaccine protein identified vaccine candidates generated usually followed two important steps typically needed bringing vaccine clinical trials first vaccine tested appropriate animal models see whether protective however animal models sarscov<NUMBER> might difficult develop virus grow wildtype mice induced mild disease transgenic animals expressing human ace<NUMBER> bao et al <NUMBER> potential animal models include ferrets nhps pathogenicity studies ongoing even absence animal model replicates human disease possible evaluate vaccine serum vaccinated animals tested vitro neutralization assays postchallenge safety data also collected cases assess complications ones seen sarscov<NUMBER> merscov vaccines second vaccines need tested toxicity animals eg rabbits usually viral challenge part process safety vaccine evaluated testing performed manner compliant glp good laboratory practice typically takes <NUMBER> months complete vaccine platforms parts safety testing might skipped already sufficient data available similar vaccines made production process vaccines human use produced processes comply current good manufacturing practice cgmp ensure constant quality safety vaccines requires dedicated facilities trained personnel proper documentation raw material produced cgmp quality processes designed amended fit sarscov<NUMBER> vaccines many vaccine candidates preclinical phase processes yet exist developed scratch sufficient preclinical data available initial batches vaccine produced cgmp quality clinical trials might initiated typically clinical development vaccines starts small phase trials evaluate safety vaccine candidates humans followed phase ii trials formulation doses established initially prove efficacy finally phase iii trials efficacy safety vaccine need demonstrated larger cohort however extraordinary situation like current one scheme might compressed accelerated regulatory approval pathway might developed efficacy shown vaccine might licensed regulatory agencies another important point production capacity produce sufficient amounts cgmpquality vaccine needs available vaccines based existing vaccine platforms eg inactivated live attenuated vaccines relatively easily achieved existing infrastructure used table <NUMBER> vaccines based novel technologies eg mrna capacity needs built typically takes time although would beneficial even limited number doses available protect health care workers vulnerable segments population goal make vaccines available global population challenging even influenza virus vaccines many production facilities exist highincome countries well lowand middleincome countries demand case pandemic would far exceed production capacity finally takes time distribute vaccines administer vaccinate large proportion population would likely take weeks given population currently naive sarscov<NUMBER> highly likely one dose vaccine needed primeboost vaccination regimens typically used cases two vaccinations usually spaced <NUMBER> weeks apart likely protective immunity achieved <NUMBER> weeks second vaccination therefore adds another <NUMBER> months timeline even shortcuts several steps mentioned earlier found unlikely vaccine would available earlier <NUMBER> months initiation clinical trials realistically sarscov<NUMBER> vaccines available another <NUMBER> months potential solutions long time frames future one possibility build production capacity globally distributed possible activated event new emerging viruses todays perspective types viruses likely cause respiratory disease leads rapid global spread surveillance animal reservoir paired virus characterization studies identify members virus families potential cause pandemics vaccine candidates using isolates could produced tested animals determine mechanisms protection tested humans establish safety vaccines unlikely viruses chosen vaccine candidates later cause outbreaks however vaccine candidate sufficiently closely related sequences vaccines could quickly switched vaccines newly emerging viruses could swiftly produced moved latestage clinical trials right away largescale production ramped globally addition stockpiled vaccines based initial candidates could deployed even slightly mismatched strain causing outbreak strategy currently used h<NUMBER> h<NUMBER> avian influenza virus vaccines would allow response within weeks could potentially stop virus locally becomes pandemic alternative challenging solution would development broadly protective vaccines cover whole virus families genera effort ongoing influenza viruses erbelding et al <NUMBER> could potentially applied coronaviruses least betacoronaviruses options costly require global political vision considering deep dive stock markets taken recent weeks given expected effect pandemic economy funding vaccine production infrastructure would allow swift response emerging viruses looks like great investment however without pandemic looming investments rarely made past except h<NUMBER> h<NUMBER> subtype influenza viruses would right time consider investing vaccines emerging viruses lead loss human lives burden global economy investment billion dollars would allow us sufficient surveillance appropriate vaccine candidates infrastructure ready could churn vaccines use global population quickly effectively potentially stopping emerging virus tracks addition need welldeveloped emergency plans allow us develop test produce distribute vaccines within weeks months years would need tight coordination among pharmaceutical companies governments regulatory agencies world health organization well novel outofthebox approaches cgmp production release processes regulatory science clinical trial design sarscov<NUMBER> vaccines might come late affect first wave pandemic however might useful additional waves occur later postpandemic scenario sarscov<NUMBER> continues circulate seasonal virus addition lessons learned handling outbreak allow us better prepared future viruses keep coming thank francesco berlandascorza providing feedback manuscript work influenza virus vaccines immunity krammer laboratory supported national institute allergy infectious diseases niaid collaborative influenza vaccine innovation centers civic contract <NUMBER>n<NUMBER>c<NUMBER> niaid centers excellence influenza research surveillance ceirs contract hhsn<NUMBER>c niaid grants ai<NUMBER> ai<NUMBER> well funding us department defense bill melinda gates foundation work sarscov<NUMBER> reagents supported ceirs institutional seed funding reagents deposited bei resources support sarscov<NUMBER> research countermeasure development vaccination effective economical way prevent viral infections review describes coronavirus vaccine design targets summarizes recent advances potential strategies coronavirus vaccine development highlights promising technological routes adjuvants improving effectiveness coronavirus vaccines <NUMBER> novel strain coronavirus found humans <NUMBER> february <NUMBER> <NUMBER> announced new name epidemic disease corona virus disease meanwhile international committee taxonomy viruses named novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> may <NUMBER>th <NUMBER> epidemic covid<NUMBER> caused <NUMBER> laboratoryconfirmed cases <NUMBER> reported deaths <NUMBER> covid<NUMBER> third known zoonotic coronavirus disease <NUMBER> sars zoonosis caused sarscov infected <NUMBER> humans including <NUMBER> deaths mortality rate <NUMBER> least <NUMBER> countries <NUMBER> another highly pathogenic coronavirus merscov reported <NUMBER> countries reported viral infection <NUMBER> associated deaths mortality rate <NUMBER> <NUMBER> research indicates sarscov transmitted civet cats humans merscov transmitted dromedary camels humans however intermediate host sarscov<NUMBER> identified <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> together sarscov merscov posed significant threats international health due high pathogenicity infectivity vaccination important strategy provide protection infectious diseases however date vaccine approved prevent coronavirus infection indicating need development novel effective vaccines coronavirus infection review illustrate vaccine design targets review current advances potential strategies vaccine development based spike protein sarscov merscov focus improve efficacy vaccines adjuvant formulations overall strategies may provide useful guidance vaccine development sarscov<NUMBER> infections animals humans according phylogenetic relationships coronavirus divided four genera alpha beta gamma delta alpha beta genera infect mammals gamma delta genera mostly avian coronaviruses <NUMBER> seven known coronavirus infect humans <NUMBER>e oc<NUMBER> nl<NUMBER> hku<NUMBER> sarscov merscov sarscov<NUMBER> first four viruses cause mild minor respiratory illness three strainssarscov merscov sarscov<NUMBER>are zoonotic lead severe respiratory syndrome <NUMBER> coronaviruses largest single positivestrand rna viruses genome <NUMBER> kb <NUMBER> named coronalike appearance sarscov merscov sarscov<NUMBER> strong humantohuman characteristics attributed interaction protein host cell surface receptors sarscov sarscov<NUMBER> use angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor <NUMBER> <NUMBER> whereas merscov uses dipeptidyl peptidase <NUMBER> dpp<NUMBER> also known cd<NUMBER> receptor <NUMBER> table <NUMBER> <NUMBER> protein large type transmembrane glycoprotein whose trimers constitute spike structure surface virus protein fig <NUMBER>b divided two functional subunits nterminal s<NUMBER> domain contains signal peptide receptor binding domain rbd cterminal s<NUMBER> domain contains fusion peptide two heptapeptide repeats hr<NUMBER> hr<NUMBER> facilitate viral fusion rbd mediates binding virus cell receptor triggers conformational change protein exposing hr<NUMBER> hr<NUMBER> form <NUMBER>helix bundle fusion core structure leading membrane fusion viral rna release <NUMBER> <NUMBER> <NUMBER> <NUMBER> furthermore protein carries bcell epitopes induces body produce neutralizing antibody provides immune protection <NUMBER> protein involved viral infection responsible inducing host immune response virusneutralizing antibodies considered key target vaccine design antigenspecific targets protein include fulllength protein s<NUMBER> subunits rbd s<NUMBER> subunits viral vector vaccines encoding fulllength protein s<NUMBER> subunits demonstrated induce high levels neutralizing antibodies various animal models <NUMBER> <NUMBER> however nonneutralizing epitopes fulllength protein s<NUMBER> subunits may compete neutralizing epitopes leading several safety concerns including inflammatory immunopathological effects pulmonary eosinophilic infiltration antibodydependent enhancement ade following subsequent viral challenge vaccinated animals <NUMBER> <NUMBER> <NUMBER> ade phenomenon nonneutralizing antibodies produced following infection vaccination leads enhanced infection <NUMBER> one approach mitigate adverse effects ade narrow immune response target critical beneficial epitopes <NUMBER> vaccines based rbd elicited robust protective immune response neutralizing antibodies time rbd contain nonneutralizing epitopes may cause harmful immune responses hot spot cov vaccine development worth mentioning rbd relatively low immunogenicity often requires repeated doses adjuvants <NUMBER> <NUMBER> <NUMBER> s<NUMBER> subunit highly conserved prone mutation s<NUMBER> region become important target development protective vaccines however reports regarding presence neutralizing epitopes s<NUMBER> protective role antibodies s<NUMBER> inconsistent several studies demonstrated s<NUMBER> domain could induce specific cellular immune response high level total igg little neutralizing antibodies coronavirus infection <NUMBER> <NUMBER> contrary also reports showed s<NUMBER> domain contains neutralizing epitopes could induce neutralizing antibodies <NUMBER> <NUMBER> n protein serves multiple functions viral replication transcription assembly viral genome complex conservative proteins therefore n protein also widely reported target antigen n proteins shown highly immunogenic capable triggering cell responses <NUMBER> remarkably many studies indicated serum containing antin protein contain neutralizing antibodies coronavirus infection <NUMBER> <NUMBER> addition vaccines based n protein failed protect homologous heterologous challenge resulted enhanced immunopathology eosinophilic infiltrates within lungs sarscovchallenged mice <NUMBER> critical cov vaccines induce robust humoral cellular immunities nucleic acid vaccines including dna rna vaccines based plasmids messenger rna encode vaccine antigens introduced host produce immunological response protect organisms diseases <NUMBER> induced durable immune responses participants maintained detectable s<NUMBER> binding antibodies cellular immune responses almost <NUMBER> year last vaccination <NUMBER> nevertheless cov dna vaccines based fulllength protein may cause th<NUMBER>related harmful immune response leading liver damage vaccinated animals one study comparing immunogenicity merscov dna vaccines expressing s<NUMBER> mice showed plasmids expressing s<NUMBER> ps<NUMBER> subunit triggered balanced th<NUMBER>th<NUMBER> response thereby avoiding risk immunopathological risk associated th<NUMBER> response <NUMBER> moreover immunization mice ps<NUMBER> vaccine induced significantly higher levels ifnγ compared ps vaccine <NUMBER> messenger rna mrna vaccines carry transcripts encoding antigens use host cell translational machinery produce antigens stimulates immune response <NUMBER> high yields vitro transcription reactions mrna potential rapid inexpensive scalable manufacturing greatly shortens development time respond quickly epidemics compared dna vaccines mrna vaccines need pass additional membrane barrier nuclear membrane safety concerns integration host genome <NUMBER> due advantages mrna vaccines becoming powerful tool coronavirus infection however application restricted instability inefficient vivo delivery nucleic acid dna mrna <NUMBER> <NUMBER> provide protection degradation facilitate entry targeted cells efficient delivery systems nucleic acid vaccines particularly nanocarriers explored extensively viral vectors molecular mechanism assists target gene enter cells infect important vector platform cov candidate vaccines <NUMBER> <NUMBER> furthermore compared merscov sencoding ad<NUMBER> vaccines merscov s<NUMBER>encoding ad<NUMBER> vaccines might induce higher levels neutralizing antibodies <NUMBER> recent study rad<NUMBER> constructs expressing cd<NUMBER>targeted s<NUMBER> fusion protein rad<NUMBER>s<NUMBER>fcd<NUMBER>l exhibited full protection lethal merscov challenge prevented severe perivascular hemorrhage within lungs compared non cd<NUMBER>targeted vaccine rad<NUMBER>s<NUMBER> <NUMBER> viruslike particles vlps multiprotein structures mimic organization subunit vaccines composed highly purified antigens require part pathogen generate protective immune response subunit vaccines characterized high security controllable performance easy production large scale thereby gradually becoming focus researchers table <NUMBER> highly purified proteins subunit vaccines usually inherently immunogenic generally directly stimulate innate immune system however development effective cov vaccines requires activation powerful humoral cellular immunity induce protective immunity virus clearance body therefore adjuvants needed incorporated subunit vaccines enhance immunogenicity weaker antigens evoke required antigenspecific immune response phenotype thus improving overall potency poorly immunogenic subunit vaccines following review discuss adjuvants commonly used subunit vaccines coronavirus infection aluminum alum adjuvant longest frequently used adjuvant licensed vaccines extensive safety record alum th<NUMBER>type adjuvant induces strong humoral immune response including production neutralizing antibodies <NUMBER> therefore alum incorporated range vaccines viral infection neutralizing antibodies viral antigens required protection including human papillomavirus rabies hepatitis b <NUMBER> aluminum adjuvant widely used development cov vaccine due variety advantages noted several studies indicated rbdbased subunit vaccines presence alum induce powerful serumspecific neutralizing antibodies providing degree protection viral challenges <NUMBER> <NUMBER> noteworthy mention eliciting powerful cellular humoral immunity critical potential cov vaccine virusspecific cells secrete ifnγ promote virus clearance meanwhile effector cells differentiate memory cells expected respond quickly effectively subsequent cov infection <NUMBER> <NUMBER> although alum successfully induces antibodymediated protective immunity ability induce cellular immune responses limited one approach overcome limitations alum use combination adjuvants enhance cellular immune responses another approach extensive history use cov vaccine adjuvants emulsions freunds adjuvant waterinoil emulsion divided complete innate immune system recognizes pathogenassociated molecular patterns table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition safety considerations design adjuvants must also pay attention ability selectively induce regulate types immune responses body effectively promote humoral cellular immunity combat coronavirus infection also noteworthy mention existing wellestablished adjuvant could combined new immunostimulants eg tlrs agonist improve breadth intensity immune responses become potential strategy exploring efficient adjuvant systems sarscov<NUMBER> spread rapidly since outbreak posed risk conflicts interest declare <NUMBER> induces production typei ifn elicits cell responses <NUMBER> tlr<NUMBER> agonist lpsmpla induces sarscov sspecific antibody virusspecific antibody <NUMBER> <NUMBER> <NUMBER> induces production th<NUMBER> cytokines elicits cell responses <NUMBER> tlr<NUMBER> agonist cpg dna noreport <NUMBER> induces production ifna ifnγ enhance nk cell cytotoxicity <NUMBER> stimulator interferon genes sting agonists sting agonist cdgmp <NUMBER> activates production host defense molecules cytokines <NUMBER> induces adaptive immune responses <NUMBER> <NUMBER> induces merscov rbdspecific igg subtype antibody igg<NUMBER> igg<NUMBER>a c ovid<NUMBER> known previously <NUMBER>ncov pneumonia disease emerged global public health crisis joining severe acute respiratory syndrome sars middle east respiratory syndrome mers growing number coronavirusassociated illnesses jumped animals people least seven identified coronaviruses infect humans december <NUMBER> city wuhan china became epicenter outbreak novel coronavirus sarscov<NUMBER> sarscov<NUMBER> isolated sequenced human airway epithelial cells infected patients <NUMBER> <NUMBER> disease symptoms range mild flulike severe cases lifethreatening pneumonia <NUMBER> global situation dynamically evolving <NUMBER> january <NUMBER> world health organization declared covid<NUMBER> public health emergency international concern pheic <NUMBER> march <NUMBER> declared global pandemic <NUMBER> may <NUMBER> <NUMBER> people confirmed infected <NUMBER> deaths <NUMBER> infections spread multiple continents humantohuman transmission observed multiple countries shortage disposable personal protective equipment <NUMBER> prolonged survival times coronaviruses inanimate surfaces <NUMBER> compounded already delicate situation heightened risk nosocomial infections advanced research activities must pursued parallel push forward protective modalities effort protect billions vulnerable individuals worldwide currently licensed preventative vaccine available covid<NUMBER> address urgent need medical countermeasure prevent dissemination sarscov<NUMBER> employed synthetic dnabased vaccine approach synthetic dna vaccines amenable accelerated developmental timelines due ability quickly design multiple candidates preclinical testing scalable manufacturing large quantities drug product possibility leverage established regulatory pathways clinic synthetic dna temperaturestable coldchain free important features delivery resourcelimited settings <NUMBER> specifically development covid<NUMBER> vaccine candidate leveraged prior experiences developing vaccine approaches sarscov <NUMBER> experience developing merscov vaccine ino<NUMBER> <NUMBER> <NUMBER> well taking advantage vaccine design manufacturing pathway previously utilized zika vaccine candidate gls<NUMBER> <NUMBER> advanced clinic <NUMBER> months ino<NUMBER> gls<NUMBER> vaccines currently clinical testing prior work demonstrated dna approach sars mers drive neutralizing antibody nab responses provide protection challenge models <NUMBER> <NUMBER> previous studies indicated immunization small large animal models dna vaccines encoding merscov spike protein provided protection disease challenge matched virus subjects immunized ino<NUMBER> merscov protein dna vaccine durable neutralizing antibodies nabs cell immune responses measured seroconversion rate <NUMBER> observed immunity followed <NUMBER> weeks study volunteers <NUMBER> ino<NUMBER> phase <NUMBER>a testing continuing south korea larger phase <NUMBER> study planned begin middle east areas affected mers infections sarscov<NUMBER> spike similar sequence structure sarscov spike protein <NUMBER> shares global protein fold architecture merscov spike protein fig <NUMBER> allowing us build prior vaccine construct design <NUMBER> unlike glycoproteins hiv influenza prefusion form coronavirus trimeric spike conformationally dynamic fully exposing receptorbinding site infrequently <NUMBER> receptorbinding site vulnerable target nabs fact mers nabs targeted receptorbinding domain rbd tend greater neutralizing potency epitopes <NUMBER> recent report demonstrated antisars antibody could crossreact rbd sarscov<NUMBER> <NUMBER> data suggest sarscov<NUMBER> rbd important target vaccine development recent data revealed sarscov<NUMBER> protein binds host receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> sarscov protein <NUMBER> describe design initial preclinical testing covid<NUMBER> synthetic dna vaccine candidates show expression sarscov<NUMBER> antigen rna protein vitro transfection cos<NUMBER> <NUMBER>t cells respectively vaccine candidates followed induction immunity selected immunogen mice guinea pigs measuring sarscov<NUMBER> proteinspecific antibody levels serum lung fluid antibody functionality competitive inhibition ace<NUMBER> binding pseudovirus live virus neutralization ino<NUMBER> vaccine induces cellular humoral host immune responses observed within days following single immunization including crossreactive responses sarscov data demonstrate immunogenicity covid<NUMBER> synthetic dna vaccine candidate targeting sarscov<NUMBER> protein supporting translational studies advance development candidate response current global health crisis design synthesis covid<NUMBER> dna vaccine constructs four spike protein sequences retrieved first four available sarscov<NUMBER> full genome sequences published gisaid global initiative sharing influenza data three spike sequences <NUMBER> matched one considered outlier <NUMBER> sequence identity sequences performing sequence alignment sarscov<NUMBER> spike glycoprotein sequence generated nterminal ige leader sequence added highly optimized dna sequence encoding sarscov<NUMBER> igespike created using inovios proprietary silico gene optimization algorithm enhance expression immunogenicity optimized dna sequence synthesized digested bamhi xhoi cloned expression vector pgx<NUMBER> control human cytomegalovirus immediateearly promoter bovine growth hormone polyadenylation signal resulting plasmids designated pgx<NUMBER> pgx<NUMBER> designed encode sarscov<NUMBER> protein threematched sequences outlier sequence respectively fig <NUMBER>a vitro characterization covid<NUMBER> dna vaccine constructs measured expression encoded sarscov<NUMBER> spike transgene rna level cos<NUMBER> cells transfected pgx<NUMBER> pgx<NUMBER> using total rna extracted transfected cos<NUMBER> cells confirmed expression spike transgene rtpcr fig <NUMBER>b vitro spike protein expression hek<NUMBER>t cells measured western blot analysis using crossreactive antibody sarscov protein cell lysates western blots lysates hek<NUMBER>t cells transfected pgx<NUMBER> pgx<NUMBER> constructs revealed bands approximate predicted protein molecular weight <NUMBER> kda slight shifts likely due <NUMBER> potential nlinked glycans protein fig <NUMBER>c immunofluorescent studies protein detected <NUMBER>t cells transfected pgx<NUMBER> pgx<NUMBER> fig <NUMBER>d summary vitro studies revealed expression spike protein rna protein level transfection cell lines candidate vaccine constructs humoral immune responses mice since candidate design observed newly published sarscov<NUMBER> spike protein sequences match pgx<NUMBER> <NUMBER> amino acid sequence identity supplementary data <NUMBER> pgx<NUMBER> therefore selected vaccine construct advance immunogenicity studies due broader coverage would likely provide compared outlier pgx<NUMBER> pgx<NUMBER> subsequently termed ino<NUMBER> immunogenicity ino<NUMBER> evaluated balbc mice postadministration tibialis anterior muscle using cellectra® delivery device <NUMBER> reactivity sera group mice immunized ino<NUMBER> measured panel sarscov<NUMBER> sarscov antigens fig <NUMBER>a analysis revealed igg binding sarscov<NUMBER> protein antigens limited crossreactivity sarscov protein antigens sera ino<NUMBER> immunized mice measured serum igg binding endpoint titers epts mice immunized pdna recombinant sarscov<NUMBER> spike protein s<NUMBER> s<NUMBER> regions fig <NUMBER>b c recombinant sarscov<NUMBER> spike protein receptor binding domain rbd fig <NUMBER>d e epts observed sera mice day <NUMBER> immunization single dose ino<NUMBER> fig <NUMBER>c e developed neutralization assay pnl<NUMBER>lucrebased pseudovirus displaying sarscov<NUMBER> spike protein neutralization titers detected reduction relative luciferase units rlu compared controls decrease rlu signal balbc mice immunized twice ino<NUMBER> days <NUMBER> <NUMBER> sera collected day <NUMBER> postsecond immunization pseudovirus incubated serial dilutions mouse sera seravirus mixture added <NUMBER>t cells stably expressing human ace<NUMBER> receptor ace<NUMBER>t <NUMBER> h neutralization id<NUMBER> average titers <NUMBER> observed ino<NUMBER> immunized mice fig <NUMBER>a b reduction rlu observed control animals neutralizing titers additionally measured two wildtype sarscov<NUMBER> virus strains prnt assay sera ino<NUMBER> immunized balbc mice neutralized sarscov<NUMBER>wh<NUMBER>human<NUMBER> sarscov<NUMBER>australiavic<NUMBER> virus strains average nd<NUMBER> titers <NUMBER> <NUMBER> respectively table <NUMBER> live virus neutralizing titers also evaluated c<NUMBER>bl<NUMBER> mice following ino<NUMBER> immunization regimen sera ino<NUMBER> immunized c<NUMBER>bl<NUMBER> mice neutralized wildtype sarscov<NUMBER> virus average nd<NUMBER> titer <NUMBER> table <NUMBER> humoral immune responses guinea pigs assessed immunogenicity ino<NUMBER> hartley guinea pig model established model intradermal vaccine delivery <NUMBER> <NUMBER> one hundred micrograms pdna administered mantoux injection skin followed cellectra® delivery device day <NUMBER> described methods section day <NUMBER> antispike protein binding serum antibodies measured elisa immunization ino<NUMBER> revealed immune response respect sarscov<NUMBER> s<NUMBER> <NUMBER> protein binding igg levels sera fig <NUMBER>a b endpoint sarscov<NUMBER> protein binding titer day <NUMBER> <NUMBER> <NUMBER> guinea pigs treated <NUMBER> µg ino<NUMBER> pvax control respectively fig <NUMBER>b next evaluated antibody neutralizing activity following intradermal ino<NUMBER> immunization guinea pig model guinea pigs treated days <NUMBER> <NUMBER> <NUMBER> pvax ino<NUMBER> sera samples collected days <NUMBER> <NUMBER> measure sera neutralizing activity pseudovirus wildtype virus respectively sarscov<NUMBER> pseudovirus neutralizing activity average nd<NUMBER> titers <NUMBER> observed ino<NUMBER> immunized guinea pigs table <NUMBER> wildtype sarscov<NUMBER> virus activity also observed ino<NUMBER> immunized guinea pigs nd<NUMBER> titers <NUMBER> prnt assay observed animals table <NUMBER> inhibition sarscov<NUMBER> protein binding ace<NUMBER> receptor induction antibodies capable inhibiting spike protein engagement host receptor considered relevant sarscov<NUMBER> vaccine development therefore examined receptor inhibiting functionality ino<NUMBER>induced antibody responses recently developed elisabased ace<NUMBER> inhibition assay surrogate neutralization assay similar principle surrogate neutralization assays validated coronaviruses <NUMBER> control assay show ace<NUMBER> bind sarscov<NUMBER> spike protein ec <NUMBER> <NUMBER> µgml fig <NUMBER>a balbc mice immunized days <NUMBER> day <NUMBER> <NUMBER> µg ino<NUMBER> serum igg purified day <NUMBER> postimmunization ensure inhibition antibodymediated compared inhibition spikeace<NUMBER> interaction using serum igg naïve mouse ino<NUMBER> pgx<NUMBER> outlier ol containing ige leader sequence sarscov<NUMBER> spike protein insert b rtpcr assay rna extracts cos<NUMBER> cells transfected duplicate pgx<NUMBER> pgx<NUMBER> extracted rna analyzed rtpcr using pcr assays designed target cos<NUMBER> βactin mrna used internal expression normalization gene delta c δ c calculated c target minus c βactin transfection concentration plotted log mass pdna transfected plotted mean ± sd c analysis vitro expression spike protein transfection <NUMBER>t cells pgx<NUMBER> pgx<NUMBER> mock plasmid western blot <NUMBER>t cell lysates resolved gel probed polyclonal antisars spike protein blots stripped probed antiβactin loading control vitro immunofluorescent staining <NUMBER>t cells transfected <NUMBER> µgwell pgx<NUMBER> pgx<NUMBER> pvax empty control vector expression spike protein measured polyclonal antisars spike protein igg antiigg secondary green cell nuclei counterstained dapi blue images captured using imagexpress pico automated cell imaging system scale bars <NUMBER> µm left <NUMBER> µm middle <NUMBER> µm right vaccinated mouse fig <NUMBER>b repeated receptor inhibition assay group five immunized mice demonstrating ino<NUMBER>induced antibodies competed ace<NUMBER> binding sarscov<NUMBER> spike protein fig <NUMBER>c supplementary fig <NUMBER> ace<NUMBER> binding inhibition evaluated guinea pig model sera collected ino<NUMBER> immunized guinea pigs inhibited binding sarscov<NUMBER> spike protein range concentrations ace<NUMBER> <NUMBER> µgml <NUMBER> µgml fig <NUMBER>d furthermore serum dilution curves revealed sera collected ino<NUMBER> immunized guinea pigs blocked binding ace<NUMBER> sarscov<NUMBER> dilutiondependent manner fig <NUMBER>e sera collected pvaxtreated animals displayed negligible activity inhibition ace<NUMBER> binding virus protein decrease od signal highest concentration serum considered matrix effect assay ace<NUMBER> considered primary receptor sarscov<NUMBER> cellular entry blocking interaction suggests ino<NUMBER>induced antibodies believed important prevent host infection summary humoral immunogenicity testing mice guinea pigs revealed covid<NUMBER> vaccine candidate ino<NUMBER> capable eliciting functional blocking antibody responses sarscov<NUMBER> spike protein biodistribution sarscov<NUMBER> reactive igg lung lower respiratory disease lrd associated severe cases covid<NUMBER> presence antibodies lung mucosa targeting sarscov<NUMBER> could potentially mediate protection lrd therefore evaluated presence sarscov<NUMBER> specific antibody lungs immunized mice guinea pigs balbc mice hartley guinea pigs immunized days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively ino<NUMBER> pvax control pdna bronchoalveolar lavage bal fluid collected following sacrifice sarscov<NUMBER> protein elisas performed balbc hartley guinea pigs received ino<NUMBER> measured statistically significant increase sarscov<NUMBER> protein binding igg bal fluid compared animals receiving pvax control fig <NUMBER>ad taken together data demonstrate presence antisarscov<NUMBER> specific antibody lungs following immunization ino<NUMBER> fig <NUMBER> balbc mouse sarscov<NUMBER> epitope mapping performed epitope mapping splenocytes balbc mice receiving <NUMBER> µg ino<NUMBER> dose thirty matrix mapping pools used stimulate splenocytes <NUMBER> h immunodominant responses detected multiple peptide pools fig <NUMBER>a responses deconvoluted identify several epitopes h<NUMBER>k clustering receptor binding domain s<NUMBER> domain fig <NUMBER>b interestingly one sarscov<NUMBER> h<NUMBER>k epitope phgvvflhv observed overlapping adjacent sarscov human hlaa<NUMBER> restricted epitope vvflhvtyv <NUMBER> summary cell responses sarscov<NUMBER> protein epitopes detected mice immunized ino<NUMBER> novel coronavirus sarscov<NUMBER> associated covid<NUMBER> disease become global pandemic significant morbidity mortality toll currently covid<NUMBER> vaccines available global dissemination sarscov<NUMBER> may continue high level herd immunity within human population described preclinical development synthetic dnabased covid<NUMBER> vaccine ino<NUMBER> combat emerging infectious disease synthetic dna vaccine design synthesis immediately initiated upon public release sarscov<NUMBER> genome sequences <NUMBER> january <NUMBER> data support expression immunogenicity ino<NUMBER> synthetic dna vaccine candidate multiple animal models humoral cell responses observed mice guinea pigs employed clinical delivery parameters observed sarscov<NUMBER> protein binding antibody titers blocking ace<NUMBER>sarscov<NUMBER> protein interaction serum samples ino<NUMBER>treated animals nabs also measured species halting rapidly emerging infectious disease requires orchestrated response global health community requires improved strategies accelerate vaccine development response <NUMBER> coronavirus outbreak employed synthetic dna medicine platform design manufacture synthetic dna vaccine represents plug play process insert target antigen sequence highly characterized clinically tested plasmid vector backbone pgx<NUMBER> construct design engineering parameters optimized vivo gene expression previously applied mers ebov zika lassa dna vaccine constructs undergoing clinical testing <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> based upon previous experience developing vaccine mers coronavirus previous published studies sars vaccines sarscov<NUMBER> protein chosen antigen target sarscov<NUMBER> protein class membrane fusion protein major envelope protein surface coronaviruses initial studies already performed indicate sarscov<NUMBER> interaction host receptor ace<NUMBER> blocked antibodies <NUMBER> vivo immunogenicity studies mouse guinea pig models revealed levels proteinreactive igg serum ino<NUMBER> immunized animals addition fulllength s<NUMBER> s<NUMBER> s<NUMBER> ino<NUMBER> immunization induced rbd binding antibodies fig <NUMBER> domain known target nabs sarscov convalescent patients <NUMBER> <NUMBER> demonstrate functionality antibodies neutralization sarscov<NUMBER> wildtype virus pseudovirus table <NUMBER> competitive inhibition sarscov<NUMBER> spike protein binding ace<NUMBER> receptor presence sera ino<NUMBER> immunized animals fig <NUMBER> importantly antisarscov<NUMBER> binding antibodies detected lung washes ino<NUMBER>immunized mice guinea pigs fig <NUMBER> presence antibodies lungs potential protect infection tissues prevent lrd associated severe cases covid<NUMBER> addition humoral responses cellular immune responses shown associated favorable recovery merscov infection <NUMBER> likely important sarscov infection <NUMBER> showed induction cell responses sarscov<NUMBER> early day <NUMBER> postvaccine delivery rapid cellular responses potential lower viral load could potentially reduce spread sarscov<NUMBER> associated covid<NUMBER> illness believe synthetic dna medicine platform several synergistic characteristics position well respond disease outbreaks covid<NUMBER> mentioned previously ability design immediately synthesize candidate vaccine constructs means vitro vivo testing potentially begin within days receiving viral sequence dna plasmid manufacture process allows scalable manufacture drug product potential circumvent complexities conventional vaccine production eggs cell culture additionally published stability profile afforded products use optimized dna formulation <NUMBER> stability characteristics mean dna drug product nonfrozen stored <NUMBER> years <NUMBER>°c room temperature rt <NUMBER> year <NUMBER> month <NUMBER>°c maintaining potency temperatures upwards <NUMBER>°c context pandemic outbreak stability profile vaccine plays directly ability deployed stockpiled efficient executable manner study observed seroconversion single intradermal administration ino<NUMBER> guinea pigs fig <NUMBER> whether single immunization sufficient humans investigated clinical trials although vaccineinduced immunopathology raised potential concern sars mers vaccine candidates possibly sarscov<NUMBER> vaccines concerns likely vaccineplatform dependent todate evidence immune pathogenesis reported mers dna vaccines mice nonhuman primate models <NUMBER> sars dna vaccines mice <NUMBER> lung immunopathology characterized th<NUMBER>related eosinophilia reported whole inactivated virus iv recombinant protein peptide andor recombinant viral vector vaccines following sarscov challenge <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently merscov challenge model <NUMBER> however majority studies protective efficacy without lung immunopathology reported sarscov merscov vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> important note majority studies demonstrating cov vaccineinduced immunopathology utilized balbc mouse model known preferentially develop th<NUMBER>type responses dna vaccine platform induces th<NUMBER>type immune responses demonstrated efficacy without immunopathology models respiratory infection including sarscov <NUMBER> merscov <NUMBER> rsv <NUMBER> sarscov<NUMBER> animal challenge studies assess ino<NUMBER>mediated protection disease vaccineenhanced disease report functional neutralization ino<NUMBER> immune sera using sarscov<NUMBER> pseudovirus assay fig <NUMBER> table <NUMBER> prnt assay two wildtype sarscov<NUMBER> strains table <NUMBER> well show ino<NUMBER> induced antibodies block sarscov<NUMBER> spike binding host receptor ace<NUMBER> using surrogate neutralization assay fig <NUMBER> study highlights immunogenicity ino<NUMBER> animal studies test protection infection summary initial results describing immunogenicity covid<NUMBER> vaccine candidate ino<NUMBER> promising particularly encouraging measure functional antibodies cell responses multiple animal models study supports evaluation ino<NUMBER> vaccine candidate covid<NUMBER> cell lines hek<NUMBER>t atcc® crl<NUMBER>™ african green monkey kidney cos<NUMBER> atcc® crl<NUMBER>™ cell lines obtained atcc old town manassas va cell lines maintained dmem supplemented <NUMBER> fetal bovine serum fbs penicillinstreptomycin vitro rna expression qrtpcr vitro mrna expression plasmid demonstrated transfection cos<NUMBER> serially diluted plasmids followed analysis total rna extracted cells using reverse transcription pcr transfections four concentrations plasmid performed using fugene® <NUMBER> transfection reagent promega resulted final masses ranging <NUMBER> <NUMBER> ng per well transfections performed duplicate following <NUMBER> <NUMBER> h incubation cells lysed rlt buffer qiagen total rna isolated well using qiagen rneasy kit following kit instructions resulting rna concentration determined od <NUMBER> samples rna diluted <NUMBER> ng per µl one hundred nanograms rna converted cdna using high capacity cdna reverse transcription revt kit applied biosystems following kit instructions revt reactions containing rna reverse transcriptase minus rt included controls plasmid dna cellular genomic dna sample contamination eight microliters sample cdna subjected pcr using primers probes specific target sequence pgx<NUMBER> forward caggac aagaacacacaggaa pgx<NUMBER> reverse caggcaggatttgggagaaa pgx<NUMBER> probe acccatcaaggactttggagg pgx<NUMBER> forward aggacaagaacacacaggaag pgx<NUMBER> reverse caggatctggga gaagttgaag pgx<NUMBER> probe acaccacccatcaaggactttgga separate reaction quantity sample cdna subjected pcr using primers probe designed βactin forward gtgacgtggacatccgta aa βactin reverse cagggcagtaatctccttctg βactin probe tac cctggcattgctgacaggatg cos<NUMBER> cell line βactin sequences primers probes synthesized integrated dna technologies inc probes labeled <NUMBER>fam black hole quencher <NUMBER> reaction used abi fast advance <NUMBER>×cat <NUMBER> final forward reverse primer concentrations <NUMBER> µm probe concentrations <NUMBER> µm using quantstudio <NUMBER> flex real time pcr studio system applied biosystems samples first subjected hold <NUMBER> min <NUMBER>°c <NUMBER> cycles pcr cycle consisting <NUMBER> <NUMBER>°c <NUMBER> <NUMBER>°c following pcr amplifications results analyzed follows negative transfection controls minus revt controls ntc scrutinized respective indications threshold cycle c transfection concentration ino<NUMBER> covid<NUMBER> target mrna βactin mrna generated quantstudio software using automatic threshold setting plasmid considered active mrna expression expression plasmid transfected wells compared negative transfection controls greater <NUMBER> c vitro protein expression western blot human embryonic kidney cells <NUMBER>t cultured transfected described previously <NUMBER> <NUMBER>t cells transfected pdna using turbofectin<NUMBER> origene transfection reagent following manufacturers protocol fortyeight hours later cell lysates harvested using modified ripa cell lysis buffer proteins separated <NUMBER> bistris gel thermofisher scientific following transfer blots incubated antisarscov spike protein polyclonal antibody novus biologicals visualized horseradish peroxidase hrpconjugated antimouse igg ge amersham immunofluorescence transfected <NUMBER>t cells vitro staining spike protein expression <NUMBER>t cells cultured <NUMBER>well glass slides labtek transfected <NUMBER> µg per well pdna using turbofectin<NUMBER> origene transfection reagent following manufacturers protocol cells fixed <NUMBER> h transfection <NUMBER> neutralbuffered formalin bbc biochemical washington state <NUMBER> min rt washed pbs staining chamber slides blocked <NUMBER> vv tritonx sigma <NUMBER> vv donkey serum pbs <NUMBER> h rt cells stained rabbit antisarscov spike protein polyclonal antibody novus biologicals diluted <NUMBER> wv bsa sigma <NUMBER> vv donkey serum <NUMBER> vv tritonx sigma <NUMBER> vv <NUMBER> g ml −<NUMBER> sodium azide sigma pbs <NUMBER> h rt slides washed three times <NUMBER> min pbs stained donkey antirabbit igg af<NUMBER> lifetechnologies a<NUMBER> <NUMBER> h rt slides washed mounted covered dapifluoromount southernbiotech antigen binding elisa elisas performed determine sera antibody binding titers nunc elisa plates coated <NUMBER> µg ml −<NUMBER> recombinant protein antigens dulbeccos phosphatebuffered saline dpbs overnight <NUMBER>°c plates washed three times blocked <NUMBER> bovine serum albumin bsa dpbs <NUMBER> tween <NUMBER> <NUMBER> h <NUMBER>°c plates washed incubated serial dilutions mouse guinea pig sera incubated <NUMBER> h <NUMBER>°c plates washed incubated <NUMBER> dilution horse radish peroxidase hrp conjugated antiguinea pig igg secondary antibody sigmaaldrich cat a<NUMBER> hrp conjugated antimouse igg secondary antibody sigmaaldrich incubated <NUMBER> h rt final wash plates developed using sureblue tm tmb <NUMBER>component peroxidase substrate kpl cat <NUMBER> reaction stopped tmb stop solution kpl cat <NUMBER> plates read <NUMBER> nm wavelength within <NUMBER> min using synergy htx biotek instruments highland park vt binding antibody epts calculated previously described <NUMBER> binding antigens tested included sarscov<NUMBER> antigens s<NUMBER> spike protein sino biological <NUMBER>v<NUMBER>h s<NUMBER> s<NUMBER> ecd spike protein sino biological <NUMBER>v<NUMBER>b<NUMBER> rbd university texas austin mclellan lab sarscov antigens spike s<NUMBER> protein sino biological <NUMBER>v<NUMBER>b<NUMBER> <NUMBER> immune tech it<NUMBER>p spike cterminal meridian life science r<NUMBER> ace<NUMBER> competition elisa mouse studies elisas performed determine sera igg antibody competition human ace<NUMBER> human fc tag nunc elisa plates coated <NUMBER> µg ml −<NUMBER> rabbit antihis<NUMBER>x <NUMBER>× pbs <NUMBER> h rt washed four times washing buffer <NUMBER>× pbs <NUMBER> tween <NUMBER> plates blocked overnight <NUMBER>°c blocking buffer <NUMBER>× pbs <NUMBER> tween <NUMBER> <NUMBER> evaporated milk <NUMBER> fbs plates washed four times washing buffer incubated full length s<NUMBER> s<NUMBER> spike protein containing cterminal tag sino biologics cat <NUMBER>v<NUMBER>b<NUMBER> <NUMBER> µg ml −<NUMBER> <NUMBER> h rt plates washed serial dilutions purified mouse igg mixed <NUMBER> µg ml −<NUMBER> recombinant human ace<NUMBER> human fc tag ace<NUMBER>ighu incubated <NUMBER> h rt plates washed incubated <NUMBER> dilution hrp conjugated antihuman igg secondary antibody bethyl cat a<NUMBER>p incubated <NUMBER> h rt final wash plates developed using <NUMBER>step ultra tmbelisa substrate thermo cat <NUMBER> reaction stopped <NUMBER> sulfuric acid plates read <NUMBER> nm wavelength within <NUMBER> min using spectramax plus <NUMBER> microplate reader molecular devices sunnyvale ca competition curves plotted area curve auc calculated using prism <NUMBER> analysis software multiple ttests determine statistical significance guinea pig studies <NUMBER>well half area assay plates costar coated <NUMBER> µl per well <NUMBER> µg ml −<NUMBER> sarscov<NUMBER> spike s<NUMBER> s<NUMBER> protein sino biological diluted <NUMBER>× dpbs thermofisher overnight <NUMBER>°c plates washed <NUMBER>× pbs buffer <NUMBER> tween sigma hundred microliters per well <NUMBER> wv bsa sigma <NUMBER>× pbs <NUMBER> tween added incubated <NUMBER> h <NUMBER>°c serum samples diluted <NUMBER> <NUMBER> wv bsa <NUMBER>× pbs <NUMBER> tween washing assay plate <NUMBER> µlwell diluted serum added incubated <NUMBER> h <NUMBER>°c human recombinant ace<NUMBER>fctag sinobiological added directly diluted serum followed <NUMBER> h incubation <NUMBER>°c plates washed <NUMBER> µl per well <NUMBER> diluted goat antihu fc fragment antibody hrp bethyl a<NUMBER>p added assay plate plates incubated <NUMBER> h rt development surebluetmb stop solution kpl md used od recorded <NUMBER> nm sarscov<NUMBER> pseudovirus neutralization assay sarscov<NUMBER> pseudotyped viruses produced using hek<NUMBER>t cells transfected genejammer agilent using igesarscov<NUMBER> plasmid genscript pnl<NUMBER>lucreplasmid nih aids reagent <NUMBER> ratio fortyeight hours post transfection transfection supernatant collected enriched fbs <NUMBER> final volume sterifiltered millipore sigma aliquoted storage −<NUMBER>°c sarscov<NUMBER> pseudotyped viruses titered yielding <NUMBER> times relative luminescence units rlu cells alone <NUMBER> h infection mouse sera ino<NUMBER> vaccinated naive groups heat inactivated <NUMBER> min <NUMBER>°c serially diluted threefold starting <NUMBER> dilution assay sera incubated fixed amount sarscov<NUMBER> pseudotyped virus <NUMBER> min hek<NUMBER>t cells stably expressing ace<NUMBER> added <NUMBER> min allowed incubate standard incubator <NUMBER> humidity <NUMBER> co <NUMBER> <NUMBER> h post infection cells lysed using britelite plus luminescence reporter gene assay system perkin elmer catalog <NUMBER> rlu measured using biotek plate reader neutralization titers id <NUMBER> calculated serum dilution rlu reduced <NUMBER> compared rlu virus control wells subtraction background rlu cell control wells sarscov<NUMBER> wildtype virus neutralization assays sarscov<NUMBER>australia vic<NUMBER> isolate neutralization assays performed public health england porton uk neutralizing virus titers measured serum samples heatinactivated <NUMBER>°c <NUMBER> min sarscov<NUMBER> australiavic<NUMBER> isolate <NUMBER> diluted concentration <NUMBER> pfu ml −<NUMBER> mixed <NUMBER> <NUMBER> fcsmem containing <NUMBER> mm hepes buffer doubling serum dilutions <NUMBER> <NUMBER> <NUMBER>well vbottomed plate plate incubated <NUMBER>°c humidified box <NUMBER> h virus transferred wells twice dpbswashed <NUMBER>well plate seeded previous day <NUMBER> × <NUMBER> <NUMBER> vero e<NUMBER> cells per well <NUMBER> fcsmem virus allowed adsorb <NUMBER>°c hour overlaid plaque assay overlay media <NUMBER>× mem<NUMBER> cmc <NUMBER> fcs final <NUMBER> days incubation <NUMBER>°c humidified box plates fixed stained plaques counted median neutralizing titers nd<NUMBER> determined using spearmankarber formula relative virus control wells sarscov<NUMBER>wh<NUMBER>human<NUMBER> isolate neutralization assays performed institute laboratory animal science chinese academy medical sciences cams approved national health commission peoples republic china seed sarscov<NUMBER> sarscov<NUMBER>wh<NUMBER>human <NUMBER> stocks virus isolation studies performed vero e<NUMBER> cells maintained dulbeccos modified eagles medium dmem invitrogen carlsbad usa supplemented <NUMBER> fetal bovine serum fbs <NUMBER> iu ml −<NUMBER> penicillin <NUMBER> µg ml −<NUMBER> streptomycin incubated <NUMBER>°c <NUMBER> co <NUMBER> virus titer determined using standard <NUMBER> tissue culture infection dose tcid<NUMBER> assay serum samples collected immunized animals inactivated <NUMBER>°c <NUMBER> min serially diluted cell culture medium twofold steps diluted samples mixed virus suspension <NUMBER> tcid <NUMBER> <NUMBER>well plates ratio <NUMBER> followed <NUMBER> h incubation <NUMBER>°c <NUMBER> co <NUMBER> incubator <NUMBER> × <NUMBER> <NUMBER> vero cells added serumvirus mixture plates incubated <NUMBER> days <NUMBER>°c <NUMBER> co <NUMBER> incubator cytopathic effect cpe well recorded microscopes neutralizing titer calculated dilution number <NUMBER> protective condition bal collection bal fluid collected washing lungs euthanized exsanguinated mice <NUMBER> μl icecold pbs containing <NUMBER> μm edta <NUMBER> sodium azide <NUMBER> tween<NUMBER> <NUMBER>× protease inhibitor pierce mucosal prep solutions mps bluntended needle guinea pig lungs washed <NUMBER> ml mps via <NUMBER> g catheter inserted trachea collected bal fluid stored −<NUMBER>c time assay ifnγ elispot spleens mice collected individually rpmi<NUMBER> media supplemented <NUMBER> fbs r<NUMBER> penicillinstreptomycin processed single cell suspensions cell pellets resuspended <NUMBER> ml ack lysis buffer life technologies carlsbad ca <NUMBER> min rt pbs added stop reaction samples centrifuged <NUMBER> × g <NUMBER> min cell pellets resuspended r<NUMBER> passed <NUMBER> µm nylon filter use elispot assay elispot assays performed using mouse ifnγ elispot plus plates mabtech <NUMBER>well elispot plates precoated capture antibody blocked r<NUMBER> medium overnight <NUMBER>°c <NUMBER> mouse splenocytes plated well stimulated <NUMBER> h pools <NUMBER>mer peptides overlapping nine amino acid sarscov<NUMBER> sarscov merscov spike proteins five peptide pools per protein additionally matrix mapping performed using peptide pools matrix designed identify immunodominant responses cells stimulated final concentration <NUMBER> μl peptide per well rpmi <NUMBER> fbs r<NUMBER> spots developed based manufacturers instructions r<NUMBER> cell stimulation cocktails invitrogen used negative positive controls respectively spots scanned quantified immunospot ctl reader spotforming unit sfu per million cells calculated subtracting negative control wells flow cytometry intracellular cytokine staining performed splenocytes harvested balbc c<NUMBER>bl<NUMBER> mice stimulated overlapping peptides spanning sarscov<NUMBER> protein <NUMBER> h <NUMBER>°c <NUMBER> co <NUMBER> cells stained following antibodies bd biosciences unless stated dilutions stated parentheses fitc antimouse cd<NUMBER>a <NUMBER> percpcy<NUMBER> antimouse cd<NUMBER> <NUMBER> apc antimouse cd<NUMBER>a <NUMBER> vivid dye <NUMBER> livedead® fixable violet dead cell stain kit invitrogen l<NUMBER> apccy<NUMBER> antimouse cd<NUMBER>e <NUMBER> bv<NUMBER> antimouse ifnγ <NUMBER> ebiosciences phorbol myristate acetate pma used positive control complete medium negative control cells washed fixed cell events acquired using facs canto bd biosciences followed flowjo software flowjo llc ashland analysis structural modeling structural models sarscov merscov constructed pdb ids <NUMBER>acc <NUMBER>×<NUMBER> order assemble prefusion model three rbds conformation sarscov<NUMBER> structural model built using sarscov structure pdb id<NUMBER>acc template rosetta remodel simulations employed make appropriate amino acid mutations build de novo models sarscov<NUMBER> loops structurally defined sarscov structure <NUMBER> amino acid positions neighboring loops allowed change backbone conformation accommodate new loops structural figures made using pymol statistics statistical analyses performed using graphpad prism <NUMBER> <NUMBER> software la jolla ca data considered significant p <NUMBER> lines graphs represent mean value error bars represent standard deviation samples animals excluded analysis randomization performed animal studies samples animals blinded performing experiment reporting summary information research design available nature research reporting summary linked article global health system consists network organizations including many private public health sectors operating different regional global levels developed stringent system provide effective protection humans emerging reemerging diseases though mortality associated various infectious diseases reduced recent years global life expectancy increased many parts world infectious disease threats still remain one major global challenges concerns even <NUMBER> global health system often confronted emerging pathogens responsible expanding array infectious diseases zika chikungunya ebola nipah severe acute respiratory syndrome sars middle east respiratory syndrome mers influenza emergence <NUMBER> novel coronavirus <NUMBER>ncov recently added list problematic emerging pathogens <NUMBER>st century suspected originate persons exposed seafood wet market wuhan hubei province china suggesting animaltohuman transmission <NUMBER> virus strain previously unknown reported infect humans first time virus continues expand rapidly throughout world many confirmed susceptible cases identified wuhan china exported cases also reported neighboring countries including thailand japan korea taiwan countries including united states canada european countries proves virus potential quick dissemination across borders response rapid spread virus many countries tightened border security investigating people showing symptoms taken necessary emergency steps control spread due increasing number cases china countries declared <NUMBER>ncov outbreak global health emergency international concern <NUMBER> january <NUMBER> <NUMBER> coronaviruses covs belongs family coronaviridae subfamily coronavirinae order nidovirales classified four genera alphacoronavirus betacoronavirus infect mammals whereas gammacoronavirus infect avian species deltacoronavirus infect mammalian avian species large enveloped virus positive sense singlestranded rna genome <NUMBER> <NUMBER> kb distributed broadly among birds humans mammals camels bats mice dogs cats <NUMBER> genome surrounded helical capsid envelope spike protein forms large protrusions envelope shape crown gives virus coronal appearance word ‘corona’ latin means crown <NUMBER> human coronaviruses hcovs major group coronaviruses known respiratory pathogens associated respiratory intestinal infections varying severity including common cold pneumonia bronchiolitis human coronaviruses hcov<NUMBER>e oc<NUMBER> nl<NUMBER> hku<NUMBER> usually cause mild infection humans however onset betacoronaviruses severe acute respiratory syndrome coronavirus sarscov outbreak guangdong province china <NUMBER> middle east respiratory syndrome coronavirus merscov disease outbreak <NUMBER> middle east resulted high pathogenicity humans demonstrated lethality virus cross species barrier animals humans viruses believed originated bats subsequently transmitted humans <NUMBER> hcovs evolved rapidly recent years due mutation high nucleotide substitution rates ability establish infection new host crossspecies transmission <NUMBER> december <NUMBER> china detected many cases viral pneumonialike disease similar sars confirmed caused novel betacoronavirus provisionally called <NUMBER> novel coronavirus <NUMBER>ncov since novel coronavirus outbreak raised attention throughout world although potential cause disease still unknown initial reports predicted virus possibly zoonotic origin <NUMBER>ncov causative agent severe respiratory infection humans termed novel coronavirusinfected pneumonia ncip <NUMBER> ncov third known coronavirus causes fatal respiratory diseases humans highly pathogenic viruses sarscov merscov chinese researchers isolated novel coronavirus infected patient early <NUMBER> virus closely related bat coronaviruses suspected bats primary reservoir virus however still unclear virus transmitted humans directly bats whether intermediate host detailed understanding enzootic patterns virus evolution surveillance essential control disease possibly prevent future epidemics similar viruses explosive outbreak <NUMBER>ncov china spread rapidly many countries probably human movement travel geographical distribution virus increasing since outbreak early february <NUMBER> thousands cases confirmed china <NUMBER> cases reported outside china numbers cases escalating daily provinces china countries virus transmitted rapidly many cases reported globally february <NUMBER> <NUMBER> nearly <NUMBER> affected cases <NUMBER> fatalities reported china confirmed cases wuhan city hubei province outside china <NUMBER> cases confirmed globally one death reported philippines singapore <NUMBER> cases confirmed <NUMBER> thailand <NUMBER> japan <NUMBER> korea <NUMBER> australia malaysia <NUMBER> united states cases reported germany france vietnam uae canada india philippines italy uk russia nepal sri lanka cambodia belgium finland sweden spain early february <NUMBER> chinese health authorities countries responded fast immediate actions taken contain virus countries implemented stringent border control screening travelers possible infection travel restrictions order prevent spread rapid spread infection frightening also causes mortality financial loss present global concern emerging disease transmission <NUMBER>ncov often spread person person respiratory droplets generated coughs sneezes infected person humantohuman transmission reported countries germany japan vietnam united states <NUMBER> confirmed cases interhuman transmission increased fear panic accompanying <NUMBER>ncov outbreak still unknown whether virus spreads human contact possible transmission oralfecal contact well incubation time varies <NUMBER>–<NUMBER> days infection clinical presentation infection resembles sarscov characterized fever dry cough shortness breath cases whereas nonrespiratory symptoms headache muscle ache dyspnoea rhinorrhoea sneezing sore throat diarrhea nausea vomiting also reported patients affected persons also develop acute respiratory distress syndrome cases critical illness showed respiratory failure septic shock organs failure require intensive care support <NUMBER> time knowledge virus limited new cases mortalities increasing daily newly emerging viral infection vaccine antiviral therapeutics treat human coronavirus infection till preventing infection current priority disease control current protocol infected patients quarantine provide supportive management palliative care best way avoid virus infection keep oneself away infected people utmost personal hygienic care essential quarantine measures shall taken separate restrict movement infected people also normal population regions epidemic outbreak recommended precautionary measures general public frequently cleaning hands wearing face mask avoiding close contact infected persons farm animals avoiding consumption raw halfcooked meateggs following good food safety practices <NUMBER> urgent need develop rapid diagnostic tools vaccines postexposure prophylaxis treat infection reliable timely laboratory diagnosis effective vaccine crucial effective disease management public health intervention effective vaccine affordable also production platform produce suitable vaccine candidates rapidly low cost especially disease outbreak advantages disadvantages current expression systems recombinant protein production given table <NUMBER> currently plant expression system offers many advantages conventional systems potential tackle production vaccine candidates rapidly affordable cost facilitating global vaccination programs especially resourcepoor nations vaccines needed <NUMBER> recent years plants focused production biopharmaceuticals viruslike particles vlp’s technologies employed production plantmade vaccines stable nuclear expression transient expression chloroplast expression based several vital factors like yield quality time cost appropriate technology chosen producing biopharmaceuticals recent advancements plant expression strategies especially development transient expression system viral vectors resulted huge increase protein yield makes plant host system promising system production various biopharmaceutical proteins <NUMBER> several reports last two decades enough evidence prove plant produced biopharmaceuticals effective mammalian cellbased proteins also elicit potent neutralizing antibodies shown therapeutic effects particular pathogen infection <NUMBER> use plants production recombinant proteins biopharmaceuticals gaining importance since plant produced biologic taliglucerase alfa commercialized <NUMBER> gaucher’s disease proclaimed new era plant made biopharmaceutical triggered innovation field biopharmaceuticals <NUMBER> furthermore many plantproduced candidates clinical pipeline close commercialization examples plantproduced recombinant antigens monoclonal antibodies infectious diseases given table <NUMBER> currently countries including thailand india japan korea european community majorly involved developing plant biopharmaceuticals several human diseases <NUMBER> many reports reviewed importance plant expression system rapid production candidate vaccines therapeutic antibodies infectious diseases <NUMBER> many biopharmaceutical companies shifted momentum towards plant expression system knowing importance various plants tobacco duckweed moss alfalfa plants used production plantmade pharmaceuticals september <NUMBER> leaf bio inc commercial partner mapp biopharmaceutical inc mapp received fast track designation us fda plantmade biopharmaceutical called zmapp treatment ebola virus disease authorization plantbased biopharmaceutical zmapp emergency use earlier ebv outbreak fda potentially major breakthrough plant molecular farming field serves endorsement technology potential investors grant funding agencies <NUMBER> many vaccine antigens expressed plants clinical advanced preclinical trials major players global plantbased biologics market include plantform ibio inc mapp biopharmaceutical inc pfizer inc ventria bioscience medicago inc greenovation biotech gmbh kentucky bioprocessing phycobiologics inc synthon fraunhofer ime healthgen planet biotechnology icon genetics gmbh plantmade biopharmaceuticals provide efficacious costeffective strategies protect emerging infectious diseases plant expression systems employed development vaccines ncov transient expression plants adapted biopharmaceutical protein production necessary produce ‘rapid response vaccines’ produces protein short time plantbased biopharmaceutical production <NUMBER>ncov include identification potential epitopes production fulllength viral surface proteins present envelope region production subunit vaccines expressing immunogenic region chimeric proteins receptorbinding domain rbd spike protein located outer membrane coronavirus mediates receptor binding plays major role virus entry host cell <NUMBER> protein could used potential vaccine candidate major target neutralizing antibodies <NUMBER> hence could considered develop potential effective vaccines therapeutics coronavirus infection virus uses angiotensinconverting enzyme <NUMBER> ace<NUMBER> host cell receptor cell entry similar like sarscov <NUMBER> monoclonal antibodies identified tested effective sars virus protein specific ace<NUMBER> produced plants shall tested efficacy ncov earlier reports showed several vaccines monoclonal antibody candidates response sarscov merscov could tested used passive immunotherapy immediate immune response <NUMBER> possibility producing vlp based vaccine also feasible expressing structural viral proteins assemble vlps plants structural functional studies viral proteins ncov might help designing better vaccines specific therapeutics producing viral proteins plants may helpful evaluate potential developing diagnostic kits protectiontherapeutic tools manufactured fast order manage highly infectious ncov open avenue characterize recombinant immunogenic viral proteins provide proof concept using plants robust rapid flexible platform producing proteinresearch reagents highly essential face potential ncov outbreaks coronavirus outbreak declared global health emergency represents one greatest risks global health virus tendency infect large number human populations outbreak cause severe medical complications economic impact particularly middleincome countries resources limited early diagnosis preventive measures human mobility air travel international trade likely increase number cases regions well continued surveillance along robust response government agencies medical practitioners researchers highly essential effective management emerging pathogen public health officials need identify source virus reservoir transmission cycle pathogenesis interhuman transmission clinical manifestations might helpful develop animal models diagnostic reagents antiviral therapies vaccines pathogen virus emerged suddenly became serious global concern need rapid vaccine development although classical expression systems biopharmaceutical proteins still amenable development transient expression plants deeply influenced pharmaceutical sector produce affordable vaccines biologics rapidly low cost hence plant expression platform shall employed biopharmaceutical production accelerate fight deadly infectious disease collaborative efforts researchers highly desirable use plant expression platform producing efficient costeffective vaccine control epidemic continuous effort research direction might helpful producing highvalue biologics pharmaceuticals large scale short time especially epidemics novel βcoronavirus βcov named middle east respiratory syndrome mers coronavirus merscov first identified humans middle east june <NUMBER> virus isolated <NUMBER>yearold saudi man diagnosed progressive communityacquired pneumonia subsequent acute renal failure fatal outcome <NUMBER> increasing numbers cases resulted merscov infection shown figure <NUMBER> <NUMBER> march <NUMBER> <NUMBER> total <NUMBER> human merscov infections <NUMBER> deaths reported middle east north africa several european countries <NUMBER> many animals considered reservoirs covs origin merscov mode disease transmission still remain unknown based sequence fragment identical merscov found taphozous perforates bat captured saudi arabia inferred bats likely reservoir merscov <NUMBER> identification merscov dromedary camels detection neutralizing antibodies sera animals suggest camels could intermediate host merscov <NUMBER> <NUMBER> thus suspected merscov emerged interspecies transmission bats animals camels humans <NUMBER> several family clusters merscov infection reported <NUMBER> <NUMBER> suggesting humantohuman transmission disease people infected merscov developed severe acute respiratory illness symptoms like fever cough shortness breath virus estimated incubation period <NUMBER> days <NUMBER> transmissibility merscov humans currently less efficient severe acute respiratory syndrome coronavirus sarscov emerged guangdong province china <NUMBER> reemerged <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER> countries throughout world <NUMBER> nonetheless mortality rate mers <NUMBER> much higher sars <NUMBER> <NUMBER> reported merscov sarscov could replicate cell lines four major chiropteran families implying ability merscov crossing species barrier humans bats <NUMBER> increased human cases high mortality rate merscov infection raised serious global concerns although still early implicate impending pandemic vaccination considered one effective strategies prevent virus infection thus development effective vaccines essential fight infectious disease proposed coronavirus study group international committee taxonomy viruses ictv three groups <NUMBER> <NUMBER> <NUMBER> coronaviridae family commonly accepted αcov βcov γcov respectively genus βcov consists four lineages namely b c <NUMBER> novel genus δcov including hku<NUMBER> hku<NUMBER> hku<NUMBER> identified birds <NUMBER> added cov genera <NUMBER> unlike previously identified covs alphacov nl<NUMBER> first reported <NUMBER> <NUMBER> well βcov hku<NUMBER> first discovered hong kong <NUMBER> <NUMBER> <NUMBER> sarscov caused worldwide outbreak <NUMBER> <NUMBER> merscov belongs lineage c βcov first known lineage c βcov associated human infections <NUMBER> phylogenetically merscov closely related bat covs hku<NUMBER> hku<NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov positivesense singlestranded rna virus genome <NUMBER> kilobase pairs kb length consisting <NUMBER> functional open reading frames orfs figure <NUMBER> table <NUMBER> viral genome encodes five unique proteins known accessory proteins <NUMBER> <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>b serve different functions known homologues cov proteins accessory protein <NUMBER>a example recently proven block production host interferon ifn <NUMBER> although accessory proteins essential virus replication recent studies reverse genetics demonstrated absence genes encoding proteins group may attenuate viral titers <NUMBER> additionally genome merscov encodes six proteins homologous known covs including two replicase proteins orfs <NUMBER>a <NUMBER>b four major structural proteins spike envelope e membrane nucleocapsid n proteins figure <NUMBER> <NUMBER> e protein transmembrane protein forming ion channel viral surface cov n protein plays important role encapsidating genomic rna interacting protein n molecules <NUMBER> protein covs type transmembrane glycoprotein displayed oligomer surface viral membrane precursor protein contains cleavage site protein could cleaved two noncovalently associated subunits distal subunit s<NUMBER> membraneanchored subunit s<NUMBER> <NUMBER> s<NUMBER> subunit contains cellular receptorbinding domain rbd <NUMBER> s<NUMBER> subunit contains putative fusion peptide transmembrane domain two heptad repeat regions heptad repeat <NUMBER> <NUMBER> hr<NUMBER> hr<NUMBER> figure <NUMBER> <NUMBER> figure <NUMBER>a lists representative structures proteins αand βcov nl<NUMBER>cov mouse hepatitis cov mhvcov sarscov <NUMBER> <NUMBER> <NUMBER> rbds cov proteins consisting respective core receptorbinding subdomains example receptorbinding motif sarscov contains residues <NUMBER> <NUMBER> form long extended loop two short antiparallel βsheets one disulfide bond c<NUMBER> c<NUMBER> <NUMBER> similar proteins covs protein merscov also contains s<NUMBER> s<NUMBER> subunits s<NUMBER> responsible receptor binding s<NUMBER> membrane fusion <NUMBER> unlike covs sarscov nl<NUMBER>cov use human angiotensinconverting enzyme <NUMBER> receptors <NUMBER> <NUMBER> merscov utilizes human dipeptidyl peptidase <NUMBER> dpp<NUMBER> also known cd<NUMBER> cellular receptor dpp<NUMBER> expressed primary bronchiolar epithelial cells regulates activity hormones chemokines proteolytic cleavage <NUMBER> <NUMBER> recent studies solved crystal structures merscov protein alone complexed receptor dpp<NUMBER> mapped rbd merscov residues covering <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> <NUMBER> according crystal structures rbd merscov also contains core receptorbinding subdomains receptorbinding motif consisting <NUMBER> amino acids v<NUMBER> l<NUMBER> form fourstranded antiparallel βsheet figure <NUMBER>b <NUMBER> <NUMBER> similar covs hr<NUMBER> hr<NUMBER> merscov form <NUMBER>helix bundle believed drive virioncell membrane fusion three hr<NUMBER> helices forming central coiledcoil core three hr<NUMBER> chains surrounding core hr<NUMBER> side grooves <NUMBER> <NUMBER> <NUMBER> figure <NUMBER> describes crystal structures sarscov merscov rbd complexed respective receptors major neutralizing epitopes sarscov rbd neutralizing monoclonal antibody sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> understanding neutralizing epitopes rbd sarscov provide useful guidance identification neutralizing epitopes merscov rbd hence designing rbdbased neutralizing epitopedependent vaccines merscov previous reviews sars summarized approaches development effective cov vaccines pointed importance sarscov protein target vaccine therapeutic development outlined roadmap product development sarscov rbd proteinbased subunit vaccine manufacturing future clinical testing <NUMBER> <NUMBER> <NUMBER> <NUMBER> review briefly discuss current stages mers vaccine development provide potential strategies developing mers vaccines based experience development sars vaccines focus subunit vaccines improve efficacy mers subunit vaccines addition also summarize current animal models merscov emphasize importance evaluation efficacy mers vaccine candidates effective animal models currently licensed mers vaccines available use however researchers working develop potential vaccines recent successes engineering replicationcompetent propagationdefective merscov using reverse genetics provide possibility developing attenuated viruses mers vaccine candidates <NUMBER> sars studies demonstrated vaccines inducing strong neutralizing antibodies completely protected immunized subjects sarscov infection moreover recovered patients infected sarscov could maintain potent persistent rbdspecific antibody responses neutralizing activity <NUMBER> revealing significance neutralizing antibodies prevention sars like case sarscov vaccines although vaccines eliciting favorable cellular immune responses may play role clearance virus infection vaccines inducing neutralizing antibodies sufficient protection merscov infection thus ability eliciting neutralizing antibodies expected one important criteria evaluating efficacy mers vaccines previous studies sarscov shown protein particularly rbd may induce highly potent neutralizing antibodies protected vaccinated animals sarscov challenge <NUMBER> <NUMBER> <NUMBER> <NUMBER> thus expected protein merscov also important development vaccines song et al shown vaccination recombinantmodified vaccinia virus ankara mva expressing fulllength protein merscov induced high levels neutralizing antibodies vaccinated mice <NUMBER> however cao colleagues reported although mvabased fulllength proteindependent sars vaccine could induce neutralizing antibody responses ferrets failed protect vaccinated animals sarscov challenge even worse vaccine associated enhanced inflammatory immunopathological effects resulting serious liver damage vaccinated ferrets viral challenge <NUMBER> therefore caution taken fulllength protein merscov used vaccine antigen since nonneutralizing epitopes protein may induce antibodymediated disease enhancement ade effects elicited protein feline infectious peritonitis virus fipv also cov <NUMBER> therefore favorable develop vaccines based protein fragments particularly rbd merscov strategy reported effective development mers vaccines studies shown neutralization merscov infection could elicited vaccinated rabbits fragment containing residues <NUMBER> merscov protein <NUMBER> induction neutralizing activity recombinant protein fragment containing residues <NUMBER> merscov rbd also demonstrated particularly truncated <NUMBER>amino acid rbd fragment containing residues <NUMBER> inside rbd residues <NUMBER> merscov protein induced strong merscov sspecific antibodies vaccinated mice blocking binding merscov rbd viral receptor dpp<NUMBER> effectively neutralizing merscov infection thus providing promise development effective safe mers vaccine <NUMBER> <NUMBER> addition protein merscov viral proteins might play role development mers candidate vaccines however studies addressed possibility particular mers recently emerged novel human disease vaccine development timeconsuming process recent study reveals structural accessory proteins orf <NUMBER>a orf <NUMBER>b orf <NUMBER> merscov may function potent ifn antagonists <NUMBER> orf <NUMBER>a protein showing greatest potential counteracting antiviral effects ifn inhibiting ifn production ifnsensitive response element signaling pathways therefore proteins may also serve targets developing mers vaccines traditionally inactivated liveattenuated virus vaccines commonly developed used vaccine types viral pathogens including sarscov types vaccines based dna viral vectors viruslike particles vlps recombinant proteins also discussed terms potential application mers vaccine candidates papers related merscov vaccine development published far rest review discuss development sarscov vaccines learn best strategy developing merscov vaccine move forward efficiently main advantages disadvantages different strategies cov vaccine development listed table <NUMBER> sarscov tested vaccine candidates proven effective provide protective immunity sarscov infection <NUMBER> <NUMBER> <NUMBER> previously reported βpropiolactoneinactivated sarscov vaccine administered subcutaneously sc mice effective inhibiting virus replication murine respiratory tract adenovirusbased n vaccine given either intranasally intramuscularly im <NUMBER> addition live impairedfidelity sarscov vaccine engineered inactivation exonuclease activity protects aged immunocompromised mice lethal virus challenge <NUMBER> apparently local serum antibody responses induced inactivated sarscovvaccinated mice <NUMBER> like sarscov might possible attenuate merscov deleting envelope e protein diminish virus growth tissue culture abrogating virulence animals <NUMBER> <NUMBER> inactivating exonuclease activity spite possibility inducing highly potent immune responses protection vaccine candidates based inactivated liveattenuated merscov might potential recovering virulence raising safety concerns vaccine type may inappropriate use highly immunosuppressed individuals dna vaccinesdna vaccines consist plasmid dna genetically engineered produce immunological response protect organisms diseases dna usually administered two routes im delivery bombardment skin using gene gun <NUMBER> currently two popular theories dna uptake used including nonspecific phagocytosis pinocytosis antigenspecific receptormediated uptake <NUMBER> <NUMBER> containing nonreplicating noninfectious components encoding protein interest dna vaccines safe use minimizing undesirable side effects <NUMBER> addition vaccines based dnas easy scaled fermentation technique <NUMBER> <NUMBER> <NUMBER> generally stable inexpensive efficacy dnabased vaccines sarscov infection widely reviewed revealed dna vaccine encoding sarscov protein induces neutralizing antibody well cell responses protect vaccinated mice sarscov challenge <NUMBER> addition igg antibody cellmediated immune responses induced dna vaccines encoding s<NUMBER> sarscov <NUMBER> interestingly expression protein sarscov augment immune responses induced np protein sarscov dna vaccine <NUMBER> nevertheless compared vaccine types inactivated liveattenuated virus vaccines dnabased vaccines usually lower immunogenicity <NUMBER> indicating need improve immune efficacy although possible use similar strategies develop dnabased vaccines merscov infection suitable measures primingboost strategy combination dna vaccines vaccination types considered improve immunogenicity dnabased mers vaccines <NUMBER> viral vectorbased vaccinesviral vectors applied important delivery vehicle developing candidate vaccines sarscov infection currently reported viral vectors sars vaccines include mva vesicular stomatitis virus rhabdovirus adenovirus adenoassociated virus attenuated parainfluenzavirus <NUMBER> <NUMBER> <NUMBER> previous reports indicated ability mvabased vaccine expressing sarscov protein induction neutralizing antibody protection vaccinated mice sarscov challenge <NUMBER> addition combination adenoviralbased sars vaccines encoding s<NUMBER> np protein respectively induced strong neutralizing antibodies tcell immune responses protecting immunized monkeys challenge sarscov <NUMBER> induction sufficient cellular humoral immune responses also demonstrated neutralizing activity adenoassociated virusbased vaccine containing rbd sarscov protection sarscov challenge <NUMBER> <NUMBER> approaches developing viral vectorbased sars vaccines adopted development mers vaccines indeed merscov protein delivered mva vector induces vaccinated mice antibody responses neutralizing activity <NUMBER> bringing hopes development viral vectorbased vaccines prevent merscov infection however noted viral vectorbased vaccines disadvantages example vectors mva adenovirus preexisting immunity cause harmful immune responses <NUMBER> <NUMBER> inflammation <NUMBER> thus cautions taken developing mers vaccines using viral vectors vlps vaccinesvlpbased vaccines developed new generation noneggbased cell culturederived vaccine candidates virus infection thus gained much attention potential promise developing effective safe vaccines sarscov <NUMBER> vlps produced several expression systems mammalian cells eg <NUMBER>t cho yeast recombinant vaccinia virus baculovirus expression systems <NUMBER> <NUMBER> worth noting minimal components essential vlp formation immunogenicity induced vlps need considered although e proteins sarscov sufficient efficient formation vlps <NUMBER> immunogenicity induced vlps without protein might greatly reduced comparison chimeric vlps carrying sarscov protein e n proteins mhvcov elicited high levels sarscovspecific neutralizing antibodies protecting vaccinated mice sarscov challenge <NUMBER> findings sarscov vlps may applied constructing vlps merscov compared inactivated liveattenuated virus vaccines vlps contain infectious materials making vlp technology promising alternative mers vaccine development however immunogenicity vlps relatively lower inactivated liveattenuated virus vaccines several strategies may explored increase immunogenicity vlps example dendritic cellstimulating molecules tolllike receptor <NUMBER> ligand flagellin genetically engineered incorporation merscov vlps increase immunogenicity enhance protective efficacy heterosubtypic virus challenge <NUMBER> <NUMBER> subunit vaccinescompared types vaccines subunit vaccines claim several unique advantages important characteristic subunit vaccines safety components contain synthetic peptides recombinant proteins expressing specific immunogenic fragments pathogen without involvement infectious viruses additionally type vaccine less likely induce side effects injection sites consistent production attained subunit vaccines constant conditions welldefined pathogenic fragments features made subunit vaccines attractive vaccine candidate like sarscov protein protein merscov also considered important target development subunit vaccines main antigenic component responsible inducing host immune responses since protein contains regions receptor binding membrane fusion proteinbased vaccines expected induce antibodies block virus binding subsequent membrane fusion neutralize viral infection <NUMBER> however protein sarscov also contains nonneutralizing epitopes immmunopredominant domain <NUMBER> may induce harmful immune responses <NUMBER> therefore essential identify exclude epitopes protein may induce harmful ade responses proteinbased merscov vaccines experience developing rbdbased sars subunit vaccines provides important guidance rational design rbd proteinbased mers vaccines since rbd sarscov contains multiple neutralizing epitopes rbdbased sars subunit vaccines covering neutralizing epitopes able induce potent neutralizing antibodies completely preventing sarscov challenge <NUMBER> <NUMBER> similarly shown rbd merscov induced strong neutralizing antibody responses infection merscov <NUMBER> <NUMBER> merscov rbd indeed contain several important neutralizing epitopes <NUMBER> accordingly optimization rbd development optimized rbdbased mers subunit vaccines containing multiple neutralizing epitopes would desirable feasible improve vaccine efficacy merscov sarscov rbds consist core receptorbinding subdomain share high degree structural similarity core subdomains receptorbinding subdomains notably divergent <NUMBER> variation receptorbinding subdomain region within subgroups coronavirus across different coronavirus groups advisable rationally design mers subunit vaccines using chimeric protein containing several neutralizing epitopes divergent subgroups approach provide strategic platform rational design subunit vaccines future emerging covs focusing chimeric protein containing neutralizing epitopes multiple virus strains across different subgroups <NUMBER> summarize although inactivated liveattenuated virus viral vectorbased vaccines able induce strong immune responses tendency recover virulence cause harmful immune responses raises safety concerns development mers vaccines dnabased vaccines high safety profile may unable induce highly potent immune response protection humans might cause toxic effect injection sites repeated vaccinations comparison development recombinant rbd proteinbased mers subunit vaccines remains high priority due variety advantages noted spite number merits proteinbased subunit vaccines might relatively lower immunogenicity compared inactivated liveattenuated vaccines <NUMBER> necessitating continued improvement immunogenicity subunit vaccines two possibilities discussed potential strategies improve immunogenicity mers vaccine candidates formulation subunit vaccines suitable adjuvantsto improve immunogenicity mers candidate vaccines adjuvants selected formulated basis mechanisms action normally vaccines limited immunogenicity require addition specific adjuvants stimulate protective longlasting immune response <NUMBER> <NUMBER> <NUMBER> although variety novel adjuvants emerging investigated approved clinical use aluminum saltbased adjuvants usually called alum mf<NUMBER> ™ induce antigenspecific humoral ctl responses <NUMBER> <NUMBER> hence potential use merscov subunit vaccines another adjuvant named glucopyranosyl lipid synthetic tlr<NUMBER> agonist also shown improve immunogenicity proteinbased vaccine candidate <NUMBER> adjuvants montanide isa<NUMBER> approved human use europe <NUMBER> <NUMBER> used making mers influenza subunit vaccines demonstrating strong ability promote induction highly potent immune responses candidate vaccines <NUMBER> <NUMBER> <NUMBER> furthermore combination two adjuvants distinct mechanisms action also feasible improve efficacy designed mers subunit vaccines since alum alone cannot induce strong th<NUMBER> immune responses thus applicable combine alum adjuvants potential complementary effects hope improve efficacy induced alumadjuvanted subunit vaccines example combination alum plus glucopyranosyl lipid applied improve efficacy sarscov rbd proteinbased subunit vaccine <NUMBER> therefore similar strategies utilized merscov subunit vaccines improve immunogenicity selection suitable administration routesseveral administration routes including im intradermal sc pathways used vaccine immunization experimental research clinical use route vaccine administration directly influences quality quantity vaccineinduced immunity <NUMBER> <NUMBER> <NUMBER> <NUMBER> traditional parenteral administration routes im intradermal sc shown induce favorable immune responses andor protection sarscov merscov infections <NUMBER> <NUMBER> <NUMBER> <NUMBER> demonstrated imvaccination rbd protein sarscov elicits longterm immune responses neutralizing activity protecting immunized mice sarscov challenge <NUMBER> additionally potent neutralizing antibodies protection sarscov infection observed mice sc vaccinated sarscov rbd proteins respectively expressed mammalian cell insect cell escherichia coli expression systems <NUMBER> <NUMBER> furthermore strong neutralizing antibody responses revealed mice scvaccinated merscov rbd proteins <NUMBER> addition inducing systemic immunity stimulation local immunity mucosal sites become important objective vaccination although unfavorable features route possibility delivering antigens central nervous system <NUMBER> well unsuitability children younger <NUMBER> years adults older <NUMBER> years especially chronic pulmonary diseases immunosuppression <NUMBER> advantages route outweigh disadvantages reports indicated vaccination effectively induced local systemic immune responses especially mucosal iga mucosal pathogens crossprotecting vaccinated animals infection homologous heterologous strains influenza virus <NUMBER> well providing longterm protection sarscov infection <NUMBER> important mucosal pathogen infecting humans via mucosal pathway <NUMBER> mers vaccines delivered via mucosal route anticipated elicit effective mucosal immune responses represented mucosal iga intranasal immunization subunit candidate vaccine containing recombinant rbd protein fused fc human igg demonstrated induce strong antirbdand antis<NUMBER>specific neutralizing antibody responses particularly iga mucosal immune responses infections merscov <NUMBER> providing fundamental basis developing effective mers mucosal vaccines therefore selection suitable vaccination routes combined antigen formulation appropriate adjuvants play important guidance developing merscov subunit vaccines evaluating efficacy merscov infection establishment effective animal models important evaluating efficacy candidate vaccines merscov unlike sarscov infect variety animals including nonhuman primates small animal models ferrets hamsters mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> animal species could infected merscov limited shown merscov unable replicate hamsters ferrets mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> significantly restricting efficacy evaluation mers vaccines small animal models although rhesus macaques infected merscov infected animals showing clinical signs disease virus replication <NUMBER> <NUMBER> high cost nonhuman primate models would prevent majority researchers using animal model therefore development effective small animal models merscov infection urgently needed <NUMBER> recently reported mice transduced adenoviral vectors expressing merscovs receptor dpp<NUMBER> susceptible merscov infection infected mice developing pneumonia clinical disease accompanied histopathological changes <NUMBER> nevertheless better transgenic mouse model gene encoding human dpp<NUMBER> integrated genome developed several laboratories <NUMBER> based previous experience developing sarscov vaccines current advancements potential strategies development merscov vaccines discussed review apart inactivated liveattenuated virus vaccines dnaand vlpbased vaccines particularly subunit vaccines containing rbd merscov protein critically important additionally suitable adjuvant formulation appropriate administration routes may need considered enhance immunogenicity vaccine candidates furthermore development effective animal models merscov infection important evaluating efficacy merscov candidate vaccines taken together strategies discussed important implications development effective mers vaccines future merscov newly emerging coronavirus raised worldwide concerns based ability cause increasing numbers human infections limited humantohuman transmission making particularly important explore efficient safe measures control disease among vaccination considered one effective strategies prevent virus infection different structural proteins e n protein merscov plays key role virus infection via s<NUMBER> binding viral receptor followed subsequent virus cell membrane fusion via s<NUMBER> dpp<NUMBER> identified cellular receptor merscov subsequently viral rbd mapped crystal structural analysis residues <NUMBER> <NUMBER> s<NUMBER> subunit protein truncated rbd containing residues <NUMBER> induced highest neutralizing antibody response virus infection vaccinated animals thus demonstrating importance developing srbdbased vaccines merscov compared vaccine types subunit vaccines possess higher safety profile potential elicit stronger immune responses including neutralizing antibodies suitable choices adjuvant formulation immunization routes increase efficacy subunit vaccines highlighting need develop merscov subunit vaccines based rbd viral protein next <NUMBER> years development effective safe subunit vaccine mers expected particular development subunit vaccine based rbd merscov protein greatest potential contain multiple neutralizing epitopes capable inducing highly potent immune responses particularly neutralizing activity merscov infection establishment effective small animal models mers infection allow economical practical detection protective efficacy designed vaccines challenges single multiple merscov strains potentially occurring humans application similar vaccine development strategies covs might cause human diseases future also anticipated • first identified humans june <NUMBER> middle east respiratory syndrome mers newly emerging infectious disease caused novel coronavirus merscoronavirus merscov currently causing increased human infections high mortality • belonging lineage c βcov phylogenetically related bathku<NUMBER> bathku<NUMBER> merscov first known lineage c βcov associated human infections • human dipeptidyl peptidase <NUMBER> identified receptor merscov receptorbinding domain rbd merscov mapped crystal structure residues covering <NUMBER> <NUMBER> respectively • truncated rbd fragment containing <NUMBER>amino acid residues <NUMBER> merscov protein induced strong rbdspecific antibodies blocking merscov rbd binding viral receptor dipeptidyl peptidase <NUMBER> effectively neutralizing merscov infection providing promise development mers candidate vaccine • merscov protein rbdbased subunit vaccines contain multiple neutralizing epitopes possess high efficacy induce strong neutralizing antibody responses protective immunity merscov infection representing direction future design effective mers vaccines • subunit vaccines formulated suitable adjuvants administered appropriate routes high potential enhance immunogenicity mers candidate vaccines many animals considered reservoirs covs origin merscov mode disease transmission still remain unknown based sequence fragment identical merscov found taphozous perforates bat captured saudi arabia inferred bats likely reservoir merscov <NUMBER> identification merscov dromedary camels detection neutralizing antibodies sera animals suggest camels could intermediate host merscov <NUMBER> <NUMBER> thus suspected merscov emerged interspecies transmission bats animals camels humans <NUMBER> several family clusters merscov infection reported <NUMBER> <NUMBER> suggesting humantohuman transmission disease people infected merscov developed severe acute respiratory illness symptoms like fever cough shortness breath virus estimated incubation period <NUMBER> days <NUMBER> transmissibility merscov humans currently less efficient severe acute respiratory syndrome cov sarscov emerged guangdong province china <NUMBER> reemerged <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER> countries throughout world <NUMBER> nonetheless mortality rate mers <NUMBER> much higher sars <NUMBER> <NUMBER> reported merscov sarscov could replicate cell lines four major chiropteran families implying ability merscov crossing species barrier humans bats <NUMBER> increased human cases high mortality rate merscov infection raised serious global concerns although still early implicate impending pandemic vaccination considered one effective strategies prevent virus infection thus development effective vaccines essential fight infectious disease proposed coronavirus study group international committee taxonomy viruses ictv three groups <NUMBER> <NUMBER> <NUMBER> coronaviridae family commonly accepted acov bcov gcov respectively genus bcov consists four lineages namely b c <NUMBER> novel genus dcov including hku<NUMBER> hku<NUMBER> hku<NUMBER> identified birds <NUMBER> added cov genera <NUMBER> unlike previously identified covs acov nl<NUMBER> first reported <NUMBER> <NUMBER> well bcov hku<NUMBER> first discovered hong kong <NUMBER> <NUMBER> <NUMBER> sarscov caused worldwide outbreak <NUMBER> <NUMBER> merscov belongs lineage c bcov first known lineage c bcov associated human infections <NUMBER> phylogenetically merscov closely related bat covs hku<NUMBER> hku<NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov positivesense singlestranded rna virus genome <NUMBER> kilobase kb pairs length consisting <NUMBER> functional open reading frames orfs figure <NUMBER> table <NUMBER> viral genome encodes five unique proteins known accessory proteins <NUMBER> <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>b serve different functions known homologs cov proteins accessory protein <NUMBER>a example recently proven block production host interferon ifn <NUMBER> although accessory proteins essential virus replication recent studies reverse genetics demonstrated absence genes encoding proteins group may attenuate viral titers <NUMBER> additionally genome merscov encodes six proteins homologous known covs including two replicase proteins orfs <NUMBER>a <NUMBER>b four major structural proteins spike envelope e membrane nucleocapsid n proteins figure <NUMBER> <NUMBER> e protein transmembrane protein forming ion channel viral surface cov n protein plays important role encapsidating genomic rna interacting protein n molecules <NUMBER> protein covs type transmembrane glycoprotein displayed oligomer surface viral membrane precursor protein contains cleavage site protein could cleaved two noncovalently associated subunits distal subunit s<NUMBER> membraneanchored subunit s<NUMBER> <NUMBER> s<NUMBER> subunit contains cellular receptorbinding domain rbd <NUMBER> s<NUMBER> subunit contains putative fusion peptide transmembrane domain two heptad repeat regions heptad repeat <NUMBER> <NUMBER> hr<NUMBER> hr<NUMBER> figure <NUMBER> <NUMBER> figure <NUMBER>a lists representative structures proteins aand bcov nl<NUMBER>cov mouse hepatitis cov mhvcov sarscov <NUMBER> <NUMBER> <NUMBER> rbds cov proteins consisting respective core receptorbinding subdomains example receptorbinding motif sarscov contains residues <NUMBER> <NUMBER> form long extended loop two short antiparallel bsheets one disulfide bond c<NUMBER> c<NUMBER> <NUMBER> similar proteins covs protein merscov also contains s<NUMBER> s<NUMBER> subunits s<NUMBER> responsible receptor binding s<NUMBER> membrane fusion <NUMBER> unlike covs sarscov nl<NUMBER>cov use human angiotensinconverting enzyme <NUMBER> receptors <NUMBER> <NUMBER> merscov utilizes human dipeptidyl peptidase <NUMBER> dpp<NUMBER> also known cd<NUMBER> cellular receptor dpp<NUMBER> expressed primary bronchiolar epithelial cells regulates activity hormones chemokines proteolytic cleavage <NUMBER> <NUMBER> recent studies solved crystal structures merscov protein alone complexed receptor dpp<NUMBER> mapped rbd merscov residues covering <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> <NUMBER> according crystal structures rbd merscov also contains core receptorbinding <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> j u n <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> j u l <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> u g <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> e p <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> c <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> n v <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> e c <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> j n <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> f e b <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> r <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> laboratory confirmed human cases merscov subdomains receptorbinding motif consisting <NUMBER> amino acids v<NUMBER> l<NUMBER> form fourstranded antiparallel bsheet figure <NUMBER>b <NUMBER> <NUMBER> similar covs hr<NUMBER> hr<NUMBER> merscov form <NUMBER>helix bundle believed drive virioncell membrane fusion three hr<NUMBER> helices forming central coiledcoil core three hr<NUMBER> chains surrounding core hr<NUMBER> side grooves <NUMBER> <NUMBER> <NUMBER> figure <NUMBER> describes crystal structures sarscov merscov rbd complexed respective receptors major neutralizing epitopes sarscov rbd neutralizing monoclonal antibody sarscov <NUMBER> understanding neutralizing epitopes rbd sarscov provide useful guidance identification neutralizing epitopes merscov rbd hence designing rbdbased neutralizing epitopedependent vaccines merscov previous reviews sars summarized approaches development effective cov vaccines pointed importance sarscov protein target vaccine therapeutic development outlined roadmap product development sarscov rbd proteinbased subunit vaccine manufacturing future clinical testing <NUMBER> <NUMBER> <NUMBER> <NUMBER> review briefly discuss current stages mers vaccine mers review informahealthcarecom vaccine development provide potential strategies developing mers vaccines based experience development sars vaccines focus subunit vaccines improve efficacy mers subunit vaccines addition also summarize current animal models merscov emphasize importance evaluation efficacy mers vaccine candidates effective animal models currently licensed mers vaccines available use however researchers working develop potential vaccines recent successes engineering replicationcompetent propagationdefective merscov using reverse genetics provide possibility developing attenuated viruses mers vaccine candidates <NUMBER> sars studies demonstrated vaccines inducing strong neutralizing antibodies completely protected immunized subjects sarscov infection moreover recovered patients infected sarscov could maintain potent persistent rbdspecific antibody responses neutralizing activity <NUMBER> revealing significance neutralizing antibodies prevention sars like case sarscov vaccines although vaccines eliciting favorable cellular immune responses may play role clearance virus infection vaccines inducing neutralizing antibodies sufficient protection merscov infection thus ability eliciting neutralizing antibodies expected one important criteria evaluating efficacy mers vaccines previous studies sarscov shown protein particularly rbd may induce highly potent neutralizing antibodies protected vaccinated animals sarscov challenge <NUMBER> <NUMBER> <NUMBER> <NUMBER> thus expected protein merscov also important development vaccines song et al showed vaccination recombinantmodified vaccinia virus ankara mva expressing fulllength protein merscov induced high levels neutralizing antibodies vaccinated mice <NUMBER> however cao colleagues reported although mvabased fulllength proteindependent sars vaccine could induce neutralizing antibody responses ferrets failed protect vaccinated animals sarscov challenge even worse vaccine associated enhanced inflammatory immunopathological effects resulting serious liver damage vaccinated ferrets viral challenge <NUMBER> therefore caution taken fulllength protein merscov used vaccine antigen since nonneutralizing epitopes protein may induce antibodymediated disease enhancement ade effects elicited protein feline infectious peritonitis virus fipv also cov <NUMBER> therefore favorable develop vaccines based protein fragments particularly rbd merscov strategy reported effective development mers vaccines studies shown neutralization merscov infection could elicited vaccinated rabbits fragment containing residues <NUMBER> merscov protein <NUMBER> induction neutralizing activity recombinant protein fragment containing residues <NUMBER> merscov rbd also demonstrated particularly truncated <NUMBER>amino acid rbd fragment containing residues <NUMBER> inside rbd residues <NUMBER> merscov protein induced strong merscov sspecific antibodies vaccinated mice blocking binding merscov rbd viral receptor dpp<NUMBER> effectively neutralizing merscov infection thus providing promise development effective safe mers vaccine <NUMBER> <NUMBER> addition protein merscov viral proteins might play role development mers candidate vaccines however studies addressed possibility particular mers recently emerged novel human disease vaccine development timeconsuming process recent study reveals structural accessory proteins orf <NUMBER>a orf <NUMBER>b orf <NUMBER> merscov may function potent ifn antagonists <NUMBER> orf <NUMBER>a protein showing greatest potential counteracting antiviral effects ifn inhibiting ifn production ifnsensitive response element signaling pathways therefore proteins may also serve targets developing mers vaccines inactivated liveattenuated sarscov tested vaccine candidates proven effective provide protective immunity sarscov infection <NUMBER> <NUMBER> <NUMBER> previously reported bpropiolactoneinactivated sarscov vaccine administered subcutaneously sc mice effective inhibiting virus replication murine respiratory tract adenovirusbased n vaccine given either intranasally intramuscularly im <NUMBER> addition live impairedfidelity sarscov vaccine engineered inactivation exonuclease activity protects aged immunocompromised mice lethal virus challenge <NUMBER> apparently local serum antibody responses induced inactivated sarscov vaccinated mice <NUMBER> like sarscov might possible attenuate merscov deleting envelope e protein diminish virus growth tissue culture abrogating virulence animals <NUMBER> <NUMBER> inactivating exonuclease activity spite possibility inducing highly potent immune responses protection vaccine candidates based inactivated liveattenuated merscov might potential recovering virulence raising safety concerns vaccine type may inappropriate use highly immunosuppressed individuals dna vaccines consist plasmid dna genetically engineered produce immunological response protect organisms diseases dna usually administered two routes im delivery bombardment skin using gene gun <NUMBER> currently two popular theories dna uptake used including nonspecific phagocytosis pinocytosis antigenspecific receptormediated uptake <NUMBER> containing nonreplicating noninfectious components encoding protein interest dna vaccines safe use minimizing undesirable side effects <NUMBER> addition vaccines based dnas easy scaled fermentation technique <NUMBER> <NUMBER> <NUMBER> generally stable inexpensive efficacy dnabased vaccines sarscov infection widely reviewed revealed dna vaccine encoding sarscov protein induces neutralizing antibody well tcell responses protect vaccinated mice sarscov challenge <NUMBER> addition igg antibody tcellmediated immune responses induced dna vaccines encoding s<NUMBER> sarscov findings sarscov vlps may applied constructing vlps merscov compared inactivated liveattenuated virus vaccines vlps contain infectious materials making vlp technology promising alternative mers vaccine development however immunogenicity vlps relatively lower inactivated liveattenuated virus vaccines several strategies may explored increase immunogenicity vlps example dendritic cellstimulating molecules tolllike receptor <NUMBER> ligand flagellin genetically engineered incorporation merscov vlps increase immunogenicity enhance protective efficacy heterosubtypic virus challenge <NUMBER> <NUMBER> compared types vaccines subunit vaccines claim several unique advantages important characteristic subunit vaccines safety components contain synthetic peptides recombinant proteins expressing specific immunogenic fragments pathogen without involvement infectious viruses additionally type vaccine less likely induce side effects injection sites consistent production attained subunit vaccines constant conditions welldefined pathogenic fragments features made subunit vaccines attractive vaccine candidate like sarscov protein protein merscov also considered important target development subunit vaccines main antigenic component responsible inducing host immune responses since protein contains regions receptor binding membrane fusion proteinbased vaccines expected induce antibodies block virus binding subsequent membrane fusion neutralize viral infection <NUMBER> however protein sarscov also contains nonneutralizing epitopes immmunopredominant domain <NUMBER> may induce harmful immune responses <NUMBER> therefore essential identify exclude epitopes protein may induce harmful ade responses proteinbased merscov vaccines experience developing rbdbased sars subunit vaccines provides important guidance rational design rbd proteinbased mers vaccines since rbd sarscov contains multiple neutralizing epitopes rbdbased sars subunit vaccines covering neutralizing epitopes able induce potent neutralizing antibodies completely preventing sarscov challenge <NUMBER> <NUMBER> similarly shown rbd merscov induced strong neutralizing antibody responses infection merscov <NUMBER> <NUMBER> merscov rbd indeed contain several important neutralizing epitopes <NUMBER> accordingly optimization rbd development optimized rbdbased mers subunit vaccines containing multiple neutralizing epitopes would desirable feasible improve vaccine efficacy merscov sarscov rbds consist core receptorbinding subdomain share high degree structural similarity core subdomains receptorbinding subdomains notably divergent <NUMBER> variation receptorbinding subdomain region within subgroups cov across different cov groups advisable rationally design mers subunit vaccines using chimeric protein containing several neutralizing epitopes divergent subgroups approach provide strategic platform rational design subunit vaccines future emerging covs focusing chimeric protein containing neutralizing epitopes multiple virus strains across different subgroups <NUMBER> summarize although inactivated liveattenuated virus viral vectorbased vaccines able induce strong immune responses tendency recover virulence cause harmful immune responses raises safety concerns development mers vaccines dnabased vaccines high safety profile may unable induce highly potent immune response protection humans might cause toxic effect injection sites repeated vaccinations comparison development recombinant rbd proteinbased mers subunit vaccines remains high priority due variety advantages noted spite number merits proteinbased subunit vaccines might relatively lower immunogenicity compared inactivated liveattenuated vaccines <NUMBER> necessitating continued improvement immunogenicity subunit vaccines two possibilities discussed potential strategies improve immunogenicity mers vaccine candidates improve immunogenicity mers candidate vaccines adjuvants selected formulated basis mechanisms action normally vaccines limited immunogenicity require addition specific adjuvants stimulate protective longlasting immune response <NUMBER> <NUMBER> <NUMBER> although variety novel adjuvants emerging investigated approved clinical use aluminum saltbased adjuvants usually called alum mf<NUMBER> tm induce antigenspecific humoral ctl responses <NUMBER> hence potential use merscov subunit vaccines another adjuvant named glucopyranosyl lipid synthetic tlr<NUMBER> agonist also shown improve immunogenicity proteinbased vaccine candidate <NUMBER> adjuvants montanide isa<NUMBER> approved human use europe <NUMBER> <NUMBER> used making mers influenza subunit vaccines demonstrating strong ability promote induction highly potent immune responses candidate vaccines <NUMBER> <NUMBER> <NUMBER> furthermore combination two adjuvants distinct mechanisms action also feasible improve efficacy designed mers subunit vaccines since alum alone cannot induce strong th<NUMBER> immune responses thus applicable combine alum adjuvants potential complementary effects hope improve efficacy induced alumadjuvanted subunit vaccines example combination alum plus glucopyranosyl lipid applied improve efficacy sarscov rbd proteinbased subunit vaccine <NUMBER> therefore similar strategies utilized merscov subunit vaccines improve immunogenicity several administration routes including im intradermal sc pathways used vaccine immunization experimental research clinical use route vaccine administration directly influences quality quantity vaccineinduced immunity <NUMBER> <NUMBER> <NUMBER> <NUMBER> traditional parenteral administration routes im intradermal sc shown induce favorable immune responses andor protection sarscov merscov infections <NUMBER> <NUMBER> <NUMBER> <NUMBER> demonstrated im vaccination rbd protein sarscov elicits longterm immune responses neutralizing activity protecting immunized mice sarscov challenge <NUMBER> additionally potent neutralizing antibodies protection sarscov infection observed mice sc vaccinated sarscov rbd proteins respectively expressed mammalian cell insect cell escherichia coli expression systems <NUMBER> <NUMBER> furthermore strong neutralizing antibody responses revealed mice scvaccinated merscov rbd proteins <NUMBER> addition inducing systemic immunity stimulation local immunity mucosal sites become important objective vaccination although unfavorable features route possibility delivering antigens central nervous system <NUMBER> well unsuitability children younger <NUMBER> years adults older <NUMBER> years especially chronic pulmonary diseases immunosuppression <NUMBER> advantages route outweigh disadvantages reports indicated vaccination effectively induced local systemic immune responses especially mucosal iga mucosal pathogens crossprotecting vaccinated animals infection homologous heterologous strains influenza virus <NUMBER> well providing longterm protection sarscov infection <NUMBER> important mucosal pathogen infecting humans via mucosal pathway <NUMBER> mers vaccines delivered via mucosal route anticipated elicit effective mucosal immune responses represented mucosal iga intranasal immunization subunit candidate vaccine containing recombinant rbd protein fused fc human igg demonstrated induce strong antirbdand antis<NUMBER>specific neutralizing antibody responses particularly iga mucosal immune responses infections merscov <NUMBER> providing fundamental basis developing effective mers mucosal vaccines therefore selection suitable vaccination routes combined antigen formulation appropriate adjuvants play important guidance developing merscov subunit vaccines evaluating efficacy merscov infection establishment effective animal models important evaluating efficacy candidate vaccines merscov unlike sarscov infect variety animals including nonhuman primates small animal models ferrets hamsters mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> animal species could infected merscov limited shown merscov unable replicate hamsters ferrets mice <NUMBER> <NUMBER> <NUMBER> <NUMBER> significantly restricting efficacy evaluation mers vaccines small animal models although rhesus macaques infected merscov infected animals showing clinical signs disease virus replication <NUMBER> <NUMBER> high cost nonhuman primate models would prevent majority researchers using animal model therefore development effective small animal models merscov infection urgently needed <NUMBER> recently reported mice transduced adenoviral vectors expressing merscovs receptor dpp<NUMBER> susceptible merscov infection infected mice developing pneumonia clinical disease accompanied histopathological changes <NUMBER> nevertheless better transgenic mouse model gene encoding human dpp<NUMBER> integrated genome developed several laboratories <NUMBER> based previous experience developing sarscov vaccines current advancements potential strategies development merscov vaccines discussed review apart inactivated liveattenuated virus vaccines dnaand vlpbased vaccines particularly subunit vaccines containing rbd merscov protein critically important additionally suitable adjuvant formulation appropriate administration routes may need considered enhance immunogenicity vaccine candidates furthermore development effective animal models merscov infection important evaluating efficacy merscov candidate vaccines taken together strategies discussed important implications development effective mers vaccines future expert commentary merscov newly emerging cov raised worldwide concerns based ability cause increasing number human infections limited humantohuman transmission making particularly important explore efficient safe measures control disease among vaccination considered one effective strategies prevent virus infection different structural proteins e n protein merscov plays key role virus infection via s<NUMBER> binding viral receptor followed subsequent virus cell membrane fusion via s<NUMBER> dpp<NUMBER> identified cellular receptor merscov subsequently vaccine mers review informahealthcarecom viral rbd mapped crystal structural analysis residues <NUMBER> <NUMBER> s<NUMBER> subunit protein truncated rbd containing residues <NUMBER> induced highest neutralizing antibody response virus infection vaccinated animals thus demonstrating importance developing srbdbased vaccines merscov compared vaccine types subunit vaccines possess higher safety profile potential elicit stronger immune responses including neutralizing antibodies suitable choices adjuvant formulation immunization routes increase efficacy subunit vaccines highlighting need develop merscov subunit vaccines based rbd viral protein next <NUMBER> years development effective safe subunit vaccine mers expected particular development subunit vaccine based rbd merscov protein greatest potential contain multiple neutralizing epitopes capable inducing highly potent immune responses particularly neutralizing activity merscov infection establishment effective small animal models mers infection allow economical practical detection protective efficacy designed vaccines challenges single multiple merscov strains potentially occurring humans application similar vaccine development strategies covs might cause human diseases future also anticipated december <NUMBER> first patient atypical form pneumonia diagnosed china disease would later referred covid<NUMBER> world health organization one month later january <NUMBER> causative agent covid<NUMBER> disease sarscov<NUMBER> virus deciphered identified genome published rapidly <NUMBER> midapril <NUMBER> extent impact covid<NUMBER> global population becoming evident adversely affected region per capita western europe seriously affected population elderly especially extensive comorbidities weakened immune systems causes regional differences covid<NUMBER> require months analysis years ascertain focused approaches reduce impacts covid<NUMBER> nearterm especially vulnerable populations need pursued parallel longerterm approaches lessen impact covid<NUMBER> coronavirusdriven diseases across demographics midapril shortterm measures implemented reduce transmission sarscov<NUMBER> taken reduce transmission sarscov <NUMBER> sars pandemic good hygiene quarantine latter far severe extensive quarantine implemented <NUMBER> shortterm measures implemented sporadic basis termed tactical treatments tactical treatments strengthen immune system rather goal containing adverse impacts viral attack examples tactical treatments tested eidd<NUMBER> remdesivir favipiravir chloroquine hydroxychloroquine combination lopinavir ritonavir tocilizumab losartan name tests far yielded mixed results second avenue pursued amelioratereduce effects covid<NUMBER> development vaccines induce viral immunity bulk present review addresses status prospects vaccine approach third leg triad approaches ameliorate ravaging effects especially vulnerable covid<NUMBER> called strategic treatment approach <NUMBER> approach goal strengthening immune system allow adaptive component neutralize incoming coronavirus without need external support strategic treatments eliminate tangible factors contribute weaken immune system examples factors based existing studies include titanium dioxide air pollution chlorpyrifos aluminum sulfate prenatal alcohol exposure zno oil fly ash many others <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> also real life exposure scenario exposed continuously combination stressors influences long term immune system response organism viral stressors <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> tsatsakis et al <NUMBER> shown pollutants influence immune system particularly modulating ahr pathway effects prevented strict regulations positive impact may result shortterm strategic treatments main impact probably longterm except whose immune systems suffered irreversible damage overwhelming genetic predisposition immune dysfunction strategic treatments appropriate specific individual difficult identify difficult eliminate ingrained habits emphasis needs placed types treatments require severe lifestyle alterations work aims analyze strategies challenges regarding development effective vaccines sarscov<NUMBER> discovery vaccine novel coronavirus important component threepronged approach described initially given pandemic cannot seem entirely stopped social distancing good hygiene practices tactical therapies identified far entirely effective especially vulnerable individuals unable prevent severe disability ultimately death healthcare systems still struggling crumble pressure coronavirus patients research laboratories around world competing produce effective vaccine sarscov<NUMBER> soon possible order able stop spread new coronavirus development vaccine complex timeconsuming process differs development conventional medicines normally period development vaccine <NUMBER> years <NUMBER> conventional medicines oriented towards treatment disease whose symptoms emerged vaccines intended use persons yet exhibiting disease symptoms order prevent occurrence diseases <NUMBER> clinical trials demonstrate effectiveness vaccine focus demonstrating ability prevent disease minimal adverse reactions shortterm since truly longterm studies humans rarely ever conducted especially order decades implies need enroll people traditional drug studies <NUMBER> traditional vaccine development methods although extremely effective combating highly contagious diseases measles require large amounts viruses bacteria last months microorganisms become key element vaccine socalled antigen warns human immune system foreign organisms invaded body must eliminated vaccines provide immune system necessary instructions recognizing mobilizing lines defense diseasecausing microorganisms bacteria viruses classical vaccines antigens distinctive molecular markers introduced body originating inactivated halfactive bacteria attenuated viruses antigens capable causing disease still capable activating immune system cells develop antibodies person comes contact native pathogen immune system already necessary antibodies ready multiply much faster already sensitized vaccination risk factors antisarscov<NUMBER> vaccine efficacy global immune deficiency risk factor anticovid<NUMBER> vaccine efficacy particularly elderly exposed myriad factors contribute weakening immune system described previously factors also result diseases obesityobesityrelated eg type ii diabetes metabolic syndrome immunemediated cancers mechanistic reasons diseases include weakness antigen recognition decreased immune cell quantity functionality increased levellength timing humoral immune alterations components reduced initiation cellular responses memory cell disorders associations immunodeficiency include agedependent humoral immune cell alterations immunosenescence malnutrition <NUMBER> proteinenergymicronutrient deficit telomere shortening <NUMBER> addition past current treatments affect scalable ineffectiveness vaccines older adults <NUMBER> children <NUMBER> especially immunocompromised <NUMBER> exposure immunosuppressive drugs <NUMBER> residence developing countries <NUMBER> low socioeconomic status associated higher viral mortality compared residence developed countries <NUMBER> current global obesity prevalence adult children also risk factor antisarscov<NUMBER> vaccine inefficacy due higher levels il<NUMBER> <NUMBER> decreased igg concentrations parasitic infections respiratory tract infections complicated pneumonia <NUMBER> also affect subsequent immune response antisarscov<NUMBER> vaccination <NUMBER> adjuvant purity safety knowledge gaps relative contribution innate adaptive responses protection individual pathogens precise mode action individual adjuvants <NUMBER> existing negative factors vaccine efficacy antisarscov<NUMBER> vaccines available vaccine market players according current orphan drug <NUMBER> vaccine legislation <NUMBER> <NUMBER> due fight sarscov<NUMBER> pandemic means design defect failure warn negligence testing may also affect vaccine efficacy conditions longterm safety testing vaccines humans nonexistent data whether antisarscov<NUMBER> vaccines first licensed developed countries <NUMBER> vaccine production facilities adequate assure reliable supply new antisarscov<NUMBER> vaccines <NUMBER> timely manner compatible specifications improved adult vaccine design strategy immunobiography <NUMBER> heterogeneity immune responses elderly subpopulations <NUMBER> vaccine safety safety vaccine initially assessed laboratory studies mice rabbits animals show signs disease receiving vaccine tests begin humans number subjects gradually increases <NUMBER> duration clinical trial average classical vaccine preclinical stagein vitro vivo tests follows <NUMBER> <NUMBER> phase also called first human test vaccine given small group healthy volunteers <NUMBER> <NUMBER> purpose test whether vaccine protects disease whether safe whether causes severe side effects phase ii candidate vaccine administered larger group subjects <NUMBER> phase iii even larger group <NUMBER> separate studies may required adults children elderly sometimes happens vaccines seem safe given small number people show side effects given larger number people explained fact rare complication less likely occur group subjects small continuous monitoring important case complications occur delayed effect <NUMBER> pandemic sequential studies may shortened partially overlapped important thousands vaccinated people followed several months general purpose vaccine approved severe signs inflammation vaccine causes immune system malfunction ways candidate vaccine may suitable widespread use adverse effects identified delays production process inevitably occur <NUMBER> present two potential vaccines sarscov<NUMBER> virus first phase derogation rule skipped animal studies fig <NUMBER> first vaccine follow research steps called mrna<NUMBER> tested first phase seattle explanation speed approval related fact coronavirus used vaccine development experimental vaccine made new method based rna basically rna molecule vaccine teaches cells produce diseasespecific antigen trains body real enemy also small problem date vaccine based mrna technology approved disease although reached second phase testing <NUMBER> second vaccine ad<NUMBER>ncov vaccine created genetic engineering tries teach body recognize coronavirus protein delivered via type<NUMBER> adenovirus adenoviruses family one hundred doublestranded dna viruses cause various diseases humans animals type<NUMBER> often used genetic recombination although clinical trials begun two candidates likely begin soon potential vaccines unlikely move phase ii earlier months vaccine efficacy vaccines stimulate immunity virus also stimulate inflammation body manifest either pain inflammation site subject injected general symptoms fever fatigue symptoms similar covid<NUMBER> disease vaccines reactions mild affect small proportion subjects vaccine causes production antibodies mice humans necessarily mean vaccine protect disease ideally moving human studies researchers able demonstrate vaccine protect laboratory animals disease experimentally infected virus case diseases caused previous coronaviruses sars mers difficult find animal species would affected disease way humans affected however previous research may help scientists speed animal testing process covid<NUMBER> protective effect human vaccine assessed using series studies similar series safety studies vaccine elicits immune system response example antibodies detected phase study larger phase ii phase iii studies performed see vaccine protects infection disease although covid<NUMBER> new disease research sars mers helped us understand human body responds coronaviruses response immune system generates protection disease <NUMBER> restricted human studies also used calculate correct dose schedule vaccine vaccines generate strong immune response single dose others require booster dose month longer strategy also increases duration studies assess whether vaccine prevents covid<NUMBER> among exposed infection tested phase iii studies setting infection actively occurring response west african ebola outbreak <NUMBER> rvsv ebola vaccine went three phases clinical development <NUMBER> months centralized coordination médecins sans frontières manufacturer period still cases ebola guinea protection vaccine demonstrated vaccinating contacts residual cases appeared community <NUMBER> vaccine manufacturing case pandemic vaccines tens hundreds millions doses needed production process takes least six months production lines already exist new vaccine involves new production process involves several quality control steps manufacturer must ensure vaccine produced consistent quality requires repeated testing moreover vaccine manufacturing biological process inevitably batches vaccines fail reasons always clear delay production quite manufacturers world produce vaccines large enough scale meet needs pandemic vaccine regulation initiating stage human testing process developer must provide evidence vaccine early indications protection safe among tested research ethics committees review clinical trial plans authorities european medicines agency ema food drug administration fda oversee entire vaccine development process approving general use assessments usually take several weeks months <NUMBER> although approvals could shortened event pandemic many potential covid<NUMBER> vaccines use new technologies regulators able rely experience similar vaccines speed process developers covid<NUMBER> vaccine given target produce vaccine <NUMBER> months historically vaccines took <NUMBER> years develop diseases vaccines yet exist despite decades work example <NUMBER> children die year respiratory diseases caused another rna virus rsv respiratory syncytial virus causes pneumonia despite <NUMBER> years research <NUMBER> products developed currently rsv vaccine available <NUMBER> numerous scientific research groups working development covid<NUMBER> vaccine using number different approaches many groups race important vaccines entering clinical trials fail safety efficacy reasons sarscov<NUMBER> brief summary sarscov<NUMBER> part coronavirus family sarscov<NUMBER> generated <NUMBER> sars epidemic merscov generated mers epidemic <NUMBER> <NUMBER> new sarscov<NUMBER> coronavirus severe acute respiratory syndrome coronavirus <NUMBER> causes respiratory infection called covid<NUMBER> coronavirus infectious disease <NUMBER> average incubation period <NUMBER> days <NUMBER> <NUMBER> days <NUMBER> disease characterized predominant respiratory symptoms cough difficulty breathing fever moderate intensity <NUMBER> cases may severe manifestations bilateral interstitial pneumonia progression respiratory failure acute respiratory distress ards main cause mortality also cases gastrointestinal manifestations especially diarrhea patients especially young ones hypoanosmia loss sense smell hypodysgeusia alteration sense taste reported early symptoms <NUMBER> shortly publication genetic structure sarscov<NUMBER> first two vaccines developed sarscov<NUMBER> virus structure composed rna molecule surrounded series structural functional proteins <NUMBER> known structural proteins protein spike leads characteristic appearance protein membrane protein e envelopes protein n nucleocapsid protein role attaching receptors human cells facilitating fusion viral content cell case sarscov<NUMBER> receptor angiotensin converting enzyme <NUMBER> ace<NUMBER> found large quantities respiratory tract lung parenchyma <NUMBER> <NUMBER> <NUMBER> <NUMBER> initial infection sarscov<NUMBER> occurs ciliary epithelial cells bronchi <NUMBER> <NUMBER> binding protein ace<NUMBER> greatly favored existence polybase cleavage site protein fragment cleaved furin enzyme commonly found human body allowing protein fragments s<NUMBER> s<NUMBER> s<NUMBER> perform function addition fusing viral envelope cell membrane virus also infects human cell endocytosis cell membrane around portion binds virus forms vesicle inside cell detaches membrane introduces virus cell via vesicle process entering cell virus loses envelope fuses cell membrane viral rna free cytoplasm carrying two processes replication transcription first cellular components responsible rna transcription produce viral proteins rna copied subsequently proteins copies initial rna packed new virions released cell spread infection <NUMBER> humoral immunity consists production specific antibodies antigens antibodies appear rapidly infection disappear rapidly igm ii antibodies appear slower persist body long time even infection cured igg <NUMBER> cellular immunity requires training certain immune cells recognize destroy virus observed sarscov<NUMBER> infection number cd<NUMBER> cd<NUMBER> lymphocytes low peripheral blood destroyed process elimination virus high concentrations activation markers <NUMBER> regarding sarscov virus memory cells capable recognizing identified blood healed patients several years infection persistence memory cells important element consider development antisarscov<NUMBER> vaccine <NUMBER> cases described sarscov<NUMBER> infection recurs considered cured <NUMBER> hand evidence coronaviruses equipped mechanisms sometimes evade immune attack first infection cell vesicles virus located lacking receptors could recognize virus invader body second interferon synthesis antiviral function inhibited coronaviruses presentation viral antigens pca low infected patients <NUMBER> strategies covid<NUMBER> vaccine development current pandemic covid<NUMBER> caused sarscov<NUMBER> global epidemiological problem solution require establishment largescale production vaccine given experience previous coronavirus outbreaks showing high variability virus required develop vaccine production platform providing scalability technological flexibility versatility vaccines must provide high efficacy safety tolerability due time required prove proposed vaccine safe effective well time required produce millions doses many candidate vaccines initially look promising likely fail testing process process developing new vaccine begins socalled candidate vaccine team scientists believes potential fastest part process takes weeks thus candidate vaccines efficient application sarscov<NUMBER> vaccines production procedure needs developed also requires largescale production followed vaccination program targeting mutimillion population different regions complex approach allow combatting coronavirus disease pandemic new technologies require work live virus making production much easier still needing scientific technological evidence fig <NUMBER> type vaccines sarscov<NUMBER> rna vaccines mrna encoding ribonucleic acid vaccine encodes stable prefused form form fused cell membrane host cell spike protein <NUMBER> protein complex required membrane fusion host cell infection target vaccines mers sars membrane fusion viral cellular essential step encapsulated viruses enter cells fusion double lipid layer requires catalysis overcome high kinetic barrier viral fusion proteins agents perform catalytic function <NUMBER> although coronavirus uses many different proteins replicate invade cells protein main surface protein uses bind receptor becomes bridge human cell protein binds human cell receptor viral membrane fuses human cell membrane allowing viral genome enter human cells initiate infection <NUMBER> mrna vaccine sarscov<NUMBER> based relatively new genetic method require growing virus laboratory technique transforms human body living laboratory whole process longer carried laboratory directly body received vaccine <NUMBER> technique actually based messenger ribonucleic acid mrna fragments genetic material copied dna encodes proteins moderna company loads vaccine viral mrna encodes proteins new coronavirus injects body immune cells lymph nodes process mrna synthesize specific viral protein antigens immune cells recognize <NUMBER> mrna like software molecule body produces viral proteins generate immune response <NUMBER> body processes viral protein often different way processes protein vaccine thus one theoretical benefits introducing mrna vaccine body causes viral protein behave exactly way virus would directed host <NUMBER> table dna vaccines dna vaccines represent latest direction development manufacture vaccines vaccines obtained recombinant dna technology produced genetic modification dna encoding target molecule introduced via plasmid viral vector suitable microorganism cell line dna expressed translated protein product subsequently recovered extraction purification injected dna plasmid plus promoter provides immunogenic protein synthesis <NUMBER> advantage type vaccine stimulates humoral cellular immunity also type vaccine stable require maintenance controlled conditions refrigeration case conventional vaccines contrast live attenuated vaccines risks arising potential inadequate attenuation vaccine strains present dna vaccines <NUMBER> advantages new technology fact plasmids used easy manufacture large quantities immunity conferred longterm disadvantages identified far regard dna vaccines due fact type vaccine limited protein immunogens <NUMBER> clinical trial new dna vaccine coronavirus begun called chadox<NUMBER> ncov<NUMBER> initially developed prevent mers <NUMBER> vaccine based adenovirus vaccine vector sarscov<NUMBER> spike protein <NUMBER> modified cannot reproduced human body genetic code transmits instructions production coronavirus spike protein added allowing adenovirus produce protein vaccination result formation antibodies spike protein known surface sarscov<NUMBER> <NUMBER> ino<NUMBER> vaccine another new dna vaccine prevent sarscov<NUMBER> infection entering human phase testing <NUMBER> phase study enroll <NUMBER> healthy adult volunteers participant receive two doses ino<NUMBER> every four weeks initial immune responses safety data study expected end summer preclinical data shown promising results immune response several animal models also preclinical results inovio sarscov<NUMBER> vaccine consistent results phase study table ii protein subunit subunit vaccines contain certain antigenic determinants pathogenic microorganisms obtained either starting conventional cultivation processes recombinant dna technology <NUMBER> antigen determinants included vaccine increase efficiency immune response presence small number pathogens reduces risk side effects subunit vaccines mainly contain surface fragments pathogens types structures weak immunogens obtain vaccines suitable efficacy antigens conjugated protein molecules <NUMBER> antigen purifiers sometimes lead loss immunogenicity requiring coupling protein carrier aluminum salt however adjuvants associated onset local reactions vaccination site also duration immunity conferred vaccination lower except live vaccines <NUMBER> table iii viral vectors along traditional virus vaccines viral vectors widely used genome one virus used deliver antigen another virus thus allowing development platform technology virus production technologies available largescale production vaccines drawbacks vaccines include large variation purification methods need reliable confirmation purity activity virus <NUMBER> tables iv v vlps viruslike particles vaccine development based recombinant proteins viruslike particles vlps innovative approach antiviral vaccines usually developed basis surface proteins form vlps production vlps cells reconstruction stable immunogenic forms multistage process substantial issues appear vlp production nonenveloped viruses nucleic acid based vaccines interesting platform technology viewpoint allowing process used production different antigens elicit humoral cell immune responses <NUMBER> production vaccines may based e coli cell fermentation corresponding technologies extraction purification plasmids ensuring structural integrity <NUMBER> table vi inactivated virus another category vaccines vaccines containing whole microorganisms inactivated chemical physical methods type vaccine advantage higher stability however effectiveness lower requires reminders immune system vaccines inactivated live virus require stabilization structure dry form separate supply solvent coldchain transportation factors complicate production process lead increase cost <NUMBER> table vii live attenuated virus live attenuated vaccines first vaccines utilized types vaccines obtained cultivation microorganisms suboptimal conditions successive passage cultures techniques determine attenuation virulence maintaining capacity induce immune response <NUMBER> although characterized effective live attenuated vaccines disadvantages risks related possible occurrence mutations leading virulence reversal well contraindication case immunocompromised persons table viii others lvsmenpdc vaccine lentiviral minigene vaccine shenzhen genoimmune medical institute entered phase clinical trial march <NUMBER> vaccine based dendritic cells modified lentiviral vector expressing synthetic minigens based selected viral protein domains administered antigenspecific cytotoxic lymphocytes <NUMBER> pathogenspecific aapc vaccine shenzhen genoimmune medical institute phase <NUMBER> clinical trial <NUMBER> based lentiviral vector modified artificial antigen presenting cells aapcs expressing synthetic minigens based selected viral protein domains challenges covid<NUMBER> vaccines stand development manufacture covid<NUMBER> vaccine urgent issue likely take many months resolve although many companies announced covid<NUMBER> vaccine ready soon quite difficult reality <NUMBER> main reason put market vaccine safe shortterm longterm important history vaccine production situations <NUMBER> example one third polio vaccines administered us <NUMBER> <NUMBER> also contained simian virus <NUMBER> sv<NUMBER> recently rotavirus vaccines discovered also swine circoviruses <NUMBER> <NUMBER> <NUMBER> order avoid situations everything tested humans first checked purity sterile production lines provided takes time rare cases certain antibodies generated immunization may promote aggravated form disease situation called ade antibody dependent enhancement <NUMBER> antibodies reestablish contact virus actually help enter cells cause infection ade described many viral infections influenza dengue zika etc also coronaviruses mechanism ade confirmed coronavirus humans <NUMBER> several animal studies shown types antisars antimers vaccines although effective generating antibodies lead severe forms disease virus subsequently inoculated <NUMBER> second reason vaccine must safe also effective must able determine synthesis antibodies certain type certain concentration titer provide protection reasonable time however vaccines never generate immunity vaccinated people <NUMBER> causes complex vary genetic immunological factors quality vaccines administered age important aspect influenza studies shown aging immune system dramatically decreases effectiveness vaccination <NUMBER> therefore future antisarscov<NUMBER> vaccine aspects evaluated primary immunization failures minimized adjusting doses number administrations assuming vaccine generate effective immune response sufficient number individuals among vaccinated time frame vaccine protection questionable <NUMBER> example measles vaccination small percentage initially respond well lose protective antibody status within years phenomenon called secondary immunization failure <NUMBER> takes time check postvaccination persistence anticovid antibodies last least safety efficacy significantly dependent type vaccine ie technology platform used technologies new therefore require careful testing others old need adapted covid<NUMBER> another aspect ability company develop technology also largescale production capacity quickly accessible globally commercially available antisarscov<NUMBER> vaccine precedent proposed platforms completely new production lines capable generating billions doses months must considered must done without stopping production current vaccines already included official protocols guidelines present capacity reached difficulty represent unprecedented effort dna rna vaccines based principle insertion nucleic acids cells vaccinated ones forcing make immunogenic viral proteins <NUMBER> although recent data seem encouraging concepts questionable efficiency humans nonreplicative vectors actually common viruses eg adenovirus genetically modified display sarscov proteins outer surface <NUMBER> common many us already met throughout lives result already immunity neutralize job attenuated viruses would variants sarscov<NUMBER> made less pathogenic genetic engineering far immunogenic risk become pathogenic mutations <NUMBER> inactivated viruses viral fragments synthetic peptides relatively weakly immunogenic analysis variables normally done <NUMBER> years form trial stages trial inflexible standardized intensely regulated purpose maximum safety efficacy final vaccine first stage preclinical research technology included vaccine selected efficacy safety profile human cells vitro animal models vivo tested expected antiinfectious effect seen vitro cells die excessively vivo animal studies conducted mice usually perfect candidate vivo studies <NUMBER> genetically similar humans relatively inexpensive raise major ethical issues <NUMBER> however one notable differences human mouse fixed case ace<NUMBER> receptor gene sars viruses bind infection mice simply make respiratory syndromes eliminate virus relatively quickly body necessary either genetically modified mouse human ace<NUMBER> receptor use ferrets monkeys makes everything much expensive difficult access preclinical stage lasts <NUMBER>½ <NUMBER>½ years far selective estimated less <NUMBER> vaccines tested able progress human tests fail product work others longer find financing <NUMBER> <NUMBER> obtaining vaccine first people vaccinated highest risk categories everyone else term sometime <NUMBER> possibly long naturally acquired immunity still many unknowns related coronavirus immunity obtaining vaccine difficult future mutations sarscov<NUMBER> could occur time automatically means high risk vaccine becoming useless vaccine obtained coronavirus far one guarantee success yet possible anticovid vaccine short time without benefits longterm testing results vaccine probably available us <NUMBER> months scientists began working coronavirus vaccines sars mers outbreaks efforts materialize myriad difficulties since extremely severe current coronavirus pandemic covid<NUMBER> spread outbreak appears much broader case sars also possibility disease becoming endemic seasonal appearance according investigators explains many research groups companies undertaking efforts develop effective vaccine sarscov<NUMBER> world also speeding usual phases needed develop test vaccine human important feature landscape vaccine research development sarscov<NUMBER> represented varied range evaluated technological platforms including nucleic acids dna rna viruslike particles peptides viral vector replicative nonreplicative recombinant proteins live attenuated viruses inactivated viruses many platforms currently basis vaccines already authorized experience areas oncology encourages developers exploit new opportunities increased development manufacturing speeds effective therapy severe covid<NUMBER> social distancing extremely costly social economic perspective therefore development effective vaccine along efforts implement immuneenhancing strategic treatments shorterterm efforts identify tactical repurposed treatments considered major public health priorities hope get key tool disease prevention quite soon unknown whether ever successful sarscov<NUMBER> vaccine efforts scientific community attempting develop vaccine without precedent thus covid<NUMBER> vaccines never ending story challenge trials sarscov<NUMBER> vaccines could ethical despite risk severe adverse events nir eyal deep health economic social crisis world result covid<NUMBER> pandemic cannot sustainably resolved without proven vaccine novel coronavirus <NUMBER> experts consider ideas accelerated testing vaccine candidates <NUMBER> one approach replace conventional phase iii testing longest expensive phase clinical research human challenge trials also known controlled human infection trials challenge trials could replace conventional efficacy testing either completely <NUMBER> weeding unpromising vaccine candidates conventional testing part either way challenge trials could make testingin multiarm adaptive platform trials <NUMBER> instancefaster manageable human challenge trial healthy participants intentionally exposed pathogen helps researchers find fast whether participants earlier randomized vaccine investigation protected participants control group typically received placebo results come much faster conventional phase iii testing significant differences group received vaccine control group start surfacing months later participants typically try avoid exposure much example donning protective gear get exposed pathogen outbreak moves elsewhere many participants exposed conventional phase iii testing fails completewhich normally cannot happen challenge trials human challenge trials regularly done seasonal flu typhoid malaria <NUMBER> typical justification carefully controlled experiments involving intentional infection often pose minor risks <NUMBER> example disease mild therapies available justification probably fails live sarscov<NUMBER> challenge since deadly risks although participant selection could make death unlikely enough respect commonly assumed limits tolerable risk consensual clinical studies <NUMBER> correction added <NUMBER> may <NUMBER> first online publication funding information added acknowledgments point proven cure <NUMBER> also technical questions much challenge trials could accelerate testing novel coronavirus <NUMBER> article defends ethics coronavirus challenge studies assumption technically could substantially accelerate testingand widespread rollout f air benefi cent treatment participants challenge trial depends simply reducing likelihood severe clinical outcomes fatality study participants might experienced similar worse events anyhow makes sense hold outcomes protocol th e trial reduce participant entire cohort much likelihood exceeds commensurate bad outcomes people two alternative scenarios delineated involve participation particular study th e idea straightforward doctors er patients surgeries toxic drugs may result severe clinical outcomes experiment new interventions time th ese approaches perfectly justifi ed doctors thereby save patients greater likelihood similar bad events without treatment experiment one thing worse getting belly cut indicated operation undergoing indicated operation say uninsured th e operation injures puts risk usually brings net benefi move fact injured belly would harm source risk conclusion uninsured blessing would fallacious assessing risks benefi ts study participants research ethics heeds simply risks study participation also heeds balance incremental risks incremental benefi ts participation matters much <NUMBER> th calculus applies human challenge trials well matters assessing er researchers make candidate participants simply socalled absolute risk <NUMBER> better described raw contributing risk comes challengewhether viral exposure poses minor controllable risks alternatively serious onesbut net risk risk participating trial minus risk person would face otherwise words matters full balance personal risk benefi th e evaluation challenge trial ought look diff erence trial would make participants health life institutional review board example heed change risk exposure would apply participant would trial alternative scenario judging ethics sarscov<NUMBER> challenge trial two alternative scenarios participation challenge trial especially pertinent one person declines participate sarscov<NUMBER> vaccine effi cacy test th scenario helps identify trial participation may aff ect person overall good ill another person participates competing form trial namely standard effi cacy trial vaccine th e latter would result delay may tempting argue kinder study participants hence ethical compare personal risks two studies shall look participants average counterpart effi cacy study whether participant challenge trial join standard effi cacy study turns compared either two alternative scenarios individual cohort net risk participating sarscov<NUMBER> vaccine challenge would negative small unclear th e net risk could clearly large diff erently put sarscov<NUMBER> challenge trial may turn constitute indirectly benefi cial research study participantsso would medically disadvantaged ultimately excluded admitted standard effi cacy trial instead properly done challenge trial certainly would expose participants known far higher prospect net harm would either alternatives might introducing sometimes deadly incurable pathogen body perfectly healthy person improve persons health welfare prospects th e explanation lies peculiarities current pandemic features highly transmissible virus overwhelms health systems worldwide individual probability incurring death disability infection x b stands probability getting infected b stands probability either dying developing longterm disability result infection x b individual participates challenge trial declines participates instead standard effi cacy trial probability largest fi rst case enough justify blocking willing decisionally capacitated adults enabling highly valuable trials gauge magnitude x b challenge trial versus outside trial versus standard effi cacy trial let us look separately b three scenarios people assume challenge trials dangerous participate usually focus probability getting infected three scenarios candidate participant likelihood getting infected clearly greater challenge trials artifi cial challenge person either declines participate trial participates standard effi cacy trial however sarscov<NUMBER> case research team select participants probability infection least larger challenge trial recent models predict widespread worldwide exposure coronavirus areas likely experience infection rates greater <NUMBER> <NUMBER> proposal recruit areas ongoingly expected high transmission rates <NUMBER> since world large variegated place candidate selection careful targeted many outlier areas among choose probability getting infected later would high time candidate selection expedited vaccine trials could shorten current global economic recession prevent many deaths worldwide would make perfect sense invest carefully selecting safely transporting hundred healthy candidate participants hightransmission areas isolated research centerseven across international borders light public health emergency related red tape removed participants selected way challenge trial much likelier hasten participants exposure impose exposure would otherwise avoided rare event exposure kills participant earlier exposure could mean individual dies months sooner exposed virus outside trial design temporal factor seems less signifi cant substantial eff ect trial participation could likely person die appropriate trial procedures smart participant selection b probability dying developing disability infected would smaller challenge trial may much smaller first proposed trial design includes frequent monitoring may catch disease enable participants receive supportive care therapeutics proven point early probably complications develop <NUMBER> outside challenge trials contrast testing could scarce many carriers could remain asymptomatic impedes testandtreat approach may deemed promising patients therapeutics proven might universally available yet would prudent fair toward trial participants prioritize novel therapeutics <NUMBER> challenge trials sarscov<NUMBER> vaccine also er guaranteed access standardofcare lifesustaining treatments including immediate assistance cardiac arrest lifesupport services reach capacity many parts developed world coming months patients hightransmission areas develop severe disease oft en die outside trials true according reports published far covid patients rely critical care survive <NUMBER> crucially younger covid patients need critical care tend survive <NUMBER> united kingdom example covid patients aged <NUMBER> <NUMBER> whose critical care outcomes reported may <NUMBER> <NUMBER> <NUMBER> could actually smaller released critical care <NUMBER> also true period intensive care covid<NUMBER> treatment may leave patients physically psychologically disabled <NUMBER> option receiving critical care significantly helps prevent worst outcome shortterm fatality clearly substantial medical benefi young patients severe covid<NUMBER> absence lifesustaining interventions makes big difference likely survival chance probability averting death event infection would substantially better inside challenge trial outside trial probability would somewhat larger standard effi cacy trial would fi nd somewhat harder provide full guarantee support thousands participants short researchers conducting challenge trials act recommended admittedly probability getting infected would remain larger inside challenge trial either outside trial standard effi cacy trial probability death disability likely much smaller inside challenge trial alternative scenarios overall x b could smaller individual inside challenge trial either outside trial standard effi cacy trial individual would lose probability averting infection probability rising could gain better protection death even eventually data calculations x b turns equal alternative scenarios slightly better unlikely case dynamic uncertain data notwithstanding x b much much smaller properly selected treated individual participate trial partakes standard effi cacy trial instead th matters espousing limit risky participating trial may justifi ably contemporary research ethicists usually describe exceeds limit terms extremely high net risk participant limit surpassed overall balance prospective medical harms medical benefi ts participant highly adverse <NUMBER> th ere another important welfare borderlinemedical benefi participation potential challenge participants simply could extinguish risk getting exposed say leave home essential work th ey could extinguish either declining participate trial participating standard effi cacy trial instead among live others would understandably worry infecting household members including cases old frail relatives th ey would know reinfection rare impossible something scientists still examining would infect long infection infectious period take place isolation putting least temporary end risk infecting others would help keep loved ones alivesurely substantial benefi <NUMBER> contrast join study participate standard effi cacy study probability infecting dearest could remain substantial long challenge participants selected supported recommended prospective harms properly understood incremental harms unlikely far exceed benefi ts individual participants th ey could actually smaller sum far answer right question appreciation net risk balance challenge trial participation could either prospectively benefi cial neutral slightly prospectively harmfulcertainly highly prospectively harmful th erefore cannot justify paternalistic protection adults requisite decisionmaking capacity wish help researchers enormous good c onsider fi potential objections argument laid exploitation one objection argument compares participation challenge trial wrong scenarios th e correct comparison could objected idealized circumstancesof greater justice otherwise vaccine producer might exploit unjust background strife candidate participants er less safety <NUMBER> exploit someone roughly use unjust disadvantage ones unfair advantage leaving less <NUMBER> example sweatshop owner makes potential workers worse er pay unfairly low degree safety exploiting alternatives unfairly even worsestarvation instance th e fundamental problem may distributive consequences say owner winds much workers little workers eff ective inability decline er simply perverse relation owner stands whatever fundamental problem may usually consider problematic inasmuch widespread infections lack access critical care fl ow injustices one could claim recruiters human challenge trials societies serve likewise exploiting unjust disadvantage instead one could argue appropriate comparator participating challenge trial living world free injustices disadvantageous sequelae indeed two senior french doctors recently condemned proposed testing coronavirus vaccines african patients based assumptions african nations fi nancial inability fi ght virus eff ectively <NUMBER> backlash probably unsympathetic somewhat racist suggestions doctors made occasion potential exploitation background economic injustices may also concern th e challenge trials discuss would probably take place leading research centers richest countries inside countries transmission rates need unavailable critical care services may typically end worst impoverished minority undocumented migrant neighborhoods among uninsured underinsured among victims societal injustice unethical historical challenge trials done participants improving participants overall risk exposure compared unjust alternatives <NUMBER> historical comparisons obviously inappropriate given abuses also involved violations consent independent review forth <NUMBER> unethical nature may also involved exploitation background injustices <NUMBER> potential kind exploitation undermine case testing sarscov<NUMBER> vaccines challenge trial design th ere simple answer concern exploitation avoid preying victims injustice likely live certain areas research teams need recruit elsewhere th e world big place unfortunately plenty areas ongoing expected high transmission well devastating demand critical care services even absent grossly unjust background poverty disparities lack insurance like locales experiencing expect surge covid<NUMBER> cases reasons preexisting systemic injusticesimply bad luck even warranted choices panned poorly example governments may invested great portion health care funds intensive care units supplies years pandemic favor investing costeff ective interventions time promote population health longevity researchers could always focus recruitment locales indeed although researchers recruit hightransmission areas need areas highest transmission rates latter locales correlate closely background injustices areas generally betteroff would course impossible project locales become hightransmission areas time test effi cacy candidate vaccine illustrative purposes however consider middleclass areas stockholm social democratic swedens recent choices avoid social distancing turn epidemiologically mistaken quite thing unjust <NUMBER> transporting hundred candidate participants afar even across borders research center rational fi nancial administrative investment toward alleviating deep recession second answer instance research teams may able recruit volunteers driven solely promoting health also altruism th e nonprofi <NUMBER>day sooner collating contact details potential volunteers live sarscov<NUMBER> challenge trials reports <NUMBER> applications time writing <NUMBER> many potential volunteers study teach elite academic institutions many selfidentifi ed effective altruists recount past altruistic acts selfreports ought taken caution may turn enough participants would volunteer full comprehension medical risks perhaps altruism misunderstandingand suff ered systemic injustice makes vulnerable exploitation avoiding fi nancial incentives participation would help select volunteers best motives <NUMBER> th e causal route e r h participation would exploitatively rely ering benefi ts thwart major injustices toward third answer ethics around nonexploitation complex avoiding exploitation defi ned would mean victims injustice denied benefi ts trial participation many people like racial minority example undernourished denied benefi vaccines tested people like th e upshot showing action would exploitative therefore unclear sometimes much better exploited exploited finally even exploiting unjust strife unavoidable challenge trials sarscov<NUMBER> vaccines concerns exploitation would strong enough unseat otherwise strong case trials true even study volunteers willing consent even given need thwart public health disaster research ethicists <NUMBER> would consider high likelihood grave harm volunteer remain forbidden <NUMBER> one know seriously argues worries benefi cial perfectly consensual research marred merely exploitative route benefi consent enough ban study expected save inordinate number lives remember challenge trial design could cut several months wait vaccine rollout translating thousands millions lives spared exponential growth direct covid deaths <NUMBER> true third one half vaccine effi cacy trials lead vaccine approval <NUMBER> chance none <NUMBER> extant vaccine candidates work approved vaccine rolled widely even portion potential lives might spared thanks sarscov<NUMBER> vaccine challenge trials covid death death serious harm diseases neglected pandemic famines halted economic development months delay could large number lives spared put dramatically main factor resting one side moral scale signifi cant chance averting great number deathsprobably vastly <NUMBER> ebola outbreak <NUMBER> deaths even <NUMBER> indian ocean tsunami around <NUMBER> deaths stands side averting serious net harm individual consideration research ethicists count th e complaint side admittedly challenge trial participation could benefi individual balance could rationally autonomously choose enroll causal roots benefi impure th balance would stop serious research ethicist approving crucial trial reasons concern exploitation even applicable cogent cannot unseat initial case conducting challenge trials th say researchers ignore concern may aff ect best conduct trialssay recruiting areas high transmission rates blatant injustices still form challenge trial remains permissible accelerate vaccine rollout highly recommended ethically inability decline challenge trials enroll individuals fully free informed consent <NUMBER> medical trials unjust background circumstances dire leave candidate participants reasonable option except enroll perhaps troubles ethicists consider challenge trials warn dire background injustices may also part worries quality consent trials novel cancer therapeutics give terminal patients last hope fi ght cancer irresponsive approved treatments <NUMBER> sense desperate patients cannot cannot aff ord say forced participate english one chooses less bad two bad options one oft en said forced compelled make choice <NUMBER> may seem invalidate consent people dire circumstances may give trial participation may make inclusion trial unfree one could argue wrongful given eff ects current pandemic anyone joining challenge trial vaccine novel coronavirus may said forced participate th argument bad alternatives trial participation invalidate consent participate cannot work would forbid many ordinary participant selection procedures cancer therapy research could even absurdly invalidate consent advanced cancer care parallel ground patient cannot aff ord say argument even questionable applied vaccine research th e risk profi le someone knows advanced cancer diff erent someone wholike vaccine trial recruitshas infected therefore far less dramatic risk especially research teams recruit young healthy individuals even infection highly unlikely translate severe disease recruits feel desperate compelled participate trial healths sakes argued health benefi ts participation recruits feel desperate persistently excluded consent process misunderstanding relevant facts psychiatric grounds respect since permit cancer studies also permit human challenge studies novel coronavirus vaccines vaccine safety vaccine candidates may turn effi cacy testing toxic <NUMBER> may turn effi cacy testing enhance covid<NUMBER> severity manifold <NUMBER> th e greater chance vaccine safety issues better respect individuals decline participate trials <NUMBER> th may suggest participating challenge trial prospectively harmful aft er let er four responses first challenge trial participants would prospectively benefi ways may still prospectively benefi overallthis risk notwithstanding second chance vaccine safety issues likely per person arise standard effi cacy trials assuming form effi cacy testing vaccines legitimate crisis factor weigh challenge trials th ird standard effi cacy trials toxicity severe disease much less safe participants erupt fi eld controlled medical environment frequent monitoring guaranteed medical help <NUMBER> th erefore vaccine unsafety far dangerous participant standard effi cacy trial one challenge trial fourth standard effi cacy trials risk toxicity enhanced severity accrues <NUMBER> <NUMBER> times many participants simple reason trials require <NUMBER> <NUMBER> times many participants short appropriate concern enhanced severity cannot constitute advantage standard effi cacy trials human challenge trial quite contrary strengthens ethical case challenge trials replace standard effi cacy testing vaccines novel coronavirus indirect benefits argued challenge trials done right incremental risk participation may smaller incremental benefi th e main benefi invoked priority access critical care therapeutics event severe covid<NUMBER> however benefi may seem irrelevant tertiary either harm allegedly matters benefi ts particular benefi indirect contempt mere benefi ts merits short response researchers well clinicians appropriately er countermeasures known riskier expected benefi ts exceed expected risks benefi ts mere enhancement mere fi nancial benefi might less important trials primary benefi participant others clearly important th e benefi ts discussed terms avoiding covid<NUMBER> fatalitythe main risk consideration indeed even clear counts reduction incremental risk increase incremental benefi <NUMBER> worth discussion worry lifesaving benefi ts nevertheless merely indirect would arise receiving intervention studied <NUMBER> treatment covid<NUMBER> among clinical benefi ts procedures scientifi cally necessary test experimental intervention study <NUMBER> anonymous reviewer earlier version article thought indirect benefi ts count toward assessment study participants balance personal risks personal benefi ts lest researchers address major risk fi nancial compensation still indirect benefi ts however purposes article set aside question whether money ever adequately compensate acute medical risk priority access covid<NUMBER>related critical care medical fi nancial benefi directly addresses main risk challenge participation namely premature covid<NUMBER>related mortality indirect benefi count addition benefi ts participation covid<NUMBER> challenge trial would direct benefi ts consider potentially better protection ones family infection provides longterm immunity safer environment episodes enhanced disease severity compared environment standard effi cacy trial participants th ese benefi ts emanate directly best scientifi c way hold study furthermore scholars looked indirect benefi ts usually propose including institutional review boards riskbenefi calculations <NUMBER> even informed consent forms <NUMBER> fact questionable view regulatory block invoking indirect benefi ts pertains united states research people cannot provide informed consent children <NUMBER> irrelevant present case challenge trials decisionally capacitated adults <NUMBER> even benefi better access critical care therapeutics challenge trial ones hightransmission area borderline direct strictly speaking scientifi cally necessary test experimental intervention study care would part trial safety ancillary care retroactive compensation trial risks covid<NUMBER> fatality instead preempts high risk covid fatality resulting viral exposure study access critical care also ethically owed study participants per accounts research ethics anyhow critical care experimental treatment might owed rich countries exquisitely rare despite participants especially strong claim denied offer critical care would preposterous challenge trial deadly disease critical care helps treat far aft erthought appease protesting unfair riskbenefi ratio critical care owed fi rst place personal risk factors candidate participant hails hightransmission area actually low risk getting infected reason sets apart neighbors personally willing able isolate extraordinarily well th en important sense trial participation could harm individual greatly trial exposure would certain whereas outside trial would remain unlikely <NUMBER> researchers go way toward identifying excluding individuals example asking candidate participants work household arrangements even surveying risk behavior perhaps informed consent forms exhort candidate participants consider personal risk factors avoid participation highly unlikely get exposed naturally however participants would less risk natural exposure researchers could know others would greater risk natural exposure researchers could know researchers ascribe candidates average risk level risk category package investigate sticking average nonomniscient researchers likely introduce net harm expected introduce less net harm expected balance risk exposure researchers ethically responsible arguably one know could reasonable eff ort fi nd objective one discussed argued right ethical question human challenge trials sarscov<NUMBER> vaccines commonly raised one likelihood leading deaths severe adverse events given diseases seriousness current lack proven therapeutics th e right question whether challenge trials would increase study participants likelihood similar bad outcomes compared two alternative scenarios nonparticipation trial participation standard effi cacy trials vaccines shown surprisingly compared two alternatives human challenge studies would balance probably benefi least dramatically harm study participants challenge trials could also reduce overall prospect harm participant cohort respect sarscov<NUMBER> ethicists advocate ban trial design may accelerate proven vaccines rollout months risks calculated wrong way let us miss chance quash current global crisis earlier perfectly permissible research conclusion follows based ethical requirement give participants fair balance risks benefi ts need important recruit individuals cohort would low risk bad outcomes trial th e balance risks benefi ts may turn similar participants would low risk trial young healthy individuals ones would high risk older people individuals relevant underlying health problems may turn compared alternative scenarios challenge trial participation prospectively benefi cial harmful potential recruits including highrisk ones indeed case would seem compatible sensibly calculated riskbenefi requirements recruit challenge trial young healthy people <NUMBER> risks benefi ts low would also seem permissible recruit old people people live health conditions make especially vulnerable covid<NUMBER> people risks benefi ts high could benefi least lose lot prospects compared participate compared participate standard effi cacy trial recruiting ample number participants several vulnerable populations may allow us skip testing vaccine safety <NUMBER> effi cacy populations earlier excluded effi cacy study move straight conditional approval alongside rigorous testing broader populations wide rollout additional months would saved race universal vaccine rollout ethical considerations may thought weigh recruiting older patients patients conditions increase risk infection one recruitment could increase risk patients would die trial procedures undermining public trust another higherrisk populations benefi guaranteed access therapeutics lifesustaining interventions event severe infection might crucial enough force participate sense expounded whether two considerations sensible weighty enough forgo cutting additional months process question shall leave another day  vaccination one significant public health interventions ever made sparing millions people infectious diseases calculated use currently available vaccines saves eight million lives annually corresponds one person saved every five seconds remarkable results achieved <NUMBER> years vaccination history largely based two basic simple technologies inactivation toxins pathogens formaldehyde treatment first performed glenny hopkins <NUMBER> ramon <NUMBER> <NUMBER> <NUMBER> <NUMBER> stable attenuation pathogens serial passage vitro <NUMBER> <NUMBER> easy technologies applied develop vaccines used worldwide control even eradicate many infectious diseases one brilliant successes vaccination eradication smallpox virus <NUMBER> estimated date smallpox eradication spared global community <NUMBER> million new smallpox victims <NUMBER> million deaths disease annual savings result vaccination stopped hospitals able converted uses estimated excess us <NUMBER> million year <NUMBER> vaccination also resulted elimination poliovirus americas <NUMBER> western pacific <NUMBER> europe june <NUMBER> goal global polio eradication initiative interrupt transmission wild poliovirus end<NUMBER> leading global certification <NUMBER> overall since initiative launched <NUMBER> number cases fallen <NUMBER> estimated <NUMBER> cases <NUMBER> cases reported first three months <NUMBER> period number polioinfected countries reduced <NUMBER> <NUMBER> <NUMBER> moreover incidence seven frightening diseases diphtheria measles rubella mumps pertussis haemophilus influenzae type b hib tetanus fallen <NUMBER> states related vaccines introduced see tab <NUMBER> chiron vaccines via fiorentina <NUMBER> <NUMBER> siena italy historical technologies vaccine production achieved remarkable successes battle infectious diseases last several million years existence earth microorganisms learnt escape surveillance immune system either hiding host responses developing capacity infecting different hosts two main mechanisms pathogen defense explain vaccines several pathogens hiv hcv streptococcus pyogenes staphylococcus aureus plasmodium falciparum schistosoma spp others difficult develop yet available moreover last <NUMBER> years big revolution microbial ecology pathogens circulated since many years whose existence ignored discovered hcv metapneumovirus etc old pathogens changed geographical habitat introduced new areas become endemic eg west nile virus north america completely new pathogens emerged pose serious threat human health hiv sars coronavirus etc pathogens thought controlled reemerged mycobacterium tuberculosis etc tab <NUMBER> soon clear old vaccine strategies unable face new challenges posed infectious diseases modern approaches needed therefore beginning <NUMBER>s taking advantage better understanding immune system emergence recombinant dna technologies new vaccines developed tab <NUMBER> moreover nowadays range technologies strategies available vaccine development extremely broad availability whole genomic sequences many pathogens considered real revolution table <NUMBER> universal routine vaccination reduced <NUMBER> incidence nine harmful diseases us eradicated two smallpox polio max common knowledge capsular polysaccharide many important bacterial pathogens major virulence factor vaccination using purified polysaccharides could protect people diseases polysaccharide vaccines developed neisseria meningitidis serogroup mena group c men c group meny group w<NUMBER> men w<NUMBER> late <NUMBER>s <NUMBER> <NUMBER> h influenzae type b <NUMBER>s <NUMBER> <NUMBER> types streptococcus pneumoniae early <NUMBER>s <NUMBER> salmonella typhi mid <NUMBER>s <NUMBER> however use vaccines inadequate polysaccharides tindependent antigens immunogenicity efficacy poor absent infants unsuitable included infant routine immunization schedule solution found covalently linking sugar carrier protein conjugation procedure converts tindependent antigens tdependent ones providing source appropriate tcell epitopes present carrier protein conjugation technology one biggest achievements novel vaccination strategies capacity transforming poor immunogens polysaccharides excellent immunonovel vaccination strategies <NUMBER> first conjugate vaccine developed one haemophilus influenzae type b hib <NUMBER> hib respiratory pathogen causes wide spectrum human infections availability hib conjugate vaccine hib leading cause bacterial meningitis especially infants developed developing countries worldwide resulting substantial morbidity mortality first hib conjugated vaccine introduced us december <NUMBER> children <NUMBER> months age older subsequently immunogenic vaccines introduced us well many countries early <NUMBER>s use infants age two months within years effectiveness public impact hib conjugate vaccines hib disease demonstrated countries introduced vaccination <NUMBER> us annual cases hib invasive disease among children five years age decreased <NUMBER> prevaccination era <NUMBER> less <NUMBER> <NUMBER> <NUMBER> general decrease incidence disease exceeded predicted basis estimated proportion population completely immunized suggesting vaccine use able generate herd immunity topic many studies shown hib conjugated vaccines able reduce nasopharyngeal carriage <NUMBER> gives major contribution herd immunity precisely hib conjugate immunization reduces nasopharyngeal colonization whether impact due decreased acquisition decreased duration carriage clear additional work immunology microbiology transmission carriage needed clarify issue hand reduction hib carriage may open ecological niches h influenzae nontype b strains <NUMBER> maria lattanzi rino rappuoli seven serotypes first licensed conjugate vaccine account <NUMBER> isolates blood cerebrospinal fluid children aged <NUMBER> years us compared <NUMBER> isolates older children adults us <NUMBER> isolates young children latin america asia <NUMBER> <NUMBER> sevenvalent conjugate pneumococcal vaccine recommended us infants three primary doses approximately <NUMBER> <NUMBER> <NUMBER> months age one booster dose ages <NUMBER> <NUMBER> months <NUMBER> vaccine repeated successes hib conjugate vaccine showing high efficacy preventing meningitis efficacy although less extent preventing pneumonia <NUMBER> acute otitis media <NUMBER> due vaccine serotypes moreover several studies established conjugate vaccine effective also reducing nasopharyngeal carriage serotypes covered vaccine potentially extending benefits beyond children vaccinated post licensure evaluation efficacy sevenvalent conjugated vaccine found reduction disease greater percentage children vaccinated evidence herd immunity <NUMBER> neisseria meningitis group c conjugate vaccines began clinical development end <NUMBER>s extensive clinical studies <NUMBER>s proved safe capable inducing highly bactericidal boostable immune responses infants children <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vaccines first introduced united kingdom late <NUMBER> used countrywide vaccination initiative populationbased active surveillance monitored agespecific capsular groupspecific incidence disease estimated vaccine coverage <NUMBER> results impressive within <NUMBER> months vaccine introduction cases menc diseases almost disappeared vaccinated population estimated vaccine efficacy <NUMBER> targeted age groups <NUMBER> according large carriage study performed united kingdom vaccine induced also <NUMBER> decrease carriage menc strain evidence increase carriage menb isolates capsular groups <NUMBER> moreover vaccine provides evidence herd immunity also reduction menc disease unvaccinated individuals ranging <NUMBER> percent <NUMBER> years old <NUMBER> percent <NUMBER> years old <NUMBER> since <NUMBER> menc conjugate vaccine licensed many european countries also canada australia either routine infant immunization catchup programs varying forms multivalent meningococcal conjugate vaccines containing groups c w<NUMBER> clinical development introduction vaccines routine infant andor toddler immunization programs could substantial effect incidence meningococcal disease <NUMBER> <NUMBER> <NUMBER>s discovered protection towards hepatitis b correlated presence antibodies surface antigen virus hbsag circulates bloodstream infected subjects large quantities discoveries led development first generation plasmaderived hbsag subunit vaccines first licensed us <NUMBER> <NUMBER> concerns safety blood products advances recombinant dna technology conducted development secondgeneration recombinant subunit vaccines produced yeast mammalian cells <NUMBER> first licensed us <NUMBER> application recombinant dna technology advantage produce safer vaccines plasmaderived ones unlimited supplies recombinant hbv vaccine highly effective standard course three doses induces protective levels antihbs ie <NUMBER> miuml <NUMBER> healthy infants children adolescents <NUMBER> healthy adults younger <NUMBER> years age <NUMBER> immunogenicity drops <NUMBER> however age <NUMBER> years <NUMBER> <NUMBER> vaccinees develop protective anti hbs titers <NUMBER> <NUMBER> <NUMBER> moreover vaccine prevents development chronic hepatitis least <NUMBER> earlyvaccinated infants born hbeagpositive mothers <NUMBER> costbenefit analyses strongly supported introduction universal immunization hbv newborns <NUMBER> since <NUMBER> called countries add hepatitis b vaccine national childhood immunization schedules substantial progress made implementing recommendation end <NUMBER> <NUMBER> countries worldwide introduced vaccine <NUMBER> substantial help achieving goal given global alliance vaccines immunization gavi vaccine fund since <NUMBER> began provide technical financial support introduce routine hbv immunization <NUMBER> worlds poorest countries <NUMBER> effectiveness routine infant hbv immunization significantly reducing eliminating prevalence chronic hbv infection demonstrated variety countries settings experience taiwan particularly impressive universal vaccination decreased prevalence hbsag carriage children younger <NUMBER> years age <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> moreover rates hepatocellular carcinoma hcc among cohorts children born routine infant immunization started mid <NUMBER>s declined greater <NUMBER> <NUMBER> results clearly show hbv vaccine first successful anticancer vaccine opening way anticancer vaccines like vaccines human papilloma virus hpv causes cervical cancer <NUMBER> helicobacter pylori responsible many gastric cancers <NUMBER> first example vaccine developed new rational strategic design taking advantage power molecular biology genomic technologies recombinant acellular pertussis vaccine vaccine composed whole killed bordetella pertussis cells available mass vaccination since late <NUMBER>s <NUMBER> vaccine efficacious preventing disease presence severe adverse reactions although proof exists caused vaccine brought drop vaccine compliance <NUMBER>s stressed need new safer vaccine considerable amount work initially required identify bacterial antigens responsible induction protection pertussis toxin pt identified major protective antigen antigens adenylate cyclase filamentous haemagglutinin fha pertactin fimbriae found provide help protective immunity several researchers developed acellular pertussis vaccines containing purified pt inactivated old classical chemical treatment formaldehyde glutaraldehyde however recognized treatment pt may associated significant reversion rates <NUMBER> overcome problems pertussis toxin detoxified using powerful tools molecular biology make stable changes sitedirected mutagenesis amino acids responsible toxicity pertussis toxin molecular approach allowed development naturally nontoxic molecule inactivated rational design need denaturing chemical treatment <NUMBER> genetically detoxified pt successfully shown safety immunogenicity clinical trials adult volunteers infants children either monovalent mutant pt alone <NUMBER> <NUMBER> association fha pertactin <NUMBER> <NUMBER> also fha pertactin association diphtheria tetanus toxoids dtap <NUMBER> <NUMBER> trials showed different acellular vaccine formulations containing nontoxic pt mutant extremely safe much safer wholecell pertussis vaccines furthermore formulations induced high titers antipt neutralizing antibodies strong antigenspecific tcell proliferative responses interestingly enough five six years primary immunization schedule vaccine still exhibited efficacy <NUMBER> antigenspecific antibody cd<NUMBER> tcell responses still detectable significant levels <NUMBER> <NUMBER> new strategy used develop genetically detoxified acellular pertussis vaccine shows approach provide tremendous advantages eliciting high protective immune responses low amounts antigen despite introduction new strategies conjugation recombinant dna etc one major issues development new vaccines identification protective antigens microorganism biochemical immunological microbiological methods successful many cases require pathogen grown laboratory conditions timeconsuming allow identification abundant antigens purified quantities suitable vaccine testing unfortunately many instances abundant proteins could good vaccine candidates moreover antigens expressed vivo infection could expressed vitro extent furthermore dealing noncultivable pathogens approach vaccine development availability complete genome sequence freeliving organism h influenzae <NUMBER> marked beginning genomic era opened novel strategies vaccine design possibility determining whole sequence genome bacterial viral parasitic led idea using genomic information discover novel antigens missed conventional vaccinology approach called reverse vaccinology involves computer silico analysis microbial genome sequence predicts antigens likely vaccine candidates <NUMBER> <NUMBER> success genomicbased strategies vaccine development highly dependent criteria used silico selection potential antigens usually secreted extracellular proteins easily accessible antibodies intracellular ones several approaches used mine genomic sequences appropriate combination various algorithms critical evaluation information generated essential proper selection antigens silico approach results selection large number genes therefore necessary use simple procedures allow large numbers genes cloned expressed like robotics pcr product pcr reaction cloned screened expression heterologous system successful expression depends predicted localization protein integral transmembrane proteins proven particularly difficult produce recombinant techniques e coli purified recombinant proteins used immunize mice postimmunization sera analyzed verify computerpredicted surface localization polypeptide ability elicit quantitative qualitative immune protective response genomic approach many novel features advantages need cultivate pathogen whole process starts silico could equally applied cultivable noncultivable microorganisms pathogens dangerous handle studied easily commensals virtually protein antigens encoded pathogens genome could become vaccine candidates regardless whether expressed vitro vivo abundant scarce process allows identification antigens seen conventional methods discovery novel antigens work totally different paradigm unfortunately reverse vaccinology suffers limitations related incomplete knowledge vaccine immunology ratelimiting step process linked rarity often absence widely accepted correlates protection reliable animal models infection constraint approach inability identify nonprotein antigens polysaccharides cd<NUMBER> restricted antigens glycolipids represent new promising vaccine candidates meningococcus b represents first example application genomic approach demonstration power novel strategy target antigen identification <NUMBER> conventional approaches menb vaccine development ineffective <NUMBER> years capsular polysaccharidebased approach extremely successful major meningococcal serogroups cannot used strain menb capsular polysaccharide identical widely distributed human carbohydrate α<NUMBER>nacetyl neuraminic acid polysialic acid condition makes polysaccharide poor immunogen humans also potential generator autoantibodies hand proteinbased approach developed using surfaceexposed proteins contained outer membrane vesicles omvs shown efficacy clinical trials homologous strains especially children five years age high sequence variability major protein antigens <NUMBER> using reverse vaccinology dna fragments screened computer analysis n meningitidis sequencing project progress screening aimed select proteins predicted surface bacterium homologies known bacterial factors involved pathogenesis virulence clearance cytoplasmic proteins known neisseria antigens <NUMBER> genes predicted code surfaceexposed membraneassociated proteins recognized successful cloning e coli expression achieved <NUMBER> proteins purified tested localization immunogenicity protective efficacy animal models <NUMBER> proteins found surface exposed <NUMBER> able induce complementmediated bactericidal antibody response convincing indication capability inducing protective immunity addition test appropriateness proteins candidate antigens conferring protection heterologous strains proteins evaluated gene presence phase variation sequence conservation panel genetically diverse menb strains representative global diversity natural n meningitidis population selected antigens able induce crossprotection heterologous strains demonstrating new antigens good candidates clinical development vaccine menb <NUMBER> <NUMBER> impressive notice within <NUMBER> months genomic approach allowed discovery potential vaccine candidates previous <NUMBER> years conventional research success menb project together availability increasing number genomic sequences faster faster development bioinformatics tools encouraged application reverse vaccinology approach many pathogens nowadays approach widely used develop vaccine candidates pathogens conventional approaches failed far potential genomic approach extensive could used bacteria also viruses parasites despite successes conjugate vaccine streptococcus pneumoniae see absence cross protection different serotypes threat serotype replacement strains represented vaccine composition makes unsuitable universal use <NUMBER> identify appropriate vaccine candidates whole genome sequence pneumoniae scanned <NUMBER> potential orfs significant homology surface proteins virulence factors bacteria identified <NUMBER> <NUMBER> proteins effectively expressed e coli used immunize mice six able confer protection pneumococcal challenge mouse sepsis model flow cytometry confirmed surface localization new proteins furthermore six protective antigens showed high degree cross reactivity majority capsular antigens expressed vivo immunogenic human infection providing good base development improved vaccines pneumoniae streptococcus agalactiae group b streptococcus leading cause bacterial sepsis pneumonia meningitis neonates us europe <NUMBER> pneumoniae capsular polysaccharide major protective antigen least nine different seroptypes exist little cross protection <NUMBER> therefore proteinbased vaccine required overcome serotype differences complete genome serotype v strain agalactiae determined analyzed <NUMBER> genome predicted code <NUMBER> orfs <NUMBER> predicted exposed surface bacteria approximately <NUMBER> orfs successfully expressed e coli used immunize mice using sera elisa flow cytometric analysis intact bacteria demonstrated <NUMBER> proteins fact measurably expressed surface bacterium new antigens evaluated vitro vivo models capacity protect invasive infection group b streptococcus identify vaccine candidates staphylococcus aureus approach based genomic peptide libraries wellcharacterized human sera developed <NUMBER> aureus peptides displayed surface e coli via fusion one two outer membrane proteins lamb fhua probed sera selected high antibody titers opsonic activity exhaustive screening two different peptide expression libraries application macs technology magnetic cell sorting enabled profile antigens expressed vivo able elicit immune response humans identified total <NUMBER> antigenic proteins identified predicted secreted located surface bacterium antibodybinding sites mapped antigens represent promising vaccine candidates evaluation process similar one used develop vaccine menb used also porphyromonas gingivalis pathogen implicated etiology chronic adult periodontitis <NUMBER> genomic sequence <NUMBER> genes <NUMBER> selected using series bioinformatics tools selected genes cloned expression e coli screened western blotting using sera human periodontitis patients animal antisera subset <NUMBER> recombinant proteins purified used immunize mice subsequently challenged live bacteria subcutaneous abscess model two recombinant proteins showing homology pseudomonas sp oprf protein demonstrated significant protection animal model therefore could represent potential vaccine candidates <NUMBER> chlamydia pneumoniae obligate intracellular parasite complex biphasic lifecycle extracellular infectious phase characterized sporelike form elementary bodies eb intracellular replicating stage characterized reticular bodies rb pathogen common cause communityacquired acute respiratory infections recently also associated atherosclerotic cardiovascular disease <NUMBER> technical difficulties working c pneumoniae absence reliable tools genetic manipulation much known cell surface composition eb define surface protein organization c pneumoniae systematic genomic proteomic approach used <NUMBER> approach based six main experimental steps silico analysis c pneumoniae genome sequence identify genes potentially encoding surface proteins including outer inner membrane periplasmic proteins ii cloning expression purification selected candidates iii use purified antigens generate mouse immune sera iv analysis sera specificity western blotting total eb extracts v assessment antigen localization facs analysis whole ebs vi identification facspositive antigens bidimensional electrophoresis <NUMBER>de maps c pneumoniae eb proteins results systematic genomeproteome approach represent first successful attempt define surface protein organization c pneumoniae raise possibility find suitable candidates purified vaccine currently licensed anthrax vaccines developed <NUMBER>s based cellfree filtrates containing mainly protective antigen pa pa common cellbinding domain capable interacting two different domains lethal edema factors elicit cell damage vaccines originally licensed selected veterinary personnel textile workers abattoir workers widely used first time us military <NUMBER> desert storm campaign however extended use raised issues controversies regarding safety efficacy unsatisfactory dosing regimen vaccine requires <NUMBER>dose series injections annual boosters <NUMBER> <NUMBER> therefore identification novel antigens essential development secondgeneration b anthracis vaccines orf products similar proteins involved bacterial pathogenesis secreted surface exposed proteins focus research using functional genomic analysis <NUMBER> candidates selected case simple method relied vitro translation linear fulllength dna selected orfs used polypeptides obtained vitro evaluated immunogenicity analysis reactivity hyperimmune antib anthracis antisera combination bioinformatic genomic analysis efficient fast screening facilitated identification unknown antigenic proteins three appear similar immunogenic pa new proteins could represent parts secondgeneration anthrax vaccine <NUMBER> old plague vaccines based killed whole cell preparations <NUMBER> <NUMBER> although appeared effective endemic plague considered protective respiratory plague form concern case biological attack moreover vaccines high rates reactions systemic local especially successive doses suffer short duration protection requiring biannual boosters liveattenuated vaccine ev<NUMBER> strain also existed vaccine seemed effective retained virulence countries considered suitable human use search novel attenuated vaccine candidates use pestis signaturetagged mutagenesis stm strategy used <NUMBER> library tagged mutants virulent pestis kimberley<NUMBER> strain generated screening <NUMBER> mutants two consecutive cycles resulted selection <NUMBER> mutant strains characterization phenotypes genotypes selected mutants led identification virulenceassociated genes coding factors involved global bacterial physiology eg purh purk dnae grea hypothetical polypeptides well virulence regulator gene lcrf one avirulent mutant strains found disrupted pcm locus presumably involved bacterial response environmental stress kimberley<NUMBER>pcm mutant superior ev<NUMBER> live vaccine strain animal model mice infected subcutaneously virulent pestis kimberley<NUMBER> strain either mutant induced <NUMBER>to <NUMBER>foldhigher antibody titers protective v f<NUMBER> antigens conferred efficacious protective immunity results indicate mutants mutations pcm locus serve platform generation novel live vaccine promise inducing efficacious protective immunity virulent pestis strains previously suggested mutants sars epidemic first infectious disease outbreak fully benefit revolutionary technologies postgenomic era thanks unprecedented collaboration effort scientists many countries coordinated including clinical epidemiological laboratory investigations within <NUMBER> days issue global alert causative agent new disease discovered <NUMBER> less month initial identification new coronavirus called sarscov infectious agent sars two independent genome sequences virus obtained <NUMBER> <NUMBER> within three months genome sequences <NUMBER> independent clinical isolates made available genbank database rapid availability genomic sequence new virus important public health perspective giving prompt answers number critical questions clear agent natural laboratoryfabricated coronavirus diagnostic kits set possible drug vaccine targets identified today vaccines based killed virus already tested preclinical even clinical trials efficacy needs shown moreover addition traditional approach number newer strategies used include subunit vaccines containing recombinant spike protein expressed mammalian cells yeast either alone combination sarscov antigens alternatively antigens could delivered dna immunization nonreplicating viruses viral vectors based adenovirus canarypox modified vaccinia virus ankara mva alphavirus particular development nonreplicating coronaviruslike particles mimic structure native virions could prove promising search successful vaccine display large repertoire antigenic sites discontinuous epitopes <NUMBER> crucial remember none approaches would possible way speed without knowledge complete genomic sequence virus make comparison last time mankind faced appearance new pandemic early <NUMBER>s appearance hiv time <NUMBER> years ago took two years identify etiologic agent infection safe effective vaccine still lacking edward jenner gave birth concept vaccination little could know <NUMBER> years mankind would still battling emerging reemerging infectious diseases however contemporary society lucky science constantly offering effective tools combat control infectious diseases question whether many social political cultural economic barriers still exist visàvis vaccines eventually overcome thus recognizing real value vaccination first cases atypical pneumonia appeared fosham guangdong province china november <NUMBER> february <NUMBER> <NUMBER> cases severe acute respiratory syndrome sars reported guangdong province china contained public health isolation quarantine measures epidemic spread <NUMBER> countries <NUMBER> continents affected <NUMBER> people <NUMBER> <NUMBER> sars infection causes respiratory disease organ systems including gastrointestinal tract also severely affected elderly immunocompromised severely affected suffer greater morbidity mortality july <NUMBER> <NUMBER> deaths attributed infection virus <NUMBER> based serologic data samples collected prior outbreak retrospectively analyzed <NUMBER> individuals working animal trade seropositive history illness <NUMBER> indicating sars may either extremely mild asymptomatic cases severe acute respiratory syndrome virus sarscov enveloped rna virus member coronaviridae family also includes human pathogens typically cause mild upper respiratory infections coronaviruses enveloped viruses positivesense singlestranded rna genome sarscoronavirus sarscov unknown prior <NUMBER> outbreak disease may mutant human coronavirus acquired new virulence factors allowing infection human population <NUMBER> genomic rna encased nucleocapsid n protein surrounded lipid membrane containing spike glycoprotein membrane glycoprotein envelope e proteins oligomers glycoprotein form characteristic spike protrudes membrane <NUMBER> <NUMBER> viral entry host target cells appears mediated sarscov spike glycoprotein dependent angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional receptor <NUMBER> addition responsible attachment cellular receptor contains epitopes viral neutralization tcell responses <NUMBER> studies performed vrc investigators colleagues shown importance sglycoprotein coronavirus assembly trafficking <NUMBER> studies demonstrated neutralization pseudovirions expressing protein serum convalescent sars patients ability dna plasmid vaccine described induce protective immunity eliciting cellular humoral immunity sarscov animal models including generation neutralizing antibodies nabs measured plaquereduction assay <NUMBER> <NUMBER> studies performed beijing china serum patients sars using neutralization assay pseudotyped lentiviral vector bearing protein indicated nabs first detected <NUMBER> days onset symptoms peaked <NUMBER> days sustained <NUMBER> days <NUMBER> nature spread severity illness prompted widespread attempts identify understand disease cause sars determined novel coronavirus virus fully sequenced may <NUMBER> <NUMBER> <NUMBER> rapid identification sequencing virus allowed scientists begin developing candidate vaccines quickly currently licensed human sars vaccines one vaccine clinical trial reported evaluating wholeinactivated sars vaccine candidate developed sinovac biotech co ltd china <NUMBER> current report describes results candidate sars dna vaccine evaluated phase clinical trial healthy adults initiated within <NUMBER> months sequence virus initially published vrc <NUMBER> protocol phase openlabel study safety tolerability immunogenicity sars recombinant plasmid dna vaccine encoding sars spike glycoprotein healthy adult subjects singlesite study conducted vaccine research center vrc national institute allergy infectious diseases niaid national institutes health nih bethesda maryland experimental guidelines us department health human services followed conduct clinical research protocol approved niaid institutional review board ten subjects ages <NUMBER> enrolled study december <NUMBER> <NUMBER> may <NUMBER> <NUMBER> three injections vaccine dose <NUMBER> mg administered study days <NUMBER> <NUMBER> <NUMBER> <NUMBER> mg dose lateral deltoid muscle via biojector <NUMBER> ® needlefree injection management system™ dose route studied trial based preclinical data data clinical trials vrc dna vaccines pathogens <NUMBER> <NUMBER> <NUMBER> subject safety monitored evaluating laboratory clinical findings adverse reactions study visits adverse events coded medical dictionary regulatory activities meddra solicited symptoms local systemic reactogenicity including pain redness swelling myalgia malaise headache chills nausea temperature collected subject self report <NUMBER>day diary cards following vaccination subjects followed total <NUMBER> weeks study visits completed december <NUMBER> vaccine vrcsrsdna<NUMBER>vp composed single closed circular plasmid dna macromolecule vrc<NUMBER> produced bacterial cell cultures containing kanamycin selection medium bacterial cell growth dependent upon expression kanamycin resistance protein encoded portion plasmid dna following growth bacterial cells harboring plasmid plasmid dna purified vaccine contain cellular viral components plasmid encodes single protein cloned expression vector cmvr previously described <NUMBER> evaluated clinical trials candidate hiv ebola dna vaccines <NUMBER> <NUMBER> plasmid constructed produce deletion mutant sars spike glycoprotein urbani strain genbank ay<NUMBER> cytoplasmic domain truncated sδcd <NUMBER> vrcsrsdna<NUMBER>vp vaccine based upon cdna expression sars spike glycoprotein urbani strain codonmodification optimize expression human cells expresses full sequence except deletion last <NUMBER> coohterminal amino acids vaccine clinical trial prepared current good manufacturing practice cgmp conditions vical inc la jolla ca vaccine met lot release specifications prior administration dna vaccine manufactured <NUMBER> mgml concentration phosphatebuffered saline pbs vrc plasmid <NUMBER> expressed <NUMBER> cells purified major protein product duplicate wells serial dilutions volunteer sera incubated <NUMBER> hours <NUMBER> ° c sars spike antigencoated blocked plates followed biotinconjugated antibody <NUMBER> minutes room temperature streptavidinehorseradish peroxidase <NUMBER> minutes room temperature tetramethylbenzidine tmb substrate <NUMBER> minutes room temperature color development stopped addition <NUMBER>m sulfuric acid plates read within <NUMBER> minutes <NUMBER> nm molecular devices spectramax <NUMBER>plus elisa plate reader sunnyvale ca mean optical density od dilution corrected mean od dilution preimmunization sample endpoint titers volunteer established last dilution preimmunization corrected od <NUMBER> subject samples assessed presence vaccineinduced neutralizing antibody two assays first luciferase reporter pseudotyped lentiviralbased assay serial dilutions sera incubated hiv<NUMBER> based luciferase reporter virus particles expressing sars spike glycoprotein produced <NUMBER>t cells previously described <NUMBER> target cells human renal adenocarcinoma cell line <NUMBER>o obtained atcc inhibitory concentration <NUMBER> ic <NUMBER> reported reciprocal dilution analysis performed using previously described methods <NUMBER> secondly twofold dilutions heatinactivated serum assayed quadruplicate wells <NUMBER>well plate using starting dilution <NUMBER> microneutralization assay measured antibodies neutralized infectivity <NUMBER> tcid <NUMBER> sarscov vero cell monolayers presence viral cytopathic effect read days <NUMBER> <NUMBER> dilution serum completely prevented cytopathic effect <NUMBER> wells calculated reedmuench formula <NUMBER> elispot performed subject samples baseline weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previously described <NUMBER> cells stimulated overnight vaccine insert specific peptide pools <NUMBER> × <NUMBER> <NUMBER> cells per well results expressed mean spotforming cells sfc per million pbmc cd<NUMBER> cd<NUMBER> tcell responses measured ics baseline weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previously described <NUMBER> cells stimulated vaccine insert specific peptide pools cells permeabilized washed stained directly conjugated antihuman cd<NUMBER> cd<NUMBER> cd<NUMBER> ifnγ il<NUMBER> antibodies assessed cd<NUMBER> cd<NUMBER> cd<NUMBER> ifnγil<NUMBER> expression facscalibur flow cytometer bdis assays treated binary respondersnonresponders use usual <NUMBER> central exact confidence intervals binomial rates <NUMBER> confident true response rates antibody assays larger lower limit calculations done r version <NUMBER> positive tcell response ics elispot data based composite criteria previously described four published studies candidate vaccines <NUMBER> <NUMBER> <NUMBER> sas version <NUMBER> sas institute splus version <NUMBER> insightful used analyses ten healthy adult subjects ages <NUMBER> <NUMBER> years mean age <NUMBER> enrolled study subject population consisted <NUMBER> male predominantly white <NUMBER> nonhispanic latino <NUMBER> subjects mean bmi <NUMBER> range <NUMBER> <NUMBER> subjects educational level college higher <NUMBER> advanced degree demographic data regarding subject gender age raceethnicity body mass index bmi educational level time enrollment shown table <NUMBER> data collected subject diary cards show <NUMBER> subjects <NUMBER> experienced least one mild injection site symptom following vaccination paintenderness swelling redness paintenderness injection site common complaint five ten <NUMBER> subjects reported least one mild systemic symptom myalgia malaise headache chills fever following vaccination among solicited symptoms none subjects reported nausea none subjects reported moderate severe symptoms following vaccination table <NUMBER> subjects followed <NUMBER> weeks safety immune response nine <NUMBER> subjects completed three dose vaccination schedule one subject subject g received oral glucocorticoid treat poison ivy contact dermatitis second vaccination consequently withdrawn vaccination schedule serious adverse events grade <NUMBER> <NUMBER> severe lifethreatening adverse events overall study vaccinations welltolerated found safe healthy subjects ages <NUMBER> years sars spike glycoprotein specific antibody detected elisa <NUMBER> <NUMBER> <NUMBER> subjects one timepoints table <NUMBER> neutralization detected microneutralization plaquereduction assay sars specific neutralizing antibody assessed pseudotyped lentiviral vector reporter neutralization assay detected <NUMBER> <NUMBER> <NUMBER> subjects one timepoints figure <NUMBER> neutralizing antibody response peaked week <NUMBER> <NUMBER> <NUMBER> subjects remaining positive week <NUMBER> pseudovirus neutralization assays highly sensitive possible reason discrepancy results two neutralization assays sars spike glycoprotein specific cd<NUMBER> cd<NUMBER> cell responses induced vaccine assessed ics elispot cd<NUMBER> cell responses sars cov spike antigen detected ics subjects <NUMBER> week <NUMBER> <NUMBER> cd<NUMBER> cell responses detected <NUMBER> <NUMBER> <NUMBER> subjects cd<NUMBER> cell responses greater frequency magnitude cd<NUMBER> responses figure <NUMBER> cd<NUMBER> cd<NUMBER> cell responses assessed elispot detected <NUMBER> <NUMBER> <NUMBER> subjects course trial <NUMBER> positive week <NUMBER> <NUMBER> weeks <NUMBER> nd dose vaccine peak cell response occurred week <NUMBER> <NUMBER> present sustained throughout <NUMBER> week trial sars represents recently emergent infectious disease caused severe illness global panic economic disruption rapid response <NUMBER> sars outbreak defines quintessential response public health biomedical communities newly emerging infectious disease ability quickly identify describe characterize develop countermeasures including vaccines future emerging infectious pathogens critical maintain public health economic stability global response sars epidemic provided insight education public health experts scientists utilized optimally respond future emerging infections including viruses avian influenza response <NUMBER> sars infections several laboratories rapidly developed vaccine candidates including sars candidate dna vaccine described report preclinical evaluation safety demonstration efficacy lethal murine challenge model <NUMBER> phase human trial reported initiated within <NUMBER> months similar candidate dna vaccines hiv ebola virus west nile virus wnv previously evaluated safe shown elicit vaccineinduced cellular humoral immune responses including neutralizing antibody responses wnv vaccine <NUMBER> like previously evaluated vrc dna vaccines sars vaccine induced vaccinespecific cell antibody responses including neutralizing antibody sars spike glycoprotein sensitive pseudotyped lentiviral reporter assay studies sars patients antibodies sars cov spike membrane envelope nucleocapsid proteins present assessed elisa neutralizing antibody elicited spike glycoprotein <NUMBER> <NUMBER> <NUMBER> openlabel phase clinical trial vrc sars dna vaccine evaluated safe well tolerated vaccine immunogenic sars spike glycoproteinspecific cell responses induced subjects neutralizing antibody responses detected <NUMBER> <NUMBER> subjects sars spike proteinspecific cellular responses primarily cd<NUMBER> cells minority subjects detectable sars spike proteinspecific cd<NUMBER> cell responses cd<NUMBER> cell response important effector mechanism viral clearance induction population goal genebased vaccines prior vrc clinical trials dna vaccines hiv ebola west nile virus vaccinespecific cd<NUMBER> cell responses detected nearly subjects frequency measurable cd<NUMBER> cell responses varied <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> aspect dna vaccineinduced immunity require additional development investigational inactivated sars vaccine candidate developed sinovac biotech co ltd found immunogenic phase <NUMBER> study conducted china <NUMBER> thirtysix healthy subjects received <NUMBER> doses inactivated sarscov vaccine either <NUMBER> <NUMBER> sarscov units placebo control vaccine recipients seroconverted day <NUMBER> postvaccination geometric mean titer nab measured plaquereduction format peaked <NUMBER> weeks following second immunization decreased <NUMBER> weeks similar kinetics observed sars dna vaccinated subjects described report vaccineinduced cellular immune responses reported studies recovered sars patients demonstrated longlived effectorcentral memory cell responses sars sprotein <NUMBER> well sars viral proteins <NUMBER> <NUMBER> <NUMBER> cd<NUMBER> cells thought play important role sars immunity <NUMBER> safety data immune responses along data previously reported trials evaluating similar dna vaccines pathogens including ebola wnv hiv indicate sars dna vaccine considered expanded clinical evaluations potential future sars outbreaks <NUMBER> <NUMBER> <NUMBER> <NUMBER> alone primeboost combination vectors sars dna vaccine induced neutralizing antibodies strongly associated recovery natural sars infection <NUMBER> well cellular immune responses may important component sars immunity neutralization activity detected sensitive pseudotyped lentiviral assay less sensitive microneutralization plaquereduction assay sars cov contained careful surveillance public health measures licensure vaccine likely require use animal rule models reflect pathogenesis humans identification validation immune correlates vaccine also demonstrates feasibility rapid manufacturing regulatory review provides additional safety immunogenicity data support concept dna vaccination potential vaccine platform future emerging infectious diseases magnitude frequency neutralizing antibody response individual subjects designated letters aj sorted ascending age xaxis ic<NUMBER> inhibitory concentration <NUMBER> reciprocal titer represented yaxis time course study shown subject week <NUMBER> yellow bars week <NUMBER> green bars week <NUMBER> blue bars week <NUMBER> orange bars vaccinations administered weeks <NUMBER> <NUMBER> <NUMBER> subject g received <NUMBER> <NUMBER> vaccinations magnitude frequency cd<NUMBER> cd<NUMBER> cell responses ics elispot analysis specific time points throughout study magnitude response represented upper graph percent positive cd<NUMBER> red bars cd<NUMBER> cells green bars ics spotforming colonies sfc elispot blue bars horizontal black bars represent mean sample considered positive thresholds indicated dashed lines separate positivity criteria cd<NUMBER> cd<NUMBER> ics elispot developed validated overlapping peptidebased stimulations frequency response represented percent responders lower graph weeks enrollment shown xaxis applicable upper lower graphs vaccinations administered weeks <NUMBER> <NUMBER> <NUMBER> week <NUMBER> <NUMBER> nd <NUMBER> nd b <NUMBER> nd <NUMBER> nd c <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> e <NUMBER> <NUMBER> <NUMBER> <NUMBER> f <NUMBER> <NUMBER> <NUMBER> <NUMBER> g <NUMBER> <NUMBER> <NUMBER> <NUMBER> h <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> j <NUMBER> <NUMBER> <NUMBER> <NUMBER> done nd subject negative elisa week <NUMBER> elisa performed timepoints subject g received <NUMBER> <NUMBER> vaccinations vaccine author manuscript available pmc <NUMBER> november <NUMBER> first cases atypical pneumonia appeared fosham guangdong province china november <NUMBER> february <NUMBER> <NUMBER> cases severe acute respiratory syndrome sars reported guangdong province china contained public health isolation quarantine measures epidemic spread <NUMBER> countries <NUMBER> continents affected <NUMBER> people <NUMBER> <NUMBER> sars infection causes respiratory disease organ systems including gastrointestinal tract also severely affected elderly immunocompromised severely affected suffer greater morbidity mortality july <NUMBER> <NUMBER> deaths attributed infection virus <NUMBER> based serologic data samples collected prior outbreak retrospectively analyzed <NUMBER> individuals working animal trade seropositive history illness <NUMBER> indicating sars may either extremely mild asymptomatic cases severe acute respiratory syndrome virus sarscov enveloped rna virus member coronaviridae family also includes human pathogens typically cause mild upper respiratory infections coronaviruses enveloped viruses positivesense singlestranded rna genome sarscoronavirus sarscov unknown prior <NUMBER> outbreak disease may mutant human coronavirus acquired new virulence factors allowing infection human population <NUMBER> genomic rna encased nucleocapsid n protein surrounded lipid membrane containing spike glycoprotein membrane glycoprotein envelope e proteins oligomers sglycoprotein form characteristic spike protrudes membrane <NUMBER> <NUMBER> viral entry host target cells appears <NUMBER> mediated sarscov spike glycoprotein dependent angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional receptor <NUMBER> addition responsible attachment cellular receptor contains epitopes viral neutralization tcell responses <NUMBER> studies performed vrc investigators colleagues shown importance sglycoprotein coronavirus assembly trafficking <NUMBER> studies demonstrated neutralization pseudovirions expressing protein serum convalescent sars patients ability dna plasmid vaccine described induce protective immunity eliciting cellular humoral immunity sarscov animal models including generation neutralizing antibodies nabs measured plaquereduction assay <NUMBER> <NUMBER> studies performed beijing china serum patients sars using neutralization assay pseudotyped lentiviral vector bearing protein indicated nabs first detected <NUMBER> days onset symptoms peaked <NUMBER> days sustained <NUMBER> days <NUMBER> nature spread severity illness prompted widespread attempts identify understand disease cause sars determined novel coronavirus virus fully sequenced may <NUMBER> <NUMBER> <NUMBER> rapid identification sequencing virus allowed scientists begin developing candidate vaccines quickly currently licensed human sars vaccines one vaccine clinical trial reported evaluating wholeinactivated sars vaccine candidate developed sinovac biotech co ltd china <NUMBER> current report describes results candidate sars dna vaccine evaluated phase clinical trial healthy adults initiated within <NUMBER> months sequence virus initially published vrc <NUMBER> protocol phase openlabel study safety tolerability immunogenicity sars recombinant plasmid dna vaccine encoding sars spike glycoprotein healthy adult subjects singlesite study conducted vaccine research center vrc national institute allergy infectious diseases niaid national institutes health nih bethesda maryland experimental guidelines us department health human services followed conduct clinical research protocol approved niaid institutional review board ten subjects ages <NUMBER> enrolled study december <NUMBER> <NUMBER> may <NUMBER> <NUMBER> three injections vaccine dose <NUMBER> mg administered study days <NUMBER> <NUMBER> <NUMBER> <NUMBER> mg dose lateral deltoid muscle via biojector <NUMBER> ® needlefree injection management system tm dose route studied trial based preclinical data data clinical trials vrc dna vaccines pathogens <NUMBER> <NUMBER> <NUMBER> subject safety monitored evaluating laboratory clinical findings adverse reactions study visits adverse events coded medical dictionary regulatory activities meddra solicited symptoms local systemic reactogenicity including pain redness swelling myalgia malaise headache chills nausea temperature collected subject self report <NUMBER>day diary cards following vaccination subjects followed total <NUMBER> weeks study visits completed december <NUMBER> vaccine vrcsrsdna<NUMBER>vp composed single closed circular plasmid dna macromolecule vrc<NUMBER> produced bacterial cell cultures containing kanamycin selection medium bacterial cell growth dependent upon expression kanamycin resistance protein encoded portion plasmid dna following growth bacterial cells harboring plasmid plasmid dna purified vaccine contain cellular viral components plasmid encodes single protein cloned expression vector cmvr previously described <NUMBER> evaluated clinical trials candidate hiv ebola dna vaccines <NUMBER> <NUMBER> plasmid constructed produce deletion mutant sars spike glycoprotein urbani strain genbank ay<NUMBER> cytoplasmic domain truncated cd <NUMBER> vrcsrsdna<NUMBER>vp vaccine based upon cdna expression sars spike glycoprotein urbani strain codonmodification optimize expression human cells expresses full sequence except deletion last <NUMBER> coohterminal amino acids vaccine clinical trial prepared current good manufacturing practice cgmp conditions vical inc la jolla ca vaccine met lot release specifications prior administration dna vaccine manufactured <NUMBER> mgml concentration phosphatebuffered saline pbs vrc plasmid <NUMBER> expressed <NUMBER> cells purified major protein product duplicate wells serial dilutions volunteer sera incubated <NUMBER> h <NUMBER> • c sars spike antigencoatedblocked plates followed biotinconjugated antibody <NUMBER> min room temperature streptavidinehorseradish peroxidase <NUMBER> min room temperature tetramethylbenzidine tmb substrate <NUMBER> min room temperature color development stopped addition <NUMBER> sulfuric acid plates read within <NUMBER> min <NUMBER> nm molecular devices spectramax <NUMBER>plus elisa plate reader sunnyvale ca mean optical density od dilution corrected mean od dilution preimmunization sample endpoint titers volunteer established last dilution preimmunization corrected od <NUMBER> subject samples assessed presence vaccineinduced neutralizing antibody two assays first luciferase reporter pseudotyped lentiviralbased assay serial dilutions sera incubated hiv<NUMBER> based luciferase reporter virus particles expressing sars spike glycoprotein produced <NUMBER> cells previously described <NUMBER> target cells human renal adenocarcinoma cell line <NUMBER>o obtained atcc inhibitory concentration <NUMBER> ic <NUMBER> reported reciprocal dilution analysis performed using previously described methods <NUMBER> secondly twofold dilutions heatinactivated serum assayed quadruplicate wells <NUMBER>well plate using starting dilution <NUMBER> microneutralization assay measured antibodies neutralized infectivity <NUMBER> tcid <NUMBER> sarscov vero cell monolayers presence viral cytopathic effect read days <NUMBER> <NUMBER> dilution serum completely prevented cytopathic effect <NUMBER> wells calculated reedmuench formula <NUMBER> elispot performed subject samples baseline weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previously described <NUMBER> cells stimulated overnight vaccine insert specific peptide pools <NUMBER> × <NUMBER> <NUMBER> cells per well results expressed mean spotforming cells sfc per million pbmc cd<NUMBER> cd<NUMBER> tcell responses measured ics baseline weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previously described <NUMBER> cells stimulated vaccine insert specific peptide pools cells permeabilized washed stained directly conjugated antihuman cd<NUMBER> cd<NUMBER> cd<NUMBER> ifn␥ il<NUMBER> antibodies assessed cd<NUMBER> cd<NUMBER> cd<NUMBER> ifn␥il<NUMBER> expression facscalibur flow cytometer bdis assays treated binary respondersnonresponders use usual <NUMBER> central exact confidence intervals binomial rates <NUMBER> confident true response rates antibody assays larger lower limit calculations done r version <NUMBER> positive tcell response ics elispot data based composite criteria previously described four published studies candidate vaccines <NUMBER> <NUMBER> <NUMBER> sas version <NUMBER> sas institute splus version <NUMBER> insightful used analyses ten healthy adult subjects ages <NUMBER> years mean age <NUMBER> enrolled study subject population consisted <NUMBER> male predominantly white <NUMBER> nonhispaniclatino <NUMBER> subjects mean bmi <NUMBER> range <NUMBER> subjects educational level college higher <NUMBER> advanced degree demographic data regarding subject gender age raceethnicity body mass index bmi educational level time enrollment shown table <NUMBER> data collected subject diary cards show <NUMBER> subjects <NUMBER> experienced least one mild injection site symptom fol lowing vaccination paintenderness swelling redness paintenderness injection site common complaint five ten <NUMBER> subjects reported least one mild systemic symptom myalgia malaise headache chills fever following vaccination among solicited symptoms none subjects reported nausea none subjects reported moderate severe symptoms following vaccination table <NUMBER> subjects followed <NUMBER> weeks safety immune response nine <NUMBER> subjects completed <NUMBER> dose vaccination schedule one subject subject g received oral glucocorticoid treat poison ivy contact dermatitis second vaccination maximum local systemic b reactogenicity local injection site reactions recorded clinicians <NUMBER> min postinjection recorded selfassessments home subjects <NUMBER>day diary card systemic reactions recorded selfassessments home subjects <NUMBER>day diary card following injection reports severe local symptoms following vaccination reports severe systemic symptoms following vaccination b consequently withdrawn vaccination schedule serious adverse events grade <NUMBER> <NUMBER> severe lifethreatening adverse events overall study vaccinations well tolerated found safe healthy subjects ages <NUMBER> years sars spike glycoprotein specific antibody detected elisa <NUMBER> <NUMBER> <NUMBER> subjects one timepoints table <NUMBER> neutralization detected microneutralization plaque table <NUMBER> sars specific antibody titer assessed elisa week <NUMBER> week <NUMBER> week <NUMBER> week <NUMBER> <NUMBER> nd <NUMBER> nd b <NUMBER> nd <NUMBER> nd c <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> e <NUMBER> <NUMBER> <NUMBER> <NUMBER> f <NUMBER> <NUMBER> <NUMBER> <NUMBER> g <NUMBER> <NUMBER> <NUMBER> <NUMBER> h <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> j <NUMBER> <NUMBER> <NUMBER> <NUMBER> done nd subject negative elisa week <NUMBER> elisa performed timepoints subject g received <NUMBER> <NUMBER> vaccinations reduction assay sars specific neutralizing antibody assessed pseudotyped lentiviral vector reporter neutralization assay detected <NUMBER> <NUMBER> <NUMBER> subjects one timepoints fig <NUMBER> neutralizing antibody response peaked week <NUMBER> <NUMBER> <NUMBER> subjects remaining positive week <NUMBER> pseudovirus neutralization assays highly sensitive possible reason discrepancy results two neutralization assays sars spike glycoprotein specific cd<NUMBER> cd<NUMBER> tcell responses induced vaccine assessed ics elispot cd<NUMBER> tcell responses sars cov spike antigen detected ics subjects <NUMBER> week <NUMBER> <NUMBER> cd<NUMBER> tcell responses detected <NUMBER> <NUMBER> <NUMBER> subjects cd<NUMBER> tcell responses greater frequency magnitude cd<NUMBER> responses fig <NUMBER> cd<NUMBER> cd<NUMBER> tcell responses assessed elispot detected <NUMBER> <NUMBER> <NUMBER> subjects course trial <NUMBER> positive week <NUMBER> <NUMBER> weeks <NUMBER>nd dose vaccine peak tcell response occurred week <NUMBER> <NUMBER> present sustained throughout <NUMBER>week trial sars represents recently emergent infectious disease caused severe illness global panic economic disruption rapid response <NUMBER> sars outbreak defines quintessential response public health biomedical communities newly emerging infectious disease ability quickly identify describe characterize develop countermeasures including vaccines future emerging infectious pathogens critical maintain public health economic stability global response sars epidemic provided insight education public health experts scientists utilized optimally respond future emerging infections including viruses avian influenza response <NUMBER> sars infections several laboratories rapidly developed vaccine candidates including sars candidate dna vaccine described report preclinical evaluation safety demonstration efficacy lethal murine challenge model <NUMBER> phase human trial reported initiated within <NUMBER> months similar candidate dna vaccines hiv ebola virus west nile virus wnv previously evaluated safe shown elicit vaccineinduced cellular humoral immune responses including neutralizing antibody responses wnv vaccine <NUMBER> like previously evaluated vrc dna vaccines sars vaccine induced vaccinespecific tcell antibody responses including neutralizing antibody sars spike glycoprotein sensitive pseudotyped lentiviral reporter assay studies sars patients antibodies sars cov spike membrane envelope nucleocapsid proteins present assessed elisa neutralizing antibody elicited spike glycoprotein <NUMBER> <NUMBER> <NUMBER> openlabel phase clinical trial vrc sars dna vaccine evaluated safe well tolerated vaccine immunogenic sars spike glycoproteinspecific tcell responses induced subjects neutralizing antibody responses detected <NUMBER> <NUMBER> subjects sars spike proteinspecific cellular responses primarily cd<NUMBER> cells minority subjects detectable sars spike proteinspecific cd<NUMBER> tcell responses cd<NUMBER> tcell response important effector mechanism viral clearance induction population goal genebased vaccines prior vrc clinical trials dna vaccines hiv ebola west nile virus vaccinespecific cd<NUMBER> tcell responses detected nearly subjects frequency measurable cd<NUMBER> tcell responses varied <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> aspect dna vaccineinduced immunity require additional development investigational inactivated sars vaccine candidate developed sinovac biotech co ltd found immunogenic phase <NUMBER> study conducted china <NUMBER> thirtysix healthy subjects received <NUMBER> doses inactivated sarscov vaccine either <NUMBER> <NUMBER> sarscov units placebo control vaccine recipients seroconverted day <NUMBER> postvaccination geometric mean titer nab measured plaquereduction format peaked <NUMBER> weeks following second immunization decreased <NUMBER> weeks similar kinetics observed sars dna vaccinated subjects described report vaccineinduced cellular immune responses reported studies recovered sars patients demonstrated longlived effectorcentral memory tcell responses sars sprotein <NUMBER> well sars viral proteins <NUMBER> <NUMBER> <NUMBER> cd<NUMBER> cells thought play important role sars immunity <NUMBER> safety data immune responses along data previously reported trials evaluating similar dna vaccines pathogens including ebola wnv hiv indicate sars dna vaccine considered expanded clinical evaluations potential future sars outbreaks <NUMBER> <NUMBER> <NUMBER> <NUMBER> alone primeboost combination vectors sars dna vaccine induced neutralizing antibodies strongly associated recovery natural sars infection <NUMBER> well cellular immune responses may important component sars immunity neutralization activity detected sensitive pseudotyped lentiviral assay less sensitive microneutralization plaquereduction assay sars cov contained careful surveillance public health measures licensure vaccine likely require use animal rule models reflect pathogenesis humans identification validation immune correlates vaccine also demonstrates feasibility rapid manufacturing regulatory review provides additional safety immunogenicity data support concept dna vaccination potential vaccine platform future emerging infectious diseases killed millions domestic fowl southeast asia tens millions culled also infected <NUMBER> persons killed <NUMBER> vietnam thailand cambodia indonesia china figure <NUMBER> <NUMBER> virus acquires ability transmit readily among humans influenza pandemic could ensue potential kill millions people <NUMBER> reports popular press <NUMBER> scientific literature <NUMBER> <NUMBER> <NUMBER> <NUMBER> raised alarms united states throughout world prospect pandemic influenza provides good reason concerned rather react panic however need determine done knowledge resources currently available prevent minimize impact potential pandemic time must ask improve infrastructure technology prepare future outbreaks unlike seasonal influenza epidemics caused viruses mutate small important ways year year process known antigenic drift pandemic influenza caused virus dramatically different circulated previously occur phenomenon referred antigenic shift <NUMBER> viruses cause pandemics people none prior immunologic exposure surface proteins viruses typical interpandemic influenza season people may residual immunity exposure previously circulating influenza strains vaccinations <NUMBER> example predominant circulating influenza virus northern hemisphere <NUMBER> influenza season h<NUMBER>n<NUMBER> virus drifted somewhat still fundamentally similar h<NUMBER>n<NUMBER> viruses circulated <NUMBER> previously nonetheless virus undergone antigenic drift cause illness death vaccination provides varying degrees protection severe illness death influenza complications <NUMBER> pandemic influenza however cause public health crisis people would immunologically naive new virus addition pandemic virus might inherently virulent interpandemic strains whereas seasonal influenza rarely threatens lives young otherwise healthy persons pandemic influenza frequently exacted serious toll healthy young adults <NUMBER> <NUMBER> december <NUMBER> outbreaks h<NUMBER>n<NUMBER> avian influenza viruses occurred domestic poultry populations least <NUMBER> countries asia eastern europe <NUMBER> h<NUMBER>n<NUMBER> viruses also isolated wild birds disease caused h<NUMBER>n<NUMBER> presence virus among thousands migratory wildfowl observed western china recently kazakhstan mongolia croatia raises possibility h<NUMBER>n<NUMBER> may spreading stronghold southeast asia migratory flyways <NUMBER> addition growing list avian species virus infected several mammalian species including tigers leopards pigs transmission among domestic cats observed laboratory <NUMBER> <NUMBER> <NUMBER> together findings suggest geographic host ranges h<NUMBER>n<NUMBER> viruses expanding true extent human h<NUMBER>n<NUMBER> infections precisely known preliminary reports suggest extent birdtohuman transmission may widespread originally thought <NUMBER> thus far virus acquired ability efficiently transmitted human human although recent report describes possible transmission h<NUMBER>n<NUMBER> within family thailand <NUMBER> h<NUMBER>n<NUMBER> avian influenza viruses circulating may likely candidates triggering influenza pandemic ongoing reports new cases humans <NUMBER> however avian influenza viruses also monitored potential infect cause disease humans figure <NUMBER> h<NUMBER>n<NUMBER> influenza virus although highly pathogenic circulated widely among birds hong kong china infected <NUMBER> children <NUMBER> <NUMBER> <NUMBER> child hong kong <NUMBER> <NUMBER> recovered five additional human infections h<NUMBER>n<NUMBER> viruses reported chinese literature <NUMBER> another avian influenza virus h<NUMBER>n<NUMBER> worrisome highly pathogenic birds appears readily transmissible human human <NUMBER> <NUMBER> large outbreak highly pathogenic avian influenza europe <NUMBER> h<NUMBER>n<NUMBER> virus detected least <NUMBER> poultry workers <NUMBER> family members contact chickens persons treated conjunctivitis influenzalike symptoms veterinarian handled infected chickens died pneumonia acute respiratory distress <NUMBER> <NUMBER> exception fatal case h<NUMBER>n<NUMBER> virus appeared relatively benign humans recent reports indicate h<NUMBER> influenza virus may circulating among chickens north korea <NUMBER> virus h<NUMBER>n<NUMBER> highly pathogenic humans acquire genetic capability enabled efficient transmissibility observed h<NUMBER>n<NUMBER> human h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> influenza viruses maintaining pathogenic potential deadly pandemic could ensue predicting preventing natural events could facilitate efficient transmission pandemic influenza virus among humans difficult however must prepared react quickly decisively event occur critical containment potential influenza pandemic diligent surveillance novel viruses human animal populations using appropriate diagnostics must also monitor viruses changes could signal increased virulence transmissibility equally important development production effective countermeasures vaccines antiviral drugs <NUMBER> vaccine development critical component pandemic influenza preparedness regard national institute allergy infectious diseases niaid national institutes health nih april <NUMBER> initiated phase clinical trial assess safety immunogenicity different doses inactivated h<NUMBER>n<NUMBER> influenza vaccine manufactured sanofi pasteur <NUMBER> study <NUMBER> healthy adult volunteers vaccinated <NUMBER> sites united states preliminary evaluation indicates vaccine safe able stimulate immune response may protective vaccine currently tested elderly testing children expected begin january <NUMBER> h<NUMBER>n<NUMBER> seed virus used make vaccine developed matter weeks use reverse genetics whereas traditional process genetic reassortment usually requires longer period time less predictable <NUMBER> additional pilot lots inactivated vaccine produced another manufacturer chiron corporation expected undergo testing early <NUMBER> chiron also produced <NUMBER> doses inactivated h<NUMBER>n<NUMBER> influenza vaccine formulated without mf<NUMBER> adjuvant clinical trials test safety immunogenicity inactivated h<NUMBER>n<NUMBER> vaccine underway promising preliminary results addition us department health human services hhs awarded several contracts pharmaceutical companies produce large quantities bulk h<NUMBER>n<NUMBER> vaccine part hhs pandemic influenza preparedness program contracts critical step toward pandemic influenza preparedness pave way manufacturer commence efficient largescale production pandemic vaccine needed hhs also awarded separate contract sanofi pasteur accelerate development cell culturebased technologies influenza vaccine production <NUMBER> addition intramural research program niaid generated live attenuated coldadapted h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> vaccine candidates proven protective mice h<NUMBER>n<NUMBER> vaccine candidate tested phase clinical trial data currently evaluated clinical evaluation h<NUMBER>n<NUMBER> vaccine planned spring <NUMBER> live attenuated vaccines especially promising generally trigger rapid robust immune responses compared induced inactivated vaccines live attenuated vaccines may also offer crossreactivity therefore greater protection different variants virus <NUMBER> concept extending vaccine supplies also pursued research suggested delivering vaccines intradermally might allow successful immunization less antigen <NUMBER> <NUMBER> <NUMBER> clinical trials compare intramuscular versus intradermal delivery h<NUMBER>n<NUMBER> vaccines began <NUMBER> preliminary safety data showed adverse effects immunogenicity data expected soon studies assess effect alum mf<NUMBER> adjuvants inactivated h<NUMBER>n<NUMBER> vaccine safety immunogenicity also anticipated research efforts focused medications treat influenza infection unfortunately currently circulating h<NUMBER>n<NUMBER> influenza viruses resistant <NUMBER> inexpensive antiinfluenza drugs rimantadine amantadine target viral m<NUMBER> protein newer drugs oseltamivir phosphate zanamivir target influenza neuraminidase protein appear effective current h<NUMBER>n<NUMBER> strains <NUMBER> hhs centers disease control prevention begun developing stockpile antiinfluenza drugs includes oseltamivir phosphate zanamivir rimantadine future use pandemic influenza occur numerous projects way identify novel drug targets develop compounds inhibit viral entry replication maturation <NUMBER> underpinning efforts basic research studies example niaid coordinates influenza genome sequencing project collaborative effort create complete genetic blueprints known human avian influenza viruses december <NUMBER> <NUMBER> total <NUMBER> influenza genome sequences made publicly available genbank niaid project <NUMBER> separate related contract awarded researchers st jude childrens research hospital animal influenza viruses wild birds live bird markets pigs hong kong north america sequenced surveillance expanded include additional sites asia goal projects rapidly sequence influenza genomes derived variety human animal sources enable scientists understand viruses evolve spread cause disease longterm goal improving methods prevention treatment develop strategies prepare influenza pandemic need address overall fragility entire vaccine research manufacturing enterprise <NUMBER> <NUMBER> <NUMBER> many pharmaceutical companies reluctant enter remain business manufacturing vaccines unpredictable consumer demands lack financial incentives make vaccine manufacturing risky business todays marketplace situation particularly true influenza vaccine strong collaborations among government academia industry needed ensure reliable vaccine supply biomedical research community help developing stateoftheart technologies sharing industry streamline manufacturing process make flexible predictable able adapt evolving nature influenza viruses pathogens financial economic incentives including fair pricing guaranteed purchase unsold supplies regulatory relief tax incentives liability protection intellectual property considerations needed ensure steady supply vaccines <NUMBER> <NUMBER> <NUMBER> although fragility vaccine industry cannot fixed overnight process needs initiated adequately prepare future pandemics recent experience outbreak severe acute respiratory syndrome sars serves instructive example preparing potential influenza pandemic <NUMBER> <NUMBER> <NUMBER> deadly respiratory disease emerged rapidly spread canada vietnam hong kong sites china ultimately resulting <NUMBER> cases <NUMBER> deaths outbreak elicited classic study epidemiologic investigation regard identifying point source tracking spread instituting containment measures taught us many important lessons academic scientists public health officials commercial pharmaceutical companies acted together unprecedented way leading development promising vaccine candidates record time etiologic agent sars previously unrecognized coronavirus identified march <NUMBER> sequenced within <NUMBER> weeks vaccine candidate developed following march december <NUMBER> clinical trial candidate sars vaccine began nih vaccine research center <NUMBER> sars coronavirus easily transmitted influenza viruses know whether actions led containment sars would successful avian influenza virus acquired ability spread efficiently person person however added advantage bracing pandemic influenza sars noted sars caused coronavirus unknown <NUMBER> outbreak current situation identified h<NUMBER>n<NUMBER> virus likely candidate triggering pandemic cannot certain next influenza pandemic emerge even whether caused h<NUMBER>n<NUMBER> unrelated virus however certain influenza pandemic eventually occur efforts currently way monitor evolution spread h<NUMBER>n<NUMBER> influenza viruses develop candidate vaccines appropriate countermeasures help developing infrastructure manufacturing capacity required scale vaccine antiviral production pandemic occurs quantities vaccine antiviral drugs pandemic influenza virus limited deciding beforehand best use resources throughout world minimize impact pandemic influenza critical global cooperation vital sars epidemic world health organization created outstanding network laboratories public health agencies countries around globe indispensable identifying ultimately containing spread virus adequately address many research issues surrounding avian influenza potential pandemic pathogens niaids office clinical research establishing southeast asia clinical trials network evaluate influenza interventions network builds upon existing infrastructure possible true partnership investigators healthcare leadership target countries international teamwork essential prepare influenza pandemic rapid emergence highly pathogenic readily transmissible coronavirus resulted global pandemic affecting millions destabilizing economies catastrophe triggered clarion call immediate deployment protective vaccine describe unique challenges developing vaccine sarscov<NUMBER> pandemic setting historically human coronaviruses received limited attention research medical communities although infections human coronaviruses eg hcov<NUMBER>e hcovoc<NUMBER> frequently cause common cold symptoms healthy individuals severe clinical illness relatively rare even immunocompromised individuals infants elderly considerably known animal coronaviruses leading vaccines prevent infection commercially important domesticated animals eg cats dogs cattle experiments many years murine hepatitis virus mhv neurotropic hepatotropic coronavirus provided substantial insight pathogenesis viral hepatitis central nervous diseases including multiple sclerosis studies enhanced understanding molecular virology pathogenesis coronaviruses recent explosive emergence highly pathogenic coronaviruses humans sparked intense interest developing countermeasures human viruses family <NUMBER> severe acute respiratory syndrome coronavirus sarscov virus emerged bats possibly civet cats china within eight months sarscov spread <NUMBER> countries around world resulting <NUMBER> human infections <NUMBER> deaths de wit et al <NUMBER> unprecedented level containment made possible extensive collaboration among international public health organizations limited transmission human disease ten years later second coronavirus middle east respiratory syndrome coronavirus merscov isolated individual suffering severe respiratory disease renal failure observed sarscov merscov spread via travel contact infected individuals resulting transmission mortality within beyond arabian peninsula <NUMBER> human cases <NUMBER> deaths serological studies identified dromedary camels principal reservoir merscov since discovery sarscov two additional human coronaviruses cause lower respiratory tract infections hcovnl<NUMBER> hcovhku<NUMBER> discovered sequencing studies bat reservoirs identified large number novel coronaviruses unknown potential emerge humans graham et al <NUMBER> appreciation considerable threat coronaviruses global health prompted remarkable advances understanding molecular virology pathogenesis sarscov merscov well efforts develop vaccines forum discuss prior study sarscov merscov enabled extraordinarily rapid development candidate vaccines hopefully curtail incendiary spread novel highly pathogenic zoonotic coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> however unprecedented pace eclipsed fundamental basic translational studies customarily guide vaccine development evaluation nonpandemic circumstances accordingly discuss challenges rapid vaccine development pandemic response sarscov<NUMBER> pandemic sarscov<NUMBER> positivesense singlestranded rna virus first isolated wuhan china december <NUMBER> cluster acute respiratory illness cases zhou et al <NUMBER> sarscov<NUMBER> infection results clinical syndrome coronavirusinduced disease<NUMBER> covid<NUMBER> characterized fever cough shortness breath progress rapidly respiratory cardiac failure requiring mechanical ventilation guan et al <NUMBER> elderly immunocompromised comorbid metabolic pulmonary cardiac conditions markedly greater risk death covid<NUMBER> virtually countries territories affected major epidemics china italy spain germany france iran united states epicenters large urban cities cases spread direct humantohuman droplet contact contribution transmission asymptomatic mildly symptomatic individuals sarscov<NUMBER> caused global pandemic <NUMBER> infections date <NUMBER> deaths <NUMBER> april <NUMBER> casefatality rate estimated <NUMBER> extensive morbidity mortality destabilizing social economic consequences highlight critical need accelerated development countermeasures rapid implementation deployment effective sarscov<NUMBER> vaccine potential lessen deleterious effects infection especially vulnerable populations curb transmission end pandemic prevent return coronaviruses round <NUMBER>nmdiameter virus particles derive name incorporation viral spike protein arrangement resembles crown virion surface three e proteins function virion morphogenesis expression sufficient formation viruslike particles although value immunogens may limited lack protein thought important target neutralizing antibodies interactions glycoprotein three structural proteins coordinate virion assembly small structural e protein multiple functions including stimulating membrane curvature required virion budding promoting lipid membrane scission virions formed nucleocapsid protein binds viral genome facilitates incorporation virus particle protein exists virions homotrimeric spikes promote coronavirus entry cells via attachment membrane fusion de wit et al <NUMBER> circumstances protein also promotes formation syncytia enabling direct celltocell transfer viral genome protein class viral fusion protein related functionally entryfusion proteins wellcharacterized viruses including influenza hemagglutinin ha hiv<NUMBER> gp<NUMBER> ebola glycoprotein gp class viral fusion proteins characteristically regulates fusogenic activity proteolytic cleavage accordingly sarscov sarscov<NUMBER> proteins cleaved sequentially entry process yield s<NUMBER> s<NUMBER> fragments followed processing s<NUMBER> yield smaller s<NUMBER> <NUMBER> protein cleavage also may occur viral egress s<NUMBER> fragment includes receptor binding domain rbd whereas carboxyl terminal s<NUMBER> portion molecule contains regions drive membrane fusion structure soluble stabilized prefusion form sarscov<NUMBER> protein solved resolution <NUMBER>å using cryoelectron microscopy revealing considerable similarity sarscov protein figure <NUMBER>b wrapp et al <NUMBER> viruses utilize human angiotensinconverting enzyme <NUMBER> ace<NUMBER> cellular receptor consistent high conservation rbd application strategies worked related viral family members provides path rapid vaccine development newly emerging virus example several antigen targets vaccine platforms clinical trial approaches used zika virus zikv emergence <NUMBER> based prior studies successes related flaviviruses several vaccine strategies sarscov merscov many focused protein developed tested extensively preclinical models zhou et al <NUMBER> within months publication sarscov<NUMBER> genome sequence work began dozens vaccine candidates httpswwwwhointblueprintprioritydiseaseskeyactionnovelcoronaviruslandscapencovpdfua<NUMBER> enabled insights sarscov merscov vaccine development wellcharacterized vaccine antigen expression platforms including shown safe humans several vaccines described entered phase <NUMBER> clinical trials evaluate safety small numbers subjects table <NUMBER> however given lack established tractable preclinical disease models sarscov<NUMBER> pathogenesis vaccines advanced human trials without data animals establishing efficacy covid<NUMBER> mrna<NUMBER> modified mrnas synthetic molecules optimized highlevel durable protein expression technology shown promise vaccine platform influenza virus nct<NUMBER> nct<NUMBER> preclinical studies infectious disease targets including zikv developed national institute allergy infectious studies identified stabilizing proline substitutions central helix s<NUMBER> reduced fusion activity allowed highlevel expression trimeric antigenically native prefusion context structure stabilized sarscov<NUMBER> antigen encoded mrna<NUMBER> solved figure <NUMBER>b phase <NUMBER> clinical trial mrna<NUMBER> nct<NUMBER> initiated march <NUMBER> openlabel doseranging study <NUMBER> subjects administered vaccine two doses <NUMBER> days apart subjects followed <NUMBER> months following second dose safety immunogenicity secondary objective ino<NUMBER> dna plasmid vaccine candidate encoding sarscov<NUMBER> protein developed inovio pharmaceuticals similar approach evaluated preclinical clinical trials vaccine merscov shown immunogenic gls<NUMBER> nct<NUMBER> three doses gls<NUMBER> elicited sproteinbinding antibodies majority <NUMBER> vaccinated individuals although neutralizing antibodies observed less frequently <NUMBER> subjects titers waned substantially course study followup modjarrad et al <NUMBER> vaccineelicited merscovspecific cell responses also detectable recipients experiences informed sarscov<NUMBER> vaccine candidate ino<NUMBER> evaluated openlabel phase <NUMBER> clinical trial volunteers receive two doses dna administered intradermally electroporation <NUMBER> days apart adenovirus vectors adenovirus ad vectors derived multiple species employed deliver vaccine antigens multiple infectious disease targets multiple advectored sarscov merscov vaccines characterized preclinical models vaccines elicited humoral cellular coronavirusreactive responses protected infection simian ad vector expressing merscov protein evaluated phase <NUMBER> clinical trial nct<NUMBER> phase <NUMBER> study explore safety immunogenicity efficacy sarscov<NUMBER> vaccine using platform initiated investigators university oxford nct<NUMBER> similar approach using human ad<NUMBER> serotype tested beijing institute biotechnology cansino biologics inc nct<NUMBER> multiple clinical studies underway explore use bacille calmetteguerin bcg immunomodulatory vaccine protect covid<NUMBER> disease table <NUMBER> bcg liveattenuated isolate mycobacterium bovis delivered lowcost vaccine <NUMBER> million children year protect mycobacterium tuberculosis tb multiple studies humans mice suggest bcg administration confers nonspecific protective effect viral infections moorlag et al <NUMBER> mechanisms bcgmediated cross protections may include enhanced th<NUMBER> th<NUMBER> responses heterologous antigens induction nonspecific memory trained immunity innate immune cells capable producing inflammatory cytokines challenged secondarily virus infection despite expedited design vaccine candidates newly emerging virus pandemic setting remain substantive challenges implementation due part need concurrently unravel fundamental aspects virus biology immunity along product development efforts approach contrasts vaccine efforts viruses studied many years eg influenza dengue denv respiratory syncytial viruses understand great detail antigenicity viral structural proteins nature protective potentially pathological immune responses multiple vaccine platforms sarscov<NUMBER> focus protein questions remain regarding key elements protective immune response <NUMBER> neutralizing antibodies correlate protection protective responses require antibody targeting specific epitopes threshold neutralizing antibody response protects sarscov<NUMBER> <NUMBER> assays commonly used vitro measure neutralization eg pseudotyped viruses faithfully predict protective activity vivo <NUMBER> role nonneutralizing antis antibodies bind surface infected cells could nonneutralizing antibodies promote effectorfunctionmediated virus clearance via fcgreceptor interactions <NUMBER> contribution mucosal immunity respiratory tract protection infection dissemination <NUMBER> humoral responses viral open reading frames orfs important immunity especially immune antagonist activity displayed cell surface secreted extracellularly <NUMBER> important cd<NUMBER> cd<NUMBER> cell responses vaccinemediated protection information gleaned preclinical early vaccine trials sarscov merscov certain correlates protection transfer pandemic sarscov<NUMBER> emergence rapid spread sarscov<NUMBER> provided short window address knowledge gaps coronavirus immunity indeed major challenge absence highthroughput small animal disease models facilitate vaccine candidate downselection detailed study protective immunity preprint manuscripts indicate conventional laboratory strains mice susceptible sarscov<NUMBER> infection httpsdoi org<NUMBER> likely mouse ace<NUMBER> cannot act cellular receptor sarscov<NUMBER> letko et al <NUMBER> transgenic mice express human ace<NUMBER> hace<NUMBER>tg develop pneumonia infection however mice yet widely available vaccine testing beyond pathogenesis immune response evaluation studies different nonhuman primate species possible animal models eg ferrets hamsters still early stages development safety primary consideration vaccine development program given anticipated administration large numbers people beyond expected reactogenicity profiles studies distantly closely related coronaviruses raised concerns humoral vaccine responses might potentiate sarscov<NUMBER> infection via immune enhancement mechanisms immune enhancement might occur via least two distinct mechanisms detailed antibodydependent enhancement ade infection describes phenomenon poorly neutralizing antibodies bind viruses increase attachment internalization infection myeloid cells expressing fcg complement receptors ade denv infection contributes severe clinical disease small fraction individuals infected second time heterologous serotype denv newborns subneutralizing levels maternal denvimmune igg ade obstacle denvvaccine development illustrated adverse events experienced denvnaive children received licensed tetravalent vaccine dengvaxia possibly similar yet undefined mechanism immunization cats vaccinia virusvectored feline infectious peritonitis virus protein vaccine resulted greater rates death upon challenge cats animal coronavirus vennema et al <NUMBER> cell culture experiments sarscov entry infection enhanced antis antibodies fcgreceptordependent independent mechanisms jaume et al <NUMBER> wan et al <NUMBER> extensive studies flaviviruses revealed ade assays cell culture correlate directly vivo outcomes enhancement demonstrated vitro many viruses immuneenhanced disease vivo may explained reductionist format traditional ade assays integrate features immune response known contribute immunity inclusion complement physiological concentrations omitted many vitro assays reduces enhancement igg subclassdependent manner ade demonstrated using immunodeficient murine models denv infection following passive transfer immune sera disease severity reduced considerably presence antiviral cells coronavirus antibodies enhance vitro tested ability exacerbate infection disease animals infection fcgreceptorexpressing myeloid cells might augmented antibodies important contributor covid<NUMBER> disease severity studies address concepts await development appropriate disease models denv compelling evidence role ade pathogenesis comes epidemiological studies humans second potential mechanism vaccineinduced disease enhancement results skewing cellular immune response enhanced respiratory disease observed <NUMBER>s recipients formalininactivated respiratory syncytial virus rsv vaccine enhanced disease characterized lung infiltration mononuclear cells including eosinophils along th<NUMBER>directed cell response ruckwardt et al <NUMBER> immune complex deposition induction binding neutralizing antibodies proposed explanation response preclinical studies multiple sarscov vaccine candidates demonstrated significant protection infection similar th<NUMBER>driven immunopathogenic response observed instances bolles et al <NUMBER> structure immunogen vaccine formulation including adjuvant age vaccine recipient may influence immune response subsequent outcome natural infection although remains unclear based recent progress rsv vaccine development eliciting neutralizing antibody response focused protective prefusion epitopes together th<NUMBER> cell response may key features safe sarscov<NUMBER> vaccine development effective viral vaccine challenge typically guided decades basic research viral biology host response infection traditional path feasible rapidly emerging highly virulent pathogen like sarscov<NUMBER> dire need vaccine exists although behavioral changes may stem spread infections vaccination likely required prevent establishment seasonal additional waves infection disease backdrop many unknowns coronavirus immunity risk associated expedited vaccine development pandemic however uncertainty must balanced enormous cost inaction studies pathogenic coronaviruses enabled rapid design candidate sarscov<NUMBER> vaccines provided insight aspects immunity may important protection identified features merit attention respect vaccine safety setting carefully designed clinical trials humans establish monitor safety define correlates durability protection may result effective countermeasure curtails pandemic also provide key mechanistic answers immune control sarscov<NUMBER> infection possibly related highly pathogenic coronaviruses could emerge future work supported intramural program niaid tcp nih contracts grants <NUMBER>n<NUMBER>c<NUMBER> r<NUMBER> ai<NUMBER> defense advanced research project agency hr<NUMBER>s<NUMBER> msd grateful dr barney graham dr heather hickman members laboratories critical comments assistance creating figure msd consultant inbios vir biotechnology ngm biopharmaceuticals scientific advisory board moderna diamond laboratory washington university school medicine received sponsored research agreements moderna coronaviruses crownlike particles spikes protruding surface enveloped viruses singlestranded positivesense rna ssrna genomes approximately <NUMBER> kb currently largest known genome size rna virus <NUMBER> rna viruses divided five branches <NUMBER> <NUMBER> certain groups particular branch might related andor share features viruses classified another branch branch <NUMBER> leviviruses eukaryotic relatives eg mitoviruses narnaviruses ourmiaviruses branch <NUMBER> represents several rna virus families eukaryotes eg orders picornavirales nidovirales families caliciviridae potyviridae astroviridae solemoviridae several dsrna viruses eg partitiviruses picobirnaviruses branch <NUMBER> certain rna viruses supergroups alphaviruses offlaviviruses nodaviruses tombusviruses many small novel groups branch <NUMBER> dsrna viruses cystoviruses reoviruses totiviruses branch <NUMBER> consists −rna viruses <NUMBER> coronaviruses classified likely related branch <NUMBER> belong order nidovirales family coronaviridae <NUMBER> international committee taxonomy viruses divided coronaviridae orthocoronavirinae letovirinae subfamilies according host targets coronaviruses also divided animal human coronaviruses many diseases domestic animals related animal coronaviruses canine respiratory coronavirus causes respiratory disease dogs <NUMBER> highly pathogenic human coronaviruses belong subfamily coronavirinae family coronaviridae viruses subfamily group four genera alphacoronavirus betacoronavirus gammacoronavirus deltacoronavirus classic subgroup clusters labeled <NUMBER>a<NUMBER>b alphacoronaviruses <NUMBER>a<NUMBER>d betacoronaviruses date including recently discovered sarscov<NUMBER> seven coronaviruses infect humans human coronavirus hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> hcovhku<NUMBER> cause common cold <NUMBER> whereas severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov cause relatively high mortality emerged <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively notably sarscov<NUMBER> currently causing worldwide epidemic sarscov merscov belong subgroups <NUMBER>b <NUMBER>c betacoronaviruses respectively <NUMBER> <NUMBER> whereas sarscov<NUMBER> new member betacoronaviruses distinct sarscov merscov <NUMBER> figure <NUMBER> shows phylogenetic tree rna viruses estimated mutation rates coronaviruses covs moderate high compared ssrna viruses <NUMBER> two gene loci sites variation sarscov one sites located spike protein gene second major site variation accessory gene open reading frame orf<NUMBER> merscov major sites variation located orf<NUMBER>b orf<NUMBER> genes <NUMBER> major differences sequence gene sarscov<NUMBER> three short insertions nterminal domain changes four five key residues receptorbinding motif <NUMBER> organizations genome gene expression similar coronaviruses orf<NUMBER>ab located <NUMBER>′ end encodes <NUMBER> nonstructural proteins nsps named nsp<NUMBER>nsp<NUMBER> orfs <NUMBER>′ end encode structural proteins including envelope e membrane nucleocapsid n proteins mutations sarscov<NUMBER> become hot research topic surface proteins sarscov batcovratg<NUMBER> nearest potential bat precursors sarscov<NUMBER> <NUMBER> <NUMBER> sequence identity respectively sarscov<NUMBER> <NUMBER> compared sarscov antigenic surface sarscov<NUMBER> highly divergent compared covs since outbreak began end <NUMBER> sarscov<NUMBER> acquired mutations throughout genome already hundreds virus strains distributed worldwide according gisaidorg may <NUMBER> <NUMBER> full genome sequences available clade full genome tree contains largest group viruses indicating mutations orf<NUMBER>l<NUMBER>s frequent temporal resolution assumes average nucleotide substitution rate <NUMBER> × <NUMBER> −<NUMBER> substitutions per site per year based mutations researchers found sarscov<NUMBER> divided two subtypes reported snps locations <NUMBER> <NUMBER> show strong linkage ct haplotype defined l type t<NUMBER> encodes leucine tc haplotype defined type c<NUMBER> encodes serine <NUMBER> accordance another study divided sarscov<NUMBER> two types <NUMBER> l type seems prevalent aggressive type may ancestral sites <NUMBER> <NUMBER> identical orthologous sites closely related viruses <NUMBER> patients may infected either types <NUMBER> gisaid update compared ratg<NUMBER> differences receptorbinding interface may favored host switching data related sequence mutations sarscov<NUMBER> also available continuously updated online china national center bioinformation cncb httpsbigdbigaccnncov history sarscov merscov sarscov<NUMBER> first case sars discovered foshan china november <NUMBER> <NUMBER> infections occurred either direct indirect contact patients july <NUMBER> sarscov spread <NUMBER> countries <NUMBER> causing <NUMBER> reported cases <NUMBER> deaths additional infections detected sars pandemic declared sarscov first isolated himalayan palm civets hpcs liveanimal market guangdong china <NUMBER> <NUMBER> animals raccoon dogs nyctereutes procyonoides along human workers market also showed evidence viral infection <NUMBER> multiple studies demonstrated reservoirs several coronaviruses including sarscovlike merscovlike viruses bats <NUMBER> <NUMBER> although palm civets might intermediary hosts sarscov <NUMBER> researchers often concluded evidence animals ultimate sources sarscov viruses cannot circulate directly palm civets wild <NUMBER> <NUMBER> guan zhengs team investigated liveanimal retail market guangdong focusing recently captured wild animals human consumption animals sampled included seven wild one domestic animal species collected nasal fig <NUMBER> phylogenetic tree coronaviruses based fulllength genome sequences complete genome sequences coronavirus downloaded ncbi reference sequence database refseq tree constructed using maximum likelihood estimation mle mega x clustal omega multiple sequence alignment method <NUMBER> bootstrap replicates bootstraps ≥<NUMBER> values shown seven known humaninfecting coronaviruses indicated red star fecal samples swabs used reverse transcriptionpolymerase chain reaction rtpcr test viral nucleic acid n gene human sarscov rtpcr assay results showed samples four six hpcs positive seven species beaver chinese ferretbadger chinese hare chinese muntjac domestic cat hogbadger raccoon dog sampled negative <NUMBER> merscov first found <NUMBER> lung sample <NUMBER>yearold patient died respiratory failure jeddah saudi arabia <NUMBER> september <NUMBER> similar type virus named human coronavirus isolated patient severe respiratory infection cases also reported countries <NUMBER> mers <NUMBER> mortality rate since emerged human population june <NUMBER> caused substantial morbidity mortality <NUMBER> <NUMBER> <NUMBER> january <NUMBER> <NUMBER> total number laboratoryconfirmed merscov infection cases reported globally world health organization <NUMBER> <NUMBER> associated deaths covering <NUMBER> countries www whointcsrdon<NUMBER>january<NUMBER>mersunitedarabemiratesen cases mers countries linked travel middle east <NUMBER> merscov identified saliva patient acute pneumonia renal failure jeddah ksa merscov detected respiratory tract secretions well feces serum urine <NUMBER> <NUMBER> <NUMBER> addition isolated environmental objects bedsheets bedrails intravenous fluid hangers xray devices <NUMBER> case known camel infection merscov transmitted camel human confirmed rna sequencing <NUMBER> end december <NUMBER> first clusters patients pneumonia caused sarscov<NUMBER> reported wuhan china <NUMBER> basic reproduction number sarscov<NUMBER> approximately <NUMBER> indicating patient would average spread infection <NUMBER> people <NUMBER> humantohuman transmission sarscov<NUMBER> occurred rapidly atypical symptoms early stage may disadvantage <NUMBER> moreover human infection might begun months prior official announcement outbreak <NUMBER> prevent spread stricter screening surveillance needed travel hubs <NUMBER> early detection diagnosis treatment also effective measures contain epidemic <NUMBER> nonetheless fatality rate sarscov<NUMBER> lower sars <NUMBER> estimated mortality risk <NUMBER> <NUMBER> sarscov<NUMBER> first isolated clinical specimens using human airway epithelial cells vero e<NUMBER> huh<NUMBER> cell lines <NUMBER> approaches assess virions include isolation lower respiratory tract specimens <NUMBER> artificially infected specific pathogenfree human airway epithelial cells <NUMBER> fluorescence quantitative pcr primers designed according specific sequences serological testing aimed igg igm used detect virus <NUMBER> sarscov merscov sarscov<NUMBER> pose major challenges global health causing infections large parts world sarscov found <NUMBER> countries merscov <NUMBER> countries sarscov<NUMBER> found <NUMBER> countries <NUMBER>th may <NUMBER> details pandemics caused sarscov<NUMBER> shown box <NUMBER> highlighting status coronaviruscaused diseases worldwide epidemiological analysis symptoms sars mers coronavirus disease <NUMBER> covid <NUMBER> clinical manifestations sars include hypoxia cyanosis high fever <NUMBER>°c accelerated breathing respiratory distress syndrome shortness breath xrays show changes lungs varying degrees case definition <NUMBER> includes following <NUMBER> fever higher <NUMBER>°c history past <NUMBER> days <NUMBER> radiological evidence new infiltrates consistent pneumonia <NUMBER> chills cough malaise myalgia known history exposure <NUMBER> positive test sarscov one assays <NUMBER> similar sarscov infection merscov infection manifests severe lower respiratory tract infection extrapulmonary involvement high fatality rates <NUMBER> symptomatic patients may present fever chills stiffness myalgia discomfort cough shortness breath gastrointestinal symptoms diarrhea vomiting abdominal pain pneumonia common severe infection acute respiratory failure renal failure shock particularly frequent among older patients <NUMBER> previous studies estimated approximately <NUMBER> merscov infections may asymptomatic <NUMBER> <NUMBER> must noted immunocompromised people high risk merscov infection <NUMBER> covid<NUMBER> fever cough myalgia fatigue commonly observed illness onset less commonly observed sputum production hemoptysis headache among others <NUMBER> <NUMBER> similar sars mers patients develop acute respiratory distress syndrome ards <NUMBER> around <NUMBER> infected patients develop mild symptoms mild pneumonia pneumonia <NUMBER> <NUMBER> severe critical status respectively <NUMBER> patients requiring icu care tend much older likely underlying comorbidities hypertension diabetes <NUMBER> additionally symptoms pharyngeal pain anorexia reported higher rates among admitted icu among nonicu patients <NUMBER> histopathologically symptoms diffuse alveolar damage dad loss cilia squamous metaplasia denudation bronchial epithelia giantcell infiltrate often occur lungs patients sars number macrophages increases prominently alveoli interstitium <NUMBER> according morphological changes observed authors subclassified lung lesions sars two three consecutive phases acute exudative inflammatory phase fibrous proliferative phase final fibrotic stage although considerable overlap histological findings among phases <NUMBER> main features first phase include extensive hyaline membrane formation edema alveolar hemorrhage fibrin exudation alveolar spaces second phase includes widening septae pneumocyte hyperplasia organizing fibromyxoid cellular exudates <NUMBER> <NUMBER> third phase includes septal alveolar fibrosis <NUMBER> several autopsies sars patients demonstrated secondary bronchopneumonia pathogens identified mainly consist staphylococcus aureus mucor sp aspergillus sp pseudomonas aeruginosa cytomegalovirus <NUMBER> sarscov also greatly affects immune system example hemorrhagic necrosis usually obvious lymph nodes spleen <NUMBER> described sarscov attacks immune cells especially cells macrophages approximately <NUMBER> lymphocytes <NUMBER> monocytes circulation becoming infected <NUMBER> <NUMBER> influence virus patients germinal centers disappear b lymphocytes depleted spleen white pulp shrinks hemorrhage necrosis occur red pulp periarterial lymphatic sheaths decrease <NUMBER> <NUMBER> <NUMBER> regard immune system sarscov infect lymphoid component intestine reason patients submucosal lymphoid tissue atrophies <NUMBER> sarscov also infect epithelial cells mucosa small large intestines digestive tract may undergo mild diffuse inflammation atrophy submucosal lymphoid tissues <NUMBER> according previous reports symptoms liver include extensive hepatocyte mitosis balloon degeneration hepatocytes mild moderate lymphocytic infiltrates fatty degeneration central lobular necrosis <NUMBER> additionally apoptosis liver cells confirmed cases <NUMBER> autopsy kidneys sars patients showed focal bleeding acute tubular necrosis different degrees one major complications ards acute kidney injury <NUMBER> <NUMBER> <NUMBER> many cases features nonspecific including benign hypertensive nephrosclerosis autolysis <NUMBER> moreover researchers detected viral particles genome sequences cytoplasm neurons hypothalamus cortex brain <NUMBER> suggests virus cross bloodbrain barrier cause degeneration necrosis neurons edema extensive glial cell hyperplasia cellular infiltration <NUMBER> pneumocytes epithelial syncytial cells important targets merscov lung tissue presents dad severe peripheral vascular diseases patchy cardiac fibrosis hepatic steatosis also found organs <NUMBER> another symptom bronchial submucosal gland necrosis <NUMBER> renal biopsy may show acute tubulointerstitial nephritis acute tubulosclerosis protein casts <NUMBER> covid<NUMBER> patients bilateral sometimes unilateral distribution patchy shadows ground glass opacity lungs typical based ct scans <NUMBER> plasma concentrations interleukins ils <NUMBER> <NUMBER> <NUMBER> granulocytecolony stimulating factor interferon ifnγinducible protein <NUMBER> monocyte chemoattractant protein <NUMBER> macrophage inflammatory protein <NUMBER>α tumor necrosis factor α increased dying patients <NUMBER> <NUMBER> addition neutrophilia related cytokine storms induced virus invasion coagulation activation related sustained inflammatory response acute kidney injury related effects virus hypoxia shock may involved mortality <NUMBER> survive intensive care may experience longterm lung damage fibrosis due aberrant excessive immune responses <NUMBER> moreover researchers found sarscov<NUMBER> spread changed across generations clinical symptoms started differentiate infected previously infected recently initial symptoms becoming insidious indicates virus may gradually evolve influenzalike virus lie dormant longer asymptomatic patients <NUMBER> conclusion terms outbreak times sarscov earliest followed merscov sarscov<NUMBER> date merscov longest duration infection sarscov<NUMBER> appears infectious sarscov merscov sarscov<NUMBER> infections similar symptoms including fever cough myalgia shortness breath among others common transmission methods symptoms three coronavirus infection shown fig <NUMBER> structural studies sarscov merscov sarscov<NUMBER> sarscov coronavirus diameter approximately <NUMBER> nm coronaviruses largest ssrna viruses contain least <NUMBER> orfs <NUMBER> protein combines viral rna form nucleocapsid involved replication sarscov abundant protein virusinfected cells <NUMBER> <NUMBER> protein membrane glycoprotein involved budding envelope formation protein sarscov type transmembrane tm glycoprotein responsible viral binding fusion entry cells well antibody induction <NUMBER> <NUMBER> protein contains signal peptide sp amino acids <NUMBER> three domains called extracellular domain amino acids <NUMBER> tm domain amino acids <NUMBER> intracellular region amino acids <NUMBER> <NUMBER> extracellular domain consists two subunits s<NUMBER> s<NUMBER> fragment located middle region s<NUMBER> subunit amino acids <NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptorbinding region s<NUMBER> subunit comprises fusion peptide fp two x <NUMBER>valent element repeats hr<NUMBER> hr<NUMBER> responsible fusion virus target cell membrane <NUMBER> thus protein may key develop vaccine generate antibodies block virus binding fusion coronaviruses fig <NUMBER> <NUMBER>′ end sars virus genome encodes <NUMBER> structural proteins helper proteins orf<NUMBER>a orf<NUMBER> orf<NUMBER>a orf<NUMBER>b proven viral structural proteins involved formation viral particles <NUMBER>′ end genome encodes <NUMBER> nonstructural proteins nsps important virus assembly may enable design small molecule drugs andor vaccines merscov belongs lineage c genus betacoronavirus βcov family coronaviridae order nidovirales first lineage c cov sixth cov known cause human infection merscov enveloped ssrna virus similar covs amino acid sequence homology merscov known covs less <NUMBER> <NUMBER> orf<NUMBER>a orf<NUMBER>b located first twothirds merscov genome involved virulence encode nsps nsp<NUMBER> remaining third genome encodes four structural proteins e n proteins well five accessory proteins orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> orf<NUMBER>b <NUMBER> <NUMBER> <NUMBER> flanking regions genome contain <NUMBER>′ <NUMBER>′ untranslated regions utrs <NUMBER> merscov proteins found cytoplasm <NUMBER> date ns<NUMBER>b protein orf<NUMBER>aencoded protein known coronavirus proteins detected nucleus <NUMBER> nsp<NUMBER> suppresses host gene expression infected cells rna cleavageinducing function promotes virus assemblybudding <NUMBER> nsp<NUMBER> viral <NUMBER>′omethyltransferase <NUMBER>′omtase encodes critical functions immune modulation infection suggesting nsp<NUMBER> conserved universal candidate rapid design live attenuated vaccine <NUMBER> orf<NUMBER>as protein mask viral dsrna play role immune evasion including type <NUMBER> ifn protein kinase rmediated antiviral stress responses <NUMBER> merscov nsp<NUMBER> fulllength coronavirus helicase contains multiple domains including nterminal cyshis rich domain three zinc atoms betabarrel domain cterminal superfamily sf <NUMBER> helicase sf<NUMBER> core two recalike subdomains protein might interfere nonsensemediated mrna decay pathway avoid degradation viral rna <NUMBER> merscov protein recognize dipeptidyl peptidase <NUMBER> dpp<NUMBER> cell surface promoting fusion viral envelope cell membrane merscov protein <NUMBER>amino acid type tm glycoprotein located viral envelope surface composed s<NUMBER> s<NUMBER> subunits <NUMBER> structure protein consists four parts sp located n terminus amino acids <NUMBER> extracellular domain amino acids <NUMBER> tm domain amino acids <NUMBER> intracellular domain amino acids <NUMBER> <NUMBER> s<NUMBER> subunit contains two independent domains nterminal domain ntd amino acids <NUMBER> <NUMBER> cterminal domain amino acids <NUMBER> may function receptorbinding domains rbds <NUMBER> domains serve critical targets development vaccines therapeutics <NUMBER> <NUMBER> facilitate involvement s<NUMBER> subunit cell receptor dpp<NUMBER> binding core structure merscov protein rbd fivestranded antiparallel sheet several short helices three disulfide bonds stabilize core connecting c<NUMBER> c<NUMBER> c<NUMBER> c<NUMBER> c<NUMBER> c<NUMBER> <NUMBER> <NUMBER> accessory subdomain cdomain hypervariable region receptor recognition fig <NUMBER> clustering spike protein coronavirus fiftyfour spike protein sequences filtered coronavirus coding sequences clustered using clans cluster analysis sequences program website mpi bioinformatics toolkit colored dot represents spike protein sequence coronavirus dots color mean genus line shows similarity two sequences darker lines indicating higher similarity lower e values coronaviridae family includes following genera alphacoronavirus colored green betacoronavirus red gammacoronavirus orange deltacoronavirus blue indicated sarscov merscov sarscov<NUMBER> belong genus betacoronavirus called receptorbinding motif rbm accessory subdomains sarscov merscov differ resulting divergent evolution leading use different receptors <NUMBER> dpp<NUMBER> consists nterminal hydrolase cterminal βpropeller domain composed eight lancets <NUMBER> rbd s<NUMBER> subunit merscov contains fp residues <NUMBER> hr<NUMBER> domain residues <NUMBER> hr<NUMBER> domain residues <NUMBER> tm domain residues <NUMBER> intracellular domain residues <NUMBER> <NUMBER> s<NUMBER> subunit responsible fusion virus target cell membrane s<NUMBER> subunit binds dpp<NUMBER> s<NUMBER> subunit inserts fp target cell membrane change conformation hr<NUMBER> helix forms homotrimer exposed surface three highly conserved hydrophobic grooves binds hr<NUMBER> form sixhelix bundle <NUMBER>hb core structure facilitates fusion bringing viral cell membranes close proximity <NUMBER> genetic material merscov enters host cell via fusion pore <NUMBER> sarscov<NUMBER> causes covid<NUMBER> spherical betacoronavirus diameter <NUMBER> nm unique spikes ranging <NUMBER> <NUMBER> nm <NUMBER> rna typical betacoronavirus organization containing <NUMBER>′ utr gene encoding replicase complex orf<NUMBER>ab gene e gene gene n gene <NUMBER>′ utr several unidentified nonstructural orfs <NUMBER> <NUMBER> length sequences <NUMBER> nt <NUMBER>′ terminal region <NUMBER> nt <NUMBER>′ terminal region <NUMBER> nt gene <NUMBER> nt e gene <NUMBER> nt gene <NUMBER> nt n gene <NUMBER> <NUMBER>ntlong orf<NUMBER>ab gene contains <NUMBER> predicted nsps <NUMBER> similar sarscov predicted orf<NUMBER> gene <NUMBER> nt length located n orf genes <NUMBER> nucleotides <NUMBER> <NUMBER> <NUMBER> may recombination breakpoints based fragments nt <NUMBER> nt <NUMBER> nt <NUMBER> end sarscov<NUMBER> seems related batslcovzc<NUMBER> batslcovzxc<NUMBER> however considering region nt <NUMBER> nt <NUMBER> sarscov<NUMBER> mostly likely grouped sarscov bat sarslike covs research required analyze recombination genome whole <NUMBER> <NUMBER> conserved replicase complex different betacoronaviruses sarscov<NUMBER> solely occupies newly created subclade within sarbecovirus subgenus <NUMBER> <NUMBER> bats may natural host owing several arguments including complicated environment wet markets wuhan remains unclear research needed <NUMBER> <NUMBER> <NUMBER> <NUMBER> free energy spike protein sarscov<NUMBER> much lower sarscov indicating sarscov<NUMBER> stable sarscov <NUMBER> high similarity rbd sequences spike protein structures sarscov<NUMBER> sarscov <NUMBER> <NUMBER> <NUMBER> also simulation spike protein sarscov<NUMBER> binding ace<NUMBER> <NUMBER> receptor sarscov results shown ace<NUMBER> plays vital role sarscov<NUMBER> entry hela cells <NUMBER> indicating sarscov<NUMBER> also uses ace<NUMBER> cell entry structural modeling ace<NUMBER>b<NUMBER>at<NUMBER> complex b<NUMBER>at<NUMBER> used obtain stable ace<NUMBER> suggests complex bind two proteins simultaneously providing important clues molecular basis coronavirus recognition infection <NUMBER> rbdace<NUMBER> binding free energy sarscov<NUMBER> significantly lower sarscov accordance fact sarscov<NUMBER> infectious sarscov <NUMBER> recent study found cd<NUMBER> kind tm glycoprotein facilitates cell entry sarscov<NUMBER> functionally affinity constant protein <NUMBER> × <NUMBER> −<NUMBER> <NUMBER> table <NUMBER> shows comparison structures sarscov merscov sarscov<NUMBER> specific function sarscov<NUMBER> proteins including e n proteins need study conclusion sarscov merscov sarscov<NUMBER> similar structure major proteins structural proteins including e n proteins accessory protein nsps nsp<NUMBER> viruses rely protein identify cell targets fuse membranes proteins composed s<NUMBER> s<NUMBER> subunits s<NUMBER> subunit contains ntd cdomain rbd accessory subdomain cdomain hypervariable region receptor recognition called rbm difference sarscov recognizes ace<NUMBER> sarscov<NUMBER> recognizes ace<NUMBER> cd<NUMBER> mers recognizes dpp<NUMBER> results difference accessory subdomains sarscov sarscov<NUMBER> merscov function accessory nonstructural proteins three viruses related viral replication assembly hence linked virulence pathogenesis sarscov merscov sarscov<NUMBER> sarscov sarscov<NUMBER> nearly identical terms invasion selfreplication whereas merscov different targets cellular receptor sarscov sarscov<NUMBER> ace<NUMBER> plus cd<NUMBER> sarscov<NUMBER> merscov dpp<NUMBER> human ace<NUMBER> protein typical zinc metallopeptidase comprises <NUMBER> amino acids contains single catalytic domain type integral membrane glycoprotein oriented extracellular n terminus catalytic site functions metabolizing circulating peptides <NUMBER> believed virusbinding hot spot ace<NUMBER> preexistent preorganized induced form upon virus binding <NUMBER> hot spot consists salt bridge surrounded hydrophobic tunnel walls general structural features hot spot favor virus binding located region ace<NUMBER> furthest membrane relatively flat free glycosylation thereby easily accessible viruses hot spot mainly intrinsic property ace<NUMBER> also dynamic structure receives structural contributions ace<NUMBER> viruses contributions ace<NUMBER> pronounced dpp<NUMBER> type ii transmembrane glycoprotein consists approximately <NUMBER> amino acids dpp<NUMBER> contains nterminal hydrolase cterminal βpropeller domain composed eight lancets <NUMBER> protein rbd binds side surface dpp<NUMBER> propeller amino acid residues lancets <NUMBER> <NUMBER> including k<NUMBER> q<NUMBER> t<NUMBER> r<NUMBER> r<NUMBER> q<NUMBER> a<NUMBER> l<NUMBER> i<NUMBER> <NUMBER> pathogenic mechanism sarscov believed include two parts virus injures target cells directly subsequent immune system dysfunction leads indirect injury <NUMBER> sarscov spreads via droplet contact transmission via fecaloral route droplet inhalation virus enters respiratory tract invades epithelial cells infection replication virus local inflammatory changes contribute lung tissue damage subsequently sarscov infects circulating resident immune cells key cells step consist mainly cells macrophages viruses carried organs including secondary lymphoid organs circulating immune cells <NUMBER> sarscov resembles hiv viruses attack immune cells cause immunodeficiency <NUMBER> sarscov causes lung injury mainly inhibiting function ace<NUMBER> virus binds ace<NUMBER> via spike protein downregulating function contributing lung injury ace<NUMBER> important component reninangiotensin system ras system angiotensinogen first converted angiotensini angi renin angiis converted ang ii influence ace<NUMBER> ace<NUMBER> downregulates levels angi ang ii bind ang ii type at<NUMBER> receptor cause certain types lung injury mainly pulmonary hypertension pulmonary fibrosis acute lung injury <NUMBER> ang ii directly induce pulmonary artery smooth muscle cells grow proliferate rapidly at<NUMBER> thus causing pulmonary hypertension <NUMBER> ang ii contributes pulmonary fibrosis promoting expression profibrotic cytokine transforming growth factorb<NUMBER> causing fibroblasts convert myofibroblasts accumulate collagen <NUMBER> several strategies used virus escape innate immune response normally viral pathogenassociated molecular patterns pamps detected host pattern recognition receptors prrs pamps include viral dsrna mrna prrs include retinoic acidinducible gene protein rigi melanoma differentiationassociated protein <NUMBER> mda<NUMBER> production type ifn induced via nuclear factorκb nfκb pathway ifn binds ifnαβ receptor signal transducer activator transcription stat proteins activated increases production antiviral proteins thus blocks sarscov replication infection <NUMBER> additionally sarscov could encode several proteins hinder signaling cascades downstream prrs cell receptor merscov dpp<NUMBER> widely expressed epithelial cells prostate alveoli kidneys liver small intestine activated leukocytes thus range merscov tissue tropism broader similar coronavirus merscov infection dendritic cells macrophages lead continuous production proinflammatory cytokines chemokines tnfα il<NUMBER> cxcl<NUMBER> ccl<NUMBER> ccl<NUMBER> ccl<NUMBER> il<NUMBER> <NUMBER> compared sarscov infection merscov infection cause higher expression levels il<NUMBER> ifnγ ip<NUMBER>cxcl<NUMBER> mcp<NUMBER>ccl<NUMBER> mip<NUMBER>αccl<NUMBER> rantesccl<NUMBER> il<NUMBER> <NUMBER> induction immune cellrecruiting cytokineschemokines might lead infiltration large number immune cells lower respiratory tract causing severe inflammation tissue damage <NUMBER> merscov also infect cells lead apoptosis avoiding host immune response facilitating faster spread <NUMBER> merscov also evolved mechanism escape host cell immune system host sensors initiate signaling pathways transcription type ifn genes begins type ifn response essential component antiviral innate immunity initiated <NUMBER> <NUMBER> <NUMBER> ifn activates transcription numerous ifnstimulated genes isgs synthesizes <NUMBER>′<NUMBER>′oligoadenylate <NUMBER>a causes rnase l activation <NUMBER> <NUMBER> <NUMBER> activated rnase l cleave viral host ssrna leading translation stagnation apoptosis limiting virus replication transmission vitro vivo <NUMBER> <NUMBER> however merscov protein ns<NUMBER>b phosphodiesterase activity antagonizes rnase l via enzymatic degradation leading inference ifn signaling although ns<NUMBER>b mainly expressed nucleus expression level ns<NUMBER>b protein cytoplasm sufficient prevent activation rnase l <NUMBER> addition merscov orf<NUMBER>a orf<NUMBER>b orf<NUMBER> proteins reported strong ifn antagonists among orf<NUMBER>a orf<NUMBER>b orf<NUMBER> proteins inhibit type ifn induction <NUMBER> <NUMBER> <NUMBER> nfκb signaling pathways similar type ifn signaling pathway <NUMBER> providing possible mechanism merscov evasion innate immunity <NUMBER> <NUMBER> sarscov<NUMBER> first cluster patients believed associated seafood market <NUMBER> however due identification patients without direct exposure market transmission humans proven <NUMBER> hospitalrelated transmission also detected via infected medical workers hospitalized patients main routes transmission include respiratory droplets close contact extended exposure aerosol environments loaded high concentrations virions addition transmission respiratory tract exposure unprotected eyes sarscov<NUMBER> might cause acute respiratory infection <NUMBER> notably virus transmitted incubation period <NUMBER> tm protease serine type <NUMBER> tmprss<NUMBER> primes protein sarscov<NUMBER> cell entry <NUMBER> based analysis ace<NUMBER> rna expression profile normal human lungs sarscov<NUMBER> mainly infects type ii alveolar at<NUMBER> cells <NUMBER> human lung cells express ace<NUMBER> <NUMBER> at<NUMBER> cells express many genes facilitate sarscov<NUMBER> infection <NUMBER> moreover cd<NUMBER> also reported probably functionally facilitates cell entry sarscov<NUMBER> <NUMBER> high expression ace<NUMBER> also detected cells digestive system upper esophageal cells accordingly system potential route infection <NUMBER> addition lungs intestines organs heart esophagus kidney bladder testis ileum adipose tissue also express ace<NUMBER> expression level higher lungs <NUMBER> <NUMBER> certain tumor tissues higher expression ace<NUMBER> making cancer patients vulnerable people <NUMBER> conclusion sarscov sarscov<NUMBER> bind cells expressing ace<NUMBER> affect ras system due affinity ace<NUMBER> much stronger sarscov<NUMBER> sarscov leading onset symptoms merscov causes symptoms producing inflammatory cytokines invading cells specific pathogenic mechanisms three viruses illustrated fig <NUMBER> diagnostic methods addition clinical manifestations definitive diagnosis confirmation coronavirus infection requires specific testing criteria diagnosis sars include <NUMBER> fever higher <NUMBER>°c history past <NUMBER> days <NUMBER> radiological evidence new infiltrates consistent pneumonia <NUMBER> chills cough malaise myalgia known history exposure <NUMBER> positive tests least one assay mers criteria diagnosis according include <NUMBER> fever cough hospitalization suspicion lower respiratory tract lesion <NUMBER> history contact probable confirmed cases <NUMBER> history travel residence within arabian peninsula <NUMBER> positive tests pcrbased detection method using respiratory samples nasopharyngeal swabs nasopharyngeal tracheal aspirates bronchoalveolar lavage bal induced sputum serological tests rapid immunochromatographic assay using highly selective monoclonal antibodies room temperature initial criteria diagnosis sars included <NUMBER> history travel residence wuhan within <NUMBER> weeks onset illness <NUMBER> exposure patients wuhan fever respiratory symptoms within <NUMBER> weeks onset illness existence clusters diseases <NUMBER> fever accompanied radiographic features pneumonia normal decreased total number white blood cells decreased lymphocyte count <NUMBER> fluorescence pcr testing positive nucleic acids sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> early diagnosis mers difficult several highly specific sensitive molecular serologic assays exist diagnosis animals humans <NUMBER> among rapid immunochromatographic assay detect merscov antigens based detection merscov nucleocapsid protein short time frame relative sensitivity specificity test <NUMBER> <NUMBER> respectively <NUMBER> nucleic acid tests realtime pcr tests mostly used detect virus early stage outbreak sarscov<NUMBER> although approach requires relatively long time conducive accelerating diagnosis largescale application therefore alternative rapid diagnostic kits sarscov<NUMBER> may used example colloidal gold detection kit uses serum plasma whole blood samples detect igmigg antibodies diagnosis <NUMBER>th day infection <NUMBER>rd day onset requires <NUMBER> min nucleic acid detection kit six respiratory viruses including sarscov<NUMBER> influenza virus uses thermostatic amplifier chips diagnosis detecting different infections may help distinguish people influenza viral infections newly developed fig <NUMBER> pathogenesis sarscov merscov sarscov<NUMBER> sarscov sarscov<NUMBER> play pathogenic role inhibiting ace<NUMBER> influence renin ace angiotensinogen converted ang ii at<NUMBER> receptor ang ii acts lung injurypromoting factor cases may cause vascular constriction inflammatory response cell proliferation fibrosis apoptosis alveolar epithelial cells resulting diseases pulmonary hypertension pulmonary fibrosis acute lung injury ace<NUMBER> converts ang ii ang <NUMBER> mas receptor ang <NUMBER> play roles vasodilation antiproliferative activity antioxidant activity sarscov downregulates activity ace<NUMBER> causes increase amount ang ii lung injury merscov infection dendritic cells macrophages lead continuous production proinflammatory cytokines chemokines leading large number immune cells infiltrating patients lower respiratory tract causing severe inflammation tissue damage merscov infect tcells human lymphoid organs causes peripheral blood inducing apoptosis intrinsic extrinsic pathways thus avoiding host immune response detection method nanopore targeted sequencing also potential efficiently detecting viruses reasonable time moreover could identify <NUMBER> respiratory viruses monitor changes virulence transmissibility caused viral mutations <NUMBER> therapeutic agents patients treated isolation <NUMBER> based previous studies drugs may developed inhibit cell entry several strategies investigated identify specific antivirals targeting protein including mersrbdtargeted nabs block viral attachment peptide inhibitors targeting s<NUMBER> prevent formation fusion core small molecules without defined mechanisms <NUMBER> sdpp<NUMBER> found bind merscov rbd high affinity suggesting sdpp<NUMBER> could serve blocker merscov attachment entry cells <NUMBER> <NUMBER> one study reported monoclonal antibody <NUMBER>d<NUMBER> binds ntd inhibit cellular entry merscov <NUMBER> experiments shown <NUMBER>d<NUMBER> inhibits binding merscov cells also effects viralcell attachment <NUMBER>d<NUMBER> inhibits virus invasion blocking binding s<NUMBER> subunit receptor interfering conformational transformation s<NUMBER> subunit virus fuses cell membrane <NUMBER> peptide fragment spanning residues <NUMBER> protein exerts neutralization activity inhibiting membrane fusion entry merscov suggesting possible develop vaccines targeting neutralizing epitope <NUMBER> griffithsin lectin derived red algae binds oligosaccharides surface sarscov protein may also prove effective sarscov<NUMBER> <NUMBER> <NUMBER> researchers found antibodies raised sarscov css<NUMBER> <NUMBER> <NUMBER> <NUMBER> could crossneutralize sarscov<NUMBER> reducing sdriven cell entry although efficiency lower observed sarscov <NUMBER> meplazumab anticd<NUMBER> humanized antibody binds cd<NUMBER> competition protein <NUMBER> thus significantly inhibiting virus invading cells reducing time negative conversion <NUMBER> <NUMBER> chloroquine could effectively inhibit sarscov<NUMBER> vitro hydroxychloroquine even potent chloroquine <NUMBER> <NUMBER> hydroxychloroquine could significantly help reduce virus load azithromycin could reinforce effect <NUMBER> arbidol could also contribute condition improvement <NUMBER> note studies generally limited trials development necessary protease inhibitors also potential coronavirus therapeutics protease inhibitors including disulfiram lopinavir ritonavir reported effective sars mers disulfiram drug alcohol dependence reported inhibit papainlike protease plpro merscov sarscov cell cultures <NUMBER> <NUMBER> vitro sarscov inhibited <NUMBER>mercaptopurine <NUMBER>thioguanine targeting plpro <NUMBER> used together ribavirin protease inhibitors lopinavir ritonavir improved outcomes patients sars compared achieved use ribavirin alone <NUMBER> inhibitors also tested patients infected sarscov<NUMBER> whether inhibitors effectively suppress <NUMBER>clpro plpro sarscov<NUMBER> remains controversial <NUMBER> drugs colistin valrubicin icatibant bepotastine epirubicin epoprostenol vapreotide aprepitant caspofungin perphenazine prulifloxacin bictegravir nelfinavir tegobuvir bind main protease sarscov<NUMBER> thus potential candidates <NUMBER> lianhuaqingwen formula kind traditional chinese medicine also recently described theoretically potential treatment candidate main virus protease <NUMBER> serine protease inhibitor camostat mesylate could partly block sarscov<NUMBER> infection lung cells inhibiting tmprss<NUMBER> <NUMBER> viral rna synthesis blockers also potential remdesivir broadspectrum activity merscov sarscov cell cultures animal models currently clinical development treatment ebola virus disease <NUMBER> <NUMBER> also reported positively based patient sarscov<NUMBER> infection us <NUMBER> another study showed able inhibit virus <NUMBER> ribavirin often used treat sars mers uncertain whether potent enough covid<NUMBER> <NUMBER> <NUMBER> regardless used alone ribavirin minimal activity sarscov may cause strong side effects often used together corticosteroids <NUMBER> preclinical study galidesivir bcx<NUMBER> adenosine analog revealed antiviral activity sarscov merscovcov <NUMBER> study favipiravir t<NUMBER> guanine analog proved activity sarscov<NUMBER> randomized trials favipiravir plus interferonα chictr<NUMBER> favipiravir plus baloxavir marboxil chictr<NUMBER> progress <NUMBER> corticosteroids may used treat sars patients suppress lung inflammation although therapy associated mortality patients mers associated delayed clearance merscov rna <NUMBER> moreover clinical evidence support use corticosteroids covid<NUMBER> treatment <NUMBER> regarding antibodies plasma therapy using convalescent plasma fully recovered patients effective coronaviruses including sarscov<NUMBER> <NUMBER> <NUMBER> tocilizumab antihuman il<NUMBER> receptor may curb immunopathology trials ongoing <NUMBER> study novel monoclonal antibodies merscov spike protein suggests mabs utilized identification specific mutations merscov <NUMBER> wang et al provided allhydrocarbonstapled peptide likely mimics native conformation cterminal short αhelical region merscov protein block formation hexameric coiledcoil fusion complex inhibit viralcell membrane fusion <NUMBER> <NUMBER> current treatments sars mainly include ribavirin ifn α plasma therapy hostdirected therapies systemic corticosteroids <NUMBER> <NUMBER> due lack clinical trial data adequate supportive care supplemented different combinations drugs remains main treatment patients <NUMBER> <NUMBER> mers despite many studies humans consensus best treatment thus randomized clinical trials needed assess potential treatment options <NUMBER> several therapeutics development including convalescent plasma lopinavirritonavir ribavirin ifn novel therapies including polyclonal antibodies broadspectrum antivirals <NUMBER> antimicrobial peptides amps may used alternative therapeutic agents <NUMBER> many effective even bacterial proteases agents <NUMBER> antiviral drugs effective activity vitro include neutralizing monoclonal antibodies antiviral peptides mycophenolic acid lopinavir ifn ribavirin nitazoxamide mycophenolate mofetil mmf alisporivir silvestro corticosteroids <NUMBER> <NUMBER> <NUMBER> although agreement ideal treatment option cure covid<NUMBER> much research activities pursued routes underway potential hosttargeted agents hostdirected strategy another approach limiting viral replication host proteases cathepsin b cathepsin l cleave spike protein sarscov drugs camostat inhibit host serine proteases interfere entry sarscov may cause many significant side effects <NUMBER> <NUMBER> pegylated ifn α<NUMBER>a <NUMBER>b may used stimulate innate antiviral responses patients chloroquine approved immune modulator reported inhibitory effects sarscov<NUMBER> certain conditions <NUMBER> researchers also proposed commercially available drugs suitable safety profiles metformin glitazones fibrates sartans atorvastin well nutrient supplements biologics might reduce immunopathology boost immune responses prevent curb ards addition ongoing cellular therapies using mesenchymal stromal cells allogeneic donors shown reduce nonproductive inflammation affect tissue regeneration evaluated phase <NUMBER> trials patients ards therapies may assayed sarscov<NUMBER>infected patients <NUMBER> <NUMBER> <NUMBER> expansion antiviral cells cellular drugs could aid preparing cell products adjunct treatment patients severe infection <NUMBER> overall similarities differences among treatments three coronaviruses notably summarize potential drugs vaccines table <NUMBER> vaccination could used prevent infection reduce disease severity different kinds vaccines dna vaccines recombinant proteins subunit vaccines inactivated viruses described <NUMBER> however highly sophisticated immune evasion mechanisms viral pathogens high mutation rates make human vaccine development major challenge <NUMBER> four nsps <NUMBER>clpro plpro helicase rdrp key enzymes viral life cycle protein responsible receptor binding cell entry attractive targets developing vaccines coronaviruses <NUMBER> among protein commonly targeted <NUMBER> based previous studies believed protein receptorbinding domain srbd located s<NUMBER> subunit important target development sars vaccine especially key neutralizing region cnd indeed cnd induce strong neutralizing antibody response crossprotection sarscov mutants one study showed recombinant fusion protein designated rbdfc containing <NUMBER>amino acid rbd human igg<NUMBER> fc fragment induce highly potent antibody responses immunized rabbits antibodies inhibited sarscov infection serum dilution <NUMBER> believed safer types vaccines <NUMBER> additionally chloroplast transgenic technology possible combine fusion gene srbd carrier molecule cholera toxin b subunit tobacco chloroplast genome obtain chloroplast transgenic tobacco plant stably expresses oral sarscov subunit vaccine <NUMBER> mers vaccines based viral protein include fulllength strimer proteinbased vaccines fulllength sbased simian adenovirus vector vaccine chadox<NUMBER> dna vaccine gls<NUMBER> <NUMBER> s<NUMBER>based vaccines ad vector encoding merscov s<NUMBER> extracellular domain ad<NUMBER>merss<NUMBER> rabv vector encoding s<NUMBER>elicited antibody <NUMBER> <NUMBER> rbdbased vaccines vaccines based regions confirmed proteins sarscov sarscov<NUMBER> quite similar researchers recently found three monoclonal antibodies developed bind protein sarscov s<NUMBER> m<NUMBER> <NUMBER>r crossreact protein rbd sarscov<NUMBER> simian adenovirus vector vaccine chadox<NUMBER>an ad vector encoding merscov s<NUMBER> extracellular domain ad<NUMBER>merss<NUMBER> rabv vector encoding s<NUMBER> elicit antibody rbdbased vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> overview lethal human coronaviruses chen et al suggesting tailored vaccines antibodies sarscov<NUMBER> must designed <NUMBER> dna vaccines also quite promising specific igg antibodies sarscov promoted gene dna vaccine mentioned protein sarscov plays important role pathogenic process synthetic peptides induced dna vaccine escherichia coli elicit specific antibodies sarscov protein might provide another approach developing sarscov vaccines <NUMBER> <NUMBER> evaluate safety immunogenicity plasmid dna vaccine gls<NUMBER> expresses protein merscov phase clinical trial healthy volunteers conducted <NUMBER> results reported another phase trial utilizing viral vector chimpanzee adenovirus oxford university <NUMBER> chadox<NUMBER> containing merscov protein expression gene started oxford university january <NUMBER> <NUMBER> addition camel vaccines merscov consideration present least two promising candidate camel vaccines undergoing development field trial evaluation progress <NUMBER> <NUMBER> one study found rbd fragment covering spike residues <NUMBER> key neutralizing receptorbinding fragment ideal candidate mers vaccines <NUMBER> another potential neutralizing epitope peptide fragment covering <NUMBER> residues protein blocks membrane fusion cellular entry merscov <NUMBER> fig <NUMBER> approaches recombinant viruses may employed generate immune response viruses two kinds recombinant viruses promising designing protective vaccine first defective nonpathogenic vector capable expressing viral proteins second vector assembled test tube stimulate assembly viruslike particles adenosine deaminase ada kind human enzyme could interact dpp<NUMBER> therefore ada could compete merscov natural antagonist virus attempts bind cells <NUMBER> addition antidpp<NUMBER> play similar role <NUMBER> however practical use method vivo dpp<NUMBER> important functions regulation several different signaling pathways <NUMBER> questions concerning coronavirushost interactions topic intrigued community understanding certain mechanisms virus interactions support drug research activities instance found sarscov<NUMBER> stronger rapid spreading ability many known viruses possible invades host cells via additional novel routes limited ace<NUMBER> example cd<NUMBER> probably involved virus invasion <NUMBER> slike protein involved invasion affinity human ace<NUMBER> protein rbd new coronavirus <NUMBER> times higher sars virus likely explains sarscov<NUMBER> spreads swiftly distinct insert present peptide fragment spanning s<NUMBER>s<NUMBER> loop sarscov<NUMBER> protein shared similarity sarscov sarsrelated viruses peptide loop impact entry pathway type sarscov<NUMBER> compared known betacoronavirus lineage b furthermore protein likely cleaved virus assembly delivery cell surface golgiresident proprotein convertases furin <NUMBER> different behavior close relatives furin found variety human tissues including lungs liver small intestine therefore exactly cell types sarscov<NUMBER> may attack yet relation last two questions noted studies also necessary investigate possibility receptorindependent virus entry sarscov<NUMBER> genome encodes nonstructural proteins structural proteins accessory proteins <NUMBER>clpro plpro helicase rdrp belong first type protein belongs second recognized promising targets developing antiviral agents sarscov merscov therefore may applied sarscov<NUMBER> nonetheless rapid identification effective interventions sarscov<NUMBER> major challenge however subject using currently known antiviral drugs frequently brought community potential shortterm strategy combat sarscov<NUMBER> drugs affecting targets status sarscov<NUMBER> listed main candidates inhibitors <NUMBER>clpro include agents sarscov<NUMBER> fig <NUMBER> targets different drug candidates three coronaviruses common targets three coronaviruses mainly protein s<NUMBER>s<NUMBER> subunits pl protein rdrp <NUMBER>cl protein helicase figure shows drug candidates black vaccines red among remdesivir trending news recently inhibits rdrp phase iii sarscov<NUMBER> may effect three viruses ribavirin combination pegylated interferon may also effect three viruses ritonavir lopinavir inhibit <NUMBER>clpro phase iii sarscov<NUMBER> effect sarscov<NUMBER> merscov dna vaccines vaccines based protein subunits protein development lopinavir ritonavir darunavir cobicistat asc<NUMBER>f phase iii combination oseltamivir sarscov<NUMBER> <NUMBER> candidates inhibitors plpro include thiopurine analogs compound <NUMBER> preclinical remdesivir phase iii marscov <NUMBER> <NUMBER> favipiravir ribavirin randomized trial sarscov<NUMBER> remdesivir among candidate inhibitors rdrp <NUMBER> previously compounds may interfere atpase helicase activities reported covid<NUMBER> bananins <NUMBER>hydroxychromone derivatives triazole derivatives preclinical <NUMBER> <NUMBER> candidates may suppress viral entry targeting protein include peptide p<NUMBER> αhelical lipopeptides preclinical <NUMBER> targeting s<NUMBER> subunit protein mainly include hr<NUMBER>p hr<NUMBER>m hr<NUMBER>l hr<NUMBER>l hr<NUMBER>p hr<NUMBER>l preclinical <NUMBER> due strong affinity ace<NUMBER> receptor rbd sarscov<NUMBER> another opportunity might development antibodies block ace<NUMBER> second method use large amount soluble ace<NUMBER> directly block spike protein third method find drug directly inhibits spike membrane fusion process aids drug enfuvirtide fourth approach identify agent inhibits activity disintegrin metalloproteinase <NUMBER> adam<NUMBER> may also prevent viral release proliferation cells protect ace<NUMBER> lungs <NUMBER> mrna vaccine technology sarscov<NUMBER> vaccines already development mrna dna vaccines promising approaches prevent cellular invasion similar coronaviruses future january <NUMBER> coalition epidemic preparedness innovations cepi announced three partnerships develop new coronavirus vaccine among moderna inovio presented mrna dna vaccine technologies respectively goal three teams least one candidate vaccine capable preventing coronavirus infection <NUMBER> weeks tested phase clinical trial modernas vaccine model designed use mrnas safely preexpose immune system small amount encoded proteins usually generated pathogen immune system becomes prepared fight future pathogens prevent infection candidate genes developed moderna contain mrnas combining multiple mrnas single vaccine might useful rapidly induce responses approach may applied future emerging pandemic threats time mrna cell degraded time mrna vaccine continue produce antigen components long time avoid risk continued stimulation immune system generally mrna vaccines also described simple prepare yield remarkable results additional advantages well disadvantages nucleic acidbased vaccines described detail furthermore basis traditional vaccines proteins polysaccharides cannot straight forward applied present many pathogens therefore mrna vaccines would suitable achieving rapid mass production emergency vaccines event major epidemic however rna easily degraded inducing cells absorb mrna quickly challenge recent years method delivery mrna cells greatly improved stemirna moderna adopted nanolipid lpp lnp lipid nanoparticle drugloading technology however still developed mrnas furthermore ensuring safety effectiveness another challenge viral mrna vaccines clinical validation carried carefully moderna worldwide leader mrna therapy currently nine mrnatype vaccine candidates eg mrna<NUMBER> sarscov<NUMBER> national institutes allergy infectious diseases niaid national institutes health nih mrna vaccine giant moderna teamed bring new coronavirus vaccine possibly phase ii within months phase iii late year simultaneously january <NUMBER> translational medicine platform dongfang hospital affiliated tongji university cooperated stemirna shanghai biotechnology co ltd rapidly promote development new coronavirus mrna vaccine february <NUMBER> chinese scientific research team announced animal testing newly developed coronavirus vaccine begun animal testing goes well new vaccine enter human clinical trials within months also february <NUMBER> zhuhai livanda biotechnology co ltd announced first batch new coronavirus mrna vaccine standard samples completed spring festival delivered relevant national authorities animal testing efficacy verification researchers detected production target antibodies mouse serum day <NUMBER> following immunization company claimed also first time worldwide new coronavirus vaccines developed based mrna technology resulted antibodies animals livanda currently pushing ahead project extensive cooperation academy military medical sciences guangdong provincial institute supervision macau university science technology antigen used development used moderna dna vaccine technology dna vaccine technology may many advantages eg safe fast less technical barriers along potential limitations <NUMBER> phase human clinical trial merscov vaccine proven safety effectiveness <NUMBER> dna vaccine based sarscov protein developed team barney graham gary nabel usnih vaccine research center vrc achieved positive results animal experiments clinical phase trial <NUMBER> <NUMBER> inovio pharmaceuticals accumulated extensive safety immunogenicity data merscov vaccine studies high degree similarity merscov sarscov<NUMBER> lessons vaccine development process may beneficial development dna vaccine sarscov<NUMBER> since january <NUMBER> inovio collaborating several experts companies china currently already begun phase clinical trials dna vaccine ino<NUMBER> chinas cansino biologics might leader announced moved phase ii testing vaccine called ad<NUMBER>ncov latter currently often reported dna vaccine precise uses viral vectors adenovirus deliver dna related sarscov<NUMBER> part project carried currently chinese military medical research institute vaccine candidate constructed using genetic engineering methods defective human type <NUMBER> adenovirus vector express sarscov<NUMBER> antigen stimulate body produce strong humoral cellular immunity sarscov merscov belong subgroups <NUMBER>b <NUMBER>c betacoronaviruses respectively sarscov<NUMBER> new member betacoronaviruses distinct sarscov merscov sarscov sarscov<NUMBER> similar terms invasion selfreplication whereas merscov different targets cellular receptor sarscov sarscov<NUMBER> ace<NUMBER> plus cd<NUMBER> sarscov<NUMBER> merscov dpp<NUMBER> cd<NUMBER> evolved mechanism escape host cell immune system sarscov sarscov<NUMBER> affect ras system suppressing ace<NUMBER> leading onset symptoms merscov causes symptoms producing inflammatory cytokines invading cells sarscov merscov sarscov<NUMBER> infections similar symptoms including fever cough myalgia shortness breath among others current treatments sars mainly include ifnα antiviral treatments eg ribavirin plasma therapy hostdirected therapies systemic corticosteroids mers several therapeutics development including convalescent plasma lopinavirritonavir ribavirin ifn novel therapies including polyclonal antibodies broadspectrum antivirals amps covid<NUMBER> candidates mainly include drugs targeting protein nonstructural proteins <NUMBER>clpro plpro helicase rdrp viral rna synthesis blockers remdesivir ribavirin vaccines dna vaccine mrna vaccine recombinant vaccines rapidly developed far century human beings experienced several epidemic outbreaks outbreak negative impact different levels including health economy even psychology human behavior future precautious measures available guide individuals groups take effective emergency measures support social stability physical mental health furthermore additional studies coronaviruses disease epidemics continue support preparation future responses medical therapies vaccines methods relieving personal anxiety review highlighted several approaches names progress related several compounds biologics currently research development well companies researchers involved efforts future directions also described differences similarities well potential routes possibilities targeting main three viruses investigated rotaviruses rvs compose genus within family reoviridae comprise seven distinct groups ag groups ac rotaviruses currently found humans animals whereas viruses groups dg found animals date knipe peter <NUMBER> rotavirus genome composed <NUMBER> segments doublestranded rna undergo genetic reassortment mixed infections leading progeny viruses novel atypical phenotypes numerous descriptions rotavirus strains isolated human animals share genetic antigenic features viruses heterologous species matthijnssens et al <NUMBER> rahman et al <NUMBER> santos hoshino <NUMBER> recently reports novel rotaviruses apparently derived transmission human sheep ciarlet et al <NUMBER> matthijnssens et al <NUMBER> emergence novel strains derived interspecies transmission implications design implementation successful reassortant rotavirus vaccine strategies group bovine rotaviruses brvs important cause diarrheal diseases neonatal calves cause significant morbidity mortality young animals epidemiologic surveillance bovine rotavirus g genotypes conducted various cattle populations throughout world shown approximately <NUMBER> bovine rotavirus isolates belong g<NUMBER> g<NUMBER> based modified jennerian approach immunization constructed characterized reassortant rotavirus stain bears single bovine rotavirus vp<NUMBER> gene encoding g genotype <NUMBER> specificity remaining <NUMBER> genes derived ovine attenuated rotavirus llr<NUMBER> reassortant rotavirus strain named r<NUMBER> parental virus strain llr<NUMBER> combined bivalent vaccine candidates inoculate colostrumsdeprived neonatal calves evaluation immunogenicity calves orally inoculated reassortant r<NUMBER> group <NUMBER> parental rotavirus llr<NUMBER> group <NUMBER> combined r<NUMBER> llr<NUMBER> group <NUMBER> serum specimens detected determine immune response igg iga antibodies results showed seroconversion positivity igg iga antibodies occurred postinoculation day pid <NUMBER> inoculated calves highest titers serum igg range <NUMBER> <NUMBER> iga range <NUMBER> <NUMBER> antibodies obtained pid <NUMBER> calves meanwhile virus shedding detected inoculation showing inoculated virus positive <NUMBER> <NUMBER> fecal specimens <NUMBER> collected inoculated calves first <NUMBER> days oral inoculation rotavirus vaccine candidates results suggested rotavirus strains r<NUMBER> llr<NUMBER> promising bivalent vaccine candidates prevention bovine g<NUMBER> g<NUMBER> rotavirus infection ß <NUMBER> elsevier bv rights reserved prior studies dual classification system based two major outer capsid proteins defines several g p genotypes group rotaviruses date <NUMBER> g <NUMBER> p genotypes identified based glycosylated vp<NUMBER> proteasesensitive vp<NUMBER> schumann et al <NUMBER> ursu et al <NUMBER> recently novel classification system based nucleotide sequences rotavirus genome segments suggested matthijnssens et al <NUMBER>ab enabling comprehensive characterization rotavirus strains based nucleotide identity cutoff percentages different genotypes defined genome segment calculated cutoff values <NUMBER> rotavirus rna segments vp<NUMBER> vp<NUMBER> vp<NUMBER> vp<NUMBER> vp<NUMBER> vp<NUMBER> nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively designate complete genetic makeup virus schematic nomenclature proposed gxpxixrxcxmxaxnxtxexhx representing genotypes respectively vp<NUMBER>vp<NUMBER>vp<NUMBER>vp<NUMBER>vp<NUMBER>vp<NUMBER>nsp<NUMBER>nsp<NUMBER>nsp<NUMBER>nsp<NUMBER>nsp<NUMBER> encoding gene segments x indicating number corresponding genotypes group rotaviruses transmitted fecaloral route selectively infect mature villous absorptive epithelial cells holland <NUMBER> cause disease varies severity including asymptomatic infection mild selflimiting diarrhea severe diarrhea excessive fluid loss severe electrolyte imbalance diarrhea one important diseases neonatal dairy beef calves substantial economic loss occurs due increased morbidity mortality treatment costs reduced growth rates house <NUMBER> example livestock poultry production <NUMBER> billion per year industry united states estimated suffer <NUMBER> annual loss potential productivity disease environmental problems united states department agriculture <NUMBER> calf loss diarrhea important segment total loss cattle industry reported late <NUMBER>s enteric pathogens killed <NUMBER> calves per year resulting <NUMBER> million losses hunt <NUMBER> rotavirus coronavirus escherichia coli strain k<NUMBER> coccidia cryptosporidium parvum main infectious agents inducing enteric infections neonatal calves less <NUMBER> months age among pathogens described rotavirus major cause neonatal bovine diarrhea bellinzoni et al <NUMBER> bendali et al <NUMBER> de la fuente et al <NUMBER> maes et al <NUMBER> reynolds et al <NUMBER> found responsible approximately <NUMBER> scours cases dairy calves snodgrass et al <NUMBER> addition causing economic losses diarrhea livestock important public health implications thus availability safe effective bovine rotavirus vaccine capable preventing enormous economic public health burden would represent global goal advent <NUMBER> first licensed human rotavirus vaccine rrv rhesus rotavirus based quadrivalent vaccine rotashield tm wyethlederle vaccines pediatrics philadelphia pa kapikian <NUMBER> provided impetus expansion programs global human rotavirus strain surveillance assessment rotavirus disease burden addition availability early <NUMBER>s reliable relatively easy methodology rotavirus g p genotyping accelerated trend das et al <NUMBER> fischer gentsch <NUMBER> gentsch et al <NUMBER> gouvea et al <NUMBER> information indeed influenced approaches development effective rotavirus vaccine example additional candidate human rotavirus vaccines constructed would give antigenic coverage g<NUMBER>g<NUMBER> also g<NUMBER> g<NUMBER> g<NUMBER> well p<NUMBER>a<NUMBER> p<NUMBER>b<NUMBER> p<NUMBER>a<NUMBER> however limited research field animal rotavirus vaccine bovine rotavirus isolate lincoln strain g<NUMBER> genotype adapted serial propagation cell culture fernelius et al <NUMBER> mebus et al <NUMBER> resulted attenuated virus calves mebus et al <NUMBER> attenuated strain incorporated vaccine licensed us department agriculture usda <NUMBER> oral inoculation newborn calves intramuscular inoculation pregnant cows provide passive protection calves apart advent new bovine rotavirus vaccine world field surveys demonstrated far g genotype g<NUMBER> g<NUMBER> epidemiologically important bovine rotavirus genotypes worldwide accounting <NUMBER> rotaviruscaused diarrhea approximately next g<NUMBER> g<NUMBER> genotypes g<NUMBER> third typical bovine rotavirus genotype alfieri et al <NUMBER> chang et al <NUMBER> falcone et al <NUMBER> garaicoechea et al <NUMBER> monini et al <NUMBER> parwani et al <NUMBER> reidy et al <NUMBER> snodgrass et al <NUMBER> china epidemiologic surveillance shown rotavirus diarrhea one important diseases neonatal calves g<NUMBER> g<NUMBER> also determined prevalent genotype bovine rotaviruses using nested rtpcr sequencing chang et al <NUMBER> since monovalent rotavirus vaccine cannot completely protect heterologous rotavirus infection feng et al <NUMBER> multivalent rotavirus vaccine candidates important research goal protective immunity rotaviruses addition reassortant rotavirus vaccine approaches successfully employed develop various human rotavirus candidate vaccines include rhesus rotavirus based bovine rotavirus based multivalent vaccines listed earlier hoshino et al <NUMBER> hoshino et al <NUMBER> midthun et al <NUMBER> midthun et al <NUMBER> study ovine rotavirus strain llr<NUMBER>based bovine rotavirus reassortant constructed combined parental virus llr<NUMBER> bivalent vaccine candidates providing attenuation phenotype ovine rotavirus bovines antigenic coverage main bovine rotavirus genotypes g<NUMBER> g<NUMBER> study showed bivalent vaccine candidates induce immune response igg iga antibodies sera inoculated colostrumdeprived neonatal calves fecal shedding rotavirus uncommon following oral inoculation calves rotavirus vaccine candidates bovine rotavirus strain ncdv g<NUMBER> p<NUMBER> originally isolated stool neonatal calf diarrhea nebraska usa <NUMBER> fernelius et al <NUMBER> obtained commercially china institute veterinary drug control beijing ovine rotavirus strain llr<NUMBER> g<NUMBER> p<NUMBER> chen et al <NUMBER> knipe peter <NUMBER> initially derived lamb diarrhea qinghai province china <NUMBER> zhou et al <NUMBER> propagated monovalent human rotavirus vaccine llr lanzhou institute biological products china bai et al <NUMBER> virus strains adapted growth ma<NUMBER> cell line passaged <NUMBER> times dmem medium gibco triple plaque purification colostrumdeprived newborn calves without antibodies rotavirus divided three groups orally inoculate candidate vaccines within <NUMBER> h birth calves kept separate group fed substituted milk primers amplification gene segments vp<NUMBER> vp<NUMBER> nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> synthesized table <NUMBER> based previous study park et al <NUMBER> rtpcr carried initial reverse transcription step <NUMBER> min <NUMBER> <NUMBER>c followed pcr activation <NUMBER> <NUMBER>c <NUMBER> min <NUMBER> cycles amplification <NUMBER> <NUMBER> <NUMBER>c <NUMBER> <NUMBER> <NUMBER>c <NUMBER>s <NUMBER> <NUMBER>c vp<NUMBER> vp<NUMBER> nsp<NUMBER> nsp<NUMBER> <NUMBER> <NUMBER> <NUMBER>c <NUMBER> <NUMBER> <NUMBER>c <NUMBER>s <NUMBER> <NUMBER>c nsp<NUMBER> nsp<NUMBER> final extension <NUMBER> min <NUMBER> <NUMBER>c pcr amplicons purified gel extraction kit tiangen biotech co ltd china sequenced shanghai sangon biological engineering technology services co ltd china sequences analyzed lasergene software version <NUMBER> rna polyacrylamide gel electrophoresis page done previously described chudzio et al <NUMBER> briefly supernatant culture lysates mixed equal volume rna extraction buffer <NUMBER> trishydrochloride ph <NUMBER> <NUMBER> nacl <NUMBER> mgcl <NUMBER> <NUMBER> sodium dodecyl sulfate <NUMBER> edta <NUMBER> sucrose <NUMBER> bromophenol blue preparation mixed onetenth volume phenolchloroform <NUMBER> vortexed <NUMBER> yield homogeneous suspension followed spinning microcentrifuge <NUMBER> â g <NUMBER> min upper layer dark blue solution containing doublestranded segments rna collected stored <NUMBER> <NUMBER>c à<NUMBER> <NUMBER>c electrophoretic analysis standard <NUMBER> polyacrylamide gel electrophoresis genomic rnas electrophoresed <NUMBER> <NUMBER> h resulting migration patterns visualized staining gel silver nitrate confluent cell line fetal rhesus monkey kidney ma<NUMBER> coinfected multiplicity infection moi one bovine rotavirus strain ncdv ovine rotavirus strain llr<NUMBER> approximately <NUMBER> infected cells exhibited cytopathic effects cultures frozen thawed three times lysate plated ma<NUMBER> cells sixwell plate selection desired reassortant desired reassortant plaque purified three times ma<NUMBER> cells genomic rnas analyzed page confirm origin genes reassortant parental origin gene questionable page indistinguishable rna segments analyzed sequence analysis confirmation plaque assay performed techniques similar matsuno et al <NUMBER> briefly ma<NUMBER> cell monolayers prepared sixwell tissue culture dishes washed three times pbs buffer serial tenfold dilutions virus prepared dmem without fbs inoculated <NUMBER>ml amounts <NUMBER> h adsorption <NUMBER> <NUMBER>c culture received <NUMBER> ml agar overlay medium consisted <NUMBER> purified agar dmem containing <NUMBER> mg trypsin per ml agar overlay solidified dishes placed inverted position co <NUMBER> incubator <NUMBER> <NUMBER>c <NUMBER> days equal amount second agar overlay medium containing <NUMBER> purified agar dmem <NUMBER> neutral red added plaques counted next day two calves orally inoculated <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> attenuated llr<NUMBER> two calves orally inoculated <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> reassortant r<NUMBER> seven calves orally inoculated simultaneously <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> attenuated llr<NUMBER> <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> reassortant r<NUMBER> table <NUMBER> rectal swab specimens collected day <NUMBER>day experimental period postinoculation detect rotavirus blood samples collected postinoculation days pids <NUMBER> <NUMBER> <NUMBER> <NUMBER> processed serum kept à<NUMBER> <NUMBER>c tested plates coated overnight <NUMBER> <NUMBER>c semipurified brv mockinfected cell culture supernatant <NUMBER> carbonatebicarbonate buffer ph <NUMBER> followed blocking step <NUMBER> h <NUMBER> <NUMBER>c <NUMBER> nonfat dry milk plates washed three times <NUMBER> tween <NUMBER> pbs ph <NUMBER> serial twofold dilutions starting <NUMBER> test sample added duplicate wells incubated <NUMBER> h <NUMBER> <NUMBER>c washing plates incubated horseradish peroxidaseconjugated monoclonal antibodies bovine igg iga dilution <NUMBER> <NUMBER> respectively <NUMBER> h <NUMBER> <NUMBER>c washing plates incubated <NUMBER> tmb <NUMBER> <NUMBER> <NUMBER> <NUMBER> tetramethylbenzidine substrate <NUMBER> min room temperature reaction stopped <NUMBER> h <NUMBER> <NUMBER> <NUMBER> read using elisa platereader zenyth <NUMBER> hvd anthos elisa antibody titer sample expressed reciprocal highest dilution corrected <NUMBER> value sample absorbance viruscoated well minus sample absorbance mock antigencoated well greater cutoff value mean corrected <NUMBER> negative controls <NUMBER>sd parreno et al <NUMBER> et al <NUMBER> view rotavirus genotypes g<NUMBER> g<NUMBER> predominating cattle worldwide jennerian modified jennerian approaches successfully employed develop various rotavirus candidate vaccines constructed g<NUMBER>based bovine rotavirus reassortant followed molecular biological characterization ma<NUMBER> cells coinfected bovine rotavirus strain ncdv ovine rotavirus strain llr<NUMBER> moi one progeny viruses grew without selective pressure generating resssortant <NUMBER> plaques picked screen llr<NUMBER>based reassortant single ncdvvp<NUMBER> gene substitution plaques routinely picked initial screening rna page analysis indistinguishable rna segments analyzed sequence analysis confirmation indicated fig <NUMBER> electrophoretic migration patterns genomic rnas parental viruses table <NUMBER> inoculation colostrumsdeprived calves rotavirus vaccine candidates detection rotavirus fecal specimens calf inoculum postinoculation day rotavirus detected <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> r<NUMBER> à à à à à à à <NUMBER> à à à à à à à <NUMBER> <NUMBER> llr<NUMBER> à à à à à à à <NUMBER> à à à à à à à <NUMBER> <NUMBER> llr<NUMBER> r<NUMBER> à à à à à à à <NUMBER> à à à à à à à <NUMBER> à à à à à <NUMBER> à à à à à à à <NUMBER> à à à à à à à <NUMBER> à à à à à à à <NUMBER> à à à à à à à à refers negative rotavirus rtpcr refers positive rotavirus rtpcr <NUMBER> indicating replication efficiency reassortant r<NUMBER> ma<NUMBER> cells influenced substitution vp<NUMBER> gene evaluate humoral immune responses induced oral administrations reassortant rotavirus r<NUMBER> one parental viruses llr<NUMBER> colostrumsdeprived newborn calves without antibodies rotavirus orally inoculated reassortant r<NUMBER> andor parental virus llr<NUMBER> within <NUMBER> h birth described table <NUMBER> two calves group <NUMBER> inoculated reassortant r<NUMBER> another two calves group <NUMBER> inoculated parental rotavirus llr<NUMBER> seven calves group <NUMBER> simultaneously inoculated reassortant r<NUMBER> parental rotavirus llr<NUMBER> blood samples collected pids <NUMBER> <NUMBER> <NUMBER> <NUMBER> prepare serum sera diluted hundredfold detect igg iga antibodies group rotavirus indirect elisa kinetics rotavirusspecific igg iga antibodies sera calves inoculated rotavirus vaccine candidates depicted fig <NUMBER> results showed seroconversion igg iga antibodies rotavirus occurred pid <NUMBER> inoculated calves increased peak pid <NUMBER> serum samples pid <NUMBER> calves serially twofold diluted starting dilution <NUMBER> followed detection titers rotavirusspecific igg iga antibodies group rotavirus indirect elisa results showed titers serum igg antibodies <NUMBER> <NUMBER> titers serum iga antibodies <NUMBER> <NUMBER> table <NUMBER> order determine profile virus shedding inoculation rotavirus vaccine candidates fecal rotavirus shedding investigated day <NUMBER>day experimental period postinocuation lowspeed centrifugation supernatants suspensions rectal swab specimens detected typed rtpcr gouvea et al <NUMBER> gouvea et al <NUMBER> results described table <NUMBER> results showed three inoculated groups first <NUMBER> days oral inoculation rotavirus vaccine candidates <NUMBER> <NUMBER> fecal specimens <NUMBER> collected <NUMBER> inoculated calves contained inoculated rotavirus two rotaviruspositive specimens collected calf <NUMBER> group <NUMBER> first third day postinoculation inoculated rotavirus detected fecal specimens collected inoculated calves <NUMBER> <NUMBER> days postinoculation prior study theil mccloskey <NUMBER> rotavirus detected <NUMBER> <NUMBER> daily fecal specimens collected calves following oral inoculation usdalicensed modified live bovine rotaviruscoronavirus vaccine study low shedding rate <NUMBER> <NUMBER> similar result <NUMBER> <NUMBER> <NUMBER> previous study indicating vaccine candidates safe well tolerated colostrumsdeprived neonatal calves <NUMBER> previously unrecognized virus recovered diarrheic calves nebraska usa described shown induce diarrhea experimentally inoculated hysterectomyderived colostrumdeprived calves mebus et al <NUMBER> virus initially referred neonatal calf diarrhea virus nebraska calf diarrhea virus reolike virus reoviruslike agent known bovine rotavirus name rotavirus ultimately chosen wheellike appearance virus transmission electron microscopy tem today rotaviral infections proven common economically important cause calf diarrhea throughout world genotypic analyses major neutralization protein vp<NUMBER> bovine rotavirus diarrheal stools collected different cattle populations throughout world shown majority typeable rotavirus isolates belong g genotypes <NUMBER> <NUMBER> alfieri et al <NUMBER> chang et al <NUMBER> falcone et al <NUMBER> garaicoechea et al <NUMBER> monini et al <NUMBER> parwani et al <NUMBER> reidy et al <NUMBER> snodgrass et al <NUMBER> since first licensed bovine rotavirus vaccine monovalent one monovalent rotavirus vaccine cannot completely protect heterologous rotavirus infection feng et al <NUMBER> constructed reassortant rotavirus strain r<NUMBER> contains single vp<NUMBER> gene encoding genotype g<NUMBER> specificity bovine rotavirus ncdv strain remaining <NUMBER> genes ovine rotavirus strain llr<NUMBER> reassortant r<NUMBER> parental rotavirus strain llr<NUMBER> used bivalent vaccine candidates provide attenuation phenotype ovine rotavirus bovines ii antigenic coverage g<NUMBER> g<NUMBER> main bovine rotavirus genotypes attenuated virus strains r<NUMBER> llr<NUMBER> shown experimentally colostrumdeprived neonatal calves able induce high levels serum igg iga antibodies rotavirus whereas fecal shedding rotaviruses uncommon inoculated calves therefore promising bivalent vaccine candidates prevention bovine g<NUMBER> g<NUMBER> rotavirus infection benefits using llr<NUMBER> strain instead attenuated bovine rotavirus strain production reassortant vaccine purposes former attenuated calves due host range restriction latter often unstable may develop back mutation thus llr<NUMBER> safe calves secondly passage history llr<NUMBER> clear attenuated strain lambs children bai et al <NUMBER> therefore safe people public health problem thirdly rna segments llr<NUMBER> easily distinguished page electrophoretic migration pattern useful identify reassortant lastly importantly llr<NUMBER> strain highly immunogenic neonatal calves nucleotide mutations vp<NUMBER> nsp<NUMBER> vp<NUMBER> nsp<NUMBER> gene segments r<NUMBER> occurred process <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> igg <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> iga <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> calves group <NUMBER> inoculated r<NUMBER> calves group <NUMBER> inoculated llr<NUMBER> calves group <NUMBER> simultaneously inoculated r<NUMBER> llr<NUMBER> generation purification reassortant existed insignificant differences <NUMBER> nucleotides nt <NUMBER>nt <NUMBER>nt <NUMBER>nt r<NUMBER> parental llr<NUMBER> vp<NUMBER> nsp<NUMBER> vp<NUMBER> nsp<NUMBER> gene segments respectively obviously possible reasons induce nucleotide mutations serial tissue culture passage sixtime plaque purifications reassortant r<NUMBER> ma<NUMBER> cells mechanisms responsible immunity rotavirus infections illness completely understood animals knipe peter <NUMBER> animal models particularly instructive elucidating role antibodies dissecting relative importance systemic local immunity initially observations related studies suggested antibodies lumen small intestine primary determinant resistance rotavirus illness whereas circulating serum antibodies failed protect offit clark <NUMBER> snodgrass wells <NUMBER> woode et al <NUMBER> subsequent study showed systemic rotavirus antibodies present lumen gastrointestinal tract neonatal calves level circulating antibodies sufficiently high serumderived mucosal antibodies provide protection experimentally induced infection diarrhea besser et al <NUMBER> association titers serum antirotavirus igg iga antibodies protection infection illness investigated <NUMBER> children <NUMBER> months age attending day care centers united states one two rotavirus seasons oryan et al <NUMBER> studies showed preexisting serum antirotavirus iga titer greater <NUMBER> igg titer greater <NUMBER> associated protection infection similar study mexican infants also demonstrated serum iga igg protective titers needed achieve significant protection higher found us study velazquez et al <NUMBER> previous studies association serum antirotavirus antibodies protection infection illness suggested serum antibodies present critical levels either protective important powerful correlate protection rotavirus disease even though host effectors may play important role well study want evaluate immunogenicity rotavirus vaccine candidates used major structural protein virus particles semipurified brv antigen detect igg iga antibodies group rotavirus serum inoculated calves results showed highest titers serum igg iga antibodies obtained pid <NUMBER> calves inoculated groups developed high levels serum antirotavirus igg antibodies range <NUMBER> <NUMBER> serum antirotavirus iga antibodies range <NUMBER> <NUMBER> results suggested animals inoculated llr<NUMBER>based vaccine candidates would develop antibodies inoculated viruses indicated attenuated virus strains llr<NUMBER> r<NUMBER> well immunogenic neonatal calves preexisting serum antirotavirus iga titers range <NUMBER> <NUMBER> reached level protective immunity however evaluation needed protective immune response llr<NUMBER>based candidate vaccines future trials date criterion fecal shedding rate rotavirus vaccine strains prior study vaccine rotavirus detected <NUMBER> <NUMBER> daily fecal specimens collected calves following oral inoculation usdalicensed modified live bovine rotaviruscoronavirus vaccine using negative stain electron microscopy contrast rotavirus demonstrable negative stain electron microscopic examination procedure <NUMBER> <NUMBER> fecal specimens collected calves inoculation virulent bovine rotavirus field strains theil mccloskey <NUMBER> study vaccine rotavirus detected <NUMBER> <NUMBER> daily rectal swab specimens collected <NUMBER> neonatal calves following oral inoculation rotavirus vaccine candidates low shedding rate <NUMBER> <NUMBER> similar result previous study <NUMBER> <NUMBER> suggesting r<NUMBER> llr<NUMBER> safe calves based uncommon fecal shedding rotavirus procedure used present study successful construction selection single vp<NUMBER> gene substitution reassortant rotavirus vaccine relatively easy perform recent years rare genotypes bovine rotavirus g<NUMBER> g<NUMBER> also isolated calves ghosh et al <NUMBER> park et al <NUMBER> procedure additional llr<NUMBER>based reassortant rotavirus vaccine candidates carry vp<NUMBER> gene encoding desired bovine rotavirus g genotype specificity generated readily future need g genotypes warranted epidemiologic studies recent decades world shaken emergence spread new viral diseases although worlds response <NUMBER> ebola epidemic laudable general consensus much could done prevent deaths thousands people billions dollars economic damage result epidemic <NUMBER> despite many laboratory studies candidate vaccines trials vesicular stomatitis virusebola virus vaccine merck kenilworth new jersey guinea <NUMBER> vaccine ever developed time alter course new disease outbreak vaccine arrived late epidemic <NUMBER> quite recently coordination stakeholder responses across institutions sectors lagged behind epidemic curves emerging infectious diseases eids <NUMBER> research development rd priorities improving preparedness driven primarily bioterrorism concerns countries leaving sparse product development pipelines eids fall outside national security agendas <NUMBER> addition development eid countermeasures unappealing manufacturers see little commercial benefit sporadic disease burden lengthy risky costly product development <NUMBER> challenges notwithstanding west african ebola epidemic led paradigm shift eid preparedness <NUMBER> <NUMBER> experimental vaccines therapeutics deployed outbreak thanks decade rd biodefenserelated ebola countermeasures vesicular stomatitis virusebola virus vaccine manufactured merck demonstrated effectiveness field trials <NUMBER> however none products ready deploy time change course outbreak due insufficiency clinical data safety efficacy plus absence product stockpiles although trials assessing vesicular stomatitis virusebola virus vaccine commence late epidemic success suggested pathway better preparedness future epidemics namely advancement biomedical countermeasures human trials anticipation emergencies making promising quickly available efficacy testing use emergencies occur acknowledgment better system would needed improve worlds preparedness response capacity future epidemic threats <NUMBER> <NUMBER> <NUMBER> <NUMBER> several important initiatives launched shortly <NUMBER> ebola epidemic contained may <NUMBER> world bank established pandemic emergency finance facility quickly release funds affected countries epidemic responses <NUMBER> time world health organization published blueprint priority diseases list eid preparedness response identifying <NUMBER> pathogens potential cause severe outbreaks near term initial list may <NUMBER> <NUMBER> <NUMBER> comprised crimeancongo hemorrhagic fever priority list ebola virus disease marburg virus disease priority list lassa fever priority list merscov severe acute respiratory syndrome priority list nipah henipaviral diseases priority list rift valley fever priority list zika virus priority list disease x priority list arenaviral hemorrhagic fevers lassa fever watchlist chikungunya watchlist highly pathogenic coronaviral diseases mers severe acute respiratory syndrome watchlist emergent nonpolio enteroviruses including ev<NUMBER> d<NUMBER> watchlist severe fever thrombocytopenia syndrome watchlist earlier year inspired call new vaccine fund <NUMBER> global thought leaders governments industry civil society also met world economic forum davos switzerland agreed explore new ways drive product innovation highpriority epidemic threats <NUMBER> davos <NUMBER> meeting <NUMBER> task teams convened <NUMBER> february june define sustainable solutions development eid vaccines improve global preparedness response capacity <NUMBER> <NUMBER> <NUMBER> <NUMBER> task teams comprised <NUMBER> thought leaders experts representing <NUMBER> organizations drew insights blueprint priorities <NUMBER> industry civilsociety perspectives role vaccines prevention humanitarian crises caused eids task team explored challenges development eid vaccines could used epidemics including pathogen prioritization clinical development manufacturing capacity regulatory pathways models product development partnerships funding strategies <NUMBER> <NUMBER> task team recommendations led formation coalition epidemic preparedness innovations cepi <NUMBER> <NUMBER> coalition design cepi reflects explicit awareness organization drive vaccine development known eids unknown pathogens epidemic potential ie disease x alone together multilateral collaborative approach complexities vaccine development delivery addressed public good cepi formally launched <NUMBER> world economic forum meeting davos close us<NUMBER> million initial funding governments norway japan germany bill melinda gates foundation wellcome <NUMBER> cepis initial strategic objectives established <NUMBER> <NUMBER> aimed advancing vaccine candidates first priority pathogens lassa virus merscov nipah virus evidence safety immunogenicity humans phase <NUMBER>a <NUMBER> establish diverse portfolio platform technologies accelerate development manufacture clinical evaluation vaccines response outbreaks new eids designated disease x january <NUMBER> cepi expanded list priority pathogens include chikungunya rift valley fever according initial estimates minimum <NUMBER> billion would required bring least <NUMBER> eid vaccines end phase <NUMBER>a trials fund investigational stockpiles case international health emergency <NUMBER> two years operation cepi already secured <NUMBER> million support mission contributions <NUMBER> government donors european commission <NUMBER> philanthropic organizations three calls proposals issued inviting applications rd investment two calls invited applications vaccine development specific priority eids initially lassa virus merscov nipah virus <NUMBER> recently rift valley fever chikungunya another call invited applications rapidresponse platform technologies accelerate development vaccines response epidemic outbreaks known eids unexpectedly emerging infections disease x <NUMBER> socalled vaccine platform technologies comprise standardized reproducible manufacturing processes adapted produce vaccines different pathogens flexibility platforms improves manufacturing efficiency shorten overall time frame vaccine development <NUMBER> <NUMBER> <NUMBER> cepi also recently invited proposals bloodspecimen collection survivors lassa fever support improved characterization immune response support development assays standards approach prove effective lassa virus cepi also consider expanding merscov nipah virus september <NUMBER> cepi signed <NUMBER> partnership agreements vaccine development partners table <NUMBER> agreements enable accelerated development lassa merscov nipah rift valley fever vaccine candidates <NUMBER> years late preclinical phase phase <NUMBER> manufacture investigational stockpile use largescale efficacy trials outbreak well latestage clinical development advanced chikungunya vaccines accelerate regulatory approval atrisk populations access vaccines far cepi initiated projects develop <NUMBER> vaccine candidates priority pathogensincluding <NUMBER> lassa virus <NUMBER> merscov <NUMBER> nipah virus <NUMBER> rift valley fever <NUMBER> chikungunyaand <NUMBER> vaccine manufacturing platforms demonstrate advantage platforms additional vaccine candidates produced tested including <NUMBER> influenza <NUMBER> rabies <NUMBER> merscov <NUMBER> marburg virus <NUMBER> lassa fever <NUMBER> respiratory syncytial virus <NUMBER> yellow fever <NUMBER> approaches rna vaccines earlier phases development show great promise application multiple pathogens rapid production addition cepi set aside funds support development ebola vaccines research funding complementary current efforts field investments coordinated funders necessary avoid duplication work past <NUMBER> years cepi made efforts engage coordinate work partners throughout global health vaccine development ensure sustainability approach vaccine development coalition working industry partnersfrom small biotechnology companies large manufacturersthrough partnerships share risks vaccine development table <NUMBER> cepi also coordinates efforts several multilateral partners principally interinstitutional roundtable refer joint coordination group joint coordination group includes key organizations responsible vaccine procurement delivery implementation well representatives important regulatory agencies works identify ways predictable access vaccines priority populations achieved emergency situations overall goal joint coordination group optimize allocation resources across disease areas vaccine development minimize funding overlap partners improve response times unexpected epidemic threats preparing next epidemic requires investment platforms capable rapid vaccine development coordination among multiple stakeholders cepi coalition partners committed substantial resources attention cepi begins turn promises progress several challenges ought acknowledged first vaccine development widely acknowledged long complex process often lasting <NUMBER> years discovery licensure <NUMBER> second vaccine development inherently risky least twothirds preclinical vaccine candidates likely fail reaching clinical proof concept <NUMBER> view risk failure full cost successfully advancing vaccine candidate preclinical clinical efficacy trials readiness emergency use vary average <NUMBER> million <NUMBER> million <NUMBER> cepi far committed <NUMBER> million eid vaccinedevelopment projects whereas full costs vaccine development expected shared funding development partners concrete clinical outcomes likely going take several years materialize vaccines developed eids prioritized average <NUMBER> billion would needed support vaccine development phase <NUMBER> trials depending cost structures vaccine development programs rd pipeline attrition <NUMBER> improved coordination among industry global health civilsociety institutions guidance regulators also needed determine public health needs key diseases iron technical regulatory pathways feasible vaccine development additional resources become available <NUMBER> cepi diversifying current vaccine rd investment portfolio include additional pathogens beginning chikungunya debilitating mosquitoborne disease spread aedes aegypti albopictus affects millions people globally rift valley fever viral zoonosis cattle domesticated livestock also infects humans <NUMBER> chikungunya infection lead substantial morbidity patients experience arthralgia months even years chronic inflammatory rheumatic disease develops small subset patients <NUMBER> substantial burden disease example coupled large vaccine pipeline relative eids could justify investments might yield clinically relevant outcomes shorter time quantity antigen generally expected different across eids however knowing quantity antibody would required induce protection chikungunya could make identification situations would allow statistical demonstration efficacy challenging feasibility development would consequently depend technical hurdles regulatory guidance appropriate clinical trial design case rift valley fever <NUMBER> outbreaks occurred <NUMBER> <NUMBER> <NUMBER> confirmed suspected cases <NUMBER> deaths <NUMBER> viral transmission people occurs primarily contact blood organs infected animals <NUMBER> however aedes culex mosquitoes also act viral reservoirs vectors <NUMBER> rift valley fever wide geographical range spreading throughout africa saudi arabian peninsula <NUMBER> risk spread europe north america also high <NUMBER> licensed vaccine available human use least <NUMBER> vaccine candidates currently phase <NUMBER> trials <NUMBER> definition regulatory pathways clinical trials emergency use need account specifics vaccine challenges posed eid present unclear regulatory processes vaccine candidates could accelerated event outbreak known eids disease x enhanced regulatory guidance normative directions coalition partners needed approval clinical trials equitable access eid vaccines outbreaks prioritization various countermeasures eg human vaccine vs animal vaccines combinations might also required optimize development effective preparedness strategies unexpected emergencies related eid outbreaks rift valley fever merscov eid threats evolve increased coordination public health agencies worldwide required ensure product development prioritized accordingly sustainable manufacturing solutions also need negotiated soon vaccine candidates nearing completion safety immunogenicity testing humans mechanisms funding maintaining global stockpiles investigational vaccines must established vaccine candidates continue move development cepi coalition partners soon must lay concrete plan procurement stockpiling system could established much system would cost would operated would need operationalized eids remain major threat global health security <NUMBER> years <NUMBER> ebola outbreak west africa threat likely grow coming years various ecological demographic economic factors accelerate disease emergence reemergence <NUMBER> alone outbreaks <NUMBER> <NUMBER> priority pathogens <NUMBER> including <NUMBER> separate ebola outbreaks democratic republic congo thankfully thousands doses vesicular stomatitis virusebola virus vaccine already manufactured vaccines rollout help avert largescale epidemic context ebola cepi plans make rd investments complement current research efforts thanks partnership efforts cepi broad range vaccine developers <NUMBER> vaccine candidates lassa fever <NUMBER> merscov <NUMBER> nipah virus development <NUMBER> rift valley vaccine candidates initiate latestage preclinical development <NUMBER> chikungunya vaccine candidates resume latestage clinical development additional cepi funding vaccine candidates hopefully meet safety immunogenicity profiles required investigational stockpiling use large clinical trials humanitarian responses outbreak conditions development <NUMBER> rapidresponse platform technologies threatening eids also initiated including pilots lassa fever merscov influenza rabies respiratory syncytial virus marburg virus yellow fever cepi continue enhance epidemic preparedness targeted funding technical oversight ultimately however cepis success depend strength coalitions collaborative efforts across sectors institutions geographic regions develop effective eid vaccines ensure equitable access global health emergencies recent decades world shaken emergence spread new viral diseases although worlds response <NUMBER> ebola epidemic laudable general consensus much could done prevent deaths thousands people billions dollars economic damage result epidemic <NUMBER> despite many laboratory studies candidate vaccines trials vesicular stomatitis virusebola virus vaccine merck kenilworth new jersey guinea <NUMBER> vaccine ever developed time alter course new disease outbreak vaccine arrived late epidemic <NUMBER> quite recently coordination stakeholder responses across institutions sectors lagged behind epidemic curves emerging infectious diseases eids <NUMBER> research development rd priorities improving preparedness driven primarily bioterrorism concerns countries leaving sparse product development pipelines eids fall outside national security agendas <NUMBER> addition development eid countermeasures unappealing manufacturers see little commercial benefit sporadic disease burden lengthy risky costly product development <NUMBER> challenges notwithstanding west african ebola epidemic led paradigm shift eid preparedness <NUMBER> <NUMBER> experimental vaccines therapeutics deployed outbreak thanks decade rd biodefenserelated ebola countermeasures vesicular stomatitis virusebola virus vaccine manufactured merck demonstrated effectiveness field trials <NUMBER> however none products ready deploy time change course outbreak due insufficiency clinical data safety efficacy plus absence product stockpiles although trials assessing vesicular stomatitis virusebola virus vaccine commence late epidemic success suggested pathway better preparedness future epidemics namely advancement biomedical countermeasures human trials anticipation emergencies making promising quickly available efficacy testing use emergencies occur acknowledgment better system would needed improve worlds preparedness response capacity future epidemic threats <NUMBER> <NUMBER> <NUMBER> <NUMBER> several important initiatives launched shortly <NUMBER> ebola epidemic contained may <NUMBER> world bank established pandemic emergency finance facility quickly release funds affected countries epidemic responses <NUMBER> time world health organization published blueprint priority diseases list eid preparedness response identifying <NUMBER> pathogens potential cause severe outbreaks near term initial list may <NUMBER> <NUMBER> <NUMBER> comprised crimeancongo hemorrhagic fever priority list ebola virus disease marburg virus disease priority list lassa fever priority list merscov severe acute respiratory syndrome priority list nipah henipaviral diseases priority list rift valley fever priority list zika virus priority list disease x priority list arenaviral hemorrhagic fevers lassa fever watchlist chikungunya watchlist highly pathogenic coronaviral diseases mers severe acute respiratory syndrome watchlist emergent nonpolio enteroviruses including ev<NUMBER> d<NUMBER> watchlist severe fever thrombocytopenia syndrome watchlist earlier year inspired call new vaccine fund <NUMBER> global thought leaders governments industry civil society also met world economic forum davos switzerland agreed explore new ways drive product innovation highpriority epidemic threats <NUMBER> davos <NUMBER> meeting <NUMBER> task teams convened <NUMBER> february june define sustainable solutions development eid vaccines improve global preparedness response capacity <NUMBER> <NUMBER> <NUMBER> <NUMBER> task teams comprised <NUMBER> thought leaders experts representing <NUMBER> organizations drew insights blueprint priorities <NUMBER> industry civilsociety perspectives role vaccines prevention humanitarian crises caused eids task team explored challenges development eid vaccines could used epidemics including pathogen prioritization clinical development manufacturing capacity regulatory pathways models product development partnerships funding strategies <NUMBER> <NUMBER> task team recommendations led formation coalition epidemic preparedness innovations cepi <NUMBER> <NUMBER> coalition design cepi reflects explicit awareness organization drive vaccine development known eids unknown pathogens epidemic potential ie disease x alone together multilateral collaborative approach complexities vaccine development delivery addressed public good cepi formally launched <NUMBER> world economic forum meeting davos close us<NUMBER> million initial funding governments norway japan germany bill melinda gates foundation wellcome <NUMBER> cepis initial strategic objectives established <NUMBER> <NUMBER> aimed advancing vaccine candidates first priority pathogens lassa virus merscov nipah virus evidence safety immunogenicity humans phase <NUMBER>a <NUMBER> establish diverse portfolio platform technologies accelerate development manufacture clinical evaluation vaccines response outbreaks new eids designated disease x january <NUMBER> cepi expanded list priority pathogens include chikungunya rift valley fever according initial estimates minimum <NUMBER> billion would required bring least <NUMBER> eid vaccines end phase <NUMBER>a trials fund investigational stockpiles case international health emergency <NUMBER> two years operation cepi already secured <NUMBER> million support mission contributions <NUMBER> government donors european commission <NUMBER> philanthropic organizations three calls proposals issued inviting applications rd investment two calls invited applications vaccine development specific priority eids initially lassa virus merscov nipah virus <NUMBER> recently rift valley fever chikungunya another call invited applications rapidresponse platform technologies accelerate development vaccines response epidemic outbreaks known eids unexpectedly emerging infections disease x <NUMBER> socalled vaccine platform technologies comprise standardized reproducible manufacturing processes adapted produce vaccines different pathogens flexibility platforms improves manufacturing efficiency shorten overall time frame vaccine development <NUMBER> <NUMBER> <NUMBER> cepi also recently invited proposals bloodspecimen collection survivors lassa fever support improved characterization immune response support development assays standards approach prove effective lassa virus cepi also consider expanding merscov nipah virus september <NUMBER> cepi signed <NUMBER> partnership agreements vaccine development partners table <NUMBER> agreements enable accelerated development lassa merscov nipah rift valley fever vaccine candidates <NUMBER> years late preclinical phase phase <NUMBER> manufacture investigational stockpile use largescale efficacy trials outbreak well latestage clinical development advanced chikungunya vaccines accelerate regulatory approval atrisk populations access vaccines far cepi initiated projects develop <NUMBER> vaccine candidates priority pathogensincluding <NUMBER> lassa virus <NUMBER> merscov <NUMBER> nipah virus <NUMBER> rift valley fever <NUMBER> chikungunyaand <NUMBER> vaccine manufacturing platforms demonstrate advantage platforms additional vaccine candidates produced tested including <NUMBER> influenza <NUMBER> rabies <NUMBER> merscov <NUMBER> marburg virus <NUMBER> lassa fever <NUMBER> respiratory syncytial virus <NUMBER> yellow fever <NUMBER> approaches rna vaccines earlier phases development show great promise application multiple pathogens rapid production addition cepi set aside funds support development ebola vaccines research funding complementary current efforts field investments coordinated funders necessary avoid duplication work past <NUMBER> years cepi made efforts engage coordinate work partners throughout global health vaccine development ensure sustainability approach vaccine development coalition working industry partnersfrom small biotechnology companies large manufacturersthrough partnerships share risks vaccine development table <NUMBER> cepi also coordinates efforts several multilateral partners principally interinstitutional roundtable refer joint coordination group joint coordination group includes key organizations responsible vaccine procurement delivery implementation well representatives important regulatory agencies works identify ways predictable access vaccines priority populations achieved emergency situations overall goal joint coordination group optimize allocation resources across disease areas vaccine development minimize funding overlap partners improve response times unexpected epidemic threats preparing next epidemic requires investment platforms capable rapid vaccine development coordination among multiple stakeholders cepi coalition partners committed substantial resources attention cepi begins turn promises progress several challenges ought acknowledged first vaccine development widely acknowledged long complex process often lasting <NUMBER> years discovery licensure <NUMBER> second vaccine development inherently risky least twothirds preclinical vaccine candidates likely fail reaching clinical proof concept <NUMBER> view risk failure full cost successfully advancing vaccine candidate preclinical clinical efficacy trials readiness emergency use vary average <NUMBER> million <NUMBER> million <NUMBER> cepi far committed <NUMBER> million eid vaccinedevelopment projects whereas full costs vaccine development expected shared funding development partners concrete clinical outcomes likely going take several years materialize vaccines developed eids prioritized average <NUMBER> billion would needed support vaccine development phase <NUMBER> trials depending cost structures vaccine development programs rd pipeline attrition <NUMBER> improved coordination among industry global health civilsociety institutions guidance regulators also needed determine public health needs key diseases iron technical regulatory pathways feasible vaccine development additional resources become available <NUMBER> cepi diversifying current vaccine rd investment portfolio include additional pathogens beginning chikungunya debilitating mosquitoborne disease spread aedes aegypti albopictus affects millions people globally rift valley fever viral zoonosis cattle domesticated livestock also infects humans <NUMBER> chikungunya infection lead substantial morbidity patients experience arthralgia months even years chronic inflammatory rheumatic disease develops small subset patients <NUMBER> substantial burden disease example coupled large vaccine pipeline relative eids could justify investments might yield clinically relevant outcomes shorter time quantity antigen generally expected different across eids however knowing quantity antibody would required induce protection chikungunya could make identification situations would allow statistical demonstration efficacy challenging feasibility development would consequently depend technical hurdles regulatory guidance appropriate clinical trial design case rift valley fever <NUMBER> outbreaks occurred <NUMBER> <NUMBER> <NUMBER> confirmed suspected cases <NUMBER> deaths <NUMBER> viral transmission people occurs primarily contact blood organs infected animals <NUMBER> however aedes culex mosquitoes also act viral reservoirs vectors <NUMBER> rift valley fever wide geographical range spreading throughout africa saudi arabian peninsula <NUMBER> risk spread europe north america also high <NUMBER> licensed vaccine available human use least <NUMBER> vaccine candidates currently phase <NUMBER> trials <NUMBER> definition regulatory pathways clinical trials emergency use need account specifics vaccine challenges posed eid present unclear regulatory processes vaccine candidates could accelerated event outbreak known eids disease x enhanced regulatory guidance normative directions coalition partners needed approval clinical trials equitable access eid vaccines outbreaks prioritization various countermeasures eg human vaccine vs animal vaccines combinations might also required optimize development effective preparedness strategies unexpected emergencies related eid outbreaks rift valley fever merscov eid threats evolve increased coordination public health agencies worldwide required ensure product development prioritized accordingly sustainable manufacturing solutions also need negotiated soon vaccine candidates nearing completion safety immunogenicity testing humans mechanisms funding maintaining global stockpiles investigational vaccines must established vaccine candidates continue move development cepi coalition partners soon must lay concrete plan procurement stockpiling system could established much system would cost would operated would need operationalized eids remain major threat global health security <NUMBER> years <NUMBER> ebola outbreak west africa threat likely grow coming years various ecological demographic economic factors accelerate disease emergence reemergence <NUMBER> alone outbreaks <NUMBER> <NUMBER> priority pathogens <NUMBER> including <NUMBER> separate ebola outbreaks democratic republic congo thankfully thousands doses vesicular stomatitis virusebola virus vaccine already manufactured vaccines rollout help avert largescale epidemic context ebola cepi plans make rd investments complement current research efforts thanks partnership efforts cepi broad range vaccine developers <NUMBER> vaccine candidates lassa fever <NUMBER> merscov <NUMBER> nipah virus development <NUMBER> rift valley vaccine candidates initiate latestage preclinical development <NUMBER> chikungunya vaccine candidates resume latestage clinical development additional cepi funding vaccine candidates hopefully meet safety immunogenicity profiles required investigational stockpiling use large clinical trials humanitarian responses outbreak conditions development <NUMBER> rapidresponse platform technologies threatening eids also initiated including pilots lassa fever merscov influenza rabies respiratory syncytial virus marburg virus yellow fever cepi continue enhance epidemic preparedness targeted funding technical oversight ultimately however cepis success depend strength coalitions collaborative efforts across sectors institutions geographic regions develop effective eid vaccines ensure equitable access global health emergencies structural analyses shown novel virus uses host cell receptor known angiotensinconverting enzyme<NUMBER> binding <NUMBER> transmission dynamics confirmed reproductive number r<NUMBER> signifies number people get infected one contagious person sarscov<NUMBER> range <NUMBER> thus potential spread rapidly <NUMBER> based clinical epidemiological data chinese health authorities clinical manifestations disease severity shown mild cases occur <NUMBER> cases severe disease seen <NUMBER> cases critical disease occurred <NUMBER> cases <NUMBER> considering infectivity severity covid<NUMBER> vaccines therapeutics tackle deadly disease greatest need hour global pandemic major public health concern modern means travel volume travel make easier virus rapidly spread across world pandemic onceinalifetime lowprobability event highcost problem ignored next pandemic anticipated virulent form influenza world currently midst novel coronavirus pandemic though middle east respiratory syndrome mers sars featured whos list critical infectious diseases <NUMBER> anticipated cause global disease within short span time <NUMBER> unpredictability global pandemic world currently facing infectivity sarscov<NUMBER> virus high compared corona viruses reported far effective vaccine best way contain rapidly escalating proliferation infection although mortality rate lower compared similar viral respiratory diseases middle east respiratory syndrome coronavirus merscov magnitude infection caused sarscov<NUMBER> severe higher large extent leading increased number deaths worldwide sarscov<NUMBER> infection potential become seasonal disease like influenza persist humanity future <NUMBER> effective vaccine help reducing rate infection significantly reduce morbidity mortality covid<NUMBER> vaccine also world currently facing unprecedented global pandemic caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> predicting next source pandemic challenging vaccination best way prevent infectious disease development effective vaccine sarscov<NUMBER> reduce morbidity mortality associated also lessen economic impact traditional method vaccine development takes many years vaccine available society vaccine development sarscov<NUMBER> speeded using pandemic approach fasttrack approvals regulatory authorities various challenges associated developing vaccine pandemic technological hurdles clinical development pathways regulatory issues support global funding agencies expressed published online april <NUMBER> <NUMBER> pii s<NUMBER> decrease probability resurgence disease future impact implementation effective vaccination way moderate economic burden unprecedented pandemic urgent need expedite development covid<NUMBER> vaccine vaccine industry able develop h<NUMBER>n<NUMBER> vaccine fairly rapidly technology regulations already place develop influenza vaccine global experiences influenza vaccines outlined urgency investing modern technologies faster vaccine development well increasing scale production customizing technologies various viruses speed vaccine development pandemic organizations coalition epidemic preparedness innovation cepi innovative global partnership public private organizations striving quicken vaccine development various potential critical diseases well facilitate uniform availability lifesaving vaccines cepi aims develop vaccines various pathogens till phase <NUMBER>a stage expedited fullscale development future outbreaks <NUMBER> cepi world bank organized conference three main imperatives covid<NUMBER> vaccine effort speed manufacture deployment scale global access ultimately led formulation covid<NUMBER> vaccine development taskforce <NUMBER> wide ranges technologies developed sarscov<NUMBER> include nucleic acids protein subunit replicating viral vector nonreplicating viral vector inactivated virus approaches newer approaches based nucleic acids dna mrna facilitate potentially rapid production need fermentation <NUMBER> platforms adjuvants could improve immune responses lower doses thus ensuring vaccination larger populations without reduction efficacy <NUMBER> currently several platforms developed list sarscov<NUMBER> vaccine candidates development given web table <NUMBER> development vaccine sarscov<NUMBER> cause distinct challenges • developing viable immunogen using various proteins sarscov<NUMBER> protein n protein protein initial challenge • development successful animal model covid<NUMBER> may challenging although two animal models one hace<NUMBER> transgenic mice model another primate macaques model successfully developed may due highly infectious pathogenic nature virus <NUMBER> • vaccine development lengthy process starting product development competition phase iii clinical trial marketing vaccine take several years usually <NUMBER> <NUMBER> years • preclinical experience sars vaccine candidates created red flags worsening disease may attributed antibodydependent enhancement • correlates protection known • planning coordinating clinical trials emergencylike situations difficult predicting trial sites outbreak well ensuring sites preparedness • highmortality situation covid<NUMBER> pandemic regulators may accept conventionally designed clinical trials comparison placebo arm • viral mutation may lead different subtypes thus causing difficulty vaccine design • vaccines generally manufactured using good manufacturing practices gmp ensure quality controlled consistency maintained many vaccine candidates current pipeline sarscov<NUMBER> gmp processes need developed time consuming • vaccines developed novel technologies gmp needs developed beginning thus adding financial burden delaying production vaccines • issues related vaccine ownership funding pricing supply chain coordinated administration strategy pose significant barriers traditional vaccine development process follows various phases product development preclinical clinical trial phases phase ii iii vaccine gets regulatory approval marketing although phase iv postmarketing surveillance studies volume <NUMBER> may <NUMBER> <NUMBER> ella mohan coronavirus vaccine light end tunnel conducted marketing product traditional approach time consuming feasible follow pandemic keeping greater benefit vaccine societal need vaccine development using pandemic approach best approach rapid development vaccines shown fig <NUMBER> type innovative approach save time spent preclinical clinical trial phases regulators consider approach faster approval vaccines vaccine development pandemic considered global health emergency specific disease related issue prerogative vaccine manufacturers public funding vaccine development top priority vaccine development particularly pandemic risky investment public funding reduce potential risk vaccine manufacturers especially low middle income countries pioneering finance mechanisms international finance facility immunization iffim successful past used fund development covid<NUMBER> vaccines <NUMBER> global alliance vaccines immunizations gavi board members also expressed support use gavis innovative financing instruments iffim gavis advance market commitment accelerate vaccine development access needed <NUMBER> global consensus urgency development pandemic vaccine national international level ensure vaccines available affordable need <NUMBER> • novel platform technologies largescale manufacturing pose significant financial risk facilities necessitate huge investments • highincome countries procure large doses vaccine population creating disparities global supply demand • high risk populations identified epidemiological serological studies vaccine delivery prioritized halt spread disease • sarscov<NUMBER> newer disease without adequate exposure population new vaccine may probably necessitate one dose vaccine protective immunity usually achieved second dose massive effort needed ensure vaccine distribution administration • scenario albeit lowprobability pandemic threat abruptly curtailed cases vaccine development continued potential vaccine candidates restrict future threats global vaccine development efforts covid<NUMBER> pandemic unparalleled current scenario indication vaccine could available early <NUMBER> would extraordinary shift usual vaccine development timeframe range <NUMBER> years new virus target newer technologies multiply vaccine development risks dictates meticulous evaluation safety efficacy every stage vaccine development robust coordination vaccine manufacturers regulatory authorities public health authorities governments essential make sure potential vaccine candidates fasttracked approval manufactured distributed seamlessly particularly lowincome countries considering economic impact covid<NUMBER> already caused initial <NUMBER> months global calamity worthwhile start investing vaccines emerging viruses including neglected diseases potentially cause significant human deaths also impact global economy global pandemics inevitable strategically prepared protocols emergency plans develop vaccines months rather years lessons learned managing covid<NUMBER> pandemic pave way creating better roadmaps face next pandemic coronavirus disease <NUMBER> begin december <NUMBER> like viral outbreak wuhan city china <NUMBER> gained rapid foothold across world resulting declared pandemic <NUMBER> april <NUMBER> th worldwide total <NUMBER> cases <NUMBER> deaths reported <NUMBER> period time continuous transmission virus across borders health burden global scale rapidly increasing urgent studies required absence effective cures majorly drugs vaccination immunization therapy imperative order target whole population likewise move forward vaccine development pipeline immunoinfomatics tools proved crucial <NUMBER> since covid<NUMBER> affected almost worlds population promiscuous epitopes binding variety hla alleles larger dissemination vital silico approaches remarkably useful helping develop cure fast manner possible <NUMBER> antibody generation activation bcell well acute viral clearance tcells along virusspecific memory generation cd<NUMBER> tcells analogously important develop immunity virus <NUMBER> protein considered highly antigenic thereby evoke strong immune responses generate neutralizing antibodies block attachment virus host cells <NUMBER> reverse vaccinology various tools silico biology used discover novel antigens studying genetic makeup pathogen genes could lead good epitopes determined method quick easy costeffective way design vaccine <NUMBER> process vaccine development novel antigens identified analyzing genomic information virus organism reverse vaccinology approach facilitates easier productive process antigen discovery <NUMBER> herein explored proteome sarscov<NUMBER> indian geographical origin human host identify potential antigenic proteins epitopes effectively elicit cellular mediated immune response covid<NUMBER> collected sarscov<NUMBER> genome indian geographical origin human host applied insilico approach significant research disclosed two promising antigenic peptide gvyfastek nfrvqptesiv surface glycoproteins protein accession qia<NUMBER> qhs<NUMBER> sarscov<NUMBER> predicted interacted class class ii mhc alleles displayed <NUMBER> conservancy significant antigenicity molecular docking analysis confirmed molecular interaction prime antigenic peptides residues hlaa<NUMBER> allele mhc class hla drb<NUMBER> allele mhc class ii careful evaluation peptides foreseen appropriate epitopes proficient elicit strong cellmediated immune response sarscov<NUMBER> reverse vaccinology approach facilitates easier productive process vaccine candidates determination outcomes significant analysis could help selecting sarscov<NUMBER> epitopes vaccine production pipelines soon novel research certainly pave way fast reliable virtuous platform provide timely countermeasure dangerous pandemic disease covid<NUMBER> highly virulent strain sarscov<NUMBER> chosen insilico analysis genome viral strain available national center biotechnology information ncbi httpswwwncbinlmnihgov refseq nc<NUMBER> twelve viral protein sequences sarscov<NUMBER> host human country india retrieved vipr database <NUMBER> various physicochemical properties protein sequences determined expasys online tool protparam <NUMBER> vaxijen v<NUMBER> <NUMBER> utilized predict antigenicity proteins software requires fastasubmitted amino acid sequences uses physicochemical properties proteins predict antigenicity feature denoted according antigenic score respectively <NUMBER> bcell tcell epitopes selected two surface glycoprotein sequences predicted via iedb immune epitope database iedb database holds large amount experimental data epitopes antibodies allows robust analysis many epitopes context tools like conservation across antigens population coverage clusters similar sequences <NUMBER> order obtain mhc classi restricted cd<NUMBER> cytotoxic tlymphocyte ctl epitopes selected surface glycoprotein sequences netmhcpan el <NUMBER> prediction method applied hlaa<NUMBER> allele mhc classii restricted cd<NUMBER> helper tlymphocyte htl epitopes obtained hla drb<NUMBER> allele using sturniolo prediction method top ten mhc classi mhc classii epitopes randomly selected basis percentile scores antigenicity scores five random bcell lymphocyte epitopes bcl selected based higher length using bipipered linear epitope prediction method <NUMBER> vaxijen v<NUMBER> utilized predict protein antigenicity software requires fastasubmitted amino acid sequences uses physicochemical properties proteins predict antigenicity feature denoted according antigenic score respectively <NUMBER> allergenicity selected epitopes predicted via allertop v<NUMBER> httpswwwddgpharmfacnetallertop transmembrane topology selected epitopes identified using transmembrane topology protein helices determinant tmhmm v<NUMBER> server httpwwwcbsdtudkservicestmhmm server predicts whether epitope would transmembrane remain inside outside membrane toxicity prediction selected epitopes carried via toxinpred server httpswebsiiitdeduinraghavatoxinpredproteinphp conservancy analysis earlier selected epitopes performed via epitope conservancy analysis tool iedb server <NUMBER> analysis sequence identity threshold kept <NUMBER> cluster analysis carried mhccluster <NUMBER> <NUMBER> cluster analysis number peptides included kept <NUMBER> number bootstrap calculations kept <NUMBER> cluster analysis netmhcpan<NUMBER> prediction method used <NUMBER>d structures selected best epitopes generated using online <NUMBER>d generating tool pepfold<NUMBER> httpbioservrpbsunivparisdiderotfrservicespepfold<NUMBER> server tool generating de novo peptide <NUMBER>dimensional structure <NUMBER> <NUMBER> <NUMBER> predocking carried ucsf chimera <NUMBER> peptideprotein docking selected epitopes performed online docking tool patchdock httpsbioinfo<NUMBER>dcstauacilpatchdockphpphp results patchdock refined rescored firedock server httpbioinfo<NUMBER>dcstauacilfiredockphpphp later docking performed hpepdock server <NUMBER> docking pose analysis done using ligplot <NUMBER> sarscov<NUMBER> strain identified twelve viral protein sequences sarscov<NUMBER> host human country india retrieved vipr database selected possible vaccine candidate identification physicochemical property analysis number amino acids molecular weights theoretical pi extinction coefficients m<NUMBER> cm<NUMBER> est halflife mammalian cell instability indexes aliphatic indexes grand average hydropathicity gravy twelve proteins predicted table<NUMBER> antigenicity prediction threshold value kept <NUMBER> proteins found antigenic table<NUMBER> physicochemical study revealed surface glycoproteins qia<NUMBER> qhs<NUMBER> highest extinction coefficient <NUMBER>m<NUMBER> cm<NUMBER> <NUMBER> m<NUMBER> cm<NUMBER> lowest gravy value <NUMBER> <NUMBER> addition surface glycoproteins stable antigenic selected surface glycoproteins analysis tcell epitopes mhc classi proteins determined netmhcpan el <NUMBER> prediction method iedb server keeping sequence length <NUMBER> server generated epitopes analyzed basis antigenicity scores percentile scores top ten potential epitopes selected randomly antigenicity allergenicity toxicity conservancy tests server ranks predicted epitopes based ascending order percentile scores table<NUMBER>a <NUMBER>b tcell epitopes mhc classii hla drb<NUMBER> allele proteins also determined iedb server table<NUMBER>a <NUMBER>b sturniolo prediction methods used protein ten top epitopes selected randomly analysis moreover bcell epitopes proteins selected using bipipered linear epitope prediction method iedb server epitopes selected based higher lengths fig<NUMBER> topology selected epitopes determined tmhmm v<NUMBER> server httpwwwcbsdtudkservicestmhmm table <NUMBER>a table <NUMBER>b list potential tcell epitopes surface glycoproteins qia<NUMBER> table <NUMBER>a table <NUMBER>b list potential tcell epitopes surface glycoproteins qhs<NUMBER> table <NUMBER> list potential bcell epitopes respective topologies antigenicity allergenicity toxicity conservancy analysis tcell epitopes found highly antigenic well nonallergenic nontoxic conservancy <NUMBER> selected among ten selected mhc classi epitopes ten selected mhc classii epitopes proteins total four epitopes selected based mentioned criteria gvyfastek tladagfik nfrvqptesi llivnnatnv cluster analysis possible mhc classi alleles may interact predicted epitopes performed online tool mhccluster <NUMBER> httpwwwcbsdtudkservicesmhccluster tool generates clusters alleles phylogenetic manner results illustrate outcome experiment red zone indicates strong interaction yellow zone corresponds weaker interaction fig<NUMBER> tcell epitopes subjected <NUMBER>d structure generation pepfold<NUMBER> server <NUMBER>d structures generated peptideprotein docking fig<NUMBER> docking performed find whether epitopes ability bind mhc classi mhc classii molecule selected epitopes docked hlaa<NUMBER> allele pdb id <NUMBER>wjl hla drb<NUMBER> pdb id <NUMBER>jlz docking performed using patchdock online docking tool results refined firedock online server results also analysed hpepdock server additional file fig<NUMBER> among four epitopes two selected glycoproteins qia<NUMBER>and qhs<NUMBER> gvyfastek mhc class epitope nfrvqptesi mhc class ii epitope showed best result lowest global energy <NUMBER> <NUMBER> docking pose analyzed via ligplot fig <NUMBER> identified highly antigenic nonallergenic bcell vaccine candidates ltpgdsssgwtag vrqiapgqtgkiad surface glycoprotein qia<NUMBER> qiapgqtgkiad ilpdpskpskrs surface glycoprotein qhs<NUMBER> vaccine one important extensively produced pharmaceutical products millions infants people getting vaccinated every year however development research processes vaccines costly sometimes takes many years develop appropriate vaccine candidate pathogen modern times various tools methods immuneinformatics bioinformatics reverse vaccinology extensively used vaccine development save time cost vaccine development process <NUMBER> <NUMBER> current study physicochemical study revealed surface glycoproteins qia<NUMBER> qhs<NUMBER> highest extinction coefficient <NUMBER>m<NUMBER> cm<NUMBER> <NUMBER> m<NUMBER> cm<NUMBER>and lowest gravy value <NUMBER> <NUMBER> addition surface glycoproteins highly stable instability index less <NUMBER> antigenic antigenicity proteins determined vaxijen v<NUMBER> server compound instability index <NUMBER> compound referred unstable <NUMBER> extinction coefficient means amount light absorbed compound certain wavelength <NUMBER> <NUMBER> various physicochemical properties like number amino acids molecular weight theoretical pi extinction coefficient instability index aliphatic index gravy determined protparam httpswebexpasyorgprotparam server two selected proteins performed quite similarly physicochemical property assessment immune system two major cells functions lymphocytic cell b lymphocytic cell <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> possible b cell cell epitopes selected sarscov<NUMBER> proteins identified iedb httpswwwiedborg server iedb server generates ranks epitopes basis antigenicity scores percentile scores top ten mhc classi mhc classii epitopes taken analysis topology selected epitopes determined tmhmm v<NUMBER> server httpwwwcbsdtudkservicestmhmm antigenicity allergenicity toxicity conservancy analysis tcell epitopes found highly antigenic well nonallergenic nontoxic conservancy <NUMBER> among ten selected mhc classi epitopes ten selected mhc classii epitopes proteins total four epitopes selected based mentioned criteria gvyfastek tladagfik nfrvqptesi llivnnatnvv well antigenic nonallergenic bcell epitopes selected vaccine candidate analysis cluster analysis possible mhc classi mhc classii alleles may interact predicted epitopes performed online tool mhc cluster <NUMBER> httpwwwcbsdtudkservicesmhccluster antigenicity defined ability foreign substance act antigen activate b cell cell responses epitope also called antigenic determinant portion <NUMBER> allergenicity defined ability substance act allergen induce potential allergic reactions within host body <NUMBER> moreover cluster analysis mhc classi alleles mhc classii alleles also carried identify relationship cluster functionally basis predicted binding specificity <NUMBER> next step peptideprotein docking carried selected epitopes mhc alleles mhc classi epitopes docked mhc classi molecule pdb id <NUMBER>wjl mhc classii epitopes docked mhc classii molecule pdb id <NUMBER>jlz respectively peptideprotein docking performed analyze ability epitopes bind respective mhc molecule predocking performed ucsfchimera later performed <NUMBER>d structure generation epitopes docking carried patchdock firedock servers also analysed hpepdock server based global energy gvyfastek nfrvqptesi generated best scores peptideprotein docking respectively vaccine candidates proved potentially antigenic nonallergenic reason cause allergenic reaction within host body however vitro vivo researches finally confirm safety efficacy potentiality predicted vaccines candidates face enormous tragedy suffering death social disaster caused covid<NUMBER> pandemic utmost importance develop effectual safe vaccine highly pandemic disease bioinformatics reverse vaccinology related technologies widely used vaccine design development since technologies reduce cost time study first potential proteins belong sarscov<NUMBER>against host human country india identified potential b cell cell epitopes effectively elicit cellular mediated immune response related selected proteins determined robust processes potential tcell epitopes gvyfastek nfrvqptesi bcell epitopes ltpgdsssgwtag vrqiapgqtgkiad qiapgqtgkiad ilpdpskpskrs play vital role subunit multiepitope vaccine construction near future conclude reverse vaccinology justified powerful tool identifying new vaccine candidates consequent precise application study lead research new effectual direction outcome study provide fast reliable significant platform search effective timely cure dangerous pandemic disease covid<NUMBER> caused sarscov<NUMBER> recent emergence middle east respiratory syndrome mers highlights need engineer new methods expediting vaccine development emerging diseases however several obstacles prevent pursuit licensable mers vaccine first lack suitable animal model mers complicates vivo testing candidate vaccines second due low number mers cases pharmaceutical companies little incentive pursue mers vaccine production costs clinical trials high addition timeline bench research approved vaccine use <NUMBER> years longer using novel methods costsaving strategies genetically engineered vaccines produced quickly costeffectively along progress mers animal model development obstacles circumvented least mitigated keywords highconsequence pathogens continue emerge reemerge globally leading increased public health concerns potential pandemics <NUMBER> current human viral disease outbreaks concern include ongoing ebola virus disease epidemic west africa <NUMBER> avian influenza caused novel influenza virus subtype h<NUMBER>n<NUMBER> china <NUMBER> enterovirus d<NUMBER> infections usa <NUMBER> topic review middle east respiratory syndrome mers caused middle east respiratory syndrome coronavirus merscov <NUMBER>present <NUMBER> emerging infections often first present limited disease outbreaks caused rare unknown pathogens increasing likelihood significance overlooked consequently financial resources routed toward infectious diseases deemed pressing given time examples rare agents caused human infections many years erupt outbreaks involving thousands rift valley fever virus <NUMBER> cases <NUMBER> <NUMBER> <NUMBER> ebola virus <NUMBER> cases <NUMBER> deaths since discovery <NUMBER> late <NUMBER> <NUMBER> cases <NUMBER> deaths december <NUMBER> march <NUMBER> <NUMBER> <NUMBER> agents severe acute respiratory syndrome coronavirus sarscov emerge unexpectedly eventually cause large epidemics <NUMBER> cases <NUMBER> deaths seemingly disappear <NUMBER> consequently global public health professionals challenged ever important task rapidly developing improved methods infectious disease detection surveillance control prevention containment widespread efforts provide swift response emerging disease mers impressive spectrum prevention treatment strategies established vitro relatively short period time antivirals monoclonal polyclonal antibodies vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vitro vivo preclinical testing led us predicament scientific community faced sars epidemic laboratory research often inefficiently translated clinical testing candidate therapeutics prophylactics delaying clinical licensure authorities final administration outbreaks summarize evaluate progress made mers vaccine development provide example various challenges encountered path medical countermeasure licensure epidemiology mers mers first recognized new disease <NUMBER>yearold saudi male patient respiratory distress admitted hospital jeddah saudi arabia june <NUMBER> <NUMBER> soon index case detected people identified suffered ailment <NUMBER> <NUMBER> majority mers infections reported western asia particular saudi arabia united arab emirates also jordan lebanon kuwait oman qatar yemen later mers also diagnosed europe austria france germany greece italy netherlands uk northern africa algeria egypt tunisia northern america usa southeastern asia malaysia philippines southern asia iran among people travel history western asia <NUMBER> humantohuman transmission merscov estimated account approximately <NUMBER> total mers cases <NUMBER> origin infection merscov unexplained rest cases risk virus transmission substantially greater index cases secondary cases <NUMBER> increasing distribution mers cases within arabian peninsula worrisome instance past <NUMBER> years concerns initiation mers pandemic prompted travel restrictions makkah saudi arabia millions muslim pilgrims preventing tens thousands potential travelers making religiously significant hajj journey although major outbreak mers occurred direct result recent hajjes trepidations remained high <NUMBER> <NUMBER> studies revealed older men individuals comorbid conditions eg diabetes hypertension chronic cardiac lung renal disease greatest risk developing fatal mers although gender bias epidemiologically unclear <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> whether physiological genetic cultural factors play role increased risk toward men unknown time writing <NUMBER> mers cases confirmed including least <NUMBER> deaths <NUMBER> however increasing evidence subclinical infections <NUMBER> suggests actual number human mers cases much higher currently confirmed number etiological agent mers novel betacoronavirus rapidly identified named middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> <NUMBER> merscov originally introduced human population mers cases recorded <NUMBER> remain determined onehumped camels camelus dromedarius currently suspected animals merscov transmitted humans suspicion stems detection merscovneutralizing antibodies onehumped camel herds egypt united arab emirates <NUMBER> <NUMBER> merscov merscovlike genome fragments codingcomplete genomes highly similar human merscov genomes detected onehumped camels <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov directly isolated several onehumped camels grown tissue culture <NUMBER> <NUMBER> <NUMBER> onehumped camels experimentally infected merscov develop minor clinical signs respiratory disease merscov replicates upper airways <NUMBER> serologic evidence merscov infection found people potential exposure infected onehumped camels three serosurveys <NUMBER> <NUMBER> <NUMBER> therefore zoonotic transmission onehumped camels people might rare event however conclusion regarded caution serosurveys performed published therefore possible merscov widely distributed among onehumped camels particular genotype virus evolve allow jump human population genomic study indeed revealed presence several genetic variants merscov individual onehumped camels whereas merscov humans exposed onehumped camels appears infected clonal merscov populations <NUMBER> onehumped camels frequently exported africa arabian peninsula western asia animal native africa could transmitting merscov onehumped camels prior exportation figure <NUMBER> based presence genome fragments genomes replicating viruses many betacoronaviruses seem maintained africa europe asia phylogenetically highly diverse bats viruses include sarscov sarscovrelated viruses horseshoe bats rhinolophus spp <NUMBER> several viruses even closely related merscov detected humans <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> therefore researchers speculate merscov could batborne virus batorigin hypothesis based betacoronavirus phylogeny receptor usage <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> isolation merscov one individual egyptian tomb bat taphozous perforatus <NUMBER> however studies suggestive epidemiological evidence battohuman battoonehumped camel transmission merscov figure <NUMBER>a yet gathered <NUMBER> incubation period <NUMBER> days mers generally presents humans lower respiratory infection fever often chills rigors dry productive cough dyspnea infrequently patients develop chest pain headaches hemoptysis myalgia andor sore throat severe cases illness quickly progress severe atypical pneumonia acute respiratory distress syndrome severe hypoxemic respiratory failure <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mers often includes extrapulmonary manifestations involving circulatory renal andor gastrointestinal systems abdominal painnausea diarrhea emesis rapidly advance septic shock renal failure refractory multiple organ failure <NUMBER> <NUMBER> <NUMBER> chest xray computed tomography imaging often reveals subtle extensive unilateral bilateral abnormalities consolidation increased bronchovascular markings pleural bronchial wall thickening reticulonodular airspace opacities cardiomegaly clinical chemistry characterized increased alanine transaminase aspartate transaminase concentrations patients increased llactate dehydrogenase concentration <NUMBER> cases low albumin hemoglobin concentrations frequent findings lymphopenia thrombocytopenia whereas lymphocytosis occurs rarely <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> viral loads usually high respiratory tract reaching <NUMBER> <NUMBER> genome copiesml may low absent blood <NUMBER> <NUMBER> <NUMBER> moment specific antiviral agents treatment mers available however several vitro studies identified drugs already clinical use potentially could repurposed treatment mers drugs include inosine monophosphate dehydrogenase inhibitor mycophenolic acid used treat coronavirus infections <NUMBER> pancoronavirus inhibitor targets membranebound coronaviral rna synthesis k<NUMBER> <NUMBER> guanosine analog ribavirin used treatment hepatitis c respiratory syncytial virus arenavirus infections interferonb <NUMBER> <NUMBER> <NUMBER> inhibitors estrogen receptor <NUMBER> used cancer treatment toremifene citrate inhibitors dopamine receptors used antipsychotics chlorpromazine hydrochloride triflupromazine hydrochloride kinase signaling inhibitors imatinib mesylate dasatinib <NUMBER> endocytosis inhibitors chlorpromazine chloroquine <NUMBER> antidiarrheal agent loperamide hiv<NUMBER> protease inhibitor lopinavir <NUMBER> transmembrane protease serine <NUMBER> protease inhibitor camostat <NUMBER> unfortunately drugs evaluated animal models mers exception <NUMBER> part due absence animal models truly reflect human disease see absence approved specific antiviral agents merscov treatment therefore based supportive care initial laboratory blood tests chest radiography patients treated broadspectrum antibiotics control often nosocomial secondary bacterial infections however majority inpatient mers cases escalate respiratory failure requiring intubation mechanical ventilation extracorporeal membrane oxygenation renal replacement therapy therefore admission intensive care unit <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> potential costs associated mers treatment disease management mers tremendous financial burden local economies event pandemic financial burden may prove catastrophic especially countries limited financial resources based small number treatmentcost analyses available <NUMBER> outbreak sars <NUMBER> <NUMBER> tourcoing hospital france additional hospital administration material resource costs alone approximated us<NUMBER> per inpatient due need increases staff containment apparatuses personal protective equipment required dealing highconsequence pathogen moreover average mers inpatient incurs added costs prolonged intensive care unit stay <NUMBER> cases mechanical ventilation <NUMBER> cases renal replacement therapy <NUMBER> cases figure <NUMBER> world bank estimates global economic losses trillions us dollars event severe influenza pandemic considers mers pathogen pandemic potential <NUMBER> global costs <NUMBER> sars epidemic alone estimated us<NUMBER> billion <NUMBER> cost developing successful vaccine approaching us<NUMBER> million effective vaccine highconsequence pathogen potential save <NUMBER> times cost single year use estimated smallpox vaccine however true costtobenefit analysis must performed determine vaccine development efforts provide benefit assume mers cases continue rate roughly <NUMBER> per year <NUMBER> hospitalization rate <NUMBER> additional cost per inpatient approximately us<NUMBER> average cumulative average cost per day per intervention per inpatient multiplied median stay per respective intervention cost developing vaccine would justified within <NUMBER> years figure <NUMBER> therefore sustained humantohuman merscov transmission occur benefit would outweigh cost general vaccine development worthwhile pursuit steps taken expedite approval safe effective vaccines emerging pathogens similar many coronaviruses major structural proteins spike protein envelope protein e membrane protein nucleoprotein n primary targets host antibodymediated immune response focus vaccine development efforts surface glycoprotein mers coronavirion mediates attachment virion target cells subsequent entry cell fusing viral host cell membranes <NUMBER> functions involve two distinct domains referred s<NUMBER> s<NUMBER> respectively s<NUMBER> contains host cell receptorbinding domain <NUMBER> <NUMBER> <NUMBER> engages primary merscov cellsurface receptor cd<NUMBER>dpp<NUMBER> <NUMBER> s<NUMBER> contains epitopes crossreactive homologous epitopes group b betacoronaviruses <NUMBER> <NUMBER> suggesting development general multivalent betacoronavirus vaccine might possible e work secure structural integrity virion nucleoprotein n encapsidates viral genomic rna <NUMBER> identification natural host reservoir emerging human pathogen first ideal step toward prevention transmission human population could educated avoid host implement proper safety measures coming contact reservoir contact reservoir host cannot avoided eg abundance economic importance vaccination host may straightforward approach prevent hosttohuman transmission addition development animal vaccine may ultimately cheaper produce faster achieve regulatory hurdles obtain licensure may stringent place human vaccine development example vaccination wildlife reservoirs rabies reduced human cases usa <NUMBER> <NUMBER> strategy also relatively new pursuit eradication tuberculosis parts europe vaccination cattle wildlife <NUMBER> <NUMBER> unfortunately described natural merscov reservoir merscov transmission cycle remain defined vaccination onehumped camel herds could feasible animals often keptraisedsold humans wild animals could identified relatively easily however adult onehumped camels tested positive merscov despite presence antimerscov antibodies <NUMBER> <NUMBER> preexisting neutralizing antimerscov antibodies necessarily protect reinfection merscov <NUMBER> observation suggests camel vaccination may review papaneri johnson wada bollinger jahrling kuhn repeated regularly may effective probably even unrealistic vaccination bats due sheer number relatively small dependent species often quite abundant animals absence clearly defined zoonotic virus ecology prompts researchers contemplate development human vaccines mers tends acute yet widespread targeting specific human populations high risk infection vaccination logical strategy prevention limitation infections development distribution vaccines therefore expedited onehumped camel handlers herders healthcare workers veterinarians travelers areas merscov infection prevalent widespread infection throughout general population expected highrisk populations eg aged people persons cormorbidities targeted vaccination given lack suitable mers animal model relatively clinical data merscov patients nature successful immune response merscov infection difficult establish serology pcrbased assays indicate many adenovirus <NUMBER> vector expressing s<NUMBER> <NUMBER> rbd fused iggfc fragment <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> accessory structural unknown essential replication <NUMBER> <NUMBER>a <NUMBER>a accessory structural unknown essential replication <NUMBER> interferon antagonist <NUMBER> <NUMBER> <NUMBER>b <NUMBER>b accessory structural unknown essential replication <NUMBER> interferon antagonist <NUMBER> <NUMBER> <NUMBER> accessory structural unknown essential replication <NUMBER> <NUMBER> interferon antagonist <NUMBER> e envelope protein major structural structural integrity virion required propagation <NUMBER> recombinant <NUMBER> experiment based bronchoalveolar lavages obtained two patients identified one succumbed mers develop th<NUMBER> response patient lower concentrations interferona interleukin<NUMBER> interferong compared patient succumb although experiment involved limited sample size data support necessity th<NUMBER> response zhao et al investigated knockout mice evaluate immunological requirements clearance merscov <NUMBER> authors demonstrated interferonaand myd<NUMBER>deficient mice could clear merscov rapidly wildtype mice similarly tcell bcell knockout mice could clear virus efficiently control mice furthermore vaccinated mice reduced viral titers serum transfer experiments provided protection homologous merscov infection data suggest efficient tand bcell response required protection indirect direct band tcell functional response included criteria candidate vaccine evaluation clinical data become available correlates protection difficult establish vaccine design strategies applicable mers historically first vaccines viral pathogens homotypic liveattenuated viruses virus isolate passaged animal host cell line nonvirulent liveattenuated strain evolved nonvirulent virus used vaccination <NUMBER> recent method developing vaccines genetically engineer virus avirulent replication incompetent <NUMBER> <NUMBER> replicationdeficient vaccine virus constructs generated expressed human parainfluenza virus<NUMBER> human respiratory syncytial virus <NUMBER> <NUMBER> similarly replicationdeficient adenoviruses developed vaccines ebola virus hiv<NUMBER> infection <NUMBER> <NUMBER> phase iia clinical trial initiated evaluate efficacy replicating modified vaccinia ankara mva expressing influenza virus proteins <NUMBER> replicating mva also used boost effect replicationdeficient adenovirusbased vaccine responses <NUMBER> main concern replicating live viral vaccines possibility disseminated infection immunosuppressed populations eg disseminated vaccinia virus infection heterotypic vaccine platforms possibility reversion virulence case homotypic candidates <NUMBER> new methods replicating vaccine development typically incorporate failsafe mechanisms mechanisms include deletion gene encoding protein required viral propagation introduction sufficient number genomic mutations make reversion extremely unlikely <NUMBER> <NUMBER> instance almazan et al engineered recombinant merscov lacking e open reading frame mers candidate vaccine however protective efficacy yet demonstrated <NUMBER> whole inactivated virion preparations often provide immunogenicity replicating viral vaccine without possibility reversion virulent phenotype virions killed inactivated chemical radiological methods prior use vaccine preparation able replicate host recipients immune system still mounts response presented antigens although examples inactivated merscov virions yet published inactivated sarscov particle vaccines tested minimal success laboratory mice domestic ferrets <NUMBER> <NUMBER> <NUMBER> use inactivated virion preparations prompted several concerns one concern toxic reagents used virion inactivation must completely removed product administration another concern irradiation used alternative toxic agents may destroy crucial epitopes therefore render preparation nonimmunogenic third concern inactivation could whatever reason incomplete resulting preparations containing fully virulent viruses concerns exacerbated increasing stigma exists among general public regarding vaccines general chemical additives vaccine preparations particular <NUMBER> <NUMBER> recombinant viral vectors upgrade replicating viral vaccine strategy ability optimize safety immunogenicity via bioengineering obvious benefit using vaccine platforms adenoviruses <NUMBER> vesiculoviruses <NUMBER> mva <NUMBER> <NUMBER> <NUMBER> <NUMBER> foreign gene immunological interest inserted heterotypic viral genome proven success vaccine recombinant virus express foreign protein stimulate protective immune response inoculated host approach also used successfully develop multivalent vaccines vaccines confer protection multiple variants strains pathogen also multiple pathogens simultaneously <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently escriou et al showed evidence bivalent protection laboratory mice measles virus sarscov infection <NUMBER> constructs codon optimization host recognition may increase attenuation protein expression yielding greater safety immunogenicity vaccine instance two vaccines mva vaccine adenovirusbased vaccine expressing codonoptimized merscov elicited serum antibodies laboratory mice used neutralize merscov vitro <NUMBER> <NUMBER> alternative method immunogen presentation viral vector nanoparticles protein interest formulated suitable adjuvant use candidate vaccine instance micellular nanoparticles merscov trimers expressed surface novavax inc gaithersburg md usa concentrated preparations recombinant baculovirus autographa californica multicapsid nucleopolyhedrovirus acmnpv expressing merscov acmnpv genes codonoptimized expression insect cells virus propagated <NUMBER> merscovneutralizing antibodies induced immunized laboratory mice dna vaccines typically consist viral genomic segment encoding neutralizing epitope contained plasmid combined adjuvant administration <NUMBER> early fabrications failed yield protective immune responses recent studies testing dna vaccines corrected shortcoming optimizing constituents delivery methods also due relatively simple lowcost processes production manufacturing dna vaccines competitive pursuit one dna vaccine quadrivalent vaccine hpv infection caused types <NUMBER> <NUMBER> <NUMBER> <NUMBER> widely used vaccination programs numerous countries <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> unpublished data inovio pharmaceuticals suggest strong neutralizing antibody elicitation possible multiple strain coverage broad cd<NUMBER> tcell responses mice immunization merscov dna vaccine inovios proprietary technology involves using syncon dna vaccine platform inovios proprietary technology involves using syncon dna vaccine platform platform incorporates dna multiple strains andor antigens dna transfected electroporation resulting efficient delivery muscle skin cells <NUMBER> novel vaccine development strategies interest use immunoinformatics predict immunogenic parts virus included vaccine achieve potent relevant neutralization resulting candidate vaccines also known subunit vaccines current mers candidate vaccines focus receptorbinding domain s<NUMBER> precise source adaptive immune response would generate effective neutralizing antibodies <NUMBER> <NUMBER> <NUMBER> using immunoinformatics sharmin islam chose focus epitope found rnadependent rna polymerase rdrp conserved across human coronaviruses <NUMBER> blocking viral replication affecting rdrp may effective vitro method yet proven effective protecting host infection rna virus one drawback approach rdrp epitopes may readily detected host immune system rdrp usually major structural component virions also antigenic processing lead wide range tcell bcell immunoreactive epitopes therefore focusing rdrp epitopes would provide broad effective cellular humoral responses combination aforementioned immunoinformatics technology realistic approach based use bcell tcell epitope predictions based viral genome sequence neutralizing antibodies merscov structural proteins primarily believed required inhibit infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition humoral immunity tcell responses considered major determinant protection infectious diseases <NUMBER> <NUMBER> approach using bcell tcell epitopes used researchers terry et al oany et al develop mers candidate vaccine <NUMBER> <NUMBER> approach innovative actual vivo merscov neutralization demonstrated date evaluation candidate vaccine highconsequence viral disease critically dependent availability animal models us fda animal rule permits use efficacy data animal models closely mimic human disease approval medical countermeasures evaluation humans ethically feasible due high lethality virus evaluation <NUMBER> best knowledge fda determined mers medical countermeasure development falls animal rule however identification development suitable animal model human disease many challenges caveats upon exposure merscov animals display respiratory distress fever tussis dyspnea gastrointestinal signs vomiting diarrhea renal failure <NUMBER> <NUMBER> <NUMBER> since merscov first identified several groups attempted develop mers animal models laboratory mice syrian hamsters mesocricetus auratus domestic ferrets mustela putorius furo evaluated potential models medical countermeasure screening understanding merscovinduced pathogenic mechanisms <NUMBER> <NUMBER> initial experiments included screening wildtype balbc stat<NUMBER> knockout laboratory mice susceptibility merscov infection development disease however mice develop clinical signs disease infectious virus could recovered <NUMBER> zhao et al overcame hurdle transducing balbc mice human cd<NUMBER>dpp<NUMBER> using adenovirus construct <NUMBER> transduced mice permissive merscov infection demonstrated minimal weight loss however candidate medical countermeasures mouse model evaluated comparing changes viral titer lungs <NUMBER> days postinoculation treated untreated animals transductionbased models may also prove quite variable due infection efficacy transducing vector nonhuman primates rhesus monkeys macaca mulatta crabeating macaques macaca fascicularis grivets chlorocebus aethiops common marmosets callithrix jacchus frequently used development animal models human viral disease immunological similarity humans merscov inoculation rhesus monkeys gave varied results leading disease limited similarity human disease <NUMBER> <NUMBER> <NUMBER> instance study yao et al revealed intratracheal inoculation rhesus monkeys merscov resulted nonlethal disease limited pathology could observed <NUMBER> days postinoculation <NUMBER> de wit et al described study nonhuman primates following inoculation combination intratracheal intranasal oral conjunctival routes <NUMBER> rhesus monkeys euthanized days <NUMBER> <NUMBER> postinoculation merscov evaluated virological immunological histopathological changes <NUMBER> <NUMBER> euthanasia time points animals signs pneumonia replicating virus could demonstrated tissues mucous membranes quantitative pcr however inherent serialsampling design disease progression induced viral infection truncated limiting data gleaned study middle east respiratory syndrome review informahealthcarecom followup study falzarano et al demonstrated administration antiinflammatory immunomodulators interferona<NUMBER>b ribavirin reduced viral burden lessened disease severity following intratracheal intranasal oral ocular challenge merscov <NUMBER> xray radiographs indicated lung infiltrates days <NUMBER> <NUMBER> postinoculation suggesting virusinduced lung disease however two studies include mockinoculated controls demonstrate observed clinical signs due generalized inflammation inoculation handling procedures recently falzarano et al described intratracheal inoculation common marmosets merscov resulted partially lethal disease <NUMBER> however animals received large volume bolus merscov <NUMBER> ml intratracheally disproportionate based small lung volume <NUMBER> ml common marmoset johnson rf unpublished observation measured computed tomography n <NUMBER> addition experiment include animals received control inocula therefore extent virusinduced pathology compared pathology due animal manipulation remains unclear overall suitable nonhuman primate model human mers still lacking onehumped camels reservoir merscov see vaccination merscov infection may provide intervention opportunity figure <NUMBER>b indeed three onehumped camels inoculated intranasal intratracheal conjunctival routes merscov developed benign clinical signs shed large quantities virus upper respiratory tract <NUMBER> comparisons drawn uniformly lethal animal model onehumped camel model would interesting mers animal model based onehumped camels many challenges large size animals relative scarcity western world classification merscov risk group <NUMBER> pathogen requiring biosafety level <NUMBER> bsl<NUMBER> containment limit number facilities could perform studies colorado state university kansas state university united states department agriculture ames ia usa commonwealth scientific industrial research organisation commonly known csiro clayton south australia bsl<NUMBER> labs could handle large animals alternative use camelids alpacas vicugna pacos guanacos lama guanicoe llamas llama glama vicuñas vicugna vicugna camelids smaller may easier obtain bactrian camels camelus bactrianus camels big onehumped camels rarer however consequence merscov inoculation animals requires evaluation recent emergence merscov reemergence several highconsequence pathogens recent years spurred retooling current vaccine strategies development procedures many current mers vaccine development strategies based sars research <NUMBER> however <NUMBER> years since first description sars vaccine prevent sarscov infection approved fact bode well researchers clinicians researchers deficient mers candidate vaccines emphasis placed improving translational research licensure procedures animal model development emerging pathogens <NUMBER> <NUMBER> transient outbreaks infectious diseases mers appear subside relatively quickly justification funding research efforts vaccine development figure <NUMBER> idealized vaccine development timeline postdiscovery preregulatory submission simplified timeline illustrates potential pitfalls encountered throughout development process optimistic estimates vaccine development candidate selection industrial production fall <NUMBER> <NUMBER> years depending type vaccine adding <NUMBER> years research prior candidate selection <NUMBER> years regulatory submission licensure final formulation hand total time approximately <NUMBER> years discovery methods bureaucratic processes approvals accelerating overall timeline could realistically shrink <NUMBER> years always straightforward unfortunately vaccine development often seems reactionary rather prospective instance vaccine development ebola virus disease overall niche activity current <NUMBER> outbreak affected thousands people rare emerging pathogen costbenefit analyses vaccine development must calculated based limited knowledge pandemic andor reemergence potential example merscov shows even sparse economical data available cost estimates shown figure <NUMBER> warrant mers vaccine development economic losses even small infectious disease outbreaks far outweigh costs associated vaccine development however faster methods move candidate vaccine laboratory bench clinic essential ondemand acceleration strategies current evaluation support efforts advanced <NUMBER> <NUMBER> <NUMBER> prediction clinical trial success based vitro research results remains major obstacle timely vaccine development particularly vaccines emerging diseases high lethality seen mers emerging pathogen control via accelerated ondemand vaccine development idealistic approach usual lag disease identification accurate clinical reporting presentation pathogenesis shortened difficulties related regulatory submission licensure vaccines addressed ondemand methods practically implemented thus far promising mers vaccine candidates proven elicit mers coronavirus merscovneutralizing antibodies use approved platform administration include vaccines novavax merscov nanoparticles inovio pharmaceuticals dna mers vaccine targeting multiple antigens mers vaccines focus targeting merscov receptorbinding domain also look promising new emerging infectious diseases continue plague world significant concern recombinant infectious agents used bioterrorism threats microbiologists increasingly asked apply scientific knowledge respond threats recent pandemic caused severe acute respiratory syndrome sars coronavirus illustrated newly evolved pathogen rapidly spread throughout world also global community unite identify causative agent control spread rapid response research mechanisms used sars accelerated vaccine initiative savi shown application emergency management techniques together rapid response research highly effective applied appropriately new infectious diseases throughout human history infectious diseases important role shaping evolving world pandemics epidemics commonplace density worlds population international travel trade increased support global spread pathogens microbial pathogens constantly evolving new pathogens continually emerging nature recent emergence many new pathogens including hiv enterohaemorrhagic escherichia coli west nile virus legionella pneumophila cryptococcus neoformans subspecies gattii various influenza strains actually biology taking normal course microorganisms evolve exploit new altered ecological niches <NUMBER> <NUMBER> therefore surprise first pandemic twentyfirst century appeared quickly late <NUMBER> severe acute respiratory syndrome coronavirus sarscov causing significant morbidity approximately <NUMBER> cases mortality <NUMBER> deaths estimated economic impact us <NUMBER> billion worldwide <NUMBER> sars outbreak provided excellent opportunity attempt harness power modern science provide rapid solutions public health emergency placed pressure many microbiologists worldwide identify sequence virus characterize disease apply modern epidemiological techniques track trace virus origins develop strategies treat control pathogen worldwide scientists responded challenges extreme vigour many achievements made fig <NUMBER> including identifying causative agent sequencing genome developing animal models infection determining pathogen originated nature globally spread human communities however despite acquisition large body scientific information sars spreading around world method controlling virus required case escaped containment measures meant alternative therapeutic preventative methods urgently needed development vaccines therapeutic agents usually takes least decade costs hundreds millions dollars yet practical solution sars needed beginning next respiratory virus season addition new microbial threats likely emerge scientists asked provide rapid solutions fast successful response sars could provide example science effectively applied response new emerging diseases unfortunately usual scientific process designed focused quickly solving practical problem grant applications peer review funding mechanisms traditionally rapid processes responding emerging infectious diseases pressing public health importance requires scientific process significantly different traditional procedures response must focus science directly practical solution problem solve several scientific problems parallel instead sequence sars pandemic provided perfect opportunity attempt develop system clinical trials regulatory affairs international collaborations developed parallel instead sequentially soon genome became available bioinformatics web site created used savi scientists well many sars researchers around world see sars bioinformatics suite online links box addition large demand worldwide fulllength sequenced clones various sars coronavirus genes several programmes put place clone express viral proteins could used reagents vaccine studies methods developed growing virus tissue culture using vero cells neutralization assay developed necessary vaccine development important factor producing vaccine quickly early availability information basis immunological protection disease although immune correlates protection sarscov yet completely defined individuals convalescing sars known develop high titres neutralizing antibodies <NUMBER> appearance neutralizing antibodies coincided onset resolution sars pneumonia <NUMBER> coronaviruses <NUMBER> inverse relationship disease severity levels preexisting serum antibodies neutralizing antibodies likely important protection sars tcell immunity also likely necessary protection sars many viruses instance low concentrations cd<NUMBER> cd<NUMBER> cells sars infection correlated increased disease severity mortality <NUMBER> specific human leukocyte antigen hla class alleles correlated sars susceptibility <NUMBER> taken together data indicated vaccine sars would need induce neutralizing antibodies possibly cd<NUMBER> cd<NUMBER> tcell responses knowledge proved helpful selecting vaccine candidates immunization approaches many potential vaccine strategies considered sarscov including whole killed viral vaccine attenuated virus adenovirus vaccinia virus expressing sars proteins recombinant sars proteins dna vaccines successful vaccines developed animal coronaviruses indicating one strategies might work information sars proteins could used candidate vaccine antigens also obtained development animal coronavirus vaccines <NUMBER> emergence sars many scientific groups worldwide began study disease canada particularly affected sarsthere <NUMBER> cases <NUMBER> deaths world health organization travel health advisory issued therefore strong interest pandemic <NUMBER> <NUMBER> michael smith genome sciences centre vancouver emergency management plan place allowed entire facility dedicated rapid sequencing infectious agent collaboration british columbia centre disease control health supplied sars clinical virus strain known toronto <NUMBER> tor<NUMBER> centre generated first genome sequence sarscov within six days receiving viral nucleic acid <NUMBER> several groups followed genome sequences shortly thereafter <NUMBER> <NUMBER> key sequencing genome quickly rapid response emergency management plan already place entailed topdown management approach taken team members parallel projects able dedicate time expertise assigned tasks success coupled concern canada quarantine would contain sarscov led provincial british columbia government providing cdn <NUMBER> million april <NUMBER> establish sars accelerated vaccine initiative savi dedicated developing human sars vaccine rapidly possible vaccine approach chosen several reasons including previous success animal coronavirus vaccines ease product development use vaccines prevent infection cases defined risk exposure healthcare workers hospitals savi established apply rapid response research public health issue designed one goal develop safe effective human sars vaccine rapidly possible savifunded vaccinedevelopment initiatives evaluated goal mind senior management committee established significant expertise animal coronavirus vaccines epidemiology clinical trials grantfunding mechanisms emergency management strategy adopted weekly teleconferences members well regular management committee discussions parallel research strategies designed vaccine development ultimate goal addition identifying vaccine candidates immunological assays intellectual property successfully commercialize vaccine strong intellectual property position needed <NUMBER> savi fortunate partnered group sequenced sarscov protected genome sequence <NUMBER> however additional intellectual property issues arise project progresses also preexisting intellectual property place must incorporated use live attenuated vectors protein expression systems savi decided make legal entity leave ownership intellectual property inventors home universities saved significant time intellectual property mechanisms already established various partner universities issues royalty rates already settled appropriate way deal intellectual property remains significant challenge worldwide development commercialization sars vaccines regulatory issues regulatory issues another consideration rapidly developing vaccine vaccines often take many years develop yet need sars vaccine urgent beginning initiative discussions held appropriate regulatory bodies health canada us fda gain support obtain documents describing regulatory guidelines biological agents addition savi worked regulatory authorities consultants define steps needed vaccine development including use clinically approved cell lines vaccine generation avoidance animal products vaccine production identification plasmids another important consideration vaccine testing availability relevant animal infection challenge model vaccine studies initiated animal models available assumed would developed quickly rapid vaccine development ultimate goal decided assuming became available initially test vaccine candidates relevant animal infection model possible nonhuman primates smallanimal vaccine models misleading time consuming soon macaque infection model published <NUMBER> <NUMBER> significant efforts made secure primates studies however recently significant concerns primate models best infection models tests many laboratories indicate exhibit mild respiratory infections <NUMBER> present ferrets seem relevant disease model <NUMBER> relevant murine models developed allow viral replication <NUMBER> owing high costs primate experiments biosafety level iii containment facilities concerns relevance primate challenge model present savi vaccines first tested ferrets mice nonhuman primates small animals safety immunogenicity similarly groups testing adenoviruses <NUMBER> modified vaccinia viruses <NUMBER> dna vaccine <NUMBER> murine macaque models although additional step adds time project necessary imperative show protection animal infection model closely mimics human disease anticipated testing multiple animal models would also help eliminate concerns regarding vaccineinduced immune enhancement immunopathology <NUMBER> addition fundamental scientific questions associated vaccine development several related issues impacted directly success project fig <NUMBER> include spike surface glycoprotein found viral surface giving viral particle crown therefore name nucleocapsid n protein found inside viral particle packages rna viral genome fig <NUMBER> deciding antigens vaccine approach use posed significant challenges advantages disadvantages research groups chose particular vaccine method familiar contrast savi chose develop three vaccine approaches parallel making final decision candidate progress human clinical trials direct comparison three vaccines relevant animal infection models strategy also provided opportunity use one vaccine primeboost strategy necessary although approach initially required work thought would significantly increase likelihood successful vaccine developed work began three strategies developing whole killed inactivated virus developing recombinant protein modifying adenovirus vaccinia virus express sarscov n proteins whole killed virus recombinant protein targeted inducing neutralizing antibodies whereas adenovirus vaccinia virus vectors targeted inducing cellular immunity neutralizing antibodies proved important bringing together disparate research communities common effort researchers obtained funding still held accountable standard grant regulations research guidelines including adequate accounting reporting completion project project director periodically reviews progress funded collaborators ensure adequate progress relevance well coordinating diverse research groups international collaboration vaccine development sars pandemic international coordination collaboration essential important role coordinating responses following epidemic addition october <NUMBER> hosted meeting geneva attended nearly main research groups working sarscov sars vaccines meeting useful many respects including allowing various groups discuss strategies progress resolving intellectual property regulatory issues selecting developing animal models several additional collaborations formed meeting well better understanding world stood regard vaccines recently february <NUMBER> held meeting rotterdam reach consensus regarding animal models represent best infection models test sars vaccine candidates although macaque model described sars <NUMBER> still questions regarding suitability vaccine testing least three north american laboratories little success observing lung pathology severe clinical signs macaques live sarscov challenge <NUMBER> factors dose strain sarscov route administration day autopsy might account variability laboratories consensus meeting rotterdam standardization conditions sarscov challenge needed different laboratories nonhuman primates could used vaccine testing strains mice balbc c<NUMBER> shown support sarscov replication demonstrate significant pathology clinical disease <NUMBER> smallanimal models sars ferrets <NUMBER> hamsters unpublished observations meeting rotterdam <NUMBER> ref <NUMBER> also support viral replication demonstrate level pathology similar humans animals offer canada united states extremely supportive willing work according riskbenefit platform sars developed next major pandemic would done everything possible expedite approval process counter risk disease sars currently major threat agree normal regulatory approval mechanisms apply expediting vaccine approval might unnecessary handling media major disease outbreak receives significant media attention continual demand updates research progress potential therapeutics preventatives vaccines therefore mechanisms need place deal responsibly media requests projects progress consequently system established enabled effective communication media needed provided consistent message handled expand expectations provided important messages progress project media briefings also provided every six months scientific symposia held every six months keep entire savi group collaborators abreast progress made different areas project funding mechanisms important hurdle rapid response research distributing funds researchers timely manner timeframe starting write peerreviewed grant application funds received laboratory usually one year unsuitable rapid response research rapid funding mechanisms must established ensure appropriate research carried timely manner savi established michael smith foundation health research provincial health research funding agency british columbia used control dispense research funds using fivemember senior management committee consisting senior scientists rapid review mechanism established short <NUMBER>page focused research proposals together proposed research budget dealt directly aspects vaccine development solicited accepted research community committee reviewed evaluated projects basis scientific merit direct need project funds dispersed successful applicants immediately usually <NUMBER> hours application submitted ensuring applications peerreviewed rapid review process significantly enhanced speed project nature reviews microbiology volume <NUMBER> july <NUMBER> <NUMBER> <NUMBER> <NUMBER> infectious diseases exemplified sars patient consent clinical samples taken especially early outbreak potential research uses samples known difficult specify exactly used however large collection clinical samples crucial understanding infectious disease mechanisms collecting sharing samples must place outbreak occurs vaccine therapeutic product used human clinical trials made stringent gmp <NUMBER> ideally rapid response research would done conditions start nearly impossible especially infectious agents instead candidate vaccine therapeutic identified work reproduced conditions significantly lengthens production time outset standardized cell lines vero cells attenuated viral vectors adenovirus adjuvant alum chosen already approved human use significant time saved product development <NUMBER> <NUMBER> sars particularly challenging requires biosafety level iii containment animal studies must done stringent containment facilities world similarly whole killed viral vaccine manufactured highly specialized biosafety level iii gmp facilities needed exist worldwide <NUMBER> owing perceived threat biological agents several biosafety level iii containment facilities recently approved construction however performing rapid response research highly infectious agents new world places major burden specialized facilities especially biosafety level iii large animal primate gmp facilities efficient use space requires global cooperation judicial prioritization commercialization commercialization sars vaccine raises several complex issues seems sars worldwide threat present significant commercial market vaccine companies unwilling spend hundreds millions dollars needed commercialize vaccine unlikely recover expenses <NUMBER> several reasons industry unwilling commit developing specific vaccines first huge cost vaccine development us <NUMBER> million small uncertain revenue traditional vaccines made vaccine manufacturers ability rapid research response emerging infectious disease significant appeal sars seen major public health threat canada several countries asia countries particular felt compelled act canada indicated concept working together rapid response research towards sars vaccine rapidly accepted researchers approached fact scholars nonlifescience areas academia also freely offered time skills deal related problems scientists willing contribute relevant expertise portion laboratorys resources work towards common goal particular individual gain immediately obvious although willingness probably accentuated one perceives significant threat ones country also powerful motivating factor seeking obtain particular expertise rapid response research similarly international cooperation coordination needed avoid significant duplication redundancy efforts well share progress ideal situation expertise around world would coordinated poses major logistical political challenges pivotal role throughout sars pandemic tracking disease also convening meetings researchers working potential vaccine therapeutics diagnostics face future pandemics coordinated international rapid response research approach essential develop new ways controlling scourges main difficulty sars research limited availability clinical samples researchers standardization samples countries national centres disease control collected coordinated clinical samples whereas others left individual hospitals important problem studying emerging alternative inexpensive disease model compared nonhuman primates although reports use small animals sarscov vaccine testing scarce however despite different animal models single animal species shown reproduce clinical signs lethality observed humans infected sarscov anticipating reemergence sars would likely occur close original site origin savi initiated collaboration chinese scientists guangdong province southern china resulted bilateral agreement work together sars vaccine trials collaboration greatly facilitated strong political support china canada two countries significantly affected sars obvious question sars vaccines evaluated human efficacy given lack human sars cases globally year ordinarily phase phase iii human clinical trials designed provide understanding safety immunogenicity vaccine humans well identification correlates immunity without outbreak sars could used test efficacy vaccines humans licensure vaccine emergency conditions might take place fdas animal efficacy rule states vaccines biological agents licensed meet two criteria human safety demonstration adequate protection deliberate infection challenge two species animals see vaccine policy online links sars vaccines go directly animals humans conditions vaccine efficacy safety must evaluated animals followed phase safety evaluation immunogenicity testing healthy human volunteers phase study currently ongoing china inactivated sars virus <NUMBER> present enough sars cases test vaccine phase ii iii trials despite lack ongoing sars threat rapid response initiatives savi continue necessary important vaccine available sars return furthermore initiatives strongly supported internationally recognized scientists strong expertise particular area research development contrast pharmaceutical companies product focus diffuse expertise suitable gmp vaccine manufacturing organizing clinical trials humans concept working together rapid response research towards sars vaccine rapidly accepted researchers approached scientists willing … work towards common goal severe acute respiratory syndrome sars infectious disease caused coronavirus sarscov marra et al <NUMBER> rota et al <NUMBER> sars detected first time guandong province china late <NUMBER> spread rapidly around world resulted <NUMBER> cases <NUMBER> resulted death <NUMBER> countries areas five continents httpwwwcdcgovmmwrmguide sarsenhtml world healh organization declared end sars outbreak july <NUMBER>th <NUMBER> nevertheless several isolated outbreaks subsequently occurred accidental contaminations laboratories taiwan singapore mainland china httpwwwwhointcsrsarsen late <NUMBER> early <NUMBER> newly infected persons contact animals infected sarscov strains significantly different predominating <NUMBER> outbreak reported <NUMBER> outbreak sera samples collected <NUMBER> positive <NUMBER> cases zheng et al <NUMBER> furthermore <NUMBER> animal traders whereas <NUMBER> vegetable traders guandong markets seropositive sarscov without showing signs disease guan et al <NUMBER> sarscov vaccines urgently needed prevent potential sars epidemics sarscov disease severity linked age higher mortalities ages <NUMBER> special attention paid vaccine development protect elderly people several types vaccines developed including inactivated viruses subunit vaccines viruslike particles vlps dna vaccines heterologous expression systems vaccines derived sarscov genome reverse genetics paper review previously published sars vaccination strategies announce new accomplishments sarscov based vaccination approaches focusing correlates protection detected serotypes vaccination side effects biosafeguards engineered recombinant vaccine approaches based sarscov genome knowledge diversity serotypes essential information vaccine design phylogenetic analysis sarscov isolates animals humans strongly suggest virus originated animals likely bats poon et al <NUMBER> amplified palm civets transmitted human population via live animal markets kan et al <NUMBER> neutralization set eight pseudoviruses expressing spike glycoprotein eight sarscov strains selected three phases sars epidemic early middle late plus another human isolate collected end <NUMBER> gd<NUMBER> two civet cat isolates <NUMBER> sz<NUMBER> sz<NUMBER> studied chineseconsortium <NUMBER> yang et al <NUMBER> human monoclonal antibodies protein frankfurt isolate fra<NUMBER> derived epsteinbarr virus transformed b lymphocytes used virus tested neutralization assays included pseudotypes made protein members four main genetic clusters defined bayesian analysis sarscov glycoproteins fig <NUMBER>a group <NUMBER> originating animals isolated <NUMBER> prototype group isolate sz<NUMBER> primarily uses civet human angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor ii group <NUMBER> low pathogenic viruses originating civets raccoon dogs sporadic human cases strain gd<NUMBER> reported sporadic sars case december <NUMBER> <NUMBER> virus represented independent introduction less pathogenic virus glycoprotein sequence divergent human strains chineseconsortium <NUMBER> general group <NUMBER> isolates appear receptor binding domain rbd capable recognizing human ace<NUMBER> receptor successfully cultured gd<NUMBER> glycoprotein contains <NUMBER> amino acid substitutions relative group <NUMBER> urbani multiple sequence alignment spike gene virus created using clustalx <NUMBER> default settings bayesian inference conducted mr bayes markov chain monte carlo sampling four chains <NUMBER> generations consensus tree generated using <NUMBER> majority rule burn <NUMBER> branch confidence values shown posterior probabilities three human isolates fall within animal cluster gz<NUMBER> gd<NUMBER> gz<NUMBER> may represent infections human acquired virus animals dashed line group <NUMBER> group <NUMBER> used represent much longer line tree ∼<NUMBER> times longer thus distance line representative distance bat human sars protein many map within neutralizing epitopes amino acids <NUMBER> <NUMBER> corresponding rbd recombinant viruses encoding gd<NUMBER> glycoprotein isolated using reverse genetics recombinant icgd<NUMBER> virus replicates <NUMBER> logs less efficiently human airway epithelial cells <NUMBER> × <NUMBER> <NUMBER> pfuml compared wt urbani <NUMBER> × <NUMBER> <NUMBER> pfuml <NUMBER> h postinfection iii group <NUMBER> highly pathogenic viruses representing <NUMBER> epidemic strains associated early middle late phase prototypes viruses early isolate middle isolates gz<NUMBER> cuhkw respectively late urbani fra<NUMBER> toronto <NUMBER> tor<NUMBER> strains iv group <NUMBER> bat sarscov strains successfully cultured sequenced samples taken rhinolophus spp like chinese horseshoe bat viruses differ urbani <NUMBER> amino acid sequence generally <NUMBER> <NUMBER> contact interface residues human ace<NUMBER> receptor using glycoprotein gene unrooted bayesian analysis suggests bat strains closely related early phase human strains basically virus pseudotyped proteins different strains neutralized extent except human gd<NUMBER> two civet cat isolates sz<NUMBER> sz<NUMBER> indicating least two human sarscov serotypes likely originated two independent transmissions virus civet cat human yang et al <NUMBER> important determine recombinant viruses bearing zoonotic glycoproteins display similar neutralization kinetics pseudotyped viruses bearing sars spikes sarscovlike isolated bats identified rhinolophus spp nucleotide identity tor<NUMBER> strain higher <NUMBER> li et al <NUMBER> addition six novel coronaviruses six different bat species described woo et al <NUMBER> four coronaviruses belong group <NUMBER> two group <NUMBER> based sequence data authors proposed classification bat cov three subgroups <NUMBER>a <NUMBER>b <NUMBER>c subgroup <NUMBER>b comprises sarscov batsarscov rp<NUMBER> isolate sequences sarscov isolates differ s<NUMBER> domain protein sequence identity fell <NUMBER> sequence divergence s<NUMBER> domain corroborated serum neutralization studies indicate although bat sera high level crossreactive antibodies failed neutralize human civet cat sarscov tested vero e<NUMBER> cells contrast authors reported <NUMBER> bat sera samples tested neutralized human sarscov isolate hku<NUMBER> using frhk<NUMBER> cells discrepancy could due presence different sarscovlike virus serotype bats studied two different groups two test systems used evaluation consequently vaccine design take account antigenic diversity interestingly recent characterization antigenic structure sarscov protein large panel mabs shown least one epitope providing susceptibility sarscov maps rbd ace<NUMBER> highly conserved virus strains therefore may confer protection sarscov strains et al <NUMBER> sarscov least seven structural proteins <NUMBER>a e <NUMBER>a <NUMBER>b n fig <NUMBER> schaecher pekosz <NUMBER> weiss navasmartin <NUMBER> sarscov <NUMBER>a e proteins viral membrane proteins domains exposed external face virus ito et al <NUMBER> shen et al <NUMBER> principle could involved protection induction neutralizing antibodies shown proteins <NUMBER>a induce vitro sarscov neutralizing antibodies protein main component protective immunity qiu et al <NUMBER> saif <NUMBER> although strong immune responses elicited n proteins subbarao et al <NUMBER> wang et al <NUMBER> zhu et al <NUMBER> passive transfer studies illustrate sspecific antibodies confer protection sarscov replication mouse model bisht et al <NUMBER> subbarao et al <NUMBER> relevance protein protection sarscov reinforced identification neutralizing antibodies convalescent patients majority coronavirus neutralizing epitopes located within spike protein virus hogan et al <NUMBER> two domains defined spike protein aminoterminus s<NUMBER> carboxyterminus s<NUMBER> halves coronaviruses apparently case sarscov protein processed two halves weiss navasmartin <NUMBER> wong et al <NUMBER> recent evidence determined sarscov neutralization sensitive deglycosylation spike protein suggesting conformational epitopes important antibody recognition song et al <NUMBER> rbd located s<NUMBER> subunit protein contains multiple conformational neutralizing epitopes suggests recombinant proteins containing rbd vectors encoding rbd sequence used develop safe effective sars vaccines continuous viral epitopes targeted antibodies plasma samples convalescent sars patients identified biopanning m<NUMBER> phage display dodecapeptide library epitopes converged short peptide fragments one spike nucleocapsid <NUMBER>a <NUMBER>b nsp<NUMBER> proteins immunoassays found patients <NUMBER> recovered sars developed antibodies epitoperich region spike s<NUMBER> domain indicating domain also immunodominant site protein s<NUMBER>targeting antibodies shown effectively neutralize sarscov moreover possible s<NUMBER>specific antibodies provided protective immunity help patients recover viral infection fact among rabbit antibodies elicited different fragments covering entire protein expressed e coli specific aa <NUMBER> include heptadrepeat sequence s<NUMBER> domain interacts form protein trimers neutralizing activities indicating region protein also carries neutralizing epitopes sarscov <NUMBER>a protein consist <NUMBER> amino acids contains three putative transmembrane domains expressed virus cell surface ito et al <NUMBER> tan et al <NUMBER>b topology <NUMBER>a protein cell surface experimentally determined first <NUMBER> aa located first transmembrane domain facing extracellular matrix akerstrom et al <NUMBER> cterminal third transmembrane domain aa <NUMBER> facing cytoplasm tan et al <NUMBER>b interestingly two separate cohorts sars patients one taiwan hong kong b cells recognizing nterminal region <NUMBER>a protein isolated patients moreover significant proportion <NUMBER> convalescent sars patients examined dot blot assay using synthetic peptide sequence corresponding amino acids <NUMBER> n terminus protein positive addition recently reported nterminal domain <NUMBER>a protein elicits strong potentially protective humoral responses infected patients zhong et al <NUMBER> accordingly rabbit polyclonal antibodies raised synthetic peptide corresponding aa <NUMBER> <NUMBER>a protein inhibit sarscov propagation vero e<NUMBER> cells contrast antibodies specific cterminal domain protein akerstrom et al <NUMBER> sarscov e <NUMBER>a proteins shown low immunogenicity tan et al <NUMBER>a sera three convalescent phase sars patients recognize proteins expressed mammalian cells accordingly sarscov e protein peptides recognized convalescent patient antisera using protein microarray qiu et al <NUMBER> study using rabbit antibodies <NUMBER> recombinant fragments associated sarscov e n <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b proteins strong neutralizing antibodies elicited s<NUMBER> fragment aa <NUMBER> protein qiu et al <NUMBER> incorrect folding proteins expressed e coli could responsible lack detection antibodies viral proteins <NUMBER>a protein known induce neutralizing antibodies see protein transmissible gastroenteritis coronavirus tgev required virus assembly budding protein specific antibodies significantly weakly neutralize tgev mediate complementdependent lysis tgev infected cells delmas et al <NUMBER> risco et al <NUMBER> woods et al <NUMBER> consistent tgev data described shown sarscov protein also induced virus neutralizing antibodies absence complement addition mixture proteins showed synergistic effect vitro synthesis tgev neutralizing antibodies immune leukocytes case sarscov immunization hamsters parainfluenza virus vector shown differential role e n proteins protection parainfluenza virus expressing protein alone provided complete protection sarscov challenge lower respiratory tract partial protection upper respiratory tract protection slightly augmented coexpression e proteins nevertheless expression e n proteins absence protein confer detectable protection results identify main sarscov neutralization protective antigen among structural proteins confers limited role sarscov protein protection sarscov n protein specific antibodies neutralize virus vitro could expected internal virus protein pang et al <NUMBER> however sarscov n protein induces tcell responses gao et al <NUMBER> accordingly dna immunization using sarscov n gene induces potent th<NUMBER> polarized immune responses mice well specific antibodies animals fact highest levels humoral response cell proliferation activity induced n gene construct jin et al <NUMBER> analysis immune response another coronavirus tgev using vitro antibody synthesis system shown optimum combination viral proteins stimulate production tgev neutralizing antibodies vitro mixture n proteins combination protein oligomers rosettes n n proteinderived peptides anton et al <NUMBER> anton et al <NUMBER> data principle suggest n protein could used vaccine promote synthesis sspecific neutralizing antibodies <NUMBER>b protein <NUMBER> aa elicits antibodies sarscov patients indicating expressed natural disease immunogenic qiu et al <NUMBER> zhong et al <NUMBER> fact <NUMBER> convalescent phase patients sera positive <NUMBER>b protein based data speculated <NUMBER>b protein could structural qiu et al <NUMBER> nevertheless presence <NUMBER>b protein sarscov virions needs proved summary available data sarscov proteins <NUMBER>a elicit strong neutralizing antibody responses whereas protein induces reduced neutralizing humoral immune response antigens probably relevant protection sarscov addition structural proteins e <NUMBER>a <NUMBER>b n possibly protein <NUMBER>b could also play role protection study role humoral immune response sarscov spike specific monoclonal antibodies neutralize virus developed subbarao et al <NUMBER> traggiai et al <NUMBER> zhang et al <NUMBER> passive transfer monoclonal antibodies immune serum naïve mice protected infection sarscov using epsteinbarr virus transformed human b cells memory repertoire patient recovered sarscov infection rescued traggiai et al <NUMBER> monoclonal antibodies exhibited neutralization activity vitro also conferred protection mouse model sarscov infection addition human igg monoclonal antibodies neutralizing sarscov developed using phage display libraries protected ferret lung disease virus shedding pharyngeal secretions ter meulen et al <NUMBER> mouse ferret models administration human monoclonal antibodies vitro neutralization activity reduced sarscov titers lungs <NUMBER> <NUMBER>log<NUMBER>unit protecting lung pathology ferrets ter meulen et al <NUMBER> overall data indicate humoral immune responses alone protect sars immune responses sarscov elicited dna vaccine encoding codon optimized sars spike protein s<NUMBER> fragment induced neutralizing antibodies zeng et al <NUMBER> well tcell responses nevertheless protection sarscov challenge mediated humoral immune response tcelldependent mechanism surprisingly immunodeficient mice clear sarscov infection showing role innate immune responses defenses sarscov c<NUMBER>bl<NUMBER> mice lack nkt cells cd<NUMBER> −− nk cells lack b cells ragl −− cleared virus day <NUMBER> infection glass et al <NUMBER> displayed high induction proinflammatory cytokines data suggest nk cells adaptative immune response essential virus clearance mice possibly interferon pathways relevant viral clearance importance interferon response reinforced infecting stat<NUMBER>deficient mice sarscov hogan et al <NUMBER> stat<NUMBER> important regulation interferons stat<NUMBER>deficient mice produced one hundredfold increase viral titer control mice additionally mutant mice developed interstitial pneumonia seen control mice hogan et al <NUMBER> alveolar damage seen lungs human patients unclear time observed pathological differences human stat <NUMBER>deficient mouse lungs due time sampling differences host responses hogan et al <NUMBER> neutralizing antibodies detected <NUMBER> weeks onset disease immunocompetent sars patients <NUMBER> patients recovered without hospitalization data indicate patients successfully respond sarscov infection although many types vaccines sarscov attempted expression recombinant proteins use virus vectors vaccines require considerable research setup time bradbury <NUMBER> therefore classical approach using inactivated cellculture based sarscov likely easiest way sars vaccine development based experience available vaccines including inactivated live polio rabies vaccines montagnon <NUMBER> zhou et al <NUMBER> case companies favored development inactivated candidate whole virus vaccine based wellestablished technologies development vaccines spruth et al <NUMBER> fast spreading sars initially prompted chinese company sinovac biotech beijin develop vaccine collaboration chinese academy medical sciences started tests vaccine inactivated form sarscov early <NUMBER> using <NUMBER> volunteers marshall enserink <NUMBER> side effects reported first patients injected inactivated virus sarscov inactivation produce killed vaccines performed using different methods instance sarscov purified ultracentrifugation inactivated ␤propiolactone administered without alhydrogel adjuvant see et al <NUMBER> virus subcutaneously administered mice efficient recombinant adenoviruses expressing either n proteins provided intranasal intramuscular routes alternative method inactivation sarscov ␤propiolactone initiating purification step immunization virus compared vaccination using dna adenovirus vectors humoral immune response effective using inactivated virus adjuvants mf<NUMBER> chiron vaccines alum pierce rockkford il associated stimulation cd<NUMBER> cd<NUMBER> response supporting use inactivated sarscov vaccine sarscov also purified <NUMBER> homogeneity ultrafiltration gel filtration exchange chromatography inactivated ␤propiolactone cynomolgus macaques immunized different amounts purified virus absence presence adjuvant monkeys challenged nasal route <NUMBER> days postimmunization high levels neutralizing antibodies prevented replication sarscov interstitial pneumonia induced qin et al <NUMBER> interestingly side effects observed even presence low titer neutralizing antibodies indicating purified sarscov vaccine safe monkeys approaches sarscov partially purified sucrose cushions completely inactivated formaldehyde virus efficiently competed binding infectious virus cells indicating inactivated virus kept functional rbs qu et al <NUMBER> polyethyleneglycol precipitated virus alone presence cholera toxin b ctb sigma cpg administered mice intranasal route elicited serum sarscovspecific neutralizing antibodies iga specific antibodies trachea lungs qu et al <NUMBER> another approach formaldehyde inactivated whole virus prepared vero cells used intramuscular immunization <NUMBER> yearold rhesus monkeys <NUMBER> weeks monkeys challenged sarscov doses <NUMBER> <NUMBER> gmonkey protected monkeys challenge <NUMBER> <NUMBER> pfu sarscov higher doses <NUMBER> g conferred complete protection contrast control animals developed typical sarscov infection challenge immunization preferentially induced th<NUMBER> responses also enhanced cellular immune responses including production ifn␥ increase activity natural killer cells inhibit virus replication systemic side effects observed vaccinated animals postimmunization even high dose <NUMBER> gmonkey two injections one vaccine manufactured large scale using fermenter cultures vero cells serum free medium based doubleinactivated whole virus vaccine spruth et al <NUMBER> virus infection moi <NUMBER> resulted generation high viral titers around <NUMBER> <NUMBER> tcid <NUMBER> ml culture supernatants harvested inactivated formalin treatment followed uv inactivation two step inactivation procedure utilized order ensure high safety margin respect residual infectivity mice immunized twice l g sarscov vaccine using adjuvant <NUMBER> aluminium hydroxide developed high antibody titers sarscov spike protein determined elisa test use adjuvant aloh <NUMBER> minor effect immunogenicity vaccine addition cell mediated immunity measured production inf␥ il<NUMBER> stimulation elicited vaccine confers <NUMBER> protection correlated antibody titer sarscov protein neutralizing antibody titer induction neutralizing antibodies titers ≥<NUMBER> sspecific elisa titer ≥<NUMBER> resulted <NUMBER> protection intranasal challenge <NUMBER> <NUMBER> tcid <NUMBER> infectious virus polypeptide containing amino acids <NUMBER> sarscov spike protein expressed using baculovirus system bisht et al <NUMBER> affinity purified protein administered mice either saponin ribi adjuvants regimens induced binding neutralizing monoclonal antibodies although best results obtained saponin polypeptide provided highest antibody response challenge protective immunity shown reduction sarscov titers upper lower respiratory tract subunit vaccine induced higher neutralizing antibody complete protection intranasal challenge achieved inoculation mice live sarscov vaccinia virus ankara mva expressing full length protein bisht et al <NUMBER> dna expressing fulllength protein lacking transmembrane cytoplasmic domains n protein provide protection sarscov infections still large number reports using n protein antigen published immune response mice vaccinated purified n protein fused glutathione stransferase gst analyzed compared response two dnabased vaccination approaches gupta et al <NUMBER> immunization ngst elicited strong tcell il<NUMBER> antibody responses minimal ifn␥ response response differed markedly immune response shown mice immunized dna encoding unmodified cytoplasmic n protein dna encoding n lamp<NUMBER> chimera targeted lysosomal mhc ii compartment dna immunizations elicited strong tcell ifn␥ ctl responses nevertheless tcell responses three immunogens elicited n peptides shown elispot analysis antigenactivated cells vivo protection experiments performed vaccines n protein sarscov expressed e coli purified balbc mice vaccinated n protein emulsified montanide isa<NUMBER> containing oligodeoxynucleotide cpg pbs first case antin antibodies found mainly igg<NUMBER>a suggesting prevalence th<NUMBER> immune response contrast antin protein antibodies mice immunized n protein pbs found mainly igg<NUMBER> reactivity antisera raised n protein formulated isa<NUMBER>cpg mice monkeys sera patients tested panel overlapping peptides region around residues <NUMBER> n protein immunogenic three models addition peptides corresponding residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> contained murine immunodominant tcell epitopes using ifn␥ secretion cell assay peptides containing residues <NUMBER> capable stimulating cd<NUMBER> cd<NUMBER> cell proliferation vitro peptides corresponding residues <NUMBER> capable stimulating inf␥ production tcell cultures derived peripheral blood mononuclear cells pbmcs macaques immunized n protein emulsified isa<NUMBER>cpg protection experiments performed immunogen requirements sarscov vlp formation differs using different expression systems cell types production viral proteins insect cells using baculovirus shown intracellular sarscov vlps assembly expressing e proteins ho et al <NUMBER> secretion vlps extracellular media required coexpression protein mortola roy <NUMBER> experiments secretion vlps relatively efficient <NUMBER> g per <NUMBER> × <NUMBER> <NUMBER> infected cells results variance obtained expressing sarscov proteins human <NUMBER> renal epithelial cells control cytomegalovirus promoter using dna plasmids system combination genes expressed n proteins without e proteins generated intracellular vlps pseudoparticles form absence n proteins single viral gene able support formation viral capsids within cells additional expression protein allowed formation budding particles morphology typical sars related coronaviruses different types vlps could formed depending protein composition sarscov vlps protection administration vlps reported development plantbased vaccines different coronaviruses tgev infectious bronchitis virus ibv porcine epidemic diarrhea virus pedv using oral delivery recombinant protein elicit protective immunity reported bae et al <NUMBER> lamphear et al <NUMBER> tuboly et al <NUMBER> zhou et al <NUMBER> one studies include protein plantbased vaccine candidate tgev advanced early phase farming trials tuboly et al <NUMBER> recently develop safe effective inexpensive vaccine candidate s<NUMBER> domain sarscov protein expressed tomato lownicotine tobacco plants pogrebnyak et al <NUMBER> high expression levels recombinant s<NUMBER> protein <NUMBER> total soluble protein observed several transgenic lines western blot analysis using protein specific antibodies plantderived antigen induced systemic mucosal immune responses mice showed significantly increased levels sarscov specific iga oral ingestion tomato fruits expressing s<NUMBER> protein pogrebnyak et al <NUMBER> sera mice parenterally primed tobaccoderived s<NUMBER> protein revealed presence sarscovspecific igg several approaches based dna vaccination described order elicit protection sars two used primeboost strategies showed combination dna vaccine whole chemically inactivated vaccine used enhance magnitude immune response also change balance humoral cellular immune response zakhartchouk et al <NUMBER>a combination dna inactivated virus induces th<NUMBER> immune responses whole killed virus vaccine induces th<NUMBER> immune responses mice immunized intramuscularly dna vaccine expressing protein intraperitoneally boosted e coli expressing peptides showed high neutralization titers <NUMBER> vaccine might practical value immunize farms growing civet cats due low cost dna vaccines express n protein alone linked calreticulin first ones preferentially induce igg responses igg<NUMBER>a isotype ifn␥ il<NUMBER> cd<NUMBER> ctl responses n protein produce strong delayedtype hypersensitivity dth could undesired side effects expression n protein linked calreticulin increases major histocompatibility complex mhc class presentation cd<NUMBER> cells absence reported adverse effects mice kim et al <NUMBER> vaccines led generation strong nspecific humoral tcellmediated immune responses mice protection experiments shown n protein also expressed linked hlamp nhlamp target antigen mhc class ii leading stronger higher memory cellular immune response associated high ifn␥ production immunization n protein alone gupta et al <NUMBER> studies dna immunization protect sars using three forms spike protein fulllength proteins cytoplasmic transmembrane domains deleted reported vaccines induced neutralizing antibodies tcell responses resulting protective immunity mice viral replication reduced six orders magnitude lungs mice vaccinated plasmid dna expression vectors protection mediated humoral tcell dependent immune mechanism shown adoptive tcell transfer donor tcells unable reduce pulmonary viral replication recipient animals contrast passive transfer purified igg immunized mice control igg provided immune protection sarscov vector expressing protein cytoplasmic domain partially deleted induced potent neutralizing antibody response using highly attenuated modified mva sarscov protein expressed several groups bisht et al <NUMBER> chen et al <NUMBER> first one shown intranasal intramuscular immunization balbc mice elicited protective immunity shown reduction sarscov titers upper lower respiratory tract challenge furthermore passive transfer serum mice immunized recombinant mva expressing protein naïve mice also reduced replication sarscov respiratory tract challenge demonstrating role protein specific antibodies protection second group showed induction neutralizing antibodies mice ferrets monkeys although protection experiments performed antibody absorption assay majority antibodies raised mva recombinant expressing fulllength protein absorbed protein fragment including aa <NUMBER> includes rbd indicating major sarscov neutralization mechanism likely occurs blocking interaction virus cellular receptor ace<NUMBER> contrast authors immunized ferrets using mva expressing sarscov protein inducing vigorous immune response prevent virus infection spreading czub et al <NUMBER> weingartl et al <NUMBER> liver inflammation found mvaspike vaccinated ferrets authors suggested results indicate induction antibody dependent enhancement ade disease similar caused feline infectious peritonitis virus fipv sars vaccines based use adenovirus vectors shown expression protein alone combination n protein led protection mice challenge sarscov efficacy immunization adenovirus vectors compared chemically inactivated partially purified virus wholekilled virus vaccine effective conferring protective immunity live sarscov see et al <NUMBER> adenovirus vaccines tested mice expressed either n protein zakhartchouk et al <NUMBER>b shown s<NUMBER> domain n protein contain strong tcell epitopes reported challenge experiments monkey model adenovirusbased vaccines induce strong sarscovspecific immune responses indicating vectors promising vaccine candidates information protection provided gao et al <NUMBER> adenovirus ad<NUMBER> vector deletion e<NUMBER> e<NUMBER> regions also used express s<NUMBER> domain sarscov protein <NUMBER> aa wistar rats immunized three times throughout consecutive weeks produce antiserum capable protecting sarscov infection cell culture histopathological examination found evident side effects immunized animals nevertheless vivo protection experiments performed therefore additional experiments required adenovirus based sars vaccines severe disease high death rates noted senescent human populations infected sarscov children <NUMBER> years age develop severe disease seen adults deming et al <NUMBER> data suggest quality immune response may play role outcome virus infection ability vaccines induce robust immune responses senescent populations evaluated determine protection elicited elderly populations senescent immune systems evaluate vaccine efficacy homologous heterologous strains urbani glycoprotein nucleocapsid genes inserted vee virus replicon particles vrps vrpn deming et al <NUMBER> addition expression influenza ha glycoprotein vrpha used control using reverse genetics synthetically resurrected recombinant viruses bearing gd<NUMBER> glycoprotein replicated high titers vero human airway epithelial cells obtained deming et al <NUMBER> importantly human convalescent sera plaque reduction neutralization titre <NUMBER> prnt <NUMBER> values <NUMBER> late phase isolates like urbani yet reduced <NUMBER> fold heterologous icgd<NUMBER> virus prnt <NUMBER> <NUMBER> fig <NUMBER>a young senescent balbc mice ages exceeding <NUMBER> year time challenge vaccinated vrpha vrps vrpn combination vrps vrpn challenged recombinant sarscov expressing urbani protein antigenically different gd<NUMBER> protein fig <NUMBER>b vaccinated animals vrps vaccines provided complete shortand longterm protection homologous challenge protecting young senescent mice urbani strain replication challenge vrps vrps vrpn vaccinated mice displayed little pathologic lesions lung whereas vrpha vaccinated aged mice demonstrate pathological lesions lung similar reported literature roberts et al <NUMBER>a vrps vaccines also provided shortterm protection young mice challenged heterologous gd<NUMBER> strain despite significantly reduced ability antiurbani antibody neutralize virus expressing gd<NUMBER> contrast vaccination senescent mice vrps provided limited protection ∼<NUMBER> combination vrps vrpn vaccines provided little longterm protection infection antigenically different sarscov gd<NUMBER> although virus titers reduced <NUMBER>fold compared vrpha controls sarscov gd<NUMBER> challenge also produced pathological lesions vrpha sarsvaccinated animals virtually indistinguishable produced infection sarscovurbani strain therefore likely declining immunity senescent animals combination reduced ability antibody neutralize heterologous challenge viruses resulted vaccine failure aged animals seems vaccine approaches induce less robust neutralization responses like dna killed vaccines might completely fail protecting senescent populations sarscov gd<NUMBER> challenge sarscov disease severity linked age comorbidities mortality rates increasing age exceeding <NUMBER> individuals <NUMBER> also known elderly respond poorly new antigens compared younger populations overall phenomena poorly studied consequently vaccine efficacy elderly key property efficacious sarscov vaccines immunosenescence common animal models clinical studies occur aging vaccine efficacy often attenuated elderly frasca et al <NUMBER> song et al <NUMBER> zheng et al <NUMBER> immune complications include generalized decrease function b cell innate immune function diminished macrophage granulocyte function diminished cellular traffic cell growth differentiation decreased natural killer cell numbers activity new different vaccine regimens developed tested ultimate goal eliciting complete protection antigenically heterologous forms sarscov especially vulnerable elderly populations need testing developing vaccines induce antin response animal models similarly described viral systems frech et al <NUMBER> mcelhaney <NUMBER> vector based existing live attenuated parainfluenza virus developed intranasal pediatric immu nization human parainfluenza virus type <NUMBER> hpiv<NUMBER> used express sarscov protein vector administration monkeys resulted production systemic immune response mucosal immunization challenge sarscov monkeys control group shed sarscov contrast viral shedding occurred group immunized parainfluenza vector expressing protein recombinant viruses expressing sarscov structural n proteins individually combination evaluated immunogenicity protection hamsters support replication sarscov parainfluenza vector single intranasal administration vector expressing glycoprotein induced high titer sarscov neutralizing antibodies two fold lower induced sarscov infection response provided complete protection sarscov challenge lower respiratory tract partial protection upper respiratory tract contrast expression n e proteins induce detectable serum sarscov neutralizing antibodies recombinant rabies virus vector used express protein sarscov faber et al <NUMBER> immunogenicity studies mice showed induction sarscov neutralizing antibodies single dose protection studies shown similarly attenuated vesicular stomatitis virus vsv vector used express protein sarscov kapadia et al <NUMBER> mice vaccinated vsvs developed sarscov neutralizing antibodies controlled challenge sarscov performed <NUMBER> <NUMBER> months single vaccination summary immunization prevent sars using different live vector systems shown protection mainly mediated humoral immune responses protein warning signal least vectors vee virus expression n protein may lead side effects effect deletion groupspecific genes different coronaviruses studied reports using mouse hepatitis virus mhv model shown deletion mutants removing orfs <NUMBER> <NUMBER>a <NUMBER>a attenuating natural host de haan et al <NUMBER>a similarly studies deleting orf <NUMBER> tgev ortego et al <NUMBER> orfs <NUMBER>abc <NUMBER>ab fipv haijema et al <NUMBER> led virus attenuation however sarscov deletion mutants lacking orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b significantly influence vitro vivo replication efficiency mouse model yount et al <NUMBER> recombinant viruses replicated wildtype levels murine model suggesting either groupspecific orfs play little role vivo replication efficiency mouse model sufficient quality discerning role groupspecific orfs disease fact surprising orfs like <NUMBER>a <NUMBER>a <NUMBER>b encode structural virus proteins schaecher pekosz <NUMBER> yount et al <NUMBER> little influence vivo virus replication mouse model deletion orf <NUMBER>a shown minor decrease one log unit virus growth yount et al <NUMBER> furthermore deletion one gene deletion orfs <NUMBER>a <NUMBER>b orf<NUMBER> showed <NUMBER> log reduction vero cells little effect growth murine model day <NUMBER> postinfection moreover little difference growth pathogenesis noted mice model wt deletion mutants lacking orf<NUMBER>a orf<NUMBER> therefore effect sarscov gene deletions needs tested relevant animal models interestingly simultaneous deletion larger combinations groupspecific genes <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b lead production infectious sarscov deletionmutant propagates cell culture titer similar parental wild type virus potential deletionmutant promising vaccine candidate studied ml dediego l enjuanes unpublished results recombinant sarscov rsarscov lacks e gene generated bacterial artificial chromososme bac attenuated vitro animal model dediego et al <NUMBER> e gene previously shown nonessential gene group <NUMBER> mhv coronavirus kuo masters <NUMBER> although elimination gene mhv genome reduced virus growth cell culture one thousandfold contrast group <NUMBER> tgev coronavirus expression e gene product essential virus release spread propagation e gene deleted tgev tgeve restored providing e protein trans curtis et al <NUMBER> ortego et al <NUMBER> role e protein sarscov propagation studied constructing sarscov deleted e gene dediego et al <NUMBER> interestingly viable viruses recovered vero e<NUMBER> cells relatively high titer around <NUMBER> <NUMBER> pfuml also huh<NUMBER> caco<NUMBER> cells reduced titers fig <NUMBER> indicating sarscov e protein essential virus replication cell culture electron microscopy observation vero e<NUMBER> cells infected sarscov wt e deletion mutant showed much higher assembly efficiency wt virus fig <NUMBER> respect sarscove behaves mhv group <NUMBER> coronavirus studied although sarscove grows considerably higher titer differential behavior e mutant viruses different coronavirus groups may indicate basic differences virion assembly life cycles among different groups hamster model used study sarscove virus pathogenicity demonstrates elements present human cases sarscov infections including interstitial pneumonitis consolidation dediego et al <NUMBER> ideal animal model completely reproduces human clinical disease pathological findings identified nevertheless hamster model reproducibly supports sarscov replication respiratory tract higher titer longer duration mice nonhuman primates virus replication model accompanied histological evidence pneumonitis animals develop viremia extrapulmonary spread virus roberts et al <NUMBER>b although overt clinical disease absent hamster model useful model evaluation sarscov infection titers recombinant sarscov rsarscov achieved respiratory tract hamsters fig <NUMBER> similar previously reported roberts et al <NUMBER>b <NUMBER>fold higher titers rsarscove virus suggesting mutant virus attenuated histopathology examination lungs infected hamsters performed two five days postinfection shown pulmonary disease notable time points detection viral antigen reduced lungs rsarscove infected hamsters pulmonary inflammation less prominent animals fig <NUMBER> growth rsarscov respiratory tract hamsters hamsters inoculated <NUMBER> <NUMBER> tcid <NUMBER> rsarscov rsarscove animals sacrified tissues harvested different times postinfection viral titers lung nasal turbinates b determined vero e<NUMBER> cells monolayers nonparametric mannwhitney ustatistical method used ascertaining significance observed differences statistical significance indicated pvalue <NUMBER> dotted line indicates lower limit detection rsarscovinfected animals indicating rsarscove attenuated vivo dediego et al <NUMBER> fact reduction sarscov titers patients associated considerable reduction pathogenicity survival rates hung et al <NUMBER> contrast challenge hamsters recombinant viruses lacking single group specific orfs<NUMBER>a orf<NUMBER> result significant reductions virus titier pathology baric et al unpublished therefore sarscove attenuated virus promising vaccine candidate evaluated different animal models mice ferrets macaques live attenuated virus vaccines face series potential concerns including reversion wt recombination repair circulating heterogeneous human coronaviruses zoonotic sars strains consequently live virus vaccine formulations include rational approaches minimizing potential reversion wt phenotype simultaneously resist recombination repair clear modifications sarscov genome could lead viruses attenuated phenotype could considered safe effective vaccine candidates replicase target attenuating coronaviruses undiscovered territory likely ripe alleles might influence replication efficiency virulence sarscov replicase represents major target future research endeavors coronaviruses characteristic strictly conserved genome organization structural genes occurring order <NUMBER> polymerase polsemn<NUMBER> mhv virus mutants genes encoding structural proteins located different order constructed de haan et al <NUMBER>b recombinant viruses tested ability replicate natural host mouse results indicate canonical coronavirus genome organization essential vivo replication mutants showed attenuated phenotype similarly observed vsv ball et al <NUMBER> therefore deliberate rearrangement viral genes may useful generation attenuated coronaviruses due reduced risk generating viable viruses recombination circulating field viruses would make safer vaccines vaccines based modifications replicase gene could principle generated mutagenesis modifications introduced mhv nsp<NUMBER>coding regions identified residues important protein processing viral rna replication may affect virus virulence could introduced vaccine candidates sars nsp<NUMBER> blocks host macromolecular synthesis abrogates ifn signaling kamitani et al <NUMBER> providing evidence nsp<NUMBER> coding regions represent potential virulence determinants alternatively tyr<NUMBER>his substitution open reading frame orf <NUMBER>bnsp<NUMBER> demonstrated attenuate mhv replication mice sperry et al <NUMBER> similarly deletion nsp<NUMBER> gene mhv sarscov shown yield viable attenuated mutant viruses replicate one log less efficiently wt virus cell culture animals may also provide foundation design live vaccines nsp<NUMBER> tyr residue nsp <NUMBER> completely conserved may possible engineer common coronaviridae attenuating alleles via recombinant dna techniques alternatively changes gene order within replicase even relocation <NUMBER> end genome tolerated may led attenuated virus phenotypes options include safeguards genetically engineered vaccines particularly prevent recovery original virulent phenotype recombination vaccine strain viruses circulating field hcov<NUMBER>e oc<NUMBER> nl<NUMBER> developed one construction replicationcompetent propagationdefective viruses pseudovirions defective one gene conferring attenuated phenotype even ability virus propagation viruses could grown packaging cell lines providing trans missing protein case sarscov vaccine candidates without e gene constructed order prevent rescue virulent phenotype recombination circulating human coronavirus deletion essential gene located position distant gene e relocation deleted gene position previously occupied gene e proposed potential recombination leading rescue gene e would lead loss essential gene alternative approach developing safer recombination resistant live coronavirus vaccines developed modifying transcriptional regulatory sequences trs vaccine strain sequence incompatible trs known circulating coronavirus idea recombinant events wt coronaviruses trs remodeled sarscov would result genomes containing lethal mixed regulatory sequences block expression subgenomic mrnas fig <NUMBER>a trs sequences among coronaviruses highly conserved direct expression fig <NUMBER> genome organization sarscov recombinant viruses generate safe attenuated viruses wildtype sarscov trs acgaac blue circles changed ccggat red circles since wildtype mutant trs signals compatible regulating subgenomic transcription recombination event resulting viral genome mixed trs signals viable b icsarscov trs sequence unique described coronaviruses trs sequences select group <NUMBER> <NUMBER> <NUMBER> coronaviruses summarized trs selected remodeled virus shown bottom subgenomic mrnas using molecular clone sarscov trs network remodeled acgaac ccggat fig <NUMBER>b rewiring genomic transcription network allows efficient replication mutant virus icsarscrg icsarscrg recombinant virus replicated titers equivalent wt virus expressed typical ratios subgenomic mrnas proteins interestingly new transcripts noted initiating replicase gene could encode nterminal truncated orf<NUMBER>a polyproteins clear novel transcripts might influence pathogenic outcomes although instances nsp<NUMBER> truncated potentially allowing establishment dominant negative phenotypes replication cell culture animals attractive sarscov vaccine could modified building attenuating mutations genetic template recombinationresistant trs rewired virus either use safe high titer seed stock making killed vaccines live virus vaccine one interesting refinement approach would include secondary traps activated recombinant genomes instance wt trs sequences designed intragenic sites essential orfs like glycoprotein genes recombinant viruses encoding wt leader trs sequences subgenomic transcription might initiate within essential structural genes resulting nterminal deletions would likely lethal severely attenuating humoral tcellmediated responses animal coronaviruses may exacerbate disease cause new health problems tcell responses implicated demyelinization brain spinal cord following infection neurotropic mhv castro perlman <NUMBER> wu et al <NUMBER> group <NUMBER> coronavirus like sarscov adverse humoral responses another group <NUMBER> coronavirus bovine coronavirus bcov also linked development shipping fever cattle oconnor et al <NUMBER> moreover previous exposure fipv passive active immunization virus group <NUMBER> coronavirus found cause early death syndrome instead providing immune protection pedersen et al <NUMBER> weiss et al <NUMBER> disease exacerbation due virusspecific antibodies facilitated enhanced uptake spread virus causing ade infectivity porterfield <NUMBER> vennema et al <NUMBER> weiss scott <NUMBER> caused spike protein specific antibodies corapi et al <NUMBER> corapi et al <NUMBER> olsen et al <NUMBER> olsen et al <NUMBER> scenario side effects caused coronavirus vaccines safety concern sarscov could induce similar antibodyor cellmediated immune pathologies concern increased mainly three reports one study utilizing lentivirus pseudotyped various sarscov proteins indicated within protein major target vaccine immunotherapy minor differences among eight strains transmitted human outbreaks early <NUMBER> whereas substantial functional changes detected derived case late <NUMBER> guandong province isolate gd<NUMBER> two palm civets sz<NUMBER> sz<NUMBER> gd<NUMBER> spike pseudotyped virus markedly resistant antibody neutralization alternatively antibodies neutralized human glycoproteins enhanced virus entry mediated two civet cat virus glycoproteins related gd<NUMBER> isolate another report shown administration ferrets mvabased sarscov vaccine mva alone followed live sarscov challenge resulted enhanced hepatitis side effects reported studies sarscov ferrets shown ferrets useful model sarscov martina et al <NUMBER> similarly data reproduced groups et al <NUMBER> furthermore ade disease observed human sarscov strain therefore important assess vaccines relevant animal models become available antibodies directed sarscov found protective enhance viral infectivity mouse hamster models bisht et al <NUMBER> roberts et al <NUMBER>b yang et al <NUMBER> using inactivated sarscov immunization recombinant adenovirus vectors expressing n proteins sarscov see et al <NUMBER> although effect humans remains unknown side effects observed animal models african green monkeys <NUMBER> months administration sarscov respiratory tract challenged sarscov evidence enhanced disease upon rechallenge shown consistent results cynomolgus macaques immunized different amounts purified virus absence presence adjuvant challenged nasal route <NUMBER> days postimmunization showed side effects even presence low titer neutralizing antibodies temperature breathing appetite mental state biochemical indexes normal immunized monkeys abnormalities observed major organs lung liver kidney etc control nonvaccinated animals showed interstitial pneumonia results indicate purified sarscov vaccine safe monkeys qin et al <NUMBER> summary immunization mice using either protein whole inactivated virus spruth et al <NUMBER> monkeys whole inactivated sarscov qin et al <NUMBER> zhou et al <NUMBER> frequently resulted absence side effects providing different types sarscov vaccines contrast vee virus expressing n protein failed induce protection either young senescent animals resulted enhanced immunopathology following viral challenge days <NUMBER> <NUMBER> postinfection therefore caution taken including n vaccine formulations expressing n protein using dna immunization vee vectors protection elicited mice homologous challenge benefit vaccination cocktail n proteins observed rather coexpression n protein vaccine regimens failed simultaneously induce strong neutralizing antis antibody response led increased number lymphocytic eosinophilic inflammatory infiltrates also characteristic immune pathology observed respiratory syncytial virus rsv infection following vaccination formalin inactivated rsv de swart et al <NUMBER> hancock et al <NUMBER> therefore concern raised expression n protein may result vaccineenhanced pulmonary disease previously described viruses like rsv kim et al <NUMBER> data suggest presence n protein vaccines evaluated vaccine formulation although thus far human sarscov vaccine shown involved ade disease possible immunopathological complications sars vaccine candidates require rigorous clinical immunological evaluation whereas production effective safe vaccines animal coronavirus previously reported satisfactory cavanagh <NUMBER> enjuanes et al <NUMBER> saif <NUMBER> production inactivated subunit vaccines based dna recombinant vectors reverse genetics using sarscov genomes seem promising optimum animal model sarscov vaccine evaluation still required preclinical trials animal models efficacy safety evaluation promising vaccine candidates described performed humans severe acute respiratory syndrome sars infectious disease caused coronavirus sarscov marra et al <NUMBER> rota et al <NUMBER> sars detected first time guandong province china late <NUMBER> spread rapidly around world resulted <NUMBER> cases <NUMBER> resulted death <NUMBER> countries areas five continents httpwwwcdcgovmmwrmguidesarsenhtml world healh organization declared end sars outbreak july <NUMBER>th <NUMBER> nevertheless several isolated outbreaks subsequently occurred accidental contaminations laboratories taiwan singapore mainland china httpwwwwhointcsrsarsen late <NUMBER> early <NUMBER> newly infected persons contact animals infected sarscov strains significantly different predominating <NUMBER> outbreak reported guandong china events indicate sars epidemic may recur time future although event likely would require generation new isolates evolving sarscovlike virus circulating animals consequence possibility sarscov could used virus glycoprotein sequence divergent human strains chineseconsortium <NUMBER> general group <NUMBER> isolates appear receptor binding domain rbd capable recognizing human ace<NUMBER> receptor successfully cultured gd<NUMBER> glycoprotein contains <NUMBER> amino acid substitutions relative group <NUMBER> urbani protein many map within neutralizing epitopes amino acids <NUMBER> <NUMBER> corresponding rbd recombinant viruses encoding gd<NUMBER> glycoprotein isolated using reverse genetics recombinant icgd<NUMBER> virus replicates <NUMBER> logs less efficiently human airway epithelial cells <NUMBER> × <NUMBER> <NUMBER> pfuml compared wt urbani <NUMBER> × <NUMBER> <NUMBER> pfuml <NUMBER> h postinfection iii group <NUMBER> highly pathogenic viruses representing <NUMBER> epidemic strains associated early middle late phase prototypes viruses early isolate middle isolates gz<NUMBER> cuhkw respectively late urbani fra<NUMBER> toronto <NUMBER> tor<NUMBER> strains iv group <NUMBER> bat sarscov strains successfully cultured sequenced samples taken rhinolophus spp like chinese horseshoe bat viruses differ urbani <NUMBER> amino acid sequence generally <NUMBER> <NUMBER> contact interface residues human ace<NUMBER> receptor using glycoprotein gene unrooted bayesian analysis suggests bat strains closely related early phase human strains basically virus pseudotyped proteins different strains neutralized extent except human gd<NUMBER> two civet cat isolates sz<NUMBER> sz<NUMBER> indicating least two human sarscov serotypes likely originated two independent transmissions virus civet cat human yang et al <NUMBER> important determine recombinant viruses bearing zoonotic glycoproteins display similar neutralization kinetics pseudotyped viruses bearing sars spikes sarscovlike isolated bats identified rhinolophus spp nucleotide identity tor<NUMBER> strain higher <NUMBER> li et al <NUMBER> addition six novel coronaviruses six different bat species described woo et al <NUMBER> four coronaviruses belong group <NUMBER> two group <NUMBER> based sequence data authors proposed classification bat cov three subgroups <NUMBER>a <NUMBER>b <NUMBER>c subgroup <NUMBER>b comprises sarscov batsarscov rp<NUMBER> isolate sequences sarscov isolates differ s<NUMBER> domain protein sequence identity fell <NUMBER> sequence divergence s<NUMBER> domain corroborated serum neutralization studies indicate although bat sera high level crossreactive antibodies failed neutralize human civet cat sarscov tested vero e<NUMBER> cells contrast authors reported <NUMBER> bat sera samples tested neutralized human sarscov isolate hku<NUMBER> using frhk<NUMBER> cells discrepancy could due presence different sarscovlike virus serotype bats studied two different groups two test systems used evaluation consequently vaccine design take account antigenic diversity interestingly recent characterization antigenic structure sarscov protein large panel mabs shown least one epitope providing susceptibility sarscov maps rbd ace<NUMBER> highly conserved virus strains therefore may confer protection sarscov strains et al <NUMBER> sarscov least seven structural proteins <NUMBER>a e <NUMBER>a <NUMBER>b n fig <NUMBER> schaecher pekosz <NUMBER> weiss navasmartin <NUMBER> sarscov <NUMBER>a e proteins viral membrane proteins domains exposed external face virus ito et al <NUMBER> shen et al <NUMBER> principle could involved protection induction neutralizing antibodies shown proteins <NUMBER>a induce vitro sarscov neutralizing antibodies protein main component protective immunity qiu et al <NUMBER> saif <NUMBER> although strong immune responses elicited n proteins subbarao et al <NUMBER> zhu et al <NUMBER> passive transfer studies illustrate sspecific antibodies confer protection sarscov replication mouse model bisht et al <NUMBER> subbarao et al <NUMBER> relevance protein protection sarscov reinforced identification neutralizing antibodies convalescent patients majority coronavirus neutralizing epitopes located within spike protein virus hogan et al <NUMBER> two domains defined spike protein aminoterminus s<NUMBER> carboxyterminus s<NUMBER> halves coronaviruses apparently case sarscov protein processed two halves weiss navasmartin <NUMBER> wong et al <NUMBER> recent evidence determined sarscov neutralization sensitive deglycosylation spike protein suggesting conformational epitopes important antibody recognition song et al <NUMBER> rbd located s<NUMBER> subunit protein contains multiple conformational neutralizing epitopes suggests recombinant proteins containing rbd vectors encoding rbd sequence used develop safe effective sars vaccines continuous viral epitopes targeted antibodies plasma samples convalescent sars patients identified biopanning m<NUMBER> phage display dodecapeptide library epitopes converged short peptide fragments one spike nucleocapsid <NUMBER>a <NUMBER>b nsp<NUMBER> proteins immunoassays found patients <NUMBER> recovered sars developed antibodies epitoperich region spike s<NUMBER> domain indicating domain also immunodominant site protein s<NUMBER>targeting antibodies shown effectively neutralize sarscov moreover possible s<NUMBER>specific antibodies provided protective immunity help patients recover viral infection fact among rabbit antibodies elicited different fragments covering entire protein expressed e coli specific aa <NUMBER> include heptadrepeat sequence s<NUMBER> domain interacts form protein trimers neutralizing activities indicating region protein also carries neutralizing epitopes sarscov <NUMBER>a protein consist <NUMBER> amino acids contains three putative transmembrane domains expressed virus cell surface ito et al <NUMBER> tan et al <NUMBER>b topology <NUMBER>a protein cell surface experimentally determined first <NUMBER> aa located first transmembrane domain facing extracellular matrix akerstrom et al <NUMBER> cterminal third transmembrane domain aa <NUMBER> facing cytoplasm tan et al <NUMBER>b interestingly two separate cohorts sars patients one taiwan hong kong b cells recognizing nterminal region <NUMBER>a protein isolated patients moreover significant proportion <NUMBER> convalescent sars patients examined dot blot assay using synthetic peptide sequence corresponding amino acids <NUMBER> n terminus protein positive addition recently reported nterminal domain <NUMBER>a protein elicits strong potentially protective humoral responses infected patients zhong et al <NUMBER> accordingly rabbit polyclonal antibodies raised synthetic peptide corresponding aa <NUMBER> <NUMBER>a protein inhibit sarscov propagation vero e<NUMBER> cells contrast antibodies specific cterminal domain protein akerstrom et al <NUMBER> sarscov e <NUMBER>a proteins shown low immunogenicity tan et al <NUMBER>a sera three convalescent phase sars patients recognize proteins expressed mammalian cells accordingly sarscov e protein peptides recognized convalescent patient antisera using protein microarray qiu et al <NUMBER> study using rabbit antibodies <NUMBER> recombinant fragments associated sarscov e n <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b proteins strong neutralizing antibodies elicited s<NUMBER> fragment aa <NUMBER> protein qiu et al <NUMBER> incorrect folding proteins expressed e coli could responsible lack detection antibodies viral proteins <NUMBER>a protein known induce neutralizing antibodies see protein transmissible gastroenteritis coronavirus tgev required virus assembly budding protein specific antibodies significantly weakly neutralize tgev mediate complementdependent lysis tgev infected cells delmas et al <NUMBER> risco et al <NUMBER> woods et al <NUMBER> consistent tgev data described shown sarscov protein also induced virus neutralizing antibodies absence complement addition mixture proteins showed synergistic effect vitro synthesis tgev neutralizing antibodies immune leukocytes case sarscov immunization hamsters parainfluenza virus vector shown differential role e n proteins protection parainfluenza virus expressing protein alone provided complete protection sarscov challenge lower respiratory tract partial protection upper respiratory tract protection slightly augmented coexpression e proteins nevertheless expression e n proteins absence protein confer detectable protection results identify main sarscov neutralization protective antigen among structural proteins confers limited role sarscov protein protection sarscov n protein specific antibodies neutralize virus vitro could expected internal virus protein pang et al <NUMBER> however sarscov n protein induces tcell responses gao et al <NUMBER> accordingly dna immunization using sarscov n gene induces potent th<NUMBER> polarized immune responses mice well specific antibodies animals fact highest levels humoral response cell proliferation activity induced n gene construct jin et al <NUMBER> analysis immune response another coronavirus tgev using vitro antibody synthesis system shown optimum combination viral proteins stimulate production tgev neutralizing antibodies vitro mixture n proteins combination protein oligomers rosettes n n proteinderived peptides anton et al <NUMBER> anton et al <NUMBER> data principle suggest n protein could used vaccine promote synthesis sspecific neutralizing antibodies <NUMBER>b protein <NUMBER> aa elicits antibodies sarscov patients indicating expressed natural disease immunogenic qiu et al <NUMBER> zhong et al <NUMBER> fact <NUMBER> convalescent phase patients sera positive <NUMBER>b protein based data speculated <NUMBER>b protein could structural qiu et al <NUMBER> nevertheless presence <NUMBER>b protein sarscov virions needs proved summary available data sarscov proteins <NUMBER>a elicit strong neutralizing antibody responses whereas protein induces reduced neutralizing humoral immune response antigens probably relevant protection sarscov addition structural proteins e <NUMBER>a <NUMBER>b n possibly protein <NUMBER>b could also play role protection study role humoral immune response sarscov spike specific monoclonal antibodies neutralize virus developed subbarao et al <NUMBER> traggiai et al <NUMBER> zhang et al <NUMBER> passive transfer monoclonal antibodies immune serum naïve mice protected infection sarscov using epsteinbarr virus transformed human b cells memory repertoire patient recovered sarscov infection rescued traggiai et al <NUMBER> monoclonal antibodies exhibited neutralization activity vitro also conferred protection mouse model sarscov infection addition human igg monoclonal antibodies neutralizing sarscov developed using phage display libraries protected ferret lung disease virus shedding pharyngeal secretions ter meulen et al <NUMBER> mouse ferret models administration human monoclonal antibodies vitro neutralization activity reduced sarscov titers lungs <NUMBER> <NUMBER>log<NUMBER>unit protecting lung pathology ferrets ter meulen et al <NUMBER> overall data indicate humoral immune responses alone protect sars immune responses sarscov elicited dna vaccine encoding codon optimized sars spike protein s<NUMBER> fragment induced neutralizing antibodies zeng et al <NUMBER> well tcell responses nevertheless protection sarscov challenge mediated humoral immune response tcelldependent mechanism surprisingly immunodeficient mice clear sarscov infection showing role innate immune responses defenses sarscov c<NUMBER>bl<NUMBER> mice lack nkt cells cd<NUMBER> −− nk cells lack b cells ragl −− cleared virus day <NUMBER> infection glass et al <NUMBER> displayed high induction proinflammatory cytokines data suggest nk cells adaptative immune response essential virus clearance mice possibly interferon pathways relevant viral clearance importance interferon response reinforced infecting stat<NUMBER>deficient mice sarscov hogan et al <NUMBER> stat<NUMBER> important regulation interferons stat<NUMBER>deficient mice produced one hundredfold increase viral titer control mice additionally mutant mice developed interstitial pneumonia seen control mice hogan et al <NUMBER> alveolar damage seen lungs human patients unclear time observed pathological differences human stat <NUMBER>deficient mouse lungs due time sampling differences host responses hogan et al <NUMBER> neutralizing antibodies detected <NUMBER> weeks onset disease immunocompetent sars patients <NUMBER> patients recovered without hospitalization data indicate patients successfully respond sarscov infection although many types vaccines sarscov attempted expression recombinant proteins use virus vectors vaccines require considerable research setup time bradbury <NUMBER> therefore classical approach using inactivated cellculture based sarscov likely easiest way sars vaccine development based experience available vaccines including inactivated live polio rabies vaccines montagnon <NUMBER> zhou et al <NUMBER> case companies favored development inactivated candidate whole virus vaccine based wellestablished technologies development vaccines spruth et al <NUMBER> fast spreading sars initially prompted chinese company sinovac biotech beijin develop vaccine collaboration chinese academy medical sciences started tests vaccine inactivated form sarscov early <NUMBER> using <NUMBER> volunteers marshall enserink <NUMBER> side effects reported first patients injected inactivated virus sarscov inactivation produce killed vaccines performed using different methods instance sarscov purified ultracentrifugation inactivated βpropiolactone administered without alhydrogel adjuvant see et al <NUMBER> virus subcutaneously administered mice efficient recombinant adenoviruses expressing either n proteins provided intranasal intramuscular routes alternative method inactivation sarscov βpropiolactone initiating purification step immunization virus compared vaccination using dna adenovirus vectors humoral immune response effective using inactivated virus adjuvants mf<NUMBER> chiron vaccines alum pierce rockkford il associated stimulation cd<NUMBER> cd<NUMBER> response supporting use inactivated sarscov vaccine sarscov also purified <NUMBER> homogeneity ultrafiltration gel filtration exchange chromatography inactivated βpropiolactone cynomolgus macaques immunized different amounts purified virus absence presence adjuvant monkeys challenged nasal route <NUMBER> days postimmunization high levels neutralizing antibodies prevented replication sarscov interstitial pneumonia induced qin et al <NUMBER> interestingly side effects observed even presence low titer neutralizing antibodies indicating purified sarscov vaccine safe monkeys approaches sarscov partially purified sucrose cushions completely inactivated formaldehyde virus efficiently competed binding infectious virus cells indicating inactivated virus kept functional rbs qu et al <NUMBER> polyethyleneglycol precipitated virus alone presence cholera toxin b ctb sigma cpg administered mice intranasal route elicited serum sarscovspecific neutralizing antibodies iga specific antibodies trachea lungs qu et al <NUMBER> another approach formaldehyde inactivated whole virus prepared vero cells used intramuscular immunization <NUMBER> yearold rhesus monkeys <NUMBER> weeks monkeys challenged sarscov doses <NUMBER> <NUMBER> μgmonkey protected monkeys challenge <NUMBER> <NUMBER> pfu sarscov higher doses <NUMBER> μg conferred complete protection contrast control animals developed typical sarscov infection challenge immunization preferentially induced th<NUMBER> responses also enhanced cellular immune responses including production ifnγ increase activity natural killer cells inhibit virus replication systemic side effects observed vaccinated animals postimmunization even high dose <NUMBER> μgmonkey two injections one vaccine manufactured large scale using fermenter cultures vero cells serum free medium based doubleinactivated whole virus vaccine spruth et al <NUMBER> virus infection moi <NUMBER> resulted generation high viral titers around <NUMBER> <NUMBER> tcid <NUMBER> ml culture supernatants harvested inactivated formalin treatment followed uv inactivation two step inactivation procedure utilized order ensure high safety margin respect residual infectivity mice immunized twice l μg sarscov vaccine using adjuvant <NUMBER> aluminium hydroxide developed high antibody titers sarscov spike protein determined elisa test use adjuvant aloh <NUMBER> minor effect immunogenicity vaccine addition cell mediated immunity measured production infγ il<NUMBER> stimulation elicited vaccine confers <NUMBER> protection correlated antibody titer sarscov protein neutralizing antibody titer induction neutralizing antibodies titers ≥<NUMBER> sspecific elisa titer ≥<NUMBER> resulted <NUMBER> protection intranasal challenge <NUMBER> <NUMBER> tcid <NUMBER> infectious virus polypeptide containing amino acids <NUMBER> sarscov spike protein expressed using baculovirus system bisht et al <NUMBER> affinity purified protein administered mice either saponin ribi adjuvants regimens induced binding neutralizing monoclonal antibodies although best results obtained saponin polypeptide provided highest antibody response challenge protective immunity shown reduction sarscov titers upper lower respiratory tract subunit vaccine induced higher neutralizing antibody complete protection intranasal challenge achieved inoculation mice live sarscov vaccinia virus ankara mva expressing full length protein bisht et al <NUMBER> dna expressing fulllength protein lacking transmembrane cytoplasmic domains n protein provide protection sarscov infections still large number reports using n protein antigen published immune response mice vaccinated purified n protein fused glutathione stransferase gst analyzed compared response two dnabased vaccination approaches gupta et al <NUMBER> immunization ngst elicited strong tcell il<NUMBER> antibody responses minimal ifnγ response response differed markedly immune response shown mice immunized dna encoding unmodified cytoplasmic n protein dna encoding n lamp<NUMBER> chimera targeted lysosomal mhc ii compartment dna immunizations elicited strong tcell ifnγ ctl responses nevertheless tcell responses three immunogens elicited n peptides shown elispot analysis antigenactivated cells vivo protection experiments performed vaccines n protein sarscov expressed e coli purified balbc mice vaccinated n protein emulsified montanide isa<NUMBER> containing oligodeoxynucleotide cpg pbs first case antin antibodies found mainly igg<NUMBER>a suggesting prevalence th<NUMBER> immune response contrast antin protein antibodies mice immunized n protein pbs found mainly igg<NUMBER> reactivity antisera raised n protein formulated isa<NUMBER>cpg mice monkeys sera patients tested panel overlapping peptides region around residues <NUMBER> n protein immunogenic three models addition peptides corresponding residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> contained murine immunodominant tcell epitopes using ifnγ secretion cell assay peptides containing residues <NUMBER> capable stimulating cd<NUMBER> cd<NUMBER> cell proliferation vitro peptides corresponding residues <NUMBER> capable stimulating infγ production tcell cultures derived peripheral blood mononuclear cells pbmcs macaques immunized n protein emulsified isa<NUMBER>cpg protection experiments performed immunogen requirements sarscov vlp formation differs using different expression systems cell types production viral proteins insect cells using baculovirus shown intracellular sarscov vlps assembly expressing e proteins ho et al <NUMBER> secretion vlps extracellular media required coexpression protein mortola roy <NUMBER> experiments secretion vlps relatively efficient <NUMBER> μg per <NUMBER> × <NUMBER> <NUMBER> infected cells results variance obtained expressing sarscov proteins human <NUMBER> renal epithelial cells control cytomegalovirus promoter using dna plasmids system combination genes expressed n proteins without e proteins generated intracellular vlps pseudoparticles form absence n proteins single viral gene able support formation viral capsids within cells additional expression protein allowed formation budding particles morphology typical sars related coronaviruses different types vlps could formed depending protein composition sarscov vlps protection administration vlps reported development plantbased vaccines different coronaviruses tgev infectious bronchitis virus ibv porcine epidemic diarrhea virus pedv using oral delivery recombinant protein elicit protective immunity reported bae et al <NUMBER> lamphear et al <NUMBER> tuboly et al <NUMBER> zhou et al <NUMBER> one studies include protein plantbased vaccine candidate tgev advanced early phase farming trials tuboly et al <NUMBER> recently develop safe effective inexpensive vaccine candidate s<NUMBER> domain sarscov protein expressed tomato lownicotine tobacco plants pogrebnyak et al <NUMBER> high expression levels recombinant s<NUMBER> protein <NUMBER> total soluble protein observed several transgenic lines western blot analysis using protein specific antibodies plantderived antigen induced systemic mucosal immune responses mice showed significantly increased levels sarscov specific iga oral ingestion tomato fruits expressing s<NUMBER> protein pogrebnyak et al <NUMBER> sera mice parenterally primed tobaccoderived s<NUMBER> protein revealed presence sarscovspecific igg several approaches based dna vaccination described order elicit protection sars two used primeboost strategies showed combination dna vaccine whole chemically inactivated vaccine used enhance magnitude immune response also change balance humoral cellular immune response zakhartchouk et al <NUMBER>a combination dna inactivated virus induces th<NUMBER> immune responses whole killed virus vaccine induces th<NUMBER> immune responses mice immunized intramuscularly dna vaccine expressing protein intraperitoneally boosted e coli expressing peptides showed high neutralization titers <NUMBER> vaccine might practical value immunize farms growing civet cats due low cost dna vaccines express n protein alone linked calreticulin first ones preferentially induce igg responses igg<NUMBER>a isotype ifnγ il<NUMBER> cd<NUMBER> ctl responses n protein produce strong delayedtype hypersensitivity dth could undesired side effects expression n protein linked calreticulin increases major histocompatibility complex mhc class presentation cd<NUMBER> cells absence reported adverse effects mice kim et al <NUMBER> vaccines led generation strong nspecific humoral tcellmediated immune responses mice protection experiments shown n protein also expressed linked hlamp nhlamp target antigen mhc class ii leading stronger higher memory cellular immune response associated high ifnγ production immunization n protein alone gupta et al <NUMBER> studies dna immunization protect sars using three forms spike protein fulllength proteins cytoplasmic transmembrane domains deleted reported vaccines induced neutralizing antibodies tcell responses resulting protective immunity mice viral replication reduced six orders magnitude lungs mice vaccinated plasmid dna expression vectors protection mediated humoral tcell dependent immune mechanism shown adoptive tcell transfer donor tcells unable reduce pulmonary viral replication recipient animals contrast passive transfer purified igg immunized mice control igg provided immune protection sarscov vector expressing protein cytoplasmic domain partially deleted induced potent neutralizing antibody response using highly attenuated modified mva sarscov protein expressed several groups bisht et al <NUMBER> chen et al <NUMBER> first one shown intranasal intramuscular immunization balbc mice elicited protective immunity shown reduction sarscov titers upper lower respiratory tract challenge furthermore passive transfer serum mice immunized recombinant mva expressing protein naïve mice also reduced replication sarscov respiratory tract challenge demonstrating role protein specific antibodies protection second group showed induction neutralizing antibodies mice ferrets monkeys although protection experiments performed antibody absorption assay majority antibodies raised mva recombinant expressing fulllength protein absorbed protein fragment including aa <NUMBER> includes rbd indicating major sarscov neutralization mechanism likely occurs blocking interaction virus cellular receptor ace<NUMBER> contrast authors immunized ferrets using mva expressing sarscov protein inducing vigorous immune response prevent virus infection spreading czub et al <NUMBER> weingartl et al <NUMBER> liver inflammation found mvaspike vaccinated ferrets authors suggested results indicate induction antibody dependent enhancement ade disease similar caused feline infectious peritonitis virus fipv sars vaccines based use adenovirus vectors shown expression protein alone combination n protein led protection mice challenge sarscov efficacy immunization adenovirus vectors compared chemically inactivated partially purified virus wholekilled virus vaccine effective conferring protective immunity live sarscov see et al <NUMBER> adenovirus vaccines tested mice expressed either n protein zakhartchouk et al <NUMBER>b shown s<NUMBER> domain n protein contain strong tcell epitopes reported challenge experiments monkey model adenovirusbased vaccines induce strong sarscovspecific immune responses indicating vectors promising vaccine candidates information protection provided gao et al <NUMBER> adenovirus ad<NUMBER> vector deletion e<NUMBER> e<NUMBER> regions also used express s<NUMBER> domain sarscov protein <NUMBER> aa wistar rats immunized three times throughout consecutive weeks produce antiserum capable protecting sarscov infection cell culture histopathological examination found evident side effects immunized animals nevertheless vivo protection experiments performed therefore additional experiments required adenovirus based sars vaccines severe disease high death rates noted senescent human populations infected sarscov children <NUMBER> years age develop severe disease seen adults deming et al <NUMBER> ng et al <NUMBER> data suggest quality immune response may play role outcome virus infection ability vaccines induce robust immune responses senescent populations evaluated determine protection elicited elderly populations senescent immune systems evaluate vaccine efficacy homologous heterologous strains urbani glycoprotein nucleocapsid genes inserted vee virus replicon particles vrps vrpn deming et al <NUMBER> addition expression influenza ha glycoprotein vrpha used control using reverse genetics synthetically resurrected recombinant viruses bearing gd<NUMBER> glycoprotein replicated high titers vero human airway epithelial cells obtained deming et al <NUMBER> importantly human convalescent sera plaque reduction neutralization titre <NUMBER> prnt <NUMBER> values <NUMBER> late phase isolates like urbani yet reduced <NUMBER> fold heterologous icgd<NUMBER> virus prnt <NUMBER> <NUMBER> fig <NUMBER>a young senescent balbc mice ages exceeding <NUMBER> year time challenge vaccinated vrpha vrps vrpn combination vrps vrpn challenged recombinant sarscov expressing urbani protein antigenically different gd<NUMBER> protein fig <NUMBER>b vaccinated animals vrps vaccines provided complete shortand longterm protection homologous challenge protecting young senescent mice urbani strain replication challenge vrps vrps vrpn vaccinated mice displayed little pathologic lesions lung whereas vrpha vaccinated aged mice demonstrate pathological lesions lung similar reported literature roberts et al <NUMBER>a vrps vaccines also provided shortterm protection young mice challenged heterologous gd<NUMBER> strain despite significantly reduced ability antiurbani antibody neutralize virus expressing gd<NUMBER> contrast vaccination senescent mice vrps provided limited protection <NUMBER> combination vrps vrpn vaccines provided little longterm protection infection antigenically different sarscov gd<NUMBER> although virus titers reduced <NUMBER>fold compared vrpha controls sarscov gd<NUMBER> challenge also produced pathological lesions vrpha sarsvaccinated animals virtually indistinguishable produced infection sarscovurbani strain therefore likely declining immunity senescent animals combination reduced ability antibody neutralize heterologous challenge viruses resulted vaccine failure aged animals seems vaccine approaches induce less robust neutralization responses like dna killed vaccines might completely fail protecting senescent populations sarscov gd<NUMBER> challenge sarscov disease severity linked age comorbidities mortality rates increasing age exceeding <NUMBER> individuals <NUMBER> also known elderly respond poorly new antigens compared younger populations overall phenomena poorly studied consequently vaccine efficacy elderly key property efficacious sarscov vaccines immunosenescence common animal models clinical studies occur aging vaccine efficacy often attenuated elderly frasca et al <NUMBER> song et al <NUMBER> zheng et al <NUMBER> immune complications include generalized decrease function b cell innate immune function diminished macrophage granulocyte function diminished cellular traffic cell growth differentiation decreased natural killer cell numbers activity new different vaccine regimens developed tested ultimate goal eliciting complete protection antigenically heterologous forms sarscov especially vulnerable elderly populations need testing developing vaccines induce antin response animal models similarly described viral systems frech et al <NUMBER> mcelhaney <NUMBER> vector based existing live attenuated parainfluenza virus developed intranasal pediatric immunization human parainfluenza virus type <NUMBER> hpiv<NUMBER> used express sarscov protein vector administration monkeys resulted production systemic immune response mucosal immunization challenge sarscov monkeys control group shed sarscov contrast viral shedding occurred group immunized parainfluenza vector expressing protein recombinant viruses expressing sarscov structural n proteins individually combination evaluated immunogenicity protection hamsters support replication sarscov parainfluenza vector single intranasal administration vector expressing glycoprotein induced high titer sarscov neutralizing antibodies two fold lower induced sarscov infection response provided complete protection sarscov challenge lower respiratory tract partial protection upper respiratory tract contrast expression n e proteins induce detectable serum sarscov neutralizing antibodies recombinant rabies virus vector used express protein sarscov faber et al <NUMBER> immunogenicity studies mice showed induction sarscov neutralizing antibodies single dose protection studies shown similarly attenuated vesicular stomatitis virus vsv vector used express protein sarscov kapadia et al <NUMBER> mice vaccinated vsvs developed sarscov neutralizing antibodies controlled challenge sarscov performed <NUMBER> <NUMBER> months single vaccination summary immunization prevent sars using different live vector systems shown protection mainly mediated humoral immune responses protein warning signal least vectors vee virus expression n protein may lead side effects effect deletion groupspecific genes different coronaviruses studied reports using mouse hepatitis virus mhv model shown deletion mutants removing orfs <NUMBER> <NUMBER>a <NUMBER>a attenuating natural host de haan et al <NUMBER>a similarly studies deleting orf <NUMBER> tgev ortego et al <NUMBER> orfs <NUMBER>abc <NUMBER>ab fipv haijema et al <NUMBER> led virus attenuation however sarscov deletion mutants lacking orfs <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>a <NUMBER>b significantly influence vitro vivo replication efficiency mouse model yount et al <NUMBER> recombinant viruses replicated wildtype levels murine model suggesting either groupspecific orfs play little role vivo replication efficiency mouse model sufficient quality discerning role groupspecific orfs disease fact surprising orfs like <NUMBER>a <NUMBER>a <NUMBER>b encode structural virus proteins schaecher pekosz <NUMBER> yount et al <NUMBER> little influence vivo virus replication mouse model deletion orf <NUMBER>a shown minor decrease one log unit virus growth yount et al <NUMBER> furthermore deletion one gene deletion orfs <NUMBER>a <NUMBER>b orf<NUMBER> showed <NUMBER> log reduction vero cells little effect growth murine model day <NUMBER> postinfection moreover little difference growth pathogenesis noted mice model wt deletion mutants lacking orf<NUMBER>a orf<NUMBER> therefore effect sarscov gene deletions needs tested relevant animal models interestingly simultaneous deletion larger combinations groupspecific genes <NUMBER> <NUMBER>a <NUMBER>b <NUMBER>a <NUMBER>b <NUMBER>b lead production infectious sarscov deletionmutant propagates cell culture titer similar parental wild type virus potential deletionmutant promising vaccine candidate studied ml dediego l enjuanes unpublished results recombinant sarscov rsarscov lacks e gene generated bacterial artificial chromososme bac attenuated vitro animal model dediego et al <NUMBER> e gene previously shown nonessential gene group <NUMBER> mhv coronavirus kuo masters <NUMBER> although elimination gene mhv genome reduced virus growth cell culture one thousandfold contrast group <NUMBER> tgev coronavirus expression e gene product essential virus release spread propagation e gene deleted tgev tgevδe restored providing e protein trans curtis et al <NUMBER> ortego et al <NUMBER> role e protein sarscov propagation studied constructing sarscov deleted e gene dediego et al <NUMBER> interestingly viable viruses recovered vero e<NUMBER> cells relatively high titer around <NUMBER> <NUMBER> pfuml also huh<NUMBER> caco<NUMBER> cells reduced titers fig <NUMBER> indicating sarscov e protein essential virus replication cell culture electron microscopy observation vero e<NUMBER> cells infected sarscov wt δe deletion mutant showed much higher assembly efficiency wt virus fig <NUMBER> respect sarscovδe behaves mhv group <NUMBER> coronavirus studied although sarscovδe grows considerably higher titer differential behavior δe mutant viruses different coronavirus groups may indicate basic differences virion assembly life cycles among different groups hamster model used study sarscovδe virus pathogenicity demonstrates elements present human cases sarscov infections including interstitial pneumonitis consolidation dediego et al <NUMBER> ideal animal model completely reproduces human clinical disease pathological findings identified nevertheless hamster model reproducibly supports sarscov replication respiratory tract higher titer longer duration mice nonhuman primates virus replication model accompanied histological evidence pneumonitis animals develop viremia extrapulmonary spread virus roberts et al <NUMBER>b although overt clinical disease absent hamster model useful model evaluation sarscov infection titers recombinant sarscov rsarscov achieved respiratory tract hamsters fig <NUMBER> similar previously reported roberts et al <NUMBER>b <NUMBER>fold higher titers rsarscovδe virus suggesting mutant virus attenuated histopathology examination lungs infected hamsters performed two five days postinfection shown pulmonary disease notable time points detection viral antigen reduced lungs rsarscovδe infected hamsters pulmonary inflammation less prominent animals rsarscovinfected animals indicating rsarscovδe attenuated vivo dediego et al <NUMBER> fact reduction sarscov titers patients associated considerable reduction pathogenicity survival rates hung et al <NUMBER> contrast challenge hamsters recombinant viruses lacking single group specific orfs<NUMBER>a orf<NUMBER> result significant reductions virus titier pathology baric et al unpublished therefore sarscovδe attenuated virus promising vaccine candidate evaluated different animal models mice ferrets macaques live attenuated virus vaccines face series potential concerns including reversion wt recombination repair circulating heterogeneous human coronaviruses zoonotic sars strains consequently live virus vaccine formulations include rational approaches minimizing potential reversion wt phenotype simultaneously resist recombination repair clear modifications sarscov genome could lead viruses attenuated phenotype could considered safe effective vaccine candidates replicase target attenuating coronaviruses undiscovered territory likely ripe alleles might influence replication efficiency virulence sarscov replicase represents major target future research endeavors coronaviruses characteristic strictly conserved genome organization structural genes occurring order <NUMBER>′polymerase polsemn<NUMBER>′ mhv virus mutants genes encoding structural proteins located different order constructed de haan et al <NUMBER>b recombinant viruses tested ability replicate natural host mouse results indicate canonical coronavirus genome organization essential vivo replication mutants showed attenuated phenotype similarly observed vsv ball et al <NUMBER> therefore deliberate rearrangement viral genes may useful generation attenuated coronaviruses due reduced risk generating viable viruses recombination circulating field viruses would make safer vaccines vaccines based modifications replicase gene could principle generated mutagenesis modifications introduced mhv nsp<NUMBER>coding regions identified residues important protein processing viral rna replication may affect virus virulence could introduced vaccine candidates sars nsp<NUMBER> blocks host macromolecular synthesis abrogates ifn signaling kamitani et al <NUMBER> providing evidence nsp<NUMBER> coding regions represent potential virulence determinants alternatively tyr<NUMBER>his substitution open reading frame orf <NUMBER>bnsp<NUMBER> demonstrated attenuate mhv replication mice sperry et al <NUMBER> similarly deletion nsp<NUMBER> gene mhv sarscov shown yield viable attenuated mutant viruses replicate one log less efficiently wt virus cell culture animals may also provide foundation design live vaccines nsp<NUMBER> tyr residue nsp <NUMBER> completely conserved may possible engineer common coronaviridae attenuating alleles via recombinant dna techniques alternatively changes gene order within replicase even relocation <NUMBER>′end genome tolerated may led attenuated virus phenotypes options include safeguards genetically engineered vaccines particularly prevent recovery original virulent phenotype recombination vaccine strain viruses circulating field hcov<NUMBER>e oc<NUMBER> nl<NUMBER> developed one construction replicationcompetent propagationdefective viruses pseudovirions defective one gene conferring attenuated phenotype even ability virus propagation viruses could grown packaging cell lines providing trans missing protein case sarscov vaccine candidates without e gene constructed order prevent rescue virulent phenotype recombination circulating human coronavirus deletion essential gene located position distant gene e relocation deleted gene position previously occupied gene e proposed potential recombination leading rescue gene e would lead loss essential gene enjuanes <NUMBER> alternative approach developing safer recombination resistant live coronavirus vaccines developed modifying transcriptional regulatory sequences trs vaccine strain sequence incompatible trs known circulating coronavirus idea recombinant events wt coronaviruses trs remodeled sarscov would result genomes containing lethal mixed regulatory sequences block expression subgenomic mrnas fig <NUMBER>a trs sequences among coronaviruses highly conserved direct expression subgenomic mrnas using molecular clone sarscov trs network remodeled acgaac ccggat fig <NUMBER>b rewiring genomic transcription network allows efficient replication mutant virus icsarscrg icsarscrg recombinant virus replicated titers equivalent wt virus expressed typical ratios subgenomic mrnas proteins interestingly new transcripts noted initiating replicase gene could encode nterminal truncated orf<NUMBER>a polyproteins clear novel transcripts might influence pathogenic outcomes although instances nsp<NUMBER> truncated potentially allowing establishment dominant negative phenotypes replication cell culture animals attractive sarscov vaccine could modified building attenuating mutations genetic template recombinationresistant trs rewired virus either use safe high titer seed stock making killed vaccines live virus vaccine one interesting refinement approach would include secondary traps activated recombinant genomes instance wt trs sequences designed intragenic sites essential orfs like glycoprotein genes recombinant viruses encoding wt leader trs sequences subgenomic transcription might initiate within essential structural genes resulting nterminal deletions would likely lethal severely attenuating humoral tcellmediated responses animal coronaviruses may exacerbate disease cause new health problems tcell responses implicated demyelinization brain spinal cord following infection neurotropic mhv castro perlman <NUMBER> wu et al <NUMBER> group <NUMBER> coronavirus like sarscov adverse humoral responses another group <NUMBER> coronavirus bovine coronavirus bcov also linked development shipping fever cattle oconnor et al <NUMBER> moreover previous exposure fipv passive active immunization virus group <NUMBER> coronavirus found cause early death syndrome instead providing immune protection pedersen et al <NUMBER> weiss et al <NUMBER> disease exacerbation due virusspecific antibodies facilitated enhanced uptake spread virus causing ade infectivity porterfield <NUMBER> vennema et al <NUMBER> weiss scott <NUMBER> caused spike protein specific antibodies corapi et al <NUMBER> corapi et al <NUMBER> olsen et al <NUMBER> olsen et al <NUMBER> scenario side effects caused coronavirus vaccines safety concern sarscov could induce similar antibodyor cellmediated immune pathologies concern increased mainly three reports one study utilizing lentivirus pseudotyped various sarscov proteins indicated within protein major target vaccine immunotherapy minor differences among eight strains transmitted human outbreaks early <NUMBER> whereas substantial functional changes detected derived case late <NUMBER> guandong province isolate gd<NUMBER> two palm civets sz<NUMBER> sz<NUMBER> gd<NUMBER> spike pseudotyped virus markedly resistant antibody neutralization alternatively antibodies neutralized human glycoproteins enhanced virus entry mediated two civet cat virus glycoproteins related gd<NUMBER> isolate another report shown administration ferrets mvabased sarscov vaccine mva alone followed live sarscov challenge resulted enhanced hepatitis side effects reported studies sarscov ferrets shown ferrets useful model sarscov martina et al <NUMBER> similarly data reproduced groups et al <NUMBER> furthermore ade disease observed human sarscov strain therefore important assess vaccines relevant animal models become available antibodies directed sarscov found protective enhance viral infectivity mouse hamster models bisht et al <NUMBER> roberts et al <NUMBER>b subbarao et al <NUMBER> yang et al <NUMBER> using inactivated sarscov immunization recombinant adenovirus vectors expressing n proteins sarscov see et al <NUMBER> although effect humans remains unknown side effects observed animal models african green monkeys <NUMBER> months administration sarscov respiratory tract challenged sarscov evidence enhanced disease upon rechallenge shown consistent results cynomolgus macaques immunized different amounts purified virus absence presence adjuvant challenged nasal route <NUMBER> days postimmunization showed side effects even presence low titer neutralizing antibodies temperature breathing appetite mental state biochemical indexes normal immunized monkeys abnormalities observed major organs lung liver kidney etc control nonvaccinated animals showed interstitial pneumonia results indicate purified sarscov vaccine safe monkeys qin et al <NUMBER> summary immunization mice using either protein whole inactivated virus spruth et al <NUMBER> monkeys whole inactivated sarscov qin et al <NUMBER> zhou et al <NUMBER> frequently resulted absence side effects providing different types sarscov vaccines contrast vee virus expressing n protein failed induce protection either young senescent animals resulted enhanced immunopathology following viral challenge days <NUMBER> <NUMBER> postinfection therefore caution taken including n vaccine formulations expressing n protein using dna immunization vee vectors protection elicited mice homologous challenge benefit vaccination cocktail n proteins observed rather coexpression n protein vaccine regimens failed simultaneously induce strong neutralizing antis antibody response led increased number lymphocytic eosinophilic inflammatory infiltrates also characteristic immune pathology observed respiratory syncytial virus rsv infection following vaccination formalin inactivated rsv de swart et al <NUMBER> hancock et al <NUMBER> therefore concern raised expression n protein may result vaccineenhanced pulmonary disease previously described viruses like rsv kim et al <NUMBER> data suggest presence n protein vaccines evaluated vaccine formulation although thus far human sarscov vaccine shown involved ade disease possible immunopathological complications sars vaccine candidates require rigorous clinical immunological evaluation whereas production effective safe vaccines animal coronavirus previously reported satisfactory cavanagh <NUMBER> enjuanes et al <NUMBER> saif <NUMBER> production inactivated subunit vaccines based dna recombinant vectors reverse genetics using sarscov genomes seem promising optimum animal model sarscov vaccine evaluation still required preclinical trials animal models efficacy safety evaluation promising vaccine candidates described performed humans mr bayes markov chain monte carlo sampling four chains <NUMBER> generations consensus tree generated using <NUMBER> majority rule burn <NUMBER> branch confidence values shown posterior probabilities three human isolates fall within animal cluster gz<NUMBER> gd<NUMBER> gz<NUMBER> may represent infections human acquired virus animals dashed line group <NUMBER> group <NUMBER> used represent much longer line tree <NUMBER> times longer thus distance line representative distance bat human sars growth rsarscov respiratory tract hamsters hamsters inoculated <NUMBER> <NUMBER> tcid <NUMBER> rsarscov rsarscovδe animals sacrified tissues harvested different times postinfection viral titers lung nasal turbinates b determined vero e<NUMBER> cells monolayers nonparametric mannwhitney ustatistical method used ascertaining significance observed differences statistical significance indicated pvalue <NUMBER> dotted line indicates lower limit detection genome organization sarscov recombinant viruses generate safe attenuated viruses wildtype sarscov trs acgaac blue circles changed ccggat red circles since wildtype mutant trs signals compatible regulating subgenomic transcription recombination event resulting viral genome mixed trs signals viable b icsarscov trs sequence unique described coronaviruses trs sequences select group <NUMBER> <NUMBER> <NUMBER> coronaviruses summarized trs selected remodeled virus shown bottom middle east respiratory syndrome coronavirus merscov hitherto unknown βcoronavirus emerged causative agent severe respiratory disease humans <NUMBER> new coronavirus first isolated sputum patient suffering severe pneumonia renal failure <NUMBER> date merscov still causes disease death humans total <NUMBER> confirmed cases including <NUMBER> fatalities <NUMBER> <NUMBER> epidemiological data suggest merscov endemic saudi arabia accounts majority primary communityacquired cases many primary cases due virus exposure direct contact dromedary camels primary animal reservoir merscov alternatively camel workers undergoing subclinical infections suggested mediate virus transmission susceptible individuals <NUMBER> <NUMBER> outbreaks mers caused nosocomial transmissions health care settings <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov infections occur within arabian peninsula ie saudi arabia qatar united arab emirates however mers cases reported various countries around world <NUMBER> <NUMBER> female balbc mice <NUMBER> <NUMBER>weekold purchased charles river laboratories sulzfeld germany experimental work mice housed isolated iso cage unit tecniplast hohenpeißenberg germany free access food water animal experiments handled compliance german regulations animal experimentation animal welfare act approved government upper bavaria munich germany primary chicken embryo fibroblasts cef prepared <NUMBER>dayold chicken embryos spf eggs valo cuxhaven germany maintained minimum essential medium eagle mem sigmaaldrich taufkirchen germany containing <NUMBER> heatinactivated fetal bovine serum fbs sigmaaldrich taufkirchen germany <NUMBER> penicillinstreptomycin sigmaaldrich taufkirchen germany <NUMBER> mem nonessential amino acid solution sigmaaldrich taufkirchen germany human hela atcc ccl<NUMBER> cells maintained mem containing <NUMBER> fbs <NUMBER> penicillinstreptomycin human hacat cls cell lines service gmbh eppelheim germany cells cultured dulbeccos modified eagles medium sigmaaldrich taufkirchen germany supplemented <NUMBER> heatinactivated fbs <NUMBER> hepessolution sigmaaldrich taufkirchen germany antibiotics described cells maintained <NUMBER> • c <NUMBER> co <NUMBER> atmosphere cdna encoding entire amino acid aa sequence <NUMBER> aa merscov n protein silico modified introducing silent codon alterations remove three termination signals tttttnt vaccinia virus early transcription two gc nucleotide runs original merscov gene sequence human betacoronavirus <NUMBER>c emc<NUMBER> genbank accession jx<NUMBER> cdna fragment generated dna synthesis invitrogen life technology regensburg germany cloned mva transfer plasmid piiih<NUMBER>red <NUMBER> place merscov n gene sequence transcriptional control vaccinia virus earlylate promoter pmh<NUMBER> <NUMBER> resulting mva vector plasmid piiih<NUMBER>redmersn recombinant mva generated using standard methodology described previously <NUMBER> briefly monolayers nearly confluent cef grown sixwell tissue culture plates sarstedt nürnbrecht germany infected nonrecombinant mva clonal isolate mva f<NUMBER> <NUMBER> multiplicity infection moi <NUMBER> min infection cef cells transfected plasmid piiih<NUMBER>redmersn dna using xtremegene dna transfection reagent lipofectamine roche diagnostics penzberg germany recommended manufacturer <NUMBER> h infection cell cultures harvested recombinant mva expressing merscov n protein clonally isolated consecutive rounds plaque purification cef screening transient coexpression red fluorescent marker protein mcherry quality control experiments performed using standard methodology <NUMBER> genetic identity genetic stability recombinant virus assessed via polymerase chain reaction pcr analysis genomic viral dna replicative capacities mva vector virus tested multistep growth experiments cef human hacat hela cells generate high titer vaccine preparations preclinical studies recombinant mva amplified cef purified ultracentrifugation <NUMBER> sucrose cushions resuspended <NUMBER> mm trishcl buffer ph <NUMBER> stored −<NUMBER> • c sucrose purified mvamersn vaccine preparations corresponded total proteintotal dna content purity profile mva candidate vaccine human use confluent cell monolayers cef hacat cells infected moi <NUMBER> recombinant mva expressing merscov n protein <NUMBER> noninfected mock wildtype mvainfected cells served controls cell lysates prepared different time points infection stored −<NUMBER> • c total cell proteins resolved electrophoresis sodium dodecyl sulfate sds<NUMBER> polyacrylamide gel sdspage subsequently transferred onto nitrocellulose membrane via electroblotting <NUMBER> h blocking phosphate buffered saline pbs buffer containing <NUMBER> wv nonfat dried milk <NUMBER> vv np<NUMBER> detergent blots incubated monoclonal mouse antimerscov nucleocapsid antibody sino biological beijing china <NUMBER> monoclonal rabbit antimerscov spike protein s<NUMBER> antibody sino biological <NUMBER> polyclonal sera merscov infected rabbits cynomolgus macaques kindly provided dr bart haagmans erasmus medical center rotterdam <NUMBER> <NUMBER> primary antibodies washing <NUMBER> np<NUMBER> pbs blots incubated antimouse igg <NUMBER> antirabbit igg antibody <NUMBER> protein <NUMBER> conjugated horseradish peroxidase cell signaling technology frankfurt main germany washing blots developed using supersignal®west dura extended duration substrate thermo fisher scientific planegg gemany groups female balbc mice n <NUMBER> <NUMBER> immunized twice within <NUMBER>day interval <NUMBER> <NUMBER> plaqueformingunits pfu recombinant mvamersn nonrecombinant mva mva pbs mock vaccine vaccinations given via intramuscular im intraperitoneal ip route using <NUMBER> µl im <NUMBER> µl ip volumes per inoculation mice monitored daily welfare potential adverse events immunization day <NUMBER> post primeboost immunization animals sacrificed cervical dislocation spleens taken cell analysis cell immune monitoring identified <NUMBER> individual synthetic peptides assigned <NUMBER> <NUMBER> silico spanning entire merscov n protein sequence human betacoronavirus <NUMBER>c emc<NUMBER> genbank accession jx<NUMBER> peptide library designed contain <NUMBER>mer peptides overlapping <NUMBER> aa eightyfour peptides could synthesized thermo fisher scientific organized twodimensional matrix peptide pools v<NUMBER> v<NUMBER> h<NUMBER> h<NUMBER> containing <NUMBER> <NUMBER> peptides described previously <NUMBER> <NUMBER> cell epitope mapping <NUMBER> aa sequence shared peptide <NUMBER> <NUMBER> trimmed <NUMBER>mer peptides also obtained thermo fisher scientific peptides dissolved pbs concentration <NUMBER> mgml stored −<NUMBER> • c use spleens harvested day <NUMBER> post primeboost vaccination splenocytes prepared passing <NUMBER> µm strainer falcon® corning brand corning usa incubating red blood cell lysis buffer sigmaaldrich taufkirchen germany cells washed resuspended rpmi <NUMBER> medium sigmaaldrich containing <NUMBER> heat inactivated fbs <NUMBER> penicillinstreptomycin splenocytes processed using quadromacs kit miltenyi biotec bergisch gladbach germany separate cd<NUMBER> cd<NUMBER> splenocytes macs micro beads miltenyi biotec bergisch gladbach germany ifnγproducing cells measured using elispot assays elispot kit mouse ifnγ mabtech germany following manufacturers instructions briefly <NUMBER> × <NUMBER> <NUMBER> splenocytes seeded <NUMBER>well plates sarstedt nürnbrecht germany stimulated peptide pools individual peptides <NUMBER> µg peptideml rpmi <NUMBER> medium <NUMBER> • c <NUMBER> h nonstimulated cells cells treated phorbol myristate acetate pma sigmaaldrich ionomycin sigmaaldrich taufkirchen germany mva f<NUMBER>l <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> peptide f<NUMBER>l spgaagydl thermo fisher scientific planegg germany <NUMBER> served negative positive controls respectively automated elispot plate reader software aelvis eliscan aelvis elispot analysis software hannover germany used count analyze spots splenocytes prepared described splenocytes added <NUMBER>well plates <NUMBER> × <NUMBER> <NUMBER> cellswell stimulated <NUMBER> h merscov nspecific peptide <NUMBER> µg peptideml rpmi <NUMBER> medium presence protein transport inhibitor brefeldin biolegend san diego ca usa <NUMBER> µgml nonstimulated cells served background control cells stimulated <NUMBER> ngml pma <NUMBER> ngml ionomycin f<NUMBER>l peptide <NUMBER> µgml rpmi <NUMBER> medium used positive controls stimulation cell surface antigens stained using peconjugated antimouse cd<NUMBER> clone <NUMBER>a<NUMBER> biolegend san diego ca usa pecy<NUMBER>conjugated antimouse cd<NUMBER> statistical analysis performed ttest using graphpad prism version <NUMBER> software graphpad software san diego ca usa pvalues less <NUMBER> considered statistically significant recombinant virus mvamersn formed cef infected mva transfected mva vector plasmid piiih<NUMBER>redmersn figure <NUMBER>a mva dna sequences piiih<NUMBER>redmersn flank<NUMBER> flank<NUMBER> targeted insertion n gene sequences site deletion iii within mva genome clonal isolation facilitated coproduction red fluorescent reporter protein mcherry allowing convenient detection mvamersn infected cells plaque purification repetitive dna sequence flank<NUMBER> fr served remove marker gene mcherry genome final recombinant virus initiating intragenomic homologous recombination marker gene deletion pcr analysis confirmed presence <NUMBER> mvamersn recombinant viruses cultures selected final markerfree recombinant viruses plaque purification screening plaques without mcherry fluorescence confirm genetic integrity proper insertion heterologous n gene sequences within mvamersn genome analyzed viral genomic dna pcr using specific oligonucleotide primers specific mva sequences adjacent deletion iii insertion site figure <NUMBER>b addition comparative western blot analysis cell lysates mvamersn mvamerss infected cef antigenspecific mouse monoclonal antibodies suggested production comparable amounts merscov candidate antigens figure <NUMBER>b observation line fact mvamerss candidate vector vaccine expresses merscov gene sequences using identical pmh<NUMBER> promoter system <NUMBER> shown previous studies detected two merscov sspecific protein bands upon infection mvamerss indicating authentic proteolytic cleavage fulllength glycoprotein <NUMBER> kda nterminal <NUMBER> kda s<NUMBER> domain cterminal <NUMBER> kda s<NUMBER> domain detected subunit <NUMBER> <NUMBER> <NUMBER> following used total protein lysates mvamersn mvamerss infected cef assess recognition merscov n antigens sera experimentally merscov infected animals western blot analysis sera infected rabbit figure <NUMBER>c cynomolgus monkey figure <NUMBER>d revealed presence antibodies specific merscov n protein recognition merscov n protein least prominent merscov antigen suggestive induction substantial nspecific antibody responses experimental merscov infections cell responses coronaviruses known long lived mostly target conserved cov internal structural n protein however information merscov n antigenspecific cell specificities still limited thus aimed first identify n polypeptidespecific cell epitopes balbc mice immunized twice recombinant virus mvamersn nonrecombinant mva control via intraperitoneal intramuscular routes eight days final immunization splenocytes prepared purified cd<NUMBER> cd<NUMBER> cells restimulated vitro overlapping peptides corresponding n protein overlapping peptides pooled using twodimensional pooledpeptide matrix system table s<NUMBER> screened ifnγ elispot stimulation splenoctyes mvamersn immunized mice peptides <NUMBER> total <NUMBER> peptide pools result detection ifnγ producing cells background numbers obtained splenocytes mock mvacontrol vaccinated animals stimulation peptides pools h<NUMBER> n <NUMBER> v<NUMBER> n <NUMBER> well use vaccinia virus positive peptide f<NUMBER>l <NUMBER> data shown showed elevated numbers ifnγ spot forming cells sfc cd<NUMBER> cell cultures figure <NUMBER>ab mvamersn immunizations given ip im routes resulted comparable cell stimulatory capacities overlapping nspecific peptides pools v<NUMBER> h<NUMBER> contrast peptides pools showed minor stimulatory activities exemplified peptides pools v<NUMBER> v<NUMBER> following peptides within v<NUMBER> h<NUMBER> peptide pools used elucidate detail cell epitope specificities subdivided peptides h<NUMBER> v<NUMBER> four new pools containing five peptides h<NUMBER> h<NUMBER> v<NUMBER> v<NUMBER> addition separately tested two <NUMBER>mer peptides <NUMBER> <NUMBER> shared pools h<NUMBER> v<NUMBER> vaccinated balbc mice mvamersn using ip im inoculations primeboost regime splenocytes prepared day eight last vaccination purified cd<NUMBER> cells restimulated subpools v<NUMBER> v<NUMBER> h<NUMBER> h<NUMBER> figure <NUMBER>a stimulation peptides pools v<NUMBER> h<NUMBER> activated minor levels ifnγ producing cells mean levels <NUMBER> sfc<NUMBER> <NUMBER> splenocytes yet stimulation subpools v<NUMBER> h<NUMBER> revealed clearly higher numbers activated cells <NUMBER> ifnγ sfc<NUMBER> <NUMBER> splenocytes comparable numbers ifnγ producing cells induced ip im immunization note stimulations <NUMBER>mer peptides <NUMBER> n<NUMBER> qnidayktfpkkekk <NUMBER> n<NUMBER> ayktfpkkekkqkap alone resulted detection substantial quantities ifnγ producing cells mean levels <NUMBER> sfc<NUMBER> <NUMBER> splenocytes mice vaccinated mvamersn immunization routes figure <NUMBER>b cd<NUMBER> cells purified mice receiving nonrecombinant mva mock vaccine pbs produce ifnγ following stimulation peptides subpools v<NUMBER>h<NUMBER> peptides <NUMBER> <NUMBER> checking specific peptides contained within subpools observed strongly stimulatory peptides <NUMBER> <NUMBER> part subpools v<NUMBER> h<NUMBER> whereas peptides absent v<NUMBER> h<NUMBER> data suggested overlapping <NUMBER>mer peptides <NUMBER> <NUMBER> contained valuable antigen epitope activation merscov nspecific cd<NUMBER> cell responses following peptides within v<NUMBER> h<NUMBER> peptide pools used elucidate detail cell epitope specificities subdivided peptides h<NUMBER> v<NUMBER> four new pools containing five peptides h<NUMBER> h<NUMBER> v<NUMBER> v<NUMBER> addition separately tested two <NUMBER>mer peptides <NUMBER> <NUMBER> shared pools h<NUMBER> v<NUMBER> vaccinated balbc mice mvamersn using ip im inoculations primeboost regime splenocytes prepared day eight last vaccination purified cd<NUMBER> cells restimulated subpools v<NUMBER> v<NUMBER> h<NUMBER> h<NUMBER> figure <NUMBER>a stimulation peptides pools v<NUMBER> h<NUMBER> activated minor levels ifnγ producing cells mean levels <NUMBER> sfc<NUMBER> <NUMBER> splenocytes yet stimulation subpools v<NUMBER> h<NUMBER> revealed clearly higher numbers activated cells <NUMBER> ifnγ sfc<NUMBER> <NUMBER> splenocytes comparable numbers ifnγ producing cells induced ip im immunization note stimulations <NUMBER>mer peptides <NUMBER> n <NUMBER> qnidayktfpkkekk <NUMBER> n <NUMBER> ayktfpkkekkqkap alone resulted detection substantial quantities ifnγ producing cells mean levels <NUMBER> sfc<NUMBER> <NUMBER> splenocytes mice vaccinated mvamersn immunization routes figure <NUMBER>b cd<NUMBER> cells purified mice receiving nonrecombinant mva mock vaccine pbs produce ifnγ following stimulation peptides subpools v<NUMBER>h<NUMBER> peptides <NUMBER> <NUMBER> checking specific peptides contained within subpools observed strongly stimulatory peptides <NUMBER> <NUMBER> part subpools v<NUMBER> h<NUMBER> whereas peptides absent v<NUMBER> h<NUMBER> data suggested overlapping <NUMBER>mer peptides <NUMBER> <NUMBER> contained valuable antigen epitope activation merscov nspecific cd<NUMBER> cell responses map precisely specific epitope within merscov n protein concentrated overlapping <NUMBER>mer peptide shared peptides <NUMBER> <NUMBER> obtained nine <NUMBER>mer peptides table <NUMBER> using peptides stimulation splenoctyes mvamersn vaccinated mice obtained highest numbers ifnγ producing cells peptide <NUMBER> mean levels <NUMBER> <NUMBER> sfc<NUMBER> <NUMBER> splenocytes peptides <NUMBER> <NUMBER> <NUMBER> availability appropriate merscovspecific immune monitoring tools prerequisite successful development vaccines therapeutic approaches development tools hampered fact still know little relevant viral antigens overall pathogenesis merscov infection recent studies describe number cases asymptomatic merscov infection humans raise questions factors influence clinical manifestation mers <NUMBER> <NUMBER> since asymptomatic mild clinical manifestations merscov infection often associated low levels seropositivity analysis merscovspecific cellular immune responses may facilitate insight immune correlates disease prevention moreover order characterize pathogenesis merscov infection indispensable monitor role virusspecific cells animal models mers precisely identify antigen specificities cell responses present study identified major histocompatibility complex mhc haplotype h<NUMBER>d restricted peptide epitope merscov n protein stimulating cells mvamersn vaccinated balbc mice <NUMBER>d matrix pool overlapping peptides mice already used various preclinical studies establish merscov protein important vaccine antigen induction virus neutralizing antibodies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> moreover balbc mice transduced human cell surface receptor dipeptidyl peptidase <NUMBER> hdpp<NUMBER> using adenovirus vector susceptible productive merscov lung infection allows testing protective efficacy merscovspecific immunization using merscov protein <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> wished specifically assess suitability mvadelivered merscov n antigen activation cellular immune responses mice general n protein well conserved internal protein major structural component incorporating viral rna within viral nucleocapsid <NUMBER> previous studies sarscov n protein also used candidate antigen vaccine development <NUMBER> experimental dna vaccine efficiently induced sarscov nspecific cellular immunity <NUMBER> <NUMBER> line data recent studies mers patients demonstrated antibody cell responses associated recovery merscov infection <NUMBER> recombinant virus mvamersn produced stable amounts merscov n antigen upon vitro infection human cells indicating unimpaired expression target gene level viral late transcription using synthetic vaccinia virusspecific promoter pmh<NUMBER> <NUMBER> moreover merscov n antigen produced mvamersn infected cells strongly recognized antibodies experimentally infected laboratory animals suggesting nspecific immune responses potently activated upon merscov infection seems noteworthy merscov productively replicates rabbits viral loads low animals develop overt disease symptoms however haagmans et al found infectious virus lung tissues rabbits revealed presence merscov n antigen bronchiolar epithelial cells epithelial cells nose <NUMBER> localization n respiratory epithelial cells may result efficient recognition innate also adaptive immune cells similar described viruses inducing robust protective immunity <NUMBER> might possible explanation efficient activation merscov nspecific antibodies despite barely productive merscov infection similar outcomes infection observed upon merscov infection cynomolgus macaques relevant nonhuman primate models <NUMBER> <NUMBER> thus induction nspecific immune responses animals emphasizes potential usefulness merscov n protein serve vaccine antigen nevertheless immunogenicity n requires characterization preclinical models merscov infection addition induction merscovspecific antibodies merscov n protein holds promise efficiently activate virusspecific cd<NUMBER> cell responses detailed studies characterizing possible role cell specificities merscovassociated immunity pathogenesis highly relevant determine n peptide epitopes allowing appropriate mhcrestricted antigen presentation activation virusspecific cells study identified new h<NUMBER>d restricted cd<NUMBER> cell epitope merscov n protein using <NUMBER>d matrix pools <NUMBER> overlapping <NUMBER>mer n peptides first identified two merscov n derived peptides n <NUMBER> qnidayktfpkkekk n <NUMBER> ayktfpkkekkqkap mapped <NUMBER>mer peptides minimal aa sequence n <NUMBER> yktfpkkekk representing decamer peptide epitope figure s<NUMBER> <NUMBER> analysis merscov sequences reveals n <NUMBER> conserved among different strains merscov table s<NUMBER> <NUMBER> availability epitope may allow detailed experimental monitoring cellular immune responses induced mva based candidate vaccine merscov mouse model potentially also preclinical models note h<NUMBER>d restricted cd<NUMBER> cell epitope enables characterization cell responses balbc mice serve wellestablished merscov infection model following adenovirus vector mediated transduction hdpp<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> particular feature mers humans observed upon investigation cluster outbreaks hospitals lack detectable merscov neutralizing antibodies patients confirmed disease <NUMBER> <NUMBER> observation attributed emergence specific virus mutants evading neutralizing antibody response already described sarscov <NUMBER> <NUMBER> thus future use cellspecific immune monitoring might contribute detailed understanding mers pathogenesis studies function merscovspecific cd<NUMBER> cells balbc mouse merscov lung infection model helpful better estimate role cellular immunity vaccine mediated protection merscov infection finally mvamersn vector virus generated study proved stable recombinant virus readily amplified obtain vaccine preparations technically fulfilling requirements preclinical even clinical development future work mvamersn candidate vaccines help elucidate potential protective capacity nspecific immune responses merscov infections models contribute better understanding mers vaccineinduced protection supplementary materials following available online httpwwwmdpicom<NUMBER> s<NUMBER> table s<NUMBER> design matrix peptide pools systematically screening h<NUMBER>d restricted cell epitopes merscov n protein protein figure s<NUMBER> sequence analysis modular organization merscov n protein table s<NUMBER> coronaviruses cov large family zoonotic viruses cause illness ranging common cold severe diseases middle east respiratory syndrome merscov severe acute respiratory syndrome sarscov last decades six strains coronaviruses identified however december <NUMBER> new strain spread across wuhan city china <NUMBER> <NUMBER> designated coronavirus disease <NUMBER> covid<NUMBER> world health organization <NUMBER> late january <NUMBER> declared outbreak global pandemic cases <NUMBER> countries covid<NUMBER> spreading fast outside china significantly south korea italy iran <NUMBER> deaths <NUMBER> cases confirmed <NUMBER> recovered <NUMBER> february <NUMBER> <NUMBER> gmt covid<NUMBER> positivesense singlestranded rna virus ssrna rna sequence approximately <NUMBER> bases length <NUMBER> belongs subgenus sarbecovirus genus betacoronavirus within family coronaviridae corona envelope e protein small integral membrane protein involved several aspects virus life cycle pathogenesis envelope formation assembly budding alongside interactions cov proteins n host cell proteins release infectious particles budding <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> infected person characterized fever upper lower respiratory tract symptoms diarrhea lymphopenia thrombocytopenia increased creactive protein lactate dehydrogenase levels combination within <NUMBER> days exposure molecular diagnosis made realtime pcr genes encoding internal rnadependent rna polymerase spikes receptor binding domain confirmed sanger sequencing full genome analysis ngs multiplex nucleic acid amplification microarraybased assays <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> phylogenetic tree mutation history family viruses possible reconstruct sufficient number sequenced genomes phylogenetic analysis indicates covid<NUMBER> likely originated bats <NUMBER> also showed highly related seven mutations relative common ancestor <NUMBER> sequence covid<NUMBER> rbd together rbm contacts receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> found similar sars coronavirus january <NUMBER> group scientists demonstrated ace<NUMBER> could act receptor covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however covid<NUMBER> differs previous strains several critical residues <NUMBER>ncov receptorbinding motif particularly gln<NUMBER> provide advantageous interactions human ace<NUMBER> <NUMBER> difference affinity possibly explains novel coronavirus contagious viruses present vaccine approved treatment humans chinese traditional medicines shufengjiedu capsules lianhuaqingwen capsules could possible treatments covid<NUMBER> however clinical trials approving safety efficacy drugs <NUMBER> main concept within immunizations ability vaccine initiate immune response faster mode pathogen although traditional vaccines depend biochemical trials induced potent neutralizing protective responses immunized animals costly allergenic timeconsuming require vitro culture pathogenic viruses leading serious concern safety <NUMBER> <NUMBER> thus need safe efficacious vaccines highly recommended peptidebased vaccines need vitro culture making biologically safe selectivity allows accurate activation immune responses <NUMBER> <NUMBER> core mechanism peptide vaccines built chemical method synthesize recognized bcell tcell epitopes immunodominant induce specific immune responses bcell epitope target molecule linked tcell epitope make immunogenic tcell epitopes short peptide fragments <NUMBER> amino acids whereas bcell epitopes proteins <NUMBER> <NUMBER> therefore study aimed design peptidebased vaccine predict epitopes corona envelope e protein using immunoinformatics analysis <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rapid studies recommended prove efficiency predicted epitopes peptide vaccine emerging infection workflow summarizing procedures epitopebased peptide vaccine prediction shown figure <NUMBER> act silico analysis software visualization comparisons complete genome sequences associated annotations <NUMBER> biomed research international <NUMBER> also applied identify regions similarity rearrangements insertions level base pair differences whole genome httpswwwsangeracuk sciencetoolsartemiscomparisontoolact first server alignmentindependent prediction protective antigens allows antigen classification solely based physicochemical properties proteins without recourse sequence alignment predicts probability antigenicity one multiple proteins based auto cross covariance acc transformation protein sequence structural cov<NUMBER> proteins n e analyzed vaxijen threshold <NUMBER> <NUMBER> httpwwwddgpharmfacnetvaxijenvaxijen vaxijenhtml software package proposed stream distinct program run nearly sequence operation well basic alignment investigations sequences e protein retrieved uniprot run bioedit determine conserved sites clustalw application settings <NUMBER> mega version <NUMBER> software comparative analysis molecular sequences used pairwise multiple sequence alignment alongside construction analysis phylogenetic trees evolutionary relationships gap penalty <NUMBER> opening <NUMBER> extending gap pairwise multiple sequence alignment bootstrapping <NUMBER> used construction maximum like hood phylogenetic tree <NUMBER> <NUMBER> httpswww megasoftwarenet epitopes iedb tools used predict conserved sequences <NUMBER>mer sequence hla class class ii tcell epitopes using artificial neural network ann approach <NUMBER> <NUMBER> <NUMBER> artificial neural network ann version <NUMBER> chosen prediction method depends median inhibitory concentration ic<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> binding analysis alleles carefully chosen length set <NUMBER> prediction done analysis epitopes binding mhc class ii molecules assessed iedb mhc prediction server httptoolsiedborgmhci httptoolsiedborgmhcii respectively conserved immunodominant peptides binding mhc ii molecules scores equal less <NUMBER> median inhibitory concentrations ic<NUMBER> <NUMBER> respectively selected analysis epitopes ic<NUMBER> greater <NUMBER> eliminated <NUMBER> population coverage epitope carefully determined iedb population coverage calculation tool due diverse binding sites epitopes different hla alleles promising epitope candidates calculated population coverage population whole world china europe get ensure universal vaccine <NUMBER> <NUMBER> httptoolsiedborgpopulation modeling reference sequence e protein retrieved genbank used input raptorx predict <NUMBER>d structure e protein <NUMBER> <NUMBER> visualization obtained <NUMBER>d protein structure performed ucsf chimera version<NUMBER> <NUMBER> <NUMBER> silico molecular docking <NUMBER> ligand preparation order estimate binding affinities epitopes molecular structure mhc mhc ii silico molecular docking used sequences proposed epitopes selected covid<NUMBER> reference sequence using ucsf chimera <NUMBER> saved pdb file obtained files optimized energy minimized hlaa <NUMBER> selected macromolecule docking crystal structure <NUMBER>uq<NUMBER> downloaded rcsb protein data bank httpwwwrcsborgpdbhomehomedo complex azobenzenecontaining peptide <NUMBER> water molecules heteroatoms retrieved target file <NUMBER>uq<NUMBER> removed target structure optimized energy minimized using swiss pdb viewer v<NUMBER> software <NUMBER> <NUMBER> molecular docking molecular docking performed using autodock <NUMBER> software based lamarckian genetic algorithm combines energy evaluation grids affinity potential find suitable binding upper window represents hcovhku<NUMBER> reference sequence genes highlighted blue starting orflab gene ending n gene middle window describes similarities difference two genomes red lines indicate match genes two genomes blue lines indicate inversion represents sequences two genomes organized opposite direction lower window represents covid<NUMBER> genes starting orflab gene ending n gene <NUMBER> <NUMBER> polar hydrogen atoms added protein targets kollman united atomic charges computed targets grid map calculated set <NUMBER> × <NUMBER> × <NUMBER> points grid spacing <NUMBER> ǻ grid box allocated properly target include active residue center genetic algorithm run set <NUMBER> docking algorithms set default finally results retrieved binding energies poses showed lowest binding energies visualized using ucsf chimera <NUMBER> artemis comparison tool reference sequence envelope protein aligned hcovhku<NUMBER> reference protein using artemis comparison tool illustrated figure <NUMBER> server mutated proteins tested antigenicity using vaxijen software envelope protein found best immunogenic target table <NUMBER> bioedit sequence alignment covid<NUMBER> envelope protein done using bioedit software shows total conservation across four sequences retrieved china usa figure <NUMBER> study evolutionary relationship seven strains coronavirus multiple sequence alignment msa performed using clustalw mega software alignment iedb website used analyze <NUMBER>ncov envelope protein tcellrelated peptides results show ten mhc class iand iiassociated peptides high population coverage tables <NUMBER> <NUMBER> figure <NUMBER> promising peptides visualized using ucsf chimera software figures <NUMBER>a <NUMBER>b designing novel vaccine crucial defend rapid endless global burden diseases <NUMBER> <NUMBER> <NUMBER> <NUMBER> last decades biotechnology advanced rapidly alongside understanding immunology assisted rise new approaches towards rational vaccine design <NUMBER> peptidebased vaccines designed elicit immunity particular pathogens selectively stimulating antigenspecific band tcells <NUMBER> applying advanced bioinformatics tools databases various peptidebased vaccines could designed peptides act ligands <NUMBER> <NUMBER> <NUMBER> approach used frequently saint louis encephalitis virus <NUMBER> dengue virus <NUMBER> chikungunya virus <NUMBER> proposing promising peptides designing vaccines covid<NUMBER> rna virus tends mutate commonly dna viruses <NUMBER> mutations lie surface protein makes covid<NUMBER> superior previous strains inducing sustainability leaving immune system blind spot <NUMBER> present work different peptides proposed designing vaccine covid<NUMBER> figure <NUMBER> beginning whole genome covid<NUMBER> analyzed comparative genomic approach determine potential antigenic target <NUMBER> artemis comparison tool act used analyze human coronavirus hcovhku<NUMBER> reference sequence vs wuhanhu<NUMBER> covid<NUMBER> results obtained figure <NUMBER> revealed extensive mutations among tested genomes new genes orf<NUMBER> orf<NUMBER> found inserted covid<NUMBER> absent hcovhku<NUMBER> might acquired horizontal gene transmission <NUMBER> high rate mutation two genomes observed region <NUMBER> bp end sequence region encodes four major structural proteins coronavirus envelope e protein nucleocapsid n protein membrane protein spike protein required produce structurally complete virus <NUMBER> <NUMBER> conserved antigenic sites revealed previous studies sequence alignment merscov bat coronavirus <NUMBER> analyzed sarscov <NUMBER> four proteins analyzed vaxijen software test probability antigenic proteins protein e found antigenic gene highest probability shown table <NUMBER> literature survey confirmed result protein e investigated severe acute respiratory syndrome sars <NUMBER> recently middleeast respiratory syndrome mers <NUMBER> furthermore conservation protein seven strains tested confirmed use bioedit package tool figure <NUMBER> phylogenetic analysis powerful tool determining evolutionary relationship strains multiple sequence alignment msa performed using biomed research international tree revealed covid<NUMBER> found clade sarscov thus two strains highly related figure <NUMBER> immune response tcells considered longlasting response compared bcells antigen easily escape antibody memory response <NUMBER> vaccines effectively generate cellmediated responses needed provide protection invading pathogen moreover cd<NUMBER> cd<NUMBER> tcell responses play major role antiviral immunity <NUMBER> thus designing vaccine tcells much important choosing protein e antigenic site binding affinity mhc molecules evaluated protein reference sequence submitted iedb mhc predication tool <NUMBER> peptides found bind mhc class different affinities table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage table <NUMBER> figure <NUMBER> <NUMBER> table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage table <NUMBER> figure <NUMBER> unfortunately iedb give result bcell epitopes might due length covid<NUMBER> <NUMBER> amino acids well known peptides recognized high number hla molecules potentially inducing immune response based aforementioned results taking consideration high binding affinity mhc class ii conservancy population coverage three peptides strongly proposed formulate new vaccine covid<NUMBER> findings confirmed results obtained molecular docking proposed peptides hlaa <NUMBER> formed complex mhc molecule three peptides yvysrvknl slvkpsfyv lailtalrl shown peptide aminoand carboxyltermini forming one three hydrogen bonds respectively two ends binding groove mhc residues least binding energy <NUMBER> kcalmol <NUMBER> kcalmol <NUMBER> kcalmol respectively figures <NUMBER>c<NUMBER>e although flu antihiv drugs used currently china treatment covid<NUMBER> chloroquine phosphate old drug treatment malaria recently found apparent efficacy acceptable safety covid<NUMBER> <NUMBER> <NUMBER> nevertheless studies required standardize therapies addition success development mouse models merscov sarscov infection candidate vaccines envelope e protein mutated deleted described <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> best knowledge first study identify certain peptides envelope e protein candidates covid<NUMBER> accordingly epitopes strongly recommended promising epitope vaccine candidates tcells extensive mutations insertion deletion discovered covid<NUMBER> strain using comparative sequencing addition number mhc class iand iirelated peptides found promising candidates among peptides yvysrvknl slvkpsfyv lailtalrl show high potentiality vaccine design adequate world population coverage tcell epitopebased peptide vaccine designed covid<NUMBER> using envelope protein immunogenic target nevertheless proposed vaccine rapidly needs validated clinically ensuring safety immunogenic profile help stop epidemic leads devastating global outbreaks feline infectious peritonitis virus fipv major pathogen felidae despite extensive efforts taken past decades development ideal live attenuated fipv vaccine successful yet present study provide data immunisation experiments recombinant fcov pair differing truncation pbfipvdf<NUMBER> completion pbfipvdf<NUMBER>r<NUMBER>i orf<NUMBER>abc regions previous vivo studies viruses proved show characters low virulent avirulent fcov phenotypes respectively therefore hypothesised ability viruses possible vaccine candidates conferring protection specific pathogen free spf domestic shorthair well conventional purebred british shorthair cats spf cats two oronasal two intramuscular vaccinations two weeks intervals vaccine candidates provided <NUMBER> protection lethal homologous challenge highly virulent fipv df<NUMBER> strain contrast conventional purebred british shorthair cats develop protection immunised vaccination regimes groups <NUMBER> pbfipvdf<NUMBER>r<NUMBER>i immunised animals developed antibodydependent enhancement ade prolonged survival observed <NUMBER> animals <NUMBER> showed fulminant disease course genetic probably immunological differences spf nonspf purebred kittens explain different outcome vaccination experiment data highlight diverse immune responses spf conventional cats suggest decisive role previous infection heterologous causative agents outcome vaccination fip ß <NUMBER> authors published elsevier bv fcov probably emerged via double recombination process type fcov type ii canine coronavirus ccov herrewegh et al <NUMBER> serotypes occur two pathotypes feline enteric coronavirus fecv replicates lower portion intestinal tract spreads faecaloral route clinical appearance characterised mild unapparent enteritis pedersen et al <NUMBER> herrewegh et al <NUMBER> contrast feline infectious peritonitis virus fipv efficiently replicates macrophages monocytes occurs sporadically causes highly lethal systemic granulomatous disease feline infectious peritonitis fip manifest either wet dry form addie jarrett <NUMBER> de grootmijnes et al <NUMBER> although extensive efforts taken past decades development ideal live attenuated fipv vaccine replicating body without clinical signs inducing protective immunity fipv pedersen <NUMBER> crowned complete success yet vaccination closely related heterologous live covs confer protection barlough et al <NUMBER> barlough et al <NUMBER> stoddart et al <NUMBER> woods pedersen <NUMBER> similarly inactivated recombinant fcov subunit vaccines reviewed haijema et al <NUMBER> immunisation fecv lowvirulence fipv sublethal amounts virulent fipv elicited partial protection pedersen black <NUMBER> pedersen et al <NUMBER> pedersen floyd <NUMBER> frequently leading antibody enhancement disease ade socalled early death syndrome currently temperaturesensitive strain fipv marketed worldwide ability protect cats fipv gerber et al <NUMBER> gerber <NUMBER> efficacy uncertain mcardle et al <NUMBER> scott et al <NUMBER> fehr et al <NUMBER> promising results obtained recombinant fipv mutants lacking orf<NUMBER>abc orf<NUMBER>ab regions provided <NUMBER> <NUMBER> protection lethal homologous challenge haijema et al <NUMBER> respectively however followup studies using vaccine candidates published far present study provide data immunisation experiments recombinant fcov pair differing truncation pbfipvdf<NUMBER> intactness pbfipvdf<NUMBER>r<NUMBER>i orf<NUMBER>abc regions bá lint et al <NUMBER> previous vivo studies using specific pathogen free spf cats pbfipvdf<NUMBER> proved low virulent shed limited titres faeces completely cleared immune system elicited medium level immune response pbfipvdf<NUMBER>r<NUMBER>i showed active intestinal replication faecal shedding possessed completely avirulent phenotype bá lint et al <NUMBER> considering advantageous characteristics two recombinant fcovs evaluated innocuity efficacy vaccine candidates conferring protection spf well conventional purebred british shorthair cats felis catus whole foetus <NUMBER> fcwf<NUMBER> cells used virus propagation titration virus neutralisation tests cell line maintained monolayer culture dulbeccos modified eagle medium sigmaaldrich saint louis mo usa supplemented <NUMBER> foetal bovine serum fbs <NUMBER> mgml glutamine <NUMBER> uml penicillin <NUMBER> mgml streptomycin <NUMBER> mgml amphotericin b <NUMBER> mm sodium pyruvate <NUMBER> nonessential amino acids sigmaaldrich fipv df<NUMBER> strain kindly provided berndt klingeborn sva uppsala sweden whole genome fipv df<NUMBER> cloned pbelobac <NUMBER> lowcopy vector allows efficient intracellular production viral rna cdna cytomegalovirus cmv immediateearly promoter order gain recombinant fcov pbfivdf<NUMBER> genbank accession number jq<NUMBER> originally truncated orf<NUMBER>abc virus replaced intact orf<NUMBER>abc type fcovlike canine coronavirus ccov reference strain elmo<NUMBER> construct pbfipvdf<NUMBER>r<NUMBER>i genbank accession number jq<NUMBER> bá lint et al <NUMBER> spf domestic shorthair iqhsdcpb kittens isoquimen sl barcelona spain conventional british shorthair cats fcov negative hungarian cattery regularly monitored two generations used challenge experiments nonspf cats originated three nonrelated queens two toms kittens arrived facility age <NUMBER> weeks acclimated used studies age <NUMBER> weeks animals kept separate groups closed facility fcov negative status checked pcr virus neutralisation tests absence feline parvovirus fpv feline herpesvirus fhv feline calicivirus fcv feline immunodeficiency virus fiv feline leukaemia virus felv conventional cats confirmed pcr andor elisa tests study purposes group structure established spf conventional kittens two study groups group <NUMBER> group <NUMBER> n <NUMBER> control group cgroup n <NUMBER> formed kittens inoculated oronasally d<NUMBER> d<NUMBER> intramuscularly d<NUMBER> d<NUMBER> <NUMBER> <NUMBER> <NUMBER> tissue culture infective doses tcid <NUMBER> recombinant viruses pfipvdf<NUMBER> group <NUMBER> pfipvfd<NUMBER>r<NUMBER>i group <NUMBER> respectively vaccinated animals unvaccinated controls oronasally challenged d<NUMBER> <NUMBER> <NUMBER> tcid <NUMBER> parent virus fipv df<NUMBER> whole clinical observation period time altogether <NUMBER> months long time kittens clinically examined daily basis cats scored several clinical signs described earlier haijema et al <NUMBER> briefly scoring based depression inactivity three consecutive days <NUMBER> point anorexia eating three consecutive days <NUMBER> point neurological disorders swaggering <NUMBER> point daily basis fever <NUMBER> <NUMBER>c <NUMBER> point jaundice yellow plasma <NUMBER> point weight loss loss <NUMBER> body weight per week <NUMBER> point lymphopenia lymphocyte count <NUMBER> â <NUMBER> <NUMBER> l scored weekly basis kittens showing signs terminal fip euthanized order avoid unnecessary suffering healthy animals exterminated day <NUMBER> postchallenge pc followed full postmortem examination animal experiments approved supervised ethical animal welfare committee national food chain safety office animals died euthanized experiment subjected pathological examination carcasses dissected within two hours death samples taken spleen kidney liver lung brain intestine fixed <NUMBER> formaldehyde embedded paraffin wax blocks sectioned <NUMBER> mm sections stained haematoxylineosin examined light microscope determine virus shedding faecal oropharyngeal swabs taken d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> d<NUMBER> placed <NUMBER> ml phosphate buffered saline pbs <NUMBER>â vortexing <NUMBER> min incubation swabs removed extract centrifuged <NUMBER> â g <NUMBER> min remove cell debris supernatant collected used subsequent pcr viral rna purified using qiaamp viral rna mini kit qiagen hilden germany measure copy numbers genome recombinant fcov taqman assay targeting <NUMBER> <NUMBER> end fipv df<NUMBER> genome applied bá lint et al <NUMBER> serum samples taken using vacuette <NUMBER> tube greiner bioone germany days faecal samples virus neutralisation vn assay twofold dilutions heatinactivated serum kittens <NUMBER> ml incubated <NUMBER> h <NUMBER> <NUMBER>c equal aliquots fipv df<NUMBER> <NUMBER> ml <NUMBER> <NUMBER> tcid <NUMBER> ml viruses added fcwf<NUMBER> cells showing <NUMBER> confluency <NUMBER>well plate incubated <NUMBER> h development cytopathic effect neutralising activity determined endpoint dilution shiba et al <NUMBER> study whether pbfipvdf<NUMBER> pbfipvdf<NUMBER>r<NUMBER>i inoculation would protect cats homologous fipv challenge vaccination challenge experiments performed group <NUMBER> group <NUMBER> cats vaccinated oronasally twice pfipvdf<NUMBER> pbfipvdf<NUMBER>r<NUMBER>i <NUMBER> <NUMBER> tcid <NUMBER> d<NUMBER> d<NUMBER> respectively vivo characteristics recombinant viruses similar earlier experiments bá lint et al <NUMBER> cats group <NUMBER> showed early mild clinical signs including transient fever d<NUMBER> d<NUMBER> anorexia slight lymphopenia table <NUMBER> cats group <NUMBER> showed neither clinical signs typical fip diarrhoea table <NUMBER> oropharyngeal shedding either pbfipvdf<NUMBER> pbfipvdf<NUMBER>r<NUMBER>i detected whole period immunisation experiments data shown shedding pbfipvdf<NUMBER> faeces group <NUMBER> detected four animals d<NUMBER> d<NUMBER> variable amounts close detection limit genomic quantitative rtpcr <NUMBER> â <NUMBER> <NUMBER> <NUMBER> â <NUMBER> <NUMBER> fcov rna copies per ml faecal extract fig <NUMBER> group <NUMBER> cats began shed pbfipvdf<NUMBER>r<NUMBER>i d<NUMBER> virus shedding peaked d<NUMBER> <NUMBER> â <NUMBER> <NUMBER> fcov rna copies per ml faecal extract remained high d<NUMBER> began decrease reaching <NUMBER> â <NUMBER> <NUMBER> fcov rna copies per ml faecal extract d<NUMBER> remained level end experiment fig <NUMBER> neutralising activity detected d<NUMBER> cat sera contrast d<NUMBER> group <NUMBER> cats seroconverted showed medium titres <NUMBER> neutralising antibodies fig <NUMBER> group <NUMBER> cats showed table <NUMBER> total clinical scores spf cats oronasal d<NUMBER> d<NUMBER> parenteral days <NUMBER> <NUMBER> vaccination pbfipv group <NUMBER> n <NUMBER> pbfipvdf<NUMBER>r<NUMBER>i group <NUMBER> n <NUMBER> unvaccinated controls cgroup n <NUMBER> vaccinated pbs virus animal three animals seroconverted d<NUMBER> vn titres remained low levels <NUMBER> compared group <NUMBER> cats fig <NUMBER> since level humoral immune response oronasal vaccination recombinant viruses relatively low two intramuscular vaccinations <NUMBER> <NUMBER> tcid <NUMBER> d<NUMBER> d<NUMBER> applied control group cgroup mock vaccinated pbs similarly oronasal vaccinations intramuscularly inoculated kittens develop signs fip table <NUMBER> faecal virus shedding pbfipvdf<NUMBER> group <NUMBER> cats detected faecal shedding pbfipvdf<NUMBER>r<NUMBER>i group <NUMBER> kittens continued low level fig <NUMBER> oropharyngeal shedding observed animal two vaccinated groups data shown neutralising antibody titres raised group <NUMBER> animals intramuscular vaccinations <NUMBER> <NUMBER> p <NUMBER> interestingly one group <NUMBER> animal seroconvert others titres significantly raised <NUMBER> <NUMBER> p <NUMBER> somewhat lower antibody values obtained four group <NUMBER> animals compared group <NUMBER> p <NUMBER> fig <NUMBER> d<NUMBER> kittens challenged oronasally <NUMBER> <NUMBER> tcid <NUMBER> virulent fipv df<NUMBER> strain monitored <NUMBER> months cgroup cats showed severe clinical signs fip starting second week table <NUMBER> two kittens died days <NUMBER> <NUMBER> postchallenge pc pathological histopathological examinations revealed lesions characteristic systemic noneffusive fip contrary vaccination pbfipvdf<NUMBER> pbfipvdf<NUMBER>r<NUMBER>i proved highly efficacious lethal fipv challenge group <NUMBER> group <NUMBER> cats remained healthy table <NUMBER> survived least <NUMBER> months vn titres boost significantly table <NUMBER> total clinical scores pbfipv n <NUMBER> pbfipvdf<NUMBER>r<NUMBER>i n <NUMBER> vaccinated spf cats challenge fipv df<NUMBER> n <NUMBER> d<NUMBER> study efficacy vaccine candidates field conditions experiment protocols repeated using conventional cats neither vaccinated kittens showed signs fatal fip table <NUMBER> group <NUMBER> inoculated animals showed slightly stronger clinical signs spf counterparts including lymphopenia characteristic sign early fipv infection anorexia observed two group <NUMBER> kittens table <NUMBER> oropharyngeal virus shedding detected vaccinated cat data shown faecal virus shedding conventional cats approximately <NUMBER> log <NUMBER> higher intense longer duration <NUMBER> days extended pbfipv inoculated animals compared spf animals fig <NUMBER> neutralising antibodies induced animals showing approximately one log <NUMBER> higher titres observed spf animals fig <NUMBER> challenge control cats showed clinical signs fip followed death day <NUMBER> <NUMBER> pc similarly spf animals slightly faster development disease earlier death table <NUMBER> pathological findings characteristic systemic noneffusive fip vaccination pbfipvdf<NUMBER> showed variable results lethal fipv challenge two group <NUMBER> cats cat <NUMBER>and cat <NUMBER> slightly higher vn antibody titres fig <NUMBER> developed fip later day <NUMBER> pc died days table <NUMBER> total clinical scores conventional cats oronasal d<NUMBER> d<NUMBER> parenteral days <NUMBER> <NUMBER> vaccination pbfipv group <NUMBER> n <NUMBER> pbfipvdf<NUMBER>r<NUMBER>i group <NUMBER> n <NUMBER> unvaccinated controls cgroup n <NUMBER> vaccinated pbs virus animal table <NUMBER> total clinical scores pbfipv group <NUMBER> n <NUMBER> pbfipvdf<NUMBER>r<NUMBER>i group <NUMBER> n <NUMBER> pbs cgroup n <NUMBER> vaccinated conventional cats challenge fipv df<NUMBER> n <NUMBER> d<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> group <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> cgroup <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> pc respectively postmortem examinations revealed characteristic fip lesions similar observed fulminant course disease three cats group <NUMBER> developed fip within week table <NUMBER> followed death days <NUMBER> pc fulminant course disease majority vaccinated animals suggested least partial adverse effect vaccination instead protection group <NUMBER> animals developed fip within week table <NUMBER> followed death days <NUMBER> pc exclusive fulminant course disease also indicated clear adverse characteristics vaccine candidate perished animals showing fulminant fip vn titres elevated rapidly death fig <NUMBER> number scientific data indicate fip consequence recent interspecies jump coronavirus considering fact disease seen <NUMBER> reviewed pedersen <NUMBER> immunological aspects fip complex fully elucidated yet fipv could negatively influence immune system intervening several points virus variant highly virulent monocytemacrophage pathogen causing systemic immune complex mediated infection vennema et al <NUMBER> takano et al <NUMBER> chang et al <NUMBER> facts may explain acquired natural immunity cats rather limited fipv also efficacious vaccine available fipv despite intensive efforts academic commercial researchers study vaccination regime applied spf conventional purebred british shorthair cats using recombinant fcov pair differing truncation pbfipvdf<NUMBER> intactness pbfipvdf<NUMBER>r<NUMBER>i orf<NUMBER>abc region vivo evaluation virus pair showed viruses possess low virulent avirulent phenotype respectively bá lint et al <NUMBER> low inconsistent level faecal shedding observed present experiments following vaccination recombinant pfipvdf<NUMBER> similar observed infection orf<NUMBER>abc truncated fcovs chang et al <NUMBER> pedersen et al <NUMBER> seroconversion reached medium level two oronasal vaccinations gradually elevated two intramuscular injections absence antibody enhancement ade leading fip strong antibody response induced group completion vaccination regime however high booster effect observed four individual inoculations reach higher antibody titres elicit significant booster effect modification vaccination protocol experiments might required vaccination pfipvdf<NUMBER> caused low level lymphopenia proved transient followed second wave significant lymphoid cell decrease characteristic course fatal fip together lack adverse clinical signs advantageous development safe vaccine vaccinations pbfipvdf<NUMBER>r<NUMBER>i clinical signs observed confirmed avirulent phenotype fecv characteristics recombinant fcov faecal virus shedding higher detected prolonged period compared pfipvdf<NUMBER> phenomenon accordance previous findings intact orf<NUMBER>abc region indispensable enteric replication fcov chang et al <NUMBER> pedersen et al <NUMBER> bá lint et al <NUMBER> high mutation frequency recombination common features coronaviruses lead increased virulence attenuated strains used vaccination reason longer persistence shedding pbfipvdf<NUMBER>r<NUMBER>i inoculation makes less favourable vaccine candidate pfipvdf<NUMBER> low inconsistent antibody response observed subsequently two oronasal vaccinations pbfipvdf<NUMBER>r<NUMBER>i antibody level significantly increased intramuscular inoculation level comparable clearly lower pbfipdf<NUMBER> vaccinated animals low inconsistent initial antibody response may consequence intact orf<NUMBER>abc directs fcov replication enterocytes restricts macrophages bá lint et al <NUMBER> case spf cats recombinant fcovs truncated complemented orf<NUMBER>abc protected <NUMBER> vaccinated animals homologous challenge highly lethal fipv df<NUMBER> strain antibody titres animals increase significantly challenge showing absence uncontrolled fipv df<NUMBER> replication nonspf spf cats reacted physiologically similarly identical vaccination regime although clinical parameters fever depression anorexia nonspf animals somewhat different observed spf cats virus shedding serological response levels also slightly higher indicating intensive virus replication immune reaction however striking difference two experiments vaccine candidates provided far less protection purebred cats challenge fipv df<NUMBER> strain cases challenge led ade case development severe symptoms fip nonspf animals independently genetic characteristics applied vaccine candidates ade pathomechanism exclusive feature fipv infection resembles adebased dengue haemorrhagic shock syndrome first described peiris porterfield <NUMBER> phenomenon also observed case flaviviruses alphaviruses lentiviruses influenzaviruses enteroviruses measles virus peiris porterfield <NUMBER> porterfield <NUMBER> takeda et al <NUMBER> tamura et al <NUMBER> chen et al <NUMBER> iankov et al <NUMBER> suspected ade might severe early fipv challenge vaccination however lack development fatal fip ade among spf cats prolonged survival two nonspf animals <NUMBER> days challenge suggest biological factors could strong effect development fip early challenge two pbfipvdf<NUMBER> vaccinated animals originated different litters common father remained symptomless weeks survival time prolonged usual <NUMBER> weeks <NUMBER> days fipv df<NUMBER> challenge rather unusual infection course disease clearly differs ade resembles latent sequestered infection fipv reactivated immunosuppressive agents felv pedersen <NUMBER> previous pilot vaccine trials used different dna immune stimulating complex iscom vaccine candidates harbouring n off<NUMBER>b genesproteins spf n <NUMBER> conventional cats n <NUMBER> applying fipv df<NUMBER> challenge strain control vaccinated animals perished within four weeks without signs ade farsang et al unpublished result studies conducted others congruent indicate virtually cats develop fip within four weeks fipv df<NUMBER> challenge reviewed pedersen <NUMBER> first case observed longterm survival vaccination trials may consequence either slightly higher neutralising antibody titre two animals result altered specificity immune response prolonged survival <NUMBER> pbfipvdf<NUMBER> vaccinated cats makes pbfipvdf<NUMBER> promising candidate pbfipvdf<NUMBER>r<NUMBER>i vaccine development genetic immunological differences spf nonspf purebred kittens explain different outcome vaccination experiment although frequent occurrence fip reported australia certain breeds including british shorthair domestic shorthair cats norris et al <NUMBER> yet significant influence genetic background animals less likely able find survival neither among domestic shorthair cat controls present experiment among vaccinated domestic shorthair cats earlier iscom dna vaccination trials fipv df<NUMBER> challenge vaccination trials revealed subneutralising level spike proteinspecific antibodies lead ade facilitating fc receptormediated uptake fcov macrophagesmonocytes contributing development early death syndrome weiss scott <NUMBER> vennema et al <NUMBER> corapi et al <NUMBER> hohdatsu et al <NUMBER> olsen et al <NUMBER> vaccination british shorthair cats pbfipvdf<NUMBER> resulted heterologous immunological response survival times despite common genetic background facts also suggest immunity status substantial role development disease course vaccination genetic background spf kittens bred isolated circumstances neither meet range pathogenic nonpathogenic parasites bacteria fungi viruses take maternal antibodies colostrum nonspf animals kept even best circumstances encounter microorganisms conventional purebred british shorthair cats developed higher vn antibody titres antibodies particular fraction might led observed ade although direct connection feline bacterial flora virus neutralising titre published far abundant scientific data confirm direct indirect influence microbiota composition outcome pathogenic infections slifka et al <NUMBER> teixeira et al <NUMBER> wilks golovkina <NUMBER> presence intestinal microbes directly facilitates infection reoviruses polioviruses vitro vivo kuss et al <NUMBER> bacterial flora promotes maturation secondary lymphoid organs intestine lee mazmanian <NUMBER> influence gene expression antigenpresenting cells way cells respond vaccines klaasen et al <NUMBER> lamousé smith et al <NUMBER> furthermore interactions macrophages probiotic bacteria lead increased antiviral response vesicular stomatitis virus vitro ivec et al <NUMBER> since fip result type iii iv hypersensitivity reaction pedersen boyle <NUMBER> paltrinieri et al <NUMBER> tempting speculate mature immune system nonspf cats predisposes animals development disease summary vaccination experiments showed hyperimmunisation spf cats low virulent recombinant fcovs conferred complete protection lethal homologous challenge however partial protection observed using vaccination protocol nonspf cats data highlight diverse immune responses spf conventional cats suggest decisive role previous infection heterologous causative agents outcome vaccination fip authors disclose financial personal relationships people organisations could inappropriately influence bias work research grants agria animal insurance company agria djurfö rsä kring swedish kennel club svenska kennelklubben skk otka nkth mobilitá <NUMBER>c otka <NUMBER> já nos bó lyai fellowship hungarian academy sciences bo<NUMBER> protein transmembrane glycoprotein promotes entrance virus host cells protein major target design vaccines inhibitors viral entry protein two domains s<NUMBER> s<NUMBER> s<NUMBER> domains contain receptor binding domain rbd mediates attachment host receptor cell whereas s<NUMBER> domain facilitates fusion virus host cell entry sarscov<NUMBER> host cells initiated binding rbd angiotensinconverting enzyme <NUMBER> ace<NUMBER> main receptor sarscov<NUMBER> host cells surface cd<NUMBER>l another receptor lower affinity <NUMBER> ace<NUMBER> receptors expressed type ii alveolar cells airway epithelial cells fibroblasts endothelial cells several immune cells s<NUMBER> subunit domain facilitates fusion viral envelope host cell membrane domains internal membrane fusion peptide fp membrane proximal external region mper two <NUMBER>peptide repeats transmembrane domain tm glycoprotein key role induction immunity infection sarscov<NUMBER> eliciting neutralizingantibodies tcell responses studies showed protein several immunodominant parts induce neutralizing antibodies rbd s<NUMBER> region potent inducer neutralizing antibodies thus fulllength glycoprotein s<NUMBER> subunit rbd domain ntd fp proposed promising candidate develop effective vaccine sarscov<NUMBER> <NUMBER> <NUMBER> mmembrane protein transmembrane glycoprotein gives definite shape virus structure binds nucleocapsid organizes virus assembly protein contains cell epitope clusters elicit neutralizing antibody sars patients e protein key role pathogenesis assembly release virus e protein inactivation modifies virulence covs due changes morphology tropism nnucelocapsid protein within phospholipid bilayer key role complex formation viral genome enhances protein interaction assembly increases replication virus e proteins form viral envelope <NUMBER> <NUMBER> <NUMBER> j u r n l p r e p r f cases according guidelines infected patients treated supportive care like bed rest oxygen saturation adequate nutrition prevention dehydration keeping electrolyte acidbase balance antibiotics isolation patients suspected confirmed covid<NUMBER> <NUMBER> several preexisting potential drug candidates including remdesivir chloroquine others considered therapeutic options could evaluated used covid<NUMBER> include molecules binding virus inhibiting enzymes involved viral replication transcription inhibitors targeting helicase proteases host cell protease inhibitors host cell endocytosis inhibitors antisense rna ribozyme neutralizing antibodies mabs targeting host cell receptor interfere s<NUMBER> rbd antiviral peptide targeting s<NUMBER> natural products <NUMBER> effective sarscov<NUMBER> vaccines crucial controlling covs pandemic vaccines decrease disease severity viral shedding person person transmission currently vaccine licensed prevent sarscov<NUMBER> infection <NUMBER> different vaccine development platforms sarscov<NUMBER> including live attenuated virus viral vectors inactivated virus subunit vaccines recombinant dna protein vaccines several studies progress requires months years develop vaccines sarscov<NUMBER> currently may many promising targets sarscov<NUMBER> covid<NUMBER> candidate vaccines development include protein rbd subunit vaccines replicating nonreplicating vector vaccines expressing mainly protein rbd several studies showed viral protein subunit vaccines displayed higher neutralizing antibody titers protection liveattenuated sarscov full dnabased protein vaccines collectively proteingene preferred target site sars vaccine development strategy potentially useful developing sarscov<NUMBER> vaccine <NUMBER> <NUMBER> live attenuated vaccine lav immunogenic vaccines require adjuvant gain optimal response due effectiveness provoke immunity mimic natural infection lav contain viable attenuated live virus low virulence property cause disease person normal immune systems reproduce slowly thus remain continuous source antigen long period single immunization reducing need booster dose <NUMBER> several lavs found market protect various disease including mumps rubella measles varicella vaccines lav produced passing virus cell cultures animals suboptimal temperatures allowing less virulent strains selection mutagenesis deletion viral genes give virulence lav suitable infants immunecompromised patients elderly people due risk inactivated wholevirus comprises entire diseasecausing virion inactivated physically heat chemically several antigenic parts host induce diverse immunologic responses pathogen inactivated wholevirus several advantages including low production cost safe involve genetic manipulation iwv conventional vaccines mature technology may become first sarscov<NUMBER> vaccine put clinical use <NUMBER> three inactivated wholevirus vaccines sarscov<NUMBER> reached phase <NUMBER> clinical trial phase <NUMBER> clinical trials done beijing institute biological products chictr<NUMBER> sinovac nct<NUMBER> wuhan institute biological products chictr<NUMBER> <NUMBER> subunit vaccines contain pathogenderived proteins antigens immunogenicity elicit host immune system subunit vaccine safe easily manufactures recombinant dna techniques requires adjuvant enhance immune response far many research institutions initiated sarscov<NUMBER> subunit vaccine use spike glycoprotein fragments s<NUMBER> s<NUMBER> rbd nucleocapsid protein prime target antigens shown table <NUMBER> <NUMBER> novavax inc developed candidate vaccine based protein far clover biopharmaceuticals constructed sarscov<NUMBER> protein trimer vaccine strimer using patented trimertag© technology <NUMBER> since rbd protein directly bind ace<NUMBER> receptor host cells rbd immunization induces specific antibodies may block recognition effectively prevent invasion virus sarscov<NUMBER> subunit vaccines currently development use rbd antigen study monkeys recombinant rbd protein used successfully reduce viral loads lungs oropharynx dna vaccines dvs plasmid particular gene incorporated encodes antigens identified pathogenic microorganism bacterial plasmid carrying desired gene delivered host translated antigenic protein stimulates immune system normally activated pathogenic microorganism dvs elicit cellmediated humoral immune genome preexisting immunity human ad<NUMBER> widespread hampering use vector vaccine development <NUMBER> chimpanzee adenovirus chadox<NUMBER> represents alternative human ad vector due safety lack preexisting immunity humans <NUMBER> mice immunized ad<NUMBER> vector encoding proteininduced systemic neutralizing antibodies mucosal tcells immunity ad<NUMBER> vectors encoding s<NUMBER> domain protein displayed stronger neutralizing antibody responses encoding full length suggesting effect immune focusing <NUMBER> synthetic peptide vaccines chemically produced fragments antigens elicites immune response vaccines inexpensive easy preparation quality control display low immunogenicity thus antigen modification adjuvant required formulation fragments j u r n l p r e p r f antigen b andor tepitope activity affect specificity immune response currently set b cell epitopes isolated n proteins sarscov epitopes highly conserved sarscov<NUMBER> may assist efforts develop vaccine covid<NUMBER> disease <NUMBER> several pharmaceutical companies like generex biotechnology developing peptide based vaccines sarscov<NUMBER> viruses producing synthetic peptides mimic crucial antigens virus chemically bonded <NUMBER>amino acid iikey ensure robust immune system activation <NUMBER> past two decades outbreaks novel reemerging infectious diseases particularly caused zoonotic viruses prompted international push develop strategies addressing research nonclinical clinical testing manufacturing regulatory evaluation increase rapidity medical countermeasure development control outbreaks prevent resurgence diseases recently emergence novel coronavirus sarscov<NUMBER> explosive disseminationresulting global disease pandemic termed coronavirus disease <NUMBER> covid<NUMBER> late april <NUMBER> associated almost <NUMBER> million confirmed infections <NUMBER> deaths <NUMBER> prompted unprecedented response scientific public health communities develop therapies vaccines publicly stated timeframes <NUMBER> months availability licensed vaccines targeted sarscov<NUMBER> optimistic would considered fantastic even decade ago response recent global public health emergencies <NUMBER> ebola virus epidemic west africa widespread emergence zika virus <NUMBER> several national international health policy funding agencies prepared lists priority pathogens considered potential cause pandemic disease promoted development platform technologies speed production new vaccines agents previously unidentified emerging pathogen often termed disease x one group platform technologies considered many key component rapid vaccine development nucleic acid vaccines genetic sequences potentially immunogenic protective antigens pathogen delivered dna rna molecules compared established approaches immunization using injection live attenuated inactivated pathogens protein subunits pathogens nucleic acidbased approaches offer several advantages rapid response including rapid adaptability simpler manufacturing processes enhanced physical stability robust safety <NUMBER> addition may benefit simplified requirements nonclinical safety evaluation alternative novel sequences inserted previously well characterized platform construct questions remain regarding immunogenicity nucleic acid vaccines compared traditional vaccine approaches significant efforts made address optimization vaccination routes timing doses use vehicles devices facilitate uptake nucleic acid host cells resulting improved performance class vaccines large animal models clinical use <NUMBER> concurrent facilitating new approaches technologies may speed vaccine development whos rd blueprint action prevent epidemics identified alignment regulatory expectations testing evaluation novel vaccine candidates key enabler effective outbreak responses <NUMBER> <NUMBER> developed guidelines assuring quality nonclinical safety evaluation dna vaccines <NUMBER> based subsequent progression several dna vaccines clinical evaluation increasing awareness potential utility dna vaccines outbreak responses initiated process revision guidelines february <NUMBER> draft publicly disseminated mid<NUMBER> comment <NUMBER> revised guidelines focus biologically manufactured bacterial plasmid dna use humans address aspects related control manufacture characterization approaches nonclinical clinical testing information may required national regulatory authorities approval clinical trials licensure revised guidelines considered unlikely applicable rna vaccines development separate documents covering rna vaccines progress <NUMBER> issue npj vaccines sheets et al provide overview revision process date report outcomes informal consultation subject matter experts held december <NUMBER> review draft revisions discuss public comments received describe timeline revision subsequent approval implementation new guidelines expert committee biological standardization <NUMBER> communication timely given current global impacts covid<NUMBER> rapid development large number candidate vaccines including several based dna nucleic acid platforms time report late april <NUMBER> <NUMBER> months following initiation development candidate dna vaccine clinicaltrialsgov identifier nct<NUMBER> candidate rna vaccine nct<NUMBER> phase <NUMBER> clinical trials dozen nucleic acid vaccine candidates development <NUMBER> two vaccines phase <NUMBER> seems rapid path clinical testing facilitated short timelines manufacturing initial clinical lots streamlined requirements nonclinical safety testing based prior nonclinical clinical experience platforms <NUMBER> <NUMBER> evaluation vaccine efficacy newly developed animal models covid<NUMBER> expected proceed parallel clinical safety testing vaccine development sarscov<NUMBER> benefiting prior experience closely related emerging coronaviruses associated severe acute respiratory syndrome sars middle east respiratory syndrome mers currently licensed vaccines coronaviruses cause respiratory diseases humans induction robust durable protective immunity infection sarscov<NUMBER> vaccination may challenging furthermore outcomes nonclinical efficacy testing candidate vaccines sars mers suggests another significant concern potential immune potentiation covid<NUMBER> lung disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> anticipated demand hundreds millions doses sarscov<NUMBER> vaccines use wide range target populations coupled likely limitations manufacturing capacity scalability single vaccine type suggests engagement coordination multiple international partners development portfolio licensed vaccines based multiple platforms ideally needed <NUMBER> current covid<NUMBER> pandemic provide nucleic acid vaccine platforms greatest opportunity demonstrate practice proposed value key components rapid response controlling global regional emerging infectious disease threats availability revised guidelines related dna vaccines currently draft subsequently final form facilitate communications vaccine developers regulatory agencies nucleic acid vaccine candidates progress towards possible licensure received <NUMBER> may <NUMBER> accepted <NUMBER> may <NUMBER> porcine epidemic diarrhea virus pedv coronavirus causes porcine epidemic diarrhea ped pigs high mortality rate piglets <NUMBER> stevenson et al <NUMBER> key distinguishing factor pedv similar transmissible gastroenteritis virus tgev suckling piglets pedv incubation period around two days varying <NUMBER> <NUMBER> days diarrhea vomiting develop within <NUMBER> h result dehydration anorexia severe weight loss occur older pigs sows morbidity varies period onset end clinical symptoms <NUMBER> weeks lee <NUMBER> stevenson et al <NUMBER> first known pedv outbreaks occurred europe <NUMBER>s <NUMBER>s including belgium pensaert de bouck <NUMBER> hungary nagy et al <NUMBER> pedv since posed less threat europe reemerged italy martelli et al <NUMBER> germany hanke et al <NUMBER> france grasland et al <NUMBER> affecting pigs ages pedv spread asia early <NUMBER>s first detected japan <NUMBER> south korea china thailand chen et al <NUMBER> since october <NUMBER> china seen severe outbreak pedv resulting high porcine mortality rates economic losses sun et al <NUMBER> pedv first detected united states us may <NUMBER> stevenson et al <NUMBER> canada january <NUMBER> ojkic et al <NUMBER> two countries experienced severe economic losses due death millions suckling piglets diarrheaderived weight loss fattening pigs chen et al <NUMBER> north american serotypes closely related recently emerged chinese serotype huang et al <NUMBER> since north american epidemic spread south korea taiwan japan lee <NUMBER> vaccines available pedv targeting asian strains effective north american strains effectiveness conditionally approved vaccine us unknown see vaccinating sows effective vaccine suckling piglets receive lactogenic immunity iga antibodies secreted milk bae et al <NUMBER> may spared vertical transmission pedv sow milk sun et al <NUMBER> pedv primarily enters pigs bodies fecaloral route although airborne transmission may play role alonso et al <NUMBER> diarrhea vomiting result spread pedv contaminated environmental sources including pigs trailers clothing lowe et al <NUMBER> sows milk sun et al <NUMBER> feed feedsupplements spraydried porcine plasma pasick et al <NUMBER> highlighting importance biosecurity pedv causes sickness actions intestines pigs virus enters porcine enterocytes line inner surface intestines via interaction viral protein enterocyte aminopeptidase n acts cellular receptor pedv receptor pedv enters enterocyte cells new virions assemble budding endoplasmic reticulum golgi apparatus membranes ducatelle et al <NUMBER> li et al <NUMBER> pedv enters enterocytes causes undergo acute necrosis jung et al <NUMBER> pedv also causes reduction number goblet cells cells secrete mucins defend microbial infection jung saif <NUMBER> cytolysis additionally leads shortening severe atrophy intestinal villi causes tips villi erode become covered attenuated epithelial cells jung et al <NUMBER> stevenson et al <NUMBER> atrophy intestinal villi results microscopic lesions typical enteritic infection sueyoshi et al <NUMBER> pedv also results swollen cells detachment cells adjacent cells membranes basal surfaces stevenson et al <NUMBER> factors inhibit pigs ability absorb water nutrients result malabsorption diarrhea discussed produce effective vaccine pedv important understand structure virus coronavirinae subfamily consists three genera alphacoronavirus betacoronavirus gammacoronavirus pedv enveloped alphacoronavirus encoded <NUMBER> kilobase singlestranded positivesense rna genome song park <NUMBER> coronaviruses largest known rna genomes viruses king <NUMBER> pedv genome seven open reading frames orfs code three nonstructural polyproteins four structural proteins spike envelope e membrane nucleocapsid n open reading frames flanked <NUMBER>′ cap <NUMBER>′ polyadenylated tail figs <NUMBER> <NUMBER> song park <NUMBER> orfs encoding nonstructural proteins consist two overlapping open reading frames orf<NUMBER>a orf<NUMBER>b encoding two polyproteins polyproteins processed three virusencoded proteases <NUMBER>clike proteinase <NUMBER>clpro two papainlike proteinases plp results <NUMBER> nonstructural proteins required genome replication mrna transcription john et al <NUMBER> prentice et al <NUMBER> accessory protein orf<NUMBER> potassium ion channel role well defined wang et al <NUMBER> reports transmissible gastroenteritis coronavirus tgev another alphacoronavirus indicate e present virion small quantities e estimated occur <NUMBER> times virion godet et al <NUMBER> n occur higher numbers ratio <NUMBER>n<NUMBER>m king <NUMBER> recent study examining mouse hepatitis virus mhv betacoronavirus severe acute respiratory syndromecoronavirus sarscov betacoronavirus feline coronavirus fcov alphacoronavirus determined coronaviruses approximately <NUMBER> dimers <NUMBER> trimers n proteins ratio <NUMBER>m<NUMBER>n <NUMBER>m<NUMBER>n neuman et al <NUMBER> thus abundant structural protein displayed viral surface four structural proteins antigenic date protein primary focus subunit vaccine design due antigenicity role plays viral entry regulates interactions host cell receptor protein aminopeptidase n bosch et al <NUMBER> contains three antigenic regions first epitope recognized spans amino acids <NUMBER> called co<NUMBER>k equivalent coe epitope induced neutralizing immune response identified sequence homology tgev induces similar clinical symptoms pigs chang et al <NUMBER> subsequently motif spanning fig <NUMBER> schematic genome pedv first two orfs <NUMBER>′ end genome cover two thirds genome code polyprotein <NUMBER>a polyprotein <NUMBER>b respectively next part genome codes protein orf<NUMBER> e finally n protein khamis <NUMBER> amino acids <NUMBER> epitope region amino acids <NUMBER> also found induce production neutralizing antibodies cruz et al <NUMBER> sun et al <NUMBER> antigenic use subunit vaccine poses challenges shown prone mutations serial passages sato et al <NUMBER> high genetic variability among pedv strainsstrains even found <NUMBER> nucleotide deletions gene masuda et al <NUMBER> indeed variability makes gene choice study genetic relatedness different pedv strains chen et al <NUMBER> difference amino acid sequence protein different strains lead different epitopes presented may explain previous vaccines failed provide effective immunity infectious strains sun et al <NUMBER> nonetheless due early recognition antigenic importance protein pedv recombinant protein production focussed work done produce epitopes escherichia coli van noi chung <NUMBER> lactobacillus casei ge et al <NUMBER> via orf virus vaccine delivery vector hain et al <NUMBER> however recombinant pedv production occurred plants plants producing scoe protein yield varied widely plant host utilized historically tobacco established developed platform highyield plantbased recombinant protein production conley et al <NUMBER> follows suit five fourteen reports scoe production carried using tobacco table <NUMBER> four reports expressed scoe stable transgenic line yields <NUMBER> tsp kang et al <NUMBER>b <NUMBER> tsp depending codon optimization kang et al <NUMBER>a one reported transient production <NUMBER> tsp kang et al <NUMBER> many alternative plant choices resulted yields either quantified low despite often using promoters enhancers tobacco studies like tobacco studies doubleenhanced <NUMBER>s <NUMBER>x<NUMBER>s cauliflower mosaic virus camv promoter used carrot potato use fusion proteins particularly heatlabile enterotoxin b subunit escherichia coli ltb recently gained popularity subunit vaccine design utilized production scoe three studies expressed fusions rice shown promise reaching equivalent accumulation levels tobacco rice used express scoe endosperm calli accumulation levels calli using rice aamylase <NUMBER>d promoter ramy<NUMBER>d reached <NUMBER> scoem celltargeting ligand co<NUMBER> fusion huy et al <NUMBER> accumulation levels endosperm ltbscoe using wheat high molecular weight glutenin subunit bx<NUMBER> endospermspecific promoter hmwbx<NUMBER>p rice actin first intron act<NUMBER>i reached <NUMBER> <NUMBER> oszvald et al <NUMBER> tamás <NUMBER> ltbcoe also produced tobacco reaching comparative levels <NUMBER> tsp kang et al <NUMBER> far three studies tested immunogenicity plantproduced scoe ltbscoe produced tobacco able bind gm<NUMBER>ganglioside intestinal membrane receptor kang et al <NUMBER> directly mice orally immunized co<NUMBER>scoe fusion protein produced rice calli threefold eightfold higher levels igg iga secreting cells lymphocytes respectively compared unimmunized mice huy et al <NUMBER> encouraging order vaccine effective antibodies produced must virusneutralizing bae et al <NUMBER> took next step showing feeding ground lyophilized transgenic tobacco containing scoe able induce immune response mice could inhibit pedv plaque formation <NUMBER> comparison controls full immunity conferred mounted immune response study marks significant achievement date plantbased pedv vaccine research antigenic protein pedv abundant component viral envelope utiger et al <NUMBER> contrast conserved showing <NUMBER> number mutations <NUMBER> serial passages chen et al <NUMBER> sato et al <NUMBER> use protein remains stable important subunit vaccine design ensure vaccine used wide variety strains locations protein tgev sarscov show virusneutralizing activity presence complement component immune system enhances ability antibodies clear pathogens virusneutralizing activity demonstrated higher comparable neutralizing capacity <NUMBER> individual protein fragments pang et al <NUMBER> woods et al <NUMBER> sequence homology infectious bronchitis virus ibv gammacoronavirus found bcell epitope cterminus amino acids <NUMBER> zhang et al <NUMBER> however likely research sequence homology studies find epitopes pedv example protein sarscov bcell epitopes n ctermini et al <NUMBER> two cytotoxic tcell epitopes second third transmembrane domain liu et al <NUMBER> protein mhv cd<NUMBER> tcell epitope cterminus xue et al <NUMBER> expression transiently n benthamiana fusion elastinlike polypeptide khamis <NUMBER> resulted production viruslike particles vlps important development subunit vaccine design subunit vaccines previously failed completely protect piglets pedv infection due subpar immunogenicity vlps immunogenic resemble native structure virion plantmade vlps influenza shown induce fourto sixfold higher levels antibody response fifty times flu antigen vlps daoust et al <NUMBER> ability produce pedv vlps using may lead first commercial plantproduced pedv vaccine much pedv vaccine research occurred asia outbreaks severe none produced vaccines completely effective asian pedv strains song park <NUMBER> available asian vaccines based strains genetically different sequenced us currently causing epidemics globally huang et al <NUMBER> display china vaccinated herds experienced pedv breakouts found due newer strains virus two pedv vaccines given conditional licenses us united states department agriculture usda first vaccine originally produced harrisvaccines inc based sirravax sm rna platform using platform part rna genome venezuelan equine encephalitis alphavirus replaced gene pedv protein injection genetic material pigs dendritic cells produce protein immune response launched produced protein harrisvaccines <NUMBER> merck animal health acquired harrisvaccines <NUMBER> merck animal health <NUMBER> product still sold conditional license us safety field trials ongoing second conditionally licensed pedv vaccine us inactivated virus particle vaccine produced zoetis inc zoetis <NUMBER> efficacy potency studies still progress zoetis vaccine duration immunity evaluated must refrigerated used opened zoetis <NUMBER> third vaccine candidate developed vidointervac vaccine infection disease organizationinternational vaccine centre canada currently undergoing field testing vaccine candidate subunit s<NUMBER> protein expressed mammalian hek<NUMBER> cells although induced production neutralizing antibodies fully protective suckling piglets makadiya et al <NUMBER> none pedv vaccines used commercially least us canada made planta ability vaccinate orally feeding plant tissue important song et al <NUMBER> demonstrated oral vaccination effective injection pedv vaccine comparing oral intramuscular administration attenuated virus vaccine song et al found igas produced orally vaccinated pigs mortality rate group <NUMBER> comparison <NUMBER> intramuscular group current vaccines market also either based prone mutations killed live attenuated vaccines live attenuated vaccines present risks potentially mutate become pathogenic allow genome segment reassortment farmsone chinese pedv strain thought evolved live attenuated vaccine chen et al <NUMBER> inactivated vaccines comparison safer high cost production present concerns reliability inactivation methods calvopinilla et al <NUMBER> live attenuated inactivated vaccines rule possibility using distinguish infected vaccinated animals diva assays contain entire virus market need effective subunit vaccine based current infectious strains research current plantmade candidates could prove fill need proof concept studies show scoe produced plants many studies show poor yields generally even higher yields reported push forward testing immunogenicity vaccine candidates occur two instances direct immunogenicity plantproduced scoe tested first incomplete test whether mounted immune response virusneutralizing huy et al <NUMBER> candidate successfully took steps test immunogenicity vaccine candidate produced bae et al <NUMBER> however immune response mice inhibited pedv plaque formation <NUMBER> comparison controls complete immunity achieved bae et al <NUMBER> likely due due need higher expression levels efforts made vaccine candidate generally even higher expression levels obtained kang et al <NUMBER> immunogenicity tested research focused increasing expression levels producing immunogenic commercial product focus scoe left gap research plant production pedv proteins however recent results shown produced planta vlps produced pedv khamis <NUMBER> vlps represent stepforward subunit vaccine design demonstrating higher immunogenicity regular subunit vaccines future advances subunit vaccine design vlps commitment improving yields testing immunogenicity protective immune responses vlps may lead commercialization plantproduced subunit pedv vaccine middle east respiratory syndrome coronavirus merscov member coronaviridae family emerged <NUMBER> kingdom saudi arabia zaki et al <NUMBER> coronaviruses typically cause mild infections upper respiratory tract already <NUMBER> severe acute respiratory syndrome cov sarscov mortality rate <NUMBER> among infected patients introduced human population sarscov spread worldwide caused <NUMBER> diagnosed infections contained within year emergence httpwwwwhointcsrsarscountrytable<NUMBER> en contrast infections merscov ongoing <NUMBER> years <NUMBER> laboratoryconfirmed cases distributed <NUMBER> countries least <NUMBER> deaths reported november <NUMBER> httpwwwwhointemergenciesmerscoven apparent casefatality rate <NUMBER> grave concern epidemic spread observed sarscov could result disastrous death toll merscov introduced zoonotically transmission dromedary camels human patients alagaili et al <NUMBER> haagmans et al <NUMBER> reusken et al <NUMBER>a serological studies indicate widespread early distribution among animal host alagaili et al <NUMBER> reusken et al <NUMBER>b therefore continuous risk transmission especially persons close contact camels evident fortunately human human transmission rate remained low aside individuals regular contact camels health care workers relatives merscov patients considerable risk infection alraddadi et al <NUMBER> drosten et al <NUMBER> still modest level nonetheless high case fatality rate recurrent outbreaks merscov infections especially risk virus adaptation potentially resulting epidemic even pandemic spread make development effective vaccine merscov international priority efficacy several vaccine candidates demonstrated different animal models even dromedary camels reviewed okba et al <NUMBER> one candidates mv vac<NUMBER> merssh malczyk et al <NUMBER> based measles virus mv vaccine platform technology mühlebach <NUMBER> encodes merscov spike protein additional antigen backbone recombinant mv vac<NUMBER> del valle et al <NUMBER> resembling vaccine strain moraten authorized use us since <NUMBER> candidate induces robust humoral functional cellular immuneresponses merscov moreover merscov viral load inflammation lung significantly reduced challenged mice vaccinated mv vac<NUMBER> merssh malczyk et al <NUMBER> experiments provided proof concept efficacy vaccine candidate mechanistic insights nature induced cell responses remain elucidated special interest since shown cells essential clearance infection coleman et al <NUMBER> zhao et al <NUMBER> depletion cd<NUMBER> cells increased overall inflammation bronchiolar inflammation lymphocyte infiltration pleuritis day <NUMBER> postinfection mice coleman et al <NUMBER> mers covsusceptible mice depleted cells unable clear virus alternative spike glycoprotein conserved internal structural proteins nucleocapsid protein n special interest putative target antiviral cell responses triggered future mers vaccines therefore also generated characterized merscov n proteinencoding vaccine candidates based mv vac<NUMBER> vaccine platform study characterize induction mers covspecific immune responses first analyzed necessity viral replication induction mers covand mvspecific immune responses using highly immunogenic mv vac<NUMBER> merssh vaccine candidate addition characterized functionality cd<NUMBER> cd<NUMBER> cell responses juvenile <NUMBER> week old adult <NUMBER> months age mice using flow cytometry functional assays vero african green monkey kidney atcc ccl<NUMBER> <NUMBER> atcc crl<NUMBER> cell lines purchased atcc manassas va usa cultured dulbeccos modified eagles medium dmem biowest nuaillé france supplemented <NUMBER> fetal bovine serum fbs biochrom berlin germany <NUMBER> mm lglutamine lgln biochrom jawsii dendritic cells atcc crl<NUMBER> purchased atcc cultured memα ribonucleosides deoxyribonucleosides gibco brl eggenstein germany supplemented <NUMBER> fbs <NUMBER> mm lgln <NUMBER> mm sodium pyruvate biochrom <NUMBER> ngml murine gmcsf peprotech hamburg germany dc<NUMBER> murine dendritic cells shen et al <NUMBER> cultured rpmi containing <NUMBER> fbs <NUMBER> mm lgln <NUMBER> nonessential aminoacids biochrom <NUMBER> mm hepes ph <NUMBER> <NUMBER> μm <NUMBER>mercaptoethanol sigmaaldrich steinheim germany cells cultured <NUMBER>°c humidified atmosphere containing <NUMBER> co <NUMBER> maximum <NUMBER> months culture thawing original stock codonoptimized gene encoding merscovn genebank accession jx<NUMBER> flanked aatiimlui binding sites plasmid pmarqmersn obtained gene synthesis invitrogen life technology regensburg germany antigen immediate early cytomegalovirus cmv promoter martin et al <NUMBER> inserted plasmids pbrmv vac<NUMBER> atup del valle et al <NUMBER> pmv vac<NUMBER> gfph via mluiaatii sfiisacii respectively generate ppoliimv vac<NUMBER> mersnp ppoliimv vac<NUMBER> mersn h construction lentiviral transfervectors encoding merscovn orf mersn amplified pcr primers encompassing flanking restriction sites nheixhoi template pmarqmersn details primers pcr available upon request pcr products cloned pcr<NUMBER>topo invitrogen life technology fully sequenced intact antigen orf cloned pcscw<NUMBER>gluciresgfp hewett et al <NUMBER> using nheixhoi restriction sites yield pcscw<NUMBER>mersniresgfp lentiviral vectors produced used generation antigenexpressing dendritic cell lines described malczyk et al <NUMBER> short hiv<NUMBER>derived vectors generated using standard <NUMBER> plasmid system transfer vector plasmid pcscw<NUMBER>mersniresgfp pei transfection subsequent purification harvest transfected <NUMBER> cells yielded virus stocks used transduce dc cell lines single cellsorted facs selected antigen expression mersn encoding vaccine candidates mv vac<NUMBER> mersnp mv vac<NUMBER> mersnh rescued described malczyk et al <NUMBER> martin et al <NUMBER> single syncytia picked overlaid onto <NUMBER> confluent vero cells cultured <NUMBER>well plates harvested passage <NUMBER> p<NUMBER> scraping freezethaw cycle cells time maximal infection subsequent passages generated described following viruses mersn encoding vaccine viruses p<NUMBER> used characterization viruses p<NUMBER> vaccination merss encoding vaccine virus mv vac<NUMBER> merssh control virus mv vac<NUMBER> atup malczyk et al <NUMBER> also used p<NUMBER> vaccination well mv vac<NUMBER> gfpp merscov isolate emc<NUMBER> zaki et al <NUMBER> used neutralization assays propagated titrated vero cells method spearman kaerber hubert <NUMBER> kärber <NUMBER> mv vac<NUMBER> merssh inactivated uvirradiation using cl<NUMBER> uv crosslinker uvp cambridge uk <NUMBER> μl virus suspension <NUMBER>wellplates ice exposed uv light <NUMBER> nm <NUMBER> cm distance uv source <NUMBER> × <NUMBER> <NUMBER> μjcm <NUMBER> <NUMBER> min inactivation virus controlled incubation vero cells control aliquot inactivated parallel virus stocks stored aliquots −<NUMBER>°c cells lysed immunoblotted previously described funke et al <NUMBER> rabbit antimerscov serum <NUMBER> used primary antibody merscovn rabbit antimvn polyclonal antibody <NUMBER> abcam mvn detection donkey hrpcoupled antirabbit igg hl polyclonal antibody <NUMBER> rockland gilbertsville pa served secondary antibody peroxidase activity visualized enhanced chemiluminescence detection kit thermo scientific bremen germany amersham hyperfilm ecl ge healthcare freiburg germany animal experiments carried compliance regulations german animal protection laws authorized rp darmstadt sixto <NUMBER>weekold <NUMBER> months old ifnar cd<NUMBER>ge mice mrkic et al <NUMBER> deficient type ifn receptor transgenically expressing human cd<NUMBER> inoculated intraperitoneally ip <NUMBER> × <NUMBER> <NUMBER> tcid <NUMBER> recombinant viruses uvinactivated vaccine preparations days <NUMBER> either day <NUMBER> <NUMBER> mice bled days <NUMBER> <NUMBER> <NUMBER> post initial infection pi serum samples stored − <NUMBER>°c mice euthanized days <NUMBER> <NUMBER> <NUMBER> pi splenocytes harvested assessment cellular immune responses quantification vnts done described malczyk et al <NUMBER> brief mouse sera serially diluted <NUMBER>fold dilution steps dmem duplicates total <NUMBER> pfu mv vac<NUMBER> gfpp <NUMBER> tcid <NUMBER> merscov strain emc<NUMBER> mixed diluted sera incubated <NUMBER>°c <NUMBER> h virus suspensions added <NUMBER> × <NUMBER> <NUMBER> vero cells seeded <NUMBER> h prior assay <NUMBER>well plates incubated <NUMBER> days <NUMBER>°c vnts calculated reciprocal highest mean dilution abolished infection murine gamma interferon ifnγ enzymelinked immunosorbent spot elispot assays ebioscience frankfurt germany performed according manufacturers instructions using multiscreen immunoprecipitation ip elispot polyvinylidene difluoride pvdf <NUMBER>well plates merck millipore darmstadt germany <NUMBER> × <NUMBER> <NUMBER> isolated medium inoculated mice served mock control vnts calculated highest dilution abolishing infectivity dots represent single animals n <NUMBER> horizontal lines represent mean per group yaxis starts detection limit mice detection limit detectable vnt g secretion ifnγ antigenspecific restimulation splenocytes harvested <NUMBER> days post prime immunization coculture jawsii left dc<NUMBER> middle dendritic cells transgenic mersn black untransduced controls nc white right analyze cellular responses directed mv splenocytes stimulated <NUMBER> μgml mv bulk antigen mv bulk left unstimulated sham reactivity splenocytes confirmed cona treatment <NUMBER> μgml tcid <NUMBER> tissue culture infectious dose <NUMBER> onewayanova tukey multiple comparison p <NUMBER> p <NUMBER> p <NUMBER> p <NUMBER> splenocytes cocultured different stimuli <NUMBER> μl rpmi <NUMBER> fbs <NUMBER> mm lgln <NUMBER> penicillinstreptomycin <NUMBER> h restimulation mers nspecific cells splenocytes cocultivated <NUMBER> × <NUMBER> <NUMBER> jawsii dc<NUMBER> dendritic cells clones either cell line encoding mersn hand splenocytes stimulated <NUMBER> μgml mv bulk antigen serion immunologics würzburg germany <NUMBER> μgml mers sderived peptide s<NUMBER> biosynthesis inc lewisville tx usa channappanavar et al <NUMBER> <NUMBER> μgml siinfekl control peptide sin ovalbumin aa <NUMBER> invivogen san diego ca usa appropriate general cell stimulation <NUMBER> μgml concanavalin cona sigmaaldrich st louis mo usa used negative control splenocytes left untreated <NUMBER> h cells removed plates plates incubated biotinconjugated antiifnγ antibodies avidinhrp according manufacturers instructions <NUMBER>amino<NUMBER>ethylcarbazole aec sigmaaldrich substrate solution development spots prepared according manufacturers instructions using aec dissolved nndimethylformamide merck millipore used peroxidasedependent staining afterwards spots counted using eliscan elispot scanner aelvis hamburg germany elispot analysis software elianalyse v<NUMBER> aelvis flow cytometrybased determination cytokine expression intracellular cytokine staining ics splenocytes vaccinated mice isolated <NUMBER> × <NUMBER> <NUMBER> splenocytes per mouse cultivated <NUMBER> μl rpmi<NUMBER> <NUMBER> fbs <NUMBER> mm lgln <NUMBER> × nonessential amino acids biochrom <NUMBER> mm hepes <NUMBER> penicillinstreptomycin <NUMBER> μm βmercaptoethanol <NUMBER> μgml brefeldin sigmaaldrich one stimuli also used elispot analysis general cell stimulation <NUMBER> μgml tetradecanoylphorbol acetate tpa sigma aldrich <NUMBER> μgml ionomycin iono sigmaaldrich used positive control medium used negative control splenocytes stimulated <NUMBER> h <NUMBER>°c subsequently cells stained fixable viability dye efluor<NUMBER> ebioscience cd<NUMBER>pe <NUMBER> bd franklin lakes nj usa cd<NUMBER>fitc <NUMBER> bd permeabilization fixationpermeabilization solution bd perm wash buffer bd stained ifnγapc <NUMBER> bd tnfαpecy<NUMBER> <NUMBER> bd cells fixed icecold <NUMBER> paraformaldehyde pfa pbs analyzed via flow cytometry using lsrii sorp flow cytometer bd fcs express software de novo software glendale ca usa since nucleocapsid protein n cov quite conserved regarded appropriate target induce antiviral cells therefore merscov n chosen alternative antigen expressed recombinant mv vaccine platform fulllength mersn cloned two different additional transcription units atus either behind p post p h post h cassettes measles vaccine strain mv vac<NUMBER> genome virus clones successfully rescued amplified vero cells titers <NUMBER> × <NUMBER> <NUMBER> tcid <NUMBER> ml essential verification antigen expression western blot analysis vero cells infected mv vac<NUMBER> mersn vaccines revealed expression n antigen little impact genomic position transgene cassette fig <NUMBER>a growth kinetics showed impairment virus replication compared respective mv vac<NUMBER> gfpp control virus fig <NUMBER> b c test efficacy mv vac<NUMBER> mersn candidate vivo genetically modified ifnar cd<NUMBER>ge mice chosen since prime small animal model analysis mvderived vaccines mrkic et al <NUMBER> thus <NUMBER> mice per group inoculated via intraperitoneal ip route days <NUMBER> <NUMBER> time <NUMBER> × <NUMBER> <NUMBER> tcid <NUMBER> mv vac<NUMBER> mersnp mv vac<NUMBER> mersnh empty control virus mv vac<NUMBER> atup mediuminoculated mice served negative controls <NUMBER> days four days boost immunization sera splenocytes immunized mice sampled respectively fig <NUMBER>d expected mice immunized recombinant mv including control virus developed high mv virus neutralizing titers vnt <NUMBER> vnt fig <NUMBER>f little evidence induction neutralizing antibodies merscov found mice expected intraparticular antigen fig <NUMBER>e vnts mv merscov detected control mice inoculated medium alone analyze splenocytes animals vaccinated mv vac<NUMBER> mersn h control animals inoculated medium mv vac<NUMBER> atup elispot assay antigenspecific ifnγ secretion antigenspecific cells restimulated vitro syngeneic murine dc cell lines jawsii dc<NUMBER> genetically modified lentiviral vector transduction stably express mersn protein thereby present respective cell epitopes mhc single cell clones derived flow cytometric sorting single gfppositive cells antigen expression transduced dcs verified western blot analysis data shown elispot assays using splenocytes vaccinated animals coculture jawsiimersn dc<NUMBER>mersn revealed <NUMBER> ifnγ secreting cells per <NUMBER> × <NUMBER> <NUMBER> splenocytes immunization mv vac<NUMBER> mersnh fig <NUMBER>g significant controls additionally cellular immune responses targeting mv antigens detected upon stimulation mv bulk antigens vaccinated mice received recombinant virus expected however mv bulk antigens stimulated <NUMBER> ifnγ secreting cells per <NUMBER> × <NUMBER> <NUMBER> splenocytes mv vaccinated animals described malczyk et al <NUMBER> finally splenocytes mice revealed similar basic reactivity unspecific cell stimulation confirmed similar numbers ifnγ secreting cells upon cona treatment fig <NUMBER>g thus generated mvbased vaccine platform expressing mersn induces significant mers nspecific cellular immune responses desired case humoral cellular responses induced vaccine candidate mv vac<NUMBER> merss considerably higher previous analyses similar conditions malczyk et al <NUMBER> therefore characterization antimerscov immunity induced mv vac<NUMBER> derived vaccines proceeded merss encoding vaccine candidate yielded approximately <NUMBER>fold higher numbers reactive cells vaccination since mers vaccine candidate mv vac<NUMBER> merssh induced robust protective humoral cellular immune responses ifnar cd<NUMBER>ge mice malczyk et al <NUMBER> interested necessity viral replication lifeattenuated vaccine induction mers covspecific immunity analyses ifnar cd<NUMBER>ge mice chosen animal model since mice standard animal model analysis mvderived vaccines mühlebach <NUMBER> genetic composition compatible established merscov challenge model shown malczyk et al <NUMBER> size allows housing regularly available conditions opposed dromedary camels know natural host merscov date morbilliviruses mvbased vaccine virions highly cellassociated transfer antigenic protein within vaccine preparation cannot excluded therefore vaccinated mvsusceptible mice either <NUMBER> × <NUMBER> <NUMBER> tcid <NUMBER> live formulation quantity uvinactivated mv vac<NUMBER> merssh primeboost regimen fig <NUMBER>a mv vac<NUMBER> atup encode additional antigen included vector control blood drawn naïve mice day <NUMBER> vaccination days <NUMBER> <NUMBER> postimmunization serum samples tested ability neutralize mv vac<NUMBER> gfpp fig <NUMBER>b f merscov fig <NUMBER>c e g sera naïve mice neutralizing antibodies either virus fig <NUMBER>b c first immunization live virus preparations induced neutralizing antibodies mv mv vac<NUMBER> atup triggering significantly higher titers <NUMBER> vnt mv vac<NUMBER> merssh <NUMBER> vnt second immunization antimv vnts increased titers <NUMBER> cohorts contrast one four animals uvinactivated vaccine group borderline neutralizing antibody titer <NUMBER> first immunization another animal titer <NUMBER> boost mv vac<NUMBER> atup uvinactivated mv vac<NUMBER> merssh vaccine induce neutralizing antibodies merscov background levels course experiment group vaccinated live mv vac<NUMBER> merssh developed titers around <NUMBER> first immunization <NUMBER> mean <NUMBER> boost taken together data reveal replication vaccine necessary induce functional antibody responses mv additional antigen merss assess capacity different mv vac<NUMBER> merssh vaccine preparations induce merscov sspecific cellular immune responses splenocytes mice already tested humoral responses fig <NUMBER>a isolated analyzed <NUMBER> days immunization antigenagdependent ifnγ secretion using elispot assay isolated splenocytes restimulated merss immunodominant peptide s<NUMBER> channappanavar et al <NUMBER> mv bulk antigen mv bulk analyze mvspecific cellular immune responses ovalbuminderived siinfeklpeptide sin served peptide negative control cells left untreated mock stimulation concanavalin cona used confirm general cell reactivity splenocyte preparations fig <NUMBER>h splenocytes mice responded cona <NUMBER> <NUMBER> spots per <NUMBER> × <NUMBER> <NUMBER> splenocytes animals vaccinated live mv vac<NUMBER> merssh could stimulated mers sspecific peptide s<NUMBER> reaching mean values <NUMBER> spots per <NUMBER> × <NUMBER> <NUMBER> splenocytes contrast splenocytes uvinactivated group control virus mv vac<NUMBER> atup could restimulated secrete ifnγ furthermore replicationcompetent vaccine viruses induced mvspecific cellular immune responses vaccinated mice restimulation mv bulk ag induced mean <NUMBER> <NUMBER> spots per <NUMBER> × <NUMBER> <NUMBER> splenocytes mv vac<NUMBER> merssh mv vac<NUMBER> atup vaccinated mice respectively consequently replication vaccine candidate essential induce arms immune system responses mv well additional merss antigen usually <NUMBER> weeks old juvenile mice used merscov neutralizing antibodies sera b c naїve mice sera mice e primeor f g boostimmunization oneway anova tukey multiple comparison p <NUMBER> p <NUMBER> p <NUMBER> p <NUMBER> h secretion ifnγ antigenspecific restimulation splenocytes ifnγ elispot analysis using splenocytes mice vaccinated days <NUMBER> <NUMBER> indicated vaccines isolated <NUMBER> days boost immunization incubation indicated stimuli merss peptide s<NUMBER> mv bulk antigen mv bulk immunodominant ovalbuminderived siinfeklpeptide sin peptide negative control untreated mock reactivity splenocytes confirmed concanavalin cona treatment <NUMBER> μgml number cells per <NUMBER> × <NUMBER> <NUMBER> splenocytes represent amount cells expressing ifnγ upon restimulation dots represent individual animals horizontal bars mean oneway anova tukey multiple comparison p <NUMBER> bs bodmer et al virology <NUMBER> <NUMBER> <NUMBER> immunization studies evaluate agedependent change vaccination efficacy approximately <NUMBER> monthsold mice vaccinated mv vac<NUMBER> merssh primeboost vaccination scheme <NUMBER> weeks prime boost vaccination fig <NUMBER>a mice sacrificed day <NUMBER> postimmunization splenocytes restimulated mvantigens merss peptide s<NUMBER> found reactive ifnγsecreting cells also specifically induced mice age fig <NUMBER>b mean <NUMBER> spots per <NUMBER> × <NUMBER> <NUMBER> splenocytes detected upon restimulation mv bulk antigen whereas <NUMBER> spots per <NUMBER> × <NUMBER> <NUMBER> splenocytes induced restimulation mers sderived peptide s<NUMBER> illustrating mvand merscovspecific cellular immune responses effectively induced adult mice gain detailed insights quality observed cell responses characterized responsive cell populations flow cytometry determining expression cd<NUMBER> cd<NUMBER> surface markers well ifnγ tnfα upon restimulation s<NUMBER> mv bulk antigen positive stimulus cell activation tetradecanoylphorbolacetate ionomycin tpaiono used exocytosis cytokines blocked addition brefeldin <NUMBER> μg ml stimulation cells permeabilized labelled fixed flow cytometry gating strategy excluded duplicates shown selected living cells fig <NUMBER>a upper panel separated cd<NUMBER> cd<NUMBER> cells fig <NUMBER>a lower panel selected cd<NUMBER> cells analyzed expression ifnγ fig <NUMBER>b left panel tnfα fig <NUMBER>b middle panel fig <NUMBER>b right panel exemplarily shown splenocytes restimulated merss peptide s<NUMBER> likewise cd<NUMBER> cells expressing ifnγ fig <NUMBER>c left panel tnfα fig <NUMBER>c middle panel fig <NUMBER>c right panel depicted restimulation mv bulk antigen vaccination mv vac<NUMBER> merssh induced significant amount mers sspecific cd<NUMBER> cells expressing either ifnγ fig <NUMBER>d left panel tnfα fig <NUMBER>d middle panel means <NUMBER> <NUMBER> total positive cells respectively among significant fraction cells revealed multifunctional mean <NUMBER> cd<NUMBER> cells <NUMBER> tnfα − responsive cells positive cytokines fig <NUMBER>d right panel moreover vaccination induced significant fraction vectorspecific cd<NUMBER> cells expressing ifnγ fig <NUMBER>e left panel tnfα fig <NUMBER>e middle panel upon restimulation mv bulk antigen among multifunctional cd<NUMBER> cells expressing cytokines induced mean <NUMBER> fig <NUMBER>e right panel conclude vaccination mv vac<NUMBER> merssh induces ifnγ tnfα expressing cells directed merscov mv also significant fraction multifunctional cytotoxic cells specific merss cd<NUMBER> cells specific mv antigens illustrating broad robust merscovspecific immune response induced vaccination mv vac<NUMBER> merssh study aimed understand induction immunity functionality induced cell responses vaccination mv vac<NUMBER> merssh vaccine candidate induces protective immunity merscov appropriate animal model parallel generated tested also alternative mvbased vaccine candidates expressing merscov n protein conserved cell antigen mv vac<NUMBER> mersn vaccine candidates indeed induced significant antigenspecific cellular immune responses vaccinated transgenic mice revealing also mers nexpression recombinant mv may useful role combat merscov since immune responses induced merss expressing candidates nevertheless considerably higher proceeded sexpressing vaccine virus characterize induction antimerscov immunity mvbased vectors using mv vac<NUMBER> merssh robust antimers cov immune responses induced also older mice replication vaccine vector necessary induce either arm adaptive immunity vector pathogen furthermore vaccination mv vac<NUMBER> merssh triggered significant numbers multifunctional mers sspecific cd<NUMBER> cells mvspecific cd<NUMBER> cells simultaneously producing ifnγ tnfα upon stimulation respective antigens since numbers also quality induced mers covspecific cell responses might relevant protection merscov quite encouraging see approx <NUMBER> ifnγ reactive cd<NUMBER> cells also expressed tnfα whereas reverse <NUMBER> tnfαreactive cd<NUMBER> cells coexpressed ifnγ upon stimulation immunedominant merss peptide induction multifunctional cells quite accordance previous studies since potential mv natural infection recombinant mv induce multifunctional antigenspecific cells already demonstrated infection macaques wildtype mv induces polyfunctional cells specific mv proteins increasing numbers cells secreting il<NUMBER> tnfα well ifnγ time nelson et al <NUMBER> polyfunctional cells directed mvh expanded pbmc human donors ndhlovu et al <NUMBER> likewise hivvaccine candidates mv<NUMBER>f<NUMBER> encode gag rt nef hiv<NUMBER> clade b clade c strain foreign antigen induce antigenspecific multifunctional cells simultaneously expressing ifnγ tnfα il<NUMBER> mice also macaques stebbings et al <NUMBER> stebbings et al <NUMBER> combination ifnγ tnfα indicates functional cells fig <NUMBER> restimulated subjected intracellular staining ics ifnγ tnfα stained extracellular tcell markers cd<NUMBER> cd<NUMBER> flow cytometry analysis c gating strategy analysis cd<NUMBER> cd<NUMBER> tcells expressing ifnγ tnfα within splenocytes stimulated b s<NUMBER> peptide c mvbulk ag duplicates shown dead cells excluded analysis b c cd<NUMBER> cd<NUMBER> cells separately subjected analysis ifnγleft panels tnfαmiddle panels doublepositive cells right panels quantification flow cytometry data cd<NUMBER> e cd<NUMBER> positive cells incubation indicated stimuli mers sspecific peptide s<NUMBER> mv bulk ag mv bulk immunodominant ovalbuminderived siinfeklpeptide sin peptide negative control untreated cells mock reactivity splenocytes confirmed tetradecanoylphorbolacetate ionomycin tpaiono treatment <NUMBER> μgml dots represent individual animals horizontal bars mean repeatedmeasures oneway anova tukey multiple comparison p <NUMBER> higher potency general expression il<NUMBER> sign induction cd<NUMBER> memory cells williams et al <NUMBER> study strong correlation ifnγ tnfα expression thus indicates high functionality induced cell responses extension antibody panel il<NUMBER> detection could yield insight durability cell responses induced mv vaccine platform future studies multifunctional cd<NUMBER> cells specific merscov may become especially important since mouse studies shown cd<NUMBER> cells crucial clearance merscov infection coleman et al <NUMBER> zhao et al <NUMBER> noteworthy viral infections human immunodeficiency virus hiv modified vaccinia virus ankara mva cytomegalovirus cmv amount ifnγ producing cells correlate ctl killing effectivity multifunctionality antigenspecific cells inversely correlated viral load betts et al <NUMBER> lichterfeld et al <NUMBER> precopio et al <NUMBER> sandberg et al <NUMBER> underlining importance multifunctionality besides cellular immune responses also considerable humoral immunity induced vaccinated animals mean vnt somewhat lower expected malczyk et al <NUMBER> still quite high alternative vaccine candidate derived modified vaccinia virus ankara mvamerss revealed protection dromedary camels natural host merscov haagmans et al <NUMBER> passive immunotherapy dromedary immune sera significantly reduced merscov titers lung tissue challenged mice starting vnt <NUMBER> zhao et al <NUMBER> neutralizing antibody titers reconvalescent plasma human patients diagnosed mers determined microneutralization tests two previous studies average <NUMBER> arabi et al <NUMBER> <NUMBER> zhao et al <NUMBER> furthermore prnt <NUMBER> titer least <NUMBER> required lower virus titers <NUMBER> log mice challenged transfer human reconvalescent plasma zhao et al <NUMBER> titers exceeded study addition mv vac<NUMBER> merssh induced higher antimerss titers c<NUMBER>bl<NUMBER> mice mvamerss balbc mice comparing studies used similar virus titers vaccination malczyk et al <NUMBER> volz et al <NUMBER> thus indicating least comparable efficacy thus also vnt determined indicate efficacy anyway statistically different published mv vac<NUMBER> merssh malczyk et al <NUMBER> nevertheless exact correlates protection merscov remain determined future studies since essential evaluate efficacy different vaccine candidates important benchmark contrast uvinactivated mv vac<NUMBER> merssh induce antibodies able neutralize merscov mv neutralizing antibodies principle also induced inactivated vaccines proteins eg fulllength truncated merss protein combination adjuvant wang et al <NUMBER> obviously amount merss antigen within mv vac<NUMBER> merssh vaccine formulation adjuvant effect inactivate sufficient application therefore replication mvderived mers vaccine candidate necessary induction immune responses vector antigen interest vaccinated animals indeed induction cellular immunity usually efficient de novo expression antigen immunization consequently application replication competent vaccine platform justified robustly induce potent responses arms adaptive immune system powerful immune responses induced juvenile mice <NUMBER> weeks age also adult mice older half year age quite interest since adult vaccinees also target group vaccination response merscov outbreak defined target product profile httpwwwwhoint blueprintwhatresearchdevelopmentmerscovtpp <NUMBER>pdf remarkably mv vaccine strain virus encoding chikungunya virus chikv antigens already tested phase clinical trial adult human vaccinees <NUMBER> years old ramsauer et al <NUMBER> adult test subjects developed significant humoral immunity chikv despite adult age interestingly also independent measles preimmunity taken together study shows mv vac<NUMBER> merssh induces surprisingly high numbers multifunctional cells specific merss also adult test subjects result replication recombinant vector therefore high quality cellular immune responses induced addition robust antibody responses vaccine candidate qualifying mv vac<NUMBER> merssh evaluation vaccine candidate merscov parallel mersn encoding mv option generate protection mers future studies constructs middle east respiratory syndrome mers newly emerged infectious disease caused novel ␤coronavirus ␤cov mers coronavirus merscov merscov first identified humans saudi arabia june <NUMBER> <NUMBER> zaki et al <NUMBER> although spread merscov among humans limited merscov infection linked several family clusters healthcare workers memish et al <NUMBER>b memish et al <NUMBER>c providing evidence humantohuman transmissibility virus merscov demonstrated increasing trend infection since first identification sporadic mers cases reported least <NUMBER> countries middle east africa europe asia north america november <NUMBER> <NUMBER> total <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths mortality rate ∼<NUMBER> reported httpwwwwhointcsrdon<NUMBER>november<NUMBER>mersen geographic spread rapid increase mers cases past several months raised concerns pandemic potential even though consequences pandemic might less severe caused severe acute respiratory syndrome coronavirus sarscov another ␤cov led worldwide outbreak <NUMBER> peiris et al <NUMBER> practical control strategy potential outbreak merscovcaused emerging infectious disease development effective vaccines become high priority number studies pointed transmission hosts merscov reported batderived coronaviruses particularly bat coronavirus hku<NUMBER> close phylogenetic relationship merscov dipeptidyl peptidase <NUMBER> dpp<NUMBER> receptor merscov also receptor hku<NUMBER> hku<NUMBER> prefers bat dpp<NUMBER> human dpp<NUMBER> merscov adapted use human dpp<NUMBER> addition bind bat dpp<NUMBER> suggesting <NUMBER> bats potential natural reservoirs merscov <NUMBER> bat coronaviruses remain threat human health potential crossspecies transmission annan et al <NUMBER> cui et al <NUMBER> ithete et al <NUMBER> memish et al <NUMBER>a yang et al <NUMBER> addition bats camels recently become focus study merscov transmission since merscov neutralizing antibodies merscov gene fragments identified dromedary camels infectious merscov recovered infected camels briese et al <NUMBER> chu et al <NUMBER> drosten et al <NUMBER> haagmans et al <NUMBER> meyer et al <NUMBER> nowotny kolodziejek <NUMBER> reusken et al <NUMBER> fact humans infected merscov exposure infected camels suggests camels likely intermediate transmission hosts merscov recently merscov rna fragments detected air sample collected barn sheltered merscovinfected camels azhar et al <NUMBER> indicating possible airborne transmission merscov animals humans although spread merscov among humans limited inefficient increased infection rate among healthcare workers month april <NUMBER> httpwww whointcsrdiseasecoronavirus infectionsarchive updatesen raised concerns future epidemic potential call development effective safe vaccines prevent control mers hotez et al <NUMBER> merscov belongs lineage c ␤cov close relationship bat coronaviruses hku<NUMBER> hku<NUMBER> first known lineage c ␤cov associated human infections chan et al <NUMBER>b woo et al <NUMBER> merscov positivesense singlestranded rna virus whose genome encodes four major structural proteins including spike protein envelope protein e membrane protein nucleocapsid protein n unique functions fig <NUMBER>a e protein transmembrane protein forms ion channel viral surface n protein interactively functions protein n molecules encapsulating genomic rna hurst et al <NUMBER> among four structural proteins merscov protein plays important roles virus infection pathogenesis displays trimer viral membrane surface precursor protein cleaved two noncovalently associated subunits distal subunit s<NUMBER> membraneanchored subunit s<NUMBER> merscov s<NUMBER> subunit contains receptorbinding domain rbd including core structure accessory subdomain receptorbinding motif rbm s<NUMBER> subunit consists putative fusion peptide transmembrane domain two heptad repeat regions termed heptad repeats <NUMBER> <NUMBER> hr<NUMBER> hr<NUMBER> fig <NUMBER>b chen et al <NUMBER>b lu et al <NUMBER>a wang et al <NUMBER> although merscov sarscov share similar core structures maintain conformational integrity rbms different chen et al <NUMBER>b li et al <NUMBER> receptors recognized coronaviruses distinctively different angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional receptor sarscov dpp<NUMBER> also known cd<NUMBER> identified receptor merscov li et al <NUMBER> raj et al <NUMBER> crystal structures sarscov rbd complexed receptor ace<NUMBER> identified rbd sarscov residues <NUMBER> rbm residues <NUMBER> li et al <NUMBER> crystal structure analysis merscov rbd alone rbddpp<NUMBER> complex mapped rbd residues <NUMBER> <NUMBER> respectively protein merscov rbm spanning residues <NUMBER> chen et al <NUMBER>b lu et al <NUMBER>a wang et al <NUMBER> fig <NUMBER> lists crystal structures sarscov merscov rbds complexes respective receptors merscov undergoes two major processes infect target cells first virus binds cellular receptor dpp<NUMBER> via rbd s<NUMBER> subunit second hr<NUMBER>hr<NUMBER> complex s<NUMBER> subunit forms fusion core leading cellvirus membrane fusion thereby mediating merscov entry target cells lu et al <NUMBER> therefore like sarscov protein protein merscov plays essential role receptor binding membrane fusion cell entry previously demonstrated protein specifically rbd sarscov played essential role developing sars vaccines du et al <NUMBER>a jiang et al <NUMBER>b thus expected rbd merscov protein important target developing vaccines mers lu et al <NUMBER>b et al <NUMBER>b antibodies induced sarscov rbd crossneutralize merscov infection since different receptors recognized two coronaviruses suggesting developing safe effective mers vaccine high priority du et al <NUMBER>c since mers newlyemerged viral disease vaccines developed clinical use however number vaccine candidates tested andor proven effective vitro preclinical studies current updates mers vaccine development including possibility developing certain vaccine types candidates mers discussed revealed recombinant modified vaccinia virus ankara mva expressing fulllength merscov protein mvamerss produced neutralizing antibodies immunized mice infections merscov cell cultures vitro song et al <NUMBER> providing basis developing viral vectorbased mers vaccines addition fulllength infectious cdna clones merscov constructed using reverse genetics systems relevant infectious viruses could rescued propagated vero a<NUMBER> huh<NUMBER> human liver cells almazán et al <NUMBER> scobey et al <NUMBER> reports also shown fullgenome sequence merscov jordann<NUMBER> strain exhibited stability sequential passages two mammalian cell lines vero african green monkey kidney mrc<NUMBER> human lung frey et al <NUMBER> studies indicate potential developing liveattenuated viruses mers vaccine candidates moreover reported high titers specific antibodies neutralizing activity generated mice vaccination nanoparticles expressing fulllength merscov protein suggesting possibility developing nanoparticlebased mers vaccines coleman et al <NUMBER>a addition aforementioned vaccine types epitopebased subunit vaccines also show promise merscov infection investigation efficacy example recent studies sequence analysis computational prediction identified immunogenic conserved epitope wdypkcdra rnadirected rna polymerase protein human coronaviruses supporting concept designing developing epitopebased universal vaccines mers sharmin islam <NUMBER> additionally recombinant proteins containing rbd merscov protein able elicit strong neutralizing antibodies vaccinated rabbits mice respectively du et al <NUMBER>c et al <NUMBER>a et al <NUMBER>b mou et al <NUMBER> reinforcing significance developing proteinbased subunit mers vaccines candidate vaccines represent first step control prevention merscov infection subunit vaccines defined based purified proteins peptides consisting major antigenic fragments pathogens hansson et al <NUMBER> subunit vaccines possess variety advantages including high safety profile minimal side effects injection sites constant immune effects welldefined pathogenic fragments du et al <NUMBER> zhang et al <NUMBER> although reports merscov rbdbased subunit vaccines limited subunit vaccines based sarscov rbd extensively studied tested since occurrence sars <NUMBER> showing sufficient efficacy strong protection sarscov infections various animal models du et al <NUMBER> du et al <NUMBER>b et al <NUMBER> zakhartchouk et al <NUMBER> therefore summary sarscov rbdbased subunit vaccines provide useful information specific guidance design effective rbdbased subunit vaccines merscov considerable evidence shown sarscov rbd contains multiple conformationdependent epitopes induce highly potent neutralizing antibodies therefore critical neutralization determinant developing sars subunit vaccines et al <NUMBER>a et al <NUMBER>b believed recombinant fusion protein rbdfc containing rbd residues <NUMBER> sarscov protein fused human igg<NUMBER> fc fragment induced strong antibody responses neutralizing activity elicited longterm protective immunity immunized rabbits mice respectively completely protecting immunized mice sarscov challenge du et al <NUMBER> et al <NUMBER> also identified recombinant rbd proteins residues <NUMBER> expressed mammalian cells <NUMBER>t cho insect cell sf<NUMBER> escherichia coli respectively able elicit sufficient neutralizing antibodies protective immunity sarscov challenge immunized mice among mammalian <NUMBER>t cellexpressed rbd induced higher neutralizing antibody responses expressed insect cell e coli systems du et al <NUMBER>b du et al <NUMBER>c moreover <NUMBER>texpressing rbd capable inducing high titers protective antirbd antibody response immunized nonhuman primates strongly neutralizing proteinmediated sars pseudovirus infection ace<NUMBER>expressing target cells wang et al <NUMBER> furthermore shown choexpressing sarscov rbd protein containing residues <NUMBER> elicited potent neutralizing antibody response immunized mice complete protective immunity yeastexpressed rbd<NUMBER>n<NUMBER> protein induced strong rbdspecific neutralizing antibody responses pseudovirus live sarscov infections interestingly recombinant rbds proteins tor<NUMBER> gd<NUMBER> sz<NUMBER> representative strains human <NUMBER> <NUMBER> sarscov palm civet sarscov respectively elicited strong crossneutralizing antibodies immunized mice rabbits pseudoviruses expressing proteins virus strains crossneutralization human palm civet sarscov rbdspecific antibodies suggests rbdbased sarscov subunit vaccines able induce broad crossprotective immunity human animal sarscov variants et al <NUMBER> noted high titers rbdspecific neutralizing antibodies persistently existed recovered patients threeyear followup study indicating rbd sarscov highly immunogenic humans cao et al <NUMBER> thus providing basis development effective subunit vaccines prevent sarscov infections humans currently rbdbased subunit vaccine preclinical testing small animal primate animal challenge models anticipation manufacture clinical evaluation next five years jiang et al <NUMBER>a summary suggests paradigm supports development merscov subunit vaccine indicating rbd merscov important target development merscov subunit vaccines like sarscov counterpart induce strong neutralizing antibody responses merscov infection du et al <NUMBER>a zhu et al <NUMBER> based previous experience developing sarscov rbdbased subunit vaccines rapidly identified rbd merscov essential vaccine target mers optimized merscov rbd region identified critical neutralizing domain among five rbd fragments tested induces highest neutralizing antibodies merscov infection et al <NUMBER>b progress development merscov rbdbased subunit vaccines summarized identify rbd merscov initially aligned sequences merscov protein sarscov protein found residues <NUMBER> merscov protein shared similar core structures sarscov rbd increasing likelihood rbd merscov might located region recombinant protein s<NUMBER>fc containing residues <NUMBER> merscov protein fused fc fragment human igg expressed culture supernatant mammalian cell <NUMBER>t purpose forming conformational structures thus increasing immunogenicity du et al <NUMBER>c expected expressed recombinant protein able form high molecularweight molecule shown nonboiled samples sdspage fig <NUMBER>a left recognized merscov s<NUMBER>specific antibodies fig <NUMBER>a right detection binding s<NUMBER>fc receptor merscov dpp<NUMBER> coimmunoprecipitation assay revealed protein bound significantly soluble dpp<NUMBER> sdpp<NUMBER> cellassociated dpp<NUMBER> dpp<NUMBER>expressing huh<NUMBER> cells recognized antidpp<NUMBER> antimerscovs<NUMBER> antibodies respectively fig <NUMBER>b elisa flow cytometry analyses indicated s<NUMBER>fc bound sdpp<NUMBER> huh<NUMBER> dosedependent manner du et al <NUMBER>c data suggest expressed recombinant protein formed conformational structures predicted <NUMBER>amino acid fragment contained merscov rbd evaluation immunogenicity identified merscov rbd demonstrated expressed recombinant s<NUMBER>fc protein induced merscov rbdspecific antibodies mice subcutaneously sc immunized two vaccinations resulting effective neutralization merscov infection vero e<NUMBER> cells vitro du et al <NUMBER>c indicating region may serve essential target developing mers subunit vaccines merscov mucosal pathogen vaccination induces production strong mucosal immune responses represented mucosal iga would increased potential prevention merscov site virus infection test ability identified merscov rbd potential mucosal vaccine immunized mice using merscov s<NUMBER>fc protein via intranasal pathway compared systemic mucosal immune responses neutralizing antibodies induced route elicited sc route evaluation humoral immune response demonstrated intranasal boost vaccination s<NUMBER>fc induced levels merscov s<NUMBER>specific igg antibodies well igg<NUMBER> th<NUMBER> igg<NUMBER>a th<NUMBER> subtypes high induced via sc route although igg antibody elicited pathway proved relatively lower elicited sc route single vaccination et al <NUMBER>a similar immunization sc route intranasal vaccination s<NUMBER>fc also capable eliciting effective longterm igg antibody responses particularly multiple vaccinations fig <NUMBER>c et al <NUMBER>a confirming ability s<NUMBER>fc induce strong humoral immune responses via mucosal route comparison mucosal immune response illustrated intranasal vaccination s<NUMBER>fc induced significantly higher level merscov s<NUMBER>specific iga antibodies induced sc route immunized mouse lungs fig <NUMBER>d although iga level slightly higher immunized mouse sera via route compared sc route et al <NUMBER>a data suggest immunization merscov s<NUMBER>fc protein induced strong local mucosal immune responses route rather sc route serum neutralizing antibody titers intranasal vaccination s<NUMBER>fc protein maintained levels similar either boiled denatured nonboiled nondenatured subjected sdspage followed coomassie blue staining western blot using antimerscovs<NUMBER> antibodies <NUMBER> <NUMBER> developed laboratories protein molecular weight marker kda indicated left b coimmunoprecipitation western blot analysis s<NUMBER>fc binding sdpp<NUMBER> receptor merscov left cellassociated dpp<NUMBER> huh<NUMBER> cells right binding affinity tested using antihuman dpp<NUMBER> monoclonal antibody <NUMBER> gml rd systems minneapolis mn antimerscovs<NUMBER> polyclonal antibodies <NUMBER> <NUMBER> c comparison longterm humoral immune responses induced s<NUMBER>fc protein scand inimmunized mice mouse sera collected <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> months <NUMBER> days postlast boost data presented mean igg endpoint titers ± standard deviation sd five mice per group comparison mucosal immune responses induced s<NUMBER>fc protein scand inimmunized mice mouse lung washes collected <NUMBER> days postlast boost data presented mean iga a<NUMBER> ± sd five mice per group indicates significant differences s<NUMBER>fc group groups p <NUMBER> comparison neutralizing antibody response merscov infection vero e<NUMBER> cells sera e lung washes f mice scand invaccinated s<NUMBER>fc protein neutralizing antibody titers expressed reciprocal highest dilutions samples completely inhibit virusinduced cytopathic effect cpe least <NUMBER> wells nt<NUMBER> samples collected <NUMBER> days postlast boost data presented mean neutralizing antibody titers ± sd five mice per group indicates significant differences s<NUMBER>fc group groups p <NUMBER> cf mice injected pbs plus respective adjuvants montanide isa<NUMBER> sc poly ic included control data presented mean igg a<NUMBER> ± sd duplicate wells c comparison receptor binding affinity rbd fragments sdpp<NUMBER> elisa binding shows dose dependency data presented mean igg a<NUMBER> ± sd duplicate wells comparison immunogenicity rbd fragments immunized mice mouse sera collected <NUMBER> days post<NUMBER>rd vaccination data presented mean igg endpoint titers ± sd five mice per group indicates significant differences s<NUMBER>fc s<NUMBER>fc groups p <NUMBER> e comparison neutralizing antibody response merscov infection vero e<NUMBER> cells rbd fragmentimmunized mice neutralizing antibody titers expressed reciprocal highest dilutions sera completely inhibit virusinduced cpe least <NUMBER> wells nt<NUMBER> mouse sera collected <NUMBER> days post<NUMBER>rd vaccination data presented mean neutralizing antibody titers ± sd five mice per group indicates significant differences s<NUMBER>fc groups p <NUMBER> sc route boost vaccination fig <NUMBER>e however worth noting neutralizing antibodies significantly higher immunized mouse lungs neutralizing merscov infections target vero e<NUMBER> cells via route rather sc route fig <NUMBER>f potentially higher titers mucosal iga antibodies induced inimmunized mouse lungs et al <NUMBER>a noted s<NUMBER>fc protein also able elicit merscov s<NUMBER>specific cellular immune responses immunized mouse spleens et al <NUMBER>a indicating cellular immune response might also play role prevention merscov infection importantly since rbdinduced systemic humoral mucosal immune responses neutralizing antibodies particular correspond protection sarscov infection du et al <NUMBER> expected neutralizing antibodies induced merscov rbd protein correlate well inhibition merscov infection nevertheless based ability merscov rbd protein induce strong systemic mucosal immune responses neutralizing activity expected merscov rbdbased vaccine effective safe mucosal candidate prevention merscov infection addition identified <NUMBER>amino acid fragment containing residues <NUMBER> three additional fragments respectively spanning residues <NUMBER> <NUMBER> <NUMBER> merscov protein defined merscov rbd groups chen et al <NUMBER>b lu et al <NUMBER>a mou et al <NUMBER> wang et al <NUMBER> also shown truncated <NUMBER>amino acid fragment spanning protein residues <NUMBER> merscov served rbd merscov identify critical neutralizing domain merscov rbd ideal mers vaccine candidate compared identified rbd fragments terms antigenicity dpp<NUMBER> receptor binding immunogenicity neutralizing activity order recombinant proteins form suitable conformational structures maintain sufficient bioactivity fused merscov rbd fragments fc human igg expressed proteins mammalian cell expression system fig <NUMBER>a previously strategy implemented proved successful expressing rbd proteins sarscov influenza virus du et al <NUMBER> du et al <NUMBER>d li et al <NUMBER> expected four merscov rbd proteins designated s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc respectively formed dimeric conformational structures maintained good antigenicity et al <NUMBER>b reacting strongly merscov rbdspecific monoclonal antibody mersmab<NUMBER> developed laboratories fig <NUMBER>b although proteins bound efficiently sdpp<NUMBER>and dpp<NUMBER>expressing huh<NUMBER> cells binding affinities notably different s<NUMBER>fc one proteins highest dpp<NUMBER>binding activity fig <NUMBER>c notably s<NUMBER>fc also maintained stronger immunogenicity proteins tested inducing significantly higher igg antibody responses immunized mice fig <NUMBER>d well igg<NUMBER> th<NUMBER> igg<NUMBER>a th<NUMBER> subtypes importantly s<NUMBER>fc protein shown elicit highest neutralizing antibody titers infections merscov fig <NUMBER>e et al <NUMBER>b study identified truncated fragment spanning residues <NUMBER> merscov rbd critical neutralizing domain thus making ideal target development subunit vaccines infections merscov et al <NUMBER>b identification critical neutralizing rbd fragment provides foundation rapid development effective safe subunit vaccines prevent spread merscov humans transmission infected camels humans vaccine candidates proved effective merscov infections vitro culture conditions need evaluated effective animal challenge models confirm protective immunity merscov shown cause transient lower respiratory tract infection rhesus macaques infected monkeys demonstrated clinical signs diseases virus replication histological lesions neutralizing antibody generation de wit et al <NUMBER>b yao et al <NUMBER> demonstrating monkeys used testing efficacy mers candidate vaccines however merscov animal model affordable researchers based high cost purchasing maintaining monkeys making particularly urgent develop small animal models merscov infection studies shown merscov susceptible human nonhuman primate cell types including huh<NUMBER> a<NUMBER> calu<NUMBER> caco<NUMBER> human vero african green monkey susceptible bhk hamster mefc<NUMBER>b<NUMBER> <NUMBER>t<NUMBER> mouse ferret primary kidney cells chan et al <NUMBER>a tao et al <NUMBER> van doremalen et al <NUMBER> findings correspond observation merscov infects human nonhuman primates replicate small animals syrian hamsters mice ferrets coleman et al <NUMBER>b de wit et al <NUMBER>a devitt <NUMBER> raj et al <NUMBER> van doremalen et al <NUMBER> although small animal models merscov still lacking devitt <NUMBER> researchers made great progress towards identification development effective small animal model merscov infections particular shown mice susceptible merscov infection prior transduction adenoviral vector expressing receptor merscov human dpp<NUMBER> infected mice developing pneumonia accompanied inflammatory cell infiltration histopathological changes thus small animal models provide practical platform affordable means evaluating efficacy current merscov vaccines accordingly transgenic dpp<NUMBER> mouse models integrate human dpp<NUMBER> genes mouse genome established several laboratories httpwwwnaturecomnewsbiologistsmakefirstmousemodelformers<NUMBER> expected tested vaccine efficacy near future development effective vaccines urgently needed control spread emerging merscov infections viral vectorbased liveattenuated virusbased vaccines potential providing effective immunity subunit vaccines offer safest means prevention although subunitbased vaccines might induce less immunogenicity vaccine types efficacy significantly improved rational design based structural analysis rbd merscov protein identification stable critical neutralizing fragment rbd eliminating nonneutralizing epitopes immunofocusing et al <NUMBER>b overall strategies development merscov rbdbased subunit vaccines provide useful information design effective vaccines merscov emerging coronaviruses might cause future pandemics expected developed mers candidate vaccines tested efficacy preventing merscov infections vivo affordable small animal models merscov become available serologic neutralization responses proteins merscov sarscov coronaviruses share low levels crossreactivity within andor across subgroups advisable merscov coronavirus vaccines designed considering construction chimeric protein containing neutralizing epitopes variant virus strains authors declared conflict interest middle east respiratory syndrome mers newly emerged infectious disease caused novel βcoronavirus βcov mers coronavirus merscov merscov first identified humans saudi arabia june <NUMBER> <NUMBER> zaki et al <NUMBER> although spread merscov among humans limited merscov infection linked several family clusters healthcare workers memish et al <NUMBER>b memish et al <NUMBER>c providing evidence humantohuman transmissibility virus merscov demonstrated increasing trend infection since first identification sporadic mers cases reported least <NUMBER> countries middle east africa europe asia north america november <NUMBER> <NUMBER> total <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths mortality rate <NUMBER> reported httpwwwwhointcsrdon<NUMBER>november<NUMBER>mersen geographic spread rapid increase mers cases past several months raised concerns pandemic potential even though consequences pandemic might less severe caused severe acute respiratory syndrome coronavirus sarscov another βcov led worldwide outbreak <NUMBER> peiris et al <NUMBER> practical control strategy potential outbreak merscovcaused emerging infectious disease development effective vaccines become high priority number studies pointed transmission hosts merscov reported batderived coronaviruses particularly bat coronavirus hku<NUMBER> close phylogenetic relationship merscov dipeptidyl peptidase <NUMBER> dpp<NUMBER> receptor merscov also receptor hku<NUMBER> hku<NUMBER> prefers bat dpp<NUMBER> human dpp<NUMBER> merscov adapted use human dpp<NUMBER> addition bind bat dpp<NUMBER> suggesting <NUMBER> bats potential natural reservoirs merscov <NUMBER> bat coronaviruses remain threat human health potential crossspecies transmission annan et al <NUMBER> cui et al <NUMBER> ithete et al <NUMBER> memish et al <NUMBER>a yang et al <NUMBER> addition bats camels recently become focus study merscov transmission since merscov neutralizing antibodies merscov gene fragments identified dromedary camels infectious merscov recovered infected camels briese et al <NUMBER> chu et al <NUMBER> drosten et al <NUMBER> haagmans et al <NUMBER> meyer et al <NUMBER> nowotny kolodziejek <NUMBER> fact humans infected merscov exposure infected camels suggests camels likely intermediate transmission hosts merscov recently merscov rna fragments detected air sample collected barn sheltered merscovinfected camels azhar et al <NUMBER> indicating possible airborne transmission merscov animals humans although spread merscov among humans limited inefficient increased infection rate among healthcare workers month april <NUMBER> httpwwwwhointcsrdiseasecoronavirusinfections archiveupdatesen raised concerns future epidemic potential call development effective safe vaccines prevent control mers hotez et al <NUMBER> merscov belongs lineage c βcov close relationship bat coronaviruses hku<NUMBER> hku<NUMBER> first known lineage c βcov associated human infections chan et al <NUMBER>b woo et al <NUMBER> merscov positivesense singlestranded rna virus whose genome encodes four major structural proteins including spike protein envelope protein e membrane protein nucleocapsid n protein unique functions fig <NUMBER>a e protein transmembrane protein forms ion channel viral surface n protein interactively functions protein n molecules encapsulating genomic rna hurst et al <NUMBER> among four structural proteins merscov protein plays important roles virus infection pathogenesis displays trimer viral membrane surface precursor protein cleaved two noncovalently associated subunits distal subunit s<NUMBER> membraneanchored subunit s<NUMBER> merscov s<NUMBER> subunit contains receptorbinding domain rbd including core structure accessory subdomain receptorbinding motif rbm s<NUMBER> subunit consists putative fusion peptide transmembrane domain two heptad repeat regions termed heptad repeats <NUMBER> <NUMBER> hr<NUMBER> hr<NUMBER> fig <NUMBER>b chen et al <NUMBER>b lu et al <NUMBER>a wang et al <NUMBER> although merscov sarscov share similar core structures maintain conformational integrity rbms different chen et al <NUMBER>b li et al <NUMBER> receptors recognized coronaviruses distinctively different angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional receptor sarscov dpp<NUMBER> also known cd<NUMBER> identified receptor merscov li et al <NUMBER> crystal structures sarscov rbd complexed receptor ace<NUMBER> identified rbd sarscov residues <NUMBER> rbm residues <NUMBER> li et al <NUMBER> crystal structure analysis merscov rbd alone rbddpp<NUMBER> complex mapped rbd residues <NUMBER> <NUMBER> respectively protein merscov rbm spanning residues <NUMBER> chen et al <NUMBER>b lu et al <NUMBER>a wang et al <NUMBER> figure <NUMBER> lists crystal structures sarscov merscov rbds complexes respective receptors merscov undergoes two major processes infect target cells first virus binds cellular receptor dpp<NUMBER> via rbd s<NUMBER> subunit second hr<NUMBER>hr<NUMBER> complex s<NUMBER> subunit forms fusion core leading cellvirus membrane fusion thereby mediating merscov entry target cells lu et al <NUMBER> therefore like sarscov protein protein merscov plays essential role receptor binding membrane fusion cell entry previously demonstrated protein specifically rbd sarscov played essential role developing sars vaccines du et al <NUMBER>a jiang et al <NUMBER>b thus expected rbd merscov protein important target developing vaccines mers lu et al <NUMBER>b et al <NUMBER>b antibodies induced sarscov rbd crossneutralize merscov infection since different receptors recognized two coronaviruses suggesting developing safe effective mers vaccine high priority du et al <NUMBER>c since mers newlyemerged viral disease vaccines developed clinical use however number vaccine candidates tested andor proven effective vitro preclinical studies current updates mers vaccine development including possibility developing certain vaccine types candidates mers discussed revealed recombinant modified vaccinia virus ankara mva expressing fulllength merscov protein mvamerss produced neutralizing antibodies immunized mice infections merscov cell cultures vitro song et al <NUMBER> providing basis developing viral vectorbased mers vaccines addition fulllength infectious cdna clones merscov constructed using reverse genetics systems relevant infectious viruses could rescued propagated vero a<NUMBER> huh<NUMBER> human liver cells almazán et al <NUMBER> scobey et al <NUMBER> reports also shown fullgenome sequence merscov jordann<NUMBER> strain exhibited stability sequential passages two mammalian cell lines vero african green monkey kidney mrc<NUMBER> human lung frey et al <NUMBER> studies indicate potential developing liveattenuated viruses mers vaccine candidates moreover reported high titers specific antibodies neutralizing activity generated mice vaccination nanoparticles expressing fulllength merscov protein suggesting possibility developing nanoparticlebased mers vaccines coleman et al <NUMBER>a addition aforementioned vaccine types epitopebased subunit vaccines also show promise merscov infection investigation efficacy example recent studies sequence analysis computational prediction identified immunogenic conserved epitope wdypkcdra rnadirected rna polymerase protein human coronaviruses supporting concept designing developing epitopebased universal vaccines mers sharmin islam <NUMBER> additionally recombinant proteins containing rbd merscov protein able elicit strong neutralizing antibodies vaccinated rabbits mice respectively du et al <NUMBER>c et al <NUMBER>a et al <NUMBER>b mou et al <NUMBER> reinforcing significance developing proteinbased subunit mers vaccines candidate vaccines represent first step control prevention merscov infection subunit vaccines defined based purified proteins peptides consisting major antigenic fragments pathogens hansson et al <NUMBER> subunit vaccines possess variety advantages including high safety profile minimal side effects injection sites constant immune effects welldefined pathogenic fragments du et al <NUMBER> zhang et al <NUMBER> although reports merscov rbdbased subunit vaccines limited subunit vaccines based sarscov rbd extensively studied tested since occurrence sars <NUMBER> showing sufficient efficacy strong protection sarscov infections various animal models du et al <NUMBER> du et al <NUMBER>b et al <NUMBER> zakhartchouk et al <NUMBER> therefore summary sarscov rbdbased subunit vaccines provide useful information specific guidance design effective rbdbased subunit vaccines merscov considerable evidence shown sarscov rbd contains multiple conformationdependent epitopes induce highly potent neutralizing antibodies therefore critical neutralization determinant developing sars subunit vaccines et al <NUMBER>a et al <NUMBER>b believed recombinant fusion protein rbdfc containing rbd residues <NUMBER> sarscov protein fused human igg<NUMBER> fc fragment induced strong antibody responses neutralizing activity elicited longterm protective immunity immunized rabbits mice respectively completely protecting immunized mice sarscov challenge du et al <NUMBER> et al <NUMBER> also identified recombinant rbd proteins residues <NUMBER> expressed mammalian cells <NUMBER>t cho insect cell sf<NUMBER> e coli respectively able elicit sufficient neutralizing antibodies protective immunity sarscov challenge immunized mice among mammalian <NUMBER>t cellexpressed rbd induced higher neutralizing antibody responses expressed insect cell e coli systems du et al <NUMBER>b du et al <NUMBER>c moreover <NUMBER>texpressing rbd capable inducing high titers protective antirbd antibody response immunized nonhuman primates strongly neutralizing proteinmediated sars pseudovirus infection ace<NUMBER>expressing target cells wang et al <NUMBER> furthermore shown choexpressing sarscov rbd protein containing residues <NUMBER> elicited potent neutralizing antibody response immunized mice complete protective immunity yeastexpressed rbd<NUMBER>n<NUMBER> protein induced strong rbdspecific neutralizing antibody responses pseudovirus live sarscov infections interestingly recombinant rbds proteins tor<NUMBER> gd<NUMBER> sz<NUMBER> representative strains human <NUMBER> <NUMBER> sarscov palm civet sarscov respectively elicited strong crossneutralizing antibodies immunized mice rabbits pseudoviruses expressing proteins virus strains crossneutralization human palm civet sarscov rbdspecific antibodies suggests rbdbased sarscov subunit vaccines able induce broad crossprotective immunity human animal sarscov variants et al <NUMBER> noted high titers rbdspecific neutralizing antibodies persistently existed recovered patients threeyear followup study indicating rbd sarscov highly immunogenic humans cao et al <NUMBER> thus providing basis development effective subunit vaccines prevent sarscov infections humans currently rbdbased subunit vaccine preclinical testing small animal primate animal challenge models anticipation manufacture clinical evaluation next five years jiang et al <NUMBER>a summary suggests paradigm supports development merscov subunit vaccine indicating rbd merscov important target development merscov subunit vaccines like sarscov counterpart induce strong neutralizing antibody responses merscov infection du et al <NUMBER>a zhu et al <NUMBER> based previous experience developing sarscov rbdbased subunit vaccines rapidly identified rbd merscov essential vaccine target mers optimized merscov rbd region identified critical neutralizing domain among five rbd fragments tested induces highest neutralizing antibodies merscov infection et al <NUMBER>b progress development merscov rbdbased subunit vaccines summarized mers vaccine developmentto identify rbd merscov initially aligned sequences merscov protein sarscov protein found residues <NUMBER> merscov protein shared similar core structures sarscov rbd increasing likelihood rbd merscov might located region recombinant protein s<NUMBER>fc containing residues <NUMBER> merscov protein fused fc fragment human igg expressed culture supernatant mammalian cell <NUMBER>t purpose forming conformational structures thus increasing immunogenicity du et al <NUMBER>c expected expressed recombinant protein able form high molecularweight molecule shown nonboiled samples sdspage fig <NUMBER>a left recognized merscov s<NUMBER>specific antibodies fig <NUMBER>a right detection binding s<NUMBER>fc receptor merscov dpp<NUMBER> coimmunoprecipitation assay revealed protein bound significantly soluble dpp<NUMBER> sdpp<NUMBER> cellassociated dpp<NUMBER> dpp<NUMBER>expressing huh<NUMBER> cells recognized antidpp<NUMBER> antimerscovs<NUMBER> antibodies respectively fig <NUMBER>b elisa flow cytometry analyses indicated s<NUMBER>fc bound sdpp<NUMBER> huh<NUMBER> dosedependent manner du et al <NUMBER>c data suggest expressed recombinant protein formed conformational structures predicted <NUMBER>amino acid fragment contained merscov rbd evaluation immunogenicity identified merscov rbd demonstrated expressed recombinant s<NUMBER>fc protein induced merscov rbdspecific antibodies mice subcutaneously sc immunized two vaccinations resulting effective neutralization merscov infection vero e<NUMBER> cells vitro du et al <NUMBER>c indicating region may serve essential target developing mers subunit vaccines immune responses neutralizing antibodies induced route elicited sc route evaluation humoral immune response demonstrated intranasal boost vaccination s<NUMBER>fc induced levels merscov s<NUMBER>specific igg antibodies well igg<NUMBER> th<NUMBER> igg<NUMBER>a th<NUMBER> subtypes high induced via sc route although igg antibody elicited pathway proved relatively lower elicited sc route single vaccination et al <NUMBER>a similar immunization sc route intranasal vaccination s<NUMBER>fc also capable eliciting effective longterm igg antibody responses particularly multiple vaccinations fig <NUMBER>c et al <NUMBER>a confirming ability s<NUMBER>fc induce strong humoral immune responses via mucosal route comparison mucosal immune response illustrated intranasal vaccination s<NUMBER>fc induced significantly higher level merscov s<NUMBER>specific iga antibodies induced sc route immunized mouse lungs fig <NUMBER>d although iga level slightly higher immunized mouse sera via route compared sc route et al <NUMBER>a data suggest immunization merscov s<NUMBER>fc protein induced strong local mucosal immune responses route rather sc route serum neutralizing antibody titers intranasal vaccination s<NUMBER>fc protein maintained levels similar sc route boost vaccination fig <NUMBER>e however worth noting neutralizing antibodies significantly higher immunized mouse lungs neutralizing merscov infections target vero e<NUMBER> cells via route rather sc route fig <NUMBER>f potentially higher titers mucosal iga antibodies induced inimmunized mouse lungs et al <NUMBER>a noted s<NUMBER>fc protein also able elicit merscov s<NUMBER>specific cellular immune responses immunized mouse spleens et al <NUMBER>a indicating cellular immune response might also play role prevention merscov infection importantly since rbdinduced systemic humoral mucosal immune responses neutralizing antibodies particular correspond protection sarscov infection du et al <NUMBER> expected neutralizing antibodies induced merscov rbd protein correlate well inhibition merscov infection nevertheless based ability merscov rbd protein induce strong systemic mucosal immune responses neutralizing activity expected merscov rbdbased vaccine effective safe mucosal candidate prevention merscov infection addition identified <NUMBER>amino acid fragment containing residues <NUMBER> three additional fragments respectively spanning residues <NUMBER> <NUMBER> <NUMBER> merscov protein defined merscov rbd groups chen et al <NUMBER>b lu et al <NUMBER>a mou et al <NUMBER> wang et al <NUMBER> also shown truncated <NUMBER>amino acid fragment spanning protein residues <NUMBER> merscov served rbd merscov identify critical neutralizing domain merscov rbd ideal mers vaccine candidate compared identified rbd fragments terms antigenicity dpp<NUMBER> receptor binding immunogenicity neutralizing activity order recombinant proteins form suitable conformational structures maintain sufficient bioactivity fused merscov rbd fragments fc human igg expressed proteins mammalian cell expression system fig <NUMBER>a previously strategy implemented proved successful expressing rbd proteins sarscov influenza virus du et al <NUMBER> du et al <NUMBER>d li et al <NUMBER> expected four merscov rbd proteins designated s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc respectively formed dimeric conformational structures maintained good antigenicity et al <NUMBER>b reacting strongly merscov rbdspecific monoclonal antibody mersmab<NUMBER> developed laboratories fig <NUMBER>b although proteins bound efficiently sdpp<NUMBER>and dpp<NUMBER>expressing huh<NUMBER> cells binding affinities notably different s<NUMBER>fc one proteins highest dpp<NUMBER>binding activity fig <NUMBER>c notably s<NUMBER>fc also maintained stronger immunogenicity proteins tested inducing significantly higher igg antibody responses immunized mice fig <NUMBER>d well igg<NUMBER> th<NUMBER> igg<NUMBER>a th<NUMBER> subtypes importantly s<NUMBER>fc protein shown elicit highest neutralizing antibody titers infections merscov fig <NUMBER>e et al <NUMBER>b study identified truncated fragment spanning residues <NUMBER> merscov rbd critical neutralizing domain thus making ideal target development subunit vaccines infections merscov et al <NUMBER>b identification critical neutralizing rbd fragment provides foundation rapid development effective safe subunit vaccines prevent spread merscov humans transmission infected camels humans vaccine candidates proved effective merscov infections vitro culture conditions need evaluated effective animal challenge models confirm protective immunity merscov shown cause transient lower respiratory tract infection rhesus macaques infected monkeys demonstrated clinical signs diseases virus replication histological lesions neutralizing antibody generation de wit et al <NUMBER>b yao et al <NUMBER> demonstrating monkeys used testing efficacy mers candidate vaccines however merscov animal model affordable researchers based high cost purchasing maintaining monkeys making particularly urgent develop small animal models merscov infection studies shown merscov susceptible human nonhuman primate cell types including huh<NUMBER> a<NUMBER> calu<NUMBER> caco<NUMBER> human vero african green monkey susceptible bhk hamster mefc<NUMBER>b<NUMBER> <NUMBER>t<NUMBER> mouse ferret primary kidney cells chan et al <NUMBER>a tao et al <NUMBER> van doremalen et al <NUMBER> findings correspond observation merscov infects human nonhuman primates replicate small animals syrian hamsters mice ferrets author manuscript author manuscript coleman et al <NUMBER>b de wit et al <NUMBER>a devitt <NUMBER> raj et al <NUMBER> van doremalen et al <NUMBER> although small animal models merscov still lacking devitt <NUMBER> researchers made great progress towards identification development effective small animal model merscov infections particular shown mice susceptible merscov infection prior transduction adenoviral vector expressing receptor merscov human dpp<NUMBER> infected mice developing pneumonia accompanied inflammatory cell infiltration histopathological changes thus small animal models provide practical platform affordable means evaluating efficacy current merscov vaccines accordingly transgenic dpp<NUMBER> mouse models integrate human dpp<NUMBER> genes mouse genome established several laboratories httpwwwnaturecomnewsbiologistsmakefirstmousemodelformers<NUMBER> expected tested vaccine efficacy near future development effective vaccines urgently needed control spread emerging merscov infections viral vectorbased liveattenuated virusbased vaccines potential providing effective immunity subunit vaccines offer safest means prevention although subunitbased vaccines might induce less immunogenicity vaccine types efficacy significantly improved rational design based structural analysis rbd merscov protein identification stable critical neutralizing fragment rbd eliminating nonneutralizing epitopes immunofocusing et al <NUMBER>b overall strategies development merscov rbdbased subunit vaccines provide useful information design effective vaccines merscov emerging coronaviruses might cause future pandemics expected developed mers candidate vaccines tested efficacy preventing merscov infections vivo affordable small animal models merscov become available serologic neutralization responses proteins merscov sarscov coronaviruses share low levels crossreactivity within andor across subgroups advisable merscov coronavirus vaccines designed considering construction chimeric protein containing neutralizing epitopes variant virus strains agnihothram et al <NUMBER> either boiled denatured nonboiled nondenatured subjected sdspage followed coomassie blue staining western blot using antimerscovs<NUMBER> antibodies <NUMBER> <NUMBER> developed laboratories protein molecular weight marker kda indicated left b coimmunoprecipitation western blot analysis s<NUMBER>fc binding sdpp<NUMBER> receptor merscov left cellassociated dpp<NUMBER> huh<NUMBER> cells right binding affinity tested using antihuman dpp<NUMBER> monoclonal antibody <NUMBER> μgml rd systems minneapolis mn antimerscovs<NUMBER> polyclonal antibodies <NUMBER> <NUMBER> c comparison longterm humoral immune responses induced presented mean igg endpoint titers ± sd five mice per group indicates significant differences s<NUMBER>fc s<NUMBER>fc groups p <NUMBER> e comparison neutralizing antibody response merscov infection vero e<NUMBER> cells rbd fragmentimmunized mice neutralizing antibody titers expressed reciprocal highest dilutions sera completely inhibit virusinduced cpe least <NUMBER> wells nt <NUMBER> mouse sera collected <NUMBER> days post<NUMBER>rd vaccination data presented mean neutralizing antibody titers ± sd five mice per group indicates significant differences s<NUMBER>fc groups p <NUMBER> primary sequence sarscov<NUMBER> protein retrieved ncbi database using accession number mn<NUMBER> <NUMBER> experimentally known <NUMBER>d structure sarscov<NUMBER> protein pdb id <NUMBER>vsb n protein pdb id <NUMBER>vyo retrieved protein data bank <NUMBER> <NUMBER>d structure protein available yet predicted interaction conformation rbd sarscov<NUMBER> protein human ace<NUMBER> retrieved recent report <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein sequence analyzed chemicals physical properties including gravy grand average hydropathicity halflife molecular weight stability index amino acid atomic composition via online tool protparam <NUMBER> tmhmm v<NUMBER> httpwwwcbsdtudkservicestmhmm applied examine transmembrane topology protein secondary structure sarscov<NUMBER> n protein analyzed psipred <NUMBER> existence disulfidebonds examined online tool dianna v<NUMBER> uses trained neural system make predictions <NUMBER> antigenicity fulllength n protein evaluated vaxijen v<NUMBER> <NUMBER> iedb immuneepitopedatabase analysisresource <NUMBER> used predict linear bcell epitopes using bepipred bepipred<NUMBER> default parameter settings kolaskar tongaonkar antigenicity parker hydrophilicity chou fasman betaturn karplus schulz flexibility bcepred <NUMBER> also used predict linear bcell epitopes using accessibility antigenic propensity exposed surface flexibility hydrophilicity polarity turns predicted linear bcell epitopes iedb bcepred combined linear bcell epitope candidate list based transmembrane topology protein predicted tmhmm v<NUMBER> epitopes outer surface remained intracellular epitopes eliminated vaxijen <NUMBER> <NUMBER> applied evaluate antigenicity remained epitopes stringent criterion used epitopes antigenicity score <NUMBER> viewed adequate initiate defensive immune reaction bcell discontinuous epitope forms antigenbinding interface fragments scattered along protein sequence discotope<NUMBER> <NUMBER> discotope score threshold <NUMBER> used predict discontinuous epitopes <NUMBER>d structure protein available opensource pymol used examine positions selected linear discontinuous epitopes <NUMBER>d structure sarscov<NUMBER> protein interacting conformation protein rbd human ace<NUMBER> <NUMBER> <NUMBER> <NUMBER> peptidebindingtomhcclassimolecules tool iedb hla class set <NUMBER> utilized predict mhc class binding tcell epitopes peptidebindingtomhcclassiimolecules tool iedb hla class ii set <NUMBER> utilized predict tcell epitopes percentile rank threshold <NUMBER> mhc class binding epitopes <NUMBER> mhc class ii binding epitopes used filter peptideallele weak binding affinity antigenicity score epitope calculated vaxijen v<NUMBER> high stringent standard used filter peptides antigenicity score larger equal <NUMBER> number binding alleles larger equal <NUMBER> mhc class binding epitopes <NUMBER> mhc class ii binding epitopes <NUMBER> top prediction chosen total <NUMBER> epitopeprotein interaction reports pepattract <NUMBER> adopted estimate docking score peptide corresponding hla allele consurf <NUMBER> used examine conservation status residue sarscov<NUMBER> analyzing amino acid sequences n protein seven known coronaviruses including sarscov protein important target vaccine development important function entering host cell protein n protein coronavirus also reported generate immunogenic epitopes table <NUMBER> antigenicity analysis fulllength protein vaxijen confirmed expected antigens antigenicity score <NUMBER> protein <NUMBER> protein <NUMBER> n protein proteins transmembrane protein transmembrane protein topologies therefore predicted tmhmm protein respectively residues <NUMBER> <NUMBER> exposed surface residues <NUMBER> <NUMBER> inside transmembraneregion residues <NUMBER> <NUMBER> within coreregion protein supplementary fig <NUMBER>a <NUMBER> residues exposed surface <NUMBER> residues inside transmembraneregion <NUMBER> residues within coreregion protein supplementary fig<NUMBER>a bcell epitopes bind antigen receptors surface b cells n protein inside virus considering protein transmembrane proteins attempted predict bcell epitopes protein even neutralization activity well known protein downstream analysis predicted tcell epitopes n protein bcell epitopes guide bcell recognize activate defense responses viral infection recognition bcell epitopes depended predictions linear epitopes antigenicity hydrophilicity accessibility surface betaturn flexibility <NUMBER> bcell epitopes protein predicted methods default settings provided iedb <NUMBER> including bcepred <NUMBER> used predict bcell epitopes using accessibility antigenic propensity exposed surface flexibility hydrophilicity polarity turns overall obtained total <NUMBER> <NUMBER> linear bcell epitopes protein respectively supplementary table <NUMBER>b vaxijen v<NUMBER> used estimate antigenicity linear bcell epitopes resulting total <NUMBER> <NUMBER> epitopes protein antigenicity score larger equal <NUMBER> respectively supplementary table <NUMBER>c based transmembrane topology protein predicted tmhmm v<NUMBER> intracellular epitopes eliminated result <NUMBER> linear bcell epitopes protein retained candidates supplementary table <NUMBER>c kcvnfnfngltg located rbd region spike head exposed region table <NUMBER> fig <NUMBER>c based predicted interacting conformation rbd domain sarscov<NUMBER> protein ace<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> ten linear bcell epitopes spike head substantially overlaps interacting surface ace<NUMBER> binds rbd <NUMBER> <NUMBER> <NUMBER> demonstrating antibody binding surface may block viral entry cells fig <NUMBER>d examining antigenicity recently reported bcell epitopes <NUMBER> <NUMBER> discovered except one epitope orf<NUMBER>a antigenicity score qgeikdatpsdf <NUMBER> supplementary table <NUMBER>d much less antigenicity score ten linear bcell epitopes identified exposed region spike protein antigenicity scores ranging <NUMBER> <NUMBER> table <NUMBER> <NUMBER>d structure protein available discontinuous bcell epitopes predicted protein discotope <NUMBER> using b c chain <NUMBER>d structure protein pdb id <NUMBER>vsb positions discontinuous epitopes mapped surface <NUMBER>d structure protein fig <NUMBER>a supplementary fig <NUMBER> discontinuous bcell epitopes mapped fullyexposed spike head region fig <NUMBER>b supplementary table <NUMBER> exposed spike stem region located spike root region supplementary table <NUMBER>e main discontinuous bcell epitopes spike head region overlapped interacting surface ace<NUMBER> binding protein fig <NUMBER>c suggesting roles blocking virus fusion cells j u r n l p r e p r f ten linear bcell epitopes rbd protein predicted nonallergen nontoxin examined hydrophobicity hydropathicity hydrophilicity charge support vector machine svm based method toxinpred supplementary table <NUMBER>a stability ten linear bcell epitopes evaluated number peptidedigesting enzymes protein digest server httpdbsystemsbiologynet<NUMBER>proteomicstoolkitproteindigesthtml nondigesting enzymes predicted epitope suggests potentially higher stability ten linear bcell epitopes found multiple nondigesting enzymes varying <NUMBER> <NUMBER> enzymes supplementary table <NUMBER>b peptidebindingtomhcclassimolecules tool iedb hla class set <NUMBER> utilized predict tcell epitopes protein percentile rank threshold <NUMBER> used filter peptideallele weak binding affinity antigenicity score peptide calculated vaxijen v<NUMBER> evaluate antigenicity peptide high antigenicity score capacity bind larger number alleles considered high potentials initiate strong defense response high stringent criteria used filter peptides antigenicity score larger equal <NUMBER> number binding alleles larger equal <NUMBER> utilizing evaluating method obtained total <NUMBER> mhc classi allele binding peptides n protein supplementary table <NUMBER>a allergenicity tcell epitopes assessed allergen fp <NUMBER> results showed two nine three nine two nine mhc classi binding peptides n protein probably nonallergen respectively supplementary table <NUMBER>a c nine thirteen nine thirteen mhc classii binding peptides protein predicted nonallergen respectively supplementary table <NUMBER>a c toxicity tcell epitopes along hydrophobicity hydropathicity hydrophilicity charge evaluated toxinpred two tcell epitopes predicted nontoxin supplementary table <NUMBER>a c stability tcell epitopes evaluated number peptides digesting enzymes protein digest server tcell epitopes kmkdlsprwy found multiple nondigesting enzymes varying <NUMBER> <NUMBER> enzymes supplementary table <NUMBER>a fig <NUMBER>ab fig <NUMBER> highly conserved exposed residues mainly located <NUMBER> <NUMBER> protein supplementary fig <NUMBER> <NUMBER> <NUMBER> protein supplementary fig <NUMBER> <NUMBER> <NUMBER> n protein supplementary fig <NUMBER> particularly epitopes without allergenicity toxicity containing one functional residue highly conserved exposed included bcell table <NUMBER> mutations observed nonallergenic nontoxic tcell epitopes n protein emergence sarscov<NUMBER> serious health threat whole society thus urgent need drugs preventative measures sarscov<NUMBER> infection characterized lung infections symptoms including fever cough shortness breath based information cdc centers disease control prevention symptoms appear <NUMBER> days long <NUMBER> days exposure virus transmit human human contact infected surfaces objects <NUMBER> <NUMBER> <NUMBER> essential identify immune epitopes quickly possible protein crucial fuse entry virus host cells <NUMBER> therefore primary target neutralizing antibodies specificity epitopebased vaccines enhanced selecting parts protein exposed surface <NUMBER> medical biotechnology important developing vaccines sarscov<NUMBER> <NUMBER> computerbased immuneinformatics improve time economic effectiveness therefore also essential method immunogenic analysis vaccine development study characterized physiochemical characteristics sarscov<NUMBER> viral genome epitope candidates adopted immuneinformatics based pipeline highly stringent criteria identify s，m n protein targeted band tcell epitopes may potentially promote immune response host antigenicity flexibility solvent accessibility disulfide bonds predicted epitopes evaluated yielding small repertoire potential bcell epitope vaccine candidates allergenicity toxicity analysis suggested ten linear bcell epitopes rbd region nonallergen nontoxin stability analysis revealed digested multiple enzymes also two mhc classi nine mhc classii binding tcell epitopes predicted interact numerous hla alleles highly antigenic allergenicity toxicity physiochemical properties tcell epitopes analyzed increase specificity selectivity stability safety confirmed digestion analysis conservation anlaysis seven known coronaviruses revealed rbd region conserved mutations generated <NUMBER> sequences sarscov<NUMBER> ngdc database observed five ten linear bcell epitopes rbd region band tcell mhc class ii epitopes without mutations would considered vaccine candidates full potentials antigenicity predict band tcell epitopes identified may assist development potent peptidebased vaccines address sarscov<NUMBER> challenge particularly epitopes without mutations conserved regions could generate immunity crossprotective across beta coronaviruses also relatively resistant ongoing virus evolution <NUMBER> epitopes predicted also potentially used design sensitive serological assays epidemiological vaccine efficiency assessments replication sarscov<NUMBER> must errorprone similar sarscov reported mutation rate <NUMBER>x<NUMBER> <NUMBER> substitutionssiteyear <NUMBER> antiviral vaccines necessary developed predicted epitopes potentially obsolete moreover immuneinformatics based pipeline also provides framework identify band tcell epitopes sarscov<NUMBER> limited specific virus time also mention limitations predicting tcell epitopes prerequisite epitope elicit cell response epitope bind mhc alleles cell receptors however binding prediction mhc alleles epitope relatively accurate binding epitope cell receptors extremely difficult j u r n l p r e p r f predicted short results useful guide design evaluation efficient specific serological assays epitopes well help prioritize vaccine target designs unprecedented crisis <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> highly contagious respiratory disease resulting lifethreatening novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> spread rapidly throughout globe causing <NUMBER> million infections <NUMBER> thousand deaths early may <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> enveloped rna virus belongs genus betacoronavirus family coronaviridae includes wellknown severe acute respiratory syndrome coronavirus sarscov well middle east respiratory syndrome coronavirus merscov <NUMBER> advancement management coronaviruses viruses like influenza virus h<NUMBER>n<NUMBER> ebola infections provided insight treating covid<NUMBER> <NUMBER> active clinical trials covid<NUMBER> performed <NUMBER> <NUMBER> chloroquine <NUMBER> <NUMBER> hydroxyl analogue hydroxychloroquine <NUMBER> lopinavirritonavir <NUMBER> <NUMBER> <NUMBER> remdesivir <NUMBER> <NUMBER> developed treating malaria human immunodeficiency virus hiv ebola virus respectively provided benefits treat covid<NUMBER> tested ongoing trials although covid<NUMBER> less fatal sars mers older patients comorbidities tend experience severe symptoms making vulnerable majority sarscov<NUMBER> infected patients displayed mild symptoms generally good prognosis classified mild covid<NUMBER> <NUMBER> <NUMBER> however large proportion patients especially among older men underlying chronic diseases rapidly progressed severe covid<NUMBER> suffered respiratory distress requiring emergent medical interventions <NUMBER> unfortunately evidence randomized clinical trials supporting vaccines efficient treatment covid<NUMBER> <NUMBER> <NUMBER> additionally recent studies shown important roles host immune responses protection pathogenesis respiratory viral infections instance sarscov merscov influenza viruses <NUMBER> <NUMBER> liao et al <NUMBER> reported increased immune cell recruitment covid<NUMBER> patients suggested crucial role cd<NUMBER> cells successful viral control proposed support therapeutic strategies target myeloid cell compartment treat covid<NUMBER>associated inflammation however little known drug screens diseaserelevant cell types drug repurposing essential universal strategy development new drugs <NUMBER> may facilitate discovery new mechanisms action existing drugs less timeconsuming costeffective let alone existing pharmaceutical supply chains formulation distribution <NUMBER> <NUMBER> considering rna virus exhibits considerable degree sequence variation drugs targeting host factors may cause less mutational resistance effective broad antivirus spectrum potential hence urgent need identify potential therapeutics new strategies emerging infectious diseases repurposing clinically assessed drugs represents one practicable strategies rapid identification treatments combat covid<NUMBER> study analyzed publicly available singlecell rna sequencing scrnaseq dataset bronchoalveolar lavage fluid balf collected mild severe cases well bulk rnaseq balf covid<NUMBER> patients different experiments figure <NUMBER> data mining performed using library integrated networkbased cellular signatures lincs <NUMBER> drug perturbation database identify potential therapies covid<NUMBER> disease total <NUMBER> candidates different courses covid<NUMBER> independent cell subtypes identified <NUMBER> clinical trials covid<NUMBER> including lopinavirritonavir <NUMBER> dexamethasone niclosamide lenalidomide hydrocortisone metformin atorvastatin sildenafil verapamil subsequently utilized side effect prediction based l<NUMBER> sepl<NUMBER> project predict adverse drug reactions adrs constructed drugadr association <NUMBER> <NUMBER> findings may aid rapid preclinical clinical evaluation therapeutics provide important drug discovery pipeline accelerate facilitate development potential treatments covid<NUMBER> genebarcode matrix files <NUMBER> donors containing <NUMBER> mild cases <NUMBER> severe cases lung balf <NUMBER> healthy control lung tissues downloaded ncbi gene expression omnibus database accession id gse<NUMBER> <NUMBER> expression matrices loaded r statistical analysis platform using seurat v<NUMBER> <NUMBER> keeping cells gene number <NUMBER> <NUMBER> unique molecular identifier umi count <NUMBER> mitochondrial gene percentage <NUMBER> total <NUMBER> cells collected three healthy subjects three mild covid<NUMBER> patients three severe covid<NUMBER> patients used analyses also collected list differentially expressed genes degs sarscov<NUMBER>infected lung balf using bulk rnaseq analysis compare singlecellbased data deg list obtained chinese national genomics data center httpsbigdbigaccn accession id cra<NUMBER> <NUMBER> lognormalize method seurat used normalizing filtered genebarcode matrix principal component analysis pca done using top <NUMBER> variable genes uniform manifold approximation projection umap performed top <NUMBER> principal components visualizing cells graphbased clustering performed pcareduced data seurat v<NUMBER> <NUMBER> mast seurat v<NUMBER> used perform differential analysis degs identified comparing cluster three groups genes average log<NUMBER>fc <NUMBER> adjusted pvalue <NUMBER> deemed degs degs first sorted log<NUMBER>fc values upregulated downregulated genes chosen identify drugs compounds lincs database using connectivity map linked user environment clue platform <NUMBER> drug connectivity score cs negative value smaller <NUMBER> used determine candidate drugs compounds covid<NUMBER> database international clinical trials registry platform ictrp httpswwwwhointictrpen updated may <NUMBER> th <NUMBER> searched clinical trials information associated drugs onlabel offlabel adverse drug reactions adrs candidate drugs collected sepl<NUMBER> database httpsmaayanlabnetsepl<NUMBER> sepl<NUMBER> data include onlabel adrs fdaapproved drugs collected sider <NUMBER> offlabel adrs pharmgkb database <NUMBER> based postmarketing adr reports fda adverse event report system faers study highlighted identification different therapeutic effects varied disease course high variability cellular compartments underlying disease progression drug repurposing profiles major cell subtypes included b nk cells macrophages epithelial cells total <NUMBER> scrnaseq balf samples including <NUMBER> healthy cases <NUMBER> mild cases <NUMBER> severe cases collected publicly available scrnaseq data supplemental table s<NUMBER> quality filtering approximately <NUMBER> gene expression values <NUMBER> cells collected clustering analysis identified six major clusters macrophage nk figure s<NUMBER> determined based unique signature genes cd<NUMBER> macrophage cell il<NUMBER>r cd<NUMBER> cd<NUMBER> cell cd<NUMBER>a cd<NUMBER> cell ms<NUMBER>a<NUMBER> b cells tppp<NUMBER> epithelial cells respectively supplemental figure s<NUMBER> compared six major clusters across healthy mild severe covid<NUMBER> cases identified differentially expressed genes two courses supplemental tables s<NUMBER>s<NUMBER> connecting lincs database smallmolecule perturbations gene expression identified candidate drugs compounds reverse upregulated downregulated genes via clue platform closer cs <NUMBER> score indicating complete reversal higher chance identification drugadverse effect associations upregulated downregulated degs words drugs may show better response reverse expression degs upregulated downregulated major cell subtypes balf total <NUMBER> candidates selected clue cs lower <NUMBER> based degs among three comparisons two courses supplementary table s<NUMBER> enable prioritization known drugs preclinical clinical evaluation therapy efficiency sarscov<NUMBER> summary among major cell subtypes patients disease course publicly disclosed clinical trial phases annotated tables <NUMBER> supplementary table s<NUMBER> provides complete list potential anticoronavirus agents current analysis focusing fda approved drugs experimental agents already tested clinical trials select candidates mild cases drugs compounds ranked according css supplementary table s<NUMBER> <NUMBER> candidate drugs identified compared controls mild vs healthy group <NUMBER> involved one cell subtype table <NUMBER> including hiv protease inhibitors lopinavirritonavir <NUMBER> combination phase <NUMBER> glucocorticoid receptor agonist dexamethasone phase <NUMBER> <NUMBER> dna replication inhibitor niclosamide phase <NUMBER> antineoplastic lenalidomide phase <NUMBER> tubulin inhibitor flubendazole widely used treating intestinal parasites potent inducer autophagy initiation decrease infection dendritic cells hiv <NUMBER> azacytidine could partially reverse aberrant dna methylation phase clinical trial combination chemotherapy conducted assess therapeutic effects children leukemia combination apr<NUMBER> myelodysplastic syndrome phase <NUMBER> clinical trial <NUMBER> bcl inhibitor abt<NUMBER> exhibits potential proapoptotic antineoplastic activities <NUMBER> <NUMBER> lopinavir widely used treatment hiv formulated combination ritonavir increase halflife lopinavir <NUMBER> <NUMBER> <NUMBER> repurposing analysis severe covid<NUMBER> patients <NUMBER> potent drugs also selected severe cases compared controls severe vs healthy group according average cs replicates <NUMBER> involved one cell subtype figure <NUMBER>b supplementary tables s<NUMBER> s<NUMBER> listed table <NUMBER> protein synthesis inhibitor brefeldina used inhibit entry viruses like human papillomavirus polyomavirus <NUMBER> egress others herpesviruses paramyxoviruses <NUMBER> indirubin active ingredient traditional chinese medicine tcm danggui longui wan potent activity myelocytic leukemia <NUMBER> therapeutic potential iavinfection <NUMBER> total <NUMBER> candidate drugs identified severe cases compared mild ones severe vs mild group <NUMBER> involved one cell subtype figure <NUMBER>c supplementary tables s<NUMBER> s<NUMBER> listed table <NUMBER> nine drugs drugs selected three separate cell types including fostamatinib syk inhibitor ver<NUMBER> hsp inhibitor ku<NUMBER> mtor inhibitor pik<NUMBER> pi<NUMBER>k inhibitor linsitinib igf<NUMBER> inhibitor tak<NUMBER> p<NUMBER> mapk inhibitor y<NUMBER> rhoassociated kinase inhibitor az<NUMBER> raf inhibitor lestaurtinib flt<NUMBER> inhibitor group except lopinavir also following listed <NUMBER> drugs clinical trials treatment covid<NUMBER> table <NUMBER> syk inhibitor fostamatinib produced clinicallymeaningful responses adult persistent chronic immune thrombocytopenia two parallel phase <NUMBER> randomized trials <NUMBER> hsp inhibitor ver<NUMBER> regulates kaposis sarcomaassociated herpesvirus lytic replication highlights potential novel antiviral agent <NUMBER> flt<NUMBER> inhibitor lestaurtinib obtained orphan drug approval fda acute myeloid leukemia <NUMBER> phase ii trial advanced multiple myeloma phase trials prostate cancer shown figures <NUMBER>a <NUMBER>b supplemental table s<NUMBER> lopinavir one identified three comparisons interestingly ritonavir common two analyses <NUMBER> additional common drugs sb<NUMBER> abt<NUMBER> jte<NUMBER> brefeldina pkcbetainhibitor indirubin gw<NUMBER> flubendazole tyrphostinag<NUMBER> memantine calyculin kinetinriboside ascorbylpalmitate on<NUMBER> mirin verrucarina emetine tpca<NUMBER> rhokinaseinhibitoriiirockout pd<NUMBER> nvpauy<NUMBER> example glycogen synthase kinase inhibitor sb<NUMBER> acts neuroprotectant <NUMBER> prevents cardiac ischemia <NUMBER> jte<NUMBER> cannabinoid receptor inverse agonist producing antiinflammatory effects <NUMBER> demonstrate usefulness strategy accomplished identification therapeutic drugs transcriptional changes balf covid<NUMBER> patients bulk rnaseq data <NUMBER> ten efficient candidates identified using analysis pipeline two including glycogen synthase kinase inhibitor sb<NUMBER> ppar receptor antagonist gw<NUMBER> also included singlecellbased candidate lists supplemental table s<NUMBER> investigations necessary characterize adrs central consideration drug development <NUMBER> therefore conducted computational approach using sepl<NUMBER> database predictive relationships drugs emergence adrs supplemental tables s<NUMBER> s<NUMBER> figure <NUMBER> shows heatmap top <NUMBER> drugadr association onlabel figure <NUMBER>a offlabel figure <NUMBER>b adrs findings highlighted drugadr associations may lead inform clinical decisions regarding treatments covid<NUMBER> covid<NUMBER> spread rapidly proven vaccine drug yet identified treat generally speaking several ways control prevent emerging coronavirus disease including antivirals smallmolecule drugs biologics vaccines <NUMBER> <NUMBER> due lack effective therapeutic agents long development cycles vaccines therefore reasonable consider repurposing existing drugs compounds covid<NUMBER> drug repurposing potentially important strategy discovery existing medicines tackle covid<NUMBER> <NUMBER> gordon et al <NUMBER> identified <NUMBER> highconfidence sarscov<NUMBER>human proteinprotein interactions drug repurposing additional study <NUMBER> tested antiviral activity <NUMBER> fda approved drugs sarscov<NUMBER> previously shown inhibit sarscov merscov another research team <NUMBER> conducted highthroughput analysis reframe library identify <NUMBER> candidates existing drugs prevent covid<NUMBER> virus replicating mammalian cells study <NUMBER> based public data patients pulmonary fibrosis database lincs several drugs identified covd<NUMBER> targets ace<NUMBER> host immune responses particularly important protection pathogenesis respiratory viral infections like sarscov merscov influenza viruses <NUMBER> <NUMBER> liao et al <NUMBER> observed nk cells accumulated epithelial cells decreased covid<NUMBER> patients compared controls meanwhile macrophages dysregulated cell compartments differed mild severe disease courses nk cells decreased severe cases cd<NUMBER> cells increased mild cases however drug screening diseaserelevant cell types still unclear analyzed publicly available data covid<NUMBER> patients performed data mining using lincs l<NUMBER> database identify potential therapies covid<NUMBER> disease sepl<NUMBER> database predict side effects approach different previous methods drug repurposing coronavirus since merely rapidly identify likely effective therapeutic agents preventing treating covid<NUMBER> tries filter specific medications patients disease courses furthermore data transcriptome derived human samples real patients two independent sets experiments lastly explore underlying risk factors associated side effects candidates overall data guide future development therapies different durations covid<NUMBER> viral respiratory infections study several limitations note first public scrnaseq data small number clinical samples n<NUMBER> without available patient information makes comparisons studies difficult fast pace expected large number published literature using patient samples candidate lists may need revised second findings may apply children sequencing data adults future work largescale data mining would help us better identification antiviral drugs pandemic covid<NUMBER> represents greatest global public health crisis generation far proven vaccines therapies identified based study thoroughly investigated potential candidates treatment covid<NUMBER> progression predicted possible adverse effects findings guide additional repurposing studies tailored different stages disease progression authors declare competing interests jh ch mw kg designed project collected data performed analysis prepared figures kg zw collected data prepared figures wrote manuscript pg performed analysis prepared tables qp revised manuscript work partially supported national institutes health p<NUMBER>gm<NUMBER> pilot grant jh codes data available httpsgithubcomguokai<NUMBER>covid<NUMBER> table <NUMBER> list potential drugs treating covid<NUMBER> based lincs database degs mild healthy samples b cd<NUMBER> cd<NUMBER> epithelial nk cells macrophage connectivity scores calculated clue platform asterisk represents clinical trial efficacy covid<NUMBER> disease indicates drugs meeting sc <NUMBER> criteria indicates drugs meeting criterion table <NUMBER> list potential drugs treating covid<NUMBER> based lincs database degs severe mild samples b cd<NUMBER> cd<NUMBER> epithelial nk cells macrophage connectivity scores calculated clue platform asterisk represents clinical trial efficacy covid<NUMBER> disease indicates drugs meeting sc <NUMBER> criteria indicates drugs meeting criterion input publicly available scrnaseq data transcriptomic data balf covid<NUMBER> patients lincs database using clue platform candidates selected emerging infectious disease middle east respiratory syndrome mers caused mers coronavirus merscov first identified <NUMBER> saudi arabia <NUMBER> since spread countries including united states july <NUMBER> <NUMBER> <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths httpwwwwhointcsrdon <NUMBER>mersen raising serious concerns pandemic potential <NUMBER> <NUMBER> bats dromedary camels likely natural reservoir intermediate transmission host respectively <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov poses longterm threat human health <NUMBER> <NUMBER> thus need development effective prophylactic strategies vaccines control spread merscov urgent spike protein merscov plays important roles mediating viral entry host cells <NUMBER> first step cell entry defined receptorbinding domain rbd spike proteins binds functional receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> host cell surface viral attachment <NUMBER> several versions merscov rbd fragments identified different groups rbd fragments encompass spike residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> extensive studies found spike rbd sars coronavirus sarscov caused sars epidemic <NUMBER> <NUMBER> critical neutralizing receptorbinding domain attractive subunit vaccine candidate sarscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> likely merscov rbd could also serve subunit vaccine candidate merscov infection indeed previously shown merscov rbd fragments immunogenic animals resulting neutralizing antibody responses <NUMBER> <NUMBER> however clear one rbd fragments represents ideal vaccine candidate mechanism behind potential differences neutralizing abilities rbd fragments study expressed merscov rbd fragments fused fc fragment human igg investigated receptor binding affinity antigenicity immunogenicity neutralizing potential found rbd fragment neutralizing potential explained mechanism behind overall study identified ideal vaccine candidate controlling merscov infections enhanced understanding design strategies vial subunit vaccines fourto sixweekold female balbc mice fourto fivemonthold female nzw rabbits used study animal studies carried strict accordance recommendations guide care use laboratory animals national institutes health animal protocol approved committee ethics animal experiments new york blood center permit number <NUMBER> construction expression purification recombinant merscov rbd fragments fc human igg done previously described modifications <NUMBER> <NUMBER> briefly genes encoding residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov protein respectively amplified pcr using codonoptimized merscov sequences genbank afs<NUMBER> template inserted pfusehigg<NUMBER>fc<NUMBER> expression vector hereinafter named fc invivogen san diego ca merscov s<NUMBER> residues <NUMBER> plus cterminal <NUMBER> s<NUMBER>his amplified inserted pjw<NUMBER> expression vector jiangsu taizhou haiyuan protein biotech co ltd china recombinant plasmids transfected <NUMBER>t cells atcc manassas va changed fresh serumfree dmem invitrogen carlsbad ca <NUMBER> h later collected supernatant containing expressed proteins <NUMBER> h posttransfection recombinant proteins purified protein affinity chromatography ge healthcare piscataway nj proteins fc ninta superflow qiagen valencia ca proteins tag according manufacturers instructions human dpp<NUMBER> ectodomain residues <NUMBER> expressed purified previously described <NUMBER> briefly recombinant human dpp<NUMBER> ectodomain containing nterminal honeybee melittin signal peptide cterminal <NUMBER> expressed insect cells using bactobac expression system invitrogen secreted cell culture medium subsequently purified ninta affinity column superdex<NUMBER> gel filtration column ge healthcare purified merscov rbd fragments analyzed sdspage western blot previously described <NUMBER> <NUMBER> briefly boiled nonboiled proteins separated <NUMBER> trisglycine sdspage gels followed transferring nitrocellulose membranes blocking overnight <NUMBER>°c using <NUMBER> nonfat milk pbst blots incubated <NUMBER> h room temperature merscov sspecific polyclonal antibodies <NUMBER> three washes blots incubated horseradish peroxidase hrpconjugated goat antimouse igg <NUMBER> invitrogen <NUMBER> h room temperature signals visualized using ecl western blot substrate reagents amersham hyperfilm ge healthcare binding merscov rbd fragments dpp<NUMBER> performed coimmunoprecipitation assay previously described <NUMBER> briefly recombinant soluble dpp<NUMBER> sdpp<NUMBER> <NUMBER> μg dpp<NUMBER>expressing huh<NUMBER> cell lysates <NUMBER>×<NUMBER> <NUMBER> ml respectively incubated merscov rbd fragments <NUMBER> μg plus protein sepharose beads <NUMBER>°c <NUMBER> h followed washing lysis buffer pbs boiling <NUMBER> min samples subjected sdspage western blot analysis followed detection using antidpp<NUMBER> monoclonal antibody <NUMBER> μgml rd systems minneapolis mn merscov s<NUMBER>specific polyclonal antibodies <NUMBER> respectively mice immunized merscov rbd fragments following previously described protocol <NUMBER> <NUMBER> briefly mice primevaccinated subcutaneously sc <NUMBER> μg mouse recombinant merscov rbd fragments presence montanide isa <NUMBER> adjuvant seppic fairfield nj boosted twice immunogen adjuvant <NUMBER>week <NUMBER> days intervals sera <NUMBER> days postlast vaccination <NUMBER> days heatinactivated <NUMBER>°c <NUMBER> minutes detected merscov sspecific antibody response neutralizing antibodies sera <NUMBER> <NUMBER> <NUMBER> <NUMBER> days postinitial immunization s<NUMBER>fc also tested merscov sspecific antibody response rabbit immunization covance research products inc denver pa followed protocol similar mice modifications briefly rabbits primevaccinated merscov s<NUMBER>fc fragment <NUMBER> μgrabbit plus freunds complete adjuvant boosted twice <NUMBER>week intervals immunogen <NUMBER> μgrabbit plus freunds incomplete adjuvant sera collected tested elisa carried test binding merscov rbd fragments sdpp<NUMBER> previously described <NUMBER> briefly <NUMBER>well elisa plates precoated sdpp<NUMBER> <NUMBER> μgml overnight <NUMBER>°c blocked <NUMBER> nonfat milk <NUMBER>°c <NUMBER> h diluted merscov rbd fragments added plates incubated <NUMBER>°c <NUMBER> h followed four washes bound antibodies incubated hrpconjugated antihuman igg <NUMBER> invitrogen <NUMBER>°c <NUMBER> h reaction visualized substrate <NUMBER>′<NUMBER>′tetramethylbenzidine tmb invitrogen stopped <NUMBER>n h <NUMBER> <NUMBER> absorbance <NUMBER> nm a<NUMBER> measured elisa plate reader tecan san jose ca detection merscov sspecific antibody responses collected mouse sera performed following protocol similar described except replacing coating antigen merscov s<NUMBER>his protein <NUMBER> μgml primary antibody serially diluted mouse sera secondary antibody antimouse igghrp <NUMBER> invitrogen <NUMBER> standard microneutralization assay used quantify neutralizing potential rbd fragments previously described <NUMBER> <NUMBER> <NUMBER> briefly serum samples diluted serial <NUMBER>fold <NUMBER>well tissue culture plates incubated <NUMBER> h room temperature <NUMBER> infectious merscovemc<NUMBER>well transferring duplicate wells vero e<NUMBER> cells grown <NUMBER>well tissue culture plates <NUMBER> h incubation virus control wells exhibited advanced virusinduced cytopathic effect cpe neutralizing capacity individual serum samples assessed determining presence absence cpe neutralizing antibody titers expressed reciprocal highest dilution serum completely inhibited virusinduced cpe least <NUMBER> wells nt <NUMBER> values presented mean standard deviation sd statistical significance among different vaccination groups calculated students ttest using stata statistical software p values less <NUMBER> considered statistically significant five human igg fcfused fragments representing defined rbd residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov spike protein rbd residues <NUMBER> control constructed expressed subjected antigenicity measurement using procedures previously described fig<NUMBER>b <NUMBER> five rbd fragments expressed high levels culture supernatants transfected <NUMBER>t cells purified high homogeneity cterminal fc tag strongly promoted formation rbd dimers evidenced almost twice molecular weight nondenatured versus denatured proteins fig <NUMBER>c top recombinant rbd fragments reacted strongly polyclonal antibodies specifically raised mice recombinant s<NUMBER> protein merscov fig <NUMBER>c bottom suggesting native antigenic conformation two alternative assays coimmunoprecipitation elisa carried measure receptorbinding activities merscov rbd fragments results coimmunoprecipitation assay showed five merscov rbd fragments coimmunoprecipitated recombinant sdpp<NUMBER> protein two clear bands corresponding sizes dpp<NUMBER> respective fcfused merscov rbd fragments readily revealed antidpp<NUMBER>and antimerscov s<NUMBER>specific antibodies whereas single band molecular weight corresponding dpp<NUMBER> detected sample containing sdpp<NUMBER> fig <NUMBER>a left addition five merscov rbd fragments coimmunoprecipitated cellassociated dpp<NUMBER> anchored huh<NUMBER> cells target proteins anticipated sizes identified using antidpp<NUMBER>and antimerscov s<NUMBER>specific antibodies respectively fig <NUMBER>a right thus coimmunoprecipitation assay demonstrated five rbd fragments specifically interact merscovs receptor dpp<NUMBER> elisa performed adding merscov rbd fragments plates coated fixed amount sdpp<NUMBER> followed identification binding affinity based od values <NUMBER> nm tested merscov rbds capable binding sdpp<NUMBER> noted existence differential binding capacity shown figure <NUMBER>b among five rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc possessed significantly higher dpp<NUMBER>binding affinity s<NUMBER>fc s<NUMBER>fc concentrations <NUMBER> <NUMBER> μgml respectively expected control higgfc protein show specific binding sdpp<NUMBER> fig <NUMBER>b therefore extended cterminus merscov rbd fragments appears negative effect receptorbinding activity evaluate immunogenicity five merscov rbd fragments immunized mice rbd fragments according dosing strategy described materials methods detected specific responses total igg antibody along igg<NUMBER> igg<NUMBER>a subtypes serum specimens immunized mice elisa results showed five rbd fragments immunogenic mice induced production igg antibodies specifically bind merscov s<NUMBER> protein without fusion fc particularly sera mice immunized s<NUMBER>fc s<NUMBER>fc acquired stronger binding merscov s<NUMBER> protein immunized three rbd fragments whereas control samples pbsimmunized mice revealed negligible binding activity fig <NUMBER>a confirming specificity igg antibody response elicited rbd fragments addition endpoint titration igg antibody response revealed s<NUMBER>fc s<NUMBER>fc immunogenic s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc eliciting merscov s<NUMBER>specific igg antibodies mice <NUMBER> vaccinations fig <NUMBER>b thus extended cterminus merscov rbd also reduces immunogenicity rbd fragments observation igg subtypes revealed s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc capable inducing significantly higher level igg<NUMBER> th<NUMBER> antibody response s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc elicited igg<NUMBER> antibody significantly higher s<NUMBER>fc fig <NUMBER>c addition s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc promoted significantly higher level igg<NUMBER>a th<NUMBER> antibody response s<NUMBER>fc whereas igg<NUMBER>a antibodies induced s<NUMBER>fc also significantly higher induced s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc respectively fig <NUMBER>d results suggest s<NUMBER>fc among rbd fragments induced high titers th<NUMBER> th<NUMBER> antibody response neutralizing potentials five rbd fragments initially evaluated immunized mice results vero e<NUMBER>based microneutralization showed five rbd fragments capable inducing neutralization antibodies among s<NUMBER>fc induced highest level neutralizing antibody response <NUMBER> th day third immunization fig <NUMBER>a expected sera pbsimmunized mice show neutralizing activity thus s<NUMBER>fc highest neutralizing potential among five rbd fragments furthermore s<NUMBER>fc used immunize rabbits confirm neutralizing potential different animal species vero e<NUMBER>based microneutralization assay demonstrated <NUMBER> th day third immunization s<NUMBER>fc high titers neutralizing antibody responses generated rabbits fig <NUMBER>b therefore s<NUMBER>fc shortest among five rbd fragments produce hightiter neutralizing antibody responses mice rabbits suggesting fragment containing residues <NUMBER> merscov spike protein critical neutralizing receptorbinding domain elucidate potential s<NUMBER>fc vaccine candidate immunized mice protein period <NUMBER> days observed kinetics antibody responses expected increasing titers igg antibodies found mouse sera initial immunization reached highest titers <NUMBER> <NUMBER> days postimmunization antibody titers decreased slightly afterwards still maintained relative high levels fig <NUMBER>c data demonstrated fragment containing residues <NUMBER> merscov spike protein able induce maintain rbdspecific immune responses vaccinated animals least four months confirming good potential developed subunit mers vaccine increasing number mers cases indicates urgency development effective vaccines merscov infection disease among merscov structural proteins spike protein particularly rbd important target effort due proven ability elicit potent neutralizing antibody response immunized laboratory animals <NUMBER> indeed recombinant rbd fragments containing residues <NUMBER> <NUMBER> merscov shown induce neutralizing antibody response immunized rabbits mice respectively <NUMBER> <NUMBER> moreover modified vaccinia virus ankara mva expressing fulllength protein merscov also proven effective vaccinated mice produce potent neutralizing antibodies restricted merscov infection vivo <NUMBER> addition aforementioned recombinant proteins viral vectors nanoparticles venezuelan equine encephalitis virus replicon particles vrpsexpressing spike protein merscov also shown great potentials mers vaccines <NUMBER> <NUMBER> study expressed five different versions merscov rbd fragments based previously published studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> investigated compared receptor binding ability antigenicity immunogenicity neutralizing potential fc human igg fused rbd fragments fc tag enhance expression purification immunogenicity viral rbd proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> results show abilities rbd fragments induce immune responses neutralizing antibodies differ significantly among rbd fragments s<NUMBER>fc demonstrated high receptorbinding affinity induced high titer igg antibody mice elicited highest titer neutralizing antibodies mice also induced high titer neutralizing antibodies rabbits crystal structure merscov rbd reveals rbd fragment encompassing residues <NUMBER> merscov spike protein stably folded structure ordered residues nand ctermini contains receptorbinding motif rbm residues <NUMBER> fig <NUMBER> almost major neutralizing epitopes identified merscov rbd many specifically recognized neutralizing monoclonal antibodies nabs <NUMBER> <NUMBER> <NUMBER> <NUMBER> epitopes clustered protruding ridge rbm region rbd overlap dpp<NUMBER>binding site fig <NUMBER> <NUMBER> <NUMBER> <NUMBER> although yet experimentally confirmed regions rbm overlap dpp<NUMBER>binding site may also contain neutralizing epitopes hand regions merscov spike overlap dpp<NUMBER>binding site likely contain nonneutralizing epitopes nonneutralizing epitopes might hinder production neutralizing antibodies may also induce harmful immune responses <NUMBER> <NUMBER> <NUMBER> regions rbd core structures contribute folding stability whole rbd thus essential however regions flanking rbd contribute protein folding receptor binding therefore necessary identify critical neutralizing epitopes rbd merscov spike protein exclude nonneutralizing epitopes without expense domain integrity stability means immunofocusing vaccine development important test immune efficacy s<NUMBER>fc animal model challenged merscov nonhuman primates rhesus macaques infected merscov showing clinical signs disease histopathological changes lungs <NUMBER> <NUMBER> however high cost purchasing maintaining monkeys performing experiments absl<NUMBER> facility prevented us using animal model small animals mice syrian hamsters ferrets infected sarscov unsusceptible merscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> although mice transduced adenoviral vectors expressing human dpp<NUMBER> infected merscov show significant clinical symptoms mers <NUMBER> therefore vivo efficacy merscov rbdbased vaccine candidate evaluated sophisticated small animal model becomes available overall rbd fragment encompassing residues <NUMBER> merscov protein ideal subunit vaccine candidate capability inducing strong neutralizing antibodies different species animals therefore focus future development mers vaccines furthermore study suggests vaccine design maybe helpful eliminate nonneutralizing epitopes rbd fragments keep rbd fragments physiological relevant conformation also allow host immune responses focus neutralizing epitopes coimmunoprecipitation assays followed western blot analyses performed determine binding affinity rbd fragments dpp<NUMBER> receptor briefly purified recombinant rbd fragments incubated either <NUMBER> μg sdpp<NUMBER> left dpp<NUMBER>expressing huh<NUMBER> cells right presence protein sepharose beads subjecting western blot analysis either antidpp<NUMBER> <NUMBER> μgml top antimerscov s<NUMBER> antibodies <NUMBER> bottom b elisa carried measure binding affinity rbd fragments recombinant sdpp<NUMBER> recombinant human igg fc higgfc protein included negative control significant differences three rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc two s<NUMBER>fc s<NUMBER>fc <NUMBER> <NUMBER> μgml respectively sera collected <NUMBER> days postlast immunization rbd fragments subjects immunogenicity study serum specimens shampbsimmunized mice included negative control data presented mean ± sd five mice group total igg antibodies specific merscov s<NUMBER> protein assessed elisa b merscov s<NUMBER>specific igg antibodies elicited groups differentially immunized mice determined elisa titers expressed endpoint dilutions remain positively detectable significant differences two rbd fragments s<NUMBER>fc s<NUMBER>fc three s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc c merscov s<NUMBER>specific igg<NUMBER> subtype antibody titers groups mice immunized indicated rbd fragments compared based endpoint analysis elisa significant differences three rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc two rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc endpoint titers merscov s<NUMBER>specific igg<NUMBER>a subtype antibodies derived mice immunized different rbd fragments compared significant differences four rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc three rbd fragments s<NUMBER>fc s<NUMBER>fc ■ s<NUMBER>fc • respectively aforementioned serum specimens subjected vero e<NUMBER>based microneutralization assays live merscov infection neutralizing antibody titers expressed reciprocal highest dilutions specimens tested resulted complete inhibition virusinduced cpe least <NUMBER> wells nt <NUMBER> neutralizing antibody titers sera mice immunized merscov rbd fragments sera <NUMBER> days post<NUMBER> rd immunization used test data presented mean ± sd five mice group significant differences s<NUMBER>fc four rbd fragments b neutralizing antibody titers sera rabbits r<NUMBER> r<NUMBER> immunized s<NUMBER>fc protein sera preimmunization <NUMBER> days post<NUMBER> rd immunization used test data presented mean ± sd duplicate wells c endpoint titers merscov s<NUMBER>specific igg antibodies elisa s<NUMBER>fcimmunized mouse sera <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> days postimmunization data presented mean ± sd five mice group merscov spike rbd wellfolded structure contains core structure blue receptorbinding motif rbm magenta helices drawn cylinders strands arrows crystallized rbd fragment encompasses residues <NUMBER> <NUMBER> nand cterminus labeled n c respectively nterminal region rbd fragment residues <NUMBER> <NUMBER> disordered indicated dashed line neutralizing epitopes recognized known nabs indicated rbm emerging infectious disease middle east respiratory syndrome mers caused mers coronavirus merscov first identified <NUMBER> saudi arabia <NUMBER> since spread countries including united states july <NUMBER> <NUMBER> <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths httpwwwwhointcsrdon<NUMBER> <NUMBER> <NUMBER> mersen raising serious concerns pandemic potential <NUMBER> <NUMBER> bats dromedary camels likely natural reservoir intermediate transmission host respectively <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov poses longterm threat human health <NUMBER> <NUMBER> thus need development effective prophylactic strategies vaccines control spread merscov urgent spike protein merscov plays important roles mediating viral entry host cells <NUMBER> first step cell entry defined receptorbinding domain rbd spike proteins binds functional receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> httpdxdoiorg<NUMBER>jvaccine<NUMBER> <NUMBER>x© <NUMBER> elsevier ltd rights reserved host cell surface viral attachment <NUMBER> several versions merscov rbd fragments identified different groups rbd fragments encompass spike residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> extensive studies found spike rbd sars coronavirus sarscov caused sars epidemic <NUMBER> <NUMBER> <NUMBER> critical neutralizing receptorbinding domain attractive subunit vaccine candidate sarscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> likely merscov rbd could also serve subunit vaccine candidate merscov infection indeed previously shown merscov rbd fragments immunogenic animals resulting neutralizing antibody responses <NUMBER> <NUMBER> however clear one rbd fragments represents ideal vaccine candidate mechanism behind potential differences neutralizing abilities rbd fragments study expressed merscov rbd fragments fused fc fragment human igg investigated receptor binding affinity antigenicity immunogenicity neutralizing potential found rbd fragment neutralizing potential explained mechanism behind overall study identified ideal vaccine candidate controlling merscov infections enhanced understanding design strategies vial subunit vaccines fourto sixweekold female balbc mice fourto fivemonthold female nzw rabbits used study animal studies carried strict accordance recommendations guide care use laboratory animals national institutes health animal protocol approved committee ethics animal experiments new york blood center permit number <NUMBER> construction expression purification recombinant merscov rbd fragments fc human igg done previously described modifications <NUMBER> <NUMBER> briefly genes encoding residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov protein respectively amplified pcr using codonoptimized merscov sequences genbank afs<NUMBER> template inserted pfusehigg<NUMBER>fc<NUMBER> expression vector hereinafter named fc invivogen san diego ca merscov s<NUMBER> residues <NUMBER> plus cterminal <NUMBER> s<NUMBER>his amplified inserted pjw<NUMBER> expression vector jiangsu taizhou haiyuan protein biotech co ltd china recombinant plasmids transfected <NUMBER>t cells atcc manassas va changed fresh serumfree dmem invitrogen carlsbad ca <NUMBER> h later collected supernatant containing expressed proteins <NUMBER> h posttransfection recombinant proteins purified protein affinity chromatography ge healthcare piscataway nj proteins fc ninta superflow qiagen valencia ca proteins tag according manufacturers instructions human dpp<NUMBER> ectodomain residues <NUMBER> expressed purified previously described <NUMBER> briefly recombinant human dpp<NUMBER> ectodomain containing nterminal honeybee melittin signal peptide cterminal <NUMBER> expressed insect cells using bactobac expression system invitrogen secreted cell culture medium subsequently purified ninta affinity column superdex<NUMBER> gel filtration column ge healthcare purified merscov rbd fragments analyzed sdspage western blot previously described <NUMBER> <NUMBER> briefly boiled nonboiled proteins separated <NUMBER> trisglycine sdspage gels followed transferring nitrocellulose membranes blocking overnight <NUMBER> • c using <NUMBER> nonfat milk pbst blots incubated <NUMBER> h room temperature merscov sspecific polyclonal antibodies <NUMBER> three washes blots incubated horseradish peroxidase hrpconjugated goat antimouse igg <NUMBER> invitrogen <NUMBER> h room temperature signals visualized using ecl western blot substrate reagents amersham hyperfilm ge healthcare binding merscov rbd fragments dpp<NUMBER> performed coimmunoprecipitation assay previously described <NUMBER> briefly recombinant soluble dpp<NUMBER> sdpp<NUMBER> <NUMBER> g dpp<NUMBER>expressing huh<NUMBER> cell lysates <NUMBER> × <NUMBER> <NUMBER> ml respectively incubated merscov rbd fragments <NUMBER> g plus protein sepharose beads <NUMBER> • c <NUMBER> h followed washing lysis buffer pbs boiling <NUMBER> min samples subjected sdspage western blot analysis followed detection using antidpp<NUMBER> monoclonal antibody <NUMBER> gml rd systems minneapolis mn merscov s<NUMBER>specific polyclonal antibodies <NUMBER> respectively mice immunized merscov rbd fragments following previously described protocol <NUMBER> <NUMBER> briefly mice primevaccinated subcutaneously sc <NUMBER> gmouse recombinant merscov rbd fragments presence montanide isa <NUMBER> adjuvant seppic fairfield nj boosted twice immunogen adjuvant <NUMBER>week <NUMBER> days intervals sera <NUMBER> days postlast vaccination <NUMBER> days heatinactivated <NUMBER> • c <NUMBER> min detected merscov sspecific antibody response neutralizing antibodies sera <NUMBER> <NUMBER> <NUMBER> <NUMBER> days postinitial immunization s<NUMBER>fc also tested merscov sspecific antibody response rabbit immunization covance research products inc denver pa followed protocol similar mice modifications briefly rabbits primevaccinated merscov s<NUMBER>fc fragment <NUMBER> grabbit plus freunds complete adjuvant boosted twice <NUMBER>week intervals immunogen <NUMBER> grabbit plus freunds incomplete adjuvant sera collected tested elisa carried test binding merscov rbd fragments sdpp<NUMBER> previously described <NUMBER> briefly <NUMBER>well elisa plates precoated sdpp<NUMBER> <NUMBER> gml overnight <NUMBER> • c blocked <NUMBER> nonfat milk <NUMBER> • c <NUMBER> h diluted merscov rbd fragments added plates incubated <NUMBER> • c <NUMBER> h followed four washes bound antibodies incubated hrpconjugated antihuman igg <NUMBER> invitrogen <NUMBER> • c <NUMBER> h reaction visualized substrate <NUMBER> <NUMBER> tetramethylbenzidine tmb invitrogen stopped <NUMBER> n h <NUMBER> <NUMBER> absorbance <NUMBER> nm a<NUMBER> measured elisa plate reader tecan san jose ca detection merscov sspecific antibody responses collected mouse sera performed following protocol similar described except replacing coating antigen merscov s<NUMBER>his protein <NUMBER> gml primary antibody serially diluted mouse sera secondary antibody antimouse igghrp <NUMBER> invitrogen <NUMBER> standard microneutralization assay used quantify neutralizing potential rbd fragments previously described <NUMBER> <NUMBER> <NUMBER> briefly serum samples diluted serial <NUMBER>fold <NUMBER>well tissue culture plates incubated <NUMBER> h room temperature ∼<NUMBER> infectious merscovemc<NUMBER>well transferring duplicate wells vero e<NUMBER> cells grown <NUMBER>well tissue culture plates <NUMBER> h incubation virus control wells exhibited advanced virusinduced cytopathic effect cpe neutralizing capacity individual serum samples assessed determining presence absence cpe neutralizing antibody titers expressed reciprocal highest dilution serum completely inhibited virusinduced cpe least <NUMBER> wells nt <NUMBER> coimmunoprecipitation assays followed western blot analyses performed determine binding affinity rbd fragments dpp<NUMBER> receptor briefly purified recombinant rbd fragments incubated either <NUMBER> g sdpp<NUMBER> left dpp<NUMBER>expressing huh<NUMBER> cells right presence protein sepharose beads subjecting western blot analysis either antidpp<NUMBER> <NUMBER> gml top antimerscov s<NUMBER> antibodies <NUMBER> bottom b elisa carried measure binding affinity rbd fragments recombinant sdpp<NUMBER> recombinant human igg fc higgfc protein included negative control significant differences three rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc two s<NUMBER>fc s<NUMBER>fc <NUMBER> <NUMBER> gml respectively values presented mean standard deviation sd statistical significance among different vaccination groups calculated students ttest using stata statistical software p values less <NUMBER> considered statistically significant five human igg fcfused fragments representing defined rbd residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> merscov spike protein rbd residues <NUMBER> control constructed expressed subjected antigenicity measurement using procedures previously described fig <NUMBER>b <NUMBER> five rbd fragments expressed high levels culture supernatants transfected <NUMBER> cells purified high homogeneity cterminal fc tag strongly promoted formation rbd dimers evidenced almost twice molecular weight nondenatured versus denatured proteins fig <NUMBER>c top recombinant rbd fragments reacted strongly polyclonal antibodies specifically raised mice recombinant s<NUMBER> protein merscov fig <NUMBER>c bottom suggesting native antigenic conformation two alternative assays coimmunoprecipitation elisa carried measure receptorbinding activities merscov rbd fragments results coimmunoprecipitation assay showed five merscov rbd fragments coimmunoprecipitated recombinant sdpp<NUMBER> protein two clear bands corresponding sizes dpp<NUMBER> respective fcfused merscov rbd fragments readily revealed antidpp<NUMBER>and antimerscov s<NUMBER>specific antibodies whereas single band molecular weight corresponding dpp<NUMBER> detected sample containing sdpp<NUMBER> fig <NUMBER>a left addition five merscov rbd fragments coimmunoprecipitated cellassociated dpp<NUMBER> anchored huh<NUMBER> cells target proteins anticipated sizes identified using antidpp<NUMBER>and antimerscov s<NUMBER>specific antibodies respectively fig <NUMBER>a right thus coimmunoprecipitation assay demonstrated five rbd fragments specifically interact merscovs receptor dpp<NUMBER> elisa performed adding merscov rbd fragments plates coated fixed amount sdpp<NUMBER> followed identification binding affinity based od values <NUMBER> nm tested merscov rbds capable binding sdpp<NUMBER> noted existence differential binding capacity shown fig <NUMBER>b among five rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc possessed significantly higher dpp<NUMBER>binding affinity s<NUMBER>fc s<NUMBER>fc concentrations <NUMBER> <NUMBER> gml respectively expected control higgfc protein show specific binding sdpp<NUMBER> fig <NUMBER>b therefore extended cterminus merscov rbd fragments appears negative effect receptorbinding activity evaluate immunogenicity five merscov rbd fragments immunized mice rbd fragments according dosing strategy described materials methods detected specific responses total igg antibody along igg<NUMBER> igg<NUMBER>a subtypes serum specimens immunized mice elisa results showed five rbd fragments immunogenic mice induced production igg antibodies specifically bind merscov s<NUMBER> protein without fusion fc particularly sera mice immunized s<NUMBER>fc s<NUMBER>fc acquired stronger binding merscov s<NUMBER> protein immunized three rbd fragments whereas control samples pbsimmunized mice revealed negligible binding activity fig <NUMBER>a confirming specificity igg antibody response elicited rbd fragments addition endpoint titration igg antibody response revealed s<NUMBER>fc s<NUMBER>fc immunogenic s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc eliciting merscov s<NUMBER>specific igg antibodies mice <NUMBER> vaccinations fig <NUMBER>b thus extended cterminus merscov rbd also reduces immunogenicity rbd fragments fig <NUMBER> immunogenicity merscov rbd fragments sera collected <NUMBER> days postlast immunization rbd fragments subjects immunogenicity study serum specimens shampbsimmunized mice included negative control data presented mean ±sd five mice group total igg antibodies specific merscov s<NUMBER> protein assessed elisa b merscov s<NUMBER>specific igg antibodies elicited groups differentially immunized mice determined elisa titers expressed endpoint dilutions remain positively detectable significant differences two rbd fragments s<NUMBER>fc s<NUMBER>fc three s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc c merscov s<NUMBER>specific igg<NUMBER> subtype antibody titers groups mice immunized indicated rbd fragments compared based endpoint analysis elisa significant differences three rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc two rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc endpoint titers merscov s<NUMBER>specific igg<NUMBER>a subtype antibodies derived mice immunized different rbd fragments compared significant differences four rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc three rbd fragments s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc ᭹ respectively observation igg subtypes revealed s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc capable inducing significantly higher level igg<NUMBER> th<NUMBER> antibody response s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc elicited igg<NUMBER> antibody significantly higher s<NUMBER>fc fig <NUMBER>c addition s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc promoted significantly higher level igg<NUMBER>a th<NUMBER> antibody response s<NUMBER>fc whereas igg<NUMBER>a antibodies induced s<NUMBER>fc also significantly higher induced s<NUMBER>fc s<NUMBER>fc s<NUMBER>fc respectively fig <NUMBER>d results suggest s<NUMBER>fc among rbd fragments induced high titers th<NUMBER> th<NUMBER> antibody response neutralizing potentials five rbd fragments initially evaluated immunized mice results vero e<NUMBER>based microneutralization showed five rbd fragments capable inducing neutralization antibodies among s<NUMBER>fc induced highest level neutralizing antibody response <NUMBER>th day third immunization fig <NUMBER>a expected sera pbsimmunized mice show neutralizing activity thus s<NUMBER>fc highest neutralizing potential among five rbd fragments furthermore s<NUMBER>fc used immunize rabbits confirm neutralizing potential different animal species vero e<NUMBER>based microneutralization assay demonstrated <NUMBER>th day third immunization s<NUMBER>fc high titers neutralizing antibody responses generated rabbits fig <NUMBER>b therefore s<NUMBER>fc shortest among five rbd fragments produce hightiter neutralizing antibody responses mice rabbits suggesting fragment containing residues <NUMBER> merscov spike protein critical neutralizing receptorbinding domain elucidate potential s<NUMBER>fc vaccine candidate immunized mice protein period <NUMBER> days observed kinetics antibody responses expected increasing titers igg antibodies found mouse sera initial immunization reached highest titers <NUMBER> <NUMBER> days postimmunization antibody titers decreased slightly afterwards still maintained relative high levels fig <NUMBER>c data demonstrated fragment containing residues <NUMBER> merscov spike protein able induce maintain rbdspecific immune responses vaccinated animals least four months confirming good potential developed subunit mers vaccine increasing number mers cases indicates urgency development effective vaccines merscov infection disease among merscov structural proteins spike protein particularly rbd important target effort due proven ability elicit potent neutralizing antibody response immunized laboratory animals <NUMBER> indeed recombinant rbd fragments containing residues <NUMBER> <NUMBER> merscov shown induce neutralizing antibody response immunized rabbits mice respectively <NUMBER> <NUMBER> moreover modified vaccinia virus ankara mva expressing fulllength protein merscov also proven effective vaccinated mice produce potent neutralizing antibodies restricted merscov infection vivo <NUMBER> addition aforementioned recombinant proteins viral vectors nanoparticles venezuelan equine encephalitis virus replicon particles aforementioned serum specimens subjected vero e<NUMBER>based microneutralization assays live merscov infection neutralizing antibody titers expressed reciprocal highest dilutions specimens tested resulted complete inhibition virusinduced cpe least <NUMBER> wells nt<NUMBER> neutralizing antibody titers sera mice immunized merscov rbd fragments sera <NUMBER> days post<NUMBER>rd immunization used test data presented mean ± sd five mice group significant differences s<NUMBER>fc four rbd fragments b neutralizing antibody titers sera rabbits r<NUMBER> r<NUMBER> immunized s<NUMBER>fc protein sera preimmunization <NUMBER> days post<NUMBER>rd immunization used test data presented mean ± sd duplicate wells c endpoint titers merscov s<NUMBER>specific igg antibodies elisa s<NUMBER>fcimmunized mouse sera <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> days postimmunization data presented mean ± sd five mice group vrpsexpressing spike protein merscov also shown great potentials mers vaccines <NUMBER> <NUMBER> study expressed five different versions merscov rbd fragments based previously published studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> investigated compared receptor binding ability antigenicity immunogenicity neutralizing potential fc human igg fused rbd fragments fc tag enhance expression purification immunogenicity viral rbd proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> results show abilities <NUMBER> merscov spike rbd wellfolded structure contains core structure blue receptorbinding motif rbm magenta helices drawn cylinders strands arrows crystallized rbd fragment encompasses residues <NUMBER> <NUMBER> nand cterminus labeled n c respectively nterminal region rbd fragment residues <NUMBER> <NUMBER> disordered indicated dashed line neutralizing epitopes recognized known nabs indicated rbm interpretation references color figure legend reader referred web version article rbd fragments induce immune responses neutralizing antibodies differ significantly among rbd fragments s<NUMBER>fc demonstrated high receptorbinding affinity induced high titer igg antibody mice elicited highest titer neutralizing antibodies mice also induced high titer neutralizing antibodies rabbits crystal structure merscov rbd reveals rbd fragment encompassing residues <NUMBER> merscov spike protein stably folded structure ordered residues nand ctermini contains receptorbinding motif rbm residues <NUMBER> fig <NUMBER> almost major neutralizing epitopes identified merscov rbd many specifically recognized neutralizing monoclonal antibodies nabs <NUMBER> <NUMBER> <NUMBER> <NUMBER> epitopes clustered protruding ridge rbm region rbd overlap dpp<NUMBER>binding site fig <NUMBER> <NUMBER> <NUMBER> <NUMBER> although yet experimentally confirmed regions rbm overlap dpp<NUMBER>binding site may also contain neutralizing epitopes hand regions merscov spike overlap dpp<NUMBER>binding site likely contain nonneutralizing epitopes nonneutralizing epitopes might hinder production neutralizing antibodies may also induce harmful immune responses <NUMBER> <NUMBER> <NUMBER> regions rbd core structures contribute folding stability whole rbd thus essential however regions flanking rbd contribute protein folding receptor binding therefore necessary identify critical neutralizing epitopes rbd merscov spike protein exclude nonneutralizing epitopes without expense domain integrity stability means immunofocusing vaccine development important test immune efficacy s<NUMBER>fc animal model challenged merscov nonhuman primates rhesus macaques infected merscov showing clinical signs disease histopathological changes lungs <NUMBER> <NUMBER> however high cost purchasing maintaining monkeys performing experiments absl<NUMBER> facility prevented us using animal model small animals mice syrian hamsters ferrets infected sarscov unsusceptible merscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> although mice transduced adenoviral vectors expressing human dpp<NUMBER> infected merscov show significant clinical symptoms mers <NUMBER> therefore vivo efficacy merscov rbdbased vaccine candidate evaluated sophisticated small animal model becomes available overall rbd fragment encompassing residues <NUMBER> merscov protein ideal subunit vaccine candidate capability inducing strong neutralizing antibodies different species animals therefore focus future development mers vaccines furthermore study suggests vaccine design maybe helpful eliminate nonneutralizing epitopes rbd fragments keep rbd fragments physiological relevant conformation also allow host immune responses focus neutralizing epitopes authors declared conflict interest recent pandemic novel coronavirus already affected thousands people continuing spread around world virus called severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> disease caused called coronavirus disease <NUMBER> <NUMBER> may <NUMBER> total <NUMBER> confirmed clinical episodes covid<NUMBER> <NUMBER> deaths reported worldwide <NUMBER>a sarscov<NUMBER>infected people experience mild moderate respiratory distress generally recover without requiring special treatment however older people generally <NUMBER> years age underlying medical complications like diabetes cardiovascular disease chronic respiratory disease cancer likely develop serious symptoms like acute respiratory disease multiorgan failure ultimately leading death lai et al <NUMBER> sarscov<NUMBER> belongs family sars severe acute respiratory syndrome mers middle east respiratory syndrome viruses responsible epidemics <NUMBER> <NUMBER> respectively lu et al <NUMBER> genomes sarscov<NUMBER> single positivestrand rna codes similar structural protein sars giving rise debate whether laboratory engineered sars virus naturally evolved new virus sequence analysis rna made available china public database showed novel virus originated possibly bats natural evolution andersen et al <NUMBER> however got transmitted bats humans high transmission rates humans humans still ambiguous infection human cells receptorbinding domain spike protein present envelope virus binds ace<NUMBER> protein present human cells initiating entry process binding induces large conformational change protein leads exposure proteolytic site proteolytic site cleaved protease causing fusion viral envelope host cell membrane completing entry virus human cell shown protein sarscov<NUMBER> higher binding affinity ace<NUMBER> compared sars wrapp et al <NUMBER> based results could concluded sarscov<NUMBER> variant sars however sarscov<NUMBER> genome additional features like presence polybasic rrar cleavage site junction s<NUMBER> s<NUMBER> subunits spike protein presence polybasic cleavage site helps effective cleavage furin proteases determines viral infectivity host range andersen et al <NUMBER> interestingly case avian influenza virus gain polybasic site ha performs similar function host receptor binding like spike protein transform virus low virulent high virulent forms along acquisition cleavage site positively selected fast replication transmission rates alexander brown <NUMBER> better understand transmission rates growth rate r <NUMBER> defines natural transmission pathogen needs calculated sars mers sarscov<NUMBER> interesting observe although belong family sarscov<NUMBER> twice transmission rate compared sars along multiplication cycles range <NUMBER> days sars mers <NUMBER> days sarscov<NUMBER> liang <NUMBER> probably reason sars mers far contained whereas covid<NUMBER> highly widespread mortality rate sarscov<NUMBER> early outbreak wuhan china calculated <NUMBER> however late february estimated rate increase <NUMBER> hand south korea registered death rate <NUMBER> less death rate italy seems several folds higher rosenbaum <NUMBER> infection advanced <NUMBER> countries territories average mortality rate <NUMBER> according recent reports rajgor et al <NUMBER> therefore therapeutic vaccine initiatives direction inevitable efforts made drug therapy well vaccine development combat covid<NUMBER> till date us food drug administration fda approved antiviral drug remsdesivir developed gilead inc usa antimalarial drug chloroquine cqhydroxychloroquine hcq treatment covid<NUMBER> array drugs approved diseases also considered potentially useful several investigational drugs study several clinical trials conducted across globe table <NUMBER>a b figure <NUMBER> order clinically manage coronavirus researchers china france team doctors rajasthan india started using antiviral drugs combination chloroquine colson et al <NUMBER> lai et al <NUMBER> recently announced global trial called solidarity investigate whether dangerous respiratory disease could treated available therapeutic aids httpsnewsunorgenstory<NUMBER> <NUMBER> however unprecedented effort includes thousands patients across many countries volunteer clinical trials trials aim test effectiveness four potential candidates <NUMBER> antiviral drug remdesivir known inhibit rna dependent rna polymerase <NUMBER> combination two hiv drugs lopinavir ritonavir <NUMBER> lopinavir ritonavir plus interferon beta <NUMBER> antimalarial drugs chloroquine hydroxychloroquine table <NUMBER>b coronavirus rna virus retroviral drugs could possibly effect treatment however cq hcq successful antimalarial currently considered part treatment strategy covid<NUMBER> colson et al <NUMBER> cq also shown possess antihiv activity posttranscriptional inhibition gp<NUMBER> present viral envelope inhibition tatmediated transactivation jiang et al <NUMBER> savarino et al <NUMBER> chloroquine also increase ph endosomes mauthe et al <NUMBER> since coronavirus encode gp<NUMBER> tat protein low ph essential uncoating virus inside host cell likely chloroquine stops viral spread blocking process uncoating release nucleic acid however current data various small nonrandomized trials show limited effects cq hcq hcqazithromycin combination treatment covid<NUMBER> since cqhcq known cause toxic effects unprescribed use led human deaths largescale randomized trials like solidarity project able convincingly prove effectiveness cqhcq drug covid<NUMBER> recently shown combination lopinavirritonavir causes adverse effects covid<NUMBER>infected adults benefits observed cao et al <NUMBER> therefore drugs used caution mechanisms well understood efficacy well established also known viruses mutate high frequencies give rise different strains thereby easily gaining resistance drugs thus indepth analysis animal models required study mechanism action ability virus gain resistance drugs animal testing also important measure absorbance drug body dissociation chemistry metabolomics mechanism drug clearance principle drugs help treatment humans contract disease longterm protection disease vaccines developed avoid global pandemic vaccines able mount immune response virus generating neutralizing antibodies would protect humans infected sarscov<NUMBER> thus avoid another outbreak virulent virus development vaccine disease combined effort academicians industries normal circumstances final product vaccine use humans takes least <NUMBER> years passing six phases assessment bregu et al <NUMBER> first phase academician identifies target potential vaccine candidate thereafter candidate challenged vaccine potential testing animal models disease safety well immune responses antigen analyzed identification development vaccine candidate bottleneck takes majority time <NUMBER> years required vaccine development steps successful taken clinical trials three phases tested humans safety phase efficacy protect disease phases ii iii take another <NUMBER> years figure <NUMBER> different companies already taken initiatives develop vaccine covid<NUMBER> important note studies sars provided important clues vaccine covid<NUMBER> also fasttracked overall process vaccine development vaccine initiatives various companies covid<NUMBER> broadly based three strategies using dna rna ii weakened virus known vlps iii targeting viral proteins protein <NUMBER>b one important factors antigen considered vaccine candidate ability mount good immune response however practicality one always constrained terms antigen used vaccine candidates thus enhance immune responses kim et al developed microneedle delivery method induces antigenspecific antibody response early week <NUMBER> immunization microneedle injection causes brief mechanical stress induces local innate immune response thus avoids use adjuvant also skin possesses high amount immune cells involved innate immune response even injecting small amount antigen lead significant activation innate immune responses antigen kim et al <NUMBER> making effective strategy antigens immunogenic order establish antigen vaccine candidate animal models profound importance various aspects vaccinology route analyses mechanism transmission disease duration induced protection host immune response infection vaccination griffin <NUMBER> thus testing animals considered important critical parameter proceed clinical trials humans one major problems associated vaccine efforts covid<NUMBER> animal disease models sarscov<NUMBER> testing absence models difficult predict outcome challenge studies humans gralinski menachery <NUMBER> animal model disease pathogen able infect animal using receptor cells used humans multiply inside host successfully additionally provide either similar clinical symptoms humans sometimes mild symptoms also work would help studying immune responses pathogen following sections discuss various animal models tested based pathogenesis infection sarscov<NUMBER> key <NUMBER> amino acid residues present ace<NUMBER> humans conserved ace<NUMBER> macaques well melin et al <NUMBER> macaques closer model system humans hence choice animal studies vaccine testing covid<NUMBER> studies macaques shown get infected pulmonary infiltrates observed radiographs high viral loads swabs nose throat shedding upper lower respiratory tract munster et al <NUMBER> rockx et al <NUMBER> taken together disease symptoms rhesus macaques matches milder symptoms sarscov<NUMBER> infection humans serum analysis demonstrate increase chemokine levels il<NUMBER>ra il<NUMBER> il<NUMBER> mcp<NUMBER> il<NUMBER> decrease tgfa levels days <NUMBER> <NUMBER> postinfection statistical significance munster et al <NUMBER> sarscov<NUMBER> known affect older people compared young ones similarly also observed macaques older ones show higher viral loads nose throat along prolonged viral shedding upper respiratory tract old animals rockx et al <NUMBER> thus rhesus macaques promising animal model challenge studies studying efficacy vaccines immune responses monkeys similar humans allow us understand monkeys challenge coronavirus protect ferrets model organisms influenza virus similar lung morphology humans actually cough sneeze supporting use animal model sarscov<NUMBER> cameron et al <NUMBER> enkirch von messling <NUMBER> team virologists led ss vasan australia already shown animals susceptible coronavirus callaway <NUMBER> virus causes increase body temperature symptoms hallmark sarscov<NUMBER> develop virus cannot replicate high levels interestingly infected ferrets spread virus high transmission rates even adjacent cages direct contact aerosols kim et al <NUMBER> since countries community transmission stage ferrets act valuable animal model study transmission sarscov<NUMBER> compared logistics cost ethical regulations using monkeys ferrets laboratorybred mice always remain convenient choice disease model however coronavirus infect mice rats <NUMBER> <NUMBER> amino acids mice <NUMBER> <NUMBER> amino acids rats differ binding region ace<NUMBER> compared humans chan et al <NUMBER> order solve problem perlman laboratory developed humanized mouse models sars incorporated human ace<NUMBER> mice mccray et al <NUMBER> humanized ace<NUMBER> mice successfully infected sars develop lethal brain disease making obvious choice test infection sarscov<NUMBER> well however due lack funding high cost maintenance mice colony discontinued breeding mice facility submitted sperms hace<NUMBER> mice jackson laboratory mice high demand jackson laboratory facing huge pressure meet demands however recent results china shown hace<NUMBER> mice support sarscov<NUMBER> infection reduce weight <NUMBER> virus replication occur lungs moreover infected hace<NUMBER> mice also suffer interstitial pneumonia bronchioles filled periodic acid schiff pas positive exudation detached bronchial epithelium unable transmit disease also infiltrates enriched macrophages tlymphocytes blymphocytes authors also confirmed mice use hace<NUMBER> entry fulfill kochs postulates indicating mice successful disease model sarscov<NUMBER> bao et al <NUMBER> animals support sars infection show maximum similarity human ace<NUMBER> <NUMBER> amino acids <NUMBER> different critical binding region ace<NUMBER> making testable model sarscov<NUMBER> infection upon infection sarscov<NUMBER> syrian hamsters demonstrate weight loss <NUMBER> along high viral load nasal turbinate lungs trachea lethality rate hamsters <NUMBER> exudative inflammation hemorrhage necrosis alveolae damage visible initial infection period inflammation intestinal mucosal epithelium causative agent diarrohea along myocardial degeneration consistent pathogenesis observed humans importantly syrian hamsters show similar immune responses humans ifnc proinflammatory cytokines induced day <NUMBER> postinfection followed decrease type ii interferon il<NUMBER> increase tgfb day <NUMBER> postinfection animal successful model system perform challenge studies also dependent ability transmit pathogen consistent syrian hamsters able transmit disease naïve hamsters upon challenge sarscov<NUMBER> chan et al <NUMBER> taken data together syrian hamsters show pathogenesis immune responses similar humans capable transmission strengthens use one testable models vaccine studies thus many promising animal models testing vaccine candidates sarscov<NUMBER> still extensive studies required confirm efficiency appropriate model covid<NUMBER> order fight coronavirus infection win race time moderna biotechnological company collaboration national institute allergy infectious disease niaid usa already begun phase clinical trial experimental vaccine mrna<NUMBER> rna vaccine testing begins <NUMBER> <NUMBER>b argument directly going phase clinical trial mrna<NUMBER> raised good antibody response immunization mice lack disease model coronavirus cansino biologics china also developed replicationdefective adenovirus expressing spike protein sarscov<NUMBER> vaccine candidate covid<NUMBER> <NUMBER>b beijing institute biological productswuhan institute biological products sinovac using inactivated method inovio pharmaceuticals using dnabased vaccine approach similarly order fasttrack vaccine development skipped animal trials currently performing phase trials phase clinical trials test safety toxicity vaccine target humans way help protecting humans sarscov<NUMBER> although looks promising fasttracking vaccine development division among scientific community bypassing animal models phase clinical trials addition agencies like peta using animals research purposes question remains vaccine research without animal model history mankind clear viral pandemics common affecting millions people problem due ability multiply inside host produce high numbers infecting single cell accompanied stability nonliving surfaces allows spread fast virus pandemics global high transmission rates thus control viruses extreme steps often needed therefore absence disease model backed antibody responses mice niaid cansino biologics moved ahead phase clinical trials bypassing animal model studies vaccines different biotechnological companies looking forward come vaccine around year year half thus decision fda bypass animal trials taken positively entrepreneurs according flexibility laws fda could avoid delays treating observed case ganciclovir although ganciclovir successful treating patients acquired immunodeficiency syndromerelated cytomegalovirus retinitis due lack animal studies get approval fda delayed <NUMBER> years van norman <NUMBER> besides overcoming time frame vaccine enter market also important note results animal studies may translate humans terms toxicity challenge studies isuprel treatment asthma rendered safe rats guinea pigs dogs monkeys still led deaths humans far less dosages great britain another instance treat human autoimmune disease monoclonal antibody tgn<NUMBER> going animal models processed phase trials introduction tgn<NUMBER> led critical illness within minutes along longterm complications phase volunteers van norman <NUMBER> however tgn<NUMBER> restored rheumatoid arthritis developing better assays studying immune responses lowering dosage monoclonal antibody brown <NUMBER> strengthening fact studies animals may always translate use humans contrast chemicals generally toxic animal studies may safe humans penicillin fatal guinea pigs would failed animal studies due lack regulations perform animal studies time came use presently successful drug similarly aspirin toxic rhesus monkeys paracetamol toxic dogs cats van norman <NUMBER> thus studies indicate animal studies predict outcomes humans although share lot genomic similarities final response disease also depend epigenome environmental differences even transgenic humanized models mimic human system must remember often genes work alone complex higherorder organisms although bypassing animal models save time effort money possible perform safety challenge studies disease humans also animal studies provide foundation study disease difficult study progression disease humans easy animal model sacrificed histopathology order follow course infection although cell lines also used study infection process animal models provide advantage studying viral multiplication respect symptoms physiology organism thus becomes really important newly originated coronavirus studied animal model studying animal models also provide detailed information potential reservoirs sarscov<NUMBER> organism another problem faced vaccine efforts viral diseases especially viruses rna genetic material repair mechanisms work rna thus lot mutations accumulated rna phenomenon known antigenic drift reason influenza shots needed every seasonal flu infection thus sarscov<NUMBER>possessing rna genome also prone antigenic drift hence animal models coronavirus help understanding selection pressure antigenic drift evolution virus vaccine administered one major disadvantages bypassing animal models observed case viral infections sometimes administration vaccines enhances susceptibility subject disease phenomenon known antibodydependent enhancement antigen sin common vaccine candidates hivaids virus dengue virus subject immunized antigen mounts immune response antigen vaccinated individual infected virus different serotype preexisting antibodies able neutralize virus formation antibodyvirus complex helps attachment fcc receptor circulating monocytes resulting efficient infection monocytes virus halstead <NUMBER> thus instead protecting subject leads higher complications death subject case infection pathogen huisman et al <NUMBER> therefore biotech companies bypassed animal models note antibodydependent enhancement also observed feline coronavirus fcov immunization mice spike protein virus mounts overall high antibody response neutralizing antibody levels low however challenge cats results enhanced susceptibility infection along death cats huisman et al <NUMBER> phenomenon especially relevant proteins prone antigenic drift protein sars mers known capable phenomena liu et al <NUMBER> houser et al <NUMBER> protein major vaccine target sarscov<NUMBER> studies animal model really required establishing vaccine candidate global emergency entire scientific community attempting effective treatment prevention disease shorten time larger interest humanity routine yet essetial processes like animal trials bypassed process development vaccine drug development options like drug repurposing already adapted varying degrees success effective targeted drugs vaccines sarscov<NUMBER> infection still awaited moreover agencies like fda already given green signal clinical trials vaccines bypassing regular process animal trials hence important access positive negative effects choosing suitable animal model one main concerns animal testing animal mimic response effects generated introduction drugvaccine humans importantly animal models rhesus macaque ferrets mice syrian hamster proving successful challenge sarscov<NUMBER> one similar symptoms humans however successful animal trial indicator success drugvaccine due physiological barriers hence decision bypassing animal model needs taken utmost caution saving time cost large number human lives failure drugvaccine could devastating consequences however covid<NUMBER> differs previous strains several critical residues <NUMBER>ncov receptorbinding motif particularly gln<NUMBER> provide advantageous interactions human ace<NUMBER> <NUMBER> difference affinity possibly explains novel coronavirus contagious viruses present vaccine approved treatment humans chinese traditional medicine shufengjiedu capsules lianhuaqingwen capsule could possible treatments covid<NUMBER> however clinical trials approving safety efficacy drugs <NUMBER> main concept within immunizations ability vaccine initiate immune response faster mode pathogen although traditional vaccines depend biochemical trials induced potent neutralizing protective responses immunized animals costly allergenic time consuming require vitro culture pathogenic viruses leading serious concern safety <NUMBER> <NUMBER> thus need safe efficacious vaccines highly recommended peptidebased vaccines need vitro culture making biologically safe selectivity allows accurate activation immune responses <NUMBER> <NUMBER> core mechanism peptide vaccines built chemical method synthesize recognized bcell tcell epitopes immunodominant induce specific immune responses bcell epitope target molecule linked tcell epitope make immunogenic tcell epitopes short peptide fragments <NUMBER> amino acids whereas bcell epitopes proteins <NUMBER> <NUMBER> therefore study aimed design peptidebased vaccine predict epitopes corona envelope e protein using immunoinformatics analysis <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rapid studies recommended prove efficiency predicted epitopes peptide vaccine emerging infection workflow summarizing procedures epitopebased peptide vaccine prediction shown fig <NUMBER> figure <NUMBER> descriptive workflow epitopebased peptide vaccine prediction full genebank files complete genomes annotation covid<NUMBER>nc<NUMBER> sarscovfj<NUMBER> mesacovnc<NUMBER> hcovhku<NUMBER>ay<NUMBER> hcovoc<NUMBER> kf<NUMBER> hcovnl<NUMBER> nc<NUMBER> hcov<NUMBER>e ky<NUMBER> retrieved national center biotechnology information ncbi fasta format envelope e protein yp<NUMBER> spike sprotein yp<NUMBER> nucleocapsid n protein yp<NUMBER> membrane protein yp<NUMBER> <NUMBER>ncov envelope e protein two chinese two american sequences yp<NUMBER> qhq<NUMBER> qho<NUMBER> qhn<NUMBER> obtained ncbi httpswwwncbinlmnihgov act silico analysis software visualization comparisons complete genome sequences associated annotations <NUMBER> also applied identify regions similarity rearrangements insertions level basepair differences whole genome httpswwwsangeracuksciencetoolsartemiscomparisontoolact first server alignmentindependent prediction protective antigens allows antigen classification solely based physicochemical properties proteins without recourse sequence alignment predicts probability antigenicity one multiple protein based auto cross covariance acc transformation protein sequence structural cov<NUMBER> protein nse analyzed vaxijen threshold <NUMBER> <NUMBER> httpwwwddgpharmfacnetvaxijenvaxijenvaxijenhtml software package proposed stream distinct program run nearly sequence operation well basic alignment investigations sequences e protein retrieved uniprot run bioedit determine conserved sites clustalw application settings <NUMBER> mega version <NUMBER> software comparative analysis molecular sequences used pairwise multiple sequences alignment alongside construction analysis phylogenetic trees evolutionary relationships gap penalty <NUMBER> opening <NUMBER> extending gap pairwise multiple sequences alignment bootstrapping <NUMBER> used construction maximum like hood phylogenetic tree <NUMBER> <NUMBER> httpswwwmegasoftwarenet iedb tools used predict conserved sequences <NUMBER>mersequence hla class class ii tcell epitopes using artificial neural network ann approach <NUMBER> <NUMBER> <NUMBER> artificial neural network ann version <NUMBER> chosen prediction method depends median inhibitory concentration ic<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> binding analysis alleles carefully chosen length set <NUMBER> prediction done analysis epitopes binding mhc class ii molecules assessed iedb mhc prediction server httptoolsiedborgmhci httptoolsiedborgmhcii respectively conserved immunodominant peptides binding mhc ii molecules score equal less <NUMBER> median inhibitory concentrations ic<NUMBER> <NUMBER> respectively selected analysis epitopes ic<NUMBER> greater <NUMBER> eliminated <NUMBER> population coverage epitope carefully determined iedb population coverage calculation tool due diverse binding sites epitopes different hla allele promising epitope candidates calculated population coverage whole world china europe population get ensure universal vaccine <NUMBER> <NUMBER> httptoolsiedborgpopulation reference sequence e protein retrieved gene bank used input raptorx predict <NUMBER>d structure e protein <NUMBER> <NUMBER> visualization obtained <NUMBER>d protein structure performed ucsf chimera version<NUMBER> <NUMBER> silico molecular docking order estimate binding affinities epitopes molecular structure mhc mhc ii silico molecular docking used sequences proposed epitopes selected covid<NUMBER> reference sequence using ucsf chimera <NUMBER> saved pdb file obtained files optimized energy minimized hlaa<NUMBER> selected macromolecule docking crystal structure <NUMBER>uq<NUMBER> downloaded rcsb protein data bank httpwwwrcsborgpdbhomehomedo complex azobenzenecontaining peptide <NUMBER> water molecules heteroatoms retrieved target file <NUMBER>uq<NUMBER> removed target structure optimized energy minimized using swiss pdb viewer v<NUMBER> software <NUMBER> molecular docking performed using autodock <NUMBER> software based lamarckian genetic algorithm combines energy evaluation grids affinity potential find suitable binding position ligand given protein <NUMBER> <NUMBER> polar hydrogen atoms added protein targets kollman united atomic charges computed targets grid map calculated set <NUMBER>×<NUMBER>×<NUMBER> points grid spacing <NUMBER> ǻ grid box allocated properly target include active residue center genetic algorithm run set <NUMBER>the docking algorithms set default finally results ccbynd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint retrieved binding energies poses showed lowest binding energies visualized using ucsf chimera reference sequence envelope protein aligned hcovhku<NUMBER> reference protein using artemis comparison tool illustrated fig <NUMBER> figure <NUMBER> artemis analysis envelope protein displaying <NUMBER> windows upper window represents hcovhku<NUMBER> reference sequence genes highlighted blue starting orflab gene ending n gene middle window describes similarities difference two genomes red lines indicate match genes two genomes blue lines indicates inversion represents sequences two genomes organized opposite direction lower windows represents covid<NUMBER>and genes started arflab ends n genes mutated proteins tested antigenicity using vaxijen software envelope protein found best immunogenic target table <NUMBER> ccbynd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint sequence alignment covid<NUMBER>envelope protein done using bioedit software shows total conservation across four sequences retrieved china usa study evolutionary relationship seven strains coronavirus multiple sequence alignment msa performed using clustalw mega software alignment used construct maximum likelihood phylogenetic tree seen fig <NUMBER> le nt ccbynd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint iedb website used analyze <NUMBER>ncov envelope protein cell related peptides results show ten mhc class ii associated peptides high population coverage tables <NUMBER> <NUMBER> fig <NUMBER> promising peptides visualized using ucsf chimera software fig<NUMBER>a b ccbynd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint <NUMBER> <NUMBER> copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint designing novel vaccine crucial defending rapid endless global burden disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> last decades biotechnology advanced rapidly alongside understanding immunology assisted rise new approaches towards rational vaccines design <NUMBER> peptidebased vaccines designed elicit immunity particular pathogens selectively stimulating antigen specific b cells <NUMBER> applying advanced bioinformatics tools databases various peptidebased vaccines could designed peptides act ligands <NUMBER> <NUMBER> <NUMBER> approach used frequently saint louis encephalitis virus <NUMBER> dengue virus <NUMBER> chikungunya virus <NUMBER> proposing promising peptides designing vaccines covid<NUMBER> rna virus tends mutate commonly dna viruses <NUMBER> mutations lied surface protein make covid<NUMBER> superior previous strains inducing sustainability leaving immune system blind spot <NUMBER> present work different peptides proposed designing vaccine covid<NUMBER> fig <NUMBER> beginning whole genome covid<NUMBER> analyzed comparative genomic approach determine potential antigenic target <NUMBER> artemis comparative tool act used analyze human coronavirus hcovhku<NUMBER> reference sequence vs wuhanhu<NUMBER> covid<NUMBER> results obtained fig<NUMBER> revealed extensive mutation among tested genomes new genes orf<NUMBER> orf<NUMBER> found inserted covid<NUMBER> absent hcovhku<NUMBER> might acquired horizontal gene transmission <NUMBER> high rate mutation two genomes observed region <NUMBER> bp end sequence region encodes four major structural proteins coronavirus envelope e protein nucleocapsid n protein membrane protein spike protein required produce structurally complete virus <NUMBER> <NUMBER> conserved antigenic sites revealed previous studies sequence alignment merscov batcoronavirus <NUMBER> analyzed sarscov <NUMBER> four proteins analyzed vaxigen software test probability antigenic proteins protein e found antigenic gene highest probability shown table <NUMBER> literature survey confirmed result protein e investigated severe acute respiratory syndrome sars <NUMBER> recently middleeast respiratory <NUMBER> <NUMBER> syndrome mers <NUMBER> furthermore conservation protein seven strains tested confirmed use bioedit package tool fig <NUMBER> phylogenetic analysis powerful tool determining evolutionary relationship strains multiple sequence alignment msa performed using clustalw seven strains coronavirus covid<NUMBER>nc<NUMBER> sarscov fj<NUMBER> mesacov nc<NUMBER> hcovhku<NUMBER> ay<NUMBER> hcovoc<NUMBER> kf<NUMBER> hcovnl<NUMBER> nc<NUMBER> hcov<NUMBER>e ky<NUMBER> maximum likelihood phylogenetic tree revealed covid<NUMBER> found clade sarscov thus two strains highly related fig <NUMBER> immune response cell considered long lasting response compared b cell antigen easily escape antibody memory response <NUMBER> vaccines effectively generate cellmediated response needed provide protection invading pathogen moreover cd<NUMBER> cd<NUMBER> cell responses play major role antiviral immunity <NUMBER> thus designing vaccine cell much important choosing protein e antigenic site binding affinity mhc molecules evaluated protein reference sequence submitted iedb mhc predication tool <NUMBER> peptides found bind mhc class different affinities table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage table <NUMBER> fig <NUMBER> analysis iedb mhc ii binding prediction tool resulted prediction <NUMBER> peptides table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage table <NUMBER> copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint groove mhc residues least binding energy <NUMBER> kcalmol <NUMBER> kcalmol <NUMBER> kcalmol respectively fig<NUMBER>c e although flu antihiv drugs used currently china treatment covid<NUMBER> chloroquine phosphate old drug treatment malaria recently found apparent efficacy acceptable safety <NUMBER> nevertheless studies required standardize therapies addition success development mouse models merscov sarscov infection candidate vaccines envelope e protein mutated deleted described <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> best knowledge first study identify certain peptides envelope e protein candidates covid<NUMBER> accordingly epitopes strongly recommended promising epitopes vaccine candidate cell extensive mutations insertion deletion discovered covid<NUMBER> strain using comparative sequencing addition number mhc class ii related peptides found promising candidates among peptides yvysrvknl slvkpsfyv lailtalrl show high potentiality vaccine design adequate world population coverage cell epitopebased peptide vaccine designed covid<NUMBER> using envelope protein immunogenic target nevertheless proposed vaccine rapidly needs validated clinically ensuring safety immunogenic profile help stopping epidemic leads devastating global outbreaks authors acknowledge deanship scientific research university bahri supportive cooperation data underlying results available part article additional source data required copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint coronaviruses cov large family zoonotic viruses cause illness ranging common cold severe diseases middle east respiratory syndrome merscov severe acute respiratory syndrome sarscov last decades six strains coronaviruses identified however december <NUMBER> new strain spread across wuhan city china <NUMBER> <NUMBER> designated coronavirus disease <NUMBER> covid<NUMBER> world health organization <NUMBER> late january <NUMBER> declared outbreak global pandemic cases <NUMBER> covid<NUMBER> positivesense single stranded rna virus ssrna rna sequence approximately <NUMBER> bases length <NUMBER> belongs subgenus sarbecovirus genus betacoronavirus within family coronaviridae corona envelope e protein small integral membrane protein involved several aspects virus life cycle pathogenesis envelope formation assembly budding alongside interactions covs proteins n host cell proteins release infectious particles budding <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> infected person characterized fever upper lower respiratory tract symptoms diarrhoea lymphopenia thrombocytopenia increased creactive protein lactate dehydrogenase levels combination within <NUMBER> days exposure molecular diagnosis made real timepcr genes encoding internal rnadependent rna polymerase spikes receptor binding domain confirmed sanger sequencing full genome analysis ngs multiplex nucleic acid amplification microarraybased assays <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> phylogenetic tree mutation history family viruses possible reconstruct sufficient number sequenced genomes phylogenetic analysis indicates covid<NUMBER> likely originated bats <NUMBER> also showed highly related seven mutations relative common ancestor <NUMBER> sequence covid<NUMBER> rbd together rbm contacts receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> found similar sars coronavirus january <NUMBER> group scientists demonstrated ace<NUMBER> could act receptor covid<NUMBER> <NUMBER> however covid<NUMBER> differs previous strains several critical residues <NUMBER>ncov receptorbinding motif particularly gln<NUMBER> provide advantageous interactions human ace<NUMBER> <NUMBER> difference affinity possibly explains novel coronavirus contagious viruses present vaccine approved treatment humans chinese traditional medicine shufengjiedu capsules lianhuaqingwen capsule could possible treatments covid<NUMBER> however clinical trials approving safety efficacy drugs <NUMBER> main concept within immunizations ability vaccine initiate immune response faster mode pathogen although traditional vaccines depend biochemical trials induced potent neutralizing protective responses immunized animals costly allergenic time consuming require vitro culture pathogenic viruses leading serious concern safety <NUMBER> <NUMBER> thus need safe efficacious vaccines highly recommended peptidebased vaccines need vitro culture making biologically safe selectivity allows accurate activation immune responses <NUMBER> <NUMBER> core mechanism peptide vaccines built chemical method synthesize recognized bcell tcell epitopes immunodominant induce specific immune responses bcell epitope target molecule linked tcell epitope make immunogenic tcell epitopes short peptide fragments <NUMBER> amino acids whereas bcell epitopes proteins <NUMBER> <NUMBER> therefore study aimed design peptidebased vaccine predict epitopes corona envelope e protein using immunoinformatics analysis <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rapid studies recommended prove efficiency predicted epitopes peptide vaccine emerging infection workflow summarizing procedures epitopebased peptide vaccine prediction shown act silico analysis software visualization comparisons complete genome sequences associated annotations <NUMBER> also applied identify regions similarity rearrangements insertions level basepair differences whole genome httpswwwsangeracuksciencetoolsartemiscomparisontoolact first server alignmentindependent prediction protective antigens allows antigen classification solely based physicochemical properties proteins without recourse sequence alignment predicts probability antigenicity one multiple protein based auto cross covariance acc transformation protein sequence structural cov<NUMBER> protein nse analyzed vaxijen threshold <NUMBER> <NUMBER> httpwwwddgpharmfacnetvaxijenvaxijenvaxijenhtml software package proposed stream distinct program run nearly sequence operation well basic alignment investigations sequences e protein retrieved uniprot run bioedit determine conserved sites clustalw application settings <NUMBER> mega version <NUMBER> software comparative analysis molecular sequences used pairwise multiple sequences alignment alongside construction analysis phylogenetic trees evolutionary relationships gap penalty <NUMBER> opening <NUMBER> extending gap pairwise multiple sequences alignment bootstrapping <NUMBER> used construction maximum like hood phylogenetic tree <NUMBER> <NUMBER> httpswwwmegasoftwarenet iedb tools used predict conserved sequences <NUMBER>mersequence hla class class ii tcell epitopes using artificial neural network ann approach <NUMBER> <NUMBER> <NUMBER> artificial neural network ann version <NUMBER> chosen prediction method depends median inhibitory concentration ic<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> binding analysis alleles carefully chosen length set <NUMBER> prediction done analysis epitopes binding mhc class ii molecules assessed iedb mhc prediction server httptoolsiedborgmhci httptoolsiedborgmhcii respectively conserved immunodominant peptides binding mhc ii molecules score equal less <NUMBER> median inhibitory concentrations ic<NUMBER> <NUMBER> respectively selected analysis epitopes ic<NUMBER> greater <NUMBER> eliminated <NUMBER> population coverage epitope carefully determined iedb population coverage calculation tool due diverse binding sites epitopes different hla allele promising epitope candidates calculated population coverage whole world china europe population get ensure universal vaccine <NUMBER> <NUMBER> httptoolsiedborgpopulation reference sequence e protein retrieved gene bank used input raptorx predict <NUMBER>d structure e protein <NUMBER> <NUMBER> visualization obtained <NUMBER>d protein structure performed ucsf chimera version<NUMBER> <NUMBER> order estimate binding affinities epitopes molecular structure mhc mhc ii silico molecular docking used sequences proposed epitopes selected covid<NUMBER> reference sequence using ucsf chimera <NUMBER> saved pdb file obtained files optimized energy minimized hlaa<NUMBER> selected macromolecule docking crystal structure <NUMBER>uq<NUMBER> downloaded rcsb protein data bank httpwwwrcsborgpdbhomehomedo complex azobenzenecontaining peptide <NUMBER> water molecules heteroatoms retrieved target file <NUMBER>uq<NUMBER> removed target structure optimized energy minimized using swiss pdb viewer v<NUMBER> software <NUMBER> molecular docking performed using autodock <NUMBER> software based lamarckian genetic algorithm combines energy evaluation grids affinity potential find suitable binding position ligand given protein <NUMBER> <NUMBER> polar hydrogen atoms added protein targets kollman united atomic charges computed targets grid map calculated set <NUMBER>×<NUMBER>×<NUMBER> points grid spacing <NUMBER> ǻ grid box allocated properly target include active residue center genetic algorithm run set <NUMBER>the docking algorithms set default finally results retrieved binding energies poses showed lowest binding energies visualized using ucsf chimera reference sequence envelope protein aligned hcovhku<NUMBER> reference protein using artemis comparison tool illustrated fig <NUMBER> figure <NUMBER> artemis analysis envelope protein displaying <NUMBER> windows upper window represents hcovhku<NUMBER> reference sequence genes highlighted blue starting orflab gene ending n gene middle window describes similarities difference two genomes red lines indicate match genes two genomes blue lines indicates inversion represents sequences two genomes organized opposite direction lower windows represents covid<NUMBER>and genes started arflab ends n genes mutated proteins tested antigenicity using vaxijen software envelope protein found best immunogenic target table <NUMBER> sequence alignment covid<NUMBER>envelope protein done using bioedit software shows total conservation across four sequences retrieved china usa study evolutionary relationship seven strains coronavirus multiple sequence alignment msa performed using clustalw mega software alignment used construct maximum likelihood phylogenetic tree seen fig <NUMBER> iedb website used analyze <NUMBER>ncov envelope protein cell related peptides results show ten mhc class ii associated peptides high population coverage tables <NUMBER> <NUMBER> fig <NUMBER> promising peptides visualized using ucsf chimera software fig<NUMBER>a b designing novel vaccine crucial defending rapid endless global burden disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> last decades biotechnology advanced rapidly alongside understanding immunology assisted rise new approaches towards rational vaccines design <NUMBER> peptidebased vaccines designed elicit immunity particular pathogens selectively stimulating antigen specific b cells <NUMBER> applying advanced bioinformatics tools databases various peptidebased vaccines could designed peptides act ligands <NUMBER> <NUMBER> <NUMBER> approach used frequently saint louis encephalitis virus <NUMBER> dengue virus <NUMBER> chikungunya virus <NUMBER> proposing promising peptides designing vaccines covid<NUMBER> rna virus tends mutate commonly dna viruses <NUMBER> mutations lied surface protein make covid<NUMBER> superior previous strains inducing sustainability leaving immune system blind spot <NUMBER> present work different peptides proposed designing vaccine covid<NUMBER> fig <NUMBER> beginning whole genome covid<NUMBER> analyzed comparative genomic approach determine potential antigenic target <NUMBER> artemis comparative tool act used analyze human coronavirus hcovhku<NUMBER> reference sequence vs wuhanhu<NUMBER> covid<NUMBER> results obtained fig<NUMBER> revealed extensive mutation among tested genomes new genes orf<NUMBER> orf<NUMBER> found inserted covid<NUMBER> absent hcovhku<NUMBER> might acquired horizontal gene transmission <NUMBER> high rate mutation two genomes observed region <NUMBER> bp end sequence region encodes four major structural proteins coronavirus envelope e protein nucleocapsid n protein membrane protein spike protein required produce structurally complete virus <NUMBER> <NUMBER> conserved antigenic sites revealed previous studies sequence alignment merscov batcoronavirus <NUMBER> analyzed sarscov <NUMBER> four proteins analyzed vaxigen software test probability antigenic proteins protein e found antigenic gene highest probability shown table <NUMBER> literature survey confirmed result protein e investigated severe acute respiratory syndrome sars <NUMBER> recently middleeast respiratory syndrome mers <NUMBER> furthermore conservation protein seven strains tested confirmed use bioedit package tool fig <NUMBER> highly related fig <NUMBER> immune response cell considered long lasting response compared b cell antigen easily escape antibody memory response <NUMBER> vaccines effectively generate cellmediated response needed provide protection invading pathogen moreover cd<NUMBER> cd<NUMBER> cell responses play major role antiviral immunity <NUMBER> thus designing vaccine cell much important choosing protein e antigenic site binding affinity mhc molecules evaluated protein reference sequence submitted iedb mhc predication tool <NUMBER> peptides found bind mhc class different affinities table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage table <NUMBER> fig <NUMBER> analysis iedb mhc ii binding prediction tool resulted prediction <NUMBER> peptides table <NUMBER> ten peptides selected vaccine design based number alleles world population percentage envelope e protein mutated deleted described <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> best knowledge first study identify certain peptides envelope e protein candidates covid<NUMBER> accordingly epitopes strongly recommended promising epitopes vaccine candidate cell extensive mutations insertion deletion discovered covid<NUMBER> strain using comparative sequencing addition number mhc class ii related peptides found promising candidates among peptides yvysrvknl slvkpsfyv lailtalrl show high potentiality vaccine design adequate world population coverage cell epitopebased peptide vaccine designed covid<NUMBER> using envelope protein immunogenic target nevertheless proposed vaccine rapidly needs validated clinically ensuring safety immunogenic profile help stopping epidemic leads devastating global outbreaks authors acknowledge deanship scientific research university bahri supportive cooperation data underlying results available part article additional source data required severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> belongs genus betacoronavirus coronaviridae family identified pathogen coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> epicenter covid<NUMBER> coronavirus outbreak central chinese city wuhan spread globally <NUMBER> th january <NUMBER> world health organization officially declared covid<NUMBER> epidemic public health emergency international concern human human transmission occurs droplets contact fomites people covid<NUMBER> show symptoms fever cough muscle aches headache diarrhea principal feature severe disease acute onset hypoxemic respiratory failure bilateral infiltrates virus genome sequenced allowed development diagnostic tests research vaccines therapeutics <NUMBER> <NUMBER> specific rtpcrbased test developed use clinical diagnoses <NUMBER> abundance publications first three months <NUMBER> indicates intensive scientific effort address molecular mechanisms therapeutic routes treating covid<NUMBER> <NUMBER> <NUMBER> clinical trials currently underway test novel repurposed compounds sarscov<NUMBER> <NUMBER> <NUMBER> certain drugs including hydroxychloroquine chloroquine remdesivir tested clinical trials <NUMBER> <NUMBER> <NUMBER> one small study reported combination therapy hydroxychloroquine azithromycin reduced detection viral rna compared control <NUMBER> <NUMBER> recent openlabel trial two protease inhibitors lopinavir ritonavir failed <NUMBER> several inactivated vaccines viral vectored vaccines adenovirus vector ankara vector nanoparticlebased vaccines fusionprotein based vaccines adjuvanted vaccines recombinant protein dna vaccines well liveattenuated vaccines also developed tested vaccines many months away market <NUMBER> <NUMBER> <NUMBER> <NUMBER> phase <NUMBER> clinical trial modernas mrnabased sarscov<NUMBER> candidate vaccine mrna<NUMBER> started march <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however first several steps clinical trial process evaluating potential benefits vaccine sarscov<NUMBER> consists single positivestranded rna four structural proteins spike glycoprotein membrane glycoprotein envelope protein e nucleocapsid protein n <NUMBER> enter host cells virus uses densely glycosylated spike protein binds angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor high affinity <NUMBER> <NUMBER> <NUMBER> structural biochemical studies suggest rbd ultrahigh binding affinity human ace<NUMBER> receptor <NUMBER> groups designed subunit vaccines sarscov<NUMBER> however workflow involved either use single protein vaccine design <NUMBER> <NUMBER> used ctl epitopes without considering importance bcell htl epitopes <NUMBER> subunitvaccines also preclinical trials <NUMBER> <NUMBER> focused designing multiepitopebased subunit vaccine sarscov<NUMBER> using <NUMBER> highly antigenic epitopes believe experimental evaluation may result novel immunogenic vaccine may confer protection sarscov<NUMBER> infection protein sequences sarscov<NUMBER> retrieved ncbi database httpswwwncbinlmnihgovnuccoremn<NUMBER> subunit vaccine development table <NUMBER> <NUMBER> proteins screened average antigenic propensity using antigenic peptides prediction tool httpimedmeducmestoolsantigenicpl proteins antigenic probability score greater <NUMBER> considered vaccine construction helper tlymphocyte htl epitopes selected sarscov<NUMBER> proteins predicted using mhcii epitope prediction tool immune epitope database iedb httptoolsiedborgmhcii selected epitopes lowest percentile rank ic <NUMBER> values additionally epitopes checked ifn epitope server httpcrddosddnetraghavaifnepitope capability induce th<NUMBER> type immune response accompanied ifnϒ production cytotoxic tlymphocyte ctl epitopes screened proteins predicted using netctl<NUMBER> server httpwwwcbsdtudkservicesnetctl bcell epitopes screened sarscov<NUMBER> proteins predicted using abcpred server httpcrddosddnetraghavaabcpred prediction toxicnontoxic nature selected htl ctl bcell epitopes checked using toxinpred module httpcrddosddnetraghavatoxinpredmultisubmitphp vaccine subunit designed adding adjuvant htl ctl bcell epitopes connected specific linkers provide adequate separation epitopes vivo eaaak linker used join adjuvant htl intra htl intra ctl bcell epitopes joined using gpgpg aay kk respectively enhance immunogenicity vaccine construct tlr<NUMBER> agonist human βdefensin <NUMBER> uniprot id p<NUMBER> used adjuvant immunogenicity vaccine determined using vaxijen server httpwwwddgpharmfacnetvaxijenvaxijenvaxijenhtml antigenpro module scratch protein predictor httpscratchproteomicsicsuciedu allergenicity vaccine checked using allertop v<NUMBER> httpwwwddgpharmfacnetallertop algpred server httpcrddosddnetraghavaalgpred physiochemical characteristics vaccine determined using protparam tool expasy database server httpwebexpasyorgprotparam secondary structure subunit vaccine construct predicted using psipred <NUMBER> protein sequence analysis workbench httpbioinfcsuclacukpsipred tertiary structure predicted de novo structure predictionbased trrosetta modeling suite trrosetta uses deep residual neural network predict interresidue distance orientation distributions input sequence converts predicted distance orientation distributions smooth restraints build <NUMBER>d structure modelsbased direct energy minimization model vaccine construct best tmscore validated prochek v<NUMBER> structures saved every <NUMBER> ps structural dynamic analysis analysis md simulation performed described earlier <NUMBER> briefly backbone java codon adaptation tool jcat httpwwwjcatde used codon optimization vaccine sequence test highlevel expression vaccine e coli strain k<NUMBER> nebcutter httpnc<NUMBER>nebcomnebcutter<NUMBER> used selection restriction enzyme cleavage sites expression vector pet<NUMBER>a selected silico clone vaccine designed using snapgene <NUMBER> restriction cloning tool amino acid sequence three sarscov<NUMBER> proteins namely nucleocapsid protein membrane glycoprotein surface spike glycoprotein retrieved ncbi database table <NUMBER> proteins known prominent role host receptor recognition viral entry pathogenicity proteins antigenic score greater <NUMBER> table <NUMBER> used prediction epitopes subunit vaccine designing schematic representation methodology construction subunit vaccine candidate shown figure <NUMBER> helper tlymphocytes key players adaptive immune response involved activation bcells cytotoxic cells antibody production killing infected target cells respectively three proteins subjected iedb mhcii epitope prediction module htl prediction total six highest immunogenic epitopes <NUMBER>mer <NUMBER> selected based percentile rank ic <NUMBER> values also epitopes showed positive scores ifnepitope server output table <NUMBER> bcells main components humoral immunity adaptive immune response produces antibodies recognize antigens therefore necessary predict bcell epitopes vaccine designing abcpred performed predicting bcell epitope total <NUMBER> epitopes top scores three proteins considered vaccine table <NUMBER> ctl epitopes essential inducing mhci cellular immune response neutralizing virusinfected cells damaged cells via releasing cytotoxic proteins like granzymes perforins etc ctl epitopes predicted selected proteins using netctl <NUMBER> server a<NUMBER> a<NUMBER> b<NUMBER> supertypes considered prediction cover least <NUMBER> total ethnic population eighteen epitopes combined score <NUMBER> finally considered vaccine table <NUMBER> selected htl ctl bcell epitopes subjected toxinpred module screen toxicity supplementary table <NUMBER> shows epitopes chosen vaccine nontoxic total <NUMBER> htls <NUMBER> ctls <NUMBER> bcell epitopes derived three proteins used design subunit vaccine <NUMBER> amino acid residues sarscov<NUMBER> supplementary figure <NUMBER> human βdefensin <NUMBER> amino acid residues sequence added adjuvant followed htl ctl bcell epitopes linked specific linkers important parameter vaccine designing ensuring constructed vaccine immunogenic induce humoral andor cellmediated immune response targeted virus computational data suggest vaccine antigenic probability score <NUMBER> <NUMBER> predicted vaxijen v<NUMBER> antigenpro servers respectively allergenicity score found −<NUMBER> algpred prediction module additionally vaccine also found nonallergic using allertop v<NUMBER> respectively suggesting vaccine thermostable hydrophilic respectively secondary structure predicted using psipred <NUMBER> server supplementary figure <NUMBER> tertiary structure vaccine predicted using trrosetta modeling suite <NUMBER>d model generated trrosetta modeling subjected procheck server ramachandran plot statistics generated output showed <NUMBER> residues present favored region <NUMBER> residues generously allowed region <NUMBER> residues disallowed regions zscore plot energy plot generated prosa web server calculated zscore −<NUMBER> lies within xray crystal structure range energy plot suggested residues low energy value modeled structure figure <NUMBER> vaccinereceptor docking performed evaluate binding energy vaccine tlr<NUMBER> receptor cluspro analysis provided <NUMBER> vaccinereceptor complexes respective energy scores lowest energy complex binding energy −<NUMBER> kjmol <NUMBER> selected subjected md simulation figure <NUMBER> binding modes dynamics stability vaccinetlr<NUMBER> complex evaluated using <NUMBER> ns md simulation study figure <NUMBER> atomiclevel interaction vaccine tlr<NUMBER> determined root mean square deviation rmsd root mean square fluctuation rmsf radius gyration rg hydrogen bond contact energy calculated rmsd data suggests receptorvaccine complex stabilized <NUMBER> ns end simulation figure <NUMBER>a calculations done <NUMBER> ns md simulation trajectory next rmsf calculation gives information residue wise dynamics protein respect initial position done average rmsf value <NUMBER> nm observed complex figure <NUMBER>b subsequent analysis changes rg vaccinetlr<NUMBER> complex simulation also determined average rg found <NUMBER> nm demonstrating compactness tlr<NUMBER> receptor vaccine subunit simulations figure <NUMBER>c analyzed hydrogen bonds typically largest associated eigenvalues define essential subspace protein dynamics occur clusters stable states pca tlr<NUMBER>vaccine complex visualized analyzed trace value calculated covariance matrix tlr<NUMBER>vaccine found <NUMBER> nm <NUMBER> suggesting complex exhibited compact behavior simulation supplementary figure <NUMBER> lastly detailed interactions tlr<NUMBER> vaccine protein computed starting structure md simulations stabilized structure complex extracted md simulated trajectory figure <NUMBER> table <NUMBER> higher total number interactions stabilized complex suggests stability tighter binding vaccine tlr<NUMBER> codon optimization index ensures relationship codon usage gene expression heterologous system jcat output analyzed nebcutter nand <NUMBER> cterminal ends optimized vaccine sequence bamhi ndei restriction sites added noncutters vaccine construct present multiple cloning site selected expression vector pet<NUMBER>a silico clone generated using snapgene <NUMBER> restriction cloning tool resulted cloned product <NUMBER> bp figure <NUMBER> reports suggest <NUMBER> <NUMBER> recovered patients wuhan test positive indicates possibility resurgence covid<NUMBER> places lockdowns already worked consequence spread also caused asymptomatic carriers <NUMBER> <NUMBER> <NUMBER> positive retest however may also original test falsenegative patient actually covidnegative whatever may case vaccine better option coronavirus management drugs efforts produce vaccine coronavirus moving rapid pace two candidate vaccines phase clinical trials adenovirus type<NUMBER> vectorbased vaccine ii lnpencapsulated mrna vaccine studies evaluating safety immunogenicity vaccines underway additionally several vaccine candidates preclinical evaluation <NUMBER> though trials underway known situations vaccines failed recently groups tried designing subunit vaccines sarscov<NUMBER> however workflow involved either use single protein vaccine design <NUMBER> <NUMBER> used ctl epitopes without considering importance bcell htl epitopes <NUMBER> considered points designing vaccine based extensive bioinformatics analysis used three proteins design multiepitope subunit vaccine novel coronavirus sarscov<NUMBER> proteins nucleocapsid protein n membrane glycoprotein surface spike glycoprotein n protein involved packaging viral genome helical ribonucleocapsid plays fundamental role viral selfassembly <NUMBER> protein responsible assembly immunogenicity virus particles protein mediates entrance virus human respiratory epithelial cells interacting cell surface receptor ace<NUMBER> protein two regions s<NUMBER> host cell receptor binding s<NUMBER> membrane fusion protein key target development vaccines therapeutic antibodies diagnostics coronavirus <NUMBER> <NUMBER> <NUMBER> although protein promising immunogen protection optimizing antigen design critical ensure optimal immune response vaccine contains suitable adjuvant htl ctl bcell epitopes joined suitable linkers furthermore epitopes screened toxicity potential subunit vaccine found thermostable antigenic nonallergenic molecular docking md simulation provided insights interaction stability dynamics vaccinereceptor complex data suggest constructive intermolecular interactions vaccine protein tlr<NUMBER> receptor also insilico cloning suggests potential expression vaccine microbial expression system thereby making potential vaccine sarscov<NUMBER> infection development vaccine lengthy expensive process high failure rates typically takes multiple candidates several years produce commercial vaccine upon optimization production process subunit vaccines rapidly tested released market consist antigenic portion pathogens may directly elicit immune response additionally vaccine utilize live pathogen thus reducing risk pathogenicity reversal hence used immunesuppressed patients well elicit longlived immunity computational studies suggest multiepitope based subunit vaccine probability showing good protective efficacy safety sarscov<NUMBER> infection humans suggest synthesis experimental evaluation vaccine determine immunogenic potency authors acknowledge riken accc hokusai supercomputing resources severe acute respiratory syndrome sars first severe readily transmissible new disease emerge <NUMBER>st century sars cases first observed midnovember <NUMBER> guangdong province southern china disease spread along international air travel routes hanoi hong kong singapore toronto february march <NUMBER> <NUMBER> chains secondary community transmission subsequently occurred hospital settings affecting doctors nurses hospital staff initially unaware new disease mode transmission although close contact usually linked viral transmission cases also observed incidental exposure <NUMBER> sars immediately perceived global threat pandemic potential initial development nonspecific symptoms disease often progressed severe lower respiratory disease requiring hospitalization intensive care high casefatality rate predictors mortality shown advancing age <NUMBER> casefatality у<NUMBER> years age underlying chronic illness elevated lactate dehydrogenase concentration white blood cell count presentation <NUMBER> <NUMBER> <NUMBER> <NUMBER> lung pathology specimens revealed hemophagocytosis giant cells macrophage origin suggesting immune system plays important role pathogenesis <NUMBER> <NUMBER> result corticosteroids combination ribavirin often administered treatment albeit limited perceived benefit <NUMBER> <NUMBER> <NUMBER> march <NUMBER> world health organization issued global alert sars support members international health community authorities affected regions implemented intense epidemiologic surveillance rigorous adherence infectioncontrol procedures strict practices patient isolation rigorous application quarantine asymptomatic contacts aggressive restrictions travel consequence international effort sars outbreaks contained midjuly cumulative impact limited <NUMBER> probable sars cases <NUMBER> fatalities <NUMBER> despite success continued vigilance indicated much like influenza respiratory pathogens human coronaviruses cause common colds follow winterseasonal pattern peaks late fall late winterearly spring <NUMBER> possible sars coronavirus cov follow similar pattern addition currently neither effective treatment sars vaccine prevent infection help coordinate robust research response needed address multidimensional sars threat national institute allergy infectious diseases niaid convened colloquium entitled sars developing research response <NUMBER> may <NUMBER> national institutes health campus participants included <NUMBER> physicians scientists policymakers united states canada china europe elsewhere program designed facilitate interaction among participants <NUMBER> areas interest sars clinical research epidemiology diagnostics therapeutics vaccines following <NUMBER> sections corresponding tables represent highlights discussions took place topics conclude discussion recent progress sars research assessment research needs remain addressed clinical manifestations careful description clinical manifestations sars well correlation longitudinal course disease clinical virologic immunologic parameters important early goal clinical research data would permit clinical investigators develop standard set criteria delineate progression thus quantify impact different interventions disease severity moreover systematic correlation symptoms histologic cytologic virologic immunologic evaluations early late changes patient samples would greatly aid understanding sars pathogenesis also important identify host viral factors predictors disease progression understanding role host genetics laboratory surrogates would help improve prognostic capabilities allow identification patients likely benefit aggressive interventions information might also value development entry criteria interventional studies clinical virology longitudinal evaluation viral shedding use polymerase chain reaction pcr viral culture lungs gastrointestinal tract sites would help patient management infection control example routinely finding infectious virus stool weeks resolution clinical illness would likely change recommendations regard isolation data would also provide information sites virus replication show whether evolve course illness previous studies animal coronavirus infections shown small changes viral envelope proteins dramatic effect tissue tropism clinical manifestations example single amino acid change spike protein changes transmissible gastroenteritis virus predominantly respiratory pathogen intestinal pathogen <NUMBER> reason evaluation viral quasi species obtained different tissues obtained patients different clinical manifestations sars obtained time single patients could rewarding error rates transcription coronavirus rnadependent rna polymerases typically order <NUMBER> <NUMBER> <NUMBER> similar rates hiv<NUMBER> reverse transcriptase high rates likely cause substantial variation viral genome occur time could permit drugresistant isolates emerge careful surveillance development drugresistant sars strains therefore part antiviral research protocol clinical immunology important thoroughly understand cellular humoral immune responses sars virus including impact sars immune function immunopathologic responses virus may engender study relationships specific immune responses subsequent clinical course would help identify correlates protective immunity would turn great value development vaccines immunebased therapies immunosuppressive element described coronavirus infections examination effect sars ability host generate immune response antigens indicated research done studies immune response recall antigens tetanus toxoid primary antigens bacteriophage phi x <NUMBER> interpretation studies must clearly distinguish effects specific sars virus infection generic serious illness better understanding role immune system sars pathogenesis critical would help development new therapeutic strategies deleterious responses may specific case crossreacting autoantibodies nonspecific overly robust inflammatory response severe lymphopenia described patients sars remains mystery could related immune mechanisms detailed study bone marrow function lymphocyte kinetics individuals sars may yield important clues cause anemia international collaboration global network research centers formed test therapeutic approaches developed help conduct basic clinical research described sars clinical centers must located countries sars occurs must cooperation local communities must also appropriately equipped must access requisite scientific expertise including clinical trial design pharmacology data management extent possible protocols trials therapies developed advance need trials must designed test new antiviral drugs antibody therapies immunomodulatory approaches use corticosteroids trials must test application therapies treatment symptomatic patients postexposure prophylaxis see therapeutics discussion therapeutic development animal reservoirs sars cov almost certainly zoonotic origin coronaviruses broad host range avian mammalian species initial sars cases guangdong province occurred among workers food preparation restaurant industry suggests practices associated liveanimal markets region source human infections <NUMBER> moreover workers liveanimal markets shenzhen china showed serologic evidence sars cov infection without history sarslike illness virologic surveillance liveanimal markets led isolation coronaviruses closely related sars cov study genetic diversity related coronaviruses broad range wild domestic animals may help identify potential animal reservoirs sars cov well virologic environmental characteristics favor zoonotic transmission natural history little known natural history sars cov infection also critical reproductive rate r quantified different subpopulations settings climates initial estimates suggest r ∼<NUMBER> considerably less highly transmissible viruses influenza virus r may change seasonally relatively small change may determine whether virus becomes established human population moreover effect host factors especially age viral transmission remains clarified children infected sars cov experience much less severe illness whereas people <NUMBER> years age suffer severe disease high mortality however yet clear probability viral transmission varies among age groups similarly prevalence asymptomatic infection possibility transmission oralfecal route blood transfusion presence host genetic factors affect susceptibility yet determined finally viral host environmental factors caused socalled superspreader incidents many people infected single individual elucidated quickly possible infectioncontrol strategies currently available strategy control sars isolation quarantine procedures needed address sars emerging infectious agents social psychological consequences isolation quarantine studied incentives people adhere implemented policies assessed efficacy infectioncontrol techniques screening febrile passengers airports also examined international collaboration experience sars underscores need establish collaborative international disease surveillance research networks especially southeast asia march rapidly established global network sars research centers modeled network influenza surveillance research centers already place helped facilitate isolation identification sars cov complete genomic sequencing multiple isolates ultimately internationally supported onsite collaborative networks allow rapid exchange information reagents among skilled professionals therefore enhance research sars emerging infectious disease threats beyond establishment collaborative centers utmost importance scientists worldwide share available epidemiologic data regard sars analyses pooled data affected countries adequately clarify complex issues role super spreaders diarrhea factors affecting transmission identification risk factors severe disease outcome benefits various treatment strategies establishing database linking epidemiologic clinical laboratory data individuals sars worldwide would therefore tremendous benefit winter months diagnostic challenges differentiating sars infections especially great means essential develop diagnostic assays differentiate sars cov respiratory pathogens rapidly simply precisely also important develop diagnostic tests disease specific rapidly recognize presence known novel pathogens serologic assays sars cov initially identified using cell culture inoculation passage followed electron microscopy genome sequence analysis standard elisas neutralization tests immunofluorescent antibody assays developed immediately thereafter use tests demonstrated individuals sars develop specific antibodies virus crossreact human coronaviruses present widely population serologic tests widely available countries active sars cov transmission occurred igg antibodies however appear least <NUMBER> days infection igm antibodies typically appear earlier igm capture assays developed similarly measurement sars covspecific iga antibodies rapid tests designed use oral fluids could prove useful pcr assays first complete genome sequence sars cov available within <NUMBER> weeks initial global alert <NUMBER> distinct isolates since deposited genomic databases <NUMBER> availability sars nucleotide sequence allowed rapid development standard reversetranscriptase pcr assays detect sars cov rna respiratory secretions lung kidney tissues stool urine specimens pcr assays exquisitely sensitive detection limit ∼<NUMBER> copies target rna however presence viral rna necessarily indicate presence infectious virus methods exceptional sensitivity may lead falsepositive results crosscontamination factors continued work standardize performance pcr assays sars determine optimal protocols remains high priority reagent repositories reagents infectious virus viral rna inactivated recombinant antigens sars covspecific polyclonal monoclonal antibodies essential tools development diagnostic assays wellvalidated clinical specimens individuals sars global public health authorities therefore continue coordinate collection storage distribution material perhaps existing new collaborating research centers alternatively niaid might consider including material reagent repository planned support assay nonhuman primate smallanimal models development bioterror threat agents moreover initial development diagnostic assays reagents also done using specimens animal models improvement models continue antiviral drug screening although antiviral chemotherapy prophylaxis great importance control sars clinically proven candidates currently exist working collaboratively united states army medical research institute infectious diseases niaid centers disease control prevention established sars antiviral drugscreening laboratory march <NUMBER> assay used laboratory measured much candidate compounds inhibit cytopathic effects sars cov growing cultured vero cells initially antiviral drugs screened included us food drug administration approved clinical development preclinical data suggested activity potential viral target protein vitro activity sars cov observed certain preparations interferona b well rimantadine high concentrations cysteine protease inhibitor antiviral drug design molecular virologic genetic studies sars cov coronaviruses suggest several possible molecular targets antiviral drugs include viral binding fusion activities mediated glycoprotein spike coronavirus surface well viral rnadependent rna polymerase papainlike cysteine protease chymotrypsinpicornavirus <NUMBER>clike protease inhibitors surface hemagglutininesterase activities involved release virus cell surfaces may also represent class useful antiviral drugs molecular modeling drug design strategies continue pursued develop compounds modulate viral activities immunomodulation therapies available clinical histopathologic data suggest immunemediated injury may important mechanism sars pathogenesis particularly late course illness thus would useful assess use immunomodulatory drugs corticosteroids either combination antivirals effectiveness administration immunoglobulins neutralizing activity sars cov therapy prophylaxis also examined preclinical studies nonhuman primate smallanimal models needed sars antiviral drug development mouse hepatitis virus group ii murine coronavirus well characterized mice may prove useful regard although may differ significantly sars cov may end prove necessary develop several models address different aspects pathogenesis sars systemic versus respiratory tract infection niaid also strengthen ability produce sufficient supplies promising experimental compounds conduct preclinical toxicology studies continue expand biocontainment laboratory facilities shortage significantly inhibited antiviral development collaboration us food drug administration antiviral drug developers occur early stages development process assess preclinical data plan clinical studies clinical trial networks niaids collaborative antiviral studies group casg expanded strengthened particularly include sites countries sars occurred collaborative clinical protocols prepared casg developed clinical protocol could used template establishment collaborative studies clinical protocols look disease progression also titer excreted virus duration excretion probable markers likelihood transmission basic science sars emerged many important basic science issues yet fully explored include identity cellular receptor virus pathogenic mechanisms cause disease initial routes infection role enteric infection plays pathogenesis transmission immunologic issues warrant intense study include relative roles innate adaptive immunity detailed description immunologic response throughout course disease whether patients immune reinfection recovery immune system changes might confer immunity experience date indicates immune response might play role sars pathogenesis important implications treatment vaccine development encouraging useful vaccines animal coronaviruses mouse hepatitis virus developed using various strategies including liveattenuated wholekilled subunit approaches however experimental vaccines based strategies directed feline infectious peritonitis virus enhance disease immunized animals crucial therefore immune responses contribute disease identified soon possible sars vaccine candidates evaluated possibility might potentiate disease vaccine development given need quick development safe effective sars vaccine multiple strategies vaccine development pursued simultaneously include development liveattenuated wholekilled vaccine candidates addition strategies elicit strong cell responses dnabased vaccines engineered adenovirus vectors well elicit production neutralizing antibodies adjuvants confer longerlived protective mucosal systemic immune responses also pursued finally subunit vaccines based protein fragments peptides epitopebased cell vaccines formulated new adjuvants target tolllike receptors also developed preclinical testing animal models sars cov infection needed test safety efficacy candidate vaccines reagent repository researchers could obtain recombinant viral proteins multiple spike proteins monoclonal antibodies plasmids immune control patient sera would extremely helpful would molecular immunology database containing descriptions b cell epitopes sars cov genomic data moving candidate sars vaccines rapidly scientific regulatory evaluation require coordinated effort government academic industrial organizations groups work together identify potential barriers product licensing cooperatively develop plans widespread testing deployment promising vaccine preparations countries sars exists first wave sars controlled vigorous international application timetested techniques isolation quarantine international research response forceful cooperative short order virus causes sars identified sequenced firstgeneration diagnostic tests developed distributed development antiviral therapies vaccines initiated much progress achieved international network research sites built largely preexisting influenza network reflection astonishingly rapid pace sars research niaid meeting summarized great many fundamental insights sars described occurred <NUMBER> weeks initial global health alert progress sars research continued even first wave disease subsided several identified research needs least partially met example vitro screening antiviral candidates sars cov moving accelerated pace result recent introduction highthroughput assays screen <NUMBER> compounds per week addition many sars vaccine candidates development around world preliminary results tests mice nonhuman primates indicate neutralizing antibodies protective vaccine candidates elicit neutralizing antibodies may shortly enter human trials <NUMBER> token however several needs cut across various fields sars research remain unfulfilled table <NUMBER> although progress reported many areas well pressing needs described methods early identification individuals sars many pcr serologic diagnostic kits available diagnostic tools development <NUMBER> existing <NUMBER> reported realtime pcr coupled improved rna extraction method allows detection viral rna nasopharyngeal aspirates <NUMBER> specificity considerable improvement firstgeneration procedures research made possible availability set wellcharacterized clinical samples individuals confirmed sars coupled matched controls rigorous testing diagnostic procedures using standardized samples remains challenge international community however addition complete understanding body virus found different stages disease might lead new diagnostic strategies example report sars cov replicate peripheral blood mononuclear cells individuals sars shortly onset symptoms indicates blood might appropriate clinical specimen diagnosis <NUMBER> <NUMBER> availability highly accurate specific diagnostic assay could detect sars cov shortly onset symptoms would tremendously valuable public health tool future sars outbreaks <NUMBER> sars pathogenesis immune response complete understanding sars pathogenesis together full picture human immune response yet achieved regard particularly important understand role human immune response plays severe disease outcomes recent report describing changes cytokine concentrations <NUMBER> patients seropositive sars cov beijing early peak recovery stages disease indicates immune system responds abnormally virus <NUMBER> kind study provide useful insights pathogenic mechanisms effectiveness experimental therapies another report indicates angiotensinconverting enzyme <NUMBER> functional receptor sars cov <NUMBER> work systematically unravel aspects sars cov interacts human host molecular physiologic levels help ensure rapid development therapeutic techniques diagnostic assays vaccines sars animal models shown virus replicate several small animals including masked palm civets raccoon dogs mice domestic cats nonhuman primates researchers variety animal models choose development vaccines therapeutic strategies rely several different models advantages different experimental settings however animal model described date reliably mimic respiratory symptoms seen humans sars recent report indicates sarsinfected ferrets become ill although animals show evidence pneumonia <NUMBER> followup work animals might lead discovery animal model reproduces sars symptoms humans enhanced mechanisms international cooperation access wellcharacterized specimens reagents still limiting factor many avenues sars research although progress made <NUMBER> <NUMBER> <NUMBER> moreover increased compilation analysis existing epidemiologic laboratory clinical data multiple sarsaffected areas would speed research example single site sufficient number superspreading events provide enough data completely explain however data pooled many sites different countries would provide much greater chance explaining important phenomenon similarly data success failure various treatment strategies already attempted rigorously compared analyzed finally although protocols clinical testing therapeutic vaccine candidates prepared common protocols implemented across multiple international sites data acquired trials made widely available acquired combat sars international public health community must effectively harness experience creative talents laboratory scientists public health workers physicians health care workers world although intense effort exerted first months <NUMBER> controlled initial outbreaks must lulled false sense security pandemic potential sars novel agent transmitted via respiratory secretions remains present today serves reminder emergence pathogens whether natural intentional devastating human economic costs reasons planning efforts future pandemics must sufficiently flexible cope emerging respiratory virus performing research needed effectively counter sars require continued global investment human financial resources ongoing commitment collaborative sharing data materials first discovered democratic republic congo <NUMBER> highly lethal ebola virus infected people number african countries leading sporadic outbreaks ebola virus disease past <NUMBER> years outbreaks limited geographic scope number cases two outbreaks last <NUMBER> years large resulting major loss life socioeconomic disruption region early <NUMBER> outbreak ebola virus disease caused zaire ebolavirus started west africa declared public health emergency international concern august year time outbreak ended <NUMBER> <NUMBER> people died <NUMBER> people infected primarily three countries guinea liberia sierra leone <NUMBER> decade prior west african outbreak research efforts biodefense purposes resulted identification promising ebola vaccine candidates protected monkeys lethal challenge wildtype ebola virus <NUMBER> vaccine candidates taken clinical development prior west african outbreak several reasons included inability demonstrate clinical efficacy absence ongoing outbreak lack interest public health vaccine development community invest lengthy costly process vaccine development without clear demand ebola vaccine <NUMBER> west african outbreak changed perspective numerous vaccines entered clinical development outbreak resulting generation safety immunogenicity data many novel vaccine candidates demonstration efficacy one vaccine <NUMBER> ervebo® live attenuated recombinant vesicular stomatitis virus rvsvbased chimericvector vaccine vsv envelope g protein deleted replaced inserting envelope glycoprotein zaire ebolavirus extraordinary efforts made advance vaccine candidate phase <NUMBER> <NUMBER> <NUMBER> clinical trials data generated context west african ebola outbreak supported licensure us food drug administration fda conditional authorization european medicines agency ema several african countries along prequalification period <NUMBER> years start phase <NUMBER> trials oct <NUMBER> approval vaccine nov <NUMBER> much faster typical <NUMBER> year timeline vaccine development approval <NUMBER> timeline key activities development ebola vaccine summarized fig <NUMBER> described detail following sections article ebola vaccine development effort number learnings identified highly relevant current vaccine development efforts response covid<NUMBER> pandemic summary key lessons learned found fig <NUMBER> field response nongovernmental service organizations medecins sans frontieres global public health entities world health organization wellcome trust gavi universities eg university geneva dalhousie university private sector companies newlink genetics idt biologika msd entities specific role broad partnership including conducting preclinical studies manufacturing good manufacturing practices gmp trial materials conducting clinical trials funding portions research development msd wellestablished history manufacturing clinical development vaccines experience taking novel vaccines regulatory process approval providing global access however msd prior experience ebola virus clinical development expertise african countries ebola outbreak taking place therefore msd relied expertise organizations already involved public health response efforts implement complete nearly clinical trials important lessons effort leveraging expertise different organizations help accelerate product development broad publicprivate partnerships require strong leadership coordination facilitate cooperation diverse partners different expertise missions furthermore concerns evaluation investigational product present less developed parts world concerns may exacerbated outbreak <NUMBER> therefore clear transparent communication community leaders community large ethical review committees local ministries health government agencies critical ensure purpose research well understood aligned accepted local international norms failure result delays roadblocks research potentially lifesaving products ultimately responsibility convert data generated collaborators coherent regulatory submission support licensure product lies marketing authorization holder recognition proactive planning eventuality help accelerate regulatory submission support product approval examples types activities include following data integration msds role advancing product licensure included integrating data generated partners support marketing authorization applications nine <NUMBER> nonclinical studies <NUMBER> <NUMBER> clinical assay validations <NUMBER> <NUMBER> clinical trials performed partners msd needed obtain datasets reports partners include license applications data clinical trials performed partners needed migrated central database could used data integration analysis reportwriting submission msd regulatory agencies lesson learned process account time needed convert different formats languages used collect data standard formats required regulatory agencies use medical dictionary regulatory activities meddra study data tabulation model sdtm clinical trials designed implemented context outbreak possible harmonize study designs issue priori conduct trials introduced challenges assembling data support licensure example possible conduct extensive integration safety data product data collected methods used different trial key lesson learned process standardization clinical trial protocols data collection preferred extent possible late stage clinical trial designs defined prior outbreaks another challenge specifically related conducting trials response emerging diseases need build clinical development capacities laboratory adverse event reporting infrastructure outbreakprone regions challenge taken individual trial sponsors affected countries required significant sustained support trial sponsors local partners establishing mechanisms maintain capabilities established outbreak response provide experienced clinical trial sites future research another key lesson learned examples action include ongoing partnership us liberia partnership research ebola vaccination prevac consortium established wake west africa outbreak clinical assays key immunogenicity endpoint assay developed validated collaborative effort private public sector partners intent provide assay available vaccine developers might ultimately allow comparison different vaccine candidates collaborative effort successful balancing input numerous partners took time consequently clinical assay validation took two years complete resulting backlog samples clinical trials needed processed lesson learned whenever possible clinical immunogenicity sample collection standardized assays validated prior start late stage clinical trials requires knowledge target pathogen well advance clinical trials challenge sarscov<NUMBER> expanded access use vaccine prior approval rapid collection efficacy data support vaccine recognized possibility new ebola outbreaks could occur ahead licensure availability licensed doses mechanism needed support access investigational product scenario necessary manufacture doses support outbreak response establish regulatory frameworks needed support vaccine deployment eg compassionate use expanded access emergency use msf groups took lead implementing expanded access protocols african countries working closely national governments ministries health effort <NUMBER> people vaccinated <NUMBER> ebola outbreak democratic republic congo <NUMBER> lesson learned deployment investigational product requires careful consideration thorough planning manufacturing process rapidly scaledup handle needs emergency use expanded access programs addition establishing final manufacturing facility approach taken msd take initial manufacturing process developed contract manufacturing organization scale clinical manufacturing facility transfer commercial manufacturing facility technology transfer establishment new manufacturing facility many steps requires significant time execute <NUMBER> years typical new vaccine limited understanding outside vaccine manufacturers regulators rigorous requirements leading approval vaccine manufacturing facility broad lack understanding lead misperceptions delays fact timelines driven elements required licensure example although clinical data available <NUMBER> vaccine could approved commercial manufacturing site established due expectations regulatory agencies manufacturing process needs validated final manufacturing site lesson learned education needed vaccines manufactured time needed establish gain approval new manufacturing facility particularly relevant clinical • exisɵng preclinical data vaccine plaƞorm accelerate start phase <NUMBER> trials outbreaks • clear communicaɵon community leaders government agencies criɵcal ensure purpose clinical research well understood • standardizaɵon clinical trial protocols data collecɵon needed late stage clinical trial designs defined prior outbreak • need build maintain clinical development capaciɵes laboratory adverse event reporɵng infrastructure outbreakprone regions • clinical immunogenicity sample collecɵon standardized assays validated prior start late stage clinical trials • deployment invesɵgaɵonal product requires careful consideraɵon thorough planning • takes ɵme convert different formats languages used collect clinical data standard formats required regulatory agencies • educaɵon needed vaccines manufactured ɵme needed establish gain approval new manufacturing facility • aggressive ɵmelines enɵcing require rightfirstɵme manufacturing execuɵon lowmedium probability success new vaccines • global regional harmonizaɵon criɵcal efficient development licensure pandemic vaccines • regulatory agency collaboraɵon criɵcal success • clinical data requirements licensure need clearly defined harmonized across global regulatory agencies • frequent discussions regulatory agencies expedited regulatory pathways accelerate program • whos leadership needed facilitate innovaɵve review processes collaboraɵve mechanisms expedite global approvals • addiɵonal regulaɵons recombinant live virus vaccines lead delays starɵng clinical trials manufacturing tesɵng shipments • harmonized labeling packaging requirements would facilitate pandemic vaccines distribuɵon • publicprivate partnerships help accelerate product development leveraging experɵse different organizaɵons • policy program system innovaɵons needed realize full promise new vaccines advancing global public health preparedness covid<NUMBER> outbreak aspects vaccine development accelerated extraordinary pace goal able produce unprecedented quantities vaccine address global needs manufacturing site selection vaccines complex decision complicated seeking move fast incomplete information company needed manage multiple factors existing space technical capability infrastructure capacity site selection also needed account regulations country manufacturing site located permits licenses necessary support efforts countrys employment environment labor laws also impact ability hire qualified staff quickly factors need considered early lesson learned aggressive timelines enticing public health partners also require rightfirsttime execution qualify facility manufacturing process probability success new vaccine likely medium low parties involved must work balance desire ambitious eg rapid development timelines execution realities stakeholder expectations parallel work extensive collaboration manufacturers needed order successfully bring sarscov<NUMBER> vaccine world regulatory agency collaboration critical success start west african ebola outbreak us fda ema health canada worked closely national regulatory authorities impacted west african countries sharing information candidate vaccines tested reviewing clinical protocols available data benefitrisk profiles frequent conversations manufacturers helped agencies expedite start clinical trials simultaneously different countries lesson learned existing preclinical data availability clinical supplies afforded opportunity start phase <NUMBER> trials rapidly west african ebola outbreak clinical data requirements licensure need clearly defined placebocontrolled randomized doubleblind studies typically used demonstrate efficacy safety new vaccines however midst ebola outbreak countries considered unethical administer placebo atrisk individuals different study designs implemented phase <NUMBER> trials clusterrandomized trial conducted world health organization guinea trial demonstrated efficacy <NUMBER> efficacy data trial together safety data <NUMBER> trials immunogenicity data validated assays accepted registration regulatory agencies lesson learned regulatory pathway licensure pandemic vaccines need clearly defined novel trial designs might need implemented order maximize possibility evaluating efficacy waning outbreak alternative endpoints using immune responses surrogate efficacy could used gain accelerated approval conditional marketing authorization frequent regulatory agency interactions important based primarily interim clinical efficacy data manufacturer applied granted access expedited regulatory pathways priority medicines prime status ema breakthrough therapy designation btd fda helped obtain alignment data requirements product approval using frequent meetings btd fda accepted rolling submissions portions biologics license application bla resulted approval december <NUMBER> three months fdas target approval date fda determined program specific advisory committee meeting needed similar frequent discussions ema prime status enabled company gain alignment key aspects development program quickly leadership needed obtain rapid global approvals recognized global public health leader regional offices many countries established connections african vaccines regulatory forum avaref order accelerate vaccine access african countries world health organizations prequalification team whopqt collaboration ema avaref developed innovative facilitated process roadmap decision making acceptability vaccine registration <NUMBER> allowed company make simultaneous submissions ema whopqt regulatory authorities <NUMBER> african countries ema acting reference agency following submission whopqt members avaref represented <NUMBER> african countries invited participate teleconferences msd ema inspection manufacturing facility positive opinion ema october <NUMBER> european commission granted conditional marketing authorization november <NUMBER>th within <NUMBER> h granted prequalification one month later african countries started approve ervebo® starting burundi democratic republic congo lesson learned strong collaboration willingness share information everyone involved resulted registration nearlysimultaneously countries needed ebola vaccine sarscov<NUMBER> vaccines regulatory agencies prepare simultaneous approval candidates multiple countries whos leadership needed facilitate innovative review processes collaborative mechanisms expedite approvals recombinant viral vaccines need overcome additional regulatory hurdles since ebola vaccine recombinant virus countries required detailed environmental risk assessment prior start clinical trials part marketing authorization application countries vaccine considered biosafety level <NUMBER> organism requiring special handling permits manufacturing testing sites permits took significant amount time obtain prevented rapid transfers material samples technology even included parts marketing authorization application required licenses export vaccine made genetic sequence two viruses considered dualuse agents subject trade controls lesson learned regulations led delays additional costs incurred starting clinical trials manufacturing testing shipments manufacturers sarscov<NUMBER> vaccines countries consider waiving requirements waiving fees expediting processes harmonized labeling packaging requirements would facilitate pandemic vaccines distribution approval companies face challenges product distribution due need follow countryspecific product labeling regulations covering package inserts cartons artwork addition serialization requirements causes supply chain issue vaccine product intended placed stockpile diverted quickly country lesson learned heterogenous requirements counter goal flexibility speed costefficiency relevant emergency preparedness urgent need harmonized solutions electronic labeling quick response qr codes could possible solution countries legislation currently exist support option urgent need find solution problem pandemic vaccines addition considering lessons related vaccine development epidemic preparedness equally important consider unique challenges opportunities related sustainable manufacturing supply access delivery vaccines scale speed needed achieve preparedness response goals challenges include rightsizing manufacturing capacity production accommodate leadtimes managing uncertain demandandsupply dynamics ensuring equitable allocation access achieving operational economic sustainability partners producing supplying vaccine inherently complex exponentially complex high levels uncertainty unpredictability across nearly every dimension program unpredictable disease unpredictable relatively low demand unpredictable stakeholders customers unpredictable timing need unpredictable geographies needs might arise policy program system innovationin parallel research development innovationneeds addressed realize full promise innovative new vaccines advancing global public health preparedness emergency preparedness response vaccines ervebo® critical tools arsenal pathogens cause pandemics publicprivate partnerships powerful effective approach develop vaccines setting clear roles expectations accountability enables partner bring respective strengths effort shared purpose trust flexibility cooperation critical ensure success highlighted report another recent article <NUMBER> variability complexity regulatory processes requirements interfere speed flexibility efficiency needed prepare respond public health emergencies urgent need global regulatory harmonization standardization approach development vaccines emergency preparedness regulatory agencies need work together remove roadblocks put solutions place allow rapid global development vaccines sarscov<NUMBER> emerging pathogens received <NUMBER> may <NUMBER> accepted <NUMBER> june <NUMBER> severe acute respiratory syndrome sars novel infectious disease caused sars coronavirus sarscov led several hundred deaths among thousands cases although sars successfully contained reemergence sarscov animal reservoirs still potential risk future epidemic supported continual reports finding sarscovlike coronavirus small animals civets raccoon dogs <NUMBER> <NUMBER> <NUMBER> bats <NUMBER> <NUMBER> sars outbreak may also recur future virus escaping laboratory accidents <NUMBER> <NUMBER> therefore development safe effective sars vaccines prevention sarscov infection important issue current sars research sarscov causative agent sars contains genome encoding nonstructural replicase polyprotein rep structural proteins spike envelope e membrane nucleocapsid n <NUMBER> <NUMBER> protein responsible virus binding receptor angiotensinconverting <NUMBER>x see front matter © <NUMBER> elsevier ltd rights reserved doi<NUMBER>jvaccine<NUMBER> <NUMBER> <NUMBER> enzyme <NUMBER> ace<NUMBER> subsequent virus entry host cells <NUMBER> <NUMBER> protein sarscov also demonstrated main antigen inducing high titer neutralizing antibodies <NUMBER> <NUMBER> <NUMBER> eliciting protective immunity infection challenged animals <NUMBER> <NUMBER> <NUMBER> thus implied main target development sars vaccines number vaccine candidates based sarscov reported terms abilities inducing neutralizing antibodies protective immunity <NUMBER> <NUMBER> <NUMBER> <NUMBER> candidates grouped inactivated virusesbased proteinbased dnabased virusbased vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> many viruses including vsv rhabdovirus adenovirus adenoassociated virus aav modified vaccinia virus ankara mva attenuated parainfluenza virus used expressing sarscov protein sars vaccine candidates <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> bukreyev et al <NUMBER> reported vaccination african green monkeys attenuated parainfluenza virus encoding sarscov resulted production sarscovspecific neutralizing antibodies protection animals virus challenge findings suggest protein sarscov good target development sarscov vaccines since dnabased virusbased vaccine candidates still caused safety concerns proteinbased vaccine may alternative candidate indeed fulllength protein s<NUMBER> subunit could induce potent neutralizing antibody responses immunized animals <NUMBER> <NUMBER> <NUMBER> however may also elicit antibodies enhance virus infection <NUMBER> <NUMBER> cause liver damage animals challenged sarscov <NUMBER> regard receptorbinding domain rbd fragment protein demonstrated major neutralization determinant implied ideal candidate development subunit vaccines sars <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> study evaluated longterm immune responses protective immunity sarscov infection mouse model bj<NUMBER> strain sarscov genbank accession ay<NUMBER> propagated vero e<NUMBER> cells conditions biosafety level <NUMBER> laboratories bsl<NUMBER> <NUMBER> <NUMBER> titer virus strain determined <NUMBER> tissueculture infectious dose tcid <NUMBER> vero e<NUMBER> cells <NUMBER>aa rbd domain sarscov protein residues <NUMBER> fused fc domain human igg<NUMBER> rbdfc produced described previously <NUMBER> <NUMBER> briefly plasmid encoding rbdfc fusion protein transfected hek<NUMBER>t cells using fugene <NUMBER> transfection reagents boehringer mannheim according manufacturers protocol supernatants harvested <NUMBER> h posttransfection recombinant rbdfc protein purified protein asepharose <NUMBER> fast flow amersham biosciences usa fulllength protein sarscov urbani accession ay<NUMBER> expressed expressf ® insect cells recombinant baculovirus d<NUMBER> purchased protein sciences corporation bridgeport ct <NUMBER> <NUMBER> group five female balbc mice age <NUMBER> weeks vaccinated intramuscularly im <NUMBER> g purified rbdfc resuspended phosphatebuffered solution pbs ph <NUMBER> presence freunds complete adjuvant fca boosted twice freshly prepared emulsion <NUMBER> g immunogen freunds incomplete adjuvant fia <NUMBER>week intervals mice boosted third time amount rbdfc fia <NUMBER> months first vaccination challenged sarscov <NUMBER> days later fig <NUMBER> mice injected amount pbs used negative control group mouse sera collected immunization <NUMBER>month interval postvaccination sera kept −<NUMBER> • c use mouse sera tested recombinant sarscov protein elisa briefly <NUMBER> gml recombinant protein coated <NUMBER>well microtiter plates corning costar acton <NUMBER> carbonate buffer ph <NUMBER> <NUMBER> • c overnight blocking <NUMBER> nonfat milk serially diluted mouse sera added incubated <NUMBER> • c <NUMBER> h followed three washes pbs containing <NUMBER> tween <NUMBER> bound antibodies detected hrpconjugated goat antimouse igg zymed south san francisco ca <NUMBER> • c <NUMBER> h three washes reaction visualized addition substrate <NUMBER> <NUMBER> tetramethylbenzidine tmb measured absorbance <NUMBER> nm a<NUMBER> elisa plate reader victor <NUMBER> multilabel counter perkinelmer usa titers neutralizing antibody mouse sera vaccinated recombinant rbdfc protein detected vero e<NUMBER> cells described qu et al <NUMBER> briefly vero e<NUMBER> cells seeded <NUMBER> × <NUMBER> <NUMBER> cellswell <NUMBER>well culture plates cultured <NUMBER> • c <NUMBER> h form monolayer serial twofold dilutions serum samples incubated <NUMBER> tcid <NUMBER> sarscov bj<NUMBER> strain <NUMBER> • c <NUMBER> h subsequently added monolayer vero e<NUMBER> cells tetrad cells infected <NUMBER> tcid <NUMBER> sarscov without virus applied positive negative controls respectively cytopathic effect cpe well observed daily recorded day <NUMBER> postinfection neutralizing titers mouse antisera completely prevented cpe <NUMBER> wells calculated reedmuench method five days last boost rbdfc mice anaesthetized isoflurane intranasally inoculated <NUMBER> l diluted sarscov bj<NUMBER> strain <NUMBER> <NUMBER> tcid <NUMBER> according national animal care use guidelines bsl<NUMBER> laboratory vaccinated mice sacrificed <NUMBER> days challenge lungs mice removed lung tissues stored −<NUMBER> • c virological tests fixed <NUMBER> paraformaldehyde stored <NUMBER> • c histopathological analysis viral rna copies lung tissues determined qrtpcr according protocol described zhai et al <NUMBER> limit detection live virus lung samples <NUMBER> × <NUMBER> <NUMBER> copiesg briefly total rna extracted <NUMBER> mg lung tissues using rneasy mini kit qiagen hilden germany following manu virus replication determined titration inoculated virus lung tissues collected sacrificed mice briefly lung tissues homogenized final concentration <NUMBER> wv suspension dulbeccos modified eagles medium dmem invitrogen usa tissue homogenates centrifuged filtrated inoculated monolayer vero e<NUMBER> cells seeded <NUMBER>well tissueculture plates results evaluated <NUMBER> days culture phasecontrast microscopy viral titers using cpebased tcid <NUMBER> test calculated reedmuench method viral titers expressed log <NUMBER> tcid <NUMBER> g tissues lowest detection limit <NUMBER> log <NUMBER> tcid <NUMBER> g total amount virus calculated multiplying weight lung tissues viral titers measured <NUMBER> tissue homogenates lung tissues immediately fixed <NUMBER> buffered paraformaldehyde embedded paraffin wax sections made <NUMBER> thickness mounted slides histopathological changes caused sarscov infection examined haematoxylin eosin staining viewed light microscopy shown fig <NUMBER>a rbdfc vaccination induced prolonged potent humoral immune response igg specific sarscov protein animals tested elisa reaching highest titer <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> mean ± se <NUMBER>rd <NUMBER>th month postvaccination although titer decreased slightly afterwards high titer sspecific igg antibody maintained least <NUMBER> months dropped <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> end <NUMBER>th month specific igg antibody increased rapidly <NUMBER>rd boost <NUMBER> months first vaccination reached titer <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> sarscov challenge fig <NUMBER>b demonstrated antibodies induced vaccination rbdfc exhibited strong neutralizing activity similar pattern elisa antibodies rbd neutralizing antibodies reached highest level <NUMBER>rd month <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> vaccination rbdfc neutralizing antibody level slightly decreased <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> end <NUMBER>th month dropped less <NUMBER> end <NUMBER>th month titer neutralizing antibody sarscov increased third boost reaching titer titers neutralizing antibodies determined highest dilutions sera could completely prevent cpe least <NUMBER> wells presented geometric means ± se five mouse sera group <NUMBER> × <NUMBER> <NUMBER> ± <NUMBER> × <NUMBER> <NUMBER> sarscov challenge however neither elisa sspecific antibodies neutralizing antibodies detected mouse sera control group five days challenged sarscov intranasal route mice sacrificed lung tissues collected virus rna copies lung tissues determined qrtpcr described rna copiesg tissues shown table <NUMBER> viral rna copies rbdfc group control group negatively correlated titer neutralizing antibodies sarscov higher titer neutralizing antibodies detected sera lower copy number viral rna found lung tissues m<NUMBER> mouse rbdfc vaccination group developed lowest titer neutralizing antibody <NUMBER> showed detectable viral rna copies <NUMBER> × <NUMBER> <NUMBER> viral rna detectable lung tissues four mice group presented higher titers neutralizing antibody <NUMBER> similarly neutralizing antibody response pbs control group correlated higher levels rna copies lung tissues <NUMBER> × <NUMBER> <NUMBER> <NUMBER> × <NUMBER> <NUMBER> results suggested neutralizing antibodies induced rbdfc vaccination play important role prevention sarscov infection virus challenged mice sarscov replication detected titration inoculated virus lung tissues evaluate efficacy rbdfc vaccination protecting sarscov infection fig <NUMBER> five mice control group vaccinated pbs high titers virus replication lungs sarscov challenge however mice vaccinated rbdfc either completely four five mice partially protected one five mice m<NUMBER> showed lower level neutralizing antibody serum sarscov challenge data indicate vaccination rbdfc titers neutralizing antibodies sera collected mouse <NUMBER> days last vaccination virus inoculation determined rna copies lung tissues mice challenged sarscov measured qrtpcr expressed rna copiesg lung tissues m<NUMBER>m<NUMBER> c<NUMBER>c<NUMBER> rbdfcvaccinated mice control mice respectively limit detection live virus lung <NUMBER> × <NUMBER> <NUMBER> copiesg able establish protective immunity prevent mice subsequent sarscov challenge histopathological changes lungs rbdfc vaccinated control mice observed stained lung tissue sections lung tissues control mice injected pbs revealed significant histopathological changes including diffuse alveolar damages characterized disruption alveolar walls flooding alveolar lumina serosanguineous exudates admixed neutrophils alveolar macrophages thickened alveolar walls lined type <NUMBER> pneumocytes alveolar macrophages alveolar lumina fig <NUMBER>a however except m<NUMBER> mouse mild level alveolar damage lung tissues four rbdfc vaccinated mice exhibited significant histopathological changes showed similar histological structures normal mouse lung tissues fig <NUMBER>b results confirm rbdfc vaccine able prevent mice subsequent sarscov infection development effective safe sars vaccines crucial prevention reoccurrence sars epidemic among four structural proteins sarscov serves important antigen development sars vaccines since plays essential roles host cell tropism virus entry ability induce neutralizing antibodies protective immunity <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> reports shown neutralizing antibodies protein protect vaccinated animals sarscov challenge thus vaccines encoding protein targeting humoral immune responsesneutralizing antibodies indispensable preventing sarscov infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> currently reported sars vaccine candidates based fulllength protein sarscov although fulllength proteinbased vaccines elicit neutralizing antibodies andor protective immunity <NUMBER> <NUMBER> <NUMBER> reported kind vaccines may also induce harmful inflammatory immune responses <NUMBER> <NUMBER> raised concerns efficacy safety vaccines containing encoding fulllength protein thus proposed use rbd fragment protein rather fulllength protein development safe effective sars subunit vaccine since contains major neutralizing epitopes <NUMBER> <NUMBER> <NUMBER> previous studies shown recombinant rbd induce high potent neutralizing antibodies sarscov variants m<NUMBER> mouse exhibited mild histopathological damages lung tissues compared control mice m<NUMBER> mouse revealed little damage thickened alveolar walls interstitial mononuclear cells lymphocytes infiltrates congestion markedly hemorrhage effusion alveolar spaces lung tissues <NUMBER> <NUMBER> know whether rbdbased vaccine protect animals sarscov infection study compared antibody responses protective immunity mice vaccinated rbdfc control mice found rbdfc elicited potent longterm humoral immune responses vaccinated mice high titers sarscov sspecific elisa antibodies virus neutralizing antibodies maintained least <NUMBER> months although antibodies dropped low level end <NUMBER>th month titers rebound rapidly mice reboosted rbdfc vaccinated mice protected sarscov challenge since significant virus replication detected lungs notably presence high titers neutralizing antibody prerequisite protective immunity higher titer neutralizing antibodies associated lower level rna copiesvirus replication stronger protective activity sarscov challenge among five mice vaccinated rbdfc four mice possessing high titer neutralizing antibodies exhibited significant virus replication histopathological changes lungs one mouse low sera neutralizing antibody titer showed marginal level virus rna copies mild histopathological changes however five mice undetectable neutralizing antibody control group presented high level rna copiesvirus replication obvious histopathological changes lungs results indicated neutralizing antibody produced rbdfc vaccinated mice plays significant role protection mice virus challenge without causing immunopathological damages summary vaccines containing rbd sarscov protein may induce sufficient neutralizing antibodies longterm protective immunity sarscov challenge established mouse model vaccine candidate may overcome disadvantages vaccine candidates mentioned protect vaccinated mice subsequent sarscov challenge results suggest rbdfc vaccine developed ideal subunit vaccine prevention sars epidemic modified vaccinia virus ankara antigen delivery system best use potential ingo drexler <NUMBER> caroline staib <NUMBER> gerd sutter <NUMBER>ã safetytested modified vaccinia virus ankara mva established potent vector system development candidate recombinant vaccines versatility vector system recently demonstrated rapid production experimental mva vaccines immunization severe acute respiratory syndrome associated coronavirus promising results also obtained delivery epsteinbarr virus human cytomegalovirus antigens clinical testing mva vectors vaccination immunodeficiency virus papilloma virus plasmodium falciparum melanoma moreover mva considered prime candidate vaccine safer protection orthopoxvirus infections thus vector development challenge dilemmas vaccinology immunization poxvirus biothreat seems possible yet right choice made beneficial use poxviruses engineered express foreign genes established tools target protein synthesis vaccine development biomedical research large packaging capacity recombinant dna precise virusspecific control target gene expression lack persistence genomic integration host high immunogenicity vaccine ease vector vaccine production important features enabling success story concerns safety poxviruses including vaccinia virus vv former smallpox vaccine addressed use viruses replicationdefective human cells among modified vaccinia virus ankara mva considered one virus strains choice preclinical clinical research <NUMBER> historically mva developed attenuation serial passage primary chicken embryo cells serve safer vaccine smallpox review see <NUMBER> <NUMBER> passages tissue culture mva lost broad cellular host range vv unable productively grow many cells mammalian origin concurrent avirulence mva laboratory animals entirely unproblematic use primary smallpox vaccination <NUMBER> <NUMBER> humans founded high safety profile recombinant mva depending nature inserted target gene used conditions biosafety level <NUMBER> capacity produce similar levels viral recombinant antigen compared replicationcompetent viruses relevant feature mva vaccines recent years significant progress made development mva vaccine technologies review informs newest developments generation recombinant mva illustrates principal features impact mva immunogenicity also describe advances made preclinical clinical evaluation mva secondgeneration poxvirus vaccine delivery heterologous antigens targeting infectious diseases cancer finally consider compatibility different mva exploitations raise question future use priority given recombinant mva among promising live viral vector systems wellestablished safety versatility production heterologous proteins recent engineering recombinant mva synthesize components necessary assembly delivery alphavirus replicon particles serves elegant example application <NUMBER> purposes however generation mva vectors straightforward requiring single genomic insertion mediated homologous recombination virus genome dna plasmid carries one two recombinant genes placed control vvspecific promoter figure <NUMBER> sites naturally occurring deletions within mva genome classical gene loci encoding vv proteins thymidine kinase hemagglutinin serve sites insertion recombinant gene sequences several wellestablished techniques clonal isolation recombinant mva involving coexpression chromogenic agents eg escherichia coli bgalactosidase bglucuronidase providing resistance antimicrobials eg e coli xanthineguaninephosphoribosyltransferase overview see <NUMBER> <NUMBER> recently methods relying growth selection recombinant mva developed protocols take advantage selective propagation cell cultures nonpermissive nonrecombinant mva one protocol vv host range gene k<NUMBER>l transiently introduced mva genome recombinant mva subsequently isolated rabbit kidney rk<NUMBER> cells <NUMBER> <NUMBER> clonal isolation vector virus k<NUMBER>l marker gene removed viral genome bearing advantage marker reused subsequently generate mva recombinant viruses harboring multiple gene insertions another recently developed host range selection technique relies growth rescue mutant mva chicken embryo fibroblast cef cells <NUMBER> mvade<NUMBER>l lacks interferon resistance gene e<NUMBER>l mva antigen delivery system drexler staib sutter <NUMBER> unable grow cef stable reinsertion e<NUMBER>l gene together target gene sequence allows quick isolation mva recombinant viruses cef <NUMBER>s highly attenuated mva primarily considered provide means safer vaccination smallpox although knowledge avirulence immunostimulating capacity infection experiments multiple animal models systematic efforts characterize molecular basis mva vaccine immunogenicity date recent past important achievements include characterization mva molecular life cycle upon infection nonpermissive mammalian cells elucidation mva genome understanding mva lost relevant poxvirus immune evasion genes target innate host responses based cytokine chemokine functions consequently defects inhibitory virus genes likely responsible mvaspecific induction host cytokine synthesis proposed decades ago review see <NUMBER> interestingly inactivation vv interferon resistance gene e<NUMBER>l mva genome resulted enhanced production type interferon cefs suggesting capacity mva stimulate innate responses may enhanced rational mutagenesis <NUMBER> assumed immunostimulation contributes particular immunogenicity mva might compensate advantage live replicationcompetent vv sustained antigen production contrast viruses eg members herpesvirus family mva replicationcompetent vv appear specifically interfere host cell antigen processing presentation allowing apparently unimpaired induction adaptive immune responses assumption agreement finding vvspecific humoral cellular immunity detected decades primary vaccination <NUMBER> recently compared conventional vv vaccines mva vaccines found elicit similar patterns vvspecific immune responses provided protection experimental orthopoxvirus infections required inoculation higher dosage <NUMBER> <NUMBER> comparative monitoring epitopespecific cd<NUMBER> tcell responses directed vaccinia virus recombinant antigens quantitation epitopespecific cells performed following one immunization humanized hlaa<NUMBER>transgenic mice <NUMBER> <NUMBER> iu either wildtype mva mvawt recombinant mvatyr mvah<NUMBER>n expressing human tumor antigens tyrosinase her<NUMBER>neu respectively ten days post vaccination peptidespecific intracellular cytokine release splenocytes determined stimulation vaccinia epitope vp<NUMBER> vv tyrosinase tyr her<NUMBER>neu peptides h<NUMBER>n cells analyzed flow cytometry presence peptidespecific activated cd<NUMBER>l low cd<NUMBER> cells magnitude specifically induced tcell response depicted cells shifted lower right indicated percentage numbers blue interferongsecreting cd<NUMBER> cells within cd<NUMBER> cell population much previous research dedicated development mva candidate recombinant vaccines multiple virus infections humans including causing aids influenza early childhood respiratory diseases measles japanese encephalitis dengue fever review see <NUMBER> effective vaccine aids urgently needed recombinant mva producing immunodeficiency virus antigens among first vector viruses evaluated candidate vaccines humans <NUMBER> <NUMBER> substantial data studies different simian immunodeficiency virus siv simian human immunodeficiency virus shiv chimera siv hiv infection models strongly support thorough clinical evaluation mvabased vaccines use heterologous primeboost strategies including mva vaccines delivering multiple siv hiv antigens proved successful elicit antibody highlevel cytotoxic tcell responses macaques immune response effectively controlled mucosal challenge shiv <NUMBER>p sivmac<NUMBER>derived viruses significantly reduced viral loads challenge infection neutralizationresistant highly replicationcompetent sivmac<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> importantly recent data suggest sivhivspecific mucosal immunity boosted peripheral mva immunization oral priming salmonella vector vaccine <NUMBER> intranasal inoculation recombinant mva stimulate immunodeficiency virusspecific immunity genital rectal tract <NUMBER> <NUMBER> elicitation potent mucosal immunity induction broadly virusneutralizing antibody responses important milestones still reached derivation successful hiv vaccine principal capacity mva elicit highly effective virusneutralizing antibody responses highlighted characterization vector vaccines severe acute respiratory syndrome sars coronavirus human cmv <NUMBER> <NUMBER> successful engineering mva expressing sars coronavirus spike protein also demonstrated suitability vector system readily respond potential threat rapidly emerging infectious diseases recently developed recombinant mva delivering multiple cmv antigens represents promising candidate clinical testing mvabased tcell vaccines <NUMBER> <NUMBER> <NUMBER> study also mirrors general interest development mva vector vaccines human herpesvirus infections <NUMBER> <NUMBER> potential activate robust cellular major histocompatibility complex mhc class iand iirestricted cd<NUMBER> cd<NUMBER> tcell responses recombinant antigens made mva vaccines attractive immunotherapeutic approaches cancer selected intracellular parasitic bacterial infectious diseases experimental cancer therapy virusassociated malignancies seem predestined targets mva vaccines taylor coworkers <NUMBER> demonstrated immunogenicity epsteinbarr virusassociated nasopharyngeal carcinoma vaccine reactivating epsteinbarr virusspecific cd<NUMBER> cd<NUMBER> memory cells vitro recently corona gutierrez colleagues <NUMBER> showed evidence therapeutic efficacy mva vaccine delivering human papillomavirus hpv e<NUMBER> antigen cervical cancer associated hpv infection phase iii clinical trial vaccines based recombinant mva expressing different tumorassociated antigens specific variety cancers currently tested mice <NUMBER> <NUMBER> <NUMBER> humans <NUMBER> often combined cytokines interleukin<NUMBER> <NUMBER> costimulatory molecules b<NUMBER> <NUMBER> measures circumvent immune inhibitory signalling ctla<NUMBER> blockade <NUMBER> cellular adjuvants like dendritic cells <NUMBER> enhance immune responses antigens likely tolerogenic selfproteins major efforts underway develop vaccines malaria caused plasmodium spp parasites preclinically heterologous primeboost immunization regimens elicited strong cd<NUMBER> tcell immunity shown substantial protection mouse malaria challenge models plasmodium berghei <NUMBER> plasmodium yoelii <NUMBER> addition safety immunogenicity established clinical trials human volunteers experimentally <NUMBER> naturally exposed plasmodium falciparum <NUMBER> recently first primeboost vaccinations tuberculosis combining dna <NUMBER> classical bacille calmettegué rin vaccine <NUMBER> recombinant mva expressing mycobacterium tuberculosis antigen <NUMBER>a proved protective mice recombinant mva prime candidate poxvirus vector generation new vaccines infections tumors portrait virus combines desirable elements highlevel biological safety ability activate appropriate innate immune mediators upon vaccination capacity deliver substantial amounts heterologous antigens adoption uptodate methodology convenient vector generation vector quality control vector vaccine immune monitoring increased pace development bringing recombinant mva vaccines clinical trials initial studies testing mva vaccines prophylaxis immunotherapy aids malaria human papilloma virusassociated cancer melanoma already completed table <NUMBER> first results overall encouraging confirm clinical safety importantly however also demonstrate clinical efficacy despite intrinsic difficulties associated target diseases renewed interest development mva candidate vaccine orthopoxvirusrelated biothreat likely provide basis feasible largescale manufacturing mva vaccines indeed first studies suggest mva would provide suitable orthopox vaccine necessary use recombinant mva simultaneously provide immunity smallpox proposed nevertheless one keep mind hasty populationwide smallpox vaccinations might desirable high level antivector immunity could limit future potential poxvirusbased vector vaccines urgently needed prophylaxis therapy uncontrolled infectious diseases cancer emerging infections recent data phase clinical trial treatment metastatic melanoma indicated vaccination mvatransduced dendritic cells vivo activate tcell responses directed recombinant antigen tyrosinase recently identified epitope within vaccinia virus envelope antigen h<NUMBER> <NUMBER> <NUMBER> immunogenicity highly attenuated mva smallpox vaccine protection monkeypox nature <NUMBER> <NUMBER> study compares mva standard dryvax vaccine monkeypox virusmacaque challenge model demonstrating similar immunogenicity substantial protective capacity mva vaccination work represents important step developing mva secondgeneration smallpox vaccine developing safe effective covid<NUMBER> vaccine global priority end pandemic doseescalation singlecentre openlabel phase <NUMBER> trial published lancet fengcai zhu colleagues <NUMBER> report safety tolerability immunogenicity recombinant adenovirus type<NUMBER> ad<NUMBER> vectored covid<NUMBER> vaccine expresses full length spike glycoprotein wuhanhu<NUMBER> strain severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> healthy adults exposed sarscov<NUMBER> aged <NUMBER> <NUMBER> years mean age <NUMBER>·<NUMBER> years <NUMBER> female sequentially enrolled receive low middle high dose vaccine given intramuscular injection observed <NUMBER> days notably high preexisting ad<NUMBER> neutralising antibody titres <NUMBER> <NUMBER> participants shown compromise seroconversion attenuate peak tcell responses although vectorrelated febrile reactions less frequent older participants <NUMBER> years found significantly lower humoral responses one firstinhuman trials covid<NUMBER> vaccine candidate showing immunogenicity two key questions whether responses sustained time whether correlate clinical protection exposure circulating strain sarscov<NUMBER> data primate models suggest measurable neutralising antibodies specific tcell responses could associated protection virus challenge vaccination reinfection studies <NUMBER> <NUMBER> research however necessary evaluate safety clinical efficacy duration protection phase <NUMBER> study experimental vaccine middle low dose begun china nct<NUMBER> canada approved early phase human trial nct<NUMBER> vaccine candidates rapid development mostly based spike glycoprotein receptor binding domain better immunogenic protective potential using different antigen delivery platforms eg recombinant protein replicating nonreplicating viralvector based vaccines dna mrna vaccines several entering phase <NUMBER> clinical trials pending results <NUMBER> <NUMBER> looking forward immunogenicity future trial design establish efficacy need define target groups eg healthcare workers individuals high risk severe illness clinical endpoints eg reduction virologically confirmed clinical illness hospitalisations deaths optimal duration observation eg virus exposure sideeffects antibody titre change anticipate antigenic change time results study indicate host factors might affect vaccine response suboptimal immunogenicity reported among older partici pants echoing challenge seen influenza vaccination study older age group inclusion individuals underlying conditions important risk severe disease might benefit vaccine prevention preexisting immunity ad<NUMBER> vector could compromise immunogenicity potentially limiting effectiveness populations virus endemic reported high seroprevalence around <NUMBER> many countries posed substantial challenges vectorbased vaccine development infections eg ebola virus hiv <NUMBER> <NUMBER> <NUMBER> whether using rarer serotype nonhuman primate adenovirus adjuvants booster higher dose regimens delivery platforms eg replicationdefective vaccinia could achieve greater degrees immunogenicity unknown research needed <NUMBER> <NUMBER> <NUMBER> another general concern possibility antibodydependent enhancement eg nonneutralising antibodies fc γreceptors increased cellular immunopathology eg thelper<NUMBER> thelper<NUMBER> cell individuals vaccinated subsequently infected circulating sarscov<NUMBER> strain suggested preclinical studies sarscov<NUMBER> middle east respiratory syndrome coronavirus vaccines wholelength spike glycoprotein leading research receptor binding domainfocused vaccine <NUMBER> <NUMBER> <NUMBER> animal studies considered assess potential risk sarscov<NUMBER> vaccine candidates <NUMBER> preexisting nonspikespecific tcell responses endemic human coronavirus exposure eg oc<NUMBER> nl<NUMBER> crossreact sarscov<NUMBER> could add complexity predicting vaccine response safety <NUMBER> <NUMBER> concerns need addressed future clinical studies close monitoring regulatory review amid uncertainties report immunogenic tolerable vaccine candidate encouraging starting line covid<NUMBER> vaccine development vaccine candidates shown efficacious require substantial well directed globally coordinated investments production delivery benefit realised nl reports nonfinancial travel meeting support shionogi consultancy fees nonfinancial travel support janssen pharmaceuticals consultancy fees hvivo consultancy fees educational programme speaker support seqirus consultancy fees nonfinancial travel support f hoffmannla roche consultancy fees nonfinancial travel support sanofipasteur consultancy fees gilead sciences educational programme speaker travel support genentech consultancy fees cidara outside area work commented declares competing interests middle east respiratory syndrome mers newly emerging acute respiratory system infectious disease characterised acute pneumonia respiratory failure renal failure caused merscoronavirus merscov <NUMBER> <NUMBER> merscov first isolated identified saudi arabia <NUMBER> new member lineage c genus betacoronavirus zoonotic virus transmitted bats camels humans <NUMBER> <NUMBER> <NUMBER> genome merscov nonsegmented positivesense singlestranded rna ssrna approximately <NUMBER> kb encoding <NUMBER> proteins include two replicase polyproteins open reading frames <NUMBER>ab <NUMBER>a four structural proteins including spike envelope e membrane nucleocapsid n proteins five nonstructural proteins open reading frames <NUMBER> <NUMBER>a <NUMBER>b <NUMBER> <NUMBER>b <NUMBER> merscov transmitted persontoperson high <NUMBER> mortality <NUMBER> june <NUMBER> <NUMBER> total <NUMBER> cases including <NUMBER> related deaths reported world health organization <NUMBER> licensed vaccine specific treatment currently available one effective strategies prevent virus infection vaccination considered indispensable especially absence effective treatment drugs continuous increase patients high mortality rate merscov infection highlight urgent need safe effective vaccines development majority recent progresses focused viral glycoprotein receptorbinding domain rbd protein <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> showed proteinbased rbdbased subunit vector vaccine contain multiple neutralizing epitopes high potentials induce strong neutralizing antibodies merscov infection thus considered promising target effective mers vaccine design <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> additionally almazan et al constructed fulllength infectious cdna clone merscov genome lacked e gene reverse genetics approach develop attenuated viruses vaccine candidates <NUMBER> theoretically nearly viral proteins potential immunogens vaccine targets thus addition protein viral proteins merscov might effective immunogen targets mers vaccine however studies analyzed tested possibility viral proteins merscov vaccine targets importantly tcellbased cellular immunity essential cleaning merscov infection yet vaccine protein mainly elicits neutralizing antibody response high mutation rate protein may result escape neutralizing antibodies merscov therefore highly conserved target elicit neutralizing antibody cellular immunity merscov essential effective vaccine development epitopes also known antigenic determinant represents minimal immunogenic region protein antigen precisely elicit specific immune responses <NUMBER> numerous studies show epitopebased vaccines could effectively elicit protective immune responses diverse pathogens human immunodeficiency virus influenza virus hepatitis b virus hepatitis c virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> nevertheless emerging highly pathogenic pathogens like merscov h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> although genome sequences available genbank database immunity associated protection currently largely unknown gaps understanding immune protection make developing vaccines highly pathogenic viruses difficult challenging <NUMBER> therefore immunoinformaticsdriven approach thoroughly screen dominant immunogens based available genome sequences data pathogens essential promising effective vaccine design emerging infectious diseases <NUMBER> study based newly available genome sequence data merscov numerous epitope vaccine candidates could elicit protective humoral cellular immune responses obtained immunoinformaticsdriven vaccine target screening strategy results provided new vaccine epitope candidates mers vaccine development indicated immunoinformaticdriven immunogen screening promising strategy accelerate vaccine development emerging highly pathogenic pathogens entire viral proteome sequences merscov isolates include structural proteins spike protein envelope protein e membrane protein nucleocapsid protein n nonstructural proteins orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> orf<NUMBER>b two replicase polyproteins orf<NUMBER>ab orf<NUMBER>a retrieved national center biotechnology information database httpwwwncbinlmnihgov used input various bioinformatics tools antigenicity assessment secondary structure <NUMBER>d model prediction epitope prediction sequences come different geographic regions saudi arabia england qatar spain germany jordan korea time ranges <NUMBER> <NUMBER> antigenicity refers ability antigen recognized immune system hence find best potential candidate antigen vaxijen v<NUMBER> server <NUMBER> httpwww ddgpharmfacnetvaxijenvaxijenvaxijenhtml used analyzing whole protein antigenicity determined potent antigenic protein vaxijen web server developed dr doytchinova ia dr flower dr faculty pharmacy medical university sofia prediction protective antigens tumor antigens subunit vaccines prediction accuracy <NUMBER> <NUMBER> discrimination antigens nonantigens <NUMBER> study virus chosen target organism default parameter single antigenic protein highest antigenicity score selected vaccine candidate analysis antigenicity closely related secondary tertiary structure protein hence determine antigenicity function target protein secondary structure target protein included solvent accessibility transmembrane helices globular regions coiled coil regions predicted using expasys secondary structure prediction server protparam <NUMBER> httpwebexpasyorgprotparam selfoptimized prediction method alignment sopma <NUMBER> httpsnpsaprabiibcpfrcgibinnpsaautomatpl pagenpsanpsasopmahtml default parameter protparam tool allows computation various parameters including molecular weight theoretical pi amino acid composition atomic composition extinction coefficient estimated halflife instability index aliphatic index grand average hydropathicity gravy given protein sopma method correctly predicts <NUMBER> secondary structure αhelix βsheet coil <NUMBER> raptorx web server <NUMBER> httpraptorxuchicagoedu used predict threedimensional <NUMBER>d structure binding residues chosen protein method kolaskar tongaonkar <NUMBER> immune epitope database iedb httptoolsimmuneepitopeorgbcell applied predict linear bcell epitopes kolaskar tongaonkar method applied large number proteins predict bcell epitopes developers results showed method predict epitopes <NUMBER> accuracy hence better known methods <NUMBER> properties bcell epitopes also include flexibility surface accessibility hydrophilicity hence predicted karplus schulz flexibility prediction <NUMBER> emini surface accessibility prediction <NUMBER> threshold <NUMBER> respectively iedb conformational bcell epitopes predicted ellipro httptoolsimmuneepitopeorg ellipro <NUMBER> minimum score value set <NUMBER> maximum distance selected <NUMBER> å ellipro allows prediction visualization bcell epitopes given protein sequence structure test ellipro benchmark dataset discontinuous epitopes inferred <NUMBER>d structures antibodyantigen complexes shown best performance compared six structurebased epitope prediction methods <NUMBER> netmhciipan <NUMBER> server <NUMBER> httpwwwcbsdtudkservicesnetmhciipan used predict helper tcell epitopes threshold strong binding peptides ic <NUMBER> set <NUMBER> nm determine binding interaction potentials helper tcell epitope peptide major histocompatibility complex mhc class ii allele netmhciipan<NUMBER> first panspecific helper tcell epitope prediction method covers human leucocyte antigen hla class ii molecules including hladr hladp hladq predict peptide binding hla class ii molecule specified protein sequence <NUMBER> method evaluated developers shown significant improvement moleculespecific methods hence considered accurate mhc class ii predictor <NUMBER> top <NUMBER> epitopes maximum binding hladr alleles selected putative epitope candidates cytotoxic lymphocyte ctl epitope prediction made using iedb analysis resource netmhcpan version <NUMBER> tool <NUMBER> <NUMBER> consensus tool <NUMBER> combines predictions ann aka netmhc <NUMBER> <NUMBER> <NUMBER> smm <NUMBER> comblib <NUMBER> netmhcpan highthroughput computational method genomeand hlawide prediction peptide binding hla class molecules contains hla class alleles hence offer truly global analysis binding antigenetic peptide hla molecule promote rational vaccine design <NUMBER> netmhc prediction method average <NUMBER> accuracy peptides binding hla class molecules employed widely predict hlabinding peptides proteomes various pathogens including sars influenza hiv <NUMBER> percentile rank threshold set <NUMBER> study top <NUMBER> epitopes maximum binding hlaa alleles selected putative epitope vaccine candidates except strong binding affinity peptides strong immunogenicity likely ctl epitopes weak immunogenicity hence iedb immunogenicity prediction tool httptoolsimmuneepitopeorg immunogenicity used predict immunogenicity candidate epitopes <NUMBER> tool predicts immunogenicity peptidehla phla complex based amino acid properties positions defined peptide epitope conservancy analysis tool httptoolsimmuneepitopeorgtoolsconservancy iedbinput iedb applied epitope conservancy analysis <NUMBER> conservancy levels obtained searching identities given protein sequence tool calculates degree conservancy epitope within given protein sequence set different degrees sequence identity degree conservancy defined fraction protein sequences containing epitope given identity level allergenicity epitopes analyzed allerhunter server <NUMBER> httptigerdbs nusedusgallerhunter allerhunter svmpairwise system assessment allergenicity allergic crossreactivity proteins aims predict allergens nonallergens high sensitivity specificity without compromising efficiency classification proteins similar sequences known allergens <NUMBER> due mhc restriction cell response peptides different hla binding specificities mean population coverage defined geographical regions peptidebased vaccine might employed population coverage rate individual epitope calculated using iedb population coverage tool httptoolsimmuneepitopeorgtools populationiedbinput <NUMBER> every epitope binding hla alleles added different geographic areas also selected selection immunogen first step vaccine design hence obtain probable antigenic protein whole viral proteomes merscov isolates retrieved screened total <NUMBER> merscov variants different geographical regions entire proteomes obtained s<NUMBER> table antigenicity protein indicated overall score produced specific protein sequence using vaxijen server whole scores n protein orf<NUMBER>b protein merscov higher e orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> orf<NUMBER>ab orf<NUMBER>a proteins moreover orf<NUMBER>b protein genbank id ail<NUMBER> n protein genbank id agv<NUMBER> possessed significantly highest antigenic scores <NUMBER> <NUMBER> respectively among query proteins s<NUMBER> table however orf<NUMBER>b protein would rapidly degraded proteasomes absence orf<NUMBER>a protein accessory protein orf<NUMBER>b <NUMBER> thus ideal antigen candidate although high antigenic score study n protein chosen candidate immunogen model protein carry epitopebased vaccine design probable antigenic protein analyzed secondary structural characteristics properties included total length <NUMBER> aa molecular weight <NUMBER> da theoretical pi <NUMBER> formula c <NUMBER> h <NUMBER> n <NUMBER> <NUMBER> <NUMBER> <NUMBER> alpha helixes <NUMBER> extended strands <NUMBER> beta turns <NUMBER> random coils obtained shown table <NUMBER> fig <NUMBER> grand average hydrophobicity rule gravy n protein linear sequence predicted negative <NUMBER> indicated property protein hydrophilic nature residues present surface means amino acids tend binding residues interacted proteins <NUMBER>d structure showed maximum <NUMBER> identity n protein merscov best template protein pdb <NUMBER>ofza rna binding domain sars nucleocapsid protein composed two separate domains pockets fig <NUMBER> protein binding site prediction showed total <NUMBER> binding residues including t<NUMBER> v<NUMBER> s<NUMBER> y<NUMBER> t<NUMBER> g<NUMBER> r<NUMBER> y<NUMBER> y<NUMBER> r<NUMBER> a<NUMBER> s<NUMBER> mapped domain<NUMBER> <NUMBER> binding residues including g<NUMBER> l<NUMBER> mapped domain<NUMBER> obviously domain<NUMBER> possessed greater ability interact proteins domain<NUMBER> might associated distribution conformational epitopes n protein merscov one key steps epitopedriven vaccine design prediction identification bcell epitopes target antigens thus obtain bcell epitope candidates n protein merscov silico identification bcell epitopes based iedb database performed based kolaskar tongaonkars method iedb total <NUMBER> linear bcell epitopes n protein merscov identified length epitopes ranged <NUMBER> <NUMBER> amino acids epitopes <NUMBER> conservancy level among specified n protein sequences notably epitopes <NUMBER> paapravsf <NUMBER> <NUMBER> npvyflrysgaikl <NUMBER> allergic human hence could vaccine candidates epitopes length sequences location conservancy allergenicity shown table <NUMBER> results showed average antigenic prospensity value predicted epitopes <NUMBER> minimum <NUMBER> maximum <NUMBER> s<NUMBER> fig since surface accessibility fragment flexibility also key features predicting bcell epitopes thus surface accessibility flexibility analyzed based methods iedb results analysis surface accessibility predicted peptides showed maximum surface probability value <NUMBER> amino acid position <NUMBER> <NUMBER> sequence hexapeptide <NUMBER> kkekkq <NUMBER> <NUMBER>e surface residue minimum value surface probability <NUMBER> peptides <NUMBER> gigavg <NUMBER> <NUMBER>g surface residue s<NUMBER> fig likewise results analysis flexibility predicted peptides showed maximum flexibility value <NUMBER> amino acid position <NUMBER> <NUMBER> sequence <NUMBER> gnsqsss <NUMBER> <NUMBER>q flexible residue minimum value flexibility probability <NUMBER> peptides <NUMBER> rwyfyyt <NUMBER> <NUMBER>f flexibility residue s<NUMBER> fig addition total <NUMBER> conformational bcell epitopes protrusion index pi score value <NUMBER> obtained ellipro highest probability conformational epitope calculated <NUMBER> pi score <NUMBER> shown fig <NUMBER>a residues involved conformational epitopes location number residues scores shown table <NUMBER> whereas positions <NUMBER>d structures shown fig <NUMBER>a <NUMBER>j since mhcii restricted cd<NUMBER> tcells activation important inducing maintaining efficient antibody response ctl response hence helper tcell epitopes n protein merscov silico identified result total <NUMBER> antigenic peptides <NUMBER>mer core sequences n protein merscov identified helper tcell epitopes using netmhciipan <NUMBER> server s<NUMBER> table bind different large number hladr alleles ic <NUMBER> value less <NUMBER>nm indicated high binding affinity hladr molecules based fact good tcell epitope interact many hla alleles possible top <NUMBER> epitopes highest number binding hladr alleles selected putative helper tcell epitope candidates table <NUMBER> <NUMBER> putative helper tcell epitopes numerous binding hladr alleles tend good epitope candidates among epitope <NUMBER> lrysgaikl <NUMBER> interacting <NUMBER> hladr alleles epitope possessing maximum number binding hladr alleles contrary <NUMBER> vkqsqpkvi <NUMBER> interacting <NUMBER> hladr alleles epitope possessing minimum number binding hladr alleles selected putative epitopes highly conserved <NUMBER> conversancy level epitope found allergic humans details predicted putative helper tcell epitopes along respective binding hladr alleles shown s<NUMBER> table know mhci restricted cd<NUMBER> cytotoxic lymphocytes ctls plays crucial role controlling virus infection hence identification ctl epitopes vital understanding principles cell activation epitopedriven vaccine design herein total <NUMBER> immunogenic peptides <NUMBER>mer sequences n protein merscov identified ctl epitopes using mhci binding predictions iedb recommended methods s<NUMBER> table bind different large number hlaa alleles high binding affinity top <NUMBER> epitopes binding hlaa alleles selected putative ctl epitope candidates based broad hla coverage table <NUMBER> among epitope <NUMBER> kqlaprwyf <NUMBER> highest number binding hlaa alleles <NUMBER> alleles followed <NUMBER> nynkwlell <NUMBER> <NUMBER> alleles yet epitopes <NUMBER> aqnagywrr <NUMBER> <NUMBER> alleles <NUMBER> rvqgsitqr <NUMBER> <NUMBER> alleles minimum number binding hlaa alleles ctl epitope candidates positive score immunogenicity showed high potential elicit strong ctl response ctl epitope candidates highly conserved <NUMBER> conservancy level among available n protein sequences merscov isolates epitope found allergic humans details predicted putative ctl epitopes along respective binding hlaa alleles shown s<NUMBER> table population coverage epitopes hla distribution varies among different ethnic groups geographic regions around world thus population coverage must taken account designing effective vaccine cover much possible populations study indicated alleles supplementary data identified optimum binders predicted epitopes used determine population coverage epitopes high population coverage found putative helper tcell epitopes ctl epitopes <NUMBER> specified geographic regions world table <NUMBER> helper tcell epitopes excellent percentage cumulative population coverage <NUMBER> epitopes obtained south asia <NUMBER> closely followed cen results indicated partial regions world central africa east asia approximately half population covered putative ctl epitopes overall results suggested putative helper tcell epitopes ctl epitopes specifically bind prevalent hla molecules target population vaccine employed emerging infectious pathogens merscov h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> highly pathogenic humans pathogens immunity associated protection remain largely unknown gaps understanding protective immunity pathogens make developing vaccines newly emerging infectious diseases difficult challenging <NUMBER> thus genomewide screening vaccine targets based newly available genome sequences data pathogens essential urgent developing efficiently vaccines newly emerging highly pathogenic pathogens study aim screen investigate antigenic protein merscov find band tcell epitopes mapped antigenic protein using strategy namely genomewide screening vaccine epitopes based advances bioinformatics immunoinformatics approach could effective essential strategy vaccine development emerging highly pathogenic pathogens study immunoinformaticsdriven approach used screen vital dominant immunogens merscov results showed n protein better antigenic protein highest antigenic scores compared viral proteins entire viral proteome however nearly current studies mers vaccine focused protein merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> protein mediated recognition host cell dpp<NUMBER> receptor mrescov induced significant immune response <NUMBER> fact protein merscov viral proteins might effective mers vaccine candidates however studies emphasized possibility tcellbased cellular immunity essential cleaning merscov infection yet vaccine protein mainly elicit neutralizing antibody response importantly high mutation rate protein merscov may cause escape neutralizing antibodies protein therefore ideal target highly conserved elicit neutralizing antibody cellular immunity merscov essential effective mers vaccine development n protein human cov abundantly produced infection exhibits strong immunogenicity conservancy act ideal immunogen elicit cellular humoral immune responses <NUMBER> noteworthy large number previous studies shown feasibility n protein immune target antigen vaccine product <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> et al demonstrated sarscov vaccine based n gene expressed dna plasmid adenovirus vector could induce detectable antibody ifnγ <NUMBER> similar studies dna vaccine based sarscov n gene shown potential inducing specific humoral cellular immunity balbc mice <NUMBER> <NUMBER> moreover multiple immunodominant bcell epitopes helper tcell epitopes ctl epitopes mapped n protein sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> additionally antigenicity n protein viruses demonstrated <NUMBER> <NUMBER> antibodies n proteins diverse human covs revealed gao et al <NUMBER> based findings concludes n protein merscov might putative valuable immunogen vaccine development screened epitopes n protein study also may valuable epitopebased vaccine candidates vitro vivo tests antigenic immunogenetic potentials purpose vaccination induce immunity specific pathogens selectively stimulating antigenspecific bcells ctls helper tcells theoretically vaccine contain two classes antigenic epitopes helper tcell epitope bcell epitope ctl epitope based combination epitopes vaccine able either induce specific humoral cellular immune specific pathogens <NUMBER> therefore bcell ctl helper tcell epitopes screened systemically n protein merscov obtain putative epitope vaccine candidates study one bcell epitope <NUMBER> eaalpfravkdgivwvhed <NUMBER> showed lower conservancy <NUMBER> among different merscov isolates compared <NUMBER> epitopes suggesting might idea epitope candidate based fact epitope conservative possible provide broader protection among different virus strains addition various continuous discontinuous bcell epitopes mapped n protein table <NUMBER> fig <NUMBER> discontinuous bcell epitopes located surface domain<NUMBER> n protein showing accessibility entered virus moreover diverse tcell epitopes including helper tcell epitopes ctl epitopes delineated dissecting n proteins tables <NUMBER> <NUMBER> notably neutralizing antibodies far enough completely clean infectious pathogens ctls needed play central role generation protective immune response diverse pathogen infection <NUMBER> study although ctl epitope <NUMBER> qlaprwyfy <NUMBER> showed highest immunogenic score <NUMBER> possessed minimal hla binding alleles among predicted ctl epitopes contrary epitope <NUMBER> kqlaprwyf <NUMBER> maximum hla binding alleles less immunogenic score <NUMBER> inconsistency immunological characteristics among different epitopes suggested various parameters needed considered screened epitopes helper tcell epitopes critical generation vigorous humoral ctl responses however response tcell epitopes restricted hla proteins moreover hla highly polymorphic diverse ethnic populations therefore induce broad immune responses diverse ethnic genetically diverse human populations hla specificity tcell epitopes must considered first major criteria screening epitopes <NUMBER> <NUMBER> based analysis get population coverage epitope candidates bind hla alleles study <NUMBER> ten helper tcell epitopes ctl epitopes bind maximum number hla alleles selected putative vaccine candidates analysis revealed putative helper tcell ctl epitopes ideal population coverage may provide broad immune protection different geographic regions around world additionally ideal epitope highly conserved among different merscov isolates thus conservancy level determined putative epitope candidates epitopes study highly conserved designated merscov isolates suggesting could ideal epitope vaccine candidates elicit protective neutralizing antibodies cellular immune responses merscov conclusion study indicated immunoinformaticsdriven genomewide screening vaccine targets emerging highly pathogenic pathogens promising strategy accelerate vaccine development based strategy bcell epitopes helper tcell epitopes ctl epitopes n protein merscov mapped selected putative mers vaccine candidates however band tcell stimulation potentials screened epitopes needed tested vitro vivo experiments along silico study efficient use vaccines merscov present study provides new valuable epitope candidates prompts future vaccine development mers emerging infectious diseases table <NUMBER>mer peptide core sequences n protein merscov predicted helper tcell epitopes using netmhciipan <NUMBER> web server doc s<NUMBER> table <NUMBER>mer peptide sequences n protein merscov predicted ctl epitopes using iedb mhci binding prediction web server middle east respiratory syndrome coronavirus merscov first identified saudi arabia <NUMBER> <NUMBER> soon first report imported cases occurred many countries outside arabian peninsula infected travelers notably outbreak south korea <NUMBER> <NUMBER> clinical signs merscovinfected patients similar severe acute respiratory syndrome coronavirus sarscov outbreaks china <NUMBER> caused acute respiratory distress syndrome humans <NUMBER> bats dromedaries considered natural reservoirs merscov <NUMBER> continuous increase human cases endemic areas reported <NUMBER> highlighting urgent develop make available effective therapeutic drugs prophylactic vaccines protect merscov date many promising approaches toward merscov vaccine candidates developed recombinant viral vectors <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> proteinbased platforms <NUMBER> <NUMBER> bacterialbased platform <NUMBER> dna vaccines <NUMBER> <NUMBER> <NUMBER> merscov vaccine candidates focused major immunedominant antigen protein virion plays significant role mediating viral entry target cells inducing neutralizing antibodies experimental animals infected individuals <NUMBER> receptorbinding domain rbd within s<NUMBER> domain protein merscov virus decides host range cellular tropism <NUMBER> <NUMBER> <NUMBER> developed two promising merscov vaccine candidates using two different platforms one uses rabies virus rv vector express s<NUMBER> domains merscov gene develop recombinant merscov vaccine applies grampositive enhancer matrix gem particles vector construct mers bacterium lactococcus lactislike particle blp vaccine displaying rbd <NUMBER> previous study utilized rv bnsp<NUMBER> vector modified rv vaccine vector spbn successfully design vaccine merscov infection <NUMBER> <NUMBER> whereas rv vector srv<NUMBER> strain used study screened street alabama dufferin sad strain plaque purification baby syrian hamster kidney cells bhk<NUMBER> cells proven safe good immunogenicity <NUMBER> gempa system novel surface display system consisting nonliving genetically unmodified gem particles protein anchor pa lactococcus lactis peptidoglycan hydrolase acma utilized system successfully display rbd protein fragment merscov inducing high neutralizing antibodies intramuscular vaccination robust antigenspecific local systemic immune responses intranasal vaccination <NUMBER> headtohead comparison available vaccine vectors necessary vaccine design <NUMBER> difference immune response induced two different merscov vaccine candidates effect antigen displayed viral bacterial vectors immune response still questionable study evaluated immunological efficacy mers blp different doses inactivated recombinant mers antigen bablc mice specifically compared ability two vaccines induce merscovspecific humoral immune response tcellmediated immune response well neutralizing antibodies merscov animal works strictly accordance welfare ethical guidance chinese laboratory animals gb <NUMBER> agreement approved animal welfare ethics committee institute veterinary medicine changchun veterinary research institute laboratory animal care use committee authorization permit number jsydw<NUMBER> baby syrian hamster kidney bhk<NUMBER> cells cultured serumfree medium viruspro ® shanghai china <NUMBER> • c <NUMBER> co <NUMBER> orbital shaker <NUMBER> rpm suspension culture virus infection mouse neuroblastoma na cells cultured dulbeccos modified eagle medium dmem thermo fisher scientific waltham usa plus <NUMBER> fetal bovine serum fbs biological industries kibbutz beit haemek israel determination viral titer verification virus inactivation spodoptera frugiperda <NUMBER> sf<NUMBER> gibco grand island ny usa insect cells grown sf<NUMBER>tm ii medium life technologies san diego ca usa protein expression recombinant rv expressing merscov s<NUMBER> protein rvmers constructed stored laboratory rvmers virus cultivated bhk<NUMBER> cells briefly bhk<NUMBER> cells <NUMBER> × <NUMBER> <NUMBER> cells per ml grown shake flask cultures infected rvmers virus multiplicity infection moi <NUMBER> rvmers harvested culture supernatant cell culture two days postinfection dpi titers recombinant virus determined median endpoint <NUMBER> tissue culture infectious dose units tcid <NUMBER> na cells described previously <NUMBER> recombinant virus inactivated <NUMBER> βpropiolactone vv mixtures incubated <NUMBER> • c overnight treated <NUMBER> • c <NUMBER> h verification virus complete inactivation detected na cells completely inactivated virus purified <NUMBER>kd hollow fiber ultrafiltration column sepharose fast flow <NUMBER> gel fractions harvested analyzed immunoblotting total protein concentration purified product determined bicinchoninic acid bca protein assay mers blp produced previously described <NUMBER> briefly fusion protein rbdlinkerpa<NUMBER> expressed baculovirus expression system gem particles used vectors construct mers blp externally displaying rbd pa<NUMBER> fusion protein concentration mers blp detected densitometrically using quantity one image analysis software version <NUMBER> size hydrodynamic diameter nm size distribution polydispersity index pdi rvmers mers blp determined using laser particle size analyzer nano zs<NUMBER> malvern instruments worcestershire uk fresh prepared rvmers mers blp suspension determined almost humidity temperature <NUMBER> • c sample measurement performed triplicate simultaneously fourto sixweekold female balbc mice purchased changchun yisi laboratory animal technology co ltd changchun china female balbc mice randomized five groups <NUMBER> mice intramuscularly primeimmunized <NUMBER> µg purified rvmers virus <NUMBER> <NUMBER> <NUMBER> µg mers blp mixed compound adjuvants consisting isa<NUMBER>vg seppic paris france poly c sigma st louis mo usa boosted twice equal volume antigen primary vaccination <NUMBER>week intervals compound adjuvants immunized negative control blood samples collected immunization two weeks vaccination serum samples inactivated <NUMBER> • c <NUMBER> min determining merscov rbdspecific antibodies neutralizing antibodies five mice selected randomly group euthanized day <NUMBER> third immunization splenocytes collected cytokines analysis enzymelinked immunosorbent assay elisa applied analyze merscov rbdspecific igg igg<NUMBER> igg<NUMBER>a igg<NUMBER>b igg<NUMBER>c igg<NUMBER> antibodies serially diluted sera added <NUMBER>well microtiter plates corningcostar corning ny usa precoated overnight mersrbd protein <NUMBER> µgml produced escherichia coli plates incubated <NUMBER> • c <NUMBER> h washed three times pbst incubated following horseradish peroxidase hrp labeled antimouse igg <NUMBER> bioworld st louis mn usa igg<NUMBER> igg<NUMBER>a igg<NUMBER>b igg<NUMBER>c igg<NUMBER> <NUMBER> southern biotech birmingham al usa <NUMBER> • c <NUMBER> h plates washed three times <NUMBER> µl tmb <NUMBER> <NUMBER> <NUMBER> <NUMBER> tetramethylbenzidine per well added color development stopped adding h <NUMBER> <NUMBER> optical density values read <NUMBER> nm using elisa plate reader biorad hercules ca usa neutralizing titers mice sera detected using merscov pseudovirus reported previous study <NUMBER> briefly serially diluted mouse sera mixed equal volume <NUMBER>× tcid <NUMBER> merspseudotyped viruses incubated <NUMBER> • c <NUMBER> min mixture incubated huh <NUMBER> cells <NUMBER> • c <NUMBER> h incubation medium replaced complete dmem containing <NUMBER> fetal bovine serum <NUMBER> penicillinstreptomycin samples incubated <NUMBER> • c <NUMBER> h luciferase activity detected using infinite m<NUMBER> microplate spectrophotometer tecan männedorf switzerland evaluate antigenspecific tcell responses splenocytes harvested day <NUMBER> third immunization stimulated <NUMBER> µm merscov peptide s<NUMBER> <NUMBER> h <NUMBER> • c <NUMBER> secreted tumor necrosis factoralpha tnfα interferongamma ifnγ interleukin <NUMBER> il<NUMBER> supernatants detected mouse elisa cytokine kits mabtech nacka sweden statistical analysis performed using graphpad <NUMBER> software results expressed mean ± sd significance differences groups analyzed using students ttest particle size polydispersity index rvmers mers blp measured dynamic light scattering dls device immunization mice shown figure <NUMBER> compare immunological efficacy two merscov vaccines derived two different vectors studied impact immunogenicity merscov blp different doses immunogenicity rvmers one certain dose mice schematic diagram group design immunizations immunological characterization shown figure <NUMBER>a total five groups mice g<NUMBER>g<NUMBER> administered three immunizations combined adjuvant intramuscular im route g<NUMBER> immunized pbs negative control g<NUMBER> immunized <NUMBER> µg inactivated purified rvmers g<NUMBER>g<NUMBER> immunized <NUMBER> µg low dose <NUMBER> µg medium dose <NUMBER> µg high dose merscov blp respectively sequential sera samples collected weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER> detected neutralizing activity pseudotyped merscov binding activity splenocytes harvested <NUMBER> weeks last immunization cytokines analysis shown figure <NUMBER>b g<NUMBER> developed neutralizing antibody response <NUMBER> weeks first immunization neutralizing antibodies g<NUMBER> g<NUMBER> g<NUMBER> detected point however neutralizing antibody g<NUMBER> g<NUMBER> g<NUMBER> significantly higher g<NUMBER> <NUMBER> <NUMBER> weeks immunization also significant differences neutralizing activity among g<NUMBER> g<NUMBER> g<NUMBER> indicating <NUMBER> µg merscov blp efficiently induce merscov neutralizing antibodies mice overall results show rvmers rapidly induce neutralizing antibody response mers blp induce higher antibody response mice total five groups mice immunized detected virusneutralizing antibody igg subtypes cytokines release group <NUMBER> g<NUMBER> negative controls group <NUMBER> g<NUMBER> vaccinated inactivated purified rabies virus rvmiddle east respiratory syndrome mers group <NUMBER> group <NUMBER> group <NUMBER> g<NUMBER> g<NUMBER> g<NUMBER> vaccinated varying doses mers bacterium lactococcus lactislike particle blp groups received second third identical vaccination boost combined adjuvant <NUMBER>week intervals primary immunization b neutralizing activity detected using mers coronavirus merscov pseudovirus data shown mean ± sd five mice group analyzed students ttest p <NUMBER> p <NUMBER> p <NUMBER> n <NUMBER> next detected merscov rbdspecific igg igg subtypes antibodies level serum <NUMBER> weeks postimmunization elisa results indicate mers antigeninduced igg antibodies specifically bind merscov rbd protein particularly g<NUMBER>g<NUMBER> acquired stronger binding merscov rbd protein g<NUMBER> whereas g<NUMBER> control samples detected negligible binding activity figure <NUMBER>a indicating specificity igg antibody response induced rbd protein additionally endpoint titers igg antibody level showed immunogenicity g<NUMBER>g<NUMBER> much stronger g<NUMBER> inducing merscov rbdspecific igg antibody response mice three vaccinations figure <NUMBER>b furthermore significant difference shown igg titers among groups g<NUMBER> g<NUMBER> g<NUMBER> suggesting <NUMBER> µg antigen protein bacterial vector sufficient induce high rbdspecific antibody level mice thus merscov antigen protein displayed surface bacterial vector significantly enhance immunogenicity rbd fragments helper <NUMBER> th<NUMBER> response associated igg<NUMBER> helper <NUMBER> th<NUMBER> response correlates igg<NUMBER>a igg<NUMBER>b igg<NUMBER>c igg<NUMBER> mice <NUMBER> order evaluate igg subtypes levels serum immunized mice production igg<NUMBER> igg<NUMBER>a igg<NUMBER>b igg<NUMBER>c igg<NUMBER> sera detected observation sera igg subtypes showed sera g<NUMBER>g<NUMBER> induced significantly higher levels igg<NUMBER> antibody g<NUMBER> figure <NUMBER>a sera g<NUMBER>g<NUMBER> induced significantly higher levels igg<NUMBER>a igg<NUMBER>b antibodies g<NUMBER> figure <NUMBER>bc significant difference igg<NUMBER>c antibody level g<NUMBER>g<NUMBER> figure <NUMBER>d sera g<NUMBER> induced significantly higher levels igg<NUMBER> antibody g<NUMBER> figure <NUMBER>e however analysis ratios igg<NUMBER>aigg<NUMBER> revealed sera g<NUMBER> remarkably higher g<NUMBER>g<NUMBER> figure <NUMBER>f collectively results suggest merscov antigen protein displayed surface viral vector appears induce stronger th<NUMBER>biased immune response bacterial vector next order analyze merscov specific tcell immune responses detected levels secreted ifnγ il<NUMBER> tnfα splenocytes restimulation mers s<NUMBER> peptide levels ifnγ il<NUMBER> g<NUMBER> significantly higher g<NUMBER> g<NUMBER> suggesting <NUMBER> µg antigen protein bacterial vector sufficient induce potent ifnγil<NUMBER>expressing tcell responses whereas levels ifnγ il<NUMBER> tnfα g<NUMBER> remarkably higher g<NUMBER>g<NUMBER> <NUMBER> weeks postimmunization wpi figure <NUMBER> results indicate merscov antigen protein displayed viral vector induces superior cellular immune response bacterial vector figure <NUMBER> immunization induced significant cytokine response mice order evaluate antigenspecific tcell responses splenocytes harvested five mice group stimulated merscov peptide s<NUMBER> <NUMBER> h level secreted ifnγ il<NUMBER> b tnfα c supernatants detected mouse elisa kits data shown mean ± sd analyzed students ttest p <NUMBER> p <NUMBER> n <NUMBER> merscov continues infect humans causing morbidity mortality since several outbreaks <NUMBER> caused potential global merscov pandemic however prophylactics therapeutics available protect mers currently licensed although researchers developed tested several merscov vaccine candidates many animal models candidate vaccines several advantages challenges preexisting immunity immunogenicity costeffectiveness developed two promising merscov vaccine candidates using two different platforms one recombinant rv expressing merscov s<NUMBER> protein fragment uses gem particles vector display merscov rbd protein fragment study compared humoral cellular responses balbc mouse model results indicate rvmers vaccine induces rapidly neutralizing antibody stronger tcell immune responses merscov blp vaccine however merscov blp vaccine induce higher level neutralizing antibodies rvmers vaccine two unique aspects highlighted study first rv vector besides merscov proven successfully utilized many emergent infectious diseases ebola virus ebov <NUMBER> lassa virus lasv <NUMBER> marburg virus marv <NUMBER> human immunodeficiency virus type <NUMBER> hiv<NUMBER> <NUMBER> lymphocytic choriomeningitis virus lcmv <NUMBER> additionally ebola virus vaccine close clinical trials <NUMBER> notably chemically inactivated rabies virus vaccines widely used vaccination humans dogs cats ferrets shows safe humans animals <NUMBER> therefore inactivated rabies virusbased vaccine also safe induce neutralizing antibodies target pathogen results show inactivated rabies virus vectors safe immunogenic profiles animals highlight promise vaccine development second unique aspect study gempa system novel surface display system flexible effective costeffective easytohandle alternative heterologous proteins displayed gem particles <NUMBER> gem particles lactococcus lactis boiled acids mainly contain bacterialshaped peptidoglycan spheres lacking cell components <NUMBER> additionally lactococcus lactis safely applied foods recent years <NUMBER> gembased vaccine recognized safe furthermore gem particles proven enhance immune response carrier displaying antigen high density adjuvant vaccine development <NUMBER> <NUMBER> <NUMBER> <NUMBER> gem particles also improve humoral cellular immune response activating maturation dendritic cells enhancing antigenpresenting capacity stimulating dcs produce cytokines <NUMBER> besides peptidoglycan main component gem particles tolllike receptor tlr <NUMBER> ligand <NUMBER> <NUMBER> <NUMBER> moreover gem particles efficiently bind antigen protein room temperature obtain purified proteins onestep centrifugation process <NUMBER> convenient economical scale vaccine development gem particles also bind different antigen proteins particles develop multivalent vaccines <NUMBER> system successfully displayed variety heterologous proteins pathogens showing strong antigenspecific immune responses parenteral vaccination mucosal vaccination including viruses bacteria parasites <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> study results suggest rbd protein merscov displayed gem particles could induce strong humoral cellular immune response even dose low <NUMBER> µg two vaccine platforms study advantages disadvantages rvbased merscov vaccine platform rapidly induce antibody immune response higher cellular immune response gembased vaccine platform however risk incomplete inactivation process inactivating rvmers additionally rvmers vaccine needs purified many purification steps factors must considered vaccine production antigen protein density distribution particle two key parameters eliciting efficient immune response vaccine design high density ordered antigenic array displayed particle makes binding events host bcell surface immunoglobulins particle occur easily important step inducing sequential immune response <NUMBER> gembased vaccine platform could display antigen protein high density rvbased vaccine platform displayed antigen protein also expressed rv gp protein may gembased vaccine merscov induces much stronger humoral immune response mice rvbased vaccine microparticles could promote humoral immune response nanoparticles much easier induce cellular immune response <NUMBER> <NUMBER> size rvmers virion <NUMBER> nm diameter mers blp particles <NUMBER> nm may critical factor inducing different cellular immune response two different vectors vaccine platforms specific molecules microbial origin intrinsic innate immune triggers endowed adjuvant activity lipopolysaccharide lps bacterial lipopeptides deoxyribonucleic acid dna ribonucleic acid rna conserved molecules <NUMBER> receptors molecules mammalian tolllike receptors tlrs members tlrs confirmed cell surface membrane tlr<NUMBER> membrane endosomes tlr<NUMBER> <NUMBER> peptidoglycan main component gem particles tlr <NUMBER> ligand activation tlr<NUMBER> receptors human peripheralblood mononuclear cells inducing th<NUMBER>type immune response <NUMBER> single stranded rna component inactivated rabies virus tlr <NUMBER> ligand <NUMBER> <NUMBER> tlr<NUMBER> agonists shown th<NUMBER> polarizing effects immune response different receptors play important role delivering different signals host cells activated antigen presenting cells apcs precisely define nature perceived danger send information secondary lymphoid organs inducing relevant adaptive immune response may another ignored factor inducing different immune response immune system thinking danger virus infection bacterial infection immune system triggered combination events stimuli vaccine immunology compound adjuvants containing emulsion polyic tlr <NUMBER> ligand may another assignable cause speed antibodies production cellular immune response needs improved future study gembased vaccine platform solve problems try screen optimum adjuvants vaccine codisplaying proteinadjuvants gem particles flagellin tlr <NUMBER> ligand furthermore gembased vaccine platform may suitable develop mucosal vaccines considering lactococcus lactis safely used probiotic foods understanding modes action gembased vaccine platform allow us design much safer costeffective protective vaccine desired immune response goal study test vaccine vectors headtohead comparison immunogenicity two merscov vaccine candidates might used real vaccines humans animals study provides important reference selecting suitable vaccine platform developing merscov vaccine special pathogens study volunteers admitted clinical trial ward evening vaccination extensive series laboratory safety tests performed volunteers vaccinated morning monitored regularly least <NUMBER> hours administration vaccine released temperature blood pressure heart rate documented <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> hours vaccination volunteers documented solicited unsolicited adverse events diary study day <NUMBER> body temperature assessed orally daily days <NUMBER> <NUMBER> evenings diary written days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> laboratory safety tests assessed ambulatory visits days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> included full blood count electrolytes <NUMBER> liver renal function tests creactive protein troponin measurements adverse events assessed categorized based whether solicited expected therefore predefined study protocol unsolicited events data solicited adverse events collected <NUMBER> days injection solicited events included local pain induration erythemaredness hematoma swelling injection site systemic adverse events namely fever chills fatigue malaise myalgia arthralgia headaches gastrointestinal symptoms diarrhea loose stool abdominal cramps nausea unsolicited adverse events events listed events arose days <NUMBER> <NUMBER> well day <NUMBER> <NUMBER> days booster vaccination occurrence serious adverse events sae monitored throughout study sae defined event results death lifethreatening required inpatient <NUMBER> hospitalization caused prolongation existing hospitalization resulted persistent disability required intervention prevent permanent impairment damage adverse events listed graded participant according medical dictionary regulatory activities meddra ae grade <NUMBER> mild <NUMBER> moderate <NUMBER> severe severity adverse events assessed using common toxicity criteria ctcae version <NUMBER> fdas <NUMBER> voluntary guidance defined study protocol general adverse events considered mild event interfere activities daily living moderate interfered daily living activities pose significant permanent risks participants severe adverse events significantly affected daily living clinical status blood pressure levels pulse rate assessed time points temperature measurements vital <NUMBER> signs remained stable significant changes data shown merscovsspecific antibodies sera vaccinated individuals quantified using inhouse s<NUMBER> enzymelinked immunosorbent assay elisa according previously validated protocol <NUMBER> briefly <NUMBER>well microtiter elisa plates coated overnight <NUMBER> μgml merscov s<NUMBER> protein plates blocked <NUMBER>h followed addition sera diluted <NUMBER> following <NUMBER>h incubation plates washed bound antibodies detected using hrplabelled rabbit antihuman igg dako signal developed using <NUMBER>tetramethylbenzidine tmb thermofisher scientific substrate reaction stopped <NUMBER>·<NUMBER>n sulfuric acid absorbance sample measured <NUMBER> nm using microplate reader infinite f<NUMBER> tecan cutoff set optical density od value <NUMBER>·<NUMBER> od<NUMBER> antimerscoronavirus elisa igg purchased euroimmun ag lübeck order number ei <NUMBER> g human serum samples analyzed according working instruction kit using bep ® behring elisa prozessor iii system brief human sera diluted <NUMBER> sample buffer allowed react merscov s<NUMBER> antigen <NUMBER> minutes three washes washing buffer antihumanigg coupled peroxidase used detection <NUMBER> min incubation substrate solution added well another wash allowed react <NUMBER> min reaction stopped od determined <NUMBER> nm <NUMBER> nm samples analysed duplicates quantification results performed using serially diluted human monoclonal antimerscov spike antibody m<NUMBER> <NUMBER> analysed every plate final concentrations standards s<NUMBER> <NUMBER> ngml s<NUMBER> <NUMBER> ngml s<NUMBER> <NUMBER>·<NUMBER> ngml s<NUMBER> <NUMBER>·<NUMBER> ngml s<NUMBER> <NUMBER>·<NUMBER> ngml s<NUMBER> <NUMBER>·<NUMBER> ngml od values standards controls test samples transferred graphpad prism <NUMBER> software calculate dose response curve using fourparameter logistic curve fitting cutoff determined minimum asymptote dose response curve results shown figure s<NUMBER> shown figure s<NUMBER> results inhouse elisa correlated well euroimmun elisa presence merscovneutralizing antibodies sera vaccinees investigated according previously published protocols <NUMBER> briefly complement inactivation serum samples carried <NUMBER>°c <NUMBER> min afterwards sera serially diluted <NUMBER>well plates starting <NUMBER> dilution sera incubated <NUMBER> h <NUMBER>°c together merscov emc<NUMBER> isolate <NUMBER> tissue culture infective doses tcid<NUMBER> using huh<NUMBER> cells cytopathic effect cpe analyzed <NUMBER> days postinfection neutralization defined absence cpe compared virus controls human monoclonal antibody served neutralization control <NUMBER> test positive control neutralizing antibody m<NUMBER> used duplicates interassay control results neutralization vs cpe checked dualcontrol principle neutralization titers calculated reciprocal values geometric mean titers four replicates titer <NUMBER> considered positive sera tested presence merscovneutralizing antibodies using plaque reduction neutralization assay prnt previously described minor modifications <NUMBER> heatinactivated serum samples serially diluted twofold starting <NUMBER> mixed <NUMBER> <NUMBER> pfu merscov emc<NUMBER> incubated <NUMBER> hours mix overlayed monolayer huh<NUMBER> cells <NUMBER>well plates incubated <NUMBER>h mix subsequently removed cells incubated <NUMBER> hours allow one replication cycle virus occur following cell infection cells fixed stained using antimerscovn protein mouse monoclonal antibody sino biological secondary peroxidaselabelled goat antimouse igg<NUMBER> southernbiotech signal developed using precipitateforming tmb substrate true blue kpl number infected cells per well counted using immunospot® image analyzer ctl europe gmbh neutralization titer serum sample determined reciprocal value highest dilution resulting least <NUMBER> reduction number infected cells prnt<NUMBER> titer ≥ <NUMBER> considered positive peripheral blood mononuclear cells pbmcs isolated cryopreserved edtablood using ficoll density gradient centrifugation interferonγ ifnγ secretion analyzed using ctl human ifnγ single color <NUMBER>well enzymelinked immuno spot assay elispot immunospot® following thawing overnight resting <NUMBER>x<NUMBER> <NUMBER> pbmcs plated well incubated serumfree medium ctl medium immunospot ® <NUMBER>h <NUMBER>°c <NUMBER> co<NUMBER> overlapping peptide pools olps spanning entire amino acid sequence merscov protein final concentration <NUMBER> µgml incubation phytohemagglutinin pha cef pool cmv ebv influenza peptide pool jpt peptide technologies served positive controls negative controls incubated ctl medium plus dimethyl sulfoxide dmso concentration used reconstitution merss peptide pools spot detection elispot image acquisition analyses performed using aid elispot robotic system aid gmbh germany spot forming cells sfc calculated using geometric mean triplicates dmso controls used normalize data positive response defined using two criteria first response <NUMBER> sfc per <NUMBER> pbmcs secondly fourfold value baseline day <NUMBER> ifnγelispot assays performed pbmcs isolated days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> post vaccination <NUMBER> antigenspecific tcells analyzed using cryopreserved pbmcs following overnight resting pbmcs incubated <NUMBER>h <NUMBER>°c overlapping peptide pools olps spanning aa sequence merscovs presence cd<NUMBER>cd<NUMBER>d bd bioscience golgistop biolegend golgiplug sigma negative controls treated dmso concentration cells stimulated olps pma cef served positive controls used following antibodies evaluate cd<NUMBER> ifnγ cd<NUMBER> ifnγ expression zombie aqua biolegend cd<NUMBER> af<NUMBER> cd<NUMBER> apccy<NUMBER> cd<NUMBER> buv<NUMBER> ifnγ pecy<NUMBER> cells analyzed lsrfortessa bd bioscience evaluated flowjo<NUMBER> gating strategy corresponding antibodypanels depicted figure s<NUMBER> subject pool mentioned study protocol page <NUMBER> refers cros database individuals contacted since individuals included subject pool cro also recruited public advertisement participants study recruited via public advertisement study specifically advertisement placed online google facebook ebay local subway trains financial reimbursement <NUMBER>€ participants offered completion study <NUMBER> participants assessed eligibility <NUMBER> ineligible since meet exclusioncriteria screening day <NUMBER> reasons screening failure given table s<NUMBER> <NUMBER> eligible individuals screened <NUMBER> enrolled study participants since cohort size predefined seven individuals eligible included study participants six healthy controls recruited period ld hd subjects three individuals <NUMBER>x<NUMBER> <NUMBER> pfu n<NUMBER> <NUMBER>x<NUMBER> <NUMBER> pfu n<NUMBER> receive booster immunization excluded perprotocol analysis ld cohort <NUMBER>x<NUMBER> <NUMBER> pfu two participants discontinued due personal reasons within first <NUMBER> days february <NUMBER> april <NUMBER> <NUMBER> replaced replacements completed followup visits included analyses hd cohort <NUMBER>x<NUMBER> <NUMBER> pfu one participant received boost immunization due unrelated urinary tract infection day <NUMBER> july <NUMBER> <NUMBER> dropped late timepoint study dropout replaced avoid substantial increase overall study duration using mannwhitneyu test pvalue <NUMBER>·<NUMBER> calculated since day <NUMBER> booster vaccination day <NUMBER> study visit potential changes day especially changes wbc neutrophils crp could observed parameters including electrolytes liver kidney parameters bilirubin albumin glucose amylase lactate dehydrogenase ldh troponin tnt creatinkinase ck remained largely within normal limits vaccination haematological laboratory changes transient returned normal levels within days significance levels calculated using wilcoxon signedrank test paired mannwhitneyu test unpaired samples hd cohort significant rise oral temperature could observed <NUMBER> hours prime booster vaccinations figure s<NUMBER>b c difference also observed oral temperatures patients ld hd cohort <NUMBER> hours prime booster vaccination gm noted temperature stayed within normal limits none volunteers ld developed fever except two participants hd cohort one vaccinee elevated temperature <NUMBER>·<NUMBER>°c one experienced fever <NUMBER>·<NUMBER>°c events occurred <NUMBER>h post prime vaccination significance levels calculated using wilcoxon signedrank test paired mannwhitneyu test unpaired samples hemoglobin leucocytes low <NUMBER> bodymass index high <NUMBER> penicillin allergy <NUMBER> eg nonattendance scheduled appointment <NUMBER> reasons persons screened participation study ineligible n number persons ineligible due respective reason total numbers participants related ae mild moderate combined per day per symptom group moderate events shown parenthesis within <NUMBER> days prime <NUMBER> boost <NUMBER> vaccination one participant mild moderate ae symptom group day moderate ae used analysis note n<NUMBER> ld n<NUMBER> hd cohort receive boost <NUMBER> dropouts total numbers related unrelated ae number participants kind event total numbers percentages grey systemic white local adverse event dark grey unrelated events representative gating strategy evaluate cd<NUMBER> ifnγ cd<NUMBER> ifnγ cells following stimulation contour plots depict gating strategy evaluate cd<NUMBER> cd<NUMBER> cells b representative plots subject day <NUMBER> vaccination pbmcs stimulated <NUMBER> different pools treated solely r<NUMBER>dmso living cd<NUMBER> cd<NUMBER> cd<NUMBER> cd<NUMBER> cells shown upper plots depict cd<NUMBER> ifnγ cells lower plots cd<NUMBER> ifnγ cells c mvamerss immunization leads ifnγ secretion subjects produced cd<NUMBER> rather cd<NUMBER> cells middle east respiratory syndrome mers viral respiratory illness active surveillance <NUMBER> placed list priority diseases high epidemic potential warrant urgent research development countermeasures <NUMBER> disease lower respiratory tract humans mers progress rapidly unspecific influenzalike symptoms severe pneumonia multiple organ failure death causative agent mers mers coronavirus merscov first identified <NUMBER> saudi arabia <NUMBER> dromedary camels serve reservoir hosts majority primary human cases traced back close frequent contact dromedaries additionally humantohuman transmission amplified healthcare settings adding healthcare workers populations high risk jan <NUMBER> <NUMBER> <NUMBER> cases reported <NUMBER> deaths <NUMBER> countries resulting casefatality rate <NUMBER>·<NUMBER> <NUMBER> large mers outbreaks occurred saudi arabia <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER> south korea <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER> although transmission predominantly reported arabian peninsula high risk exporting cases areas outside middle east result travel far supportive therapy isolation patients contact tracing remain main pillars mers treatment prevention highlighting urgent need develop countermeasures vaccines block transmission combat potential future disease outbreaks development mers vaccine candidates challenging determinants protective immunity remain incompletely understood limited number mers cases made difficult efficacy trials although optimal animal models identification protective immune correlates mers still scarce current mouse models suggest crucial role antibodies cells induction protective immunity <NUMBER> <NUMBER> <NUMBER> humans one study showed positive correlation cd<NUMBER> tcell responses neutralising antibodies severe disease progression positive correlation strong virusspecific cd<NUMBER> tcell responses reduced mor bidity <NUMBER> conversely another study reported positive association early cd<NUMBER> tcell responses disease severity acute merscov infection <NUMBER> role antibodies protection shown mice received convalescent sera survivors <NUMBER> animal human data underline mers vaccine candidate preferentially induce humoral cellmediated immune responses timing dose vaccine could crucial protection study used recombinant modified vaccinia virus ankara rmva vaccine vector platform shown safe immuno genic humans <NUMBER> mva vaccine candidates demon strated favourable safety profile various populations disease settings <NUMBER> <NUMBER> <NUMBER> merscov spike glycoprotein consists s<NUMBER> s<NUMBER> subunits mediates viral attachment host cells entry membrane fusion <NUMBER> target neutralising antibodies therefore vaccine development evidence study middle east respiratory syndrome mers zoonotic viral respiratory illness caused mers coronavirus merscov mers active surveillance scrutiny far licensed vaccine available prevent disease viral spread mvamerss novel vaccine candidate based recombinant modified vaccinia virus ankara mva vaccine vector platform reported safe immunogenic mice dromedary camels searched clinicaltrialsgov aug <NUMBER> <NUMBER> keywords mers vaccine five studies listed except one study evaluated immunoglobulins treatment mers four tested mers vaccine platforms three vaccine platforms tested phase <NUMBER> trials chadox<NUMBER> mva dna vaccine latter progressing phase <NUMBER>a trials dna vaccine phase <NUMBER> trial done usa phase <NUMBER>a study recently initiated seoul south korea first human data mers vaccine candidate published july <NUMBER> presenting safety immunogenicity dna vaccine candidate gls<NUMBER> aimed assess safety immunogenicity data first mva viral vector vaccine candidate mers proceeding clinical trials study provides comprehensive results phase <NUMBER> trial testing mva vectorbased vaccine expressing merscovs protein study reveals benign safety profile mvamerss provides first insight immunogenicity vaccine candidate participants received high dose <NUMBER> × <NUMBER>⁸ plaqueforming unit pfu experienced mildtomoderate adverse events showed seroconversion <NUMBER> patients showed tcell responses lowdose group <NUMBER> × <NUMBER>⁷ pfu showed similar safety profile seroconversion <NUMBER> participants tcell immunity <NUMBER> participants aftermath ebola virus outbreak west africa <NUMBER> flagged need timely development vaccines highthreat pathogens including merscov data presented support clinical development candidate vaccine mvamerss add critical insight field vaccine research coronaviruses emerging pathogens mers vaccine candidate mvamerss investigated study encodes full merscov spike glycoprotein preclinical studies shown mvamerss induced neutralising antibodies <NUMBER> conferred protection merscov mice <NUMBER> expressing dipeptidyl peptidase <NUMBER> dpp<NUMBER> receptor furthermore reduction viral replication merscov challenge mvamerss vaccination successfully demonstrated dromedary camels <NUMBER> preclinical data support advancement vaccine candidate mvamerss test safety immunogenicity human clinical trials aimed assess safety tolerability immunogenicity data novel viralvectored mers candidate vaccine healthy adults openlabel phase <NUMBER> study done university medical center hamburgeppendorf hamburg germany participants recruited public advertisement included men women aged <NUMBER> years clinically significant health problems determined medical history physical examination bodymass index <NUMBER>·<NUMBER>·<NUMBER> kgm² weight <NUMBER> kg screening negative pregnancy test women key exclusion criterion previous mva immunisation full list inclusion exclusion criteria provided protocol appendix pp <NUMBER> participants provided written informed consent study design reviewed approved competent national authority paulehrlichinstitut langen germany ethics committee hamburg medical association study done accordance declaration helsinki fortaleza brazil <NUMBER> international conference harmonisation good clinical practice local safety monitoring board provided clinical oversight mvamerss based rmva vector encoding fulllength merscov spike glycoprotein based sequence emc<NUMBER> genbank accession number jx<NUMBER> <NUMBER> vaccine manufactured idt biologika dessau germany primary chicken embryo fibroblasts prime immunisation participants received doses <NUMBER> × <NUMBER>⁷ plaqueforming unit pfu lowdose group <NUMBER> × <NUMBER>⁸ pfu highdose group mvamerss intramuscularly deltoid muscle nondominant arm second identical dose administered intramuscularly booster immunisation <NUMBER> days first injection safety reasons participants vaccinated staggered manner appendix p <NUMBER> <NUMBER> days administration prime boost doses last study participant lowdose group review safety data local safety board staggered mode vaccinations applied highdose group control group immunogenicity analyses blood samples drawn identical study timepoints six healthy adults receive injections individual underwent physical examination drug pregnancy testing received electrocardiogram evening immunisation clinical trial center north hamburg germany heart rate blood pressure body temperature recorded study personnel <NUMBER> h <NUMBER> h <NUMBER> h <NUMBER> h <NUMBER> h <NUMBER> h vaccination blood drawn chemical haematological safety analyses participants monitored longitudinally <NUMBER> days study visits day vaccination day <NUMBER> day vaccination day <NUMBER> days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vaccination including two overnight stays approximate duration <NUMBER> h days <NUMBER> <NUMBER> prime immunisation days <NUMBER> <NUMBER> booster immunisation clinical laboratory evaluations done study visit appendix p <NUMBER> laboratory analyses included measurements complete blood counts creatinine creactive protein crp troponin liver function markers local systemic reactogenicity well medication use recorded participants <NUMBER> days vaccination daily notification sheet recorded followup visits study personnel adverse events classified mild interference activities daily living moderate interference daily living activities pose substantial permanent risks participants severe considerably affect daily living clinical status adverse events assessed categorised basis whether solicited expected therefore predefined protocol unsolicited events solicited events included local pain induration redness haematoma swelling injection site systemic adverse events fever chills fatigue malaise myalgia arthralgia headaches gastrointestinal symptoms diarrhoea loose stools abdominal cramps nausea unsolicited adverse events events defined solicited events arose days <NUMBER> <NUMBER> well day <NUMBER> <NUMBER> days booster vaccination occurrence serious adverse events monitored throughout study serious adverse event defined event results death lifethreatening required inpatient hospital admission caused prolongation existing hospital stay resulted persistent disability required inter vention prevent permanent impairment damage adverse events listed graded study personnel according common terminology criteria adverse events version <NUMBER> medical dictionary regulatory activities appendix pp <NUMBER> serum analysed days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> evaluate humoral immune responses see online appendix elisa coating <NUMBER>well microtitre plates <NUMBER> μgml merscov s<NUMBER> protein previously described <NUMBER> absorbance measured <NUMBER> nm cutoff set optical density <NUMBER>·<NUMBER> optimised commercial merscov s<NUMBER> elisa assay euroimmun lubeck germany done posthoc additional analysis presence merscovneutralising antibodies sera participants investigated virus neutralisation test used measure neutralising capacity sera huh<NUMBER> cells infected merscov emc<NUMBER> four replicates reciprocal titre <NUMBER> considered positive previously described <NUMBER> neutralisation defined absence cytopathic effects additionally sera tested neutralisation capacity plaque reduction neutralisation test using emc<NUMBER> <NUMBER> plaque reduction neutral isation test prnt titre serum sample reciprocal value highest dilution resulting infection reduction <NUMBER> prnt <NUMBER> titre <NUMBER> considered positive details three methods described appendix pp <NUMBER> <NUMBER> peripheral blood mononuclear cells pbmcs isolated cryopreserved edta blood using ficoll density gradient centrifugation tcell responses assessed interferonγ ifnγlinked enzymelinked immune absorbent spot elispot immunospot cellular technology cleveland oh usa <NUMBER>well plate following thawing resting pbmcs stimulated <NUMBER> h triplicates five overlapping peptide pools spanning entire merscovs amino acid sequence phytohemagglutinin pool cytomegalovirus epsteinbarr virus influenza peptide pool jpt peptide technologies berlin germany served positive controls serumfree medium cellular technology supplemented dimethyl sulphoxide served negative controls response defined positive two criteria met first <NUMBER> spotforming cells sfcs per million pbmcs second number sfcs per million pbmcs four times higher baseline day <NUMBER> value details see appendix p <NUMBER> antigenspecific cd<NUMBER> ifnγexpressing cd<NUMBER> ifnγexpressing cells analysed using flowcytometry following overnight resting pbmcs incubated <NUMBER> h <NUMBER>°c overlapping peptide pools cells analysed lsrfortessa bd biosciences franklin lakes nj usa evaluated flowjo<NUMBER> version <NUMBER> flowjo ashland usa primary endpoints frequency severity adverse events measured occurrence solicited local systemic reactogenicity signs symptoms <NUMBER> days vaccination occurrence unsolicited adverse events <NUMBER> days vaccination change baseline safety laboratory measures occurrence serious adverse events throughout study period <NUMBER> months secondary endpoint immunogenicity magnitude merscov spikespecific antibody responses measured elisa preplanned exploratory analyses included evaluation tcell immunity elispot trial designed exploratory trial powered statistically measure specific outcome determine dose finding participants vaccinated least included safety analysis immunogenicity analysed participants completed <NUMBER> months followup recorded adverse events depicted frequency participants dose group experienced least one adverse event indicated symptom group case participant reported two adverse events differing degrees symptom group severe event recorded correlate binding neutralising antibodies merscov spearman correlation elisa optical density values reciprocal titre neutralising antibodies analysed data wilcoxon signedrank testing paired samples mannwhitney u testing unpaired samples p value <NUMBER>·<NUMBER> less considered significant p values corrected multiple comparisons statistical analyses using graphpad prism version <NUMBER> trial registered clinicaltrialsgov nct<NUMBER> eudract <NUMBER> funder investigatorinitiated study role study design data collection data analysis data interpretation writing report corresponding author full access data study final responsibility decision submit publication dec <NUMBER> <NUMBER> june <NUMBER> <NUMBER> <NUMBER> individuals screened <NUMBER> participants enrolled figure <NUMBER> details participants baseline characteristics summarised table <NUMBER> three individuals one lowdose group two highdose group receive booster immunisation excluded immunogenicity analysis however data included safety investigations two participants lowdose group discontinued personal reasons within first <NUMBER> days study replaced replacements completed followup visits third person highdose group dropped received booster immunisation unrelated urinary tract infection day <NUMBER> person replaced stage trial full primeboost vaccination regimen administered <NUMBER> participants interval <NUMBER> days <NUMBER> participants completed scheduled followup visits <NUMBER> months one participant lowdose group moved day <NUMBER> followup visit day <NUMBER> change residence timepoint excluded immuno genicity analysis protocol violations monitoring acute reactogenicity following immunisations serious adverse events reported <NUMBER> vaccinerelated adverse events reported ten <NUMBER> <NUMBER> participants lowdose group <NUMBER> reported ten <NUMBER> <NUMBER> participants highdose group majority solicited mild moderate severe adverse events adverse events appeared early administration vaccine median <NUMBER> day iqr <NUMBER> highdose group adverse events prime boost immunisations lowdose group figure <NUMBER>a adverse events resolved quickly median <NUMBER> day iqr <NUMBER> generally required treatment solicited local reactions common adverse events pain observed <NUMBER> <NUMBER> seven participants lowdose group vs ten highdose group parti cipants swelling ten <NUMBER> two vs eight participants induration ten <NUMBER> one vs nine participants headaches observed seven participants lowdose group vs nine participants highdose group fatigue malaise ten vs seven participants common solicited systemic adverse events figure <NUMBER>b details adverse events listed appendix pp <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> two participants highdose group elevated temperature fever <NUMBER> h prime immunisation temperatures <NUMBER>·<NUMBER>°c <NUMBER>·<NUMBER>°c respectively appendix pp <NUMBER> <NUMBER> <NUMBER> significant transient asymptomatic decreases white blood cell neutrophil counts day <NUMBER> day <NUMBER> well lymphocyte thrombo cyte counts day <NUMBER> day <NUMBER> observed highdose group figure <NUMBER> table <NUMBER> lowdose group also similar differences lower extent crp concentration day <NUMBER> significantly higher highdose group lowdose group appendix p <NUMBER> laboratory parameters vital signs show significant alterations vaccinations data shown seroconversion detected <NUMBER> <NUMBER> <NUMBER> participants nine <NUMBER> <NUMBER> participants lowdose group <NUMBER> <NUMBER> participants highdose group timepoint throughout study table <NUMBER> antibody responses predominantly detected second vaccine dose either low high dose mvamerss two vaccinated participants one lowdose group one highdose group showed positive elisa response day <NUMBER> single mvamerss administration <NUMBER> days boost immunisation day <NUMBER> merscov s<NUMBER>specific antibodies detectable dose groups table <NUMBER> majority vaccinated participants showed positive elisa responses days <NUMBER> <NUMBER> table <NUMBER> control group participants seronegative except one participant showed borderline optical density value <NUMBER>·<NUMBER> day <NUMBER> exact cutoff value seropositivity figure <NUMBER>a table <NUMBER> geometric mean optical density values antibody concentrations day <NUMBER> similar cohorts table <NUMBER> antibody concentrations groups decreased time positive elisa responses still observed <NUMBER> <NUMBER> <NUMBER> participants day <NUMBER> day <NUMBER> three <NUMBER> <NUMBER> participants lowdose group none highdose group remained positive merscov spikespecific antibodies observed significant dose dependency immunogenicity readouts lowdose highdose groups day <NUMBER> p<NUMBER>·<NUMBER> day <NUMBER> p<NUMBER>·<NUMBER> day <NUMBER> p<NUMBER>·<NUMBER> mannwhitney u test data shown posthoc additional immuno genicity investigation optimised commercial elisa assay euroimmun showed similar confirmatory results appendix pp <NUMBER> <NUMBER> timepoint throughout study sera <NUMBER> <NUMBER> <NUMBER> participants vaccinated neutralised merscov using virus neutralisation test figure <NUMBER>b single injection mvamerss showed induction neutralising antibodies virus neutralisation test revealed detectable neutralising capacity boosting mainly participants lowdose group peak response day <NUMBER> seven <NUMBER> <NUMBER> participants reacted positively compared two <NUMBER> <NUMBER> participants highdose group end study day <NUMBER> two <NUMBER> one dose group still detectable neutralising capacity virus neutralisation test sensitive prnt <NUMBER> assay figure <NUMBER>c antibody responses mirrored similar pattern observed using inhouse elisa figure <NUMBER>a single vaccine administration induced neutralising antibodies one participant lowdose group boost immunisation nine <NUMBER> participants lowdose group nine <NUMBER> participants highdose group showed responses boosting elicited significant increase neutralising antibody responses day <NUMBER> compared baseline groups day <NUMBER> p<NUMBER>·<NUMBER> groups wilcoxon signedrank test appendix p <NUMBER> linear correlation elisa optical density values reciprocal titre neutralising antibodies pnrt <NUMBER> observed day <NUMBER> r<NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> figure <NUMBER>d suggesting high proportion functional antibodies among vaccineinduced merscov spikespecific binding antibodies highest number positive responses inhouse merscov s<NUMBER> elisa prnt <NUMBER> assays detected days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vaccinated participants seven lowdose group nine highdose group data shown antibodies directed vaccines vector also assessed boost vaccination mvaspecific neutralising antibodies detectable <NUMBER> <NUMBER> <NUMBER> vaccine recipients eight lowdose group <NUMBER> highdose group correlation merscovspecific binding neutralising antibody responses observed data shown merscov spikespecific tcell responses evaluated elispot using five overlapping peptide pools figure <NUMBER>a representative elispot wells shown appendix p <NUMBER> tcell responses merscov spike emerged single vaccination mvamerss participants enhanced boost immunisation overall ifnγ secretion detected ten <NUMBER> <NUMBER> participants lowdose group ten <NUMBER> <NUMBER> participants highdose group one timepoints throughout study tcell responses observed peptide pools however responses pool m<NUMBER> frequently detected figure <NUMBER>b groups showed increase ifnγ secretion compared day <NUMBER> detected lowdose group day <NUMBER> highdose group day <NUMBER> earliest peak response observed m<NUMBER> day <NUMBER> appendix p <NUMBER> highest magnitudes ifnγ responses observed two participants lowdose group upon m<NUMBER>pool stimulation <NUMBER> <NUMBER> sfcs per million pbmcs respectively additional posthoc analysis subgroup six participants three group demonstrated merscov spikespecific secretion ifnγ predominantly cd<NUMBER> cells rather cd<NUMBER> cells using flowcytometry appendix p <NUMBER> taking account number assay responders time dose cohorts showed similar pattern earliest assay responders identified day <NUMBER> figure <NUMBER>c day <NUMBER> lowdose group six <NUMBER> <NUMBER> participants one participant removed day <NUMBER> analysis outlined previously still showed positive tcell responses highdose group one participant showed response evaluate breadth tcell responses assessed number pools participants responded highdose group revealed response one pool already day <NUMBER> reduced breadth time com parison lowdose group showed increase breadth boost immunisation figure <NUMBER>d taken together data show immunisation mvamerss induced tcell responses decreased study period remained detectable following homologous prime boost immunisations mvamerss single severe serious adverse events observed participants received either low dose high dose vaccine participants experienced transient selflimiting mildtomoderate adverse events mostly dosedependent local reactions well unspecific systemic adverse events data demonstrate favourable safety profile doses two administrations safety signals similar observed phase <NUMBER> trial testing influenza vaccine mvah<NUMBER>sfmr <NUMBER> participants received doses identical mva backbone similar safety profiles observed trials using mva platform inserted antigens derived pathogens <NUMBER> <NUMBER> <NUMBER> comparison mvamerss vaccineinduced safety profiles suggests vectorspecific rather insertspecific safety signals merscovspecific adverse events outlined brighton collaboration observed vaccination mvamerss elicited humoral cellular immune responses merscov spike mostly detectable following boost rather prime immunisation humoral immune responses measured elisa two different viral neutralisation assays revealed peak antibody responses days <NUMBER> <NUMBER> maintained day <NUMBER> declined baseline levels majority study participants end study <NUMBER> months vaccination although exact contribution merscovspecific antibodies immune protection mers remains elucidated preclinical data support role protection virus challenge animal models <NUMBER> <NUMBER> <NUMBER> <NUMBER> significant reduction excreted infectious virus viral rna transcripts mvamerssvaccinated dromedary camels observed following merscov challenge associated merscovspecific neutralising antibodies <NUMBER> albeit optimal animal model mouse studies support investigation protective mechanisms mice susceptible merscov expression human dpp<NUMBER> transgenic mice adenoviralmediated delivery merscov infect mouse cells challenge experiments supported impact antibodies immune protection passive immunotherapy subsequent challenge experi ments evaluated passive immunotherapy merscov challenge using merscovspecific mono clonal antibodies sera obtained merscovpositive immune dromedary camels showed protection mice expressing human dpp<NUMBER> <NUMBER> <NUMBER> <NUMBER> although safety tolerability antimerscov polyclonal antibody treat ment humans demonstrated <NUMBER> protection mers humans yet documented notably mouse experiments demonstrated generation neutralising antibodies upon mvamerss vaccination partially mediated neutralisation receptorbinding domain rbd <NUMBER> indicating parts merscov spike glycoprotein might also induce neutralising antibodies context notable outcome mouse experiments protective capacity s<NUMBER>specific nonrbd s<NUMBER>specific neutralising mouse antibodies merscov <NUMBER> <NUMBER> <NUMBER> furthermore demonstrated s<NUMBER> monoclonal antibodies showed moderate neutralising capacity vitro highly protective challenge vivo suggesting strong neutralising activity conditional protection <NUMBER> future analyses therefore include merscov s<NUMBER>specific also s<NUMBER>specific antibody assays functional antibody readouts beyond neutralisation capacity currently understudied systemsserology approaches including nonneutralising functions antibodydependent cellular cytotoxicity antibodydependent cellular phagocytosis might provide insight mvamerssinduced immunity dissect addi tional mechanisms antibodymediated protection however noted although animal studies indicate crucial role antibodies protection mers human data available merscovinfected individuals far reveal clear strong correlation merscovspecific antibody responses merscov viral load <NUMBER> <NUMBER> reports individuals merscov infection revealed predominantly tcell responses opposed antibody responses survivors well exposed dromedary camel workers <NUMBER> <NUMBER> although yet determined tcell responses crucial merscov clearance humans animal models provided evidence cells support viral clearance mice <NUMBER> <NUMBER> study detected vaccineinduced tcell responses merscov spike present even second immunisation responses persisted day <NUMBER> third study participants seven <NUMBER> <NUMBER> participants suggesting vaccineinduced tcell responses maintained slightly longer humoral immune responses three <NUMBER> <NUMBER> participants observed stronger robust tcell responses lowdose group highdose group although finding significant might considered future studies focus dose finding including larger number participants however exact contribution tcell immunity vaccineinduced natural protection disease viral clearance remains determined needs investigation complement analyses vaccineinduced immunity merscov spike antigenic insert vector vaccine also investigated vector immunity mva backbone mvaspecific humoral responses mva vector assessed posthoc using virus neutralisation test assay wildtype mva address potential effect merscov spikespecific antibodies although mvaspecific neutralising antibodies induced correlation merscovspecific binding neutralising antibody responses observed currently strong evidence induced preexisting mvaspecific immunity interferes vaccineinduced immune responses using mva vector study trial using mvah<NUMBER>sfmr <NUMBER> show mvabased vaccines elicit antibody responses antigenic insert following second third immunisation despite induction antivector immunity prime injection exact impact preexisting immune responses mva requires investigation future studies rapid induction vaccineinduced immunity following singleshot vaccination schemes considered part cularly useful outbreak scenarios however mvamerss showed induction strong mvamerssspecific immune responses following single prime vaccination might reduce direct applicability acute outbreak scenarios context limited human data correlates protection currently challenging predict whether mvamerss suitable rapidly evolving epidemic situations remains unclear specific parameters relevant defence merscov conceivable homologous mva primeboost vaccination might final optimised vaccination schedule mvamerss different strategies including heterologous primeboost regimens evaluated future trials several mers vaccine candidates currently tested phase <NUMBER> <NUMBER> clinical trials coalition epidemic preparedness innovations funding five different vaccine platforms mvamerss chadox<NUMBER> dna advanced first mers vaccine trial humans reported date investigated dnabased vaccine gls<NUMBER> <NUMBER> homologous primeboostboost regime used similar study authors observed favourable safety profile induction humoral cellular immune responses although seroreactivity cellular responses largely maintained study period <NUMBER> weeks neutralising antibodies detectable <NUMBER> vaccine recipients peaked <NUMBER> weeks second boost rapidly declined additional clinical trials needed evaluate whether heterologous primeboost vaccination schedules mvamerss chadox<NUMBER> dna prime boost mvamerss induce immune responses protective merscov infection least favourably modulate mers disease course studies warranted improve detailed understanding role antibody titres neutralising nonneutralising antibodies cellular immune responses natural vaccineinduced pro tective merscovspecific immunity enhance accelerate strategic vaccine development mers ultimate assessment vaccine efficacy challenging outbreaks unpredictable number mers cases relatively low although data presented make valuable contribution mers vaccine agenda enterprise study also limitations restricted number study participants phase <NUMBER> trial limits generalisability results necessitates followup studies larger cohorts study also include additional late boost induced strong increased antibody responses previous mvah<NUMBER>sfmr trial <NUMBER> early study format also allow data generation antibody dependent enhancement context merscov infections previously discussed severe acute respiratory syndrome sars coronavirus <NUMBER> future studies animal models possibly including adoptive transfer experiments sera derived vaccinated individuals well clinical trials need address crucial aspect conclusion phase <NUMBER> trial investigating candidate vaccine mvamerss showed benign safety profile provides first evidence humoral cellular immunogenicity induced candidate vaccine humans data generated far support development mers vaccine candidate homologous heterologous vaccination schemes possibly involving viral vector vaccines <NUMBER> coalition epidemic preparedness innovations included mvamerss funding portfolio support scalable manufacturing clinical development evaluate safety immunogenicity larger cohorts endemic areas favourable profile mvamerss might also make useful contributions development future vaccine strategies coronavirus pathogens recently emerged sars coronavirus <NUMBER> however crucial knowledge gaps remain addressed blh listed inventor middle east respiratory syndrome coronavirus patent application authors declare competing interests individual participant data shared including data dictionaries individual participant data collected trial shared deidentification documents made available include study protocol informed consent forms data available immediately following publication end datethe data shared anyone wishes access data data available purpose analyses data please contact corresponding author middle east respiratory syndrome mers emerging infectious disease first identified june <NUMBER> caused novel merscoronavirus merscov <NUMBER> merscov zoonotic virus bats natural reservoir possibly dromedary camels intermediate host <NUMBER> <NUMBER> merscov infects humans especially elderly people diabetes chronic lung diseases immunocompromised persons causing severe disease high mortality <NUMBER> mers outbreak resulted <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths august <NUMBER> <NUMBER> <NUMBER> still possibility merscov spread within healthcare facilities number cases linked <NUMBER> <NUMBER> mers cases reported saudi arabia south korea second largest country travelassociated mers cases traced back saudi arabia continuous spread merscov possibly cameltohuman humantohuman transmission raised worldwide concerns calling immediate steps develop effective safe vaccines genome merscov encodes least four unique accessory proteins <NUMBER> <NUMBER>a <NUMBER>b <NUMBER> two replicase proteins open reading frame <NUMBER>a <NUMBER>b four major structural proteins including spike envelope e nucleocapsid n membrane proteins <NUMBER> accessory proteins play nonessential roles merscov replication likely structural proteins interferon antagonists modulating vivo replication efficiency andor pathogenesis case sarscov <NUMBER> <NUMBER> <NUMBER> proteins merscov maintain different functions virus replication e protein example involves virulence deleting ecoding gene results replicationcompetent propagationdefective viruses attenuated viruses <NUMBER> protein particularly essential mediating virus binding cells expressing receptor dipeptidyl peptidase<NUMBER> dpp<NUMBER> receptorbinding domain rbd s<NUMBER> subunit whereas s<NUMBER> subunit subsequently mediates virus entry via fusion virus target cell membranes <NUMBER> <NUMBER> therefore viral structural proteins particularly protein may serve targets vaccine development demonstrated circulating human merscov strains represent one single serotype virus isolates parts outbreaks differences emc<NUMBER> prototype strain replication interferon escape responses serum neutralization suggesting vaccines developed based prototype virus strain unlikely affect success virus strains <NUMBER> mers vaccines available human use vaccines merscov thus far developed laboratory categorized based viral vectors adenovirus ad modified vaccinia virus ankara mva based recombinant viral proteins dnas nanoparticles recombinant virus table <NUMBER> viral vectorbased mers vaccines use fulllength s<NUMBER> protein merscov coding antigens exhibit immunogenicity vaccinated animals reports indicated recombinant ad<NUMBER> vectors encode fulllength s<NUMBER> extracellular domain merscov protein induced merscov sspecific antibody responses immunized mice neutralizing merscov infection vitro <NUMBER> ad<NUMBER> ad<NUMBER> vectors expressing fulllength protein merscov elicited merscovspecific antibody responses neutralizing antibodies tcell responses immunized mice <NUMBER> moreover viral vector mvabased mers vaccine expressing viral protein termed mvamerss demonstrated efficacy merscov infection addpp<NUMBER>transduced mice <NUMBER> <NUMBER> studies suggest potential applying merscov protein vaccine target german center infection research dzif supported phase clinical trial mvamerss vaccine candidate humans usd <NUMBER> million awarded initiate trial <NUMBER> addition viral vectorbased vaccines vaccines based recombinant merscov protein particular rbd demonstrated efficacy protecting immunized animals merscov infection <NUMBER> <NUMBER> several fragments including residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rbd merscov shown induce merscov neutralizing antibody responses mice andor rabbits <NUMBER> <NUMBER> thus similar rbd severe acute respiratory syndrome coronavirus sarscov merscov rbd also contains critical neutralizing domain cnd capable eliciting highly potent neutralizing antibodies protective immunity infection merscov particularly fragment containing residues <NUMBER> <NUMBER> merscov rbd identified cnd able protect ad<NUMBER>hdpp<NUMBER>transduced hdpp<NUMBER>transgenic mice merscov notably s<NUMBER> <NUMBER> effective immunogen <NUMBER> µg s<NUMBER> <NUMBER> protein could induce potent neutralizing antibody responses similar raised high doses <NUMBER> <NUMBER> µg respectively <NUMBER> <NUMBER> reports confirm rbdcnd merscov protein important target development mers subunit vaccines dna vaccines proven effective merscov infection optimized dna vaccine encoding fulllength protein merscov able elicit antigenspecific neutralizing antibodies mice camels rhesus macaques nonhuman primates nhps six eight vaccinated macaques showing radiographic evidence infiltration merscov challenge interestingly potent antigenspecific cellular immune responses induced immunized macaques suggesting cell responses may also play role merscov protection <NUMBER> inovio pharmaceuticals inc collaboration geneone life science perform phase clinical trial dnabased vaccine <NUMBER> addition dnaonly strategy dnapriming proteinboosting could alternative vaccine approach merscov revealed fulllength dna priming s<NUMBER> subunit protein boosting immunization mice nhps induced robust neutralizing antibody responses several merscov strains protecting nhps merscov challenge <NUMBER> potential candidates suggested mers vaccines example purified merscov fulllength nanoparticles combination appropriate adjuvants could elicit neutralizing antibodies immunized mice <NUMBER> using reverse genetics recombinant merscov may efficiently replicate cell culture human cell lines broad tissue tropism allowing engineered mutant merscov lacking structural e protein rescued propagate cells expressing e protein trans thus providing platform develop liveattenuated recombinant merscovbased vaccines <NUMBER> <NUMBER> induction neutralizing antibodies key prevention merscov infection supported fact reduction lung pathogenesis protection merscov infection correlated neutralizing antibody levels animal models <NUMBER> <NUMBER> addition vaccines enjoy high safety profile combined ability induce broadspectrum immune responses strong protective neutralizing antibodies top priority development efficacy protective immunity mers candidate vaccines necessity evaluated appropriate animal models thus moving clinical trials nhp rhesus macaque common marmoset models <NUMBER> <NUMBER> camel model <NUMBER> established utilized purposes however use nhp camel models financially facility restrictive many researchers fortunately recent advancements establishing small animal models including ad<NUMBER>hdpp<NUMBER>transduced mouse model <NUMBER> hdpp<NUMBER>transgenic mouse models <NUMBER> provided portable economical platform assessing efficacy mers candidate vaccines despite fact animal models advantages disadvantages although promising recombinant merscovbased vaccines need characterized suitable merscov animal models confirm efficacy safety viral vectorbased vaccines hand may show protective immunity challenged mouse animals however vaccines might safety concerns presence preexisting immunity humans case ad potential induce harmful immune responses thus safety tests strongly recommended also vaccine type might lead incomplete protection fail protect aged groups shown case sarscov vaccines <NUMBER> comparison recombinant proteinbased subunit vaccines possess highest safety profile utilize fulllength spike protein subunit eg s<NUMBER> fragment eg rbd antigen presence suitable adjuvants type vaccine generally able induce higher titers neutralizing antibody responses elicited vaccine types easily injected via different pathways including intramuscular injection adopted route human vaccines importantly mers subunit vaccines shown protective merscov infection challenged mouse andor nhp models <NUMBER> <NUMBER> demonstrating ability scaleup andor human clinical trials among recombinant proteinbased subunit vaccines believe rbdbased vaccines effective safer based fulllength protein rbd contains cnd protein highly potent neutralizing antibodies target rbd <NUMBER> recombinant proteins containing rbd induce strong neutralizing antibody responses protection vaccinated animals merscov infection <NUMBER> <NUMBER> contrast fulllength protein contains nonneutralizing immunodominant domains may compromise immunogenicity cnd rbd even induces virusenhancing harmful immune responses demonstrated protein sarscov <NUMBER> may one reasons development fulllength proteinbased sars vaccine discontinued one may criticize vaccines based rbd sequences current merscov strains might effective future emerged merscov strains mutations rbd problem rbdbased vaccines rbd contains several conformational neutralizing epitopes thus mutations one epitope may significantly affect neutralizing activity antibodies elicited epitopes example rbdspecific mab f<NUMBER> could neutralize bisha<NUMBER> strain merscov whose rbd contains <NUMBER> mutation susceptible neutralization d<NUMBER> another merscov rbdspecific mab <NUMBER> previous studies demonstrated rbd sarscov tor<NUMBER> strain contains six different conformational neutralizing epitopes induces antibodies vaccinated animals neutralizing activity sarscov strains tested including caused early sars outbreaks eg gd<NUMBER> strain late sars pandemics eg urbani strain well sarslike cov strain civets sz strain <NUMBER> although epitopes outside merscov rbd may neutralizing activity ability significantly lower rbd example neutralizing mabs g<NUMBER> g<NUMBER> target epitopes merscov s<NUMBER> s<NUMBER> respectively outside rbd neutralizing ability potent rbdspecific mabs f<NUMBER> d<NUMBER> <NUMBER> nevertheless nonrbd neutralizing epitopes clearly identified could potentially included vaccine design increase breadth strength merscov vaccines common knowledge process vaccine approval long complicated regulatory restrictions shortage funds case point ad<NUMBER>merssad<NUMBER>merss<NUMBER> viral vector fulllength ss<NUMBER> mice preclinical <NUMBER> mvamerss viral vector fulllength hdpp<NUMBER>transduced mice preclinical <NUMBER> s<NUMBER> <NUMBER> <NUMBER>fc recombinant protein s<NUMBER>rbd <NUMBER> <NUMBER> rabbits preclinical <NUMBER> merscov rrbd recombinant protein s<NUMBER>rbd <NUMBER> <NUMBER> mice preclinical <NUMBER> srbdfc recombinant protein s<NUMBER>rbd <NUMBER> <NUMBER> mice preclinical <NUMBER> s<NUMBER> <NUMBER>fc recombinant protein s<NUMBER>rbd <NUMBER> <NUMBER> mice rabbits hdpp<NUMBER>mice preclinical <NUMBER> <NUMBER> mers dna fulllength mice camels nhps preclinical <NUMBER> sdnas<NUMBER> protein dna recombinant protein fulllength ss<NUMBER> mice nhps preclinical <NUMBER> merss nanoparticles fulllength mice preclinical <NUMBER> rmerscovrmers mers vaccines urgently needed yet big pharma consistently refused invest funds manufacturing developing preclinical clinical studies based uncertainty immediate return investments addition adequate financial support government entities guaranteed general lack funds noted however firms us dzif academy germany taken first step toward clinical trials two mers vaccines based dna viral vector respectively big pharma governments countries parts world take note signal act accordingly authors funded nih grants r<NUMBER>ai<NUMBER> r<NUMBER>ai<NUMBER> r<NUMBER>ai<NUMBER> well intramural funds new york blood center grant nyb<NUMBER> authors relevant affiliations financial involvement organization entity financial interest financial conflict subject matter materials discussed manuscript includes employment consultancies honoraria stock ownership options expert testimony grants patents received pending royalties papers special note highlighted either interest considerable interest readers one papers showing protective immunity induced merscov fulllength sbased vaccines nhps middle east respiratory syndrome mers emerging infectious disease first identified june <NUMBER> caused novel merscoronavirus merscov <NUMBER> merscov zoonotic virus bats natural reservoir possibly dromedary camels intermediate host <NUMBER> <NUMBER> merscov infects humans especially elderly people diabetes chronic lung diseases immunocompromised persons causing severe disease high mortality ∼<NUMBER> mers outbreak resulted <NUMBER> laboratoryconfirmed cases including <NUMBER> deaths august <NUMBER> <NUMBER> <NUMBER> still possibility merscov spread within healthcare facilities number cases linked <NUMBER> <NUMBER> mers cases reported saudi arabia south korea second largest country travelassociated mers cases traced back saudi arabia continuous spread merscov possibly cameltohuman humantohuman transmission raised worldwide concerns calling immediate steps develop effective safe vaccines genome merscov encodes least four unique accessory proteins <NUMBER> <NUMBER>a <NUMBER>b <NUMBER> two replicase proteins open reading frame <NUMBER>a <NUMBER>b four major structural proteins including spike envelope e nucleocapsid n membrane proteins <NUMBER> accessory proteins play nonessential roles merscov replication likely structural proteins interferon antagonists modulating vivo replication efficiency andor pathogenesis case sarscov <NUMBER> <NUMBER> <NUMBER> proteins merscov maintain different functions virus replication e protein example involves virulence deleting ecoding gene results replicationcompetent propagationdefective viruses attenuated viruses <NUMBER> protein particularly essential mediating virus binding cells expressing receptor dipeptidyl peptidase<NUMBER> dpp<NUMBER> receptorbinding domain rbd s<NUMBER> subunit whereas s<NUMBER> subunit subsequently mediates virus entry via fusion virus target cell membranes <NUMBER> <NUMBER> therefore viral structural proteins particularly protein may serve targets vaccine development demonstrated circulating human merscov strains represent one single serotype virus isolates parts outbreaks differences emc<NUMBER> prototype strain replication interferon escape responses serum neutralization suggesting vaccines developed based prototype virus strain unlikely affect success virus strains <NUMBER> <NUMBER> mers vaccines available human use vaccines merscov thus far developed laboratory categorized based viral vectors adenovirus ad modified vaccinia virus ankara mva based recombinant viral proteins dnas nanoparticles recombinant virus table <NUMBER> viral vectorbased mers vaccines use fulllength s<NUMBER> protein merscov coding antigens exhibit immunogenicity vaccinated animals reports indicated recombinant ad<NUMBER> vectors encode fulllength s<NUMBER> extracellular domain merscov protein induced merscov sspecific antibody responses immunized mice neutralizing merscov infection vitro <NUMBER> ad<NUMBER> ad<NUMBER> vectors expressing fulllength protein merscov elicited merscovspecific antibody responses neutralizing antibodies tcell responses immunized mice <NUMBER> moreover viral vector mvabased mers vaccine expressing viral protein termed mvamerss demonstrated efficacy merscov infection addpp<NUMBER>transduced mice <NUMBER> <NUMBER> studies suggest potential applying merscov protein vaccine target german center infection research dzif supported phase clinical trial mvamerss vaccine candidate humans usd <NUMBER> million awarded initiate trial <NUMBER> addition viral vectorbased vaccines vaccines based recombinant merscov protein particular rbd demonstrated efficacy protecting immunized animals merscov infection <NUMBER> <NUMBER> several fragments including residues <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rbd merscov shown induce merscov neutralizing antibody responses mice andor rabbits <NUMBER> <NUMBER> thus similar rbd severe acute respiratory syndrome coronavirus sarscov merscov rbd also contains critical neutralizing domain cnd capable eliciting highly potent neutralizing antibodies protective immunity infection merscov particularly fragment containing residues <NUMBER> merscov rbd identified cnd able protect ad<NUMBER>hdpp<NUMBER>transduced hdpp<NUMBER>transgenic mice merscov notably s<NUMBER> effective immunogen <NUMBER> μg s<NUMBER> protein could induce potent neutralizing antibody responses similar raised high doses <NUMBER> <NUMBER> μg respectively <NUMBER> <NUMBER> reports confirm rbdcnd merscov protein important target development mers subunit vaccines dna vaccines proven effective merscov infection optimized dna vaccine encoding fulllength protein merscov able elicit antigenspecific neutralizing antibodies mice camels rhesus macaques nonhuman primates nhps six eight vaccinated macaques showing radiographic evidence infiltration merscov challenge interestingly potent antigenspecific cellular immune responses induced immunized macaques suggesting cell responses may also play role merscov protection <NUMBER> inovio pharmaceuticals inc collaboration geneone life science perform phase clinical trial dnabased vaccine <NUMBER> addition dnaonly strategy dnapriming proteinboosting could alternative vaccine approach merscov revealed fulllength dna priming s<NUMBER> subunit protein boosting immunization mice nhps induced robust neutralizing antibody responses several merscov strains protecting nhps merscov challenge <NUMBER> potential candidates suggested mers vaccines example purified merscov fulllength nanoparticles combination appropriate adjuvants could elicit neutralizing antibodies immunized mice <NUMBER> using reverse genetics recombinant merscov may efficiently replicate cell culture human cell lines broad tissue tropism allowing engineered mutant merscov lacking structural e protein rescued propagate cells expressing e protein trans thus providing platform develop liveattenuated recombinant merscovbased vaccines <NUMBER> <NUMBER> induction neutralizing antibodies key prevention merscov infection supported fact reduction lung pathogenesis protection merscov infection correlated neutralizing antibody levels animal models <NUMBER> <NUMBER> addition vaccines enjoy high safety profile combined ability induce broadspectrum immune responses strong protective neutralizing antibodies top priority development efficacy protective immunity mers candidate vaccines necessity evaluated appropriate animal models thus moving clinical trials nhp rhesus macaque common marmoset models <NUMBER> <NUMBER> camel model <NUMBER> established utilized purposes however use nhp camel models financially facility restrictive many researchers fortunately recent advancements establishing small animal models including ad<NUMBER>hdpp<NUMBER>transduced mouse model <NUMBER> hdpp<NUMBER>transgenic mouse models <NUMBER> provided portable economical platform assessing efficacy mers candidate vaccines despite fact animal models advantages disadvantages although promising recombinant merscovbased vaccines need characterized suitable merscov animal models confirm efficacy safety viral vectorbased vaccines hand may show protective immunity challenged mouse animals however vaccines might safety concerns presence preexisting immunity humans case ad potential induce harmful immune responses thus safety tests strongly recommended also vaccine type might lead incomplete protection fail protect aged groups shown case sarscov vaccines <NUMBER> comparison recombinant proteinbased subunit vaccines possess highest safety profile utilize fulllength spike protein subunit eg s<NUMBER> fragment eg rbd antigen presence suitable adjuvants type vaccine generally able induce higher titers neutralizing antibody responses elicited vaccine types easily injected via different pathways including intramuscular injection adopted route human vaccines importantly mers subunit vaccines shown protective merscov infection challenged mouse andor nhp models <NUMBER> <NUMBER> demonstrating ability scaleup andor human clinical trials among recombinant proteinbased subunit vaccines believe rbdbased vaccines effective safer based fulllength protein rbd contains cnd protein highly potent neutralizing antibodies target rbd <NUMBER> <NUMBER> <NUMBER> <NUMBER> recombinant proteins containing rbd induce strong neutralizing antibody responses protection vaccinated animals merscov infection <NUMBER> <NUMBER> contrast fulllength protein contains nonneutralizing immunodominant domains may compromise immunogenicity cnd rbd even induces virusenhancing harmful immune responses demonstrated protein sarscov <NUMBER> may one reasons development fulllength proteinbased sars vaccine discontinued one may criticize vaccines based rbd sequences current merscov strains might effective future emerged merscov strains mutations rbd problem rbdbased vaccines rbd contains several conformational neutralizing epitopes thus mutations one epitope may significantly affect neutralizing activity antibodies elicited epitopes example rbdspecific mab f<NUMBER> could neutralize bisha<NUMBER> strain merscov whose rbd contains <NUMBER> mutation susceptible neutralization d<NUMBER> another merscov rbdspecific mab <NUMBER> previous studies demonstrated rbd sarscov tor<NUMBER> strain contains six different conformational neutralizing epitopes induces antibodies du vaccinated animals neutralizing activity sarscov strains tested including caused early sars outbreaks eg gd<NUMBER> strain late sars pandemics eg urbani strain well sarslike cov strain civets sz strain <NUMBER> although epitopes outside merscov rbd may neutralizing activity ability significantly lower rbd example neutralizing mabs g<NUMBER> g<NUMBER> target epitopes merscov s<NUMBER> s<NUMBER> respectively outside rbd neutralizing ability potent rbdspecific mabs f<NUMBER> d<NUMBER> <NUMBER> nevertheless nonrbd neutralizing epitopes clearly identified could potentially included vaccine design increase breadth strength merscov vaccines common knowledge process vaccine approval long complicated regulatory restrictions shortage funds case point mers vaccines urgently needed yet big pharma consistently refused invest funds manufacturing developing preclinical clinical studies based uncertainty immediate return investments addition adequate financial support government entities guaranteed general lack funds noted however firms us dzif academy germany taken first step toward clinical trials two mers vaccines based dna viral vector respectively big pharma governments countries parts world take note signal act accordingly merging reemerging zoonotic viral diseases major threats global human health economic stability national security <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> incidence human zoonotic disease estimated surpass <NUMBER> billion cases per year novel emerging infectious diseases accruing hundreds billions dollars economic losses <NUMBER> <NUMBER> losses greatly magnified new emerging viruses coronaviruses covs devastate economically critical livestock populations across globe continued encroachment human populations animal habitats close contact domesticated animals zoonoses continue increase human livestock population numbers density expand next century fact recent study recognized majority emerging infectious disease events origins wildlife <NUMBER> <NUMBER> underscoring importance developing broadly applicable strategies vaccine design virus families harbored within extensive zoonotic pools vaccines well established capacity reduce viral disease burden liveattenuated vaccines elicit balanced innate adaptiveand often lifelongprotective immune responses including lactogenic immunity ideal candidates vaccine development humans animals <NUMBER> however utility broadly applicable vaccine platforms long limited risks reversion attenuated vaccine strains virulence largely stability attenuation cannot clearly evaluated assured emergence severe acute respiratory syndrome coronavirus sarscov middleeast respiratory syndrome coronavirus merscov <NUMBER>st century emphasizes threat pandemic viral infections originating crossspecies transmission events <NUMBER> <NUMBER> <NUMBER> highly pathogenic variants prime models development broadbased strategies evaluating live virus vaccines nidovirales order coronaviruses covs reproduce conserved replication strategies emphasizing strength rapidly adaptable potential vaccine design platform takes advantage biology covs replicate transcribe subgenomic rnas sgrnas via discontinuous transcription mechanism mediated transcription regulatory sequences trss series conserved nucleotide sequences positioned near <NUMBER>′end genome several locations immediately <NUMBER>′ downstream open reading frame orf fig <NUMBER> trss regulate transcription attenuation program via basepairing interactions leader trs body trss results production sgrnas downstream orfs translated within trs <NUMBER>to <NUMBER>nt core sequence acgaac sarscov guides basepairing duplex formation nascent rna leader trs <NUMBER> <NUMBER> <NUMBER> collective trs arrangement transcription regulatory network trn conserved laboratory shown possible rewire guide sequence sarscov trn produce infectious virus <NUMBER> also showed recombination rewired trn virus wildtype wt sarscov viable indicating recombinationmediated reversion cov vaccine platform featuring rewired trn highly unlikely based conservation trn biology across covs report explores feasibility development stably attenuated vaccine platform featuring completely rewired trn candidate strategy broadly applicable rapidly implementable cov vaccine platform highly resistant recombination repair stably attenuated young highly vulnerable mouse models human disease <NUMBER>nt trn mutant attenuated virulence previous study laboratory demonstrated sarscov trn could reprogrammed provided individual trss replaced matching sequences <NUMBER> rewired trn replaced conserved <NUMBER>nt trs <NUMBER>nt cassette used characterized covs encoding net change <NUMBER> nts acgaac ccggau previous work showed rewired trn refractory recombination wt genomes <NUMBER> therefore tested replication pathogenesis young aged balbc mice consistent earlier reports wt sarscov caused weight loss aged animals contrast crg<NUMBER> replicated caused weight loss young <NUMBER>weekold mice fig <NUMBER>a minimal weight loss aged <NUMBER>monthold balbc mice fig <NUMBER>b young mice p <NUMBER> titer wilcoxon test p <NUMBER> weight loss mannwhitney test old mice p <NUMBER> titer p <NUMBER> weight loss wt recombinant viruses replicated high titers detectable days <NUMBER> <NUMBER> postinfection pi young aged animals titers beginning clear day <NUMBER> pi fig <NUMBER>c usually observed mice infected sarscov <NUMBER> vaccination crg<NUMBER> protects mice challenge high replication titer low absent virulence young aged mouse models paired inherently recombinationrefractory genome suggested crg<NUMBER> virus would ideal vaccine candidate test crg<NUMBER>s efficacy protecting homologous heterologous challenge virus administered mice singledose vaccination alongside viral replicon particles vrps expressing viral spike attachment protein vrps control <NUMBER> day <NUMBER> postvaccination mice challenged either mouseadapted sarscov ma<NUMBER>homologous challenge sarscov expressing spike gene himalayan palm civet paguma larvata strain hcsz<NUMBER> heterologous challenge mice observed morbidity mortality surviving animals euthanized day <NUMBER> pi upon homologous challenge crg vaccination protective weight loss mortality young aged mice detectable viral titer lungs <NUMBER> days pi contrast pbs vrps subcutaneous vaccination fig <NUMBER>ad supplementary fig <NUMBER>ab importantly heterologous challenge crg<NUMBER> vrps vaccines crg vaccination induced sarscov neutralizing antibody titers approaching <NUMBER> log <NUMBER> young aged mice nearly <NUMBER>fold higher titers induced vrps vaccination p <NUMBER> twoway anova supplementary fig <NUMBER>e moreover crg vaccination largely protected aged mice extensive inflammatory cell infiltration tissue damage perivascular cuffing edema septal thickening observed pbsand vrpsvaccinated mice supplementary fig <NUMBER> crg<NUMBER> reverts pandemicassociated mutations liveattenuated vaccine candidate demonstrate phenotypic stability infected host populations therefore test resistance reversion virulence crg<NUMBER> subjected five independent serial passages parallel wt sarscov aged <NUMBER>monthold balbc mice course six <NUMBER>day passages crg<NUMBER> passaged viruses acquired virulent phenotype weight losses percent survival curves mirroring kinetic rates emergence virulence seen wt passaged viruses supplementary fig <NUMBER> attempt identify genotypic causes phenotypic reversion virulence genomes <NUMBER> independent plaque isolates passage <NUMBER> viruses wt p<NUMBER> crg<NUMBER> p<NUMBER> submitted sanger sequencing surprisingly contrary expectations mutations either spike membrane proteinboth targets mutational selection <NUMBER> separate adaptations sarscov urbani mice fig <NUMBER>a identified wt crg<NUMBER> revertants instead <NUMBER> <NUMBER> crg<NUMBER> p<NUMBER> isolates showed evidence often large deletions accessory orfs <NUMBER>b <NUMBER>a <NUMBER>b fig <NUMBER>a b deletions often inframe reminiscent several incidences host rangeassociated deletions identified human isolates <NUMBER> sarscov epidemic including <NUMBER>nt deletion orf<NUMBER> relative himalayan palm civet strain <NUMBER> <NUMBER>nt <NUMBER> <NUMBER>nt <NUMBER> deletions region contrast deletions accessory orfs rare virulent wt revertants rather scattered nonsynonymous mutations identified orf<NUMBER>a orf<NUMBER>a orf<NUMBER>a orf<NUMBER> notably <NUMBER> wt revertant exhibited small deletion orf<NUMBER>b collectively findings demonstrated region sarscov genome inherently unstable subjected replication pressure especially aged animals indicated trnrewired virus would require additional stabilizing mutations feasible vaccine candidate attenuated sarscov mutant <NUMBER>nt trn replacement demonstration secondsite reversion virulence upon passage crg<NUMBER> suggested ideal trnrewired vaccine candidate would one would less likely phenotypically revert vivo cov trs networks finely tuned regulate expression highly abundant lowfrequency mrna transcripts thus small changes trs might subtly alter regulation subgenomic transcripts <NUMBER> moreover exact regulatory milieu around trs uncertain beyond recognition upand downstream sequences influence mrna expression efficiency perhaps trn sequencespecific manner <NUMBER> <NUMBER> hypothesized extensive remodeling trs network may better disrupt finely tuned network abundant lowfrequency transcripts altering natural regulation global gene expression thereby leading decreased virulence addition possible virulence observed crg<NUMBER> p<NUMBER> isolates due least part mouse adaptation passage therefore evaluate effects extensive trn rewiring lethal pathogenic model stabilize trn recombination repair mutation selection trn mutant constructed featured following <NUMBER> set fig <NUMBER> replacements yielded infectious crg<NUMBER>ma virus capable replicating titers equivalent mouseadapted wt background virus sarsma<NUMBER> though pinpoint plaque phenotype remained stable tissue culture passage crg<NUMBER>ma <NUMBER> crg<NUMBER> replacements virulent sarsma<NUMBER> backbone also generated control trnrewired virus northern blot analysis crg<NUMBER>ma versus crg<NUMBER> sarsma<NUMBER> revealed virus produced expected bands similar proportions wt virus although additional lowabundance transcripts also noted crg<NUMBER>ma supplementary fig <NUMBER> viruses evaluated replication virulence young <NUMBER>weekold aged <NUMBER>monthold balbc mice comparison sarsma<NUMBER> young mice crg<NUMBER>ma attenuated compared crg<NUMBER>ma sarsma<NUMBER> causing <NUMBER>df infection aged balbc mice <NUMBER> log <NUMBER> <NUMBER> log <NUMBER> <NUMBER> log <NUMBER> pfu crg<NUMBER>ma sarsma<NUMBER> emphasized attenuated virulence phenotype <NUMBER>log <NUMBER> pfu infection crg<NUMBER>ma causing almost weight loss course infection despite replicating titers <NUMBER> log <NUMBER> <NUMBER> log <NUMBER> pfu infections fig <NUMBER>g crg<NUMBER>ma sarsma<NUMBER> infections <NUMBER> mice infected <NUMBER> log <NUMBER> <NUMBER> log <NUMBER> pfu <NUMBER> mice infected <NUMBER> log <NUMBER> pfu surviving course crg<NUMBER>ma infection contrast <NUMBER> mice infected <NUMBER> log <NUMBER> pfu sarsma<NUMBER> survived infection mice infected <NUMBER> log <NUMBER> <NUMBER> log <NUMBER> pfu survived days <NUMBER> <NUMBER> pi maximum respectively p <NUMBER> logrank test fig <NUMBER>i crg<NUMBER>ma serially passaged young <NUMBER>weekold balbc mice contrast rapid phenotypic reversion observed crg<NUMBER> crg<NUMBER>ma remained phenotypically stable passage mice losing minimal <NUMBER> amount starting weight <NUMBER>day infections throughout <NUMBER> passages supplementary fig <NUMBER>a viral titer also remained stable passage <NUMBER> log <NUMBER> pfu detectable <NUMBER> days pi passage supplementary fig <NUMBER>b furthermore crg<NUMBER>ma serially passaged independently three times six passages aged mice replicating passage conditions crg<NUMBER> reverted virulence crg<NUMBER>ma exhibit increase virulence causing <NUMBER> weight loss infected animals and<NUMBER> mortality upon infection <NUMBER>monthold balbc mice <NUMBER> <NUMBER> pfu crg<NUMBER>ma postpassage essentially replicating mortality shown aged mice infected nonpassaged crg<NUMBER>ma virus distinct <NUMBER> mortality caused wildtype sarsma<NUMBER> infection aged mice see fig <NUMBER>i supplementary fig <NUMBER>c supplementary table <NUMBER> finally crg<NUMBER>ma evaluated capacity protect lethal sarsma<NUMBER> challenge aged <NUMBER>monthold mice mice vaccinated <NUMBER> log <NUMBER> pfu either crg<NUMBER>ma exonma previously demonstrated effective vaccine sarsma<NUMBER> backbone aged balb c mouse model sarscov pathogenesis <NUMBER> day <NUMBER> postvaccination mice challenged lethal dose <NUMBER> log <NUMBER> pfu sarsma<NUMBER> evaluated weight loss mice lost minimal amounts <NUMBER> starting weights vaccines p <NUMBER> viruses versus pbs vaccination wilcoxon test indicating crg<NUMBER>ma exonma equally protective lethal sarsma<NUMBER> challenge fig <NUMBER> liveattenuated vaccines remain key players reducing global disease burden associated viral infections humans critically important livestock companion animals historically contemporarily liveattenuated vaccines used success help control measles mumps rubella polio yellow fever chickenpox infections outbreaks <NUMBER> <NUMBER> <NUMBER> however liveattenuated vaccines also associated risk reversion either mutationor recombinationdriven processes cause dangerous outbreaks unvaccinated populations including animals <NUMBER> example highly pathogenic porcine epidemic diarrhea virus pedv strains emerged china <NUMBER> circumventing existing vaccines rna recombination events wildtype liveattenuated pedv avian infectious bronchitis virus ibv strains seeded new outbreaks <NUMBER> <NUMBER> <NUMBER> <NUMBER> therefore measures needed stabilize liveattenuated vaccines reversion selective pressure particularly viruses like covs employ recombination standard feature replication cycle incidental recombination events context coinfection could unintentionally introduce alleles enhanced virulence attenuated vaccine genome consequences could difficult predict <NUMBER> <NUMBER> <NUMBER> several groups including developed novel strategies fidelity regulation control attenuate rna virus pathogenesis case covs development mutants prevent reversion repair virulence <NUMBER> <NUMBER> recombination repair wellcharacterized process essential genome evolution many biological systems plays critical roles spread virulence pathogenesis <NUMBER> general strategies engineer recombinationresistant rna viruses limited covs lesser extent enteroviruses <NUMBER> <NUMBER> context cov infection recombination occurs viral rnadependent rna polymerase rdrp switches templates nascent rna synthesis using nascent rna primer rdrp reassociates template genome likelihood recombination event occurring regulated several viral factors including replication rates rna secondary structure genome size nature replicase transcriptase protein complex however heritability recombination occurred mediated replication fitness resulting progeny genome <NUMBER> several reports described emergence covs enhanced virulence upon genome analysis clearly originated recombination events related viruses avian mammalian hosts including sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> furthermore reservoir species bats prevailing evidence suggests potentially lethal human covs sarscov merscov emerged shown harbor multiple cov species recombinant rna genomes frequently identified within colonies among individual infected animals increasing likelihood recombinationdriven alterations species specificity virulence <NUMBER> <NUMBER> <NUMBER> <NUMBER> thus engineering elements render genome recombinationrefractory essential step towards ensuring liveattenuated vaccine candidate cannot regain virulence incidental coinfection another trncompatible cov genome sarscov highly pathogenic pneumoenteric pathogen captures many disease features seen among covs trn conserved sequence cs motifs utilized crg<NUMBER> crg<NUMBER> backgrounds ccggau uggucgc respectively unique sequence motifs compared known cov genome trn sequences greatly reducing likely eliminating possibility recombination unmodified genomes canonical trs loci previous work demonstrated introducing mismatched trss lethal rna recombinant virus replication <NUMBER> furthermore showed crg<NUMBER> trn replacement revert primary sites mutation indicating rewired trn stable sufficient selective pressure revert even vivo coordinated interactions required trn function trn reversion unlikely given requirement nearly simultaneous reversions multiple sites across genome largersized trs css <NUMBER> nts within trn may prove effective evolution appears selected cov rna polymerase heavily focused recognizing <NUMBER>to <NUMBER>nt trs cs within trn regulate subgenomic transcription attenuation resulting trn rewiring likely attributed alterations viral transcription profile lowabundance transcripts either encode reduce expression previously unidentified outofframe orfs viral host factor interactions viral genome rewired trn produces obvious novel viral rna species supplementary fig <NUMBER> novel rna species may serve functional mrnas producing noncanonical viral protein products attenuate viral replication pathogenesis alternatively novel rna species may compete canonical viral rna species replication transcription attenuating viral replication andor pathogenesis due altered availability transcripts encoding bona fide viral virulence factors furthermore rewired trn may serve attenuating factor virus discontinuous transcription program alters programmed rnaprotein interactions involving viral host proteins either directly ie altering bases required rnaprotein interactions indirectly ie changes rnas secondary structure affect steric availability rnaprotein interaction sites moreover di et al arterivirus model used nextgeneration sequencing analysis show noncanonical transcripts produced course wildtype infection indicating coding capacity nidoviruses actually much larger characterized using sanger sequencing biochemical detection methods findings suggest attenuation via trn may able target noncanonical rna species might able impact pathogenesis fewer effects replication structural protein production <NUMBER> fascinating possibilities focus future studies mechanism trnrelated attenuation hypothesis alterations expression profiles canonical viral rna species protein products attenuate pathogenesis strengthened paired observations types mutations selected upon passage crg<NUMBER> aged mice mutation profiles different selection occurred young versus aged populations frieman et al previously demonstrated mutations spike nonstructural protein <NUMBER> nsp<NUMBER> repetitively selected several independent passages mutations conferred virulence young days postinfection mice suggesting spikeviral receptor interactions nsp<NUMBER>replicase protein interactions important virulence <NUMBER> severely ill sarscovinfected humans predominantly <NUMBER> years age deletions around orf<NUMBER> identified discussed earlier <NUMBER> <NUMBER> <NUMBER> <NUMBER> deletions different accessory orfs frequently observed changes selection aged animals furthermore aged mice nearly combination <NUMBER> sarsma<NUMBER>identified alleles shown fig <NUMBER>a also conferred increased virulence likely reflecting increased susceptibility aged mice lethal outcomes data suggest cov adaptation virulence different young aged animals especially coupled variations virus pathogenic determinants immune senescence enhance virus virulence <NUMBER> data support novel hypothesis virulent zoonotic coronaviruses may emerge quickly vivo passage especially aged multiple evolutionary pathways exist program virus virulence disproportionate identification mutations accessory orfs following passage crg<NUMBER> trn virus aged animals may reflect roles accessory orfs hypothesized play modulation host immunity <NUMBER> aged animals immune systems respond differently usually severely microbial challenge immune response skewed towards severe innate immune effects defects adaptive immunity <NUMBER> however context cov infection augmented immune response presented context accessory orf deletion may serve virulence fulcrum balance poised essential immune recognition severe disease possibly due defects spread persistence potential effects host immunity argue stable vaccine candidate consider potential changes accessory orfs welldesigned vaccine candidate include genetic traps either independently attenuating triggered recombination events previously demonstrated stable attenuation protection lethal challenge inactivations nsp<NUMBER> exonuclease <NUMBER> nsp<NUMBER> <NUMBER>′omethyltransferase <NUMBER> activities addition züst et al demonstrated partial deletion murine hepatitis virus mhv nsp<NUMBER> replicase protein could protect homologous heterologous challenge <NUMBER> combining alleles render virus recombinationrefractory alter rna replication fidelity result altered host immune response could produce stable reversionproof liveattenuated viruses induce robust neutralizing immunity attenuating alleles coupled rewired trn anticipated increase stability attenuation minimize chances rna recombination repair strategies reported herein coupled availability new molecular clones covs cause severe disease livestock populations provide vehicle improved live virus vaccine design <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> may also possible tune cov trn attenuating changes concentrated virulence alleles accessory genes known impact pathogenesis alterations potential greater enhance stability vaccine candidate particularly considering trs context outside <NUMBER>to <NUMBER>nt core sequence studies would benefit rna structure also considered trs accessibility likely modulated structural elements cov rna genome studies focus future work continuing identification zoonotic pools covs genetically resemble lethal human animal covs often percentage points difference zoonotic lethal human sequences <NUMBER> necessity rapidly implementable universal attenuation platform cov liveattenuated vaccine design underscored report described design implementation cov attenuation strategy easily rapidly adapted cov genome presence <NUMBER> characterized trss within cov genome css <NUMBER> nts offers large complex target primary site reversion likely event single recombination events would decouple trn expression networks recombinants would lethal therefore attenuation strategy paired alleles resist selection events lead secondsite reversion could bring liveattenuated cov vaccines within reach realization face evergrowing threat new human animal covbased epidemics viruses cells virus stocks propagated veroe<NUMBER> cells described <NUMBER> virus work performed biological safety cabinet biosafety level <NUMBER> laboratory construction sars plasmids viruses trn<NUMBER>based plasmids constructed <NUMBER> trn<NUMBER> mutations introduced sars plasmids f using cassettes generated biobasic generate sarsf plasmids containing trn mutations mouseadapted mutation nt <NUMBER> mouseadapted mutation cloned f trn plasmids via pcr restriction digestion strategy generate sarsf plasmids containing trn mutations mouseadapted mutation nt <NUMBER> mouseadapted mutation cloned f trn plasmids via pcr restriction digestion strategy plasmids fbstz <NUMBER>′ggaggcgcaatttttgtacctctatgccttg<NUMBER>′ rmamut <NUMBER>′agctatcgtctccgcttctcaacggtaatagtaccgttgtctg<NUMBER>′ fmamut <NUMBER>′agctatcgtctccaagcttaaacaactcctggaacaa tggaac<NUMBER>′ rmsc <NUMBER>′gtggcttagctacttcgttgcttcctt caggc<NUMBER>′ used generate <NUMBER> amplicons resulting amplicons restrictiondigested bsmb ligated purified ligated amplicons parent vectors restrictiondigested bstz<NUMBER> msc ligated ligated vectors transformed topten e coli cells resulting colonies screened sequenceverified viruses constructed described ref <NUMBER> northern blot analysis intracellular rna isolated using ribopure reagents ambion austin tx <NUMBER> h postinfection <NUMBER> mrna isolated using qiagen oligotex mrna isolation kit treated glyoxal separated agarose gel using northernmaxgly ambion rna transferred brightstarplus membrane ambion <NUMBER> h crosslinked using uv light prehybridized probed n genespecific oligonucleotide probe <NUMBER>′cttgactgccgcctctgct b b ccct b ct b gc b <NUMBER>′ biotinylated nucleotides denoted superscripted b blot hybridized overnight washed lowand highstringency buffers incubated phosphataseconjugated streptavidin blot incubated cdpstar overlaid film developed mouse infections sarscov mutants experimental protocols involving mice reviewed approved institutional animal care use committee university north carolina chapel hill nc usa following mice used <NUMBER>weekold female balbc charles river laboratories wilmington usa <NUMBER>monthold female balbc harlan laboratories indianapolis usa mice lightly anesthetized infected intranasally varying doses <NUMBER> <NUMBER> <NUMBER> <NUMBER> pfu depending experiment sarscov ma<NUMBER> trn mutants mice weighed daily certain days specified experiment mouse lungs harvested virus titer andor rna serial passages inoculated passage <NUMBER> subsequent passages inoculated <NUMBER> μl clarified lung homogenate lungs homogenized <NUMBER> ml pbs previous passage experiments used minimum n <NUMBER> mice per virus per dosagecondition applicable per timepoint infectionchallenge studies mice infected <NUMBER> <NUMBER> <NUMBER> <NUMBER> pfu indicated vaccine virus weighed <NUMBER> days following initial infection challenged lethal dose <NUMBER> <NUMBER> pfu ma<NUMBER> challenge infection determination virus titer infected mouse lungs lungs harvested virus titer weighed homogenized <NUMBER> ml pbs <NUMBER> rpm <NUMBER> magnalyser roche basel switzerland virus titers determined plaque assay vero cells determination viral neutralization antibody titers mouse sera heatinactivated <NUMBER> min <NUMBER>°c serially diluted <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> pbs volume <NUMBER> μl next <NUMBER> μl pbs containing lowconcentration sarscov ma<NUMBER> <NUMBER> pfu highconcentration sarscov ma<NUMBER> <NUMBER> pfu added serum dilution virusserum mixtures incubated <NUMBER>°c <NUMBER> min following incubation virus titers mixtures determined plaque assay finally calculated <NUMBER> plaque reduction neutralization titer prnt <NUMBER> values serum dilutions plaque formation reduced <NUMBER> relative virus stock treated serum viral genome sequencing determine sequences viral genomes present mouse lungs passage plaques isolated lung samples described briefly individual viral plaques harvested collecting agarose plugs using <NUMBER>μl pipette tip agarose plug dropped <NUMBER> ml pbs allowed diffuse <NUMBER> h <NUMBER>°c applied to<NUMBER> confluent monolayers veroe<NUMBER> cells t<NUMBER> flasks incubated <NUMBER> h <NUMBER>°c infected cell monolayers harvested <NUMBER> ml trizol firststrand cdna generated described ref <NUMBER> amplicons viral genomes generated described ref <NUMBER> sequence results analyzed using geneious r<NUMBER> biomatters auckland new zealand serial cloner <NUMBER> serialbasics httpserialbasics freefrhomehomehtml statistical analyses statistical analyses performed using graphpad prism <NUMBER> graphpad software la jolla ca usa tests run depended experimental design specified text significance set p <NUMBER> viral genome sequence datasets available via ncbi genbank accession identifiers mk<NUMBER> mk<NUMBER> data generated andor analyzed current study available corresponding author reasonable request received <NUMBER> january <NUMBER> accepted <NUMBER> september <NUMBER> mucosa human respiratory tract represents primary target large number microbial pathogens typically colonization asymptomatic process resulting interplay bacterial factors host clearance mechanisms clinical illness may result either local release bacterial toxins systemic dissemination pathogen breaching mucosal barrier course respiratory infections adaptive immune responses could significantly impaired might lead severe forms disease superinfections turn complicate clinical management patient severe forms respiratory infection tend occur young children among elderly immune competence eroded immaturity immunesenescence respectively addition patients immunocompromised result disease therapeutic interventions greatest risk developing fatal infection despite availability new antimicrobials effective vaccines communityacquired pneumonia remains common serious illness fact leading contributor nearly <NUMBER> million deaths occurring year due respiratory infections especially children developing countries <NUMBER> <NUMBER> main causative agents pneumonia differ according patient age geographic area addition relatively comprehensive studies specific aetiology pneumonia <NUMBER> due overlaps clinical manifestations different syndromes ii difficulties establishing precise aetiology iii frequent occurrence coinfections however streptococcus pneumoniae haemophilus influenzae respiratory syncytial virus rsv parainfluenza virus type <NUMBER> piv<NUMBER> identified main agents responsible acute respiratory infections children whereas influenza virus related pneumonia leading cause diseaserelated deaths elderly addition availability new sensitive diagnostic tests contributed identification hitherto unknown lower respiratory pathogens human metapneumonovirus hmpv novel coronaviruses causing severe acute respiratory syndrome sars significant efforts invested last two decades develop new diagnostic tools elucidate molecular mechanisms microbial pathogenesis understand host clearance mechanisms resulted improved knowledge host responses infection immunopathogenesis turn facilitated establishment new prophylactic therapeutic interventions however despite accomplishments vaccine development many pathogens vaccines adequate therapies available existent ones suboptimal main approach applied vaccine development radically changed recent years whole cell vaccines systematically replaced subunit vaccines purified antigens coding genes exploited combination new adjuvants andor delivery systems result many vaccines development exhibit consistently improved stability safety efficacy profiles also amenable mucosal administration thereby mimicking natural infections influenza viruses commonly responsible severe respiratory illness humans followed influenza b populations susceptibly infection renewed annually rapid antigenic variation virus antigenic variation due accumulation point mutations two major surface glycoproteins virus haemagglutinin ha neuraminidase na lead antigenic drift virus often leaves current influenza vaccines outdated ineffective antigenic shift also occur due segmented nature viral genome favours emergence reassorted strains entire glycoprotein acquired different animal influenza virus types variation represent critical bottleneck establishment robust vaccination strategy influenza fact influenza virus capacity spread persontoperson complete new glycoprotein subtype suddenly emerges worldwide pandemic outbreak result <NUMBER> earliest vaccines influenza whole cell vaccines obtained <NUMBER>s inactivating viruses grown allantoic cavity embryonated chicken eggs formalin contemporary inactivated influenza vaccines still produced embryonated eggs improvements manufacturing resulted highly purified lessreactogenic detergentsplit product three viral strains selected basis previous years surveillance data prevalent subtypes therefore vaccine composition may vary yeartoyear vaccination high benefitcost ratio since influenzarelated illness eg hospitalizations deaths effectively prevented <NUMBER> worlds total vaccine production approximately <NUMBER> million doses maximum capacity <NUMBER> million doses however world health organization estimates <NUMBER> billion people high risk severe influenza outcomes eg elderly <NUMBER> years age infants health care workers children adults underlying cardiopulmonary disease furthermore global infrastructure would able handle timely manufacturing distribution vaccine pandemic outbreak <NUMBER> one alternative would lower quantity antigen per dose add adjuvants vaccine formulation needs tested clinical trials <NUMBER> another solution would improve current vaccine production technologies ie eggderived vaccines however limited number egg producers viral strains emerge could easily adapted embryonated eggs overcome problems several pharmaceutical companies embarked projects development vaccines produced growing virus cell lines influenza virus adapted grow variety mammalian cell lines including vero perc<NUMBER> madindarby canine kidney mdck cells <NUMBER> <NUMBER> <NUMBER> strategy would also improve possibility upscaling vaccine production face pandemic spread alternatively would possible develop vaccine influenza virus avian h<NUMBER>n<NUMBER> strain using reverse genetics techniques <NUMBER> see advances vaccinology cold adaptation found reliable efficient procedure derivation live attenuated viral vaccine strains humans coldadapted ca virus strains grow primary chick kidney cells embryonated eggs <NUMBER>°c however exhibit reduced replication <NUMBER>°c process genetic reassortment transfer six internal genes stable attenuated ca master donor strain influenza b new prevailing wildtype epidemic strain used generate attenuated coldreassorted vaccines proper level attenuation genetic stability immunogenicity show low absent transmissibility <NUMBER> medimmune wyeth developed along lines trivalent live ca vaccine flumist intranasal spray delivery licensed <NUMBER> contrast parenterallyadministered vaccines formulation triggers immune responses resembling observed natural infections <NUMBER> despite moderate hemagglutinationinhibiting antibody titres observed vacinees flumist showed <NUMBER> efficacy <NUMBER>year period children including protection antigenic variants circulated second year <NUMBER> <NUMBER> <NUMBER> ca vaccine also stimulated production nasal iga well tcell interferon responses <NUMBER> cellmediated immunity virus matrix nucleoprotein antigens may favour viral clearance early recovery illness <NUMBER> advisory committee immunization practices recommended use persons <NUMBER> <NUMBER> years age since sideeffects observed young children wheezing nasal congestion data available elderly <NUMBER> <NUMBER> despite remarkable genetic stability vaccine kept <NUMBER>°c thus new heat stable derivative recently developed showed good efficacy clinical trials <NUMBER> live vaccine based master virus strain developed institute applied microbiology austria growing wild influenza virus vero cells <NUMBER>°c also demonstrated safe welltolerated immunogenic intranasal immunization young adults <NUMBER> number subunitor dnabased vaccines also various stages development influenza vaccine formulated virosomes commercialized berna biotech inflexal ® v contains surface spikes three currently circulating influenza virus strains inserted vesicle membranes three corresponding virus types details see section pseudoviruses antigen delivery systems <NUMBER> company also developed virosomebased nasal formulation however withdrawn market due presence sideeffects ie bells palsy assumed linked presence escherichia coli heat labile toxin lt adjuvant two companies yeda bionvax also developing peptidebased influenza vaccine nasal administration showed protective efficacy humanized mice <NUMBER> subunit vaccine containing recombinant ha protein produced using baculovirus system successfully tested phase ii trial <NUMBER> <NUMBER>yearold volunteers epidermal dnabased influenza vaccine contained ha gene apanama<NUMBER> delivered particlemediated epidermal delivery also tested humans powderject <NUMBER> serum haemagglutinationinhibition antibody responses observed volunteers receiving single dose <NUMBER> <NUMBER> <NUMBER> g dna strongest consistent responses subjects vaccinated highest dosage immunization approaches aim development universal vaccine broad spectrum protective activity different influenza strains <NUMBER> among use highly conserved transmembrane m<NUMBER> protein virion mentioned recombinant particulate vaccine engineered genetically fusing copies m<NUMBER> hepatitis b core antigen hbc m<NUMBER>hbc fusion protein spontaneously assembled viruslike particles vlp provided complete protection lethal challenge influenza virus mice <NUMBER> <NUMBER> promising results also obtained vaccination m<NUMBER> peptide conjugated neisseria meningitidis outer membrane protein complex ompc monkeys <NUMBER> human piv hpiv consist four serotypes hpiv<NUMBER> second leading cause bronchitis pneumonia infants vaccine licensed date piv however several approaches currently investigation initial attempts provide protection using vaccines based formalininactivated viruses failed subsequent work demonstrated glycoproteins haemagglutininneuraminidase hn f responsible virus attachment fusion able stimulate elicitation neutralizing antibodies animals however poor immunogenicity naïve subjects led currently favoured approach based use live attenuated piv live attenuated piv vaccines developed human bovine strains amenable delivery intranasal route candidate vaccines able replicate induce protective immune response young infants even presence maternally acquired antibodies two main attenuated strains studied detail one hpiv<NUMBER> strain cp<NUMBER> selected <NUMBER> passages virus african green monkey cells low temperature bovine piv bpiv<NUMBER> strain antigenically related hpiv<NUMBER> replicates poorly humans cp<NUMBER> bpiv<NUMBER> evaluated phase iii trials seropositive seronegative children young infants found overattenuated seropositive children immunogenic seronegative children infants <NUMBER> however magnitude antihn response lower children received bpiv<NUMBER> vaccine <NUMBER> prompted engineering chimeric bovinehuman piv<NUMBER> candidates eg hpivnb strain human nucleocapsid replaced bovine counterpart bpiv<NUMBER> strain expresses f hn proteins hpiv<NUMBER> attenuated chimeric viruses contain piv<NUMBER> cp<NUMBER> internal genes f hn genes either piv<NUMBER> piv<NUMBER> also tested hamsters <NUMBER> berna biotech also developing virosomal formulation piv<NUMBER> <NUMBER> using successful approach influenza vaccine formalininactivated candidate respiratory syncytial virus rsv tested children <NUMBER>s consequence hospitalization <NUMBER> vaccinees two deaths <NUMBER> moreover vaccinated children also suffered severe disease subsequent exposure virus compared unvaccinated controls <NUMBER> demonstrated elicitation strong immune response sufficient confer protection disease even lead immunopathological reactions thus essential stimulate right type immune response particular case rsv host responses play important role pathogenesis disease thereby making development preventive vaccine extremely difficult addition naturally acquired immunity rsv neither complete longlasting recurrent infections often occur <NUMBER> however older children adults usually protected suggesting protection severe disease develops several consecutive infections passive immunization rsvneutralizing immune globulins also shown prevent rsv infection newborns underlying cardiopulmonary disease <NUMBER> demonstrates antibodies play major role protection disease whereas tcell immunity targeted internal viral proteins appears contribute clearance although live attenuated vaccines seem preferable immunization naïve infants subunit vaccines may choice elderly highrisk children pregnant women candidate subunit vaccines based purified f proteins pfp<NUMBER> <NUMBER> <NUMBER> demonstrated safe immunogenic even pregnancy <NUMBER> maternal immunization using pfpbased vaccine could interesting strategy protect infants younger <NUMBER> months age <NUMBER> however significant protection reported phase iii trial performed children <NUMBER> years age cystic fibrosis vaccination subunit vaccine based pfp<NUMBER> <NUMBER> formulation based surface glycoproteins f g together virion matrix protein rsva tested healthy adult volunteers presence either alum polyphosphazene adjuvant shortlive neutralizing antibody responses rsva rsvb detected <NUMBER> vaccinees suggesting annual boosting needed <NUMBER> <NUMBER> <NUMBER> central domain g protein rsva relatively conserved among viruses groups b thus recombinant vaccine candidate bbg<NUMBER>na developed fusing g<NUMBER>na domain albumin binding region streptococcal protein g candidate shown moderate immunogenic adult human volunteers clinical development interrupted due appearance purpura vaccinees <NUMBER> main two difficulties associated generation live attenuated vaccines rsv overor underattenuation virus limited genetic stability temperaturesensitive ts ca coldpassaged cp mutant viral strains generated despite attenuation shown adults seropositive children cpts mutants still caused moderate congestion upper respiratory tract seronegative infants <NUMBER> months old <NUMBER> recombinant rsv vaccines deletions non essential genes eg sh ns<NUMBER> ns<NUMBER> also carry cp ts mutations essential genes currently evaluated <NUMBER> recombinant dna technology chimeric viruses engineered contain genes hpiv<NUMBER> surface glycoproteins f nh together rsv glycoproteins f g bpiv<NUMBER> genetic background one candidates found attenuated able induce elicitation immune responses hpiv<NUMBER> rsv rhesus monkeys <NUMBER> similarly bpiv<NUMBER> genome engineered express hpiv<NUMBER> f hn proteins either native soluble rsv f protein <NUMBER> resulting strain induced rsv neutralizing antibodies protective immunity rsv challenge african green monkeys needs tested safety efficacy rsv piv<NUMBER> infants emerging disease originally described guangdong province china <NUMBER> even global outbreak sars control <NUMBER> new infections reported persons contacts animals <NUMBER> <NUMBER> <NUMBER> typical sarscovlike virus transmitted animals humans however certain conditions virus evolve early human sarscov ability transmitted animals humans even humans humans thereby leading localized outbreaks mild disease early human sarscov selective pressure humans may evolve late human sarscov cause local global outbreaks typical sars <NUMBER> sars easily grown cell cultures <NUMBER> thus urgent need vaccines prevent naturally occurring epidemic outbreaks also tool threat biological weapons several structural proteins expressed sarscov including nucleocapsid envelope spike proteins <NUMBER> latter type transmembrane glycoprotein responsible virus binding fusion entry major target neutralizing antibodies <NUMBER> <NUMBER> extracelullar domain protein consists two subunits s<NUMBER> s<NUMBER> <NUMBER> s<NUMBER> subunit possess receptorbinding domain rbd responsible viral binding one receptors <NUMBER> <NUMBER> vectorbased vaccines expressing protein well dna vaccines encoding fulllength protein assessed preclinical studies <NUMBER> <NUMBER> modified vaccinia virus ankara mva coding fulllength protein administered either intranasal intramuscular route neutralizing antibodies elicited <NUMBER> however vaccination ferrets resulted liver damage challenge raising concerns safety approach <NUMBER> vaccines formulated using different synthetic peptides encompassing linear b cell epitopes protein identified using sera convalescent patients stimulated high antibody titres nevertheless none triggered elicitation neutralizing activity hand studies demonstrated although antibodies protein late sarscov urbani strain exhibit neutralizing activity also enhance infection early human sarscov isolate gd<NUMBER>t<NUMBER> civet sarscovlike viruses derivative protein truncation amino acid aa <NUMBER> fails cause antibody dependent enhancement infection retains ability induce neutralizing antibodies findings suggest elimination putative heptad repeated <NUMBER> hr<NUMBER> aa <NUMBER> implicated viral fusion might abrogate stimulation virus infectionenhancing antibodies <NUMBER> <NUMBER> use nucleoprotein coronavirus dna vaccination protocol also led stimulation protective response <NUMBER> contrast protection achieved recombinant piv<NUMBER> expressing nucleoprotein alone together matrix protein used <NUMBER> demonstrates selection delivery system immunization strategy play critical role vaccine efficacy human adenoviruses divided six subgroups af adenovirus cause largescale epidemics acute respiratory disease dissemination especially favoured conditions persons housed communally subgroup viruses ad<NUMBER> associated pneumonia immunocompromised patients neutralizing antibodies directed capsid hexon fiber proteins seems main effector mechanism prevent reinfections adenovirus <NUMBER> <NUMBER> military recruits usa administered entericcoated capsules containing live viruses serotypes <NUMBER> <NUMBER> virus attenuated delivered respiratory route able replicate gastrointestinal tract without causing disease thereby stimulating protective responses respiratory tract <NUMBER> vaccine went production outbreaks respiratory diseases caused adenovirus reemerged among military recruits <NUMBER> since serotypes <NUMBER> <NUMBER> <NUMBER> <NUMBER> cause <NUMBER> adenovirus associated respiratory disease young children development tetravalent vaccine similar mentioned might solve problem children <NUMBER> however implementation vaccine live attenuated adenovirus carefully evaluated since recombinant adenoviruses proposed vaccine vectors tools transfer foreign genes gene therapy protocols polysaccharidebased vaccines pneumoniae <NUMBER> macleod et al <NUMBER> reported protective efficacy capsular polysaccharide ps vaccine military personnel outbreak pneumococcal pneumonia immunization purified ps showed drastically reduced reactogenicity comparison previously used inactivated whole cell vaccines major breakthrough terms safety also demonstrated specific virulence factor purified effectively implemented prevention infectious disease thereby paving road modern non toxoidbased subunit vaccines although serological correlates immunity poorly defined typespecific anticapsular antibodies responsible protective immunity however immunity serotype specific rendering extremely difficult development universal vaccine part due elevate number serotypes regional variations dominant serotypes lack updated seroprevalence data certain regions problems partially solved use psbased polyvalent vaccines currently licensed formulations contain <NUMBER> serotypes pneumoniae cover approximately <NUMBER> serious pneumococcal disease western industrialized countries relatively good antibody responses <NUMBER> elicited healthy adults <NUMBER> weeks single intramuscular subcutaneous immunization <NUMBER> unfortunately poorly immunogenic children aged less <NUMBER> years immune compromised individuals eg aids patients elderly people concomitant disease induce good immunological memory randomized controlled trials healthy elderly young men also failed show beneficial effect pneumonia <NUMBER> however vaccination recommended healthy people <NUMBER> years age confer protection invasive disease <NUMBER> psbased vaccines also used pregnant women stimulate production antibodies transferred foetus via placenta newborns breastfeeding however still matter controversy whether maternal vaccination indeed protect newborns pneumococcal infections <NUMBER> second generation psbased conjugate vaccines stimulates stronger antibody responses even infants young children immune deficient individuals well immunological memory vaccines also suppress nasopharyngeal carriage pathogen reduce bacterial transmission community leading herd immunity adds considerable value implementation introduction vaccines usa <NUMBER> resulted dramatic decline rates invasive pneumococcal disease <NUMBER> <NUMBER> <NUMBER> significant reduction incidence rates among non vaccinated individuals also observed result herd immunity <NUMBER> <NUMBER> however licensed sevenvalent vaccine contain serotypes cause severe disease developing countries ie serotypes <NUMBER> <NUMBER> new conjugate vaccines including serotypes ninevalent vaccine wyeth two <NUMBER>valent vaccines glaxosmithkline sanofipasteur provide better serotype coverage new approaches develop proteinbased subunit vaccines pneumoniae currently pursued different research groups expected enable generation universal vaccine conferring protective immunity large number serotypes well avoid complexity manufacturing conjugate vaccine <NUMBER> different pneumococcal candidate antigens pneumolysin neuraminidase autolysin pneumococcal surface protein pspa adhesin psaa early phase clinical development <NUMBER> addition several promising candidates identified currently tested preclinical experimental models <NUMBER> among two iron uptake abc transporters pneumoniae piaa piua trigger protective immunity invasive pneumococcal disease mice screening pneumoniae genomic expression libraries sera convalescent patients bacterial surface proteins identified eg bvh<NUMBER> bvh<NUMBER> promote elicitation protective antipneumococcal antibodies mice <NUMBER> recombinant hybrid protein bvh<NUMBER>v successfully tested toddlers elderly volunteers candidate vaccine able trigger serotypeindependent responses since bvh<NUMBER> bvh<NUMBER> antigens common serotypes pneumoniae major obstacle developing effective vaccine h influenzae capsular ps related inherently poor immunogenicity tcellindependent antigen antibody responses ps agerelated extremely poor immunogenicity infants first <NUMBER> months life unfortunately age group exhibits highest risk invasive infections caused h influenzae psbased vaccine h influenzae type b hib licensed united states <NUMBER> children <NUMBER> months old <NUMBER> <NUMBER> protective efficacy licensure studies showed inefficacy vaccine infants also older children <NUMBER> problem solved generation conjugate hib vaccine end hib ps ie polyribosylribitol phosphate prp covalently linked immunogenic carrier protein thereby leading tcelldependent responses ps different conjugate hib vaccines currently exist vaccines hboc prpt prpomp make use mutant diphtheria toxin crm<NUMBER> tetanus toxoid outer membrane protein group b n meningitidis carriers respectively trigger similar immune responses recommended doses however dynamic elicited response may vary <NUMBER> <NUMBER> efficacy studies vaccines showed confer protection meningitis also pneumonia <NUMBER> <NUMBER> <NUMBER> although hib vaccines highly effective cost still prohibitive worlds poorest nations however establishment global alliance vaccines immunization gavi moved consistently ahead making also available developing countries gavi approved establishment hib initiative support countries wishing sustain hib vaccination well exploring whether introduction could considered priority near future although introduction conjugated ps vaccines significantly decreased prevalence invasive hib disease paediatric infections due non typeable h influenzae nthi still highly prevalent nthi often associated otitis media sinusitis bronchitis addition nthi important cause lower respiratory infection adults chronic obstructive pulmonary disease copd thus development vaccine nthi considered important goal public health contrast hib vaccines nonencapsulated nthi strains must directed alternative virulence factors lipoproteins p<NUMBER> widely distributed antigenically conserved among h influenzae strains also trigger elicitation protective immunity animals vaccinated mucosal route <NUMBER> <NUMBER> <NUMBER> <NUMBER> thus incorporation vaccine candidates might facilitate generation universal vaccine typeable non typeable h influenzae even age vaccine availability b pertussis continues major cause childhood morbidity mortality ie approximately <NUMBER> million cases <NUMBER> deaths occur annually worldwide since late <NUMBER>s incidence whooping cough dramatically decreased developed countries result widespread immunization first vaccine formulations still use consist preparations based killed b pertussis frequent incidence minor adverse effects eg fever protracted crying local erythematous reactions well concerns raised reports serious neurological sideeffects resulted decline vaccine acceptance use <NUMBER> turn led reemergence whooping cough complications serious problem prompted development new generation acellular vaccines <NUMBER> japan first country successfully introduce acellular vaccines whooping cough immunisation programme <NUMBER> leading consistent reduction reported sideeffects mid <NUMBER>s major phase iii trial acellular vaccines undertaken sweden time banning whole cell vaccine resulted pertussis epidemic country <NUMBER> first vaccine trials contained chemically detoxified pertussis toxin pt filamentous haemagglutinin fha detoxified pt alone results trials showed whilst producing good antibody responses vaccines failed give adequate level protection infants monocomponent vaccine conferred protection infection whereas use two component candidate gave incomplete protection infection <NUMBER> results obtained japan sweden stimulated vaccine companies usa europe establish vigorous research programmes aimed development new generation acellular vaccines higher efficacy currently available vaccines incorporated chemically genetically inactivated pt additional virulence factors fha outer membrane protein pertactin prn fimbrial proteins fims efficacy studies second generation acellular vaccines demonstrated confer levels protection equivalent whole cell vaccines advent improved techniques antigenic characterisation introduction acellular vaccines containing genetically defined components also resulted reduction lottolot variation comparison conventional whole cell vaccines acellular formulation originally introduced japan however despite wide implementation vaccination campaigns infants children disease continues endemic addition countries high vaccine coverage observing consistent increment cases pertussis adolescents adults <NUMBER> <NUMBER> <NUMBER> patients transmit disease infants thereby representing primary reservoir bacterial transmission cycling community abovementioned observations explained one following factors improved detection techniques ii major awareness possibility bacteria may affect age groups iii vaccinedriven antigenic changes circulating isolates iv reduction vaccine efficacy time context concerns raised genetic variation strains used vaccine preparation circulating isolates seems true since currently used whole cell acellular vaccines prepared strains isolated mass vaccine introduction show clear mismatches respect circulating strains steady tendency decrease diversity recent isolates together clonal expansion epidemic outbreaks <NUMBER> <NUMBER> time least two surface proteins pt prn may changed sufficiently allow increase incidence disease unfortunately global information antigenic variation disease adults adolescent extremely limited thus despite widespread introduction pertussis vaccines essential continue surveillance studies collection circulating strains present view successful control pertussis community may require routine immunization adolescents adults new acellular vaccines perhaps combination diphtheria tetanus toxoids dtap intervention might help turn reduce burden disease transmission infants chlamydia pneumonia intracellular bacterium transmitted persontoperson via respiratory droplets pathogen common cause pneumonia infections usually oligosymptomatic asymptomatic young age groups however rate asymptomatic carriage normal population unknown also tremendous gap understanding host response infections caused c pneumoniae studies focused development efficient diagnostic methods however less work done vaccine development paucity knowledge microbial components may serve target antigens fact present licensed vaccines c pneumoniae however potential different antigens major omp<NUMBER> <NUMBER> assessed experimental animal models nevertheless mice vaccinated omp<NUMBER> using protocol based priming dna boosting recombinant vlp showed partial protection <NUMBER> recent studies also suggested ctl responses play role protection clearance <NUMBER> animals immunized minigene encoding seven h<NUMBER>brestricted ctl epitopes fused endothelial reticulumtranslocation signal showed protection following intranasal challenge virulent c pneumoniae <NUMBER> current view multicomponent vaccine required order induce protective response <NUMBER> using promising approach reverse vaccinology combined proteomics see section reverse vaccinology wholegenome c pneumoniae screened searching vaccine candidate antigens among exposed immune accessible surface proteins <NUMBER> selected candidates expressed heterologous system used immunization studies approximately <NUMBER> proteins able trigger elicitation c pneumoniaebinding antibodies tested secondary screenings six also able neutralize bacteria vitro four inhibited systemic dissemination c pneumoniae hamster model <NUMBER> moraxella catarrhalis third common bacterial etiologic agent otitis media children furthermore catarrhalis important cause respiratory infections patients copd thus different studies carried characterize potential protective antigens context two major omp cd e identified considered prime candidate antigens vaccine development proteins expressed surface show high degree conservation among circulating strains omp triggered elicitation bactericidal antibodies protective immunity preclinical models <NUMBER> additional candidates uspa<NUMBER> protein <NUMBER> seems required bacterial colonization human upper respiratory tract ironinduced omp b<NUMBER> lbp ironrepressed omp b<NUMBER> <NUMBER> conjugate vaccine based detoxified lipooligosaccharide also tested mice intranasal route encouraging results <NUMBER> <NUMBER> candidates planned tested clinical studies soon <NUMBER> mycoplasmas commensal microorganisms well opportunistic pathogens mycoplasma pneumoniae one causative agents acute chronic human respiratory diseases main responsible primary atypical pneumonia accounting approximately <NUMBER> communityacquired pneumonia <NUMBER> considerable underreporting pneumoniaeassociated diseases part due wide diversity clinical manifestations difficulties associated cultivation clinical specimens lack adequate diagnostic tools vaccines currently available pathogen however studies conducted human volunteers late <NUMBER>s demonstrated formalininactivated whole cell vaccine acellular extract able confer moderately protective immunity pneumoniae <NUMBER> unfortunately immune pathological reactions observed following challenge live organisms therefore studies still needed understand underlying mechanisms observed autoimmune responses <NUMBER> specifically need elucidate specific role played humoral cellular response protection pneumoniae pneumoniae one smallest selfreplicating prokaryotic pathogens approximately <NUMBER> kb complete genome sequence available expected expand knowledge physiological virulence properties agent well new hints vaccine development previously unrecognized bacterium isolated outbreak legionnaires disease <NUMBER> designated legionella pneumophila <NUMBER> <NUMBER> spreading l pneumophila increasing due use airconditioners humidifiers since infections occur inhalation aerosolized contaminated water sources several approaches developed fight facultative intracellular pathogen infection immunization induce rapid increase antibody titres however antibodies seem play significant role host resistance particularly aerosol challenge <NUMBER> <NUMBER> <NUMBER> authors also suggested antibodies promote bacterial phagocytosis thereby favouring invasion subsequent intracellular replication <NUMBER> contrast cellular responses appear important protection different vaccine candidates tested past heat acetoneand formalinkilled l pneumophila vaccines able confer protective immunity guinea pigs whereas animals immunized l pneumophila membranes survive aerosol challenge virulent bacteria <NUMBER> <NUMBER> additional work demonstrated also purified antigens major secretory protein <NUMBER> major cytoplasmatic membrane protein <NUMBER> peptidoglycanassociated lipoprotein <NUMBER> omps <NUMBER> flagella <NUMBER> confer protection challenge virulent l pneumophila finally different live attenuated mutants l pneumophila used animal infection models promising results <NUMBER> cystic fibrosis cf patients particularly susceptible severe bacterial infections lung pseudomonas aeruginosa one prominent etiologic agents thus significant efforts invested develop vaccine pathogen surface ps among antigens intensively assessed berna biotech developed octavalent vaccine eight prevalent serotypes based ops conjugated exotoxin <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> consistent reduction number cf patients chronic p aeruginosa lung infection observed cohort receiving basic immunization protocol followed yearly boosters period <NUMBER> years <NUMBER> <NUMBER> conjugate vaccine induced production specific igg antibodies increased number igg memory b cells still unclear cellular responses might contribute overall protection conferred vaccine however strong proliferative responses lymphocytes th<NUMBER> phenotype observed vaccinated individuals response carrier exotoxin protein <NUMBER> alternative vaccination strategies currently tested clinical trials among formulations based fusion protein outer membrane proteins f administered parenteral mucosal routes <NUMBER> <NUMBER> formulations demonstrated safe volunteers conferred increased protection p aeruginosa cf patients cellsurface alginate flagella components type iii secretion system inactivated toxins proteases proposed target antigens <NUMBER> already clinical trials alone combination <NUMBER> pasteur returned summer holidays <NUMBER> continue studies chicken cholera inoculated chickens old culture pasteurella multocida left whole summer bench animals received preparation protected challenge performed fresh isolate thus pasteur developed hypothesis pathogens could attenuated exposure environmental insults eg high temperature oxygen chemicals <NUMBER> strategy successfully extrapolated developing anthrax vaccines livestock <NUMBER>s significant economic benefits followed generation attenuated vaccines rabies important pathogens towards end nineteenth century pasteurs approach attenuating inactivating pathogenic organisms still constitutes cornerstone vaccine technology <NUMBER> exemplifies recently major achievements vaccinology facilitated technological eg adjuvants delivery systems reverse vaccinology genetic engineering rather immunological advances <NUMBER> <NUMBER> <NUMBER> however expected impressive knowledge accumulated recent years fields immunology immune pathology microbial pathogenesis pave road new golden era vaccinology knowledge technology enable rational vaccine design <NUMBER>th century pertussis vaccines progressed crude bacterial preparations highly purified antigens used acellular vaccines similar quantum jump technology allowed development subunit vaccines influenza hib pneumoniae well production antigens recombinant dna techniques eg genetically inactivated pt despite fact techniques enable production almost foreseeable antigen identification suitable targets still remained main bottleneck vaccine development <NUMBER> advent genomics exploitation vaccinology field rendered possible implementation systematic holistic approach screening identification prioritisation candidate antigens new approach called reverse vaccinology <NUMBER> require cultivation original pathogen thereby amenable highlypathogenic non culturable microorganisms possible predict select promising candidates analysis genomic sequences silico cloned expressed heterologous systems resulting proteins used perform immunological andor functional studies select promising candidates eg able induce production microbicidal neutralizing antibodies capacity confer protective immunity flanking studies usually carried molecular epidemiological analysis assess degree conservation among circulating strains transcriptional profiling evaluate expression natural infections <NUMBER> timeconsuming process highly expressed components vitro cultivable organism identified one time separated different components one disadvantages reverse vaccinology solved conventional method usually requires <NUMBER> years arrive clinical trial whereas reverse vaccinology reduces process approximately <NUMBER> years reverse vaccinology also allows identification hundreds potential candidates days comparison small number antigens conventional approaches provided decades research moreover reverse vaccinology offers possibility select potential candidates independent expression levels purification easiness reverse vaccinology approach proved usefulness field viral bacterial pathogens eg hepatitis c virus group b meningococci group b streptococci <NUMBER> <NUMBER> reverse vaccinology also become essential tool several vaccine development projects agents causing communityacquired pneumonia eg c pneumoniae streptococci potential speed genomicbased approaches also shown nucleotide sequence coronavirus causing sars made available less one month addition increasing number available genomes bacteria viruses would allow comparative genomic studies thereby providing hints conserved protein families andor functional domains would facilitate generation vaccines using immunogens covering multiple microorganisms <NUMBER> despite incredible potential reverse vaccinology approach also important limitations tab <NUMBER> among fact possible identify nonprotein antigens eg ps glycolipids cornerstone many successful vaccines eg pneumococcal hib vaccines currently available influenza vaccines see based inactivated viruses recently attenuated ca viruses virosomes vaccines exploit starting material wildtype virus inactivated attenuated last approach consists coinfection chicken eggs new isolate master attenuated strain subsequent selection reassorted viruses desired genotypephenotype however virulence certain virus strains h<NUMBER>n<NUMBER> renders difficult implementation traditional strategy use reverse genetics represents valid alternative generation vaccines rna respiratory viruses influenza virus piv rsv consists production virus cloned dna <NUMBER> thereby allowing development vaccines pandemic viral strain cases eg avian h<NUMBER>n<NUMBER> additional mutagenesis step would required attenuate virulence <NUMBER> new ha na segments would transferred appropriate influenza virus master strain adapted grow cell line final reassorted virus antigenic specificity pandemic strain growth characteristics master strain <NUMBER> <NUMBER> technology would also allow production influenza vaccine cells cotransfected plasmids encoding different frag <NUMBER> therefore complete genome inside cell virus produced assembled one main advantages plasmid encoding ha na easily replaced therefore reassortment selection become unnecessary method would considerably reduce time vaccine production many months weeks another advantage would simple manipulation genome contained plasmids would enable detoxification specific virulence factors similar approaches implemented viruses rsv piv sarscov however intellectual property liability issues still obstacles industrial development reversegeneticsbased vaccines <NUMBER> furthermore since resulting viruses considered genetically modified organisms additional problems may arise regulatory stand point <NUMBER> infective agents either limited mucosal membranes need transit across order cause disease therefore highly desirable elicit efficient immune response local site first line defence laid stimulation pathogenspecific response portal entry expected impair infection ie colonization thereby reducing risk transmission susceptible hosts parenterally administered vaccines mainly stimulate systemic responses whereas vaccines given mucosal route mimic natural infections thereby leading efficient mucosal systemic responses thus considerable interest development mucosal vaccines however antigens administered route usually poorly immunogenic different strategies pursued overcome bottleneck among cited use advanced synthetic delivery systems ii live attenuated bacterial viral vectors iii bacterial ghosts iv pseudoviruses v mucosal adjuvants <NUMBER> <NUMBER> <NUMBER> <NUMBER> advanced synthetic mucosal delivery systems particulate antigens immunogenic solution due vulnerability degradation enzymes extreme ph thus would helpful incorporate protective vehicle often vehicles serve protect also enhance uptake promote targeting antigen presenting cells serve adjuvants <NUMBER> commonly exploited delivery systems gelatine capsules dissolved alkaline ph intestine stomach ii mucoadhesive polymers highly viscous inert ps iii eldexomer carboxymethyl cellulose used oral nasal vaginal delivery iv lipidbased structures entrapped antigens immune stimulating complexes iscoms liposomes v biodegradable micronanospheres based biocompatible materials starch copolymers lactic glycolic acid <NUMBER> <NUMBER> approaches currently explored develop vaccines agents causing communityacquired pneumonia encouraging results obtained among others using surface antigens pneumoniae encapsulated microspheres <NUMBER> iscomadjuvanted vaccine obtained reverse genetics influenza virus preclinical models <NUMBER> attenuated viruses bacteria used vaccine candidates per se also delivery systems heterologous antigens thus many attenuated microorganisms exploited scaffold development subunit vaccines agents premise expression recombinant antigens increase pathogenic potential humans animals frequently exploited bacterial vectors attenuated derivatives salmonella enterica shigella spp bacille calmetteguérin bcg example vaccination attenuated salmonella expressing oprfopri also shown able confer protection p aeruginosa murine experimental infection model <NUMBER> addition also demonstrated recombinant bcgbased vaccine expressing pspa confers protection pneumoniae infection animal model <NUMBER> use commensals represents alternative attenuated organisms eg lactobacilli context demonstrated oral administration lactobacillus expressing proteins coronavirus protect gastric infection <NUMBER> thus approach also proposed combat sars promising results also obtained using x chlamydia psittaci <NUMBER> hand different attenuated viruses mva bovine attenuated hpiv<NUMBER> adenovirus used delivery systems heterologous antigens <NUMBER> <NUMBER> fact mva recently exploited antigens sars associated coronavirus <NUMBER> alternative approach use live attenuated carriers given use bacterial ghosts ghosts generated conditional expression lethal lysis gene e bacteriophage phix<NUMBER> gramnegative bacteria <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> leads formation transmembrane tunnel bacterial cellular envelope <NUMBER> due high internal osmotic pressure cytoplasm content expelled tunnel thereby leading empty bacterial cell envelope <NUMBER> presence envelope components ghosts provides strong danger signal activation pattern recognition receptors <NUMBER> addition bacterial ghosts efficiently taken antigenpresenting cells stimulating maturation activation <NUMBER> bacterial ghosts retain morphological structural antigenic features cell wall used vaccine candidates per se ghosts also externally loaded purified antigens alternatively ghosts generated recombinant bacteria expressing heterologous antigens hence avoiding difficulties associated purification steps technology also offers possibility manipulate topology recombinant antigen eg antigen bound inner membrane secreted periplasmic space associated surface encouraging results obtained preclinical models using ghosts expressing chlamydial antigens <NUMBER> <NUMBER> promising results reported using different types pseudoviruses virosomes viruslike particles vlp nonreplicating virallike structures virosomes based principle reconstituting empty viral envelopes integration viral envelope proteins liposomes offer versatility liposomes terms lipid composition advantage including viral membrane proteins virosomes produced disassembling viral membrane envelope detergents viral nucleocapsid removed ultracentrifugation reconstitution fig <NUMBER> contrast vlp exploit capacity recombinant viral coat proteins spontaneously selfassemble thereby mimicking structural level viral capsid vlp isolated protein expression eukaryotic cells vitro assemblage subunits produced heterologous system <NUMBER> main advantages lack viral genetic material intact envelope fact significantly immunogenic soluble proteins used vaccines per se well delivery system proteinor nucleic acid based vaccines carriers small molecules foreign antigens expressed surface simply encapsulated addition amphiphilic adjuvants incorporated membranes thereby offering advantage combining adjuvant antigen one entity without covalent attachment pseudoviruses especially attractive mucosal vaccination protocols since offer opportunity use natural route transmission agents induction serum antibodies secretory iga helper ctl responses protection mucosal pathogen challenge reported studies animals humans <NUMBER> <NUMBER> <NUMBER> virosomes generated using influenza virus retain membrane fusion properties similar naïve virus therefore able deliver material cytosol target cells offering possibility access mhc class irestricted pathway antigen presentation prime ctl activity <NUMBER> <NUMBER> <NUMBER> bacterial toxins derivatives among first molecules used mucosal adjuvants characterized presence moiety enzymatic activity b moiety mediates toxin binding target cells cholera toxin closely related escherichia coli heatlabile toxin showed potent adjuvant activity coadministrated different antigens mucosal route <NUMBER> <NUMBER> <NUMBER> however use humans hampered intrinsic toxicity thus mutated derivatives developed subunit modified remove adpribosylating activity resulting polypeptides retain adjuvanticity absence detectable toxicity <NUMBER> <NUMBER> <NUMBER> however additional studies demonstrated even derivatives lead potential severe sideeffects retrograde homing adjuvant antigen neural tissues <NUMBER> might explain least part sideeffects observed intranasal vaccination influenza virosomesbased formulation containing heatlabile toxin ie bells palsy turn led retraction market however chimeric derivatives lacking targeting moiety neural tissues ie b subunit available <NUMBER> might allow exploitation high potential molecules development vaccines respiratory pathogens fact preclinical studies provided proofofconcept usefulness derivatives bacterial toxins generation acellular vaccines microorganisms pneumonia h influenzae <NUMBER> <NUMBER> bacterial components also explored activity adjuvants monophosphoryl lipid retains much immune stimulatory properties lps without inherent toxicity <NUMBER> hand extracellular matrix binding proteins fibronectin binding protein streptococcus pyogenes also exhibit adjuvant activity <NUMBER> offers possibility using dual antigenadjuvant moieties formulation recent reports also demonstrate vaccine formulations containing adamantylamide dipeptide nontoxic compound obtained linking lalaninedisoglutamine residue muramyl dipeptide antiviral drug amantadine confer protection non typeable h influenzae preclinical models <NUMBER> innate immune system plays critical early role host defence pathogenic microorganisms recognition pathogenassociated molecular patterns <NUMBER> achieved stimulation patternrecognition receptors prr sense broad range exogenous endogenous danger signals <NUMBER> <NUMBER> tolllike receptors tlr represent bestcharacterized family prr natural synthetic tlr agonists used immune modulators optimize responses vaccination since identification tlr<NUMBER> many mammalian tlr homologues identified ie <NUMBER> humans <NUMBER> mice <NUMBER> tlr member binds specifically different ligands tab <NUMBER> alone combinations eg heterodimers formed tlr<NUMBER> either tlr<NUMBER> tlr<NUMBER> example tlr agonist bacterial dna vertebrate dna synthetic oligodeoxynucleotides containing unmethylated cpg motifs act tlr<NUMBER> thereby inducing strong th<NUMBER> responses activation dendritic cells <NUMBER> <NUMBER> cpg motifs successfully used adjuvants preclinical studies different candidate vaccines agents causing communityacquired pneumonia <NUMBER> <NUMBER> <NUMBER> another important adjuvant tlrbinding capacities mycoplasmaderived macrophageactivating lipopeptide malp<NUMBER> act level tlr heterodimer <NUMBER> <NUMBER> <NUMBER> malp<NUMBER> promotes global activation cells innate adaptive immune system <NUMBER> <NUMBER> macrophages dc tand blymphocytes <NUMBER> <NUMBER> coadministered antigen either parenteral mucosal route malp<NUMBER> promotes elicitation humoral cellular responses systemic mucosal level <NUMBER> preclinical studies suggested malp<NUMBER> could exploited vaccine formulations sarsassociated coronavirus catarrhalis influenza virus among others unpublished data dna vaccination offers advantage normal antigen vaccination fact necessary express antigen contrast biosynthetic machinery present cells vaccinees takes care work furthermore since eukaryotic cells charge protein synthesis glycosylation folding optimal however largescale purification dna might associated high costs solved use attenuated inactivated bacteria viruses delivery systems <NUMBER> approach also lead enhanced induction antibodies otherwise poor using conventional naked dna vaccines recently demonstrated bacterial ghosts also exploited delivery system dna vaccines vivo ex vivo applications <NUMBER> potential approach demonstrated fact possible optimize performance broad range manipulations choice optimal promoters ii use codon optimized genes expression mammalian cells iii addition nuclear localization signals ubiquitination signals improve expression processing iv codelivery dna constructs coding immune modulatory molecules <NUMBER> addition presence immune stimulatory cpg motifs dna vaccine constructs builtin adjuvant properties vaccination approach particularly suited stimulation cellular immune responses <NUMBER> interestingly several reports suggest dna vaccines may represent valid alternative prime neonatal immune system even presence passive transferred maternal antibodies <NUMBER> <NUMBER> fact promising results also obtained preclinical models communityacquired pneumonia influenza <NUMBER> pneumoniae <NUMBER> furthermore dna coding vaccine antigens appears induce excellent immunological memory reawakened later immunization exposure pathogen knowledge generated several basic disciplines immunology microbial pathogenesis allowed identification critical bottlenecks establishing successful vaccination strategy expected coming years develop customized approaches address order stimulate efficient protection infective agents specific clinical settings ie newborns aging individuals immunocompromised patients importance immunological memory b lymphocytes differentiated plasma cells producers antigenspecific igg antibodies bonemarrow bm plasma cells short life therefore bm reservoir needs replenished stimulation memory b cells <NUMBER> <NUMBER> maximal life span bm plasma cells still debated factors identified control differentiation antigenspecific b cells toward shortor longlife plasma cells memory b cells <NUMBER> beside requirement cd<NUMBER> cells nature antigen <NUMBER> dose also important higher antigen doses well rapid vaccination schedules closely spaced vaccine doses tend favour rapid induction shortterm effectors whereas lower doses antigens preferentially support induction immune memory <NUMBER> <NUMBER> <NUMBER> <NUMBER> demonstrated neonatal vaccination priming infant boosting might effective even pathogen exposure occurs early life children vaccineinduced hib antibody titres fallen undetectable levels memory readily demonstrated <NUMBER> however immune memory per se enough protect pathogens required high levels neutralizing antibodies delay memory bcell reactivation differentiation may limit ability interrupt pathogen invasion therefore important establish vaccination protocols population boosted different ages order maintain required levels antibodies particularly important diseases antibodies play central role microbial clearance toxin neutralization particular case communityacquired pneumonia consider aging individuals neglected many vaccination programs however strategies proposed elderly would different used small children since main factors affecting vaccine efficacy immune senescence immaturity respectively attempts give rational solution issue discussed next sections immune system children immune responses bacterial viral antigens usually increase age stepwise manner <NUMBER> prompt immunization birth required induce active immunity diseases may occur early life unfortunately strategy limited relative immaturity neonatal infant immune system factors implicated poor response limited switch igm igg<NUMBER> antibodies impaired complementmediated reactions deficient organization splenic marginal zone vaccination studies performed newborn mice suggested limited germinal centre reactions may results delayed development follicular dc limit plasma cell differentiation <NUMBER> also showed neonatal bm limited capacity support establishment longlife antibodysecreting plasma cells <NUMBER> thus responses glycoconjugates tcelldependent antigens usually affected <NUMBER> therefore highly immunogenic vaccines show significant protective efficacy single dose infants limited igg responses extended first year life addition immune responses particularly antibodies elicited first year life vaccination rapidly decline <NUMBER> however problem observed infants terms magnitude duration immune response seem affect efficient priming fact immune memory generated neonates may recalled later life <NUMBER> nevertheless strategies generate strong longlasting protective responses infants still needed part due presence maternal antibodies inactivate clear vaccine antigens thereby rendering difficult stimulation immature immune system <NUMBER> addition effects adjuvants reported adults cannot extrapolated neonates <NUMBER> potential strategy overcome problems would implement vaccination pregnancy provide required antibodies placenta later maternal feeding <NUMBER> <NUMBER> <NUMBER> <NUMBER> could complemented early priming immature immune system newborn dna vaccination followed boost second half first year later life <NUMBER> polypathology multiple organ failure rule rather exception aging individuals thus many systems affected eg endocrine cardiovascular immune system exception mechanisms involved immune senescence process turn may lead poor response vaccination fully understood however clear responses certain vaccines affected immune senescence others eg psbased vaccines pneumoniae <NUMBER> contrast responses boost dose antitetanus vaccine hardly affected age <NUMBER> rapid decline antibody responses together relative restriction tcell repertoire characteristic immune senescence process restriction reduction pool naïve cells explain poor cd<NUMBER> cell responses antigens crossreacting proteins seen earlier life contrast tcells responses healthy elderly individuals new antigens often unaffected nevertheless overall response vaccination elderly less efficient young adults making vigorous approaches necessary fig <NUMBER> case influenza actual strategy annual revaccination however concerns regarding capacity increase antibodies proper specificity reassorted viruses aging adults repeatedly infected immunized exposure new crossreacting antigenic variant individuals may respond producing antibodies however antibodies could primarily directed influenza strains encountered earlier life figure <NUMBER> factors affecting responses young adults aging individuals vaccination process immune senescence impairs host response infection vaccination critical issue needs considered vaccine design require development special approaches example individuals previously exposed old h<NUMBER>n<NUMBER> influenza strain ie <NUMBER> years ago may respond differently naïve adults vaccinated new h<NUMBER>n<NUMBER> strain accumulated different mutations former might produce antibodies ha old h<NUMBER>n<NUMBER> strain rather crossreacting epitopes new strain <NUMBER> phenomenon socalled original antigenic sin <NUMBER> basis observations proposed variations vaccine efficacy might due differences antigenic distance vaccine strains epidemic strains responsible influenza outbreaks <NUMBER> however hypothesis confirmed epidemiologic studies <NUMBER> even individuals aged <NUMBER> years older annually vaccinated showed significantly reduced mortality risk therefore seems antigenic sin represent major practical obstacle influenza vaccination additional strategies may required despite broad availability vaccines agents causing communityacquired pneumonia still represent important cause death human suffering economic losses however dramatically expanded knowledge pathophysiology diseases caused respiratory pathogens virulence factors effector mechanisms responsible clearance becoming clearer microbial components attractive vaccine targets well type immune response needed confer protection disease thus possible address vaccine development using rational rather empiric approaches facilitated powerful bioinformatics tools accurate prediction epitopes proteasome trimming <NUMBER> <NUMBER> <NUMBER> well availability broad palette immune modulators delivery systems therefore predict new improved vaccines etiologic agents communityacquired pneumonia considerably reduce global impact disease coming years new disease called severe acute respiratory syndrome sars originated china late <NUMBER> spread rapidly many countries upon outbreak global collaboration network coordinated result unprecedented international effort novel type coronavirus sarscov identified etiologic agent sars <NUMBER> <NUMBER> march <NUMBER> genomic sequence sarscov completed know sarscov features characteristics coronaviruses quite different previously known coronaviruses groups iiii representing new group group iv <NUMBER> <NUMBER> assumed sarscov mutant coronavirus transmitted wild animal developed ability productively infect humans <NUMBER> <NUMBER> genome sarscov singlestranded plussense rna<NUMBER> kb length containing five major open reading frames encode nonstructural replicase polyproteins structural proteins spike envelope e membrane nucleocapsid protein n order approximately sizes coronaviruses <NUMBER> reason sarscov induces severe respiratory distress infected individuals still unclear patients sars probable sars cases virus detected sputum stool plasma rtpcr <NUMBER> <NUMBER> patients developed serum antibodies sarscov high antibody titers n protein maintained <NUMBER> months infection <NUMBER> generally poor pathogenicity difficulty propagation vitro studies regarding immunity human coronaviruses oc<NUMBER> <NUMBER>e veterinary field however coronaviruses known many years cause variety lung liver gut diseases animals learned animal models humoral cellular immune responses may contribute protection coronavirus diseases including sars review see <NUMBER> clinical manifestation sars hardly distinct common respiratory viral infections including influenza influenza epidemic may occur simultaneously reemergence sars urgently required develop effective sars vaccines well sensitive diagnostic tests specific sars recently angiotensinconverting enzyme <NUMBER> ace<NUMBER> identified cellular receptor sarscov <NUMBER> first step viral infection presumably binding protein receptor ace<NUMBER> murine mhv model proteins known contain important virusneutralizing epitopes elicit neutralizing antibodies mice <NUMBER> <NUMBER> therefore protein would first candidate coronavirus protein induction immunity however n proteins also known contribute generating host immune response <NUMBER> <NUMBER> following established vaccine protocol one best ways shorten time cost new vaccine development currently available vaccines humans inactivated applied cutaneously except oral polio vaccine adjuvant usage mostly limited aluminum hydroxide gel alum order know immunogenicity inactivated sarscov vaccine candidate immunized mice uvinactivated sarscov either without alum report evaluation humoral cellular immunity elicited uvinactivated sarscov administered subcutaneously sarscov hku<NUMBER> kindly supplied dr jsm peiris department microbiology university hong kong virus amplified vero e<NUMBER> cells purified sucrose density gradient centrifugation concentrated virus exposed uv light <NUMBER> jcm <NUMBER> order inactivate virus confirmed virus completely lost infectivity method female balbc mice purchased nippon slc inc shizuoka japan housed specific pathogenfree conditions experimental procedures carried niidrecommended guidelines mice subcutaneously injected via back right left hind leg footpads <NUMBER> lg uvinactivated purified sarscov without <NUMBER> mg alum boosted procedure <NUMBER> weeks priming blood obtained tail vein allowed clot overnight <NUMBER>°c sera collected centrifugation elisa microtiter plates dynatech chantily va coated overnight <NUMBER>°c sarscovinfected mockinfected vero e<NUMBER> cell lysates treated <NUMBER> np<NUMBER> followed uvinactivation detect n protein plates coated <NUMBER> np<NUMBER> lysates chick embryo fibroblasts infected n proteinexpressing dis attenuated vaccinia virus <NUMBER> plates blocked <NUMBER> ova pbstween <NUMBER> incubated sera serially diluted <NUMBER> <NUMBER> <NUMBER> h room temperature plates incubated either peroxidaseconjugated antimouse igg <NUMBER> zymed san francisco ca igm iga <NUMBER> southern biotechnology birmingham al antibody detection igg subclasses either peroxidaseconjugated antimouse igg <NUMBER> igg <NUMBER>a igg <NUMBER>b <NUMBER> zymed igg <NUMBER> <NUMBER> southern biotechnology used plates washed three times pbstween step antibodies detected ophenylenediamine zymed absorbance well read <NUMBER> nm using model <NUMBER> microplate reader biorad hercules ca standard igg detection serum obtained hyperimmunized mouse od<NUMBER>nm value <NUMBER> uml standard was<NUMBER> assays sarscovspecific igg titer calculated follows sarsspecific igg titer uml unit value obtained wells coated virusinfected cell lysates unit value obtained wells coated noninfected cell lysates recombinant n protein amino acids <NUMBER> <NUMBER> sarscov biodesign saco diluted <NUMBER> lgml pbs added <NUMBER> per well plates supported nitrocellulose filter millipore bedford overnight incubation <NUMBER>°c plates washed pbs three times blocked <NUMBER>°c overnight <NUMBER> ova pbstween <NUMBER> erythrocyte lysis single cell suspensions bms suspended rpmi supplemented <NUMBER> fcs <NUMBER> <NUMBER> <NUMBER> ÿ<NUMBER> <NUMBER>me <NUMBER> mm lglutamine <NUMBER> uml penicillin <NUMBER> lgml streptomycin applied plates concentration <NUMBER> <NUMBER> <NUMBER> <NUMBER> cells per well <NUMBER> h cultivation plates recovered stained alkaline phosphataseconjugated antimouse igg <NUMBER> antibody southern biotechnologies alkaline phosphatase activity visualized using <NUMBER>aminoethyl carbozole napthol asmx phosphatefast blue bb sigma frequency plasma cells specific n protein determined n proteincoated plates background uncoated plates subtracted serum inactivated incubation <NUMBER>°c <NUMBER> min known tissue culture infectious dose tcid sarscov incubated <NUMBER> h presence absence serum antibodies serially diluted <NUMBER>fold added vero e<NUMBER> cell culture grown confluently <NUMBER>well microtiter plate <NUMBER> h cells fixed <NUMBER> formaldehyde stained crystal violet visualize cytopathic effect induced virus <NUMBER> neutralization antibody titers expressed minimum dilution number serum inhibited cytopathic effect purified sarscov virion <NUMBER> lg fractionated sdspage reduced conditions proteins transferred pvdf membrane genetics tokyo japan reacted diluted sera <NUMBER> obtained mice inoculated uvirradiated sarscov washing membrane reacted hrpconjugated fab<NUMBER> <NUMBER> fragment antimouse igg hl <NUMBER> <NUMBER> jackson immuno research west grove pa followed visualization bands xray film kodak rochester ny using chemiluminescent regents amasham biosciences piscataway nj popliteal inguinal lymph nodes spleens harvested mice <NUMBER> week boost vaccination preparation single cell suspension cells purified depletion b<NUMBER> gr<NUMBER> cd<NUMBER>b igd igm cells using magnetic cell sort system macs miltenyi biotec bergisch gladbach germany prepare antigenpresenting cells apc normal balbc mouse splenocytes depleted cd<NUMBER> cells macs irradiated <NUMBER> cgy purified cells taken lymph nodes <NUMBER> <NUMBER> <NUMBER> <NUMBER> cellswell cultured irradiated apc <NUMBER> <NUMBER> <NUMBER> <NUMBER> cellswell presence absence uvirradiated purified sarscov virion <NUMBER> <NUMBER> lgml four days cultivation level cytokine concentration culture supernatant measured flow cytometry using mouse th<NUMBER>th<NUMBER> cytokine cytometric bead array kit becton dickinson san jose ca tcell proliferation monitored incorporation <NUMBER> hthymidine <NUMBER> kbqwell icn biomedicals costa mesa ca added <NUMBER> h prior cell harvest cells harvested <NUMBER>well microplate bonded gfb filter packard instruments meriden ct incorporated radioactivity counted microplate scintillation counter packard instruments inoculation uvinactivated sarscov results antigenspecific igg <NUMBER> response probably generating longterm ascs well memory cells examine level antisarscov response mice inoculation vaccine candidates three mice group subcutaneously inoculated <NUMBER> lg uvinactivated purified sarscov virionalum without alum virion inoculated alum alone alum left untreated none control fig <NUMBER> one month inoculation vaccinated mice elicited antisars cov igg antibody sera high levels expected alum adjuvant enhanced level igg antibody response <NUMBER>fold higher level without adjuvant fig <NUMBER>c compared b mice boosted <NUMBER> weeks level igg antibody groups mice increased<NUMBER>fold primary response fig <NUMBER>b c notably level serum antibodies induced single injection virion even absence alum adjuvant maintained least <NUMBER> months fig <NUMBER>d results suggest longterm ascs established single shot uvinactivated virion administration upon restimulation antigen memory b cells rapidly differentiate ascs migrate bone marrow establish longterm asc pool <NUMBER> <NUMBER> enumerate number plasma cells specific sarscov performed elispot assay using recombinant n proteins amino acid numbers <NUMBER> n<NUMBER> <NUMBER> n<NUMBER> coating antigens consistent serum antisars cov igg level sarsspecific igg <NUMBER> plasma cells maintained bone marrow day <NUMBER> boost immunization virionalum fig <NUMBER> contrast number spots control mice detection limit ie <NUMBER> asc<NUMBER> <NUMBER> <NUMBER> <NUMBER> cells determined subclass serum antisarscov igg antibodies boosted mice using antimouse igg <NUMBER> igg <NUMBER>a igg <NUMBER>b igg <NUMBER> second antibody elisa fig <NUMBER> interestingly level antisarscov igg <NUMBER>a mice immunized virionalum comparable mice immunized virion alone whereas level antisarscov igg <NUMBER> higher mice virionalum mice virion alone contrast levels igg <NUMBER>b igg <NUMBER> antibodies fairly low groups therefore results indicated vaccination combination inactivated virion alum induced predominantly th<NUMBER>type immune response also measured serum immunoglobulins igg early late phases immunization avoid high igg concentrations interfering detection igm iga antibodies serum igg absorbed protein gconjugated beads <NUMBER> levels antisarscov igm antibodies iggdepleted sera obtained <NUMBER> weeks priming detection limit likewise antisarscov iga antibody iggdepleted sera obtained <NUMBER> week booster detectable data shown whether immune sera possess neutralizing activity sarscov crucial aspect vaccination estimated neutralizing activity sera obtained <NUMBER> week boost inoculation table <NUMBER> observed neutralizing activity sarscov detected high level sera mice inoculated virionalum virion alone taken together results indicate subcutaneous vaccination uvinactivated sarscov virion able elicit sufficient amount igg antibodies neutralizing activity using immune sera mice boosted virionalum <NUMBER> week analyzed specificity serum igg western blot analysis see methods shown fig <NUMBER>a robust signal detected <NUMBER> kda corresponds n protein sarscov predicted genome size <NUMBER> <NUMBER> band near <NUMBER> kda appears correspond protein analogous protein human coronaviruses hcv<NUMBER>e hcvoc<NUMBER> known heavily glycosylated detected <NUMBER> kda <NUMBER> kda respectively <NUMBER> result consistent data reported recently xiao et al expressed fulllength glycoprotein sarscov tor<NUMBER> strain <NUMBER> cells showed protein rañ <NUMBER> kda sds gels <NUMBER> origins <NUMBER> kda faint <NUMBER> kda bands unknown however similar bands also detected fluorogram using antin mabs ohnishi k sakaguchi takasuka n et al unpublished data suggesting related n protein specificity igg immune sera also determined elisa plates coated lysates cells infected either sor nexpressing recombinant vaccinia viruses fig <NUMBER>b results indicated antis well antin protein igg antibodies elicited virionalum vaccination examine whether subcutaneously vaccinated mice gained induced tcell response sarscov mice immunized either virionalum virion alum via footpad cells mice enriched spleen regional lymph nodes <NUMBER> week booster immunization cultured irradiated apcs presence absence uvinactivated sarscov virion <NUMBER> <NUMBER> lgml shown fig <NUMBER> regional lymph node cells proliferated vitro response uvinactivated virion virionalumimmunized mice lesser extent virionimmunized mice mice inoculated virionalum showed high basal level proliferation lymph node cells absence antigen much difference net proliferative response cells virion alum group virion group hand splenic cells low level proliferation observed virionalum group mice level proliferation cells however viriondose independent therefore results suggest subcutaneous injection inactivated virion even without alum induce cell activation extent draining lymph node result hardly occurs systemically also measured level cytokine production supernatant lymph node cells stimulated inactivated virion vitro <NUMBER> days found inactivated virion induced production cytokines il<NUMBER> il<NUMBER> il<NUMBER> ifnc tnfa cells virionalumimmunized mice dosedependent manner fig <NUMBER>b likewise cells virionimmunized mice produced low yet significant levels cytokines dosedependent manner except il<NUMBER> contrast lymph node cells normal mice produce cytokines response virion suggesting virion possess innate stimulating activity bacterial products lipopolysaccharide lps purified protein derivative mycobacterium tuberculosis ppd taken together results suggest subcutaneous vaccination uvinactivated sarscov able activate cd<NUMBER> cells regional lymph nodes cells produce several immunoregulatory cytokines including ifnc present results demonstrated even single subcutaneous administration uvirradiated virion without alum adjuvant induced high level systemic antisarscov antibody response mice probably followed generation longterm antibodysecreting cells memory cells bone marrow considering polyvalent particulate six mice examined detectable neutralizing activity sera obtained mice <NUMBER> week boost vaccination subjected sarscov neutralizing activity assay described methods titer reciprocal number minimum serum dilution inhibits cytopathic effect structures hepatitis b virus surface antigenbased hiv<NUMBER> gagbased ty viruslike particles shown elicit humoral well cellular immune responses <NUMBER> particulates probably comparable dimensions structures pathogens targeted uptake apcs facilitate induction potent immune responses antibodies elicited mice vaccinated current protocol without adjuvant recognized n proteins sarscov able neutralize infection virus vero e<NUMBER> cells however serum antisarscov iga antibody detectable probably owing route vaccination addition present vaccination protocol caused cell response regional lymph nodes although allow induction sufficient cellular immune response systemically show potentiality subcutaneous injection inactivated virion alum utilized current human vaccinations alum used adjuvant vaccines diphtheria pertussis tetanus vaccines long safety record human use <NUMBER> observed addition alum vaccine formula resulted large augmentation serum igg <NUMBER> production igg <NUMBER>a production level igg <NUMBER> alumvaccinated mice reached level similar found hyperimmunized mice subcutaneously injected <NUMBER> lg inactivated virion emulsified complete freund adjuvant followed consecutive threetimes intravenous boosters <NUMBER> lg virion alum known selectively stimulate igg <NUMBER> dominant type <NUMBER> immune response reviewed <NUMBER> activation complement alum could contribute type <NUMBER>biased immune response partly via inhibition il<NUMBER> production interestingly quite recent report demonstrated aluminduced gr<NUMBER> myeloid cell population produced il<NUMBER> activated bcells <NUMBER> various diseases associated animal coronavirus infection clinical manifestations disease correlates protection immunity studied extensively animal coronavirus infections reviewed <NUMBER> although antibodies cells may play role exacerbating pathology animal coronavirus infections <NUMBER> <NUMBER> humoral cellular immune responses known contribute protection coronavirus infection murine hepatitis virus group <NUMBER> coronavirus mortality susceptible mice partially prevented transfer immune serum containing neutralizing antibody prior challenge <NUMBER> recently zhiyong et al reported murine acute infection model neutralizing antibody elicited vaccination dna encoding protective cellular components vaccinated mice required inhibition viral replication <NUMBER> twice parenteral administration inactivated virion alum induced high level antibodies able neutralize sarscov vaccination protocol may certain effect protection humans sarscov infection observed two successive inoculations inactivated virus <NUMBER> week intervals generated sarscovspecific cells cells restimulated irradiated virus vitro response low terms level proliferation production infc il<NUMBER> however irrespective vaccination protocols without alum adjuvant virusprimed cells vaccinated animals capable producing il<NUMBER> high levels upon vitro stimulation comparable reports variety vaccination studies <NUMBER> <NUMBER> outlook seems compatible idea present vaccine protocol may tend select tcell subsets th<NUMBER> phenotype however remains elucidated whether cells may exhibit serological memory phenotype persist immune system vaccination long memory b cells may persist <NUMBER> days post vaccination addition analysis needed clarify whether tcell response crucial factor longterm protection sarscov infections efforts develop sarscov vaccine carried many profitable nonprofitable organizations various ways example recently reported combination adenovirus vector expressing sarss n protein elicited neutralizing capacity serum nspecific tcell response rhesus macaques <NUMBER> however still uncertain whether immunity components sarscov sufficient virus protection sarscov tends cause replication errors may allow virus escape hostimmune response result seasonal outbreak point view resembles influenza virus influenza virus inactivated ha vaccine showed incomplete protection certain efficacy safety record long period time indeed approach used veterinary field bovine coronavirus <NUMBER> canine coronavirus <NUMBER> advantages make whole killed virion prime candidate sars vaccine even may best protective ability unfortunately information available far immune correlates protection human coronaviruses including sarscov consideration sarscov transmission occurs direct contact droplets fecal oral route mucosal secretary iga lower respiratory tract digestive tract seem crucially important failure induce igatype antibodies current systemic vaccination method improved notably iga antibodies detectable sera bronchoalveolar lavage fluid obtained mice hyperimmunized uvirradiated virus data shown therefore nontoxic potent adjuvant becomes available human use subcutaneous injection inactivated virion would become effective vaccination method reduce number susceptible people future necessary determine whether inactivated whole virion vaccine possesses protective ability sarscov infection use adequate animal models furthermore whether alum addition augmented protection effective period sarscov virion vaccination addressed currently used inactivated influenza virus whole virion vaccine significantly effective without adjuvant meanwhile also need develop potent adjuvant induction much stronger mucosal immunity addition evaluating available methods virion inactivation vaccines remain one greatest accomplishments human ingenuity scientific endeavor combined global efforts public health community rates incidence mortality associated infection rna viruses polio measles mumps rubella declined greater <NUMBER> compared prevaccination rates <NUMBER> though highly successful past conventional approaches rna virus vaccine development liveattenuation passaging forward genetics inactivation may less efficient generating good candidates rational targeted mutagenesis reverse genetics advancements recombinant dna technology virus reverse genetics provided key critical insights replication pathogenesis rna viruses facilitate vaccine development targeted modifications directed attenuation advent reverse genetics molecular engineering viruses transformed field open access virology permitting study targeted genetic changes virus genomes <NUMBER> first infectious rna virus clone isolated cdna generate poliovirus <NUMBER> since reverse genetics technology recombinant virus design employed generate reverse genetic clones representing major virus families addition techniques approaches become focus new efforts design vaccines incorporate specific changes either componentbased virusbased systems induce lasting immunity host without health risks deleterious effects since development effective liveattenuated vaccines new vaccine preparations utilizing wellestablished vectors expression specific viral proteins components subunit vaccines development viruslike particles vlps continued shape domain vaccine discovery development challenge establishing safe immunogenic platform induces lasting immunity context wide variety viral systems resulted remarkable creativity variability approaches employed use replicating viruses vaccines liveattenuated chimeric vectorbased platforms benefits high immunogenicity lower costs ease transport administer yet viruses potential revert pathogenic phenotypes may underattenuated immunocompromised hosts conversely component subunit killed pathogen vaccines benefits generally safer used display immunogenic antigens however costs time development weaker induced immune responses present challenges design implementation review describe rna virus reverse genetics systems provide overview current efforts use reverse genetics technology development safe effective vaccines current rna virus reverse genetics systems make use multiple common features rna virus biology first rna viruses generate genomic copies activity viral rnadependent rna polymerase rdrp addition nearly rna virus replication strategies independent host cell nucleus instead reside cytoplasm positivestrand rna viruses poliovirus immediately entry uncoating genomic rna directly translated host ribosomes generate viral protein products since virus rarely needs package additional nonstructural proteins virion positivesense rna virus reverse genetics systems largely focus delivery either transcribed genomic rna cell cytoplasm delivery cdna control viral transcription promoter t<NUMBER> cmv figure <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however negativestrand doublestrand rna virus reverse genetic systems often require use additional helper constructs introduce rdrp essential proteins initiate genomic replication recent alternative approach employed field influenza research synthesize viral rna drive mrna production activity host polymerases pol pol ii <NUMBER> <NUMBER> approach simplified logistics plasmid transfection increased efficacy recombinant virus recovery similar approach successfully employed recovery arenavirus lymphocytic choriomenigitis virus lcmv <NUMBER> one additional platform employed rna virus infectious clone generation bacterial artificial chromosome bac bac constructs singlecopy dna plasmids based fplasmid bacteria genetically stable e coli permit insertion large dna fragments transcribed control transcriptional promoter t<NUMBER> bac constructs employed many years recovery large dna viruses however genetic stability constructs led use recombinant rna virus platforms several positivestrand rna viruses one negativestrand rna virus used bacs platform reverse genetic design table <NUMBER> since rna virus replication strategies segregated host genome replication machinery rna viruses modify host gene expression cause oncogenesis result rna reverse genetic systems typically account potential transformation host cells lastly rna viruses limited small genome sizes majority smaller <NUMBER> kb due reduced genomic stability lowered fidelity viral rdrp subsequently reverse genetic approaches often employ use cdna genetic clones greater versatility manipulation modification virus genome rdrp t<NUMBER> polymerase negativestrand rna virus reverse genetic platforms often involve transfection electroporation genomic commonly subgenomic cdna permissive cells combination either helper virus helper plasmids driven rdrp negativestrand rna systems employ host polymerase pol ii pol ii promoters drive viral rna synthesis mrna production positiveand negativestrand reverse genetics systems rdrp typically constitutively transiently expressed permissive cell type positivestrand rna viruses genomes infectious upon entry host cells upon entry host ribosomes translate viral rna one polyproteins require either host viral proteases processing although many different reverse genetics platforms used generate positivestrand rna virus clones nearly share common goal introduce either sense genomic rna transcripts directly cdna transcribed included rdrp figure <NUMBER> describe approaches employed generate infectious clones picornaviruses coronaviruses flaviviruses strategies currently applied develop vaccines picornaviruses family nonenveloped positivestrand rna viruses collectively infect wide range human animal hosts human picornaviral pathogens cause illnesses vary common cold poliomyelitis picornavirus virion consists icosahedral capsid structure surrounding rna genome ranging approximately <NUMBER> <NUMBER> kb size poliovirus rhinovirus remain two extensively studied picornaviruses date become model systems study rna virus biology pathogenesis epidemiology <NUMBER>s extensive efforts began develop implement polio vaccine hopes eradicate virus since nonhuman primate reservoirs known exist nature effectiveness inactivated salk vaccine liveattenuated sabin vaccines led increased efforts develop design vaccines many human pathogens international vaccination efforts aimed eradicating disease success employed strategies implementation vaccines poliovirus opened door evaluating new approaches efforts study understand rna virus biology major step occurred <NUMBER> racaniello baltimore introduced fulllength cdna clone poliovirus cell recovered infectious virus <NUMBER> although initially mechanism cdna clone plasmid could give rise productive rna virus infection unknown cdna platform approach used racaniello <NUMBER> <NUMBER> advances understanding engineering plasmids gene delivery led efficient cdnabased systems represent primary reverse genetics approaches used recovery picornaviruses today commercially available rhinovirus vaccines exist today despite effective reverse genetics platforms several serotypes rhinoviruses remain primary cause common cold worldwide extensively studied <NUMBER> years yet great puzzle developing broadly protective rhinovirus vaccine involves solving overwhelming task developing immunogenic platform provide protective immunity greater <NUMBER> serotypes rhinovirus currently circulate nature <NUMBER> <NUMBER> capsid rhinovirus comprised four distinct serotypespecific proteins vp<NUMBER> vp<NUMBER> vp<NUMBER> vp<NUMBER> known immunogenic potentially elicit crossreactive antibodies <NUMBER> <NUMBER> <NUMBER> <NUMBER> yet development broadlyneutralizing rhinovirus protection likely require formulation polyvalent vaccine includes incorporation several serotype variants immunogenic capsid proteins <NUMBER> efforts designing polyvalent rhinovirus vaccine formulations yet provide broad immunogenic memory necessary effective however regions vp<NUMBER> precursor vp<NUMBER> vp<NUMBER> shown conserved across b group rhinoviruses combination h <NUMBER> promoting adjuvant induced crossserotype immune response mice <NUMBER> discovery conserved epitopes recent development chimeric new reverse genetics platforms including mouse model infection may provide novel avenue efficient display epitopes breadth rhinovirus diversity <NUMBER> <NUMBER> <NUMBER> coronaviruses enveloped positivestrand rna viruses encode largest known rna virus genomes varying size <NUMBER> <NUMBER> kb <NUMBER> coronavirus infections humans associated upper lower respiratory illness ranging severity common cold severe acute respiratory syndrome sars last <NUMBER> years four new human coronaviruses identified including sars coronavirus recent middle east respiratory syndrome mers coronavirus <NUMBER> despite high clinical economic burden potential emerging infectious disease commercially available vaccines currently exist currently two common platforms used generating fulllength infectious coronavirus clones first platform involves vitro transcription capping fulllength cdna clone coronavirus genome followed introduction competent cells either transfection electroporation coronavirus genome approximately <NUMBER> kb size often maintained fragments lowcopy plasmids virus assembly fragments restriction digested ligated together prior transcription approach successfully used recover clones many coronaviruses including transmissible gastroenteritis virus tgev <NUMBER> murine hepatitis virus mhv <NUMBER> nl<NUMBER> <NUMBER> sars coronavirus <NUMBER> sarslike bat coronaviruses <NUMBER> mers coronavirus <NUMBER> another common platform utilizes existing bac technology coronavirus genome introduced bac construct control cmv promoter approach successfully used recover clones human viruses oc<NUMBER> mers coronavirus <NUMBER> <NUMBER> approaches yield productive infections high titers progeny virus third approach involving vaccinia vector platform also used successfully production human <NUMBER>e infectious clones <NUMBER> efforts design coronavirus vaccine focused variety approaches including development inactivated virus liveattenuated virus variety subunit vaccines one major focus current coronavirus vaccine efforts focusing ways create liveattenuated vaccine strain combines existing treatments less virulent stable virus platform sars epidemic patients showed little improvement treated ribavirin recent studies shown coronaviruses resistant ribavirin treatment due presence viral exonuclease nsp<NUMBER> proofreading activity <NUMBER> <NUMBER> additionally deletion exonuclease proofreading activity results hypermutation phenotype appears genetically stable induces protection murine models <NUMBER> <NUMBER> <NUMBER> recent outbreak merscov triggered demand development mers vaccine <NUMBER> several approaches explored including identifying effective neutralizing antibodies use receptorbinding domain spike glycoprotein component induce immunity direct changes recombinant merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> availability effective reverse genetics platforms coronaviruses associated high mortality viruses sars mers coronaviruses potential low cost development implementation provide promise creating effective vaccine platform flaviviruses small enveloped positivestrand rna viruses infect wide range hosts flavivirus genomes markedly smaller coronaviruses approximately <NUMBER> kb size transmission flaviviruses dependent upon arthropod vector hence common name arboviruses flavivirus diseases range asymptomatic severe neurological disease encephalitis meningitis myelitis <NUMBER> yellow fever virus yfv deadly flavivirus associated <NUMBER> deaths annually identified <NUMBER> walter reed first human viral pathogen ever discovered <NUMBER> <NUMBER> <NUMBER> outbreaks disease connected flaviviruses stressed importance developing reverse genetic platforms efficacious vaccines similar picornaviruses nearly flavivirus reverse genetics platforms involve either vitro transcription fulllength ligated cdna fragments genome use bacterial artificial chromosome bac platform table <NUMBER> subsequently transfected electroporated competent cells reverse genetics platforms developed wide range flaviviruses including yfv <NUMBER> <NUMBER> dengue types <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> jev <NUMBER> kunjin virus <NUMBER> tickborne encephalitis virus tbev <NUMBER> <NUMBER> <NUMBER> murray valley encephalitis virus <NUMBER> langat virus <NUMBER> west nile virus wnv <NUMBER> <NUMBER> omsk hemorrhagic fever virus <NUMBER> advances recombinant flavivirus approaches instrumental new vaccine design efforts first vaccine efforts directed generating inactivated liveattenuated strains vaccinations flaviviruses <NUMBER> max theiler developed safe yfv liveattenuated vaccine called <NUMBER>d use serial passaged virus originally isolated african patient <NUMBER> vaccine composition used today remains largely first developed <NUMBER> years ago provides protective immunity <NUMBER> years <NUMBER> <NUMBER> <NUMBER> jev first isolated studied <NUMBER>s inactivated vaccine derived mouse brain first developed japan <NUMBER> <NUMBER> <NUMBER> current formulations jev vaccines include inactivated beijing<NUMBER> strain liveattenuated strains elicit greater immunogenicity broader protection original nakayama strain <NUMBER> despite success vaccine development yfv jev unique challenges presented developing vaccines wellknown flaviviruses dengue virus new emerging flaviviruses wnv dengue virus endemic tropical subtropical locations worldwide date five distinct serotypes dengue virus known including new serotype identified <NUMBER> <NUMBER> <NUMBER> infection one serotype increases severity disease upon secondary infection different serotype <NUMBER> consequently dengue virus vaccine must either provide protection extent serotypes prevent priming increased disease heterotypic infection remove immunogenic components virus cause increased disease severity upon heterotypic infections efforts develop stable chimeric platforms development dengue virus vaccines recently focused expressing dengue virus surface proteins chimeric viruses stable flaviviruses yfv <NUMBER> <NUMBER> <NUMBER> one vaccine candidate tetravalent vaccine sanofi pasteur involves formation chimeric yfv strain <NUMBER>d virus containing prme genes dengue serotype <NUMBER> approach also recently adapted develop similar vaccine candidates recently identified wnv <NUMBER> <NUMBER> despite several commercially available wnv vaccines veterinary purposes remains approved wnv vaccine humans future licensure dengue wnv vaccines likely continue focus development liveattenuated inactivated virus models vaccination due high immunogenicity flavivirus infections negativestrand rna virus genomes antigenomes cannot act mrna substrate rdrp must encapsidated nucleocapsid form ribonucleoprotein complexes rnps antigenomes negativestrand rna viruses introduced either linearized cdna plasmid t<NUMBER> promoter normally cotransfected one plasmids encoding nucleocapsid replicase machinery due biological requirements initiate infection development negativestrand rna virus reverse genetics systems slower positivestrand virus systems initial recovery efforts generate infectious clones involved recovery viruses using helper viruses could supply viral genes proteins necessary replication however approaches made difficult isolate mutants interest first recovery negativestrand rna virus completely cdna achieved <NUMBER> rabies virus <NUMBER> <NUMBER> despite biological limitations challenges working negativestrand rna viruses several effective negativestrand rna virus vaccines successfully introduced many currently varying phases clinical trials describe approaches employed generate infectious clones vaccines paramyxoviruses orthomyxoviruses paramyxoviruses enveloped negativesense singlestrand rna viruses responsible variety human animal diseases human paramyxoviruses identified responsible diseases including measles mumps pneumonia common cold paramyxoviruses carry single copy genome typically <NUMBER> <NUMBER> kb length like negativestrand rna viruses paramyxoviruses must incorporate replication machinery including rdrp virion assembly paramyxovirus reverse genetic systems employ similar mechanisms first fulllength genome antigenome helper plasmids expressing nucleocapsid polymerase proteins cloned cdna transcriptional control promoter t<NUMBER> rna polymerase plasmids cotransfected permissive cell lines earlier reverse genetics systems utilized coinfection approach vaccinia virus expressing t<NUMBER> however modern reverse genetics systems use t<NUMBER> cell line transfect t<NUMBER> plasmid recently first bacbased reverse genetics system negativestrand rna virus developed respiratory syncytial virus rsv <NUMBER> reverse genetics systems many paramyxoviruses generated including measles virus <NUMBER> mumps virus <NUMBER> hendra virus <NUMBER> nipah virus <NUMBER> rsv <NUMBER> <NUMBER> despite availability reverse genetics systems development paramyxovirus vaccines met variable success first paramyxovirus vaccine developed <NUMBER>s john enders able develop cultivation system measles virus cultured attenuated measles virus called edmonston strain named child isolated edmonston strain though initially underattenuated later adapted led successfully license measles vaccine <NUMBER> <NUMBER> maurice hilleman able build success liveattenuated measles vaccine cultured adapted passage fertilized hens eggs strain mumps called jeryl lynn named daughter isolated <NUMBER> hilleman later instrumental development mmr vaccine combining liveattenuated strains measles mumps rubella wistar ra <NUMBER> strain first licensed use <NUMBER> <NUMBER> early success measles mumps vaccines prompted renewed efforts develop vaccines pathogenic rna viruses one greatest challenges viral vaccine design remains development vaccine respiratory syncytial virus rsv respiratory syncytial virus rsv first isolated <NUMBER> chimpanzee displaying upper respiratory illness <NUMBER> since identification rsv become recognized leading cause infant mortality virus worldwide <NUMBER> <NUMBER> united states alone rsv upper lower respiratory infections led <NUMBER> hospitalizations annually <NUMBER> <NUMBER> <NUMBER> despite high clinical burden licensed rsv vaccines available current treatments cost prohibitive providing passive immunity administration prophylactic antibodies <NUMBER> <NUMBER> <NUMBER> susceptible population rsv infection young infants <NUMBER> <NUMBER> <NUMBER> consequently ideal rsv vaccine must immunogenic genetically stable safe vaccination infants however early tragic failure <NUMBER>s formalininactivated rsv vaccine dampened efforts develop implement new vaccines <NUMBER> <NUMBER> date clinically advanced rsv vaccine candidates liveattenuated viruses developed virus passage reconstitution reverse genetics <NUMBER> <NUMBER> <NUMBER> one promising candidates date medi<NUMBER> includes many introduced mutations render virus temperaturesensitive provides level protection <NUMBER> <NUMBER> however candidates able achieve level protection genetic stability necessary implementation <NUMBER> ongoing studies continue evaluate new targets attenuation however successful development rsv vaccine require finding proper balance attenuation immunogenicity orthomyxoviruses enveloped negativesense rna viruses whose genomes consist multiple linear segments approximately <NUMBER> <NUMBER> kb size similar paramyxoviruses many orthomyxoviruses cause respiratory illnesses humans notable influenza flu key hallmark orthoymyxovirus evolution reassortment virus genomes coinfection cell order transcriptionally active influenza viruses require functionally active viral ribonucleoprotein complex rnp consists viral genomic rna nucleoprotein np viral rdrp comprised pb<NUMBER> pb<NUMBER> pa proteins <NUMBER> first reverse genetics approaches developed orthomyxoviruses generated influenza virus iav however systems utilized helper viruses selected recover recombinants <NUMBER> <NUMBER> first helper virusfree systems developed around turn millennium <NUMBER> <NUMBER> first systems required cotransfection four plasmids control pol ii promoter well eight plasmids expressing eight viral rna segments number plasmids cotransfected recovery varied greatly depending upon number viral genomic segments organization helper protein constructs ranging <NUMBER> expressed two helper proteins two plasmids using pol ii promoter ires many <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however recent advances reverse genetics platforms reduced number total plasmids needed <NUMBER> less using bidirectional expression system <NUMBER> <NUMBER> system human pol promoter coupled either murine poli terminator drives viral rna synthesis cmv pol ii promoter responsible viral mrna synthesis <NUMBER> improved production iav however generation recombinant virus vaccines limited select number mammalian cell lines african green monkey kidney epithelial cells vero madin darby canine kidney mdck cells <NUMBER> <NUMBER> however cell lines limited transfectability differences pol pol ii compatibility hindered efficacy uniand bidirectional approaches incorporation speciesspecific polymerase promoters provided improved efficacy recovery several cell lines <NUMBER> <NUMBER> recent advancement combination <NUMBER> pol driven iav genes single plasmid <NUMBER> pol ii drive genes additional plasmid approach improves probability single cell receiving necessary plasmids recovery <NUMBER> availability applicable reverse genetics systems studying identifying structure function influenza proteins revolutionized influenza vaccination strategies many years trivalent vaccine currently provided consisted three separated strains <NUMBER> strains <NUMBER> b strain selected based recommendations prior next flu season however vaccines made using either liveattenuated coldadaptation inactivated virus grown fertilized chicken eggs next generation vaccination strategies include tetravalent quadrivalent vaccines may grown animal cell cultures rather chicken eggs viruslike particles vlps cultures frugiperda insect sf<NUMBER> cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> fda approved seasonal influenza vaccine comprised purified ha proteins prepared using baculovirusexpression system <NUMBER> recombinant vaccines successfully used vaccinate individuals <NUMBER> <NUMBER> years age represents major step influenza vaccine design implementation system reduces production time compared conventional eggbased approach <NUMBER> major frontier synthetic biology development new vaccines therapeutics improvement implementation efficacy already market one major complication successful implementation vaccines currently limitations time vaccine design production influenza viruses require seasonal vaccinations determination proper formulations leaves little time development implementation new advances reverse genetics technology reducing potential time recovery production months weeks instance dormitzer et al developed improved platform approach demonstrated current reverse genetics technology feasible generate recombinant influenza virus new ha na sequences within <NUMBER> days <NUMBER> new emerging viruses continue appear pandemics continue occur rapid approaches recover adapt viruses instrumental public health response development common chimeric reverse genetic platforms rapid cloning expression surface antigens emergent pathogens help increase efficacy timing delivery epidemic pandemic outbreaks one key limitation development effective liveattenuated vaccines genetic stability rna viruses generally exhibit high mutation rates due decreased fidelity rdrp yet recent studies shown codonusage bias used alter translation consequently replication viruses several groups shown substituting nonpreferred codons based host cell codon usage bias process referred codondeoptimization genome poliovirus resulted reduction plaque areas virus yields <NUMBER> <NUMBER> changing codons rather amino acids amount viral protein may modulated without impairment function importantly potential reversion greatly limited due sheer number codon changes introduced coding sequence approach represents promising new avenue develop attenuated genetically stable vaccine platforms despite presence reverse genetics systems many human pathogens resulted successful vaccine platforms advances biotechnology key discoveries led novel reverse genetic approaches may employed new generation vaccines structural vaccinology structurebased antigen design become common practice optimizing antigens display vaccines <NUMBER> mentioned previously rsv remains key hurdle reducing viral childhood morbidity since discovery implementation palivizumab currently licensed prophalytic inhibitory measure rsv infection considerable energy devoted evaluating antigenic sites rsv fusion f protein optimizing f expression constructs higher immunogenicity <NUMBER> current structural vaccinology efforts evaluate prefusion postfusion antigenic forms rsv f protein led induction identification potent neutralizing antibodies higher neutralizing potencies palivizumab <NUMBER> <NUMBER> availability new structures sequences made predictive structural modeling structurebased antigen design viable options renewed efforts design vaccines current vaccines exist advances biotechnology shaped field virology much field science capacity engineer reverse genetics platforms study manipulation rna virus genomes revolutionized field vaccine design described rna virus reverse genetic systems past current efforts develop vaccines provide immunity several human rna virus pathogens incorporation new advances reverse genetics technology adjuvants nonhuman models infection surveillance continue drive development next generation vaccines pathogens already vaccination strategies well currently ongoing changes human demographics accessibility health care likely modify costbenefit analyses provoke allocation new resources scientific study development vaccines despite ongoing evolution vaccine design implementation hallmarks effective viral vaccine remain high efficacy safety stability coronavirus disease <NUMBER> covid<NUMBER> pandemic caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> led <NUMBER> million cases covid<NUMBER> vaccines development occurring unprecedented speed partially due coalition epidemic preparedness innovations cepi <NUMBER> cepi formed <NUMBER> novel partnership private public philanthropic civil society organizations aims develop vaccines future epidemics enable equitable access vaccines people epidemics cepi mandated accelerate development manufacture vaccines previously unknown pathogens <NUMBER> weeks identification antigen vaccine candidate release clinical trials <NUMBER> cepi announced initiation nine covid<NUMBER> vaccine programs <NUMBER> rapid response platforms vaccine development supported cepi utilized platform technology use systems basic components backbone insert new protein genetic sequences adapt use different pathogens <NUMBER> vaccine candidates include dna vaccine administered electroporation molecularclamp vaccine synthesis viral surface proteins attach host cells infection clamps shape immune system recognize correct antigen recombinant protein nanoparticle technology generate antigens derived coronavirus spike protein proprietary saponinbased adjuvant recombinant protein vaccine trimer replicationdeficient simian adenoviral vaccine chadox<NUMBER>s measlesvector vaccine liveattenuated influenza vaccine two mrna vaccines pandemic vaccine adjuvant available enhance development <NUMBER> cepi also launched call organisations large manufacturing capabilities vaccine candidates advance effective vaccine transfer vaccine platform global network largescale manufacturing <NUMBER> currently <NUMBER> covid<NUMBER> vaccines candidates clinical trials including four funded cepi including mrna first enter clinical trials codeveloped national institute allergy infectious diseases niaid usa dna chadox<NUMBER>s protein subunit vaccine shown table <NUMBER> <NUMBER> vaccine candidates targeting sarscov spike protein <NUMBER> displayed virus surface composed two subunits <NUMBER> <NUMBER> s<NUMBER> subunit contains receptorbinding domain rbd binds host cell receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> protein priming occurs serine protease tmprss<NUMBER> cleave protein s<NUMBER>s<NUMBER> fusing viral host membranes occurs s<NUMBER> subunit protein induces neutralizingantibody tcell responses well protective immunity infection sarscov <NUMBER> vaccine formulation delivery developed induce strong neutralizing antibodies predominant cd<NUMBER> helper <NUMBER> cell th<NUMBER> immune response balanced cd<NUMBER>cd<NUMBER> polyfunctional cell responses favorable antiviral properties <NUMBER> traditional timeline develop vaccine <NUMBER> <NUMBER> years covid<NUMBER> hope vaccine available <NUMBER> months accelerated timelines vaccine development achieve emergency use listing using regulatory pathways national regulatory authorities common adverse events occur shortly vaccination may detected clinical trials rare adverse events delayed onset likely detected large populations immunized addition dna rna vaccines licensed humans date safety surveillance accompanying deployment critical historic example real adverse reactions detected widespread vaccine use guillainbarré syndrome gbs following <NUMBER> swine flu vaccine program enhanced disease post infection vaccination dengue vaccine coincidental events later found caused vaccine autism following mmr vaccine sudden infant death syndrome sids whole cell pertussis vaccines undermine immunization program highlight critical role robust safety monitoring adverse events special interest aesis serious nonserious events significant medical scientific concern specific sponsors program product require ongoing monitoring communication investigator sponsor might require investigation characterize understand rapid communication trial sponsor regulators could related vaccines general specific vaccine platforms disease aesis reporting assessment done high priority could change benefitrisk profile vaccine require prompt public communication covid<NUMBER> vaccines aesis could potentially include vaccineenhanced disease vaccination could make subsequent infection sarscov<NUMBER> severe <NUMBER> enhanced disease deaths associated dengue vaccine reported formalininactivated respiratory syncytial virus rsv vaccine young children received vaccine subsequently infected natural rsv <NUMBER> enhanced disease seen preclinical studies aesi aesis relevant covid<NUMBER> disease could potentially include respiratory including pneumonia acute respiratory distress syndrome cardiac including cardiogenic shock cardiomyopathy arrhythmia coronary artery disease myocarditis pericarditisacute renal hepatic injury neurological including encephalopathy encephalitis gbs anosmia ageusia sepsis septic shock hypercoagulability rhabdomyolysis multisystem inflammatory syndrome children <NUMBER> aesis related novel adjuvants vaccine platforms eg cardiac ae including myopericarditis mva arthritis vsv platforms vaccination eg anaphylaxis thrombocytopenia seizures gbs also considered adverse event following immunization aefi untoward medical occurrence follows immunization necessarily causal relationship usage vaccine aefis include background rate diseases postvaccination may include excess burden diseases vaccine causes vaccine adverse reaction safety surveillance must capable investigating aefis aesis understanding biological mechanisms adverse reactions limitations must anticipate coincidental events clinicians media public may attribute vaccine safety surveillance must able detect rapidly investigate aesis aefis determine temporal relationship causal coincidental preparations need made order ensure emergency vaccine use accompanied robust vaccine safety surveillance process safety assessment maintain public confidence vaccine vaccine likely used covid<NUMBER> widely circulating thus safety surveillance need distinguish health outcomes caused disease versus caused vaccine real coincidental aesis aefis potential undermine vaccine program exacerbate public fear around pandemic active sentinel surveillance systems necessary rapidly rigorously evaluate safety profile vaccines many highincome countries large healthcare administrative databases conduct active surveillance vaccine experience however lowand middleincome countries lmic generally lack capacity conduct active safety surveillance large healthcare administrative databases equitable access vaccines people epidemics imperative active safety surveillance lmic critical ensure safety surveillance also equitable done prior launch <NUMBER> h<NUMBER>n<NUMBER> vaccines active surveillance systems calculate incidence background rates aesi prior vaccine roll <NUMBER> establishing background rates disease prior vaccination allows stable rate based upon multiple years data rates outcomes vaccine roll compared cepi developing comprehensive list aesis incidence outcomes vary tremendously based upon region underlying population methods use case ascertainment highly dependent characteristics active sentinel surveillance system surveillance lmic must established preparation vaccine roll background rates aesis calculated several approaches used establish active surveillance systems lmic limited access large healthcare administrative databases lmic india also essential countries regions plan real coincidental aesis aefis scientifically rigorous publicly credible process separate real adverse reactions coincidental background rates disease safety signals require careful evaluation often involving chart review potential cases time labor intensive recommended global vaccine safety blueprint gvsb <NUMBER> countries regions establish either national expert committee aefis regional advisory committees equivalent objective panels spelled terms reference <NUMBER> public credibility optimized ensuring committees independent conflicts interest ministries health industry immunization program vaccine safety communication plans clear national subnational vaccine safety communication roles responsibilities developed provide timely evidencebased messaging describe known known done fill gaps covid<NUMBER> pandemic global crisis enormous human financial costs present efforts aimed curbing pandemic social distancing may helpful ultimately vaccine likely important longterm tool however must invest active vaccine safety surveillance globally particularly lmic ensure potential covid<NUMBER> vaccine realized crisis comes opportunity expand global vaccine safety system meet needs covid<NUMBER> routine emergency use vaccines global vaccine safety blueprint <NUMBER> offers framework must fully funded implemented emerging viral diseases evds making headlines past two decades subsequent outbreak emphasizes global lack preparedness controlling minimizing spread diseases human animal populations burden evds public health global economy massive direct indirect costs zoonotic diseases estimated exceed us<NUMBER> billion last decade alone <NUMBER> <NUMBER> rise evd cases traced number causes growing global population expected reach <NUMBER> billion people <NUMBER> resulted expanding urbanization deforestation exposing populations reservoirs new viruses furthermore highdensity living conditions often associated low quality life insufficient health care thus facilitating disease transmission climate change also plays major role enabling emergence infections new locations warmer weather increasing range arthropod disease vectors mosquitoes ticks globalization dramatic growth international travel also increase rapidity scale emerging disease dissemination particular concern top seven priority pathogens designated world health organization likely cause major outbreak associated high mortality rates due lack effective medical treatments countermeasures <NUMBER> pathogens zoonotic include crimeancongo hemorrhagic fever virus cchfv ebola marburg viruses ebov lassa virus lasv middle east respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov nipah virus niv rift valley fever virus rvfv additionally chikungunya virus chikv zika virus zikv declared health emergencies epidemic potential <NUMBER> despite low mortality rates mosquitoborne arboviruses rapidly spread large populations zoonotic viruses transmitted directly humans animal reservoirs example niv acquired bat shedding merscov camels sarscov civets <NUMBER> alternately transmission occur intermediate hosts niv infection pigs followed transmission pigs humans <NUMBER> ebov transmission bats nonhuman primates nhps humans <NUMBER> larger human outbreaks subsequently occur individuals come contact body fluids urine saliva aerosolized droplets blood infected person air travel trading ships carrying infected persons animals vectors result intercontinental spread diseases pandemics several vaccine platforms developed preventative care diseases preparedness future outbreaks review discuss measles virus mv vector promising alternative conventional vaccine development methods strengths vaccination platform emerging diseases compare approaches platform based replicating mv vaccine vector demonstrated proofofprinciple humans preclinical track record rapid adaptability effectiveness variety pathogens tackling unpredictability regarding evds arise requires strong international disease surveillance networks well commitment development preventative measures postexposure treatments reason may <NUMBER> <NUMBER>th world health assembly welcomed development blueprint accelerating research development epidemics health emergency situations insufficient preventive curative solutions taking account relevant work streams within <NUMBER> rd blueprint aims reduce time declaration international public health emergency availability effective tests vaccines antivirals treatments save lives avert public health crisis following initiative coalition epidemic preparedness innovations httpcepinet created cepi alliance governments industry academia philanthropy intergovernmental institutions civil society aims finance coordinate development new vaccines prevent contain infectious disease epidemics epidemics disproportionately affect lowincome countries cepi ensure vaccines affordable available populations need currently drugs available efficiently treat acute virus infection viral inhibitors ribavirin others reduce slow viral replication giving host immune system chance develop clear virus however treatment window acute viral infections short symptoms often appear late course infection viral clearance phase fig <NUMBER> host become infectious passive immunization used emergency cases high exposure areas seen ebov <NUMBER> niv <NUMBER> hendra virus <NUMBER> outbreaks approach practical general implementation due high cost limited efficacy therefore prophylactic vaccination remains simple safe effective way prevent viral infections subsequent outbreaks indeed vaccines crucial control elimination many deadly viral diseases represent efficient method prevent viral infection inactivated killed viruses live attenuated viruses subunit vaccines comprise conventional mode vaccination inactivatedvirus vaccines made whole virus particles treated chemicals heat radiation live attenuated virus vaccines created passaging virulent virus strains animals cell culture virus adapted new host longer pathogenic target animals humans usually <NUMBER> <NUMBER> <NUMBER> passages inactivatedvirus subunit vaccines nonreplication competent risk reversion infectivity usually effective enough elicit strong host immune responses immunization efficacy requires use adjuvants several boosters turn cause side effects severe allergic reactions hand live attenuated vaccines elicit longterm protective immune responses replicate inside host however depending number attenuation mutations viral family risk reversion virulence regained reassortment pathogenic strains observed oral live polio vaccine <NUMBER> moreover conventional attenuation lengthy process requiring numerous passages take <NUMBER> months several years work rendering impractical prompt response ongoing outbreaks nevertheless given efficacy simple administration regimens ease largescale manufacture live attenuated vaccines remain attractive choices vaccine design highly successful examples live attenuated vaccines include developed smallpox yellow fever poliomyelitis measles latter three successfully implemented lowand middleincome countries expanded program immunization epi welltested effective live attenuated virus vaccines modified modern recombinant dna technology combine advantages replicating viral vectors need rapid methods developing new vaccines emerging reemerging diseases live replicating vectors mv vector characterized induction longlived protective immunity one two administrations reverse genetics technology viral vector vaccine platform created carry antigenic proteins another circulating virus yield vaccine candidate quickly tested established animal models plugandplay platform capacity provide rapid responses future emerging viral diseases ranging <NUMBER> <NUMBER> nm due flexibility envelope structure inside particles genomic viral rna tightly wrapped n p l constitute helicoidal ribonucleoprotein rnp complex autoreplicative host cytoplasm rnp serves template viral rna synthesis n molecule associated <NUMBER> nucleotides efficient replication requires genome length respects socalled rule six means total number genome nucleotides dividable <NUMBER> <NUMBER> since helicoidal structure highly flexible like spring genome tolerates large insertions long total length complies rule six viral genes transcribed succession n l genes polymerase stops restarts intergenic regions however efficiency reinitialization <NUMBER> mrnas produced decreasing amounts <NUMBER> <NUMBER> <NUMBER> <NUMBER> end genome resulting greatest abundance n lowest abundance l protein accumulation intracellular n protein promotes shift transcription replication replication l synthesizes complete copy entire genome positivesense antigenome serves template generation fulllength negativesense genomes packaging viral particles assembled n p l proteins synthesized cytoplasm budding plasma membrane together envelope proteins localized surface membrane live attenuated mv vaccine one safest effective vaccines available several mv vaccine strains schwarzmoraten edmonstonzagreb aikc strains developed pathogenic wildtype virus multiple passages various cellular substrates chicken eggs chicken embryo fibroblasts different conditions past <NUMBER> years mv vaccine administered safely <NUMBER> billion children case reversion reported induces humoral cellular immune responses efficiently stimulating longlasting memory tcells provides lifelong immunity efficacy rate approximately <NUMBER> one administration <NUMBER> two administrations virus replicates cytoplasm hence possibility viral genome integration host genome thanks nonsegmented negativesense rna genome genomic recombination possible observed viruses furthermore mv vaccine currently produced large scale many countries globally distributed low cost epi therefore mv vector platform provides means rapidly generating potent vaccine candidates broad spectrum epidemic disease targets accessible manufacturing process provides means rapidly scaleup vaccines low cost stockpiling purposes rapid response vaccine countermeasure epidemic threats recombinant mv vectors generated attenuated mv vaccine strains attractive choices developing vaccine candidates viral infections due helicoidal packaging genome mv vector take foreign genes <NUMBER> kb size possibly heterologous proteins stably expressed high levels <NUMBER> passages rescued recombinant viruses retain growth capabilities similar original mv strain <NUMBER> mv delivery platform developed preclinical stages clinical proofofconcept several indications preclinical track record fast effective adaptability variety pathogens mv vectors immunogenic mice nhps inducing longterm neutralizing antibodies cellular immunity even context preexisting immunity vector <NUMBER>e<NUMBER> initial pioneer cloning fulllength infectious mv achieved <NUMBER> group billeter zurich <NUMBER> later schwarz strain mv cloned institut pasteur paris commercially approved mostly attenuated efficient widely used mv vaccine strain <NUMBER> generate infectious clone fulllength antigenomic viral cdna fig <NUMBER>b cloned ptm plasmid control t<NUMBER> rna promoter dna sequences containing ggg motif hammerhead hepatitis delta viral ribozymes added facilitate accurate cleavage viral rna ensure production fulllength viral rna virus produced rescued transfection ptmmvschw plasmid together plasmid expressing schwarz mv l gene transcomplemented human cells hek<NUMBER> cells constitutively expressing t<NUMBER> rna polymerase mv n mv p transfected cells cocultured mv permissive cell line vero mrc<NUMBER> chicken embryonic fibroblasts plaques picked seeded amplification characterization rescued viruses cdna clone possess sequence parental schwarz strain demonstrating stability negativesense genome enable insertion foreign antigens several additional transcription units atus based mv cisacting sequences introduced ptmmvschw various sites genome cloning sites accommodate inserts <NUMBER> kb length multiples six base pairs respect rule six essential measles genome replication <NUMBER> one common concern regarding use mv vaccine vector preexisting immunity due broad coverage mv vaccines human populations worldwide however demonstrated recombinant mv vaccines induce strong immune responses even previously immunized animals humans <NUMBER> <NUMBER> <NUMBER> although surprising mv properties may account phenomenon first recombinant mv replicating therefore although low doses used vaccine amplified vivo upon cell infection recombinant mv expresses measles proteins well heterologous antigens mv particles assembled released cell heterologous antigens either secreted cell expressed cell surface depending nature antigen stimulate immune response second virus delivers antigens directly dendritic cells macrophages b cells effective antigen presenting cells viral particles transmitted cell cell cell contacts lastly recently shown additional antigens expressed replicating mv vectors naturally adjuvanted defective interfering genomes produced recombinant virus contributing robust induction interferon conferring vaccine efficacy <NUMBER> vaccine technology platform capacity address challenge rapid vaccine development combining strong safety immunogenicity profile demonstrated multiple applications ability target antigens infectious pathogens preclinical clinical settings robust antigenindependent scalable manufacturing process several recombinant measles vaccines number viral pathogens far generated tested animal models fig <NUMBER> target pathogens include hiv <NUMBER>e<NUMBER> west nile virus wnv <NUMBER> <NUMBER> dengue virus denv <NUMBER> <NUMBER> hepatitis b virus hbv <NUMBER> human papilloma virus hpv <NUMBER> chikv <NUMBER> niv <NUMBER> respiratory syncytia virus rsv <NUMBER> sarscov <NUMBER> merscov <NUMBER> h<NUMBER>n<NUMBER> influenza virus iav unpublished zikv unpublished lasv unpublished ebov unpublished preclinical immunogenicity protection lethal challenges shown mice nhps wnv chikv hiv<NUMBER> sarscov h<NUMBER>n<NUMBER> iav zikv lasv cases hiv<NUMBER> zikv chikv recombinant vaccine candidates successfully completed phase clinical trials adults last progressing phase ii trials chikungunya virus chikv enveloped positivesense singlestranded rna virus family alphaviridae approximately <NUMBER> infected patients develop debilitating chronic polyarthralgia last months even years initially thought african virus emerged <NUMBER>e<NUMBER> la reunion island indian ocean infecting third island population spreading throughout india giving rise indian ocean lineage <NUMBER> reemerged caribbean island martinique since chikv found <NUMBER> countries americas africa asia europe <NUMBER> million people infected mvbased chikv vaccine developed expressing chikv structural genes c e<NUMBER> e<NUMBER> <NUMBER>k e<NUMBER> cloned clinical isolate chikv <NUMBER> ecsa strain <NUMBER> expression chikv structural genes results formation viruslike particles infection vero cells preclinical studies cd<NUMBER>þifnaràà mice showed full protection lethal chikv challenge single immunization even presence preexisting immunity vector <NUMBER> mvchikv vaccine candidate introduced clinical trials themis bioscience httpthemisbio com immunogenicity demonstrated phase clinical trial <NUMBER> seroconversion rate single injection <NUMBER> seroconversion boosting <NUMBER> days <NUMBER> months apart <NUMBER> serious adverse reactions observed even group receiving high dose <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> displayed mild reactions headache flulike symptoms mild muscle pain similar observed control standard mv vaccine <NUMBER> importantly study demonstrated immune response measles chikv vlp dampened previous mv immunization since volunteers preimmune measles <NUMBER> phase ii clinical trial ongoing <NUMBER> volunteers austria germany eudract <NUMBER> additionally two independent phase studies initiated usa nih puerto rico dod june <NUMBER> clinicaltrialsgov nct<NUMBER> nct<NUMBER> success mvchikv thus far reaffirms mv vector excellent platform vaccine development dengue virus denv enveloped positivesense singlestranded rna virus family flaviviridae causes tropical disease endemic southeast asia latin america identified dengue neglected disease potential emergence new geographical areas due climate change <NUMBER> major complication dengue infection four distinct serotypes virus circulate first denv infection host acquires lifelong immunity particular serotype provide crossprotection serotypes rather nonneutralizing antibodies enhance infection cells carrying fc receptors used denv host cell entry phenomenon called antibodydependent enhancement ade <NUMBER> <NUMBER> due ade complications strategy denv vaccine development focus tetravalent vaccines simultaneously stimulate immune responses four denv serotypes recently licensed denv vaccine dengvaxia cydtdv tetravalent yf<NUMBER>dbased recombinant vaccine completed phase <NUMBER> clinical trials distributed southeast asia south america <NUMBER> however vaccine poses safety concern associated increased risk disease exacerbation recipients previously exposed denv sanofi pulled vaccine philippines recent concerns vaccine use recommended individuals prior exposure denv given limitations current vaccine options still explored mvbased tetravalent vaccine candidate development well denv antigen used consists domain iii e glycoprotein ediii four serotypes contains serotypespecific neutralizing epitopes fused ectodomain membrane protein <NUMBER> ectodomain essential immunogenicity inserted tetravalent ediii due adjuvant properties induction proinflammatory antiviral cytokines chemokines <NUMBER> preclinical trials revealed immunized mice macaques developed neutralizing antibodies four serotypes unpublished data zika virus zikv flavivirus closely related denv approximately <NUMBER> amino acid difference compared <NUMBER>e<NUMBER> difference four denv serotypes <NUMBER> <NUMBER> zikv first identified among humans primates mosquitoes zika forest uganda <NUMBER> <NUMBER> <NUMBER> emerged southeast asia became largely endemic tropical regions first massive outbreak seen yap island <NUMBER> <NUMBER> population became infected <NUMBER> disease reached latin america major outbreak brazil zikv infection shares common symptoms arbovirus infections fever flulike symptoms rashes brazilian outbreak around half cases exhibited symptoms virus could detected saliva infected individuals <NUMBER> zikv declared emergency public health concern <NUMBER> due neurological complications associated guillain barr e syndrome reported french polynesia microcephaly newborns reported brazil <NUMBER> congenital zikv syndromes suggested humantohuman transmission sexual intercourse breast milk placental transfer <NUMBER> <NUMBER> close evolutionary relationship denv ade viruses reported vitro sera denvinfected individuals facilitate zikv infection usually nonpermissive cells <NUMBER> although confirmed humans phenomenon could complicate vaccine development zikv denv vaccines currently preclinical trials include mvbased vaccine developed cloning fulllength prm e genes prme zikv ptmmvschw vector vaccine candidate highly immunogenic conferred full protection mice monkeys phase clinical trial initiated <NUMBER> themis bioscience httpthemisbiocom severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov enveloped positivesense singlestranded rna viruses possessing genomes approximately <NUMBER> <NUMBER> kb size respectively viruses thought originate bats first known case sars occurred transmission palm civet <NUMBER> foshan china november <NUMBER> spreading throughout china countries tallied <NUMBER> reported cases <NUMBER> countries <NUMBER> due global effort disease management outbreak declared july year ten years first sars incidence merscov emerged saudi arabia <NUMBER> cases arising transmission dromedary camels humans merscov observed spread person person like sarscov localized outbreak arising imported case observed south korea result nosocomial transmission single infected traveler <NUMBER> structural spike proteins covs identified targets neutralizing antibodies considered potential targets subunit viral vector vaccine development institut pasteur mvbased vaccine sarscov developed human codonoptimized gene encoding native sarscov soluble form inserted atu p sequences ptmmvschw <NUMBER> gene insertions interfere recombinant mv growth titer vaccine tested mice found induce neutralizing antibodies immunized animals protected lethal dose sarscov challenge delivered intranasally native observed potent eliciting antibodies soluble counterpart antibodies found possess high neutralizing activity sarscov mv <NUMBER> higher igg<NUMBER>a igg<NUMBER> levels observed suggesting th<NUMBER>biased response merscov mvbased vaccine generated using modified edmonston strain backbone carrying either fulllength soluble merscov p genes <NUMBER> like sarscov version vaccine also induced neutralizing antibodies antigenspecific cytotoxic tcells elispot assays intracellular cytokine staining flow cytometry showed strong increase specific cd<NUMBER> þ cd<NUMBER> þ cells vaccinated mice ex vivo restimulation antigen well positive killing assay <NUMBER> promising results thus far demonstrate mv vector great potential sarscov merscov vaccine development ebola marburg viruses ebov marv enveloped negativesense singlestranded rna viruses filoviridae family responsible hemorrhagic fevers associated high fatality rates <NUMBER> ebov first discovered <NUMBER> congo sudan circulation generally restricted central african countries several ebov strains marv cause frequent outbreaks continue cause sporadic outbreaks reemerging regularly eastern central africa december <NUMBER> however unprecedented outbreak emerged western african country guinea causing major crisis rapid spread within country well neighboring sierra leone liberia air travel led imported cases many countries us spain mali uk turning ebov epidemic global public health emergency <NUMBER> <NUMBER> documents indicate total <NUMBER> reported cases ebov infection <NUMBER> reported deaths concerted international effort managed stem outbreak ebov outbreaks predicted persist next decade <NUMBER> recent outbreak reenergized ebov vaccine development massive influx funding several vaccine candidates placed accelerated development among two viralvector vaccines targeting envelope glycoprotein gp ebov currently phase iiiii clinical trials first vaccine based vesicular stomatitis virus vsv vector expressing ebov zaire strain gp rvsvzebov <NUMBER> <NUMBER> vector based cattle virus frequently associated human infection nhp experiments demonstrated vaccine protects ebov challenge also effective postinfection treatment within days infection drawbacks rvsvzebov vaccine include unknown duration protection possible adverse effects depending dose used phase clinical trial abruptly stopped due serious joint pain dermatitis <NUMBER> however vaccine proven effective limiting disease spread implemented ring vaccination scheme guinea <NUMBER> <NUMBER> <NUMBER> second vaccine candidate ebov adenovirus vector ad expressing ebovgp vaccine vector provides benefit nonpathogenic humans naturally controlled immune system however first generation adbased vaccines reduced effectiveness due preexisting immunity later overcome use chimpanzee adenovirus strain chad <NUMBER> regardless preexisting immunity confer longlasting immunity huad chad platforms require booster delivered heterologous modified vaccinia virus ankara mva vector primeboost protocols difficult set ebovemerging countries healthcare systems weak unavailable areas moreover dose required efficient protection <NUMBER> <NUMBER> tcid <NUMBER> highly challenging task manufacturing vaccine millions individuals mv vector provides attractive alternative vaccine development circumvent possible safety issues associated rvsv vector manufacturing hurdles complex regimen adv vector approach particular mv ability elicit humoral cellular responses advantageous efficient protection tcell responses shown play role controlling ebov infection <NUMBER> probably instrumental maintaining longterm memory furthermore large insertion capacity mv vector enables development combined vaccine ebov marv mv expressing different forms gp ebov zaire strain currently tested immunogenicity efficacy nhp model institut pasteur lassa virus lasv bisegmented negativesense singlestranded rna virus family arenaviridae causes hemorrhagic fever humans natal multimammate rat natural reservoir infections occurring rodenttohuman transmission humantohuman spread occur direct contact infected body fluids nosocomial settings lassa fever causes nonspecific symptoms severe cases vascular leakage multiorgan failure reported disease first identified nigeria <NUMBER> detected throughout western central africa within decade unlike ebov infection lassa fever occurs annually posing major threat local populations travelers healthcare workers us cdc estimates lasv causes <NUMBER>e<NUMBER> cases <NUMBER> deaths yearly among hemorrhagic fever viruses lasv causes highest global burden due stability aerosol transmission also render potential bioterrorism threat several virusbased vectors including vsv <NUMBER> vaccinia virus <NUMBER> yellow fever virus yf<NUMBER>d <NUMBER> carrying surface glycoprotein complex gpc lasv showed promising immunological results guinea pig nhp models ninety percent nhp survived lethal lasv challenge vaccination vaccinialasvgp <NUMBER> study also confirmed cellmediated immune responses key lasv protection however use vacciniabased vaccine desirable high hiv prevalence regions africa still unclear whether immunosuppressed individuals face risks increased vaccinia replication generalized infection hand yf<NUMBER>d vector expressing lasvgpc observed exhibit genetic instability antigen due vectors small insertion capacity <NUMBER> various versions gp<NUMBER> gp<NUMBER> glycoproteins tested yf<NUMBER>d resolve issue loss antigen expression still observed five passages recombinant virus mvbased vaccine mvlasvnpþgpc currently developed institut pasteur problem antigen instability due high insertion capacity vector experiments macaques shown great efficacy vaccine candidate protect animals single immunization lethal lasv challenge unpublished data nipah virus niv henipavirus paramyxoviridae family enveloped negativesense singlestranded rna virus causes disease humans animals reservoir fruit bat transmission occurs contact bat saliva urine often consumption contaminated fruits date palm sap disease first emerged fatal case acute encephalitis town nipah malaysia <NUMBER> followed hundred cases disease <NUMBER> mortality virus reemerged india bangladesh <NUMBER>e<NUMBER> higher fatality rate <NUMBER>e<NUMBER> pigs act amplifying hosts infection causes mostly respiratory symptoms known barking pig disease direct transmission infected pigs humans reported <NUMBER> addition fact number infected patients never came contact either bats pigs indicates occurrence humantohuman transmission niv <NUMBER> <NUMBER> vaccine target antigens niv fusion protein f glycoprotein g surface proteins important host cell attachment viral entry various immunization strategies summarized previous review <NUMBER> canarypox virus carrying f g developed use animals showed protection intranasal challenge piglets <NUMBER> human vaccination vaccinia virus adenovirus mv vsv <NUMBER> <NUMBER> <NUMBER> <NUMBER> used viral vectors vaccine candidates elicited specific neutralizing antibodies protected challenge hamster ferret models vsvnivg demonstrating partial protection lethal challenge nhps well although lesions observed brain cells suggesting viral replication central nervous system <NUMBER> mvbased vaccine involved insertion niv g gene edmonston strainbased vector initial immunogenicity testing performed hamsters showed full protection lethal challenge second immunization nhp model monkeys vaccinated <NUMBER> â <NUMBER> <NUMBER> tcid <NUMBER> rmvnivg one booster showed clinical signs challenge niv demonstrating full protection vaccinated monkeys <NUMBER> rift valley fever virus rvfv phlebovirus trisegmented negativesense singlestranded rna genome transmitted several aedes spp culex spp mosquitoes livestock humans infection causes acute severe disease ruminants fever loss appetite aborted fetuses high mortality rate newborn animals humans deadend hosts infection results febrile illness approximately <NUMBER> infected presenting severe symptoms encephalitis hemorrhagic syndromes first appeared rift valley region kenya virus isolated <NUMBER> several major outbreaks reported throughout africa first appearing outside region <NUMBER> large outbreak arabian peninsula three segments rvfv genome named small medium large l genes two envelope glycoproteins gn gc serve receptorbinding proteins facilitate virus attachment infection rendering targets vaccine development subunit vaccines targeting gn gc shown elicit specific rvfv neutralizing antibodies <NUMBER> many vaccine platforms used develop vaccine candidates rvfv licensed vaccines humans available yet animal vaccines include live attenuated smithburn inactivated rvfv africa <NUMBER> unfortunately diva differentiating infected vaccinated animals vaccines present problem export livestock products among vaccines pipeline clinical trials conducted formalininactivated attenuated vaccines demonstrated seroconversion longterm protection rvfv animals humans <NUMBER> <NUMBER> nevertheless attenuated vaccine retains risk reversion reassortment field strains mv vector yet used development rvfv vaccine considering drawbacks current vaccine options candidates advantages provide strong argument pursue approach furthermore mv shown infect animals nectin<NUMBER> receptor without requiring cd<NUMBER> unpublished making platform viable animal vaccines well mv platform highly flexible enabling easy modification create replicating delivery vector various protective antigens platform benefits advantages live attenuated vaccines without risks drawbacks plugandplay property help ensure timely availability preventive vaccines whenever new epidemic occurs platform track record safety immunogenicity relevant antigens pathogens wellestablished production process allows substantial acceleration development timelines various mvvectored vaccines demonstrated solid performance early phase clinical trials provide proofofconcept mv platform powerful tool fight current emerging viral pathogens middle east respiratory syndrome coronavirus merscov emerged novel lethal human pathogen causes severe acute respiratory infection since identification plos one httpsdoiorg<NUMBER>journalpone<NUMBER> july <NUMBER> <NUMBER> <NUMBER> <NUMBER> a<NUMBER> a<NUMBER> a<NUMBER> a<NUMBER> a<NUMBER> saudi arabia <NUMBER> <NUMBER> virus causes respiratory diseases fever cough shortness breath may lead pneumonia acute renal failure immunocompromised patients elderly <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> date <NUMBER> laboratoryconfirmed merscov infection cases including <NUMBER> related deaths <NUMBER> countries reported world health organization httpwwwwhointemergenciesmerscoven currently cases increasingly reported merscov also potential widespread outbreak observed <NUMBER> south korea <NUMBER> currently lack prophylactic therapeutic measures created urgent need effective vaccine development merscov infections <NUMBER> <NUMBER> merscov enveloped positivesense singlestranded rna virus belongs lineage c genus betacoronavirus βcov family coronaviridae <NUMBER> <NUMBER> <NUMBER> merscov genome encodes four structural proteins spike envelope e membrane nucleocapsid n <NUMBER> <NUMBER> protein type transmembrane glycoprotein virus surface contains two functional subunits mediates viral infection s<NUMBER> subunit comprises nterminal domain ntd receptorbinding domain rbd recognizes binds dipeptidyl peptidase <NUMBER> dpp<NUMBER> also known cd<NUMBER> receptor host cell surface initiate infection <NUMBER> <NUMBER> <NUMBER> s<NUMBER> subunit two heptad repeats hr hr<NUMBER> hr<NUMBER> facilitates fusion virus host cell membrane <NUMBER> <NUMBER> glycoprotein considered suitable vaccine candidate eliciting neutralizing antibodies block viral entry neutralize viral infection <NUMBER> <NUMBER> <NUMBER> spike proteinbased vaccine candidates developed investigated wholeinactivated virus <NUMBER> subunit vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> dnabased vaccines <NUMBER> <NUMBER> <NUMBER> viral vectorbased vaccines <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> using spike protein whole spike protein fragments vaccine candidates induced humoral immune responses neutralizing antibody responses well cellular immune responses however vaccination strategy focused rbd alone several issues may optimal generating neutralizing antibody responses <NUMBER> induce partial protection merscov infection <NUMBER> <NUMBER> detailed structural analysis revealed rbdspecific antibodies stimulate emergence viral escape mutation region therefore generation diverse antibodies directed toward rbd outside domain may better strategy developing effective vaccines <NUMBER> <NUMBER> designed constructed recombinant adenovirusbased vaccine candidates encoding ntd rbd fulllength spike protein assessed immunogenicity compared immune responses generated vaccination via different routes found radspike could induce strongest humoral cellular immune responses additionally immunization radspike conferred longlasting neutralizing antibody responses suggesting radspike best candidate effective merscov vaccine development female balbc mice aged <NUMBER> weeks purchased orient bio inc seoul korea mice maintained specific pathogenfree conditions experimental facility ewha womans university mice group housed cages containing four mice approximately <NUMBER>˚c <NUMBER> h lightdark cycle cage changes performed weekly end experiment food water replenished needed study mice checked daily ensure health animal welfare mice sacrificed co <NUMBER> euthanasia animal studies approved ewha womans university institutional animal care use committee iacuc approval <NUMBER> carried strict compliance suggestions given institute laboratory animal resources guide care use laboratory animals hek<NUMBER> cells atcc crl<NUMBER> cultured mem welgene korea containing <NUMBER> fetal bovine serum fbs <NUMBER>tn cells huh<NUMBER> cells purchased atcc collection manassas va grown dmem welgene supplemented <NUMBER> fbs spodoptera frugiperda <NUMBER> sf<NUMBER> insect cells invitrogen carlsbad ca usa propagated sf<NUMBER> ii serumfree medium gibco brl <NUMBER>˚c used produce recombinant ntd rntd protein normal human nasal epithelial nhne cells cultured described previously <NUMBER> briefly passage<NUMBER> nhne cells <NUMBER>×<NUMBER> <NUMBER> cellsculture seeded <NUMBER> ml culture medium transwell clear culture inserts <NUMBER>mm <NUMBER>mm pore size costar co cambridge usa cells cultured <NUMBER> mixture basal epithelial growth medium dmem containing previously described supplements cultures grown submerged first <NUMBER> days culture medium changed day <NUMBER> every day thereafter airliquid interface ali created day <NUMBER> removing apical medium feeding cultures basal compartment culture medium changed daily initiation ali add antibiotics <NUMBER> penicillin streptomycin media subculture culture stages also add antifungal agent fungizone <NUMBER> ml <NUMBER> ml media life technologies grand island ny usa filtering media experiments described used cultured nasal epithelial cells <NUMBER> days creation ali amino acid sequence merscov spike protein merscovkorknih <NUMBER> genbank kt<NUMBER> residues <NUMBER> spike gene codonoptimized synthesized mammalian cell expression genscript piscataway nj optimal kozak translation sequence also included immediately upstream atg synthetic dna subcloned pshuttlecmv vector bgliinoti double digestion used templates polymerase chain reaction pcr amplification subsequently constructs expressing different merscov spike protein fragments designed coding sequence rbd residues <NUMBER> amplified pcr using forward <NUMBER>gagctagcgaggc caagccctctggc<NUMBER> reverse primers <NUMBER>gactcgagttatcacttgtcatcatcg tccttgtagtcgtactccacgcaattgcccag<NUMBER> contain two stop codons flag tag sequence coding sequence ntd residues <NUMBER> amplified pcr using forward <NUMBER>ga gctagctacgtcgatgtgggacc<NUMBER> reverse primers <NUMBER>gactcgagttatcagtggtggtggtggtgatgggactcatagctacagtgcag<NUMBER> contain two stop codons sixhistidine tag sequence finally pcr products rbd ntd gene inserted pshuttlecmv vector nheixhoi double digestion respectively pshuttlecmv plasmid designed include start codon signal sequence human tissue plasminogen activator tpa upstream transgene sequence replicationdefective adenoviruses serotype <NUMBER> generated inserting foreign sequences via homologous recombination subsequent purification recombinant adenovirus rad described previously <NUMBER> briefly shuttle vector plasmid electroporated electrocompetent bj<NUMBER> cells carrying padeasy<NUMBER> adenoviral genomic dna recombinant adenoviral dna isolated linearized paci subsequently transfected hek<NUMBER> cells generate radspike radrbd radntd viruses mock adenovirus radmock generated method using empty pshuttlecmv vector recombinant viruses amplified hek<NUMBER> cells purified doublecesium chloride cscl <NUMBER> gradient ultracentrifugation expression secretion spike rbd proteins radinfected hek<NUMBER> cells verified via western blot analysis employing antimerscov s<NUMBER> protein rabbit polyclonal antibody amino acids aa <NUMBER> <NUMBER>t<NUMBER> sino biological inc beijing china hrpconjugated goat antirabbit igg antibody abcam cambridge uk expression secretion ntd protein validated infecting hek<NUMBER> cells conducting western blot analysis using radspikeimmunized mouse serum <NUMBER> dilution hrpconjugated rabbit antimouse igg antibody abcam secondary antibody female balbc mice aged <NUMBER> weeks immunized rad vaccine control virus via intranasal intramuscular im sublingual sl routes immunization mice lightly anesthetized via isoflurane ifran hana pharm kyonggido korea inhalation <NUMBER> μl vaccine control virus solution inoculated left nostril im immunization <NUMBER> μl vaccine injected right hind leg mice sl immunization mice anesthetized intraperitoneal ip injection <NUMBER> mgkg body weight ketamine yuhan co seoul korea <NUMBER> mgkg body weight rompun bayer seoul korea mixture pbs subsequently <NUMBER> μl vaccine inoculated tongue blood collected retroorbital plexus using heparinized capillary tube blood samples centrifuged sera obtained stored −<NUMBER>˚c mice sacrificed <NUMBER> <NUMBER> <NUMBER> weeks undergoing last immunization tracheotomy performed bronchoalveolar lavage fluid balf collected washing lung airways <NUMBER> ml pbs balf centrifuged supernatant used measure secretory iga neutralizing antibody titers rntd protein prepared using bactobac baculovirus expression system invitrogen according manufacturers protocol ntd gene amplified pcr described cloned pfastbac<NUMBER> vector <NUMBER>terminal tpa protein secretion expression cassette inserted baculovirus genome within dh<NUMBER>bac invitrogen recombinant bacmidencoding ntd rbacntd plasmid transfected sf<NUMBER> cells using cellfectin transfection reagent invitrogen primary recombinant baculovirus harvested <NUMBER> days transfection amplified infecting new largescale sf<NUMBER> cell cultures obtain rntd protein final culture supernatants infected sf<NUMBER> cells collected loaded onto <NUMBER>ml histrap hp column ge healthcare binding buffer <NUMBER> mm kpo <NUMBER> <NUMBER> mm nacl <NUMBER> mm imidazole ph <NUMBER> column washed binding buffer eluted using elution buffer <NUMBER> mm kpo <NUMBER> <NUMBER> mm nacl <NUMBER> mm imidazole ph <NUMBER> removing impurities eluted target protein fractions pooled concentrated bufferexchanged pbs purified rntd protein concentration determined using nanodrop <NUMBER> spectrophotometer thermo fisher scientific antigenspecific igg iga antibody titers immunized mice determined direct enzymelinked immunosorbent assay elisa briefly <NUMBER>well plates nunc maxisorp thermo fisher scientific coated <NUMBER> ngwell s<NUMBER> aa <NUMBER> <NUMBER>v<NUMBER>b<NUMBER> s<NUMBER> aa <NUMBER> <NUMBER>v<NUMBER>b rbd aa <NUMBER> <NUMBER>v<NUMBER>b<NUMBER> sino biological inc rntd aa <NUMBER> merscov spike protein <NUMBER> μl pbs incubated overnight <NUMBER>˚c antigencoated well blocked pbs containing <NUMBER> nonfat milk <NUMBER> tween <NUMBER> <NUMBER> h room temperature rt subsequently serial dilutions sera balfs added well incubated <NUMBER> h rt washing pbs containing <NUMBER> tween <NUMBER> hrpconjugated rabbit antimouse igg abcam hrpconjugated goat antimouse iga zymed laboratories san francisco ca added secondary antibody incubated <NUMBER> h rt dark conditions plates washed reaction developed <NUMBER>tetramethylbenzidine tmb peroxidase substrate kpl gaithersburg md gradually reaction stopped <NUMBER> h <NUMBER> po <NUMBER> analyzed <NUMBER> nm wavelength using thermo multiskan ex vantaa finland gfpexpressing lentiviral transfer plasmid constructed using plenti<NUMBER> gateway vector kits invitrogen according manufacturers protocol fulllength merscov spike proteinexpressing envelope plasmid constructed inserting codonoptimized synthetic dna sequence genscript pcagg plasmid addgene wwwaddgeneorg produce merscov spike pseudotyped lentivirus <NUMBER>tn cells cotransfected packaging plasmids plp<NUMBER> plp<NUMBER> lentiviral transfer plasmid envelope plasmid pcaggmerscov spike using lipofectamine <NUMBER> transfection regent invitrogen overnight incubation transfection medium replaced fresh <NUMBER> dmem fortyeight hours later culture supernatants containing pseudovirus collected centrifuged remove debris passed <NUMBER>μm filter stored −<NUMBER>˚c huh <NUMBER> cells <NUMBER> cells per well plated <NUMBER>well plates day neutralization assay sera balfs heatinactivated <NUMBER>˚c <NUMBER> min merscov spike pseudovirus preincubated serially diluted sera balfs <NUMBER> h <NUMBER>˚c mixture added huh <NUMBER> cells overnight incubation cells changed fresh <NUMBER> dmem cultured another <NUMBER> h subsequently cells harvested trypsinedta analyzed using facscalibur flow cytometer bd biosciences san diego ca merscov pseudovirus transduction measured transduction nhne cells infected virus solution merscov <NUMBER> μlpbs <NUMBER> ml korea centers disease control prevention korea <NUMBER> day total rna isolated using trizol life technology seoul korea cdna synthesized <NUMBER> μg rna random hexamer primers moloney murine leukemia virus reverse transcriptase perkin elmer life sciences waltham usa roche applied science indianapolis usa amplification performed using taqman universal pcr master mix pe biosystems foster city ca usa according manufacturers protocol briefly amplification reactions total volume <NUMBER> μl contained <NUMBER> μl cdna reverse transcription mixture oligonucleotide primers final concentration <NUMBER> nm taqman hybridization probe <NUMBER> nm realtime pcr probes labeled <NUMBER> end carboxyfluorescein fam <NUMBER> end quencher carboxytetramethylrhodamine tamra quantify cellular viral level host gene expression cellular rna used generate cdna merscov mrna level monitored using quantitative pcr n<NUMBER> gene mers primers n<NUMBER> gene merscov purchased applied biosystems foster city ca usa realtime pcr performed using pe biosystems abi prism <NUMBER> sequence detection system thermocyling parameters follows <NUMBER>˚c <NUMBER> min <NUMBER>˚c <NUMBER> min <NUMBER> cycles <NUMBER>˚c <NUMBER> <NUMBER>˚c <NUMBER> min pcr assays quantitative utilized plasmids containing target gene sequences standards reactions performed triplicate realtime pcr data normalized level housekeeping gene glyceraldehyde phosphate dehydrogenase gapdh <NUMBER>×<NUMBER> <NUMBER> copies correct variations samples using syringe lungs perfused <NUMBER> ml pbs containing <NUMBER> uml heparin sigma st louis mo via right ventricle obtain singlecell suspensions tissues homogenized passed <NUMBER>μm cell strainers spl kyonggido korea mhc class tetramer analysis lymphocytes washed facs buffer <NUMBER> fbs <NUMBER> nan<NUMBER> pbs blocked purified rat antimouse cd<NUMBER>cd<NUMBER> bd pharmingen san diego ca <NUMBER> μgml streptavidin invitrogen cells stained anticd<NUMBER>a <NUMBER> anticd<NUMBER> im<NUMBER> biolegend san diego ca k s<NUMBER> kyysiiphsi tetramer <NUMBER> min <NUMBER>˚c dark conditions staining cells fixed facs lysing solution bd biosciences evaluate cytokineproducing cells intracellular staining performed lung lymphocytes resuspended iscoves modified dulbeccos medium imdm welgene supplemented <NUMBER> fbs stimulated <NUMBER> μm mers s<NUMBER> peptide kyysiiphsi <NUMBER> μgml mers s<NUMBER> protein aa <NUMBER> sino biological inc presence brefeldin ebioscience san diego ca recombinant human il<NUMBER> biolegend <NUMBER> h <NUMBER>˚c stimulation cells initially stained anticd<NUMBER>a lymphocytes isolated lung spleen described previously <NUMBER> subsequently cells stained anticd<NUMBER> <NUMBER> anticd<NUMBER> h<NUMBER>f<NUMBER> anticd<NUMBER> <NUMBER>e<NUMBER> biolegend k s<NUMBER> tetramer identify dead cells cells fixed subsequently stained dapi biolegend <NUMBER> min rt analysis flow cytometer data stained cells acquired using bd lsr fortessa bd biosciences analyzed using flowjo software treestar inc ashland data presented mean ± standard error mean sem n <NUMBER> statistical differences two means analyzed using twotailed students test comparisons multiple groups oneway analysis variance anova twoway anova along bonferroni posttest used appropriate statistical significance considered p values <NUMBER> designed generated three recombinant adenoviruses vaccine candidates containing codonoptimized fulllength spike rbd ntd region spike coding sequences fulllength spike <NUMBER> rbd <NUMBER> ntd <NUMBER> cloned shuttle vector control cytomegalovirus cmv promoter subsequently inserted adenovirus genome via homologous recombination construction schemes recombinant replicationdefective adenoviruses designated radspike radrbd rad ntd shown fig <NUMBER>a confirm transgene expression hek<NUMBER> cells infected radspike radrbd radntd western blotting performed western blot performed using merscov s<NUMBER>specific antibody revealed two prominent bands at<NUMBER> kda and<NUMBER> kda culture supernatant lysate radspikeinfected cells fig <NUMBER>b considered protein species higher molecular weight <NUMBER> kda glycosylated s<NUMBER>s<NUMBER> spike protein species lower molecular weight of<NUMBER> kda s<NUMBER> subunit spike protein cleaved host cell protease <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rbd domain detected single band molecular weight <NUMBER> kda lysate culture supernatant radrbdinfected cells fig <NUMBER>c molecular weight rbd increased slightly culture supernatant might due different patterns glycosylation culture supernatant lysate <NUMBER> single band of<NUMBER> kda observed culture supernatant radntdinfected hek<NUMBER> cells inhouse rad spikeimmunized mouse serum fig <NUMBER>d compare immunogenicity recombinant adenoviral vaccine candidates balbc mice immunized twice day <NUMBER> day <NUMBER> radntd radrbd radspike control adenovirus radmock via route mice sacrificed <NUMBER> days boost immunization analyze humoral cellular immune responses candidate vaccines induced significant s<NUMBER>specific systemic igg responses sera opposed negative control radmock vaccine fig <NUMBER>a notably radspikeimmunized group induced highest s<NUMBER>specific serum igg responses among three groups mucosal iga respiratory tract plays critical roles host defense respiratory virus infections <NUMBER> thus measured spikespecific mucosal iga antibody responses balfs s<NUMBER>specific iga detected vaccination groups control group fig <NUMBER>b among three vaccination groups radspike group elicited highest levels s<NUMBER>specific iga response radntd group showed higher titer shown radrbd group next examine ability candidate vaccines induce cellular immune responses mice sacrificed <NUMBER> days boost injection peak cd<NUMBER> tcell responses lung cells harvested lung lymphocytes stained k s<NUMBER> tetramer quantify spikespecific cd<NUMBER> cells previous studies reported cd<NUMBER> tcell responses merscov spike protein dominantly directed toward s<NUMBER> kyysiiphsi epitope <NUMBER> studies also screened epitopes rbd region measure antigenspecific cd<NUMBER> tcell responses frequency ifnγproducing cd<NUMBER> cells responding peptides seems either undetectable low <NUMBER> <NUMBER> therefore employed s<NUMBER> immunodominant epitope evaluate spikespecific cd<NUMBER> tcell responses significant percentages k s<NUMBER> tetramerpositive cd<NUMBER> cells detected lungs radntdor radspikeimmune mice lungs mice radmock radrbd group fig <NUMBER>c <NUMBER>d s<NUMBER>specific cd<NUMBER> cells observed radrbdimmunized mice rbd aa residues <NUMBER> <NUMBER> contain s<NUMBER> epitope assess levels effector cd<NUMBER> cd<NUMBER> cells secreting ifnγ lung lymphocytes stimulated s<NUMBER> peptide mers s<NUMBER> protein respectively ifnγproducing cd<NUMBER> cells also increased significantly radspike radntd groups ifnγproducing cd<NUMBER> cells increased significantly radspike group s<NUMBER> fig subsequently neutralizing activities immune sera balfs evaluated using merscov spike pseudotyped particles among candidate vaccine groups rad spikeimmune mice exhibited highest levels neutralizing antibody sera balfs followed mice radntd group fig <NUMBER>a<NUMBER>c however radrbd group exhibited significant difference neutralizing activity compared radmock control group confirm neutralizing activity radspikeinduced antibody authentic merscov infection human primary respiratory cells merscov preincubated immune sera radspike radmock group infection nhne cells subsequently viral replication levels measured quantitative rtpcr shown fig <NUMBER>d pretreatment radspikeimmune sera significantly inhibited merscov replication radmock sera taken together results demonstrate immunization radspike efficient eliciting neutralizing antibody responses serum balf tcell responses recent studies shown neutralizing antibodies could also directed nonrbds ntd besides rbd <NUMBER> <NUMBER> results also indicate ntd elicit neutralizing antibody responses immunization therefore investigated regional specificity neutralizing activities induced immunization rad vaccines first serum igg responses analyzed elisa using ntd rbd s<NUMBER> protein coating antigens rntd protein prepared purified using baculovirus expression system s<NUMBER> fig radntd radspike groups exhibited significantly higher levels ntdspecific serum igg control group significant difference ntdspecific serum igg levels radntd radspike groups fig <NUMBER>a rad rbd radspike groups exhibited significantly higher levels rbdspecific serum igg negative control group fig <NUMBER>b expected radspike group showed significantly higher s<NUMBER>specific serum igg responses control group fig <NUMBER>c investigate target domains mainly involved neutralization compared changes neutralizing activity sera collected radspike group using protein competitors sera diluted <NUMBER> preincubated <NUMBER> μg ntd rbd s<NUMBER> s<NUMBER> protein <NUMBER>˚c <NUMBER> h neutralization assay subsequently performed shown fig <NUMBER> shown fig <NUMBER>d neutralization activity immune sera significantly reduced preincubation ntd rbd s<NUMBER> protein competitors especially competition s<NUMBER> protein inhibited neutralizing activity by<NUMBER> ntd rbd competitors inhibited neutralization activity by<NUMBER> and<NUMBER> respectively contrast soluble s<NUMBER> protein competitor effect neutralization activity results demonstrate radspike induce neutralizing antibody responses targeting various regions s<NUMBER> including ntd rbd also suggests employing radspike might better vaccination strategy eliciting broader spectrum neutralizing antibody responses previously showed among vaccine candidates radspike possesses strongest immunogenicity inducing humoral cellular immune responses investigated best route immunization injecting mice radspike via im sl route sera collected <NUMBER> weeks immunization measured specific igg elisa significant spikespecific igg levels detected regardless immunization route fig <NUMBER>a notably immunization induced highest igg antibody responses among groups boost immunization significant spikespecific iga levels detected balfs mice sl groups im group fig <NUMBER>b response also highest group investigate whether immunization route affects neutralizing antibody responses neutralizing activity sera balfs collected group analyzed using pseudotyped virus immunization routes generated significant serumneutralizing antibody levels opposed radmock control group fig <NUMBER>a <NUMBER>b however neutralization activity observed balf mice immunized via im route finding consistent mucosal iga response shown fig <NUMBER> ic <NUMBER> neutralization titer show statistically significant differences sl immunization taken together results indicate mucosal immunization radspike vaccine induce systemic mucosal neutralizing antibodies im immunization could elicit systemic responses <NUMBER> <NUMBER> <NUMBER> investigate influence immunization route establishment lung rm cells balbc mice administered im vaccine containing radspike concentration <NUMBER>×<NUMBER> <NUMBER> pfus memory time point day <NUMBER> mice intravenously injected anticd<NUMBER>apc antibody sacrificed <NUMBER> min discriminate circulating cells lunglocalized cells <NUMBER> shown s<NUMBER> fig cells stained anticd<NUMBER> ab identified circulating cells blood cells protected vivo labeling confined lung parenchyma time point mice immunized via route significantly higher frequencies numbers k s<NUMBER> tetramerpositive cd<NUMBER> cells airway lung parenchyma compared imimmunized mice fig <NUMBER>a <NUMBER>b contrast significant differences numbers k s<NUMBER> tetramerpositive cd<NUMBER> cells lung vasculature spleen im immunization groups subsequently assessed coexpression cd<NUMBER> cd<NUMBER> canonical makers lung rm <NUMBER> majority k s<NUMBER> tetramerpositive cd<NUMBER> cells airway lung parenchyma inimmunized mice cd<NUMBER> cd<NUMBER> cd<NUMBER> frequencies significantly higher imimmunized mice fig <NUMBER>c <NUMBER>d taken together results show immunization efficient establishing antigenspecific cd<NUMBER> rm cells airway lung parenchyma im immunization persistence maintenance immune responses following vaccination important vaccine efficacy <NUMBER> thus assessed whether radspike immunization could induce long term antibody responses balbc mice inoculated three times weeks <NUMBER> <NUMBER> <NUMBER> <NUMBER>×<NUMBER> <NUMBER> pfus radspike via route sera collected <NUMBER> <NUMBER> <NUMBER> <NUMBER> weeks specific antibody responses subsequently measured elisa fig <NUMBER>a spikespecific serum igg mucosal iga titers gradually increased immunization maintained <NUMBER> weeks obvious decline fig <NUMBER>b <NUMBER>c evaluate neutralizing activities assay performed using sera collected <NUMBER> <NUMBER> weeks well balfs obtained <NUMBER> weeks agreement igg responses serum neutralizing activities <NUMBER> weeks similar <NUMBER> weeks fig <NUMBER>d absolute titer neutralization balf <NUMBER> weeks lower earlier time point shown fig <NUMBER> remained significant level comparison control fig <NUMBER>e overall results demonstrate immunization radspike could induce longlasting neutralizing antibodies might beneficial protection merscov infection since emergence spread mers development safe effective vaccines merscov urgently required <NUMBER> <NUMBER> merscov spike protein main mediator virus entry target cells <NUMBER> <NUMBER> therefore spike protein one key targets development vaccines therapeutics <NUMBER> several vaccine candidates targeting rbd spike protein investigated <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however seems efficacy rbdbased vaccine candidates limited confined breadth antibody responses subsequent emergence escape mutants <NUMBER> <NUMBER> <NUMBER> indeed shown several mutations rbd region result generation neutralization escape variants <NUMBER> <NUMBER> <NUMBER> <NUMBER> several studies reported regions spike protein rather rbd also targets neutralizing antibodies <NUMBER> <NUMBER> <NUMBER> <NUMBER> study constructed adenovirusbased vaccine candidates express ntd rbd fulllength spike compared immunogenicity neutralizing activity induced candidates results clearly showed radspike vaccine expressing fulllength spike protein best candidate terms immunogenicity neutralizing efficacy likely neutralizing epitopes spike protein located nonrbd s<NUMBER> subunit well rbd based results protein competitor experiments fig <NUMBER> use fulllength spike immunogen radspike vaccine might increase breadth antibody responses help reduce risk escape mutations <NUMBER> <NUMBER> <NUMBER> however yet clear whether s<NUMBER> region also contributes inducing neutralizing antibodies radspike vaccination s<NUMBER> subunit protein competitor reduce neutralizing activities immune sera protein competitor experiments fig <NUMBER> might due inappropriate conformation s<NUMBER> subunit <NUMBER> <NUMBER> studies needed determine whether s<NUMBER> subunit also contributes eliciting neutralizing antibodies noteworthy radspike vaccine induced systemic igg mucosal iga tcell responses together upon immunization addition neutralizing antibodies virusspecific cd<NUMBER> cells also play important role merscov clearance <NUMBER> indeed several studies suggest virusneutralizing antibodies cytotoxic cd<NUMBER> cell responses necessary complete protection merscov infection <NUMBER> <NUMBER> <NUMBER> therefore radspike vaccine expressing fulllength spike protein rather rbd ntd alone might potent one among vaccine candidates results also demonstrate immunization induces superior responses compared im sl immunization terms neutralizing efficacy merscov infection occurs respiratory tracts humans <NUMBER> <NUMBER> accordingly vaccination routes capable inducing local mucosal immunity secretory iga would potent preventing merscov infection addition immunization radspike vaccine induced significantly higher numbers specific rm cells airway lung parenchyma compared imimmunized mice fig <NUMBER> likely lungresident rm cells mediate effective protective immunity respiratory infections <NUMBER> <NUMBER> thus immunization radspike eliciting systemic igg secretory iga rm responses together might promising regimen compared immunization routes provide superior protection summary generated several recombinant adenovirusbased vaccine candidates merscov compared systemic local humoral responses cellular responses via different immunization routes found single immunization rad spike successfully induces systemic igg secretory iga lung rm responses provides longlasting neutralizing immunity therefore recombinant adenovirusbased vaccine onset symptoms may transmitted people without symptoms rapid development protective vaccine covid<NUMBER> therefore paramount importance demonstrate recombinantly expressed receptor binding domain rbd spike protein homologous sars binds ace<NUMBER> viral receptor higly repetitive display rbd immunologically optimized viruslike particles derived cucumber mosaic virus resulted vaccine candidate rbdcumvtt induced high levels specific antibodies mice able block binding spike protein ace<NUMBER> potently neutralized sarscov<NUMBER> virus vitro covid<NUMBER> caused novel coronavirus closely related viruses causing sars mers disease caused two viruses covid<NUMBER> mainly manifests symptoms lung causes cough fever <NUMBER> disease covid<NUMBER> less severe sars mers beneficial per se leads easier wider spread virus particular due infected individuals little symptoms spreaders long incubation time <NUMBER> weeks combined viral shedding long disease onset <NUMBER> vaccine rapid onset protection therefore high demand control pandemic currently taking course spike protein covid<NUMBER> highly homologous spike protein sars viruses share receptor angiotensin converting enzyme <NUMBER> ace<NUMBER> <NUMBER> <NUMBER> receptor binding domain rbd sars spike protein binds ace<NUMBER> important target neutralizing antibodies <NUMBER> <NUMBER> <NUMBER> analogy rbd covid<NUMBER> spike protein may expected similarly target neutralizing antibodies blocking interaction virus receptor previously shown antigens displayed viruslike particles vlp induce high levels antibodies species tested including humans <NUMBER> recently developed immunologically optimized vlp platform based cucumber mosaic virus cumvtt vlps hereafter cumvtt incorporate universal cell epitope derived tetanus toxin providing preexisting cell help addition production process vlps package bacterial rna ligand tolllike receptor <NUMBER> serves potent adjuvants <NUMBER> using antigens displayed vlps <NUMBER> possible induce high levels specific antibodies mice rats cats dogs horses treat diseases atopic dermatitis dogs insect bite hypersensitivity horses <NUMBER> <NUMBER> <NUMBER> generate covid<NUMBER> vaccine candidate therefore attempted display rbd domain cumvtt fig <NUMBER>a end genesynthesized covid<NUMBER> rbd domain fused fc molecule better expression expected protein bound efficiently viral receptor ace<NUMBER> determined sandwich elisa fig <NUMBER>b next step protein chemically coupled surface cumvtt using well established chemical crosslinkers sata smph ref <NUMBER> sdspage western blotting confirmed efficient coupling rbdfusion molecule cumvtt resulting vaccine candidate rbdcumvtt fig <NUMBER>cd test immunogenicity vaccine candidate mice immunized three times weekly schedule rbdfusion molecule alone conjugated surface cumvtt formulated montanide adjuvants shown fig <NUMBER>a c coupling vlps dramatically increased immunogenicity rbd shown elisa recombinant rbd rbdcumvtt showed strongly increased immunogenicity timepoints tested one week vaccine injection timepoints assess potential antiviral activity assessed whether induced antibodies able block binding rbd protein viral receptor ace<NUMBER> shown fig <NUMBER> immune sera obtained two boosts day <NUMBER> able strongly inhibit rbd binding ace<NUMBER> best correlate protection viral neutralization end generated pseudotyped retroviruses <NUMBER> expressing sarscov<NUMBER> spike protein luciferase quantification infection fig <NUMBER>a using viruses neutralizing capacity sera immunized mice assessed ace<NUMBER>transfected cells fig <NUMBER>b directly demonstrating high antiviral neutralizing activity induced antibodies hence rbdcumvtt vaccine candidate able induce high levels sarscov<NUMBER> neutralizing antibodies furthermore cumvtt based vaccine based highly efficient expression systems chemical conjugation technologies rendering attractive candidate large scale production cgmp previous studies similar vlpbased conjugate vaccine demonstrated high levels specific antibodies mounted within week <NUMBER> <NUMBER> see also fig <NUMBER>a offering additional possibilities rapidly immunize individuals exposed infected humans kept quarantine thus vaccines based sarscov<NUMBER> rbd domain displayed vlps may potential critically interfere global spread virus <NUMBER> sarscov<NUMBER> receptorbinding domain rbd nterminal peptidase domain human ace<NUMBER> expressed using <NUMBER>f cells invitrogen sarscov<NUMBER> rbd residues arg<NUMBER>phe<NUMBER> nterminal il<NUMBER> signal peptide secretion cterminal fc tag purification inserted pfusemigg<NUMBER>fc<NUMBER> vector invitrogen construct transformed bacterial dh<NUMBER>α competent cells extracted plasmid transfected <NUMBER>f cells density <NUMBER>×<NUMBER> <NUMBER> cellsml using pei invitrogen cell culture supernatant containing secreted rbd harvested <NUMBER> h infection concentrated bufferexchanged hbs <NUMBER> mm hepes ph <NUMBER> <NUMBER> mm nacl rbd captured protein resin ge healthcare eluted glyhcl buffer ph <NUMBER> fractions containing rbd collected neutralized ph <NUMBER> <NUMBER>m tris elisa coating ace<NUMBER> cleaved fc part using thrombin described manufacturers manual human ace<NUMBER> residues ser<NUMBER>ser<NUMBER> nterminal il<NUMBER> signal peptide secretion cterminal <NUMBER>×his tag purification inserted pfusevector invitrogen human ace<NUMBER> expressed essentially protocol used sarscov<NUMBER> rbd ace<NUMBER> captured ninta resin ge healthcare eluted <NUMBER> mm imidazole hbs buffer rbd purified gel filtration chromatography using superdex <NUMBER> column ge healthcare preequilibrated hbs buffer fractions containing ace<NUMBER> collected antibody competitive binding activities serum assayed elisa ace<NUMBER> <NUMBER>ugml incubated <NUMBER>well plate overnight <NUMBER>°c incubation plate blocked <NUMBER> bsa <NUMBER>h <NUMBER>°c washed five times pbs containing <NUMBER> tween <NUMBER> bsa used negative control followed addition mixture <NUMBER>fold diluted serum rbdmfc <NUMBER>ugml followed incubation <NUMBER> min gentle shaking <NUMBER>°c plates washed five times pbs containing <NUMBER> tween <NUMBER> pbt followed <NUMBER> µl horseradish peroxidaseantimfc antibody conjugate diluted <NUMBER> pbt buffer incubated <NUMBER> min gentle shaking plates washed five times pbt buffer developed <NUMBER> µl freshly prepared <NUMBER>tetramethylbenzidine tmb substrate reaction stopped <NUMBER> µl <NUMBER> h<NUMBER>po<NUMBER> read spectrophotometrically <NUMBER> nm microtiter plate reader <NUMBER> production cumvtt described detail zeltins et al <NUMBER> briefly e coli c<NUMBER> cells rbd conjugated cumvtt using crosslinker succinimidyl <NUMBER>betamaleimidopropionamido hexanoate smph thermo fisher scientific <NUMBER>molar excess <NUMBER> minutes <NUMBER>°c coupling reactions performed <NUMBER>x molar excess rbd <NUMBER>x rbd equal molar amount rbd regarding cumvtt shaking <NUMBER>°c <NUMBER> hours <NUMBER> rpm dsg titertek flow laboratories irvine united kingdom unreacted smph rbd proteins removed using amiconultra <NUMBER> <NUMBER>k merckmillipore burlington mass vlp samples centrifuged <NUMBER> minutes <NUMBER> rpm measurement nd<NUMBER> coupling efficiency calculated densitometry previously described il<NUMBER>acumvtt vaccine <NUMBER> result approximately <NUMBER> <NUMBER> pseudovirus expressing sarscov<NUMBER> spike protein produced lentivirus second <NUMBER>tace<NUMBER> cells stably express ace<NUMBER> receptors cell membrane prepared transfection ace<NUMBER> gene <NUMBER>t cells using lentivirus system pseudoviruses prepared added <NUMBER>tace<NUMBER> cells <NUMBER> × <NUMBER> <NUMBER> cellswell <NUMBER> μl polybrene <NUMBER>μgml <NUMBER> h infection monitored using luciferase assay system promega titer calculated based serial dilutions pseudovirus mouse serum samples <NUMBER> μl diluted <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively mixed equal volume pseudovirus stock incubation <NUMBER>°c <NUMBER> h mixture inoculated <NUMBER>tace<NUMBER> cells <NUMBER> x <NUMBER> <NUMBER> cellswell time pseudovirusdmem medium set positive control dmem medium set negative control cells incubated <NUMBER> hours serum neutralization measured luciferase activity infected pseudovirus cutoff <NUMBER> used determine neutralizing titer viral respiratory infections influenza measles cause severe acute respiratory symptoms responsible many epidemics spring <NUMBER> outbreak severe acute respiratory infection sari spread globally <NUMBER> <NUMBER> <NUMBER> world health organization coined acronym sars severe acute respiratory syndrome sari subsequently named causative coronavirus sarscov summer <NUMBER> another sari broke saudi arabia found caused new coronavirus named respiratory disease middle east respiratory syndrome also known acronym mers called causative coronavirus merscov winter <NUMBER> another sari outbreak occurred wuhan china quickly spread around world culprit identified another novel coronavirus named sarscov<NUMBER> due similarities sarscov disease called coronavirus disease <NUMBER> sarscov<NUMBER> newly emergent coronavirus closely related sars mers <NUMBER> covid<NUMBER> respiratory tract infection causes mild symptoms majority cases also lead issn <NUMBER> review coronavirus disease <NUMBER> latest developments potential treatments drugsincontextcom mortality morbidity current reports suggest covid<NUMBER> causes milder symptoms children including fever cough coinfection also observed <NUMBER> <NUMBER> however covid<NUMBER> associated severe outcomes older population immunocompromised patients chronic cardiovascular respiratory conditions <NUMBER> present pharmaceutical products shown reliable safe effective treating covid<NUMBER> <NUMBER> midst current global pandemic many research groups around world actively developing treatments disease reduce morbidities mortalities long term goal develop vaccine prevent infections future outbreaks however effective vaccine may take years develop manufacture global scale furthermore unknown newborns patients already recovered covid<NUMBER> need vaccinated also uncertain vaccine protect individuals novel coronavirus future narrative review summarise latest body evidence ongoing research development pharmacological therapies covid<NUMBER> aim also review suggested pathophysiology prophylactic treatments therapeutic modalities covid<NUMBER> articles retrieved using pubmed clinical queries search term coronavirus covid<NUMBER> regardless date publication <NUMBER> articles clinical study categories category therapy scope broad <NUMBER> systematic reviews discussion based limited search results severe acute respiratory syndrome viral respiratory disease zoonotic origin caused sarscov sars outbreak november <NUMBER> july <NUMBER> resulted <NUMBER> cases <NUMBER> deaths <NUMBER> countries around world giving casefatality rate <NUMBER> <NUMBER> <NUMBER> treatments sars outbreak mainly supportive known effective antiviral agents use broadspectrum antibiotics treat secondary bacterial infections main treatment regimen <NUMBER> ribavirin broadspectrum purine nucleoside analogue empirically used broadspectrum antiviral agent <NUMBER> human immunodeficiency virus hiv protease inhibitor lopinavirritonavir also used found weak vitro antiviral activity prototype sarscov <NUMBER> <NUMBER> therapies included immunomodulators eg corticosteroid convalescent plasma pentaglobulin interferons traditional chinese medicine tcm <NUMBER> <NUMBER> development vaccines underway end epidemic effective vaccine since emerged middle east respiratory syndrome caused merscov may transmitted humans infected camels mers outbreak september <NUMBER> january <NUMBER> reported caused <NUMBER> laboratoryconfirmed cases <NUMBER> associated deaths globally giving casefatality rate <NUMBER> <NUMBER> <NUMBER> still effective vaccine treatment disease although number antiviral medications investigated <NUMBER> <NUMBER> systematic review therapeutic agents merscov showed still general consensus optimal treatment strategy merscov infection <NUMBER> miracle trial merscov infection treated combination lopinavir ritonavir interferonβ<NUMBER>b first randomised controlled trial assess feasibility efficacy safety combination lopinavirritonavir interferonβ<NUMBER>b hospitalised patients mers <NUMBER> <NUMBER> trial started july <NUMBER> enrolled <NUMBER> participants although results yet published <NUMBER> sarscov mers sarscov<NUMBER> zoonotic βcoronaviruses crossed animals humans <NUMBER> origin sarscov still mystery remains controversial topic sarscov closely related civet bat covs phylogenetically divergent coronaviruses associated human infections including issn <NUMBER> review coronavirus disease <NUMBER> covid<NUMBER> latest developments potential treatments drugsincontextcom oc<NUMBER> nl<NUMBER> <NUMBER>e hku<NUMBER> <NUMBER> fulllength genome sequence sarscov<NUMBER> shows similar sarscov sharing <NUMBER> sequence identity <NUMBER> sarscov<NUMBER> sarscov use cellular receptor angiotensinconverting enzyme ii ace<NUMBER> receptor enter host cells <NUMBER> pathophysiology covid<NUMBER> yet confirmed likely involve inflammatory processes trigger massive cytokine storm cytokine profile critically ill patients revealed increased levels interleukin il<NUMBER> il<NUMBER> il<NUMBER> granulocytecolony stimulating factor interferonγ inducible protein <NUMBER> monocyte chemoattractant protein <NUMBER> macrophage inflammatory protein <NUMBER>α tumour necrosis factorα <NUMBER> histopathological examination lungs patients covid<NUMBER> revealed immunopathological changes including diffuse alveolar damage desquamation pneumocytes pulmonary oedema hyaline membrane formation interstitial mononuclear inflammatory infiltrates <NUMBER> according limited number reports biopsyautopsy results patients covid<NUMBER> pathological features resemble seen sars mers virus infections <NUMBER> <NUMBER> <NUMBER> similarities sarscov sarscov<NUMBER> suggest development potential prophylactics therapeutics covid<NUMBER> could based research sars <NUMBER> important strategy would possibly control viral replication using effective antiviral agent minimise subsequent inflammation tissue damage due high viral loads immunomodulators could play rescue therapy role pathological findings suggest immunopathological damage <NUMBER> <NUMBER> although sarscov<NUMBER> protein receptorbinding domain higher affinity sarscov protein receptorbinding domain development vaccines sarscov<NUMBER> could still based research sarscov <NUMBER> <NUMBER> <NUMBER> therapeutics covid<NUMBER> majority covid<NUMBER> patients especially children either asymptomatic mild symptoms likely recover managing symptoms without need hospitalisation <NUMBER> <NUMBER> also launched solidarity international clinical trial investigating effective treatments currently comparing four promising treatment options remdesivir lopinavirritonavir lopinavirritonavir plus interferon β<NUMBER>a hydroxychloroquine <NUMBER> <NUMBER> countries joined solidarity international clinical trial <NUMBER> following discussion summarise latest evidence research progress literature focus pharmacological therapies table <NUMBER> empirical antimicrobials started within <NUMBER> hour detection sepsis based clinical diagnosis local epidemiology <NUMBER> critically ill covid<NUMBER> patients intensive care treatment include oxygen therapy noninvasive mechanical ventilation invasive mechanical ventilation extracorporeal membrane oxygenation <NUMBER> addition standard management acute respiratory distress syndrome literature also suggests lower intubation threshold early prone positioning cautious fluid status management considering incidence myocardial dysfunction covid<NUMBER> patients high <NUMBER> discussion intensive care management covid<NUMBER> patients beyond scope review remdesivir remdesivir gs<NUMBER> nucleoside analogue prodrug inhibits viral rna polymerases developed gilead science response ebola outbreak <NUMBER> <NUMBER> <NUMBER> <NUMBER> considered one promising broadspectrum antivirals treating covid<NUMBER> vitro antiviral activities remdesivir demonstrated sarscov merscov sarscov<NUMBER> <NUMBER> <NUMBER> early april preliminary report describing clinical outcomes cohort <NUMBER> hospitalised covid<NUMBER> patients received remdesivir <NUMBER> patients showed improvement oxygensupport status <NUMBER> patients reported adverse events followup <NUMBER> subsequently doubleblinded randomised controlled trial <NUMBER> adult patients severe covid<NUMBER> showed remdesivir associated statistically significant clinical benefits whilst adverse events reported <NUMBER> patients <NUMBER> separately results interim analysis adaptive covid<NUMBER> treatment trial involving <NUMBER> patients encouraging indicated patients received redmesivir <NUMBER> faster time recovery received placebo median time recovery <NUMBER> versus <NUMBER> days <NUMBER> recently phase <NUMBER> simple clinical trial demonstrated patients receiving <NUMBER>day <NUMBER>day treatment course remdesivir achieved similar improvements clinical status <NUMBER> reported preliminary studies included elevated hepatic enzymes diarrhoea constipation hypoalbuminaemia rash renal impairment anaemia thrombocytopenia hypotension <NUMBER> <NUMBER> potential drugdrug interactions medications metabolised cytochrome p<NUMBER> system also reported safety profile drug needs evaluated randomised controlled trials remdesivir still ongoing two studies phase iii clinical trials evaluate safety efficacy remdesivir <NUMBER> <NUMBER> <NUMBER> <NUMBER> lopinavirritonavir lopinavirritonavir combination therapy used treat hiv ritonavir inhibitor cytochrome p<NUMBER> used increase plasma halflife lopinavir <NUMBER> lopinavir protease inhibitor demonstrated antiviral effects sars merscov sarscov<NUMBER> vitro <NUMBER> <NUMBER> several trials investigating efficacy lopinavirritonavir compared drugs treatment covid<NUMBER> <NUMBER> nevertheless results far indicate lopinavirritonavir treatment little benefit standalone therapy sarscov<NUMBER> infection clinical trial involving <NUMBER> patients laboratoryconfirmed sarscov<NUMBER> infection lopinavirritonavir treatment associated clinical improvements compared standard care <NUMBER> furthermore lopinavirritonavir treatment caused gastrointestinal adverse events nearly <NUMBER> recipients could complete full <NUMBER>day course treatment <NUMBER> adverse effects included gastrointestinal intolerance hepatotoxicity pancreatitis qt prolongation use ritonavir cause severe drugdrug interactions medications metabolised cytochrome system tolerance side effects might limit dosage needed concentration necessary inhibit viral replication relatively high <NUMBER> clinical trials testing lopinavirritonavir combined different drugs different combinations ritonavir interferon <NUMBER>b <NUMBER> <NUMBER> early use lopinavirritonavir additional treatment ritonavirmethylprednisolone sarscov associated reduction overall death rate intubation rate compared matched cohort <NUMBER> clinical phase ii trial investigating use lopinavirritonavir combined interferon β<NUMBER>b treatment mers since <NUMBER> trial ongoing results yet published <NUMBER> ribavirin ribavirin guanosine analogue interferes replication rna dna viruses <NUMBER> vitro antiviral activities ribavirin demonstrated sarscov merscov <NUMBER> <NUMBER> experiences sarscov use ribavirin monotherapy limited required high concentration inhibit viral replication ribavirin usage associated dosedependent haemolysis liver toxicity <NUMBER> <NUMBER> treatment sars mers ribavirin used combination interferon lopinavirritonavir <NUMBER> <NUMBER> use ribavirin combination interferon lopinavir ritonavir recommended latest chinese national treatment guidelines covid<NUMBER> <NUMBER> recent multicentre randomised phase <NUMBER> trial showed triple antiviral therapy lopinavirritonavir ribavirin interferon β<NUMBER>b superior lopinavirritonavir alone alleviating symptoms shortening duration viral shedding hospital stay patients mildtomoderate covid <NUMBER> <NUMBER> chloroquine hydroxychloroquine chloroquine hydroxychloroquine widely used treatment malaria certain autoimmune diseases drugs established safety profile readily available relatively low cost hydroxychloroquine sulphate demonstrated less toxic chloroquine phosphate animal studies <NUMBER> drugs reported antiviral effects sarscov sarscov<NUMBER> vitro potential mechanisms action include blocking viral entry cells inhibiting glycosylation host receptors reducing viral replication blocking export newly constructed virions <NUMBER> <NUMBER> trial china involving <NUMBER> patients covid<NUMBER> showed chloroquine better able inhibit exacerbation pneumonia improve lung imaging findings compared control treatment <NUMBER> recent small openlabel nonrandomised clinical trial showed patients given daily hydroxychloroquine significantly reduced viral load measured nasopharyngeal swab day <NUMBER> <NUMBER> however results study may confounded factors patients also received azithromycin <NUMBER> combination hydroxychloroquine azithromycin used caution patients risk qt prolongation use chloroquine alone also risk factor qt prolongation phase iib clinical trial assessing safety efficacy highdose chloroquine terminated early due prolonged qtc <NUMBER> ms high lethality highdose group compared lowdose group <NUMBER> recent analysis multinational registry <NUMBER> hospitalised covid<NUMBER> patients revealed hydroxychloroquine chloroquine associated decreased inhospital survival mortality <NUMBER> versus <NUMBER> increased frequency ventricular arrhythmia <NUMBER> however concerns raised veracity data analyses study led retraction article <NUMBER> adverse effects chloroquine include retinopathy rash nausea glucose fluctuation diarrhoea use chloroquine contraindicated patients porphyria chloroquine hydroxychloroquine used treat covid<NUMBER> tested clinical trials determine optimal dosage balance efficacy safety chloroquine hydroxychloroquine suggested candidate prophylactics covid<NUMBER> populations high risk covid<NUMBER> infections italy new york <NUMBER> antiviral treatments antiviral treatments covid<NUMBER> currently undergoing clinical trials include protease inhibitors nelfinavir camostat mesilate ritonavir danoprevir darunavir flavopiridol relacatib nucleoside analogues galidesivir fusion inhibitors umifenovir rna polymerase inhibitors favipiravir neuraminidase inhibitors oseltamivir <NUMBER> corticosteroids corticosteroid therapies intravenous methylprednisolone currently tested treatment covid<NUMBER> <NUMBER> methylprednisolone already used covid<NUMBER> patients combination antibiotics oseltamivir oxygen therapy <NUMBER> long colleagues reported corticosteroid therapy using methylprednisolone dexamethasone hydrocortisone beneficial treating issn <NUMBER> review coronavirus disease <NUMBER> covid<NUMBER> latest developments potential treatments drugsincontextcom sarscov patients <NUMBER> significantly prolonged survival time clinical cases <NUMBER> however studies reported use corticosteroids early stages sars infection increased viral load <NUMBER> furthermore studies use corticosteroids adjuvant therapy merscov infection unable prove efficacy patients died <NUMBER> based recommendation frontline chinese physicians local clinical experience sars epidemic short course corticosteroids lowtomoderate dose probably justifiable critically ill patients <NUMBER> <NUMBER> corticosteroids effective treating autoinflammatory cytokine activation syndrome reported side effects osteonecrosis concerning data still conflicting recent recommendations use corticosteroids based circumstantial evidence routine use corticosteroids recommended corticosteroids may prolong worsen disease found prolong viral shedding mers sars based current body evidence corticosteroids may justified certain medical indications ie acute respiratory distress syndrome sepsis discretion physician charge convalescent plasma might promising postexposure prophylaxis covid<NUMBER> potential treatment infection also used salvage therapy sars mers epidemics <NUMBER> <NUMBER> <NUMBER> considering huge number people exposed covid<NUMBER> use convalescent plasma postexposure prophylaxis may justifiable could still treatment option observational study sars epidemic showed lower mortality rate receiving convalescent plasma treatment sars <NUMBER> studies clinical effects outcomes critically ill covid<NUMBER> patients treated convalescent plasma far shown encouraging results although noted studies based small case series <NUMBER> <NUMBER> furthermore studies use convalescent plasma sars patients report significant side effects <NUMBER> <NUMBER> randomised trials convalescent plasma therapy still needed eliminate effects treatments investigate safety efficacy optimal timing administration highly purified preparations neutralising antibodies sarscov<NUMBER> would preferable would safer higher activity might technically difficult mass produce <NUMBER> several pharmaceutical companies starting develop hyperimmune immunoglobulins covid<NUMBER> <NUMBER> <NUMBER> monoclonal antibodies use tocilizumab monoclonal antibody il<NUMBER> recently suggested treatment covid<NUMBER> patients risk cytokine storms <NUMBER> tocilizumab il<NUMBER> inhibitor may effective treating covid<NUMBER> <NUMBER> level il<NUMBER> found correlated severity covid<NUMBER> levels creactive protein lactate dehydrogenase ddimer cells <NUMBER> retrospective study <NUMBER> covid<NUMBER> patients receiving tocilizumab found <NUMBER> decreased oxygen requirement <NUMBER> according diagnosis treatment protocol china national health commission state administration traditional chinese medicine tocilizumab used patients extensive pulmonary lesions patients increased il<NUMBER> levels <NUMBER> clinical trials efficacy intravenous tocilizumab treatment covid<NUMBER> ongoing <NUMBER> <NUMBER> however serious adverse effects reported including gastrointestinal perforation anaemia hepatitis infusion reaction tcm employs phytotherapeutic formulations cultural concepts originated <NUMBER> years ago <NUMBER> use tcm coadjuvant therapy early stage sars infection epidemic reported increase oxyhaemoglobin arterial saturation <NUMBER> cochrane review found chinese herbs combined western medicines sars patients could improve symptoms quality life absorption pulmonary infiltration well decrease corticosteroid usage <NUMBER> specific components glycyrrhizin baicalin mol<NUMBER> shown antisars activities vitro <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> patients china received tcm reviewed yang colleagues <NUMBER> use tcm included chinese national treatment guidelines covid<NUMBER> patients recommended different stages severity disease table <NUMBER> <NUMBER> however effectiveness tcm treating covid<NUMBER> patients still remains unclear welldesigned largescale randomised doubleblinded placebocontrolled studies necessary confirm efficacy tcm making recommendations use management patients covid<NUMBER> complementary therapies high doses vitamins acupuncture exercise suggested promote health however reports specific targeted effects coronaviruses randomised trials complementary therapies treatments covid<NUMBER> several case series reported combination therapy could effective treating patients covid<NUMBER> patients <NUMBER> singlecentre case series <NUMBER> hospitalised patients covid<NUMBER> <NUMBER> nonicu <NUMBER> icu patients treated combination therapy moxifloxacin lopinavir interferon methylprednisolone given icu patients showed good treatment effects mortality rate less <NUMBER> <NUMBER> <NUMBER> another study <NUMBER> covid<NUMBER> patients <NUMBER> <NUMBER> patients treated combination traditional chinese medicine interferona<NUMBER>b lopinavir ritonavir shortterm cold dampness stagnation lung syndrome raw ephedra <NUMBER> g raw gypsum <NUMBER> g almond <NUMBER> g loquat <NUMBER> g gardenia <NUMBER> g guanzhong <NUMBER> g dilong <NUMBER> g xu changqing <NUMBER> g huoxiang <NUMBER> g peilan <NUMBER> g cangzhu <NUMBER> g yunling <NUMBER> g atractylodes <NUMBER> g jiao sanxian <NUMBER> g magnolia officinalis <NUMBER> g betel coconut <NUMBER> g yarrow fruit <NUMBER> g ginger <NUMBER> g betel nut <NUMBER> g apple <NUMBER> g magnolia <NUMBER> g zhimu <NUMBER> g scutellaria baicalensis <NUMBER> g bupleurum <NUMBER> g red peony <NUMBER> g forsythia <NUMBER> g artemisia annua <NUMBER> g decocted later green leaves <NUMBER> g raw licorice <NUMBER> g dampness stagnation lung syndrome raw ephedra <NUMBER> g bitter almond <NUMBER> g raw gypsum <NUMBER> g raw coix seed <NUMBER> g grass root <NUMBER> g patchouli <NUMBER> g artemisia annua <NUMBER> g polygonum cuspidatum <NUMBER> g verbena <NUMBER> g dried reed root <NUMBER> g gardenia <NUMBER> g orange red <NUMBER> g raw licorice <NUMBER> g cold dampness lung syndrome atractylodes lancea <NUMBER> g chenpi <NUMBER> g magnolia <NUMBER> g aquilegia <NUMBER> g grass fruit <NUMBER> g raw ephedra <NUMBER> g zhihuo <NUMBER> g ginger <NUMBER> g betel nut <NUMBER> g plague poison lungclosing syndrome raw ephedra <NUMBER> g almond <NUMBER> g raw gypsum <NUMBER> g licorice <NUMBER> g fragrant fragrant <NUMBER> g back magnolia <NUMBER> g atractylodes <NUMBER> g grass fruit <NUMBER> g pinellia <NUMBER> g poria <NUMBER> g raw rhubarb <NUMBER> g back mongolian milkvetch root <NUMBER> g gardenia <NUMBER> g red peony <NUMBER> g gypsum fried first <NUMBER> g zhimu <NUMBER> g raw land <NUMBER> g buffalo horn fried first <NUMBER> g red sage <NUMBER> g black ginseng <NUMBER> g forsythia <NUMBER> g paeonia <NUMBER> g chinese goldthread rhizome <NUMBER> g peony <NUMBER> g gardenia <NUMBER> g raw licorice <NUMBER> g coronaviruses similar nature defined clinical presentations lower prevalence coronavirus diseases children might accounted lower exposure relatively mild clinical presentation paediatric population many mild asymptomatic cases often overlooked therefore go undiagnosed comparing immunopathology sarscov<NUMBER> infection children adults could reveal pathology disease might lead possible treatment strategies recurrent novel coronavirus infections currently approved antiviral treatment patients suspected confirmed covid<NUMBER> research sars mers epidemics data vitro studies show antiviral therapy may beneficial antiviral therapies adjunctive treatments therefore considered covid<NUMBER> patients unstable clinical condition clinical deterioration patients comorbidities covid<NUMBER> situation develops learn safety efficacy specific treatments treatment recommendations likely change reflect latest evidence time writing urgent issue curtail spread covid<NUMBER> vaccines could answer crisis vaccines likely many months away take time scaleup manufacture global scale meantime public health officials focusing nonpharmaceutical interventions measures personal hygiene wearing masks general population social distancing surveillance programs testing suspected cases lung spleen qi deficiency syndrome french pinellia <NUMBER> g chenpi <NUMBER> g codonopsis <NUMBER> g sunburn astragalus <NUMBER> g stirfried atractylodes <NUMBER> g poria <NUMBER> g huoxiang <NUMBER> g amomum villosum <NUMBER> g licorice <NUMBER> g qi yin deficiency syndrome north south radix salviae <NUMBER> g ophiopogonis <NUMBER> g american ginseng <NUMBER> g schisandra <NUMBER> g gypsum <NUMBER> g light bamboo leaves <NUMBER> g mulberry leaves <NUMBER> g reed root <NUMBER> g salviae miltiorrhiza <NUMBER> g raw liquorice <NUMBER> g one patient died <NUMBER> case report <NUMBER>yearold woman covid<NUMBER> treated thalidomide <NUMBER> mg orally day methylprednisolone <NUMBER> mg intravenously bid <NUMBER> days reduced day <NUMBER> days overall improved status increased oxygen index decreased symptoms nausea vomiting lower cytokine levels <NUMBER> however cannot draw definitive conclusions single case report control although sarscov<NUMBER> third reemergence coronavirus past two decades abruptly put halt social economic activity around world consequences immeasurable <NUMBER> pandemic undoubtedly change daily habits social routines serve huge wakeup call shown vulnerability human race global battle covid<NUMBER> continues together inevitably defeat coronavirus hard lessons learned better prepare us next pandemic early quarantine vigilant contact tracing preventing healthcarerelated transmission key factors stopping covid<NUMBER> pandemic <NUMBER> although safe effective treatment yet found sheer number clinical trials started since beginning epidemic nothing short impressive combining advanced technologies field genomics computer science potential treatments could identified machine learning complex molecular dynamics artificial intelligence joint efforts research communities around world hopeful effective treatment vaccine covid<NUMBER> developed near future <NUMBER> pandemic also raise awareness governments pharmaceutical companies contributions authors contributed equally preparation review named authors meet international committee medical journal editors icmje criteria authorship article take responsibility integrity work whole given approval version published authors declare conflicts interest international committee medical journal editors icmje potential conflicts interests form authors available download httpswwwdrugsincontextcomwpcontentuploads<NUMBER>dic<NUMBER>coipdf since outbreak severe acute respiratory syndrome coronavirus sarscov <NUMBER> emergence expansion endemic epidemic coronaviruses accelerating scale seen group viruses pandemic potential past two decades alone five new human coronaviruses discovered three highly pathogenic <NUMBER> <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> pandemic latest example danger posed zoonotic diseases foreshadowed regional unabated emergence middle east respiratory syndrome corona virus merscov <NUMBER> recognition intrinsic threat public health prototypical member family coronaviridae <NUMBER> prioritised merscov pathogen increased resources dedicated countermeasure research development newly established coalition epidemic preparedness innovations followed suit investments development candidate merscov vaccines <NUMBER> subsequent years three vaccine candidates completed initial clinical evaluation ready advanced testing <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> lancet infectious diseases two groups <NUMBER> report results phase <NUMBER> clinical trials nonreplicating viral vector merscov vaccines pedro folegatti colleagues <NUMBER> summarise safety immunogenicity chimpanzee adenovirusvectored vaccine chadox<NUMBER> mers till koch colleagues <NUMBER> poxvirusvectored vaccine mvamerss two vaccines demonstrated tolerable safety profiles vaccinerelated serious adverse events reported either vaccine induced humoral cellular immune responses peak postvaccination timepoints chadox<NUMBER> mers administered single injection whereas mvamerss given twodose regimen <NUMBER>day interval doses products tested doseescalating design although frequency severity adverse events proportional vaccine dose studies higher doses chadox<NUMBER> mers improved immunogenicity single dose chadox<NUMBER> mers also showed earlier ascent slower decay antibodymediated cellmediated immunity although question applicable many viruses answer question elusive among coronaviruses <NUMBER> <NUMBER> without previous identification potential correlate protection becomes difficult ascertain relevance immunogenicity outputs second remains lack consensus methodology immunogenicity outputs measured <NUMBER> although two trials report similar assessments humoral responsesbinding antibody wildtype mers virus pseudovirus neutralisation assaysit difficult know individual results compare studies koch colleagues <NUMBER> found strong correlation binding neutralising antibody titres spearmans correlation r<NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> whereas folegatti colleagues <NUMBER> spearmans r<NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> represent immunologically relevant difference vaccineinduced responses methodological difference laboratories finally animal studies suggest certain sarscov merscov vaccines might upon viral challenge associated eosinophilic pulmonary infiltrates finding underscores importance factoring safety design monitoring longterm followup coronavirus vaccine trialssomething cannot fully addressed two earlystage report see httpswwwwhoint blueprintaboutrdblueprint planofactionpdf vaccine candidates see httpsbrightoncollaboration usbrightoncollaborationcepicovid<NUMBER>webconference mers vaccine trials herein undoubtedly considered future efficacy trials experience sars emergence mers particularly outbreaks <NUMBER> arabian korean peninsulas harbingers consequences covid<NUMBER> similar pathogens sectors societynot overall morbidity mortality also capacity level economies disrupt social order <NUMBER> mers eclipsed pandemic cousin lessons learned prepared global vaccine research development community moving coronavirus vaccines forward accelerated pace firstinhuman covid<NUMBER> vaccine trials moving unprecedented shortened timelines stay ahead increasingly frequent outbreaks field must maintain momentum advancing rapid scalable translatable vaccine strategies merscov even urgently sarscov<NUMBER> ultimately next novel coronavirus leaps animal host humans 